program Pre-meeting Courses: october 25-26, 2013 opening lecture and awards: october 26, 2013

Transcription

1 program B O O K Pre-meeting Courses: october 5-6, 0 opening lecture and awards: october 6, 0 Scientific Sessions: october 6-0, 0

2 IMPORTANT LOCATIONS ACR Office... A; Telephone: (69) Attendee Lounge.... Sails Pavilion Business Center.... Hall D Lobby Career Connection... Exhibit Hall F-G, Discovery Center - Booth 4 Child Care... Call for Location; Telephone: (858) Clinical Trials Posters... Sails Pavilion Coat/Baggage Check.... Under Hall D Escalator Concierge Center... Sails Pavilion Discovery Center.... Exhibit Hall F-G, Booth 4 Exhibit Hall... Exhibit Hall F-G First Aid... Box Office G Foundation Booth... Exhibit Hall F-G, Discovery Center - Booth 4 Foundation Donors Lounge... 4B-C Graffiti Walls... Sails Pavilion and Exhibit Hall F-G Hotel Reservations... Sails Pavilion Industry-Supported Symposia Information.... Hall D Lobby Innovation Theater Exhibit Hall F-G, Booth 7 Lost and Found... ACR Office (A) Membership Booth... Sails Pavilion Newsroom... 6A-B; Telephone: (69) Nursing Mothers Room... 7A Overflow Rooms.... 5B (San Diego Convention Center) 08 (Hilton San Diego Bayfront Center) Poster Hall... Exhibit Hall B-C-D Prayer Room... Recharge Areas... exhibit Hall F-G, Attendee Lounge (Sails Pavilion) Registration... Sails Pavilion Restaurant Reservations Hall B Lobby and Sails Pavilion Ribbon Distribution.... Registration (Sails Pavilion) SessionSelect Lounge... Hall D Lobby (Monday Wednesday) Shuttle Bus... Hall E Lobby Simple Tasks.... Exhibit Halls F-G, Discovery Center - Booth 4 Speaker Ready Room... Technology Center (CME/Internet)... Sails Pavilion Visitor Information... Hall B Lobby Wheelchairs... order through ScootAround, Inc.; Telephone: (888) (The San Diego Convention Center does not provide wheelchairs for general use.) Wi-Fi Way... Exhibit Hall F-G Special Needs If you require special arrangements, please contact the ACR Office (A); Telephone: (69) Emergency Contact Information Space is provided on the back of your badge to list name and telephone numbers of your emergency contacts. Please complete this information before inserting your badge in your badge holder.

3 program B O O K ABOUT THE ANNUAL MEETING Participation Statement This annual meeting is sponsored by the American College of Rheumatology for educational purposes only. The material presented is not intended to represent the only or the best methods appropriate for the medical conditions being discussed, but rather is intended to present the opinions of the authors or presenters, which may be helpful to other healthcare professionals at arriving at their own conclusions and consequent application. Attendees participating in this medical education program do so with full knowledge that they waive any claim they may have against the College for reliance on any information presented during these educational activities. The College does not guarantee, warrant or endorse any commercial products or services. The ACR s CME purpose is to provide comprehensive education to improve the knowledge and performance of physicians, scientists and other health professionals. The ACR will offer evidence-based educational activities designed to enhance practice performance and improve the quality of care in those with or at risk for arthritis and rheumatic and musculoskeletal diseases. Global Learning Objectives At the conclusion of the 0 ACR/ARHP annual meeting, participants should be able to: identify recent developments in the diagnosis and management of patients with rheumatic diseases outline new technologies for the treatment of rheumatologic problems describe potential challenges in the delivery of care to patients with rheumatic diseases and to specify possible solutions utilize new research data to improve the quality of care of patients with rheumatic diseases summarize recent rheumatology research findings The program is the result of a planning process that identified educational needs to change or enhance the knowledge, competence or performance of rheumatology professionals. The program s content was derived from both needs assessment and practice gap analysis that took professional activities, practice setting, ABIM recertification requirements and physician attributes into account. Printing of this publication is supported by Amgen, Inc. This publication was printed by an FSC validated printer on eco-friendly paper.

4 TABLE OF CONTENTS POLICIES Copyright Materials Policy... Media... Embargo Policy... MEETING INFORMATION Cell Phones, PDAs & Other Electronic Devices... Children... Child Care... Nursing Mothers Room... Registration... Exhibit Hall... Meeting Room Capacity/Imortant First Safety Information... Photoograpy and Videotaping... Name Badges... No Smoking... MEETING NAVIGATION GUIDE Track Icons... Session Formats... Abstract Formats...4 Abstract Categories...4 MEETING SERVICES My Annual Meeting...7 Discovery Center...7 Membership Booth...7 Lost and Found...8 Newsroom...8 Attendee Lounge...8 Concierge Center...8 Career Connection...8 Shuttle Bus...8 Speaker Ready Room...8 Wi-Fi Way and Recharge Access...8 Rheumatology Research Foundation Donors Lounge...8 SPECIAL OFFERS SessionSelect...9 What Would Make the Meeting Better...0 Medical Bag...0 POSTER SESSIONS Poster Session Presenter Instructions...0 Poster Preseter No-shows...0 Guided Poster Tours...0 PRE-MEETING PROGRAM Friday, October 5, 0 ACR Musculoskeletal Ultrasound Course for Rheumatologists Fundamentals Day One... ACR Certified Rheumatology Coder Course... ACR Basic Research Conference: Beyond Germline Genetics: New Perspectives on Rheumatic Disease Predisposition Day One... ACR Clinical Research Conference: Preclinical Rheumatic Disease Day One...4 ACR/ABIM Maintenance of Certification Learning Session 0 Update in Rheumatology...5 Saturday, October 6, 0 ACR Musculoskeletal Ultrasound Course for Rheumatologists Fundamentals Day Two...5 ACR Clinical Research Conference: Preclinical Rheumatic Disease Day Two...6 ACR Review Course...7 ACR Basic Research Conference: Beyond Germline Genetics: New Perspectives on Rheumatic Disease Predisposition Day Two...8 ARHP Clinical Focus Course: Meeting the Challenges of Measuring Outcomes in Rheumatology Clinical Practice...9 ACR Practice Management Pre-Meeting Course...0 ACR/ARHP ANNUAL MEETING PROGRAM SCIENTIFIC SESSIONS Saturday, October 6, 0 ACR/ARHP Opening Lecture and Awards... ACR/ARHP Champagne Reception... Sunday, October 7, 0 ACR Sessions ACR Pediatric Rheumatology Town Hall Meeting... Adult Onset Still s Disease: A Clinical Review from Pathophysiology to Therapies... ACR Session Year in Review... ACR Sessions Macrophage Polarization... Patient Engagement/Privacy and Security... ARHP Networking Event ARHP First-time Attendee Orientation... ACR Meet the Professor Sessions Antiphospholipid Syndrome (00)... Crystal: Diagnosis and Management of Gout (00)... Dermatological Manifestations of Rheumatic Diseases (00)... Pediatric Systemic Lupus Erythematosus (004)... Pediatrics: Spondylarthritis in Children (005)... Psoriatic Arthritis (006)... Rheumatoid Arthritis: Challenging Cases (007)... Rheumatoid Arthritis: Outcome Measures in Clinical Practice (008)... Spondylarthropathy: An Update (009)... Systemic Lupus Erythematosus: Novel Treatments (00)... ACR Workshops Histopathology of Rheumatic Lung Disease (0) Magnetic Resonance Imaging in the Diagnosis and Management of Spondyloarthritis: A Clinician s Guide (0)...4 Muscle Involvement in Rheumatic Diseases (0) Program Book

5 TABLE OF CONTENTS ARHP Networking Event ARHP Moderator Orientation...4 ACR Sessions Legislative Update From Capitol Hill...4 Medical Education: The Year in Review...4 Where s the Money? A Comprehensive Approach to Funding Your Research...4 ACR Poster Session A and Poster Tours Abstracts (#-760) ACR Sessions CORC FORUM: Disaster Planning: How to Prepare for a Catastrophe and Minimize your Liability...5 Inflammation and Atherosclerosis: Autoimmunity and Cardiovascular Disease...5 New Therapies for Modulating Cell Signaling in Rheumatoid Arthritis...5 Rheumatology Research Foundation Memorial Lecture: Pediatric Rheumatology - Where We ve Been, Where We re Going...6 Rheumatology Research Foundation Oscar S. Gluck, MD, Memorial Lectureship: The Contribution of Bone to Whole Organism Physiology...6 The Link Between Inflammation in the Joint and the Gut...6 Update on Thrombotic Microangiopathies...6 ARHP Session Keynote Address: Words that Heal...6 Exhibits and Innovation Theater See page 5 for the complete Innovation Theater listing. ACR Workshops Advanced Musculoskeletal Ultrasound (04)...7 Basic Statistical Concepts for the Medical Researcher (05)...7 Dermatopathology of Rheumatic Diseases (06)...7 Peripheral Magnetic Resonance Imaging in Rheumatology Practice (07)...7 Physical Examination Skills for Improved Detection of Synovitis and Cervical Thoracolumbar Disorders (08)...7 ARHP Sessions Health Literacy Universal Precautions for the Rheumatology Setting...7 Immunology Boot Camp Session : The Basics of Targeted Therapies...7 Mediation Analysis: Theory and Method for Causal Inference...8 ACR Plenary Session I: Discovery 0 Abstracts (#76-765)...8 ACR Sessions Opportunities for Social Media in Medical Education...40 Why Every U.S. Rheumatologist Should Join the National Rheumatology Registry (RISE)...4 ARHP Networking Event Networking Forum...4 ACR Session ACR Knowledge Bowl- Preliminary Round...4 ACR Meet the Professor Sessions Adult Inflammatory Myopathy (0)...4 Behçet s Disease (0)...4 Cutaneous Vasculitis (0)...4 Fibromyalgia 0: Update on Management (04)...4 Hereditary Angioedema Update (05)...4 Inflammatory Eye Disease/Uveitis (06)...4 Reactive Arthritis: An Update (07)...4 Scleroderma Mimics (08)...4 Systemic Lupus Erythematosus: Lupus Nephritis (09)...4 Understanding of Approach to the Care of Patients with Vasculitis (00)...4 ACR Sessions Alopecia 0 for the Rheumatologist...4 Mechanisms of Pain in Osteoarthritis...4 Telomeres, Telomerase and Age-Related Disease...4 ACR Workshops Beyond Musculoskeletal Ultrasound for Rheumatologists (09)...4 Clinical Anatomy and Physical Exam: Essential Tools in Lower Extremity Regional Pain Syndromes (0)...4 Osteoporosis: Interpreting Dual Energy X-ray Absorptiometry and Clinical Risk Factors: The New Fracture Risk Assessment Algorithm ()...4 ACR Sessions Molecular Mechanisms of Muscle Dysfunction in Inflammatory Myopathy and Muscular Dystrophy...4 Osteoarthritis Pathophysiology, Diagnosis and Management: What Can I Tell my Osteoarthritis Patient to Do Other Than Weight Loss and Quadriceps Strengthening?...4 Sentinels of the Immune System: Dendritic cell and Plasmacytoid Dendritic Cells...44 The Great Debate: Biologics or Triple Therapy for the Treatment of Rheumatoid Arthritis?...44 Vascular Disease in Scleroderma: A Multi-Organ Challenge...44 ACR Concurrent Abstract Sessions Biology and Pathology of Bone and Joint I: Cartilage Biology and Osteoarthritis (#766-77)...44 Cytokines, Mediators, Cell-cell Adhesion, Cell Trafficking and Angiogenesis I: Identifying Novel Factors that Facilitate Neovascularization and Cell Trafficking (#77-777)...45 Epidemiology and Health Services Research I: Comorbidities in Rheumatic Diseases (#778-78)...45 Miscellaneous Rheumatic Diseases (# )...46 Pediatric Rheumatology: Clinical and Therapeutic Disease: Juvenile Idiopathic Arthritis (# )...47 Rheumatoid Arthritis - Clinical Aspects I: Treatment Strategies in Rheumatoid Arthritis (#796-80)...47 Rheumatoid Arthritis Treatment - Small Molecules, Biologics and Gene Therapy: Safety Issues (#80-807)...48 Rheumatoid Arthritis- Autoantibodies and Citrullinated Proteins (#808-8)...49 Spondylarthropathies and Psoriatic Arthritis: Clinical Aspects and Treatment: Therapeutics and Outcomes in Psoriatic Arthritis (#84-89)...49 Systemic Sclerosis, Fibrosing Syndromes and Raynaud s Pathogenesis, Animal Models and Genetics I: Therapeutic Interventions in Preclinical Animal Models of Scleroderma (#80-85)...50 ACR/ARHP Combined Abstract Session ACR/ARHP Combined Rehabilitation Abstract Session (#86-8) Program Book

6 TABLE OF CONTENTS ARHP Sessions Best Practices for Diagnostic Imaging in Evaluating Rheumatologic Conditions...5 Influence of Cardiac Comorbidities on Exercise in Individuals With Rheumatic Diseases Juvenile Systemic Lupus Erythematosus...5 ARHP Concurrent Abstract Session ARHP Exemplary Abstracts (#8-87)...5 ACR Workshops Joint Injection Techniques ()...5 Musculoskeletal Exam Skills I: General Musculoskeletal Examination for Arthritis ()...5 Musculoskeletal Ultrasonography: Basic (4)...5 Synovial Fluid Analysis and Crystal Identification (5)...5 ACR Sessions OA-OMICS...5 Pediatric Inflammatory Brain Diseases...5 Quality Measures in Rheumatology: Developing and Implementing Meaningful Measures as Health Care Reform Advances...5 Regenerative and Stem Cell Medicine...54 Sex and Autoimmunity: Hormones and Beyond...54 Thieves Market: Show Me Your Best Cases...54 ACR Concurrent Abstract Sessions Fibromyalgia, Soft Tissue Disorders and Pain: Diagnosis and Disease Epidemiology (#88-84)...54 Health Services Research, Quality Measures and Quality of Care - Pediatrics, Immunization and Choosing Wisely (# )...55 Imaging of Rheumatic Diseases: Imaging in Vascular and Extra-articular (# )...55 Metabolic and Crystal Arthropathies I (#856-86)...56 Osteoporosis and Metabolic Bone Disease: Clinical Aspects and Pathogenesis (#86-867)...57 Rheumatoid Arthritis - Clinical Aspects II: Identifying Rheumatoid Arthritis in At-Risk Populations (#868-87)...57 Rheumatoid Arthritis Treatment - Small Molecules, Biologics and Gene Therapy: Efficacy of Approved Biologics II (# )...58 Systemic Lupus Erythematosus - Clinical Aspects and Treatment: Lupus Nephritis and Genetics (# )...59 Systemic Lupus Erythematosus - Human Etiology and Pathogenesis I (# ) - 0 Lee C. Howley, Sr. Prize for Arthritis Research Introductory Talk...60 Vasculitis I (#89-896)...6 ACR Meet the Professor Sessions Ankylosing Spondylitis: 0 Update (0)...6 Crystal: Diagnosis and Management of Gout (0)...6 Juvenile Dermatomyositis (0)...6 Osteoarthritis: Update 0 (04)...6 Pain: Evaluation and Treatment of Back Pain (05)...6 Rheumatoid Arthritis: Biological Agents (06)...6 Rheumatoid Arthritis: Challenging Cases (07)...6 Systemic Lupus Erythematosus: Novel Treatments (08)...6 Systemic Sclerosis: Disease Staging and Subsetting in Clinical Practice (09)...6 Vasculitis: Update (00)...6 ARHP Sessions Fine Tuning Your Skills in Utilizing Disease Activity Measurement Tools for Rheumatic Arthritis...6 Postural Changes: How to Improve Joint Protection, Strength and Gain Efficiency...6 Rheumatic Disease Update: Myositis, An Overview and Differentiation From Metabolic Myopathies...6 ARHP Concurrent Abstract Sessions Epidemiology and Public Health (#897-90)...6 Psychology/Social Sciences (#90-908)...64 Industry-Supported Symposia...5 Monday, October 8, 0 ACR Sessions Clinicopathologic Conference: A Patient With Rheumatoid Arthritis and Systemic Disease...65 Interleukin (IL-6), The Pleiotrophic Cytokine: New Clinical Roles and Therapeutic Opportunities...65 Medical Marijuana and the Rheumatologist...65 Mitigating Health Disparities in Rheumatologic Disease...65 Tyro/Axl/Mer (TAM) Receptors and Innate Immune Regulation...65 ARHP Sessions An Overview of Qualitative Research...66 Immunology Boot Camp Session : The Basics of Autoimmunity and Immunodeficiency - When Good Cells Go Bad...66 Piloting Your Research to Success: The Why, What and How of Pilot Studies...66 ACR Session Improving Quality, Outcomes and Spending in Health Care: Good Data and Measures Are Just the Beginning...66 ACR Meet the Professor Sessions Antiphospholipid Syndrome (0)...66 Calcium Crystal Arthritis (0)...66 Controversies in Sjögren s Syndrome (0)...67 Dermatological Manifestations of Rheumatic Diseases (04)...67 Infections With Biologics (05)...67 Pediatrics: Periodic Fevers in Children (06)...67 Pregnancy and Rheumatic Diseases (07)...67 Systemic Lupus Erythematosus: Central Nervous System (08)...67 Vasculitis Mimics (09)...67 Vitamin D and Bone Health (040)...67 ACR Workshops Clinical Anatomy and Physical Exam: Essential Tools in Upper Extremity Regional Pain Syndromes (6)...67 Musculoskeletal Ultrasonography: Basic (7)...68 X-ray Challenges in Rheumatic Diseases (8)...68 ACR Sessions Atypical Myopathies...68 Good Reviewers Make Good Authors: A Guide to Conducting Excellent Manuscript Reviews...68 Kawasaki Disease: Putting Out the Fire...68 Rheumatology Research Foundation Special Session: Clinician Scholar Educators Program Book

7 TABLE OF CONTENTS ACR/ARHP Poster Session B, Thieves Market Posters and Poster Tours Abstracts (# )...69 ACR Sessions How to Maintain Your Medical License and Certification After 0: Changes Will Impact All Physicians. Are You Prepared?...70 Poor Sleep: Consequences and Cures...70 ARHP Session Distinguished Lecturer: Integrating Concepts of Behavioral Change and Technology to Promote Health in Persons With Arthritis...70 Exhibits and Innovation Theater See page 5 for the complete Innovation Theater listing. ACR/ARHP Workshops Dermatopathology of Rheumatic Diseases (9)...70 Joint Injections (Knee, Ankle, Shoulder and Wrist) (0)...70 Musculoskeletal Exam Skills II: Regional Musculoskeletal Examination of the Neck and Low Back ()...7 Renal Histopathology in Systemic Lupus Erythematosus and Vasculitis ()...7 ACR Sessions ACR Knowledge Bowl-Final Round...7 Personalized Medicine: Transforming 00 Billion Points of Data into Diagnostics, Therapeutics, and New Insights into Disease...7 Rheumatology Research Foundation Paul Klemperer, MD, Memorial Lectureship: Rheumatoid Arthritis and Autoimmunity: Good Genes, Elegant Mechanisms, Bad Results...7 Navigating the System: The Key to Obtaining Medications for Your Patients...7 Obesity and Rheumatic Disease...7 Rheumatic Manifestations of Endocrine Disorders...7 ACR Plenary Session II: Discovery 0 Abstracts (# )...7 ARHP Networking Event Networking at Noon...75 ACR Sessions ACR Special Session: Career Opportunities in Rheumatology: Making a Choice...75 Inter-professional Collaborative Practice and Education: A Review of the Field and Report of a New Center of Excellence in Musculoskeletal Care...76 ACR Meet the Professor Sessions Challenging Cases in Osteoporosis Management (04)...76 Immunodeficiency Syndromes (04)...76 Macrophage Activation Syndrome (04)...76 Myopathy: Issues in Diagnosis and Treatment (044)...76 Pulmonary Manifestations of Rheumatic Disease (045)...76 Raynaud s and Digital Ischemia (046)...76 Rheumatoid Arthritis: Biological Agents (047)...77 Rheumatoid Arthritis: Safety of Novel Therapies (048)...77 Systemic Lupus Erythematosus: Difficult to Treat Systemic Lupus Erythematosus (049)...77 What is Not Central Nervous Angiitis: Making the Right Diagnosis (050)...77 ACR Sessions Behçet s Disease...77 Winning at Clue: The Clinical Rheumatologist s Guide to Figuring out Who Killed Who, With What and Where in the Rheumatic Diseases...77 ACR Workshops Magnetic Resonance Imaging in the Diagnosis and Management of Spondyloarthritis: A Clinician s Guide ()...77 Peripheral Magnetic Resonance Imaging in Rheumatology Practice (4)...77 Synovial Fluid Analysis and Crystal Identification (5)...78 ACR Session Autoimmunity Caused by Immune Deficiency: When Not Enough Is Too Much...78 Crystal Diseases: How Does Joint Damage Occur and Why do Attacks Resolve Spontaneously?...78 Curbside Consults - Ask the Experts...78 Functional Genomics: Approaches to Identifying Causal Variants...78 Janus Kinase (JAK) Inhibitors in Rheumatoid Arthritis...78 ACR Concurrent Abstract Sessions Epidemiology and Health Services Research II: Epidemiology in Systemic Lupus Erythematosus and Rheumatoid Arthritis (# , 06)...79 Genetics and Genomics of Rheumatic Disease I (#70-707)...79 Health Services Research, Quality Measures and Quality of Care Rheumatoid Arthritis (#708-7, 95)...80 Imaging in Pediatric Arthritis, Spondyloarthritis, and Osteoarthritis (#74-79)...8 Metabolic and Crystal Arthropathies II (#70-75, 90)...8 Rheumatoid Arthritis - Animal Models I (#76-7)...8 Rheumatoid Arthritis Treatment - Small Molecules, Biologics and Gene Therapy: Efficacy and Safety of Novel Entities (#7-77)...8 Systemic Lupus Erythematosus - Clinical Aspects and Treatment: Biologic Therapy (#78-74)...8 Systemic Sclerosis, Fibrosing Syndromes, and Raynaud s - Clinical Aspects and Therapeutics I (# )...84 Vasculitis II (# )...85 ACR/ARHP Combined Abstract Session ACR/ARHP Combined Epidemiology Abstract Session (#756-76)...86 ARHP Session Aerobic, Strength and Biomechanical Considerations for Treatment Progression in Osteoarthritis: What is the Evidence?...86 Designing a Qualitative Study and an Example of the Use of Qualitative Study Design in Patients With Rheumatologic Disease...86 Rheumatic Disease Update Debate: Calcium and Vitamin D, What Does the Research Support?...87 Rheumatic Diseases in Women of Childbearing Years: Fertility, Pregnancy and Lactation...87 ACR/ARHP Workshops Getting Electronic Health Records Right (6)...87 Musculoskeletal Exam Skills III: Regional Musculoskeletal Examination of the Shoulder and Knee (7)...87 Musculoskeletal Ultrasound (8)...87 The Rheumatologic Musculoskeletal Screening Exam, With Emphasis on Objective Disease-specific Measurements (9) Program Book 5

8 TABLE OF CONTENTS ACR Sessions Bone is Hard or is it? Mechanisms Regulating Bone Qualities...88 Challenges in Systemic Lupus Erythematosus Management...88 Gout and Pseudogout: What s New in Treatments and Diagnostic Modalities? Inflammasomes in Health and Disease...88 Updated ACR Recommendations for the Treatment of Juvenile Idiopathic Arthritis...88 ACR Concurrent Abstract Sessions Cytokines, Mediators, Cell-cell Adhesion, Cell Trafficking and Angiogenesis II: Mechanisms That contribute to autoimmune inflammation (#76-767)...89 Epidemiology and Health Services Research II: Healthcare Costs and Mortality in Rheumatic Disease (#768-77)...89 Muscle Biology, Myositis and Myopathies I: Insights Into Mechanisms of the Idiopathic Inflammatory Myopathies (# )...90 Pediatric Rheumatology - Clinical and Therapeutic Aspects II: Autoinflammatory Disease and Systemic Juvenile Idiopathic Arthritis (# )...9 Rheumatoid Arthritis - Clinical Aspects III: Predictors of Disease Course in Rheumatoid Arthritis (#786-79)...9 Rheumatoid Arthritis Treatment - Small Molecules, Biologics and Gene Therapy: Safety & Efficacy of Small Molecule Agents (#79-797)...9 Spondylarthropathies and Psoriatic Arthritis: Clinical Aspects and Treatment: Therapeutics and Outcomes in Spondyloarthritis (#798-80)...9 Systemic Lupus Erythematosus - Clinical Aspects: Non-biologic Disease-modifying Antirheumatic Drugs (# )...94 Systemic Sclerosis, Fibrosing Syndromes, and Raynaud s - Clinical Aspects and Therapeutics II (#80-85)...94 ACR Meet the Professor Sessions Ankylosing Spondylitis: Disease Modification (05)...95 Basic Immunology for Clinical Rheumatologists (05)...95 Pain: Evaluation and Treatment of Back Pain (05)...95 Pediatric Rheumatology for Adult Rheumatologists (054)...95 Polymyalgia Rheumatica (055)...95 Psoriatic Arthritis (056)...95 Pulmonary Hypertension in the Rheumatic Diseases (057)...95 Rheumatoid Arthritis: Challenging Cases (058)...96 Temporal Arteritis (059)...96 Vaccinations for Patients on Biologic Therapies (060)...96 ARHP Sessions Body Image with Rheumatic Conditions...96 Rheumatoid Arthritis Management: Views from Around the World...96 Work, Health and Well-being: Arthritis and Employment Across the Life Course...96 ARHP Concurrent Abstract Session Rehabilitation Sciences (#86-8)...97 ACR Study Groups ACR Musculoskeletal Ultrasound Study Group...97 ACR-EULAR Exchange Study Group - Joint Imaging and Beyond...97 Autoantibodies in Diagnosis and Follow-up of Rheumatic Diseases Study Group...97 Behҫet s Syndrome Study Group...98 Biosimilars in Rheumatology Study Group...98 Capillaroscopy in Rheumatic Diseases Study Group...98 Crystal Study Group...98 Decision Aids in Rheumatology Study Group...98 Global Musculoskeletal Health Initiative Study Group...98 High-Resolution peripheral Quantitative Computed Tomography (HR-pQCT) - Early Damage Detection in Inflammatory and Degenerative Arthritis Study Group...99 JAW (Juvenile Arthritis Workgroup)...99 Latin American Study Group...99 Neuro Endocrine Immunology Study Group...99 Pediatric Rheumatology Imaging Study Group...99 Polymyalgia Rheumatica Study Group...99 Primary Sjögren s Syndrome Study Group...99 Veterans Affairs Rheumatology Study Group...99 Tuesday, October 9, 0 ACR Sessions Care of Chronic Non-Healing Wounds...00 Non-coding DNA: Signals, Switches, and Complex Regulation of Genes...00 Pediatric Autoimmune and Inflammatory Skin Disease...00 ARHP Sessions Rheumatic Disease and Pain Management in Special Needs Populations...00 Rheumatology Update: Inflammatory Bowel Disease...00 The Results Section in Medical Research Literature: The Appropriate and Inappropriate Use of Statistics...0 ACR Sessions Rheumatology Research Foundation Special Session: Disease Targeted Research...0 Risk Management-A Case Study...0 ACR Meet the Professor Sessions Ankylosing Spondylitis: 0 Update (06)...0 Antiphospholipid Syndrome (06)...0 Crystal: Diagnosis and Management of Gout (06)...0 Myopathy: Issues in Diagnosis and Treatment (064)...0 Osteoporosis: Novel Treatments (065)...0 Pregnancy and Rheumatic Diseases (066)...0 Rheumatoid Arthritis: Safety of Novel Therapies (067)...0 Rheumatology Practice 0: Starting Out in Practice for the Graduating Fellow (068)...0 Systemic Sclerosis: Disease Staging and Subsetting in Clinical Practice (069)...0 Temporal Arteritis (070)...0 ACR/ARHP Workshops Advanced Musculoskeletal Ultrasound (0)...0 Histopathology of Vasculitis ()...0 Joint Injections (Knee, Ankle, Shoulder and Wrist) ()...0 Knee Braces and Foot Orthosis for Knee Osteoarthritis ()...0 ACR Session Contract Negotiations for Physicians...0 ACR Sessions Chart Etiquette: Creating Meaningful Notes...0 Choosing and Monitoring Rheumatoid Arthritis Therapy in ACR/ARHP Poster Session C, Thieves Market Posters and Poster Tours Abstracts (#8-64) Program Book

9 TABLE OF CONTENTS ACR Sessions Ready or Not It s Coming: Implementation of ICD The Role of B cells in Rheumatic Disease...05 The Role of Th7 Cells in Health and Disease...05 ARHP Sessions An Integrative Approach to Pediatric Wellness...05 Anxiety Disorders in Rheumatic Disease...05 Immunology Boot Camp Session : Biologic Logic, An Update...05 Knowledge Is Power, but Sample Size Matters More: The Role of Sample Size in the Power and Precision of Study Results...05 Exhibits and Innovation Theater See page 5 for the complete Innovation Theater listing. ACR Workshops Musculoskeletal Ultrasound (4)...06 Tai Chi and Alternative Therapies in Rheumatic (5)...06 The Rheumatologic Musculoskeletal Screening Exam, With Emphasis on Objective Disease-specific Measurements (6)...06 ACR Session Mechanics, Matrix Disruption, and the Development of Osteoarthritis...06 ARHP Sessions Nonalcoholic Fatty Liver Disease...06 Oral Health in Rheumatologic Disease...06 Persistent Pain: Mechanisms of Chronic Pain and Innovative Treatment Options...07 ACR Sessions Assessment Tool Selection in Health Professions Education...07 Audits-Are You at Risk?...07 Protein Citrullination and Biological Response Modification: Rheumatoid Arthritis and Beyond...07 Selected Topics Related to Spondylarthropathies...07 ACR Plenary Session III: Discovery 0 Abstracts (# )...07 ACR Meet the Professor Sessions Adult Inflammatory Myopathy (07)...0 Basic Immunology for Clinical Rheumatologists (07)... Behçet s Disease (07)... Infections with Biologics (074)... Pediatrics: Difficult to Treat Juvenile Idiopathic Arthritis (075)... Psoriatic Arthritis (076)... Rheumatoid Arthritis: Biological Agents (077)... Rheumatoid Arthritis: Challenging Cases (078)... Systemic Lupus Erythematosus: Lupus Nephritis (079)... Vasculitis: Update (080)... ACR Sessions Animal Models in Rheumatic Disease How Useful Are They?... Hench Lecture: Evolutionary Medicine and Chronic Inflammatory State - Known and New Concepts in Pathophysiology... Inflammatory Eye Disease: An Update for Rheumatologists... ACR Study Groups A Multi-Disciplinary Approach to Post Fracture Management Study Group... Antiphospholipid Study Group... Expert Journal Club Study Group... Gout Classification Criteria Study Group... Hypermobility Study Group... Interstitial Lung Diseases in Connective Tissue Disease Study Group.. Macrophage Activation Syndrome Study Group... Myositis Study Group... Non-Vasculitic Vasculopathy Study Group... Osteoarthritis Study Group... Spondyloarthritis Study Group... Takayasu s Arteritis Study Group... ACR Workshops Joint Injection Techniques (7)...4 Osteoporosis: Interpreting Dual Energy X-ray Absorptiometry and Clinical Risk Factors: The New Fracture Risk Assessment Algorithm (8) Renal Histopathology in Systemic Lupus Erythematosus and Vasculitis (9)...4 ACR Session ACR Business Meeting...4 ACR Sessions Adipose Tissue and Inflammation...4 Novel Insight Into the Pathogenesis of Systemic Vasculitis...4 Osteoporosis Treatment Strategies for Today and Tomorrow...5 Vaccinology and DMARD Use in Immunocompromised and High-Risk Populations...5 ACR Concurrent Abstract Sessions Antiphospholipid Syndrome (# )...5 Epidemiology and Health Services Research VI: Risk Factors in Rheumatic Disease Susceptibility (#656-66)...6 Health Services Research, Quality Measures and Quality of Care - Innovations in Health Care Delivery (#66-667)...7 Osteoarthritis I: Therapeutics in Osteoarthritis (#668-67)...7 Pediatric Rheumatology - Clinical and Therapeutic Aspects III: Systemic Lupus Erythematosus and Other Disease Outcomes (# )...8 Rheumatoid Arthritis - Clinical Aspects IV: Comorbidities in Rheumatoid Arthritis (# )...9 Rheumatoid Arthritis Treatment - Small Molecules, Biologics and Gene Therapy: Novel Treatment Strategies in Rheumatoid Arthritis (#686-69)...9 Spondylarthropathies and Psoriatic Arthritis - Pathogenesis, Etiology (#69-697)...0 Systemic Lupus Erythematosus - Human Etiology and Pathogenesis II (#698-70)... Systemic Sclerosis, Fibrosing Syndromes, and Raynaud s II: Pathogenesis, Animal Models, Genetics: Novel Signaling Pathways Mediating Fibrosis (# ) T cell Biology and Targets in Autoimmune Disease (#70-74, 70)... ARHP Sessions Defining the Roles of the Rheumatology Nurse Internationally... Inflammatory Arthropathies of the Foot and Ankle: Assessment and Non-pharmacological Foot Care Interventions... You Can Improve Hand Function in Scleroderma... ARHP Concurrent Abstract Session Clinical Practice/Patient Care (#76-7)... 0 Program Book 7

10 TABLE OF CONTENTS ACR Workshops Patient Questionnaires: Multi-Dimensional Health Assessment Questionnaire/Routine Assessment of Patient Index Data and Beyond Toward a Standard, Scientific, Quantitative Patient History (40)...4 Proficiency in Teaching: Engaging Learners (4)...4 Systemic Sclerosis: How to Perform Skin Scores (4)...4 ACR Sessions Cell Death and Toll-like Receptor (TLR) Recognition of Nucleic Acid Ligands Critical Care Rheumatology...5 International League of Associations for Rheumatology (ILAR) Pediatric Rheumatology in Developing Countries...5 Large Vessel Vasculitis: What Should the Clinician Know...5 Update on Safety Issues in the Treatment of Rheumatic Diseases From the FDA and Beyond ACR Concurrent Abstract Sessions 0 Rheumatology Research Foundation Edmond L. Dubois, MD Memorial Lectureship (#7-77)...6 Biology and Pathology of Bone and Joint II: Osteoclast Biology and Arthritis (#78-7)...6 Genetics and Genomics of Rheumatic Disease II (#74-79)...7 Innate Immunity and Rheumatic Disease (# )...7 Miscellaneous Rheumatic and Inflammatory Diseases I: Autoinflammatory Syndromes (#746-75)...8 Osteoarthritis II: Risk Factors and Natural History of Osteoarthritis (#75-757)...9 Rheumatoid Arthritis - Clinical Aspects V: Observational Studies in Rheumatoid Arthritis (#758-76)...9 Rheumatoid Arthritis Treatment - Small Molecules, Biologics and Gene Therapy: Efficacy of Approved Biologics I (# )...0 Sjögren s Syndrome: Basic Science (# )... Spondylarthropathies and Psoriatic Arthritis: Clinical Aspects and Treatment: Clinical Features of Spondylarthritis (#776-78)... Vasculitis III (#78-787)... ACR Meet the Professor Sessions Controversies in Sjögren s Syndrome (08)...4 Osteoarthritis: Update 0 (08)...4 Pulmonary Manifestations of Rheumatic Disease (08)...4 Raynaud s and Digital Ischemia (084)...4 Reactive Arthritis: An Update (085)...4 Still s Disease and Autoinflammatory Syndromes (086)...4 Systemic Lupus Erythematosus: Central Nervous System (087)...4 Systemic Lupus Erythematosus: Difficult to Treat Systemic Lupus Erythematosus (088)...4 Understanding of Approach to the Care of Patients With Vasculitis (089)...4 Vaccinations for Patients on Biologic Therapies (090)...5 ACR/ARHP Combined Abstract Session ACR/ARHP Combined Pediatrics Abstract Session (#788-79) ARHP Sessions Enhancing Clinical Practice with Patient Engagement and Self-management Support Strategies...6 Pharmacist-Physician Partnership in Rheumatic Disease Management...6 The Age of Information Technology: Registries, Administrative Databases, and the Role of the Internet in Rheumatic Disease Research...6 Industry-Supported Symposia...5 Wednesday, October 0, 0 ACR Sessions Glycoregulation of Autoimmunity...7 Microparticles: Real Effectors or Just Mini-Me...7 Rheumatology Roundup: Highlights From the 0 Annual Meeting.. 7 ARHP Sessions Rheumatic Disease Update: Rheumatoid Arthritis...7 The Risks, Screening and Management of Human Papillomavirus in Patients With Rheumatologic Disease...7 ACR Session Emerging and Unexpected Regulatory Roles for Complement in the Rheumatic Diseases...7 ACR Sessions Current Management of Sjögren s Syndrome...7 Molecular and Cellular Profiling of the Immune Response...8 Patient-reported Outcome Measures for Rheumatologists...8 Policy Changes That Will Affect Your Practice in 04: Meaningful Use, Value-based Purchasing, PQRS, and ICD ACR Concurrent Abstract Sessions B cells in Systemic Lupus Erythematosus (# )...8 Imaging in Rheumatoid Arthritis (# )...9 Infection Related Rheumatic Diseases (#806-8)...40 Medical Education (#8-87)...40 Rheumatoid Arthritis - Animal Models II (#88-8)...4 Rheumatoid Arthritis - Clinical Aspects VI: Cardiovascular Disease in Rheumatoid Arthritis (#84-89)...4 Systemic Lupus Erythematus Clinical Aspects: Pregnancy (#80-85)...4 Spondylarthropathies and Psoriatic Arthritis: Clinical Aspects and Treatment: Clinical and Imaging Aspects of Axial Spondyloarthritis (#86-84)...4 ARHP Sessions Rheumatology Practice in the Age of the Affordable Care Act...44 Update on Orthotic Management for Rheumatic Diseases Through the Lifespan...44 ARHP Concurrent Abstract Session Education/Community Programs (#84-847)...44 ACR Sessions 0 ACR-EULAR Scleroderma Classification Criteria...45 PCMH-Model and the Rheumatology Specialty...45 ACR Concurrent Abstract Sessions Fibromyalgia, Soft Tissue Disorders and Pain: Treatment and Outcome Assessment (#848-85, )...45 Orthopedics, Low Back Pain, Rehabilitation and Mechanisms of Pain in Arthritis (# )...46 Pediatric Rheumatology - Pathogenesis and Genetics (# ).. 47 Rheumatoid Arthritis - Clinical Aspects VII: Remission, Flare and Outcome Measures in Rheumatoid Arthritis (#866-87)...47 Rheumatoid Arthritis - Pathogenetic Pathways (#87-877) Program Book

11 TABLE OF CONTENTS Sjögren s Syndrome: Clinical Advances (#878-88)...49 Spondylarthropathies and Psoriatic Arthritis: Clinical Aspects and Treatment: Imaging in Axial Spondylarthropathies: Challenges, Advances (# )...50 Systemic Lupus Erythematosus - Animal Models (# )...50 Systemic Lupus Erythematosus - Clinical Aspects: Cardiovascular and Other Complications of Lupus (#896-90)...5 Systemic Sclerosis, Fibrosing Syndromes and Raynaud s Pathogenesis, Animal Models and Genetics: Pathogenesis of Systemic Sclerosis (#90-907)...5 Systemic Sclerosis, Fibrosing Syndromes, and Raynaud s - Clinical Aspects and Therapeutics III...5 ARHP Session Highlights for the 0 ARHP Annual Scientific Meeting...5 ARHP Concurrent Abstract Session Research and Health Services (#908-9)...5 Industry-Supported Post-meeting Symposia...55 ACR POSTER SESSION A Antiphospholipid Syndrome: Clinical Manifestations and New Biomarkers in Antiphospholipid Syndrome Abstracts (#-)...54 B cell Function and Targeting in Systemic Lupus Erythematosus Abstracts (#4-4)...56 Biology and Pathology of Bone and Joint (Cartilage and Osteoarthritis) Abstracts (#4-86)...57 Epidemiology and Health Services I Abstracts (#87-7)...60 Fibromyalgia, Soft Tissue Disorders and Pain I Abstracts (#8-45)...6 Genetics and Genomics of Rheumatic Disease I Abstracts (#46-80)...64 Health Services Research, Quality Measures and Quality of Care Rheumatoid Arthritis Abstracts (#8-)...67 Imaging of Rheumatic Diseases I: Imaging in Gout, Pediatric, Soft and Connective Tissue Diseases Abstracts (#-4)...70 Osteoarthritis - Clinical Aspects I: Risk Factors for and Sequelae of Osteoarthritis Abstracts (#5-67)...7 Pediatric Rheumatology - Clinical and Therapeutic Aspects I: Juvenile Idiopathic Arthritis Abstracts (#68-99)...74 Spondylarthropathies and Psoriatic Arthritis: Clinical Aspects and Treatment: Psoriatic Arthritis: Clinical Aspects and Treatment Abstracts (#00-55)...77 Rheumatoid Arthritis - Clinical Aspects I: Comorbidities in Rheumatoid Arthritis Abstracts (#56-4)...8 Rheumatoid Arthritis Treatment - Small Molecules, Biologics and Gene Therapy I Abstracts (#44-50)...88 Sjögren s Syndrome: Clinical Aspects Abstracts (#50-5)...96 Spondyloarthropathies and Psoriatic Arthritis: Pathogenesis, Etiology, Animal Models I Abstracts (#5-59)...98 Systemic Lupus Erythematosus - Animal Models Abstracts (#540-57)...99 Systemic Lupus Erythematosus - Clinical Aspects I - Renal, Malignancy, Cardiovascular Disease Abstracts (#574-66)...0 Systemic Lupus Erythematosus - Human Etiology and Pathogenesis: Mechanisms and Biomarkers Abstracts (#67-646)...06 Systemic Sclerosis, Fibrosing Syndromes and Raynaud s I Abstracts (# )...08 Systemic Sclerosis, Fibrosing Syndromes, and Raynaud s - Clinical Aspects and Therapeutics I Abstracts (#67-709)...09 T cell Biology and Targets in Autoimmune Disease: Signaling Pathways in T cell Differentiation Abstracts (#70-77)... Vasculitis I Abstracts (#78-760)...4 ACR/ARHP POSTER SESSION B B cells in Human and Animal Arthritis Abstracts (#909-96)...8 Cytokines, Mediators, Cell-cell Adhesion, Cell Trafficking and Angiogenesis I Abstracts (#97-959)...9 Education: Medical Education Abstracts (#960-98)... ARHP Education/Community Programs Abstracts (#984-99)... Epidemiology and Health Services II Abstracts (#99-0)...4 Epidemiology and Health Services III Abstracts (#0-07)...7 ARHP Epidemiology and Public Health Abstracts (#07-080)...0 Fibromyalgia, Soft Tissue Disorders and Pain II Abstracts (#08-09)...0 Imaging of Rheumatic Diseases II: Imaging in Spondyloarthritis and Osteoarthritis Abstracts (#0-6)... Infection Related Rheumatic Diseases Abstracts (#7-4)...4 Innate Immunity and Rheumatic Disease Abstracts (#4-7)...5 Metabolic and Crystal Arthropathies I Abstracts (#7-00)...6 Miscellaneous Rheumatic and Inflammatory Diseases I: Autoinflammatory Syndromes Abstracts (#0-4)...8 Osteoporosis and Metabolic Bone Disease: Clinical Aspects and Pathogenesis Abstracts (#5-48)...9 Pain - Basic Mechanisms Abstracts (#49-5)...4 Pediatric Rheumatology - Clinical and Therapeutic Aspects II: Pediatric Systemic Lupus Erythematosus, Pediatric Vasculitis and Pediatric Myositis Abstracts (#54-77)...4 Rheumatoid Arthritis - Animal Models I Abstracts #78-0)...44 Rheumatoid Arthritis - Clinical Aspects II: Predictors of Disease Course in Rheumatoid Arthritis - Treatment Approaches Abstracts (#0-7) Program Book 9

12 TABLE OF CONTENTS Rheumatoid Arthritis - Human Etiology and Pathogenesis Abstracts (#7-408)...5 Rheumatoid Arthritis Treatment - Small Molecules, Biologics and Gene Therapy II Abstracts (# )...56 Sjögren s Syndrome: Pathogenesis Abstracts (# )...6 Spondylarthropathies and Psoriatic Arthritis: Clinical Aspects and Treatment II Abstracts (# )...65 Systemic Lupus Erythematosus - Clinical Aspects II: Central Nervous System Manifestations, Therapeutics Abstracts (#559-64)...69 Systemic Lupus Erythematosus - Human Etiology and Pathogenesis: Genetics and Genomics Abstracts (#65-69)...75 T cell biology in Autoimmune Diseases Abstracts (# )...77 Vasculitis II Abstracts (# )...78 ACR/ARHP POSTER SESSION C Biology and Pathology of Bone and Joint (Bone and Arthritis) Abstracts (#8-89)...8 Cytokines, Mediators, Cell-cell Adhesion, Cell Trafficking and Angiogenesis II Abstracts (#840-87)...84 Genetics and Genomics of Rheumatic Disease II Abstracts (#87-905)...86 Health Services Research, Quality Measures and Quality of Care Innovations in Health Care Delivery Abstracts (#906-96)...90 ARHP Health Services Research Abstracts (#97-940)...9 Imaging in Rheumatoid Arthritis Abstracts (#94-978)...9 ARHP Imaging of Rheumatic Disease: Research Methodology Abstracts (#979-98)...96 Metabolic and Crystal Arthropathies II Abstracts (#98-009)...96 Miscellaneous Rheumatic and Inflammatory Diseases II: Miscellaneous Rheumatic Diseases Abstracts (#00-05)...98 Muscle Biology, Myositis and Myopathies: Advances in the Epidemiology, Immunology and Therapy of Myositis Abstracts (#05-089)...0 ARHP Orthopedics, Low Back Pain and Rehabilitation: Rehabilitation Sciences Abstracts (#090-0)...05 Orthopedics, Low Back Pain, and Rehabilitation Abstracts (#-7)...06 Osteoarthritis - Clinical Aspects II: Symptoms and Therapeutics in Osteoarthritis Abstracts (#8-56)...07 ARHP Osteoarthritis - Clinical Aspects: Psychology/Social Sciences Abstracts (#57-6)...09 Pediatric Rheumatology - Clinical and Therapeutic Aspects III: Juvenile Idiopathic Arthritis and Other Pediatric Rheumatic Diseases Abstracts (#64-87)...0 Pediatric Rheumatology - Pathogenesis and Genetics Abstracts (#88-07)... ARHP Pediatrics Abstracts (#08-)...4 Rheumatoid Arthritis - Animal Models II Abstracts (#-6)...4 Rheumatoid Arthritis - Clinical Aspects III: Outcome Measures, Socioeconomy, Screening, Biomarkers in Rheumatoid Arthritis Abstracts (#7-05)...6 ARHP Rheumatoid Arthritis - Clinical Aspects: Clinical Practice/ Patient Care Abstracts (#06-5)... Rheumatoid Arthritis Treatment - Small Molecules, Biologics and Gene Therapy III Abstracts (#6-9)... Rheumatoid Arthritis: Human Etiology and Pathogenesis II Abstracts (#9-4)...0 Spondylarthropathies and Psoriatic Arthritis: Clinical Aspects and Treatment III Abstracts (#4-487)... Spondyloarthropathies and Psoriatic Arthritis: Pathogenesis, Etiology, Animal Models II Abstracts (#488-50)...7 Systemic Lupus Erythematosus - Clinical Aspects III: Biomarkers, Quality of Life and Disease Indicators, Late Complications Abstracts (# )...8 Systemic Sclerosis, Fibrosing Syndromes, and Raynaud s II Abstracts (#558-57)...4 Systemic Sclerosis, Fibrosing Syndromes, and Raynaud s - Clinical Aspects and Therapeutics II Abstracts (#574-6)...44 Vasculitis III Abstracts (#6-64)...47 INNOVATION THEATER...5 INDUSTRY-SUPPORTED SYMPOSIA...5 CERTIFICATES OF CME CREDIT OR PARTICIPATION Accreditation Statement...59 Meeting Evaluations, CME Credit/Certificates for Participation...59 Conflict of Interest/Disclosure...59 Disclosure Policy...59 RECOGNITIONS ACR/ARHP Annual Meeting Leadership...60 Exhibitors...64 Supporter Acknowledgements...68 INDICIES Invited Speaker Moderator Index...70 ACR/ARHP Abstract Author Index...XX ACR/ARHP Abstract Moderator Index...XX 0 0 Program Book

13 The most comprehensive online collection of rheumatology-related images. Serving as a centralized resource for clinicians, researchers and health care professionals, the Rheumatology Image Bank provides invaluable assistance in self-study or the education of others. Start your visual exploration of rheumatology today at Stop by the Discovery Center, located in the Exhibit Hall F-G (Booth #4) or the Concierge Center, located in the Sails Pavilion, and speak with staff to learn more about the Rheumatology Image Bank and all it can offer you. COPYRIGHT MATERIALS POLICY The annual meeting is a private event. Programs presented at the meeting are for the education of attendees and purchasers of recorded presentations as authorized by the ACR. The information and materials displayed and presented during this meeting are the property of the ACR and the presenter and cannot be photographed, copied, photocopied, transformed to electronic format, reproduced, or distributed without written permission of the ACR and the presenter. Any use of the program content for commercial purposes, which includes, but is not limited to oral presentations, audiovisual materials used by speakers, and program handouts without the written consent of the ACR is prohibited. This policy applies before, during and after the meeting. The ACR will enforce its intellectual property rights and penalize those who infringe upon it. The names, insignias, logos and acronyms of the ACR, the ARHP and the RRF are proprietary marks. Use of the names in any fashion, by any entity, for any purpose, is prohibited without the express written permission of the ACR. MEDIA Credentialed media attend the annual meeting to cover stories for consumer, trade and other media outlets, and are easily identified by their black press ribbons. Media has access to all general sessions and limited access (at the discretion of speakers) to meet the Professor and Workshop sessions. Media may use hand-held audio recorders and still cameras; moving video recording is also permitted with the permission of the presenter(s). The exception to this policy is that no photos or video are allowed in the exhibit hall. Press who would like general photos of the exhibit hall can obtain these after the meeting from the ACR. Attendees who have questions about the ACR s media policies should contact Bonny Spurlock at [email protected]. EMBARGO POLICY Accepted abstracts are made available to the public online in advance of the meeting and are published in a supplement of Arthritis & Rheumatism. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the 0 Program Book

14 availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until 4:0 PM Eastern Time on Saturday, October 6, 0. Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. MEETING INFORMATION Cell Phones, PDAs & Other Electronic Devices As a courtesy to meeting attendees, electronic devices must be operated in silent/vibrate mode within educational sessions; devices that beep, ring, etc. are prohibited. Cell phone conversations are not permitted in meeting rooms. Children For safety reasons, strollers are not permitted in the exhibit hall and all children must be accompanied by an adult. Only registered attendees will be permitted into meeting rooms. Child Care KiddieCorp is providing childcare services for our attendees during meeting hours. If you did not reserve space in advance, you can inquire about space availability by calling (858) Nursing Mothers Room During scientific session hours, a staffed Nursing Mothers room will be available in room 7A. This room will have a private seating area, a refrigerator and a bulletin board for information exchange, advice and suggestions. Registration Registration counters are located in the registration hall (Sails Pavilion). Registration Hours Friday, October 5...6:0 am - 6:00 pm Saturday, October 6...6:0 am - 6:0 pm Sunday, October 7...6:0 am - 6:00 pm Monday, October 8...7:00 am - 6:00 pm Tuesday, October 9...7:00 am - 6:00 pm Wednesday, October 0...7:00 am - :00 pm Exhibit Hall Located in Exhibit Hall F-G, you will find the latest technology and services demonstrated or on display in the exhibit hall. Exhibit Hall hours: Sunday, October :00 AM 5:00 PM Monday, October :00 AM 5:00 PM Tuesday, October :00 AM :0 PM Meeting Room Capacity/Important Fire Safety Information Attendance at scientific sessions is on a first-come, first-served basis. Rooms which have reached the maximum capacity may be closed according to local fire and safety regulations. Standing in the aisle or against the walls is not permitted. If overcrowding occurs, staff/security personnel will close the session. If space does not permit you to attend a session, the session may be available on SessionSelect or replayed in the SessionSelect Lounge located in the Hall D Lobby of the convention center. Photography and Videotaping Photographers will be present at the meeting. Registration and attendance at, or participation in, ACR meetings and other activities constitutes an agreement by the registrant for the ACR s use and distribution (both now and in the future) of the registrant or attendee s image or voice in photographs, videotapes, electronic reproductions, and audio tapes of such events and activities. Visual reproduction of sessions is prohibited without prior written permission of the ACR. The ACR reserves the rights to audio and video reproduction at the 0 ACR/ARHP Annual Meeting. See copyrighted materials policy for more information on page. Name Badges For security reasons, your badge will be required for admittance to all sessions, exhibits, social events and shuttle buses. Please wear your badge so it can be easily seen at all times. Lost badges should be reported to the registration staff immediately. No Smoking All meeting facilities at the convention center, hotel meeting rooms and other venues have been designated as non-smoking areas. 0 Program Book

15 MEETING NAVIGATION GUIDE Use the following track icons to help you identify the most relevant content based on your specialty. PM Basic Science Business/Administration Clinical Practice Clinical Science PAIN MANAGEMENT The ACR designates certain sessions for pain management credit as required by the Medical Board of California (AB487). This designation is identified by the icon shown and will be placed next to the session title. PS PATIENT SAFETY The ACR designates certain sessions that will satisfy patient safety/risk management requirements of the Medical Board of Pennsylvania. This designation is identified by the icon shown and will be placed next to the session title. * Pain management and patient safety tracks are referenced in the Session Tracker and online in My Annual Meeting only. SESSION FORMATS ACR Sessions provide an update on the most recent scientific developments in the field of rheumatology and provide instruction to improve patient care. Developments from other specialties and practical patient management skills will be emphasized. ACR and ARHP Concurrent Abstract Sessions provide a platform for the presentation the most up-to-date basic science and clinical research data in the field of rheumatology. Sessions are grouped by topic or theme and include short oral presentations of high scoring accepted abstracts. Exhibits and Industry-Supported Sessions provide attendees with an opportunity to learn about the latest technological advances in the treatment of rheumatic diseases within the exhibit hall via various exhibitions and non-cme sessions in the Innovation Theater, as well as evening and post-meeting symposia. Meet the Professor Sessions provide an opportunity for interaction and consultation with highly respected professionals who have expertise in a particular area. A separate registration is required. Networking Events provide unique opportunities to socialize and network with peers in smaller group settings. Poster Sessions include accepted abstracts not selected for oral presentation. Poster sessions and arranged by topic/category. Presenters are required to accompany their posters during designated poster presentation times. Pre-Meeting Courses offer attendees, with a specific interest, a unique learning opportunity. A separate registration is required. Study Groups bring together attendees with a common interest in one disease, a group of related disorders, or a specialized field of study for discussion and dissemination of information. Workshops foster hands-on learning, and provide an opportunity for interaction and consultation with highly respected professionals who have expertise in a particular area. A separate registration is required. ARHP Sessions offer educational programs of interest to various health professionals. Concurrent sessions include invited speakers; peer-reviewed programs and lectures; and research and special interest abstract sessions. 0 Program Book

16 ABSTRACT FORMATS Late-Breaking Session features truly late-breaking research. Oral Presentations are the main forum for didactic presentation of original research related to rheumatic diseases. Plenary Sessions highlight abstracts of significant novelty and importance. There will be three theme-based sessions offered. Poster Presentations feature poster displays of abstracts, while facilitating one-on-one interaction between the presenter and the audience. Poster Tours are small groups guided by experts in a particular field. Each tour will highlight selected posters of novel or recent developments within an abstract category. There is no additional cost to participate, although a separate registration is required. ABSTRACT CATEGORIES ACR Basic Science. B cell Biology and Targets in Autoimmune Disease: B-lymphocyte differentiation, B-cell subsets, plasma cells, autoantigens, autoreactive B-cells and tissue injury.. Biology and Pathology of Bone and Joint: joint biology and biochemistry, cartilage and chondrocyte biology, basic studies of osteoarthritis, bone structure and function, bone mineral and matrix, osteoblasts and osteoclasts.. Cytokines, Mediators, Cell-cell Adhesion, Cell Trafficking and Angiogenesis: cytokines, chemokines and their receptors; downstream signaling effects and biologic pathways; cell-cell recognition and adhesion molecules, cell-matrix interactions, matrix characteristics and properties, lymphoid organogenesis. 4. Genetics, Genomics and Proteomics: techniques, strategies and observations related to disease susceptibility 5. Innate Immunity and Rheumatic Disease: dendritic cells, antigen presentation, auto-inflammatory pathogenesis, pattern recognition receptors and their ligands, NK cells, complement and Fc receptors. 6. Pain - Basic Aspects: biology, mechanism and animal models of pain. 7. Pediatric Rheumatology - Pathogenesis and Genetics: pathological, genetic and other laboratory-based aspects of pediatric rheumatology conditions. 8. Rheumatoid Arthritis Animal Models: animal models of inflammatory synovitis, mechanisms and treatment. 9. Rheumatoid Arthritis - Human Etiology and Pathogenesis: genetics, susceptibility loci, etiology and pathogenesis. 0. Spondylarthropathies Psoriatic Arthritis - Pathogenesis, Etiology: etiology and pathogenesis, including genetics, reactive arthritis and animal models.. Systemic Lupus Erythematosus - Animal Models: animal models, mechanisms and treatment.. Systemic Lupus Erythematosus - Human Etiology and Pathogenesis: genetics, susceptibility loci, etiology and pathogenesis.. Systemic Sclerosis, Fibrosing Syndromes and Raynaud s Pathogenesis, Animal Models and Genetics: cellular and molecular mechanisms, biomarkers. 4. T cell Biology and Targets in Autoimmune Disease: T-lymphocyte antigens and subpopulations, cognate interactions, T-lymphocyte activation and proliferation. Clinical 5. Antiphospholipid Syndrome: pathophysiology, presentation and management. 6. Education: research on curriculum design and implementation; educational research projects; and outcomes research on physician and trainee education including associated health training. 7. Epidemiology and Health Services Research: descriptive and/or analytical studies of populations as well as economic analysis; decision making. 8. Fibromyalgia, Soft Tissue Disorders and Clinical Pain Syndromes: regional pain syndromes, pain mechanisms and management, local diseases of muscle, ligament and tendon, fibromyalgia. 9. Health Services Research, Quality Measures and Quality of Care: delivery of care affecting patients with rheumatic disease. 0. Imaging of Rheumatic Diseases: radiography, nuclear medicine, magnetic resonance imaging (MRI), ultrasound and computed tomography (CT).. Infection-related Rheumatic Disease: musculoskeletal manifestations of infectious disease, infectious arthritis and pathogenesis.. Metabolic and Crystal Arthropathies: crystal-induced arthritis, metabolic conditions including endocrine abnormalities.. Miscellaneous Rheumatic and Inflammatory Diseases: rheumatic manifestations and therapy of less common and even rare illnesses not included in other categories (e.g., RSPE, reticulohistiocytosis, SAPHO). 4. Muscle Biology, Myositis and Myopathies: muscle biology, inflammatory and non-inflammatory muscle disease. 4 0 Program Book

17 5. Orthopedics, Low Back Pain and Rehabilitation: orthopedic conditions and interventions, physical medicine techniques and outcomes, sports medicine. 6. Osteoarthritis - Clinical Aspects: patient-oriented studies of osteoarthritis, including treatment, diagnosis and outcomes. 7. Osteoporosis and Metabolic Bone Disease - Clinical Aspects and Pathogenesis: patient-oriented studies of bone structure and integrity and its change in various disease states. 8. Pediatric Rheumatology - Clinical and Therapeutic Aspects: clinical aspects and treatment of inflammatory and non-inflammatory pediatric conditions. 9. Rheumatoid Arthritis - Clinical Aspects: clinical aspects of rheumatoid arthritis. Should not contain any treatment studies. 0. Rheumatoid Arthritis - Small Molecules, Biologics and Gene Therapy: treatment of human rheumatoid arthritis including DMARDs, NSAIDs, glucocorticoids, new potential small molecules, biologics and gene therapy approaches. Human use only.. Sjögren s Syndrome: pathophysiology, presentation and treatment.. Spondylarthropathies and Psoriatic Arthritis - Clinical Aspects and Treatment: small molecule and biologic therapies of spondyloarthropathies, reactive arthritis and psoriatic arthritis.. Systemic Lupus Erythematosus - Clinical Aspects and Treatment: diagnosis, clinical manifestations, outcomes, and treatment, including new small molecules, biologics and gene therapy. Human lupus only. 4. Systemic Sclerosis, Fibrosing Syndromes, and Raynaud s Clinical Aspects and Therapeutics: clinical aspects of these syndromes and of treatments. 5. Vasculitis: genetics, etiology, pathogenesis, polygmatic rheumatica, presentation and management. share scientific findings, controlled studies and other analysis of rheumatology related data. 9. Health Services Research: health care systems and delivery economic evaluations and analysis. Research presentations share scientific findings, controlled studies and other analysis of rheumatology related data. 40. Pediatrics: pediatric practice and patient care. Research presentations share scientific findings, controlled studies and other analysis of rheumatology related data. 4. Psychology/Social Sciences: psychology, social work, social and behavioral factors affecting patients, families and providers. Research presentations share scientific findings, controlled studies and other analysis of rheumatology related data. 4. Rehabilitation Sciences: physical therapy, occupational therapy, exercise programs and other rehabilitation services. Research presentations share scientific findings, controlled studies and other analysis of rheumatology related data. 4. Research Methodology: questionnaire design, new assessment tools and methodology, new analytical techniques, and subject recruitment and retention. Research presentations share scientific findings, controlled studies and other analysis of rheumatology related data. ARHP 6. Clinical Practice/Patient Care: care of patients, practice management, medication monitoring/adherence and behavioral aspects of care. Research presentations share scientific findings, controlled studies and other analysis of rheumatology related data. 7. Education/Community Programs: patient education, professional education, community-based programs and public health programs. Research presentations share scientific findings, controlled studies and other analysis of rheumatology related data. 8. Epidemiology and Public Health: descriptive and analytical studies of health status and health outcomes of populations and patient groups. Research presentations 0 Program Book 5

18 NinEtW he t Hall! Exhibi Discovery Center the Spot for All Things ACR, ARHP and the Foundation! Stop by the Discovery Center to see what s new with the College! We re located in the center of the Exhibit Hall (Booth #4). Within the Discovery Center you can: D emo popular online tools and resources G et details about educational activities in 04 V iew and order the latest poster in the Rodnan Commemorative Gout Print poster series S peak with key representatives from the ACR and ARHP journals H ear about the latest advocacy efforts and learn how you can get involved E nroll in the new ACR Rheumatology Musculoskeletal Ultrasound Certification program H ear about the Foundation s programs and new initiatives Get answers to your coding and billing questions C ollect complimentary product brochures, publications and patient education materials T alk to ACR staff about HIT programs, CME activities, registries, MOC tools and much more! Come discover all the College has to offer you, your patients and your practice at the Discovery Center where the resources you need are all in one place! Discovery Center Hours: Sunday, October :00 am 5:00 pm Monday, October :00 am 5:00 pm Tuesday, October :00 am :0 pm A Take-Away Gift Just for You! Come by the Discovery Center and take home a meeting souvenir get your picture taken with one of the landmarks of San Diego and discover where the 04 ACR/ARHP Annual Meeting will be held!

19 MEETING SERVICES My Annual Meeting Everything You Need, in One Place Search the program, access syllabi, view abstracts, track your CME and retrieve recorded sessions on SessionSelect. See page 9 for more information on SessionSelect. Discovery Center The Spot for All Things ACR, ARHP and the Foundation! Discovery Center Hours: Sunday, October : 0 0 AM 5:00 PM Monday, October : 0 0 AM 5:00 PM Tuesday, October : 0 0 AM :0 PM Located in the center of Exhibit Hall F-G, booth 4, the new Discovery Center is designed to highlight all of the College s exceptional programs and services. ACR s professional staff is on hand to demonstrate online tools and resources, introduce new initiatives of the College that are under way, provide information and answer any questions you may have. The Discovery Center has it all in one place! See page 6 for more information. Look for these specific areas in the Discovery Center: Advocacy Get the most up-to-date information on the legislative and regulatory issues affecting your profession. We have talking points on all ACR legislative priorities and tips on how to get more involved with the ACR s advocacy efforts. You can also receive information on RheumPAC the ACR s political action committee. Education Learn about ACR/ARHP educational offerings and upcoming meetings in 04 and beyond. You can also demo online products, tools and training programs like SessionSelect, Advanced and Fundamentals of Rheumatology Courses and the popular Rheumatology Image Bank. Rheumatology Research Foundation Learn about the latest activities the Foundation is doing to ensure the future of rheumatology. View and order the latest poster in the Rodnan Commemorative Gout Print poster series, hear about Foundation programs and initiatives. Practice Management & Coding Visit with ACR certified coders and practice management experts for any coding, billing, insurance or practice management questions. We have all the resources you need for an efficient rheumatology practice. You can also pick up the latest copy of the ACR s monthly RheumWATCH. Publications The editorial office staff of the Arthritis & Rheumatism and Arthritis Care & Research journals will be available to answer questions concerning online article submission and article review processes for the journals. Simple Tasks Learn how the ACR s Simple Tasks campaign is educating lawmakers, referring physicians and others who influence rheumatology on the severity of inflammatory rheumatic diseases and the importance of rheumatologists and rheumatology health professionals in the treatment of those diseases. You can also learn how you can get involved in the Campaign in Action initiative. Quality & Informatics Learn how enrollment in the Rheumatology Clinical Registry can benefit you by providing hands-on measurement tools and reports that enable you to comparatively assess the quality and outcome of rheumatologic care you provide. Plan on attending interactive demonstrations of this tool offered throughout the meeting. Certification Need help navigating Maintenance of Certification? We have answers to help steer your route to success with the American Board of Internal Medicine s Maintenance of Certification program. An ABIM representative will be on-site to help answer your questions. Musculoskeletal Ultrasound Certification Interested in certifying in ultrasound? The ACR is providing a voluntary pathway for physicians, physician assistants and nurse practitioners who perform ultrasound as part of their practice in rheumatology to demonstrate competence to patients, peers and payers through its first certification program. Career Connection Employers and candidates are encouraged to take advantage of the online Career Connection to post position openings, search nationwide rheumatology career opportunities and much more. On Friday, October 5 from 6:00 9:00 pm, potential employers and candidates can meet in the Indigo Ballroom at the Hilton San Diego Bayfront and enjoy complimentary hors d oeuvres and beverages while discussing career opportunities. During this time employers can distribute handouts, flyers or business cards to potential candidates. aa A Take-Away Gift Just for You! Come by the Discovery Center and take home a meeting souvenir get your picture taken with one of the landmarks of San Diego and discover where the 04 ACR/ARHP Annual Meeting will be held! Membership Booth Located in the Sails Pavilion near Registration, this is the place to go if you want to become a member, pay dues, reinstate your membership, learn more about member benefits and awards, or volunteer to serve on a committee. 0 Program Book 7

20 Lost and Found Found items should be returned to the ACR Office, room A. If you are looking for a lost item, go to the ACR Office or call (69) Newsroom Located in room 6A-B, use of the Newsroom is limited to media representatives with press passes. Attendee Lounge Located in the Sails Pavillion, attendees are welcome to relax and enjoy seating while networking with colleagues, checking , and recharging their laptops or smartphones. Concierge Center Need directions to your next session or interested in discovering all things ACR? Stop by the Concierge Center located in the center of the Sails Pavilion. Staff is on hand to assist you and answer general questions about the annual meeting, ACR/ARHP events, programs, resources and services of the College and we re happy to give directions to your next session, too. Concierge Center Hours: Friday, October : 0 AM 6:00 PM Saturday, October : 0 AM 6:0 PM Sunday, October : 0 AM 6:00 PM Monday, October : 0 0 AM 6:00 PM Tuesday, October : 0 0 AM 6:00 PM Wednesday, October : 0 0 AM :00 PM Shuttle Bus Shuttle service will be provided to and from the San Diego Convention Center and ACR hotels which are designated as non-walking hotels. On Friday, Saturday and Wednesday service operates continuously. On Sunday through Tuesday, service operates from 6:0-0:0 am and :0-6:0 pm. Full shuttle service information will be posted in ACR hotel lobbies, at the shuttle bus entrance of the convention center. Speaker Ready Room Hours: Friday, October : 0 AM 6:00 PM Saturday, October : 0 AM 6:0 PM Sunday, October : 0 AM 6:00 PM Monday, October : 0 AM 8:00 PM Tuesday, October : 0 AM 6:00 PM Wednesday, October : 0 AM :0 PM Wi-Fi Way and Recharge Access Complimentary Wi-Fi access is available in all rooms of the convention center. Recharge areas will be available in the Exhibit Hall F-G, Attendee Lounge (Sails Pavilion) and in large meeting rooms. Rheumatology Research Foundation Donors Lounge Plan to spend time in the Foundation Donors Lounge, located in room 4B-C, and take advantage of special perks! Enjoy a hot breakfast each morning and gourmet afternoon coffee service; catch up on work and check at one of the private computer stations; or relax by watching some television and catching up with your colleagues. An official 0 Donors Lounge Access Pass is required for entry and will be distributed to qualified donors at the meeting. A minimum cumulative donation of $500 to the Rheumatology Research Foundation Annual Giving Campaign during fiscal year 0 (July, 0 through June 0, 0) qualifies. Donors Lounge Hours: Saturday, October 6... Noon 5:00 PM Sunday, October : 0 0 AM 6:00 PM Monday, October : 0 0 AM 6:00 PM Tuesday, October : 0 0 AM 6:00 PM Wednesday, October : 0 0 AM :0 PM This service is complimentary for attendees and registered guests who booked their rooms through ACR Housing. Attendees who have booked their rooms on their own in contracted or noncontracted ACR hotels may purchase an ACR shuttle bus pass at the ACR registration counter for $40. Speaker Ready Room Located in room. Check-in is expected of all speakers. Plan to check in hours prior to your presentation time. In the Speaker Ready Room, you can review your presentation and approve the file to be uploaded to the central server. Professional audiovisual technicians will be available to assist you. Computers in the Speaker Ready Room will be configured with hardware and software exactly like the ones in the meeting rooms and will allow you to preview your presentation, identify problems and make corrections as necessary before your presentation. 8 0 Program Book

21 Get On-Demand Annual Meeting Education with SessionSelect! ATTENDEE BONUS! Your annual meeting registration fee gives you FREE access to the online content of the 0 annual meeting for one year! SessionSelect is a comprehensive digital library of recorded presentations from the annual meeting. Within 4 hours of virtually every live session, you can view fully-synchronized presentations with speaker slides and audio just as if you were actually in the room. Take advantage of the most convenient way to experience the education from the annual meeting at your own pace. With SessionSelect you can: Stay up to date on the most relevant information and research pertaining to rheumatic diseases Apply session information to your practice to enhance your knowledge, competence and performance View content on your mobile device or download MP files for listening to audio on-the-go SessionSelect Lounge No Need to Miss a Session While You re Onsite! Got some down time between sessions? Relax while you replay sessions at your convenience on dedicated computer terminals. Location: Hall D Lobby Hours: Monday, October 8...7:00 am 6:00 pm Tuesday, October 9...7:00 am 6:00 pm Wednesday, October 0...7:00 am :00 pm To learn more about SessionSelect or to view a demo, come by the Discovery Center, located in the Exhibit Hall F-G (Booth #4) or the Concierge Center, located in the Sails Pavilion. Recordings of individual sessions are subject to change. Ticketed sessions and pre-meeting courses are not included in complimentary access.

22 SPECIAL OFFERS AT THE ANNUAL MEETING SessionSelect no need to miss a session! Within 4 hours of virtually every live session at the annual meeting, video recordings of the presentations, including oral abstracts, will be available through SessionSelect. As an attendee benefit, you get FREE online access for one year to hundreds of hours of annual meeting content over $500 of added value. SessionSelect Lounge Need something to do between sessions? Relax while you replay sessions at your convenience on dedicated computer terminals. The SessionSelect lounge is located in the Hall D Lobby SessionSelect Lounge Hours: Monday, October : 0 0 AM 6:00 PM Tuesday, October : 0 0 AM 6:00 PM Wednesday, October : 0 0 AM :00 PM Please note; recordings of individual sessions are subject to change. Ticketed sessions and pre-meeting courses are not included in complimentary access. CME credit is not available for viewing 0 sessions online. What Would Make This Meeting Better? You ve got ideas to share, and we ve made it easy for you to share them. Post a suggestion on one of the graffiti walls for all to see. Tweet your idea using the #ACR hashtag. Drop a comment into one of the idea boxes around the convention center. Medical Bag Don t forget to pick up a Medical Bag prior to visiting the exhibits. Each bag contains special offers and invitations from our exhibitors and will be distributed from the exhibition entrance while supplies last. POSTER SESSIONS Poster presentations facilitate one-on-one interaction between the presenters and attendees. Posters are grouped by topic and will remain displayed in the poster hall (Exhibit Hall B-C-D) from 8:0 AM - 4:00 pm, Sunday, October 7 - Tuesday, October 9. One poster session will be held each day. There is no poster session on Wednesday. The number on the poster boards refers to the abstract presentation number, and this number will change for each poster session. NEW THIS YEAR! Poster presentations will be unopposed during the 0:00 :00 am hour. ARHP abstracts will be incorporated with ACR abstracts by topic area. A new ACR basic science category entitled Pain: Basic Aspects has been added. Posters must be mounted by 8:0 am of the designated poster session and dismantled after 4:00 pm as outlined in the abstract acceptance notification. Posters not dismantled by 5:00 PM each day will be recycled. Poster storage will not be available in the poster hall. In order to ensure a positive experience for both attendees and poster presenters, it is important to make sure that all posters are properly mounted and presenters are present from 9:00 - :00 am for poster presentations and to answer questions from attendees. Poster presenter ribbons will be available in the Speaker Ready Room (room ). Poster Presenter No-shows Please note: The ACR will be monitoring posters during the presentation hours in an effort to make certain the College is meeting the educational needs and expectations of attendees. Poster Sessions - Sunday, October 7 through Tuesday, October 9 from 9:00 am - 4:00 pm Set Up:... 7:00 8:0 AM Presentation: :00 :00 AM Poster Tours:... 9:00 9:45 AM 0:5 :00 AM Posters to remain up until 4:00 pm Poster pick up:... 4:00 6:0 PM ACR Removal:... 6:0 PM* * The ACR will remove and promptly recycle all posters not picked up by 6:0 pm each day. Guided Poster Tours Guided poster tours, led by experts in the field, will guide small groups of attendees during the poster presentation times to highlight novel or recent developments. Selected posters from various abstract categories will be included in the tours. Although there is no fee to participate, pre-registration is required and each tour is limited to 0 registered scientific attendees. If you would like to participate and have not registered you can check tour availability and request a ticket at registration, located in the Sails Pavilion or the My Annual Meeting website. If you registered in advance of the meeting your ticket is located on the back of your name badge. Once you have your ticket, it is important that you collect your headset and meet your group 0 minutes before your tour departs from the entrance of the poster hall, located in Exhibit Hall B-C-D. Poster tour reservations will be released to stand-by attendees 5 minutes before the tour. 0 0 Program Book

23 Submission Deadline: Friday, November, 0 at noon. ACR/ARHP 04 Annual Meeting Call for Proposals and Study Group Applications Share your ideas and make a contribution to the 04 Annual Meeting program. To make a suggestion or submit a session proposal, visit Coordinate a study group and create a unique networking opportunity for your colleagues. To view the guidelines and submit an application, visit FRIDAY october 5, 0 acr/arhp scientific SESSIONS FRIDAY, OCTOBER 5, 0 ACR MUSCULOSKELETAL ULTRASOUND COURSE FOR RHEUMATOLOGISTS DAY ONE 7:45 AM - 5:0 PM 6 A-B Admission to the ACR Musculoskeletal Ultrasound Course for Rheumatologists requires a separate registration. Registration includes complimentary continental breakfast and a boxed lunch. Moderator: Amy M. Evangelisto, MD Faculty: Rany Al Haj, MD; Maria Barilla-LaBarca, MD; Jurgen Craig-Muller, MD; Paul DeMarco, MD; Amy Evangelisto, MD; Jay Higgs, MD; Gurjit Kaeley, MBBS, MRCP; Eugene Kissin, MD; Minna Kohler, MD; Gary Kunkel, MD; Daniel Malone, MD; Bethany Marston, MD; Jane Nishio, MD; Anthony Reginato, MD; Johannes Roth, MD; Jonathan Samuels, MD; Darren Tabechian, MD; Siddarth Tambar, MD; Karina Torralba, MD; Alicia Weeks, MD; Alvin Wells, MD, PhD demonstrate proper ultrasound exam technique and procedure guidance applying standardized protocols identify and describe normal sonographic anatomy and fundamental pathology for rheumatology indications explain the requirements for documentation related to musculoskeletal ultrasound 6:0-7:45 am Continental Breakfast 7:45-8:00 am Opening Remarks Amy M. Evangelisto, MD 8:00-8:0 am Principles of Musculoskeletal Ultrasound for Rheumatologists Jay B. Higgs, MD denotes Hilton San Diego Bayfront room location 0 Program Book

24 FRIDAY october 5, 0 8:0-9:5 am Introduction to Typical Sonographic Findings and Tissue Characteristics in Rheumatology Johannes Roth, MD 9:5-9:0 am Morning Break :00 pm Demonstration: Scanning of the Shoulder Gurjit S. Kaeley, MBBS, MRCP :5 pm Hands-on Scanning: The Shoulder All Faculty 9:0 - :0 am Hand and Wrist 9:0 am Lecture: Standard Scans, Sonographic Anatomy and Basic Sonographic Pathology Minna J. Kohler, MD 0:00 am Demonstration: Scanning of the Hand and Wrist Minna J. Kohler, MD 0:5 am Hands-on Scanning: The Hand and Wrist All Faculty :0 am - :0 pm Boxed Lunch :0 - :5 pm The Elbow :0 pm Lecture: Standard Scans, Sonographic Anatomy, and Basic Sonographic Pathology Amy M. Evangelisto, MD :00 pm Demonstration: Scanning of the Elbow Amy M. Evangelisto, MD :5 pm Hands-on Scanning: The Elbow All Faculty :5 - :0 pm Afternoon Break :0-4:0 pm The Shoulder :0 pm Lecture: Standard Scans, Sonographic Anatomy, and Basic Sonographic Pathology Gurjit S. Kaeley, MBBS, MRCP 4:0-5:0 pm Pediatrics 4:0 pm Lecture: Pediatric Anatomy in Musculoskeletal Ultrasound Johannes Roth, MD 5:00 pm Hands-on Scanning: The Upper Extremity in Pediatrics Johannes Roth, MD and Bethany A. Marston, MD ACR CERTIFIED RHEUMATOLOGY CODER COURSE: THE ANATOMY OF RHEUMATOLOGY CODING 9:00 AM - 5:00 PM A-B Admission to the ACR Certified Rheumatology Coder Course requires a separate registration. Registration includes complimentary continental breakfast and a boxed lunch. This course is not eligible for CME credit. Speakers: Antanya Chung, CPC, CPC-I, CRHC, CCS-P and Melesia Tillman, CPC, CPC-I, CRHC, CHA exhibit ability in adjudicating claims for accurate medical coding of diagnoses, procedures and services in physicianbased settings display proficiency across a wide range of services, which include evaluation and management, surgical services, radiology, pathology and medicine demonstrate knowledge of medical coding rules and regulations including compliance and reimbursement. A trained medical coding professional can better handle issues such as medical necessity, claims denials, bundling issues and charge capture distinguish how to integrate medical coding and reimbursement rule changes into a practice s reimbursement processes 0 Program Book denotes Hilton San Diego Bayfront room location

25 8:00-9:00 am Continental Breakfast 9:00-0:00 am Presentation/Discussion 0:00-0:5 am Morning break 0:5 am - Noon Presentation/Discussion Noon - :00 pm Boxed Lunch :00 - :00 pm Presentation/Discussion :00 - :5 pm Afternoon Break :5-5:00 pm Presentation/Discussion :00 - :45 pm Key Note Lecture: Epigenetics and Human Disease Speaker: Tomas J. Ekström, PhD :45-4:5 pm Session I: Overview of General Principles Moderator: Robert M. Plenge, MD, PhD :45 pm X Chromosome Inactivation Huntington F. Willard, PhD :5 pm Epigenetics and Twins Eric Gershwin, MD :45 pm Epigenetics of Immune Development John J. O Shea, MD :5 - :0 pm Afternoon Break :0 pm Transcription Factor Binding Motifs and ChIP-seq Christina Leslie, PhD 4:00 pm Questions and Answers FRIDAY october 5, 0 ACR BASIC RESEARCH CONFERENCE: BEYOND GERMLINE GENETICS: NEW PERSPECTIVES ON RHEUMATIC DISEASE PREDISPOSITION DAY ONE :00-6:00 PM 6 A Admission to the Basic Research Conference requires a separate registration. describe underlying principles and evidence demonstrating the inheritance of susceptibility by factors outside of the genetic encoding sequences examine the molecular factors and regulatory organizing factors responsible for these epigenetic pathways describe disease states that arise independent of the influence of genetic independent variants consider why genetically identical individuals may display differences in phenotype and disease discordance 4:5-6:00 pm Session II: Non-encoding RNA and Methylation in the Regulation of the Rheumatic Diseases Moderator: Susan A. Boackle, MD 4:5 pm MicroRNA 46a in Autoimmunity and Innate Immune Responses Edward K.L. Chan, PhD 4:45 pm MiR Regulation of DUSPs and Myeloid Cell Differentiation Gary S. Stein, PhD 5:5 pm Epigenetic Regulation of Inflammation in Rheumatic Diseases Lionel B. Ivashkiv, MD 5:45 pm Questions and Answers 6:00-7:00 pm Networking Reception Networking reception combined with ACR Clinical Research Conference participants. denotes Hilton San Diego Bayfront room location 0 Program Book

26 FRIDAY october 5, 0 ACR CLINICAL RESEARCH CONFERENCE: PRECLINICAL RHEUMATIC DISEASE DAY ONE :00-6:00 PM 6 D Admission to the ACR Clinical Research Conference requires a separate registration. explain issues pertaining to the nomenclature and definitions of preclinical rheumatic diseases discuss the immunologic changes known to be occurring in preclinical rheumatic diseases, and identify potential novel biomarkers that can be assessed in preclinical disease outline the current knowledge regarding the role of environmental factors and mucosal biology in the preclinical period of rheumatic disease development discuss the current understanding of the prediction of future onset rheumatic disease in individuals who currently do not have clinically-apparent disease discuss the role of imaging in preclinical rheumatic disease discuss potential approaches for the prevention of rheumatic disease identify several key future directions for research into the preclinical phases of rheumatic diseases discuss cutting-edge research pertaining to preclinical rheumatic diseases presented through oral abstract presentations :00 - :0 pm Session I: Introduction to Preclinical Rheumatic Disease Moderators: Kevin D. Deane, MD, PhD and Karen H. Costenbader, MD, MPH :00 pm Defining the Phases of Development of Rheumatic Diseases: Lessons From Rheumatoid Arthritis Karim Raza, MD, PhD :45 pm Why is Study of the Preclinical Phases of Rheumatic Disease Important? V. Michael Holers, MD :5 pm Questions and Answers :45-4:00 pm Session II: Immunology of Rheumatoid Arthritis and Systemic Lupus Erythematosus During the Pre-clinical Phase of Disease Development Moderator: V. Michael Holers, MD :45 pm Evolution of Rheumatoid Arthritis-related Autoantibody Responses During the Preclinical Phase of Rheumatoid Arthritis-related Autoimmunity Solbritt M. Rantapaa-Dahlqvist, MD, PhD :5 pm Autoantibodies in the Evolution of Systemic Lupus Erythematosus John B. Harley, MD, PhD 4:00-6:00 pm Session III: The Role of Environmental Factors in the Development of Autoimmunity Moderator: Jill M. Norris, MPH, PhD 4:00 pm Genetic and Environmental Factors and Risk for Systemic Lupus Erythematosus Christine G. Parks, PhD 4:0 pm Genetic and Environmental Factors in the Prediction of Risk for Future Onset of Rheumatoid Arthritis Hani S. El-Gabalawy, MD 5:00 pm Genetic and Environmental Factors and Risk for Seronegative Spondylarthropathies Robert A. Colbert, MD, PhD 5:0 pm Questions and Answers 5:45 pm Wrap-up Jill M. Norris, MPH, PhD 6:00-7:00 pm Networking Reception Networking reception combined with ACR Basic Research Conference participants. :0 - :45 pm Afternoon Break 4 0 Program Book denotes Hilton San Diego Bayfront room location

27 ACR/ABIM MAINTENANCE OF CERTIFICATION LEARNING SESSION 0 UPDATE IN RHEUMATOLOGY :00-6:00 PM A Admission to the ACR/ABIM Maintenance of Certification Learning Session requires a separate registration. Learn in an interactive environment as clinical experts lead you through 0 case-based questions from ABIM s 0 Update in Rheumatology Module. After the session, submit your answers online to the ABIM to receive 0 medical knowledge points for the Maintenance of Certification program. Moderator: Carol A. Langford, MD, MHS assess strengths and weaknesses in rheumatology medical base knowledge state major developments in rheumatology over the past ten years satisfy a self-evaluation requirement for the American Board of Internal Medicine Maintenance of Certification program :00 - :0 pm Overview :0 - :40 pm Session I: Questions From 0 Update Speaker: Seetha U. Monrad, MD :40 - :00 pm Break SATURDAY, OCTOBER 6, 0 ACR MUSCULOSKELETAL ULTRASOUND COURSE FOR RHEUMATOLOGISTS DAY TWO 7:5 AM - 5:0 PM 6 A-B Admission to the ACR Musculoskeletal Ultrasound Course for Rheumatologists requires a separate registration. Registration includes complimentary continental breakfast and a boxed lunch. Moderator: Amy M. Evangelisto, MD Faculty: Rany Al Haj, MD; Maria Barilla-LaBarca, MD; Jurgen Craig-Muller, MD; Paul DeMarco, MD; Amy Evangelisto, MD; Jay Higgs, MD; Gurjit Kaeley, MBBS, MRCP; Eugene Kissin, MD; Minna Kohler, MD; Gary Kunkel, MD; Daniel Malone, MD; Bethany Marston, MD; Jane Nishio, MD; Anthony Reginato, MD; Johannes Roth, MD; Jonathan Samuels, MD; Darren Tabechian, MD; Siddarth Tambar, MD; Karina Torralba, MD; Alicia Weeks, MD; Alvin Wells, MD, PhD demonstrate proper ultrasound exam technique and procedure guidance applying standardized protocols identify and describe normal sonographic anatomy and fundamental pathology for rheumatology indications explain the requirements for documentation related to musculoskeletal ultrasound 6:0-7:5 am Continental Breakfast FRIDAY october 5, 0 SATURDAY october 6, 0 :00-4:0 pm Session II: Questions From 0 Update Speaker: Kristine M. Lohr, MD, MS 4:0-6:00 pm Session III: Questions From 0 Update Speaker: Carol A. Langford, MD, MHS 7:5 am Opening Remarks Amy M. Evangelisto, MD 7:0-9:5 am The Hip 7:0 am Lecture: Standard Scans, Sonographic Anatomy, and Basic Sonographic Pathology Jonathan Samuels, MD 8:00 am Demonstration: Scanning of the Hip Jonathan Samuels, MD 8:5 am Hands-on Scanning: The Hip All Faculty 9:5-9:0 am Morning Break denotes Hilton San Diego Bayfront room location 0 Program Book 5

28 9:0 - :0 am The Knee 9:0 am Lecture: Standard Scans, Sonographic Anatomy, and Basic Sonographic Pathology Gary A. Kunkel, MD 5:00-5:0 pm Pediatrics 5:00 pm Hands-on Scanning: Pediatrics Johannes Roth, MD and Bethany A. Marston, MD SATURDAY october 6, 0 0:00 am Demonstration: Scanning of the Knee Gary A. Kunkel, MD 0:5 am Hands-on Scanning: The Knee All Faculty :0 am - :0 pm Boxed Lunch :0 - :0 pm Foot and Ankle :0 pm Lecture: Standard Scans, Sonographic Anatomy, and Basic Sonographic Pathology Minna J. Kohler, MD :00 pm Demonstration: Scanning of Foot and Ankle Minna J. Kohler, MD :5 pm Hands-on Scanning: Foot and Ankle All Faculty :0 pm Lecture: Billing, Coding and Report Generations Paul J. DeMarco, MD :00 - :5 pm Afternoon Break :5 pm Lecture: Evidence Base and Technique Guidance of Procedures Eugene Y. Kissin, MD :45 pm Panel Discussion: Implementing Musculoskeletal Ultrasound in the Practice of Rheumatology Amy M. Evangelisto, MD; Eugene Y. Kissin, MD; Darren Tabechian, MD and Alvin F. Wells, MD, PhD ACR CLINICAL RESEARCH CONFERENCE: PRECLINICAL RHEUMATIC DISEASE DAY TWO 7:0 am - 4:0 pm 6 D Admission to the ACR Clinical Research Conference requires a separate registration. Registration includes complimentary continental breakfast and a boxed lunch. explain issues pertaining to the nomenclature and definitions of preclinical rheumatic diseases discuss the immunologic changes known to be occurring in preclinical rheumatic diseases, and identify potential novel biomarkers that can be assessed in preclinical disease outline the current knowledge regarding the role of environmental factors and mucosal biology in the preclinical period of rheumatic disease development discuss the current understanding of the prediction of future onset rheumatic disease in individuals who currently do not have clinically-apparent disease discuss the role of imaging in preclinical rheumatic disease discuss potential approaches for the prevention of rheumatic disease identify several key future directions for research into the preclinical phases of rheumatic diseases discuss cutting-edge research pertaining to preclinical rheumatic diseases presented through oral abstract presentations 6:0-7:0 am Continental Breakfast 7:0 am Introduction Kevin D. Deane, MD, PhD 7:40-9:0 am Session IV: Mucosal Biology in the Etiology of Rheumatic Moderator: Ted R. Mikuls, MD, MSPH 4:5 pm Hands- Scanning: Ultrasound Injection Guidance With Phantoms All Faculty 7:40 am The Microbiome and Initiation and Propagation of Rheumatoid Arthritis Jose U. Scher, MD 8:0 am Mucosal Inflammatory Responses and the Seronegative Spondyloarthropathies Charles O. Elson, MD 6 0 Program Book denotes Hilton San Diego Bayfront room location

29 8:40 am Lung Inflammation and the Development of Rheumatoid Arthritis -related Autoimmunity Anca Catrina, MD, PhD 9:0-9:0 am Morning Break 9:0 - :0 am Session V: Predicting Future Clinically-apparent Rheumatic Moderator: Leonid Padyukov, MD, PhD 9:0 am Prediction of Future Onset of Rheumatoid Arthritis in Individuals Without Current Inflammatory Arthritis Dirkjan van Schaardenburg, MD, PhD 0:00 am Screening Populations for Those At-risk for Future Disease: Promises and Pitfalls Ned Calonge, MD, MPH 0:45 am Questions and Answers :00 am Abstract Presentations :00 pm Modification of Autoimmunity to Prevent Persistent Rheumatoid Arthritis in At-risk Individuals: What does Treatment of Early Rheumatoid Arthritis tell us about Possible Prevention? Axel Finckh, MD, PD :0 pm Prevention Trials in TDM What Lessons Can We Learn for Rheumatic Diseases? Aaron Michels, MD :00 pm Afternoon Break :5 pm Tolerization for Rheumatic Diseases Ranjeny Thomas, MBBS, MD :45-4:0 pm Session VIII: Summing Moderators: Kevin D. Deane, MD, PhD and Karen H. Costenbader, MD, MPH Speaker: Lars Klareskog, MD, PhD 4:5 pm Questions and Answers SATURDAY october 6, 0 :0 am - :0 pm Boxed Lunch :0 - :00 pm Session VI: Detecting Early Organ Injury in Preclinical Rheumatic Moderator: Sherine E. Gabriel, MD, MSc :0 pm Symptom Assessment and Joint Examination in Pre-clinical Rheumatoid Arthritis: How to Assess in an Accurate, Valid and Reproducible Fashion? Vivian P. Bykerk, MD :00 pm Imaging and Identification of Inflammatory Joint Disease in Pre-clinical Rheumatoid Arthritis: Can We do Better than a Physical Examination? Lisa A. Mandl, MD, MPH :0 pm Is Pre-clinical Autoimmunity Benign? Darcy S. Majka, MD :00 - :45 pm Session VII: Preventing the Development of Clinicallyapparent Rheumatic Disease Moderator: Kevin D. Deane, MD, PhD ACR REVIEW COURSE 8:00 am - 4:00 pm Hall B Admission to the ACR Review Course requires a separate registration. Registration includes complimentary continental breakfast and a boxed lunch. Moderators: Kristine M. Lohr, MD, MS and Virginia D. Steen, MD 6:0-8:00 am Continental Breakfast 8:00 am Update on Juvenile Idiopathic Arthritis: Adolescence and Beyond Peter A. Nigrovic, MD define the clinical subtypes of juvenile idiopathic arthritis recognize special problems of arthritis in a child manage patients with juvenile idiopathic arthritis through their transition to adult rheumatology care 8:45 am Update on Systemic Sclerosis Richard M. Silver, MD describe the appropriate diagnostic, staging and screening procedures for different organ systems in scleroderma review recent treatment advancements for skin and organ involvement report the potential for future treatments for scleroderma, including stem cell, biologics newer agents denotes Hilton San Diego Bayfront room location 0 Program Book 7

30 SATURDAY october 6, 0 9:0 am Rheumatic Diseases and Pregnancy Megan E. B. Clowse, MD, MPH detect rheumatic disease activity in pregnancy describe the impact of increased rheumatic disease activity on obstetric outcomes manage contraception and pregnancy in the rheumatologic diseases 0:5-0:45 am Morning Break 0:45 am Psoriatic Arthritis: Is There a New Treatment Paradigm? Christopher T. Ritchlin, MD, MPH perform a more complete evaluation of psoriatic arthritis and distinguish key features in these patients that differ from other forms of inflammatory arthritis manage both the articular and non-articular features of psoriatic arthritis with a clear understanding of how treatment differs from strategies applied in rheumatoid arthritis cite evidence regarding the efficacy and safety of pipeline agents to treat psoriatic arthritis and describe how these new therapies will influence treatment paradigms in the near future :0 am Osteoarthritis: Current and Future Treatment Joanne M. Jordan, MD, MPH describe the epidemiology and risk factors for osteoarthritis identify current treatment and management approaches to osteoarthritis outline future directions of osteoarthritis treatment and how close we are to real treatment :5 - :5 pm Boxed Lunch :45 - :5 pm Afternoon Break :5 pm Hypercoagulable States in Rheumatic Diseases Robert Roubey, MD develop a rational diagnostic approach to common hypercoagulable states, with a focus on antiphospholipid syndrome discuss presence of antiphospholipid antibodies with no clinical events manage treatment and prevention of thrombosis in rheumatic diseases ACR BASIC RESEARCH CONFERENCE: BEYOND GERMLINE GENETICS: NEW PERSPECTIVES ON RHEUMATIC DISEASE PREDISPOSITION DAY TWO 8:00 am - 4:0 pm 6 A Admission to the ACR Basic Research Conference requires a separate registration. Registration includes complimentary continental breakfast and a boxed lunch. describe underlying principles and evidence demonstrating the inheritance of susceptibility by factors outside of the genetic encoding sequences examine the molecular factors and regulatory organizing factors responsible for these epigenetic pathways describe disease states that arise independent of the influence of genetic independent variants consider why genetically identical individuals may display differences in phenotype and disease discordance 7:00-8:00 am Continental Breakfast :5 pm Use of Opioids in Chronic Pain Management Mark S. Wallace, MD recognize the biologic effects of opioid use describe adverse effects associated with long-term opioid use construct a rational management plan for chronic nonmalignant pain :00 pm Morbidity of Rheumatic Disease Therapy (DMARDs and Biologics) Clifton O. Bingham III, MD describe the appropriate screening and immunization prior to initiating treatment in rheumatoid arthritis describe the different complications associated with the use of DMARDS and biologics in treatment of rheumatoid arthritis describe the risk factors associated with various morbidities with the use of these agents 8:00 am - :00 pm Session III: Epigenetics of Autoimmune Disease Moderator: Gregg J. Silverman, MD 8:00 am Epigenetic Marks and Genome-wide Association Study Soumya Raychaudhuri, MD, PhD 8:0 am Epigenetics of Rheumatoid Arthritis Gary S. Firestein, MD 9:00 am The Interaction of Acetylation, Methylation, Sumoylation and Medical International Research (mir) in Rheumatoid Arthritis Steffen Gay, MD 8 0 Program Book denotes Hilton San Diego Bayfront room location

31 9:0-0:00 am Morning Break :45 pm Abstract Presentations 0:00 am Epigenetics and Systemic Lupus Erythematosus Bruce C. Richardson, MD, PhD 0:0 am MicroRNA Expression Profiles in Sjögren s Syndrome Ilias Alevizos, DMD :5 am Epigenetics and Systemic Sclerosis Timothy Radstake, MD :45 am Questions and Answers Noon - :45 pm Boxed Lunch :45 - :5 pm Session IV: Cartilage, Bone and Related Tissues Moderator: Michael H. Pillinger, MD :45 pm Epigenetics and Bone Biology Jane Lian, PhD :5 pm Epigenetics and Cartilage Biology Mary B. Goldring :45 pm MicroRNA and Arthritis Hiroshi Asahara, MD :5-4:0 pm Session V: Therapeutics Targeting Non-genetic Moderator: Soumya Raychaudhuri, MD, PhD :5 pm MicroRNA as Agents for Therapeutic Targeting in the Rheumatic Diseases Mathieu Lupien, PhD :45 pm Novel Experimental Therapies for Inflammatory Arthritis Charles J. Malemud, PhD :5 pm Questions and Answers 4:5 pm Wrap-up ARHP CLINICAL FOCUS COURSE: MEETING THE CHALLENGES OF MEASURING OUTCOMES IN RHEUMATOLOGY CLINICAL PRACTICE 8:00 am - 4:0 pm A-B Admission to the ARHP Clinical Focus Course requires a separate registration. Registration includes complimentary continental breakfast and a boxed lunch. Moderator: Patricia P. Katz, PhD explain the importance of outcomes measurement determine which outcomes are appropriate to focus on integrate information from different outcomes measurements address challenges in outcomes measurement identify current and projected future uses of outcomes measurement summarize trends in outcomes measurement 6:0-8:00 am Continental Breakfast 8:00 am Overview of the Day: Meeting the Challenges of Measuring Outcomes Patricia P. Katz, PhD 8:5 am Why Measuring Outcomes Is Important Alison Hoens, BSc(PT), MSc 9:00-9:45 am Challenge : What Measure to Use: Selecting Measures for Community Standards Using Rheumatoid Arthritis as an Example 9:00 am History of the Process and Methods Mark L. Robbins, MD, MPH 9:0 am Getting to the Answer Salahuddin Kazi, MD SATURDAY october 6, 0 :0 - :45 pm Afternoon Break 9:45-0:00 am Morning Break denotes Hilton San Diego Bayfront room location 0 Program Book 9

32 0:00 - :00 am Challenge : Which Outcomes to Focus on: Evaluating Outcomes in Conditions With Multiple Manifestations Using Fibromyalgia as an Example :05 pm Using Outcomes Measures for Quality Assessment and Improvement Jinoos Yazdany, MD, MPH SATURDAY october 6, 0 0:00 am Defining the Important Domains and Measures David A. Williams, PhD 0:0 am Integrating and Interpreting the Results Mary-Ann Fitzcharles, MBChB, MD :00 am - :00 pm Challenge : Which Perspective: The Joint, the Person, or Both? Using Rehabilitation as an Example :00 am The Joint Carol A. Oatis, PT, PhD :5 am The Person Catherine L. Backman, PhD, FCAOT :5 pm Panel Discussion 4:5-4:0 pm Concluding Remarks Speaker: Patricia P. Katz, PhD ACR PRACTICE MANAGEMENT PRE-MEETING COURSE 8:00 am - 5:00 pm A Admission to the Practice Management Pre-meeting Course requires a separate registration. Registration includes complimentary continental breakfast and a boxed lunch. Moderators: Elizabeth Perkins, MD, Melissa Francisco and Melesia Tillman, CPC :50 am Panel Discussion :00 - :45 pm Boxed Lunch :45 - :45 pm Challenge 4: How to Include Everyone? Evaluating Outcomes in Vulnerable Populations :45 pm Minority Populations Maria E. Suarez-Almazor, MD, PhD :5 pm Limited Literacy/Numeracy Jennifer Barton, MD :45 - :0 pm Challenge 5: Can New Technologies Be Used? :45 pm New Technology Jennifer N. Stinson, PhD, RN, CPNP :05 pm Medical Informatics C. J. Inman, MD, MS :0 - :45 pm Afternoon Break :45 - :0 pm Challenge 6: What Do We Do With the Results? :45 pm Using Outcomes Measures in Clinical Practice Dorcas Beaton, PhD 6:0-8:00 am Continental Breakfast 8:00 am Lean-measuring Culture to Improve Performance Kristina Hahn, MHA understand the five principles of lean understand how to implement lean initiatives and how to measure success identify resources on sustaining, managing and communicating goals evaluate how lean increases staff efficiency 9:5 am Transitioning to ICD-0 Shelly Cronin, CPC, CPC-I, CPMA, CPPM, CANPC, CGSC, CGIC review the conversion challenges and successes and discuss best practices to adopt during implementation process identify tracking mechanism to secure accurate and timely reimbursement discuss how to maximize the resources available via your practice management and EHR system evaluate the training requirements and needs for your staff and physicians 0:00-0:5 am Morning Break 0:5 - :00 am Emotional Intelligence-Being an Effective Leader Melvin Smith, PhD explain the value of an emotionally intelligent leader develop awareness of your own emotional intelligence identify your leadership style recognize the keys to successful leadership 0 0 Program Book denotes Hilton San Diego Bayfront room location

33 :00 am Human Resource Management Linda D Spain, CMPE, CMCO, CMC, CMIS, CMOM discuss the legal environment of human resource management, to include employee handbook and personnel files evaluate and discuss how to establish, upgrade positions, salary and benefits discuss the hiring, performance appraisals and termination process evaluate your staffing needs :00 - :00 pm Boxed Lunch :00 pm Strategic Planning-How to Succeed in an Environment of Transition Audrey Coaxum, CHI, CMCO, CMC, CMIS, CMOM discuss the importance financial planning has on protecting the livelihood of your practice discuss SWOT (strength, weakness, opportunities and threats) analysis impact during and environment of transition evaluate how in-office accounting, such as, accounts receivables, payables and payroll impact the practice s strategic plan discuss the impact federal regulations and reporting requirements have on the practice :00 pm Streamlining Accounts Receivables: Mastering the Revenue Cycle Maxine Collins, MBA, CPA, CMC, CMIS, CMOM optimize collections at the time of service by improving staffing models and providing staff with the tools and support they need to collect at the time of service identify key revenue components, to include patient financial, charge capture entry, payment posting, account follow-up denial management, patient collections and reimbursement identify discrepancies in reimbursement from insurance carriers identify the reasons for low collections and recognize warning signs to take immediate action to optimize practice revenue. :00 - :0 pm Afternoon Break :0 pm Managing Your Staff: Professional Development-Profitability for the Future NOW! Audrey Coaxum, CHI, CMCO, CMC, CMIS, CMOM discuss how to manage staff professional development evaluate how to use staff s strength and weaknesses and apply staffing models, such as work rotation, segmentation, extension and super training to improve their professional development while staffing for the future now evaluate how to coordinate the practice s needs with staff potential identify the relationship between professional and staff development and the bottom line 4:00 pm Preventing Fraud and Embezzlement Linda D Spain, CMPE, CMCO, CMC, CMIS, CMOM identify high risk areas in the practice daily operations, to include supplies both clinical and clerical and money transactions discuss different checks-and-balance processes required to prevent fraud. discuss key individuals to contact once fraud or embezzlement is detected and proper protocol to document and address ACR/ARHP OPENING LECTURE AND AWARDS 4:0-6:5 pm Ballroom 0 A 4:0 pm ACR Presidential Address 5:00 pm Recognition of 0 ACR Masters Recognition of the 0 ACR Awards of Distinction Recipients Recognition of ARHP Merit Award Recipients Recognition of 0 Distinguished Fellows Awards Recipients Fellows Awards Recognition of Rheumatology Research Foundation Corporate Roundtable Donors 5:0-6:5 pm Opening Lecture: Life at the Speed of Light Speaker: Craig Venter, PhD identify the origins of synthetic life engineering discuss current challenges and controversies of the science of synthetic life engineering outline the projected impacts of human life and our environment ACR/ARHP CHAMPAGNE RECEPTION 6:5-7:0 pm Sails Pavilion Join us as we toast the opening of the 0 ACR/ARHP Annual Meeting and salute you, our guests. Network with your colleagues before you enjoy an evening on your own in San Diego. SATURDAY october 6, 0 denotes Hilton San Diego Bayfront room location 0 Program Book

34 SUNDAY october 7, 0 ACR SESSIONS 7:0-8:0 am 6 C SUNDAY, OCTOBER 7, 0 ACR Pediatric Rheumatology Town Hall Meeting Moderators: Polly J. Ferguson, MD and Anna Huttenlocher, MD delineate the changes scheduled for implementation to the ABP MOC program recognize the current issues affecting the pediatric rheumatology community identify various pediatric rheumatology organizations and their program of work 7:0 am Update on the Modified American Board of Pediatrics Maintenance of Certification Program C. Egla Rabinovich, MD, MPH 8:00 am Update on ACR Activities involving Pediatric Rheumatology Polly J. Ferguson, MD 8:0 am Update on Childhood Arthritis and Rheumatology Research Alliance including the Childhood Arthritis and Rheumatology Research Alliance Network Laura E. Schanberg, MD 8:0 am Update on Pediatric Rheumatology Symposium Brian M. Feldman, MD, MSc Ballroom 0 A Adult Onset Still s Disease: A Clinical Review From Pathophysiology to Therapies Moderator: Shelly P. Kafka, MD Speaker: Raphaela T. Goldbach-Mansky, MD, MSc describe the features of adult onset Still s disease review and update the pathophysiology of the disease discuss the evidence of biological treatment and review new therapies Hall B Year in Review Moderator: Chester V. Oddis, MD discuss selected recent publications on the pathophysiological basis of rheumatic diseases by literature review of important publications describe selected treatment modalities for rheumatic diseases from the recent published literature enumerate how these new advances may impact the practice of rheumatology 7:0 am Clinical Perspective David Wofsy, MD 8:00 am Basic Science Perspective Steven R. Goldring, MD ACR SESSIONS 7:0-9:00 am Indigo E Macrophage Polarization Moderators: Richard M. Pope, MD and Harris R. Perlman, PhD describe the mechanisms that regulate Th7 differentiation identify the mechanism by which Th7 cells promote immune homeostasis define the mechanisms by which Th7 cells contribute to autoimmune disease pathogenesis 7:0 am The State of Macrophage Activation: An Overview of M/M David M. Mosser, MD, PhD 8:00 am M/M Polarization During Fibrosis Thomas Wynn, PhD 8:0 am Conversion of M to M Macrophages During Resolution of Atherosclerosis Edward Fisher, MD, PhD 8 D Patient Engagement/Privacy and Security Moderator: Melissa Francisco describe how providers can use online communication to support more effective and efficient patient care employ strategies to encourage patient engagement per the provisions in the CMS EHR Incentive Program, while implementing efficient workflow processes to respond to patient requests for electronic access to health information explain privacy and security requirements and best practices to ensure that electronic patient health information is secure 7:0 am How to Use Online Communication to Improve Patient Care Aliza Lipson, MD 8:00 am Maintaining Effective Workflow Processes while Fostering Patient Engagement Larry Garber, MD 8:0 am Best Practices to Address Privacy and Security Concerns Robert Warren, MD, PhD, MPH ARHP NETWORKING EVENT 7:45-8:0 AM A ARHP First-time Attendee Orientation This session is not eligible for CME credit. Coffee and tea will be provided. Moderator: Benjamin J. Smith, PA-C 0 Program Book denotes Hilton San Diego Bayfront room location

35 ACR MEET THE PROFESSOR SESSIONS 7:45-9:5 am Admission to Meet the Professor sessions requires a separate registration and ticket. To verify which session you registered for, the registration code on your ticket needs to match the -digit code in parentheses below. If you are interested in participating in one of these sessions or exchanging your ticket, visit the ACR registration desk to check space availability. View the session overview in My Annual Meeting at * Sessions denoted with an asterisk were sold out as of August 0. Pediatrics: Spondylarthritis in Children (005) Speaker: Thomas J. A. Lehman, MD describe differences between spondylarthritis in children and adults discuss the approach to diagnosis and treatment of children with spondylarthritis 5 B *Psoriatic Arthritis (006) Speaker: M. Elaine Husni, MD, MPH *Antiphospholipid Syndrome (00) Speaker: Doruk Erkan, MD review the spectrum of antiphospholipid syndrome explain the diagnostic utility of antiphospholipid antibody tests discuss the management of persistently antiphospholipid antibody-positive patients with different antiphospholipid antibody-related clinical manifestation Crystal: Diagnosis and Management of Gout (00) Speaker: Michael A. Becker, MD discuss the pathogenesis and pathophysiology of acute and chronic gout, including the distinctive treatment modalities affecting patient outcomes explain the renal mechanisms underlying the hyperuricemia of most gout patients and therapeutic rationales applied to urate-lowering therapies critically assess current ACR recommendations for the treatment of acute and chronic manifestations of gout 4 A Dermatological Manifestations of Rheumatic Diseases (00) Speaker: Ruth Ann Vleugels, MD, MPH identify cutaneous findings associated with underlying rheumatologic disease construct a differential diagnosis for these conditions design a strategy for management of skin disease seen in patients with rheumatologic diseases discuss advances in diagnosis and classification of psoriatic arthritis determine if patients with psoriatic arthritis should be treated aggressively determine treatment options for patients with psoriatic arthritis 6 A *Rheumatoid Arthritis: Challenging Cases (007) Speaker: Jonathan Kay, MD discuss the management of patients with refractory rheumatoid arthritis identify novel treatment options for those failing conventional therapies create effective management plans for complicated rheumatoid arthritis patients 6 B * Rheumatoid Arthritis: Outcome Measures in Clinical Practice (008) Speaker: J. Timothy Harrington, MD discuss outcome measures used in rheumatoid arthritis integrate outcome measures into an office-based practice 7 A *Spondylarthropathy: An Update (009) Speaker: Robert D. Inman, MD identify the challenge in the early diagnosis of spondyloarthritis discuss mechanisms of disease pathogenesis describe current treatment options for spondyloarthritis SUNDAY october 7, 0 4 B Pediatric Systemic Lupus Erythematosus (004) Speaker: Kelly A. Rouster-Stevens, MD, MSc 5 A discuss the epidemiology of pediatric systemic lupus erythematosus (psle) describe the differences in organ involvement between pediatric and adult systemic lupus erythematosus discuss the management and treatment of psle review consensus treatment plans for the induction of proliferative lupus nephritis in pediatric patients discuss novel biomarkers that in the future may be beneficial in managing psle denotes Hilton San Diego Bayfront room location 7 B *Systemic Lupus Erythematosus: Novel Treatments (00) Speaker: Mary Anne Dooley, MD, MPH determine off-label use of commercially available agents for features of systemic lupus erythematosus discuss various new approaches to treatment: B cell depletion, cytokine inhibitors, costimulatory pathway inhibition identify risks for these new therapies discuss host factors that have influence on therapeutic responses discuss belimumab, its action and issues associated with its use 0 Program Book

36 ACR WORKSHOPS 7:45-9:45 am Admission to Workshops requires a separate registration and ticket. To verify which session you registered for, the registration code on your ticket needs to match the -digit code in parentheses below. If you are interested in participating in one of these sessions or exchanging your ticket, visit the ACR registration desk to check space availability. View the session overview online in My Annual Meeting at www. ACRannualmeeting.org. * Sessions denoted with an asterisk were sold out as of August 0. ARHP NETWORKING EVENT 8:0-9:00 am B ARHP Moderators Orientation This session is not eligible for CME credit. Coffee and tea will be provided. Moderators: Hazel L. Breland, PhD, OTR/L ACR SESSIONS 8:0-0:00 am SUNDAY october 7, 0 A 4 B Histopathology of Rheumatic Lung Disease (0) Speakers: Allen Burke, MD and Jonathon Heath, MD learn the basic patterns of lung injury as seen microscopically compare pathologic findings in rheumatologic lung diseases with their idiopathic counterparts distinguish histologic features of drug induced lung injury from rheumatologic injury Magnetic Resonance Imaging in the Diagnosis and Management of Spondylarthritis: A Clinician s Guide (0) Speaker: Walter P. Maksymowych, MD identify which types of office magnetic resonance imaging systems are available and how each is used for optimal practice discuss the logistics of implementation of peripheral magnetic resonance imaging in the outpatient setting recognize indications for peripheral magnetic resonance imaging scans in clinical rheumatology discuss the most recent research using office-based magnetic resonance imaging identify anatomical structures of joints on acquired magnetic resonance imaging images review the merits and pitfalls of magnetic resonance imaging technology Muscle Involvement in Rheumatic Diseases (0) Speaker: Sakir Humayun Gultekin, MD identify the histologic abnormalities of steroid myopathy, polymyositis, dermatomyositis, and inclusion body myositis examine the major differential diagnostic possibilities in possible myositis cases interpret the findings in the muscle biopsy pathology report 06 A Legislative Update From Capitol Hill Moderator: Timothy Laing, MD Speaker: To be determined describe the latest developments in federal health policy discuss legislative initiatives currently before Congress and how outcomes could affect the rheumatology community recognize the value of engaging in grassroots advocacy with members of Congress Sapphire A Medical Education: The Year in Review Moderator: Kenneth S. O Rourke, MD Speaker: Katherine Chretien, MD recognize the major research reports and scholarship in the field of medical education over the past year translate results of educational research to their own educational programs formulate ideas for educational research at their own institution 0 A Where s the Money? A Comprehensive Approach to Funding Your Research Moderator: Alfred Kim, MD, PhD and Alexis Ogdie, MD, MSCE define types of grants available (e.g. career development awards, pilot grants, project grants, loan repayment program) identify funding mechanisms available to early career investigators through federal and private sources, the organizations that support them and ways in which to find such awards 8:0 am Grants for Developing Your Career Leslie J. Crofford, MD 8:55 am Building Your Research Portfolio Peter A. Merkel, MD, MPH 9:0 am Testimonial Edward M. Behrens, MD 4 0 Program Book denotes Hilton San Diego Bayfront room location

37 9:45 am Panel Discussion Leslie J. Crofford, MD and Peter A. Merkel, MD, MPH Rheumatoid Arthritis Treatment - Small Molecules, Biologics and Gene Therapy Poster Tour (09) Tour Guide: Josef S. Smolen, MD ACR POSTER SESSION A AND POSTER TOURS 8:0 am - 4:00 pm Poster presenters will be available from 9:00 - :00 am (abstracts # - 760). Poster tours will be held 9:00-9:45 am and 0:5 - :00 am. Morning snacks will be available from 8:0-0:00 am. Poster Hall (Exhibit Hall B-C-D) Guided Poster Tours Guided poster tours allow scientific attendees to ask questions and gain insights from some of the best-known rheumatology leaders. Tours are complimentary; however, registration is required and is limited to scientific attendees. If you preregistered for a tour, you should have received a ticket with your meeting materials. Once you have your ticket, check in at the tour desk 5 minutes prior to the start of your tour to receive your headset. Your reservation will be held only until 5 minutes prior to the start of the tour. After this time, your reservation is not guaranteed and may be released to standby attendees. If you did not pre-register, tickets may be available in the registration area (Sails Pavilion). Alternatively, you may go directly to the poster tour desk and wait for a standby ticket. Standby tickets will be assigned on a first-come, first served basis 5 minutes prior to the start of each tour. Each tour participant will receive a wireless headset which will be registered against the participants registration ID. Participants will be charged $50 if the headset is not returned within 5 minutes of the end of the tour. 9:00-9:45 am Fellows Only: How to Navigate the Poster Hall (0) Tour Guide: Calvin R. Brown Jr., MD Pediatric Rheumatology: Clinical Aspects Poster Tour (0) Tour Guide: Andrew Zeft, MD, MPH Rheumatoid Arthritis: Treatment: Small Molecules, Biologics and Gene Therapy Poster Tour (0) Tour Guide: Martin Aringer, MD Rheumatology Research Foundation Poster Tour: Innate Immunity (04) Tour Guide: Mary K. Crow, MD Spondylarthropathies and Psoriatic Arthritis: Clinical Aspects and Treatment Poster Tour (05) Tour Guide: Atul A. Deodhar, MD Systemic Lupus Erythematosus: Clinical Aspects Poster Tour (06) Tour Guide: Kenneth C. Kalunian, MD 0:5 - :00 am Epidemiology and Health Services Research Poster Tour (07) Tour Guide: Gabriela Schmajuk, MD Genetics, Genomics and Proteomics Poster Tour (08) Tour Guide: John B. Harley, MD, PhD Rheumatoid Arthritis: Clinical Aspects Poster Tour (0) Tour Guide: Jennifer L. Barton, MD Spondylarthropathies and Psoriatic Arthritis: Clinical Aspects and Treatment Poster Tour () Tour Guide: Desiree van der Heijde, MD, PhD Systemic Lupus Erythematosus: Clinical Aspects Poster Tour () Tour Guide: David A. Isenberg, MD ACR SESSIONS 9:00-0:00 am 6 D Sapphire I CORC FORUM: Disaster Planning: How to Prepare for a Catastrophe and Minimize your Liability Moderator: Douglas White, MD, PhD Speaker: Emily Friedman examine their current liability coverage and determine additional coverage required draft and/or revise an emergency plan discuss the impact a potential disaster can have to their practice livelihood Inflammation and Atherosclerosis: Autoimmunity and Cardiovascular Disease Moderators: Richard M. Pope, MD and Harris R. Perlman, PhD Speaker: Ira Tabas, MD, PhD describe the scientific basis for the development of inflammation in atherosclerosis discuss the pathogenesis of atherosclerosis in rheumatoid arthritis and systemic lupus erythematosus summarize the impact therapies that target inflammation on atherosclerotic lesion formation Ballroom 0 A New Therapies for Modulating Cell Signaling in Rheumatoid Arthritis Moderator: Gregg J. Silverman, MD Speaker: Arthur Kavanaugh, MD define the basic factors and cell types involved in these pathways, and the inflammatory responses they control examine the rationale for the development of new agents that target cell membrane associated kinases, such as the Janus tyrosine kinases, Bruton s tyrosine kinase and Spleen tyrosine kinase review recent clinical trial results and appreciate the potential benefits and toxicities that have been reported for inhibitors of protein kinases SUNDAY october 7, 0 denotes Hilton San Diego Bayfront room location 0 Program Book 5

38 6 C Rheumatology Research Foundation Memorial Lecture: Pediatric Rheumatology - Where We ve Been, Where We re Going Moderator: Deborah K. McCurdy, MD recognize how the field of pediatric rheumatology has evolved over time describe current efforts in collaborative research in pediatric rheumatology 9:00 am Reflections on Dr. Bowyer Andrew Lasky, MD Hall B Update on Thrombotic Microangiopathies Moderators: George Stojan, MD and Dinesh Khanna, MD, MSc Speaker: Michael H. Rosove, MD recognize the features that unite the thrombotic microangiopathies and the subtle clinical differences among them that can guide a diagnosis summarize updates in our understanding of the pathophysiology of the thrombotic microangiopathies most relevant to rheumatologic clinical care review updates on the management of patients with thrombotic microangiopathies, including novel therapies SUNDAY october 7, 0 6 A 9:0 am Pediatric Rheumatology: Where We ve Been, Where We re Going Christy I. Sandborg, MD Rheumatology Research Foundation Oscar S. Gluck, MD, Memorial Lectureship: The Contribution of Bone to Whole Organism Physiology Moderator: Michael J. Maricic, MD Speaker: Gerard Karsenty, MD, PhD describe the cross-talk between bone mass, the brain, the gut, energy metabolism and reproduction discuss how some of these advances in basic science can impact our therapeutic approaches to degenerative diseases of the skeleton 0 E The Link Between Inflammation in the Joint and the Gut Moderator: S. Louis Bridges Jr., MD, PhD describe the overlap between genetic regions involved in the pathogenesis of inflammatory arthritis and inflammatory bowel disease identify similarities and differences of gut microbiota in inflammatory arthritis and inflammatory bowel disease state how the shared mechanisms of disease susceptibility and pathogenesis impact on treatment of inflammatory bowel disease and inflammatory arthritis 9:00 am Inflammatory Bowel Disease and Inflammatory Arthritis: Common Mechanisms Dirk Elewaut, MD, PhD ARHP SESSION 9:00-0:00 am 9 D Keynote Address: Words that Heal Moderator: Afton L. Hassett, PsyD Speaker: Anne Curzan, PhD summarize the historical context of the language of medicine focusing on the lexicon of rheumatology describe the debates about the evolution and potential power of language in the internet age discuss some of the seminal studies related to health communications including the power of the placebo effect choose words that could be more likely to promote healing and flourishing environments EXHIBITS 0:00 am - 5:00 pm Exhibit Hall F-G Join your colleagues in the Exhibit Hall for morning and afternoon refreshments from 0:00 - :00 AM and :00 - :00 PM. (Booth #7) Innovation Theater Non-CME accredited presentations have been planned and will be implemented in accordance with the requirements of the FDA and applicable standards of the PhRMA Code on Interactions with Healthcare Professionals. These presentations will be held from 0:0 - :5 AM, :0 - :5 PM and :00 - :45 PM. For a complete listing of Innovation Theater presentations, see page 5. 9:0 am Spondyloarthropathies: Common Mechanisms With Inflammatory Bowel Disease Dermot P. B. McGovern, MD 6 0 Program Book denotes Hilton San Diego Bayfront room location

39 ACR WORKSHOPS 0:0 am - :0 pm Admission to Workshops requires a separate registration and ticket. To verify which session you registered for, the registration code on your ticket needs to match the -digit code in parentheses below. If you are interested in participating in one of these sessions or exchanging your ticket, visit the ACR registration desk to check space availability. View the session overview online in My Annual Meeting at www. ACRannualmeeting.org. * Sessions denoted with an asterisk were sold out as of August 0. Physical Examination Skills for Improved Detection of Synovitis and Cervical Thoracolumbar Disorders (08) Speakers: Edward Keystone, MD discuss sensitive techniques for the detection of synovitis in peripheral joints, especially elbows, wrists, hands, feet and knees demonstrate techniques to determine the origin of referred pain from the neck and thoracolumbar spine describe simple techniques to improve the symptoms of mechanical neck and back pain at the bedside 4 B A *Advanced Musculoskeletal Ultrasound (04) Speaker: Jay B. Higgs, MD demonstrate improvement in their techniques for performing selected MSUS examinations use practical knowledge of ultrasound technology to improve image quality Basic Statistical Concepts for the Medical Researcher (05) Speakers: Dorothy D. Dunlop, PhD and Jungwha Lee, PhD, MPH identify factors influencing sample size and power interpret confidence intervals, odds ratio and relative risk identify factors that confound study results *Dermatopathology of Rheumatic Diseases (06) Speaker: Daniel Miller, MD identify what information can be gained from a skin biopsy in patients with rheumatic diseases describe the importance of dermatopathology in clinical decision making in patients with rheumatic diseases apply the knowledge gained to clinical practice ARHP SESSIONS :00 AM - Noon B Health Literacy Universal Precautions for the Rheumatology Setting Moderator: Hazel L. Breland, PhD, OTR/L discuss the benefits of health literacy universal precautions for all patients with rheumatic disease describe key drivers for practice change and health literacy tools related to the drivers navigate the Health Literacy Universal Precautions Toolkit for rheumatology navigate the Rheumatology Quick Start Guides for rheumatology :00 am Adaptation of The Agency for Healthcare Research and Quality Health Literacy Universal Precautions Toolkit for Rheumatology Practices Leigh F. Callahan, PhD :0 am Clinician Perspectives on the Use of the Rheumatology Health Literacy Universal Precautions Toolkit and Quickstart Guides in the Practice Setting Beth L. Jonas, MD SUNDAY october 7, 0 Peripheral Magnetic Resonance Imaging in Rheumatology Practice (07) Speakers: Philip G. Conaghan, MD, PhD and Mikkel Ostergaard, DMSc, MD, PhD recognize the most common types of magnetic resonance images (as T- and T-weighted, fat-saturated, STIR and contrast-enhanced), and the appearance of the most common joint pathologies on these discuss the rationale and evidence for using magnetic resonance imaging in clinical practice identify the advantages and disadvantages of dedicated extremity magnetic resonance imaging Indigo D Immunology Boot Camp Session : The Basics of Targeted Therapies Moderators: Christine A. Stamatos, ANP-C Speakers: Troy R. Torgerson, MD, PhD describe the basic building blocks of the immune system summarize the components of innate immunity: sensing self and foreign matter explain the body s immediate response to an antigen discuss the unique adaptive immunity: central and peripheral tolerance denotes Hilton San Diego Bayfront room location 0 Program Book 7

40 SUNDAY october 7, 0 A Mediation Analysis: Theory and Method for Causal Inference Moderator: Yuqing Zhang, DSc, MPH define what is meant by mediation describe what is meant by the counterfactual framework in causal inference recognize the difference between the counterfactual method of determining direct and indirect effects compared with traditional methods by Baron and Kenny discuss the counterfactual methodology of mediation analysis, their strengths and limitations :00 am Mediation Analysis: Theory and Method for Causal Inference Linda Valeri, PhD :50 am Questions and Answers Linda Valeri, PhD ACR PLENARY SESSION I DISCOVERY 0 :00 am - :0 pm the effect disappeared shortly after APR was stopped at week 4. Improvement in OU pain (VAS) was significantly higher with APR (-44.7 ± 4.0 vs -6.0 ±.54; P<0.000). At week, significantly more patients receiving APR had a complete response (OU-free) (7% [9/55], APR; 9% [6/56], PBO; P<0.000). Among the limited number of patients with GU at baseline (n=6), 0/0 receiving APR had a complete response at week vs /6 receiving PBO (p=0.06). The mean change from baseline in the BDCAF, BSAS and BDQOL scores were significantly higher in the APR group (APR vs PBO -.5 ±.84 vs -0. ±.5; P=0.0007, -. ± 7.9 vs -5.9 ± 8.; p<0.000 and -4.5 ± 7.6 vs -.6 ± 5. P=0.097 respectively). There were serious AEs with APR ( diplegia, anal fissure and hemorrhoids) and with PBO ( disease flares, fever episode). The diplegia in patient was transient and was not thought to be related to APR. Conclusion: APR was effective in the treatment of OU, the cardinal manifestation of BS, with an acceptable safety profile. There were also indications of efficacy in several secondary endpoints, including GU, a highly specific lesion for BS. Further trials are warranted to test the efficacy of APR for other manifestations of BS. Hall B ACR Plenary Session I: Discovery 0 Moderators: Audrey B. Uknis, MD and Chester Oddis, MD :00 am Rheumatology Research Foundation Corporate Roundtable Awards :5 am 76. Apremilast for The Treatment Of Behçet s Syndrome: A Phase II Randomized, Placebo-Controlled, Double-Blind Study Gulen Hatemi, Istanbul University, Cerrahpasa Medical Faculty, Rheumatology, Istanbul, Turkey Background/Purpose: Mucocutaneous manifestations of Behçet s syndrome (BS) can be resistant to conventional treatment and at times disabling. Apremilast (APR), an oral phosphodiesterase 4 inhibitor, modulates inflammatory pathways. This study investigated the efficacy of APR in BS patients with active oral ulcers (OU). Methods: This was a phase II, multicenter, randomized, placebo (PBO)-controlled study with an open-label extension. Patients with BS without major organ involvement but OU were randomized to APR 0 mg BID or PBO for weeks followed by a -week active-treatment period for all patients and a 8-day post-treatment observational follow-up. The primary endpoint was the number of OU at week. Secondary endpoints were the number of genital ulcers (GU) at week, efficacy over time (AUC for OU and GU, first weeks), disease activity (BSAS, BDCAF), patient-reported outcomes (BDQOL, SF-6), and adverse events (AEs). Results: patients (mean age 4.5 ± 0. years, 69% women) were randomized (55 APR, 56 PBO) and 95 completed the treatment phase (50 APR, 45 PBO). Mean (±SD) number of OU at week was 0.5 ±.0 with APR and. ±.58 with PBO (P<0.000). The figure shows the mean number of OU over time. Notably, the beneficial effect of APR on OU started within weeks. There was a sustained effect while on APR, but Disclosures: G. Hatemi, None. :0 am 76. Inhibition of TGF-Beta Signaling in Articular Chondrocytes Leads to Osteoarthritis-Like Pathological Defects and Pain- Related Behavior Change In Mice Jia Li, Rush University, Chicago, IL Background/Purpose: TGF-β signaling plays an important role in chondrocyte differentiation and osteoarthritis (OA) pathogenesis. However TGF-β downstream target genes and signaling mechanism in OA development remains poorly understood. In the present studies, we investigated TGF-β signaling in OA development. Methods: Tgfbr conditional knockout (Tgfbr ColER ) mice were generated by breeding Tgfbrflox/flox mice with Col-CreER transgenic mice. Deletion of the Tgfbr gene was achieved by administration of tamoxifen into -week-old Tgfbr ColER mice. Changes in histology, gene expression and pain-related behavior were analyzed. Tgfbr/Mmp and Tgfbr/Adamts5 double KO mice were generated by breeding Tgfbr ColER mice with Mmp flox/flox mice and Adamts5 -/- mice. Results: Deletion of the Tgfbr gene in articular chondrocytes resulted in up-regulation of Runx, Atf4, Mmp, Adamts5 and Col0 expression. Histological analysis showed articular cartilage degradation, increased chondrocyte hypertrophy in superficial zone, early osteophyte formation, and increased subchondral bone mass in -month-old Tgfbr ColER mice. Loss of entire articular cartilage, formation of extensive osteophytes, and substantially increased subchondral bone mass were observed in 6-month-old Tgfbr ColER mice. Histomorphometric analysis and evaluation with OARSI scoring system showed a significant decrease in articular cartilage area in Tgfbr ColER 8 0 Program Book denotes Hilton San Diego Bayfront room location

41 mice. Significant reduction in spontaneous rearing activity and ambulation counts were also observed in 4-, 5-, 6-, 7-, and 8-month-old Tgfbr ColER mice. To determine if up-regulation of Mmp and Adamts5 expression is responsible for Tgfbr ColER - induced OA development, we generated Tgfbr/Mmp and Tgfbr/Adamts5 double KO mice. Deletion of the Mmp gene significantly alleviates OA-like pathological changes observed in - and 6-month-old Tgfbr ColER mice. In contrast, deletion of the Adamts5 gene only reversed OA-like phenotype in -month-old Tgfbr ColER mice. These changes were confirmed by histomorphometric analysis and by evaluation with OARSI scoring system. We also investigated the signaling mechanism and found that inhibition of TGF-β signaling prevented Runx degradation. Runx directly bound to its binding site located in the proximal region of the Mmp promoter and activated Mmp transcription. ATF4 interacted with Runx and enhanced Runx-induced Mmp transcription. Conclusion: In this study, we demonstrate that inhibition of TGF-β signaling in articular chondrocytes leads to a progressive OA-like phenotype in mice. Mmp and Adamts5 are critical downstream target genes of TGF-β signaling during OA development. Disclosures: J. Li, None. :45 am 76. The Risk of Myocardial Infarction in Systemic Sclerosis: A Population-Based Cohort Study Iman Hemmati, University of British Columbia, Vancouver, BC Background/Purpose: An increased risk of premature atherosclerosis has been well described in patients with rheumatoid arthritis and systemic lupus erythematosus. However, there is limited data on the risk of atherosclerotic diseases, myocardial infarction (MI) in patients with Systemic Sclerosis (SSc). Moreover, the scarce information has come from selected populations. To fill this knowledge gap, we estimated the risk of newly recorded MI events among incident cases with SSc compared to controls from the general population using physician billing and hospitalization databases that cover the entire population from our province (~ 5 million). Methods: Our data included all visits to health professionals and hospital admissions covered by the comprehensive provincial medical services plan (from Jan990 until Dec 00) and all dispensed medication (from Sept 995 to Dec 00); for all individuals >= 8 years of age. We conducted a matched cohort analysis among patients satisfying at least one of the following criteria: a) diagnosis of SSc on at least two visits within a two-year period between Jan 996 and Dec 00 by a non-rheumatologist physician; b) diagnosis of SSc on at least one visit by a rheumatologist or from a hospital. To increase specificity we excluded cases that were not confirmed by a rheumatologist if they were seen at a later point. Ten controls matched by birth year, sex and calendar year of follow-up were selected from the general population for each case. Newly recorded MI events from hospital or death certificate were recorded as an outcome. We estimated relative risks (RRs) comparing SSc with age-, sex- and entry time-matched comparison cohorts, adjusting for potential cardiovascular risk factors. Results: Among,08 individuals with incident SSc (84% female, mean age of 56 yrs [SD 5.0]), 90 developed MI (incidence rate= 0. per 000 person years) (Table ). Compared with non-ssc individuals (N=,080), the age-, sex-, and entry-timematched RR for MI was.8 (95% CI,.9 to 4.8). The risk was 9 times greater within the first year after the disease onset and progressively decreases over time. After further adjustment for angina, COPD, obesity, cardiovascular disease, diabetes, hormone replacement therapy, dyslipidemia, non steroidal antiinflammatory drugs, Cox- inhibitors, number of hospitalizations and Charlson s comorbidity index at baseline; the RR remained similar (4.0, 95% CI,. to 5.). These results persisted among men, women and different age groups (Table ). Conclusion: This large population-based study indicates an increased risk of MI in patients with SSc, especially within the first year of disease diagnosis. These findings support increased monitoring of MI complication and risk factors in those with SSc, particularly during the early phase of SSc diagnosis. Incidence Rate Ratios of MI SSc (n =,08) Non-SSc (n =,080) Cases, N 90 8 Incidence Rate/000 Person-Years Age-sex-entry time matched RRs (95% CI).8 (.9 4.8).0 Multivariable RRs (95% CI) 4.0 (. 5.).0 Disease Duration < year 9.0 (5.8.9) years.0 (.0 4.4).0 5+ years.6 (0.8.).0 Female 4. (.0 5.6).0 Male 4. (. 7.9).0 Age Group < 45.0 (0.7 4.) (.9 9.4) (. 5.) (. 9.).0 Table. Relative risk of incident MI according to Systemic Sclerosis status. Disclosures: I. Hemmati, None. Noon 764. Inflammatory Disease Due to Dysregulated Nuclear Factor-κB Activation and Impaired Type I Interferon Response Resulting From a De Novo Human NEMO Hypomorphic Mutation Alex Wessel and Eric Hanson, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD Background/Purpose: The NF-kB family of transcription factors regulate innate and adaptive immunity, in addition to driving pro-inflammatory-disease states. The type I interferon response acts in parallel, and is mediated by IRF and IRF7 transcription factors. The IRFs are triggered by the RIG-I-like family of receptors (RLRs) in fibroblasts and Toll-like receptors (TLRs) in dendritic cells and macrophages. Both NF-kB activation and the Type I IFN response require the NF-kB essential modulator (NEMO) for normal function. The mechanisms by which NEMO is regulated to integrate various upstream signals to direct transcription in antiviral immune defense and inflammatory disease is unknown. We present the molecular mechanism by which a naturally occurring NEMO mutation associated with inflammatory disease leads to aberrant cell responses. Methods: Genomic DNA and cdna from dermal fibroblasts and peripheral blood cells from a patient with optic neuritis, panniculitis and physical characteristics consistent with NEMO SUNDAY october 7, 0 denotes Hilton San Diego Bayfront room location 0 Program Book 9

42 SUNDAY october 7, 0 mutation were analyzed to determine the genotype and effect on NEMO protein product. Patient cells were stimulated with TNF, anti-cd/cd8,viral nucleic acid analogs, and RSV and HPIV infection. Gene expression profiling, cytokine production and biochemical analysis was performed to characterize and determine the mechanism of aberrant signaling produced by the mutant form of NEMO. Results: We identified an individual with Ectodermal Dysplasia, a history of in utero cytomegalovirus exposure, and persistent inflammatory disease. Sanger sequencing revealed a de novo synonymous mutation in IKBKG, which encodes NEMO, the NF-kB essential modulator. The mutation results in an mrna splicing defect which leads to the production of a mutant protein containing an in-frame deletion of 5 residues, lacking a previously identified TANK (TRAF family member-associated NFKB activator) interaction domain. Co-immunoprecipitation studies revealed that the mutant form of NEMO from patient T cells is unable to recruit the IRF kinase TANK-binding kinase- (TBK), due to impaired association with TANK. Patient fibroblasts stimulated with the RLR ligand poly(i:c) led to impaired induction of IRF response genes IFNB, CCL5, CXCL0, IP0, OASL, and DDX58. Consequently, dermal fibroblasts infected with RSV or hpiv demonstrated increased virus propagation relative to healthy control cells. Impaired gene expression occurred despite enhanced nuclear translocation of IRF, suggesting that the mechanism of impaired activation is not a simple defect in nuclear localization of the transcription factor. In contrast to the impaired type I IFN response, canonical IKK activation and gene induction in dermal fibroblasts appeared relatively normal following TNF treatment. Conclusion: These results illustrate a novel mechanism of autoinflammatory disease due to aberrant expression of an alternately spliced NEMO and deficient IRF-mediated response. Disclosures: A. Wessel, None; E. Hanson, None. Results: PE occurred in 0% of pregnancies (7 at <4 wks; 9 at any time) and other poor outcomes in 0%. Compared to SLE patients without poor OC, levels of sflt (Fig A) and sflt/ PlGF ratios were significantly higher as early as -5 wks in those destined for PE or other complications, and remained elevated through weeks. The rate of increase in sflt from 6 wks through weeks was higher in patients with PE (<4 wks, any time) or non-pe OC compared to those without poor OC (p < all comparisons). In contrast, and consistent with impaired placental development, the rate of increase in PlGF was lower in those destined for poor OC (p < all comparisons). Ln sflt/plgf ratios for those who developed PE were markedly and consistently higher throughout pregnancy compared to SLE patients without poor OC or HC (p< all comparisons) (Fig B). Based on ROC analysis, a ln sflt/plgf ratio cutpoint of 4.4 at the -5 wk measure yielded 78% sensitivity and 7% specificity for PE < 4 wk. Conclusion: We demonstrate that in pregnant SLE and/or APL patients, alterations in the balance of angiogenic factors early in pregnancy are strongly associated with subsequent PE and other poor outcomes. Absolute levels of sflt, ratio of sflt/plgf and rate of change of angiogenic factors may be used to identify those at risk before 5 wks, allow early intervention and reveal novel targets for treatment. 5 pm 765. Angiogenic Factor Dysregulation and Risk of Adverse Pregnancy Outcome in Lupus Pregnancies Jane E. Salmon, Hospital for Special Surgery, New York, NY Background/Purpose: Pregnant women with lupus and APL are at increased risk for adverse outcomes, particularly preeclampsia (PE), yet identification of those destined for complications remains elusive. Dysregulation of angiogenic factors contributes to pathogenesis of placental insufficiency and preeclampsia. Placentally derived sflt antagonizes proangiogenic proteins (placental growth factor, PlGF; VEGF) which are necessary for development of the placenta and for vascular homeostasis. We prospectively studied patients to determine whether levels of angiogenic factors early in pregnancy would predict outcomes. Methods: The PROMISSE Study (Predictors of pregnancy Outcome: BioMarkers In antiphospholipid antibody Syndrome and Systemic Lupus Erythematosus) enrolled 84 pregnant women with 4 ACR SLE criteria and/or APL and 5 healthy pregnant controls (HC). Subjects were evaluated and blood collected monthly beginning at < wks gestation. Exclusion criteria were multi-fetal pregnancy, prednisone >0mg/d, proteinuria >gm/4hr, and creatinine >. mg/dl. Poor pregnancy outcomes (OC) were defined as preeclampsia, fetal death, neonatal death, preterm delivery <6 wks because of IUGR or placental insufficiency, and/or growth restriction <5th %ile. Levels of angiogenic factors were measured by ELISA and compared between groups at each time point using Wilcoxon rank sum test. In addition, linear mixed effects models were fit to rank transformed data to estimate and compare rates of change in these factors over the entire gestational period. Disclosures: J. E. Salmon, Roche Pharmaceuticals,, Alexion Pharmaceuticals, Inc., Novartis, 5. ACR SESSIONS :0 - :00 pm Sapphire A Opportunities for Social Media in Medical Education Moderator: Kristine M. Lohr, MD, MS describe and identify preferred social media tools for medical education, particularly in rheumatology recognize principles of using social media responsibly recognize generational differences in technology/social media use and views on professionalism know privacy and security issues pertaining to social media use :0 pm The Use of Social Media in Medical Education Katherine Chretien, MD :5 pm The Use of Social Media in Rheumatology Education and Practice Christopher E. Collins, MD 40 0 Program Book denotes Hilton San Diego Bayfront room location

43 Sapphire I Why Every U.S. Rheumatologist Should Join the National Rheumatology Registry (RISE) Moderator: Melissa Francisco summarize the importance of data collection and synthesis in evidence-based care explain the importance of their role as participant in the RISE registry develop strategies for participating in the registry and accessing collective data as part of improving patient care :0 pm Leveraging Registry Capabilities for Seamless Quality Reporting Salahuddin Kazi, MD Know Bones About It Jason R. Kolfenbach, MD; Itziar Quinzanos, MD and Anthony Kahr, MD Mississippi Rheumatology Missiles Vikas Majithia, MD, MPH; Trayton Mains, DO and Seth A. Compton, MD New Orleans Mardi Gras Robert Quinet, MD; Omar Khan, MD and Minzi Chen, MD Rheum of the Arabia Mohammed Hammoudeh, MD; Magdi Abdelrahman, MRCP and Abdul Razzakh Poil, MD Rheum Rush Winston Sequeira, MD; Narender Annapureddy, MD and David Giangreco, MD :00 pm Using the RISE Registry to Enhance Quality of Care Jinoos Yazdany, MD, MPH :0 pm Assessing the Value of Patient Registries in Clinical Research Peter J. Embi, MD, MS ARHP NETWORKING EVENT :0 - :5 pm Sapphire Ballroom L Networking Forum All ARHP attendees are invited to this kick-off forum for the annual meeting. A box lunch will be provided for the first 50 people. You will have an opportunity to meet and network with other health professionals. Discipline tables will be arranged to help facilitate connections. This session is not eligible for CME credit. ACR SESSIONS :45 - :5 pm Ballroom 0 A ACR Knowledge Bowl- Preliminary Round Moderator: Rebecca L. Manno, MD, MHS Judges: Lawrence H. Brent, MD; Calvin R. Brown Jr., MD and Ann K. Rosenthal, MD identify key images that are important to recognize in clinical practice recall factual information related to various rheumatic diseases identify historical facts relevant to the field of rheumatology Teams AGAR FORCE Abraham G. Kutzbach, MD; Isa Iraheta, MD and Helga G. Ferrer, MD Southwestern UT QTs Kara H. Prescott, MD; Arshad Mustafa, MD and Katarzyna Gilek, MD Team Temple Bita Shakoory, MD; Thais Moldovan, MD and Srikanth Mukkera, MD The Hawkeyes Namrata Singh, MD; Lindsay J. Orris, DO and Mohammadomid Chad Edrissian, MD The Portlandumabs Pascale Schwab, MD; Abhijeet Danve, MD and Neha Grg, MD USC Trojan Force Daniel Arkfeld, MD; Hitasha Singh, MD and Michael Elist, DO ACR MEET THE PROFESSOR SESSIONS :45 - :5 pm Admission to Meet the Professor sessions requires a separate registration and ticket. To verify which session you registered for, the registration code on your ticket needs to match the -digit code in parentheses below. If you are interested in participating in one of these sessions or exchanging your ticket, visit the ACR registration desk to check space availability. View the session overview online in My Annual Meeting at www. ACRannualmeeting.org. * Sessions denoted with an asterisk were sold out as of August 0. *Adult Inflammatory Myopathy (0) Speaker: Robert L. Wortmann, MD CANCELLED review the clinical manifestations of inflammatory myopathies including important extra-muscle manifestations discuss diagnostic pearls for the evaluation of someone suspected of having an inflammatory myopathy discuss the treatment paradigm for inflammatory myopathies SUNDAY october 7, 0 Hurricane Katrina Nirupa J. Patel, MD; Jen Erbil, MD and Joseph Martinez, MD denotes Hilton San Diego Bayfront room location 0 Program Book 4

44 SUNDAY october 7, 0 *Behçet s Disease (0) Speaker: Yusuf Yazici, MD discuss the epidemiology, disease mechanisms and the differential diagnosis of Behçet s syndrome describe current approaches to the management of patients with Behçet s syndrome 4 A Cutaneous Vasculitis (0) Speaker: Ruth Ann Vleugels, MD, MPH use the cutaneous exam to help distinguish between small and medium-sized vasculitides observe the histopathological features of cutaneous vasculitis, which lead directly to clinical disease observable on the skin identify vasculitis mimickers with cutaneous involvement define the role of dermatologists in the diagnosis, work-up and management of cutaneous vasculitides 4 B *Fibromyalgia 0: Update on Management (04) Speaker: Daniel J. Clauw, MD identify newly proposed biological mechanisms whereby distress could be converted into chronic pain discuss the role of autonomic dysfunction in the pathogenesis of fibromyalgia describe how complexity science paradigms may help to understand fibromyalgia describe scientific holistic therapies 5 A Hereditary Angioedema Update (05) Speaker: Peter Deane, MD discuss the pathophysiology of hereditary angioedema discuss the proper approach to the patient with angioedema discuss current treatment options 5 B *Inflammatory Eye Disease/Uveitis (06) Speaker: Sergio Schwartzman, MD review the clinical manifestations of inflammatory eye disease encountered by rheumatologists discuss diagnostic pearls for the evaluation of someone with inflammatory eye disease discuss the treatment paradigms used for the inflammatory eye diseases 6 A *Reactive Arthritis: An Update (07) Speaker: John D. Reveille, MD identify various causes of reactive arthritis discuss mechanisms of disease pathogenesis describe current treatment options for reactive arthritis 6 B Scleroderma Mimics (08) Speaker: Faye N. Hant, DO, MSCR present an overview of scleroderma-like conditions review the clinical phenotypes and classification of scleroderma create a differential diagnosis for conditions that may mimic features of scleroderma discuss features of specific scleroderma mimics and strategies to distinguish them explain potential diagnostic and initial management/ treatment of these conditions 7 A *Systemic Lupus Erythematosus: Lupus Nephritis (09) Speaker: Brad H. Rovin, MD review immunosuppressive therapy of lupus nephritis Classes II-V, including novel biologics discuss the use of renoprotective and anti-proteinuria therapies in lupus nephritis discuss diagnosis and treatment of renal thrombotic microangiopathy and podocytopathies outline the future research agenda for clinical trials in lupus nephritis 7 B * Understanding of Approach to the Care of Patients with Vasculitis (00) Speaker: Paul A. Monach, MD, PhD review advances in diagnosis and staging of vasculitis, and updates on prognostic information of interest to clinicians and patients review advances in therapeutic intervention (including biologics) in the treatment of the systemic vasculitides such as granulomatosis with polyangiitis, cryoglobulinemic vasculitis, and giant cell arteritis assess how to incorporate recent research data and practices into providing clinical care in the community for patients with vasculitis ACR SESSIONS :00 - :00 pm 6 A Alopecia 0 for the Rheumatologist Moderator: Shelly P. Kafka, MD Speaker: Maria Hordinsky, MD describe the different types of alopecia formulate a differential diagnosis of alopecia initiate an appropriate diagnostic evaluation of the patient with alopecia describe current therapeutic options for alopecia 4 0 Program Book denotes Hilton San Diego Bayfront room location

45 0 E Mechanisms of Pain in Osteoarthritis Moderator: Joel A. Block, MD Speaker: Anne-Marie Malfait, MD, PhD describe how pain is mediated in joints affected by osteoarthritis list key pain mediators in osteoarthritis define which pain mediators could be new targets for therapy Indigo C Telomeres, Telomerase and Age-Related Disease Moderator: Leonard H. Sigal, MD Speaker: Mary Armanios, MD discuss the spectrum of disease associated with telomere dysfunction describe the pathophysiology of telomere-mediated disease define indications for telomerase genetic testing ACR WORKSHOPS :5 - :5 pm 4 Admission to Workshops requires a separate registration and ticket. To verify which session you registered for, the registration code on your ticket needs to match the -digit code in parentheses below. If you are interested in participating in one of these sessions or exchanging your ticket, visit the ACR registration desk to check space availability. View the session overview online in My Annual Meeting at www. ACRannualmeeting.org. * Sessions denoted with an asterisk were sold out as of August 0. Beyond Musculoskeletal Ultrasound for Rheumatologists (09) Speaker: Richard Hoppmann, MD identify non-musculoskeletal uses of ultrasound in rheumatology patients recognize some common ultrasound abnormalities in patients with rheumatic diseases explain the importance of proper ultrasound transducer selection and system settings to obtain adequate ultrasound images perform ultrasound scanning techniques for nonmusculoskeletal scanning Clinical Anatomy and Physical Exam: Essential Tools in Lower Extremity Regional Pain Syndromes (0) Speakers: Robert A. Kalish, MD and Pablo Villasenor Ovies, MD demonstrate clinical anatomy of the lower extremities in performing the physical examination. apply knowledge of clinical anatomy to better understanding and diagnosis of the common regional pain syndromes. perform the physical examination of the lower extremities on healthy volunteers. denotes Hilton San Diego Bayfront room location A Osteoporosis: Interpreting Dual Energy X-ray Absorptiometry and Clinical Risk Factors: The New Fracture Risk Assessment Algorithm () Speaker: Stuart L. Silverman, MD use bone mineral density and clinical risk factors in determination of absolute risk of fracture discuss the concept of intervention threshold address limitations of FRAX in clinical practice ACR SESSIONS :0-4:00 pm Indigo E Molecular Mechanisms of Muscle Dysfunction in Inflammatory Myopathy and Muscular Dystrophy Moderator: Dana P. Ascherman, MD outline the evidence supporting a role for innate and adaptive immune responses in inflammatory myopathies identify the contribution of non-immune mechanisms to the pathogenesis and clinical phenotype of inflammatory myopathies describe the interplay between immune and non-immune mechanisms in inflammatory myopathies disease expression summarize the pathogenic link between inflammatory myopathies and other muscle disorders such as Duchenne s Muscular Dystrophy :0 pm Immune Mechanisms in Inflammatory Myopathies What is the Evidence? Ingrid E. Lundberg, MD, PhD :00 pm Non-immune Mechanisms Contributing to Muscle Dysfunction in Inflammatory Myopathies Kanneboyina Nagaraju, DVM, PhD :0 pm Inflammatory Myopathies and Muscular Dystrophy Is There a Connection? James Tidball, PhD Ballroom 0 A Osteoarthritis Pathophysiology, Diagnosis and Management: What Can I Tell my Osteoarthritis Patient to Do Other Than Weight Loss and Quadriceps Strengthening? Moderator: Jasvinder A. Singh, MD, MPH review the advances in osteoarthritis epidemiology, including the role of synovitis, bone lesions and cartilage defects explain the role for imaging in osteoarthritis and what should be used clinically in routine management of osteoarthritis patients assess the emerging role of biomarkers in osteoarthritis, and its current and future application to the clinical care of osteoarthritis patients 0 Program Book 4 SUNDAY october 7, 0

46 SUNDAY october 7, 0 6 D :0 pm Advances in Epidemiology of Osteoarthritis: What are Synovitis, Cartilage Defects, Meniscal Damage and Bone Lesions Doing to Symptoms in My Osteoarthritis Patient? Leena Sharma, MD :00 pm Can Imaging Really Help Me in Managing My Osteoarthritis Patient Better? David J. Hunter, MBBS, PhD :0 pm Biomarkers in Osteoarthritis: Are We Ready? Erwin (W.E.) van Spil, MD Sentinels of the Immune System: Dendritic cell and Plasmacytoid Dendritic Cells Moderator: Gregg J. Silverman, MD describe the overall organization of the immune system and the regulatory circuits that are controlled through involvement of dendritic cells define the risks associated with dysregulation of dendritic cells and plasmacytoid dendritic cells responses in patients with rheumatic disease distinguish the central features of tolerogenic vs. immunogenic responses :0 pm Dendritic cells: Reinforcers of Tolerance or Initiators of Autoimmunity Nina Bhardwaj, MD, PhD :5 pm Plasmacytoid Dendritic Cells: Arsonists or Firemen of the Immune System Lars Ronnblom, MD, PhD Hall B The Great Debate: Biologics or Triple Therapy for the Treatment of Rheumatoid Arthritis? Moderator: Eric L. Matteson, MD, MPH discuss the efficacy of biologics in the treatment of rheumatoid arthritis discuss the efficacy of triple therapy (methotrexate, sulfasalazine, and hydroxychloroquine) for the treatment of rheumatoid arthritis describe the safety issues with biologic therapy compared to triple therapy discuss the cost effectiveness of triple therapy compared to biologic therapy provide rationale for choosing one type of therapy biologics or triple therapy over the other for the treatment of rheumatoid arthritis :0 pm Biologic Therapy is the Most Effective Treatment for Rheumatoid Arthritis Ronald van Vollenhoven, MD, PhD 6 A :5 pm Triple Therapy is Just as Effective as Biologics for the Treatment of Rheumatoid Arthritis James R. O Dell, MD Vascular Disease in Scleroderma: A Multi-Organ Challenge Moderator: Dinesh Khanna, MD, MSc identify patients at risk for major vascular complications in scleroderma discuss the evaluation of patients with complicated vascular disease define management strategies of complicated patients with scleroderma vascular disease :0 pm Raynaud s and Digital Ischemia Laura K. Hummers, MD, ScM :00 pm Scleroderma Pulmonary Arterial Hypertension Rajeev Saggar, MD :0 pm Scleroderma Renal Crisis Marie Hudson, MD, MPH ACR CONCURRENT ABSTRACT SESSIONS :0-4:00 pm 0 A Biology and Pathology of Bone and Joint I: Cartilage Biology and Osteoarthritis Moderators: Hiroshi Asahara, MD and Frank Beier, PhD :0 pm 766. Cholesterol Accumulation by Synovial Lining Macrophages Results in Ectopic Bone Formation During Experimental Osteoarthritis Wouter de Munter, Arjen B. Blom, Monique M. Helsen, Birgitte Walgreen, Peter M. van Der Kraan, Leo A. Joosten, Wim B. van den Berg and Peter L. van Lent, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, Department of Medicine, Radboud University Nijmegen Medical Center, Nijmegen, Netherlands, Rheumatology Research and Advanced Therapeutics, Department of Rheumatology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands :45 pm 767. Zinc Finger Protein ZCCHC6 Is Highly Expressed in Osteoarthritic Cartilage and Regulate the Expression of Interleukin-6 in Human Chondrocytes Nahid Akhtar, Ahmad Arida and Tariq M. Haqqi, North East Ohio Medical University, Rootstown, OH 44 0 Program Book denotes Hilton San Diego Bayfront room location

47 :00 pm 768. Inhibition of X-Box Binding Protein (XBP) Is Chondroprotective by Promoting Autophagy and Inhibiting Catabolic Responses Ru L. Bryan, Robert Terkeltaub and Ramon Serrano, VA Medical Center/University of California San Diego, San Diego, CA, VA Medical Ctr/University of California San Diego, San Diego, CA, VA Medical Center, San Diego, CA :5 pm 769. Synovial Wnt and WISP Expression Induces Expression of Cartilage-Degrading Metalloproteinases in the Synovium Martijn H. van den Bosch, Arjen B. Blom, Sylvia W. Suen, Anke E. van Erp, Fons A. van de Loo, Esmeralda N. Blaney Davidson, Peter M. van der Kraan, Peter L. van Lent and Wim B. van den Berg, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, Rheumatology Research and Advanced Therapeutics, Department of Rheumatology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands :0 pm 770. Suppressor of Cytokine Signaling- Is a Critical Regulator of gp0 Cytokine Signaling in Articular Chondrocytes Xiao Liu, Kate E Lawlor, Ben A Croker and Ian P Wicks, Walter & Eliza Hall Institute of Medical Research, Parkville, Australia :45 pm 77. The S00A9 Inhibitor Paquinimod (ABR-5757) Reduces Synovial Activation, Osteophyte Formation and Cartilage Damage in Experimental Osteoarthritis Rik Schelbergen, Arjen B. Blom, Tomas Leanderson, Helena Eriksson, Wim B. van den Berg 4 and Peter L.E.M. van Lent, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, Lund University, Lund, Sweden, Active Biotech AB, Lund, Sweden, 4 Rheumatology Research and Advanced Therapeutics, Department of Rheumatology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands 8 B Cytokines, Mediators, Cell-cell Adhesion, Cell Trafficking and Angiogenesis I: Identifying Novel Factors That Facilitate Neovascularization and Cell Trafficking Moderator: David L. Boyle and Shiva Shahrara, PhD :0 pm 77. Neovascularization and CD5s Influence Long Distance Migration of Synovial Fibroblasts From Patients With Rheumatoid Arthritis Birgit Zimmermann, Sina Köppert, Stephanie Lefèvre, Stefan Rehart, Ulf Müller-Ladner and Elena Neumann, Justus-Liebig- University of Gießen, Kerckhoff-Klinik, Bad Nauheim, Germany, Markus-Hospital, Frankfurt, Germany :45 pm 77. Adioponectin-Induced p8 MAPK and AMPK Pathways in Rheumatoid Arthritis Synovial Fibroblasts Are Adiponectin Isoform Dependent Kiran Khawaja, Klaus W. Frommer, Stefan Rehart, Ulf Müller-Ladner and Elena Neumann, Justus-Liebig-University of Gießen, Kerckhoff-Klinik, Bad Nauheim, Germany, Markus- Hospital, Frankfurt, Germany :00 pm 774. Citrullination of ENA-78/CXCL5 Changes Its Receptor Affinity From CXCR To CXCR and Induces Monocyte Migration Ken Yoshida, Alisa E. Koch, Ray A. Ohara, Phillip L. Campbell, M. Asif Amin, David A. Fox and Jeffrey H. Ruth, University of Michigan Medical School, Ann Arbor, MI :5 pm 775. Cytokine-Mediated Repression of the Lncrna Hotair Enhances Intracellular Signaling and the Expression of Adhesion Molecules in Synovial Fibroblasts Michelle Trenkmann, Mojca Frank Bertoncelj, Matthias Brock, Christoph Kolling, Renate E. Gay, Beat A. Michel 4, Diego Kyburz, Lars C. Huber and Steffen Gay, Center of Experimental Rheumatology, University Hospital Zurich and Zurich Center of Integrative Human Physiology (ZIHP), Zurich, Switzerland, Department of Internal Medicine, University Hospital Zurich, Zurich, Switzerland, Schultess Clinic, Zurich, Switzerland, 4 Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland :0 pm 776. Tumor Necrosis Factor Alpha Modifies Chromatin Landscape and Amplifies Inflammatory Responses to Subsequent Stimuli in Synovial Fibroblasts Angela Lee, Lionel B. Ivashkiv and George D. Kalliolias, Hospital for Special Surgery, New York, NY :45 pm 777. A Unique Role for Galectin-9 in Angiogenesis and Inflammatory Arthritis Martin O Brien, Qiang Shu, Pei-Suen Tsou, William Stinson 4, Jeffrey H. Ruth, Takeo Isozaki, Alisa E. Koch 5, David A. Fox and M. Asif Amin, University of Michigan Medical School, Ann Arbor, MI, University of Michigan Medical School and Qilu Hospital of Shandong University, Ann Arbor, MI, Division of Rheumatology, University of Michigan Medical Center, Ann Arbor, MI, 4 University of Michigan, Ann Arbor, MI, 5 VA Medical Service, Ann Arbor, MI 06 A Epidemiology and Health Services Research I: Comorbidities in Rheumatic Diseases Moderators: Gabriela Schmajuk, MD, MS and Cynthia Crowson, MS :0 pm 778. Relationship of Meeting Physical Activity Guidelines and Quality Adjusted Life Years Kai Sun, Jing Song, Larry Manheim, C. Kent Kwoh, Rowland W. Chang, Pamela A. Semanik, Dorothy D. Dunlop and Charles Eaton 4, Northwestern University, Chicago, IL, University of Pittsburgh, Pittsburgh, PA, Northwestern University Medical School, Chicago, IL, 4 Brown University, Providence, RI :45 pm 779. Low Cardiovascular Mortality Among Early Rheumatoid Arthritis Patients A Nationwide Register Study Anne M. Kerola, Tuomo Nieminen, Lauri J. Virta, Hannu Kautiainen 4, Kari Puolakka 5, Tuomas Kerola 6, Timo Pohjolainen 7 and Markku J. Kauppi 6, Medical School, University of Helsinki, Helsinki, Finland, Division of Cardiology, Helsinki University Central Hospital, Helsinki, Finland, Research Department, the SUNDAY october 7, 0 denotes Hilton San Diego Bayfront room location 0 Program Book 45

48 SUNDAY october 7, 0 Social Insurance Institution, Turku, Finland, 4 Unit of Primary Health Care, Helsinki University Central Hospital, Helsinki, Finland, 5 Department of Medicine, South Karelia Central Hospital, Lappeenranta, Finland, 6 Department of Internal Medicine, Päijät-Häme Central Hospital, Lahti, Finland, 7 ORTON Rehabilitation Centre, ORTON Foundation, Helsinki, Finland :00 pm 780. Serious Infection Rates Among Patients With Systemic Lupus Erythematosus Receiving Corticosteroids and Immunosuppressants Candace H. Feldman, Linda T. Hiraki, Francisco M. Marty, Wolfgang C. Winkelmayer 4, Jessica M. Franklin 5, Daniel H. Solomon 6, Seoyoung C. Kim and Karen H. Costenbader 7, Division of Rheumatology, Immunology and Allergy, Brigham and Women s Hospital, Harvard Medical School, Boston, MA, Brigham and Women s Hospital, Harvard School of Public Health, Boston, MA, Brigham and Women s Hospital, Boston, MA, 4 Stanford University School of Medicine, Stanford, CA, 5 Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women s Hospital, Boston, MA, 6 Harvard Medical School, Brigham and Women s Hospital, Division of Rheumatology, Division of Pharmacoepidemiology, Boston, MA, 7 Brigham and Women s Hospital, Harvard Medical School, Boston, MA :5 pm 78. Mortality Rates, Readmissions and Revascularisation Following a First Myocardial Infarction in Patients With Autoimmune Rheumatic Disease Compared With Controls Sharon Van Doornum, Megan Bohensky, Mark Tacey, Caroline Brand, Vijaya Sundararajan and Ian Wicks, The University of Melbourne, Melbourne, Australia, University of Melbourne, Melbourne, Australia, Royal Melbourne Hospital, Melbourne, Australia :0 pm 78. Rates of Malignancies in Patients From 5 Rheumatoid Arthritis Registries Across the World Johan Askling, Niklas Berglind, Stefan Franzén, Thomas Frisell, Christopher Garwood, Jeffrey D. Greenberg 4, Meilien Ho 5, Marie Holmqvist, Laura Horne 6, Kathy Lampl 6, Kaleb Michaud 7, Fredrik Nyberg 8, Dimitrios A. Pappas 9, George Reed 0, Eiichi Tanaka, Trung Tran, Suzanne Verstappen, Hisashi Yamanaka and Deborah Symmons, Karolinska Institutet, Stockholm, Sweden, AstraZeneca R&D Mölndal, Mölndal, Sweden, Arthritis Research UK Epidemiology Unit, The University of Manchester, Manchester, United Kingdom, 4 NYU Hospital for Joint Diseases, New York, NY, 5 AstraZeneca R&D Alderley Park, Macclesfield, United Kingdom, 6 AstraZeneca R&D Wilmington, Wilmington, DE, 7 University of Nebraska Medical Center, Omaha, NE, 8 AstraZeneca R&D, Mölndal, Sweden, 9 Columbia University, New York, NY, 0University of Massachusetts Medical School, Worcester, MA, Tokyo Women s Medical University, Tokyo, Japan, MedImmune LLC, Gaithersburg, MD :45 pm 78. Outcome in Patients With Rheumatoid Disease: Simple Screening Tools Predict Cardiovascular Events and Death Stefan Kleinert, Margret Breunig, Hans-Peter Tony, Martin Feuchtenberger, Marc Schmalzing, Christian Kneitz 4, Stefanie Lehmann 5, Christiane Angermann, Georg Ertl and Stefan Störk 5, University Hospital Würzburg, Würzburg, Germany, University Hospital Würzburg, Würzburg, Wuerzburg, Germany, Kreiskliniken Altötting-Burghausen, Burghausen, Germany, 4 Hospital Südstadt, Rostock, Germany, 5 University of Würzburg, Würzburg, Germany 9 D Miscellaneous Rheumatic Diseases Moderators: Loic Guillevin, MD and Jonathan Kay, MD :0 pm 784. IgG4+ Plasmablasts Are a Novel Biomarker in IgG4-Related Disease Mollie Carruthers, Hamid Mattoo, Zachary S. Wallace, Vinay Mahajan, Shiv Pillai and John H. Stone, Massachusetts General Hospital, Boston, MA, Massachusetts General Hospital, Harvard Medical School, Boston, MA :45 pm 785. Ophthalmic Manifestations of IgG4-Related Disease: A Single-Center Experience Zachary S. Wallace, Vikram Deshpande and John H. Stone, Massachusetts General Hospital, Boston, MA :00 pm 786. Antibodies Against Drp-4 and Macropain Subunit C as a Potential Marker of Aosd Niklas T. Baerlecken, Nils Pursche, Torsten Witte, Reinhold E. Schmidt, Marius Hoepfner, Frank Moosig 4, Wolfgang L. Gross 5, Eugen Feist 6 and Dirk Foell 7, Medical University Hannover, Hannover, Germany, Medical University of Hannover, Hannover, Germany, Medical University Hannover, Hanover, Germany, 4 University Hospital Schleswig Holstein and Klinikum Bad Bramstedt, Bad Bramstedt, Germany, 5 Medical University at Lubeck, Lubeck, Germany, 6 Charite University Hospital, Berlin, Germany, 7 University of Muenster, Muenster, Germany :5 pm 787. Serum Leucine-Rich Alpha- Glycoprotein as a Marker For Disease Activity in Adult-Onset Still s Disease You-Jung Ha, Jung-Soo Song, Eun-Jin Kang, Sang-Won Lee, Yong-Beom Park, Soo-Kon Lee and Sang Tae Choi, Yonsei University College of Medicine, Seoul, South Korea, Chung-Ang University College of Medicine, Seoul, South Korea, Busan Medical Center, Busan, South Korea :0 pm 788. Efficacy of Tocilizumab in Refractory Adult-Onset Still s Disease: Multicenter Study of Patients Francisco Ortiz-Sanjuan, Ricardo Blanco, Javier Narvaez, Esteban Rubio Romero 4, Alejandro Olivé 5, Santos Castañeda 6, Adela Gallego Flores 7, M. Victoria Hernández 8, Cristina Mata, Inmaculada Ros Vilamajo 9, Alberto Sifuentes Giraldo 0, M Caracuel, Mercedes Freire, Catalina Gómez Arango, José Llobet 4, Sara Manrique Arija 5, Carlos Marras 6, Concepcion Moll Tuduri 7, Chamaida Plasencia Rodriguez 8, Rosa Roselló 9, Ana Urruticoechea 0, Maria Luisa Velloso Feijoo, Javier Loricera, Vanesa Calvo-Rio and Miguel A González-Gay, Hospital Universitario Marqués de Valdecilla. IFIMAV. Santander. Spain, Santander, Spain, Hospital Universitario Marqués de Valdecilla. IFIMAV, Santander, Spain, Hospital Universitario de Bellvitge, Barcelona, Spain, 4 HU Virgen del Rocío, Sevilla, Spain, 5 Hospital Universitario Germans Trias i Pujol, Badalona, Spain, 6 Hospital Universitario de La Princesa, IIS Princesa, Madrid, Spain, 46 0 Program Book denotes Hilton San Diego Bayfront room location

49 7 Hospital de Mérida, Mérida, Spain, 8 Hospital Clinic, Barcelona, Spain, 9 Hospital Son Llàtzer, Palma de Mallorca, Spain, 0H Ramón y Cajal, Madrid, Spain, Hospital de Córdoba., Córdoba, Spain, Hospital Universitario Juan Canalejo. La Coruña, La Coruña, Spain, HU Basurto, Bilbao, Spain, 4 H Sant Pau, Barcelona, Spain, 5 HRU Carlos Haya, Málaga, Spain, 6 Hospital Universitario Virgen de la Arrixaca, Murcia, Spain, 7 H Mateu Orfila, Mahón, Spain, 8 HU La Paz, Madrid, Spain, 9 H San Jorge, Huesca, Spain, 0 Hospital Can Misses, Ibiza, Spain, H Valme, Sevilla, Spain :45 pm 789. Sirolimus Plus Prednisone for Erdheim-Chester Disease: A Pilot Trial Davide Gianfreda, Federico Alberici, Maricla Galetti, Maria Nicastro, Carlo Buzio and Augusto Vaglio, University of Parma, Parma, Italy, Nephrology University of Parma, Parma, Italy 8 D Pediatric Rheumatology: Clinical and Therapeutic Disease: Juvenile Idiopathic Arthritis Moderators: Andrew Zeft, MD and Murray H. Passo, MD :0 pm 790. Predictors and Sustainability Of Clinical Inactive Disease in Polyarticular Juvenile Idiopathic Arthritis Given Aggressive Therapy Very Early in The Disease Course Carol A. Wallace, Edward H. Giannini, Steven J. Spalding, Philip J. Hashkes 4, Kathleen M. O Neil 5, Andrew S. Zeft, Ilona S. Szer 6, Sarah Ringold 7, Hermine I. Brunner, Laura E. Schanberg 8, Robert P. Sundel 9, Diana Milojevic 0, Marilynn G. Punaro, Peter Chira, Beth S. Gottlieb, Gloria C. Higgins 4, Norman T. Ilowite 5, Yukiko Kimura 6, Anne Johnson, Bin Huang 7 and Daniel J. Lovell, Seattle Childrens Hosp & Research Institute, Seattle, WA, Cincinnati Children s Hospital Medical Center, Cincinnati, OH, The Cleveland Clinic, Cleveland, OH, 4 Shaare Zedek Medical Center, Jerusalem, Israel, 5 Riley Hospital for Children, Indianapolis, IN, 6 Rady Childrens Hosp San Diego, San Diego, CA, 7 Seattle Children s Hospital, Seattle, WA, 8 Duke University Medical Center, Durham, NC, 9 Boston Children s Hospital and Harvard Medical School, Boston, MA, 0University of California, San Francisco, San Francisco, CA, Texas Scottish Rite Hospital, Dallas, TX, Indiana University School of Medicine, Riley Hospital for Children, Indianapolis, IN, Cohen Children s Medical Center of New York, New Hyde Park, NY, 4 Nationwide Childrens Hosp, Columbus, OH, 5 The Children s Hospital at Montefiore, Bronx, NY, 6 Joseph M Sanzari Children s Hospital, Hackensack University Medical Center, Hackensack, NJ, 7 Cincinnati Children s Hospital Medical Center/University of Cincinnati School of Medicine, Cincinnati, OH :45 pm 79. Efficacy and Safety of Tocilizumab in Patients With Polyarticular-Course Juvenile Idiopathic Arthritis: -Year Data from Cherish Hermine I. Brunner, Nicolino Ruperto, Zbigniew Zuber, Rubén J. Cuttica, Ricardo Xavier, Inmaculada Calvo, Nadina Rubio, Ekaterina Alekseeva, Vyacheslav Chasnyk 4, Jose Chavez, Gerd Horneff, Violetta Opoka-Winiarska, Pierre Quartier, Alberto Spindler, Caroline Keane 5, Kamal N. Bharucha 6, Jianmei Wang 5, Daniel J. Lovell, Alberto Martini and Fabrizio De Benedetti 7, PRCSG, Cincinnati, OH, PRINTO, Genoa, Italy, Pediatric Rheumatology International Trials Organization (PRINTO)- 6 C Istituto Gaslini, Genova, Italy, 4 Saint-Petersburg State Pediatric Medical University, Saint-Petersburg, Russia, 5 Roche, Welwyn Garden City, United Kingdom, 6 Genentech, South San Francisco, CA, 7 IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy :00 pm 79. Methotrexate Polyglutamates in Erythrocytes Are Associated With Lower Disease Activity in Juvenile Idiopathic Arthritis Patients Maja Bulatovic Calasan, Ethan den Boer, Maurits C.F.J. De Rotte, S.J. Vastert, Sylvia Kamphuis, Robert De Jonge and Nico M. Wulffraat, University Medical Center Utrecht, Utrecht, Netherlands, Erasmus Medical Center, Rotterdam, Netherlands, Eramus MC Sophia Children s Hospital, Rotterdam, Netherlands :5 pm 79. Efficacy and Safety of Adalimumab in Pediatric Patients With Enthesitis Related Arthritis Rubén Burgos-Vargas, Shirley M.L. Tse, Gerd Horneff, Aileen L. Pangan 4, Kristina Unnebrink 5 and Jaclyn K. Anderson 6, Hospital General de Mexico, Universidad Nacional Autonoma de Mexico, Mexico City, Mexico, University of Toronto, The Hospital for Sick Children, Toronto, ON, Asklepios Klinik Sankt Augustin, Sankt Augustin, Germany, 4 AbbVie Inc., North Chicago, IL, 5 AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany, 6 AbbVie, North Chicago, IL :0 pm 794. Recent Trends In Medication Usage for the Treatment of Juvenile Idiopathic Arthritis and the Influence of TNF Inhibitors Melissa L. Mannion, Fenglong Xie, Jeffrey R. Curtis and Timothy Beukelman, University of Alabama at Birmingham, Birmingham, AL :45 pm 795. Second TNF-Inhibitor or Alternative Biologic in Juvenile Idiopathic Arthritis (JIA) Patients Failing a First TNF-Inhibitor Kirsten Minden, Klaus Tenbrock, Gerd Horneff and Hans- Iko Huppertz 4, pediatric rheumatology, Berlin, Germany, University Aachen, Aachen, Germany, Asklepios Klinik Sankt Augustin, Sankt Augustin, Germany, 4 Prof. Hess Childrens Hospital, Bremen, Germany Rheumatoid Arthritis - Clinical Aspects I: Treatment Strategies in Rheumatoid Arthritis Moderators: Merete Hetland, DMSc, MD, PhD and Clifton O. Bingham III, MD :0 pm 796. Drug Exposure Limitations of Oral Methotrexate (MTX) At Doses >5mgs May Be Overcome by Using a Subcutaneous MTX Auto-Injector in Patients With Rheumatoid Arthritis (RA) Michael H. Schiff, Lee S. Simon, Bruce Freundlich, Jonathan Jaffe 4 and Kaushik J. Dave 4, University of Colorado, Denver, CO, SDG LLC Consulting, West Newton, MA, University of Pennsylvania, Philadelphia, PA, 4 Antares Pharma Inc, Ewing, NJ :45 pm 797. Methotrexate Exposure Assessment in Routine Clinical Rheumatology Practice: Effect of Dosing and Route of Administration on Polyglutamate Levels Roy A. Kaplan, Brigid Freyne, Derren Barken and Thierry Dervieux, Private Practice / Scripps Health, Encinitas, CA, Private Practice, Murietta, CA, Exagen Diagnostics, Vista, CA SUNDAY october 7, 0 denotes Hilton San Diego Bayfront room location 0 Program Book 47

50 SUNDAY october 7, 0 0 E :00 pm 798. Targeting Ultrasound Remission in Early Rheumatoid Arthritis - Results of The Taser Study James Dale, Anne Stirling, Iain B. McInnes and Duncan Porter, University of Glasgow, Glasgow, United Kingdom, Gartnavel General Hospital, Glasgow, United Kingdom :5 pm 799. Clinical and Radiological Outcomes of Two Years Remission Steered Treatment in Early Arthritis Patients L. Heimans, K.V.C. Wevers-de Boer, G. Akdemir, H.K Ronday, T.H.E. Molenaar, J. H. L. M. Van Groenendael 4, A.J. Peeters 5, I. Speyer 6, G. Collee 7, P.B. de Sonnaville 8, B.A. Grillet 9, T.W.J. Huizinga and C.F. Allaart, Leiden University Medical Center, Leiden, Netherlands, Haga Hospital, The Hague, Netherlands, Groene Hart Hospital, Gouda, Netherlands, 4 Franciscus Hospital, Roosendaal, Netherlands, 5 Reinier de Graaf Gasthuis, Delft, Netherlands, 6 Bronovo Hospital, Den Haag, Netherlands, 7 MCH, The Hague, Netherlands, 8 Admiraal de Ruyter hospital, Goes, Netherlands, 9 Zorgsaam Hospital, Terneuzen, Netherlands :0 pm 800. A Strategy for Selecting Individuals With Rheumatoid Arthritis for Reduction of Anti-TNF Therapy Using Combined Clinical and Ultrasound Assessment Christopher R. Holroyd, Brian Davidson, Sarah Bennett, David Waghorn, Caron Underhil, Cyrus Cooper, Antonia Calogeras, Elaine M. Dennison, Nicholas C. Harvey, Ray Armstrong, Stephan Gadola and Christopher J. Edwards 4, University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom, MRC Lifecourse Epidemiology Unit, Southampton, United Kingdom, University of Southampton, Southampton, United Kingdom, 4 NIHR Wellcome Trust Clinical Research Facility, University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom :45 am 80. Remaining Pain is Common in Early Rheumatoid Arthritis Patients Treated With Methotrexate Results From the EIRA Cohort and the Swedish Rheumatology Quality Register Reem Altawil, Saedis Saevarsdottir, Sara Wedren, Lars Alfredsson, Lars Klareskog and Jon Lampa 4, Rheumatology Unit, Department of Medicine, Karolinska University Hospital, Karolinska Institute, Stockholm, Sweden, Rheumatology unit, Karolinska University Hospital, Karolinska Institute, Stockholm, Sweden, Institute of Environmental Medicine, Karolinska Institute, Stockholm, Sweden, 4 Karolinska Institutet, Stockholm, Sweden Rheumatoid Arthritis Treatment - Small Molecules, Biologics and Gene Therapy: Safety Issues Moderators: John J. Cush, MD and Sergio Schwartzman, MD :0 pm 80. Tofacitinib, An Oral Janus Kinase Inhibitor: Analysis of Malignancies Across the Rheumatoid Arthritis Clinical Program X. Mariette, J. R. Curtis, E. B. Lee, B. Benda 4, I. Kaplan 5, K. Soma 5, R. Chew 5, J. Geier 6, L. Wang 5 and R. Riese 5, Paris-Sud University, Paris, France, University of Alabama at Birmingham, Birmingham, AL, Seoul National University, Seoul, South Korea, 4 Pfizer Inc, Collegeville, PA, 5 Pfizer Inc, Groton, CT, 6 Pfizer Inc, New York, NY :45 pm 80. The Risk of Serious Infections in Patients Receiving Rituximab for Rheumatoid Arthritis: Results From the British Society for Rheumatology Biologics Register-Rheumatoid Arthritis Lucía Silva-Fernández, Mark Lunt, Audrey S. Low, Kath D. Watson, BSRBR Control Centre Consortium, Deborah P. Symmons, Kimme L. Hyrich and On behalf of the BSRBR, Arthritis Research UK Epidemiology Unit, University of Manchester, Manchester, United Kingdom, Arthritis Research UK Epidemiology Unit, Manchester Academic Health Sciences Centre, Institute of Inflammation and Repair, The University of Manchester, Manchester, United Kingdom, British Society for Rheumatology, London, United Kingdom :00 pm 804. Tumour Necrosis Factor Inhibitors and the Risk Of Acute Coronary Syndrome in Rheumatoid Arthritis A National Cohort Study Lotta Ljung, Johan Askling, Solbritt M. Rantapää-Dahlqvist, Lennart T.H. Jacobsson and The ARTIS Study Group, Umeå University, Umeå, Sweden, Karolinska Institutet, Stockholm, Sweden, Department of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden :5 pm 805. Good Response on Tumour Necrosis Factor Inhibitors Are Associated With a Decreased Risk of Acute Coronary Syndromes in Patients With Rheumatoid Arthritis Lotta Ljung, Lennart T.H. Jacobsson, Solbritt M. Rantapää- Dahlqvist, Johan Askling and The ARTIS Study Group, Umeå University, Umeå, Sweden, Department of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden, Karolinska Institutet, Stockholm, Sweden :0 pm 806. Risk of Cancer Recurrence or New Tumors In RA Patients With Prior Malignancies Treated With Various Biologic Agents Anja Strangfeld, Dagmar Pattloch, Peter Herzer, Edmund Edelmann 4, Silke Zinke 5, Martin Aringer 6, Joachim Listing 7 and Angela Zink 8, German Rheumatism Research Center, a Leipniz Institute, Berlin, Germany, German Rheumatism Research Center, Berlin, Berlin, Germany, University of Munich, Munich, Germany, 4 Rheumatologist, Bad Aibling, Germany, 5 Rheumatological Office, Berlin, Germany, 6 University Clinical Center Technical University of Dresden, Dresden, Germany, 7 German Rheumatism Research Center, Berlin, Germany, 8 German Rheumatism Research Centre and Charité University Medicine, Berlin, Germany :45 pm 807. Perioperative Use of Anti-Rheumatic Agents Does Not Increase Early Postoperative Infection Risks: A Veteran Affairs Administrative Database Study Zaki AbouZahr, Andrew Spiegelman, Maria Cantu and Bernard Ng 4, Baylor College of Medicine, Houston, TX, Michael E DeBakey Veteran Affairs Medical Center, Houston, TX, Baylor College Of Medicine, Houston, TX, 4 Michael E. DeBakey VA Medical Center, Houston, TX 48 0 Program Book denotes Hilton San Diego Bayfront room location

51 04 A Rheumatoid Arthritis-Autoantibodies and Citrullinated Proteins Moderators: William H. Robinson, MD, PhD and T.W.J. Huizinga, MD PhD :0 pm 808. A Genome Wide Association Study of Rheumatoid Arthritis Without Antibodies Against Citrullinated Peptides Lara Bossini-Castillo, Carolien de Kovel, Henrik Kallberg, Marieke J.H. Coenen 4, Paul P. Tak 5, Marcel D. Posthumus 6, Cisca Wijmenga 7, Thomas W.J. Huizinga 8, Annette H.M. van der Helm-van Mil 8, Luis Rodriguez-Rodriguez 9, Isidoro Gonzalez- Alvaro 0, Miguel Angel Gonzalez-Gay, Irene E. van der Horst-Bruinsma, B.A.C Dijkmans, G. J. Wolbink, Roel A. Ophoff, Piet L.C.M. van Riel 4, Lars Klareskog, J.B.A. Crusius 5, Elisabeth Brouwer 6, Javier Martin 7, Niek de Vries 5, René E.M. Toes 8, Leonid Padyukov and Bobby P.C. Koeleman, Instituto de Parasitología y Biomedicina López-Neyra, IPBLN-CSIC, Granada, Spain, Department of Medical Genetics, UMCU Utrecht, Utrecht, Netherlands, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden, 4 Department of Human Genetics, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, 5 Division of Clinical Immunology and Rheumatology and Department of Experimental Immunology, Academic Medical Center / University of Amsterdam, Amsterdam, Netherlands, 6 University of Groningen, University Medical Center, Groningen, Netherlands, 7 University Medical Hospital Groningen, University of Groningen, Groningen, Netherlands, 8 Leiden University Medical Center, Leiden, Netherlands, 9 Hospital Clínico San Carlos, Madrid, Spain, 0Hospital Universitario de La Princesa, Madrid, Spain, Hospital Universitario Marqués de Valdecilla. IFIMAV. Santander, Santander, Spain, VU University Medical Center, Amsterdam, Netherlands, Jan van Breemen Research Institute Reade, Amsterdam, Netherlands, 4 Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, 5 Vrije Universiteit Medical Center, Amsterdam, Netherlands, 6 University of Groningen, University Medical Center Groningen, Groningen, Netherlands, 7 Instituto de Parasitologia y Biomedicina López- Neyra, IPBLN-CSIC, Granada, Spain :45 pm 809. IgM Rheumatoid Factor as a Potentiator of Anti- Citrullinated Protein Antibody Mediated Inflammation in Rheumatoid Arthritis Jeremy Sokolove, Danye Cheng, Dannette S. Johnson, Ted R. Mikuls and William H. Robinson 4, VA Palo Alto Health Care System and Stanford University, Palo Alto, CA, Jackson VA and University of Mississippi Medical Center, Jackson, MS, Omaha VA and University of Nebraska Medical Center, Omaha, NE, 4 Stanford University School of Medicine, Stanford, CA :00 pm 80. Inducible Bronchus Associated Lymphoid Tissue in the Lung Is Associated With Seropositivity for Rheumatoid Arthritis-Related Autoantibodies in Subjects With and Without Clinically Diagnosed Rheumatoid Arthritis M. Kristen Demoruelle, Adam W. Bagley, Mark C. Parish, David E. Heinz, V. Michael Holers, Carlyne D. Cool and Kevin D. Deane, University of Colorado School of Medicine, Aurora, CO :5 pm 8. Influence of Smoking on Citrullinated Proteins and Porphyromonas Gingivalis in The Lung: A Priming Site for Autoimmunity in Rheumatoid Arthritis Elena B. Lugli, Patrick Venables, Raquel Correia, Karin Lundberg 4, Ken Bracke 5 and Guy Brusselle 5, Kennedy Institute of Rheumatology, Oxford, United Kingdom, University of Oxford, Oxford, United Kingdom, Univerity of Oxford, Oxford, United Kingdom, 4 Rheumatology unit, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden, 5 Gent University, Gent, Belgium :0 pm 8. Alveolar Bone Loss Is Associated With Disease Activity and ACPA Expression In Rheumatoid Arthritis Ted R. Mikuls, Jeffrey Payne, Fang Yu, Geoffrey M. Thiele, Shawneen Gonzalez, Jeffrey Markt 4, Jeremy Sokolove 5, William H. Robinson 6, Richard J. Reynolds 7, Grant W. Cannon 8, David McGowan 9, Gail S. Kerr 0, Robert Redman, Andreas M. Reimold, Garth Griffiths, Mark Beatty, Marian Schmid, Paul Johnson, Debra Bergman 4, Bartlett C. Hamilton III, Alan R. Erickson 4 and James R. O Dell 4, Omaha VA and University of Nebraska Medical Center, Omaha, NE, University of Nebraska Medical Center, Lincoln, NE, Univ of Nebraska Med Ctr, Omaha, NE, 4 University of Nebraska Medical Center, Omaha, NE, 5 Stanford University, Palo Alto, CA, 6 Stanford University School of Medicine, Stanford, CA, 7 University of Alabama at Birmingham, Birmingham, AL, 8 Salt Lake City VA and University of Utah, Salt Lake City, UT, 9 George E. Wahlen VA Medical Center, Salt Lake City, UT, 0Washington DC VAMC, Georgetown and Howard University, Washington, DC, Washington DC VA, Georgetown and Howard University, Washington, DC, Dallas VA and University of Texas Southwestern, Dallas, TX, University of Nebraska Medical Center and Omaha VA Medical Center, Omaha, NE, 4 Omaha VA and University of Nebraska Medical Center, LaVista, NE :45 pm 8. Citrulline Specific CD4+ T Cells Exhibit a Th Memory Phenotype in Rheumatoid Arthritis Subjects and Their Ex Vivo Frequency Is Influenced By Both Disease Duration and Biologic Therapy Eddie James, Mary Rieck, Jennifer Pieper, John Gebe, Betty Yue, Megan Tatum, Charlotta Sandin 4, Lars Klareskog 5, Vivianne Malmström 6 and Jane Buckner 7, Benaroya Research Institute, Seattle, WA, Karolinska Institutet, Rheumatology Unit, Stockholm, Sweden, Benaroya Research Institute at Virginia Mason, Seattle, WA, 4 Rheumatology Unit, Karolinska Institutet, Stockholm, Sweden, 5 Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden, 6 Rheumatology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden, 7 Translational Research Program, Benaroya Research Institute, Seattle, WA 980, USA,, Seattle, WA A Spondylarthropathies and Psoriatic Arthritis: Clinical Aspects and Treatment: Therapeutics and Outcomes in Psoriatic Arthritis Moderators: Philip S. Helliwell, MA, PhD and Oliver M. Fitzgerald, MD SUNDAY october 7, 0 denotes Hilton San Diego Bayfront room location 0 Program Book 49

52 SUNDAY october 7, 0 :0 pm 84. Results of a Randomised Controlled Trial Comparing Tight Control of Early Psoriatic Arthritis (TICOPA) With Standard Care: Tight Control Improves Outcome Laura C. Coates, Anna R. Moverley, Lucy McParland, Sarah Brown, Howard Collier, Jennifer Law, Sarah R. Brown, Neil Corrigan, Nuria Navarro-Coy, Paul Emery, Philip G. Conaghan and Philip S. Helliwell, NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds, United Kingdom, Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, United Kingdom, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom :45 pm 85. Long-Term (5-Week) Results of a Phase, Randomized, Controlled Trial of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients With Psoriatic Arthritis (PALACE ) Maurizio Cutolo, Gary E. Myerson, Roy M. Fleischmann, Frédéric Lioté 4, Federico Díaz-González 5, Filip Van den Bosch 6, Helena Marzo-Ortega 7, Eugen Feist 8, Kamal Shah 9, ChiaChi Hu 9, Randall M. Stevens9 and Airi Poder 0, University of Genova, Genova, Italy, Arthritis and Rheumatology of Georgia, Atlanta, GA, Metroplex Clinical Research Center, University of Texas Southwestern Medical Center, Dallas, TX, 4 Hôpital Universitaire Lariboisière, Paris, France, 5 University of La Laguna, Hospital Universitario de Canarias, La Laguna, Spain, 6 Gent University Hospital, Gent, Belgium, 7 Leeds Musculoskeletal Biomedical Research Unit and University of Leeds, Leeds, United Kingdom, 8 Charite University Hospital, Berlin, Germany, 9 Celgene Corporation, Warren, NJ, 0Clinical Research Centre Ltd, Tartu, Estonia :00 pm 86. Apremilast, an Oral Phosphodiesterase 4 Inhibitor, Is Associated With Long-Term (5-Week) Improvements In Enthesitis and Dactylitis in Patients With Psoriatic Arthritis: Pooled Results from Three Phase, Randomized, Controlled Trials Dafna D. Gladman, Philip J. Mease, Arthur Kavanaugh, Adewale O. Adebajo 4, Juan J. Gomez-Reino 5, Jürgen Wollenhaupt 6, Maurizio Cutolo 7, Georg Schett 8, Eric Lespessailles 9, Kamal Shah 0, ChiaChi Hu 0, Randall M. Stevens 0, Christopher J. Edwards and Charles A. Birbara, University of Toronto, Toronto Western Hospital, Toronto, ON, Swedish Medical Center and University of Washington School of Medicine, Seattle, WA, University of California San Diego, San Diego, CA, 4 University of Sheffield, Sheffield, United Kingdom, 5 Hospital Clinico Universitario, Santiago, Spain, 6 Schön Klinik Hamburg Eilbek, Hamburg, Germany, 7 University of Genova, Genova, Italy, 8 University of Erlangen-Nuremberg, Erlangen, Germany, 9 University of Orléans, Orléans, France, 0Celgene Corporation, Warren, NJ, University of Southampton, Southampton, United Kingdom, University of Massachusetts Medical School, Worcester, MA :5 pm 87. Clinical Response to Brodalumab, an Anti-Interleukin-7 Receptor Antibody, In Subjects With Psoriatic Arthritis Mark C. Genovese, Philip J. Mease, Maria W. Greenwald, Christopher T. Ritchlin 4, André Beaulieu 5, Atul Deodhar 6, Richard Newmark 7, JingYuan Feng 7, Ngozi Erondu 7 and Ajay Nirula 7, Stanford University, Palo Alto, CA, Swedish Medical Center and University of Washington School of Medicine, Seattle, WA, Desert Medical Advances, Palm Desert, CA, 4 University of Rochester, Rochester, NY, 5 Faculty of Medicine, Laval University, Quebec, QC, 6 Oregon Health and Science University, Portland, OR, 7 Amgen Inc, Thousand Oaks, CA :0 pm 88. HLA-B*080 Is Strongly Associated With Asymmetrical Sacroiliitis and HLA-B*7 With Symmetrical Involvement in Psoriatic Arthritis: Results Of a Long-Term Follow-Up Study Examining Clinical and Genetic Predictors Of Radiographic Sacroiliitis Muhammad Haroon, Agnes Szentpetery, Phil Gallagher, Robert Winchester and Oliver FitzGerald, Dublin Academic Medical Centre, St. Vincent s University Hospital, Dublin, Ireland, Columbia University, New York, NY :45 am 89. Low Diagnostic Utility of Candidate Definitions for a Positive MRI of The Spine in Axial Spondyloarthritis Ulrich Weber, Veronika Zubler, Zheng Zhao, Robert GW Lambert, Kaspar Rufibach 4, Stanley Chan, Susanne Juhl Pedersen 5, Mikkel Ostergaard 6 and Walter P. Maksymowych, Balgrist University Hospital, Zurich, Switzerland, Department of Rheumatology, University of Alberta and PLA General Hospital, Beijing, PR China, Beijing, China, University of Alberta, Edmonton, AB, 4 reprostat, Basel, Switzerland, 5 Copenhagen University Hospital at Glostrup, Copenhagen, Denmark, 6 Copenhagen Center for Arthritis Research, Glostrup, Denmark Indigo C Systemic Sclerosis, Fibrosing Syndromes and Raynaud s Pathogenesis, Animal Models and Genetics I: Therapeutic Interventions in Preclinical Animal Models of Sclerodermaoderma Moderators: Christopher P. Denton, PhD and John Varga, MD :0 pm 80. CC-0: A Clinical Stage Immunomodulatory, Antifibrotic Drug for Systemic Sclerosis Jörg HW Distler, Yongqing Wang, Pawel Zerr, Katrin Palumbo 4, Gerald Horan 5, Peter Schafer 5 and Bashar Kahaleh, Department of Internal Medicine and Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, University of Toledo, Toledo, OH, Department of Internal Medicine III and Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, 4 University of Erlangen-Nuremberg, Erlangen, Germany, 5 Celgene Corporation, Summit, NJ :45 pm 8. Activation of The Signal Transducer and Activator of Transcription By Transforming Growth Factor-Beta Promotes Fibroblast Activation and Tissue Fibrosis Barbora Sumova, Katrin Palumbo-Zerr, Clara Dees, Pawel Zerr, Oliver Distler 4, Georg Schett, Ladislav Senolt 5 and Joerg H. W. Distler, Department of Rheumatology of the First Faculty of Medicine, Institute of Rheumatology and Connective Tissue Research Laboratory, Prague, Czech Republic, Department of Internal Medicine III and Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, University of Erlangen-Nuremberg, Erlangen, Germany, 4 Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland, 5 Institute of Rheumatology, Department 50 0 Program Book denotes Hilton San Diego Bayfront room location

53 of Rheumatology, st Faculty of Medicine, Charles University, Prague, Czech Republic :00 pm 8. Inhibition of Casein Kinase II Reduces TGFβ Induced Fibroblast Activation and Ameliorates Experimental Fibrosis Yun Zhang, Internal Medicine, University of Erlangen- Nuremberg, Erlangen, Germany, Erlangen, Germany :5 pm 8. Activation of Liver X Receptors Inhibits Experimental Fibrosis By Interfering With Interleukin-6 Release From Macrophages Christian Beyer, Jürgen Beer, Katrin Palumbo-Zerr, Pawel Zerr, Alfiya Distler, Clara Dees, Louis E. Munoz, Gerhard Krönke, Oliver Distler, Steve Anderson, Georg A. Schett 4 and Joerg H. W. Distler, Department of Internal Medicine III and Institute for Clinical Immunology, University of Erlangen- Nuremberg, Erlangen, Germany, Department of Rheumatology and Center of Experimental Rheumatology, University Hospital Zurich, Zurich, Switzerland, Lexicon Pharmaceuticals Inc., The Woodlands, TX, 4 University of Erlangen-Nuremberg, Erlangen, Germany :0 pm 84. Bosentan Improves Vascular Abnormalities In Endothelial Cell-Specific Fli Knockout Mice By Increasing the DNA Binding Ability Of Fli - a Possible Mechanism Explaining The Effect of Bosentan on Scleroderma Vasculopathy Kaname Akamata, Yoshihide Asano, Takashi Taniguchi, Takehiro Takahashi, Yohei Ichimura, Tetsuo Toyama, Maria Trojanowska and Shinichi Sato, University of Tokyo Graduate School of Medicine, Tokyo, Japan, Boston University, Boston, MA :45 pm 85. Activating Transcription Factor Regulates Canonical Transforming Growth Factor Beta Signaling In Experimental Fibrosis Tatjana Mallano, Katrin Palumbo-Zerr, Christian Beyer, Clara Dees, Jingang Huang, Tsonwin Hai, Georg A. Schett and Joerg H. W. Distler, Department of Internal Medicine III and Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, University of Erlangen-Nuremberg, Erlangen, Germany, The Ohio State Biochemistry Program, The Ohio State University, Columbus, USA, Colombus, OH ACR/ARHP COMBINED ABSTRACT SESSION :0-4:00 pm C ACR/ARHP Combined Rehabilitation Abstract Session Moderators: Benjamin J. Smith, PA-C and Elena Louisa, PhD :0 pm 86. The Value of History and Physical Examination Findings in the Diagnosis Of Symptomatic Meniscal Tear Among Middle- Age Subjects With Knee Pain Jeffrey N. Katz, Yan Dong, John Wright, Stephanie Chen, Scott Martin, Laurel Donnell-Fink, Benjamin N. Rome and Elena Losina, Brigham and Women s Hospital, Boston, MA :45 pm 87. Cost-Effectiveness and Cost-Utility of a One-Year Coaching Program for Healthy Physical Activity in Rheumatoid Arthritis Nina Brodin, Malin Lohela Karlsson, Emma Swärdh and Christina H. Opava, Karolinska Institutet, SE 48 Huddinge, Sweden, Karolinska Institutet, Stockholm, Sweden, Karolinska Institutet, Huddinge, Sweden :00 pm 88. Psychosocial Determinants of Total Knee Arthroplasty Outcomes Years After Surgery Aparna Ingleshwar, Maria A. Lopez-Olivo, Glenn C. Landon, Sherwin J. Siff, Andrea Barbo 4 and Maria E. Suarez-Almazor 5, The University of Texas, MD Anderson Cancer Center, Houston, TX, Houston, TX, University of Texas. M.D Anderson Cancer Center, Houston, TX, St. Luke s Episcopal Health System, Houston, TX, 4 MD Anderson Cancer Center, Houston, TX, 5 University of Texas MD Anderson Cancer Center, Houston, TX :5 pm 89. Is the Severity of Knee Osteoarthritis on MRI Associated With Outcome of Exercise Therapy? Jesper Knoop, Joost Dekker, Marike van der Leeden, Martin van der Esch, J.P. Klein, David J. Hunter, Leo D. Roorda, Martijn P.M. Steultjens 4 and Willem F. Lems, Reade, centre for rehabilitation and rheumatology, Amsterdam, Netherlands, VU University Medical Center, Amsterdam, Netherlands, University of Sydney, Sydney, Australia, 4 Glasgow Caledonian University, Glasgow, Scotland :0 pm 80. Ethnic Variations at Time of Surgery and During Follow-Up in Patients Undergoing Total Knee Arthroplasty Aparna Ingleshwar, Andrea Barbo, Glenn C. Landon, Sherwin J. Siff, Sofia De Achaval 4 and Maria E. Suarez-Almazor 5, The University of Texas, MD Anderson Cancer Center, Houston, TX, Houston, TX, MD Anderson Cancer Center, Houston, TX, St. Luke s Episcopal Health System, Houston, TX, 4 U.T. MD Anderson Cancer Center, Houston, TX, 5 University of Texas MD Anderson Cancer Center, Houston, TX :45 pm 8. Relationships Between Clinical Outcome Measures and Gait Variables Before and After Total Hip Arthroplasty Kharma C. Foucher and Omar Behery, University of Illinois at Chicago, Chicago, IL, Rush University Medical Center, Chicago, IL ARHP SESSIONS :0-4:00 pm Indigo D Best Practices for Diagnostic Imaging in Evaluating Rheumatologic Conditions Moderator: Barbara A. Slusher, PA-C, MSW review common rheumatology conditions that can be diagnosed with the aid of imaging review differences between x-ray, MRI, CT and US for evaluating conditions and when/why a specific modality is preferred over another order the optimal plain film views and MRI imaging SUNDAY october 7, 0 denotes Hilton San Diego Bayfront room location 0 Program Book 5

54 :0 pm Choosing the Correct Imaging Modality Gregory C. Gardner, MD :00 pm Imaging of Common Rheumatologic Conditions P. Scott Pollock, MD ARHP CONCURRENT ABSTRACT SESSION :0-4:00 pm B ARHP Exemplary Abstracts Moderators: Mujahed Alikhan, MD and Robert W. Lightfoot Jr., MD SUNDAY october 7, 0 :0 pm Review of Plain Films and Magnetic Resonance Images to Make the Correct Diagnosis John C. Hunter, MD Sapphire A Influence of Cardiac Comorbidities on Exercise in Individuals With Rheumatic Diseases Moderator: Kim D. Jones, PhD identify epidemiology of cardiac comorbidities in patients with rheumatic diseases discuss risk factor assessment for cardiac comorbidities in rheumatic diseases identify appropriate modifications to fitness assessments for those with rheumatic diseases determine modifications for exercise prescriptions for those comorbidities and rheumatic diseases :0 pm Update on Cardiac Risk Factors in Rheumatic Diseases Peter A. Valen, :5 pm One Size Does Not Fit All - Fitness Assessments and Exercise Modifications for Individuals With Rheumatic Diseases and Cardiac Comorbidities Audrey Lynn Millar, PhD, PT Sapphire I Juvenile Systemic Lupus Erythematosus Moderator: Thuy T. Beam, BSN, RN review the criteria for the diagnosis of juvenile systemic lupus erythematous clinical management of juvenile systemic lupus erythematous psychosocial well-being of the patients and families :0 pm Diagnosis and Management of Juvenile Systemic Lupus Erythematous Kathleen M. O Neil, MD :0 pm Questions and Answers Kathleen M. O Neil, MD :0 pm Inside Looking Out: Perspectives From a Lupus Patient Kiana Johnson, PhD :55 pm Questions and Answers Kiana Johnson, PhD :0 pm 8. Factors That Affect Tender and Swollen Joint Counts in Rheumatoid Arthritis Christine L. Amity, Marisa Eckels, Kenneth N. Gold, Kelly A. Reckley 4, Niveditha Mohan 5, Stephen R. Wisniewski 6, Elizabeth A. Schlenk 7, Marc C. Levesque 7 and Terence W. Starz 8, Univ of Pittsburgh, Pittsburgh, PA, University of Pittsburgh Medical Center, Pittsburgh, PA, Arthritis & Internal Medicine, Pittsburgh, PA, 4 University of Pittsburgh School of Medicine, Pittsburgh, PA, 5 Univ of Pittsburgh Arth Inst, Pittsburgh, PA, 6 University of Pittsburgh, Graduate School of Public Health, Pittsburgh, PA, 7 University of Pittsburgh, Pittsburgh, PA, 8 Arth & Internal Med Associates, Pittsburgh, PA :45 pm 8. Cardiovascular Diseases in Rheumatoid Arthritis: Can Early Treatment With Disease-Modifying Antirheumatic Drugs Alter the Risk? Rishi Desai, Jaya Rao, Richard Hansen, Gang Fang, Matthew Maciejewski 4 and Joel Farley, Brigham & Women s Hospital, Harvard Medical School, Boston, MA, University of North Carolina, Chapel Hill, NC, Auburn University, Auburn, AL, 4 Duke University, Durham, NC :00 pm 84. Physical Activity Behavior in Patients With Arthritis Gustavo J. Almeida and Sara R. Piva, University of Pittsburgh, Pittsburgh, PA :5 pm 85. The Association of Worsening Structural Disease With Trajectories of Decline in Physical Function in Knee Osteoarthritis: Results From Two Cohort Studies Daniel K. White, Tuhina Neogi, Jingbo Niu, Uyen Sa D.T. Nguyen, David T. Felson, Barton L. Wise, C.E. Lewis, Michael C. Nevitt 4, James Torner 5 and Yuqing Zhang, Boston University School of Medicine, Boston, MA, UC Davis School of Medicine, Sacramento, CA, University of Alabama, Birmingham City, Brimingham, AL, 4 University of California, San Francisco, San Francisco, CA, 5 University of Iowa, Iowa City, Iowa City, IA :0 pm 86. Comprehensive Behavioral Intervention Compared to Standard of Care Exercise Program After Total Knee Arthroplasty: A Pilot Randomized Trial Sara R. Piva, Maria Beatriz Catelani and Gustavo J. Almeida, University of Pittsburgh, Pittsburgh, PA :45 pm 87. The Validity of the Satisfaction With Appearance Scale and the Brief Satisfaction With Appearance Scale for Patients With Limited and Diffuse Systemic Sclerosis Rina M. Sobel-Fox, Sarah D. Mills, Shadi Gholizadeh, Erin L. Merz, Philip J. Clements, Suzanne Kafaja, Vanessa L. Malcarne, Dinesh Khanna 4 and Daniel E. Furst, SDSU/UCSD Joint Doctoral Program in Clinical Psychology, San Diego, CA, David Geffen School of Medicine, UCLA, Los Angeles, CA, Department of Psychology, San Diego State University, Psychology, San Diego, CA, 4 University of Michigan Medical School, Ann Arbor, MI 5 0 Program Book denotes Hilton San Diego Bayfront room location

55 ACR WORKSHOPS 4:00-6:00 pm Admission to Workshops requires a separate registration and ticket. To verify which session you registered for, the registration code on your ticket needs to match the -digit code in parentheses below. If you are interested in participating in one of these sessions or exchanging your ticket, visit the ACR registration desk to check space availability. View the session overview online in My Annual Meeting at www. ACRannualmeeting.org. * Sessions denoted with an asterisk were sold out as of August 0. Joint Injection Techniques () Speakers: Atul A. Deodhar, MD and Kenneth S. O Rourke, MD discuss indications and contraindications for joint aspirations and injections identify and avoid common mistakes in joint injection procedures perform common joint and soft tissue injections on upper and lower extremities ACR SESSIONS 4:0-6:00 pm 6 C OA-OMICS Moderator: Richard F. Loeser, MD list the key genes discovered by genome wide analysis to be most associated with osteoarthritis review transcriptional regulation of genes in joint tissues that contribute to osteoarthritis outline the proteins recently discovered by proteomics analysis to be altered in osteoarthritis 4:0 pm Recent Advances in the Genetics of Osteoarthritis John Loughlin, PhD 5:00 pm The Osteoarthritis Transcriptome Linda Sandell, PhD 5:0 pm Osteoarthritis Proteomics Francisco J. Blanco, V, MD SUNDAY october 7, 0 4 B Musculoskeletal Exam Skills I: General Musculoskeletal Examination for Arthritis () Speakers: George V. Lawry, MD and Paul C. Utrie, MD participate in a hands-on, skill building workshop where participants are paired together for one-on-one practice complete a general musculoskeletal exam in a systematic, efficient and clinically effective way in approximately six minutes review strategies for increasing exposure of medical students, resident and fellow trainees to basic musculoskeletal physical examination skills Musculoskeletal Ultrasonography: Basic (4) Speakers: Janak R. Goyal, MD and Gurjit S. Kaeley, MBBS, MRCP explain basic concepts of ultrasound physics learn to perform a proper ultrasound examination identify various tissues in an ultrasound image Synovial Fluid Analysis and Crystal Identification (5) Speakers: Brian F. Mandell, MD, PhD; Lan Chen, MD, PhD and Gilda M. Clayburne, MLT prepare synovial fluid samples for microscopic examination identify various components of synovial fluid identify crystals in synovial fluid denotes Hilton San Diego Bayfront room location 0 E 6 A Pediatric Inflammatory Brain Diseases Moderators: C. Egla Rabinovich, MD, MPH and Susa Bensler, MD, PhD describe the differential of pediatric inflammatory brain diseases identify how to make the diagnosis of a pediatric inflammatory brain disease initiate treatment in pediatric inflammatory brain diseases 4:0 pm Overview of Pediatric Inflammatory Brain Diseases Heather Van Mater, MD, MSc 5:00 pm Pediatric Demyelinating Disorders Mark P. Gorman, MD 5:0 pm Antibody-mediated Inflammatory Brain Disease Sean J. Pittock, MD Quality Measures in Rheumatology: Developing and Implementing Meaningful Measures as Health Care Reform Advances Moderator: Jinoos Yazdany, MD, MPH explain the ACR measure development process and how it aligns with national standards for measure development outline how ACR rheumatology measures can be incorporated in your practice both for internal quality improvement and for participation in key performance reporting programs describe the quality measurement implementation tools available from the ACR 0 Program Book 5

56 4:0 pm Quality Measure Development: The Battle to Define Meaningful Measures for Rheumatologists Mark L. Robbins, MD, MPH 5:00 pm Incorporating ACR Quality Measures into Your Daily Practice: Improving Quality Locally Eric D. Newman, MD 5:0 pm ACR-Developed Tools to Facilitate Implementation of Quality Measures Salahuddin Kazi, MD Ballroom 0 A Regenerative and Stem Cell Medicine Moderator: Mark F. Gourley, MD Hall B Thieves Market: Show Me Your Best Cases Moderators: Rula Hajj-Ali, MD and N. Lawrence Edwards, MD compare their diagnostic and management approaches of selected clinical problems with those of other rheumatologists and the presenters learn about unusual presentations of common diseases identify and recognize essential mimics of the rheumatic diseases 4:0 pm Image Competition Presentation Brian E. Daikh, MD 4:50 pm Case # Anisha B. Dua, MD SUNDAY october 7, 0 describe what regenerative medicine entails identify the various types of stem cells discuss potential use of regenerative medicine 4:0 pm Stem Cells: How, What and Why? Mahendra Rao, MD, PhD 5:00 pm Stem Cells in Rheumatic Diseases Alan G. Tyndall, MD 5:0 pm Stem Cell Therapies: How Will They be Regulated? Melissa Carpenter, PhD Indigo E Sex and Autoimmunity: Hormones and Beyond Moderator: Wael N. Jarjour, MD describe the role of sex hormones, their impact on the immune response and their potential role in autoimmunity assess the evidence for the role of the sex chromosome on autoimmune diseases in humans and in animal models examine the relationship between estrogen receptors and immune function in health and autoimmunity 4:0 pm Estrogen and Progesterone: Friends or Foes in Autoimmunity? Eric Gershwin, MD 5:00 pm X Chromosome: Above and Beyond Hormonal Effects Ram Raj Singh, MD 5:0 pm Estrogen Receptors in Immunity and Autoimmunity Gary S. Gilkeson, MD 5:00 pm Case # Ashima Malik, MD 5:0 pm Case # Uma Thanarajasingam, MD, PhD 5:0 pm Case #4 Nilofar Syed, MD 5:0 pm Case #5 Angela Bryan, MD, BS 5:40 pm Case #6 Kiley Dru Toder, MD ACR CONCURRENT ABSTRACT SESSIONS 4:0-6:00 pm Sapphire I Fibromyalgia, Soft Tissue Disorders and Pain: Diagnosis and Disease Epidemiology Moderators: Lisa G. Suter, MD and Terry H. Oh, MD 4:0 pm 88. Recommendations for the Classification and Diagnosis of Fibromyalgia Syndrome Provided By Independently Developed Evidence-Based Interdisciplinary Guidelines Spanning Three Continents Mary-Ann Fitzcharles, Yoram Shir, Jacob N. Ablin, Dan Buskila, Howard Amital 4, Peter Henningsen 5 and Winfried Häuser 5, McGill University Health Centre, Montreal, QC, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, Ben-Gurion University, Beer-Sheva, Israel, 4 Department of Medicine B, Center for Autoimmune Diseases, Sheba Medical Center, Tel-hashomer, Israel, 5 Klinikum Saarbrücken, Saarbrücken, Germany 54 0 Program Book denotes Hilton San Diego Bayfront room location

57 4:45 pm 89. A Paradigm Change for Treatment Strategies for Fibromyalgia Syndrome Reflected By Recommendations of Recent Evidence-Based Interdisciplinary Guidelines Developed Independently in Three Countries Jacob N. Ablin, Dan Buskila, Howard Amital, Mary-Ann Fitzcharles 4, Yoram Shir 4, Peter Henningsen 5 and Winfried Häuser 5, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, Ben- Gurion University, Beer-Sheva, Israel, Department of Medicine B, Center for Autoimmune Diseases, Sheba Medical Center, Tel-hashomer, Israel, 4 McGill University Health Centre, Montreal, QC, 5 Klinikum Saarbrücken, Saarbrücken, Germany 5:00 pm 840. Fibromyalgia, Somatic Symptoms, and Mental Illness in View of The 0 Diagnostic and Statistical Manual of Mental Disorders Frederick Wolfe, Brian T. Walitt, Robert S. Katz and Winfried Häuser 4, National Data Bank for Rheumatic Diseases, Wichita, KS, Washington Hospital Center, Washington, DC, Rush Medical College, Chicago, IL, 4 Klinikum Saarbrücken, Saarbrücken, Germany 5:5 pm 84. The Prevalence of Fibromyalgia in the General Population A Comparison of the ACR 990, 00 and Modified 00 Classification Criteria Gareth T. Jones, Marcus Beasley, Fabiola Atzeni, Elisa Flüß, Piercarlo Sarzi-Puttini and Gary Macfarlane, University of Aberdeen, Aberdeen, United Kingdom, Rheumatology Unit, L. Sacco University Hospital, Milan, Italy 5:0 pm 84. A Cytokine/Chemokine Multiplex Assay That Is Sensitive and Specific for Fibromyalgia Compared to Controls, Systemic Lupus Erythematosus, and Rheumatoid Arthritis Daniel J. Wallace, Igor Gavin, Oleksiy Karpenko and Bruce S. Gillis, Cedars-Sinai Medical Center, Los Angeles, CA, University of Illinois College of Medicine at Chicago, Chicago, IL 4:45 pm 845. Improving Pneumococcal Vaccination Rate in the Pediatric Rheumatology Clinic Julia G. Harris, Kristyn I. Maletta, Bixiang Ren and Judyann C. Olson, Children s Hospital of Wisconsin, Milwaukee, WI, National Outcomes Center, Children s Hospital of Wisconsin, Milwaukee, WI, Medical College of Wisconsin, Milwaukee, WI 5:00 pm 846. Applying Choosing Wisely: Identifying Inefficiencies of Antinuclear Antibody Subserology Testing in a Safety Net Health System Lisa A. Davis, Barbara L. Goldstein, Vivian Tran, Angela Keniston, Jinoos Yazdany, Joel M. Hirsh, Amy Storfa and Joann Zell, Denver Health and Hospital Authority, Denver, CO, National Jewish Health, Denver, CO, University of California, San Francisco, San Francisco, CA 5:5 pm 847. Do Rheumatologists (and Other Specialists) Practice What We Preach? A Study of Serology Ordering Patterns With Attention to Subserologies When the Antinuclear Antibody By Enzyme Linked Immunosorbent Assay Is Negative; and The Clinical Significance of These Positive Subserology Results David Bulbin, Alicia Meadows, Alfred E. Denio, H. Lester Kirchner, Sandi Kelsey and Harold Harrison, Geisinger Medical Center, Danville, PA, Geisinger Health System, Danville, PA 5:0 pm 848. Human Papillomavirus Vaccine Uptake Among Children and Young Adults With Autoimmune Diseases Candace H. Feldman, Linda T. Hiraki, Joyce Lii and Seoyoung C. Kim, Division of Rheumatology, Immunology and Allergy, Brigham and Women s Hospital, Harvard Medical School, Boston, MA, Brigham and Women s Hospital, Harvard School of Public Health, Boston, MA, Brigham and Women s Hospital, Boston, MA SUNDAY october 7, 0 5:45 pm 84. Endogenous Pain Modulation in the Ehlers-Danlos Syndrome, Hypermobility Type Inge De Wandele, Ghent University, Ghent, Belgium 8 D Health Services Research, Quality Measures and Quality of Care - Pediatrics, Immunization and Choosing Wisely Moderators: Una E. Makris, MD and Esi Morgan DeWitt, MD, MSCE 4:0 pm 844. Level and Determinants of Health Related Quality of Life in Childhood-Onset Systemic Lupus Erythematosus Jordan T. Jones, Shannen L. Nelson, Janet Wootton, Brianna Liberio 4, Alexandria J. Greenler, Jennifer L. Huggins, Laura E. Schanberg and Hermine I. Brunner, Cincinnati Children s Hospital Medical Center, Cincinnati, OH, Cincinnati Children s Hospital Medical Center, Cincinnati, OH, Duke University Medical Center, Durham, NC, 4 University of Cincinnati College of Medicine, Cincinnati, OH 5:45 pm 849. Reasons For Failure to Obtain Influenza and Pneumococcal Vaccines Among Immunosuppressed Individuals With Systemic Lupus Erythematosus Erica F. Lawson, Laura Trupin, Emily von Scheven, Edward H. Yelin and Jinoos Yazdany, UC San Francisco, San Francisco, CA C Imaging of Rheumatic Diseases: Imaging in Vascular and Extra-articular Moderators: Annamaria Iagnocco, MD, PhD and Jonathan Samuels, MD 4:0 pm 850. Salivary Gland Ultrasonography: A Highly Specific Tool for the Early Diagnosis of Primary Sjögren s Syndrome Nicoletta Luciano, Chiara Baldini, Gaia Tarantini, Rachele Pascale, Francesca Sernissi, Linda Carli, Francesco Ferro, Rosaria Talarico, Marta Mosca, Davide Caramella and Stefano Bombardieri, Rheumatology Unit, Pisa, Italy, Department of Diagnostic and Interventional Radiology, University of Pisa, Pisa, Italy, Rheumatology Unit, University of Pisa, Pisa, Italy denotes Hilton San Diego Bayfront room location 0 Program Book 55

58 SUNDAY october 7, 0 4:45 pm 85. Salivary Gland Ultrasonography Improves the Diagnostic Performance Of ACR 0 Classification Criteria for Sjögren s Syndrome, Even in the Early Stages of the Disease Divi Cornec, Sandrine jousse-joulin, Thierry Marhadour, Jacques-Olivier Pers, Yves Renaudineau, Alain Saraux 4 and Valerie Devauchelle-Pensec 5, Brest Occidentale University, Brest, France, Brest university medical school, EA 6, UBO and CHU de la Cavale Blanche,, Brest, France, CHU de la Cavale Blanche, Brest, France, 4 CHU Brest et Université Bretagne Occidentale, Brest, France, 5 Brest Occidentale university, Brest, France 5:00 pm 85. Systemic Lupus Erythematosous and Primary Sjogren s Syndrome May Display Joint Erosions on MRI as Well as Healthy Control, but Cannot Be Considered as Erosive Disease Such as Rheumatoid Arthritis: An MRI Observational Study of 90 Subjects Frédérique Gandjbakhch, Violaine Foltz, Jérôme Renoux, Nahalie Cozic, Nathalie Costedoat-Chalumeau 4, Damien Sene 5, Guillaume Mercy 6, Zahir Amoura 7, Jean-Charles Piette 7, Nathalie Morel 8, Pierre Bourgeois 9 and Bruno Fautrel 0, APHP, Pitié Salpétrière Hospital, Universite Paris 6, Paris, France, Pitie- Salpetriere Hospital, Paris, France, APHP, Pitie Salpetriere Hospital, department of statistics, Paris, France, 4 Hopital Cochin, Paris, France, 5 Hopital Lariboisière, Paris, France, 6 APHP, Pitie- Salpétrière Hospital, paris, France, 7 CHU Pitié-Salpêtrière, Paris, France, 8 Groupe Hospitalier Pitié-Salpétrière, Paris, France, 9 APHP,Pitie-Salpetriere Hospital, Paris 6, Paris, France, 0 Paris 6 Pierre et Marie Curie University; AP-HP, Rheumatology, Pitié- Salpêtrière Hospital, - GRC-UPMC 08 EEMOIS, Paris, France 5:5 pm 85. Capillaroscopy Compared With Color Doppler Ultrasound of Digital Arteries for Distinguishing Primary From Secondary Raynaud s Phenomenon Wolfgang A. Schmidt, Katharina Pagel, Bernd Schicke and Andreas Krause 4, Med Ctr Rheumatology Berlin Buch, Immanuel Krankenhaus Berlin, Berlin, Germany, Medical Ctr Rheumatol Berlin Buch, Immanuel Krankenhaus Berlin, Berlin, Germany, Tumorzentrum Berlin, Berlin, Germany, 4 Immanuel Krankenhaus Berlin, Berlin, Germany 5:0 pm 854. Aortic Wall Thickness In Patients Without Aortitis: A Computed Tomography-Based Study of 00 Patients Afif Nakhleh, Irina Rukhkyan, Vladimir Wolfson, Itzhak A. Rosner, Majed Odeh and Gleb Slobodin, Bnai Zion Medical Center, Haifa, Israel 5:45 pm 855. Ultrasound Evaluation of the Greater Trochanter Pain Syndrome: Bursitis or Tendinopathy? Cristian Quiroz, Santiago Ruta, Javier Rosa, David A. Navarta, Ricardo Garcia-Monaco and Enrique R. Soriano, Rheumatology Unit, Internal Medical Services, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, Radiology and Imagenology Department, Hospital italiano de Buenos Aires, Buenos Aires, Argentina, Rheumatology Unit, Internal Medical Services, Hospital Italiano de Buenos Aires, Instituto Universitario Hospital Italiano de Buenos Aires, and Fundacion PM Catoggio, Buenos Aires, Argentina Sapphire A Metabolic and Crystal Arthropathies I Moderators: Naomi Schlesinger, MD and Fernando Perez Ruiz, MD, PhD 4:0 pm 856. Cost-Effectiveness of Urate Lowering Strategies for the Management of Gout Eric Jutkowitz, Karen Kuntz, Laura T Pizzi and Hyon Choi 4, University of Minnesota, Minneapolis, MN, Division of Health Policy and Management, School of Public Health, University of Minnesota, Minneapolis, MN, Thomas Jefferson University, Philadelphia, PA, 4 Boston University School of Medicine, Boston, MA 4:45 pm 857. Impact of Urate Lowering Therapy on Renal Disease Progression in Patients With Hyperuricemia Gerald D. Levy, T. Craig Cheetham, Nazia Rashid and Fang Niu, Southern California Permanente Medical Group, Downey, CA, Kaiser Permanente, Downey, CA, Kaiser Permanente Southern California, Downey, CA 5:00 pm 858. Monosodium Urate Crystal Induced Macrophage Inflammation Is Attenuated By Chondroitin Sulfate: Pre-Clinical Model for Gout Prophylaxis? Eric W. Orlowsky, Thomas V. Stabler, Eulalia Montell, Josep Verges and Virginia B. Kraus, Duke University Medical Center, Durham, NC, Pre-Clinical R&D Area, Pharma Science Division, Bioibérica, Barcelona, Spain 5:5 pm 859. Knee Effusion: Sensitivity and Specificity of Ultrasound for The Identification of Calcium Pyrophosphate Crystals Erika Catay, Santiago Ruta, Javier Rosa, David A. Navarta, Marina Scolnik, Ricardo Garcia-Monaco and Enrique R. Soriano 4, Rheumatology Unit, Internal Medical Services, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, Rheumatology Section, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, Radiology and Imagenology Department, Hospital italiano de Buenos Aires, Buenos Aires, Argentina, 4 Rheumatology Unit, Internal Medical Services, Hospital Italiano de Buenos Aires, Instituto Universitario Hospital Italiano de Buenos Aires, and Fundacion PM Catoggio, Buenos Aires, Argentina 5:0 pm 860. Diet-Induced Obesity Results in a Pro-Inflammatory Resting Environment With No Impact on Monosodium Urate Crystal-Induced Inflammation Odette Shaw, Bregina Pool, Nicola Dalbeth and Jacquie Harper, Malaghan Institute of Medical Research, Wellington, New Zealand, University of Auckland, Auckland, New Zealand 56 0 Program Book denotes Hilton San Diego Bayfront room location

59 5:45 pm 86. Many Gout Patients Treated By Rheumatologists Do Not Meet Established Treatment Goals Despite Long-Term Urate Lowering Therapy: Results of a Gout Patient Encounter Survey Max I. Hamburger, Michael H. Pillinger, Robert Sederman and Gary Fernandez 4, Rheumatology Associates, Melville, NY, NYU School of Medicine, Division of Rheumatology, New York, NY, C Consulting, LLC, Summit, NJ, 4 Savient Pharmaceuticals, Bridgewater, NJ 0 A Osteoporosis and Metabolic Bone Disease: Clinical Aspects and Pathogenesis Moderators: Anthony D. Woolf, MBBS and Robin K. Dore, MD 4:0 pm 86. Ten-Year Incidence of Self-Reported Nonvertebral Fractures in 9,70 Japanese Patients With Rheumatoid Arthritis: A Prospective Observational Cohort Study Kensuke Ochi, Takefumi Furuya, Eisuke Inoue, Katsunori Ikari, Atsuo Taniguchi, Hisashi Yamanaka and Shigeki Momohara, Institute of Rheumatology, Tokyo Women s Medical University, Tokyo, Japan, Tokyo Women s Medical University, Tokyo, Japan 4:45 pm 86. Romosozumab Administration Is Associated With Significant Improvements In Lumbar Spine and Hip Volumetric Bone Mineral Density and Content Compared With Teriparatide H K Genant, S Boonen, M A Bolognese, C Mautalen 4, J P Brown 5, C Recknor 6, S Goemaere 7, K Engelke 8, Y-C Yang 9, M Austin 9, A Grauer 9 and C Libanati 9, UCSF & Synarc Inc., San Francisco, CA, Leuven University Division of Geriatric Medicine, Leuven, Belgium, The Bethesda Health Research Center, Bethesda, MD, 4 Centro de Osteopatias Medicas, Buenos Aires, Argentina, 5 CHU de Québec Research Centre and Laval University, Québec, QC, 6 United Osteoporosis Centers, Gainesville, GA, 7 Ghent University Hospital, Ghent, Belgium, 8 Synarc Germany, Hamburg, Germany, 9 Amgen Inc., Thousand Oaks, CA 5:5 pm 865. Vertebral Fractures in the Year Period Following Steroid Initiation Among Children With Chronic Illnesses Johannes Roth, Jinhui Ma, David A. Cabral, Peter B. Dent, Janet E. Ellsworth 4, Adam M. Huber 5, Kristin M. Houghton 6, Roman Jurencak, Bianca A. Lang 7, Maggie Larche, Claire MA Leblanc 8, Brian Lentle 6, MaryAnn Matzinger, Paivi M. Miettunen 9, Kiem Oen 0, Claire Saint-cyr, Rosie Scuccimarri, Nazih Shenouda, Leanne M. Ward and The Canadian STOPP Consortium, University of Ottawa, Ottawa, ON, BC Children s Hospital, Vancouver, BC, McMaster University, Hamilton, ON, 4 University of Alberta, Edmonton, AB, 5 IWK Health Centre and Dalhousie University, Halifax, NS, 6 University of British Columbia, Vancouver, BC, 7 Dalhousie University, Halifax, NS, 8 McGill University, Montréal, QC, 9 University of Calgary, Calgary, AB, 0 University of Manitoba, Winnipeg, MB, Université de Montréal, Montreal, QC, Montreal Children s Hospital and McGill University, Montréal, QC, National Pediatric Bone Health Working Group, Ottawa, ON 5:0 pm 866. Use of Non Steroidal Anti-Inflammatory Drugs Prevent Bone Loss in Patients With Early Inflammatory Back Pain: Results From the DESIR Cohort Karine Briot, Simon Paternotte, Corinne Miceli-Richard, Maxime Dougados and Christian Roux, Paris Descartes University, Paris, France, Université Paris Sud, Le Kremlin Bicêtre, France, Paris- Descartes University, Paris, France 5:45 pm 867. Reduced Hip Cortical Porosity Upon Denosumab Treatment: A Likely Mechanism Contributing to the Reduction of Hip Fracture Risk in Women With Osteoporosis R. M. Zebaze, C. Libanati, M. R. McClung, J. R. Zanchetta 4, D. L. Kendler 5, A. Høiseth 6, A. Wang, A. Ghasem-Zadeh and E. Seeman, Austin Health, University of Melbourne, Melbourne, Australia, Amgen Inc., Thousand Oaks, CA, Oregon Osteoporosis Center, Portland, OR, 4 Instituto de Investigaciones Metabólicas, Buenos Aires, Argentina, 5 University of British Columbia, Vancouver, BC, 6 Curato Røntgen, Oslo, Norway SUNDAY october 7, 0 5:00 pm 864. Further Reduction in Nonvertebral Fracture Rate Is Observed Following Years of Denosumab Treatment: Results With Up to 7 Years in the Freedom Extension Jonathan D. Adachi, Serge Ferrari, Carol Zapalowski, Paul D. Miller 4, Jean-Yves Reginster 5, Ove Törring 6, Nadia Daizadeh, Andrea Wang, Cynthia O Malley, Rachel B. Wagman and E. Michael Lewiecki 7, McMaster University, Hamilton, ON, Geneva University Hospital, Geneva, Switzerland, Amgen Inc., Thousand Oaks, CA, 4 Colorado Center for Bone Research, Lakewood, CO, 5 University of Liège, Liège, Belgium, 6 Karolinska Institutet, Södersjukhuset, Stockholm, Sweden, 7 New Mexico Clinical Research & Osteoporosis Center, Albuquerque, NM 9 D Rheumatoid Arthritis - Clinical Aspects II: Identifying Rheumatoid Arthritis in At-Risk Populations Moderators: Vivian P. Bykerk, MD and Kevin D. Deane, MD, PhD 4:0 pm 868. Serum Immunoglobulin Free Light Chains and Rheumatoid Arthritis: A Population-Based Study John M. Davis III, S. Vincent Rajkumar, Cynthia S. Crowson, Xiaoli Deng, Angela Dispenzieri, Dirk R. Larson, Terry M. Therneau, Eric L. Matteson, Robert A. Kyle, Jerry Katzmann and Sherine E. Gabriel, Mayo Clinic, Rochester, MN, Peking University Third Hospital, Beijing, China denotes Hilton San Diego Bayfront room location 0 Program Book 57

60 SUNDAY october 7, 0 4:45 pm 869. Anti-Carbamylated Protein Antibodies Are Present Prior to the Diagnosis Of Rheumatoid Arthritis and Predict Future Disease Onset Ryan W. Gan, Leendert A. Trouw, Jing Shi, René E.M. Toes, Tom W. J. Huizinga, Gary O. Zerbe, Kevin D. Deane 4, Jess Edison 5, William R. Gilliland 5, Jill M. Norris and V. Michael Holers 4, Colorado School of Public Health, Aurora, CO, Leiden University Medical Center, Leiden, Netherlands, Colorado School of Public Health / University of Colorado Anschutz Medical Campus, Aurora, CO, 4 University of Colorado School of Medicine, Aurora, CO, 5 Walter Reed National Military Medical Center, Bethesda, MD 5:00 pm 870. How to Predict That Early Arthritis Without Rheumatoid Factor and ACPA Becomes Rheumatoid Arthritis According to ACR/EULAR 00 After a -Years Follow-Up? Results From the Espoir Cohort Gaël Mouterde, Cédric Lukas, Nathalie Rincheval, Alain Saraux 4, Philippe Dieude 5 and Bernard Combe 6, Montpellier University, Lapeyronie Hospital, Montpellier, France, Lapeyronie Hospital, Montpellier, France, Institut Universitaire de Recherche Clinique, Montpellier, France, 4 CHU Brest et Université Bretagne Occidentale, Brest, France, 5 Rheumatology departement & INSERM U699, Paris Diderot university, APHP, Bichat hospital, Paris, France, 6 Lapeyronie Hospital, Montpellier I university, Montpellier, France 5:5 pm 87. Do We Need to Lower the Cut Point of the 00 ACR/ EULAR Classification Criteria for Diagnosing Rheumatoid Arthritis?! M. van der Ven, J.J. Luime, A.H. Gerards, C. Alves, P.J. Barendregt, D. van Zeben 4, M.H. de Jager 5, P.B.J. de Sonnaville 6, B.A. Grillet 7 and J.M.W. Hazes, Erasmus University Medical Center, Rotterdam, Netherlands, Vlietland Hospital, Schiedam, Netherlands, Maasstad Hospital, Rotterdam, Netherlands, 4 Sint Franciscus Gasthuis, Rotterdam, Netherlands, 5 Albert Schweitzer Hospital, Dordrecht, Netherlands, 6 Admiraal de Ruyter Ziekenhuis, Goes, Netherlands, 7 Zorgsaam Hospital, Terneuzen, Netherlands 5:0 pm 87. Spontaneous Remission in Patients Fulfilling The 00 Classification Criteria for Rheumatoid Arthritis: The Impact of Duration of Joint Swelling Ellen Sauar Norli, Elisabeth Lie, Gina Hetland Brinkmann, Olav Bjørneboe, Halvor Nygaard 4, Anne Julsrud Haugen, Patrik Stolt 5, Cathrine Thunem 6, Tore K. Kvien and Maria Mjaavatten, Martina Hansens Hospital, Gjettum, Norway, Diakonhjemmet Hospital, Oslo, Norway, Østfold Hospital Trust, Fredrikstad, Norway, 4 Revmatismesykehuset Lillehammer, Lillehammer, Norway, 5 Innlandet Hospital Trust, Brumunddal, Norway, 6 Betanien Hospital, Skien, Norway 6 D 5:45 pm 87. Health Fair Evaluations to Identify Subjects At-Risk for Future Inflammatory Arthritis and Rheumatoid Arthritis Kristen E. Beck, M. Kristen Demoruelle, Christopher C. Striebich, Kaylynn Aiona, Marie L. Feser 4, Lezlie A. Derber 4, Stacey Brake 5, Jill Lysengen 6, Laura Rosseisen 6, Julia J. Rhiannon, Stuart M. Weisman 4, Jill M. Norris, V. Michael Holers and Kevin D. Deane, University of Colorado School of Medicine, Aurora, CO, University of Colorado Denver, Aurora, CO, Colorado School of Public Health, Aurora, CO, 4 University of Colorado School of Medicine, Division of Rheumatology, Aurora, CO, 5 9Health Fair, Denver, CO, 6 Arthritis Foundation, Great West Region, Denver Office, Denver, CO Rheumatoid Arthritis Treatment - Small Molecules, Biologics and Gene Therapy: Efficacy of Approved Biologics II Moderators: Joseph A. Markenson, MD and William F. C. Rigby, MD 4:0 pm 874. Sustained and Consistent Clinical Benefit With Intravenous Golimumab Therapy in Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy: Results Through -Year of a Phase, Randomized, Multicenter, Double- Blind, Placebo-Controlled Trial Clifton O. Bingham III, Rene Westhovens, Alan M. Mendelsohn, Lilianne Kim, Kim Hung Lo and Michael E. Weinblatt 4, Johns Hopkins University, Baltimore, MD, University Hospital KU Leuven, Leuven, Belgium, Janssen Research & Development, LLC., Spring House, PA, 4 Brigham and Women s Hospital, Boston, MA 4:45 pm 875. Microrna Expression Profiles Associated With Response to Adalimumab and Methotrexate Versus Methotrexate: A Placebo-Controlled Clinical Trial Sophine B. Krintel, Christian Dehlendorff, Merete L. Hetland, Kim Hørslev-Petersen 4, Klaus K. Andersen, Peter Junker 5, Jan Pødenphant 6, Torkell Ellingsen 7, Palle Ahlqvist 8, Hanne M. Lindegaard 9, Asta Linauskas 0, Annette Schlemmer, Mette Y. Dam, Ib Hansen, Hans Chr Horn 4, Anette Jørgensen, Johnny Raun 4, Christian G. Ammitzbøll, Mikkel Østergaard 5, Kristian Stengaard-Pedersen and Julia S. Johansen 6, Copenhagen University and Glostrup Hospital, Copenhagen, Denmark, Danish Cancer Society Research Center, Copenhagen, Denmark, DANBIO, Center for Rheumatology and Spine Diseases, Glostrup Univ Hospital, Glostrup, Denmark, 4 University of Southern Denmark, Graasten, Denmark, 5 University of Southern Denmark, Odense, Denmark, 6 Copenhagen University at Gentofte, Hellerup, Denmark, 7 Silkeborg Regional Hospital, Silkeborg, Denmark, 8 University of Southern Denmark, Vejle, Denmark, 9 Odense University Hospital, Odense, Denmark, 0 Vendsyssel Hospital, Hjørring, Denmark, Aalborg University Hospital, Aalborg, Denmark, Arhus University Hospital, Aarhus, Denmark, Viborg Hospital, Viborg, Denmark, 4 Vejle Hospital, Vejle, Denmark, 5 Copenhagen University Hospital Glostrup, Copenhagen, Denmark, 6 Herlev Hospital, Herlev, Denmark 58 0 Program Book denotes Hilton San Diego Bayfront room location

61 5:00 pm 876. Prediction of TNF Inhibitor Response In Rheumatoid Arthritis Patients Using Single Cell Network Profiling of Intracellular Immune Signaling Jason Ptacek, Rachael Hawtin, Brent Louie, Erik Evensen, James Cordeiro, Barbara Mittleman, Michelle Atallah, Alessandra Cesano, Clifton O. Bingham III, Stacey Cofield, Jeffrey R. Curtis, Maria I. Danila, Richard A. Furie 4, Mark C. Genovese 5, Marc C. Levesque 6, Larry W. Moreland 6, Peter A. Nigrovic 7, James R. O Dell 8, William H. Robinson 5, Nancy A. Shadick 7, E. William St Clair 9, Christopher C. Striebich 0, Geoffrey M Thiele 8, Peter K. Gregersen 4 and S. Louis Bridges Jr., Nodality, Inc., South San Francisco, CA, Johns Hopkins University, Baltimore, MD, University of Alabama at Birmingham, Birmingham, AL, 4 The Feinstein Institute for Medical Research and North Shore-Long Island Jewish Health System, Lake Success, NY, 5 Stanford University, Palo Alto, CA, 6 University of Pittsburgh, Pittsburgh, PA, 7 Brigham and Women s Hospital/Harvard University, Cambridge, MA, 8 Omaha VA and the University of Nebraska Medical Center, Omaha, NE, 9 Duke Unversity Medical Center, Durham, NC, 0 University of Colorado Denver, Aurora, CO 5:5 pm 877. Results From the RATE-RA Study: A Multicenter, Single- Arm Study to Evaluate the Safety of Administering Rituximab at a More Rapid Infusion Rate in Patients With Rheumatoid Arthritis Charles H. Pritchard, Maria W. Greenwald, Joel M. Kremer, Norman B. Gaylis 4, William Rigby 5, Steve Zlotnick 6, Carol Chung 6, Birgit Jaber 7 and William Reiss 6, Drexel University College of Medicine, Willow Grove, PA, Desert Medical Advances, Palm Desert, CA, Center for Rheumatology, Albany Medical College, Albany, NY, 4 Arthritis & Rheumatic Disease Specialties, Aventura, FL, 5 Geisel School of Medicine at Dartmouth, Lebanon, NH, 6 Genentech Inc., South San Francisco, CA, 7 F. Hoffmann-La Roche Ltd., Basel, Switzerland 5:0 pm 878. Responders to Tocilizumab Identified By Serological Measurement of Connective Tissue Type I Collagen in Patients With Rheumatoid Arthritis Anne Sofie Siebuhr, Anne C. Bay-Jensen, Diana J. Leeming, Adam Platt, Inger Byrjalsen, Claus Christiansen, Désirée van de Heijde 4 and Morten Asser Karsdal, Nordic Bioscience, Biomarkers and Research, Herlev, Denmark, Roche Products Ltd, Welwyn Garden City, United Kingdom, Center for Clinical and Basic Research and C4Pain, Aalborg, Denmark, 4 Leiden Univerisity, Leiden, Netherlands 5:45 pm 879. Serological Biomarkers of Specific Mode of Action for Early Identification of Rheumatoid Arthritis Patients Who Respond to Anti-IL6 Or Anti-TNF Treatment Anne C. Bay-Jensen, Natasja Stæhr Gudman, Anne Sofie Siebuhr, Claus Christiansen and Morten Asser Karsdal, Nordic Bioscience, Biomarkers and Research, Herlev, Denmark A Systemic Lupus Erythematosus - Clinical Aspects and Treatment: Lupus Nephritis and Genetics Moderators: Cynthia Aranow, MD and Maria Dall Era, MD 4:0 pm 880. Role of Urinary Podocyte Number and Urinary Podocalyxin Level as Biomarkers of Glomerulonephritis in Systemic Lupus Erythematosus and ANCA-Associated Vasculitis Hiroshi Kajiyama, Keiju Hiromura, Daisuke Ikuma, Hidekazu Ikeuchi, Hiroyuki Kurosawa, Yoshiaki Hirayama, Fumio Gondaira, Masanori Hara 4, Yoshihisa Nojima and Toshihide Mimura, Saitama Medical University, Saitama, Japan, Gunma University Graduate School of Medicine, Maebashi, Gunma, Japan, Denka Seiken Co. Ltd., Niigata, Japan, 4 Yoshida Hospital, Niigata, Japan 4:45 pm 88. Time To Renal Flare and Renal Disease Activity Over a Year Period Is Associated With Urinary TWEAK Levels in Patients With Systemic Lupus Erythematosus Nicolas Wisniacki, Chris Stebbins, Jadwiga Bienkowska, Susan Gawlak, Donald Bennett 4, Yuhong Xiang, Andrea Dearth 5, Linda C. Burkly, Ann Ranger 5, Carrie Wager, Laurence S. Magder 6 and Michelle Petri 7, Biogen Idec, Maidenhead, United Kingdom, Biogen Idec, Cambridge, MA, Biogen Idec Inc., Cambridge, MA, 4 Biogen idec, Cambridge, MA, 5 Biogen Idec Inc, Cambridge, MA, 6 University of Maryland, Baltimore, MD, 7 Johns Hopkins University School of Medicine, Baltimore, MD 5:00 pm 88. Association of a Neutrophil Gene Signature Comprised of Low Density Granulocyte (LDG)-Enriched Genes With Both Future Systemic Lupus Erythematosus Disease Activity and Poor Longterm Outcomes Michelle Petri, Laurence S. Magder, Hong Fang, Jadwiga Bienkowska, Andrea Dearth 4, Norm Allaire and Ann Ranger 4, Johns Hopkins University School of Medicine, Baltimore, MD, University of Maryland, Baltimore, MD, Biogen Idec Inc., Cambridge, MA, 4 Biogen Idec Inc, Cambridge, MA 5:5 pm 88. Sex Bias in Autoimmune Diseases: Increased Risk of 47,XXX in Systemic Lupus Erythematosus (SLE) and Sjögren s Syndrome (SS) Supports the Gene Dose Hypothesis Ke Liu, Kenneth M. Kaufman, Judith A. James, Roland Jonsson, Biji T. Kurien 4, Xavier Mariette 5, Joan T. Merrill, Roald Omdal 6, Maureen Rischmueller 7, Timothy J. Vyse 8, Marie Wahren- Herlenius 9, Torsten Witte 0, Christopher J. Lessard, Sarah L. Zimmerman, Susan D. Thompson, Gideon Hirschfield 4, Gang Xie 5, Courtney G. Montgomery, Wan-Fai Ng 6, Gunnel Nordmark 7, Patrick M. Gaffney, Katherine A. Siminovitch 5, Kathy L. Sivils, Slegen (International Consortium For The Genetics Of SLE) 8 and R. Hal Scofield, Cincinnati Children s Hospital Medical Center and the University of Cincinnati, Cincinnati, OH, Oklahoma Medical Research Foundation, Oklahoma City, OK, Haukeland University Hospital, Bergen, Norway, 4 U.S. Department of Veterans Affairs Medical Center, Oklahoma City, OK, 5 Bicêtre University Hospital, Le Kremlin Bicetre, France, 6 Stavanger University Hospital, Stavanger, Norway, 7 Queen Elizabeth Hospital, Adelaide, Australia, SUNDAY october 7, 0 denotes Hilton San Diego Bayfront room location 0 Program Book 59

62 SUNDAY october 7, 0 8 King s College London, London, United Kingdom, 9 Karolinska Institutet, Stockholm, Sweden, 0 Medical University Hannover, Hanover, Germany, University of Oklahoma Health Sciences Center, Oklahoma City, OK, Cincinnati Children s Hospital Medical Center, Cincinnati, OH, Cincinnati Children s Hospital Medical Center, Cincinnati, OH, 4 University of Birmingham, Birmingham, United Kingdom, 5 Mount Sinai Hospital, Toronto, ON, 6 Newcastle University, Newcastle upon Tyne, United Kingdom, 7 Uppsala University, Uppsala, Sweden, 8 International Consortium For The Genetics Of Systemic Lupus Erythematosus, Cincinnati, OH 5:0 pm 884. Treatment of Lupus Nephritis With Abatacept Plus Low- Dose Pulse Cyclophosphamide Followed By Azathioprine (the Euro-Lupus Regimen): Twenty-Four Week Data From a Double- Blind Controlled Trial David Wofsy, Anca Askanase, Patricia C. Cagnoli, W. Winn Chatham 4, Gabriel Contreras 5, Maria Dall Era 6, Mary Anne Dooley 7, Hilda Fragoso-Loyo 8, David R. Karp 9, Meenakshi Jolly 0, Kenneth Kalunian, Diane L. Kamen, Iris Lee, Marc C. Levesque 4, S. Sam Lim 5, Meggan Mackay 6, Cesar Ramos-Remus 7, Brad H. Rovin 8, Tammy O. Utset 9, Swamy Venuturupalli 0, Robert Winchester, Linna Ding, Wendy Gao, Lynette Keyes-Elstein and Patti Tosta 4, University of California San Francisco and NIAID Autoimmunity Centers of Excellence, San Francisco, CA, NYU School of Medicine, New York, NY, University of Michigan Health, Ann Arbor, MI, 4 University of Alabama at Birmingham, Birmingham, AL, 5 University of Miami, Miami, FL, 6 University of California, San Francisco, San Francisco, CA, 7 University of North Carolina at Chapel Hill, Chapel Hill, NC, 8 Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico, Mexico, 9 UT Southwestern Medical Center, Dallas, TX, 0 Rush University Medical Center, Chicago, IL, UCSD School of Medicine, La Jolla, CA, Medical University of South Carolina, Charleston, SC, Temple University, Philadelphia, PA, 4 University of Pittsburgh, Pittsburgh, PA, 5 Emory University, Atlanta, GA, 6 Feinstein Institute for Medical Research, Manhasset, NY, 7 Unidad de Investigacion en Enfermedades Cronico-Degenerativas, Guadalajara, Mexico, 8 Ohio State University Medical Center, Columbus, OH, 9 University of Chicago Department of Medicine, Chicago, IL, 0 Cedars-Sinai Medical Center, Los Angeles, CA, Columbia University, New York, NY, NIAID, Bethesda, MD, Rho Federal Systems, Inc., Chapel Hill, NC, 4 Immune Tolerance Network, San Francisco, CA 5:45 pm 885. Fatigue in SLE Is Associated With Upregulation of Interferon- Alpha Related Gene Transcripts Maureen A. McMahon, Jennifer M. Grossman, Bevra H. Hahn, Lori Sahakian, Isao Matsuura, Elaine Lourenco and Brian Skaggs, UCLA David Geffen School of Medicine, Los Angeles, CA Indigo C Systemic Lupus Erythematosus - Human Etiology and Pathogenesis I Moderators: Mariana J. Kaplan, MD and Jane E. Salmon, MD 4:0 pm 0 Lee C. Howley, Sr. Prize for Arthritis Research Introductory Talk Speaker: George C. Tsokos, MD 4:45 pm 886. Lupus Neutrophil Extracellular Traps Render High Density Lipoprotein Oxidized and proatherogenic Carolyne K. Smith, Anuradha Vivekanandan-Giri, Jason S. Knight, Paul Ryan Thompson 4, Subramaniam Pennathur and Mariana J. Kaplan, University of Michigan, Ann Arbor, MI, University of Michigan Nephrology, Ann Arbor, MI, University of Michigan Rheumatology, Ann Arbor, MI, 4 The Scripps Research Institute, Jupiter, FL 5:00 pm 887. Atherosclerosis and Cardiovascular Disease in Systemic Lupus Eryhematosus Are Related to An Inflammatory/ Oxidative Status Linked to The Autoimmune Condition and the Clinical Activity of the Disease. Effect of Statins Treatment Chary Lopez-Pedrera Sr., Patricia Ruiz-Limon, Carlos Perez- Sanchez, Mª Angeles Aguirre, Nuria Barbarroja, Tomás Cerdó-Ráez, Maria Laura Bertolaccini, Munther A. Khamashta, Antonio Rodriguez-Ariza, Yolanda Almaden 4, Husam Khraiwesh 5, Jose Antonio Gonzalez-Reyes 6, Jose Manuel Villalba 6, Eduardo Collantes 7 and Mª Jose Cuadrado 8, IMIBIC-Reina Sofia Hospital, Cordoba, Spain, Imibic, Córdoba, Spain, Lupus Research Unit, The Rayne Institute, Kings College London School of Medicine, London, United Kingdom, 4 Imibic, Códoba, Spain, 5 UCO, Córdoba, Spain, 6 University of Cordoba, Cordoba, Spain, 7 Hospital Reina Sofia, Cordoba, Spain, 8 The Rayne Institute, London, United Kingdom 5:5 pm 888. Role of Calcium/Calmodulin Kinase IV on Podocyte Function in Lupus Nephritis Kunihiro Ichinose, Takeshi Ushigusa, Tomohiro Koga, George C. Tsokos 4 and Atsushi Kawakami, Unit of Translational Medicine, Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, 4 BIDMC, Harvard Medical School, Boston, MA 5:0 pm 889. Podocytes Take Up Adsdna Autoantibody Complexes Anja Hillmann, Elisabeth Jung, Annika Engbers, Hedda Wardemann, Annett M. Jacobi and Thomas Pap, University Hospital Münster, Münster, Germany, Max Planck Institute for Infection Biology, Berlin, Germany 5:45 pm 890. Quantitative Cell Distance Mapping in Human Nephritis Reveals Organization of In Situ Adaptive Immune Responses Marcus R. Clark, Vladimir M. Liarski, Natalya Kavernia, Maryellen L. Giger, Anthony Chang, Yahui Peng and Daniel F. Brandt, University of Chicago, Chicago, IL 60 0 Program Book denotes Hilton San Diego Bayfront room location

63 8 B Vasculitis I Moderators: Kenneth J. Warrington, MD and Eamonn Molloy, MD 4:0 pm 89. A Single Amino Acid in the β Chain of HLA-DR Explains The Majority of the HLA Association With Giant Cell Arteriti Javier Martin, F. David Carmona, Jose Ezequiel Martin, Aurora Serrano, Lara Bossini-Castillo, Roser Solans 4, Jose A. Miranda-Filloy 5, Santos Castañeda 6, Maria C. Cid 7, Jose A. Hernandez 8, Inmaculada C. Morado 9, Javier Narvaez 0, Ricardo Blanco, Bernardo Sopeña, M. Jesus García-Villanueva, Jordi Monfort 4, Norberto Ortego-Centeno 5, Ainhoa Unzurrunzaga 6, Begoña Marí-Alfonso 7, Cesar Magro 5, Ana Hidalgo-Conde 8, Marta Conde-Jaldon 9, María F. González-Escribano 9, Paul de Bakker 0, Bobby P.C. Koeleman and Miguel A. González-Gay, Instituto de Parasitologia y Biomedicina Lopez-Neyra (IPBLN- CSIC), Granada, Spain, Consejo Superior de Investigaciones Científicas, Armilla (Granada), Spain, Instituto de Parasitología y Biomedicina López-Neyra, IPBLN-CSIC, Granada, Spain, 4 Hospital Vall d Hebron, Barcelona, Spain, 5 Hospital Xeral- Calde, Lugo, Spain, 6 Hospital Universitario de La Princesa, IIS Princesa, Madrid, Spain, 7 Hospital Clínic. University of Barcelona. IDIBAPS, Barcelona, Spain, 8 Hospital Clinic. University of Barcelona, IDIBAPS,, Barcelona, Spain, 9 Hospital Clínico San Carlos, Madrid, Spain, 0 Hospital Universitario de Bellvitge, Barcelona, Spain, Hospital Universitario Marqués de Valdecilla, IFIMAV, Santander, Spain, Complejo Hospitalario Universitario de Vigo (CHUVI), Vigo, Spain, Hospital Ramón y Cajal, Madrid, Spain, 4 Hospital del Mar, Barcelona, Spain, 5 Hospital Clínico San Cecilio, Granada, Spain, 6 Hospital de Galdakano, Vizcaya, Spain, 7 Corporació Sanitaria Parc Taulí, Instituto Universitario Parc Taulí, UAB, Sabadell, Spain, 8 Hospital Universitario Virgen de la Victoria, Málaga, Spain, 9 Hospital Universitario Virgen del Rocío, Sevilla, Spain, 0 University Medical Center Utrecht, Utrecht, Netherlands, Department of Medical Genetics, UMCU Utrecht, Utrecht, Netherlands, Hospital Universitario Marqués de Valdecilla. IFIMAV. Santander. Spain, Santander, Spain 4:45 pm 89. The Functional PTPN Variant R60W Is Strongly Associated With Giant Cell Artetitis Predisposition F. David Carmona, Sarah L. Mackie, Aurora Serrano, Ana Marquez 4, Roser Solans 5, Jose A. Miranda-Filloy 6, Jose Hernández-Rodríguez 7, Maria C. Cid 7, Santos Castañeda 8, Inmaculada C. Morado 9, Javier Narvaez 0, Ricardo Blanco, Bernardo Sopeña, M. Jesus García-Villanueva, Jordi Monfort 4, Norberto Ortego-Centeno 5, Ainhoa Unzurrunzaga 6, Begoña Marí-Alfonso 7, Julio Sánchez-Martín 8, Eugenio de Miguel 9, Cesar Magro 5, Enrique Raya 0, Niko Braun, Joerg Latus, Øyvind Molberg, Benedicte A. Lie, Frank Moosig, Torsten Witte 4, Ann W. Morgan, Miguel A. González-Gay and Javier Martin, Consejo Superior de Investigaciones Científicas, Armilla (Granada), Spain, NIHR-Leeds Musculoskeletal Biomedical Research Unit and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, Instituto de Parasitologia y Biomedicina Lopez- Neyra (IPBLN-CSIC), Granada, Spain, 4 Instituto de Parasitología y Biomedicina López-Neyra (IPBLN-CSIC), Granada, Spain, 5 Hospital Vall d Hebron, Barcelona, Spain, 6 Hospital Xeral-Calde, Lugo, Spain, 7 Hospital Clínic. University of Barcelona. IDIBAPS, Barcelona, Spain, 8 Hospital Universitario de La Princesa, IIS Princesa, Madrid, Spain, 9 Hospital Clínico San Carlos, Madrid, Spain, 0 Hospital Universitario de Bellvitge, Barcelona, Spain, Hospital Universitario Marqués de Valdecilla. IFIMAV. Santander. Spain, Santander, Spain, Complejo Hospitalario Universitario de Vigo (CHUVI), Vigo, Spain, Hospital Ramón y Cajal, Madrid, Spain, 4 Hospital del Mar, Barcelona, Spain, 5 Hospital Clínico San Cecilio, Granada, Spain, 6 Hospital de Galdakano, Vizcaya, Spain, 7 Corporació Sanitaria Parc Taulí, Instituto Universitario Parc Taulí, UAB, Sabadell, Spain, 8 Hospital Universitario de Octubre, Madrid, Spain, 9 Hospital Universitario La Paz, Madrid, Spain, 0 University Hospital San Cecilio, Granada, Spain, Division of Nephrology, Robert-Bosch- Hospital, Stuttgart, Germany, Oslo University Hospital, Oslo, Norway, University of Luebeck, Bad Bramstedt, Germany, 4 Medical University Hannover, Hanover, Germany 5:00 pm 89. Association Between Human Leukocyte Antigen-B s Amino Acid Variation and Disease-Susceptibility to Takayasu s Arteritis Hajime Yoshifuji, Chikashi Terao, Kosaku Murakami, Daisuke Kawabata, Koichiro Ohmura, Takao Fujii, Yasushi Kawaguchi, Hisashi Yamanaka and Tsuneyo Mimori, Graduate School of Medicine, Kyoto University, Kyoto, Japan, Tokyo Women s Medical University, Tokyo, Japan 5:5 pm 894. Intermittent Fever, Immune Dysregulation, and Systemic Vasculopathy Due to Loss-of-Function Mutations in Adenosine Deaminase Qing Zhou, Dan Yang, Andrey Zavialov, Amanda Ombrello, Hyesun Kuehn 4, Jae Jin Chae, Anton Zavialov, David Chin, Deborah Stone, Camilo Toro, Joshua Milner 5, Chyi-chia Lee 6, Edward Cowen 6, Fabio Candotti, Elaine Remmers, Susan Moir 5, Raman Sood, Shawn Burgess, Massimo Gadina 7, Sergio Rosenzweig 5, Michael Hershfield 8, Daniel L. Kastner, Manfred Boehm and Ivona Aksentijevich, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, University of Turku, Turku, Finland, 4 Clinical Center, National Institutes of Health, Bethesda, MD, 5 National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, 6 National Cancer Institute, National Institutes of Health, Bethesda, MD, 7 National Institute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, MD, 8 Duke University Medical Center, Durham, NC 5:0 pm 895. The Relative Risk of Aortic Aneurysm In Patients With Giant Cell Arteritis Compared With the General Population Joanna Robson, Amit Kiran, Joseph Maskell, Andrew Hutchings 4, Nigel K. Arden 5, Bhaskar Dasgupta 6, William Hamilton 7, Akan Emin 8, David Culliford and Raashid A. Luqmani, Nuffield Department of Orthopaedics Rheumatology and Musculoskeletal Sciences, Botnar Research Centre, University of Oxford, Oxford, United Kingdom, University of Oxford, Oxford, United Kingdom, University of Southampton, SUNDAY october 7, 0 denotes Hilton San Diego Bayfront room location 0 Program Book 6

64 SUNDAY october 7, 0 Southampton, United Kingdom, 4 London School of Hygiene and Tropical Medicine, London, United Kingdom, 5 Oxford NIHR Musculoskeletal Biomedical Research Unit, University of Oxford, Oxford, United Kingdom, 6 Southend University Hospital, Westcliff-on-sea, United Kingdom, 7 University of Exeter Medical School, Exeter, United Kingdom, 8 The Royal College of Surgeons of England, London, United Kingdom 5:45 pm 896. Increased Rho Kinase (ROCK) Activity in Temporal Artery Biopsies From Patients With Giant Cell Arteritis (GCA) Lindsay Lally, Navneet Narula, Alessandra B. Pernis, Wei-Ti Huang, Uzunma Udeh and Robert F. Spiera, Hospital for Special Surgery, New York, NY, Weill Cornell Medical College, New York, NY ACR MEET THE PROFESSOR SESSIONS 4:0-6:00 pm Admission to Meet the Professor sessions requires a separate registration and ticket. To verify which session you registered for, the registration code on your ticket needs to match the -digit code in parentheses below. If you are interested in participating in one of these sessions or exchanging your ticket, visit the ACR registration desk to check space availability. View the session overview online in My Annual Meeting at www. ACRannualmeeting.org. * Sessions denoted with an asterisk were sold out as of August 0. *Ankylosing Spondylitis: 0 Update (0) Speaker: Michael H. Weisman, MD discuss the natural history of ankylosing spondylitis and spondylarthritis and its early diagnosis describe clinical and radiographic outcome measures used in trials and clinical practice summarize available guidelines in the management of ankylosing spondylitis Crystal: Diagnosis and Management of Gout (0) Speaker: Theodore R. Fields, MD discuss the usefulness of the ice test, evaluation of laboratory tests used in the diagnosis of gout and usefulness of imaging, especially ultrasonography in the diagnosis of gout discuss current treatments for acute and chronic gout discuss treatments in development 4 A Juvenile Dermatomyositis (0) Speaker: Susan Kim, MD discuss what is known about the pathogenesis and epidemiology of juvenile dermatomyositis discuss the approach to the evaluation of a patient referred with possible juvenile dermatomyositis discuss different therapeutic approaches to the treatment of juvenile dermatomyositits, ranging from mild to severe 4 B Osteoarthritis: Update 0 (04) Speaker: Joanne M. Jordan, MD, MPH describe the pathogenesis of osteoarthritis including factors that lead to its development and the underlying biology responsible for the progression of osteoarthritis discuss advances in the management of osteoarthritis that include non-pharmacologic interventions evaluate the potential benefits of new disease- or structuremodifying treatments for osteoarthritis 5 A Pain: Evaluation and Treatment of Back Pain (05) Speaker: Rajiv Dixit, MD describe the clinically relevant anatomy of the lumbar spine clinically evaluate a patient with acute or chronic back pain or a patient with an associated nerve root compression syndrome formulate a rational and cost effective management plan with a clear understanding of surgical indications 5 B *Rheumatoid Arthritis: Biological Agents (06) Speaker: Josef S. Smolen, MD Describe similarities and differences between approved biological agents in terms of efficacy and safety Discuss issues around biosimilars Address the place of biologicals in the therapeutic cascade according to the updated EULAR management recommendations Appreciate the potential of induction therapy with biologics followed by withdrawal of the biologic as a potential future treatment approach 6 A Rheumatoid Arthritis: Challenging Cases (07) Speaker: Stanley B. Cohen, MD discuss the management of patients with refractory rheumatoid arthritis identify novel treatment options for those failing conventional therapies create effective management plans for complicated rheumatoid arthritis patients 6 B *Systemic Lupus Erythematosus: Novel Treatments (08) Speaker: Susan Manzi, MD, MPH describe the history of therapeutic agents and the rationale for further drug development in lupus review new data to support standard therapies for management of lupus discuss the newest therapies approved for lupus and those currently under investigation 6 0 Program Book denotes Hilton San Diego Bayfront room location

65 7 A Systemic Sclerosis: Disease Staging and Subsetting in Clinical Practice (09) Speaker: Robyn T. Domsic, MD, MPH use clinical and serologic classification systems of systemic sclerosis to identify the natural history of clinical subsets explain the concept of disease staging in both diffuse and limited cutaneous systemic sclerosis use knowledge of clinical/serologic classification and disease staging to develop screening and management plans 7 B *Vasculitis: Update (00) Speaker: Raashid A. Luqmani, DM describe the current definitions of vasculitis according to affected vessel size disucss the role of simple clinical evaluation alongside the various available laboratory and imaging tests, including antineutrophil cytoplasm antibodies identify current and novel therapeutic modalities ARHP SESSIONS 4:0-6:00 pm A Fine Tuning Your Skills in Utilizing Disease Activity Measurement Tools for Rheumatic Arthritis Moderator: Barbara A. Slusher, PA-C, MSW review the history and development of disease activity measurement tools used in rheumatology care and specifically the treatment of rheumatoid arthritis describe the importance of using disease activity measurement tools in daily practice, barriers hindering routine widespread use, and techniques to overcome these barriers in nearly any practice setting present the Health Assessment Questionnaire (HAQ), Disease Activity Score 8 (DAS8), the Clinical Disease Activity Index (CDAI), and the Routine Assessment of Patient Index Data (RAPID) tools perform the HAQ, DAS8, CDAI and RAPID 4:0 pm Overview of the Use of Disease Activity Tools in Patients With Rheumatoid Arthritis Arthur M. Mandelin II, MD, PhD 04 A Postural Changes: How to Improve Joint Protection, Strength and Gait Efficiency Moderator: Judy Foxworth, PhD, PT discuss the current ideal posture and how to assess it describe poor postures and their effect on the biomechanics of the shoulders, hip and ankles which impede proper, efficient movement, leading to detrimental joint stress identify the causative factors that poor posture can have on muscle fatigue, and thereby effecting dynamic posture, movement and gait describe educational interventions designed to improve standing posture, leading to optimized breathing patterns, decreased vertebral column stress and improved dynamic posture for efficient movements 4:0 pm Stand Up Straight! Scott Siverling, PT, OCS 4:50 pm Postural Interventions for the Lower Quarter Ioonna Felix, PT, DPT, OCS 5:0 pm Postural Interventions for the Upper Quarter Scott Siverling, PT, OCS 5:50 pm Questions and Answers Indigo D Rheumatic Disease Update: A Review of Inflammatory Myositis Moderator: Christine Chhakchhuak, MD review inflammatory myositis describe how myositis can be differentiated from inflammatory myositis 4:0-5:0 pm A Review of Inflammatory Myositis Rohit Aggarwal, MD, MS 4:55 pm A Description of the Differentiation of Metabolic Myopathies and Inflammatory Myositis Robert L. Wortmann, MD CANCELLED SUNDAY october 7, 0 5:00 pm Practicing the use of Disease Activity Tools Jeffrey R. Curtis, MD, MPH, MS 5:0 pm A Patient s Perspective on the Measurement of Disease Flare in Rheumatoid Arthritis: What Tools Miss Amye L. Leong, MBA ARHP CONCURRENT ABSTRACT SESSIONS 4:0-6:00 pm 06 A Epidemiology and Public Health Moderators: Robert R. McLean, DSc, MPH and Carol A. Datis, PT PhD denotes Hilton San Diego Bayfront room location 0 Program Book 6

66 SUNDAY october 7, 0 4:0 pm 897. Characterization of Low Back Symptoms In a Community- Based Sample of Older Adults: The Johnston County Osteoarthritis Project Adam P. Goode, Kelli D. Allen, Timothy S. Carey and Joanne M. Jordan 4, Duke University, Durham, NC, Duke and Durham VA Medical Center, Durham, NC, Cecil G. Sheps Center for Health Services Research University of North Carolina, Chapel Hill, NC, 4 University of North Carolina Thurston Arthritis Research Center, Chapel Hill, NC 4:45 pm 898. Sex-Specific Employment Participation Restriction Across Occupational Groups Among Working-Age (8-64 years) U.S. Adults With and Without Arthritis Kristina A. Theis and Louise Murphy, Centers for Disease Control and Prevention, Atlanta, GA, CDC, Atlanta, GA 5:00 pm 899. Foot Pain, but Not Foot Structure Or Foot Function, Are Associated With Self-Reported Physical Limitations: the Framingham Foot Study Alyssa B. Dufour, Patricia P. Katz, Virginia A. Casey, Marian T. Hannan and Hylton B. Menz 4, Hebrew SeniorLife & Harvard Medical School, Boston, MA, University of California, San Francisco, San Francisco, CA, Hebrew SeniorLife, Boston, MA, 4 La Trobe University, Bundoora, Victoria 086, Australia 5:5 pm 900. Foot Symptoms Increase Odds of Falling: The Johnston County Osteoarthritis Project Yvonne M. Golightly, Marian T. Hannan, Alyssa B. Dufour, Amanda E. Nelson, Adam Dore and Joanne M. Jordan, University of North Carolina at Chapel Hill, Chapel Hill, NC, Hebrew SeniorLife & Harvard Medical School, Boston, MA, University of North Carolina Thurston Arthritis Research Center, Chapel Hill, NC 5:0 pm 90. Smokers and Overweight Persons Are At Increased Risk of New Onset of Severe Foot Pain and Persistent Severe Foot Pain in a Population Study Alyssa B. Dufour, Hylton B. Menz, Arunima Awale, Thomas J. Hagedorn, Virginia A. Casey, Patricia P. Katz 4 and Marian T. Hannan, Hebrew SeniorLife & Harvard Medical School, Boston, MA, La Trobe University, Bundoora, Victoria 086, Australia, Hebrew SeniorLife, Boston, MA, 4 University of California, San Francisco, San Francisco, CA 5:45 pm 90. The Effect of Obesity on Physical Function: The Osteoarthritis Initiative Study Jingbo Niu, Daniel K. White, David T. Felson, Michael C. Nevitt and Yuqing Zhang, Boston University School of Medicine, Boston, MA, University of California, San Francisco, San Francisco, CA B Psychology/Social Sciences Moderator: Christine A. Stamatos, ANP-C 4:0 pm 90. A Qualitative Study of The Educational Needs of Children With Scleroderma and Their Parents Cindy F. Mendelson, Ana-Alicia Huerta, Jane Kastning, Bernadette Vargas and Janet L. Poole, University of New Mexico, Albuquerque, NM, Univeristy of New Mexico, Albuquerque, NM 4:45 pm 904. Worse Mental Health in Employed Adult Patients With Juvenile Idiopathic Arthritis (JIA): More Than Just a Job Nadia E. Aikawa, Jms Gordo, R Krieger, LE Paula 4 and Claudia Goldenstein-Schainberg 5, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil, Faculdade de Medicina, Universidade de São Paulo, Sao Paulo, Brazil, Universidade de Sao Paulo, Sao Paulo, Brazil, 4 Faculdade de Medicina, Universidade de São Paulo, Sao PAulo, Brazil, 5 Reumatologia, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil 5:00 pm 905. Lupus and Reproductive Health Considerations: A Pilot Training For Reproductive Health Care Providers Serving Teens and Young Adults Jillian A. Rose, Dariana M. Pichardo, Monica C. Richey, Josephine Isgro and Roberta Horton, Hospital for Special Surgery, New York, NY, Hospital For Special Surgery, New York, NY, Morgan Stanley Children s Hospital of New-York Presbyterian, Columbia University Medical Center, New York, NY 5:5 pm 906. Longitudinal Patterns of Depression in Lupus Patricia P. Katz, Chris Tonner, Laura Trupin and Jinoos Yazdany, University of California, San Francisco, San Francisco, CA 5:0 pm 907. The Role of Social Relationships and Perceived Independence in the Employment Participation of Young Adults With Rheumatic Disease Research Institute; Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Toronto Western Research Institute, University Health Network, Toronto, ON, Scientist, Institute for Work & Health, Toronto, ON 5:45 pm 908. Appearance Dissatisfaction, Social Discomfort, and Helplessness in Patients With Systemic Sclerosis Shadi Gholizadeh, Sarah D. Mills, Rina M. Sobel-Fox, Philip J. Clements, Suzanne Kafaja, Vanessa L. Malcarne, Dinesh Khanna 4 and Daniel E. Furst, SDSU/UCSD Joint Doctoral Program in Clinical Psychology, San Diego, CA, David Geffen School of Medicine, UCLA, Los Angeles, CA, Department of Psychology, San Diego State University, Psychology, San Diego, CA, 4 University of Michigan Medical Center, Ann Arbor, MI 64 0 Program Book denotes Hilton San Diego Bayfront room location

67 INDUSTRY-SUPPORTED SYMPOSIA 6:0-9:0 pm These symposia are both CME-accredited and non-cme company-directed programs. For CME-accredited symposia, the sponsoring organization is responsible for planning and providing CME credit. All non-cme programs are wholly sponsored and supported by commercial entities. Please visit the organization s exhibit booth, the industry-supported symposia booth or see page 5 for more information. ACR SESSIONS 7:0-8:0 am MONDAY, OCTOBER 8, 0 Ballroom 0 A Medical Marijuana and the Rheumatologist Moderator: Mark F. Gourley, MD explain the physiologic mechanisms of the cannabinoid system in the inflammatory arthritides outline the analgesic properties of cannabinoids describe risks and benefits of marijuana use in the rheumatic diseases 7:0 am Physiologic Mechanisms of Cannabinoids Jason J. McDougall, PhD 8:00 am Marijuana Use in the Rheumatic Diseases Mary-Ann Fitzcharles, MBChB, MD Hall B Clinicopathologic Conference: A Patient With Rheumatoid Arthritis and Systemic Disease Moderator: Mary E. Cronin, MD discuss the evaluation of patients with rheumatoid arthritis and signs and symptoms of systemic disease review the differential diagnosis of systemic disease in rheumatoid arthritis discuss the potential treatment of systemic disease in rheumatoid arthritis 7:0 am Case Presentations Doquyen H. Huynh, MD 7:45 am Radiologic Findings Tudor Hughes, MD B Mitigating Health Disparities in Rheumatologic Disease Moderator: Greg Dennis, MD communicate why the reduction of health disparities is a public health priority discuss lupus as an important case study on the impact of health care disparities identify the significance of an emphasis on health disparities in medical education 7:0 am Novel Approaches to Enhancing Our Understanding of Health Disparities Michael M. Ward, MD 8:00 am Industry Clinical Trials and the Reduction of Health Disparities Mark S. Johnson, MD, MPH SUNDAY october 7, 0 MONDAY october 8, 0 6 A 8:00 am Pathologic Findings X. Frank Zhao, MD 8:5 am Case Discussion Arthur Kavanaugh, MD Interleukin-6 (IL-6), The Pleiotrophic Cytokine: New Clinical Roles and Therapeutic Opportunities Moderator: Andrew P. Cope, MD, PhD Speaker: Simon A. Jones, BSc, PhD report the key functional properties of interleukin 6 and the different pathways through which IL-6R signals are transduced describe the molecular and cellular pathways that underpin interleukin 6 mediated pathology discuss the distinct methods of targeted inhibition of IL-6/ IL-6R and how these can be manipulated to the benefit of patients in a range of chronic inflammatory diseases 6 D 8:5 am The Lupus Initiative, A Model Program Designed to Reduce Health Disparities S. Sam Lim, MD, MPH Tyro/Axl/Mer (TAM) Receptors and Innate Immune Regulation Moderator: Gregg J. Silverman, MD Speaker: Greg Lemke, PhD define the basic molecular and immune regulatory features of responses mediated by the TAM family of tyrosine receptor kinases describe the cellular biology of TAM driven responses in macrophages and dendritic cells in the maintenance of immune homeostasis deduce evidence that TAM receptors play central roles in fundamental mechanisms that limit or contribute to the resolution of inflammatory responses discuss recent evidence that defects in TAM receptor mediated responses may contribute to the pathogenesis of systemic lupus erythematosus, multiple sclerosis and rheumatoid arthritis denotes Hilton San Diego Bayfront room location 0 Program Book 65

68 ARHP SESSIONS 7:0-8:0 am ACR SESSION 7:0-9:00 am MONDAY october 8, 0 Sapphire A An Overview of Qualitative Research Moderator: Elizabeth G. Salt, PhD Speaker: Sharan Merriam, EdD present a definition of qualitative research describe the major types of qualitative research describe the processes used during qualitative research Indigo D Immunology Boot Camp Session : The Basics of Autoimmunity and Immunodeficiency - When Good Cells Go Bad Moderator: Christine A. Stamatos, ANP-C Speaker: Troy R. Torgerson, MD, PhD review the cellular changes responsible for autoimmunity describe the relevance of genetic predisposition for rheumatic diseases recognize when the immune system fails to recognize and mount an appropriate response identify at least three new mechanisms of action for rheumatic disease pharmacologic intervention 04 A Piloting Your Research to Success: The Why, What and How of Pilot Studies Moderator: Linda C. Li, PhD, PT recognize the importance of collecting pilot data and the relationships between a pilot study and the main research project discuss the design, interpretation and reporting of pilot studies for randomized controlled trials and major qualitative research identify funding sources for pilot studies and strategies for obtaining pilot data with a limited budget 7:0 am Getting Funded: Why Pilot Data Are Important for Grant Applications? Nancy A. Baker, MPH, OTR, OTR/L 7:50 am Getting Started: What Are the appropriate designs, interpretation and Reporting Strategies for Pilot Studies? Susan L. Murphy, ScD 8:0 am Getting Resources: How to Get Funding and Resources to Conduct Pilot Studies? Kelli D. Allen, PhD 0 A Improving Quality, Outcomes and Spending in Health Care: Good Data and Measures Are Just the Beginning Moderator: Charles M. King II, MD Speaker: Dana G. Safran, ScD identify the elements of a patient experience survey learn how physician performance measurement data can drive changes in the practices that lead to improvements in patient experience explore opportunities for your practice to engage patients explain how payers are using this data to rate physicians on access to care, efficiency and quality ACR MEET THE PROFESSOR SESSIONS 7:45-9:5 am Admission to Meet the Professor sessions requires a separate registration and ticket. To verify which session you registered for, the registration code on your ticket needs to match the -digit code in parentheses below. If you are interested in participating in one of these sessions or exchanging your ticket, visit the ACR registration desk to check space availability. View the session overview online in My Annual Meeting at www. ACRannualmeeting.org. * Sessions denoted with an asterisk were sold out as of August 0. *Antiphospholipid Syndrome (0) Speaker: Munther A. Khamashta, MD discuss the spectrum of antiphospholipid syndrome identify the diagnostic utility of antiphospholipid antibody tests describe the controversial aspects of primary and secondary thrombosis prevention in antiphospholipid syndrome discuss the management of catastrophic antiphospholipid syndrome patients Calcium Crystal Arthritis (0) Speaker: Ann K. Rosenthal, MD describe the common clinical pictures of calcium pyrophosphate disease and basic calcium phosphate arthritis identify unusual presentations explain currently available and emerging diagnostic modalities to confirm suspected calcium crystal arthritis, including ultrasound and novel techniques for BCP crystal identification describe currently available therapies and rationale behind some promising new therapies for these diseases 66 0 Program Book denotes Hilton San Diego Bayfront room location

69 4 A *Controversies in Sjögren s Syndrome (0) Speaker: Alan N. Baer, MD identify the best approach to establish a diagnosis of Sjögren s syndrome differentiate among various causes of salivary and/or lacrimal gland swelling discuss current treatment algorithms for dry eyes, dry mouth and systemic manifestations identify risk factors and markers for lymphoma in Sjögren s syndrome patients 4 B Dermatological Manifestations of Rheumatic Diseases (04) Speaker: Ruth Ann Vleugels, MD, MPH identify cutaneous findings associated with underlying rheumatologic disease construct a differential diagnosis for these conditions design a strategy for management of skin disease seen in patients with rheumatologic diseases 6 B Systemic Lupus Erythematosus: Central Nervous System (08) Speaker: Cynthia Aranow, MD identify neuropsychiatric manifestations attributable to systemic lupus erythematosus recognize the utility of diverse autoantibodies in the diagnosis of neuropsychiatric syndromes of systemic lupus erythematosus patients formulate a treatment plan in patients with neuropsychiatric lupus 7 A Vasculitis Mimics (09) Speaker: John H. Stone, MD, MPH identify major systemic conditions that can mimic and confound the diagnosis of systemic vasculitis consider and discuss appropriate approaches to the diagnosis and treatment of vasculitis mimickers identify clinical pearls that help distinguish systemic vasculitis from its array of mimickers 5 A *Infections With Biologics (05) Speaker: Kathryn H. Dao, MD discuss the risk of infection related to inflammation and disease discuss the risk factors for infection recognize the magnitude of risk imposed by steroids and biologics determine the approach to risk reduction (TB and SIE) 7 B Vitamin D and Bone Health (040) Speaker: Nancy E. Lane, MD state current Food and Nutrition Board recommendations for vitamin D intake in older men and women recall evidence-based medicine conclusions regarding vitamin D and osteoporotic fracture identify the range of serum 5(OH)D levels believed optimal for bone health MONDAY october 8, 0 5 B Pediatrics: Periodic Fevers in Children (06) Speaker: Daniel L. Kastner, MD, PhD describe the differential diagnosis and expanding spectrum of these syndromes relate the pathogenesis of these syndromes to knowledge of the various gene functions discuss the treatment rationale based on the pathogenesis and to expand on practical issues in the management of these patients 6 A *Pregnancy and Rheumatic Diseases (07) Speaker: Eliza F. Chakarvarty, MD describe risk factors for adverse maternal and fetal outcomes in systemic autoimmune diseases. describe key elements of preclinical risk assessment and counseling for women who desire a future pregnancy discuss the impact of active maternal autoimmune disease upon pregnancy outcomes. discuss the risk-to-benefit analysis of common anti rheumatic and immunosuppressive medications during pregnancy denotes Hilton San Diego Bayfront room location ACR WORKSHOPS 7:45-9:45 am Admission to Workshops requires a separate registration and ticket. To verify which session you registered for, the registration code on your ticket needs to match the -digit code in parentheses below. If you are interested in participating in one of these sessions or exchanging your ticket, visit the ACR registration desk to check space availability. View the session overview online in My Annual Meeting at www. ACRannualmeeting.org. * Sessions denoted with an asterisk were sold out as of August 0. Clinical Anatomy and Physical Exam: Essential Tools in Upper Extremity Regional Pain Syndromes (6) Speakers: Robert A. Kalish, MD and Pablo Villasenor Ovies, MD demonstrate clinical anatomy of the lower extremities in performing the physical examination apply knowledge of clinical anatomy to better understanding and diagnosis of the common regional pain syndromes perform the physical examination of the lower extremities on healthy volunteers 0 Program Book 67

70 MONDAY october 8, 0 4 B Musculoskeletal Ultrasonography: Basic (7) Speakers: Janak R. Goyal, MD and Gurjit S. Kaeley, MBBS, MRCP explain basic concepts of ultrasound physics learn to perform a proper ultrasound examination identify various tissues in an ultrasound image *X-ray Challenges in Rheumatic Diseases (8) Speakers: Donald J. Flemming, MD describe the potential causes and exacerbating factors of the disease discuss the appropriate use of laboratory testing and imaging modalities design an efficacious, safe and cost-effective therapeutic strategy ACR SESSIONS 8:0-0:00 am Ballroom 0 A Atypical Myopathies Moderator: Kristine M. Lohr, MD, MS describe the clinical spectrum and approach to asymptomatic elevations in serum muscle enzymes discuss the presentation, diagnostic approach and management of amyopathic dermatomyositis describe the clinical spectrum and risks of statin-induced myotoxicity 8:0 am Approach to the Patient With Asymptomatic Elevations in Serum Muscle Enzymes Rohit Aggarwal, MD, MS 9:00 am Amyopathic Dermatomyositis David Fiorentino, MD, PhD 9:0 am Statin-induced Myopathy Andrew L. Mammen, MD, PhD 6 C 8:0 am Outline and Key Points of Conducting a Review Joan M. Bathon, MD; Marian T. Hannan, DSc, MPH 8:50 am Panel Presentation: Reviewing Clinical Science Articles Karen H. Costenbader, MD, MPH 9:05 am Panel Presentation: Reviewing Translational/Basic Science Articles Richard J. Bucala, MD, PhD 9:0 am Panel Presentation: Reviewing Genetics/Genome-Wide Association Study Articles Robert M. Plenge, MD, PhD 9:0 am Panel Presentation: Reviewing From a Biostistics Perspective Michael P. Lavalley, PhD 9:40 am Question and Answer Kawasaki Disease: Putting Out the Fire Moderator: Karen Onel, MD identify new therapeutic targets and agents for Kawasaki disease explore mechanisms of action of IVIg in treatment of Kawasaki disease recognize mimics of Kawasaki disease 8:0 am Kawasaki Disease: Where Are We Now? Jane C. Burns 9:00 am Intravenous Immunoglobulin (IVIG) and Kawasaki Disease: Mystery Solved at Last? Alessandra Franco, MD, PhD 9:0 am When Kawasaki Disease Isn t Really Kawasaki Disease Robert P. Sundel, MD 06 A Good Reviewers Make Good Authors: A Guide to Conducting Excellent Manuscript Reviews Moderators: Joan M. Bathon, MD and Marian T. Hannan, DSc, MPH create peer-review of a scientific manuscript within a field of interest assess one s own work prior to submission in terms of clarity of message and importance of the findings describe the requirements and scientific preferences of the journals of the ACR 8 B Rheumatology Research Foundation Special Session: Clinician Scholar Educators Moderator: Michael J. Battistone, MD discuss novel approaches to curriculum development for medical students and residents in the musculoskeletal and rheumatic diseases discuss new approaches to teaching in the rheumatic and musculoskeletal diseases explain the unique and important roles of the clinician scholar educator in medical education and training 68 0 Program Book denotes Hilton San Diego Bayfront room location

71 8:0 am A Competency Based Musculoskeletal Ultrasound Curriculum Eugene Y. Kissin, MD 9:00 am Methodology for Teaching Medical Students Rheumatology Seetha U. Monrad, MD 9:0 am Developing Objective Structured Clinical Examinations for Pediatric Rheumatology David D. Sherry, MD ACR/ARHP POSTER SESSION B, THIEVES MARKET POSTERS, AND POSTER TOURS 8:0 am - 4:00 pm Poster presenters will be available from 9:00 - :00 am (abstracts # ). Poster tours will be held 9:00-9:45 am and 0:5 - :00 am. Morning snacks will be available from 8:0-0:00 am. Poster Hall (Exhibit Hall B-C-D) Thieves Market Posters Thieves Market posters feature cases with interesting imaging studies or pictorial displays of physical findings. A Curious Skin Lesion Thomas Schmidt, MD A Late Presentation of Loeys-Dietz Syndrome: Joint Hypermobility is Not Always Benign Puja Mehta, MD A New twist in Pulmonary-renal Syndrome Rajaie Namas, MD A Sweet Cause of a Fatty Condition Mitsuyo Kinjo, MD, MPH Anti-synthetase Syndrome Complicated by Hemorrhagic Myositis Kim M. Wu, DO Back Pain and Vitamin D Deficiency: A Novel Genetic Link Puja Mehta, MD Chronic Lymphocytic Inflammation With Pontine Perivascular Enhancement Responsive to Steroid Maryam Gul, MD Gravid and Gasping Kimberly C. Smith, BS, MD Kikuchi Fujimoto Disease - Histiocytic Necrotizing Lymphadenitis: An Unusual Cause of Cervical Adenopathy and Pyrexia Maryam Gul, MD Mystery of Myopathy Uncovered After a Screening Colonoscopy Manisha Sharma, MBBS, MD Rare Cause of a CVA in a 55 yo Male Michael Thomas Avery, DO The Great Mimic Yashaar Chaichian, BA, MD Poster Hall (Exhibit Hall B-C-D) Guided Poster Tours Guided poster tours allow scientific attendees to ask questions and gain insights from some of the best-known rheumatology leaders. Tours are complimentary; however, registration is required and is limited to scientific attendees. If you preregistered for a tour, you should have received a ticket with your meeting materials. Once you have your ticket, check in at the tour desk 5 minutes prior to the start of your tour to receive your headset. Your reservation will be held only until 5 minutes prior to the start of the tour. After this time, your reservation is not guaranteed and may be released to standby attendees. If you did not pre-register, tickets may be available in the registration area (Sails Pavilion). Alternatively, you may go directly to the poster tour desk and wait for a standby ticket. Standby tickets will be assigned on a first-come, first served basis 5 minutes prior to the start of each tour. Each tour participant will receive a wireless headset which will be registered against the participants registration ID. Participants will be charged $50 if the headset is not returned within 5 minutes of the end of the tour. 9:00-9:45 am Epidemiology and Health Services Research Poster Tour () Tour Guide: Jeffrey R. Curtis, MD, MPH, MS Imaging of Rheumatic Diseases Poster Tour (4) Tour Guide: To Be Announced Pediatric Rheumatology: Clinical Aspects Poster Tour (5) Tour Guide: Andrea Doria, MD Rheumatoid Arthritis Treatment - Small Molecules, Biologics and Gene Therapy Poster Tour (6) Tour Guide: Eric M. Ruderman, MD Rheumatoid Arthritis: Clinical Aspects Poster Tour (7) Tour Guide: Inmaculada del Rincon, MD, MSc Spondylarthropathies and Psoriatic Arthritis: Clinical Aspects and Treatment Poster Tour (8) Tour Guide: Atul A. Deodhar, MD 0:5 - :00 am Pediatric Rheumatology: Clinical Aspects Poster Tour (9) Tour Guide: C. Egla Rabinovich, MD, MPH Rheumatoid Arthritis Treatment - Small Molecules, Biologics and Gene Therapy Poster Tour (0) Tour Guide: Joseph A. Markenson, MD Rheumatoid Arthritis: Clinical Aspects Poster Tour () Tour Guide: Iain B. McInnes, PhD Spondylarthropathies and Psoriatic Arthritis: Clinical Aspects and Treatment Poster Tour () Tour Guide: Luis R. Espinoza, MD MONDAY october 8, 0 denotes Hilton San Diego Bayfront room location 0 Program Book 69

72 MONDAY october 8, 0 Systemic Lupus Erythematosus: Human Etiology and Pathogenesis Poster Tour () Tour Guide: Mary K. Crow, MD Vasculitis Poster Tour (4) Tour Guide: Alexandra Villa-Forte, MD, MPH ACR SESSION 9:00-0:00 AM 0 E How to Maintain Your Medical License and Certification After 0: Changes Will Impact All Physicians. Are You Prepared? describe the potential changes to state medical licensure renewal based on the Maintenance of Licensure model explain the ABIM requirements for Maintenance of Certification that will be effective in 04 explain how the ABIM requirements will affect rheumatologists with lifetime certificates state the ACR resources available to help rheumatologists meet the maintenance of certification and maintenance of licensure requirements 9:00 am What is Changing (Current Versus Future Requirements)? Why the Change? Joan Marie Von Feldt, MD, MSEd 9:5 am What Do You Need to Do? How can the ACR Help You Understand and Complete the Process? Carol A. Langford, MD, MHS 9:50 am Questions and Answers ACR and ABIM Staff review current data on adherence to pharmacologic and nonpharmacologic therapies in specific populations of adults with arthritis identify new areas for applications of technology in health and wellness in persons with arthritis describe the application of mobile technologies for promoting adherence to therapies and synthesize the evidence on program success EXHIBITS 0:00 am - 5:00 pm Exhibit Hall F-G Join your colleagues in the exhibit hall for morning and afternoon refreshments from 0:00 - :00 am and :00 - :00 pm. (Booth #7) Innovation Theater Non-CME accredited presentations have been planned and will be implemented in accordance with the requirements of the FDA and applicable standards of the PhRMA Code on Interactions with Healthcare Professionals. These presentations will be held from 0:0 - :5 am, :0 - :5 pm and :0 - :5 pm. For a complete listing of Innovation Theater presentations, see page 5. ACR/ARHP WORKSHOPS 0:0 am - :0 pm Admission to Workshops requires a separate registration and ticket. To verify which session you registered for, the registration code on your ticket needs to match the -digit code in parentheses below. If you are interested in participating in one of these sessions or exchanging your ticket, visit the ACR registration desk to check space availability. View the session overview online in My Annual Meeting at www. ACRannualmeeting.org. * Sessions denoted with an asterisk were sold out as of August 0. Hall B Poor Sleep: Consequences and Cures Moderator: Shreyasee Amin, MD, CM, MPH Speaker: Sonia Ancoli-Israel, PhD discuss the medical consequences of poor sleep on general health and cognitive function recognize sleep-related disorders, including sleep apnea describe strategies for improving sleep quality A Dermatopathology of Rheumatic Diseases (9) Speaker: Daniel Miller, MD identify what information can be gained from a skin biopsy in patients with rheumatic diseases describe the importance of dermatopathology in clinical decision making in patients with rheumatic diseases apply the knowledge gained to clinical practice ARHP SESSION *Joint Injections (Knee, Ankle, Shoulder and Wrist) 9:00-0:00 am (0) Indigo D Speaker: Gregory C. Gardner, MD and Kenneth R. Margules, MD Distinguished Lecturer: Integrating Concepts of Behavioral Change and Technology to Promote describe indications for lower extremity joint injection and Health in Persons With Arthritis aspiration Moderator: Afton L. Hassett, PsyD identify anatomic landmarks for injection of the knee and Speaker: Maura D. Iversen, BSc, DPT, SD, MPH ankle using joint prosthetics apply principles of joint aspiration and injection using ankle and knee joint prosthetics 70 0 Program Book denotes Hilton San Diego Bayfront room location

73 B Musculoskeletal Exam Skills II: Regional Musculoskeletal Examination of the Neck and Low Back () Speakers: George V. Lawry, MD and Paul C. Utrie, MD participate in a hands-on, skill building workshop where participants are paired together for one-on-one practice complete the neck and low back exams in a systematic, efficient and clinically effective way in two to six minutes review strategies for increasing exposure of medical students, resident and fellow trainees to basic musculoskeletal physical examination skills Renal Histopathology in Systemic Lupus Erythematosus and Vasculitis () Speaker: Anthony Chang, MD identify the pathologic changes that occur in lupus nephritis discuss the pathologic basis for the classification of lupus nephritis and how it relates to clinical management describe the histological changes in the kidneys of patients with vasculitis ACR SESSIONS :00 AM - Noon Ballroom 0 A ACR Knowledge Bowl- Final Round Moderator: Rebecca L. Manno, MD, MHS Judges: Lawrence H. Brent, MD; Calvin R. Brown Jr., MD and Ann K. Rosenthal, MD identify key images that are important to recognize in clinical practice recall factual information related to various rheumatic diseases identify historical facts relevant to the field of rheumatology 0 E Personalized Medicine: Transforming 00 Billion Points of Data into Diagnostics, Therapeutics, and New Insights into Disease Moderator: John Varga, MD Speaker: Atul Butte, MD, PhD explain the current approaches to develop systems biology approaches integrating molecular, clinical and epidemiologic data to understanding disease discuss current research toward the application of personalized medicine identify novel approaches to drug repositioning in personalized medicine Hall B Rheumatology Research Foundation Paul Klemperer, MD, Memorial Lectureship: Rheumatoid Arthritis and Autoimmunity: Good Genes, Elegant Mechanisms, Bad Results Moderators: David I. Daikh, MD, PhD Speakers: Robert Winchester, MD describe the current understanding of the shared epitope and the central role of the MHC genotypes in determining susceptibility recognize the intricate genetic basis of the disease will provide the basis for a personalized medicine approach explain the increasing ethnic and individual differences within the seropositive disease that are being recognized, and their implications for clinical trial design and ultimately for the choice of therapeutic agents ARHP SESSIONS :00 AM - Noon Sapphire I Navigating the System: The Key to Obtaining Medications for Your Patients Moderator: Laura Wright, MBA outline the various forms of prior authorization, including the process for biologic agents review patient assistance programs, including co-pay assistance and foundations for patients without insurance explain the new regulations regarding prior authorizations under the Affordable Care Act offer practical solutions on how to best obtain medications for your patients :00 am The Ins and Outs of Prior Authorizations Melissa Frey, MSW, LCSW :0 am Obtaining Financial Assistance for Your Patients Katherine Krajci, LCSW 9 D Obesity and Rheumatic Disease Moderator: Robert R. McLean, DSc, MPH Speaker: Marian T. Hannan, DSc, MPH describe the latest advances in the understanding of obesity and rheumatic diseases. present evidence regarding the time-line between obesity across the life span and osteoarthritis specifically with insights regarding pain mechanisms and patient characteristics discuss how obesity interacts with joint pain and disability in rheumatologic patients critique the use of patient-oriented weight loss assessment and outcomes into clinical practice MONDAY october 8, 0 denotes Hilton San Diego Bayfront room location 0 Program Book 7

74 MONDAY october 8, 0 Indigo D Rheumatic Manifestations of Endocrine Disorders Speakers: Jonathan D. Graf, MD identify key signs and symptoms of endocrine diseases that can mimic rheumatic disease identify the soft tissue complications of diabetes avoid misdiagnosis, identify appropriate therapy ACR PLENARY SESSION II DISCOVERY 0 :00 AM - :0 PM 6 A ACR Plenary Session II: Discovery 0 Moderators: Eric L. Matteson, MD, MPH and Mary E. Cronin, MD :00 am 690. Impaired Vitamin D Receptor Signaling Upregulates Transforming Growth Factor Beta (TGFβ) Signaling in Systemic Sclerosis Pawel Zerr, Department of Internal Medicine III and Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany Background/Purpose: Vitamin D receptor (VDR) is a member of the nuclear receptor superfamily. Its ligand,,5-(oh)d, is a metabolically active hormone derived from vitamin D. Activated VDR binds to specific VDR elements in the promoters of target genes to regulate their expression. The levels of vitamin D have been shown to be significantly decreased in patients with systemic sclerosis (SSc). However, the functional consequences remain unknown. Our aim was to find a potential link between impaired VDR signaling and fibrosis. Methods: VDR expression was analyzed by real-time PCR, Western Blot and IF. VDR agonist paricalcitol was used in in vitro and in vivo experiments. Collagen synthesis was quantified in fibroblasts overexpressing or lacking VDR. Interaction of VDR and Smad was shown by Co-IP. VDR was analyzed in two different mouse models of SSc: bleomycin-induced dermal fibrosis and mice overexpressing a constitutively active TGFβ receptor I (TBR). Results: VDR mrna levels were reduced by 78 % in skin of SSc patients compared to healthy individuals (p = 0.0). Similar decreases were observed on the protein level. VDR mrna and protein levels were also decreased in the bleomycin-induced ( %; p = 0.0) and the TBR-induced fibrosis (45 %; p = 0.0). Chronic stimulation with TGFβ strongly decreased VDR mrna and protein levels in fibroblasts. VDR knockdown fibroblasts showed significantly increased levels of Cola mrna (+6 %; p = 0.00) and collagen protein (+65 %; p = 0.0) compared to TGFβ stimulated controls. In contrast, VDR overexpression inhibited the pro-fibrotic effects of TGFβ with decreased Cola mrna levels, collagen release and prevented differentiation into myofibroblasts. Co-IP showed that paricalcitol stimulated the formation of high affinity complexes of VDR and active, phosphorylated Smad in fibroblasts. Reporter assays confirmed that binding of VDR to phosphorylated Smad impaired the transcriptional activity of phosphorylated Smad. Moreover, potent anti-fibrotic effects of paricalcitol were observed in different mouse models of SSc. Mice treated with paricalcitol were less sensitive to TBR induced dermal fibrosis with reduced dermal thickening (-46%, p = 0.0), myofibroblast counts (-69%, p = 0.00) and hydroxyproline content (-77%, p = 0.0). Paricalcitrol also significantly ameliorated bleomycin-induced fibrosis. Conclusion: We demonstrate that VDR is a crucial regulator of TGFβ / Smad signaling. Pharmacological activation of VDR inhibits TGFβ signaling and reduces fibrosis. Impaired VDR signaling with reduced levels of its ligand vitamin D may thus contribute to hyper-active TGFβ signaling and aberrant fibroblast activation in SSc. These findings may have direct clinical implications, considering the higher binding affinity and the less calcaemic effects with more prolonged administration of paricalcitol compared to the natural ligand and the potent antifibrotic effects, the good tolerability and the availability of VDR agonists in clinical trials. Disclosures: P. Zerr, None. :5 am 69. The STAT Signaling Pathway in Giant Cell Arteritis Bjorn Hartmann and Cornelia M. Weyand, Stanford University School of Medicine, Stanford, CA Background/Purpose: In giant cell arteritis (GCA), CD4 T cells, macrophages and multinucleated giant cells form granulomatous lesions in the walls of medium and large arteries. A plethora of innate and adaptive cytokines are produced within the vasculitic infiltrates, but it is not known whether a hierarchy of cytokines exists that initiates and sustains vessel wall damage, drives intimal hyperplasia and promotes persistent immune activation. Most cytokines function by triggering JAK/STAT signaling pathways in target cells to regulate gene programs that drive cellular activation, differentiation, and survival, all critical in the maladaptive response of the inflamed artery and the acute phase response underlying systemic inflammation. Methods: To induce experimental GCA, NOD.Cg-Prkdc scid Ilrg tmwjl/szj mice (NSG) mice were engrafted with human medium-sized arteries and reconstituted with PBMC from patients with biopsy-proven GCA. Following induction of vasculitis, chimeras were treated with either dexamethasone (5 mg/kg) or tofacitinib (4 mg/kg) or both for 5 days. Explanted artery grafts or temporal artery biopsies from patients with GCA were analyzed for gene expression profiles by RT-PCR. Plasma was harvested from GCA patients and from untreated or treated reconstituted chimeras and cytokines were quantified by ELISA. Results: To identify signaling pathways involved in vasculitis, we screened temporal artery biopsy samples and plasma from GCA patients for induction of signal transducer and activator of transcription (STAT) activity. STAT- transcripts were abundantly expressed in tissue lesions. The major inducer cytokine of STAT-, IFN-γ, was 0-fold higher in GCA patients than in age-matched controls. To examine the relevance of STAT- signaling, we compared the effects of two classes of immunosuppressive agents (corticosteroids and the JAK/STAT-inhibitor tofacitinib, CP-690,550, a potent kinase inhibitor for JAK > JAK > JAK) in experimentally induced vasculitis in 7 independent experiments. Dexamethasone primarily suppressed innate immunity with inhibition of dendritic cell activation (P = 0.005), IL-6 and IL-β expression in the vascular lesions. Conversely, dexamethasone spared adaptive immunity and left IFN-γ-producing TH unaffected (P = 0.98). The kinase inhibitor effectively prevented T cell accumulation in the vessel wall and suppressed IFN-γ production (P = 0.0) and signaling. JAK/STAT inhibition reduced blood levels of IFN-γ in the chimera mice by 65% (P = 0.004). The underlying mechanism involved a reprogramming of T cell trafficking, barring vasculitic T cells from arterial wall infiltration. 7 0 Program Book denotes Hilton San Diego Bayfront room location

75 Conclusion: STAT- signaling is a key pathogenic pathway in GCA, is sustained by excessive activity of the adaptive cytokine IFN-γ and persists despite suppression of innate immunity. Retention of vasculitic T cells in the vessel wall is a major determinant of vasculitic activity and emerges as a novel therapeutic target. Disclosures: B. Hartmann, None; C. M. Weyand, None. :0 am 69. Characterization of Changes in Gene Expression and Inflammatory Proteins in Systemic Juvenile Idiopathic Arthritis Patients on Canakinumab Therapy Nanguneri. R Nirmala, Novartis Institutes for Biomedical Research, Cambridge, MA Background/Purpose: Interleukin (IL)-β plays a key role in the pathogenesis of systemic juvenile idiopathic arthritis (SJIA). Canakinumab (CAN), a selective, fully human, anti-il-β monoclonal antibody, has been shown to be efficacious in the treatment of SJIA. Here we present the analysis of changes in peripheral blood gene expression and inflammatory proteins in SJIA patients (pts) on CAN therapy and report the identified baseline biomarkers that predict clinical response to CAN treatment. Methods: Levels of inflammatory biomarkers (IL-6; total IL-8) and gene expression profiles of active SJIA pts (aged to <0 yrs) before and during CAN treatment enrolled in phase III trials were analyzed. Results: Gene Expression: Transcriptional changes upon CAN treatment at Day were assessed. When applying cut-offs of fold and p 0.05, no transcript passed this filter for placebotreated pts (n=9) or for CAN treated pts (n=) that were ACR0 (adapted pediatric ACR) non-responders at Day 5, while 7 probesets passed the filter for pts (n=5) showing ACR0 response. Pts who showed strong transcriptional changes also showed a strong ACR response ( ACR50) at Day 5, while pts with <ACR50 at Day 5 showed a much weaker transcriptional response at Day. Strongly repressed genes included many known inflammation- and innate immunity-related genes (eg, TLR, TLR4, TLR5, TLR6, TLR8), including several members of the IL-β signaling pathway, such as IL-β, ILR, ILR and ILRAP. A set of transcripts was identified for which high baseline expression levels predicted a subgroup of strong ( ACR50) responders at Day 5. However, another subgroup of strong responders was indistinguishable from weak responders ( ACR0) based on baseline transcript levels. Protein markers: IL-6 protein levels were strongly reduced by Day (4.7 x and 4.4 x with p=0.00 and 0.000, n=0 and n=5 for the trials), and at Day 9 (.5 x and 8. x with p=0.0 and , n=0 and n=65) while total IL-8 levels remained largely unchanged until Day 9 (n= and n=76) and showed a moderate reduction only at Day 57. For IL-6, stronger reduction at Day and Day 9 was observed for pts who showed stronger ACR response at Day 5. Only baseline samples were available from pts who developed macrophage activation syndrome during the studies. Conclusion: CAN treatment resulted in a rapid, strong reduction of many pro-inflammatory leukocyte transcripts and serum IL-6. Compared with IL-6, IL-8 protein levels were reduced upon treatment much later and less strongly. About two thirds of pts with a strong treatment response ( ACR50) were characterized by a set of leukocyte transcripts with high baseline levels and strong reduction upon CAN treatment. However, the remaining one third of CAN strong responders did not show these characteristic transcriptional patterns, suggesting some heterogeneity at the molecular level in SJIA pts showing strong response to CAN treatment. Disclosures: N. R. Nirmala, Novartis,, Novartis,. :45 am 69. Initial Triple DMARD Therapy Is More Efficient Than Methotrexate Monotherapy in Recent Onset Rheumatoid Arthritis; -Year Data of a Randomized Clinical Trial (treach) P.H.P. de Jong, Erasmus University Medical Center, Rotterdam, Netherlands Background/Purpose: Recommended treatment for DMARD naïve patients is methotrexate (MTX) with or without glucocorticoids (GCs). Triple DMARD therapy however is not recommended, because well proven evidence of superior efficacy is suggested to be lacking. Furthermore possible drug toxicities might influence the physician s choice of induction therapy. Therefore, our aim is to compare one-year clinical efficacy of: () triple DMARD therapy vs. MTX mono-therapy and () oral GCs bridging therapy vs. dose of intramuscular (im) GCs in patients with early RA. Methods: The one-year data of single-blinded randomized clinical trial in patients with recent-onset arthritis (treach) were used. Patients were included who had a high probability (> 70%) of progressing to persistent arthritis, based on the prediction model of Visser. The Visser algorithm and 00 criteria for RA have similar discriminative abilities to identify patients at risk of persistent arthritis at year. Patients were randomized into induction therapy strategies: (A) triple DMARD therapy (MTX 5 mg + sulfasalazine (SASP) gr. + hydroxychloroquine (HCQ)) 400 mg with im GCs (Depomedrol 0mg), (B) triple DMARD therapy with an oral GCs tapering scheme (starting 5 mg) and (C) MTX with oral GCs similar to B. Treatment strategies were tightly controlled, with patients being examined every months and treatment decisions based upon the original DAS thresholds for low disease activity. We investigated following response parameters over time: DAS, HAQ, using the area under the curve (AUC). We also looked at radiographic progression after months of therapy, medication usage and adverse events. Results: A total of 8 patients were included in the high probability stratum and randomly assigned to (A) (n=9), (B) (n=9) or (C) (n=97). Patients were mostly females (68%) with an average symptom duration of 66 days (95% CI: 56 77). At baseline 67 (95%) of patients fulfilled the 00 criteria for RA, 6 (77%) patients were ACPA positive and 48 (6%) patients had erosions. Over time disease activity and functional ability were respectively - 9 (-4 77 to -0 00, 95%CI) and - 67 (- 5 to 0 0, 95%CI) lower in patients with triple DMARD therapy compared with MTX mono-therapy. After months, less treatment failure occurred in the triple DMARD therapy groups, resulting in the prescription of 50% fewer biologicals. This difference remained over time. No differences MONDAY october 8, 0 denotes Hilton San Diego Bayfront room location 0 Program Book 7

76 were seen between both GC bridging therapies. Respectively 5%, 0%, and 8% of patients in arm A, B, and C had radiographic progression after year. No differences in serious adverse events were seen. Conclusion: In patients with early RA triple DMARD therapy is superior to MTX mono-therapy even after months of therapy. Furthermore both intramuscular and oral GCs can be used as bridging therapy. Analyses used multiple linear regression with an ITT approach. Results: We randomised 6 subjects age years (mean age 55.5 years (SD 7.5 years); 7 females (57.%). Mean pain score at baseline was Ninety of the 5 with MRI scans (7%) had PF BML s at baseline. Subjects wore the brace for a mean of 7.4 hrs/day. Six subjects withdrew during the RCT (an additional did not attend one session, and therefore had only one MRI). Compared with the control group, the brace group had both a significant reduction in PF-related knee pain and a decrease in the volume of BML s in the PF but not in the TF joint (see Table). Conclusion: A patellofemoral brace is efficacious for treatment of PF OA reducing both symptoms and BML volumes in the targeted compartment. BML s may be a responsive outcome measure in OA trials. RANDOMISED TRIAL RESULTS Variable NO BRACE GROUP BRACE GROUP 6 weeks In: Mean change (95% CI) Mean change (95% CI) Between Groups Difference Mean difference in change (95% CI) p MONDAY october 8, 0 Disclosures: P. H. P. de Jong, None. Noon 694. A Randomised Trial of a Brace for Patellofemoral Osteoarthritis Targeting Knee Pain and Bone Marrow Lesions David T. Felson, University of Manchester, Manchester, United Kingdom Background/Purpose: Patellofemoral (PF) braces have been shown to increase contract area in this joint, decreasing focal stress and may also correct patellar malalignment. Bone marrow lesions (BMLs) are lesions in the subchondral bone of osteoarthritis (OA) knees on MRI that are caused in part by focal stress in the joint. Because BML size correlates with knee pain severity, because they predict structural progression and because recent evidence suggests, unlike cartilage, that their volumes fluctuate substantially in as little as 6 weeks, BML s may be a good outcome to test short term structure modification in OA trials. We performed a trial testing the efficacy of the BIOSKIN patellar tracking Q brace (Ossur, inc). Methods: Eligible subjects had to have pain daily of >=40/00 for the last months during a PF activity and on examination had tenderness over patellar facet or a positive patellar compression test. X-rays had to show KL grade or PFOA which was worse than tibiofemoral disease. At baseline, subjects were randomly allocated to immediate or 6 weeks provision of the brace; the trial lasted 6 weeks. Subjects with other forms of arthritis were excluded as were those ineligible for MRIs or with impaired renal function. Gadolinium MRIs were acquired on a.5 T MRI at baseline, and at 6 weeks. Postgadolinium fat suppressed sagittal and PD weighted axial images were used for BML s which were manually segmented (blinded to sequence and to treatment) at all time points. The primary symptom outcome was the change in pain at 6 weeks (0 00 VAS scale) during the PF painful activity in the more symptomatic knee and the primary structural outcome was BML volume in the PF joint of that knee (patella and trochlea). We also examined tibiofemoral (TF) BML volumes as a control untreated region. PRIMARY Symptom OUTCOME: Nominated VAS (0 00) Primary Structural Outcome: BML Volume in PF joint (in mm) Secondary Structural Outcome: BML Volume in TF Joint (in mm) -.9 (-6.9,.80) 0.66 (-9.80, 498.).79 (-49.67, 496.6) Disclosures: D. T. Felson, None (-.88, -.44) (-964.0, -45.8) (-.44, ) 6.87 (9.0, 4.4) (-6.57, ) 96.9 (-55.5, 907.7) <0.00 :5 pm 695. Ustekinumab Is Effective in Inhibiting Radiographic Progression in Patients With Active Psoriatic Arthritis: Integrated Data Analysis of Two Phase, Randomized, Placebo- Controlled Studies Iain B. McInnes, University of Glasgow, Glasgow, United Kingdom Background/Purpose: We describe the effect of ustekinumab (UST), an IL-/ p40 inhibitor, on inhibition of progression of structural damage in patients with active psoriatic arthritis (PsA) at wk4 and wk5 in the PSUMMIT and PSUMMIT trials. Methods: Adult PsA patients with active disease ( 5 SJC and 5 TJC; CRP 0.mg/dL [ULN.0 mg/dl]) despite DMARD and/ or NSAID therapy (PSUMMIT, n=65; PSUMMIT, n=) or previously treated with DMARD and/or NSAID, and prior anti-tnfα therapy (PSUMMIT, n=80) were randomized to UST45mg, 90mg, or PBO at wks 0, 4, and qwks, thereafter. At wk6, patients with <5% improvement in TJC & SJC entered blinded early escape [EE] (PBO UST45mg; UST45mg 90mg; 90mg 90mg). No concomitant DMARDs with the exception of MTX (approximately 50% of patients in each study) were permitted. Radiographs of hands and feet were taken at wks 0, 4, and 5 regardless of EE status, or at the time of study drug discontinuation (unless radiographs were completed within the prior 8wks). Erosions and joint space narrowing (JSN) were evaluated by independent readers blinded to treatment, patient IDs and image time sequence using PsA modified van der Heijde-Sharp (vdh-s) method (total score ranging from 0-58). The major secondary endpoint of change from baseline in total Program Book denotes Hilton San Diego Bayfront room location

77 vdh-s scores at wk4 was analyzed based on a pre-specified integrated data analysis using data combined from both studies. Imputation of missing data was done using linear extrapolation or median change of 0. Results: Baseline disease characteristics including total vdh-s, TJC, SJC and CRP were comparable between PSUMMIT &. In the integrated analyses, both UST 45 mg and 90 mg treated patients demonstrated a significant difference in change from baseline in total vdh-s scores at wk4 vs PBO (Table). Moreover, continued inhibition was demonstrated through wk 5; patients randomized to PBO who initiated UST at wk6 or 4 demonstrated slowing of radiographic progression by wk5 (mean change in total vdh-s wk4 to wk5 of 0.08). These observations were reproduced when PSUMMIT was evaluated alone. In PSUMMIT, a demonstrable effect of UST on inhibition of structural damage progression could not be discerned; these results may have been impacted by missing radiographic data, especially among PBO-treated patients (% missing radiographs). Conclusion: Based upon the pre-specified integrated data analysis, ustekinumab inhibits radiographic progression at wk4. ARHP NETWORKING EVENT Noon - :00 pm Sapphire Ballroom K-L-O-P Networking at Noon Sit down with your colleagues over a complimentary lunch, and participate in open discussion on various research, practice and clinical topics. Each roundtable discussion will be facilitated by a rheumatology expert. All ARHP attendees are welcome to participate in this event. This session is not eligible for CME credit. Roundtable Topics Advocates for Arthritis/Win a trip to DC Arthritis and Employment Issues Available Foundation Dollar$$ Clinical Research Coordinators Enhancing Patient Adherence Epidemiology/Public Health Form Sharing Adult Form Sharing Pediatric Getting Started In Research Global/International Networking ICD-0 & Infusion and Injectable Therapies Issues in Healthcare Education Managing a Rheumatology Practice/Managing Office Politics Measurement of Disease Activity Medications for Rheumatic Diseases Nurse Practitioners Adult Nurse Practitioners Pediatric Nursing Practice Issues Orthopedic & Manual Therapy Pain Management Physical Activity Physician Assistants Prior Authorizations Sleep/Fatigue Social Media to Improve Patient Health Care Models MONDAY october 8, 0 Disclosures: I. B. McInnes, Novartis, Janssen Research & Development, LLC., 8, UCB, 9. ACR SESSIONS :0 - :00 pm Indigo C ACR Special Session: Career Opportunities in Rheumatology: Making a Choice Moderator: Marcy B. Bolster, MD provide examples of different career paths available to rheumatologists discuss the pros and cons of the various career paths in rheumatology :0 pm Academic Medicine Tuhina Neogi, MD, PhD :50 pm Private Practice Elizabeth Perkins, MD :0 pm Clinician Education Michael H. Pillinger, MD denotes Hilton San Diego Bayfront room location :0 pm Industry Gregory J. Dennis, MD 0 Program Book 75

78 MONDAY october 8, 0 Sapphire I Inter-professional Collaborative Practice and Education: A Review of the Field and Report of a New Center of Excellence in Musculoskeletal Care Moderators: Kenneth S. O Rourke, MD and Deana M. Lazaro, MD discuss the current state of inter-professional and interdisciplinary education, in the context of clinical settings describe how inter-professional and interdisciplinary educational collaborations can be created within the context of rheumatic diseases, bone health consider practical steps for developing and implementing the collaborative efforts, including possible sources of funding :0 pm Inter-professional and Interdisciplinary Collaborative Practice and Education: State of the Art Michael J. Battistone, MD :00 pm The Center of Excellence in Musculoskeletal Medicine: An Inter-professional, Interdisciplinary Patient Care and Education Initiative at the George E. Whalen Veterans Affairs Salt Lake City Health Care System Andrea Barker, MPAS, PA-C :0 pm Practical Steps in Implementing Inter-professional Collaborations Grant W. Cannon, MD ACR MEET THE PROFESSOR SESSIONS :45 - :5 pm Admission to Meet the Professor sessions requires a separate registration and ticket. To verify which session you registered for, the registration code on your ticket needs to match the -digit code in parentheses below. If you are interested in participating in one of these sessions or exchanging your ticket, visit the ACR registration desk to check space availability. View the session overview online in My Annual Meeting at www. ACRannualmeeting.org. * Sessions denoted with an asterisk were sold out as of August 0. *Challenging Cases in Osteoporosis Management (04) Speaker: Kenneth G. Saag, MD, MSc Immunodeficiency Syndromes (04) Speaker: Troy R. Torgerson, MD, PhD review the immunology and clinical manifestations of the major immune deficiency syndromes that both adult and pediatric rheumatologists might encounter discuss the diagnostic evaluation for someone suspected of having an immune deficiency syndrome illustrate therapeutic options with cases 4 A *Macrophage Activation Syndrome (04) Speaker: Alexei A. Grom, MD recognize the signs and symptoms of macrophage activation syndrome (MAS) in rheumatology recognize markedly distinct nature of the systemic form of juvenile idiopathic arthritis and the fact that MAS most frequently occurs in patients with this disease. discuss current treatment approaches in MAS 4 B *Myopathy: Issues in Diagnosis and Treatment (044) Speaker: Rohit Aggarwal, MD, MS differentiate myositis mimics from idiopathic inflammatory myopathies explain importance of myositis antibodies and muscle magnetic resonance imaging in diagnosis and prognosis review myositis diagnosis in difficult cases including review of clinical features, muscle biopsy and electromyography review management of refractory myopathy including management of extra-muscular manifestations especially interstitial lung disease 5 A Pulmonary Manifestations of Rheumatic Disease (045) Speaker: Aryeh Fischer, MD identify emerging concepts regarding the pathophysiology of inflammation and fibrosis in autoimmune lung disease recognize the appropriate use of diagnostic tests in the evaluation of patients with rheumatic disorders and autoimmune lung disease discuss the limits of traditional therapeutic options and possible emerging therapies in managing autoimmune lung disease gain familiarity with bisphosphonate drug holidays discuss timing of use of various anti-osteoporosis therapies in postmenopausal osteoporosis recognize current treatment approaches to steroid-induced osteoporosis identify other forms of metabolic bone disease that present to rheumatologists as low bone mass 5 B *Raynaud s and Digital Ischemia (046) Speaker: Janet E. Pope, MD, MPH discuss the etiology of Raynaud s and differentiate Raynaud s from mimickers describe the appropriate investigations for Raynaud s phenomenon and be aware of those patients at risk for the development of a connective tissue disease review treatment options for Raynaud s, threatened digital ischemia and digital ulcers that are evidence based including new data from recent trials 76 0 Program Book denotes Hilton San Diego Bayfront room location

79 6 A *Rheumatoid Arthritis: Biological Agents (047) Speaker: Edward Keystone, MD describe the newer trends in the use of biologics discuss the emerging biologics, including biosimilars, and their advantages for the therapeutic algorithm describe the risk/benefit profiles of biologic agents 6 B *Rheumatoid Arthritis: Safety of Novel Therapies (048) Speaker: Lee S. Simon, MD examine the drug safety literature with greater expertise prescribe DMARDs with a broader and deeper knowledge of potential toxicities discuss DMARD toxicities with their patients with greater comfort manage potential DMARD toxicities with greater skill 7 A * Systemic Lupus Erythematosus: Difficult to Treat Systemic Lupus Erythematosus (049) Speaker: Maria Dall Era, MD review established data from the medical literature in order to improve clinical practice related to the treatment of systemic lupus erythematosus (SLE) including: examine management strategies for refractory cutaneous manifestations of SLE discusss management of progressive or relapsing lupus nephritis discuss management of severe cytopenias 7 B * What is Not Central Nervous Angiitis: Making the Right Diagnosis (050) Speaker: Leonard H. Calabrese, DO list and elaborate on the diagnostic criteria for primary angiitis of the central nervous system (PACNS) discuss the test operating characteristic of commonly employed neurodiagnostics i.e. magnetic resonance, angiography, cerebrospinal fluid analysis, etc. list and appraise diagnostic heuristics for the recognition and diagnosis of PACNS and the separation of mimics that can confound the diagnosis ACR SESSIONS :00 - :00 pm 6 A Behçet s Disease Moderator: Mark F. Gourley, MD Speaker: Cailin H. Sibley, MD describe the different manifestations of Behçet s disease recognize new scientific finding regarding Behçet s provide optimal therapy to Behçet s patients denotes Hilton San Diego Bayfront room location Ballroom 0 A Winning at Clue: The Clinical Rheumatologist s Guide to Figuring out Who Killed Who, With What and Where in the Rheumatic Diseases Moderator: Stacy P. Ardoin, MD, MS Speaker: Antony Rosen, MD define key cytokine and death inducing pathways in systemic lupus erythematosus, myositis, rheumatoid arthritis, and Sjögren s discuss what is known about tissue repair pathways in myositis and other rheumatic syndromes review the impact of tissue damage and repair on our approach to the management of patients with rheumatic disease ACR WORKSHOPS :5 - :5 pm 4 A Admission to Workshops requires a separate registration and ticket. To verify which session you registered for, the registration code on your ticket needs to match the -digit code in parentheses below. If you are interested in participating in one of these sessions or exchanging your ticket, visit the ACR registration desk to check space availability. View the session overview online in My Annual Meeting at www. ACRannualmeeting.org. * Sessions denoted with an asterisk were sold out as of August 0. Magnetic Resonance Imaging in the Diagnosis and Management of Spondylarthritis: A Clinician s Guide () Speaker: Walter P. Maksymowych, MD identify which types of office magnetic resonance imaging systems are available and how each is used for optimal practice discuss the logistics of implementation of peripheral magnetic resonance imaging in the outpatient setting recognize indications for peripheral magnetic resonance imaging scans in clinical rheumatology discuss the most recent research using office-based magnetic resonance imaging identify anatomical structures of joints on acquired magnetic resonance imaging images review the merits and pitfalls of magnetic resonance imaging technology Peripheral Magnetic Resonance Imaging in Rheumatology Practice (4) Speakers: Philip G. Conaghan, MD, PhD and Mikkel Ostergaard, DMSc, MD, PhD recognize the most common types of magnetic resonance images (as T- and T-weighted, fat-saturated, STIR and contrast-enhanced), and the appearance of the most common joint pathologies on these discuss the rationale and evidence for using magnetic resonance imaging in clinical practice identify the advantages and disadvantages of dedicated extremity magnetic resonance imaging 0 Program Book 77 MONDAY october 8, 0

80 MONDAY october 8, 0 B Synovial Fluid Analysis and Crystal Identification (5) Speakers: Brian F. Mandell, MD, PhD; Lan Chen, MD, PhD and Gilda M. Clayburne, MLT prepare synovial fluid samples for microscopic examination identify various components of synovial fluid identify crystals in synovial fluid ACR SESSIONS :0-4:00 pm 6 C 6 A Autoimmunity Caused by Immune Deficiency: When Not Enough Is Too Much Moderator: Dominic Co, MD, PhD identify patients requiring further immune evaluation initiate an immune deficiency workup discuss the clinical manifestations and diagnosis of IPEX-like syndromes discuss the clinical manifestations and diagnosis of CVID :0 pm Immune Deficiency for the Rheumatologist Jennifer Puck, MD :00 pm Disorders of Tolerance: Immune Dysregulation, Polyendocrinopathy, Enteropathy, X-linked (IPEX) and IPEX-like Syndromes Troy R. Torgerson, MD, PhD :0 pm A Guide to Common Variable Immunodeficiency (CVID) for the Practicing Rheumatologist Kate Sullivan, MD, PhD Crystal Diseases: How Does Joint Damage Occur and Why do Attacks Resolve Spontaneously? Moderator: Tuhina Neogi, MD, PhD review the mechanisms of joint damage in gout, including IL-beta and tophi describe the mechanisms that contribute to spontaneous reduction of the inflammatory response in crystal arthropathies discuss the mechanism for pathogenicity of crystals in osteoarthritis, particularly BCP and HA :0 pm Mechanisms of Joint Damage in Gout Nicola Dalbeth, MBChB, MD :00 pm What Limits Gout Inflammation? Robert Terkeltaub, MD :0 pm How Do Calcium Crystals Induce Inflammation and Contribute to Osteoarthritis Geraldine M. McCarthy, MD Hall B Curbside Consults - Ask the Experts Moderators: Rula Hajj-Ali, MD and N. Lawrence Edwards, MD 6 D compare their personal management approaches to selected clinical problems with those of the presenters develop an approach to evaluating and managing patients presenting with peripheral neuropathy delineate an approach to evaluating and managing patients presenting with pulmonary hemorrhage describe therapeutic choices and management options for several common but difficult complications of scleroderma :0 pm The Challenges of Peripheral Neuropathy in Rheumatic Disease Julius Birnbaum, MD, MHS :00 pm Pulmonary Hemorrhage! Help! Ulrich Specks, MD :0 pm Difficult Scleroderma: How Do I Approach this Patient? Francesco Boin, MD Functional Genomics: Approaches to Identifying Causal Variants Moderator: S. Louis Bridges Jr., MD, PhD describe how genomic technologies have been used to identify causal genetic variant discuss the methods employed to interrogate large datasets cite the wide range of experimental approaches for assigning phenotypes to specific genotypes :0 pm Systems Genetics: What to Do With the Data Enrico Petretto, PhD :00 pm Identifying Causal Variants Using Genetic and Cell Type Specific Epigenetic Data Soumya Raychaudhuri, MD, PhD :0 pm From Genotype to Phenotype Jane Buckner, MD Ballroom 0 A Janus Kinase (JAK) Inhibitors in Rheumatoid Arthritis Moderator: Mark F. Gourley, MD identify the mechanism of action of tofacitinib describe the results of clinical trials of tofacitinib cite the benefits and risk of this therapy :0 pm What Are JAKs and Their Importance in Inflammation? John J. O Shea, MD 78 0 Program Book denotes Hilton San Diego Bayfront room location

81 :00 pm Tofacitinib, the Clinical Data Iain B. McInnes, PhD :0 pm Kinase Inhibition in the Future Joel M. Kremer, MD ACR CONCURRENT ABSTRACT SESSIONS :0-4:00 pm C Epidemiology and Health Services Research II: Epidemiology in Systemic Lupus Erythematosus and Rheumatoid Arthritis Moderators: Nasim Khan, MD and Cheryl Barnabe, MD, MSc :0 pm 696. Prevalence and Incidence of Systemic Lupus Erythematosus in a Population-Based Registry of American Indian and Alaska Native People in the United States, Elizabeth D. Ferucci, Janet Johnston, Jasmine Gaddy, Lisa Sumner 4, James Posever 4, Tammy L. Choromanski, Caroline Gordon 5, S. Sam Lim 6 and Charles G. Helmick 7, Alaska Native Tribal Health Consortium, Anchorage, AK, Univeristy of Alaska Anchorage, Anchorage, AK, Oklahoma City Area Indian Health Service, Oklahoma City, OK, 4 Phoenix Indian Medical Center, Phoenix, AZ, 5 University of Birmingham, Birmingham, United Kingdom, 6 Emory University, Atlanta, GA, 7 Centers for Disease Control and Prevention, Atlanta, GA :45 pm 697. Are Patients With Rheumatoid Arthritis Still at an Increased Risk Of Tuberculosis and What Is the Role of Biological Treatment? Elizabeth V. Arkema, Jerker Jonsson, Eva Baecklund, Maud Rutting 4, Judith Bruchfeld, Nils Feltelius 4 and Johan Askling 5, Karolinska Institutet, Stockholm, Sweden, Swedish Institute for Communicable Disease Control, Solna, Sweden, Uppsala University Hospital, Uppsala, Sweden, 4 Swedish Medical Products Agency, Uppsala, Sweden, 5 Karolinska University Hospital, Stockholm, Sweden :00 pm 698. Sex-Related Differences and Trends In Mortality of Juvenile-Onset Systemic Lupus Erythematosus (SLE) in The United States Over the Last Forty Years, Eric Y. Yen, Jennifer M.P. Woo and Deborah K. McCurdy, Mattel Children s Hospital, University of California at Los Angeles, Los Angeles, CA, Mattel Children s Hospital, University of California, Los Angeles, Los Angeles, CA :5 pm 699. Development of Systemic Lupus Erythamatosus Among Possible Systemic Lupus Erythamatosus Patients Seen In Consultation: Long-Term Follow-Up May Al Daabil, Bonnie L. Bermas, Tabatha Norton, Hsun Tsao, Patricia Ho, Joseph F. Merola, Peter H. Schur, Elena M. Massarotti and Karen H. Costenbader, Brigham and Women s Hospital, Harvard Medical School, Boston, MA denotes Hilton San Diego Bayfront room location :0 pm 700. Which Are the Most Common Disease Modifying Antirheumatic and Biologic Treatment Pathways for Rheumatoid Arthritis Patients? Sofia Pedro, Frederick Wolfe, James O Dell and Kaleb Michaud, National Data Bank for Rheumatic Diseases, Wichita, KS, University of Nebraska Medical Center, Omaha, NE, National Data Bank for Rheumatic Diseases & University of Nebraska Medical Center, Omaha, NE :45 pm *06. The Brief Index of Lupus Damage As a Predictor of Mortality in a Cohort of Patients With Systemic Lupus Erythematosus Stephanie Rush, Laura Trupin, Jinoos Yazdany and Patricia P. Katz, University of California, San Francisco, San Francisco, CA * Break in presentation number sequence is due to the addition of a substitute abstract. 04 A Genetics and Genomics of Rheumatic Disease I Moderators: Betty P. Tsao, PhD and John B. Harley, MD, PhD :0 pm 70. Identification of Multiple Genetic Susceptibility Loci in Takayasu s Arteritis Guher Saruhan-Direskeneli, Travis Hughes, Patrick S. Coit, Joel M. Guthridge, Judith A. James, Peter A. Merkel of behalf of the Vasculitis Clinical Research Consortium 4, Haner Direskeneli on behalf of the Turkish Takayasu Study Group 5 and Amr H. Sawalha, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey, University of Michigan, Ann Arbor, MI, Oklahoma Medical Research Foundation, Oklahoma City, OK, 4 University of Pennsylvania, Philadelphia, PA, 5 Marmara University, Faculty of Medicine, Istanbul, Turkey :45 pm 70. High Density Genotyping of Immune-Related Disease Genes Identifies 7 New Susceptibility Loci for Behçet s Disease Masaki Takeuchi, Nobuhisa Mizuki, Akira Meguro, Michael J. Ombrello, Colleen Satorius, Yohei Kirino, Tatsukata Kawagoe, Duran Ustek 4, Ilknur Tugal-tutkun 5, Emire Seyahi 6, Yilmaz Ozyazgan 6, Shigeaki Ohno 7, Atsuhisa Ueda, Yoshiaki Ishigatsubo, Ahmet Gül 5, Daniel L. Kastner and Elaine Remmers, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, Yokohama City University Graduate School of Medicine, Yokohama, Japan, National Institute of Arthritis Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, 4 Institute of Experimental Medicine, Istanbul University, Istanbul, Turkey, 5 Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey, 6 Cerrahpasa Faculty of Medicine, Istanbul University, Istanbul, Turkey, 7 Hokkaido University Graduate School of Medicine, Hokkaido, Japan :00 pm 704. Mapping the Shared and Distinct HLA Alleles for Seropositive and Seronegative Rheumatoid Arthritis Buhm Han, Stephen Eyre, Dorothee Diogo, John Bowes, Yukinori Okada, Leonid Padyukov 4, Robert M. Plenge, Lars Klareskog 4, Jane Worthington, Peter K. Gregersen 5, Paul de Bakker 6 and Soumya Raychaudhuri, Brigham and Women s 0 Program Book 79 MONDAY october 8, 0

82 MONDAY october 8, 0 Hospital, Harvard Medical School, Boston, MA, Arthritis Research UK Epidemiology Unit, University of Manchester, Manchester, United Kingdom, Arthritis Research UK Epidemiology Unit, The University of Manchester, Manchester, United Kingdom, 4 Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden, 5 Feinstein Institute for Medical Research, Manhasset, NY, 6 University Medical Center Utrecht, Utrecht, Netherlands :5 pm 705. Genetic Associations in Anterior Uveitis Implicate T-Cell Co-Stimulation and Other Immune Pathways Philip Robinson, Dorith Claushuis, Paul Leo, Pamela Mukhopadhyay, P. Wordsworth 4, Michael H. Weisman 5, Walter P. Maksymowych 6, Proton Rahman 7, Robert Inman 8, Alex Hewitt 9, Tammy M. Martin 0, James T. Rosenbaum, Dennis Wakefield, John D. Reveille and Matthew A. Brown 4, University of Queensland Diamantina Insititute, Brisbane, Australia, The University of Queensland Diamantina Institute, Brisbane, Australia, The University of Queensland Diamantina Insititute, Brisbane, Australia, 4 University of Oxford, Oxford, United Kingdom, 5 Cedars-Sinai Medical Center, Los Angeles, CA, 6 University of Alberta, Edmonton, AB, 7 Memorial University, St. Johns, NF, 8 University of Toronto and Toronto Western Hospital, Toronto, ON, 9 University of Western Australia, Perth, Australia, 0 Oregon Health & Science Univ, Portland, OR, Oregon Health and Science University, Portland, OR, University of New South Wales, Sydney, Australia, University of Texas Health Science Center at Houston, Houston, TX, 4 University of Queensland Diamantina Institute, Brisbane, Australia :0 pm 706. Fine-Mapping Major Histocompatibility Complex Variation Associated With Ankylosing Spondylitis Susceptibility Adrian Cortes, International Genetics of Ankylosing Spondylitis Consortium (IGAS), Paul de Bakker and Matthew A. Brown 4, The University of Queensland Diamantina Insititute, Brisbane, Australia, University of Queensland Diamantina Institute, brisbane, Australia, University Medical Center Utrecht, Utrecht, Netherlands, 4 University of Queensland Diamantina Institute, Brisbane, Australia :45 pm 707. Biological Insights From Genetics of Rheumatoid Arthritis Contribute to Drug Discovery Yukinori Okada, Di Wu, Chikashi Terao, Katsunori Ikari 4, Yuta Kochi 5, Koichiro Ohmura, Akari Suzuki 5, Hisashi Yamanaka 4, Joshua C. Denny 6, Jeffrey D. Greenberg 7, Robert R. Graham 8, Matthew A. Brown 9, Sang-Cheol Bae 0, Jane Worthington, Leonid Padyukov, Lars Klareskog, Peter K. Gregersen 4, Peter M. Visscher 5, Katherine A. Siminovitch 6 and Robert M. Plenge, Brigham and Women s Hospital, Harvard Medical School, Boston, MA, Department of Statistics, Harvard University, Cambridge, MA, Graduate School of Medicine, Kyoto University, Kyoto, Japan, 4 Institute of Rheumatology, Tokyo Women s Medical University, Tokyo, Japan, 5 RIKEN, Yokohama, Japan, 6 Department of Biomedical Informatics, Vanderbilt University School of Medicine, Nashville, TN, 7 NYU Hospital for Joint Diseases, New York, NY, 8 Genentech, Inc., South San Francisco, CA, 9 The University of Queensland Diamantina Insititute, Brisbane, Australia, 0 Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, Arthritis Research UK Epidemiology Unit, The University of Manchester, Manchester, United Kingdom, Rheumatology Unit, Department of Medicine, Karolinska University Hospital, Solna, Karolinska Institutet, Stockholm, Sweden, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden, 4 Feinstein Institute for Medical Research, Manhasset, NY, 5 Queensland Brain Institute, The University of Queensland, St Lucia, Brisbane, Australia, 6 Mount Sinai Hospital, Toronto, ON 8 D Health Services Research, Quality Measures and Quality of Care Rheumatoid Arthritis Moderators: Eric D. Newman, MD and J. Timothy Harrington, MD :0 pm 708. Can People With Rheumatoid Arthritis Self Monitor Their Disease Activity? Noura AL Osaimi, Erin Carruthers, Charles H Goldsmith, Paul M Adam 4 and Diane Lacaille 5, University of British Columbia, Vancouver, BC, Arthritis Research Centre of Canada, Richmond, BC, Simon Fraser University, Burnaby, BC, 4 Mary Pack Arthritis Centre, Vancouver, BC, 5 Arthritis Research Centre of Canada, University of British Columbia, Richmond, BC :45 pm 709. Rheumatoid Arthritis Patient Cardiovascular Disease Prevention Experiences: Qualitative Analysis and Implications Christie M. Bartels, Sarah Tweddell, Barbara Bowers, Elizabeth Jacobs and Tonya Roberts, University of Wisconsin School of Medicine and Public Health, Madison, WI, UW School of Medicine and Public Health, Madison, WI, UW School of Nursing, Madison, WI :00 pm 7. Folic Acid Prescription Among Older Adult Methotrexate Initiators Is Poor Gabriela Schmajuk, Jinoos Yazdany, Yinghui Miao, David I. Daikh and Michael Steinman, UCSF / San Francisco VA Medical Center, San Francisco, CA, University of California, San Francisco, San Francisco, CA, San Francisco Veterans Affairs Medical Center, San Francisco, CA :5 pm 7. Identification of Factors Associated With Agreement Between Rheumatoid Arthritis Electronic Medication Lists and Prescribed Disease Modifying Treatment Plans Ilinca D. Metes, Heather Eng, June Feng, G.K. Balasubramani, Stephen R. Wisniewski and Marc C. Levesque, University of Pittsburgh, Pittsburgh, PA, University of Pittsburgh, Graduate School of Public Health, Pittsburgh, PA :0 am 7. Disparity in Biologic Therapy in Ethnic Minorities With Rheumatoid Arthritis: Can It All Be Due to Lack of Access to Drug? Gail S. Kerr, Ted R. Mikuls, Christopher J. Swearingen, Chunqiao Luo 4 and Yusuf Yazici 5, Washington DC VAMC, 80 0 Program Book denotes Hilton San Diego Bayfront room location

83 Georgetown and Howard University, Washington, DC, Omaha VA and University of Nebraska Medical Center, Omaha, NE, Pediatric Biostatistics, University of Arkansas for Medical Sciences, Little Rock, AR, 4 University of Arkansas for Medical Sciences, Little Rock, AR, 5 NYU Hospital for Joint Diseases and New York University School of Medicine, New York, NY :45 pm *95. Major Cost Savings Associated With Reduced Biologic Dosing Frequency in Inflammatory Arthritis Claire-Louise Murphy, Miriam O Sullivan, Sohail Awan, Shawn Chavrimootoo, Clara Bannon, Linzi Martin, Trevor Duffy, Eithne Murphy and Maurice Barry, Connolly hospital, Dublin 5, Dublin, Ireland, Connolly hospital, Dublin, Ireland * Break in presentation number sequence is due to the addition of a substitute abstract. 06 A Imaging in Pediatric Arthritis, Spondyloarthritis, and Osteoarthritis Moderators: Maria-Antonietta D Agostino, MD, PhD and Paul J. DeMarco, MD :5 pm 77. Do Bone Marrow Edema (BME) Lesions in The Sacroiliac Joint (SIJ) Change into Fatty Lesions Over a -Month Period in Patients With Axial Spondyloarthritis (axspa)? Manouk de Hooge, Rosaline van den Berg, Victoria Navarro- Compán, Monique Reijnierse, Floris van Gaalen, Karen Fagerli, Robert Landewé, Maikel van Oosterhout 4, Roberta Ramonda 5, Tom Huizinga and Désiréé van der Heijde, Leiden University Medical Center, Leiden, Netherlands, Diakonhjemmet Hospital, Oslo, Norway, Academic Medical Center, Amsterdam, Netherlands, 4 GHZ Hospital, Gouda, Netherlands, 5 University of Padova, Padova, Italy :0 pm 78. Reading oft Sacroiliac Joints on Plain Radiographs: Agreement Between Clinical Practice and Trained Central Reading of the DESIR-Cohort Rosaline van den Berg, Grégory Lenczner, Antoine Feydy, Désirée van der Heijde, Monique Reijnierse, Alain Saraux 4 and Pascal Claudepierre, Leiden University Medical Center, Leiden, Netherlands, Henri Mondor Teaching Hospital, AP-HP, Créteil, France, Paris Descartes University, Côchin Hospital, APHP, Paris, France, 4 Université Brest Occidentale, Brest, France :0 pm 74. Grey-Scale and Power Doppler Findings of Lower Extremity Entheses in Healthy Children Clara Lin and Diana Milojevic, University of California-San Francisco, San Francisco, CA, University of California, San Francisco, San Francisco, CA :45 pm 75. Detection of Enthesitis in Children With Enthesitis- Related Arthritis: Dolorimeter Examination Compared to Ultrasonography Pamela F. Weiss, Nancy Chauvin, Andrew J. Klink, Russell A. Localio 4, Chris Feudtner 5, Diego Jaramillo, Robert A. Colbert 6, David D. Sherry and Ron Keren, The Children s Hospital of Philadelphia, Philadelphia, PA, Children s Hospital of Philadelphia, PHILADELPHIA, PA, Children s Hospital of Philadelphia, Philadelphia, PA, 4 University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, 5 Division of General Pediatrics, Children s Hospital of Philadelphia; University of Pennsylvania Center for Clinical Epidemiology and Biostatistics, Philadelphia, PA, 6 NIAMS NIH, Bethesda, MD :00 pm 76. Childhood-Onset Systemic Lupus Erythematosus With Clinical Neurocognitive Dysfunction Have Lower Nodal Density and Connectivity on Diffusion Tensor Imaging Jordan T. Jones, Mark DiFrancesco, Ahmad I. Zaal, Marisa S. Klein-Gitelman, Darren Gitelman 4, Jun Ying 5 and Hermine I. Brunner, Cincinnati Children s Hospital Medical Center, Cincinnati, OH, Damascus University-Children s Hospital, Damascus, Syria, Children s Memorial Hospital, Chicago, IL, 4 Northwestern University, Chicago, IL, 5 University of Cincinnati, Cincinnati, OH :45 pm 79. High Reliability Was Found for Ultrasound Scoring of Osteophytes in Patients With Hand Osteoarthritis Using an Atlas as Reference; An Omeract Initiative Hilde B. Hammer, Alexander Mathiessen, Annamaria Iagnocco, Emilio Filippucci, Frédérique Gandjbakhch 4, Marion C. Kortekaas 5, Ingrid Möller 6, Esperanza Naredo 7, Richard J. Wakefield 8, Philippe Aegerter 9 and Maria-Antonietta D Agostino 0, Diakonhjemmet Hospital, Oslo, Norway, University La Sapienza, Rome, Italy, Università Politecnica delle Marche, Ancona, Italy, 4 APHP, Pitié Salpétrière Hospital, Universite Paris 6, Paris, France, 5 Leiden University Medical Center, Leiden, Netherlands, 6 Instituto Poal de Reumatologia, Barcelona, Spain, 7 Hospital General Universitario Gregorio Marañón, Madrid, Spain, 8 Leeds Institute of Molecular Medicine, University of Leeds and NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals, Leeds, United Kingdom, 9 Versailles-Saint Quentin en Yvelines University- APHP, Ambroise-Paré Hospital,, Boulogne-Billancourt,, France, 0 Ambroise Paré Hospital, and Versailles Saint Quentin en Yvelines University, Boulogne-Billancourt, France Indigo E Metabolic and Crystal Arthropathies II Moderators: Fernando Perez Ruiz, MD, PhD and Lisa K. Stamp, PhD :0 pm 70. Risk of Cardiovascular Disease and Use of Xanthine Oxidase Inhibitorsfor Gout Seoyoung C. Kim, Sebastian Schneeweiss, Niteesh Choudhry, Jun Liu, Robert J. Glynn and Daniel H. Solomon, Brigham and Women s Hospital, Boston, MA MONDAY october 8, 0 denotes Hilton San Diego Bayfront room location 0 Program Book 8

84 MONDAY october 8, 0 :45 pm 7. A Prediction Tool for Incident Gout Among Those With Hyperuricemia Liseth Siemons and Eswar Krishnan, University of Twente, Enschede, Netherlands, Stanford University, Palo Alto, CA :00 pm 7. Does Starting Allopurinol Prolong Acute Treated Gout? Erica Hill, Jay B. Higgs, Karen Sky, Michelle Sit and Angelique N. Collamer 4, San Antonio Military Medical Center, Fort Sam Houston, TX, US Department of Veterans Affairs, Alaska VA Healthcare System, Anchorage, AK, David Grant Medical Center, Travis AFB, CA, 4 Langley AFB Hospital, Langley AFB, VA :5 pm 7. Lesinurad, An Inhibitor of The Uric Acid Transporter URAT and a Potential Therapy for Gout, Requires URAT Phenylalanine 65 for High Affinity Inhibition Philip K. Tan, David Hyndman and Jeffrey N. Miner, Ardea Biosciences, San Diego, CA, Ardea Biosciences, Inc., San Diego, CA :0 pm 74. The Role of Low-Grade Inflammation in the Association Between Uric Acid and Atherosclerosis: The Codam Study José M.A. Wijnands, Annelies Boonen, Pieter C. Dagnelie, Marleen M.J. van Greevenbroek, Carla J.H, van der Kallen, Isabel Ferreira, Casper G. Schalkwijk, Edith J.M. Feskens, Sjef van der Linden, Coen D.A. Stehouwer and Ilja C.W. Arts, Maastricht University, Maastricht, Netherlands, Maastricht University Medical Center, Maastricht, Netherlands, Wageningen University, Wageningen, Netherlands :45 pm 90. The Synergistic Effects Of Metabolic Syndrome Indicators and Hyperuricemia in Contributing to Cardiac Event Risk: A Cross-Sectional Examination of the Nhanes III Data Daniel A. Albert and Sayyad Kyazimzade, The Dartmouth Institute for Health Policy and Clinical Practice, Lebanon, NH, The Dartmouth Institute for Health Policy & Clinical Practice, Lebanon, NH, Lebanon, NH This abstract is out of order due to abstract #75 being withdrawn. B Rheumatoid Arthritis - Animal Models I :0 pm 76. Survivin Inhibition Disturbs Bcl-6 and Blimp- Control of Lymphocyte Maturation and Alleviates Antigen-Induced Arthritis Mattias Svensson, Karin Andersson, Malin Erlandsson, Ing- Marie Jonsson and Maria Bokarewa, University of Gothenburg, Gothenburg, Sweden, Göteborgs University, Göteborg, Sweden :45 pm 77. Novel Selective Inhibitors of Nuclear Export Attenuate Inflammation and Prevent Bone Mineral Density Loss in Multiple Preclinical Models of Rheumatoid Arthritis Mwanasha Hamuza, Yosef Landesman, Boris Klebanov, Michael Kauffman, Sharon Shacham, Judith Endres, David A. Fox and Dilara McCauley, Karyopharm Therapeutics Inc., Natick, MA, University of Michigan Medical Center, Ann Arbor, MI :00 pm 78. Amelioration of Collagen-Induced Arthritis By Modulation of Inhibitory Apoptosis Stimulating Protein of p5 to Activate Transcription Factor p7 Chrong-Reen Wang, Shih-Yao Chen, Ai-Li Shiau, Yuan-Tsung Li, Chia-Tse Weng, I-Ming Jou, Ming-Fei Liu and Chao-Liang Wu, College of Medicine, National Cheng Kung University, Tainan, Taiwan :5 pm 79. Cell Cycle Regulation Therapy Combined With Cytokine Blockade Enhances Anti-Arthritic Effects Without Increase of Immune Suppression Tadashi Hosoya, Hideyuki Iwai, Yu Yamaguchi, Nobuyuki Miyasaka and Hitoshi Kohsaka, Department of Medicine and Rheumatology, Tokyo Medical and Dental University, Tokyo, Japan :0 pm 70. Novel Role for Ly6C- Monocyte Subsets and Joint Macrophages in Mouse Model of Rheumatoid Arthritis Alexander Misharin, Carla M. Cuda, Rana Saber, Angelica K. Gierut, G. Kenneth Haines III 4, Steffen Jung 5 and Harris R. Perlman, Northwestern University, Chicago, IL, Northwestern University Feinberg School of Medicine, Chicago, IL, Northwestern Med Faculty Found, Chicago, IL, 4 Yale University, New Haven, CT, 5 Weizmann Institute, Rehovot, Israel :45 pm 7. Treatment of Innate Immune Arthritis With a Toll-Like Receptor 7 Agonist Requires Type I Interferon Maripat Corr, Tomoko Hayashi, Dennis A. Carson, Howard Cottam and Joshua Yang, Univ of California-San Diego, La Jolla, CA, UCSD School of Medicine, La Jolla, CA, ucsd School of Medicine, La Jolla, CA 9 D Rheumatoid Arthritis Treatment - Small Molecules, Biologics and Gene Therapy: Efficacy and Safety of Novel Entities Moderators: Jonathan Kay, MD and Iain B. McInnes, PhD :0 pm 7. Efficacy and Safety of Subcutaneous Administration of Tabalumab, An Anti-B Cell Activating Factor Monoclonal Antibody, in Rheumatoid Arthritis: Results From a Phase Multicenter, Randomized, Double-Blind Study Mark C. Genovese, Gregg J. Silverman, Paul Emery, Ramesh Gupta 4, Anne Gill 5, Wendy J. Komocsar 5, Melissa Veenhuizen 5, Li Xie 5, Pierre-Yves Berclaz 5 and Chin Lee 5, Stanford University, Palo Alto, CA, NYU School of Medicine, New York, NY, University of Leeds, Leeds, United Kingdom, 4 Private Practice, Memphis, TN, 5 Eli Lilly and Company, Indianapolis, IN :45 pm 7. Early and Sustained Improvement in Pain and Physical Function as Measured By Visual Analog Scale and Short Form-6 Physical Component Summary Score in Rheumatoid Arthritis Patients Treated With Mavrilimumab, an Investigational Anti-GM-CSFR-Alpha Monoclonal Antibody, in a Phase a Study Gerd-Rüdiger Burmester, Tsutomu Takeuchi, Olga Barbarash, Duncan Porter 4, Didier Saurigny 5, David Close 5, Alex Godwood 5, 8 0 Program Book denotes Hilton San Diego Bayfront room location

85 Yoojung Yang 6 and Ancilla W. Fernandes 6, Charite University Hospital, Berlin, Germany, Keio University School of Medicine, Tokyo, Japan, SIH Kemerovo Regional Clinical Hospital, Kemerovo, Russia, 4 Gartnavel General Hospital, Glasgow, United Kingdom, 5 MedImmune, Ltd, Cambridge, United Kingdom, 6 MedImmune, LLC, Gaithersburg, MD :00 pm 74. A Phase Ib Clinical Trial With Dekavil (F8-IL0), an Immunoregulatory Armed Antibody for the Treatment of Rheumatoid Arthritis, Used in Combination With Methotrexate M. Galeazzi, L Bazzichi, E Prisco, G D Sebastiani 4, D. Neri 5, L Giovannoni 6, F Bacchion 7, M Bardelli, C Baldi, E Selvi, G Minisola 8, R Caporali 9 and S Bombardieri 0, Rheumatology Unit, University Hospital of Siena, Siena, Siena, Italy, Division of Rheumatology, University of Pisa, Pisa, Pisa, Italy, Deptartment of Rheumatology, University of Pavia, IRCCS Policlinico San Matteo Foundation, Pavia, Pavia, Italy, 4 Rheumatology Unit, San Camillo-Forlanini Hospital, Rome, Rome, Italy, 5 Chemistry and Applied Sciences, Swiss Federal Institute of Technology, Zurich, Zurich, Switzerland, 6 Clinical Research Unit, Philogen S.p.A., Siena, Sovicille - (SI), Italy, 7 Clinical Research Unit, Philogen S.p.A, Siena, Sovicille - (SI), Italy, 8 Rheumatology Unit, San Camillo-Forlanini Hospital, Rome, Rome, Italy, 9 Department of Rheumatology, University of Pavia, IRCSS Policlinico San Matteo Foundation, Pavia, Pavia, Italy, 0 Department of Rheumatology, University of Pisa, Pisa, Pisa, Italy :5 pm 75. A Phase IIb Study of the Efficacy and Safety of Subcutaneous Clazakizumab (anti-il-6 monoclonal antibody) With or Without Methotrexate In Adults With Moderateto-Severe Active Rheumatoid Arthritis and an Inadequate Response to Methotrexate M Weinblatt, P Mease, E Mysler, T Takeuchi 4, E Drescher 5, A Berman 6, M Zilberstein 7, J Xing 7 and P Emery 8, Brigham and Women s Hospital, Boston, MA, Swedish Medical Center and University of Washington, Seattle, WA, Organización Médica de Investigación, Buenos Aires, Argentina, 4 Keio University, Tokyo, Japan, 5 Csolnoky Ferenc Hospital, Veszprém, Hungary, 6 Centro Médico Privado de Reumatología, Tucuman, Argentina, 7 Bristol- Myers Squibb, Princeton, NJ, 8 University of Leeds, Leeds, United Kingdom :0 pm 76. A Randomized, Controlled, Multicenter, Arm, Parallel Group, Double-Blind Study to Demonstrate the Equivalence of CT-P0 to Innovator Rituximab With Respect to Pharmacokinetic Profile in Patients With Rheumatoid Arthritis Dae-Hyun Yoo, Won Park, Slawomir Jeka, Fidencio Cons Molina 4, Pawel Hrycaj 5, Piotr Wiland 6, Wolfgang Spieler 7, Jan Brzezicki 8, Eun Young Lee 9, Francisco G. Medina-Rodriguez 0, Pavel Shesternya, Sebastiao Radominski, Marina Stanislav, Volodymyr Kovalenko 4, Dong Hyuk Sheen 5, Mie Jin Lim, Jung-Yoon Choe 6, Sung Young Lee 7, Seung-Cheol Shim 8 and Chang-Hee Suh 9, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, Inha University Hospital, Incheon, South Korea, Clinic of Rheumatology and Connective Tissue Diseases University Hospital No in Bydgoszcz Collegium Medicum UMK in Torun, Bydgoszcz, Poland, 4 Centro de denotes Hilton San Diego Bayfront room location Investigacion en Artritis y Osteoporosis SC, Mexicali, Mexico, 5 Poznan University of Medical Sciences, Poznan, Poland, 6 Medical University of Wroclaw, Wroclaw, Poland, 7 ZeFOR GmbH Zentrum für Forschung, Zerbst, Germany, 8 Wojewodzki Szpital Zespolony Oddzial Reumatologiczny, Elblag, Poland, 9 Division of Rheumatology, Department of Internal Medicine, Seoul National University, Seoul, South Korea, 0 Centro de Investigación Farmacológica y Biotecnológica, Mexico City, Mexico, Krasnoyarsk State Medical University, Krasnoyarsk, Russia, CETI Centro de Estudos em Terapias Inovadoras Ltda, Curitiba, Brazil, Russian Academy of Medical Science, Moscow, Russia, 4 National Scientific Center, Kiev, Ukraine, 5 Eulji University Hospital, DaeJeon, South Korea, 6 Daegu Catholic University Medical Center, Daegu, South Korea, 7 CELLTRION, Inc., Incheon, South Korea, 8 Chungnam National University Hospital, Daejeon, South Korea, 9 Ajou University Hospital, Suwon, South Korea :45 pm 77. Association of HLA-DRB Alleles With Clinical Responses to the Anti-Interleukin 7A Monoclonal Antibody Secukinumab In a Cohort Of Patients With Active Rheumatoid Arthritis: An Exploratory Phase Biomarker Study Gerd R Burmester, Patrick Durez, Galina Shestakova, Yue Li 4, Amanda Wang 5, Steve Lewitzky 5, Irina Koroleva 5, David Lee 4 and Wolfgang Hueber 4, Charité-Universitätsmedizin Berlin, Free University and Humboldt University of Berlin, Berlin, Germany, Université Catholique de Louvain, Brussels, Belgium, Kaluga State Pedagogical Tsiolkovsky University, Kaluga, Russia, 4 Novartis Pharma AG, Basel, Switzerland, 5 Novartis Pharma AG, Cambridge, MA A Systemic Lupus Erythematosus - Clinical Aspects and Treatment: Biologic Therapy Moderators: Dafna Gladman, MD and Maureen A. McMahon, MD :0 pm 78. Epratuzumab Maintains Improvements in Disease Activity for Over Years in Patients With Moderate-to-Severe Systemic Lupus Erythematosus: Results From an Open-Label Long-Term Extension Study Megan E. B. Clowse, Frederic Houssiau, Michelle A. Petri, Brian Kilgallen 4, Kenneth Kalunian 5, Vibeke Strand 6, Sabine Bongardt 7, Caroline Gordon 8 and Daniel J. Wallace 9, Duke University Medical Center, Durham, NC, Université catholique de Louvain, Brussels, Belgium, Johns Hopkins University School of Medicine, Baltimore, MD, 4 UCB Pharma, Smyrna, GA, 5 UCSD School of Medicine, La Jolla, CA, 6 Stanford University, Palo Alto, CA, 7 UCB Pharma, Brussels, Belgium, 8 University of Birmingham, Birmingham, United Kingdom, 9 Cedars-Sinai Medical Center, Los Angeles, CA :45 pm 79. Sustained British Isles Lupus Assessment Group- Measured Improvement in Moderately-and-Severely Affected Body Systems in Patients With Systemic Lupus Erythematosus By Epratuzumab: Results From an Open-Label Extension Study Kenneth Kalunian, Megan E. B. Clowse, Frederic Houssiau, Michelle A. Petri 4, Brian Kilgallen 5, Caroline Gordon 6, Vibeke Strand 7, Sabine Bongardt 8 and Daniel J. Wallace 9, UCSD School 0 Program Book 8 MONDAY october 8, 0

86 MONDAY october 8, 0 of Medicine, La Jolla, CA, Duke University Medical Center, Durham, NC, Université catholique de Louvain, Brussels, Belgium, 4 Johns Hopkins University School of Medicine, Baltimore, MD, 5 UCB Pharma, Raleigh, NC, 6 University of Birmingham, Birmingham, United Kingdom, 7 Stanford University, Palo Alto, CA, 8 UCB Pharma, Brussels, Belgium, 9 Cedars-Sinai Medical Center, Los Angeles, CA :00 pm Month Outcomes Associated With Belimumab in Patients With Systemic Lupus Erythematosus in Clinical Practice Settings: The Observe Study Christopher E. Collins, Maria Dall Era, Alan Oglesby, Michael B. McGuire 4, Ramesh Pappu, Hong Kan and Charles T. Molta 5, Washington Hospital Center, Washington, DC, University of California, San Francisco, San Francisco, CA, GlaxoSmithKline, Research Triangle Park, NC, 4 Medical Data Analytics, Parsippany, NJ, 5 GlaxoSmithKline, King of Prussia, PA :5 pm 74. Correlation of The Interferon Gene Signature With Systemic Lupus Erythematosus Disease Activity Is Dependent on the Associated Level of the BAFF Gene Transcript Michelle Petri, Laurence S. Magder, Hong Fang, Julie Czerkowicz, Andrea Dearth, Jadwiga Bienkowska 4, Norm Allaire 4, Patrick Cullen, Alice Thai and Ann Ranger, Johns Hopkins University School of Medicine, Baltimore, MD, University of Maryland, Baltimore, MD, Biogen Idec Inc, Cambridge, MA, 4 Biogen Idec Inc., Cambridge, MA :0 pm 74. Effects of Blisibimod, an Inhibitor of B Cell Activating Factor, on Serum Immunoglobulins and Infection Risk in Patients With Systemic Lupus Erythematosus: Observations From the Placebo-Controlled Pearl-SC and Open-Label Extension Studies Richard A. Furie, Matthew Thomas, Alvina Chu, Renee S. Martin, Colin Hislop and Morton A. Scheinberg 4, The Feinstein Institute for Medical Research and North Shore-Long Island Jewish Health System, Lake Success, NY, Health and Research Centre, Trivandrum, Kerala, India, Anthera Pharmaceuticals Inc, Hayward, CA, 4 Rheumatology Hospital Abreu Sodre Pesquisa Clínica, São Paulo, Brazil :45 pm 74. Administration of AMG 557, a Human Anti-B7RP- (ICOSL) Antibody, Leads to the Selective Inhibition of Anti- KLH IgG Responses in Subjects With SLE: Results of a Phase Randomized, Double-Blind, Placebo-Controlled, Sequential, Rising, Multiple-Dose Study Barbara Sullivan, Wayne H. Tsuji, Vishala L. Chindalore, Thomas D. Geppert 4, Alla Rudinskaya 5, Patricia Pardo 6, Alan Kivitz 7, C. Michael Neuwelt 8, Meggan Mackay 9, R. John Looney 0, J. Carter Thorne, Marilee Andrew, Greg Arnold, Michael Boedigheimer, Kit Chiu, Cherie Green, Arunan Kaliyaperumal, Christine Wang, Andrew Welcher and James Chung, Amgen, Thousand Oaks, CA, Amgen, Seattle, WA, Anniston Medical Clinic PC, Anniston, AL, 4 Metroplex Clinical Research Center, LLC, Dallas, TX, 5 Danbury Hospital, Danbury, CT, 6 MRA Clinical Research, Miami, FL, 7 Altoona Center for Clinical Research, Duncansville, PA, 8 East Bay Rheumatology Research Institute, San Leandro, CA, 9 Feinstein Institute for Medical Research, Manhasset, NY, 0 University of Rochester, Rochester, NY, Southlake Regional Health Centre, Newmarket, ON Sapphire A Systemic Sclerosis, Fibrosing Syndromes, and Raynaud s - Clinical Aspects and Therapeutics I Moderators: Murray Baron, MD and Tracy M. French, MD :0 pm 744. Identifying Trajectories of Lung Function Change Over Time in Scleroderma Ada Man, Todd Davidyock, Laura Western, Michael Ieong, Yuqing Zhang and Robert W. Simms, Boston University School of Medicine, Boston, MA, University of Maryland, Baltimore, MD :45 pm 745. Prediction of Pulmonary Complications In Systemic Sclerosis - Model Development and Validation Svetlana I. Nihtyanova, Benjamin E. Schreiber, Voon H. Ong, John G. Coghlan 4, Athol U. Wells 5 and Christopher P. Denton, Royal Free and University College Medical School, London, United Kingdom, National Pulmonary Hypertension Service, London, United Kingdom, The Royal Free and University College Medical School, London, United Kingdom, 4 The Royal Free Hospital NHS Foundation Trust, London, United Kingdom, 5 Department of Radiology, London, United Kingdom :00 pm 746. Pericardial Effusions Are Not a Poor Prognostic Factor in Systemic Sclerosis Patients With Pulmonary Hypertension Elana J. Bernstein, Jessica K. Gordon, Wei-Ti Huang and Virginia D. Steen, Hospital for Special Surgery, New York, NY, Georgetown University Medical Center, Washington, DC :5 pm 747. Plasma MCP- and IL-0 Levels Predict Long-Term Progression Of Interstitial Lung Disease in Patients With Early Systemic Sclerosis Minghua Wu, Claudia Pedroza, Gloria Salazar, Xiaodong Zhou, John D. Reveille, Maureen D. Mayes and Shervin Assassi, University of Texas Health Science Center at Houston, Houston, TX :0 pm 748. Autoantibodies to RuvBL and RuvBL: A Novel Systemic Sclerosis-Related Antibody Associated With Diffuse Cutaneous and Skeletal Muscle Involvement Kenzo Kaji, Noreen Fertig, Thomas A. Medsger Jr., Takashi Sathoh, Kana Hoshino, Yasuhito Hamaguchi, Minoru Hasegawa, Mary Lucas, Andrew Schnure, Fumihide Ogawa 4, Shinichi Sato 5, Kazuhiko Takehara, Manabu Fujimoto and Masataka Kuwana, Kanazawa University Graduate School of Medical Sciences, Kanazawa, Japan, University of Pittsburgh, Pittsburgh, PA, Keio University School of Medicine, Tokyo, Japan, 4 Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, 5 The University of Tokyo, Tokyo, Japan :45 pm 749. Treatment Strategies and Outcomes in Patients With Systemic Sclerosis and Acute Myocardial Infarction Priya Prakash, Dhaval Kolte, Sahil Khera, Jagadish Khanagavi, Marjan Mujib, Chandrasekar Palaniswamy, Farrah Gutwein, Sachin Sule, Wilbert S. Aronow, William H. Frishman and Julia Ash, New York Medical College, Valhalla, NY 84 0 Program Book denotes Hilton San Diego Bayfront room location

87 0 E Vasculitis II Moderators: Rula Hajj- Ali, MD and Yusuf Yazici, MD :0 pm 750. Short and Long-Term Biological Therapy in Refractory Uveitis of Behcet s Syndrome. Multicenter Study of 4 Patients Francisco Ortiz-Sanjuan, Vanesa Calvo-Río, Ricardo Blanco, Emma Beltrán, Juan Sánchez-Bursón 4, Marina Mesquida 5, Alfredo M. Adan 5, M Hernandez Grafella, E Valls Pascual 6, L Martínez-Costa 6, Agustí Sellas-Fernàndez 7, Miguel Cordero- Coma 8, Manuel Diaz-llopis 9, David Salom 9, Jl García Serrano 0, Norberto Ortego 0, JM Herreras, Alejandro Fonollosa, A Aparicio, O Maíz 4, A Blanco 4, I Torre 5, Cruz Fernández- Espartero 6, V Jovani 7, D Peitado-Lopez 8, Esperanza Pato 9, J Cruz 0, J. Carlos Fernandez-Cid 0, E. Aurrecoechea, M García, M Caracuel, Carlos Montilla 4, A Atanes 5, F Francisco 6, S Insua 7, S González-Suárez 8, A Sánchez-Andrade 9, F Gamero 0, Luis Linares, F Romero-Bueno, AJ García González, Raquel Almodovar 4, E Minguez 5, C Carrasco Cubero 6, Alejandro Olive Marques 7, J Vázquez 8, O Ruiz Moreno 9, F Jimenez-Zorzo 9, J Manero 9, Javier Loricera and Miguel Angel González- Gay, Hospital Universitario Marqués de Valdecilla. IFIMAV. Santander. Spain, Santander, Spain, Hospital Universitario Marqués de Valdecilla. IFIMAV, Santander, Spain, Hospital General Universitario, Valencia, Valencia, Spain, 4 Hospital de Valme. Sevilla, Sevilla, Spain, 5 Hospital Clínic of Barcelona, Barcelona, Spain, 6 Hospital Peset Valencia, Valencia, Spain, 7 Hospital Val d Hebron. Barcelona, Barcelona, Spain, 8 Hospital de León, León, Spain, 9 Hospital Universitario La Fe de Valencia, Valencia, Spain, 0 Hospital San Cecilio. Granada, Granada, Spain, Hospital Universitario, IOBA. Valladolid, Valladolid, Spain, Hospital de Cruces. Bilbao, Bilbao, Spain, Hospital de Toledo., Toledo, Spain, 4 Hospital Donosti San Sebastian, San Sebastián, Spain, 5 Hospital Basurto. Bilbao, Bilbao, Spain, 6 Hospital Universitario de Móstoles, Madrid, Spain, 7 Hospital General de Alicante., Alicante, Spain, 8 Hospital Universitario La Paz Madrid, Madrid, Spain, 9 Hospital Clínico San Carlos. Madrid, Madrid, Spain, 0 Hospital de Pontevedra, Pontevedra, Spain, Hospital Sierrallana. Torrelavega, Torrelavega, Spain, Hospital La Princesa. Madrid, Madrid, Spain, Hospital de Córdoba., Córdoba, Spain, 4 Hospital Universitario de Salamanca, Salamanca, Spain, 5 HUCA La Coruña., A Coruña, Spain, 6 Hospital Doctor Negrín Canarias., Canarias, Spain, 7 Hospital Universitario Santiago de Compostela, Santiago de Compostela, Spain, 8 Hospital Cabueñes, Gijón, Gijón, Spain, 9 Hospital Lucus Augusti Lugo, Lugo, Spain, 0 Hospital San Pedro Alcantara Caceres, Caceres, Spain, Hospital Universitario Virgen de la Arrixaca. Murcia, Murcia, Spain, Fundación Jimenez Díaz. Madrid, Madrid, Spain, Hospital de Octubre. Madrid, Madrid, Spain, 4 Hospital Universitario Fundación Alcorcón. Madrid, Alcorcon. Madrid, Spain, 5 Hospital Clínico de Zaragoza, Zaragoza, Spain, 6 Hospital de Mérida, Mérida, Spain, 7 Hospital Germans Trias i Pujol. Badalona, Barcelona, Spain, 8 Hospital de Ferrol. A Coruña, A Coruña, Spain, 9 Hospital Universitario Miguel Servet. Zaragoza, Zaragoza, Spain :45 pm 75. Ethnicity-Related Differences in Behçet s Disease in a French Multiethnic Country David Saadoun, Mathieu Resche Rigon, Bertrand Wechsler, Du Le Thi Huong, Jean-Charles Piette 4 and Patrice P. Cacoub Sr. 4, Department of Internal Medicine and Laboratory I Immunology, Immunopathology, Immunotherapy, UMR CNRS 7, INSERM U959, Groupe Hospitalier Pitié-Salpetrière, Université Pierre et Marie Curie, Paris 6, Paris, France, Paris, France, CHU Pitié-Salpêtrière, Paris, France, Groupe Hospitalier Pitié-Salpétrière, Paris, France, 4 Assistance Publique-Hôpitaux de Paris, Hopital Pitié-Salpétrière, Paris, France :00 pm 75. Behçet s Disease Activity: An Important Factor for Immunogenicity of Unadjuvanted Influenza A/HN Vaccine Leandro L. Prado, Carla G.S. Saad, Julio C. B. Moraes, Ana Cristina Medeiros Ribeiro, Nadia E. Aikawa, Clovis A. Silva, Claudia G Schainberg, Percival D Sampaio-Barros, Alexander R. Precioso, Maria A. Ishida, Eloisa Bonfa 4 and Celio Goncalves, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil, Instituto Butantan, São Paulo, Brazil, Instituto Adolfo Lutz, São Paulo, Brazil, 4 University of Sao Paulo, Rheumatology Division, São Paulo, Brazil :5 pm 75. An Outcome Survey of 40 Patients With Budd-Chiari Syndrome Due to BEHÇET S Syndrome Followed By a Single Center Emire Seyahi, SerdaL Ugurlu, Erkan Caglar, Fatih Kantarci, Abdullah Sonsuz, Sebahattin Yurdakul and Hasan Yazici, Cerrahpasa Medical Faculty, University of Istanbul, Istanbul, Turkey :0 pm 754. Safety and Efficacy of Peg-IFNa/Ribavirin/Protease Inhibitor Combination in 4 Patients With HCV-Mixed Cryoglobulinemia Vasculitis David Saadoun, Stanislas Pol, Vincent Thibault, Gilles Pialoux 4, François Blanc 5, Lucile Musset 6, Alexandre Karras 7, Olivier Decaux 8, Jean-Marc Ziza 9, Olivier Lambotte 0 and Patrice Cacoub Sr., Department of Internal Medicine and Laboratory I Immunology, Immunopathology, Immunotherapy, UMR CNRS 7, INSERM U959, Groupe Hospitalier Pitié-Salpetrière, Université Pierre et Marie Curie, Paris 6, Paris, France, Paris, France, Hepatology, Cochin Hospital, Paris, France, Virology, Pitié-Salpétrière, Paris, France, 4 hôpital Tenon, Paris, France, 5 hôpital Montpellier, Montpellier, France, 6 Laboratoire d immunochimie, Pitié- Salpêtrière, Paris, France, 7 Hôpital Européen Georges Pompidou, APHP, Paris, France, 8 Rennes University Hospital, Rennes, France, 9 Croix Saint Simon Hospital, Paris, France, 0 Hopital Kremlin Bicêtre, Kremlin Bicêtre, France, CHU Pitié-Salpêtrière, Paris, France :45 pm 755. Genetic Association of Mitochondrial DNA Polymorphisms With Behçet s Disease in a Korean Population Mi-Hye Kwon, Chung-Il Joung and Jiwon Hwang, Konyang university hospital, Daejeon, South Korea, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea MONDAY october 8, 0 denotes Hilton San Diego Bayfront room location 0 Program Book 85

88 MONDAY october 8, 0 ACR/ARHP COMBINED ABSTRACT SESSION :0-4:00 pm Indigo C ACR/ARHP Combined Epidemiology Abstract Session Moderators: Alyssa B. Dufour, PhD :0 pm 756. Trends in Incidence and Mortality in Rheumatoid Arthritis and Systemic Autoimmune Rheumatic Diseases in Quebec, Canada: A Population-Based Study Sonia Jean, Philippe Gamache, Marie Hudson, Louis Bessette 4, Paul R. Fortin 5, Gilles Boire 6 and Sasha Bernatsky 7, National Institute of public health of Quebec, Quebec, QC, National institute of public health of Quebec, Quebec, QC, McGill University, Montreal, QC, 4 Centre Hospitalier Universitaire de Québec, pavillon CHUL, Sainte-Foy, QC, 5 Centre de Recherche du Chu de Québec et Université Laval, Quebec City, QC, 6 Centre Hospitalier Universitaire de Sherbrooke, Université de Sherbrooke, Sherbrooke, QC, 7 Research Institute of the McGill University Health Ctre, Montreal, QC :45 pm 757. Does Foot Pain Mediate the Effect of Knee Osteoarthritis and Risk of Indoor and Outdoor Falls in Older Men and Women? Uyen Sa D.T. Nguyen, Yuqing Zhang, Jingbo Niu, Robert H. Shmerling, Douglas P. Kiel, Suzanne G. Leveille 4, Carol A. Oatis 5 and Marian T. Hannan, Boston University School of Medicine, Boston, MA, Beth Israel Deaconess Med Ctr, Boston, MA, Hebrew SeniorLife & Harvard Medical School, Boston, MA, 4 University of Massachusetts-Boston, Boston, MA, 5 Arcadia University, Glenside, PA :45 pm 76. The Link of Foot Structure and Foot Function With Falls: The Johnston County Osteoarthritis Project Yvonne M. Golightly, Marian T. Hannan, Howard J. Hillstrom, Alyssa B. Dufour, Amanda E. Nelson 4, Adam Dore and Joanne M. Jordan 4, University of North Carolina at Chapel Hill, Chapel Hill, NC, Hebrew SeniorLife & Harvard Medical School, Boston, MA, Hospital Special Surgery (HSS), New York, NY, 4 University of North Carolina Thurston Arthritis Research Center, Chapel Hill, NC ARHP SESSIONS :0-4:00 pm A Aerobic, Strength and Biomechanical Considerations for Treatment Progression in Osteoarthritis: What is the Evidence? Moderator: Judy Foxworth, PhD, PT evaluate biomechanical, aerobic and strength baselines for individuals with osteoarthritis identify current best practice for aerobic and strength training for individuals with osteoarthritis perform a biomechanical evaluation (bone alignment in static and dynamic positions) to determine treatment options apply principles of aerobic and strength exercise prescription to a case example :0 pm Aerobic and Strength Evaluation and Prescription Mary E. Christenson, PhD, PT :00 pm 758. Low Literacy Decision Aid Enhances Knowledge and Reduces Decisional Conflict Among Diverse Population of Adults With Rheumatoid Arthritis: Results Of a Pilot Trial Jennifer Barton, Laura Trupin, Gina Evans-Young, John B. Imboden, Dean Schillinger, Victor M. Montori 4 and Edward H. Yelin, University of California, San Francisco, San Francisco, CA, UC San Francisco, San Francisco, CA, UCSF, San Francisco, CA, 4 Mayo Clinic, Rochester, MN :5 pm 759. The Effect of Knee Replacement On Self-Reported Participation and Gait Speed: The Multicenter Osteoarthritis Study and the Osteoarthritis Initiative Jessica L. Maxwell, Boston Univ Sargent College, Boston, MA :00 pm Biomechanical Evaluation and Treatment Considerations in Adults With Osteoarthritis Maura D. Iversen, BSc, DPT, SD, MPH :0 pm Case Studies Sapphire I Designing a Qualitative Study and An Example of the Use of Qualitative Study Design in Patients With Rheumatologic Disease Moderator: Elizabeth G. Salt, PhD describe the use of a theoretical framework in qualitative :0 pm study design 760. Relationships Between Driving Distance, Rheumatoid describe the role of the prior research in qualitative research Arthritis Diagnosis, and Disease-Modifying Anti-Rheumatic discuss the formulation of a problem statement and research Drug Receipt question Jennifer M. Polinski, M. Alan Brookhart, John Z. Ayanian, provide an example of a qualitative study design in patients Jeffrey N. Katz, Seo Young Kim, Chris Tonner, Edward with rheumatologic disease H. Yelin and Daniel H. Solomon 4, Brigham and Women s :0 pm Hospital, Boston, MA, University of North Carolina, Chapel Designing a Qualitative Study Hill, NC, University of California, San Francisco, San Francisco, Sharan Merriam, EdD CA, 4 Harvard Medical School, Brigham and Women s Hospital, Division of Rheumatology, Division of Pharmacoepidemiology, Boston, MA 86 0 Program Book denotes Hilton San Diego Bayfront room location

89 :0 pm An Example of the Use of Qualitative Study Design in Patients With Rheumatologic Disease Elizabeth Hale, MSc Indigo D Rheumatic Disease Update Debate: Calcium and Vitamin D, What Does the Research Support? Moderator: Barry Gruber, MD discuss the criteria for defining vitamin d deficiency. evaluate the evidence for and against vitamin D replacement to reduce fracture and fall risk integrate the latest recommendations of the U.S. Preventive Services Task Force with knowledge of existing research to generate recommendations for practice regarding bone health as it relates to adequate calcium and vitamin D describe non skeletal benefits of vitamin D supplementation :0 pm Rheumatic Disease Update Debate: Calcium and Vitamin D, What Does the Research Support? Robert P. Heaney, MD :00 pm Rheumatic Disease Update Debate: Calcium and Vitamin D, What Does the Research Support? To Be Announced 8 B Rheumatic Diseases in Women of Childbearing Years: Fertility, Pregnancy and Lactation Moderator: Laurie A. Hughell, PA-C, MPH review how fertility is affected by rheumatic illnesses and medications used to treat them recognize the impact that pregnancy has on women with various rheumatic illnesses review information regarding how rheumatic illnesses and treatments are affected while a patient is breastfeeding :0 pm Fertility and Conception Issues in Rheumatic Illness Megan E. B. Clowse, MD, MPH :5 pm Rheumatic Illness and Pregnancy and Lactation Lisa R. Sammaritano, MD ACR/ARHP WORKSHOPS 4:00-6:00 pm Admission to Workshops requires a separate registration and ticket. To verify which session you registered for, the registration code on your ticket needs to match the -digit code in parentheses below. If you are interested in participating in one of these sessions or exchanging your ticket, visit the ACR registration desk to check space availability. View the session overview online in My Annual Meeting at www. ACRannualmeeting.org. A 4 Getting Electronic Health Records Right (6) Speaker: Salahuddin Kazi, MD describe the basic structure and capability of an electronic health record explain the principles and design of rheumatology-specific templates and order sets identify the key elements in current clinical processes and workflow to help optimize the utilization of an electronic health record Musculoskeletal Exam Skills III: Regional Musculoskeletal Examination of the Shoulder and Knee (7) Speakers: George V. Lawry, MD and Paul C. Utrie, MD participate in a hands-on, skill building workshop where participants are paired together for one-on-one practice complete the neck and low back exams in a systematic, efficient and clinically effective way in two to six minutes review strategies for increasing exposure of medical students, resident and fellow trainees to basic musculoskeletal physical examination skills Musculoskeletal Ultrasound (8) Speakers: Eugene Y. Kissin, MD and Amy M. Evangelisto, MD demonstrate how to properly position the ultrasound transducer to visualize targeted musculoskeletal structures based on an understanding of the local bony landmarks differentiate tissue types based on their ultrasound properties recognize the ultrasound appearance of some of the basic musculoskeletal pathologies The Rheumatologic Musculoskeletal Screening Exam, With Emphasis on Objective Disease-specific Measurements (9) Speaker: Arthur M. Mandelin II, MD, PhD Facilitators: Barbara A. Slusher, PA-C, MSW and Kori A. Dewing, DNP, ARNP characterize the importance of using disease activity measurement tools in daily practice, the barriers which hinder routine widespread use, and how these barriers can be overcome in nearly any practice setting utilize disease activity measurement tools used in rheumatology care; including the disease activity score for 8 Joints and Crohn s Disease Activity Index for rheumatoid arthritis, psoriasis area and severity Index scoring for psoriatic skin involvement, measurements of spine and hip flexibility for spondyloarthropathies, and the modified Rodnan skin score for systemic sclerosis MONDAY october 8, 0 * Sessions denoted with an asterisk were sold out as of August 0. denotes Hilton San Diego Bayfront room location 0 Program Book 87

90 ACR SESSIONS 4:0-6:00 pm 6 C Bone is Hard or Is It? Mechanisms Regulating Bone Qualities Moderators: Steven R. Goldring, MD describe the determinants of bone qualities define genetic and biological contributors to bone qualities review how osteocytes function and contribute to bone qualities 4:0 pm Determinants of Bone Qualities Mary Bouxsein, PhD 5:00 pm Mechanisms Regulating Bone Remodeling: Lessons From Mouse Models To Be Announced Ballroom 0 A Gout and Pseudogout: What s New in Treatments and Diagnostic Modalities? Moderator: Jasvinder A. Singh, MD, MPH describe the utility of new imaging techniques in the diagnosis and management of gout understand the advances in treatment, pathophysiology and epidemiology of pseudogout discuss the factors related to low adherence to gout treatments and how to improve adherence to therapy 4:0 pm What Can I See in My Gout Patient That I Didn t Before: Role of New Imaging Techniques in Diagnosis and Management of Gout Use? Nicola Dalbeth, MBChB, MD 5:00 pm Pseudogout, the Forgotten Crystal Disease: What is New in Treatment, Disease Pathophysiology and Epidemiology? Ann K. Rosenthal, MD MONDAY october 8, 0 5:0 pm Osteocyte Function and Bone Biology Teresita M. Bellido, PhD Hall B Challenges in Systemic Lupus Erythematosus Management Moderator: George Stojan, MD highlight major challenges in the management of systemic lupus erythematosus patients with emphasis on neurologic, hematologic and skin manifestations choose optimal therapy for severe lupus manifestations by incorporating new evidence-based data into clinical decisionmaking 6 D 5:0 pm Lack of Adherence to Gout Therapy: Why Won t My Patient With Gout Take His/Her Medicine? Lars Osterberg, MD, MPH Inflammasomes in Health and Disease Moderator: Richard M. Pope, MD describe the inflammasome system explain the contribution of inflammasomes to human disease identify mechanism which regulate the inflammasome 4:0 pm Overview of Inflammasomes Jenny Ting, PhD 4:0 pm Overview of Challenges in Systemic Lupus Erythematosus Management Michelle Petri, MD, MPH 4:50 pm Treatment of Severe Thrombocytopenia in Systemic Lupus Erythematosus: Role of New Agents Brady L. Stein, MD 5:0 pm Posterior Reversible Encephalopathy Syndrome, Myelitis and Small Fiber Neuropathies in Lupus: New Insights Julius Birnbaum, MD, MHS 5:0 pm Severe Cutaneous Lupus Subsets: What the Dermatologist Has to Offer Andrew G. Franks Jr., MD 5:00 pm Clinical Manifestations of Dysregulation of Inflammasome Hal M. Hoffman, MD 5:0 pm Novel Mechanisms to Regulate Inflammasome Activation Christian Stehlik, PhD Indigo E Updated ACR Recommendations for the Treatment of Juvenile Idiopathic Arthritis Moderators: Yuki Kimura, MD and Rayfel Schneider, MB, BCh describe the process used to update the 0 ACR juvenile idiopathic arthritis treatment guideline identify new treatment recommendations for management of systemic juvenile idiopathic arthritis explain the current data regarding etiology of macrophage activation syndrome and current paradigms for the treatment of macrophage activation syndrome explain the rationale for certain treatment approaches to systemic juvenile idiopathic arthritis in the context of the biology of systemic juvenile idiopathic arthritis 88 0 Program Book denotes Hilton San Diego Bayfront room location

91 4:0 pm Overview of Guideline Development Process and Literature Review Sarah Ringold, MD, MS 4:50 pm Treatment Guidelines for the Management of Juvenile Idiopathic Arthritis, Particularly Systemic Juvenile Idiopathic Arthritis Pamela F. Weiss, MD, MSCE 5:0 pm Macrophage Activation Syndrome: A State-of-the-Art Review Edward M. Behrens, MD 5:5 pm The Biology of Systemic Juvenile Idiopathic Arthritis: Bench to Bedside Marilynn G. Punaro, MD ACR CONCURRENT ABSTRACT SESSIONS 4:0-6:00 pm Sapphire A Cytokines, Mediators, Cell-cell Adhesion, Cell Trafficking and Angiogenesis II: Mechanisms that contribute to Autoimmune Inflammation Moderators: Peter A. Nigrovic, MD and Douglas J. Veale, MD 4:0 pm 76. Endogenous IL- Regulates Th Responses and Plays a Pathogenic Role After the Onset of Arthritis Shivali Justa, Xiaoqun Zhou and Sujata Sarkar, University of Arizona, Tucson, AZ 4:45 pm 76. IL4-0 Synerkine: A Novel Immunoregulatory Drug to Prevent Immunopathology in Rheumatic Diseases Sarita Hartgring, Cristine Steen-louws, C.E. Hack, Martin De Smet, Floris Lafeber and J.A.G. van Roon, University Medical Center Utrecht, Utrecht, Netherlands, UMC Utrecht, Utrecht, Netherlands 5:00 pm 764. Binding of Apoptotic Fetal Cardiocytes By Anti-Ro Antibodies Stimulates upa/upar- Dependent Macrophage Infiltration and M Type Phenotype Paraskevi Briasouli, Savvas Pavlides, Leslie Gold, Mark Halushka 4 and Jill P. Buyon 5, New York University Medical Center, New York, NY, New York University Medical Center, new York, NY, new York University Medical Center, new York, NY, 4 John Hopkins PAthology, Baltmore, MD, 5 NYU School of Medicine, New York, NY 5:5 pm 765. Complement Component C5a Permits the Co-Existence Of Pathogenic Th7 Cells and Type I Interferon in Lupus Marc C. Levesque, Sudesh Pawaria, Kelly Maers and Partha Biswas, University of Pittsburgh, Pittsburgh, PA 5:0 pm 766. Role of IL in the Inflammation of Takayasu Arteritis David Saadoun, Marlène Garrido, Julien Gaudric, Cloé Comarmond 4, Michele Rosenzwacjg 5 and Patrice Cacoub 6, Department of Internal Medicine and Laboratory I Immunology, Immunopathology, Immunotherapy, UMR CNRS 7, INSERM U959, Groupe Hospitalier Pitié-Salpetrière, Université Pierre et Marie Curie, Paris 6, Paris, France, Paris, France, Pitié-Salpétrière, Paris, France, Department of Vascular surgery GHPS, Paris, France, 4 Hôpital Pitié Salpétrière, Paris, France, 5 Department of Immunology GHPS, Paris, France, 6 Hopital Pitié-Salpétrière, Paris, France 5:45 pm 767. Gender, Race, and Soluble Mediators Distinguish Blood Relatives Who Develop Incomplete Lupus or Classified SLE in the Lupus Autoimmunity in Relatives (LAUREL) Study Melissa E. Munroe, Kendra A. Young, Jill M. Norris, Joel M. Guthridge, Diane L. Kamen, Timothy B. Niewold 4, Gary S. Gilkeson, Michael H. Weisman 5, Mariko L. Ishimori 5, Daniel J. Wallace 5, David R. Karp 6, John B. Harley 7 and Judith A. James, Oklahoma Medical Research Foundation, Oklahoma City, OK, Colorado School of Public Health, Aurora, CO, Medical University of South Carolina, Charleston, SC, 4 Mayo Clinic, Rochester, MN, 5 Cedars-Sinai Medical Center, Los Angeles, CA, 6 UT Southwestern Medical Center, Dallas, TX, 7 Cincinnati Children s Hospital Medical Center, Cincinnati, OH C Epidemiology and Health Services Research II: Healthcare Costs and Mortality in Rheumatic Disease Moderators: Elena Losina, PhD and Liron Caplan, MD, PhD 4:0 pm 768. Value of Arthroscopic Partial Meniscectomy in Treatment of Symptomatic Patients With Meniscal Tears and Knee Osteoarthritis: Is More Research Warranted? Elena Losina, A. David Paltiel, Elizabeth Dervan, Yan Dong, Kurt P. Spindler, Lisa A. Mandl 4, Morgan Jones 5, John Wright and Jeffrey N. Katz, Brigham and Women s Hospital, Boston, MA, Yale School of Public Health, New Haven, CT, Vanderbilt University, Nashville, TN, 4 Hospital for Special Surgery, New York, NY, 5 Cleveland Clinic, Cleveland, OH 4:45 pm 769. Direct and Indirect Costs for Patients With Systemic Lupus Erythematosus in National Cohorts in Sweden Andreas Jönsen, Anders A. Bengtsson, Christine Bengtsson, Iva Gunnarsson, Johanna Gustafsson, Frida Hjalte 4, Dag Leonard 5, Susanne Pettersson, Solbritt Rantapää Dahlqvist 6, Lars Rönnblom 7, Christopher Sjöwall 8, Katarina Steen Carlsson 4, Elisabet Svenungsson, Minna Willim 9 and Ola Nived 0, Lund University, Lund, Sweden, Rheumatology, Umeå, Sweden, Karolinska Institutet, Stockholm, Sweden, 4 Health Economy, Lund, Sweden, 5 Department of Medical Sciences, Section of Rheumatology, Uppsala University, Uppsala, Sweden, 6 Umeå University Hospital, Umeå, Sweden, 7 Section of Rheumatology, Uppsala University, Uppsala, Sweden, 8 Linköping University, Linköping, Sweden, 9 Lund University, Malmö, Sweden, 0 Rheumatology, Lund, Sweden MONDAY october 8, 0 denotes Hilton San Diego Bayfront room location 0 Program Book 89

92 5:00 pm 770. All-Cause Mortality for Patients With Rheumatoid Arthritis in a Universal Public Health Care System Jessica Widdifield, J. Michael Paterson, Sasha Bernatsky, Bindee Kuriya, J. Carter Thorne 4, Simon Hollands and Claire Bombardier 5, Institute for Clinical Evaluative Sciences, Toronto, ON, McGill University, Montreal, QC, Mount Sinai Hospital, University of Toronto, Toronto, ON, 4 Southlake Regional Health Centre, Newmarket, ON, 5 University of Toronto, Toronto, ON 4:45 pm 775. Use Of Computer-Aided Lung Informatics For Pathology Evaluation and Rating Software in High-Resolution Computed Tomography in Patients With Idiopathic Inflammatory Myopathy and Interstitial Lung Disease Katelynn Wilton, Brian Bartholmai, Sanjay Kalra, Cynthia S. Crowson, Helen Khun and Floranne C. Ernste, Mayo Clinic College of Medicine, Rochester, MN, Mayo Clinic, Rochester, MN, Mayo Clinic Rochester, Rochester, MN MONDAY october 8, 0 5:5 pm 77. Cost-Effectiveness of Different Treatment Sequences Including Adalimumab in the Treat-to-Target Frameworkf Early Rheumatoid Arthritis In Germany Malte Wolff, Zheng-Yi Zhou, James Signorovitch, James W. Shaw and Arijit Ganguli, AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany, Analysis Group, Inc., Boston, MA, AbbVie Inc., North Chicago, IL 5:0 pm 77. Better Cost-Effectiveness and Worker Productivity in Triple DMARD Therapy Versus Methotrexate Monotherapy in Early Rheumatoid Arthritis; Cost-Utility Analysis of the Treach Trial P.H.P. de Jong, A.E.A.M. Weel, J.J. Luime, P.J. Barendregt, A.H. Gerards, P.A. van der Lubbe, M.H. de Jager 4, P.B. de Sonnaville 5, D. van Zeben 6, B.A. Grillet 7 and J.M.W. Hazes, Erasmus University Medical Center, Rotterdam, Netherlands, Maasstad Hospital, Rotterdam, Netherlands, Vlietland Hospital, Schiedam, Netherlands, 4 Albert Schweitzer Hospital, Dordrecht, Netherlands, 5 Admiraal de Ruyter hospital, Goes, Netherlands, 6 Sint Franciscus Gasthuis, Rotterdam, Netherlands, 7 Zorgsaam Hospital, Terneuzen, Netherlands 5:45 pm 77. The Contribution of Environmental Factors to Familial Risk of Rheumatoid Arthritis By Serologic Phenotypes Among Women in a Longitudinal Cohort Study Jeffrey A. Sparks, Chia-Yen Chen, Linda T. Hiraki, Susan Malspeis, Karen H. Costenbader and Elizabeth W. Karlson, Brigham and Women s Hospital, Harvard Medical School, Boston, MA, Harvard School of Public Health, Boston, MA, Brigham and Women s Hospital, Harvard School of Public Health, Boston, MA Indigo C Muscle Biology, Myositis and Myopathies I: Insights into Mechanisms of the Idiopathic Inflammatory Myopathies Moderators: Steven R. Ytterberg, MD and Carol B. Lindsley, MD 4:0 pm 774. Sepsis Is the Leading Cause of Hospital Mortality In Dermatomyositis/Polymyositis: Data From a Population-Based Study Sara Murray, Laura Trupin, Chris Tonner, Matthew Cascino, Gabriela Schmajuk, Mary Margaretten, Jennifer Barton, Patricia P. Katz, Edward H. Yelin and Jinoos Yazdany, University of California, San Francisco, San Francisco, CA, UC San Francisco, San Francisco, CA 5:00 pm 776. Peripheral Blood Memory B Cell Numbers Predict Clinical Response Following Rituximab Treatment of Adult and Childhood Myositis Rohit Aggarwal, Chester V. Oddis, Erich R Wilkerson, Diane Koontz, Ilinca D. Metes, Ann M. Reed, Dana P. Ascherman and Marc C. Levesque, University of Pittsburgh, Pittsburgh, PA, Mayo Clinic, Rochester, MN, University of Miami Miller School of Medicine, Miami, FL 5:5 pm 777. Antibodies Against TIF-Gamma in Cancer Associated Myositis May Precede Cancer Symptoms and Persist After Cancer Removal Ingrid E. Lundberg, Lara Dani, Maryam Dastmalchi, Maria Angeles Martinez, Moises Labrador-Horrillo 4 and Albert Selva O Callaghan 4, Rheumatology Unit, Department of Medicine, Karolinska University Hospital in Solna, Karolinska Institutet, Stockholm, Sweden, Karolinska University Hospital in Solna, Karolinska Institutet, Stockholm, Sweden, Sant Pau Hospital, Barcelona, Spain, 4 Vall d Hebron General Hospital, Barcelona, Spain 5:0 pm 778. Physical Interactions Between Histidyl-tRNA Synthetase and Endogenous/Exogenous Alarmins Enhance Immunogenicity in a Model of Antigen-Induced Myositis Irina Fernandez, Lisa Harlow, William Ridgway and Dana P. Ascherman, University of Miami Miller School of Medicine, Miami, FL, University of Cincinnati, Cincinnati, OH 5:45 pm 779. A Randomized Controlled, Clinical, Histological and mrna Profiling Pilot Study Of Endurance Exercise In Myositis Li Alemo Munters, Ingela M. Loell, Joan Raouf, Maryam Dastmalchi 4, Eva Lindroos 5, Christina Ottosson 6, Yi-Wen Chen 7, Annemarie F van Delden 6, Mona Esbjörnsson 8, Marina Korotkova 9, Helene Alexanderson 0, Kanneboyina Nagaraju 7 and Ingrid E. Lundberg, Rheumatology Unit,, Karolinska University Hospital in Solna, Karolinska Institutet, Stockholm, Sweden, Rheumatology Unit, Department of Medicine, Karolinska University Hospital in Solna, Karolinska Institutet, Stockholm, Sweden, Rheumatology Unit, Karolinska University Hospital in Solna, Karolinska Institutet, Stockholm, Sweden, Stockholm, Sweden, 4 Karolinska University Hospital in Solna, Karolinska Institutet, Stockholm, Sweden, 5 Rheumatology Unit, Karolinska University Hospital in Solna, Karolinska Institutet, Stockholm, Sweden., Stockholm, Sweden, 6 Rheumatology Unit, Karolinska University Hospital Solna, Karolinska Institutet, Stockholm, Sweden., Stockholm, Sweden, 7 Research Center for Genetic Medicine, Children s National Medical Center, 90 0 Program Book denotes Hilton San Diego Bayfront room location

93 Washington DC, USA., Washington DC, DC, 8 Karolinska Institutet, Huddinge, Sweden, 9 Rheumatology Unit, Department of Medicine, Karolinska University Hospital in Solna, Karolinska Institutet, Stockholm, Sweden, Stockholm, Sweden, 0 Division of Physiotherapy, Karolinska Institutet, Huddinge, Stockholm, Sweden B Pediatric Rheumatology - Clinical and Therapeutic Aspects II: Autoinflammatory Disease and Systemic Juvenile Idiopathic Arthritis Moderators: C. Egla Rabinovich, MD, MPH and Sarah Ringold, MD 4:0 pm 780. The Randomized Placebo Phase Study of Rilonacept in the Treatment of Systemic Juvenile Idiopathic Arthritis Norman T. Ilowite, Kristi Prather, Yuliya Lokhnygina, Laura E. Schanberg, Melissa Elder 4, Diana Milojevic 5, James W. Verbsky 6, Steven J. Spalding 7, Yukiko Kimura 8, Lisa F. Imundo 9, Marilynn G. Punaro 0, David D. Sherry, Stacey E. Tarvin, Lawrence S. Zemel, James D. Birmingham 4, Beth S. Gottlieb 5, Michael L. Miller 6, Kathleen M. O Neil 7, Natasha M. Ruth 8, Carol A. Wallace 9, Nora G. Singer 0 and Christy I. Sandborg, The Children s Hospital at Montefiore, Bronx, NY, Duke Clinical Research Institute, Durham, NC, Duke University Medical Center, Durham, NC, 4 University of Florida, Gainesville, HI, 5 University of California, San Francisco, San Francisco, CA, 6 Medical College of Wisconsin, Milwaukee, WI, 7 The Cleveland Clinic, Cleveland, OH, 8 Joseph M Sanzari Children s Hospital, Hackensack University Medical Center, Hackensack, NJ, 9 Morgan Stanely Children s Hospital of New York-Presbyterian, Columbia University Medical Center, New York, NY, 0 Texas Scottish Rite Hospital, Dallas, TX, Children s Hospital of Philadelphia, Philadelphia, PA, Riley Hospital for Children, Indianapolis, IN, Pediatric Rheumatology Collaborative Study Group, Cincinnati, OH, 4 Michigan State University College of Human Medicine, Grand Rapids, MI, 5 Cohen Children s Medical Center of New York, New Hyde Park, NY, 6 Childrens Memorial Hospital, Chicago, IL, 7 University of Oklahoma Health Sciences Center, Oklahoma City, OK, 8 Medical University of South Carolina, Charleston, SC, 9 Seattle Childrens Hosp & Research Institute, Seattle, WA, 0 MetroHealth Medical Center, Cleveland, OH, Stanford University, Palo Alto, CA 4:45 pm 78. Clinical Variation in Children With Mutations in MEFV Karyl S Barron, Amanda K. Ombrello, Ivona Aksentijevich, Anne Jones and Daniel L. Kastner, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, National Human Genome Research Institute,National Institute of Health, Bethesda, MD, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD 5:00 pm 78. Chronic Atypical Neutrophilic Dermatosis With Lipodystrophy and Elevated Temperatures (CANDLE): Clinical Characterization and Initial Response to Janus Kinase Inhibition With Baricitinib Gina A. Montealegre Sanchez, Adam L. Reinhardt, Paul Brogan, Yackov Berkun 4, Diane Brown 5, Peter Chira 6, Ling Gao 7, Dawn C. Chapelle, Nicole Plass, Hanna Kim, Michael Davis, Adriana Almeida de Jesus, Yin Liu, Yan Huang, Colleen Hadigan 8, Theo Heller 9, Zlotogorski Zlotogorski 0, John J. O Shea, Chyi-chia Lee, Suvimol C. Hill, Kristina Rother 9, Massimo Gadina and Raphaela T. Goldbach-Mansky, National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH, Bethesda, MD, Children s Hosp of Omaha/UNMC, Omaha, NE, Paediatric Rheumatology International Trials Organization (PRINTO), Istituto Giannina Gaslini, Genova, Italy, 4 Hadassah Medical Center, Mount Scopus, Jerusalem, Israel, 5 Children s Hospital Los Angeles, Los Angeles, CA, 6 Indiana University School of Medicine, Riley Hospital for Children, Indianapolis, IN, 7 University of Arkansas for Medical Sciences, Little Rock, AR, 8 National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD, 9 National Institute of Diabetes and Digestive Kidney Diseases, NIH, Bethesda, MD, 0 Department of Dermatology, Hadassah- Hebrew University Medical Center, Jerusalem, Israel., Jerusalem, Israel, National Cancer Institute, National Institutes of Health, Bethesda, MD, NIH Clinical Center, Bethesda, MD 5:5 pm 78. Canakinumab Treatment in Active Hyper-IgD With Periodic Fever Syndrome Juan Ignacio Aróstegui, Inmaculada Calvo, Jordi Anton, Angel Robles 4, Jordi Yagüe, Ruth Viana 5, Lillian Tseng 6 and Ken Abrams 6, Hospital Clinic Barcelona, Barcelona, Spain, Hospital La Fe, Valencia, Spain, Hospital Sant Joan de Deu, Barcelona, Spain, 4 Hospital La Paz, Madrid, Spain, 5 Novartis Farmacéutica, S.A., Barcelona, Spain, 6 Novartis Pharmaceuticals Corporation, East Hanover, NJ 5:0 pm 784. Effectiveness of First Line Use of Recombinant IL-RA Treatment in Steroid Naïve Systemic Juvenile Idiopathic Arthritis: Results of a Prospective Cohort Study S.J. Vastert, Wilco de Jager, Bo Jan Noordman, Dirk Holzinger, Wietse Kuis, Berent J. Prakken and Nico M. Wulffraat, University Medical Center Utrecht, Utrecht, Netherlands, University Muenster, Muenster, Germany 5:45 pm 785. Structural Determinants of Low Vertebral Strength in Pediatric Systemic Lupus Erythematosus Jon M. Burnham, Babette S. Zemel, David C. Lee, Tony M. Keaveny and Mary Beth Leonard, The Children s Hospital of Philadelphia and the Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, O.N. Diagnostics, LLC, Berkeley, CA, University of California, Berkeley, CA and O.N. Diagnostics, LLC, Berkeley, CA MONDAY october 8, 0 denotes Hilton San Diego Bayfront room location 0 Program Book 9

94 MONDAY october 8, 0 Indigo D Rheumatoid Arthritis - Clinical Aspects III: Predictors of Disease Course in Rheumatoid Arthritis Moderators: Diane V. Lacaille, MD, MHSc and Shahin Jamal, MD, MSc 4:0 pm % of Early RA Patients Are Positive for Serum 4--η or Its Auto-Antibodies Walter P. Maksymowych, Dirkjan van Schaardenburg, Désirée van der Heijde, Robert Landewé 4, Gilles Boire 5, Maarten Boers 6, Vivian P. Bykerk 7, Edward C. Keystone 8, Katherine A. Siminovitch 9, Mairead Murphy 0 and Anthony Marotta 0, University of Alberta, Edmonton, AB, Jan van Breemen Research Institute Reade, Amsterdam, Netherlands, Leiden University Medical Center, Leiden, Netherlands, 4 Academic Medical Center, Amsterdam, Netherlands, 5 Centre Hospitalier Universitaire de Sherbrooke, Université de Sherbrooke, Sherbrooke, QC, 6 VU University Medical Center, Amsterdam, Netherlands, 7 Hospital for Special Surgery, Weill Cornell Medical College, New York, NY, 8 Mount Sinai Hospital, University of Toronto, Toronto, ON, 9 Mount Sinai Hospital, Toronto, ON, 0 Augurex Life Sciences Corp, North Vancouver, BC 4:45 pm 787. Does Age at Disease Onset Influence Disease Activity and Function in Rheumatoid Arthritis Patients? Results From the Ontario Best Practices Research Initiative (OBRI) Registry Thanu Nadarajah, Binu Jacob, Pooneh Akhavan, Bindee Kuriya, Edward C. Keystone and Claire Bombardier, University of Toronto, Toronto, ON, Mount Sinai Hospital/University of Toronto, Toronto, ON, Mount Sinai Hospital, University of Toronto, Toronto, ON 5:00 pm 788. The Multi-Biomarker Disease Activity Test (Vectra DA) Estimates Risk of Radiographic Progression for Patients With Rheumatoid Arthritis From The Leiden Early Arthritis Clinic Wanying Li, DJ Haney, Guy Cavet, Thomas W. Huizinga, Eric H. Sasso and A. H. M. van der Helm-van Mil, Crescendo Bioscience Inc., South San Francisco, CA, Leiden University Medical Center, Leiden, Netherlands 5:5 pm 789. In Early Rheumatoid Arthritis,the Individual Biomarkers that Comprise the Multiple Biomarker Disease Activity Score Relate Differentially to Clinical Response and Radiographic Progression: Results From a Randomized Trial Karen Hambardzumyan, Saedis Saevarsdottir, Rebecca Bolce, Kristina Forslind, Sofia Ernestam 4, Ingemar F. Petersson 5, Pierre Geborek 5, David Chernoff, Douglas J. Haney, Eric H. Sasso and Ronald F van Vollenhoven, Karolinska Institutet, Stockholm, Sweden, Crescendo Bioscience Inc., South San Francisco, CA, Section of Rheumatology, Department of Medicine, Helsingborg General Hospital, Helsingborg, Sweden, 4 Karolinska University Hospital, Huddinge, Sweden, 5 Lund University, Lund, Sweden 0 E 5:0 pm 790. Serum Amyloid a Levels Model Rheumatoid Arthritis Disease Activity Better than C-Reactive Protein Levels Especially During Treatment With Anti-Tumor Necrosis Factor α Therapy (Etanercept) Ilinca D. Metes, Douglas W. Chew, Aarat M. Patel, G.K. Balasubramani, Jeffrey R. Curtis, S. Louis Bridges Jr., Stephen R. Wisniewski, Larry W. Moreland and Marc C. Levesque, University of Pittsburgh, Pittsburgh, PA, University of Pittsburgh, Graduate School of Public Health, Pittsburgh, PA, University of Alabama at Birmingham, Birmingham, AL 5:45 pm 79. Reaching the Target of Low Disease Activity at 6 Months Predicts Better Long-Term Functional Outcome in Patients With Early Rheumatoid Arthritis Pooneh Akhavan, Bindee Kuriya, Edward C. Keystone, Juan Xiong, Janet E. Pope 4, Gilles Boire 5, Diane Tin 6, Boulos Haraoui 7, Carol A. Hitchon 8 and Vivian P. Bykerk 9, Early Rheumatoid Arthritis Program, Mount Sinai Hospital and University of Toronto, Toronto, ON, Mount Sinai Hospital, University of Toronto, Toronto, ON, Mount Sinai Hospital, Toronto, ON, 4 St Joseph Health Care, London, ON, 5 Centre Hospitalier Universitaire de Sherbrooke, Université de Sherbrooke, Sherbrooke, QC, 6 Southlake Regional Health Centre, Newmarket, ON, 7 Centre Hospitalier de l Université de Montréal, Montreal, QC, 8 University of Manitoba, Winnipeg, MB, 9 Mount Sinai Hospital/University of Toronto, Toronto, ON Rheumatoid Arthritis Treatment - Small Molecules, Biologics and Gene Therapy: Safety and Efficacy of Small Molecule Agents Moderators: Ronald F. van Vollenhoven, MD, PhD and Bruce N. Cronstein, MD 4:0 pm 79. Inhibition of Chemokine Receptors CCR and CCR6 as Promising Therapies for Autoimmune Diseases Such as Rheumatoid Arthritis and Psoriasis Daniel Dairaghi, Penglie Zhang, Manmohan Leleti, Robert Berahovich, Karen Ebsworth, Linda Ertl, Shichang Miao, Zhenhua Miao, Lisa Seitz, Joanne Tan, Matthew Walters, Yu Wang, Jay Powers, Thomas J. Schall and Juan C. Jaen, ChemoCentryx, Inc., Mountain View, CA, ChemoCentryx, Mountain View, CA 4:45 pm 79. Oskira-: A Phase III, Multicenter, Randomized, Double- Blind, Placebo-Controlled Parallel-Group Study of Dosing Regimens of Fostamatinib In Rheumatoid Arthritis Patients With an Inadequate Response to Methotrexate Michael Weinblatt, Mark C. Genovese, Meilien Ho, Sally Hollis, Krystyna Rosiak-Jedrychowicz 4, Arthur Kavanaugh 5, David Millson, Gustavo Leon 6, Millie Wang and Désiréé van der Heijde 7, Division of Rheumatology, Brigham & Women s Hospital, Boston, MA, Stanford University, Palo Alto, CA, AstraZeneca R&D Alderley Park, Macclesfield, United Kingdom, 4 Przychodnia Neuromedyka, Zyrardów, Poland, 5 University of California, San Diego, La Jolla, CA, 6 Instituto de Ginecología y Reproducción-Cirugía Mínimamente Invasiva, Surco, Peru, 7 Leiden University Medical Center, Leiden, Netherlands 9 0 Program Book denotes Hilton San Diego Bayfront room location

95 5:00 pm 794. The Jak Inihibitor Tofacitinib Suppresses Synovial Jak- Stat Signalling in Rheumatoid Arthritis D. L Boyle, N. Wei, A. K. Singhal, D. R. Mandel 4, P Mease 5, A. Kavanaugh, R. Shurmur 6, J. Hodge 7, Z. Luo 8, S. Krishnaswami 8, D. Gruben 8, S. H. Zwillich 8, K. Soma 8, J. D. Bradley 8 and G. S. Firestein, UCSD School of Medicine, La Jolla, CA, Arthritis Treatment Center, Frederick, MD, Southwest Rheumatology Research LLC, Mesquite, TX, 4 Office of David R Mandel MD, Inc., Mayfield Village, OH, 5 Seattle Rheumatology Associates, Seattle, WA, 6 Associated Internal Medicine Specialists, Battle Creek, MI, 7 Pfizer Inc, Collegeville, PA, 8 Pfizer Inc, Groton, CT 5:5 pm 795. An Active Metabolite Contributes to the Pharmacodynamics and Efficacy of GLPG064, a Selective JAK Inhibitor Florence Namour, Galapagos SASU, Romainville, France 5:0 pm Week Results of a Phase b Dose-Ranging Study of Baricitinib, an Oral JAK/ JAK Inhibitor in Japanese Patients With Rheumatoid Arthritis on Background Methotrexate Therapy Yoshiya Tanaka, Kahaku Emoto, Mika Tsujimoto, Douglas E. Schlichting and William Macias, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, Eli Lilly Japan K.K., Kobe, Japan, Eli Lilly and Company, Indianapolis, IN 5:45 pm 797. A Randomized, Dose-Ranging, Placebo-Controlled, 84- Day Study of INCB090, a Selective Janus Kinase- Inhibitor, in Patients With Active Rheumatoid Arthritis Monica Luchi, Rosanne Fidelus-Gort, Diane Douglas, Haifeng Zhang, Robert Flores, Robert Newton, Peggy Scherle, Swamy Yeleswaram, Xuejun Chen and Victor Sandor, Incyte Corporation, Wilmington, DE 9 D Spondylarthropathies and Psoriatic Arthritis: Clinical Aspects and Treatment: Therapeutics and Outcomes in Spondyloarthritis Moderators: Jürgen Braun, MD and Pedro Machado, MD 4:0 pm 798. Ustekinumab for the Treatment of Patients With Active Ankylosing Spondylitis: Results of a 8-Week, Prospective, Open-Label, Proof-of-Concept Study (TOPAS) Denis Poddubnyy, Johanna Callhoff, Joachim Listing and Joachim Sieper, Charité Universitätsmedizin Berlin, Berlin, Germany, German Rheumatism Research Center, Berlin, Germany 4:45 pm 799. Effect of Certolizumab Pegol Over 48 Weeks in Patients With Axial Spondyloarthritis, Including Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis Robert B. M. Landewé, Martin Rudwaleit, Désirée M. van der Heijde, Maxime Dougados 4, Philip J. Mease 5, John D. Reveille 6, Jessica Walsh 7, Alan J. Kivitz 8, Walter P. Maksymowych 9, Jürgen Braun 0, Atul A. Deodhar, Christian Stach, Bengt Hoepken, Pritibha Singh and Joachim Sieper, Academic Medical Center/University of Amsterdam & Atrium Medical Center, Amsterdam, Netherlands, Endokrinologikum Berlin, Berlin, Germany, Leiden University Medical Center, Leiden, Netherlands, 4 Paris-Descartes University, APHP, Cochin Hospital, Paris, France, 5 Swedish Medical Center and University of Washington, Seattle, WA, 6 University of Texas Health Science Center at Houston, Houston, TX, 7 University of Utah Hospital, Salt Lake City, UT, 8 Altoona Center for Clinical Research, Duncansville, PA, 9 University of Alberta, Edmonton, AB, 0 Rheumazentrum Ruhrgebiet, Herne, Germany, Oregon Health & Science University, Portland, OR, UCB Pharma, Monheim, Germany, Charité Universitätesmedizin Berlin, Berlin, Germany 5:00 pm 800. Persistent Fatty Lesions in the Vertebrae in Ankylosing Spondylitis Favor Subsequent New Syndesmophytes: Imaging Results of a Phase III, Randomized, Placebo-Controlled Study Kay-Geert A. Hermann, Xenofon Baraliakos, Jürgen Braun, Stephen Xu and Benjamin Hsu, Charité Universitätsmedizin Berlin, Campus Mitte, Berlin, Germany, Rheumazentrum Ruhrgebiet, Herne, Germany, Janssen Research & Development, LLC., Spring House, PA 5:5 pm 80. Relationship Between MRI and Clinical Remission in Patients With Non-Radiographic Axial Spondyloarthritis After Two Years of Adalimumab Therapy Désiréé van der Heijde, Walter P. Maksymowych, Joachim Sieper, Robert Lambert 4, Matthew A. Brown 5, Suchitrita S. Rathmann 6, Jaclyn K. Anderson 7 and Aileen L. Pangan 6, Leiden University Medical Center, Leiden, Netherlands, University of Alberta, Edmonton, AB, Charité Universitätesmedizin, Berlin, Germany, 4 University of Alberta Hospital, Edmonton, AB, 5 University of Queensland Diamantina Institute, Brisbane, Australia, 6 AbbVie Inc., North Chicago, IL, 7 AbbVie, North Chicago, IL 5:0 pm 80. A Major Clinical Response to Anti-Tumor Necrosis Factor Agents Is Associated With a Reduced Development of Fatty Changes in the Spine of Patients With Ankylosing Spondylitis Xenofon Baraliakos, Frank Heldmann, Joachim Listing, Johanna Callhoff and Jügen Braun, Rheumazentrum Ruhrgebiet, Herne, Germany, German Rheumatism Research Center, Berlin, Germany 5:45 pm 80. Is Site of Back Pain Related to Location of Inflammatory and Structural Lesions on MRI in Patients With Chronic Back Pain? Manouk de Hooge, Rosaline van den Berg, Floris van Gaalen, Victoria Navarro-Compán, Monique Reijnierse, Karen Fagerli, Maureen C. Turina, Maikel van Oosterhout 4, Roberta Ramonda 5, Tom Huizinga and Désirée van der Heijde, Leiden University Medical Center, Leiden, Netherlands, Diakonhjemmet Hospital, Oslo, Norway, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, 4 GHZ Hospital, Gouda, Netherlands, 5 University of Padova, Padova, Italy MONDAY october 8, 0 denotes Hilton San Diego Bayfront room location 0 Program Book 9

96 MONDAY october 8, 0 A Systemic Lupus Erythematosus - Clinical Aspects: Non-biologic Disease-modifying Antirheumatic Drugs Moderators: Kenneth C. Kalunian, MD and Jennifer M. Grossman, MD 4:0 pm 804. Effect of Mycophenolate on the White Blood Cell Count and the Frequency of Infection in Systemic Lupus Erythematosus Ananta Subedi, Hong Fang and Michelle Petri, Good Samaritan Hospital, Baltimore, MD, Johns Hopkins University School of Medicine, Baltimore, MD 4:45 pm 805. Hydroxychloroquine Levels Identify Four Distinct Subsets of Systemic Lupus Erythematosus Patients Michelle Petri, Hong Fang and William Clarke, Johns Hopkins University School of Medicine, Baltimore, MD 5:00 pm 806. Association Between Hydroxychloroquine Exposure and Incidence of Diabetes Mellitus in Systemic Lupus Erythematosus Michelle Petri and Laurence S. Magder, Johns Hopkins University School of Medicine, Baltimore, MD, University of Maryland, Baltimore, MD 5:5 pm 807. Do We Know How and When to Taper and Stop In Immunosuppressants in Lupus Patients? Zahi Touma, Murray B. Urowitz, Dominique Ibanez and Dafna Gladman, University of Toronto, Toronto Western Hospital, Toronto, ON 5:0 pm 808. Impact of Baseline Disease Severity and Treatments on Outcomes in Clinical Trials of SLE: Results From The Soccit Program Kenneth C. Kalunian, Mimi Kim, Timothy W. Behrens, Sabine Bongardt 4, Paul Brunetta 5, Paola Daly 6, Nathalie Franchimont 7, Richard Furie 8, Matthew Linnik 9, Bevra H. Hahn 0, Leslie M. Hanrahan, Jan L. Hillson, Jane Salmon, Neil Solomons 4 and Joan T. Merrill 5, UCSD School of Medicine, La Jolla, CA, Albert Einstein College of Medicine, Bronx, NY, Genentech, Inc, South San Francisco, CA, 4 UCB Pharma, Brussels, Belgium, 5 Genentech, So San Francisco, CA, 6 Lupus Foundation of America, Washington DC, DC, 7 Biogen Idec Inc., Weston, MA, 8 North Shore-LIJ Health System, Lake Success, NY, 9 Lilly Research Laboratories, La Jolla, CA, 0 UCLA David Geffen School of Medicine, Los Angeles, CA, Lupus Foundation of America, Washington, DC, Bristol-Myers Squibb, Seattle, WA, Hospital for Special Surgery, New York, NY, 4 Vifor Pharma, New York, NY, 5 Oklahoma Medical Research Foundation, Oklahoma City, OK 5:45 pm 809. Topline Results of the Biomarkers of Lupus Disease (BOLD) Study: Clinical and Mechanistic Perplexities of Lupus Treatment Trials Can Be Mitigated By Eliminating Background Immune Suppressants Joan T. Merrill, Frederick W. Immermann, Tianhui Zhou, Margot O Toole 4, Maryann Whitley 5, Andrew A. Hill 5, Ying Zhang 5, David von Schack 5, Padmalatha S. Reddy 5, Jaime L. Masferrer 4, Stan Kamp 6, Joel M. Guthridge, Aikaterini Thanou, Paul Wu 5, Theresa Paradis 5, William M. Mounts 5, Judith A. James and Sudhakar T. Sridharan, Oklahoma Medical Research Foundation, Oklahoma City, OK, Pfizer Inc, Collegeville, PA, Bristol Myers Squibb, Princeton, NJ, 4 independent consultant, Cambridge, MA, 5 Pfizer Inc, Cambridge, MA, 6 Oklahoma Medical Research Foundation, Oklahoma CIty, OK 8 B Systemic Sclerosis, Fibrosing Syndromes, and Raynaud s - Clinical Aspects and Therapeutics II Moderators: Svetlana I. Nihtyanova, MBBS and Virginia D. Steen, MD 4:0 pm 80. Evaluation of the New American College of Rheumatology/European League Against Rheumatism Criteria for the Classification of Systemic Sclerosis in the Canadian Scleroderma Research Group Cohort Hebah Alhajeri, Marie Hudson, Marvin J. Fritzler, Janet E. Pope, Canadian Scleroderma Research Group - 4 and Murray Baron 4, McGill University, Montreal, QC, University of Calgary, Calgary, AB, St Joseph Health Care, London, ON, 4 Jewish General Hospital, Montreal, QC 4:45 pm 8. Validation of the ICD-CM-9 Code for Systemic Sclerosis Using Updated ACR/EULAR Classification Criteria Aaliya Yaqub, Lorinda Chung, David Fiorentino and Eswar Krishnan 4, Stanford Univ Medical Center, Stanford, CA, Stanford University Medical Center, Palo Alto, CA, Stanford University School of Medicine, Redwood City, CA, 4 Stanford University, Palo Alto, CA 5:00 pm 8. Adverse Events in Connective Tissue Disease-Associated Pulmonary Arterial Hypertension Compared to Idiopathic Pulmonary Arterial Hypertension Rennie L. Rhee, Nicole B. Gabler, Amy Praestgaard, Peter A Merkel and Steven M. Kawut, University of Pennsylvania, Philadelphia, PA, University of Pennsylvania and VA Medical Center, Philadelphia, PA 5:5 pm 8. Evaluation of the Effect of Sildenafil on the Microvascular Blood Flow and on the Endothelial Progenitor Cells in Patients With Early Systemic Sclerosis: A Randomized, Double-Blind, Placebo-Controlled Study Fernando V. Andrigueti, Pâmela C.C. Ebbing, Maria I. Arismendi and Cristiane Kayser, Universidade Federal de São Paulo, São Paulo, Brazil 5:0 pm 84. The Risk of Pulmonary Embolism and Deep Venous Thrombosis in Systemic Sclerosis: A Population-Based Cohort Study J. Antonio Avina-Zubieta, Iman Hemmati, Eric C. Sayre, Kamran Shojania and Hyon K. Choi, Arthritis Research Centre of Canada, University of British Columbia, Richmond, BC, University of British Columbia, Vancouver, BC, Arthritis Research Centre of Canada, Richmond, BC 94 0 Program Book denotes Hilton San Diego Bayfront room location

97 5:45 pm 85. Asymmetric Dimethylarginine Levels in the Early Detection of Systemic Sclerosis-Related Pulmonary Arterial Hypertension Vivek Thakkar, Wendy Stevens, David Prior, Joanne Sahhar, Janet E. Roddy, Jane Zochling 4, Peter Nash 5, Peter Youssef 6, Susanna Proudman 7 and Mandana Nikpour 8, St Vincent s Hospital, Melbourne, Australia, Monash Medical Centre, Clayton, Australia, Royal Perth Hospital, Perth, Australia, 4 Menzies Research Institute Tasmania, Hobart, Australia, 5 Nambour Hospital, Sunshine Coast, Australia, 6 Royal Prince Alfred Hospital, Sydney, Australia, 7 Royal Adelaide Hospital, Adelaide, Australia, 8 University of Melbourne, Fitzroy, Australia ACR MEET THE PROFESSOR SESSIONS 4:0-6:00 pm Admission to Meet the Professor sessions requires a separate registration and ticket. To verify which session you registered for, the registration code on your ticket needs to match the -digit code in parentheses below. If you are interested in participating in one of these sessions or exchanging your ticket, visit the ACR registration desk to check space availability. View the session overview online in My Annual Meeting at www. ACRannualmeeting.org. * Sessions denoted with an asterisk were sold out as of August 0. *Ankylosing Spondylitis: Disease Modification (05) Speakers: Joachim Sieper, MD outline what is known about the pathophysiology of disease modification in spondylarthritis review outcomes relevant to the concept of disease modification in spondylarthritis and assess their relevance to clinical practice review therapeutic issues relevant to the concept of disease modification discuss assessment of disease modification clinical trial Basic Immunology for Clinical Rheumatologists (05) Speaker: Antony Rosen, MD describe how the immune system functions in normal individuals identify abnormalities of immune regulation that lead to autoimmunity 4 A Pain: Evaluation and Treatment of Back Pain (05) Speaker: Rajiv Dixit, MD describe the clinically relevant anatomy of the lumbar spine clinically evaluate a patient with acute or chronic back pain or a patient with an associated nerve root compression syndrome formulate a rational and cost effective management plan with a clear understanding of surgical indications denotes Hilton San Diego Bayfront room location 4 B Pediatric Rheumatology for Adult Rheumatologists (054) Speaker: Daniel J. Lovell, MD, MPH identify how the evaluation of children with rheumatic diseases may be different from that of adults, in particular where mistakes may cause harm diagnose the various forms of arthritis that are unique to children describe current treatment of arthritis in children 5 A Polymyalgia Rheumatica (055) Speaker: Bhaskar Dasgupta, MD apply the recent guidelines for polymyalgia rheumatica which outline an evaluative process and clues that help differentiate it from other conditions and identify overlap with inflammatory arthritis and large vessel vasculitis recognize the EULAR ACR classification criteria which outline clinical, laboratory, and ultrasound criteria items for a scoring algorithm for polymyalgia rheumatica evaluate outcome studies to assess disease activity, quality of life and disability discuss the status of disease modifying therapies and clinical trials, on-going and in setup, including the use of biological agents and other novel therapies 5 B *Psoriatic Arthritis (056) Speaker: Arthur Kavanaugh, MD discuss advances in diagnosis and classification of psoriatic arthritis determine if patients with psoriatic arthritis should be treated aggressively determine treatment options for patients with psoriatic arthritis 6 A Pulmonary Hypertension in the Rheumatic Diseases (057) Speaker: James R. Seibold, MD describe the World Health Organization classification of pulmonary hypertension and how to recognize the frequent overlap of these syndromes in the clinical setting of connective tissue disease discuss the utility, sensitivity and specificity of non-invasive screening tests and algorithms for determining which patients are appropriate for right heart catheterization explain the benefits, risks, costs and effects on outcome of the available therapies for pulmonary arterial hypertension 0 Program Book 95 MONDAY october 8, 0

98 MONDAY october 8, 0 6 B Rheumatoid Arthritis: Challenging Cases (058) Speaker: Stanley B. Cohen, MD discuss the management of patients with refractory rheumatoid arthritis identify novel treatment options for those failing conventional therapies create effective management plans for complicated rheumatoid arthritis patients 7 A Temporal Arteritis (059) Speaker: Robert F. Spiera, MD discuss current concepts in the diagnosis of temporal arteritis including use of imaging modalities identify evolving concepts of the treatment of temporal arteritis including the appropriate use of glucocorticoids and the efficacy of steroid sparing agents describe the relationship between temporal arteritis and polymyalgia rheumatica outline current concepts of the pathogenesis of temporal arteritis 7 B *Vaccinations for Patients on Biologic Therapies (060) Speaker: Clifton O. Bingham III, MD recognize the importance of appropriate vaccinations in patients with autoimmune disease identify the different types of immunizations especially those which are live viruses describe the effect of different classes of immunomodulatory medications on vaccine efficacy and safety ARHP SESSIONS 4:0-6:00 pm Sapphire I Body Image With Rheumatic Conditions Moderator: Meenakshi Jolly, MD, MS identify changes in body image that occur with rheumatic diseases, particularly lupus discuss how neuropsychological functioning interfaces with body image changes and coping associate ways that teaching cognitive-behavioral and mindfulness interventions can promote positive change in body image identify patient barriers towards effective participation in interventions directed at improving body image 4:0 pm Body Image Issues and Interventions Among Women With Lupus Elizabeth Hale, MSc 4:55 pm Body Image Issues and Interventions Among Women With Lupus Kristin Peters, PhD 5:45 pm Questions and Answers 8 D Rheumatoid Arthritis Management: Views From Around the World Moderator: Atul A. Deodhar, MD describe variations in practice models across the world appraise international perspectives on establishment of registries and guidelines compare management of rheumatoid arthritis in underserved populations with limited resources 4:0 pm Rheumatoid Arthritis Management: A Latin American Perspective Jose Antonio Maldonado-Cocco, MD 5:00 pm A Developing World Perspective on the Management of Rheumatoid Arthritis Anand N. Malaviya, MD 5:0 pm Establishment of Registries and Guidelines in the Africa Middle East Region Mohammed Hammoudeh, MD 06 A Work, Health and Well-being: Arthritis and Employment Across the Life Course Moderator: Edward H. Yelin, PhD describe the impact of work on health and on the individual s general and economic well-being apply a biopsychosocial and multi-disciplinary perspective to identifying facilitators and barriers to the assessment and management of arthritis and musculoskeletal conditions in the work setting consider the economic implications of work on the individual and society across the life span associate the wider influence on and reciprocal relationships of work on health and social participation 4:0 pm Employment Transitions and Implications Across The Working Life Course Kristina A. Theis, MPH 5:00 pm Healthy Work Life Expectancy in Older Adults and the Impact of Arthritis Ross Wilkie, BSc, PhD 96 0 Program Book denotes Hilton San Diego Bayfront room location

99 5:0 pm The Relationships of Arthritis, Work and Personal Life Roles in Individuals With Inflammatory Arthritis and Osteoarthritis Monique A. Gignac, PhD ARHP CONCURRENT ABSTRACT SESSION 4:0-6:00 pm 5:0 pm 80. Assessing 4-Hour Physical (In)Activity and Sleep in People With Early Rheumatoid Arthritis Christopher Feehan, Eric C. Sayre, Erin Carruthers and Lynne M. Feehan, University of British Columbia, Vancouver, BC, Arthritis Research Centre of Canada, Richmond, BC, Arthritis Research Centre of Canada and University of British Columbia, Vancouver, BC A Rehabilitation Sciences Moderator: Kristine M. Lohr, MD, MS 4:0 pm 86. Exercise Therapy Reduces Pain Sensitivity in Patients With Knee Osteoarthritis: A Randomized Controlled Trial Marius Henriksen, Louise Klokker, Thomas Graven-Nielsen, Cecilie Bartholdy, Tanja Schjoedt Joergensen, Elisabeth Bandak, Bente Danneskiold-Samsøe 4, Robin Christensen 4 and Henning Bliddal, The Parker Institute, Copenhagen University Hospital at Frederiksberg, Copenhagen F, Denmark, Aalborg University, Aalborg, Denmark, The Parker Institute, Department of Rheumatology, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Copenhagen F, Denmark, 4 The Parker Institute, Department of Rheumatology, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Denmark, Frederiksberg, Denmark 4:45 pm 87. The Clinical Burden of Generalized Osteoarthritis Represented By Activity Limitations and Health Related Quality of Life: A Cross-Sectional Study Nienke Cuperus, Thea Vliet Vlieland, Elien Mahler, Clarinda Kersten, Thomas Hoogeboom and Els van den Ende, Sint Maartenskliniek, Nijmegen, Netherlands, University Medical Center Leiden, Leiden, Netherlands, CAPHRI school for public health and primary care, CCTR centre for Care Technology Research, Maastricht University, Maastricht, Netherlands 5:00 pm 88. Automated Telephone-Linked Communication: A Novel Approach to Enhance Long-Term Adherence to Resistance Training Exercise Among People With Knee Osteoarthritis Kristin Baker, Aileen Ledingham, Michael P. Lavalley, Julie J. Keysor and David T. Felson, Boston University Sargent College, Boston, MA, Boston University, Boston, MA, University of Manchester, Manchester, United Kingdom 5:45 pm 8. Benefits of Progressive Muscle Strengthening Using a Swiss Ball in Patients With Ankylosing Spondylitis: A Randomized Controlled Trial Marcelo Souza, Fabio Jennings, Hisa Morimoto and Jamil Natour, Universidade Federal de Sao Paulo, Sao Paulo, Brazil, Universidade Federal de São Paulo, São Paulo, Brazil ACR STUDY GROUPS 6:0-7:45 pm Study Groups are non-cme activities open to all attendees. A ACR Musculoskeletal Ultrasound Study Group 6:0 pm D Fusion and Interactive Imaging in Rheumatology Emilio Filippuci, MD 6:50 pm Elastosonography: A New Imaging Modality to Evaluate Fibrotic Disorders Peter V. Balint, MD, PhD 7:05 pm Systemic Sclerosis: From Skin to Lung Marwin Guttierrez, MD 7:5 pm Ultrasound Assessment of Salivary Glands in Sjogren s Syndrome: Towards New Diagnosis Criteria Sandrine Jousse-Joulin, MD 5 A ACR-EULAR Exchange Study Group - Joint Imaging and Beyond Speaker: Marina Backhaus, MD, PhD MONDAY october 8, 0 5:5 pm 89. Effectiveness of Pilates Method for the Treatment of Chronic Mechanical Neck PAIN Luciana A. Cazotti, Anamaria Jones, Diego Roger Silva, Luiza H. C. Ribeiro and Jamil Natour, Universidade Federal de Sao Paulo, Sao Paulo, Brazil, Universidade Federal de São Paulo, São Paulo, Brazil A Autoantibodies in Diagnosis and Follow-up of Rheumatic Diseases Study Group 6:0 pm Improving Antiphospholipid Antibody Testing through International Collaboration via Antiphospholipid Syndrome Alliance for Clinical Trials and International Networks (APS ACTION) Doruk Erkan, MD denotes Hilton San Diego Bayfront room location 0 Program Book 97

100 MONDAY october 8, 0 6:55 pm Advances in Novel Technologies and Microchip Methods to Detect Autoantibodies Yehuda Shoenfeld, MD 7:0 pm Strengths and Limitations in High Throughput Autoantibody Detection Technologies Pier Luigi Meroni, MD 0 E Behҫet s Syndrome Study Group 6:0 pm Behçet s Syndrome Yusuf Yazici, MD 6:5 pm Genetics of Behçet s Syndrome Ahmet Gul, MD 7:09 pm Major Vessel Disease in Behçet s Sydnrome Emire Seyahi, MD 7:7 pm Management of Behçet s Syndrome Gulen Hatemi, MD Biosimilars in Rheumatology Study Group 6:0 pm Introduction and Update Jonathan Kay, MD 7:00 pm Capillaroscopy in Systemic Sclerosis: Basic Science Maurizio Cutolo, MD 7:5 pm Practical Issues in Capillaroscopy Alberto Sulli, MD 9 D Crystal Study Group 6:0 pm The 0 ACR Guidelines for the Management Thomas Bardin, MD 7:5 pm Gout Flare Mechanism Update Frédéric Lioté, MD, PhD 8 D Decision Aids in Rheumatology Study Group 6:0 pm Introduction to Shared Decision Making and Decision Aids in Rheumatology Richard W. Martin, MD, MA 6:55 pm Dynamic Computer Interactive Decision Application Nick Bansback, PhD 7:0 pm Shared Decision Making With the Child: Parent Dyad in Juvenile Idiopathic Arthritis Esi Morgan DeWitt, MD, MSCE 6:45 pm European Viewpoint Thomas Dorner, MD 7:00 pm South American Perspective Morton A. Scheinberg, MD, PhD 7:5 pm Asian Scenario Arvind Chopra, DNB, MBBS, MD 7:0 pm Patient Centric Issues in Developing World-India: An Example Manjit Saluja, MScCRA, BSc C Capillaroscopy in Rheumatic Diseases Study Group 6:0 pm Update on Microcirculation Assessment Tools Alberto Sulli, MD 6:45 pm Capillaroscopy in Systemic Sclerosis: Clinical Applications Vanessa Smith, MD, PhD Global Musculoskeletal Health Initiative Study Group 6:0 pm Global Variations in Biologic Therapy Francis Guillemin, MD, PhD 6:55 pm Global Variations in Access to Fracture Liaison Services Lyn March, MBBS, MSc, PhD 7:0 pm Global Variations in Access for Total Joint Replacement Surgery Gillian A. Hawker, MD, MSc 7:45 pm Training First Line Clinicians and Empowering Patients: Experience of the ARMS Program in the Philippines Sandra V. Navarra, MD 8:0 pm Improving Surveillance of Musculoskeletal Burden The EUMusc Experience Loreto Carmona, MD, PhD 98 0 Program Book denotes Hilton San Diego Bayfront room location

101 4 A High-Resolution Peripheral Quantitative Computed Tomography (HR-pQCT) - Early Damage Detection in Inflammatory and Degenerative Arthritis Study Group 6:0 pm HR-pQCT Technology: The Fundamentals Steven K. Boyd, PhD 6:45 pm Imaging of Inflammatory Arthritis With HR-pQCT: Typical Features of Periarticular Bone Changes Cheryl Barnabe, MD, MSc 4 B Neuro Endocrine Immunology Study Group 6:0 pm Overview of Neuro Endocrine Immunology (NEI) in Aging Rainer H. Straub, MD 6:55 pm Ghrelin as a Mediator of NEI Dennis Taub, MD 7:0 pm Vasculitis in the Elderly: Influence of NEI Cornelia M. Weyand, MD, PhD 7:00 pm Imaging of Degenerative Arthritis With HR-pQCT: Typical Features of Periarticular Bone Changes Stephanie Finzel, MD 7:5 pm Quantification of Bone Damage in HR-pQCT Kathryn Stok, PhD 7:0 pm Application of HR-pQCT in Clinical Research: Potential Uses for Intervention Studies and Observational Cohorts Georg A. Schett, MD 6 B JAW (Juvenile Arthritis Workgroup) Study Group 6:0 pm Comparison of Short Versus Long Magnetic Resonance Imaging (MRI) Protocols to Diagnose Temporomandibular Joint (TMJ) Involvement in Juvenile Idiopathic Arthritis Andrea S. Doria, MD, PhD, MSc 6:50 pm Developing a Scoring System to Assess TMJ Arthritis by MRI in Children With Juvenile Arthritis (JIA) Randy Q. Cron, MD, PhD 7:0 pm Cone Beam Computed Tomography Evaluation of Facial Dysmorphology Secondary to TMJ Arthritis in Children With JIA Bernd Koos, DDS B Latin American Study Group 6:0 pm A Chilean Cohort of Patients With Systemic Lupus Erythematosus: Sociodemographic, Clinical, Immunologic and Genetic Characteristics Paula Burgos, MD 6:55 pm Central Nervous System Involvement in Systemic Lupus Erythematosus Simone Appenzeller, MD, PhD 5 B Pediatric Rheumatology Imaging Study Group 6:0 pm Standardization of Pediatric Ultrasound Johannes Roth, MD 6:45 pm Standardization of Pediatric MRI Marion A.J. Van Rossum, MD, PhD 7:00 pm Ultrasound Definition of Synovitis Sandrine Jousse-Joulin, MD 7:5 pm MRI Definition of Synovitis Mario Maas, MD, PhD 6 A Polymyalgia Rheumatica Study Group 6:0 pm EULAR ACR PMR Guidelines: Progress Made So Far Bhaskar Dasgupta, MD 6:55 pm Polymyalgia Rheumatica (PMR) Guidelines Panel Responses Eric L. Matteson, MD, MPH 7 A Primary Sjögren s Syndrome Study Group 6:0 pm Pathogenic Role of Innate Immunity and Microbioma in Primary Sjogren s Syndrome (pss) Umesh Deshmukh, PhD 6:55 pm New Insights into the Pathogenesis of pss Robert Hal Scofield, MD 7:0 pm Update on Risk Factors of pss-related Lymphomas Elke Theander, MD, PhD 7:45 pm New Perspectives in Topical and Oral Treatment of Dryness Frederick B. Vivino, MD MONDAY october 8, 0 denotes Hilton San Diego Bayfront room location 0 Program Book 99

102 MONDAY october 8, 0 TUESDAY october 9, 0 8 B Veterans Affairs Rheumatology Study Group 6:0 pm Computerized Patient Record System (CPRS) Templates and Associated Encounter Forms Elizabeth Chang, MD 6:55 pm CPRS Templates and Associated Encounter Forms Salahuddin Kazi, MD 7:0 pm CPRS Templates and Associated Encounter Forms Mathilde H. Pioro, MD 7:45 pm CPRS Templates and Associated Encounter Forms David Gregg Gordon, RN 8:0 pm National Advances in Veterans Affairs Specialty Grant W. Cannon, MD ACR SESSIONS 7:0-8:0 am TUESDAY, OCTOBER 9, 0 Hall B Care of Chronic Non-Healing Wounds Moderator: Kenneth S. O Rourke, MD Speaker: Joseph Molnar, MD, PhD 0 E discuss the extent of the problem of problem wounds, and their impact describe the stages of wound healing, and the pathophysiology of wound healing failure construct a plan for the evaluation and management of wounds, to include consideration of the roles played by nutrition, medical comorbidities and immunosuppressive medications, debridement, anti-infectives, and absorbants, relating therapies to current clinical practice guidelines Non-coding DNA: Signals, Switches, and Complex Regulation of Genes Moderator: S. Louis Bridges Jr., MD, PhD Speaker: John Stamatoyannopoulos, MD review the current state of the art on mechanisms by which non-coding DNA regulates gene expression describe potential ways in which the new information on noncoding DNA might impact on diagnosis, therapy, or prevention of human disease explain the previously unknown functions of what used to be called junk DNA identify the future work that needs to be completed in order to fully understand the complexities of regulation of gene expression among different cell types in humans discuss the implications of new data on gene regulation on human disease 6 C Pediatric Autoimmune and Inflammatory Skin Disease Moderator: Stacy P. Ardoin, MD, MS Speaker: Elaine Siegfried, MD identify the clinical manifestation and differential diagnosis of common pediatric inflammatory dermatoses discuss recent advances in understanding the pathophysiology of inflammatory pediatric dermatoses outline current evidence-based treatments for pediatric inflammatory dermatoses ARHP SESSIONS 7:0-8:0 am 04 A Rheumatic Disease and Pain Management in Special Needs Populations Moderator: recognize and assess pain in elders with dementia/cognitive impairment treat and manage acute and chronic pain in elders with dementia evaluate and diagnose rheumatic disease with severe psychiatric comorbidities treat and manage rheumatic disease and the psychiatric disorders 7:0 am Assessment and Management of Pain in Elders With Dementia/ Cognitive Impairment Devyani Misra, MD 8:00 am Recognizing and Treating Rheumatic Disease in People With Severe Psychiatric Disorders Lesley M. Arnold, MD Indigo D Rheumatology Update: Inflammatory Bowel Disease Moderator: Jennifer L. Trizuto, MPT Speaker: Andreas M. Reimold, MD discuss the presentation of inflammatory bowel disease in association with enteropathic arthritis review the basic immunology behind inflammatory bowel disease along with seronegative spondyloarthropathies discuss the current management principles and treatments for inflammatory bowel disease and enteropathic arthritis 00 0 Program Book denotes Hilton San Diego Bayfront room location

103 B The Results Section in Medical Research Literature: The Appropriate and Inappropriate Use of Statistics Moderator: Alyssa B. Dufour, PhD differentiate between p-value and confidence intervals in the role of random error interpret results of associative and inferential statistics, including multivariable statistical modeling to control confounding identify common statistical errors in reporting and interpretation of statistics, and be able to differentiate between statistical errors and philosophical differences in statistical approaches describe ways to minimize the propagation of errors in the literature, and improve the quality of reporting and interpreting statistics 7:0 am Understanding the Results Section: How to Read and Interpret Statistical Tests Nancy A. Baker, MPH, OTR, OTR/L 7:55 am Common Mistakes in Statistical Methods or Interpretation of Medical Research Cynthia S. Crowson, MS 8:0 am Questions & Answers ACR SESSIONS 7:0-9:00 am Indigo C Rheumatology Research Foundation Special Session: Disease Targeted Research Moderator: Anne Davidson, MBBS gain critical insight into rheumatoid arthritis pathogenesis and understand essential proof of concept that treatment of periodontal disease could serve as a target in a strategy aimed at rheumatoid arthritis prevention identify synovial fibroblasts and cadherin- as key targets in the inflammatory pathways of rheumatoid arthritis that were not well appreciated previously describe the role of innate receptors on development and function of osteoclasts, especially under inflammatory conditions in the SKG mouse model of rheumatoid arthritis 7:0 am Periodontal Disease and P. Gingivalis in Rheumatoid Arthritis Ted R. Mikuls, MD, MSPH 8:00 am Innovative Approach for Identifying Infectious Agents and Autoantigens in Rheumatoid Arthritis Allen C. Steere, MD 8:0 am Quality of Care in Rheumatoid Arthritis: An Analysis of the Healthcare Effectiveness Data and Information Set (HEDIS) Gabriela Schmajuk, MD, MS Sapphire I Risk Management A Case Study Moderator: Charles M. King II, MD Speaker: Ike Devji, JD analyze and discuss risk factors that increase liability discuss the most common causes of malpractice/liability claims recognize behaviors that may place providers at risk of medical legal action state the physician s role in a deposition identify techniques that may increase the likelihood of a successful deposition or decrease the risk of escalation to trial ACR MEET THE PROFESSOR SESSIONS 7:45-9:5 Am Admission to Meet the Professor sessions requires a separate registration and ticket. To verify which session you registered for, the registration code on your ticket needs to match the -digit code in parentheses below. If you are interested in participating in one of these sessions or exchanging your ticket, visit the ACR registration desk to check space availability. View the session overview online in My Annual Meeting at www. ACRannualmeeting.org. * Sessions denoted with an asterisk were sold out as of August 0. *Ankylosing Spondylitis: 0 Update (06) Speaker: Michael H. Weisman, MD discuss the natural history of ankylosing spondylitis and spondylarthritis and its early diagnosis describe clinical and radiographic outcome measures used in trials and clinical practice summarize available guidelines in the management of ankylosing spondylitis Antiphospholipid Syndrome (06) Speaker: Munther A. Khamashta, MD discuss the spectrum of antiphospholipid syndrome identify the diagnostic utility of antiphospholipid antibody tests describe the controversial aspects of primary and secondary thrombosis prevention in antiphospholipid syndrome discuss the management of catastrophic antiphospholipid syndrome patients TUESDAY october 9, 0 denotes Hilton San Diego Bayfront room location 0 Program Book 0

104 TUESDAY october 9, 0 4 A Crystal: Diagnosis and Management of Gout (06) Speaker: Michael A. Becker, MD discuss the pathogenesis and pathophysiology of acute and chronic gout, including the distinctive treatment modalities affecting patient outcomes explain the renal mechanisms underlying the hyperuricemia of most gout patients and therapeutic rationales applied to urate-lowering therapies critically assess current ACR recommendations for the treatment of acute and chronic manifestations of gout 4 B Myopathy: Issues in Diagnosis and Treatment (064) Speaker: Rohit Aggarwal, MD, MS differentiate myositis mimics from idiopathic inflammatory myopathies state the importance of myositis antibodies and muscle magnetic resonance imaging in diagnosis and prognosis review myositis diagnosis in difficult cases including review of clinical features, muscle biopsy and electromyography review management of refractory myopathy including management of extra-muscular manifestations especially interstitial lung disease 5 A Osteoporosis: Novel Treatments (065) Speaker: Linda Russell, MD review the basic biology of bone as it relates to treatment examine the potential benefits and risks of antiresorptive therapies discuss the potential benefits and risks of anabolic therapies review the current knowledge and understanding of how to pick the best therapy for each patient and for how long to treat each patient, with osteoporosis 5 B Pregnancy and Rheumatic Diseases (066) Speaker: Eliza F. Chakarvarty, MD describe risk factors for adverse maternal and fetal outcomes in systemic autoimmune diseases. describe key elements of preclinical risk assessment and counseling for women who desire a future pregnancy discuss the impact of active maternal autoimmune disease upon pregnancy outcomes. discuss the risk-to-benefit analysis of common anti rheumatic and immunosuppressive medications during pregnancy 6 A *Rheumatoid Arthritis: Safety of Novel Therapies (067) Speaker: Lee S. Simon, MD examine the drug safety literature with greater expertise prescribe DMARDs with a broader and deeper knowledge of potential toxicities discuss DMARD toxicities with their patients with greater comfort manage potential DMARD toxicities with greater skill 6 B Rheumatology Practice 0: Starting Out in Practice for The Graduating Fellow (068) Speaker: Alexandru F. Kimel, MD prepare for their first job search assess expectation when starting out (perceptions versus reality) adapt to new practice styles and build a referral base identify ways to ensure long term success and personal life balance 7 A Systemic Sclerosis: Disease Staging and Subsetting in Clinical Practice (069) Speaker: Robyn T. Domsic, MD, MPH use clinical and serologic classification systems of systemic sclerosis to identify the natural history of clinical subsets explain the concept of disease staging in both diffuse and limited cutaneous systemic sclerosis use knowledge of clinical/serologic classification and disease staging to develop screening and management plans 7 B Temporal Arteritis (070) Speaker: Robert F. Spiera, MD discuss current concepts in the diagnosis of temporal arteritis including use of imaging modalities identify evolving concepts of the treatment of temporal arteritis including the appropriate use of glucocorticoids and the efficacy of steroid sparing agents describe the relationship between temporal arteritis and polymyalgia rheumatica outline current concepts of the pathogenesis of temporal arteritis ACR/ARHP WORKSHOPS 7:45-9:45 am 4 Admission to Workshops requires a separate registration and ticket. To verify which session you registered for, the registration code on your ticket needs to match the -digit code in parentheses below. If you are interested in participating in one of these sessions or exchanging your ticket, visit the ACR registration desk to check space availability. View the session overview online in My Annual Meeting at www. ACRannualmeeting.org. * Sessions denoted with an asterisk were sold out as of August 0. *Advanced Musculoskeletal Ultrasound (0) Speaker: Jay B. Higgs, MD demonstrate improvement in their techniques for performing selected MSUS examinations obtain image quality using ultrasound technology 0 0 Program Book denotes Hilton San Diego Bayfront room location

105 A Histopathology of Vasculitis () Speaker: Allen Burke, MD and Jonathon Heath, MD describe histological features of normal blood vessels distinguish pathologic reactions to vascular injury identify histological features of major vasculitis syndromes 8:50 am Contract Negotiations and the Legal Ramifications of the Contract. How to Optimize the Contract and Protect Yourself Frank Gamma, JD, MBA 9:0 am Questions and Answers *Joint Injections (Knee, Ankle, Shoulder and Wrist) () Speaker: Gregory C. Gardner, MD and Kenneth R. Margules, MD describe indications for lower extremity joint injection and aspiration identify anatomic landmarks for injection of the knee and ankle using joint prosthetics apply principles of joint aspiration and injection using ankle and knee joint prosthetics Knee Braces and Foot Orthosis for Knee Osteoarthritis () Speakers: Howard J. Hillstrom, PhD and Kelly D. Krohn, MD review the biomechanical rationale for the use of knee braces and foot orthoses for knee osteoarthritis discuss the clinical data to support these modalities apply these modalities to their patients ACR SESSION 8:00-9:0 am 8 D Contract Negotiations for Physicians Moderator: Sharon L. Kolansinski, MD negotiate a fair academic or industrial letter of offer/contract explain the value of legal advice prior to signing a contract and the legal ramifications of the contract identify a fair private practice or hospital practice contract and how to successfully modify it to correspond with their individual needs 8:00 am Contract Negotiations for Academics: How to Optimize Your Academic Offer Letter/Contract Gary S. Firestein, MD 8:5 am Contract Negotiations for Industry- How to Optimize your Industrial Letter of Offer/Contract Gregory J. Dennis, MD 8:0 am Contract Negotiations for Private Practice - How to Identify a Fair Private Practice or Hospital Practice Contract and How to Successfully Modify it to Correspond with their Individual Needs Herbert S. B. Baraf, MD denotes Hilton San Diego Bayfront room location ACR SESSIONS 8:0-0:00 am C Chart Etiquette: Creating Meaningful Notes Moderator: Melissa Francisco assess and evaluate individual practices for documenting patient encounters describe the role of chart notes within the context of electronic health record systems, with emphasis on misperceptions that may result from copy-and-paste tendencies develop strategies for creating documentation that fulfills compliance and legal considerations while balancing efficiency concerns 8:0 am Maximizing the Value of Documentation Salahuddin Kazi, MD 9:00 am Best Practices to Address Compliance and Legal Considerations Steven K. Magid, MD 9:0 am Managing the Challenges of a Dual-System Environment Carin Dugowson, MD, MPH Ballroom 0 A Choosing and Monitoring Rheumatoid Arthritis Therapy in 0 Moderator: Alan N. Baer, MD describe the unique characteristics of specific newer rheumatoid arthritis treatment modalities choose the most appropriate therapeutic agent for the rheumatoid arthritis patient who has failed methotrexate, considering efficacy, cost, safety, and unique biologic characteristics of the patient s disease identify steps that should be taken to ensure the safe use of these rheumatoid arthritis therapies 8:0 am Management of Rheumatoid Arthritis With Newer Agents Daniel Aletaha, MD, MSc 9:0 am Monitoring Advanced Therapeutics in Rheumatoid Arthritis Clifton O. Bingham III, MD 0 Program Book 0 TUESDAY october 9, 0

106 ACR/ARHP POSTER SESSION C, THIEVES MARKET POSTERS, Late-BREAKING Posters AND POSTER TOURS 8:0 am - 4:00 pm Poster presenters will be available from 9:00 - :00 am (abstracts # 8-64). Poster tours will be held 9:00-9:45 am and 0:5 - :00 am. Morning snacks will be available from 8:0-0:00 am. Poster Hall (Exhibit Hall B-C-D) Thieves Market Posters Thieves Market posters feature cases with interesting imaging studies or pictorial displays of physical findings. A Case of Multi-system IgG4-related Disease Frank Tay Sen Hee, MBBS A Rare Reaction to Hydroxychloroquine Meghan Greenfield, MD A Young Patient With Weakness Krati Chauhan, MD, MSPH Double Vision and a Nose Bleed Cristina Gale Arriens, MD Gotta Go! (Polyuria) Cristina Gale Arriens, MD Hereditary Hemochromatosis With Bbilateral Sacroiliitis Mudappa Karineravanda Kalaiah, MBBS Normocalcemic Hyperparathyroidism Claire-Louise Murphy, MB, BCH, BAO (MRCPI) 9:00-9:45 am Antiphospolipid Syndrome Poster Tour (5) Tour Guide: Pier Luigi Meroni, MD Miscellaneous Rheumatic and Inflammatory Diseases Poster Tour (6) Tour Guide: Laura Carbone, MD Rheumatoid Arthritis: Clinical Aspects Poster Tour (7) Tour Guide: Eric L. Matteson, MD Rheumatoid Arthritis: Human Etiology and Pathogenesis Poster Tour (8) Tour Guide: David S. Pisetsky, MD, PhD Rheumatology Research Foundation Poster Tour: Designing A Clinical Study for Rheumatic Disease (9) Tour Guide: Michael M. Ward, MD Spondylarthropathies and Psoriatic Arthritis: Clinical Aspects and Treatment Poster Tour (0) Tour Guide: Jürgen Braun, MD 0:5 - :00 am Metabolic and Crystal Arthropathies Poster Tour () Tour Guide: N. Lawrence Edwards, MD Muscle Biology, Myositis and Myopathies Poster Tour () Tour Guide: Frederick W. Miller, MD, PhD Pediatric Rheumatology: Clinical Aspects Poster Tour () Tour Guide: Emily von Scheven, MD Rheumatoid Arthritis - Small Molecules, Biologics and Gene Therapy Poster Tour (4) Tour Guide: Jonathan Kay, MD TUESDAY october 9, 0 Oral Histoplasmosis as a Rare Complication of Anti-TNF Therapy for Relapsing Polychondritis Floranne C. Ernste, MD Poster Hall (Exhibit Hall B-C-D) Guided Poster Tours Guided poster tours allow scientific attendees to ask questions and gain insights from some of the best-known rheumatology leaders. Tours are complimentary; however, registration is required and is limited to scientific attendees. If you preregistered for a tour, you should have received a ticket with your meeting materials. Once you have your ticket, check in at the tour desk 5 minutes prior to the start of your tour to receive your headset. Your reservation will be held only until 5 minutes prior to the start of the tour. After this time, your reservation is not guaranteed and may be released to standby attendees. If you did not pre-register, tickets may be available in the registration area (Sails Pavilion). Alternatively, you may go directly to the poster tour desk and wait for a standby ticket. Standby tickets will be assigned on a first-come, first served basis 5 minutes prior to the start of each tour. Each tour participant will receive a wireless headset which will be registered against the participants registration ID. Participants will be charged $50 if the headset is not returned within 5 minutes of the end of the tour. Spondylarthropathies and Psoriatic Arthritis Clinical Aspects and treatment Poster Tour (6) Tour Guide: Walter Maksymowych, MD Systemic Sclerosis, Fibrosing Syndromes, and Raynaud s - Clinical Aspects and Therapeutics Poster Tour (5) Tour Guide: Murray Baron, MD ACR SESSIONS 9:00-0:00 AM 0 A Ready or Not It s Coming: Implementation of ICD-0 Moderator: Robert T. Keenan, MD, MPH Speaker: Antanya Chung, CPC, CPC-I, CRHC, CCS-P explain the differences in the coding sets and the importance in learning the new coding set discuss how the new requirements of ICD-0 will impact administrative and business operations describe the importance of correct documentation and how it relates to the new coding structure 04 0 Program Book denotes Hilton San Diego Bayfront room location

107 6 A The Role of B cells in Rheumatic Disease Moderator: Andrew P. Cope, MD, PhD Speaker: Thomas Dorner, MD outline the molecular and cellular pathways of B cell activation and differentiation discuss the repertoire of B cell effector and regulatory responses that have been described in the context of autoimmune disease clarify the emerging portfolio of B cell directed therapies and how the mechanisms by which they attenuate the disease process provide insight into the pathogenesis of rheumatic diseases 6 D The Role of Th7 Cells in Health and Disease Moderator: Richard M. Pope, MD Speaker: Vijay K. Kuchroo, MD, PhD describe the mechanisms that regulate Th7 differentiation identify the mechanism by which Th7 cells promote immune homeostasis define the mechanisms by which Th7 cells contribute to autoimmune disease pathogenesis ARHP SESSIONS 9:00-0:00 am B An Integrative Approach to Pediatric Wellness Moderator: Sandra Mintz, BSN review the utilization of integrative medicine in pediatric pain management describe different complementary and alternative medicine therapies and the evidence for pediatric pain management discuss the biopsychosocial model in approaching pain management in pediatrics 9:00 am An Integrative Approach to Pediatric Wellness Jeffrey I. Gold, PhD 9:00 am Anxiety in Rheumatic Disease: An Overview Perry M. Nicassio, PhD 9:0 am Pharmacological and Non-Pharmacological Treatment of Anxiety in Rheumatic Disease Lesley M. Arnold, MD Indigo D Immunology Boot Camp Session : Biologic Logic, An Update Moderator: Karla B. Jones, CNP Speaker: Daniel F. Battafarano, DO review the current FDA approved indications for biologics in rheumatic disease analyze long term efficacy and safety data for biologic agents describe clinical applications for monitoring including perioperative management 04 A Knowledge Is Power, But Sample Size Matters More: The Role of Sample Size in the Power and Precision of Study Results Moderator: Cynthia S. Crowson, MS describe how the sample size affects the power for a study comparing two groups with a continuous outcome measure, as well as for a dichotomous outcome measure discuss the role of sample size in determining the confidence interval for the mean for a continuous outcome measure, as well as for a dichotomous outcome measure list settings where the effect of sample size is modified in how it affects the power and precision provide examples of properly powered and under-powered rehabilitation studies and evaluation of confidence interval ranges in these studies 9:00 am The Fundamentals of Study Design and Measures of Effect in Determining Sample Size and Power Michael P. Lavalley, PhD TUESDAY october 9, 0 9:50 am Questions and Answers 06 A Anxiety Disorders in Rheumatic Disease Moderator: David A. Williams, PhD summarize the anxiety disorders most commonly observed in rheumatic disease along with associated complications utilize diagnostic criteria and screening instruments to identify cases of anxiety discuss pharmacological and non-pharmacological treatment options for anxiety disorders in the context of other common treatments for rheumatic disease patients 9:0 am Estimating Power and Sample Size in Rehabilitation Studies in Rheumatology Daniel K. White, PT, ScD, MSc 9:50 am Questions and Answers EXHIBITS 0:00 am - :0 pm Exhibit Hall F-G Join your colleagues in the Exhibit Hall for morning refreshments from 0:00 - :00 am. denotes Hilton San Diego Bayfront room location 0 Program Book 05

108 TUESDAY october 9, 0 (Booth #7) Innovation Theater Non-CME accredited presentations have been planned and will be implemented in accordance with the requirements of the FDA and applicable standards of the PhRMA Code on Interactions with Healthcare Professionals. These presentations will be held from 0:0 - :5 am and :0 - :5 pm. For a complete listing of Innovation Theater presentations, see page 5. ACR/ARHP WORKSHOPS 0:0 am - :0 pm 4 B Admission to Workshops requires a separate registration and ticket. To verify which session you registered for, the registration code on your ticket needs to match the -digit code in parentheses below. If you are interested in participating in one of these sessions or exchanging your ticket, visit the ACR registration desk to check space availability. View the session overview online in My Annual Meeting at www. ACRannualmeeting.org. * Sessions denoted with an asterisk were sold out as of August 0. Musculoskeletal Ultrasound (4) Speakers: Eugene Y. Kissin, MD and Amy M. Evangelisto, MD demonstrate how to properly position the ultrasound transducer to visualize targeted musculoskeletal structures based on an understanding of the local bony landmarks differentiate tissue types based on their ultrasound properties recognize the ultrasound appearance of some of the basic musculoskeletal pathologies Tai Chi and Alternative Therapies in Rheumatic (5) Speakers: Mary Jurisson, MD and Don Marcus, MD Describe the practice of Tai chi and qigong, and advise patients of its evidence- based benefits and risks Practice or qigong exercises independently Describe the differences between the regulation of dietary supplements and conventional medications, and to inform patients about current evidence concerning their efficacy and safety Inform patients about the efficacy of acupuncture for relief of back pain and osteoarthritis The Rheumatologic Musculoskeletal Screening Exam, With Emphasis on Objective Disease-specific Measurements (6) Speaker: Arthur M. Mandelin II, MD, PhD Facilitators: Barbara A. Slusher, PA-C, MSW and Kori A. Dewing, DNP, ARNP characterize the importance of using disease activity measurement tools in daily practice, the barriers which hinder routine widespread use, and how these barriers can be overcome in nearly any practice setting utilize disease activity measurement tools used in rheumatology care; including the disease activity score for 8 Joints and Crohn s Disease Activity Index for rheumatoid arthritis, psoriasis area and severity Index scoring for psoriatic skin involvement, measurements of spine and hip flexibility for spondyloarthropathies, and the modified Rodnan skin score for systemic sclerosis ACR SESSION :00 AM - Noon 0 E Mechanics, Matrix Disruption, and the Development of Osteoarthritis Moderator: Richard F. Loeser, MD Speaker: Robert L. Sah, MD, ScD express how biomechanical factors contribute to the development of osteoarthritis discuss the surface lubrication of articular cartilage define mechanisms by which abnormal biomechanical forces lead to failure of the articular cartilage ARHP SESSIONS :00 AM - Noon Sapphire A Nonalcoholic Fatty Liver Disease Moderator: Peter Chira, MD, MS spectrum of nonalcoholic fatty liver disease including the subphenotype of nonalcoholic steatohepatitis differences of nonalcoholic fatty liver disease in children and adults describe the effects of rheumatologic medications on liver chemistry :00 am Nonalcoholic Fatty Liver Disease Jeffrey B Schwimmer, MD :50 am Questions and Answers Sapphire I Oral Health in Rheumatologic Disease Moderator: Stuart L. Silverman, MD recognize oral disease common to clinical practice of rheumatology explain how to conduct a thorough oral examination and to identify oral anatomic structure discuss the impact of Sjögren s and systemic lupus erythematosus on oral health describe the association of osteoporosis medications and osteonecrosis of the jaw 06 0 Program Book denotes Hilton San Diego Bayfront room location

109 :00 am What Every Rheumatology Practitioner Should Know About Oral Health and Diseases Parish P. Sedghizadeh, DDS, MS :0 am Oral Health in Systemic Lupus Erythematosus and Sjögrens Daniel Wallace, MD :40 am Oral Health and Osteoporosis Therapy Stuart L. Silverman, MD 8 B Persistent Pain: Mechanisms of Chronic Pain and Innovative Treatment Options Moderator: Christine A. Stamatos, ANP-C review the pathophysiologic mechanisms that occur when acute pain becomes chronic pain identify the various multidisciplinary roles and techniques of the pain management team evaluate various treatment options for the treatment of centralized pain syndromes discuss the latest findings regarding the use of opioids, including data suggesting that blocking opioid systems using low dose naltrexone might be an effective strategy for some subsets of chronic pain patients :00 am Pathophysiology of Acute Versus Chronic Pain Daniel J. Clauw, MD :0 am Future Perspectives for Persistent Pain Management Sean Mackey, MD, PhD ACR SESSIONS :00 am - :0 pm 06 A Assessment Tool Selection in Health Professions Education Moderators: Kenneth S. O Rourke, MD and Jessica Berman, MD Speaker: Constance Bowe, MD discuss the strengths and weaknesses of selected assessment approaches and strategies describe the role and limitations of self-assessment, and how it relates to assessment from other sources discuss the evolving assessment design strategies that require further investigation Ballroom 0 A Protein Citrullination and Biological Response Modification: Rheumatoid Arthritis and Beyond Moderator: Dana P. Ascherman, MD explain the biology of protein citrullination as a form of posttranslational modification identify triggers of citrullination/post-translational modification in the synovium as well as extra-articular structures describe the relationship between citrullination and the generation of targeted autoimmune response in rheumatoid arthritis illustrate the potential role of ACPA profiling in tissue-specific biomarker development :00 am Biology of Citrullination Paul Ryan Thompson, PhD :45 am Protein Citrullination and the Breakdown of Tolerance in Rheumatoid Arthritis Patrick Venables, MD Hall B Selected Topics Related to Spondylarthropathies Moderator: Shelly P. Kafka, MD describe the features of inflammatory back pain, review the current pathophysiology, genetic associations and update diagnosis including imaging studies review the topic of reactive arthritis, current theories in regard to an infectious etiology as well as diagnosing in regard to new testing and imaging discuss new information in regard to inflammatory bowel disease and spondylarthritis including current prevalence, clinical manifestations, and treatment regimens :00 am Overview of Inflammatory Back Pain Joachim Sieper, MD :0 am Update on Reactive Arthritis Atul A. Deodhar, MD :00 pm Inflammatory Bowel Disease and Spondylarthritis Andreas M. Reimold, MD TUESDAY october 9, 0 A Audits-Are You At Risk? Moderator: Douglas White, MD, PhD Speaker: Karen Zupko identify key audits risk areas impacting rheumatology practices outline successful compliance measures to avoid or mitigate the impact of an audit discuss best practices to manage audits and prepare to handle new risks denotes Hilton San Diego Bayfront room location ACR PLENARY SESSION III DISCOVERY 0 :00 am - :0 pm 6 A ACR Plenary Session III: Discovery 0 Moderators: Richard M. Pope, MD and John Varga, MD 0 Program Book 07

110 TUESDAY october 9, 0 :00 am 644. Phase IB/Iia Study on Intravenous Administration of Expanded Allogeneic Adipose-Derived Mesenchymal Stem Cells in Refractory Rheumatoid Arthritis Patients JM Alvaro-Gracia, Hospital Universitario de La Princesa, Madrid, Spain Background/Purpose: Expanded adipose-derived stem cells (eascs) are shown to have immune-modulatory effects both in vitro and in animal models of arthritis. eascs are currently under investigation as potential treatments targeting auto-immune and inflammatory diseases such as Rheumatoid Arthritis (RA). The aim of the study was to determine the safety, feasibility and tolerance of intravenous (IV) administration of allogeneic eascs in RA patients. Methods: A 4-week, single blind dose-escalating study in RA patients under treatment with at least one non-biological DMARD and who previously failed treatment with at least two biologicals was conducted in centers in Spain. Fifty-three patients with moderate to high disease activity (DAS8>.) were assigned to receive x0 6 eascs/kg (cohort A: 0 patients), x0 6 eascs/kg (cohort B: 0 patients), 4x0 6 eascs/kg (cohort C: 6 patients) or placebo (Ringer s lactate solution: 7 patients). All patients received IV easc infusions at day, 8 and 5. Tolerability and treatment emergent adverse events such as Dose Limiting Toxicities (DLTs), serious adverse events (SAEs) and non-serious adverse events (AEs) were primary endpoints. ACR0/50/70, DAS 8, and SF-6 were secondary endpoints. Results: Patient and disease characteristics were comparable for all three dose groups. Median disease duration was years Repeated IV infusion of eascs did not show any major safety signals and the dose-limiting safety signal was not identified Three serious adverse events were reported (lacunar infarction, peroneal palsy and fever of unknown origin) of which, lacunar infarction was possibly related and lead to discontinuation with patient recovery. Most frequent non-serious AEs (threshold: > 4%) in patients treated with eascs, included pyrexia (9%), headache (%), urinary tract infection (%), upper respiratory tract infection (%), nausea (%), malaise, respiratory tract infection, vomiting and asthenia (6% each). In secondary endpoints, a clear dose-response effect was not observed. Maximum clinical benefit in the ITT population was observed in cohort A. ACR0/50/70 responses were observed in 45/0/5% of patients in cohort A versus 8/4/5% of patients on placebo at month. At month, ACR responses were 5/5/5 and 0/0/0 in cohort A and placebo respectively. The DAS 8 good/moderate response was 0/5% in cohort A and 0/4% in the placebo group at month. These values were 0/0% and 0/0% at month for cohort A and placebo respectively. Conclusion: These early clinical results are the first to suggest that IV infusion of eascs is well tolerated along 4 weeks and could be associated with clinical benefit in the treatment of refractory RA. Disclosures: J. Alvaro-Gracia, None. Methods: We separated proteins extracted from human umbilical vein endothelial cells (HUVECs) and HeLa cells by -dimensional electrophoresis and transferred them onto membranes. Antigens that were positive only in the HUVEC samples but not in the HeLa cell samples were detected by western blot, using serum samples from patients with vasculitis. Next, we identified the detected proteins by peptide mass finger-printing and characterized their antigenicity by preparing recombinant antigens and antibodies to them. Furthermore, we investigated the frequency, clinical significance, and pathological roles of AECA against individual identified target autoantigens. Results: We identified 6 proteins, one of which was peroxiredoxin (Prx), an anti-oxidative enzyme. Using immunocytochemistry, antibodies against Prx were found to bind to the cell surface of live HUVECs. IgG antibodies to Prx were detected in 60% (8/0) of the patients with KD, but not in healthy controls. Furthermore, IgG antibodies to Prx were detected in all tested KD patients with coronary artery lesions. Stimulating endothelial cells (ECs) with anti-prx antibodies resulted in increased H O levels in the cell lysates. The anti- Prx antibodies also increased various inflammatory cytokine secretions significantly; in particular, IL-6 in HUVECs and G-CSF in human coronary artery ECs. In addition, anti-prx antibodies induced the increased expression of adhesion molecules, such as E-selectin and ICAM-, on ECs. EC ELISA indicated that Prx proteins were released from ECs stimulated by inflammatory cytokines. By themselves, Prx proteins induced various inflammatory cytokine secretions, such as IL-6, IL-8, TNF-α and GM-CSF, from ECs, and the expression of adhesion molecules such as E-selectin and ICAM- on ECs. Interestingly, these effects of Prx proteins were enhanced significantly by the appearance of anti-prx antibodies and were inhibited significantly by blocking Toll-like receptor 4 (TLR4) signaling with a TLR4-specific inhibitory peptide. Clinically, the duration of fever (>7.5 C) in KD patients was significantly longer in the anti-prx positive group than in the anti-prx negative group. There was no significant difference in inflammatory markers such as white blood cell counts and C-reactive protein between both groups. Conclusion: IgG antibodies to Prx are expected to be useful markers for KD. Expression of endothelial adhesion molecules and inflammatory cytokine production are induced by the binding of anti-prx antibodies to Prx proteins on ECs, and by the activation of TLR4 by extracellular Prx proteins, which could result in endothelial injury. Furthermore, anti-prx antibodies may cause endothelial injury by inhibiting the anti-oxidative activity of intracellular Prx proteins. Disclosures: R. Karasawa, None. :0 am 646. Cost-Effectiveness Analysis of Triple Therapy Versus Etanercept Plus Methotrexate in Early Aggressive Rheumatoid Arthritis: Analysis Based on the TEAR Trial Hawre Jalal, University of Minnesota, Minneapolis, MN and Kaleb Michaud, National Data Bank for Rheumatic Diseases & :5 am University of Nebraska Medical Center, Omaha, NE 645. Pathological Roles of the Anti-Oxidative Enzyme Background/Purpose: The long-term cost-effectiveness Peroxiredoxin in Patients With Kawasaki Disease of triple therapy (methotrexate [MTX], sulfasalazine [SSZ], Rie Karasawa, Institute of Medical Science, St. Marianna hydroxychloroquine [HCQ]) disease modifying anti-rheumatic University School of Medicine, Kawasaki, Japan drugs (DMARDs) compared to a combination of MTX and anti- Background/Purpose: Anti-endothelial cell antibodies (AECA) TNF therapy in patients with early rheumatoid arthritis (RA) are autoantibodies that are detected frequently in vasculitis is unknown. In this study, we used patient-level data from the caused by, for example, Kawasaki disease (KD). However, AECA Treatment of Early Aggressive RA (TEAR) trial and the National target molecules have been poorly identified, which hampers Data Bank for Rheumatic Diseases (NDB) to evaluate the costeffectiveness our understanding of the roles of AECA. We aimed to detect of immediate combination therapy (with biologic target proteins of AECA comprehensively by proteomics and or non-biologic DMARDs) versus stepping up to combination investigate their clinical importance in patients with KD. therapy at 6 months if disease activity persists despite MTX monotherapy Program Book denotes Hilton San Diego Bayfront room location

111 Methods: We developed a Markov simulation model to estimate quality-adjusted life years (QALYs) and costs associated with the treatment strategies examined in the TEAR trial. We evaluated four strategies: immediate triple (IT), immediate etanercept (IE), step-up triple (ST), and step-up etanercept (SE). The step-up strategies involved switching those with persistent disease activity (DAS8 >=.) from MTX monotherapy to MTX plus either etanercept or triple therapy at 6 months. The simulation model extends the -year trial to the life-time horizon, using parameters taken from longitudinal NDB data for therapy discontinuation rates, HAQ transitions, and DAS8-HAQ- QALY mappings as well as the published literature for direct and indirect cost estimates. Annual discontinuation rates of triple therapy and etanercept from the NDB were estimated to be % and 0%, respectively. Those who discontinued were assumed to continue to receive methotrexate. Markov health states were defined by DAS8. DAS8 score transitions were obtained directly from individual patients in the trial. Death was modeled as an additional state with background mortality estimated from the 007 US Life Tables. HAQ scores were used as a secondary variable to estimate QALYs, RA-specific mortality, and direct and indirect costs (e.g., due to productivity loss). We assumed a -month cycle length, and discounted both costs and effectiveness by % annually. Results: The etanercept strategies (SE and IE) were more costly than the triple strategies (ST and IT) mainly due to treatment costs [Table]. The lifetime benefits from IT, ST and SE were numerically similar (within 0.06 QALYs). Although IE was more effective than IT, the incremental cost-effectiveness ratio (ICER) of IE relative to IT was $87,00/QALY. These results were robust to parametric sensitivity analyses. Conclusion: We used patient-level data from the TEAR trial, and then projected their lifetime costs and benefits using the NDB. The benefits from all strategies were comparable, but biologics strategies were almost twice more expensive than triple strategies, producing ICERs greater than what most healthcare settings find acceptable. Treatment Strategies Cost ($) Cost-Effectiveness Analysis of TEAR Strategies Effectiveness (QALY) Immediate Triple (IT) 5, Incremental Cost ($)* Incremental Effectiveness (QALY)* Step-up Triple (ST) 54, Step-up Etanercept (SE) Immediate Etanercept (IE) *Compared to IT 69, , ICER ($/QALY) Reference Strategy Excluded (dominated by IT, more effective) Excluded (dominated by IT, more effective) 8, , ,00 Disclosures: H. Jalal, None; K. Michaud, University of Nebraska Medical Center,, National Data Bank for Rheumatic Diseases,. :45 am 647. Recombinant Monoclonal Antibodies Derived From Single CD9+ Synovial B Cells of Rheumatoid Arthritis Patients With Tertiary Lymphoid Structures Display a Strong Immunoreactivity Towards Citrullinated Histones Elisa Corsiero, William Harvey Research Institute, QMUL, London, United Kingdom Background/Purpose: Rheumatoid arthritis (RA) is characterised by breach of self-tolerance towards citrullinated proteins. Around 40% of patients display synovial tertiary lymphoid structures (TLS) with functional B cell follicles supporting a germinal-centre response and local autoantibody production (). However, the nature of the main (auto)antigenic reactivity of synovial B cells is unknown. Here we characterized the autoreactive B cell response of lesional B cells isolated from TLS+ RA synovium. Methods: Single CD9+ B cells were FACS sorted from synovial cell suspension of 4 TLS+ RA patients. RNA was used to amplify Ig VH and VL genes and PCR products were cloned and expressed as recombinant monoclonal antibodies displaying identical specificity of the original B cells (). Recombinant antibodies were then tested ) to determine the frequency of polyreactive clones and ) to define their immunoreactivity towards native and citrullinated antigens using a synovial antigen microarray platform (). Results: We obtained 9 individual VH sequences of which % were IgM, 40% IgG, 7% IgA and 75 VL sequences and we generated a total of 66 complete (H+L chains) recombinant monoclonal antibodies. Analysis of the VH gene somatic mutation rate showed evidence of antigen selection and intrasynovial clonal diversification. No skewed distribution of the VH and VL gene usage was observed. Around 0% of synovial monoclonal antibodies were reactive towards citrullinated histones in the antigen microarray, in particular citha and cithb. This reactivity was confirmed by citha and cithb ELISA. Moreover, reactivity towards the citrullinated form of fibrinogen was observed. Conclusion: Here we provided novel evidence that highly mutated, locally differentiated B cells within RA synovial germinal centre-like structures display a strong immunoreactive bias towards citrullinated histones. This suggests that citrullinated histones are the main antigens driving in situ B cell activation and differentiation sustaining the humoral autoimmune response within the RA joints. References:. Humby F, Bombardieri M, Manzo A, Kelly S, Blades MC, Kirkham B, Spencer J, Pitzalis C. Ectopic lymphoid structures support ongoing production of class-switched autoantibodies in rheumatoid synovium. PLoS Med. 009 Jan ;6():e. Wardemann H, Yurasov S, Schaefer A, Young JW, Meffre E, Nussenzweig MC. Predominant autoantibody production by early human B cell precursors. Science. 00 Sep 5;0(568):74-7. Robinson WH, DiGennaro C, Hueber W, Haab BB, Kamachi M, Dean EJ, Fournel S, Fong D, Genovese MC, de Vegvar HE, Skriner K, Hirschberg DL, Morris RI, Muller S, Pruijn GJ, van Venrooij WJ, Smolen JS, Brown PO, Steinman L, Utz PJ. Autoantigen microarrays for multiplex characterization of autoantibody responses. Nat Med. 00 Mar;8():95-0. Disclosures: E. Corsiero, None. Noon 648. Characterization of Histidyl-tRNA Synthetase Specific Th Cell Response in Blood and Broncheoalveolar Lavage (BAL) of Myositis Patients Inka Albrecht, Karolinska University Hospital, Department of Medicine, Solna, Unit of Rheumatology, Stockholm, Sweden Background/Purpose: Idiopathic inflammatory myopathy is a rare chronic inflammatory disease that is associated with the presence of autoantibodies pointing to a contribution of adaptive immune responses to disease manifestation. One of the most frequent myositis-specific autoantibodies is raised against histidyl-trna synthetase (Jo). This autoantibody can be detected in 0% of myositis patients and is associated TUESDAY october 9, 0 denotes Hilton San Diego Bayfront room location 0 Program Book 09

112 TUESDAY october 9, 0 with interstitial lung disease (ILD). ILD may precede myositis symptoms implicating that the autoimmune reaction may start in the lungs. The release of Jo and fragments thereof into the extracellular milieu is believed to trigger both activation of T cells by antigen-presenting cells and influx of CCR5 expressing cells e.g. dendritic cells and Th lymphocytes. So far, there is only limited knowledge about Jo-reactive T cells in myositis patients. Methods: A candidate T cell epitope was predicted from the N-terminal part of the Jo- protein. In order to identify and characterize Jo antigen-specific Th cells, we stimulated peripheral blood (n=9) and BAL cells (n=) of myositis patients with either recombinant Jo protein or the aa peptide covering the predicted epitope. Subsequently, CD+CD4+T cells were analyzed for up-regulation of CD40L by flow cytometry at day 5. In addition, T cells were examined for effector functions by measuring expression of intracellular cytokines. Finally we compared the phenotype of T cells in blood and BAL (n=4) by staining for Th associated chemokine receptors. Results: Stimulation of cells from blood and BAL with Jo protein caused a high up-regulation of CD40L on CD + CD4 + T cells. Thus, Jo-specific CD4 + T cells can be detected in both blood and BAL fluid of myositis patients. Upon activation, Jo- specific T cells mainly show Th effector functions as evident by IFNg expression. Stimulation of cells with the aa peptide corresponding to our novel candidate T cell epitope also resulted in a high up-regulation of CD40L. Moreover, Jo-reactive T cells are highly enriched in the BAL fluid. Those antigen-specific T cells have a highly pronounced Th phenotype as around 60% produce IFNg in response to antigen stimulation compared to only 0% IFNg responders in the corresponding blood samples. Interestingly, BAL T cells were all (00%) positive for CXCR and CCR5, two chemokine receptors specifically expressed on Th cells. In contrast, CD4 + T cells derived from blood only showed 0% positivity for CCR5 and CXCR expression, respectively. Conclusion: In this study, we were able to demonstrate presence of Jo-reactive CD4+ T cells in inflammatory myopathies and thus provide evidence that those T cells do react with epitopes on this autoantigen. Jo reactive CD4 + T cells are also present in the lung and show here pronounced Th effector functions. Moreover, we were able to identify a novel T cell epitope of the histidyl-trna synthetase. This will open up new ways for studying disease mechanisms and might provide novel starting points for therapeutic intervention. Disclosures: I. Albrecht, None. :5 pm 649. Rituximab for The Treatment of IgG4-Related Disease: A Prospective Clinical Trial Mollie Carruthers, Massachusetts General Hospital, Boston, MA and John Stone, Massachusetts General Hospital, Harvard Medical School, Boston, MA Background/Purpose: IgG4-related disease (IgG4-RD) is a multiorgan, fibro-inflammatory disorder. An open label pilot trial of rituximab (RTX) in IgG4-RD conducted at twocentershas enrolled 9 of the targeted 0 patients. We report preliminary results on8 patientsfollowed for a minimum of one month. Methods: The trial was approved by institutional review boards at the Massachusetts General Hospital and Mayo Clinic. All patients had histopathologically-proven diagnoses of IgG4-RD, includingat least two out of the three major featuresoflymphoplasmacytic infiltrate, storiform fibrosis, and obliterative phlebitis AND immunoperoxidase staining >0 IgG4+ plasma cells per HPF and a >40% IgG4/IgG ratio.all patients had active disease, based on the IgG4-RD Responder Index (IgG4-RD RI). Patients were treated with RTX(000 mg) times two doses (days 0 and 5) but not treated with maintenance RTX. Patients received methylprednisolone 00 mg with each RTX dose. Trial visits were performed at,, 5, 6, 8, 0, and months after the first rituximab infusion. The primary outcome was defined by three measures: ) disease response (decrease of responder index of points from baseline); ) no disease flares before month 6; and, ) no glucocorticoids between months and 6. Complete remission was defined as an IgG4-RD RI disease activity score of zero. Results: The organ system involvement among patients in the trial spanned the full spectrum of IgG4-RD, including the orbits, salivary glands, hypopharynx, lungs, lymph nodes, pericardium, pancreas, biliary tree, retroperitoneum, kidney, prostate, and others. The mean IgG4-RD RI at baseline was.7 (range: 5 6). The mean serum IgG4 concentration was 54 mg/dl (normal < ; range: 4780), but patients (4%) had normal values at baseline. Prednisone was used concomitantly with RTX at baseline for remission induction in only of the 8 patients. Twenty-six of the 8 patients followed for at least one month and of 4 followed for three months achieved steroidfree achieved disease responses (9% and 9% at these two timepoints, respectively). Among the patients completing six months of follow-up to date, 0 (87%) have achieved the primary outcome. Only of the 8 patients required an increase in prednisone dose after Month. Two patients were hospitalized during the study, one for Legionnaire s disease (prebaseline infection) and the other for a cold agglutinin-mediated autoimmune hemolytic anemia. No serious adverse events related to rituximab were reported. Conclusion: Rituximab has promise as a safe, effective treatment for IgG4-RD.Excellent disease responses have been observed to date despite the absence of concomitant glucocorticoid use in this trial. Disclosures: M. Carruthers, None; J. Stone, None. ACR MEET THE PROFESSOR SESSIONS :45 - :5 pm Admission to Meet the Professor sessions requires a separate registration and ticket. To verify which session you registered for, the registration code on your ticket needs to match the -digit code in parentheses below. If you are interested in participating in one of these sessions or exchanging your ticket, visit the ACR registration desk to check space availability. View the session overview online in My Annual Meeting at www. ACRannualmeeting.org. * Sessions denoted with an asterisk were sold out as of August 0. Adult Inflammatory Myopathy (07) Speaker: Robert L. Wortmann, MD review the clinical manifestations of inflammatory myopathies including important extra-muscle manifestations discuss diagnostic pearls for the evaluation of someone suspected of having an inflammatory myopathy discuss the treatment paradigm for inflammatory myopathies CANCELLED 0 0 Program Book denotes Hilton San Diego Bayfront room location

113 Basic Immunology for Clinical Rheumatologists (07) Speaker: Antony Rosen, MD describe how the immune system functions in normal individuals identify abnormalities of immune regulation that lead to autoimmunity 6 A *Rheumatoid Arthritis: Biological Agents (077) Speaker: Edward Keystone, MD describe the newer trends in the use of biologics discuss the emerging biologics, including biosimilars, and their advantages for the therapeutic algorithm describe the risk/benefit profiles of biologic agents 4 A *Behçet s Disease (07) Speaker: Yusuf Yazici, MD discuss the epidemiology, disease mechanisms and the differential diagnosis of Behçet s syndrome describe current approaches to the management of patients with Behçet s syndrome 4 B *Infections With Biologics (074) Speaker: Kathryn H. Dao, MD discuss the risk of infection related to inflammation and disease discuss the risk factors for infection recognize the magnitude of risk imposed by steroids and biologics determine the approach to risk reduction (TB and SIE) 5 A Pediatrics: Difficult to Treat Juvenile Idiopathic Arthritis (075) Speaker: Thomas J. A. Lehman, MD discuss the differences in the treatment of the difficult situations for the different subtypes of juvenile idiopathic arthritis recognize some of the complications of the disease and appropriate management explain the difficulties posed by non-adherence and inadequate decision making 5 B *Psoriatic Arthritis (076) Speaker: M. Elaine Husni, MD, MPH discuss advances in diagnosis and classification of psoriatic arthritis determine if patients with psoriatic arthritis should be treated aggressively determine treatment options for patients with psoriatic arthritis 6 B *Rheumatoid Arthritis: Challenging Cases (078) Speaker: Jonathan Kay, MD discuss the management of patients with refractory rheumatoid arthritis identify novel treatment options for those failing conventional therapies create effective management plans for complicated rheumatoid arthritis patients 7 A *Systemic Lupus Erythematosus: Lupus Nephritis (079) Speaker: Brad H. Rovin, MD review immunosuppressive therapy of lupus nephritis Classes II-V, including novel biologics discuss the use of renoprotective and anti-proteinuria therapies in lupus nephritis discuss diagnosis and treatment of renal thrombotic microangiopathy and podocytopathies outline the future research agenda for clinical trials in lupus nephritis 7 B Vasculitis: Update (080) Speaker: Raashid A. Luqmani, DM describe the current definitions of vasculitis according to affected vessel size discuss the role of simple clinical evaluation alongside the various available laboratory and imaging tests, including antineutrophil cytoplasm antibodies identify current and novel therapeutic modalities ACR SESSIONS :00 - :00 pm 6 C Animal Models in Rheumatic Disease How Useful Are They? Moderator: Dana P. Ascherman, MD Speaker: William Ridgway, MD confirm animal models as tools to study mechanisms involved in organ-based as well as systemic autoimmune disease list the potential utility of animal models in the development of novel therapeutic strategies identify the limitations of animal models as replicates of human disease TUESDAY october 9, 0 denotes Hilton San Diego Bayfront room location 0 Program Book

114 TUESDAY october 9, 0 Ballroom 0 A Hench Lecture: Evolutionary Medicine and Chronic Inflammatory State - Known and New Concepts in Pathophysiology Moderator: Eric L. Matteson, MD, MPH Speaker: Rainer H. Straub, MD recall systemic neuroendocrine responses in chronic inflammatory diseases are tightly regulated along the circadian rhythm to allocate energy-rich fuels from stores to an activated immune system describe how the neuroendocrine immune network has been evolutionarily positively selected to serve short-lived inflammation but not long-standing inflammatory diseases role of antagonistic pleiotropy classify important systemic disease sequelae of chronic inflammatory diseases (metabolic syndrome, anemia, depression/fatigue etc) as consequence of long-standing misguided energy regulation explain how systemic neuroendocrine responses in chronic inflammatory diseases are part of etiology and diseaseaggravating per se Hall B Inflammatory Eye Disease: An Update for Rheumatologists Moderators: Shelly P. Kafka, MD and Margaret R. Wilkes, MD describe the basic anatomical structures of the eye discuss the pathogenesis and differential diagnosis of inflammatory ophthalmic diseases review potential treatment strategies for the patient with inflammatory eye disease :00 pm Inflammatory Eye Disease: A Comprehensive Review for Rheumatologists George Papaliodis, MD :0 pm Treatment of Inflammatory Eye Disease by the Rheumatologist Sergio Schwartzman, MD ACR STUDY GROUPS :00 - :00 pm :5 pm A Rheumatologic Protocol for Osteoporotic Fracture Management Colleen Watkins, MD :0 pm A Fracture Liaison Service in a Multi-Specialty Practice: Rheumatology and Orthopedics Linda K. Myers, MD :45 pm Cost Effectiveness of Fracture Liaison Services Daniel H. Solomon, MD, MPH A Antiphospholipid (APS) Study Group :00 pm Mechanisms of Adverse Pregnancy Outcomes in Women With Antiphospholipid Antibodies Vikke Abrahams, PhD :5 pm Update on Diagnosis and Management of Obstetric APS Ware Branch, MD :0 pm The Role of Tissue Factor in APS Nigel Mackman, PhD :45 pm Update on Standardization of Antiphospholipid Antibody Silvia S. Pierangeli, PhD 06 A Expert Journal Club Study Group :00 pm Self-criticism in Manuscript Preparation Theodore Pincus, MD :5 pm Selection Bias Samy Suissa, PhD :40 pm Measuring Effectiveness Theodore Pincus, MD C A Multi-Disciplinary Approach to Post Fracture Management Study Group :00 pm A Multi-Disciplinary Approach to Secondary Fracture Prevention: Park Nicollet Methodist Hospital John T. Schousboe, MD, PhD B Gout Classification Criteria Study Group :00 pm Systematic Literature Review of Imaging in Gout Nicola Dalbeth, MBChB, MD :5 pm Rheumatologists Competency in Crystal Diagnosis Tim L. Jansen, MD, PhD :50 pm Balancing Sensitivity and Specificity in Gout Classification Tuhina Neogi, MD, PhD 0 Program Book denotes Hilton San Diego Bayfront room location

115 Sapphire A Hypermobility Study Group :00 pm A Rheumatologist s Quick Guide to Genetic Testing in Hypermobility-Related Disorders Fransiska Malfait, MD, PhD :5 pm Prolapse, Sexual Problems and Incontinence in Femal Patients With Benign Joint Hypermobility Syndrome Heleni Mastoroudes, MBBS Indigo D Myositis Study Group :00 pm The History and Current Status of Classification Criteria for Adult and Juvenile Dermatomyositis and Polymyositis Ingrid E. Lundberg, MD, PhD :5 pm The History and Current Status of Classification Criteria for Inclusion Body Myositis Anthony A. Amato, MD :0 pm Hypermobility and the Complex Regional Pain Syndrome/ Fibromyalgia Syndrome/Chronic Fatigue Syndrome Overlap Helen Cohen, MD, PhD :45 pm Psychological Aspects of the Hypermobility Syndrome Carolina Baeza-Velasco, PhD 8 D Interstitial Lung Diseases (ILD) in Connective Tissue Disease Study Group :00 pm Treatment of Pulmonary Hypertension in Patients With ILD Aryeh Fischer, MD :5 pm The Role of Reflux and Aspiration in ILD Paul F. Dellaripa, MD :50 pm Clinical Use of Auto Antibodies in Myositis Masataka Kuwana, MD, PhD Indigo C Macrophage Activation Syndrome (MAS) Study Group :00 pm Development and Validation of Clinical Diagnostic Criteria for MAS Angelo Ravelli, MD :5 pm Perforin Mutations and Polymorphisms in Systemic Juvenile Idiopathic Arthritis and MAS Nico M. Wulffraat, MD, PhD :50 pm Open Discussion of Myositis Classification Criteria Frederick W. Miller, MD, PhD Sapphire I Non-Vasculitic Vasculopathy Study Group :00 pm Organ-Specific Pathology in Degos Disease and Similarity to Non-Vasculitic Rheumatic Vaculopathies Cynthia Magro, MD :0 pm The Genetics of Vascular Remodeling Manfred Boehm, MD :40 pm Linkage Analysis in Rare Vasculopathies Marc Lewis, PhD 9D Osteoarthritis Study Group 0 A Spondyloarthritis Study Group :00 pm Chronic Low Back Pain in the U.S.: Economic and Clinical Impact Michael H. Weisman, MD :5 pm Inflammatory Back Pain in the U.S. John D. Reveille, MD :50 pm Spondylarthritis Martin Rudwaleit, MD TUESDAY october 9, 0 :0 pm IL-6 in the Development of MAS Fabrizio De Benedetti, MD, PhD :45 pm Novel Degranulation Assays for the Diagnosis of MAS Yenan Bryceson, PhD 8 B Takayasu s Arteritis Study Group :00 pm Core Disease Domains to be Measured in Takayasu s Arteritis Sibel Z. Aydin, MD :5 pm Utility of Current Composite Measures for Takayasu s Arteritis Haner Direskeneli, MD denotes Hilton San Diego Bayfront room location 0 Program Book

116 :0 pm Utility of Magnetic Resonance Imaging and Positron Emission Tomography as Outcome Measure in Takayasu s Arteritis Daniel Blockmans, MD, PhD :45 pm Clinical Trial Design Options in Takayasu s Arteritis Peter A. Merkel, MD, MPH ACR WORKSHOPS :5 - :5 pm ACR SESSION :0 - :00 pm 6 A ACR Business Meeting This session is not eligible for CME credit. Moderator: Audrey B. Uknis, MD ACR, Foundation and ARHP Updates Election of ACR Treasurer Admission to Workshops requires a separate registration and ticket. To verify which session you registered for, the registration code on your ticket needs to match the -digit code in parentheses below. If you are interested in participating in one of these sessions or exchanging your ticket, visit the ACR registration desk to check space availability. View the session overview online in My Annual Meeting at www. ACRannualmeeting.org. * Sessions denoted with an asterisk were sold out as of August 0. Joint Injection Techniques (7) Speakers: Atul A. Deodhar, MD and Kenneth S. O Rourke, MD discuss indications and contraindications for joint aspirations and injections identify and avoid common mistakes in joint injection procedures perform common joint and soft tissue injections on upper and lower extremities Election of ACR Board of Director Members Installation of 77th ACR President ACR SESSIONS :0-4:00 pm 6 D Adipose Tissue and Inflammation Moderator: John Varga, MD describe the biologic mechanisms linking adipose tissue and inflammation define the mechanisms for adipose tissue modulation of inflammatory cell activity distinguish the features of metabolic regulation of macrophage function :0 pm Inflammation, Metabolic Syndrome and Obesity Jerrold M. M. Olefsky, MD TUESDAY october 9, 0 A B Osteoporosis: Interpreting Dual Energy X-ray Absorptiometry and Clinical Risk Factors: The New Fracture Risk Assessment Algorithm (8) Speaker: Stuart L. Silverman, MD use bone mineral density and clinical risk factors in determination of absolute risk of fracture discuss the concept of intervention threshold address limitations of FRAX in clinical practice Renal Histopathology in Systemic Lupus Erythematosus and Vasculitis (9) Speaker: Anthony Chang, MD identify the pathologic changes that occur in lupus nephritis discuss the pathologic basis for the classification of lupus nephritis and how it relates to clinical management describe the histological changes in the kidneys of patients with vasculitis :00 pm Obesity and Metabolic Regulation of Macrophages Anthony W. Ferrante, Jr., MD, PhD :0 pm Metabolic Regulation of Innate Immunity Ajay Chawla, MD, PhD Indigo E Novel Insight into the Pathogenesis of Systemic Vasculitis Moderator: Rula Hajj-Ali, MD examine recent advances in the pathogenesis of small and large vessel vasculitis describe the role of the adaptive and innate immune system in the pathogenesis of small and large vessel vasculitis define the role of genetic, epigenetic and environmental factors in the pathogenesis of small and large vessel vasculitis :0 pm Pathogenesis of Small Vessel Vasculitis Ronald Falk, MD :5 pm Pathogenesis of Large Vessel Vasculitis Cornelia M. Weyand, MD, PhD 4 0 Program Book denotes Hilton San Diego Bayfront room location

117 Hall B Osteoporosis Treatment Strategies for Today and Tomorrow Moderator: Margaret R. Wilkes, MD describe current data regarding bisphosphonate therapy and calcium supplementation and adverse events evaluate the evidence and best data supporting duration of bisphosphonate therapy for treatment osteoporosis review medications associated with drug induced bone loss and develop treatment strategies for managing osteoporosis in patients on these agents identify potential new therapies for treatment of osteoporosis :0 pm Calcium, Vitamin D & Bisphosphonates Benefits, Risks and Drug Holidays Michael McClung, MD :00 pm Medication Induced Osteoporosis: Clinical Implications for the Rheumatologist Mary Beth Humphrey, MD, PhD :0 pm Osteoporosis Treatments on the Horizon Michael J. Maricic, MD Ballroom 0 A Vaccinology and DMARD Use in Immunocompromised and High-Risk Populations Moderators: Leonard H. Calabrese, DO and Jasvinder A. Singh, MD, MPH describe the data supporting related to vaccination in rheumatoid arthritis patients explain the impact of biologic and synthetic DMARDs on vaccine response in patients with rheumatic diseases decreases the risk of cardiac disease in rheumatoid arthritis assess the safety and risks of use of biologic DMARDs in reproductive issues and during pregnancy and lactation :0 pm Biologics During Pre-conception, Pregnancy and Lactation Eliza F. Chakarvarty, MD :00 pm The Impact of DMARD (biologic and non-biologic) Therapy on Vaccine Responses in Rheumatic Disease: Implications for Practice Jeffrey R. Curtis, MD, MPH, MS :0 pm Vaccination in Immunocompromised Patients in 0: What Does the Evidence Tell Us? Kevin L. Winthrop, MD, MPH ACR CONCURRENT ABSTRACT SESSIONS :0-4:00 pm 6 A Late-breaking Abstracts Session Moderator: Chester V. Oddis, MD Indigo D Antiphospholipid Syndrome Moderators: Pier Luigi Meroni, MD and Joyce Rauch, PhD :0 pm 650. Silent Ischemic Heart Disease in Patients With Primary Antiphospholipid Syndrome Antonio R. Cabral, Gregoria Gómez-Hernández, Martha Morelos-Guzmán, Tatiana Rodriguez-Reyna 4, Carlos Alberto Núñez-Alvarez 5 and Jorge Vazquez-Lamadrid, Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubirán, Mexico, Mexico, Instituto Nacional De Ciencias Médicas y Nutrición Salvador Zubirán, Mexico, Mexico, Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico, 4 National Institute of Medical Sciences and Nutrition, Mexico City, Mexico, 5 Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico :45 pm 65. The Association Between Antiphospolipid Antibodies and Related Clinical Outcomes: A Critical Review of The Literature Cecilia B. Chighizola, Laura Andreoli, Alessandra Banzato, Guilherme Ramires de Jesus 4, Guillermo J. Pons-Estel 5, Doruk Erkan 6 and On Behalf of APS Action 7, Istituto Auxologico Italiano, University of Milan, Cusano Milanino, Italy, Rheumatology Unit, University of Brescia, Brescia, Italy, Department of Cardiac Thoracic and Vascular Sciences, University of Padua, Padua, Italy, 4 Department of Obstetrics, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil, 5 Department of Autoimmune Diseases, Institut Clìnic de Medicina i Dermatologia, Hospital Clìnic, Barcelona, Spain, 6 Hospital for Special Surgery, New York, NY, 7 APS ACTION, New York, NY :00 pm 65. Ovarian Reserve in Women With Primary Antiphospholipid Syndrome Lucas Yamakami, Paulo Serafini, Daniel B. Araujo, Eloisa Bonfá 4, Elaine P. Leon 4, Edmund C. Baracat 4 and Clovis A. Silva 5, Faculdade de Medicina da Universidade de São Paulo, Sao Paulo, Brazil, MD; PhD, Sao Paulo, Brazil, Faculdade de Medicina da Universidade de São Paulo (FMUSP), São Paulo, Brazil, 4 Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, 5 University of São Paulo, São Paulo, Brazil :5 pm 65. Low Vitamin D Is Associated With Increased Risk of Venous Thrombosis in Systemic Lupus Erythematosus, Regardless of Lupus Anticoagulant Status Michelle Petri and Hong Fang, Johns Hopkins University School of Medicine, Baltimore, MD TUESDAY october 9, 0 denotes Hilton San Diego Bayfront room location 0 Program Book 5

118 TUESDAY october 9, 0 :0 pm 654. IgG Antibodies Directed Against Domain I of ß- Glycoprotein I Are Significant Predictors of Thromboembolic Events In Patients With Antiphospholipid Antibodies. A Prospective Cohort Study Stephane Zuily, Bas de Laat, Francis Guillemin, Pierre Kaminsky 4, Hilde Kelchtermans 5, Roger Albesa 6, Gary L. Norman 6, Anne-Christine Rat 7, Philip de Groot 8, Thomas Lecompte 9, Veronique Regnault 0 and Denis Wahl, CHU de Nancy, Vascular Medicine Division and Regional Competence Center For Rare Vascular And Systemic Autoimmune Diseases, Nancy, F-54000, France; Inserm, UMR_S 6, Nancy, F-54000, France; Université de Lorraine, Nancy, F-54000, France, Nancy, France, Biochemistry, CARIM, Maastricht University, The Netherlands; Clinical Chemistry and Hematology, UMC Utrecht, The Netherlands; Synapse BV, Maastricht, The Netherlands; Sanquin Research, Amsterdam, The Netherlands, Maastricht, Netherlands, CHU Nancy, Clinical Epidemiology and Evaluation, Université de Lorraine, Paris Descartes University, APEMAC, EA 460, Nancy, France, 4 Université de Lorraine, Nancy, F-54000, France; CHU de Nancy, Orphan disease unit, Nancy, F-54000, France;, Nancy, France, 5 Biochemistry, CARIM, Maastricht University, The Netherlands; Synapse BV, Maastricht, The Netherlands, Maastricht, Netherlands, 6 INOVA Diagnostics, San Diego, CA, 7 Université de Lorraine, Nancy, F-54000, France; Inserm, CIC-EC CIE6, Nancy, F-54000, France; CHU de Nancy, Clinical Epidemiology and Evaluation Department, Nancy, F-54000, France; CHU de Nancy, Rheumatology department, Nancy, France, 8 Clinical Chemistry and Hematology, UMC Utrecht, The Netherlands, Utrecht, Netherlands, 9 Inserm, UMR_S 6, Nancy, F-54000, France; Université de Lorraine, Nancy, F-54000, France; CHU de Nancy, Haematology Laboratory, Nancy, F-54000, France; Division of Haematology, HUG, Geneva, Switzerland (current address), Geneva, Switzerland, 0 Inserm, UMR_S 6, Nancy, F-54000, France; Université de Lorraine, Nancy, F-54000, France; CHU de Nancy, Contrat d interface, Nancy, F-54000, France, Nancy, France :45 pm 655. Therapeutic Effect of βgpi and Its Synthetic derivative Loaded Tolerogenic Dendritic Cells in Experimental Antiphospholipid Syndrome, is Associated With mirna b, 4-p and Expression and Tregs Upregulation Miri Blank, Silvia S. Pierangeli, Honorio Torres-Aguilar and Yehuda Shoenfeld 4, Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center, Tel-Hashomer, affiliated to Sackler Medical School, Tel Aviv University, Ramat Gan, Israel, University of Texas Medical Branch, Galveston, TX, National Center for Blood Transfusion, Mexico City, Mexico, 4 Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center, Affiliated to Sackler Faculty of Medicine, Tel-Aviv University,Tel- Aviv, Tel-Aviv, Israel 8 B Epidemiology and Health Services Research VI: Risk Factors in Rheumatic Disease Susceptibility Moderators: Diane V. LaCaille, MD and Laura L. Tarter, MD :0 pm 656. Performance of Prediction Models for Rheumatoid Arthritis Serologic Phenotypes Among Women Using Family History, Genetics and Environmental Factors Jeffrey A. Sparks, Chia-Yen Chen, Xia Jiang, Linda T. Hiraki 4, Lars Klareskog 5, Lars Alfredsson, Karen H. Costenbader and Elizabeth W. Karlson, Brigham and Women s Hospital, Harvard Medical School, Boston, MA, Harvard School of Public Health, Boston, MA, Karolinska Institutet, Stockholm, Sweden, 4 Brigham and Women s Hospital, Harvard School of Public Health, Boston, MA, 5 Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden :45 pm 657. Interactions Between Cigarette Smoking, Body Mass Index and Inflammatory Cytokine Levels in Determining the Risk of Developing Rheumatoid Arthritis Elizabeth V. Arkema, Susan Malspeis, Bing Lu, Linda T. Hiraki, Elizabeth W. Karlson 4 and Karen H. Costenbader 5, Harvard School of Public Health, Boston, MA, Brigham and Women s Hospital, Boston, MA, Brigham and Women s Hospital, Harvard School of Public Health, Boston, MA, 4 Brigham and Women s Hospital, Harvard Medical School, Boston, MA, 5 Division of Rheumatology, Immunology and Allergy, Brigham and Women s Hospital, Harvard Medical School, Boston, MA :00 pm 658. Dipeptidyl Peptidase-4 Inhibitors in Type Diabetes May Reduce The Risk of Autoimmune Diseases Seoyoung C. Kim, Sebastian Schneeweiss, Robert J. Glynn, Michael Doherty, Allison Goldfine and Daniel H. Solomon, Brigham and Women s Hospital, Boston, MA, Joslin Diabetes Center, Boston, MA, Harvard Medical School, Brigham and Women s Hospital, Division of Rheumatology, Division of Pharmacoepidemiology, Boston, MA :5 pm 659. Antibodies to Citrullinated Enolase, Fibrinogen, and Vimentin Are Associated With Markerso Endothelial Dysfunction in First-Degree Relatives of Patients With Rheumatoid Arthritis: The Studies of the Etiology Of Rheumatoid Arthritis Jan M. Hughes-Austin, Kendra A. Young, Kevin D. Deane, Michael H. Weisman 4, Jane H. Buckner 5, Ted R. Mikuls 6, James R. O Dell 7, Richard M. Keating 8, Peter K. Gregersen 9, Jeremy Sokolove 0, William H. Robinson, V. Michael Holers and Jill M. Norris, University of California, San Diego, La Jolla, CA, Colorado School of Public Health, Aurora, CO, University of Colorado School of Medicine, Aurora, CO, 4 Cedars-Sinai Med Ctr, Los Angeles, CA, 5 Benaroya Research Institute, Seattle, WA, 6 Omaha VA and University of Nebraska Medical Center, Omaha, NE, 7 University of Nebraska Medical Center, Omaha, NE, 8 The University of Chicago, Chicago, IL, 9 Feinstein Institute for Medical Research, Manhasset, NY, 0 VA Palo Alto Health Care System and Stanford University, Palo Alto, CA, Stanford University School of Medicine, Stanford, CA 6 0 Program Book denotes Hilton San Diego Bayfront room location

119 :0 pm 660. Omega- Supplement Use Is Associated With a Reduced Risk of Anti-Cyclic Citrullinated Protein Positivity in a Population Without Rheumatoid Arthritis, But At Risk for Future Disease Ryan W. Gan, Kendra A. Young, Gary O. Zerbe, M. Kristen Demoruelle, Michael H. Weisman 4, Jane H. Buckner 5, Peter K. Gregersen 6, Ted R. Mikuls 7, James R. O Dell 8, Richard M. Keating 9, Michael J. Clare-Salzler 0, Kevin D. Deane, V. Michael Holers and Jill M. Norris, Colorado School of Public Health, Aurora, CO, Colorado School of Public Health / University of Colorado Anschutz Medical Campus, Aurora, CO, University of Colorado School of Medicine, Aurora, CO, 4 Cedars-Sinai Medical Center, Los Angeles, CA, 5 Benaroya Research Institute, Seattle, WA, 6 Feinstein Institute for Medical Research, Manhasset, NY, 7 Omaha VA and University of Nebraska Medical Center, Omaha, NE, 8 University of Nebraska Medical Center, Omaha, NE, 9 The University of Chicago, Chicago, IL, 0 University of Florida, College of Medicine, Gainesville, FL :45 pm 66. Physical Activity, Adiposity, and the Risk of Gout in Women: The Nurses Health Study Hyon K. Choi, Lindsay C Burns, Yuqing Zhang, Sharan Rai and Gary Curhan 4, Arthritis Research Centre of Canada, Richmond, BC, University of British Columbia, Vancouver, BC, Boston University School of Medicine, Boston, MA, 4 Harvard Medical School, Boston, MA 8 D Health Services Research, Quality Measures and Quality of Care - Innovations in Health Care Delivery Moderators: Salahuddin Kazi, MD and Jinoos Yazdany, MD, MPH :0 pm 66. Quality of Care Predicts Disease Outcomes Among Patients With Systemic Lupus Erythematosus Jinoos Yazdany, Laura Trupin, Patricia P. Katz, Gabriela Schmajuk and Edward H. Yelin, University of California, San Francisco, San Francisco, CA, UC San Francisco, San Francisco, CA :45 pm 66. Moving Towards Personalized Healthcare: A Patient Reported Outcome Based Algorithm Can Aid Rheumatologists and Patients in Monitoring Rheumatoid Arthritis in Daily Clinical Practice Jos Hendrikx, Jaap Fransen, Alessandro Toniolo and Piet L.C.M. van Riel, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, Pfizer Pharmaceuticals, Rome, Italy :00 pm 664. Evaluation of Osteoporosis Medication Starts in Patients Based on T-Score and FRAX Absolute Fracture Risk Model in a Large Health Care System Robert A. Overman and Chad L. Deal, Cleveland Clinic, Cleveland, OH denotes Hilton San Diego Bayfront room location :5 pm 665. Efficiency Gains for Rheumatology Consultation From an Electronic Referral System in a Safety Net Health System Meghan M. Scheibe, John B. Imboden, Gabriela Schmajuk, Mary Margaretten, Jonathan D. Graf, Alice Chen, Edward H. Yelin and Jinoos Yazdany, California Pacific Medical Center, San Francisco, CA, University of California, San Francisco, San Francisco, CA :0 pm 666. Implementing a Personalized Health Plan to Improve Therapeutic Outcomes in Veterans With Gout Astrud Lorraine Leyva, Una E. Makris and Salahuddin Kazi, UT Southwestern Medical Center, Dallas, TX, UT Southwestern Medical Center, VA Medical Center, Dallas, TX :45 pm 667. Fast-Track Pathway in Giant Cell Arteritis: A Cost- Effectivenss Analysis Katerina Achilleos, Pravin Patil, Win Win Maw, Laura Bown, David Halsall, Charles Dobson, Christian Dejaco, Frances Borg, Sunil Gupta and Bhaskar Dasgupta, Southend University Hospital, Westcliff-on-sea, United Kingdom, National Health Service England, Leeds, United Kingdom, Clinical Commissioning Group, Southend-on-sea, United Kingdom 06 A Osteoarthritis I: Therapeutics in Osteoarthritis Moderators: Tuhina Neogi, MD, PhD and Martin Englund, MD, PhD :0 pm 668. A Randomized, Double-Blind, Dose Ranging Study Comparing FX006, an Intra-Articular (IA) Sustained-Release Formulation of Triamcinolone Acetonide (TCA), to an Approved Injectable Suspension of TCA in Patients With Osteoarthritis (OA) of the Knee Neil Bodick, Joelle Lufkin, Christina Willwerth, Pierre Lachance, Gregory Jasey, Anil Gupta 4, Anthony Chris 5, Marc Russo 6, Michael O Mahony 7, Sam Henein 8, Louise Murdoch 9, Ferdinandus de Looze 0, David Hunter and Michael Clayman, Flexion Therapeutics, Burlington, MA, Clinique St-Louis (Recherche) Inc, Quebec, QC, North Walkerville Orthopaedic Associates, Windsor, ON, 4 Anil K. Gupta Medicine Professional Corporation, Toronto, ON, 5 Aim Health Group, Waterloo, ON, 6 Hunter Clinical Research, Broadmeadow, Australia, 7 London Road Diagnostic Clinic and Medical Centre, Sarnia, ON, 8 SKDS Research Inc., Newmarket, ON, 9 Emeritus Research, Malvern East, Australia, 0 AusTrials Pty Limited, Sherwood, Australia, Royal North Shore Hospital, St. Leonards, Australia :45 pm 669. Treatment of Knee Osteoarthritis Patients With Strontium Ranelate Reduces the Loss of Cartilage Volume and Bone Marrow Lesions as Assessed By Magnetic Resonance Imaging: Data From the Phase III Strontium Ranelate Efficacy in Knee Osteoarthrtis Trial Johanne Martel-Pelletier, Camille Roubille, Jean-Pierre Raynauld, François Abram, Marc Dorais, Philippe Delorme and Jean-Pierre Pelletier, Osteoarthritis Research Unit, University of Montreal Hospital Research Centre (CRCHUM), Montreal, QC, Imaging Research & Development, ArthroLab Inc., Montreal, QC, StatSciences Inc., Notre-Dame de l Île Perrot, QC 0 Program Book 7 TUESDAY october 9, 0

120 TUESDAY october 9, 0 :00 pm 670. Does Change in Femorotibial Cartilage Thickness Differ Between Acutely Anterior-Cruciate Ligament Injured Knees Treated With and Without Reconstructive Surgery Wolfgang Wirth, Felix Eckstein, Martin Hudelmaier, Stefan Lohmander and Richard Frobell, Paracelsus Medical University, Salzburg, Austria, Department of Orthopedics, Clinical Sciences Lund, Lund University, Lund, Sweden, Lund University, Lund, Sweden :5 pm 67. The Relationship Between Toe-Out Angle During Walking and Risk of Medial Knee Osteoarthritis Incidence: The Multicenter Osteoarthritis Study K. Douglas Gross, Yuqing Zhang, Emily K. Quinn, Michael C. Nevitt, Neil A. Segal 4, Cora E. Lewis 5 and David T. Felson, Boston University, Boston, MA, Boston University School of Medicine, Boston, MA, University of California, San Francisco, San Francisco, CA, 4 University of Iowa, Iowa City, IA, 5 University of Alabama, Birmingham, Birmingham, AL :0 pm 67. Associations Between Popliteal Artery Wall Thickness and Knee Structure in Adults Without Clinical Knee Disease: A Prospective Cohort Study Yuanyuan Wang, Diaz Novera, Anita Wluka, Jessica Fairley, Graham Giles, Richard O Sullivan, Andrew Teichtahl and Flavia Cicuttini 4, Monash University, Melbourne, Australia, University of Melbourne, Melbourne, Australia, Epworth Hospital, Melbourne, Australia, 4 Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, 004, Australia :45 pm 67. Mortality in Clinically Relevant Osteoarthritis and Rheumatoid Arthritis Compared With the General Population Aleksandra Turkiewicz, Tuhina Neogi, George Peat and Martin Englund, Department of Orthopedics, Clinical Sciences Lund, Lund University, Lund, Sweden, Boston University School of Medicine, Boston, MA, Research Institute for Primary Care & Health Sciences, Keele University, Keele, United Kingdom Sapphire A Pediatric Rheumatology - Clinical and Therapeutic Aspects III: Systemic Lupus Erythematosus and Other Disease Outcomes Moderators: Emily von Scheven, MD and Ricardo A. G. Russo, MD :0 pm 674. Vitamin D Deficiency is Common and Associated With Increased C-Reactive Protein in Children With Lupus: An Atherosclerosis Prevention in Pediatric Lupus Erythematosus Substudy Angela B. Robinson, Vin Tangpricha, Eric Yow, Reut Gurion, Grace McComsey and Laura E. Schanberg 4, Rainbow Babies and Children s Hospital / Case Medical Center, Cleveland, OH, Emory University School of Medicine, Atlanta, GA, Duke Clinical Research Institute, Durham, NC, 4 Duke University Medical Center, Durham, NC :45 pm 675. Phase Trial on Triptorelin for Ovary Protection In Childhood-Onset Systemic Lupus Erythematosus Rina Mina, Andreas Reiff, Clovis A. Silva, Patricia Vega Fernandez 4, Gloria C. Higgins 5, Lisa F. Imundo 6, Marisa S. Klein- Gitelman 7, Calvin Williams 8, Carol A. Wallace 9, Nadia E. Aikawa 0, Shannen L. Nelson, Jun Ying, Susan R. Rose and Hermine I. Brunner 4, Cincinnati Children s Hospital Medical Center/ University of Cincinnati School of Medicine, Cincinnati, OH, Children s Hospital Los Angeles, Los Angeles, CA, Faculdade de Medicina da Universidade de São Paulo, Sao Paulo, Brazil, 4 Cincinnati Children s Hospital Medica Center, CINCINNATI, OH, 5 Nationwide Childrens Hosp, Columbus, OH, 6 Morgan Stanely Children s Hospital of New York-Presbyterian, Columbia University Medical Center, New York, NY, 7 Children s Memorial Hospital, Chicago, IL, 8 Medical College of Wisconsin, Milwaukee, WI, 9 Seattle Childrens Hosp & Research Institute, Seattle, WA, 0 Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil, Cincinnati Children s Hospital Medical Center, Cincinnati, OH, University of Cincinnati, Cincinnati, OH, Cincinnati Children s Hospital Medical Center, Cincinnati, OH, 4 PRCSG, Cincinnati, OH :00 pm 676. Increased Pulse Wave Velocity in Juvenile Idiopathic Arthritis Patients Compared to Controls From the General Population Hanne A. Aulie, Anne Marit Selvaag, Vibke Lilleby, Oyvind Molberg, Anders Hartmann, Hallvard Holdaas and Berit Flato, Department of Rheumatology, Oslo University Hospital, Rikshospitalet, Oslo, Norway, Department of Nephrology (and specialised Endocrinology), Oslo University Hospital, Rikshospitalet, Oslo, Norway :5 pm 677. Disease Progression into Adulthood in Patients With Juvenile Idiopathic Arthritis A Longitudinal 0 Year Follow-Up Study Anne Marit Selvaag, Hanne Aulie, Vibke Lilleby and Berit Flatø, Department of Rheumatology, Oslo University Hospital, Rikshospitalet, Oslo, Norway :0 pm 678. Medically Significant Infections Are Increased in Patients With Juvenile Idiopathic Arthritis Treated With Etanercept. Results From the British Society for Paediatric and Adolescent Rheumatology Etanercept Cohort Study Rebecca Davies, Taunton R. Southwood, Lianne Kearsley-Fleet, Mark Lunt, Kimme L. Hyrich and on Behalf Of The BSPAR Etanercept Cohort Study, Arthritis Research UK Epidemiology Unit, University of Manchester, Manchester, United Kingdom, Institute of Child Health, University of Birmingham and Birmingham Children s Hospital, Birmingham, United Kingdom, Arthritis Research UK Epidemiology Unit, Manchester Academic Health Sciences Centre, Institute of Inflammation and Repair, The University of Manchester, Manchester, United Kingdom 8 0 Program Book denotes Hilton San Diego Bayfront room location

121 :45 pm 679. Incidence Rates of Serious Infections and Infection Subtypes Among Pediatric Systemic Lupus Erythematosus Patients Enrolled in Medicaid, According to Medication Use Linda T. Hiraki, Candace H. Feldman, Mary Beth Son, Jessica M. Franklin 4, Michael A. Fischer 4, Daniel H. Solomon 5, Seoyoung C. Kim 6, Wolfgang C. Winkelmayer 7 and Karen H. Costenbader 8, Brigham and Women s Hospital, Harvard School of Public Health, Boston, MA, Division of Rheumatology, Immunology and Allergy, Brigham and Women s Hospital, Harvard Medical School, Boston, MA, Children s Hospital Boston, Boston, MA, 4 Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women s Hospital, Boston, MA, 5 Harvard Medical School, Brigham and Women s Hospital, Division of Rheumatology, Division of Pharmacoepidemiology, Boston, MA, 6 Brigham and Women s Hospital, Boston, MA, 7 Stanford University School of Medicine, Stanford, CA, 8 Brigham and Women s Hospital, Harvard Medical School, Boston, MA A Rheumatoid Arthritis - Clinical Aspects IV: Comorbidities in Rheumatoid Arthritis Moderators: Paul F. Dellaripa, MD and Loreto Carmona, MD, PhD :0 pm 680. Risk of Subsequent Infection Among Rheumatoid Arthritis Patients Using Biologics Huifeng Yun, Fenglong Xie, Elizabeth S. Delzell, Lang Chen, Emily Levitan, James Lewis, Kenneth G. Saag, Timothy Beukelman, Kevin L. Winthrop, John Baddley, Paul M. Muntner and Jeffrey R. Curtis, University of Alabama at Birmingham, Birmingham, AL, University of Pennsylvania, Philadelphia, PA, Oregon Health & Science University, Portland, OR :45 pm 68. Reduced Fertility in Women With Rheumatoid Arthritis: Influence of Disease Activity and Medication Use Jenny Brouwer, Johanna MW Hazes, Joop SE Laven and Radboud JEM Dolhain, Erasmus University Medical Center, Rotterdam, Netherlands :00 pm 68. Incidence Trends and Predictors of Orthopedic Surgery in Patients With Rheumatoid Arthritis Results From a Well Defined Population Korosh Hekmat, Lennart Jacobsson, Jan-Åke Nilsson, Minna Willim, Martin Englund, Ingemar F. Petersson and Carl Turesson, Lund University, Malmö, Sweden, Lund University, Lund, Sweden, Musculoskeletal Scienes, Department of Orthopedics, Clinical Sciences, Lund, Sweden :5 pm 68. Application of a Multi-Biomarker Disease Activity (Vectra DA) Score for Assessing Rheumatoid Arthritis Patients With Fibromyalgia or Low C-Reactive Protein Yvonne C. Lee, James Hackett, Claire Alexander, Michelle A. Frits, Christine K. Iannaccone, Nancy A. Shadick, Michael E. Weinblatt, Oscar Segurado and Eric H. Sasso, Brigham and Women s Hospital, Boston, MA, Hackett & Associates, Inc., San Diego, CA, Crescendo Bioscience Inc., South San Francisco, CA denotes Hilton San Diego Bayfront room location 6 C :0 pm 684. Impact of Anti-Rheumatic Treatment on Immunogenicity of Pandemic HN Influenza Vaccinein Patients With Arthritis Meliha C. Kapetanovic, Lars-Erik Kristensen, Tore Saxne, Teodora Aktas 4, Andreas Mörner 4 and Pierre Geborek, Dept of Clinical Sciences Lund, Section of Rheumatology, Lund University, Lund, Sweden, Department of Clinical Sciences, Section of Rheymatology, University Hospital of Skåne, Lund, Sweden, Lund University, Lund, Sweden, 4 Vaccinology Unit, Department of Diagnostics and Vaccinology, Swedish Institute for Communicable Disease Control, Solna, Sweden., Solna, Sweden :45 pm 685. Anti-Peptidylarginine Deiminase /4 Cross-Reactive Antibodies Are Associated With Radiographic Interstitial Lung Disease in Rheumatoid Arthritis, an Effect Potentiated By Smoking Jon T. Giles, Erika Darrah, Sonye K. Danoff, Cheilonda Johnson, Felipe Andrade, Antony Rosen and Joan M. Bathon 4, Columbia University, College of Physicians & Surgeons, New York, NY, Johns Hopkins University, Baltimore, MD, Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, 4 Columbia University, New York, NY Rheumatoid Arthritis Treatment - Small Molecules, Biologics and Gene Therapy: Novel Treatment Strategies in Rheumatoid Arthritis Moderators: Gerd R Burmester, MD and Arthur Kavanaugh, MD :0 pm 686. Impact of Methotrexate Dose Reduction Upon Initiation of Adalimumab on Clinical and Ultrasonographic Parameters in Patients With Moderate to Severe Rheumatoid Arthritis Gurjit S. Kaeley, Amy M. Evangelisto, Midori Jane Nishio, Shufang Liu 4 and Hartmut Kupper 5, University of Florida, Jacksonville, FL, Arthritis, Rheumatic and Back Disease Associates, Voorhees, NJ, Diablo Clinical Research, Walnut Creek, CA, 4 AbbVie Inc., North Chicago, IL, 5 AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany :45 pm 687. Very High Remission Rates Are Achieved By Methotrexate and Intraarticular Glucocorticoids Independent of Induction Therapy With Adalimumab; Year Clinical Results of an Investigator-Initiated Randomised, Controlled Clinical Trial of Early, Rheumatoid Arthritis (OPERA) Kim Hørslev-Petersen, Merete L. Hetland, Peter Junker, Jan Pødenphant 4, Torkell Ellingsen 5, Palle Ahlqvist 6, Hanne M. Lindegaard 7, Asta Linauskas 8, Annette Schlemmer 9, Mette Y. Dam 0, Ib Hansen, Tine Lottenburger 6, Anette Jørgensen 0, Sophine B. Krintel, Johnny Raun, Christian G. Ammitzbøll 0, Julia Johansen, Mikkel Østergaard and Kristian Stengaard- Pedersen 0, University of Southern Denmark, Graasten, Denmark, DANBIO, Center for Rheumatology and Spine Diseases, Glostrup Univ Hospital, Glostrup, Denmark, University of Southern Denmark, Odense, Denmark, 4 Copenhagen University at Gentofte, Hellerup, Denmark, 5 Silkeborg Regional Hospital, Silkeborg, Denmark, 6 University of Southern Denmark, Vejle, Denmark, 7 Odense University Hospital, Odense, Denmark, 8 Vendsyssel Hospital, Hjørring, Denmark, 9 Aalborg University 0 Program Book 9 TUESDAY october 9, 0

122 Hospital, Aalborg, Denmark, 0 Arhus University Hospital, Aarhus, Denmark, Viborg Hospital, Viborg, Denmark, Copenhagen University and Glostrup Hospital, Copenhagen, Denmark, Copenhagen University Hospital Glostrup, Copenhagen, Denmark Monaco, France, 8 University Hospital of Poitiers, Poitiers, France, 9 Nantes University Hospital, Nantes, France, 0 Centre Hospitalier Général de Belfort, Belfort, France, Bicêtre University Hospital, Le Kremlin Bicetre, France, Universite Paris Diderot, Paris, France TUESDAY october 9, 0 :00 pm 688. Methotrexate Dose Has Minimal Effects On Methotrexate-Related Toxicity in Patients With Early Rheumatoid Arthritis Treated in Combination With Adalimumab Results of Concerto Trial Gerd R. Burmester, Alan J. Kivitz, Ronald F. van Vollenhoven, Stefan Florentinus 4, Piyalal M. Karunaratne 5, Hartmut Kupper 6, Maxime Dougados 7 and Roy M. Fleischmann 8, Charité - Universitätsmedizin Berlin, Berlin, Germany, Altoona Center for Clinical Research, Duncansville, PA, The Karolinska Institute, Stockholm, Sweden, 4 AbbVie, Rungis, France, 5 AbbVie Inc., North Chicago, IL, 6 AbbVie Deutschland GmBH & Co KG, Ludwigshafen, Germany, 7 René Descartes University, Paris, France, 8 University of Texas Southwestern Medical Center, Dallas, TX :5 pm 689. Assessing Maintenance of Remission After Withdrawal of Etanercept Plus Methotrexate, Methotrexate Alone, or Placebo in Early Rheumatoid Arthritis Patients Who Achieved Remission With Etanercept and Methotrexate: The Prize Study Paul Emery, Wolfgang Spieler, Maria Stopinska-Polaszewska, Nikolay I Korshunov 4, Jack Bukowski 5, Ronald Pedersen 5, Theresa Williams 6, Stefanie Gaylord 6 and Bonnie Vlahos 6, Institute Rheumatic and Musculoskeletal Medicine University of Leeds, Leeds, United Kingdom, ZeFOR GmbH Zentrum für Forschung, Zerbst, Germany, Family Physicians Specialists Clinic, Torun, Poland, 4 State Budgetary Healthcare Institution of Yaroslavl Region, Yaroslavl, Russia, 5 Pfizer Inc, Collegeville, PA, 6 Pfizer Inc., Collegeville, PA :0 pm 690. Survival of the Second Biologic After the First Tumor Necrosis Factor Alpha Inhibitor s Failure in the Treatment of Rheumatoid Arthritis: Prospective Observational Data from Biorx.Si Registry ŽIga Rotar and Matija Tomsic, University Medical Centre Ljubljana, 000 Ljubljana, Slovenia, University Medical Centre Ljubjana, Ljubljana, Slovenia :45 pm 69. Results of the Strass Trial Regarding Impact of Progressive Spacing of Tnf-Blocker Injections in Rheumatoid Arthritis Patients in Das8 Remission: Is There a Difference Between Drugs - Adalimumab and Etanercept - or Their Mode of Use - Monotherapy or Combination? Bruno Fautrel, Thao Pham, Jacques Morel, Toni Alfaiate 4, Emmanuelle Dernis 5, Philippe Gaudin 6, Olivier Brocq 7, Elisabeth Solau-Gervais 8, Jean-Marie Berthelot 9, Jean-Charles Balblanc 0, Xavier Mariette and Florence Tubach, Paris 6 Pierre et Marie Curie University; AP-HP, Rheumatology, Pitié-Salpêtrière Hospital, - GRC-UPMC 08 EEMOIS, Paris, France, Sainte Marguerite Hospital, Marseille, France, Lapeyronie Hospital, Montpellier, France, 4 AP-HP, Paris, France, 5 Le Mans Hospital, Le Mans, France, 6 CHU Hôpital Sud, Grenoble Teaching Hospital, Echirolles, France, 7 Hospital of Princesse Grâce de Monaco, C Spondylarthropathies and Psoriatic Arthritis - Pathogenesis, Etiology Moderators: Judith A. Smith, MD, PhD and Rik Lories, MD, PhD :0 pm 69. Evidence that Fat Metaplasia is a Key Intermediary in the Development of Sacroiliac Joint Ankylosis Following Repair of Erosions in Patients With Spondyloarthritis Walter P. Maksymowych, Stephanie Wichuk, Praveena Chiowchanwisawakit, Robert GW Lambert and Susanne Juhl Pedersen, University of Alberta, Edmonton, AB, Mahidol University, Bangkok, Thailand, Copenhagen University Hospital at Glostrup, Copenhagen, Denmark :45 pm 69. Proof of Concept: Enthesitis and New Bone Formation in Spondyloarthritis Are Driven By Mechanical Strain and Stromal Cells Peggy Jacques, Stijn Lambrecht, Eveline Verheugen, Elin Pauwels, Marleen Verhoye, Annemie Van der Linden, George Kollias 4, Rik J. Lories 5 and Dirk Elewaut 6, Laboratory for Molecular Immunology and Inflammation, Ghent University, Ghent, Belgium, UGCT, Ghent University, Ghent, Belgium, University of Antwerp, Antwerp, Belgium, 4 Biomedical Sciences Research Center Alexander Fleming, Vari, Greece, 5 Laboratory for Skeletal Development and Joint Disorders, KU Leuven, Leuven, Belgium, 6 Department of Rheumatology Ghent University Hospital, Ghent, Belgium :00 pm 694. HLA-B7 Expression Prevents Tnfα-Induced Inhibition of Bone Formation in Vitro in IFNγ/Tnfα-Treated Osteoblasts Eva Yang, Grace Kwon, Robert A. Colbert and Gerlinde Layh- Schmitt, NIAMS NIH, Bethesda, MD :5 pm 695. Host Genetic Background Disrupts the Relationship Between Microbiota and Gut Mucosal Tolerance Leading to Spondyloarthritis and Ileitis After a Dectin- Trigger Linda Rehaume, Stanislas Mondot, Daniel Aguirre de Cárcer, Jared Velasco, Helen Benham, Sumaira Hasnain, Jaclyn Bowman, Merja Ruutu, Philip Hansbro 4, Michael McGuckin, Mark Morrison and Ranjeny Thomas, University of Queensland Diamantina Institute, Brisbane, Australia, CSIRO Livestock Industries, Brisbane, Australia, Mater Medical Research Institute, Brisbane, Australia, 4 Center for Asthma and Respiratory Disease and Hunter Medical Research Institute, Newcastle, Australia 0 0 Program Book denotes Hilton San Diego Bayfront room location

123 0 E :0 pm 696. Impaired Bacterial Clearance and an Exuberant Inflammatory Response Promote Chlamydia-Induced Reactive Arthritis in SKG Mice Athan Baillet, Linda Rehaume, Helen Benham, Connor O Meara, Charles Armitage 4, Marina Harvie 4, Geraldine Brizard 5, Jared Velasco, John V. Forrester 6, Mariapia Degli-Esposti 5, Kenneth Beagley 4 and Ranjeny Thomas, The University of Queensland, Brisbane, Australia, University of Queensland Diamantina Institute, Brisbane, Australia, Institute of Health & Biomedical Innovation, Biomedical Sciences, Faculty of Health, Queensland University of Technology, Brisbane, Australia, 4 Institute of Health & Biomedical Innovation, Brisbane, Australia, 5 Lions Eye Institute, Nedlands, Australia, 6 Lions Eye Institute, Nedlands, Bahrain :45 pm 697. Identification of Genetic and Epigenetic Alterations in Spondyloarthritis Tibor A. Rauch, Beata Tryniszewska, Andras Vida, Timea Ocsko, Sandor Szanto, Holly L. Rosenzweig, Matthew A. Brown 4, Gethin P Thomas 5, Katalin Mikecz and Tibor T. Glant, Rush University Medical Center, Chicago, IL, University of Debrecen, Debrecen, Hungary, Oregon Health & Science University, Portland, OR, 4 University of Queensland Diamantina Institute, Brisbane, Australia, 5 University of Queensland Diamantina Institute, Woolloongabba, Australia Systemic Lupus Erythematosus - Human Etiology and Pathogenesis II Moderators: Vasileios C. Kyttaris, MD and Alessandra B. Pernis, MD :0 pm 698. The Treg/Th7 Imbalance of Patients With Systemic Lupus Erythematosus Were Mediated By Mir-66 Through Down-Regulating TGF-β Secretion of Bone Marrow-Derived Mesenchymal Stem Cells Lingyu Geng, Xia Li, Xuebing Feng and Lingyun Sun, Department of Rheumatology and Immunology, the Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China :45 pm 699. Transcription Factor RFX Regulates Th7 Differentiation and Its Role in the Pathogenesis of Systemic Lupus Erythematosus Ming Zhao, Gongping Liang, Qian Tang, Yang Yang, Yixin Tan and Qianjin Lu, Second Xiangya Hospital, Central South University, Changsha, China :00 pm 700. Abnormal Mitochondrial Electron Transport Chain Activity at Complex I Is Regulated By Nitric Oxide and N-Acetylcysteine in Lupus Lymphocytes Edward Doherty and Andras Perl, SUNY Upstate, Syracuse, NY, SUNY Upstate Medical University, Syracuse, NY :5 pm 70. Spleen Tyrosine Kinase (Syk) Regulates Systemic Lupus Erythematosus T Cell Signaling Alexandros P. Grammatikos, Debjani Ghosh and Vasileios C. Kyttaris, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, The Brody School of Medicine, East Carolina University, Greenville, NC, BIDMC, Harvard Medical School, Boston, MA :0 pm 70. Molecular Pathogenesis and Genetics of Tartrate- Resistant Acid Phosphatase Deficiency in Systemic Lupus Erythematosus Jie An, Tracy A. Briggs, Audrey Dumax-vorzet, Alice Wiedeman, Laurence Chaperot, Joel Plumas, Yanick J. Crow and Keith B. Elkon, University of Washington, Seattle, WA, University of Manchester, Manchester, United Kingdom, Immunobiology & Immunotherapy of Cancers, La Tronche, France :45 pm 70. An Intronic CR Polymorphism Associated With Systemic Lupus Erythematosus Alters CTCF Binding and CR Expression Jian Zhao, Brendan M. Giles, Rhonda L. Taylor, Gabriel A. Yette, Kara M. Lough, Lawrence J. Abraham, Hui Wu, Patrick M. Gaffney 4, Jennifer A. Kelly 4, Kenneth M. Kaufman 5, John B. Harley 6, Carl D. Langefeld 7, Elizabeth E. Brown 8, Jeffrey C. Edberg 9, Robert P. Kimberly 8, Daniela Ulgiati, Betty P. Tsao and Susan A. Boackle, David Geffen School of Medicine University of California Los Angeles, Los Angeles, CA, University of Colorado School of Medicine, Aurora, CO, University of Western Australia, Perth, Western Australia, Australia, 4 Oklahoma Medical Research Foundation, Oklahoma City, OK, 5 Cincinnati Children s Hospital Medical Center and the University of Cincinnati, Cincinnati, OH, 6 Cincinnati Children s Hospital Medical Center, Cincinnati, OH, 7 Wake Forest School of Medicine, Winston-Salem, NC, 8 University of Alabama at Birmingham, Birmingham, AL, 9 Department of Medicine, University of Alabama at Birmingham, Birmingham, AL A Systemic Sclerosis, Fibrosing Syndromes, and Raynaud s II: Pathogenesis, Animal Models, Genetics: Novel Signaling Pathways Mediating Fibrosis Moderators: Sergio A. Jimenez, MD and Maria Trojanowska, MD :0 pm 704. Twist Regulates Transforming Growth Factor Beta Dependent Activation of Fibroblasts in Fibrosis Katrin Palumbo-Zerr, Andrea Liebl, Pawel Zerr, Michal Tomcik, Alfiya Distler, Christian Beyer, Oliver Distler, Georg Schett 4 and Joerg H. W. Distler, Department of Internal Medicine III and Institute for Clinical Immunology, University of Erlangen- Nuremberg, Erlangen, Germany, Institute of Rheumatology, Department of Rheumatology, st Faculty of Medicine, Charles University, Prague, Czech Republic, Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland, 4 University of Erlangen-Nuremberg, Erlangen, Germany TUESDAY october 9, 0 denotes Hilton San Diego Bayfront room location 0 Program Book

124 :45 pm 705. Inhibition of Microrna-55 Ameliorated Experimental Fibrosis By Suppressing Wnt and Akt Pathways Qingran Yan, Qiong Fu, Jie Chen, Xinfang Huang, Nan Shen and Chunde Bao, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China, Shanghai Institute of Rheumatology, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China :00 pm 706. Fli Haploinsufficiency Exacerbates Dermal Fibrosis Via Activation of Fibroblasts, Endothelial Cells and Macrophages in Bleomycin-Treated Mice Takashi Taniguchi, Yoshihide Asano, Kaname Akamata, Shinji Noda, Takehiro Takahashi, Yohei Ichimura, Tetsuo Toyama, Maria Trojanowska and Shinichi Sato, University of Tokyo Graduate School of Medicine, Tokyo, Japan, Boston University, Boston, MA 9 D T cell Biology and Targets in Autoimmune Disease Moderators: Terri M. Laufer, MD and I-Cheng Ho, MD, PhD :0 pm 70. Deficiency of the Protein Kinase Ataxia Telangiectasia Mutated Accelerates T Cell Aging in Rheumatoid Arthritis Zhen Yang, Hiroshi Fujii, Eric L. Matteson, Jorg J. Goronzy and Cornelia M. Weyand, Stanford University School of Medicine, Stanford, CA, Tohoku University, Sendai, Japan, Mayo Clinic, Rochester, MN :45 pm 7. Self-Specific Polyclonal CD4 T Cells Enter a FR4hi CD7hi Anergic State to Prevent Immunopathology and Serve as a Reservoir for the Differentiation of Protective Foxp+ Tregs Lokesh Kalekar and Daniel L. Mueller, University of Minnesota Medical School, Minneapolis, MN TUESDAY october 9, 0 :5 pm 707. Downregulation Of KLF5 and Fli Cooperatively Contribute to Distinct Manifestations of Systemic Sclerosis In Vitro and In Vivo Shinji Noda, Yoshihide Asano, Katsuhito Fujiu, Ichiro Manabe, Ryozo Nagai, Kaname Akamata, Takashi Taniguchi, Takehiro Takahashi, Yohei Ichimura, Tetsuo Toyama, Daisuke Tsuruta, Maria Trojanowska and Shinichi Sato, University of Tokyo Graduate School of Medicine, Tokyo, Japan, Osaka City University Graduate School of Medicine, Osaka, Japan, Boston University, Boston, MA :0 pm 708. The Hedgehog Transcription Factor Gli- is a Novel Downstream Mediator of the Pro-Fibrotic Effects of Transforming Growth Factor-Beta Barbora Sumova, Cinzia Cordazzo, Katrin Palumbo-Zerr, Clara Dees 4, Pawel Zerr, Oliver Distler 5, Georg Schett 4, Ladislav Senolt 6 and Joerg H. W. Distler, Department of Rheumatology of the First Faculty of Medicine, Institute of Rheumatology and Connective Tissue Research Laboratory, Prague, Czech Republic, Dipartimento Cardiotoracico e Vascolare, Laboratory of Respiratory Cell Biology, University of Pisa, Pisa, Italy, Department of Internal Medicine III and Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, 4 University of Erlangen-Nuremberg, Erlangen, Germany, 5 Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland, 6 Institute of Rheumatology, Department of Rheumatology, st Faculty of Medicine, Charles University, Prague, Czech Republic :45 pm 709. Secreted Frizzled-Related Protein 4 Can Be Induced By Transforming Growth Factor-β, is Regulated By Caveolin- and Can Induce Non-Canonical Wnt Signaling in Fibroblasts Justin Gillespie, Giuseppina Abignano, Michael McDermott, Paul Emery and Francesco Del Galdo, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom :00 pm 7. Increased Soluble PD-: A Link Between Generation of Immunological Memory and Risk of Disease Flare in Early RA Stinne Greisen, Tue W. Kragstrup, Kristian Stengaard- Pedersen, Merete Lund Hetland, Kim Hørslev-Petersen 4, Malene Hvid and Bent Deleuran, Aarhus University, Aarhus, Denmark, Arhus University Hospital, Aarhus, Denmark, The Danish Rheumatologic Database (DANBIO), Glostrup Hospital., Copenhagen, Denmark, 4 University of Southern Denmark, Graasten, Denmark :5 pm 7. IL- Inhibited Follicular Regulatory T Cells to Promote Autoreactive Germinal Center Development in Autoimmune BXD Mice Yanna Ding, Hui-Chen Hsu, Jun Li, PingAr Yang, Qi Wu, Allan J. Zajac and John D. Mountz, University of Alabama at Birmingham, Birmingham, AL, Birmingham VA Medical Center, Birmingham, AL :0 pm 74. Commensal Intestinal Microbiota Drives Spontaneous Interleukin-- and T Helper 7-Mediated Arthritis in Mice Shahla Abdollahi-Roodsaz, Rebecca Rogier, Tom Ederveen, Harm Wopereis, Raish Oozeer, Marije I. Koenders and Wim B. van den Berg, Rheumatology Research and Advanced Therapeutics, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, Rheumatology Research and Advanced Therapeutics, Radboud University Nijmegen Medical Center, Nijmegen, Netherlands, Danone Research, Wageningen, Netherlands :45 pm *70. Interleukin-6 Driven STAT Phosphorylation in Circulating Lymphocytes is Specific for CD4 + T Cells in Early Rheumatoid Arthritis Amy E. Anderson, Christine Routledge, Philip Mawson, John D. Isaacs and Arthur G. Pratt, Newcastle University, Newcastle upon Tyne, United Kingdom, The Freeman Hospital, Newcastle upon Tyne, United Kingdom * Break in presentation number sequence is due to the addition of a substitute abstract. 0 Program Book denotes Hilton San Diego Bayfront room location

125 ARHP SESSIONS :0-4:00 pm Sapphire I Defining the Roles of the Rheumatology Nurse Internationally Moderator: Deanna S. Yamamoto, NP define, review and distinguish nursing roles in the United States, the Netherlands and Japan identify differences and compare nursing roles between countries describe nursing scopes of practice internationally discuss content, consensus and implementation of ACR/ EULAR recommendations for the role of the nurse :0 pm The Nursing Role: A Perspective From the United States Kori A. Dewing, DNP, ARNP :00 pm The Nursing Role: A Perspective From the Netherlands Yvonne JL van Eijk-Hustings, MSc, RN :0 pm The Nursing Role: A Japanese Perspective Masako Iida B You Can Improve Hand Function in Scleroderma Moderator: Leslie Kahl, MD explain the pathophysiology of vascular, fibrosis inflammation that can lead to hand problems in scleroderma identify interventions used to manage vascular changes, ulcers, pain and skin changes describe the types of exercises and modalities particular to the scleroderma hand and the evidence to support these interventions determine the importance of early education and intervention to maintain optimal hand function :0 pm Ischemic Ulcers in the Scleroderma Hand: Issues and Challenges Maureen D. Mayes, MD, MPH :00 pm Early Intervention and Patient Education: Strategies for Success Jane M. Denay, BSN, MSN, CFNP :0 pm Modalities and Exercises to Improve Hand Function Janet L. Poole, OTR, PhD 0 A Inflammatory Arthropathies of the Foot and Ankle: Assessment and Non-pharmacological Foot Care Interventions Moderator: Marian T. Hannan, DSc, MPH describe the latest advances in the understanding of foot pain disability and impairment in inflammatory arthropathies incorporate the use of validated foot outcome assessment instruments and outcome measures into clinical practice formulate evidence-based non-pharmacological treatment strategies based on pain mechanisms and unique patient characteristics demonstrate how concepts and strategies presented during the symposium can be used to address complex cases of rheumatologic patients with foot pain, impairment and disability :0 pm Non-pharmacological Approach to the Management of Foot Problems in Gout Keith Rome, PhD :00 pm Evaluation and Management of Foot Problems in Rheumatoid Perspective Smita Rao, PT, PhD :0 pm Foot and Ankle Osteoarthritis: A Matter of Structure and Function Howard J. Hillstrom, PhD ARHP CONCURRENT ABSTRACT SESSION :0-4:00 pm 04 A Clinical Practice/Patient Care Moderator: Karen Huisinga, ARNP, MN and Leonard H. Sigal, MD :0 pm 76. Support For Psychological State May Be Effective to Attain Remission Of Boolean-Based Definition Of Patient Global Assessment In Patients With Rheumatoid Arthritis Mie Fusama, Kumiko Yukioka, Takanori Kuroiwa, Chikako Yukioka, Miyako Inoue, Tae Nakanishi, Norikazu Murata, Noriko Takai, Kayoko Higashi 4, Taro Kuritani 4, Keiji Maeda 4, Yasushi Miura, Hajime Sano 5, Masao Yukioka and Hideko Nakahara 4, Kobe University Graduate School of Health Sciences, Kobe, Japan, Yukioka Hospital, Osaka, Japan, Yukioka College of Health Science, Osaka, Japan, 4 NTT West Osaka Hospital, Osaka, Japan, 5 Hyogo College of Medicine, Nishinomiya-city, Japan :45 pm 77. Fatigue in Rheumatoid Arthritis Is Associated With Modifiable Lifestyle Factors Patricia P. Katz, Vladimir Chernitskiy and David I. Daikh, University of California, San Francisco, San Francisco, CA, University of California San Francisco, San Francisco, CA TUESDAY october 9, 0 denotes Hilton San Diego Bayfront room location 0 Program Book

126 TUESDAY october 9, 0 :00 pm 78. Exploring E-Health Ethics and Multi-Morbidity: A Qualitative Study Of Patient and Clinician Experiences Using Digital Media For Health Purposes Anne F. Townsend, Paul Adam, Linda C. Li, Jenny Leese, Michael McDonald, Sheila Kerr 4, Gordon Whitehead 4 and Catherine L. Backman, Arthritis Research Centre of Canada, Richmond, BC, Mary Pack Arthritis Centre, Vancouver, BC, University of British Columbia, Vancouver, BC, 4 Consumer Advisory Board, Vancouver, BC :5 pm 79. Urinary Angiostatin As Alternative To Biopsy In lupus Nephritis Patients Among Egyptian Shereen Algergawy, Osama Alshaar and Rania Zakaria, associate prof at benha university faculty of medicine rheumatology and rehabilitation department Egypt, cairo, Egypt, benha university faculty of medicine, benha, Egypt, benha university faculty of medicine, benha, Egypt :0 pm 70. Providing Comprehensive, Comparative Post-TJR Outcome Feedback To Surgeons For Quality Monitoring and Value Decisions Patricia D. Franklin, Bruce Barton, Leslie R. Harrold, Wenjun Li, Regis O Keefe, Jeroan Allison and David Ayers, University of Massachusetts Medical School, Worcester, MA, University of Rochester Medical Center, Rochester, NY :45 pm 7. Exercise Therapy and Ultrasound Guided Glucocorticoid Injection In Patients With Painful Shoulder: A Randomised Controlled Trial Karen Ellegaard, Robin Christensen, Sara Rosager Mortensen, Cecilie Bartholby, Søren Torp-Pedersen 4, Thomas Bandholm 5, Bente Danneskiold-Samsøe 4, Henning Bliddal 4 and Marius Henriksen 6, The Parker Institute, Copenhagen, Denmark, Musculoskeletal Statistics Unit, The Parker Institute, Department of Rheumatology, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Denmark, The Parker Institute, Copenhangen, Denmark, 4 The Parker Institute, Department of Rheumatology, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Denmark, Frederiksberg, Denmark, 5 Hvidovre Hospital, Copenhagen, Denmark, 6 The Parker Institute, Copenhagen University Hospital at Frederiksberg, Copenhagen F, Denmark ACR WORKSHOPS 4:00-6:00 pm Admission to Workshops requires a separate registration and ticket. To verify which session you registered for, the registration code on your ticket needs to match the -digit code in parentheses below. If you are interested in participating in one of these sessions or exchanging your ticket, visit the ACR registration desk to check space availability. View the session overview online in My Annual Meeting at www. ACRannualmeeting.org. * Sessions denoted with an asterisk were sold out as of August 0. A 4 Patient Questionnaires: Multi-Dimensional Health Assessment Questionnaire/Routine Assessment of Patient Index Data and Beyond Toward a Standard, Scientific, Quantitative Patient History (40) Speaker: Theodore Pincus, MD summarize the rationale for the use of MDHAQ/RAPID to help establish an agenda apply scoring RAPID and recognize of implications of different levels of scores for clinical decisions recognize how to use other components of MDHAQ beyond RAPID, including RADAI self-report joint count (rheumatoid arthritis disease activity index), review of systems, and recent medical history, to improve doctor-patient communication and improve office efficiency Proficiency in Teaching: Engaging Learners (4) Speaker: Kristen Hayward, MD, MS describe benefits of interactive teaching methods identify at least techniques to promote learner engagement apply techniques in a real life teaching scenario Systemic Sclerosis: How to Perform Skin Scores (4) Speaker: Daniel Furst, MD, MPH review the usefulness and reasons to do a modified Rodman skin score explain how to do a modified Rodman skin score perform a modified Rodman skin score under the supervision of experts ACR SESSIONS 4:0-6:00 pm Indigo E Cell Death and Toll-like Receptor (TLR) Recognition of Nucleic Acid Ligands Moderator: Robert Lafyatis, MD explain recent advances in cell death critique recent advances related to DNA and it targeting to TLRs state recent advances in TLR processing and signal propagation 4:0 pm Cell Death and DNA-containing Immune Complexes (DNA-IC) Trafficking Douglas R. Green, PhD 5:00 pm Dendritic Cell Receptors for Nucleic Acids and Damaged Cells Irina Caminschi, PhD 4 0 Program Book denotes Hilton San Diego Bayfront room location

127 5:0 pm Toll-like Receptor Processing after Nucleic Acid Binding Greg M. Barton, PhD Ballroom 0 A Critical Care Rheumatology Moderators: George Stojan, MD identify the most common critical care presentations of connective tissue diseases list a practical differential diagnosis for the most common critical care problems encountered by rheumatologists choose the appropriate diagnostic testing taking into account the time limiting constraints in life threatening situations institute adequate therapy and be aware of critical care complications of the medications commonly used in rheumatology 4:0 pm Neuromuscular Disorders in the Intensive Care Unit (ICU): All Weakness Is Not Myositis Vern Juel, MD 5:00 pm Myocarditis in the ICU: How to Recognize a Broken Heart Leslie T. Cooper Jr., MD 5:0 pm Reversible Posterior Encephalopathy Syndrome in the ICU Alejandro A. Rabinstein, MD A International League of Associations for Rheumatology (ILAR) Pediatric Rheumatology in Developing Countries Moderator: Audrey B. Uknis, MD recognize the prevalence of pediatric rheumatic diseases across the globe and the impact it has on the patient population describe pediatric educational programs funded by ILAR to address the need to advance the development of rheumatology outline how the programs can be utilized in other regions of the world 4:0 pm Pan American League of Associations for Rheumatology (PANLAR) Training in Pediatric Rheumatology: Latin America Claudia Saad Magalhaes, MD 5:00 pm Asian Pacific League of Association for Rheumatology (APLAR) AsPREN Development of Asia-Pacific Pediatric Rheumatology Research and Education Network Thaschawee Arkachaisri, MD Hall B Large Vessel Vasculitis: What Should the Clinician Know Moderators: Rula Hajj-Ali, MD and Eric L. Matteson, MD, MPH 6 A describe the diagnostic challenges in giant cell arteritis explain the involvement of large vessel disease and the emerging treatment of giant cell arteritis outline the management of Takayasu arteritis 4:0 pm Giant Cell Arteritis: What is Beyond Steroid Therapy Bhaskar Dasgupta, MD 5:00 pm Large Vessel Vasculitis and Giant Cell Arteritis Kenneth J. Warrington, MD 5:0 pm Takayasu Arteritis: How Do I Treat, How Do I Follow Eamonn Molloy, MD, MS Update on Safety Issues in the Treatment of Rheumatic Diseases From the Food and Drug Administration (FDA) and Beyond Moderators: Michael Wiseman, MD identify important safety issues in the drug treatment of rheumatic diseases integrate knowledge of new safety issues into their treatment strategies advise patients fully about the safety issues related to treatments for rheumatic diseases recognize the evolutions at the FDA that will affect drug safety monitoring and reporting 4:0 pm Introduction Safety: Strengths and Weakness of Data From Different Sources Daniel Solomon, MD, MPH 4:55 pm Update and Safety Issues of Recently Approved Agents for Rheumatic Diseases Nikolay P. Nikolov, MD 5:0 pm The Year in Review- Update on Safety Issues at the FDA for the last Months Janet W. Maynard, MD 5:45 pm Questions and Answers TUESDAY october 9, 0 5:0 pm African League of Associations for Rheumatology (AFLAR) Enhancement of Pediatric Rheumatology Education and Practice James Chipeta, BSc, MBChB, PhD denotes Hilton San Diego Bayfront room location 0 Program Book 5

128 ACR CONCURRENT ABSTRACT SESSIONS 4:0-6:00 pm 6 C 0 Rheumatology Research Foundation Edmond L. Dubois, MD Memorial Lectureship Moderators: Keith B. Elkon, MD and Jennifer H. Anolik, MD, PhD 4:0 pm 7. In Vivo Administration of MiR-46a Protects C57BL/6 Mice From Pristane-Induced Pulmonary Hemorrhage Via Suppressing Type I Interferon Response Dong Liang, Shiyu Zhou, Zheng Liu, Zhengyuan Shan, Philip Brohawn, Yihong Yao, John B. Harley and Nan Shen, Cincinnati Children s Hospital Medical Center, Cincinnati, OH, Shanghai Institutes for Biological Sciences Chinese Academy of Sciences & Shanghai Jiao Tong University School of Medicine, Shanghai, China, MedImmune, LLC, Gaithersburg, MD 4:45 pm 7. Role of Interferon-Inducible RNA-Dependent Protein Kinasein The Pathogenesis of Systemic Lupus Erythematosus Aurélie De Groof, Benoît Van den Eynde, Frédéric A. Houssiau and Bernard Lauwerys, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain, Brussels, Belgium, Institut de Duve, Université catholique de Louvain, Brussels, Belgium 5:00 pm 74. camp Responsive Element Modulator (CREM) α Governs CD8 Expression and Contributes to the Generation of CD + CD4 - CD8 - T Cells in Lupus Christian M. Hedrich, José C. Crispín, Thomas Rauen, Christina Ioannidis, Tomohiro Koga, Noe Rodriguez Rodriguez, Sokratis A. Apostolidis, Vasileios C. Kyttaris and George C. Tsokos, BIDMC, Harvard Medical School, Boston, MA, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA Indigo D Biology and Pathology of Bone and Joint II: Osteoclast Biology and Arthritis Moderators: Mary C. Nakamura, MD and Edward M. Schwarz, PhD 4:0 pm 78. The Small Ubiquitin Related Modifier- (SUMO-) Regulates Osteoclast Differentiation In Vitro and In Vivo. Svetlana Frank, Daniel Umlauf, Olli A. Jänne and Thomas Pap 4, University Hospital Münster, Muenster, Germany, University Hospital Muenster, Muenster, Germany, Univ Helsinki, Inst Biomed Physiol, Biomedicum, Helsinki, Finland, 4 University Hospital Münster, Münster, Germany 4:45 pm 79. Identification of Osteoarthritis Patients With Chronic Inflammation Driven Disease Progression Anne Sofie Siebuhr, Kristian Kjaer Petersen, Lars Arendt- Nielsen, Line Egsgaard, Thomas Navndrup Eskehave, Ole Simonsen 4, Claus Christiansen, Hans Christian Hoeck, Morten Asser Karsdal and Anne C. Bay-Jensen, Nordic Bioscience, Biomarkers and Research, Herlev, Denmark, Center for Sensory- Motor Interaction, Aalborg, Denmark, Center for Clinical and Basic Research and C4Pain, Aalborg, Denmark, 4 Frederikshavn Hospital, Frederikshavn, Denmark 5:00 pm 70. Netrin Is a Critical Autocrine Factor for Osteoclast Differentiation Aranzazu Mediero, Bhama Ramkhelawon, Kathryn Moore, P. Edward Purdue, Steven R. Goldring and Bruce N. Cronstein, NYU School of Medicine, New York, NY, Hospital for Special Surgery, New York, NY, NYU School of Medicine, Division of Rheumatology, New York, NY TUESDAY october 9, 0 5:5 pm 75. Regulation of Aberrant CD4 T Cell Activation By Suppressor of Cytokine Signaling- (SOCS) Mimetic Peptide, Has Relevance to Human Systemic Lupus Erythematosus Tenisha Wilson, Cristina Armbruster, Simone Bedoya, Howard M. Johnson, Westley H. Reeves, Yi Li, Ying Yi Zheng, Laurence Morel and Joseph Larkin III, University of Florida, Gainesville, FL 5:0 pm 76. A Polymorphism in the Mif Gene Is Associated With Cardiovascular Morbidity in Systemic Lupus Erythematosus A Pilot Study Eric F. Morand, Kathryn Connelly and Alberta Y. Hoi, Monash University, Melbourne, Australia 5:45 pm 77. Immunologic and Inflammatory Markers of Impending Disease Flare in Systemic Lupus Erythematosus Patients Not Taking Immunosuppressive Medications in the Biomarkers of Lupus Disease (BOLD) Study Joel M. Guthridge, Mikhail G. Dozmorov, Melissa E. Munroe, Krista M. Bean, Sudhakar T. Sridharan, Joan T. Merrill and Judith A. James, Oklahoma Medical Research Foundation, Oklahoma City, OK, Pfizer Inc, Collegeville, PA, Oklahoma Medical Research Foundation and University of Oklahoma Health Sciences Center, Oklahoma City, OK 5:5 pm 7. An Acetyl-Histone Mimetic Blocks Proinflammatory Activation of Rheumatoid Arthritis Fibroblast-Like Synoviocytes P. A. Kabala, A.M. Grabiec, C. Angiolilli, Nicholas Smithers, Jason Witherington, Paul Peter Tak, Rabinder Prinjha and Kris A. Reedquist, Department of Clinical Immunology and Rheumatology Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands, GlaxoSmithKline, Stevenage, United Kingdom, Academic Medical Center / University of Amsterdam, Department of Clinical Immunology and Rheumatology & GlaxoSmithKline, Amsterdam, Netherlands 5:0 pm 7. Inhibition of Autophagy Prevents Ovariectomy Induced Bone Loss Neng-Yu Lin, Joerg H. W. Distler, Alfiya Distler, Christian Beyer, Georg Schett and Oliver Distler, Department of Internal Medicine III and Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, University of Erlangen-Nuremberg, Erlangen, Germany, Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland 6 0 Program Book denotes Hilton San Diego Bayfront room location

129 5:45 pm 7. Spontaneous Osteoarthritis in Mice By Genetic Deletion of Nfatc and Nfatc Susan Y. Ritter, Matthew B. Greenblatt, Kelly Tsang, Dorothy Z. Hu, John Wright and Antonios O. Aliprantis, Brigham and Women s Hospital, Boston, MA, Massachusetts General Hospital, Boston, MA 5:0 am 78. Microrna-Mediated Regulation Explains Allelic Risk of TLR7 Variant Predisposing to Systemic Lupus Erythematosis n Deng, Jian Zhao, Jennifer M. Grossman and Betty P. Tsao, David Geffen School of Medicine University of California Los Angeles, Los Angeles, CA, UCLA David Geffen School of Medicine, Los Angeles, CA Sapphire A Genetics and Genomics of Rheumatic Disease II Moderators: Nan Shen, MD and Soumya Raychaudhuri, MD, PhD 4:0 pm 74. Epigenetic Control of a Gene Regulatory Network Associated With Experimental Autoimmune Arthritis and Rheumatoid Arthritis Andras Vida, Janos Gal, Gyorgyi Soos, Attila Balog, Laszlo G. Puskas 4, Katalin Mikecz, Tibor T. Glant and Tibor A. Rauch, Rush University Medical Center, Chicago, IL, Bacs-Kiskun County Hospital, Kecskemet, Hungary, Albert Szent-Gyorgyi University, Szeged, Hungary, 4 Biological Research Center, Szeged, Hungary 4:45 pm 75. Integrative Analysis of Multiple Omics Technologies Reveals a Novel Therapeutic Target for Rheumatoid Arthritis (RA) David L. Boyle, John Whitaker, Beatrix Bartok, Wei Wang and Gary S. Firestein, UCSD School of Medicine, La Jolla, CA, UCSD, La Jolla, CA 5:00 pm 76. High Density Microarray Analysis Identifies Novel Differentially Expressed Long Noncoding RNAs in Rheumatoid Arthritis Synovial Fibroblasts Mojca Frank Bertoncelj, Michelle Trenkmann, Christoph Kolling, Beat A. Michel, Renate E. Gay and Steffen Gay, Center of Experimental Rheumatology, University Hospital Zurich and Zurich Center of Integrative Human Physiology (ZIHP), Zurich, Switzerland, Schultess Clinic, Zurich, Switzerland, Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland 5:5 pm 77. In Vivo MiR-46a Administration Ameliorates Murine Lupus Nephritis Dong Liang, Shiyu Zhou, Zheng Liu, Zhengyuan Shan, Philip Brohawn, Yihong Yao, Indu Raman 4, Quan-Zhen Li 4, John B. Harley and Nan Shen, Cincinnati Children s Hospital Medical Center, Cincinnati, OH, Shanghai Institutes for Biological Sciences Chinese Academy of Sciences & Shanghai Jiao Tong University School of Medicine, Shanghai, China, MedImmune, LLC, Gaithersburg, MD, 4 University of Texas Southwestern Medical Center, Dallas, TX 5:45 pm 79. Immunochip Analysis Identifies New Susceptibility Loci for Systemic Sclerosis: Implications for Pathogenesis Maureen D. Mayes for the US Scleroderma GWAS Group, Lara Bossini-Castillo for the Spanish Scleroderma Group, Olga Gorlova, Jose Ezequiel Martin, Xiaodong Zhou, Wei Chen, Shervin Assassi, Jun Ying, John D. Reveille, Peter K. Gregersen 4, Annette T. Lee 4, Maria Teruel, Francisco David Carmona 5, Bobby P.C. Koeleman 6, Matthew A. Brown and the Immunochip Consortium 7, Christopher P. Denton 8, Murray Baron for the Canadian Scleroderma Research Group 9, Jasper Broen 0, T.R.D.J. Radstake 0 and Javier Martin, University of Texas Health Science Center at Houston, Houston, TX, Instituto de Parasitología y Biomedicina López-Neyra, IPBLN-CSIC, Granada, Spain, UT M.D. Anderson Cancer Center, Houston, TX, 4 Feinstein Institute for Medical Research, Manhasset, NY, 5 Instituto de Parasitología y Biomedicina López-Neyra, IPBLN- CSIC, Armilla (Granada), Spain, 6 Department of Medical Genetics, UMCU Utrecht, Utrecht, Netherlands, 7 University of Queensland Diamantina Institute, Brisbane, Australia, 8 Royal Free and University College Medical School, London, United Kingdom, 9 Jewish General Hospital, Montreal, QC, 0 University Medical Center Utrecht, Utrecht, Netherlands, Instituto de Parasitologia y Biomedicina López-Neyra, IPBLN-CSIC, Granada, Spain C Innate Immunity and Rheumatic Disease Moderators: Diego Kyburz, MD and Ranjeny Thomas, MBBS, MD 4:0 pm 740. High Efficacy of Toll-Like Receptor 4 Targeting in Murine and Humanized Models of Rheumatoid Arthritis in Comparison With IL- and TNF Inhibitors Shahla Abdollahi-Roodsaz, Marije I. Koenders, Leo A. Joosten, Fons A. van de Loo and Wim B. van den Berg, Rheumatology Research and Advanced Therapeutics, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, Rheumatology Research and Advanced Therapeutics, Radboud University Nijmegen Medical Center, Nijmegen, Netherlands, Department of Medicine, Radboud University Nijmegen Medical Center, Nijmegen, Netherlands 4:45 pm 74. Evidence That STAT Controls NLRP inflammasome dependent Release Of IL-β and Pyronecrosis Through Regulation of Mitochondrial Activity Jehad H. Edwan, Jae Jin Chae, Raphaela T. Goldbach-Mansky and Robert A. Colbert, NIAMS NIH, Bethesda, MD, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH, Bethesda, MD TUESDAY october 9, 0 denotes Hilton San Diego Bayfront room location 0 Program Book 7

130 TUESDAY october 9, 0 5:00 pm 74. Blau Syndrome-Associated NOD Mutations Limit Production of IL-6 and KC/IL-8 In Knock-in Mice and in Patients Suggesting a Loss of Function Disease Mechanism Jae Dugan, Eric Griffiths, Paige Snow, Holly L. Rosenzweig, Carlos D. Rose, Daniel Carr, James T. Rosenbaum and Michael Davey, Dept. of Veterans Affairs Medical Center, Portland, OR, Thomas Jefferson University/ AI dupont Hospital for Children, Wilmington, DE, Oregon Health and Science University, Portland, OR 5:5 pm 74. Targeted Activation of the Metabolic Super-Regulator AMP-Activated Protein Kinase (AMPK) Blunts Gouty Inflammation Ru L. Bryan, Robert Terkeltaub and Yun Wang, VA Medical Center/University of California San Diego, San Diego, CA, VA Medical Ctr/University of California San Diego, San Diego, CA, VA Medical Ctr, San Diego, CA 5:0 pm 744. Caspase 8 Modulates the Polarisome To Prevent Lung Fibrosis in a Murine Ssc-Like Disease Model Carla M. Cuda, Alexander Misharin, Gokhan Mutlu, Luisa Morales-Nebreda, GR Scott Budinger and Harris R. Perlman, Northwestern University Feinberg School of Medicine, Chicago, IL, Northwestern University, Chicago, IL 5:45 pm 745. Reshaping Inflammatory Macrophage Development and Functions by a Monosaccharide Analogue in Rheumatoid Arthritis Jun Li, Hui-Chen Hsu, PingAr Yang, Qi Wu, Bao Luo, Amber L Rowse, David M. Spalding, James A Mobley, S. Louis Bridges Jr. and John D. Mountz, University of Alabama at Birmingham, Birmingham, AL, Birmingham VA Medical Center, Birmingham, AL 9 D Miscellaneous Rheumatic and Inflammatory Diseases I: Autoinflammatory Syndromes Moderators: Pierre Quartier, MD 4:0 pm 746. A Novel Autoinflammatory Disorder Characterized By Ectodermal Dysplasia, Metaphyseal Chondrodysplasia, Growth Failure and Hyper-IgD In a Single Family Edward J. Oberle and James W. Verbsky, Medical College of Wisconsin, Milwaukee, WI 4:45 pm 747. Canakinumab Treatment in Schnitzler s Syndrome: A Multi-Center Randomized Placebo-Controlled 4-Month Study Karoline Krause, Karsten Weller, Martin Metz and Marcus Maurer, Dept. of Dermatology and Allergy, Allergie-Centrum- Charité, Charité Universitätsmedizin Berlin, Germany, Berlin, Germany 5:00 pm 748. Safety Results From the Beta Confident Registry in Canakinumab-Treated Patients With Cryopyrin-Associated Periodic Syndrome Hal Hoffman, Jasmin B. Kuemmerle-Deschner, Philip N. Hawkins, T. van der Poll 4, Ulrich A. Walker 5, Michael Nebesky 6, Ken Abrams 7 and Hugh Tilson 8, University of California at San Diego, San Diego, CA, University Hospital Tuebingen, Tuebingen, Germany, University College London Medical School, London, United Kingdom, 4 Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands, 5 Universitäts-Poliklinik, Felix-Platter Spital, Basel, Switzerland, 6 Novartis Pharma AG, Basel, Switzerland, 7 Novartis Pharmaceuticals Corporation, East Hanover, NJ, 8 The University of North Carolina, Gillings School of Global Public Health, Chapel Hill, NC 5:5 pm 749. Amyloidosis and Its Related Factors in Patients With Familial Mediterranean Fever: A Nationwide Multicenter Study Timucin Kasifoglu, Sule Yasar, Ismail Sari, Dilek Solmaz, Soner Senel, Hakan Emmungil 4, Levent Kilic 5, Sibel Yilmaz Oner 6, Fatih Yildiz 7, Sedat Yilmaz 8, Muhammet Cinar 8, Duygu Ersozlu Bakirli 9, Muge Aydin Tufan 7, Sema Yilmaz 0, Veli Yazisiz, Yavuz Pehlivan, Cemal Bes, Gozde Yildirim Cetin 4, Sukran Erten 5, Emel Gonullu, Tuncer Temel, Servet Akar, Kenan Aksu 4, Umut Kalyoncu 5, Haner Direskeneli 6, Eren Erken 7, Bunyamin Kisacik, Mehmet Sayarlioglu 7 and Cengiz Korkmaz 8, Eskisehir Osmangazi University School of Medicine, Eskisehir, Turkey, Dokuz Eylul University School of Medicine, Izmir, Turkey, Kayseri Erciyes University School of Medicine, Kayseri, Turkey, 4 Ege University School of Medicine, Izmir, Turkey, 5 Hacettepe University School of Medicine, Ankara, Turkey, 6 Marmara University School of Medicine, Istanbul, Turkey, 7 Cukurova University School of Medicine, Adana, Turkey, 8 Gulhane School of Medicine, Ankara, Turkey, 9 Adana Numune Training and Research Hospital, Adana, Turkey, 0 Selcuk University School of Medicine, Konya, Turkey, Akdeniz University School of Medicine, Antalya, Turkey, Gaziantep University School of Medicine, Gaziantep, Turkey, Bolu Izzet Baysal School of Medicine, Bolu, Turkey, 4 Kahramanmaras University School of Medicine, Kahramanmaras, Turkey, 5 Ataturk Training and Research Hospital, Ankara, Turkey, 6 Marmara University, School of Medicine, Istanbul, Turkey, 7 Ondokuz Mayis University School of Medicine, Samsun, Turkey, 8 Eskisehir Osmangazi University, Eskisehir, Turkey 5:0 pm 750. Long-Term Efficacy and Safety of IL Receptor Antagonist In Schnitzler s Syndrome: A French Multicenter Study Antoine Néel, Agathe Masseau, Sebastien Barbarot, Benoit Henry, Pierre-Jean Weiller, Olivier Decaux 4, Xavier Kyndt 5, Xavier Puechal 6, Arnaud Hot 7, Pierre Pottier, Amar Smail 8, David Launay 9, Jean-Marie Berthelot, Eric Hachulla 9, Leonardo Astudillo 0, Pierre-Yves Hatron 9, Laurent Sailler 0, Aurelien Lorleac h, Achille Aouba, Bérangère Cador 4, Renato Fior, Robin Dhote 4, Fabrice Bonnet 5, Jean-Dominique de Korwin 6 and Mohamed Hamidou, Nantes University Hospital, Nantes, France, Pitié-Salpêtrière University Hospital, Paris, France, La Timone University Hospital, Marseille, France, 4 Rennes University Hospital, Rennes, France, 5 Hospital of Valenciennes,, 8 0 Program Book denotes Hilton San Diego Bayfront room location

131 Valenciennes, France, 6 Hôpital Cochin, Paris, France, 7 Edouard Herriot University Hospital, Lyon, France, 8 Amiens University Hospital, Amiens, France, 9 Claude Huriez University Hospital, Lille, France, 0 Toulouse University Hospital, Toulouse, France, Lorient Hospital, Lorient, France, Necker University Hospital, Paris, France, Antoine Béclère University Hospital, Clamart, France, 4 Avicenne University Hospital, Bobigny, France, 5 Bordeaux University Hospital, Bordeaux, France, 6 Nancy University Hospital, Nancy, France 5:45 pm 75. Recurrent Pericarditis in Children and Adolescents: Etiology, Presentation, Therapies, and Outcomes in a Multicenter Retrospective Cohort of 00 Patients Antonio Brucato, Massimo Imazio, Marco Gattorno, Antonella Insalaco 4, Chiara Di Blasi Lo Cuccio, Simona Marcora 5, Rolando Cimaz 6, Luca Cantarini 7, Luciana Breda 8, Manuela Marsili 8, Fabrizia Corona 9 and Alberto Martini 0, USC Internal Medicine, Ospedale Papa Giovanni XXIII, Bergamo, Italy, Maria Vittoria Hospital, Torino, Italy, G. Gaslini Institute, Genova, Italy, 4 Ospedale Pediatrico Bambino Gesù, Roma, Italy, 5 Ospedale Papa Giovanni XXIII, Bergamo, Italy, 6 A. Meyer Children s Hospital, Florence, Italy, 7 Policlinico Le Scotte, University of Siena, Siena, Italy, 8 University of Chieti G. D Annunzio, Chieti, Italy, 9 Paediatric Department University of Milano, Milano, Italy, 0 Istituto G Gaslini, Pediatria II, Reumatologia, Genova, Italy 06 A Osteoarthritis II: Risk Factors and Natural History of Osteoarthritis Moderators: Grace H. Lo, MD, MSc and Stephen P. Messier, PhD 4:0 pm 75. Good, Moderate and Poor Outcome Trajectories of Pain Severity In Early Symptomatic Knee Osteoarthritis; 5 Year Follow-Up Of Check study Janet Wesseling, Alex N. Bastick, Sita M.A. Bierma-Zeinstra and Johannes W.J. Bijlsma, University Medical Center Utrecht, Utrecht, Netherlands, Erasmus MC - University Medical Center, Rotterdam, Netherlands 4:45 pm 75. Relationship of Pre-Radiographic MRI Lesions With Prevalent Frequent Knee Symptoms and Incident Persistent Knee Symptoms in Persons At Higher Risk for Knee Osteoarthritis Leena Sharma, Joan S. Chmiel, Orit Almagor, Dorothy D. Dunlop, Marc C. Hochberg, Charles Eaton 4, C. Kent Kwoh 5, Rebecca D. Jackson 6, Joan M. Bathon 7, Ali Guermazi 8, Frank Roemer 9, Michel Crema 8, W. Jerry Mysiw 6 and Michael C. Nevitt 0, Northwestern University, Chicago, IL, Northwestern University Medical School, Chicago, IL, University of Maryland, Baltimore, MD, 4 Brown University, Providence, RI, 5 University of Pittsburgh, Pittsburgh, PA, 6 Ohio State University, Columbus, OH, 7 Columbia University, New York, NY, 8 Boston University, Boston, MA, 9 Klinikum Augsburg, Augsburg, Germany, 0 University of California, San Francisco, San Francisco, CA 6 D 5:00 pm 754. Trajectory of Cartilage Thickness Change During The Years Prior to Knee Replacement: Data From the Osteoarthritis Initiative Felix Eckstein, Robert M. Boudreau, Zhijie Wang, Michael J. Hannon, Wolfgang Wirth, Sebastian Cotofana, Ali Guermazi 4, Frank Roemer 5, Michael C. Nevitt 6, Markus John 7, Christoph Ladel 8, David J. Hunter 9 and C. Kent Kwoh, Paracelsus Medical University, Salzburg, Austria, University of Pittsburgh, Pittsburgh, PA, University of Pittsburgh School of Medicine, Pittsburgh, PA, 4 Boston University, Boston, MA, 5 Klinikum Augsburg, Augsburg, Germany, 6 University of California, San Francisco, San Francisco, CA, 7 Novartis Pharma AG, Basel, Switzerland, 8 Merck KG, Darmstadt, Germany, 9 University of Sydney, Sydney, Australia 5:5 pm 755. The Clinical Significance and Natural History of Knee Bone Marrow Lesions Over 8 Years Yi Chao Foong, Hussain Ijaz Khan, Dawn Aitken, Changhai Ding, Flavia Cicuttini and Graeme Jones, Menzies Research Institute Tasmania, University of Tasmania, Hobart, 7000, Australia, Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, 004, Australia 5:0 pm 756. Serum Periostin Is Associated With Prevalent Knee Osteoarthritis and Predicts Disease Progression in Women: The Ofely Study Jean-Charles Rousseau, Elisabeth Sornay-Rendu, Cindy Bertholon, Patrick Garnero and Roland Chapurlat, INSERM UMR 0, Lyon, France, INSERM, UMR 0, Lyon and Cisbio Bioassays, Bagnols/Cèze, France, INSERM UMR 0 and Université de Lyon, Hôpital Edouard Herriot, Lyon, France 5:45 pm 757. Metabolomics for the Identification of Urinary Biomarkers in Knee Osteoarthritis Progression Puja Saxena, Richard F. Loeser, Wimal Pathmasiri, Susan Sumner, Daniel Beavers, David J. Hunter 4 and Stephen P. Messier 5, Wake Forest University School of Medicine, Winston- Salem, NC, Wake Forest School of Medicine, Winston-Salem, NC, NIH Eastern Regional Comprehensive Metabolomics Resource Core, Research Triangle Park, NC, 4 University of Sydney, Sydney, Australia, 5 Wake Forest University, Winston-Salem, NC Rheumatoid Arthritis - Clinical Aspects V: Observational Studies in Rheumatoid Arthritis Moderators: Ernest Choy, MD and Kristine Phillips, MD, PhD 4:0 pm 758. Quantifying the Risk of Incident Type II Diabetes Following Oral Glucocorticoid Therapy in Patients With Rheumatoid Arthritis: Association With Dose and Duration of Use William G. Dixon, Mohammad Movahedi, Marie-Eve Beauchamp, David W. Ray and Michal Abrahamowicz, The University of Manchester, Manchester, United Kingdom, McGill University, Montreal, QC, Institute of Human Development, The University of Manchester, Manchester, United Kingdom TUESDAY october 9, 0 denotes Hilton San Diego Bayfront room location 0 Program Book 9

132 TUESDAY october 9, 0 4:45 pm 759. Can RA Registries Provide Contextual Safety Data for Modern RCTs? Kaleb Michaud, Johan Askling, Hisashi Yamanaka, Deborah Symmons 4, Marie Holmqvist, Thomas Frisell, George Reed 5, Dimitrios A. Pappas 6, Eiichi Tanaka, Eisuke Inoue, Suzanne M.M. Verstappen 4, Christopher Garwood 4, Laura Horne 7, Kathy Lampl 7, Niklas Berglind 8, Stefan Franzen 8, Fredrik Nyberg 9, Trung Tran 0, Meilien Ho and Jeffrey D. Greenberg, National Data Bank for Rheumatic Diseases & University of Nebraska Medical Center, Omaha, NE, Karolinska Institutet, Stockholm, Sweden, Tokyo Women s Medical University, Tokyo, Japan, 4 Arthritis Research UK Epidemiology Unit, The University of Manchester, Manchester, United Kingdom, 5 University of Massachusetts Medical School, Worcester, MA, 6 Columbia University, New York, NY, 7 AstraZeneca R&D Wilmington, Wilmington, DE, 8 AstraZeneca R&D Mölndal, Mölndal, Sweden, 9 AstraZeneca R&D, Mölndal, Sweden, 0 MedImmune LLC, Gaithersburg, MD, AstraZeneca R&D Alderley Park, Macclesfield, United Kingdom, NYU Hospital for Joint Diseases, New York, NY 5:00 pm 760. Incidence and Severity of Myocardial Infarction in Subjects Receiving Anti Tumour Necrosis Factor Drugs for Rheumatoid Arthritis: Results From Linking the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis and Myocardial Ischaemia National Audit Project Audrey SL Low, Kimme L. Hyrich, Mark Lunt, Louise K. Mercer, Christopher Gale 4, Kath Watson, British Society for Rheumatology Biologics Registers (BSRBR) Control Centre Consortium, William G. Dixon 5, Deborah P. Symmons and On behalf of the BSRBR 6, Arthritis Research UK Epidemiology Unit, The University of Manchester, Manchester, United Kingdom, Arthritis Research UK Epidemiology Unit, Manchester Academic Health Sciences Centre, Institute of Inflammation and Repair, The University of Manchester, Manchester, United Kingdom, Arthritis Research UK Epidemiology Unit, University of Manchester, Manchester, United Kingdom, 4 Department of Cardiology,York Teaching Hospital NHS Foundation Trust, York, United Kingdom, 5 The University of Manchester, Manchester, United Kingdom, 6 British Society for Rheumatology, London, United Kingdom 5:5 pm 76. Comparative Risks of Herpes Zoster Among RA Patients Switching Biologics in the U.S. Medicare Program Huifeng Yun, Fenglong Xie, Elizabeth S. Delzell, Lang Chen, Emily Levitan, James Lewis, Kenneth G. Saag, Timothy Beukelman, Kevin L. Winthrop, John Baddley and Jeffrey R. Curtis, University of Alabama at Birmingham, Birmingham, AL, University of Pennsylvania, Philadelphia, PA, Oregon Health & Science University, Portland, OR 5:0 pm 76. Rheumatoid and Psoriatic Arthritis Are Not Associated With Higher Risk of Incident Diabetes Mellitus Susan Mathew, Xiaoqin Tang, H. Lester Kirchner, Mary Chester M. Wasko 4 and Androniki Bili, Geisinger Medical Center, Danville, PA, Geisinger Center for Health Research, Danville, PA, Geisinger Health System, Danville, PA, 4 Temple University School of Medicine, Pittsburgh, PA 0 E 5:45 pm 76. Carotid Atherosclerosis as a Predictor of Mortality in Rheumatoid Arthritis Inmaculada del Rincon, Roy W. Haas, Jose Felix Restrepo, Daniel F. Battafarano, Daniel H. O Leary, Emily Molina 4 and Agustin Escalante, University of Texas Health Science Center, San Antonio, TX, Brooke Army Medical Ctr, San Antonio, TX, Tufts University-Boston Campus, Boston, MA, 4 University of Texas Health Science Center at San Antonio, San Antonio, TX Rheumatoid Arthritis Treatment - Small Molecules, Biologics and Gene Therapy: Efficacy of Approved Biologics I Moderators: Daniel H. Solomon, MD, MPH and Mark C. Genovese, MD 4:0 pm 764. Combination of Intra-Articular Steroid Injection and Tocilizumab More Effective Than Tocilizumab in Rapid Radiographic Progression Patients With Rheumatoid Arthritis. A Randomized, Open Label, x Ray Reader Blinded Study Kensuke Kume, Kanzo Amano, Susumu Yamada, Toshikatsu Kanazawa, Hiroshi Komori, Hiroyuki Ohta, Noriko Kuwaba 4 and Kazuhiko Hatta 5, Hiroshima Clinic, Hiroshima, Japan, hiroshima clinic, hiroshima, Japan, hiroshima clinic, Hiroshima, Japan, 4 Sanki Clinical Link, Hiroshima, Japan, 5 Hatta Clinic, Kure, Japan 4:45 pm 765. A Double-Blind Randomized Placebo-Controlled Trial of Lovastatin in Patients with Rheumatoid Arthritis Cynthia Aranow, John J. Cush, Marcy B. Bolster, Christopher C. Striebich 4, Maria Dall Era 5, Meggan Mackay, Ewa Olech 6, Tracy M. Frech 7, J. Box 8, Richard M. Keating 9, Mary Chester M. Wasko 0, E. William St Clair, Alan Kivitz, Betty Diamond, Anne Davidson, Meagan Spychala, Ellen A. Goldmuntz 4 and Autoimmunity Centers of Excellence 5, Feinstein Institute for Medical Research, Manhasset, NY, Baylor Research Institute and Baylor University Medical Center, Dallas, TX, Medical University of South Carolina, Charleston, SC, 4 University of Colorado Denver, Aurora, CO, 5 University of California, San Francisco, San Francisco, CA, 6 Oklahoma Medical Research Foundation, Oklahoma City, OK, 7 University of Utah School of Medicine, SLC, UT, 8 Carolina Bone and Joint, Charlotte, NC, 9 The University of Chicago, Chicago, IL, 0 Temple University School of Medicine, Pittsburgh, PA, Duke Unversity Medical Center, Durham, NC, Altoona Center for Clinical Research, Duncansville, PA, Rho, Inc., Chapel Hill, NC, 4 NIAID/NIH, Bethesda, MD, 5 National Institutes of Health, Bethesda, MD 5:00 pm 766. Improvement in Insulin Resistance Greater With the Use of Infliximab Following Intensive Treatment of Early Rheumatoid Arthritis Lesley-Anne Bissell, Elizabeth Hensor, Sarah L. Mackie, Agata Burska, Jackie L. Nam, Lukasz Kozera, Helen I. Keen, Edith Villeneuve, Heike Eberl, Helena Donica 4, Philip G. Conaghan 5, Jacqueline Andrews, Paul Emery 6 and Ann W. Morgan, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and NIHR Leeds Musculoskeletal Biomedical Research 0 0 Program Book denotes Hilton San Diego Bayfront room location

133 Unit, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, NIHR-Leeds Musculoskeletal Biomedical Research Unit and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, Roche Molecular Diagnostics, Burgess Hill, United Kingdom, 4 Department of Biochemical Diagnostics, Medical University of Lublin, Lublin, Poland, 5 NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds, United Kingdom, 6 Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom 5:5 pm 767. Tocilizumab in Combination Therapy and Monotherapy Versus Methotrexate in Methotrexate-Naive Patients With Early Rheumatoid Arthritis: Clinical and Radiographic Outcomes From a Randomized, Placebo-Controlled Trial Gerd R. Burmester, William Rigby, Ronald F. van Vollenhoven, Jonathan Kay 4, Andrea Rubbert-Roth 5, Ariella Kelman 6, Sophie Dimonaco 7 and Nina Mitchell 7, Charité - Universitätsmedizin Berlin, Berlin, Germany, Dartmouth-Hitchcock Medical Center and Dartmouth Medical School, Lebanon, NH, Karolinska Institute, Stockholm, Sweden, 4 UMass Memorial Medical Center and University of Massachusetts Medical School, Worcester, MA, 5 University of Cologne, Cologne, Germany, 6 Genentech, South San Francisco, CA, 7 Roche, Welwyn Garden City, United Kingdom 5:0 pm 768. Intravenous Golimumab Inhibits Radiographic Progression and Maintains Clinical Efficacy and Safety in Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy: -Year Results of a Phase Trial of Intravenous Golimumab Michael E. Weinblatt, Clifton O. Bingham III, Alan M. Mendelsohn, Lilianne Kim, Kim Hung Lo, Lenore Noonan, Daniel Baker and Rene Westhovens 4, Brigham and Women s Hospital, Boston, MA, Johns Hopkins University, Baltimore, MD, Janssen Research & Development, LLC., Spring House, PA, 4 University Hospital KU Leuven, Leuven, Belgium 5:45 pm 769. Clinical Remission After 5 Weeks of Treatment Is a Predictor of Adalimumab-Free Disease Control in Patients With Early Rheumatoid Arthritis: Hopeful Study Yoshiya Tanaka, Hisashi Yamanaka, Naoki Ishiguro, Nobuyuki Miyasaka 4, Katsuyoshi Kawana 5, Tadamichi Kubo 5, Aki Kuroki 5 and Tsutomu Takeuchi 6, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, Tokyo Women s Medical University, Tokyo, Japan, Nagoya Univeristy Graduate School of Medicine, Nagoya, Japan, 4 Tokyo Medical and Dental University, Tokyo, Japan, 5 AbbVie GK, Tokyo, Japan, 6 Keio University School of Medicine, Tokyo, Japan 8 D Sjögren s Syndrome: Basic Science Moderator: Robert I. Fox, MD, PhD and Roland Jonsson, DMD, PhD 4:0 pm 770. Complex Functional Effects Within the HLA Contribute to Sjögren s Syndrome Pathogenesis and May Influence Both Transcriptional Regulation and Peptide Binding Christopher J. Lessard, He Li, Indra Adrianto, John A. Ice, Mikhail G. Dozmorov, Roland Jonsson, Maureen Rischmueller 4, Gunnel Nordmark 5, Xavier Mariette 6, Corinne Miceli-Richard 7, Marie Wahren-Herlenius 8, Torsten Witte 9, Michael T. Brennan 0, Roald Omdal, Lars Rönnblom 5, Patrick M. Gaffney, Wan- Fai Ng, Nelson L. Rhodus, Barbara M. Segal 4, Jonathan D. Wren, R. Hal Scofield 5, Juan-Manuel Anaya 6, John B. Harley 7, Courtney G. Montgomery and Kathy L. Sivils, University of Oklahoma Health Sciences Center, Oklahoma City, OK, Oklahoma Medical Research Foundation, Oklahoma City, OK, University of Bergen, Bergen, Norway, 4 Queen Elizabeth Hospital, Adelaide, Australia, 5 Uppsala University, Uppsala, Sweden, 6 Bicêtre University Hospital, Le Kremlin Bicetre, France, 7 Université Paris Sud, Le Kremlin Bicêtre, France, 8 Karolinska Institutet, Stockholm, Sweden, 9 Medical University Hannover, Hanover, Germany, 0 Carolinas Medical Center, Charlotte, NC, Stavanger University Hospital, Stavanger, Norway, Newcastle University, Newcastle upon Tyne, United Kingdom, University of Minnesota, Minneapolis, MN, 4 Hennepin County Medical Center, Minneapolis, MN, 5 US Department of Veterans Affairs Medical Center, Oklahoma City, OK, 6 School of Medicine and Health Sciences, Universidad del Rosario. Center for Autoimmune Diseases Research (CREA), Bogotá, Colombia, 7 Cincinnati Children s Hospital Medical Center, Cincinnati, OH 4:45 pm 77. The NKp0/B7H6 Axis Contributes to Pathogenesis in Primary Sjögren s Syndrome Gaetane Nocturne, Sylvie Rusakiewicz, Damien Sene, Gunnel Nordmark 4, Maija-Leena Eloranta 5, Per Eriksson 6, Elke Theander 7, Helena Forsblad-d Elia 8, Roald Omdal 9, Marie Wahren-Herlenius 0, Roland Jonsson, Lars Rönnblom 5, Joanne Nititham, Kimberly E. Taylor, Christopher J. Lessard 4, Kathy L. Moser 4, Jacques-Eric Gottenberg 5, Lindsey A. Criswell, Corinne Miceli-Richard, Laurence Zitvogel 6 and Xavier Mariette 7, Université Paris Sud, Le Kremlin Bicêtre, France, IGR INSERM U05, Villejuif, France, Pitie-Salpetriere Hospital, Paris, France, 4 Uppsala University, Uppsala, Sweden, 5 Section of Rheumatology, Uppsala University, Uppsala, Sweden, 6 Rheumatology/AIR, Linköping University, Linköping, Sweden, Linköping, Sweden, 7 Lund University, Malmö, Sweden, 8 University of Gothenburg, Gothenburg, Sweden, 9 Stavanger University Hospital, Stavanger, Norway, 0 Karolinska Institutet, Stockholm, Sweden, University of Bergen, Bergen, Norway, University of California, San Francisco, Rosalind Russell Medical Research Center for Arthritis, San Francisco, CA, University of California, San Francisco, San Francisco, CA, 4 Oklahoma Medical Research Foundation, Oklahoma City, OK, 5 Strasbourg University Hospital, Strasbourg, France, 6 IGR INSERM U05, Villejuif, France, 7 Bicêtre University Hospital, Le Kremlin Bicetre, France TUESDAY october 9, 0 denotes Hilton San Diego Bayfront room location 0 Program Book

134 TUESDAY october 9, 0 5:00 pm 77. Identification of a Sjögren s Syndrome-Associated Variant That Influences OAS Isoform Switching He Li, John A. Ice, Jennifer A. Kelly, Indra Adrianto, Stuart B. Glenn, Kimberly S. Hefner, Evan G. Vista 4, Donald U. Stone, Raj Gopalakrishnan 5, Glen D. Houston, David M. Lewis, Michael Rohrer 5, Pamela Hughes 5, John B. Harley 6, Courtney G. Montgomery, James Chodosh 7, James A. Lessard 8, Juan-Manuel Anaya 9, Barbara M. Segal 0, Nelson L. Rhodus 5, Lida Radfar, R. Hal Scofield, Christopher J. Lessard and Kathy L. Sivils, University of Oklahoma Health Sciences Center, Oklahoma City, OK, Oklahoma Medical Research Foundation, Oklahoma City, OK, Hefner Eye Care and Optical Center, Oklahoma City, OK, 4 University of Santo Tomas, Taguig City, Philippines, 5 University of Minnesota, Minneapolis, MN, 6 US Department of Veterans Affairs Medical Center, Cincinnati, OH, 7 Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, MA, 8 Valley Bone and Joint Clinic, Grand Forks, ND, 9 School of Medicine and Health Sciences, Universidad del Rosario, Bogotá, Colombia, 0 Hennepin County Medical Center, Minneapolis, MN 5:5 pm 77. Genome-Wide DNA Methylation Patterns in naïve CD4+ T Cells From Patients With Primary Sjögren s Syndrome Nezam I. Altorok, Patrick S. Coit, Travis Hughes, Kristi A. Koelsch, R. Hal Scofield, Kathy L. Sivils, A. Darise Farris 4 and Amr H. Sawalha, University of Michigan, Ann Arbor, MI, Oklahoma Medical Research Foundation, Okalahoma City, OK, Oklahoma Medical Research Foundation, Oklahoma City, OK, 4 Oklahoma Medical Research Foun, Oklahoma City, OK 5:0 pm 774. Distinct Role of Plasmacytoid Dendritic Cells and Mast Cells in the Pathogenesis of Sjӧgren s Syndrome Jidong Zhao, Kunihiro Yamaoka, Satoshi Kubo, Shingo Nakayamada and Yoshiya Tanaka, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan 5:45 pm 775. Adenosine Ab Receptor Agonist Bay Restores Salivary Gland Function in a Mouse Model for Sjögren s Syndrome Barbara Szczerba, Paulina Rybakowska, Paromita Dey, Harini Bagavant and Umesh Deshmukh, University of Virginia, Charlottesville, VA A Spondylarthropathies and Psoriatic Arthritis: Clinical Aspects and Treatment: Clinical Features of Spondyloarthritis Moderators: Robert D. Inman, MD and John D. Reveille, MD 4:0 pm 776. Ankylosing Spondylitis Is Associated With An Increased Likelihood of Cardiovascular Disease: A Nationwide Matched Cohort Study in Primary Care Linda E. Dean, Gary J. Macfarlane, Alan G. MacDonald and Gareth T. Jones, University of Aberdeen, Aberdeen, United Kingdom, Aberdeen Royal Infirmary, Aberdeen, United Kingdom 4:45 pm 777. Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis: Part of a Common Spectrum or Distinct Diseases? Analysis of a Longitudinal Prospective Cohort Dinny Wallis, Nigil Haroon, Renise Ayearst, Adele Carty and Robert D. Inman, Toronto Western Hospital, University of Toronto, Toronto, ON, University of Toronto, Toronto Western Hospital, Toronto, ON 5:00 pm 778. Mortality in United States Veterans With the HLA-B7 Gene Jessica Walsh, Brian C. Sauer, Daniel O. Clegg, Grant W. Cannon, Xi Zhou and Chiachen Teng, George E. Wahlen Veteran Affairs Medical Center, Salt Lake City, UT, Salt Lake City VA and University of Utah, Salt Lake City, UT 5:5 pm 779. A Novel Evidence-Based Detection of Undiagnosed Spondyloarthritis in Patients Presenting With Acute Anterior Uveitis: The DUET (Dublin Uveitis Evaluation Tool) Algorithm Muhammad Haroon, Michael Anthony O Rourke, Pathma Ramasamy, Conor Murphy and Oliver FitzGerald, Dublin Academic Medical Centre, St. Vincent s University Hospital, Dublin, Ireland, Royal Victoria Eye and Ear Hospital, Dublin, Ireland 5:0 pm 780. Cumulative Exposure to Elevated Inflammatory Markers Is Associated With Increased Burden of Atherosclerosis in Psoriatic Arthritis Patients: A Cohort Study Lihi Eder, Arane Thavaneswaran, Vinod Chandran, Richard J. Cook and Dafna D. Gladman, University of Toronto, Toronto Western Hospital, Toronto, ON, University of Waterloo, Waterloo, ON 5:45 pm 78. The Disease Characteristics and Predictors of Minimal Disease Activity on TNF Blockers- Results From a Longitudainal Observational Cohort Amir Haddad, Arane Thavaneswaran, Ioana Ruiz Arruza, Vinod Chandran, Richard J. Cook and Dafna Gladman, University of Toronto, Toronto Western Hospital, Toronto, ON, University of Waterloo, Waterloo, ON 8 B Vasculitis III Moderators: Carol A. Langford, MD, MHS and Alfred Mahr, MD 4:0 pm 78. Retreatment With Rituximab in the Rituximab in ANCA- Associated Vasculitis (RAVE) Trial Eli Miloslavsky, Ulrich Specks, Peter A Merkel, Philip Seo 4, Robert F. Spiera 5, Carol A. Langford 6, Gary S. Hoffman 7, Cees G.M. Kallenberg 8, E. William St Clair 9, Nadia Tchao 0, Linna Ding, David Ikle, Brett Jepson, Paul Brunetta and John H. Stone 4, Massachusetts General Hopsital, Boston, MA, Mayo Clinic, Rochester, MN, University of Pennsylvania and VA Medical Center, Philadelphia, PA, 4 Johns Hopkins Vasculitis Center, Baltimore, MD, 5 Hospital for Special Surgery, 0 Program Book denotes Hilton San Diego Bayfront room location

135 New York, NY, 6 Cleveland Clinic, Cleveland, OH, 7 Cleveland Clinic Foundation, Cleveland, OH, 8 University Medical Center Groningen, Groningen, Netherlands, 9 Duke Unversity Medical Center, Durham, NC, 0 Immune Tolerance Network, Bethesda, MD, NIAID, Bethesda, MD, Rho, Chapel Hill, NC, Genentech, So San Francisco, CA, 4 Massachusetts General Hospital, Boston, MA 4:45 pm 78. Rituximab Versus Azathioprine for Maintenance In Antineutrophil Cytoplasmic Antibodies-Associated Vasculitis: Follow Up At 9 Months Benjamin Terrier, Christian Pagnoux, Alexandre Karras, Chahera Khouatra 4, Olivier Aumaître 5, Pascal Cohen, Francois Maurier 6, Olivier Decaux 7, Hélène Desmurs-Clavel 8, Pierre Gobert 9, Thomas Quemeneur 0, Claire Blanchard-Delaunay, Pascal Godmer, Xavier Puéchal, Luc Mouthon 4 and Loic Guillevin 5, Cochin University Hospital, Paris, France, Division of Rheumatology, Mount Sinai Hospital, Toronto, ON, Hôpital Européen Georges Pompidou, APHP, Paris, France, 4 CHU Lyon, Lyon, France, 5 Division of internal Medicine, Centre Hospitalier Universitaire, Hôpital Gabriel Montpied, Clermont Ferrand, Clermont Ferrand, France, 6 Division of internal Medicine, CHR Metz, Metz, Metz, France, 7 Rennes University Hospital, Rennes, France, 8 Hospices Civils de Lyon, Hôpital Louis Pradel, Lyon, France, 9 Centre Hospitalier d Avignon, Avignon, France, 0 CHR de Valenciennes, Valenciennes, France, Hôpital de Niort, Niort, France, Department of Internal Medicine, Centre Hospitalier Bretagne Atlantique de Vannes, Vannes, France, Hôpital Cochin, AP-HP, Université Paris Descartes, Sorbonne Paris Cité, Paris, France, 4 Department of Internal Medicine, Referral Center for Rare Autoimmune and Systemic Diseases, Hôpital Cochin, AP HP, Université Paris Descartes, Paris, France, Paris, France, 5 Division of Internal Medicine, Hôpital Cochin, University Paris Descartes, Paris, France 5:00 pm 784. Mononeuritis Multiplex Predicts the Need for Immunosuppressive Or Immunomodulatory Drugs for Eosinophilic Granulomatosis With Polyangiitis, Polyarteritis Nodosa and Microscopic Polyangiitis Patients Without Poor- Prognosis Factors Maxime Samson, Xavier Puéchal, Hervé Devilliers, Camillo Ribi 4, Pascal Cohen 5, Boris Bienvenu 6, Christian Pagnoux 7, Luc Mouthon, Loic Guillevin 8 and French Vasculitis Study Group (FVSG), Department of Internal Medicine, Referral Center for Rare Autoimmune and Systemic Diseases, Hôpital Cochin, AP HP, Université Paris Descartes, Paris, France; Internal Medicine and Clinical Immunology, Hôpital du Bocage, Dijon, France, Paris, France, Department of Internal Medicine, Referral Center for Rare Autoimmune and Systemic Diseases, Hôpital Cochin, AP HP, Université Paris Descartes, Paris, France, Paris, France, Internal medicine, Hôpital Général, Dijon, France, Dijon, France, 4 Immunology and Allergology, Internal Medicine, University Hospitals of Geneva, Geneva, Switzerland, Geneva, Switzerland, 5 Cochin University Hospital, Paris, France, 6 Division of Internal Medicine, Centre Hospitalier Régional Universitaire de Caen, Côte de Nacre, Caen, France, Caen, France, 7 Rheumatology, Mount Sinai Hospital, Toronto, Canada, Toronto, ON, 8 Referral Center for Rare Autoimmune and Systemic Diseases, Hôpital Cochin, AP HP, Université Paris Descartes, Paris, France 5:5 pm 785. Urinary Inflammatory Cells Strongly Reflect the Disease Activity and Renal Function in Antineutrophil Cytoplasmic Autoantibody-Associated Vasculitis Yoko Wada, Minoru Sakatsume, Masaaki Nakano and Ichiei Narita, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan, School of Health Sciences, Faculty of Medicine, Niigata University, Niigata, Japan 5:0 pm 786. Review of the Expert Panel Methodology in the Diagnostic and Classification Criteria for Vasculitis Study: A Pilot Study Cristina Ponte, Anthea Craven, Joanna Robson, Peter C. Grayson, Ravi Suppiah 4, Richard A. Watts 5, Peter A. Merkel 6 and Raashid A. Luqmani, Rheumatology and Metabolic Bone Diseases Department, Hospital de Santa Maria, CHLN and Rheumatology Research Unit, Instituto de Medicina Molecular, Faculdade de Medicina da Universidade de Lisboa, Lisbon, Portugal, Nuffield Department of Orthopaedics Rheumatology and Musculoskeletal Sciences, Botnar Research Centre, University of Oxford, Oxford, United Kingdom, Section of Rheumatology & the Clinical Epidemiology Unit, Boston University School of Medicine, Vasculitis Center, Boston, MA, 4 Auckland District Health Board, Auckland, New Zealand, 5 Rheumatology Department Ipswich Hospital and University of East Anglia, Ipswich, United Kingdom, 6 University of Pennsylvania, Philadelphia, PA 5:45 pm 787. The Effect of Smoking on the Clinical Expression of ANCA-Associated Vasculitis Neil Basu, Aladdin Mohammad, Richard A. Watts, Paul Gatenby 4, Luis F. Flores-Suarez 5 and Alfred Mahr 6, University of Aberdeen, Aberdeen, United Kingdom, Skåne University Hospital, Lund, Sweden, Rheumatology Department Ipswich Hospital and University of East Anglia, Ipswich, United Kingdom, 4 ANU Medical School, The Canberra Hospital, Canberra, Australia, 5 Instituto Nacional de Enfermedades Respiratorias, Mexico City, Mexico, 6 Department of Internal Medicine, Hospital Saint-Louis, Paris, France ACR MEET THE PROFESSOR SESSIONS 4:0-6:00 pm Admission to Meet the Professor sessions requires a separate registration and ticket. To verify which session you registered for, the registration code on your ticket needs to match the -digit code in parentheses below. If you are interested in participating in one of these sessions or exchanging your ticket, visit the ACR registration desk to check space availability. View the session overview online in My Annual Meeting at www. ACRannualmeeting.org. * Sessions denoted with an asterisk were sold out as of August 0. TUESDAY october 9, 0 denotes Hilton San Diego Bayfront room location 0 Program Book

136 TUESDAY october 9, 0 4 Controversies in Sjögren s Syndrome (08) Speaker: Alan N. Baer, MD identify the best approach to establish a diagnosis of Sjögren s syndrome differentiate among various causes of salivary and/or lacrimal gland swelling discuss current treatment algorithms for dry eyes, dry mouth and systemic manifestations identify risk factors and markers for lymphoma in Sjögren s syndrome patients Osteoarthritis: Update 0 (08) Speaker: Joanne M. Jordan, MD, MPH describe the pathogenesis of osteoarthritis including factors that lead to its development and the underlying biology responsible for the progression of osteoarthritis discuss advances in the management of osteoarthritis that include non-pharmacologic interventions evaluate the potential benefits of new disease- or structuremodifying treatments for osteoarthritis 4 A Pulmonary Manifestations of Rheumatic Disease (08) Speaker: Aryeh Fischer, MD identify emerging concepts regarding the pathophysiology of inflammation and fibrosis in autoimmune lung disease recognize the appropriate use of diagnostic tests in the evaluation of patients with rheumatic disorders and autoimmune lung disease discuss the limits of traditional therapeutic options and possible emerging therapies in managing autoimmune lung disease 4 B Raynaud s and Digital Ischemia (084) Speaker: Janet E. Pope, MD, MPH discuss the etiology of Raynaud s and differentiate Raynaud s from mimickers describe the appropriate investigations for Raynaud s phenomenon and be aware of those patients at risk for the development of a connective tissue disease review treatment options for Raynaud s, threatened digital ischemia and digital ulcers that are evidence based including new data from recent trials 0 Program Book 5 A Reactive Arthritis: An Update (085) Speaker: John D. Reveille, MD identify various causes of reactive arthritis discuss mechanisms of disease pathogenesis describe current treatment options for reactive arthritis 5 B Still s Disease and Autoinflammatory Syndromes (086) Speaker: John J. Cush, MD describe the clinical features of Still s disease and other febrile syndromes describe the immunogenetic mechanisms and treatment for adult Still s disease and related syndromes 6 A Systemic Lupus Erythematosus: Central Nervous System (087) Speaker: Meggan Mackey, MD, MS identify neuropsychiatric manifestations attributable to systemic lupus erythematosus recognize the utility of diverse autoantibodies in the diagnosis of neuropsychiatric syndromes of systemic lupus erythematosus patients formulate a treatment plan in patients with neuropsychiatric lupus 6 B * Systemic Lupus Erythematosus: Difficult to Treat Systemic Lupus Erythematosus (088) Speaker: Maria Dall Era, MD review established data from the medical literature in order to improve clinical practice related to the treatment of SLE including: examine management strategies for refractory cutaneous manifestations of systemic lupus erythematosus discusss management of progressive or relapsing lupus nephritis discuss management of severe cytopenias 7 A Understanding of Approach to the Care of Patients With Vasculitis (089) Speaker: Paul A. Monach, MD, PhD review advances in diagnosis and staging of vasculitis, and updates on prognostic information of interest to clinicians and patients review advances in therapeutic intervention (including biologics) in the treatment of the systemic vasculitides such as granulomatosis with polyangiitis, cryoglobulinemic vasculitis, and giant cell arteritis assess how to incorporate recent research data and practices into providing clinical care in the community for patients with vasculitis denotes Hilton San Diego Bayfront room location

137 7 B Vaccinations for Patients on Biologic Therapies (090) Speaker: Clifton O. Bingham III, MD recognize the importance of appropriate vaccinations in patients with autoimmune disease identify the different types of immunizations especially those which are live viruses describe the effect of different classes of immunomodulatory medications on vaccine efficacy and safety ACR/ARHP COMBINED ABSTRACT SESSION 4:0-6:00 pm Indigo C ACR/ARHP Combined Pediatrics Abstract Session Moderators: Michael Blakley, MD and Stacey E. Tarvin, MD 4:0 pm 788. Reliability and Responsivenss of the Standardized Universal Pain Evaluations for Rheumatology Providers for Children and Youth (SUPER-KIDZ) Nadia Luca, Jennifer N. Stinson, Susanne M. Benseler, Brian M. Feldman, Dorcas Beaton and Ahmed Bayoumi, Hospital for Sick Children, Toronto, ON, Scientist, Institute for Work & Health, Toronto, ON, Keenan Research Centre of the Li Ka Shing Knowledge Institute of St. Michael s Hospital, Toronto, ON 4:45 pm 789. Enhancing Uveitis Screening Compliance in Juvenile Idiopathic Arthritis Patients Melissa S Oliver, Jennifer E. Weiss, Suzanne C. Li, Kathleen A. Haines, Ginger L. Janow, Esi Morgan DeWitt and Yukiko Kimura, UMDNJ New Jersey Medical School, Newark, NJ, Joseph M Sanzari Children s Hospital, Hackensack University Medical Center, Hackensack, NJ, Cincinnati Children s Hospital Medical Center, Cincinnati, OH 5:00 pm 790. The Research in Arthritis In Canadian Children Emphasizing Outcomes (ReACCh Out) Cohort: Are We Achieving Clinically Important Outcomes? Deborah M. Levy, Shirley ML Tse, Elizabeth Stringer, Jaime Guzman, Roberta A. Berard 4, Karen Watanabe Duffy 5, Dax Rumsey, Mercedes O. Chan, Rosie Scuccimarri 6, Adam M. Huber, Lori B. Tucker 7, Rae SM Yeung, Ciaran M. Duffy 5, Kiem Oen 8 and The ReACCh Out Investigators, The Hospital for Sick Children and University of Toronto, Toronto, ON, IWK Health Centre and Dalhousie University, Halifax, NS, BC Children s Hospital and University of British Columbia, Vancouver, BC, 4 Children s Hospital of Western Ontario, London, ON, 5 Children s Hospital of Eastern Ontario and University of Ottawa, Ottawa, ON, 6 Montreal Children s Hospital and McGill University, Montréal, QC, 7 University of British Columbia, Vancouver, BC, 8 Children s Hospital of Winnipeg and University of Manitoba, Winnipeg, MB 5:5 pm 79. Telephone Consultation Usage in a Pediatric Rheumatology Clinic: Considerations in Optimizing Nursing Resources Julie Lemieux, Audrey Tran, Vincent Brienza and Roman Jurencak, Children s Hospital of Eastern Ontario, Ottawa, ON, University of Western Ontario, London, ON, University of Ottawa, Ottawa, ON 5:0 pm 79. Pediatric Rheumatology Care and Outcomes Improvement Network Demonstrates Performance Improvement on Juvenile Idiopathic Arthritis Quality Measures Julia G. Harris, Esi Morgan DeWitt, Ronald M. Laxer, Stacy P. Ardoin 4, Beth S. Gottlieb 5, Judyann C. Olson, Murray H. Passo 6, Jennifer E. Weiss 7, Daniel J. Lovell 8, Tzielan C. Lee 9, Sheetal S. Vora 0, Nancy Griffin, Jason A. Stock, Lynn M. Darbie and Catherine A. Bingham, Children s Hospital of Wisconsin, Milwaukee, WI, Cincinnati Children s Hospital Medical Center, Cincinnati, OH, University of Toronto, Toronto, ON, 4 Ohio State University College of Medicine, Columbus, OH, 5 Cohen Children s Medical Center of New York, New Hyde Park, NY, 6 Medical University of South Carolina, Charleston, SC, 7 Hackensack University Medical Center, Hackensack, NJ, 8 Cincinnati Children s Hospital Medical Center, Cincinnati, OH, 9 Stanford University School of Medicine, Stanford, CA, 0 University of North Carolina Chapel Hill, Chapel Hill, NC, Penn State Hershey Children s Hospital, Hershey, PA 5:45 pm 79. Towards Developing a Rheumatology-Specific Transition of Care Program Rina Mina, Janalee Taylor, Pamela A. Heydt, Terry M. Moore 4, Julie V. Ranz, Mary Beth Burns, Paula G. Melson 5, Abigail Nye, Jill Segerman, Yolanda Farhey 6, John Houk 6, Avis Ware 6, Jennifer L. Huggins and Lisa Vaughn, Cincinnati Children s Hospital Medical Center/University of Cincinnati School of Medicine, Cincinnati, OH, Cincinnati Children s Hospital Medical Center, Cincinnati, OH, Childrens Hospital Medical Center, Cincinnati, OH, 4 Cincinnati Chiildren s Hospital Medical Center, Cincinnati, OH, 5 Children s Hosp Medical Center, Cincinnati, OH, 6 University of Cincinnati, Cincinnati, OH TUESDAY october 9, 0 denotes Hilton San Diego Bayfront room location 0 Program Book 5

138 TUESDAY october 9, 0 ARHP SESSIONS 4:0-6:00 pm 04 A Enhancing Clinical Practice With Patient Engagement and Self-management Support Strategies Moderator: Charles M. King II, MD describe effectiveness of major forms of self-management support and identify opportunities to incorporate selfmanagement into clinical practice state ways patient reported outcomes can improve patientclinician interactions and create a sense of partnership to effectively engage patients in their care decisions discuss how effective patient communication and shared decision-making can enhance outcomes and improve overall care identify ways that effective patient engagement can improve adherence, aid in successful self-management, achieve treat to target goals, and reduce errors and adverse events 4:0 pm Supporting Self-management: Easier and Harder Than You Think Teresa J. Brady, PhD 5:00 pm Effectively Incorporating Patient Reported Outcomes Into Patient Consultations Jeffrey R. Curtis, MD, MPH, MS 5:0 pm Overcoming Obstacles to Shared Decision Making Elizabeth Riggs, PhD, MSN, BSN, RN 5:45 pm Engaging Patients as Partners Kelly Young, BA 0 A Pharmacist/Physician Partnership in Rheumatic Disease Management Moderator: Kam Nola, PharmD, MS describe the education and training of pharmacists working in rheumatology describe potential roles for pharmacists within the interdisciplinary team discuss the supportive role pharmacists play in making referrals to physical therapy, occupational therapy, selfmanagement, psychiatry, and other non-pharmacologic therapies describe the partnership and collaboration between prescribers and pharmacists 4:0 pm Multidimensional roles of the Pharmacist in Delivering Patientcentered Care Beth Resman-Targoff, PharmD 5:00 pm Making Pharmacists the Frontline for Arthritis Care in the Real World Carlo A. Marra, PharmD, PhD 5:0 pm The Evidence that Pharmacists Should be the Experts in the Frontline Diagnosis and Treatment of Knee Osteoarthritis John Esdaile, MD, MPH Sapphire I The Age of Information Technology: Registries, Administrative Databases, and the Role of the Internet in Rheumatic Disease Research Moderator: Allan C. Gelber, MD, PhD discuss the purpose of registries such as the Function and Outcomes Research for Comparative Effectiveness in Total Joint Replacement (FORCE-TJR) database and discuss the suitability of such registries in rheumatic disease research evaluate the generalizability and representativeness, as well as limitations, of using registries such as Consortium of Rheumatology Researchers of North America (CORRONA) or health maintenance organization (HMO) administrative databases in rheumatic disease research determine the suitability of the internet for different research study designs 4:0 pm Registries/Administrative Databases: Purpose, Suitability, and Benefits for Research Purposes Patricia D. Franklin, MD, MBA, MPH 4:55 pm Registries/Administrative Databases: Strengths and Limitations Leslie R. Harrold, MD, MPH 5:0 pm The Suitability of the Internet for Different Research Study Designs Yuqing Zhang, DSc, MPH 5:45 pm Panel Discussion Patricia D. Franklin, MD, MBA, MPH; Leslie R. Harrold, MD, MPH and Yuqing Zhang, DSc, MPH INDUSTRY-SUPPORTED SYMPOSIA 6:0-9:0 pm These symposia are both CME-accredited and non-cme company-directed programs. For CME-accredited symposia, the sponsoring organization is responsible for planning and providing CME credit. All non-cme programs are wholly sponsored and supported by commercial entities. Please visit the organization s exhibit booth, the industry-supported symposia booth or see page 5 for more information. 6 0 Program Book denotes Hilton San Diego Bayfront room location

139 ACR SESSIONS 6 C 7:0-8:0 am WEDNESDAY, OCTOBER 0, 0 Glycoregulation of Autoimmunity Moderator: Gregg J. Silverman, MD Speaker: Jamey Marth, PhD analyze how carbohydrate binding proteins (i.e., lectins) can regulate systemic immune responses describe the control of posttranslational glycosylation and how these change the in vivo properties of many secreted and cell membrane associated proteins discuss the overall roles of glycconjugates in immune regulation, and how dysregulation, can lead to the development of autoimmune disease 6 A Microparticles: Real Effectors or Just Mini-Me Moderator: Mary E. Cronin, MD Speaker: David S. Pisetsky, MD, PhD explain the origin of microparticles describe the biologic properties of microparticles state the role of microparticles in rheumatic disease Hall B Rheumatology Roundup: Highlights From the 0 Annual Meeting Moderator: Chester V. Oddis, MD Speakers: John J. Cush, MD and Arthur Kavanaugh, MD list research highlights from the scientific presentations discuss the clinical impact of selected research reports presented at the ACR meeting evaluate the therapeutic potential of selected clinical trials presented at the meeting ARHP SESSIONS 7:0-8:0 am Indigo D Rheumatic Disease Update: Rheumatoid Arthritis Moderator: Mary Chester M. Wasko, MD, MSc discuss the approach to diagnosis of rheumatoid arthritis review new insights into pathogenesis of rheumatoid arthritis outline approaches to rheumatoid arthritis management and therapeutics discuss rheumatoid arthritis and comorbidities/prognosis 7:0 am Rheumatioid Arthritis Update What s New in 0? Anisha B. Dua, MD, MPH 8 B The Risks, Screening and Management of Human Papillomavirus in Patients With Rheumatologic Disease Moderator: Susan Chrostowski, MS, ANP-C, RN Speaker: Seoyoung C. Kim, MD, MSCE review the risks of human papillomavirus (HPV) infection and use of HPV vaccine in patients with rheumatic disease describe appropriate cervical cancer screening and management of HPV infection in patients with rheumatic disease ACR SESSION 9:00-0:00 am Ballroom 0 A Emerging and Unexpected Regulatory Roles for Complement in the Rheumatic Diseases Moderator: Gregg J. Silverman, MD Speaker: V. Michael Holers, MD describe the molecular basis for complement mediated immune pathways discuss the clinical presentation of diseases regulated by complement summarize the data regarding therapeutic opportunities that may arise through manipulation of complement pathways ACR SESSIONS 9:00-0:0 am Hall B Current Management of Sjögren s Syndrome Moderator: Alan N. Baer, MD describe the management of patients with dry eye disease summarize the proper oral and dental care for patients with Sjögren s syndrome outline the emerging role of biologic agents in the therapy of Sjögren s syndrome 9:00 am Management of Dry Eye Disease in Sjögren s Syndrome George Papaliodis, MD 9:0 am Oral and Dental Care of the Patient With Sjögren s Syndrome Ava Wu, DDS 0:00 am Emerging Role of Biologic Agents in Sjögren s Syndrome E. William St. Clair, MD WEDNESDAY october 0, 0 8:0 am Questions and Answers denotes Hilton San Diego Bayfront room location 0 Program Book 7

140 WEDNESDAY october 0, 0 6 C 6 A Molecular and Cellular Profiling of the Immune Response Moderator: Andrew P. Cope, MD, PhD describe new technologies for the characterization of immune cell subsets and appreciate the complexities of immune phenotypes in health and disease discuss how gene expression profiling provides new insights into aetiopathogenesis of rheumatic disease acknowledge how vaccine studies have provided new insights into complex immune system networks 9:00 am Emerging Technologies for Defining Immune Signatures Garry Nolan, PhD 9:0 am Host immune Transcriptional Profiles in Rheumatic Diseases M. Virginia Pascual, MD 0:00 am Insights into the Human Immune System Through the Application of Systems Vaccinology W. Nicholas Haining, BM, BCh Patient-reported Outcome Measures for Rheumatologists Moderators: Dinesh Khanna, MD, MSc and Meenakshi Jolly, MD, MS restate the importance of assessing patient-reported outcomes explain the importance of capturing patient-reported outcomes in clinical practice discuss incorporation of patient-reported outcomes in the electronic medical records discuss the PROMIS initiatives in adults and pediatric population 9:00 am Why Patient-reported Outcome Are Important - Growing Implications and Applications for Rheumatologist Ron Hays, PhD 9:0 am PRO tools Including PROMIS in Rheumatology James P. Witter, MD, PhD 0:00 am How to Incorporate Patient-reported Outcome in Clinical Practice of Rheumatologists Esi Morgan DeWitt, MD, MSCE Sapphire A Policy Changes That Will Affect Your Practice in 04: Meaningful Use, Value-based Purchasing, Physician Quality Reporting System (PQRS), and ICD-0 Moderator: Melissa Francisco recognize the major impact areas and timing of these changes on your practice identify the ICD-0 and ACA compliance timeframes and the steps for meeting them use meaningful-use dashboard and clinical quality measures to improve patient safety and satisfaction 9:00 am Understanding Meaningful Use, Value-based Purchasing, & PQRS Robert Warren, MD, PhD, MPH 9:45 am How to Prepare for ICD-0 Medical Classifications Antanya Chung, CPC, CPC-I, CRHC, CCS-P ACR CONCURRENT ABSTRACT SESSIONS 9:00-0:0 am 8 B B cells in Systemic Lupus Erythematosus Moderators: Gregg J. Silverman, MD and William Stohl, MD, PhD 9:00 am 794. Characterisation of Antigens Driving In Situ Autoantibody Production in Human Lupus Tubulointerstitial Nephritis (TIN) Andrew Kinloch, Scott Henderson, Natalya Kaverina, Anthony Chang, D. James Haddon, Justin Jarrel, Carole Henry Dunand, Patrick C. Wilson, Paul Utz and Marcus R. Clark, University of Chicago, Chicago, IL, Stanford University School of Medicine, Stanford, CA 9:5 am 795. B Cell Derived Cytokines Induce Glomerular Injury in Mice Alfred Kim, Shreeram Akilesh, Jeffrey Miner and Andrey Shaw, Washington Univ School of Med, St. Louis, MO, University of Washington, Seattle, WA, Washington University School of Medicine, Saint Louis, MO 9:0 am 796. Effects of BAFF Inhibition on B Cell Selection in Murine SLE Alexis Boneparth, Ramalingam Bethunaickan, Weiqing Huang and Anne Davidson, Feinstein Institute for medical Research, Manhasset, NY, Feinstein Institute for Medical Research, Manhasset, NY 8 0 Program Book denotes Hilton San Diego Bayfront room location

141 9:45 am 797. B-Lymphocyte Stimulator and a Proliferation Inducing Ligand In Lupus Nephritis: Low Serum Levels of BLyS Predict Treatment Response Ioannis Parodis, Agneta Zickert, Elisabet Svenungsson, Vivianne Malmström and Iva Gunnarsson, Rheumatology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden, Karolinska Institutet, Stockholm, Sweden 0:00 am 798. Bone Marrow in Systemic Lupus Erythematosus Patients Contain a Highly Elevated Proportion of Somatically Mutated, Activated Naive Cells Comprised of Substantial Clonal Expansions Jennifer Hom, Christopher Tipton, Christopher Fucile, Bridget Neary, Chungwen Wei, F. Eun-Hyung Lee, Alex Rosenberg and Inaki Sanz, Emory University, Atlanta, GA, University of Rochester, Rochester, NY 0:5 am 799. Identification Of IL-0 Producing Plasma Cells in Human and Its Deficiency in Systemic Lupus Erythematosus Patients Xiaoqian Wang, James Roger and Ignacio Sanz, Emory University, Allergy, Immunology and Rheumatology, Atlanta, GA, University of Rochester, Rochester, NY, Emory University School of Medicine, Atlanta, GA 9 D Imaging in Rheumatoid Arthritis Moderators: Mikkel Ostergaard, DMSc, MD, PhD 9:00 am 800. Dose-Response Effects Of Denosumab, a Novel Subcutaneous RANKL Inhibitor, on The Progression of Bone Erosion in Japanese Patients With Rheumatoid Arthritis Treated With Methotrexate: Results of Phase II DRIVE Study A Twelve Month Placebo Controlled, Randomized, Double Blind Study Tsutomu Takeuchi, Yoshiya Tanaka, Naoki Ishiguro, Hisashi Yamanaka 4, Toshiyuki Yoneda 5, Harry K. Genant 6 and Désirée van der Heijde 7, Keio University School of Medicine, Tokyo, Japan, University of Occupational and Environmental Health, Kitakyushu, Japan, Nagoya University Graduate School of Medicine, Nagoya, Japan, 4 Institute of Rheumatology Tokyo Women s Medical University, Tokyo, Japan, 5 Indiana University School of Medicine, Indianapolis, IN, 6 University of California, San Francisco, CCBR-Synarc, Newark, Tiburon, CA, 7 Leiden University Medical Center, Leiden, Netherlands 9:5 am 80. Comparative Longitudinal Analysis of Periarticular Bone Structure in Patients Treated With Methotrexate in Combination of Either TNF Blockers or Tocilizumab Sebastian Kraus, Matthias Englbrecht, Juergen Rech, Roland Kocijan, Georg A. Schett and Stephanie Finzel, University of Erlangen-Nuremberg, Erlangen, Germany 9:0 am 80. A Treat-to-Target Strategy With Methotrexate and Intra- Articular Triamcinolone With or Without Added Adalimumab Reduces Synovitis, Osteitis and Tenosynovitis and Halts Structural Damage Progression in Early Rheumatoid Arthritis: The Opera Magnetic Resonance Imaging Sub-Study Mette Bjørndal Axelsen, Iris Eshed, Kim Hørslev-Petersen, Kristian Steengaard-Petersen 4, Merete L. Hetland 5, Jakob M. Møller 6, Peter Junker 7, Jan Pødenphant 8, Torkell Ellingsen 9, Palle Ahlquist 0, Hanne M. Lindegaard, Asta Linauskas, Annette Schlemmer, Mette Yde Dam 4, Ib Hansen 5, Hans Chr Horn 6, Christian G. Ammitzbøll 7, Anette Jørgensen 7, Sophine B. Krintel 8, Johnny Raun 9, Julia S. Johansen 0, Niels Steen Krogh and Mikkel Østergaard 5, Copenhagen University, Copenhagen, Denmark, Sheba Medical Center, Tel Hashomer, Israel, South Jutland Hospital, Graasteen, Denmark, 4 Aarhus University Hospital, Aarhus, Denmark, 5 Copenhagen University Hospital Glostrup, Copenhagen, Denmark, 6 Copenhagen University Hospital at Herlev, Copenhagen, Denmark, 7 Odense University Hospital, Odense C, Denmark, 8 Copenhagen University at Gentofte, Hellerup, Denmark, 9 Diagnostic Centre Region Hospital Silkeborg Denmark, 8600 Silkeborg, Denmark, 0 Vejle Regional Hospital, Vejle, Denmark, Odense University Hospital, Odense, Denmark, Vendsyssel Hospital, Hjørring, Denmark, Aalborg University Hospital, Aalborg, Denmark, 4 Silkeborg Regional Hospital, Silkeborg, Denmark, 5 Viborg Hospital, Viborg, Denmark, 6 Vejle Hospital, Vejle, Denmark, 7 Arhus University Hospital, Aarhus, Denmark, 8 Copenhagen University Hospital at Glostrup, Glostrup, Denmark, 9 University of Southern Denmark, Graasten, Denmark, 0 Herlev Hospital, Herlev, Denmark, ZiteLab ApS, Copenhagen, Denmark 9:45 am 80. Can Ultrasonographic Findings Predict Response to Tumor Necrosis Factor-α Inhibitor Treatment in Rheumatoid Arthritis? Nevsun Inanc, Gülsen Ozen and Haner Direskeneli, Marmara University, School of Medicine, Istanbul, Turkey, Marmara University School of Medicine, Istanbul, Turkey 0:00 am 804. Radiological Outcome of Joints With MRI Detected Subclinical Inflammation in Early Arthritis Patients A. Krabben, W. Stomp, J. A. B. van Nies, T.W.J. Huizinga, D. van der Heijde, J.L Bloem, M. Reijnierse and A. H. M. van der Helmvan Mil, Leiden University Medical Center, Leiden, Netherlands WEDNESDAY october 0, 0 denotes Hilton San Diego Bayfront room location 0 Program Book 9

142 WEDNESDAY october 0, 0.0:5 am 805. Synovial Explant Inflammatory Mediator Production Is Associated With Synovitis While Not With Bone Marrow Edema in Rheumatoid Arthritis: A Cross Sectional Study Martin Andersen, Mikael Boesen, Karen Ellegaard, Robin Christensen, Kalle Söderström, Søren Torp-Pedersen, Bente Danneskiold-Samsøe, Else Marie Bartels, Nina Vendel 4, Niels H. Søe 5, Pieter Spee, Ulrik GW Mørch 6, Lars Karlsson and Henning Bliddal, The Parker Institute, Department of Rheumatology, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Denmark, Frederiksberg, Denmark, Department of Radiology, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Denmark, Frederiskberg, Denmark, Translational Immunology, Biopharmaceutical Research Unit, Måløv, Novo Nordisk, Denmark, Måløv, Denmark, 4 Department of Anaesthesiology, Intensive Care and Operations, Gentofte University Hospital, Denmark, Hellerup, Denmark, 5 Department of Orthopedics, Section of Hand Surgery, Gentofte University Hospital, Denmark, Hellerup, Denmark, 6 Biomarkers, Søborg, Novo Nordisk, Denmark, Søborg, Denmark 06 A Infection Related Rheumatic Diseases Moderators: James S. Louie, MD and Robert Inman, MD 9:00 am 806. Low Risk of Hepatitis B Virus Surface Antigen Seroreversion in HBsAg Negative/Anti-Hbc Positive Carriers Undergoing Rituximab for Rheumatoid Arthritis Valentina Varisco, Mauro Vigano, Alberto Batticciotto, Pietro Lampertico, Antonio Marchesoni 4, Patrizia Gibertini 4, Raffaele Pellerito 5, Guido Rovera 5, Roberto Caporali 6, Monica Todoerti 6, Michele Covelli 7, Antonella Notarnicola 7 and Piercarlo Sarzi- Puttini, Rheumatology Unit, L. Sacco University Hospital, Milan, Italy, San Giuseppe hospital, University of Milan,, Milan, Italy, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, University of Milan,, Milan, Italy, 4 Istituto Ortopedico Gaetano Pini, Milano, Italy, 5 Ospedale Mauriziano, Turin, Italy, 6 Rheumatology, IRCCS Policlinico San Matteo Foundation and University of Pavia, Pavia, Italy, 7 D.I.M.I.M.P, Rheumatology Unit - University of Bari, Bari, Italy 9:5 am 807. Management of Vertebral Osteomyelitis: A Randomized Clinical Trial Comparing 6 Versus Weeks of Antibiotic Treatment Louis Bernard, Aurélien Dinh, Idir Ghout, Valérie Zeller 4, Bertrand Issartel 5, Nadia Belmatoug 6, Michel Dupon 7 and Denis Mulleman 8, University hospital of Tours, Tours, France, University hospital of Paris, Garches, France, University Hospital of Paris, Boulogne, France, 4 La Croix Saint Simon Hospital, Paris, France, 5 Clinique du Tonkin, Lyon, France, 6 University hospital of Paris, Clichy, France, 7 University Hospital of Bordeaux, Bordeaux, France, 8 CHU Trousseau Tours, Tours, France 9:0 am 808. Favorable Outcome of Hepatitis E Virus Infection in Patients With Inflammatory Arthritides Treated With Immunosupressants Hélène Bauer, Cécile Luxembourger, Sophie Fournier, Alain G. Cantagrel, Jean Marie Peron, Anne Marie Roque Afonso 4, Pascal Claudepierre 5, S. Fabre 6, Christophe Hudry 7, Guillaume Lefevre 8, Antoine Martin 9, Laurent Messer 0, Béatrice Pallot Prades, Christian Roux, Christelle Sordet, Claire Veissier 4, Daniel Wendling 5, Jacques-Eric Gottenberg and Jean Sibilia 6, CHU de Hautepierre, Strasbourg, France, CHU de Toulouse, Toulouse, France, Centre Hospitalier Universitaire de Toulouse, Toulouse, France, 4 virologie hôpital Paul Brousse, Villejuif, France, 5 Henri Mondor Teaching Hospital, AP-HP, Créteil, France, 6 CHU MONTPELLIER, Montpellier, France, 7 Hopital Cochin, Paris, France, 8 Lille University Hospital, Internal Medicine Department, Lille, France, 9 Centre Hospitalier De St Brieuc, St Brieuc, France, 0 Hopitaux Civils de Colmar, Colmar, France, CHU St Etienne, St Etienne, France, CHU L Archet University Nice, Nice, France, Strasbourg University Hospital, Strasbourg, France, 4 CHU de Bordeaux, Bordeaux, France, 5 University Hospital, Besancon, France, 6 CHU Hautepierre, Strasbourg, France 9:45 am 809. Prevalence and Clinical Presentation of Lyme Arthritis in a Large Cohort Of Patients With Recent-Onset Arthritis Jeska K. De Vries-Bouwstra, Nathalie D. van Burgel, Tom Vreeswijk, Aloys C.M. Kroes, Tom W.J. Huizinga and Annette H. M. van der Helm- van Mil, Leiden University Medical Center, Leiden, Netherlands 0:00 am 80. Follow-Up Testing of Interferon-Gamma Release Assays for the Diagnosis of Hidden Tuberculosis Infection in Patients Receiving Tumor Necrosis Factor Alpha Antagonists Chan-Nam Son, Tae-Hwan Kim, Il-Hoon Sung, Jae-Bum Jun and Dae-Hyun Yoo, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea 0:5 am 8. Disease Characteristics and Treatment Patterns in US Veterans With Rheumatoid Arthritis and Concomitant Hepatitis C Infection Ruchika Patel and Joshua Baker, University of Pennsylvania, Philadelphia, PA Indigo E Medical Education Moderators: Juliet Aizer, MD, MPH and Michael J. Battistone, MD 40 0 Program Book denotes Hilton San Diego Bayfront room location

143 9:00 am 8. A Rheumatology Objective Structured Clinical Examination Using Challenging Patient Scenarios Shows Trainee Use of Medical Jargon Correlates Inversely With Patient Perceptions of Professionalism Jessica Berman, Juliet Aizer, Anne R. Bass, Anne Davidson, Edward Dwyer 4, Theodore R. Fields, Jane Kang 4, Leslie Kerr 5, Svetlana Krasnokutsky-Samuels 6, Deana M. Lazaro 7, Stephen A. Paget, Julie S. Schwartzman-Morris 8 and Michael H. Pillinger 9, Hospital for Special Surgery, Weill Cornell Medical College, New York, NY, Hospital for Special Surgery Weill Cornell Medical College, New York, NY, Feinstein Institute for Medical Research, Manhasset, NY, 4 Columbia School of Medicine, New York, NY, 5 Mount Sinai School of Medicine, New York, NY, 6 NYU School of Medicine, New York, NY, 7 Brooklyn VA, Brooklyn, NY, 8 Albert Einstein College of Medicine, Bronx, NY, 9 NYU School of Medicine, Division of Rheumatology, New York, NY 0:5 am 87. Objective Assessment of Musculoskeletal Physical Examination Skills During Continuing Education Programs for Primary Care Providers Adds Significant Information Not Obtained Through Self-Assessment Andrea M. Barker, Michael J. Battistone, J Peter Beck, Jorie Butler, Marissa Grotzke, Timothy A. Huhtala, Amy C. Cannella, David I. Daikh 4, Meika A Fang 5, Antonio A. Lazzari 6, Pedro Roldan 7, Joan Marie Von Feldt 8 and Grant W. Cannon, Salt Lake City VA and University of Utah, Salt Lake City, UT, Salt Lake City VA, Salt Lake City, UT, Omaha Veterans Affairs Hospital and University of Nebraska Medical Center, Omaha, NE, 4 University of California, San Francisco, San Francisco, CA, 5 VA Greater Los Angeles Healthcare System, Los Angeles, CA, 6 Boston VA Medical Center, Boston, MA, 7 Leesburg VA CBOC, Leesburg, FL, 8 Univ of Pennsylvania/Philadelphia VAMC, Philadelphia, PA 9:5 am 8. Expert Panel Consensus on Content of a Rheumatology Objective Structured Clinical Examination Lisa G. Criscione-Schreiber, Marcy B. Bolster, Beth L. Jonas, Richard Sloane, Jeffrey Hawley 4 and Kenneth S. O Rourke 5, Duke University Health System, Durham, NC, Massachussetts General Hospital, Boston, MA, University of North Carolina at Chapel Hill, Chapel Hill, NC, 4 Duke University School of Nursing, Durham, NC, 5 Wake Forest School of Medicine, Winston-Salem, NC 9:0 am 84. The Resident-Fellow Interaction: Limiting Barriers and Maximizing Learning Eli Miloslavsky, Amy Sullivan, Jeremy Richards, Jakob I. McSparron, David Roberts and Alberto Puig 4, Massachusetts General Hopsital, Boston, MA, Beth Israel Deaconess Medical Center, Boston, MA, Brigham and Women s Hospital, Boston, MA, 4 Massachusetts General Hospital, Boston, MA 9:45 am 85. Preliminary Entrustable Professional Activities in Muscloskeletal Ultrasound for Rheumatology Fellowship Training Amy C. Cannella, Eugene Y. Kissin, Gurjit S. Kaeley, Jay B. Higgs 4, Kelly J. Caverzagie 5 and Karina D. Torralba 6, Omaha Veterans Affairs Hospital and University of Nebraska Medical Center, Omaha, NE, Boston University, Boston, MA, University of Florida, Jacksonville, FL, 4 San Antonio Military Medical Center, Fort Sam Houston, TX, 5 University of Nebraska Medical Center, Omaha, NE, 6 Loma Linda University, Loma Linda, CA 0:00 am 86. Pilot Phase Outcomes From The ACR/Carra Inter- Institutional Mentoring Program in Pediatric Rheumatology Peter A. Nigrovic, Eyal Muscal, Lakshmi N. Moorthy, Sampath Prahalad 4, Marisa S. Klein-Gitelman 5, Meredith P. Riebschleger 6, B. Anne Eberhard 7 and Rayfel Schneider 8, Boston Children s Hospital, Boston, MA, Baylor College of Medicine, Houston, TX, Robert Wood Johnson Medical School-UMDNJ, New Brunswick, NJ, 4 Emory Children s Center, Atlanta, GA, 5 Children s Memorial Hospital, Chicago, IL, 6 University of Michigan Health System, Ann Arbor, MI, 7 Cohen Children s Hospital Medical Center, New Hyde Park, NY, 8 Pediatric Rheumatology Collaborative Study Group (PRCSG), Cincinnati, OH Sapphire I Rheumatoid Arthritis - Animal Models II Moderators: Alison Finnegan, PhD and Harris R. Perlman, PhD 9:00 am 88. Functional Genetics of the Rheumatoid Arthritis Susceptibility Locus PTPN: Heterozygous Knock-Out Increases Severity of Spontaneous Arthritis in Mice Karen Doody, Dennis J. Wu, Michel L. Tremblay and Nunzio Bottini, La Jolla Institute for Allergy and Immunology, La Jolla, CA, McGill University, Montréal, QC 9:5 am 89. Administration Of a Multi-Epitope Citrullinated Peptide Attuneuates adjuvant Induced Arthritis In Rats Via Induction Of Immune Tolerance Howard Amital, Smadar Gertel and Yehuda Shoenfeld, Sheba Medical Center,Tel-Hashomer, Tel-Aviv University, Telhashomer, Israel, Sheba Medical Center, Tel-Hashomer, Israel, Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center, Affiliated to Sackler Faculty of Medicine, Tel-Aviv University,Tel-Aviv, Tel-Aviv, Israel 9:0 am 80. Disease-Regulated Local Interleukin-0 Gene Therapy Diminishes Synovitis and Articular Cartilage Damage in Experimental Arthritis Eline A. Vermeij, Mathijs G.A. Broeren, Miranda B. Bennink, Onno J. Arntz, Inger Gjertsson, Wim B. van den Berg and Fons A.J. van de Loo, Rheumatology Research and Advanced Therapeutics, Department of Rheumatology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, Department of Rheumatology and Inflammation Research, Institute of Medicine, University of Gothenburg, Gothenburg, Sweden, Gothenburg, Sweden 9:45 am 8. Evaluation of Selective Manipulation of the CD8 Co- Stimulation Pathway in the Rhesus Monkey Model of Collagen- Induced Arthritis Michel P.M. Vierboom, Elia Breedveld, Bert t Hart, Flora Coulon and Bernard Vanhove, Biomedical Primate Research Centre, Rijswijk, Netherlands, Institut National de la Santé et de la Recherche Médicale, Nantes, France, INSERM UMR-S 064, Nantes, France WEDNESDAY october 0, 0 denotes Hilton San Diego Bayfront room location 0 Program Book 4

144 WEDNESDAY october 0, 0 6 D 0:00 am 8. IKKε Deficiency Prolongs Neutrophil Survival Paradoxically Prolonging Inflammation in the Absence of a Type I Interferon Response Maripat Corr, Christopher Chung, Seong-Kyu Kim, D. L Boyle and G. S. Firestein, Univ of California-San Diego, La Jolla, CA, UCSD School of Medicine, La Jolla, CA, Catholic University of Daegu School of Medicine, Daegu, South Korea 0:5 am 8. FLIP Deficiency in Dendritic Cells Promotes Spontaneous Inflammatory and Erosive Arthritis Qi Quan Huang, Harris R. Perlman, Robert Birkett, Renee E. Koessler, Syamal K. Datta and Richard M. Pope 4, Northwestern University, Chicago, IL, Northwestern University Medical School, Chicago, IL, Northwestern University FSM, Chicago, IL, 4 Northwestern Univ Med School, Chicago, IL Rheumatoid Arthritis - Clinical Aspects VI: Cardiovascular Disease in Rheumatoid Arthritis Moderators: Shahin Jamal, MD and Piet van Riel, MD, PhD 9:00 am 84. Urinary Microalbumin Is Associated With Arterial Stiffness in Patients With Rheumatoid Arthritis Karima Becetti, Annette Oeser, Joseph F. Solus, Paolo Raggi, C. Michael Stein and Cecilia P. Chung, Vanderbilt University, Nashville, TN, Vanderbilt Medical Center, Nashville, TN, University of Alberta, Edmonton, AB 9:5 am 85. The Influence of Early Menopause on Cardiovascular Risk in Women With Rheumatoid Arthritis Emily Pfeifer, Cynthia S. Crowson, Shreyasee Amin, Sherine E. Gabriel and Eric L. Matteson, Mayo Clinic, Rochester, MN 9:0 am 86. Performance of Five Current Risk Algorithms in Predicting Cardiovascular Events in Rheumatoid Arthritis Patients Elke.E.A. Arts, Calin Popa, Alfons A. den Broeder, Anne G. Semb, Tracey Toms 4, George Kitas 4, Piet L.C.M. van Riel and Jaap Fransen, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, Sint Maartenskliniek, Nijmegen, Netherlands, Diakonhjemmet Hospital, Oslo, Norway, 4 Dudley Group of Hospitals NHS Trust, Russells Hall Hospital, Dudley, United Kingdom 9:45 am 87. Effect of Biologic Agents on Lipids and Cardiovascular Risk in Rheumatoid Arthritis Patients Dimitrios A. Pappas, Ani John, Jeffrey R. Curtis, George W. Reed 4, Jeffrey D. Greenberg 5, Ashwini Shewade, Daniel H. Solomon 6, Joel M. Kremer 7 and Tanya Sommers 4, Columbia University, New York, NY, Genentech Inc., South San Francisco, CA, University of Alabama at Birmingham, Division of Clinical Immunology and Rheumatology, Birmingham, AL, 4 CORRONA, Inc., Southborough, MA, 5 New York Hospital for Joint Diseases, New York, NY, 6 Harvard Medical School, Brigham and Women s Hospital, Division of Rheumatology, Division of Pharmacoepidemiology, Boston, MA, 7 Albany Medical College and The Center for Rheumatology, Albany, NY 0:00 am 88. The Performance of the Original and an Updated Cardiovascular Risk Algorithm (SCORE) in Patients With Rheumatoid Arthritis Elke.E.A. Arts, Calin Popa, Alfons A. den Broeder, Anne Grete Semb, Tracey Toms 4, George Kitas 4, Piet L.C.M. van Riel and Jaap Fransen, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, Sint Maartenskliniek, Nijmegen, Netherlands, Diakonhjemmet Hospital, Oslo, Norway, 4 Dudley Group of Hospitals NHS Trust, Russells Hall Hospital, Dudley, United Kingdom 0:5 am 89. Statin Adherence and Risk of Mortality in Patients With Rheumatoid Arthritis: A Population-Based Study Mary De Vera, Michal Abrahamowicz and Diane Lacaille, Arthritis Research Centre of Canada, Richmond, BC, McGill University, Montreal, QC, Arthritis Research Centre of Canada, University of British Columbia, Richmond, BC 8 D Systemic Lupus Erythematosus Clinical Aspects: Pregnancy Moderators: Megan E. B. Clowse, MD, MPH and Victoria K. Shanmugam, MBBS, MRCP 9:00 am 80. First Stage of a Simon s Two-Stage Optimal Approach Supports Placental Transfer of Hydroxychloroquine and a Reduced Recurrence Rate of The Cardiac Manifestations of Neonatal Lupus Peter M. Izmirly, Nathalie Costedoat-Chalumeau, Amit Saxena, Amanda Zink, Zoey Smith, Deborah Friedman and Jill P. Buyon, New York University School of Medicine, New York, NY, Hopital Cochin, Paris, France, New York Medical College, Valhalla, NY 9:5 am 8. Increased Risk of Autism Spectrum Disorders in Children Born to Women With SLE: Preliminary Data From The O S L E R Cohort Evelyne Vinet, Susan Scott, Christian A. Pineau, Lawrence Joseph, Ann E. Clarke, Eric Fombonne 4, Robert W. Platt and Sasha Bernatsky, McGill University Health Center, Montreal, QC, McGill University Health Centre, Montreal, QC, McGill University, Montreal, QC, 4 Oregon Health and Sciences University, Portland, OR 9:0 am 8. The Effect Of Maternal Antimalarial Intake During Pregnancy On The Risk Of Neonatal Lupus Julie Barsalou, Edgar Jaeggi and Earl D. Silverman, The Hospital for Sick Children, University of Toronto, Toronto, ON 9:45 am 8. Increased Cardiac Septal Defects in Children Born to Women With Systemic Lupus Erythematosus: Results From the O S L E R Study Evelyne Vinet, Susan Scott, Christian A. Pineau, Ann E. Clarke, Robert W. Platt and Sasha Bernatsky, McGill University Health Center, Montreal, QC, McGill University Health Centre, Montreal, QC, McGill University, Montreal, QC 4 0 Program Book denotes Hilton San Diego Bayfront room location

145 0:00 am 84. Maternal Data Analysis of the French Registry of 05 Cases of Immune Congenital Heart Block (Neonatal Lupus) Kateri Levesque, Nathalie Morel, Gaëlle Guettrot-Imbert, Mohamed Hamidou 4, Jean Loup Pennaforte 5, Pauline Orquevaux 5, Jean-Charles Piette 6, Christophe Deligny 7, Zahir Amoura 6, Olivier Meyer 8, Olivier Fain 9, Agathe Masseau 4, Holly Bezanahary 0, Pascal Cathebras, Elizabeth Diot, Yves Dulac, Loic Guillevin 4, Eric Hachulla 5, Jean-Louis Pasquali 6, Anne Besancon-Bergelin 7, Bernard Bonnotte 8, Jérome Lebidois 9, Alice Maltret 0, Elisabeth Villain 0 and Nathalie Costedoat- Chalumeau, Hopital Cochin, Paris, France, COCHIN, Paris, France, Centre Hospitalier de Clermont-Ferrand, Clermont- Ferrand, France, 4 Nantes University Hospital, Nantes, France, 5 CHU Reims, Reims, France, 6 CHU Pitié-Salpêtrière, Paris, France, 7 Centre hospitalier Universitaire de Fort de France, Fort de France, Martinique, 8 Bichat University Hospital, Paris, France, 9 Internal Medicine, Jean Verdier Hospital, Bondy, France, 0 University Hospital of Limoges, Limoges, France, University Hospital St Etienne, St Etienne, France, Department of Internal Medicine, Hôpital Bretonneau, Centre Hospitalier Régional Universitaire de Tours, Tours, France, Tours, France, University Hospital Toulouse, Paris, France, 4 Division of Internal Medicine, Hôpital Cochin, University Paris Descartes, Paris, France, 5 University Hospital Lilles, Lille CEDEX, France, 6 Hôpitaux Universitaires de Strasbourg, Hôpital civil, Service de médecine interne et immunologie clinique, Strasbourg, France, 7 Internal Medicine, Le Mans Hospital, Le Mans, France, 8 Centre Hospitalier de Dijon, Dijon, France, 9 Cardiac Institute, Paris, France, 0 Groupe Hospitalier Necker - Enfants Malades, Paris, France 0:5 am 85. Safety of Gardasil Vaccine in Systemic Lupus Erythematosus J. Patricia Dhar, Lynnette Essenmacher, Renee Dhar, Ardella Magee, Joel Ager, Malini Venkatram, Harpreet Sagar and Robert Sokol, Wayne State University, Detroit, MI C Spondylarthropathies and Psoriatic Arthritis: Clinical Aspects and Treatment: Clinical and Imaging Aspects of Axial Spondyloarthritis Moderators: Filip Van den Bosch, MD, PhD and Walter P. Maksymowych, MD 9:00 am 86. Development of a Health Index in Patients With Ankylosing Spondylitis (ASAS HI) Final Result of a Global Initiative Based on the International Classification of Functioning, Disability and Health (ICF) Guided By Assesment of Spondyloarthritis International Society (ASAS) Uta Kiltz, Désiréé van der Heijde, Annelies Boonen, Alarcos Cieza 4, Gerold Stucki 5, Muhammad Asim Khan 6, Walter P. Maksymowych 7, Helena Marzo-Ortega 8, John D. Reveille 9, Simon Stebbings 0, Cristina Bostan and Juergen Braun, Rheumazentrum Ruhrgebiet, Herne, Germany, Leiden University Medical Center, Leiden, Netherlands, Maastricht University Medical Center, Maastricht, Netherlands, 4 University Southampton, Southampton, United Kingdom, 5 University of Lucerne, Lucerne, Switzerland, 6 Case Western Reserve denotes Hilton San Diego Bayfront room location University Hospital, Cleveland, OH, 7 University of Alberta, Edmonton, AB, 8 Leeds Musculoskeletal Biomedical Research Unit and University of Leeds, Leeds, United Kingdom, 9 Univ of Texas Health Science Center at Houston, Houston, TX, 0 University of Otago, Otago, New Zealand, Paraplegic Research Unit, Nottwil, Switzerland 9:5 am 87. Higher Disease Activity Leads to More Damage in tthe Early Phases of Ankylosing Spondylitis: -Year Data From the OASIS Cohort Sofia Ramiro, A.M. van Tubergen, Désirée van der Heijde, Carmen Stolwijk, Maxime Dougados 4, Filip Van den Bosch 5 and Robert Landewé 6, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands, Maastricht University Medical Center, Maastricht, Netherlands, Leiden University Medical Center, Leiden, Netherlands, 4 Rheumatology B Department, Paris-Descartes University, Cochin Hospital, Paris, France, 5 Gent University Hospital, Gent, Belgium, 6 Academic Medical Center Amsterdam & Atrium Medical Center, Heerlen, Netherlands 9:0 am 88. Relationship Between Active Inflammatory Lesions in the Spine and Sacroiliac Joints and Development of Fatty Lesions on Whole-Body MRI In Patients With Early Axial Spondyloarthritis Long-Term Data of the Esther Trial In-Ho Song, Kay-Geert A. Hermann, Hildrun Haibel, Christian Althoff 4, Denis Poddubnyy, Joachim Listing 5, Anja Weiss 6, Ekkehard Lange 7, Bruce Freundlich 8, Martin Rudwaleit 9 and Joachim Sieper 0, Charité Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin, Germany, Charité Universitätsmedizin Berlin, Campus Mitte, Berlin, Germany, Charité Universitätsmedizin Berlin, Berlin, Germany, 4 Charite Universitätsmedizin Berlin, Campus Mitte, Berlin, Germany, 5 German Rheumatism Research Center, Berlin, Germany, 6 German Rheumatism Research Centre, Berlin, Germany, 7 Pfizer Pharma AG, Berlin, Germany, 8 University of Pennsylvania, Philadelphia, PA, 9 Endokrinologikum Berlin, Berlin, Germany, 0 Charité Universitätsmedizin Berlin, Campus Benjamin-Franklin, Berlin, Germany 9:45 am 89. Effects of Treatment on Spinal Fat Lesions as Assessed By MRI With the Fat Spondyloarthritis Spine Score Hospital at Glostrup, Copenhagen, Denmark, Department of Rheumatology, University of Alberta and PLA General Hospital, Beijing, PR China, Beijing, China, University of Alberta, Edmonton, AB 0:00 am 840. Predictors of Spinal Mobility Progression in a Multiethnic Cohort of Patients With Ankylosing Spondylitis Roozbeh Sharif, Trisha M. Parekh, Lianne S. Gensler, MinJae Lee, Mohammad Rahbar 4, Laura A. Diekman 4, Michael H. Weisman 5, Michael M. Ward 6, Shervin Assassi and John D. Reveille, University of Texas Medical Branch, Galveston, TX, University of California, San Francisco, San Francisco, CA, University of Texas Health Science Center at Houston, Houston, TX, 4 The University of Texas Health Science Center at Houston, Houston, TX, 5 Cedars-Sinai Medical Center, Los Angeles, CA, 6 NIAMS/NIH, Bethesda, MD 0 Program Book 4 WEDNESDAY october 0, 0

146 0:5 am 84. Inflammation and Structural Progression in the Sacroiliac Joints of Patients With Axial Spa Treated With Adalimumab or Placebo aas Assessed By The Berlin and the Spondyloarthritis Research Consortium of Canada MRI Methods Susanne Juhl Pedersen, Denis Poddubnyy, Inge Juul Sørensen, Anne Gitte Loft 4, Jens Skjødt Hindrup 5, Gorm Thamsborg 6, Karsten Asmussen 7, Elka Kluger 8, Jesper Nørregaard 9, Torben Grube Christensen 0, Anne G. Jurik, J.M. Møller, Thomas Skjødt, Dorrit Mikkelsen 4 and Mikkel Østergaard 5, Copenhagen University Hospital at Glostrup, Copenhagen, Denmark, Charité Universitätsmedizin Berlin, Berlin, Germany, Hvidovre Hospital, Copenhagen, Denmark, 4 Department of Rheumatology, Sygehus Lillebaelt, Vejle, Denmark, 5 Gentofte Hospital, Copenhagen, Denmark, 6 Glostrup Hospital, Copenhagen, Denmark, 7 Department of Rheumatology, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Denmark, 8 King Christian 0th Rheumatism Hospital at Gråsten, Graasten, Denmark, 9 Hørsholm Hospital, Hørsholm, Denmark, 0 MD, Slagelse, Denmark, Aarhus University Hospital, Aarhus, Denmark, Copenhagen University Hospital in Herlev, Copenhagen, Denmark, Vejle Hospital, Vejle, Denmark, 4 Aabenraa Hospital, Aabenraa, Denmark, 5 Copenhagen University Hospital Glostrup, Copenhagen, Denmark ARHP SESSIONS 9:00-0:0 am 0 A Update on Orthotic Management for Rheumatic Diseases Through the Lifespan Moderator: To Be Announced describe best practice of orthotic management for those with juvenile idiopatic arthritis describe best practice for upper quarter orthotic management in adult populations describe best practice for lower quarter orthotic management in adult populations evaluate supporting evidence for orthotic management in all populations 9:00 am Update on the Evidence and Orthotic Management of Patients With Juvenile Idiopathis Arthritis Susan Klepper, PhD, PT 9:5 am Update on the Evidence and Orthotic Management of the Upper Extremity in Rheumatic Populations Renee Andersen, CHT, OTR/L 9:50 am Update on the Evidence and Orthotic Management of the Lower Extremity in Rheumatic Populations Smita Rao, PT, PhD WEDNESDAY october 0, 0 Indigo D Rheumatology Practice in the Age of the Affordable Care Act Moderator: Kori A. Dewing, DNP, ARNP discuss the impact of the Affordable Care Act and the challenges of providing rheumatologic care in this new environment identify strategies that may be effective to meet the increased demand for rheumatologic care evaluate the financial, educational, and clinical implications of bringing a mid-level provider into an academic practice describe the utilization of mid-level providers in private practice as demonstrated in a recent survey of nurse practitioners and physician assistants working in a variety of rheumatology practice settings 9:00 am The Affordable Care Act: What Does It Mean to Rheumatology Practices? Michael Schweitz, MD 9:40 am Successful Models of Delivery: How to Make It Work in an Academic Setting Daniel F. Battafarano, DO 0:05 am Expanded Access to Improve Community Health Daniel Solomon, MD, MPH ARHP CONCURRENT ABSTRACT SESSION 9:00 am - 0:0 am A Education/Community Programs Moderator: Jill R. Blitz, PT DPT and Elizabeth G. Salt, PhD 9:00 am 84. Cochrane Systematic Review of Self-Management Education Programs for People With Osteoarthritis Féline P.B. Kroon, Lennart R.A. van der Burg, Rachelle Buchbinder, Richard H. Osborne and Veronica Pitt 4, Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, Monash Department of Clinical Epidemiology at Cabrini Hospital, Department of Epidemiology and Preventive Medicine, Monash University, Malvern, Victoria, Australia, Deakin University, Melbourne, Australia, 4 National Trauma Research Institute, The Alfred Hospital, Monash University, Melbourne, Australia 9:5 am 84. An Education Needs Assessment: Findings From Surveys of Patients and Caregivers Elizabeth M. Badley, Monique A. Gignac, Lynn Moore, Christina H. Chan, Xingshan Cao 4 and Julie Bowring, University of Toronto, Toronto, ON, Toronto Western Research Institute, University Health Network, Toronto, ON, The Arthritis Society, Toronto, ON, 4 Arthritis Community Research and Evaluation Unit, Toronto Western Research Institute, Toronto, ON 44 0 Program Book denotes Hilton San Diego Bayfront room location

147 9:0 am 844. The Assessment of Education Requirements for Ppatients With Rheumatoidarthritis, Based on the Polish version of the Educational Needs Assessment Tool (Pol-ENAT) Matylda Sierakowska, Malgorzata Klepacka, Stanislaw Sierakowski, Justyna Sierakowska, Piotr Leszczynski 4, Maria Majdan 5, Marzena Olesinska 6, Wojciech Romanowski 7, Małgorzata Bykowska-Sochacka 8, Slawomir Jeka 9, Mwidimi Nondosi 0 and Elzbieta Krajewska-Kulak, Medical University of Bialystok, Bialystok, Poland, Medical University in Bialystok, Bialystok, Poland, University of Bialystok, Bialystok, Poland, 4 Medical University in Poznan and J. Strus, Poznan, Poland, 5 Medical University in Lublin, Lublin, Poland, 6 Institute of Rheumatology, Warsaw, Poland, 7 Poznań Centre of Rheumatology in Srem, Srem, Poland, 8 9Dr. Jadwiga Titz-Kosko Regional Hospital for Rheumatic Diseases in Sopot, Sopot, Poland, 9 Clinic of Rheumatology and Connective Tissue Diseases University Hospital No in Bydgoszcz Collegium Medicum UMK in Torun, Bydgoszcz, Poland, 0 University of Leeds, Leeds, United Kingdom 9:45 am 845. Work It Recruitment: Lessons Learned From an Arthritis Work Disability Prevention Randomized Trial Rawan Alheresh, Saralynn H. Allaire, Michael P. Lavalley, Mary Vaughan, Rebecca Emmetts and Julie J. Keysor, Boston University Sargent College, Boston, MA, Boston Univ School of Medicine, Boston, MA, Boston University, Boston, MA 0:00 am 846. Baseline Work Participation of a Novel Intervention to Prevent Work Disability Among Persons With Arthritis: The Work It Study Rawan Alheresh, Saralynn H. Allaire, Michael P. Lavalley, Mary Vaughan and Julie J. Keysor, Boston University Sargent College, Boston, MA, Boston Univ School of Medicine, Boston, MA, Boston University, Boston, MA 0:5 am 847. The Employment Experience of People With Arthritis: Findings From an On-Line Survey Monique A. Gignac, Elizabeth M. Badley, Lynn Moore, Julie Bowring and Xingshan Cao, Toronto Western Research Institute, University Health Network, Toronto, ON, The Arthritis Society, Toronto, ON, Arthritis Community Research and Evaluation Unit, Toronto Western Research Institute, Toronto, ON ACR SESSIONS :00 am - :0 pm 6 A 0 ACR-EULAR Scleroderma Classification Criteria Moderators: Dinesh Khanna, MD, MSc and Thomas A. Medsger Jr., MD explain the rationale for development of new scleroderma classification criteria describe the methodology used to develop new scleroderma classification criteria, and review the new criteria set review the role and importance of the new scleroderma classification criteria in clinical research :00 am New Classification Criteria: Why, Rules and Presentation of New Criteria Frank H.J. van den Hoogen, MD, PhD :0 am Methodology used to Develop New ACR-EULAR Scleroderma Criteria Sindhu R. Johnson, MD. PhD :40 am Operationalization of the New Criteria Janet E. Pope, MD, MPH :00 pm Questions and Answers Sapphire I PCMH-Model and the Rheumatology Specialty Moderator: Angus Worthing, MD Speakers: Hal Yee Jr., MD, PhD identify the role of the rheumatologist and rheumatology medical practice in the PCMH and PCMH-N model recognize the benefits of care coordination agreements as well as the barriers to creating the agreements outline the benefits and barriers to utilizing nontraditional patient encounters that may facilitate a rheumatologists success in the PCHM/PCHM-N model ACR CONCURRENT ABSTRACT SESSIONS :00 am - :0 pm 06 A Fibromyalgia, Soft Tissue Disorders and Pain: Treatment and Outcome Assessment Moderators: Mary-Ann Fitzcharles, MBChB, MD and Jacob N. Ablin, MD WEDNESDAY october 0, 0 denotes Hilton San Diego Bayfront room location 0 Program Book 45

148 WEDNESDAY october 0, 0 :00 am 848. A Randomised Controlled Trial (RCT) of Telephone Delivered Cognitive Behaviour Therapy (tcbt) and Exercise in the Management Of Chronic Widespread Pain (CWP): Identifying Long-Term Outcome and Who Benefits From Which Treatment Gary J. Macfarlane, Marcus Beasley, Philip Keeley, Karina Lovell, Philip Hannaford, Deborah PM Symmons, Steve Woby, Gordon J. Prescott and The MUSICIAN study team 4, University of Aberdeen, Aberdeen, United Kingdom, University of Manchester, Manchester, United Kingdom, Pennine Acute Hospital NHS Trust, Manchester, United Kingdom, 4 Universities of Manchester and Aberdeen, Manchester and Aberdeen, United Kingdom :5 am 849. Medication Adherence and Healthcare Costs Among Patients With Fibromyalgia: Combination Medication Versus Duloxetine, Pregabalin, and Milnacipran Initiators Nicole Marlow, Kit Simpson, James Zoller and E. Baron Short, Medical University of South Carolina, Charleston, SC :0 am 850. Once Daily Controlled-Release Pregabalin In Fibromyalgia Patients: A Phase Double-Blind, Randomized Withdrawal, Placebo-Controlled Study Lesley M. Arnold, Pierre Arsenault, Cynthia Huffman, Jeffrey L. Patrick 4, Michael Messig 4, Marci L. Chew 4, Luis Sanin 4, Lynne Pauer 4 and Andrew Clair 4, University of Cincinnati College of Medicine, Cincinnati, OH, Université de Sherbrooke, Sherbrooke, QC, Meridien Research, Tampa, FL, 4 Pfizer Inc, New York, NY :45 am 85. The Polysymptomatic Distress Scale as a Measure of Disease and Practice Severity in Fibromyalgia Frederick Wolfe, Don L. Goldenberg, Brian T. Walitt and Winfried Häuser 4, National Data Bank for Rheumatic Diseases, Wichita, KS, Newton-Wellesley Hosp, Newton, MA, Washington Hospital Center, Washington, DC, 4 Klinikum Saarbrücken, Saarbrücken, Germany Noon 85. Real-Life Assessment of the Validity Of Patient Global Impression of Change in Fibromyalgia John S. Sampalis, Mary-Ann Fitzcharles, Peter A. Ste-Marie, Emmanouil Rampakakis and Yoram Shir, McGill University, Montreal, QC, McGill University Health Centre, Montreal, QC :5 pm *. Comparative Burden of Chronic Widespread Pain and Fibromyalgia in the U.S. Population Caroline Schaefer, Rachael Mann, Elizabeth T. Masters, Joseph C. Cappelleri 4, Shoshana Daniel 5, Gergana Zlateva, Heather McElroy 6, Arthi B. Chandran, Edgar H. Adams, Annlouise R. Assaf 4, Michael McNett 7, Philip Mease 8, Stuart L. Silverman 9 and Roland Staud 0, Covance Market Access Services Inc., Gaithersburg, MD, Covance Market Access Services Inc., San Diego, CA, Pfizer Inc., New York, NY, 4 Pfizer Inc., Groton, CT, 5 Covance Market Access Services Inc., Conshohocken, PA, 6 Covance Market Access Services, Sydney, Australia, 7 Aurora Pain Program, Milwaukee, WI, 8 Swedish Medical Center, Seattle, WA, 9 Cedars-Sinai Medical Center, UCLA Center of Excellence, Beverly Hills, CA, 0 University of Florida, Gainesville, FL * Break in presentation number sequence is due to the addition of a substitute abstract. 9 D Orthopedics, Low Back Pain, Rehabilitation and Mechanisms of Pain in Arthritis Moderators: David J. Hunter, PhD and Steven Vlad, MD, PhD :00 am 854. Restricting Back Pain and Subsequent Mobility Disability in Community-Living Older Persons Una E. Makris, Liana Fraenkel, Ling Han, Linda Leo-Summers and Thomas M. Gill 4, UT Southwestern Medical Center, VA Medical Center, Dallas, TX, Yale University School of Medicine, Veterans Affairs Connecticut Healthcare System, New Haven, CT, Department of Medicine, New Haven, CT, 4 Yale University, New Haven, CT :5 am 855. Association of Back Pain With Functional Limitations in Patients With Knee and Hip Osteoarthritis Adam P. Goode, Hayden B. Bosworth, Cynthia Coffman, Amy Jeffreys, Eugene Z. Oddone, William S. Yancy Jr. and Kelli D. Allen, Duke University, Durham, NC, Duke and Durham VA Medical Center, Durham, NC :0 am 856. Influence of Mechanical Symptoms on Treatment Outcomes For Meniscal Tear in The Setting of Osteoarthritis Jeffrey N. Katz, John Wright, Lisa A. Mandl, Brian Cole, Laurel Donnell-Fink, Ali Guermazi 4, Morgan Jones 5, Bruce Levy 6, Scott Martin, Robert Marx, Anthony Miniaci 5, Kurt P. Spindler 7, Rick Wright 8 and Elena Losina, Brigham and Women s Hospital, Boston, MA, Hospital for Special Surgery, New York, NY, Rush University, Chicago, IL, 4 Boston University, Boston, MA, 5 Cleveland Clinic, Cleveland, OH, 6 Mayo Clinic, Rochester, MN, 7 Vanderbilt University, Nashville, TN, 8 Washington University, Saint Louis, MO :45 am 857. The Role of FAM7b as a Newly Identified Regulator of Chronic Pain Hanneke Willemen, Annemiek Kavelaars, Rafael González Cano, Cobi Heijnen and Niels Eijkelkamp, UMC Utrecht, Utrecht, Netherlands, MD Anderson Cancer Center, Houston, TX, University of Granada, Granada, Spain Noon 858. Inhibition Of Chronic Pain By IL4-0 Synerkine Is Superior to IL-4 or IL-0 Monotherapy: A Novel Strategy to Restrain Pain in Rheumatic Diseases Niels Eijkelkamp, Sarita Hartgring, Cristine Steen-Louws, Hanneke Willemen, Qiu-Ling Mao-Ying, Cobi Heijnen, Erik Hack, Annemiek Kavelaars and J.A.G. van Roon, UMC Utrecht, Utrecht, Netherlands, University Medical Center Utrecht, Utrecht, Netherlands, MD Anderson Cancer Center, Houston, TX :5 pm 859. Pain Pathway Activation in Dorsal Root Ganglia and Dorsal Horn in a Murine Surgical Model of Osteoarthritis Rachel E. Miller, Phuong Tran, Richard J. Miller and Anne- Marie Malfait, Rush University Medical Center, Chicago, IL, Northwestern University, Chicago, IL 46 0 Program Book denotes Hilton San Diego Bayfront room location

149 Sapphire A Pediatric Rheumatology - Pathogenesis and Genetics Moderators: Karryl Barron, MD and Leonard L. Dragone, MD, PhD :00 am 860. Mir-6a, Mir-0b and HER: New Players on Lupus Nephritis Pathogenesis Patrícia Costa-Reis, Pierre Russo and Kathleen E. Sullivan, The Children s Hospital of Philadelphia, Philadelphia, PA :5 am 86. Accounting for Parental Load and Identification of Multiple Risk Variants for Anti-Ro Congenital Heart Block Through High-Density Genotyping of Immune-Related Loci Robert M. Clancy, Jill P. Buyon, Nathalie Costedoat-Chalumeau, Antonio Brucato, Kateri Levesque, Véronique Ramoni 4, Miranda C. Marion 5, Mary Comeau 5, Satria Sajuthi 6, Paula S. Ramos 7, Robert P. Kimberly 8, Timothy D. Howard 6 and Carl D. Langefeld 5, New York University School of Medicine, New York, NY, Hopital Cochin, Paris, France, USC Internal Medicine, Ospedali Riuniti, Bergamo, Italy, 4 Rheumatology University of Pavia, Pavia, Italy, 5 Wake Forest University Health Sciences, Winston-Salem, NC, 6 Wake Forest School of Medicine, Winston- Salem, NC, 7 Medical University of South Carolina, Charleston, SC, 8 University of Alabama at Birmingham, Birmingham, AL :0 am 86. Autoantigen Microarray Analysis of Sera From New- Onset Pediatric Systemic Lupus Erythematosus Patients: A Distinct Autoantibody Profile Associated With Class III/IV Lupus Nephritis Imelda Balboni, David Haddon, Vivian Diep, Cindy Limb and Paul Utz, Stanford University School of Medicine, Palo Alto, CA, Stanford University School of Medicine, Stanford, CA :45 am 86. Copy Number Variations of Complement C4A and C4B Genes Are Genetic Risk Factor and Disease Modification Factor, Respectively, for Juvenile Dermatomyositis Anjali Patwardhan, Katherine Lintner, Lisa G. Rider, Frederick W. Miller, Terrance O Hanlon, Yee Ling Wu, Bi Zhou, Huanyu Wang, David Newsom, Peter White, Charles H. Spencer and C. Yung Yu, The Research Institute at Nationwide Children s Hospital and The Ohio State University, Columbus, OH, NIEHS, NIH, Bethesda, MD, Nationwide Childrens Hospital, Columbus, OH Noon 864. Whole Exome Sequencing in Pediatric Patients With Early Onset Rare Immunodysregulatory Diseases that Present With Fever and Systemic Inflammation Adriana Almeida de Jesus, Julie Niemela, Yin Liu, Steven Boyden, Ivona Aksentijevich 4, Daniel L. Kastner 4, Thomas A. Fleisher, Raphaela Goldbach-Mansky and Zuoming Deng, National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH, Bethesda, MD, Laboratory Medicine, NIH Clinical Center, Bethesda, MD, National Human Genome Research Institute, NIH, Bethesda, MD, 4 National Human Genome Research Institute, National Institutes of Health, Bethesda, MD 6 D :5 pm 865. Gene Expression Profiles of Fibroblast-Like Synoviocytes in Early Stage of Oligoarticular Juvenile Idiopathic Arthritis Are Different in Extended Versus Persistent Course AnneMarie C. Brescia, Megan M. Simonds, Suzanne M. McCahan, Paul T. Fawcett and Carlos D. Rose, Thomas Jefferson University/ AI dupont Hospital for Children, Wilmington, DE, Nemours/AI dupont Hospital for Children, Wilmington, DE Rheumatoid Arthritis - Clinical Aspects VII: Remission, Flare and Outcome Measures in Rheumatoid Arthritis Moderators: Jennifer Barton, MD and Reike Alten, MD :00 am 866. Determining the Absolute Change in the Clinical Disease Activity Index (CDAI) to Define a Minimally Important Difference Jeffrey R. Curtis, Shuo Yang, Lang Chen, Janet E. Pope, Edward C. Keystone, Boulos Haraoui 4, Gilles Boire 5, J. Carter Thorne 6, Diane Tin 6, Carol A. Hitchon 7, Clifton O. Bingham III 8 and Vivian P. Bykerk 9, University of Alabama at Birmingham, Birmingham, AL, St Joseph Health Care, London, ON, Mount Sinai Hospital/University of Toronto, Toronto, ON, 4 Centre Hospitalier de l Université de Montréal, Montreal, QC, 5 Centre Hospitalier Universitaire de Sherbrooke, Université de Sherbrooke, Sherbrooke, QC, 6 Southlake Regional Health Centre, Newmarket, ON, 7 University of Manitoba, Winnipeg, MB, 8 Johns Hopkins University, Baltimore, MD, 9 Hospital for Special Surgery, New York, NY :5 am 867. Using Patient Reported Outcomes Measurement Information System Instruments to Identify Disease Flares in People With Rheumatoid Arthritis Susan J. Bartlett, Ana-Maria Orbai, Trisha Duncan and Clifton O. Bingham III, Johns Hopkins School of Medicine, Baltimore, MD, Johns Hopkins University, Baltimore, MD :0 am 868. Reliability and Validity of Patient-Reported Joint Counts and Determinants of Disagreement With the Physician in Recent Onset Rheumatoid Arthritis Karen Visser, Janet E. Pope, Ernest Choy, Clifton O. Bingham III 4, Susan J. Bartlett 5, Gilles Boire 6, Carol A. Hitchon 7, J. Carter Thorne 8, Boulos Haraoui 9, Diane Tin 8, Edward Keystone 0 and Vivian P. Bykerk, Leiden University Medical Center, Leiden, Netherlands, St Joseph Health Centre, London, ON, Cardiff University, Cardiff, ENGLAND, United Kingdom, 4 Johns Hopkins University, Baltimore, MD, 5 Johns Hopkins School of Medicine, Baltimore, MD, 6 Centre Hospitalier Universitaire de Sherbrooke, Université de Sherbrooke, Sherbrooke, QC, 7 University of Manitoba, Winnipeg, MB, 8 Southlake Regional Health Centre, Newmarket, ON, 9 Institut de Rhumatologie de Montréal, Montreal, QC, 0 University of Toronto, Toronto, ON, Hospital for Special Surgery, New York, NY WEDNESDAY october 0, 0 denotes Hilton San Diego Bayfront room location 0 Program Book 47

150 WEDNESDAY october 0, 0 :45 am 869. Changes in Patient-Reported Joint Counts and Composite Indices Can Identify Flare of Disease Activity in Recent Onset Rheumatoid Arthritis Karen Visser, Susan J. Bartlett, Clifton O. Bingham III, Ernest Choy 4, Daming Lin 5, Juan Xiong 6, Gilles Boire 7, Boulos Haraoui 8, Carol A. Hitchon 9, Edward Keystone 0, Janet E. Pope, J. Carter Thorne, Diane Tin and Vivian P. Bykerk, Leiden University Medical Center, Leiden, Netherlands, Johns Hopkins University, Baltimore, MD, Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, 4 Cardiff University, Institute of Infection and Immunity, Cardiff, United Kingdom, 5 Mount Sinai Hospital, University of Toronto, Toronto, ON, 6 Mount Sinai Hospital, Toronto, ON, 7 Centre Hospitalier Universitaire de Sherbrooke, Université de Sherbrooke, Sherbrooke, QC, 8 Osteoarthritis Research Unit, University of Montreal Hospital Research Centre (CRCHUM), Montreal, QC, 9 University of Manitoba, Winnipeg, MB, 0 University of Toronto, Toronto, ON, St Joseph Health Care, London, ON, Southlake Regional Health Centre, Newmarket, ON, Hospital for Special Surgery, Weill Cornell Medical College, New York, NY Noon 870. Higher Disease Activity and Serum Levels of Angiogenic Factors in Patients With Rheumatoid Arthritis in Clinical Remission With Synovitis on Ultrasound Julio Ramirez, Virginia Ruiz-Esquide, Isaac Pomés, Raquel Celis, Jaume Pomés, Sonia Cabrera, M. Victoria Hernández, Oscar M Epis, Jose L. Pablos 4, Raimon Sanmarti 5 and Juan D. Cañete, Hospital Clínic, Barcelona, Spain, Hospital Clinic, Barcelona, Spain, Ospedale Niguarda Cà Granda, Milano, Italy, 4 Instituto de Investigación Hospital de Octubre, Madrid, Spain, 5 Hospital Clínic of Barcelona, Barcelona, Spain :5 pm 87. Validation of the FLARE Self-Report Questionnaire For Assessing FLARE out of the Clinical Visit in Rheumatoid Arthritis Jacques Morel, Jean-Marie Berthelot, Arnaud L. Constantin, Michel De Bandt 4, Philippe Gaudin 5, Olivier Vittecoq 6, Jean Francis Maillefert 7, Olivier Meyer 8, Thao Pham 9, Alain Saraux 0, Elisabeth Solau Gervais, Elisabeth Spitz, Daniel Wendling, Francis Guillemin 4 and Bruno Fautrel 5, Lapeyronie Hospital, Montpellier, France, Nantes University Hospital, Nantes, France, Purpan University Hospital, Toulouse, France, 4 Centre hospitalier Universitaire de Fort de France, Fort de France, Martinique, 5 CHU Hôpital Sud, Grenoble Teaching Hospital, Echirolles, France, 6 Department of Rheumatology, Rouen University Hospital & Inserm 905, Institute for Biomedical Research, University of Rouen, Rouen Cedex, France, 7 Rheumatology, Dijon, France, 8 Bichat University Hospital, Paris, France, 9 Sainte Marguerite Hospital, Marseille, France, 0 CHU de la Cavale Blanche, Brest Cedex, France, CHU de Poitiers, Poitiers, France, APEMAC-EA460, Metz, France, University Hospital, Besancon, France, 4 CHU Nancy, Clinical Epidemiology and Evaluation, Université de Lorraine, Paris Descartes University, APEMAC, EA 460, Nancy, France, 5 Paris 6 Pierre et Marie Curie University; AP-HP, Rheumatology, Pitié-Salpêtrière Hospital, - GRC-UPMC 08 EEMOIS, Paris, France C Rheumatoid Arthritis - Pathogenetic Pathways Moderators: Marpiat Corr, MD and Pierre Miossec, MD, PhD :00 am 87. Long Noncoding RNA Nron Regulates the Cytoplasmic- Nuclear Shuttling and Activity oof NFAT5 in Rheumatoid Arthritis Synovial Fibroblast Kunihiko Umekita, Michelle Trenkmann, Christoph Kolling, Beat A. Michel, Renate E. Gay, Steffen Gay and Mojca Frank Bertoncelj, Center of Experimental Rheumatology, University Hospital Zurich and Zurich Center of Integrative Human Physiology (ZIHP), Zurich, Switzerland, Schultess Clinic, Zurich, Switzerland, Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland :5 am 87. The Ion Channel TRPV Is New Suppressor of Arthritis Severity and Joint Damage Teresina Laragione, Max Brenner, Christine Beeton and Percio Gulko, Hosftra North Shore-LIJ School of Medicine, Manhasset, NY, Baylor College of Medicine, Houston, TX :0 am 874. Biological Roles of C5orf0 in Rheumatoid Arthritis Synovial Fibroblasts Munitta Muthana, Holly Davies, Sachin Khetan, Gbadebo Adeleke Adeleke, Sarah Hawtree and Anthony G. Wilson, University of Sheffield, Sheffield, United Kingdom, Dr, Sheffield, United Kingdom :45 am 875. Metabolic Profiles of Synovial Fibroblasts Sabrina Kapoor, Andrew Filer, Christopher D. Buckley, Karim Raza and Stephen Young, University of Birmingham, Birmingham, United Kingdom, Rheumatology Department, Birmingham, United Kingdom, School of Immunity and Infection, MRC Center for Immune Regulation, Birmingham, United Kingdom Noon 876. Key Rheumatoid Arthritis-Associated Pathogenic Pathways Revealed By Integrative Analysis of RA Omics Datasets John Whitaker, Wei Wang and Gary S. Firestein, UCSD School of Medicine, La Jolla, CA, UCSD, La Jolla, CA :5 pm 877. Potential of Integrating Human Genetics and Electronic Medical Records for Drug Discovery: The Example of TYK and Rheumatoid Arthritis Dorothee Diogo, Katherine P. Liao, Robert S. Fulton, Robert R. Graham 4, Jing Cui, Jeffrey D. Greenberg 5, Stephen Eyre 6, John Bowes 7, Annette T. Lee 8, Dimitrios A. Pappas 9, Joel M. Kremer 0, Anne Barton 6, Marieke J.H. Coenen, Xavier Mariette, Corrine Richard-Miceli, Helena Canhão 4, João E. Fonseca 5, Niek de Vries 6, Fina Kurreeman 7, Ted R. Mikuls 8, Yukinori Okada, Isaac Kohane 9, Joshua C. Denny 0, Jane Worthington 6, Soumya Raychaudhuri, Timothy W. Behrens, Michael F. Seldin, Peter K. Gregersen 8, Elaine R. Mardis and Robert M. Plenge, Brigham and Women s Hospital, Harvard Medical School, Boston, MA, 48 0 Program Book denotes Hilton San Diego Bayfront room location

151 Brigham and Women s Hospital, Boston, MA, The Genome Institute, Washington University School of Medicine, Saint Louis, MO, 4 Genentech, Inc., South San Francisco, CA, 5 NYU Hospital for Joint Diseases, New York, NY, 6 Arthritis Research UK Epidemiology Unit, University of Manchester, Manchester, United Kingdom, 7 Arthritis Research UK Epidemiology Unit, The University of Manchester, Manchester, United Kingdom, 8 Feinstein Institute for Medical Research, Manhasset, NY, 9 Columbia University, College of Physicians and Surgeons, New York, NY, 0 Center for Rheumatology, Albany Medical College, Albany, NY, Department of Human Genetics, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, Bicêtre University Hospital, Le Kremlin Bicetre, France, Hôpital Bicêtre, Université Paris-sud, Paris, France, 4 Instituto de Medicina Molecular, Faculdade de Medicina da Universidade de Lisboa and Rheumatology Department, Centro Hospitalar de Lisboa Norte, EPE, Hospital de Santa Maria, Lisboa, Portugal, 5 Rheumatology Research Unit, Instituto de Medicina Molecular, Faculdade de Medicina da Universidade de Lisboa, Lisbon, Portugal, 6 Division of Clinical Immunology and Rheumatology and Department of Experimental Immunology, Academic Medical Center / University of Amsterdam, Amsterdam, Netherlands, 7 Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 8 Omaha VA and University of Nebraska Medical Center, Omaha, NE, 9 on behalf of ib ; Brigham and Women s Hospital, Boston, MA, 0 Department of Biomedical Informatics, Vanderbilt University School of Medicine, Nashville, TN, Genentech, Inc, South San Francisco, CA, Department of Biochemistry and Molecular Medicine, University of California, Davis, CA 8 B Sjögren s Syndrome: Clinical Advances Moderators: Alan N. Baer, MD and Simon J. Bowman, PhD :00 am 878. The Importance of Germinal Center-Like Structures in Primary Sjögren s Syndrome Salivary Glands Beyond Lymphoma Risk Elke Theander, Thomas Mandl, Rolf Liedholm, Roland Jonsson 4, Malin V. Jonsson 4 and Gunnar Warfvinge, Lund University, Malmö, Sweden, Skåne University Hospital Malmo, Lund University, Sweden, Malmö, Sweden, Skåne University Hospital Malmö, Lund University, Malmö, Sweden, 4 University of Bergen, Bergen, Norway :5 am 879. Prognostic Value of Minor Salivary Gland Assessments in Primary Sjögren s Syndrome Anna Risselada, A.A. Kruize, J.A.G. van Roon, F.P.J.G. Lafeber and J.W.J. Bijlsma, University Medical Center Utrecht, Utrecht, Netherlands :0 am 880. Impact of Different End Points on the Patient Cohort Size Needed to Demonstrate the Efficacy of a Therapeutic Intervention in Pss. A Post Hoc Analysis of the Tears Study (Tolerance and efficacy of Rituximab in primary Sjögren Syndrome study) Valerie devauchelle-pensec, Sandrine jousse-joulin, Xavier Mariette, Jean-Marie Berthelot 4, Aleth Perdriger 5, Eric Hachulla 6, Xavier Puechal 7, Véronique le Guern 8, Jean Sibilia 9, Jacques-Eric Gottenberg 9, Laurent Chiche Sr. 0, Vincent Goeb, Gilles Hayem, Jacques Morel, Charles Zarnitsky 4, Jean Jacques Dubost 5, Jacques-Olivier Pers 6, Divi Cornec 6, Raphaèle Seror 7, Emmanuel Nowak 8 and Alain Saraux 9, Brest Occidentale university, Brest, France, CHU de la Cavale Blanche, Brest, France, Bicêtre University Hospital, Le Kremlin Bicetre, France, 4 Nantes University Hospital, Nantes, France, 5 Hôpital Sud, Rennes, France, 6 Internal Medicine, Lille CEDEX, France, 7 Department of Internal Medicine, Referral Center for Rare Autoimmune and Systemic Diseases, Hôpital Cochin, AP HP, Université Paris Descartes, Paris, France, Paris, France, 8 Cochin Hospital, Paris, France, 9 Strasbourg University Hospital, Strasbourg, France, 0 Internal Medicine, CHU Marseille, Marseille, France, Amiens University Hospital, Amiens, France, Bichat Hospital, Paris, France, Lapeyronie Hospital, Montpellier, France, 4 Le Havre General Hospital, Le Havre, France, 5 CHU G.-Montpied, Clermont-Ferrand, France, 6 Brest Occidentale University, Brest, France, 7 Bicetre university hospital, LE Kremlin-Bicetre, France, 8 CHU Brest, Brest, France, 9 Université Brest Occidentale, Brest, France :45 am 88. Ultrasonographic Salivary Glands Response to Rituximab in Primary Sjögren Syndrome Patients in the Tolerance and Efficacy of Rituximab in Primary Sjogren Syndrome Study Is Not Associated With the Anatomopathology Changes Sandrine Jousse-Joulin, Valerie Devauchelle-Pensec, Divi Cornec, Simon Gestin 4, Luc Bressollette, Thierry Marhadour 5, Jacques-Olivier Pers, Emmanuel Nowak 4 and Alain Saraux 6, Brest university medical school, EA 6, UBO and CHU de la Cavale Blanche,, Brest, France, Brest Occidentale university, Brest, France, Brest Occidentale University, Brest, France, 4 CHU Brest, Brest, France, 5 CHU de la Cavale Blanche, Brest, France, 6 CHU Brest et Université Bretagne Occidentale, Brest, France Noon 88. B-Cell Depletion Modulates T-Helper Cell Balance in Patients With Primary Sjögren s Syndrome WH Abdulahad, FGM Kroese, Gwenny Verstappen, MG Huitema, PM Meiners, A Vissink and H Bootsma, University Medical Center Groningen, Groningen, Netherlands, University of Groningen and University Medical Center Groningen, Groningen, Netherlands WEDNESDAY october 0, 0 :5 pm 88. Clinical Characteristics of Rheumatoid Arthritis Patients with Secondary Sjögren s Syndrome and Association With Joint Damage Lindsay E. Brown, Michelle A. Frits, Christine K. Iannaccone, Michael E. Weinblatt, Nancy A. Shadick and Katherine P. Liao, Massachusetts General Hospital, Boston, MA, Brigham and Women s Hospital, Boston, MA denotes Hilton San Diego Bayfront room location 0 Program Book 49

152 WEDNESDAY october 0, 0 Indigo D Spondylarthropathies and Psoriatic Arthritis: Clinical Aspects and Treatment: Imaging in Axial Spondylarthropathies: Challenges, Advances Moderators: Atul Deodhar, MD and R. Landewe, MD, PhD :00 am 884. Prevalence of Structural Lesions Seen on MRI-Spine in Patients With (Possible) Axial Spondyloarthritis (axspa) Included in the SPACE-Cohort Manouk de Hooge, Rosaline van den Berg, Victoria Navarro- Compán, Monique Reijnierse, Floris van Gaalen, Karen Fagerli, Maureen C. Turina, Maikel van Oosterhout 4, Roberta Ramonda 5, Tom Huizinga and Désirée van der Heijde, Leiden University Medical Center, Leiden, Netherlands, Diakonhjemmet Hospital, Oslo, Norway, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, 4 GHZ Hospital, Gouda, Netherlands, 5 University of Padova, Padova, Italy :5 am 885. Erosions and Sclerosis, but Not Squaring, Predict The Development of New Syndesmophytes: A -Year Longitudinal Analysis (OASIS) Sofia Ramiro, A.M. van Tubergen, Désirée van der Heijde, Carmen Stolwijk, Maxime Dougados 4, Filip Van den Bosch 5 and Robert Landewé 6, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands, Maastricht University Medical Center, Maastricht, Netherlands, Leiden University Medical Center, Leiden, Netherlands, 4 Rheumatology B Department, Paris-Descartes University, Cochin Hospital, Paris, France, 5 Gent University Hospital, Gent, Belgium, 6 Academic Medical Center Amsterdam & Atrium Medical Center, Heerlen, Netherlands :0 am 886. Prevalence of Structural Lesions on MRI of tthe Sacroiliac Joints in Patients With Early Axial Spondyloarthritis and Patients With Back Pain Rosaline van den Berg, Manouk de Hooge, Victoria Navarro- Compán, Monique Reijnierse, Floris van Gaalen, Karen Fagerli, Maureen Turina, Maikel van Oosterhout 4, Roberta Ramonda 5, Tom Huizinga and Désirée van der Heijde, Leiden University Medical Center, Leiden, Netherlands, Diakonhjemmet Hospital, Oslo, Norway, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, 4 GHZ Hospital, Gouda, Netherlands, 5 University of Padova, Padova, Italy :45 am 887. The Spondyloarthritis Research Consortium of Canada MRI Sacroiliac Joint Structural Score: A Method For Reliable Detection of Structural Progression Walter P. Maksymowych, Stephanie Wichuk, Praveena Chiowchanwisawakit, Robert GW Lambert and Susanne Juhl Pedersen, University of Alberta, Edmonton, AB, Mahidol University, Bangkok, Thailand, Copenhagen University Hospital at Glostrup, Copenhagen, Denmark Noon 888. Frequent Detection of Inflammation and Fat Infiltration Suggestive of Spondyloarthritis on MRI of the Entire Spine in Healthy Subjects and Patients With Mechanical Back Pain Ulrich Weber, Zheng Zhao, Veronika Zubler, Stanley Chan, Robert GW Lambert, Mikkel Ostergaard 4, Susanne Juhl Pedersen 5, Kaspar Rufibach 6 and Walter P. Maksymowych, Balgrist University Hospital, Zurich, Switzerland, Department of Rheumatology, University of Alberta and PLA General Hospital, Beijing, PR China, Beijing, China, University of Alberta, Edmonton, AB, 4 Copenhagen Center for Arthritis Research, Glostrup, Denmark, 5 Copenhagen University Hospital at Glostrup, Copenhagen, Denmark, 6 reprostat, Basel, Switzerland :5 pm 889. Bone Marrow Edema and Structural Lesions in the Sacroiliac Joint iin a Large Cohort of Patients With Axial Spondyloarthritis, Chronic Low Back Pain and Healthy Controls L. van Hoeven, J.J. Luime, P.D.M. de Buck, J.M.W. Hazes and A.E.A.M. Weel, Erasmus University Medical Center, Rotterdam, Netherlands, MC Haaglanden, Den Haag, Netherlands, Maasstad Hospital, Rotterdam, Netherlands Indigo C Systemic Lupus Erythematosus - Animal Models Moderators: Keith B. Elkon, MD and Laurence Morel, PhD :00 am 890. Novel Selective Inhibitors of Nuclear Export (SINE) Decrease Type I Interferon Activation and Deplete Autoreactive Plasma Cells in the Kidney in Murine Lupus Teresa Owen, Javier Rangel-Moreno, Boris Klebanov, Yosef Landesman, Michael Kauffman, Sharon Shacham and Jennifer H. Anolik, University of Rochester Medical Center, Rochester, NY, Karyopharm Therapeutics Inc., Natick, MA :5 am 89. Loss of Caspase 8 Exacerbates Dendritic Cell Activation in a MyD88- and RIPK-Dependent Manner That Is Controlled By Inhibitory Molecules Transcribed By IRF Carla M. Cuda, Alexander V. Misharin, Rana Saber and Harris R. Perlman, Northwestern University Feinberg School of Medicine, Chicago, IL, Northwestern University, Chicago, IL :0 am 89. Masp-/ Deficient MRL/Lpr Mice Lack the Alternative Complement Pathway Activation and Are Protected From Development of Lupus-Like Glomerulonephritis Takeshi Machida, Natsumi Sakamoto, Teizo Fujita, Minoru Takahashi and Hideharu Sekine, Fukushima Medical University School of Medicine, Fukushima, Japan :45 am 89. Intestinal Microbiota Plays a Critical Role in the Production of Antinuclear Antibodies in Lymphopenia-Induced Autoimmunity Toshiki Eri, Kimito Kawahata, Mitsuru Imamura, Takeyuki Kanzaki, Lisa Akahira, Kazuya Michishita, Makoto Dohi, Takeshi Tokuhisa and Kazuhiko Yamamoto, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan, Yamanashi Prefectural Central Hospital, Yamanashi, Japan, Graduate School of Medicine, Chiba University, Chiba city, Chiba, Japan 50 0 Program Book denotes Hilton San Diego Bayfront room location

153 Noon 894. Triggering Receptor Expressed on Myeloid Cells in Systemic Lupus Erythematosus Laurie Davis, Yong Du, Tianfu Wu and Chandra Mohan, UT Southwestern Medical Center, Dallas, TX, University of Texas, Southwestern Medical Center at Dallas, Dallas, TX, University of Texas Southwestern Medical Center, Dallas, TX :5 pm 895. Bacterial Amyloids Promote Type I Interferon Production and Accelerate Autoimmunity Paul Gallo, Glenn Rapsinski, Cagla Tukel and Stefania Gallucci, Laboratory of Dendritic Cell Biology, Temple Autoimmunity Center, Temple University School of Medicine, Philadelphia, PA A Systemic Lupus Erythematosus - Clinical Aspects: Cardiovascular and Other Complications of Lupus Moderators: S. Sam Lim, MD, MPH and Arezou Khosroshahi, MD :00 am 896. Damage in Systemic Lupus Erythematosus Is a Potentially Modifiable Outcome: Results From the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort Ian N. Bruce, Aidan O Keefe, Li Su, Vernon Farewell, John G. Hanly 4, Susan Manzi 5, Murray B. Urowitz 6 and Systemic Lupus International Collaborating Clinics (SLICC) 7, Arthritis Research UK Epidemiology Unit and NIHR Manchester Musculoskeletal Biomedical Research Unit, The University of Manchester, Manchester, United Kingdom, University of Cambridge, Cambridge, United Kingdom, MRC Biostatistics Unit, Cambridge, United Kingdom, 4 Dalhousie University and Capital Health, Halifax, NS, 5 West Penn Allegheny Health System, Pittsburgh, PA, 6 University of Toronto, Toronto Western Hospital, Toronto, ON, 7 Toronto Western Hospital, Toronto, ON :5 am 897. The Risk of Deep Vein Thrombosis and Pulmonary Embolism in Systemic Lupus Erythematosus: A Population- Based Cohort Study J. Antonio Avina-Zubieta, Eric C. Sayre, Diane Lacaille and John M. Esdaile, Arthritis Research Centre of Canada, University of British Columbia, Richmond, BC, Arthritis Research Centre of Canada, Richmond, BC :0 am 898. Atherosclerosis in Systemic Lupus Erythematosus (SLE) and Controls, -An Analysis of SLE Subgroups Johanna Gustafsson, Kerstin Jensen-Urstad, Marie Herlitz- Lindberg, Sonia Möller, Susanne Pettersson, Iva Gunnarsson, Anders Larsson and Elisabet Svenungsson, Karolinska Institutet, Stockholm, Sweden, Akademiska Hospital, Uppsala, Sweden :45 am 899. Outcome of Incidental Silent Strokes in Systemic Lupus Erythematosus Jamal Mikdashi, University of Maryland School of Medicine, Baltimore, MD Noon 900. Predictors 0f Damage Accrual Over a Year Period in a Large Multi-Racial/Ethnic Lupus Cohort Megan E. B. Clowse, Jennifer M. Grossman, Joan T. Merrill, Anca Askanase 4, Olga Dvorkina 5, Michael D. Lockshin 6 and Cynthia Aranow 7, Duke University Medical Center, Durham, NC, UCLA David Geffen School of Medicine, Los Angeles, CA, Oklahoma Medical Research Foundation, Oklahoma City, OK, 4 New York University School of Medicine, New York, NY, 5 SUNY Downstate Medical Center, Brooklyn, NY, 6 Hospital for Special Surgery, New York, NY, 7 The Feinstein Institute, Manhasset, NY :5 pm 90. Standardized Incidence Ratios for Cancer After Renal Transplant in Systemic Lupus Erythematosus and Non-Systemic Lupus Erythematosus Recipients Rosalind Ramsey-Goldman, Amarpali Brar, Moro Salifu, Ann E. Clarke, Rahul M. Jindal 4 and Sasha Bernatsky, Northwestern University Feinberg School of Medicine, Chicago, IL, SUNY Downstate, Brooklyn, NY, McGill University, Montreal, QC, 4 Uniformed Services University and George Washington University, Washington, DC Indigo C NOTE TIME CHANGE Systemic Sclerosis, Fibrosing Syndromes and Raynaud s Pathogenesis, Animal Models and Genetics: Pathogenesis of Systemic Sclerosis Moderators: Robert A. Lafyatis, MD and Arnold E. Postlethwaite, MD :00 am 9:00 am 90. Key Roles for Interferon and Macrophage Activation in Progressive Lung Fibrosis Associated With Systemic Sclerosis Romy Christmann, Giuseppina Stifano, Claudia Borges, Carlos Carvalho, Ronaldo Kairalla, Edwin R. Parra, Avrum Spira, Robert W. Simms, Percival Sampaio-Barros, Vera L. Capelozzi and Robert Lafyatis, Boston University School of Medicine, Boston, MA, CEUMA University, Sao Luis do Maranhao, Brazil, University of Sao Paulo School of Medicine, Sao Paulo, Brazil :5 am 9:5 am 90. Perturbed Response to Experimental Renal Injury in a TGFβ Dependent Mouse Model of Scleroderma Emma Derrett-Smith, Mark Neal, David J. Abraham, Alan Salama, Mark A. Little and Christopher P. Denton, UCL Medical School, London, United Kingdom :0 am 9:0 am 904. Gadolinium-Based Compounds Induce NLRP-Dependent IL-β Production and Peritoneal Inflammation Jonathan Kay, Lukas Bossaller, Christian Schmidt-Lauber, Hani H. Abujudeh, Gregory Vladimer, Eicke Latz, Katherine A. Fitzgerald, Ann Marshak-Rothstein and Ellen M. Gravallese, UMass Memorial Medical Center and University of Massachusetts Medical School, Worcester, MA, University of Massachusetts Medical School, Worcester, MA, Massachusetts General Hospital and Harvard Medical School, Boston, MA WEDNESDAY october 0, 0 denotes Hilton San Diego Bayfront room location 0 Program Book 5

154 WEDNESDAY october 0, 0 :45 am 9:45 am 905. Demethylation of ITGAL (CDa) regulatory sequences in CD4+T lymphocytes of Systemic Sclerosis Yaoyao Wang, Ye Shu, Qing Wang, Ming Zhao, Gongping Liang, Qianjin Lu and Rong Xiao, Second Xiangya Hospital, Central South University, Changsha, China, Hunan Children s Hospital, Changsha, China Noon 0:00 am 906. Peripheral Blood Mononuclear Cells Co-Cultured With Autologous Skin Fibroblasts Up-Regulate IL-7A and Play Anti- Fibrotic Effects in Systemic Sclerosis Serena Vettori, Giuseppe Pasquale, Michele Iudici, Giovanna Cuomo, Giusi Barra, Barbara Russo, Raffaele De Palma and Gabriele Valentini, Rheumatology Unit, Second University of Naples, Naples, Italy, Immunology Unit, Second University of Naples, Naples, Italy :5 pm 0:0 am 907. D98G Variant of Hepatocyte Growth Factor Receptor A Potential Biomarker of Severe Interstitial Lung Diseasein African American Scleroderma Patients Ilia Atanelishvili, Tanjina Akter, Richard M. Silver and Galina S. Bogatkevich, Medical University of SC, Charleston, SC ARHP SESSION :00 am - :0 pm 04 A Highlights for the 0 ARHP Annual Scientific Meeting Moderator: Jan K. Richardson, PT, PhD, OCS, FAPTA summarize the highlights from the 0 ARHP Annual Scientific Meeting evaluate the diversity of the scientific research and content areas of the ARHP presentations recognize the important trends in ARHP research gain insights into sessions to be viewed in SessionSelect :00 am Clinical Perspectives Donah Z. Crawford, BS, MA :45 am Research Perspectives Robert R. McLean, DSc, MPH 0 E NOTE TIME CHANGE Systemic Sclerosis, Fibrosing Syndromes, and Raynaud s - Clinical Aspects and Therapeutics III Moderator: Tracy M. Frech, MD :00 am 7:00 am 94. Serum Proteins and Whole Blood Transcripts Suppressed By An Anti-Type I Interferon Receptor Monoclonal Antibody In Subjects With Systemic Sclerosis Xiang Guo, Brandon W. Higgs, Christopher Kane, Chris, A. Morehouse, Zheng Liu, Liangwei Wang, Stephen Yoo, Yihong Yao, Lorin Roskos and Wendy White, MedImmune, LLC, Gaithersburg, MD, MedImmune, Gaithersburg, MD :5 am 7:5 am 95. Effect Of Menopause On Skin Thickening In Systemic Sclerosis Evelyne Vinet, Sasha Bernatsky, Christian A. Pineau, Marie Hudson, Murray Baron and the Canadian Scleroderma Research Group, McGill University Health Center, Montreal, QC, McGill University, Montreal, QC, McGill University Health Centre, Montreal, QC :0 am 7:0 am 96. Anti-Fibrillarin Antibodies Are Associated With More Severe Gastrointestinal Involvement and Poorer Survival Shervin Assassi, Marie Hudson, Maureen D. Mayes, Jennifer Walker, Murray Baron, Wendy Stevens 4, Karen Patterson 5, Tiffany Graham, Solene Tatibouet, James Wick 6, Matt Stephenson 6 and Marvin J. Fritzler 6, University of Texas Health Science Center at Houston, Houston, TX, McGill University, Montreal, QC, Flinders Medical Centre, Adelaide, Australia, 4 St Vincent s Hospital, Melbourne, Australia, 5 Institute of Medical and Veterinary Science, North Adelaide, Australia, 6 University of Calgary, Calgary, AB :45 am 7:45 am 97. Mortality, Recurrence, and Hospital Course of Patients With Systemic Sclerosis Related Acute Intestinal Pseudo- Obstruction Chris T. Derk, Nora Sandorfi, Shivani Purohit and Christopher Mecoli, University of Pennsylvania, Philadelphia, PA, Thomas Jefferson Univ Med Coll, Philadelphia, PA, Rheumatology Division, Department of Medicine, Thomas Jefferson University, Philadelphia, PA 5 0 Program Book denotes Hilton San Diego Bayfront room location

155 :00 pm 8:00 am 98. Survival After Lung Transplantation In Systemic Sclerosis. A Systematic Review Irfan Y. Khan, Lianne G. Singer, Marc de Perrot, John T. Granton 4, Shaf Keshavjee, Cathy Chau 5, Amie T. Kron 6 and Sindhu R. Johnson 7, Pulmonary Hypertension Programme, University Health Network, University of Toronto, Toronto, ON, Division of Respirology, University of Toronto; and Toronto Lung Transplant Program, University Health Network, Toronto, ON, Toronto Lung Transplant Program, Division of Thoracic Surgery, University Health Network, University of Toronto, Toronto, ON, 4 Toronto Pulmonary Hypertension Programme, Toronto General Hospital and University of Toronto, Toronto, ON, 5 Toronto Scleroderma Research Program, Toronto Western Hospital, Mount Sinai Hospital, University of Toronto, Toronto, ON, 6 Toronto Scleroderma Research Program, Toronto Western Hospital, Mount Sinai Hospital, and University of Toronto, Toronto, ON, 7 Division of Rheumatology, Toronto Western Hospital, University Health Network Pulmonary Hypertension Programme, Toronto General Hospital, Mount Sinai Hospital and University of Toronto, Toronto, ON :0 am 90. Differences in Abatacept Use in Rheumatoid Arthritis Patients Across Europe: A Pan-European Database Analysis of Abatacept in European RA Registries David Neto, Axel Finckh, Florenzo Iannone, Estíbaliz Loza 4, Elisabeth Lie 5, Piet L.C. Van Riel 6, Merete L. Hetland 7, Karel Pavelka 8, Jacques-Eric Gottenberg 9, Xavier Mariette 0 and Carl Turesson, University of Geneva, Geneva, Switzerland, Geneva University Hospital, Geneva, Switzerland, D.I.M.I.M.P, Rheumatology Unit - University of Bari, Bari, Italy, 4 Spanish Society of Rheumatology, Madrid, Spain, 5 Diakonhjemmet Hospital, Oslo, Norway, 6 Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, 7 Copenhagen University Hospital Glostrup, Copenhagen, Denmark, 8 Department of Clinical and Experimental Rheumatology, Charles University, Prague, Czech Republic, 9 Strasbourg University Hospital, Strasbourg, France, 0 Bicêtre University Hospital, Le Kremlin Bicetre, France, Skåne University Hospital, Malmö, Sweden :5 pm 8:5 am 99. The Clinical Utility Of Flow-Mediated Dilation In Systemic Sclerosis Tracy M. Frech, Ashley Walker, Zachary Barrett-Okeefe, Russell Richardson, D. Walter Wray and Anthony Donato, Salt Lake City VAMC, Salt Lake, UT, University of Utah, Salt Lake, UT ARHP CONCURRENT ABSTRACT SESSION :00 am - :0 pm A Research and Health Services Moderator: Marie D. Westby, PT, PhD and Linda C. Li, PhD, PT :00 am 908. The Roles of Nurse Practitioners and Physician Assistants iin Rheumatology Practices in the United States Erika Brown, Asaf Bitton, Liana Fraenkel, Hsun Tsao, Jeffrey N. Katz and Daniel H. Solomon 4, Brigham and Women s Hospital, Boston, MA, Yale University School of Medicine, Veterans Affairs Connecticut Healthcare System, New Haven, CT, Brigham and Women s Hospital, Harvard Medical School, Boston, MA, 4 Harvard Medical School, Brigham and Women s Hospital, Division of Rheumatology, Division of Pharmacoepidemiology, Boston, MA :5 am Medical Care Expenditures Among U.S. Adults With Arthritis Miriam Cisternas, Louise Murphy, David Pasta, Edward H. Yelin 4 and Charles G. Helmick 5, MGC Data Services, Carlsbad, CA, CDC, Atlanta, GA, DMA Corporation, Palo Alto, CA, 4 UC San Francisco, San Francisco, CA, 5 Centers for Disease Control and Prevention, Atlanta, GA :45 am 9. The Challenge to Develop a Multidimensional Computerized Adaptive Test for Fatigue in Rheumatoid Arthritis Stephanie Nikolaus, Christina Bode, Erik Taal, Cees A.W. Glas and Mart A.F.J. van de Laar, University of Twente, Enschede, Netherlands, Medisch Spectrum Twente & University of Twente, Enschede, Netherlands Noon 9. Integrating Patient Electronic Health Records With an Electronic Data Capture System in a Biologics Registry for Inflammatory Arthritides Inge C. Olsen, Espen A. Haavardsholm, Tore K. Kvien, Ellen Moholt and Elisabeth Lie, Diakonhjemmet Hospital, Oslo, Norway :5 pm 9. The Validity of Patient-Reported Short-Term Complications Following Total Hip and Knee Arthroplast Leslie R. Harrold, David Ayers, Regis O Keefe, Courtland Lewis, Vincent Pellegrini 4 and Patricia D. Franklin, University of Massachusetts Medical School, Worcester, MA, University of Rochester Medical Center, Rochester, NY, Hartford Hospital, Hartford, CT, 4 Medical University of South Carolina, Charleston, SC INDUSTRY-SUPPORTED POST-MEETING SYMPOSIA :00-4:00 pm For CME-accredited symposia, the sponsoring organization is responsible for planning and providing CME credit. Please visit the organization s exhibit booth, the industry-supported symposia booth or see page 5 for more information. WEDNESDAY october 0, 0 denotes Hilton San Diego Bayfront room location 0 Program Book 5

156 ACR POSTER SESSION A SUNDAY, OCTOBER 7, 0 Exhibit Hall B-C-D Antiphospholipid Syndrome: Clinical Manifestations and New Biomarkers in Antiphospholipid Syndrome. Anti-âGP- Domain- Antibodies Are a Marker Of APS Severity. Nancy Agmon-Levin, Luciana Seguro, Cristina Rosário, Michael Mahler 4, Mariele Gatto 5, Nir Tomer 6, Elaine P. Leon 7, Andrea Doria 8, László Kovács 9, Nathalie Costedoat-Chalumeau 0, Boris Gilburd and Yehuda Shoenfeld, The Zabludowicz Center for Autoimmune Diseases, Tel-Hashomer, Israel, Division of Rheumatology, University of São Paulo School of Medicine, Sao Paulo, Brazil, Internal Medicine Department, Hospital de Pedro Hispano, Rua Dr. Eduardo Torres Matosinhos, Porto, Portugal, 4 INOVA Diagnostics, San Diego, CA, 5 Department of Medicine, University of Padova, Padova, Italy, 6 The Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center, Tel-Hashomer, Ramat Gan, Israel, 7 Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, 8 University of Padova, Padova, Italy, 9 University of Szeged, Szeged, Hungary, 0 Hopital Cochin, Paris, France, The Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center, Tel-Hashomer, Ramat-Gan, Israel, Sheba Medical Center, Ramat Gan, Israel. Charaterization Of Micrornas Involved In The Regulation Of Atherotrhombosis In Antiphospholipid Syndrome and Systemic Lupus Erythematosus. Chary Lopez-Pedrera Sr., Patricia Ruiz-Limon, Raul Teruel, Ángeles Aguirre Zamorano, Rosario M. Carretero-Prieto, Nuria Barbarroja, Antonio Rodriguez-Ariza, Eduardo Collantes-Estevez, Rocio gonzalez-conejero, Constantino Martinez, Mª Jose Cuadrado and Carlos Perez-Sanchez, IMIBIC-Reina Sofia Hospital, Cordoba, Spain, Regional Centre for Blood Donation, University of Murcia, Murcia, Spain, The Rayne Institute, London, United Kingdom. The Global Antiphospholipid Syndrome Score (GAPSS) In Primary APS. Savino Sciascia, Giovanni Sanna, Veronica Murru, Dario Roccatello, Munther A. Khamashta and Maria Laura Bertolaccini, Centro di Immunopatologia e Documentazione su Malattie rare, Torino, Italy, Louise Coote Lupus Unit, St. Thomas Hospital, London, United Kingdom, Lupus Research Unit, The Rayne Institute, Kings College London School of Medicine, London, United Kingdom 4. Proteomic Analyses Of Monocyte Responses To IgG From Patients With Antiphospholipid Syndrome. Vera M. Ripoll, Anastasia Lambrianides, Wendy Heywood, Anisur Rahman, Yiannis Ioannou and Ian Giles, University College London, London, United Kingdom 5. Plasma Levels Of PF-4var/CXCL4L, A Non Allelic Variant Of Platelet Factor-4 (PF-4/CXCL4), Are Elevated In Patients With Antiphospholipid Syndrome (APS). Marina Sikara, Markos Patsouras, Elias Eliopoulos and Panayiotis Vlachoyiannopoulos, School of Medicine, National University of Athens, Athens, Greece, Agricultural University of Athens, Athens, Greece 6. Researchers Own Experience In Managing Obstetric Complications In Pregnant Women With Antiphospholipid Syndrome. Lidia Ostanek, Danuta Bobrowska - Snarska, Barbara Nestorowicz and Marek Brzosko, Pomeranian Medical University, Szczecin, Poland, Szczecin, Poland, Pomeranian Medical University, Szczecin, Poland, Szczecin, Poland, Department of Rheumatology and Internal Diseases Pomeranian Medical University in Szczecin, Szczecin, Poland 7. Prospective Validation Of The Global Antiphospholipid Syndrome Score (GAPSS). Savino Sciascia, Mª Jose Cuadrado, Giovanni Sanna, Veronica Murru 4, Dario Roccatello, Oier Ateka 5, Munther A. Khamashta 4 and Maria Laura Bertolaccini 4, Centro di Immunopatologia e Documentazione su Malattie rare, Torino, Italy, The Rayne Institute, London, United Kingdom, Louise Coote Lupus Unit, St. Thomas Hospital, London, United Kingdom, 4 Lupus Research Unit, The Rayne Institute, Kings College London School of Medicine, London, United Kingdom, 5 Lupus Unit, London, United Kingdom 8. Clinical Evaluation Of Two Anti-Beta glycoprotein I Domain Autoantibody Assays To Aid In The Diagnosis and Risk Assessment Of The Antiphospholipid Syndrome. Rohan Willis, Michael Mahler, Francesca Pregnolato, Charis Pericleous 4, Anisur Rahman 4, John Ioannou 5, Ian Giles 4, Gabriella Lakos, Roger Albesa, Navid Zohoury, Pier-Luigi Meroni 6 and Silvia S. Pierangeli, University of Texas Medical Branch, Galveston, TX, INOVA Diagnostics, San Diego, CA, Lab of Immunology, IRCCS Istituto Auxologico Italiano, Milan, Italy, 4 University College London, London, United Kingdom, 5 Rayne Institute, University College London, London, UK, London, United Kingdom, 6 University of Milan, Milano, Italy 9. Domain Is The Main Specificity Of Anti-β glycoprotein I Antibodies In Systemic Autoimmune Diseases. Laura Andreoli, Cecilia Nalli, Maria-Orietta Borghi, Francesca Pregnolato, Alessandra Zanola, Claudia Grossi 4, Maria Gerosa 5, Flavio Allegri, Michael Mahler 6, Gary L. Norman 6, Pier Luigi Meroni 7 and Angela Tincani, Rheumatology Unit, University of Brescia, Brescia, Italy, Lab of immunology, IRCCS Istituto Auxologico Italiano, Department of Clinical Sciences and Community Health, University of Milan, Milano, Italy, Lab of Immunology, IRCCS Istituto Auxologico Italiano, Milan, Italy, 4 Laboratory of Immuno-rheumatology, IRCCS Istituto Auxologico Italiano, Milan, Italy, 5 Division of Rheumatology, Gaetano Pini Institute, Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy, 6 INOVA Diagnostics, San Diego, CA, 7 Division of Rheumatology, Gaetano Pini Institute, Milano, Italy 0. Autoantibodies Targeting Domain Of Beta Glycoprotein I As Promising Marker In The Diagnosis and Risk Stratification Of The Antiphospholipid Syndrome. Navid Zohoury, Munther A. Khamashta, Tatsuya Atsumi, Jacek Musial 4, Toshiyuki Watanabe 5, Maria Papp 6, Concepción González-Rodríguez 7, Roger Albesa, Gary L. Norman, Pier-Luigi Meroni 8 and Michael Mahler, INOVA Diagnostics, San Diego, CA, Lupus Research Unit, The Rayne Institute, Kings College London School of 54 0 Program Book

157 ACR POSTER SESSION A Medicine, London, United Kingdom, Hokkaido University Graduate School of Medicine, Sapporo, Japan, 4 Jagiellonian University Medical College, Krakow, Poland, 5 Hokkaido University Graduate School of Medicine, Hokkaido, Japan, 6 University of Debrecen, Debrecen, Hungary, 7 Virgen Macarena University Hospital, Seville, Spain, 8 University of Milan, Milano, Italy. Catastrophic Antiphospholipid Syndrome (CAPS): Clinical, Immunologic Features, and Outcome Of 44 Patients From The CAPS Registry. Ignasi Rodriguez, Gerard Espinosa and Ricard Cervera, Fellow, Barcelona, Spain, Department of Autoimmune Diseases, Hospital Clínic, Barcelona, Barcelona, Spain, Hospital Clinic, Barcelona, Spain. Phosphatidiyserine-Prothrombin Complex (aps/pt) IgG Antibodies Correlate With Lupus Anticoagulant and Specific Pregnancy Complications In Patients With Antiphospholipid Syndrome. Rohan Willis, Anne E. Tebo, Gabriella Lakos, Michael Mahler, Gary L. Norman, Ware D. Branch 4, Jane Salmon 5, Marta M. Guerra 5 and Silvia S. Pierangeli, University of Texas Medical Branch, Galveston, TX, University of Utah, Salt Lake City, UT, INOVA Diagnostics, San Diego, CA, 4 Univ of Utah, Salt Lake City, UT, 5 Hospital for Special Surgery, New York, NY. A MORE Specific Immunoassay For The Diagnosis Of APS. Claudia Grossi, Maria Borghi, Elizabeth Papalardo, Silvia S. Pierangeli and Pier Luigi Meroni 4, Lab of immunology, IRCCS Istituto Auxologico Italiano, Milano, Italy, Louisville APL Diagnostics, Inc, Seabrook, TX, University of Texas Medical Branch, Galveston, TX, 4 Division of Rheumatology, Gaetano Pini Institute, Milan, Italy, Milan, Italy 4. Isotype Dependent Performance Of Beta glycoprotein I Immunoassays In Two Diverse Patient Cohorts: Implications For Assay Harmonization and Standardization. Anne E. Tebo, Rohan Willis, Troy Jaskowski, Jane E. Salmon 4, Michelle Petri 5, Ware D. Branch 6 and Silvia S. Pierangeli, University of Utah, Salt Lake City, UT, University of Texas Medical Branch, Galveston, TX, ARUP Laboratories, Salt Lake City, UT, 4 Hospital for Special Surgery, New York, NY, 5 Johns Hopkins University School of Medicine, Baltimore, MD, 6 Univ of Utah, Salt Lake City, UT 5. Establishment Of Standardized International Units For IgM ANTI-β glycoprotein Antibody Measurement. Rohan Willis, Claudia Grossi, Maria Borghi, Pier Luigi Meroni, Gabriella Lakos 4, Tammy Buckner 5, Fernando S. Cavalcanti 6, Maria Crisostomo 7, Corina Dima 8, Kerrie Jaskal 9, Matthias Kast 0, Luis R. Lopez, Nina Olschowka 0, Sarah Paul, Tony Prestigiacomo 7, Josep Puig 6, Wendy Vandam 7, Alfredo Villarreal, Roger Walker 7, Mike Watkins and Silvia S. Pierangeli, University of Texas Medical Branch, Galveston, TX, Lab of immunology, IRCCS Istituto Auxologico Italiano, Milano, Italy, Division of Rheumatology, Gaetano Pini Institute, Milan, Italy, Milan, Italy, 4 INOVA Diagnostics, San Diego, CA, 5 Corgenix, Broomfield, CO, 6 Biokit, Barcelona, Spain, 7 Bio-Rad Laboratories, Hercules, CA, 8 Theratest Laboratories Inc, Lombard, IL, 9 Instrumentation Laboratories, Bedford, MA, 0 Phadia Thermofisher, Freiburg, Germany, Corgenix Inc, Broomfield, CO, Bio- Rad Laboratories, Benicia, CA 6. Only IgG and IgA β glycoprotein I Antibody Isotypes Are Associated With Venous Thrombosis In Systemic Lupus Erythematosus. Anne Tebo, Rohan Willis, Troy Jaskowski, Laurence S. Magder 4, Silvia S. Pierangeli, Ware Branch 5 and Michelle Petri 6, University of Utah, Salt Lake City, UT, University of Texas Medical Branch, Galveston, TX, ARUP Laboratories, Salt Lake City, UT, 4 University of Maryland, Baltimore, MD, 5 Univ of Utah, Salt Lake City, UT, 6 Johns Hopkins University School of Medicine, Baltimore, MD 7. Autoantibodies Against Component Of Complement One Contribute To The Complement Activation and Clinical Manifestation Of Antiphospholipid Syndrome (APS) Especially In Refractory Cases. Kenji Oku, Olga Amengual, Ikuma Nakagawa, Toshiyuki Watanabe, Yusaku Kanetsuka, Toshiyuki Bohgaki, Tetsuya Horita, Shinsuke Yasuda and Tatsuya Atsumi, Hokkaido University Graduate School of Medicine, Sapporo, Japan, Hokkaido University Graduate School of Medicine, Hokkaido, Japan 8. Clinical Correlates Of Positive Anti-Cardiolipin and β- Glycoprotein Antibodies In a Cohort Of 0 Patients At Mayo Clinic. Uma Thanarajasingam, Cynthia S. Crowson, Melissa R. Snyder, Rajeev Pruthi, Harvinder S. Luthra and Kevin G. Moder, Mayo Clinic, Rochester, MN 9. Association Of Antiphospholipid Antibodied Detected In The Aphl ELISA With Clinical Manifestations Of The Antiphospholipid Syndrome In Two Lupus Cohorts. Silvia S. Pierangeli, Rohan Willis, Michelle Petri, Hong Fang, Monica Smikle, Karel de Ceulaer 4 and E. Nigel Harris 5, University of Texas Medical Branch, Galveston, TX, Johns Hopkins University School of Medicine, Baltimore, MD, University of the West Indies, Kgn 7, Jamaica, 4 University of the West Indies, KIngston, Jamaica, 5 The University of the West Ind, Kingston, Jamaica 0. Complement Deposition On Platelets Is Associated To Venous Thrombosis In Systemic Lupus Erythematosus. Christian Lood, Helena Tydén, Birgitta Gullstrand, Gunnar Sturfelt, Andreas Jönsen, Lennart Truedsson and Anders A. Bengtsson, Lund University, Lund, Sweden. Factor Xa Reactive Antibodies In Patients With Systemic LUPUS Erythematosus and Antiphospholipid Syndrome Have Differential Effects Upon Coagulation Assays and Endothelial CELLS. Bahar Artim-Esen, Natalia Smoktunowicz, Charis Pericleous, Vera M. Ripoll, Ian Mackie, Rachel Chambers, David A. Isenberg, Anisur Rahman, Yiannis Ioannou and Ian Giles, University College London, London, United Kingdom. WHAT Is The Prevalence Of NON CRITERIA ANTIPHOSPHOLIPID ANTIBODIES IN Patients With Antiphospholipid Syndrome? Veronica Rodriguez- Garcia, Yiannis Ioannou, D.A. Isenberg and Ian Giles, Hospital Regional Universitario Carlos Haya, Malaga, Spain, University College London, London, United Kingdom. Seizures In Systemic Lupus Erythematosus Are Not An 0 Program Book 55

158 ACR POSTER SESSION A 56 Inflammatory Manifestation Of Lupus Anticoagulant. Michelle Petri and Hong Fang, Johns Hopkins University School of Medicine, Baltimore, MD B cell Function and Targeting in Systemic Lupus Erythematosus 4. Plasma Cells In Acute Systemic Lupus Erythematosus Flares Are Characterized By a Highly Diversified Repertoire Accentuated By Clonal Expansions Of VH4-4 Antibodies. Christopher Tipton, Christopher Fucile, Alex Rosenberg, Scott Jenks, Jennifer Hom, F. Eun-Hyung Lee and Inaki Sanz, Emory University, Atlanta, GA, University of Rochester, Rochester, NY, Emory University School of Medicine, Atlanta, GA 5. SLE Flares Are Characterized By Generalized Polyclonal Expansions Of Antibody Secreting Cells Without Preference For Autoimmune Responses. H. Travis Ichikawa, Emory University, Atlanta, GA 6. Autoantibodies Directed Against Cell Surface Components In Autoimmune Disease Patients: Proposal Of a Novel ELISA For The Detection Of Anti-Endothelial Cell Antibodies. Keiji Miura, Ayako Kondo, Kazuo Takahashi, Daisuke Hirano, Yoshiyuki Hiki, Shunji Yoshida, Yukio Yuzawa and Yoshikazu Kurosawa, Fujita Health Universtiy, Toyoake, Japan, Fujita Health Universtiy School of Medicine, Toyoake, Japan 7. Specificity Of Autoantibodies In Patients With Rheumatologic Inflammatory Syndrome Following Mineral Oil Injections Is Similar To Those In Mice With Adjuvant Mineral Oil-Induced Autoimmunity. Minoru Satoh, Olga Vera-Lastra, Claudia Martínez, Jesús Sepulveda- Delgado, Luis J. Jara 4, Raúl Vargas-Ramírez 5, Beatriz Teresita Martin- Marquez 6, S. John Calise, Edward K.L. Chan and Monica Vázquez-Del Mercado 7, University of Florida, Gainesville, FL, MD, Mexico City, Mexico, Hospital de Especialidades Centro Médico Nacional La Raza, IMSS, Mexico City, Mexico, 4 Hospital de Especialidades Centro Medico La Raza, México City, Mexico, 5 Instituto de Investigación en Reumatología y del Sistema Músculo Esquelético, Universidad de Guadalajara, Guadalajara, Jalisco, México, Mexico, 6 Instituto de Investigación en Reumatología y del Sistema Músculo Esquelético, Guadalajara, Mexico, 7 Universidad de Guadalajara, Guadalajara, Jalisco, México, Mexico 8. Differentiation, Activation, and Autoreactivity Of CDc+ B Cells (ABCs). Alice E. Wiedeman, Natalia V. Giltiay, Lena Tanaka and Keith B. Elkon, University of Washington, Seattle, WA 9. A Novel CD7 (-) B-Cell Subset Identified Based On Intracellular Characteristics Is Expanded In SLE. S.J. Fleischer, Capucine Daridon and Thomas Dörner, Charité University Medicine Berlin, Berlin, Germany, Charité University Medicine / German Rheumatism Research Centre Berlin (DRFZ), Berlin, Germany, Charité university medecine/ German Rheumatism Research Centre Berlin (DRFZ), Berlin, Germany 0. Gene Expression Profiling Analysis Of Human B-Cell 0 Program Book Subsets In Health and Systemic Lupus Erythematosus. Chungwen Wei, Edward Ramos, Norm Allaire, Suzanne Szak, Susan Kalled, Ann Ranger and Ignacio Sanz, Emory University, Atlanta, GA, Biogen Idec Inc, Cambridge, MA. IgD- CD7- B Cells From Systemic Lupus Erythematous Patients Have Increased Expression Of Genes Involved In RNA Sensing and Toll-Like Receptor Signaling Pathways. Scott Jenks, Edward Ramos and Ignacio Sanz, Emory University School of Medicine, Atlanta, GA, Emory University, Atlanta, GA. Understanding The Stimulatory Pathways Responsible For Naïve B Cell Activation In Systemic Lupus Erythematosus. Emily Blalock, Chris Scharer, Scott Jenks, Jeremy Boss and Ignacio Sanz, Emory University School of Medicine, Atlanta, GA. B Cell Receptor Signaling As A Potential Clinical Parameter In Lupus. Michael Faludi, Christian A. Pineau, Evelyne Vinet, Ann E. Clarke, Sasha Bernatsky, Joyce Rauch and Emil P. Nashi, McGill University Health Center, Montreal, QC 4. Dichotomous Responses Of Human Systemic Lupus Erythematosus B Cell Subsets To B Cell Receptor Stimulation. Franziska Matzkies, Anthony DeFranco, Andrew J. Gross, Maria Dall Era and Michelle Hermiston, University of California, San Francisco, San Francisco, CA 5. Defective Regulatory Function Of Granzyme B-Producing B Cells In Patients With Systemic Lupus Erythematosus. Naoko Ueki, Hiroaki Niiro, Shun-ichiro Ota, Hirofumi Tsuzuki, Siamak Jabbarzadeh-Tabrizi, Yuri Hirosaki, Kumiko Noda, Naoyasu Ueda, Atsushi Tanaka, Masahiro Ayano, Sho Ueda, Satomi Hisamoto, Daisuke Oryoji, Mitsuteru Akahoshi, Yojiro Arinobu, Hiroshi Tsukamoto, Takahiko Horiuchi and Koichi Akashi, Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan 6. IFN-α Induces Altered Transitional B Cell Signaling and Function In Systemic Lupus Erythematosus. Joan E. Wither, Nan-Hua Chang, Timothy Li, Julie Kim, Carolina Landolt-Marticorena, Paul R. Fortin 4, Dafna D. Gladman 5 and Murray B. Urowitz 5, Toronto Western Research Institute, Toronto Western Hospital, University of Toronto, Toronto, ON, Toronto Western Hospital, Toronto, ON, Toronto Western Hospital, University of Toronto, Toronto, ON, 4 Centre de Recherche du Chu de Québec et Université Laval, Quebec City, QC, 5 University of Toronto, Toronto Western Hospital, Toronto, ON 7. Follicular Entry Of Lymphotoxin-Expressing B Cells Via Type I Interferon Disrupts Marginal Zone Barrier Integrity and Exacerbates Systemic Autoimmunity. Hao Li, Hui- Chen Hsu, Qi Wu, Jun Li, PingAr Yang, Yang-Xin Fu and John D. Mountz, University of Alabama at Birmingham, Birmingham, AL, Birmingham VA Medical Center, Birmingham, AL, The University of Chicago, Chicago, IL 8. Use Of An In Vitro Whole Blood Depletion ASSAY To Compare The Efficacy Of B CELL Depleting Agents In Patients With Systemic LUPUS Erythematosus. Venkat

159 ACR POSTER SESSION A Reddy, Geraldine Cambridge, D.A. Isenberg, Mark Cragg and Maria Leandro, University College London, London, United Kingdom, Southampton University, Southampton, United Kingdom 9. Chaperone-Mediated Autophagy As a Target Of Therapeutic P40 Peptide Used In Lupus. Sylviane Muller, CNRS, Strasbourg, France 40. Preclinical Characterization Of a Humanized Antagonistic Anti-CD40 Mab. Kerry Ralph, Amy Nicoletti, Eunice Musvasva, Susan Cannan, Susan VanTongeren, Diann Blanset, Scott Brodeur, Jennifer Ahlberg, Hua Li, Steve Fogal, Sudha Desai, Kathy O Shea, Rachel Kroe-Barrett, Gerald Nabozny, Helen Wu, Gale Hansen, Keith Canada, Sanjaya Singh, Meera Ramanujam and Christine Grimaldi, Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT 4. Targeting Cereblon With The High Affinity Immunomodulatory Compound CC-0: A Novel Therapeutic Agent For Autoimmunity. Peter Schafer, Emily Rychak, Derek Mendy, Stacey Parton, Lori Capone, Antonia Lopez-Girona, Dorota Cedzik, Jolanta Kosek, Ling-Hua Zhang and Rajesh Chopra, Celgene Corporation, Summit, NJ, Celgene Signal Research, San Diego, CA 4. Inhibition Of B Cell Differentiation To The Plasmablast and Plasma Cell Lineage By CC-0, a Potent Modulator Of The Cereblon E Ubiquitin Ligase Complex. Peter Schafer, Lori Capone, Lei Wu and Rajesh Chopra, Celgene Corporation, Summit, NJ Biology and Pathology of Bone and Joint (Cartilage and Osteoarthritis) 4. Overexpression Of Lamin A In Mesenchymal STEM CELLS Compromises Chondrogenesis and Enhances Adipogenesis. Jesús Mateos, Arancha Landeira, Alexandre De la Fuente, Iván Lesende-Rodríguez, Pablo Fernández- Pernas, Maria Carmen Arufe and Francisco J. Blanco, CIBER-BBN, Zaragoza, Spain, Department of Medicine, Area of Anatomy and Human Embryology, University of A Coruña-INIBIC, A Coruña, Spain, Department of Medicine. University of Santiago de Compostela, Santiago de Compostela, Spain 44. Suppressor Of Cytokine Signaling Negatively Modulates Leptin-Mediated Catabolic and Proinflammatory Effects In Cartilage - New Potential Mechanism To Target Obesity-Induced Osteoarthritis. Anna Koskinen, Katriina Vuolteenaho, Riku Korhonen, Teemu Moilanen and Eeva Moilanen, The Immunopharmacology Research Group, University of Tampere School of Medicine and Tampere University Hospital, Tampere, Finland 45. WITHDRAWN 46. Alarmins S00A8/A9 Regulate Osteophyte Formation In Experimental Osteoarthritis With High Synovial Activation. Rik Schelbergen, Arjen B. Blom, Wouter de Munter, Annet W. Sloetjes, Thomas Vogl, Johannes Roth, Wim B. van den Berg and Peter L.E.M. van Lent, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, University of Muenster, Muenster, Germany, Rheumatology Research and Advanced Therapeutics, Department of Rheumatology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands 47. Exogenous Hydrogen Sulfide Donors Show Anti-Catabolic and Anti-Inflammatory Properties But Limited Anti- Oxidant Capability On Human Articular Osteoarthritic Chondrocytes. Elena F. Burguera, Angela Vela-Anero, Rosa Meijide-Failde and Francisco J. Blanco, Tissue Engineering and Cellular Therapy Group (CBTTC-CHUAC), CIBER BBN/ISCIII, A Coruña, Spain, Department of Medicine, University of A Coruña, A Coruña, Spain 48. The In Vivo Role Of Bone Specific EphB4 Receptor Overexpression In Osteoarthritic Synovial Membrane. Gladys Valverde-Franco, David Hum, Bertrand Lussier, Koichi Matsuo, Jean-Pierre Pelletier, Mohit Kapoor and Johanne Martel-Pelletier, Osteoarthritis Research Unit, University of Montreal Hospital Research Centre (CRCHUM), Montreal, QC, Department of Clinical Sciences, Faculty of Veterinary Medicine, University of Montreal, Saint-Hyacinthe, QC, Laboratory of Cell and Tissue Biology, School of Medicine, Keio University, Tokyo, Japan 49. Chondrocyte-Specific Bone Morphogenetic Protein- Overexpression Results In Severe Aggravation Of Osteophyte Formation In Experimental Osteoarthritis Without Altering Cartilage Damage In Young Mice. Esmeralda N. Blaney Davidson, Elly L. Vitters, Miranda B. Bennink, Fons AJ Loo, Wim B. van den Berg and Peter M. van der Kraan, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, Rheumatology Research and Advanced Therapeutics, Department of Rheumatology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands 50. Cartilage Matrix Remodeling and Activation Of Canonical Wnt- Signaling Precedes Calcification and OA-Like Changes In Mice. Jessica Bertrand, Tabea Kräft, Yvonne Nitschke, Thelonius Hawellek, Jan Hubert, Lars Godmann and Thomas Pap, University Hospital Münster, Münster, Germany, University Hospital Münster, Muenster, Germany, University Hospital Hamburg, Hamburg, Germany 5. Collagen-Based Microspheres Delivering TGF-β For Mesenchymal STEM CELL Differentiation: An Innovative Strategy For Cartilage Engineering. Marc Mathieu, E Belamie, M-N Labour, Sylvain Vigier, Christian Jorgensen and Daniele Noel 4, INSERM U844, Montpellier, France, ICGM UMR 55, MONTPELLIER, France, Inserm U844, CHU saint-eloi, Université Montpellier, CHU Lapeyronie, Montpellier, France, 4 UM, Montpellier, France 5. Altered Lipid Metabolism In Osteoarthritis With Subsequent Proinflammatory Properties Of Apolipoprotein A-I. Dominique de Seny, Gaël Cobraiville, Edith Charlier, Sophie Neuville, Laurence Lutteri, Denis Malaise, Olivier Malaise, Jean-Paul Chapelle, Biserka Relic and Michel G. Malaise, GIGA Research - University of Liège - CHU Liège, Liège, Belgium, Medical Chemistry - CHU Liège, Liège, Belgium, University of Liège, Liège, 0 Program Book 57

160 ACR POSTER SESSION A 58 Belgium 5. Adenosine A A Receptor As a Potential New Therapeutic Target For The Prevention/Treatment Of Osteoarthritis. Aranzazu Mediero, Tuere Wilder and Bruce N. Cronstein, NYU School of Medicine, New York, NY, NYU School of Medicine, Division of Rheumatology, New York, NY 54. ANTI-Fibrotic and ANTI-Hypertrophic Effect Of Adipose Mesenchymal Stromal CELLS On Osteoarthritic Chondrocytes. Marie Maumus, C. Manferdini, Karine Toupet, A. Piacentini, A. Gabusi, A. Facchini, G. Lisignoli, Christian Jorgensen and Daniele Noel 4, INSERM U844, Montpellier, France, IOR BOLOGNA, BOLOGNA, Italy, Inserm U844, CHU saint-eloi, Université Montpellier, CHU Lapeyronie, Montpellier, France, 4 UM, Montpellier, France 55. Glucocorticoid Receptor Modulator Compound A Does Not Induce Leptin In Human Osteoarthritic Synovial Fibroblasts and In Dedifferentiated Chondrocytes. Olivier Malaise, Biserka Relic, Edith Charlier, Mustapha Zeddou, Florence Quesada-Calvo, Sophie Neuville, Dominique de Seny and Michel G. Malaise, GIGA Research - University of Liège - CHU Liège, Liège, Belgium 56. Age-Related Loss Of The Transforming Growth Factor Beta Receptor ALK5 Precedes Osteoarthritis Development In Cartilage. Arjan van Caam, Esmeralda N. Blaney Davidson, Eva Thijssen, Wim B. van den Berg and Peter M. van der Kraan, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands 57. Role Of Procatabolic Cytokines In Dysregulation Of O-Linked N-Acetylglucosamine Modified Proteins In Human Osteoarthritic Chondrocytes. Raquel Largo, Ane Larranaga-Vera, Sandra Pérez-Baos, Gabriel Herrero- Beaumont and Jessica Andrés-Bergós, Jiménez Díaz Foundation University Hospital, Madrid, Spain, Joint and Bone Research Unit. IIS-Fundación Jiménez Díaz. UAM, Madrid, Spain, Tissue Engineering Repair and Regeneration Program, Hospital for Special Surgery and Weill Cornell Medical College, New York, NY 58. Saturated Fatty Acids Act Synergistically With Interleukin Beta To Increase Inflammation, Endoplasmic Reticulum Stress and Cell Death In Human Articular Chondrocytes. Oscar Alvarez-Garcia, Nicole H Rogers, Roy G Smith and Martin K. Lotz 4, Department of Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, CA, California Institute for Biomedical Research (Calibr), La Jolla, CA, Department of Metabolism and Aging, The Scripps Research Institute, Jupiter, FL, 4 The Scripps Research Institute, La Jolla, CA 59. Downregulated Forkhead-Box Class O Transcription Factors Attenuate Oxidative Stress Resistance In Human Chondrocytes. Yukio Akasaki and Martin K. Lotz, The Scripps Research Institute, La Jolla, CA 60. O-Linked N-Acetylglucosamine Modified Proteome Of Human Osteoarthritic Cartilage: Biological Significance. Jessica Andrés-Bergós, María Luisa Hernáez, Miguel 0 Program Book Otero, Ane Larranaga-Vera, Sandra Pérez-Baos, Mary B. Goldring, Gabriel Herrero-Beaumont and Raquel Largo 4, Tissue Engineering Repair and Regeneration Program, Hospital for Special Surgery and Weill Cornell Medical College, New York, NY, Proteomics Unit, Universidad Complutense de Madrid-Parque Científico de Madrid, ProteoRed ISCIII, Madrid, Spain, Joint and Bone Research Unit. IIS-Fundación Jiménez Díaz. UAM, Madrid, Spain, 4 IIS- Fundación Jiménez Díaz, Madrid, Spain 6. Epigenome-Wide DNA Methylation Study Reveals Hypermethylated Collagen Genes and Suggests a Role for TGFβ in Osteoarthritis. Matlock A. Jeffries, Amr H. Sawalha and Judith A. James, University of Oklahoma Health Sciences Center, Oklahoma City, OK, University of Michigan, Ann Arbor, MI, Oklahoma Medical Research Foundation, Oklahoma City, OK 6. Tenogenic Effect Of Homeobox Mohawk gene for Bone Marrow Mesenchymal Stem Cells. Koji Otabe, Hiroyuki Nakahara, Akihiko Hasegawa, Martin K. Lotz and Hiroshi Asahara, The Scripps Research Institute, La Jolla, CA 6. Investigations On The Role Of Delta/Notch Like EGF- Related Receptor In The Pathogenesis Of Osteoarthritis. Lucija Berninger, Anna Balkenhol, Clemens Baier, Stefan Rehart, Markus Rickert 4, Ulf Müller-Ladner, Elena Neumann and Matthias Geyer, Justus-Liebig-University of Gießen, Kerckhoff-Klinik, Bad Nauheim, Germany, University of Regensburg, Bad Abbach, Germany, Markus- Hospital, Frankfurt, Germany, 4 University Hospital Giessen and Marburg, Giessen, Germany 64. Fibulin- In Joint Aging and Osteoarthritis Pathogenesis. Akihiko Hasegawa, Tomo Yonezawa, Noboru Taniguchi, Koji Otabe, Yukio Akasaki, Tetsuya Matsukawa, Masahiko Saito, Masashi Neo 4, Lihua Y. Marmorstein 5 and Martin K. Lotz, Osaka Medical College, Takatsuki, Osaka, Japan, The Scripps Research Institute, La Jolla, CA, Toho University Sakura Medical Center, Sakura, China, 4 Osaka Medical College, Osaka, Japan, 5 University of Arizona, Tucson, AZ 65. The Frequency Of Bone Marrow Oedema Adjacent To The Cruciate Ligament Peri-Entheseal Vascular Channels In Inflammatory and Degenerative Arthritis. Daniel Binks, Melissa Matzelle, Diane Bergin, Richard J. Hodgson, Ai Lyn Tan, Ellen M. Gravallese 4, Dennis McGonagle 5 and Aleksandra Radjenovic, University of Leeds, Leeds, United Kingdom, University of Massachusetts Medical School, Worcester, MA, Galway University Hospitals, Galway, Ireland, 4 UMass Memorial Medical Center, Worcester, MA, 5 Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom 66. Follistatin-Like Protein Is An Important Regulator Of Chondrogenesis. Yury Chaly, Sonja Smith, Daniel Bushnell, Brian Campfield, Harry Blair and Raphael Hirsch, University of Iowa Carver College of Medicine, Iowa City, IA, Children s Hospital of Pittsburgh of UPMC, Pittsburgh, PA, University of Pittsburgh School of Medicine, Pittsburgh, PA

161 ACR POSTER SESSION A 67. Heparin-Binding Epidermal Growth Factor-Like Growth Factor (HB-EGF) As a Potential Mediator In Osteoarthritis. Richard F. Loeser and David A. Long, Wake Forest School of Medicine, Winston-Salem, NC, Wake Forest University, Winston-Salem, NC 68. Autophagy Activation Protects From Mitochondrial Dysfunction In Human Chondrocytes. Beatriz Caramés, Paloma López de Figueroa, Martin Lotz and Francisco J. Blanco, Osteoarticular and Aging Research Lab, INIBIC Complejo Hospitalario Universitario A Coruña, SPAIN, A Coruña, Spain, The Scripps Research Institute, La Jolla, USA, La Jolla, CA, Osteoarticular and Aging Res. Lab. CIBER- BBN. INIBIC- University of A Coruña, A Coruña, Spain 69. Interconnected Cellular Projections and Gap Junctions Mediate Metabolic Coupling Between Chondrocytes Located In Different Layers Of The Tissue: Cell-To-Cell Communication In Normal and Osteoarthritic Cartilage. Maria Dolores Mayan, Paula Carpintero-Fernández, Raquel Gago-Fuentes, Patricia Fernández-Puente, Purificacion Filgueira-Fernandez, Noa Goyanes, Virgin Valiunas 4, Peter Brink 4, Gary Goldberg 5 and Francisco J. Blanco 6, Correspondence to: Ma.Dolores.Mayan.Santos@ sergas.es and [email protected], A Coruña, Spain, These authors contribute equally to this work, A Coruña, Spain, Osteoarticular and Aging Research Group. Rheumatology Division, Biomedical Research Center (INIBIC). Hospital Universitario A Coruña, Xubias de Arriba 84, 5006, A Coruña, Spain, 4 Department of Physiology and Biophysics. State University of New York, Stony Brook, New York, SC, 5 Department of Molecular Biology. Medical Center Drive, University of Medicine and Dentistry of New Jersey, Stratford, NJ, 6 Osteoarticular and Aging Res. Lab. CIBER- BBN. INIBIC- University of A Coruña, A Coruña, Spain 70. Chondrocyte Hypertrophy, Measured By The Secretion Of Collagen Type X, Is Associated With Cartilage Degradation and Systemic Inflammation In Osteoarthritis. Yi He, Natasja Stæhr Gudman, Niels Ulrik Hansen, Jianxia Wang, Di Su, Qinlong Zheng, Ole Simonsen 4, Kristian Kjaer Petersen 5, Moustapha Kassem 6, Morten Asser Karsdal and Anne C. Bay-Jensen, Nordic Bioscience, Herlev, Denmark, Nordic Bioscience, Biomarkers and Research, Herlev, Denmark, Nordic Bioscience China, Beijing, China, 4 Frederikshavn Hospital, Frederikshavn, Denmark, 5 Center for Sensory-Motor Interaction, Aalborg, Denmark, 6 Odense University Hospital and University of Southern, Odense, Denmark 7. Subchondral Bone Turnover and Osteophyte Formation Are Key Aspects In The Progression Of Osteoarthritis and May Be Assessed and Predicted By a-ctx. Morten Asser Karsdal, Janet L. Huebner, Virginia Byers Kraus, Diana J. Leeming, Edward Coleman, Gary E. McDaniel, Kim M. Huffman, Kim Henriksen and Anne C. Bay-jensen, Nordic Bioscience, Biomarkers and Research, Herlev, Denmark, Duke University Medical Center, Durham, NC 7. Autophagy Changes During Aging: A Study In GFP-LC Mice. Beatriz Carames, William B. Kiosses, Merissa Olmer and Martin Lotz 4, Osteoarticular and Aging Research Lab, INIBIC Complejo Hospitalario Universitario A Coruña, SPAIN, A Coruña, Spain, The Scripps Research Institute, La Jolla, CA, The Sripps Research Institute, La Jolla, CA, 4 The Scripps Research Institute, La Jolla, USA, La Jolla, CA 7. Fibrillin- Expression and Function Is Needed For Normal Joint Function and Mutations Leads To Osteoarthritis. Wasabha Ramanayake, Helen Jones, Isabel Orriss, Tim Arnett, Andrew Pitsillides, Christopher P. Denton, David J. Abraham and Blandine Poulet, UCL Medical School, London, United Kingdom, University College London, London, United Kingdom, Royal Veterniary College, London, United Kingdom 74. Terminal Uridyltransferase Enzyme ZCCHC Regulates Interleukin-6 Expression In Primary Human Osteoarthritis Chondrocytes. Abdul Haseeb, Mohammad Shahidul Makki, Ahmad Arida and Tariq M. Haqqi, Northeast Ohio Medical University (NEOMED), Rootstown, OH, North East Ohio Medical University, Rootstown, OH 75. Decorin-Deficiency Alters Cartilage Stiffness and Attenuates The Development Of Osteoarthritis In Mice. Tobias Gronau, Uwe Hansen, Daniela Seidler, Renato Iozzo, Attila Aszodi, Carina Prein 4, Hauke Clausen- Schaumann 4, Karsten Krüger 5, Frank Mooren 5, Jessica Bertrand, Thomas Pap, Peter Bruckner and Rita Dreier, University Hospital Münster, Münster, Germany, Thomas Jefferson University, Philadelphia, PA, Ludwig-Maximilians- University Munich, Munich, Germany, 4 Munich University of Applied Sciences, Munich, Germany, 5 Justus-Liebig University Giessen, Giessen, Germany 76. Protective Effect Of Intra-Articular Injection Of Alginate- Chitosan Beads In An Hydrogel Against The Development Of Experimental Osteoarthritis Lesions In Rabbit. Frédéric Oprenyeszk, Mickael Chausson, Véronique Maquet, Jean-Emile Dubuc and Yves Henrotin, Bone and Cartilage Research Unit, Liège, Belgium, KitoZyme SA, Herstal, Belgium, Orthopaedic Department, Bruxelles, Belgium 77. Human Mesenchymal Stem Cells Cultured On Collagen Scaffolds For Cartilage Tissue Engineering. Clara Sanjurjo- Rodríguez, Adela Helvia Martínez-Sánchez, Tamara Hermida-Gómez, Isaac M. Fuentes-Boquete, Francisco J. De Toro, Julia Buján, Silvia Díaz-Prado and Francisco J. Blanco, Osteoarticular and Aging Res. Lab. CIBER-BBN. INIBIC- University of A Coruña, A Coruña, Spain, INIBIC- Universidade da Coruña, A Coruña, Spain, Department of Medical Specialties, Madrid, Spain 78. Norepinephrine (NE) Inhibits Mesenchymal Stem Cell (MSCs) Chondrogenesis By Accelerating Hypertophy Relevance For Cartilage Regeneration. Zsuzsa Jenei-Lanzl, Peter Angele, Frieder Kees, Georg Pongratz 4 and Rainer H. Straub 5, Laboratory of Experimental Rheumatology and Neuroendocrine Immunology, Regensburg, Germany, Department of Trauma Surgery, University Hospital Regensburg, Germany, Regensburg, Germany, University of Regensburg, Regensburg, Germany, 4 University Hospital Regensburg, Regensburg, Germany, 5 Laboratory of Exp. Rheumatology and Neuroendocrino-Immunology, University Hospital of Regensburg, Regensburg, Germany 0 Program Book 59

162 ACR POSTER SESSION A Synovial Activation In Experimental OA Drives Immuno suppressive Effects Of Adipose-derived Stem Cells After Local Administration and Protects Against Chondrogenesis In Ligaments. Peter L.E.M. van Lent, Rik Schelbergen, Menno C. ter Huurne, Arjen B. Blom, Johannes Roth, Thomas Vogl, Christian Jorgensen and Wim B. van den Berg 4, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, University of Muenster, Muenster, Germany, Inserm U844, CHU saint-eloi, Université Montpellier, CHU Lapeyronie, Montpellier, France, 4 Rheumatology Research and Advanced Therapeutics, Department of Rheumatology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands 80. Tidemark Duplication In Osteoarthritis: Evidence Of Incremental Progression? Martine P. Roudier, Paul A. Manner and Peter A. Simkin, University of Washington, Seattle, WA 8. Synovial Expression Of CCL9, MCP-, and Their Receptors In Patients With Meniscal Injury: Variability and Relationship With Knee Symptoms. Justin B. Gan, Anjali Nair, Kanta Saha, Nikhil Verma, Charles Bush-Joseph, Matthew Tetreault, Anne-Marie Malfait, Kumar B. Rajan and Carla R. Scanzello, Rush University Medical Center, Chicago, IL 8. Anatomical Variation In The Morphology Of The Posterior Cruciate Ligament Synovio-Entheseal Complex and Correlation With Degenerative Change. Daniel Binks, Diane Bergin, Tony Freemont, Aleksandra Radjenovic and Dennis McGonagle 4, University of Leeds, Leeds, United Kingdom, Galway University Hospitals, Galway, Ireland, University of Manchester, Manchester, United Kingdom, 4 Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom 8. Oleuropein Or Rutin Consumption Decreases The Spontaneous Development Of OA In Hartley Guinea Pig. Christelle Sanchez, Marie-Noëlle Horcajada, Fanny Membrez Scalfo, Pierre Drion, Fanny Comblain, Elizabeth Offord and Yves Henrotin, University of Liège, Liege, Belgium, Nestle Research Center, Lausanne, Switzerland, University of Liège, Liège, Belgium 84. New Formulation With Potential To Prevent and Treat Osteoporosis and Osteoarthritis. A. Torrent, E. Montell, J. Vergés, P. Dalmau, R. Ruhí, M.C. Carceller, A. Blanco, M.C. Terencio, M.L. Ferrándiz and M.J. Alcaraz, Pre- Clinical R&D Area, Pharmascience Division, BIOIBERICA S.A., Barcelona, Spain, Technological Extraction Dept, BIOIBERICA S.A., Palafolls, Spain, Department of Pharmacology and IDM, University of Valencia, Burjassot, Spain 85. Cartilaginous Uric Acid Deposition In Advanced Osteoarthritis: Innocent Bystander Or Promotor Of Cartilage Destruction? Tim Bongartz, Andre M Oliveira, Rafael J Sierra, Arlen D Hanssen and Michael J Taunton, Mayo Clinic, Rochester, MN 0 Program Book 86. The Role Of Meniscal Cells In Osteoarthritis Calcification. Andrea Roberts, David Mauerhan and Yubo Sun, Carolinas Healthcare System, Charlotte, NC, Carolinas Medical Center, Charlotte, NC Epidemiology and Health Services I 87. Global and Country Specific Burden Of Musculoskeletal Disorders:a Report From The Global Burden Of Diseases Musculoskeletal Expert Group. Lyn March, Damian Hoy, Emma Smith, Rachelle Buchbinder 4, Marita Cross, Peter Brooks 5, Theo Vos and Anthony D. Woolf 6, University of Sydney Institute of Bone and Joint Research, Royal North Shore Hospital, St Leonards, Australia, School of Population Health, University of Queensland, Brisbane, Australia, University of Sydney, Insitute of Bone and Joint Research, Royal North Shore Hospital, St Leonards NSW, Australia, 4 Monash Department of Clinical Epidemiology at Cabrini Hospital, Department of Epidemiology and Preventive Medicine, Monash University, Malvern, Victoria, Australia, 5 Australian Health Workforce Institute, University of Melbourne, Melbourne, Australia, 6 Royal Cornwall Hospital, Truro Cornwall, United Kingdom 88. Musculoskeletal Diseases Have The Worst Impact On Physical Health Compared With Other Diseases - Results Of The Dutch cross-sectional Study. Antje van der Zee- Neuen, Polina Putrik, Sofia Ramiro, Andras P. Keszei, Rob de Bie, Astrid M. Chorus 4 and Annelies Boonen 5, Maastricht University, Maastricht, Netherlands, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands, School for Oncology and Developmental Biology, Maastricht, Netherlands, 4 Netherlands Organization for Applied Scientific Research, Leiden, Netherlands, 5 Maastricht University Medical Center, Maastricht, Netherlands 89. Meta-Analysis of Randomized Controlled Trials Assessing the Effects of Vitamin D Supplementation On Skeletal Muscle Strength. Charlotte Beaudart, Fanny Buckinx, Véronique Rabenda, Sophie Gillain, Etienne Cavalier, Jean Petermans, Jean-Yves Reginster and Olivier Bruyere, University of Liege, Liege, Belgium, University of Liège, Liège, Belgium, CHU de Liege, Liege, Belgium 90. Insufficient Evidence For An Increase In Prevalence and Incidence Of Gout: A Systematic Review and Meta- Regression Analysis. José M.A. Wijnands, Wolfgang Viechtbauer, Kristof Thevissen, Ilja C.W. Arts, Pieter C. Dagnelie, Coen D.A. Stehouwer, Sjef van der Linden and Annelies Boonen, Maastricht University, Maastricht, Netherlands, Maastricht University Medical Center, Maastricht, Netherlands 9. Risk Factors For Incident Hyperuricemia During Mid- Adulthood In African American and White Men and Women Enrolled In The Atherosclerosis Risk In Communities Study. Mara McAdams DeMarco, Andrew Law, Janet W. Maynard, Josef Coresh and Alan N. Baer 4, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, Johns Hopkins, Baltimore, MD, Johns Hopkins University School of Medicine, Division of Rheumatology, Baltimore, MD, 4 Johns Hopkins University, Baltimore, MD

163 ACR POSTER SESSION A 9. Kidney Function and Alcohol Intake and The Risk Of Incident Gout In a Population-Based Cohort Of Adults: Atherosclerosis Risk In Communities Study. Mara McAdams DeMarco, Anna Kottgen, Andrew Law, Janet W. Maynard 4, Morgan Grams, Josef Coresh and Alan N. Baer 5, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, University Hospital Freiburg, Freiburg, Germany, Johns Hopkins, Baltimore, MD, 4 Johns Hopkins University School of Medicine, Division of Rheumatology, Baltimore, MD, 5 Johns Hopkins University, Baltimore, MD 9. Higher Consumption Of Sugar-Sweetened Soft Drinks Increases The Risk Of Hyperuricemia In Korean Population: The Korean Multi-Rural Communities Cohort Study. Seong-Kyu Kim, Jisuk Bae, Jung-Yoon Choe, Byung- Yeol Chun, Pil Sook Park and Dong Hoon Shin 4, Catholic University of Daegu School of Medicine, Daegu, South Korea, Kyungpook National University School of Medicine, Daegu, South Korea, Kyungpook National University, Daegu, South Korea, 4 School of Medicine Keimyung University, Daegu, South Korea 94. Smoking and The Risk For Incident Gouty Arthritis. Weiqi Wang, Vidula Bhole and Eswar Krishnan, stanford university, palo alto, CA, EpiSolutions Consultancy Services, Thane, India, Stanford University, Palo Alto, CA 95. Hip Osteoarthritis and Risk Of All Cause and Disease- Specific Mortality Among Older Women: A Population- Based Cohort Study. Kamil E. Barbour, Li-Yung Lui, Charles G. Helmick, Kristina A. Theis, Michael C. Nevitt, Nancy E. Lane 4, Louise Murphy, Jennifer M. Hootman 5, Marc C. Hochberg 6 and Jane A. Cauley 7, Centers for Disease Control and Prevention, Atlanta, GA, California Pacific Medical Center, San Francisco, CA, San Francisco, CA, University of California, San Francisco, San Francisco, CA, 4 UC Davis School of Medicine, Sacramento, CA, 5 Centers for Disease Control and Prevention, Kennesaw, GA, 6 University of Maryland, Baltimore, MD, 7 University of Pittsburgh, Pittsburgh, PA 96. Epidemiology and Health Services Use For Osteoarthritis By First Nations People In Alberta, Canada. Cheryl Barnabe, Allyson Jones, Ed Enns, Don Voaklander, Christine Peschken 4, Joanne Homik, John Esdaile 5, Sasha Bernatsky 6, Brenda Hemmelgarn and Deborah Marshall, University of Calgary, Calgary, AB, University of Alberta, Edmonton, AB, Alberta Bone and Joint Health Institute, Calgary, AB, 4 University of Manitoba, Winnipeg, MB, 5 University of British Columbia, Vancouver, BC, 6 Research Institute of the McGill University Health Ctre, Montreal, QC 97. Incidence and Trend Of Osteoarthritis In An Administrative Database From British Columbia, Canada. M Mushfiqur Rahman, Jolanda Cibere, Charles H Goldsmith, Aslam H. Anis 4 and Jacek A. Kopec, Arthritis Research Centre of Canada, Richmond, BC, University of British Columbia, VANCOUVER, BC, Simon Fraser University, Burnaby, BC, 4 Centre for Health Evaluation and Outcome Sciences, Vancouver, BC 98. Prevalence Of Femoroacetabular Impingement Among Chinese Living In Vancouver, Canada: A Population-Based Study. Linda C. Li, Jacek A. Kopec, Hubert Wong, Jolanda Cibere, Charlie Zhang 4, Eric C. Sayre, Joanna Ye, Morgan Barber, Helen Prlic 5 and John Esdaile 6, Arthritis Centre of Canada, Richmond, BC, Arthritis Research Centre of Canada, Richmond, BC, St Paul s Hospital, University of British Columbia, Vancouver, V6Z Y6, Canada, Vancouver, BC, 4 University of British Columbia, Vancouver, BC, 5 Arthritis Research Centre of Canada, Vancouver, BC, 6 Arthritis Research Centre of Canada, University of British Columbia, Richmond, BC 99. Twenty-First Century Prevalence Of Frequent Knee Pain, Radiographic, Symptomatic and Clinical Knee Osteoarthritis According to American College Of Rheumatology Criteria In Southern Sweden. Aleksandra Turkiewicz, Maria Gerhardsson de Verdier, Gunnar Engström, Stefan Lohmander and Martin Englund, Department of Orthopedics, Clinical Sciences Lund, Lund University, Lund, Sweden, Astra Zeneca R&D Molndal, Molndal, Sweden, Molndal, Sweden, Dept of Cardiovascular epidemiology, Clinical Sciences, Lund University, Lund, Sweden 00. Myocardial Infarction and Mortality after Joint Surgery in Patients with Rheumatoid Arthritis Compared with the General Population. Joanne Tropea, Mark Tacey, Megan Bohensky, Caroline Brand, Ian Wicks and Sharon Van Doornum, Royal Melbourne Hospital, Melbourne, Australia, The University of Melbourne, Melbourne, Australia 0. Trends In Prescription Of Opioids From In Persons With Knee Osteoarthritis. Elizabeth Wright, Jeffrey N. Katz, Stanley Abrams, Daniel H. Solomon and Elena Losina, Brigham and Women s Hospital, Boston, MA, Harvard Medical School, Brigham and Women s Hospital, Division of Rheumatology, Division of Pharmacoepidemiology, Boston, MA 0. Association Of Area-Level Socioeconomic Status With Pain and Function At Presentation For Total Knee Arthroplasty. Candace H. Feldman, Yan Dong, Jeffrey N. Katz, Laurel Donnell-Fink and Elena Losina, Division of Rheumatology, Immunology and Allergy, Brigham and Women s Hospital, Harvard Medical School, Boston, MA, Brigham and Women s Hospital, Boston, MA 0. Proportion Of U.S. Older Adults Meeting Inclusion Criteria For 00 ACR Recommendations On Glucocorticoid- Induced Osteoporosis. Robert A. Overman, Joshua C. Toliver, Jun-Yen Yeh, Margaret L. Gourlay and Chad L. Deal, Cleveland Clinic, Cleveland, OH, University of North Carolina, Chapel Hill, NC, Long Island University, Brooklyn, NY 04. Incidence Of Osteoporotic Hip Fractures In Estonia Between 005 and 0. Mikk Jürisson, Anneli Uusküla, Riina Kallikorm, Sigrid Vorobjov and Margus Lember, Faculty of Medicine, Tartu University, Tartu, Estonia, National Institute for Health Development, Tallinn, Estonia 05. Medication Use With Denosumab (Prolia ) In a Large Claims Database In The United States. Emily Durden, 0 Program Book 6

164 ACR POSTER SESSION A Lung-I Cheng, Elnara Eynullayeva, Christopher Gregory and Bradley Stolshek, Truven Health Analytics, Washington, DC, Amgen, Inc., Thousand Oaks, CA 06. Antinuclear Antibodies Positive But No Autoimmune Disease. M Herold and Werner Klotz, Medical University of Innsbruck, Innsbruck, Austria, Innsbruck Medical University, Innsbruck, Austria 07. Duration Of Symptoms Before Diagnosis In Patients With Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis. Merete Lund Hetland and Jan Sørensen, The Danish Rheumatologic Database (DANBIO), Glostrup Hospital., Copenhagen, Denmark, Center for Applied Health Services Research, University of South Denmark, Odensen, Denmark 08. Cost-Effectiveness Analysis Of Diagnostic Tests In The Work-Up Of Patients With Intermediate Risk Of Developing Rheumatoid Arthritis. Jolanda J. Luime, Maureen Rutten, Leander Buisman, Mark Oppe and Johanna M.W. Hazes, Erasmus Medical Center, Rotterdam, Netherlands, Erasmus University, Rotterdam, Netherlands 09. Comparison Of Characteristics In Rheumatoid Arthritis Between International and National Databases In Europe: A Systematic Literature Review. E. Gvozdenovic, R. Koevoets, J. Langenhoff, C.F. Allaart and R. Landewe, Leiden University Medical Center, Leiden, Netherlands, Academic Medical Center / University of Amsterdam, Amsterdam, Netherlands 0. Differing Disease Expression In Latin American Mestizo and Spanish Caucasian Patients With Rheumatoid Arthritis With The Same Access To Healthcare and Antirheumatic Treatment. Virginia Ruiz-Esquide, Sonia Cabrera, Julio Ramirez, M. Victoria Hernández 4, José Inciarte, J. D. Cañete and Raimon Sanmarti 4, Hospital Clinic of Barcelona, Barcelona, Spain, Hospital Clínic, Barcelona, Spain, Hospital Clinic, Barcelona, Spain, 4 Hospital Clínic of Barcelona, Barcelona, Spain. Identifying Groups At Increased Risk Of Developing Rheumatoid Arthritis Using Family History and Genetic Risk Scores. Jeffrey A. Sparks, Chia-Yen Chen, Xia Jiang, Johan Askling 4, Linda T. Hiraki 5, Lars Klareskog 6, Lars Alfredsson, Karen H. Costenbader and Elizabeth W. Karlson, Brigham and Women s Hospital, Harvard Medical School, Boston, MA, Harvard School of Public Health, Boston, MA, Karolinska Institutet, Stockholm, Sweden, 4 Karolinska University Hospital, Stockholm, Sweden, 5 Brigham and Women s Hospital, Harvard School of Public Health, Boston, MA, 6 Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden. Sugar-Sweetened Soft Drink Consumption and Risk Of Developing Rheumatoid Arthritis In Women. Yang Hu, Karen H. Costenbader, Frank Hu, Daniel H. Solomon 4, Elizabeth W. Karlson and Bing LU 5, Brigham and Women s Hospital, Boston, MA, Brigham and Women s Hospital, Harvard Medical School, Boston, MA, Harvard School of Public Health, Boston, MA, 4 Harvard Medical School, Brigham and Women s Hospital, Division of Rheumatology, Division of Pharmacoepidemiology, Boston, MA, 5 Brigham & Women s Hospital and Harvard Medical School, Boston, MA. Posttraumatic Stress Disorder and Risk For Incident Rheumatoid Arthritis. Yvonne C. Lee, Susan Malspeis, Jessica Agnew-Blais, Katherine Keyes, Laura Kubzansky, Andrea Roberts, Karestan Koenen and Elizabeth Karlson 4, Brigham and Women s Hospital, Boston, MA, Harvard School of Public Health, Boston, MA, Columbia University Mailman School of Public Health, New York, NY, 4 Brigham and Woman s Hospital, Boston, MA 4. Patients With Regular Physical Activity Before Onset Of Rheumatoid Arthritis Present With Milder Disease. Maria E.C. Sandberg, Sara Wedren, Christina H. Opava, Lars Klareskog 4, Lars Alfredsson and Saedis Saevarsdottir 4, Karolinska Institutet, Stockholm, Sweden, Rheumatology Unit, Department of Medicine, Karolinska University Hospital, Karolinska Institute, Stockholm, Sweden, Karolinska Institutet, Huddinge, Sweden, 4 Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden 5. Association Between History Of Periodontitis and Risk Of Rheumatoid Arthritis In Individuals With and Without Diabetes Mellitus: A Population-Based Cohort Study. Hsin- Hua Chen, D.Y. Chen and Nicole Huang, National Yang- Ming University, Taipei, Taiwan, Taichung Veterans General Hospital, Taichung, Taiwan 6. Lack Of Association Between Preclinical Markers For Cardiovascular Disease and Rheumatoid Arthritis- Related Autoimmunity In First-Degree Relatives Without Rheumatoid Arthritis. Jill M. Norris, Ryan W. Gan, Jan M. Hughes-Austin, Kevin D. Deane, M. Kristen Demoruelle, Elaine M. Urbina 4, Kerrie Moreau, Peter K. Gregersen 5, Michael H. Weisman 6 and V. Michael Holers, Colorado School of Public Health, Aurora, CO, University of California, San Diego, La Jolla, CA, University of Colorado School of Medicine, Aurora, CO, 4 Cincinnati Children s Hospital Medical Center, Cincinnati, OH, 5 Feinstein Institute for Medical Research, Manhasset, NY, 6 Cedars-Sinai Medical Center, Los Angeles, CA 7. Postmenopausal Hormone Therapy and The Risk Of Rheumatoid Arthritis: Results From The Swedish EIRA Study. Cecilia Orellana, Saedis Saevarsdottir, Lars Klareskog, Lars Alfredsson and Camilla Bengtsson, Karolinska Institutet, Stockholm, Sweden, Rheumatology unit, Karolinska University Hospital, Karolinska Institute, Stockholm, Sweden Fibromyalgia, Soft Tissue Disorders and Pain I 8. The Controversies and Points Of Debate That Remain a Challenge For Fibromyalgia Care. Mary-Ann Fitzcharles, Peter A. Ste-Marie, Don L. Goldenberg, John X. Pereira, Susan Abbey 4, Manon Choinière 5, Gordon Ko 6, Dwight E. Moulin 7, Pantelis Panopalis, Johanne Proulx 8 and Yoram Shir, McGill University Health Centre, Montreal, QC, Newton-Wellesley Hosp, Newton, MA, University of Calgary, Calgary, AB, 4 University of Toronto, Toronto, ON, 6 0 Program Book

165 ACR POSTER SESSION A Canada, Toronto, ON, 5 University of Montreal, Montreal, QC, 6 University of Toronto, Toronto, ON, 7 University of Western Ontario, London, ON, 8 Patient Representative, Montreal, QC 9. Routine Assessment Of Patient Index Data In Fibromyalgia: A Rapid and Reliable Instrument For Evaluating Disease Severity? Ece Kaptanoglu, Ozlem Sahin, Yunus Durmaz, Ahmet Kivanc Cengiz and Sami Hizmetli, Cumhuriyet University, Sivas, Turkey 0. The Symptom Severity In Korean Patients With Fibromyalgia Is Associated With Socioeconomic Status, But Not With Obesity. Dong-Jin Park, Shin-Seok Lee, Seong-Ho Kim, Seong-Su Nah 4, Ji Hyun Lee 5, Seong-Kyu Kim 6, Yeon-Ah Lee 7, Seung-Jae Hong 7, Hyun-Sook Kim 8, Hye-Soon Lee 9, Hyoun Ah Kim 0, Chung-Il Joung and Sang-Hyon Kim, Chonnam National University Medical School, Gwangju, South Korea, Chonnam National University Medical School and Hospital, Gwangju, South Korea, Division of Rheumatology, Inje University College of Medicine, Haeundae Paik Hospital, Busan, South Korea, 4 Soonchunhyang University Cheonan Hospital, Cheonan, South Korea, 5 Maryknoll Medical Center, Busan, South Korea, 6 Catholic University of Daegu School of Medicine, Daegu, South Korea, 7 Kyung Hee University, Seoul, South Korea, 8 Division of Rheumatology, Department of Internal Medicine, Soonchunhyang University of Korea, Seoul, Korea, Seoul, South Korea, 9 Hanyang University Guri Hospital, Guri, South Korea, 0 Ajou University Hospital, Suwon, South Korea, Konyang university hospital, Daejeon, South Korea, Division of Rheumatology, Department of Internal Medicine, Keimyung University School of Medicine, Daegu, South Korea. Comparative Burden Of Chronic Widespread Pain and Fibromyalgia In The US Population. Caroline Schaefer, Rachael Mann, Elizabeth T. Masters, Joseph C. Cappelleri 4, Shoshana Daniel 5, Gergana Zlateva, Heather McElroy 6, Arthi B. Chandran, Edgar H. Adams, Annlouise R. Assaf 4, Michael McNett 7, Philip Mease 8, Stuart L. Silverman 9 and Roland Staud 0, Covance Market Access Services Inc., Gaithersburg, MD, Covance Market Access Services Inc., San Diego, CA, Pfizer Inc., New York, NY, 4 Pfizer Inc., Groton, CT, 5 Covance Market Access Services Inc., Conshohocken, PA, 6 Covance Market Access Services, Sydney, Australia, 7 Aurora Pain Program, Milwaukee, WI, 8 Swedish Medical Center, Seattle, WA, 9 Cedars-Sinai Medical Center, UCLA Center of Excellence, Beverly Hills, CA, 0 University of Florida, Gainesville, FL. Rheumatologists Lack Confidence in Their Knowledge of Cannabinoid Molecules and Use in the Management of Rheumatic Disease Patients: Analysis of a Needs Assessment. Mary-Ann Fitzcharles, Peter A. Ste-Marie, Daniel J. Clauw, Shahin Jamal, Jacob Karsh 4, Sharon Leclercq 5, Jason J. McDougall 6, Yoram Shir, Kamran Shojania and Zach Walsh 7, McGill University Health Centre, Montreal, QC, University of Michigan, Ann Arbor, MI, University of British Columbia, Vancouver, BC, 4 Ottawa Hosp Riverside, Ottawa, ON, 5 University of Calgary, Calgary, AB, 6 Dalhousie University, Halifax, NS, 7 University of British Columbia, Kelowna, BC. Association Of Rheumatic Diseases With Symptom Severity, Quality Of Life, and Treatment Outcome In Patients With Fibromyalgia. Juan Jiao, John M. Davis III, Ann Vincent, Connie A. Luedtke, Stephen Cha and Terry H. Oh, Mayo Clinic, Rochester, MN 4. Disability In Fibromyalgia Is Associated With Greater Self-Reported Symptoms and Functional Impairment. Emmanouil Rampakakis, Mary-Ann Fitzcharles, Peter A. Ste-Marie, John S. Sampalis and Yoram Shir, JSS Medical Research, St-Laurent, QC, McGill University Health Centre, Montreal, QC 5. Correlation Of Findings In Clinical and High Resolution Ultrasonography Examinations Of The Painful Shoulder. Raphael Micheroli, Diego Kyburz, Adrian Ciurea, Beat Dubs, Martin Toniolo, Samuel Bisig 4 and Giorgio Tamborrini 5, University of Zurich, Zurich, Switzerland, University Hospital of Zurich, Zurich, Switzerland, Sonography Institute Bethanien Zurich, Zurich, Switzerland, 4 Swiss Federal Institute of Technology Zurich, Zurich, Switzerland, 5 Bethesda Hospital Basel, Basel, Switzerland 6. Subgrouping Of Rheumatoid Arthritis Patients Based On Pain, Fatigue, Inflammation and Psychosocial Factors. Yvonne C. Lee, Michelle A. Frits, Christine K. Iannaccone, Michael E. Weinblatt, Nancy A. Shadick, David A. Williams and Jing Cui, Brigham and Women s Hospital, Boston, MA, Univ of MI Hlth System-Lobby M, Ann Arbor, MI 7. Clinical Application Of Pain Diagrams In Fibromyalgia. Amanda Steele, Dana Dailey and Kathleen Sluka, University of Iowa Hospitals and Clinics, Iowa City, IA, University of Iowa, Iowa City, IA 8. Frequency Of Axial Spondyloarthropathy Among Patients Suffering From Fibromyalgia A Magnetic Resonance Immaging Study With Application Of The Assessment Of Spondylo-Arthritis International Society Classification Criteria. Jacob N. Ablin, Iris Eshed, Valerie Aloush, Irena Wigler, Dan Caspi, Maria Likhter, Mark Berman, Yonatan Wolman, Daphna Paran 4, Marina Anouk 5 and Ori Elkayam, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, Sheba Medical Center, Tel Hashomer, Israel, Tel Aviv Sourasky Medical Center and the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel, 4 Tel Aviv Sourasky Medical Ctr, Tel-Aviv university, Tel Aviv, Israel, 5 Tel Aviv Sourasky Medical Ctr, Tel-Aviv University, Tel Aviv, Israel 9. Identifying Predictors Of A Fibromyalgia Diagnosis: A Retrospective Electronic Medical Record Analysis. Elizabeth T. Masters, Jack Mardekian, Andrew Clair and Stuart L. Silverman, Pfizer Inc, New York, NY, Cedars-Sinai Medical Center, UCLA Center of Excellence, Beverly Hills, CA 0. Mindfulness Is Associated With Psychological Symptoms, Self-Efficacy and Quality Of Life Among Patients With Fibromyalgia. Nani Morgan, Lucas Morgan, Lori Lyn Price and Chenchen Wang 4, University of Hawaii, Honolulu, HI, University of Massachusetts, Honolulu, HI, Tufts University, Boston, MA, 4 Tufts Medical Center, Boston, MA 0 Program Book 6

166 ACR POSTER SESSION A 64. Prevalence and Antecedents Of Fibromyalgia In Elderly Women. Brian T. Walitt and Frederick Wolfe, Washington Hospital Center, Washington, DC, National Data Bank for Rheumatic Diseases, Wichita, KS. Relation Of Age With Symptom Severity and Quality Of Life In Patients With Fibromyalgia. Juan Jiao, Ann Vincent, Connie A. Luedtke, Stephen Cha and Terry H. Oh, Mayo Clinic, Rochester, MN. Cross-Sectional Neurocognitive Data Do Not Support a Transition From Fibrofog To Alzheimer s Disease In Fibromyalgia Patients. Robert S. Katz and Frank Leavitt, Rush Medical College, Chicago, IL, Rush University Medical Center, Chicago, IL 4. Lower Socioeconomic Status Associates With Increased Symptom Severity and Functional Impairment In Fibromyalgia. Mary-Ann Fitzcharles, Emmanouil Rampakakis, Peter A. Ste-Marie, John S. Sampalis and Yoram Shir, McGill University Health Centre, Montreal, QC, JSS Medical Research, St-Laurent, QC 5. Evaluation Of The Quality Of Life and Sleep In Patients With Benign Joint Hypermobility Syndrome. Ilknur Albayrak, Halim Yilmaz, Ekrem Akkurt, Ali Salli and Gulten Karaca, MD, Konya, Turkey, MD, KONYA, Turkey, Associate Professor, Konya, Turkey 6. The Detection Of Primary Hyperparathyroidism In Patients Diagnosed With Fibromyalgia. Michael Tsoukas, Peter A. Ste-Marie, Yoram Shir, Mary-Ann Fitzcharles and Elliot Mitmaker, McGill University Health Centre, Montreal, QC 7. A Population-Based Survey and Physician Assessment Of The Characteristics and Prevalence Of Fibromyalgia. Edgar H. Adams, Shoshana Daniel, Arthi B. Chandran, Heather McElroy 4, Caroline Schaefer, Rachael Mann 5, Gergana Zlateva, Joseph C. Cappelleri 6, Elizabeth T. Masters 7, Annlouise R. Assaf 6, Michael McNett 8, Stuart L. Silverman 9, Roland Staud 0 and Philip Mease, Covance Market Access Services Inc., Gaithersburg, MD, Covance Market Access Services Inc., Conshohocken, PA, Pfizer Inc., New York, NY, 4 Covance Market Access Services, Sydney, Australia, 5 Covance Market Access Services Inc., San Diego, CA, 6 Pfizer Inc., Groton, CT, 7 Pfizer Inc, New York, NY, 8 Aurora Pain Program, Milwaukee, WI, 9 Cedars-Sinai Medical Center, UCLA Center of Excellence, Beverly Hills, CA, 0 University of Florida, Gainesville, FL, Swedish Medical Center, Seattle, WA 8. Long Term Outcomes In Fibromyalgia. Lesley M. Arnold and Thomas Blom, University of Cincinnati College of Medicine, Cincinnati, OH 9. Pain and Other Symptoms During The Childhood Of Fibromyalgia Patients. Robert S. Katz, Alexandra Small, Ben J. Small and Susan Shott 4, Rush Medical College, Chicago, IL, University of Illinois Medical School, Chicago, IL, Rush University Medical School, Chicago, IL, 4 Rush University Medical Center, Chicago, IL 40. Fibromyalgia and Pregnancy: Challenges Of The Savella 0 Program Book (Milnacipran) Pregnancy Registry. Damien Hirsch, Denise Leclair, Robert H. Palmer, Vikki Brown, Susan Sinclair Roberts and Janice McLean, Forest Research Institute, Inc., Jersey City, NJ, INC Research, LLC, Wilmington, NC 4. Skin Disease and Fibromyalgia: Dermatologic Diagnoses Encountered In a Series Of 845 Patients With Fibromyalgia At Mayo Clinic In 008. Valerie Laniosz, David Wetter and Desiree Godar, Mayo Clinic, Rochester, MN 4. Home Tender Point Measurement In Fibromyalgia Patients. Robert S. Katz, Hannah Bond and Jessica L. Polyak, Rush Medical College, Chicago, IL, Rheumatology Associates, Chicago, IL 4. Rapid Infrared Microscopy (IRMS) For Differential Diagnosis Of Fibromyalgia and Other Central Sensitivity Syndromes. Kevin V. Hackshaw, Luis Rodriguez-Saona, Irving L. Rosenberg, Marcal Plans and C.A. Tony Buffington, The Ohio State University, Columbus, OH 44. Cytokines, Oxidative Stress Markers and Brain-Derived Neurotrophic Factor In Fibromyalgia Syndrome. Aline Ranzolin, Claudio Antônio da C. Neto, Bruna Maria Ascoli, Bianca Wollenhaupt-Aguiar 4, Angela Luzia B. Pinto Duarte, Markus Bredemeier 5, Flávio Kapczinski and Ricardo M. Xavier 6, Programa de Pós-Graduação em Ciências Médicas da Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil, Faculdade de Medicina, Universidade Federal de Pernambuco - Hospital das Clínicas de Pernambuco, Recife, Brazil, Programa de Pós-Graduação em Ciências Médicas da Universidade Federal do Rio Grande do Sul: Psiquiatria, Porto Alegre, Brazil, 4 Programa de Pós-Graduação em Ciências Biológicas: Bioquímica, da Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil, 5 Hospital Nossa Senhora da Conceição - Grupo Hospitalar Conceição, Porto Alegre, Brazil, 6 Faculdade de Medicina, Universidade Federal do Rio Grande do Sul - Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil 45. Autonomic Nervous System Decomplexification In Fibromyalgia. A Proof Of Concept Study Looking At The Fractality Of Heart Rhythms. Manuel Martinez- Lavin, Claudia Lerma, Laura Aline Martinez-Martinez, Oscar Infante and Angelica Vargas, National Institute of Cardiology, Mexico City, Mexico Genetics and Genomics of Rheumatic Disease I 46. The Arthritis Severity Locus Cia4 Is An Early Regulator of IL-6, IL-β, and NFκB activators Expression in Pristane- Induced Arthritis. Max Brenner, Teresina Laragione and Percio Gulko, Hosftra North Shore-LIJ School of Medicine, Manhasset, NY 47. Modular Analysis Of In Peripheral Blood Gene Expression In Rheumatoid Arthritis Captures Reproducible Gene Expression Changes In TNF Responders. Mark Curran, Michaela Oswald, Sarah Lamberth, Carrie Brodmerkel, Zhenya Cherkas and Peter K. Gregersen, Janssen Research & Development, LLC., Spring House, PA, The Feinstein Institute for Medical Research, Manhasset, NY, Feinstein Institute for Medical Research, Manhasset, NY

167 ACR POSTER SESSION A 48. Microarray Analysis Of Synovial Specimen of Early Human (CHECK) and Experimental Osteoarthritis to Identify Pathways and Processes Associated with Pathology. Arjen B. Blom, Peter L. van Lent, Martijn H. van den Bosch, Hans Cats, Frank H.J. van den Hoogen, Peter M. van der Kraan and Wim B. van den Berg 4, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, Rheumatology Centre Sint Maartenskliniek, Nijmegen, Netherlands, Rheumatology Centre Sint Maartenskliniek and University Medical Centre St Radboud, Ubbergen (Nijmegen), Netherlands, 4 Rheumatology Research and Advanced Therapeutics, Department of Rheumatology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands 49. Comparative Proteomic Analysis Of Neutrophils From Patients With Microscopic Polyangiitis and Granulomatosis With Polyangiitis. Teisuke Uchida, Kohei Nagai, Toshiyuki Sato, Nobuko Iizuka, Mitsumi Arito, Yukiko Takakuwa 4, Hiromasa Nakano 4, Seido Ooka 4, Manae Kurokawa, Naoya Suematsu, Kazuki Okamoto, Shoichi Ozaki 4 and Tomohiro Kato, St. Marianna University School of Medicine, kawasaki, Japan, Kinki University, Wakayama, Japan, St. Marianna University Graduate School of Medicine, Kawasaki, Japan, 4 St. Marianna University School of Medicine, Kawasaki, Japan 50. A Subset Of Osteoarthritis Individuals Has Elevated IL-6 Pathway Activation Associated With Worse Symptoms. Michael Kuziora, Zheng Liu, Brandon W. Higgs, Philip Brohawn, Kim Lehmann, Fernanda Pilataxi, Katie Streicher, Lydia Greenlees, Meina Liang, Rozanne Lee, Amy Schneider, Raffaella Faggioni, Yihong Yao and Koustubh Ranade, MedImmune, LLC, Gaithersburg, MD, MedImmune, LLC, Hayward, CA 5. The mtdna Haplogroups Influence The Cartilage Integrity In Osteoarthritis. Data From The Osteoarthritis Initiative (OAI). Ignacio Rego-Pérez, Angel Soto-Hermida, Mercedes Fernández-Moreno, Sonia Pértega-Díaz, Juan Fernández- Tajes, María Eugenia Vázquez-Mosquera, Estefanía Cortés-Pereira, Sara Relaño-Fernández, Natividad Oreiro- Villar, Carlos Fernández-López and Francisco J. Blanco, INIBIC-Hospital Universitario A Coruña. Rheumatology Division. Genomic Group, A Coruña, Spain, INIBIC-Hospital Universitario A Coruña. Epidemiology and Public Health Unit, A Coruña, Spain, Osteoarticular and Aging Res. Lab. CIBER-BBN. INIBIC- University of A Coruña, A Coruña, Spain 5. The Uncoupling mtdna Haplogroup T Associates With Better Radiographic Progression Of Osteoarthritis. Data From The Osteoarthritis Initiative (OAI). Angel Soto- Hermida, Ignacio Rego-Pérez, Mercedes Fernández- Moreno, Sonia Pértega-Díaz, Juan Fernández-Tajes, María Eugenia Vázquez-Mosquera, Estefanía Cortés-Pereira, Sara Relaño-Fernández, Natividad Oreiro-Villar, Carlos Fernández-López and Francisco J. Blanco, INIBIC-Hospital Universitario A Coruña. Rheumatology Division. Genomic Group, A Coruña, Spain, INIBIC-Hospital Universitario A Coruña. Epidemiology and Public Health Unit, A Coruña, Spain, CIBER-BBN-ISCIII, Madrid, Spain 5. Identification Of Autoimmune Disease Risk Alleles That Are Under Recent Selection In The Sea Island Gullah African Americans. Carl D. Langefeld, Satria Sajuthi, Jasmin Divers, Yiqi Huang, Uma Nayak, Wei-Min Chen, Kelly J. Hunt, Diane L. Kamen, Gary S. Gilkeson, Jyotika K. Fernandes, Ida J. Spruill, W. Timothy Garvey 4, Michèle M. Sale and Paula S. Ramos, Wake Forest School of Medicine, Winston-Salem, NC, University of Virginia, Charlottesville, VA, Medical University of South Carolina, Charleston, SC, 4 University of Alabama at Birmingham, Birmingham, AL 54. Identification Of Autoimmune Disease Genes In Regions Under Selection In The Gullah African American Population Of South Carolina. Paula S. Ramos, Nathan Titus, Satria Sajuthi, Jasmin Divers, Yiqi Huang, Uma Nayak, Wei-Min Chen, Kelly J. Hunt, Diane L. Kamen, Gary S. Gilkeson, Jyotika K. Fernandes, Ida J. Spruill, W. Timothy Garvey 4, Michèle M. Sale and Carl D. Langefeld, Medical University of South Carolina, Charleston, SC, Wake Forest School of Medicine, Winston-Salem, NC, University of Virginia, Charlottesville, VA, 4 University of Alabama at Birmingham, Birmingham, AL 55. Exome Sequencing For Identification Of Potential Causal Variants For Diffuse Cutaneous Systemic Sclerosis. Angel CY Mak, M Kari Connolly, Tamiko Katsumoto, Paul Wolters 4, Clare Cleveland, Blanca M Herrera, Paul LF Tang, Simi Mathauda, Richard Lao, Pui-Yan Kwok and Lindsey A. Criswell, University of California, San Francisco, Institute for Human Genetics, San Francisco, CA, University of California, San Francisco, Department of Dermatology, San Francisco, CA, University of California, San Francisco, Rosalind Russell Medical Research Center for Arthritis, San Francisco, CA, 4 University of California, San Francisco, Department of Medicine, Pulmonary Division, San Francisco, CA 56. Cartilage Peptide Profiling: Identifying Novel OA Biomarkers For Early Disease Detection. Valentina Calamia, Lucía Lourido, Diego López, Jesus Mateos, Patricia Fernández-Puente, Carolina Fernández-Costa, Beatriz Rocha, Cristina Ruiz-Romero and Francisco J. Blanco, Osteoarticular and Aging Research Laboratory, Proteomics Unit-Associated Node to ProteoRed-ISCIII, INIBIC-CHUAC, A Coruña, Spain 57. Application Of a Multiplex Gene Polymorphism Assay For Variants Associated With Rheumatoid Arthritis Susceptibility: Results Of 68 Single Nucleotide Polymorphisms In The Optima Study. Jeffrey F. Waring, Viswanath Devanarayan, Kenneth Idler, Feng Hong, Josef S. Smolen, Arthur Kavanaugh 4, Hartmut Kupper 5, Hendrik Schulze-Koops 6 and Alla Skapenko 6, AbbVie Inc., North Chicago, IL, AbbVie Bioresearch Center, Worchester, MA, Medical University of Vienna and Hietzing Hospital, Vienna, Austria, 4 University of California San Diego, La Jolla, CA, 5 AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany, 6 University of Munich, Munich, Germany 58. The Use Of Autoantigenomics To Rapidly Identify Targets Of Human Autoantibodies. Wei-Hong Yang, Emily G. Bloch, Daniel F. Berenson, Rita L. Galdos, Pankaj Arora, Connie Wu and Donald B. Bloch, Massachusetts General 0 Program Book 65

168 ACR POSTER SESSION A Hospital and Harvard Medical School, Boston, MA 59. Transcriptomic Blood Markers and Molecular Stratification In Sarcoidosis. Robert Su, Michael Li, Nirav Bhakta, Misha Agarwal, Prescott Woodruff and Laura Koth, University of California San Francisco, San Francisco, CA 60. Association Analysis Of The Organic Anion Transporter 4 and Urate Transporter Locus With Gout In New Zealand Case-Control Sample Sets Reveals Multiple Ancestral- Specific Effects. Tony R. Merriman, Amanda Phipps- Green, Jade E. Hollis-Moffatt, Marilyn E. Merriman, Ruth Topless, Grant Montgomery, Brett Chapman, Lisa K. Stamp, Nicola Dalbeth 4 and Tanya Flynn, University of Otago, Dunedin, New Zealand, Queensland Institute of Medical Research, Brisbane, Australia, University of Otago, Christchurch, Christchurch, New Zealand, 4 University of Auckland, Auckland, New Zealand 6. HK9 Demethylation By LSD Contributes To IL--Induced mpges- Expression In OA Chondrocytes. Fatima Ezzahra El Mansouri and Hassan Fahmi, Osteoarthritis Research Unit, University of Montreal Hospital Research Centre (CRCHUM), Notre-Dame Hospital, Montreal, QC 6. Genotypic and Haplotypic Effects Of 7 Single-Nucleotide Polymorphisms In the CRP Gene On Levels Of C-Reactive Protein and DAS8 In a Cohort Of 80 Untreated Newly Diagnosed Rheumatoid Arthritis Patients (OPERA Study). Christian G. Ammitzbøll, Rudi Steffensen, Peter Junker, Mikkel Østergaard 4, Julia Johansen 5, Jan Pødenphant 6, Merete Lund Hetland 7, Hanne M. Lindegaard 8, Torkell Ellingsen 9 and Kristian Stengaard-Pedersen, Arhus University Hospital, Aarhus, Denmark, Aalborg University Hospital, Aalborg, Denmark, University of Southern Denmark, Odense, Denmark, 4 Copenhagen University Hospital Glostrup, Copenhagen, Denmark, 5 Copenhagen University and Glostrup Hospital, Copenhagen, Denmark, 6 Copenhagen University at Gentofte, Hellerup, Denmark, 7 The Danish Rheumatologic Database (DANBIO), Glostrup Hospital., Copenhagen, Denmark, 8 Odense University Hospital, Odense, Denmark, 9 Diagnostic Centre Region Hospital Silkeborg Denmark, 8600 Silkeborg, Denmark 6. The Frequency Of Single Nucleotide Polymorphisms In Urate Transporter Genes and Their Association With Uric Acid Concentration Based On Data From Genome-Wide Association Studies In The Korean Population. Chan-Nam Son, So-Young Bang, Sang-Cheol Bae and Jae-Bum Jun, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, Hanyang University Guri Hospital, Guri, South Korea 64. Haptoglobin Chains As Potential Biomarkers In Serum Of Osteoarthritis Disease. Carolina Fernandez-Costa, Valentina Calamia, Patricia Fernandez-Puente, Jesus Mateos, Beatriz Rocha, Lucia Lourido, Jose Luis Capelo, Cristina Ruiz-Romero and Francisco J. Blanco, Osteoarticular and Aging Research Laboratory, Proteomics Unit-Associated Node to ProteoRed-ISCIII, INIBIC- CHUAC, A Coruña, Spain, BIOSCOPE Group, REQUIMTE, Departamento de Química, Faculdade de Ciências e Tecnologia, FCT, Universidade Nova de Lisboa,, Caparica, Portugal, CIBER-BBN, INIBIC-CHUAC, A Coruña, Spain 65. New Insights Into The Metabolic Origin Of Osteoarthritis. Ignacio Rego-Pérez, María Eugenia Vázquez-Mosquera, Angel Soto-Hermida, Mercedes Fernández-Moreno, Juan Fernández-Tajes, Estefanía Cortés-Pereira, Sara Relaño-Fernández, Natividad Oreiro-Villar, Carlos Fernández-López and Francisco J. Blanco, INIBIC-Hospital Universitario A Coruña. Rheumatology Division. Genomic Group, A Coruña, Spain, INIBIC-Hospital Universitario A Coruña, A Coruña, Spain 66. The Potential Role Of Protein Tyrosine Phosphatase Receptor D (PTPRD) Gene Copy Number Variation In Susceptibility To Rheumatoid Arthritis. Su Jin Yoo, Mi Kyoung Lim, Donghyuk Sheen, In Seol Yoo, Jinhyun Kim, Seong Wook Kang and Seung-Cheol Shim, Chungnam National University School of Medicine, Daejeon, South Korea, Eulji University Hospital, Daejeon, South Korea, Chungnam National University Hospital, Daejeon, South Korea 67. Association Of Functional Polymorphisms In IRF With Systemic Lupus Erythematosus In a Japanese Population. Aya Kawasaki, Hiroshi Furukawa, Nao Nishida, Eiji Warabi, Yuya Kondo, Satoshi Ito 4, Isao Matsumoto, Makio Kusaoi 5, Akiko Suda 6, Shouhei Nagaoka 7, Keigo Setoguchi 8, Tatsuo Nagai 9, Shunsei Hirohata 9, Katsushi Tokunaga 0, Yoshinari Takasaki 5, Hiroshi Hashimoto, Takayuki Sumida, Shigeto Tohma and Naoyuki Tsuchiya, University of Tsukuba, Tsukuba, Japan, Sagamihara Hospital, National Hospital Organization, Sagamihara, Japan, National Center for Global Health and Medicine, Ichikawa, Japan, 4 Niigata Rheumatic Center, Shibata, Japan, 5 Juntendo University, Tokyo, Japan, 6 Yokohama City University, Mecical Center, Yokohama, Japan, 7 Yokohama Minami Kyousai Hospital, Yokohama, Japan, 8 Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, Japan, 9 Kitasato University School of Medicine, Sagamihara, Japan, 0 The University of Tokyo, Tokyo, Japan, Juntendo University School of Medicine, Tokyo, Japan 68. Predicting The Severity Of Joint Damage In Rheumatoid Arthritis; The Contribution Of Genetic Factors. Hanna W. van Steenbergen, Roula Tsonaka, Tom W.J. Huizinga, Saskia le Cessie and Annette H.M. van der Helm-van Mil, Leiden University Medical Center, Leiden, Netherlands 69. Effects Of Chondroitin Sulfate On The Gene Expression Profile In Interleukin-β Stimulated Synovial Fibroblast Cells Cultures. Cécile Lambert, Jean-Emile Dubuc, Eulalia Montell, Josep Verges and Yves Henrotin, Bone and Cartilage Research Unit, Liège, Belgium, Orthopaedic Department, Bruxelles, Belgium, Pre-Clinical R&D Area, Pharmascience Division, BIOIBERICA S.A., Barcelona, Spain 70. Association Of BMI, 8 SNPs Reported To Be Related To Gout Phenotype and Their Interaction In Gout Incidence In Framingham Heart Study. Jasvinder A. Singh, Ana Vazquez, Richard Reynolds, Vinodh Srinivasasainagendra, S. Louis Bridges Jr. and David Allison, University of Alabama, Tuscaloosa, AL, University of Alabama at Birmingham, Birmingham, AL, University of alabama at 66 0 Program Book

169 ACR POSTER SESSION A birmingham, birmingham, AL 7. Effects Of Chondroitin Sulfate On The Gene Expression Profile In The Inflamed Synovial Membrane. Cécile Lambert, Jean-Emile Dubuc, Eulalia Montell, Josep Verges and Yves Henrotin, Bone and Cartilage Research Unit, Liège, Belgium, Orthopaedic Department, Bruxelles, Belgium, Pre-Clinical R&D Area, Pharmascience Division, BIOIBERICA S.A., Barcelona, Spain 7. Transcript Profiling Of Kidney Biopsies From Chinese Patients With Lupus Nephritis Suggests a Prevalence Of Infiltrating CD8+ T Cells, Monocytes/Macrophages, and B Cells In ISN/RPS Class IV Disease. Zheng Liu, Chris Morehouse, Xinfang Huang, Philip Brohawn, Nan Shen, Gabor G. Illei, Yihong Yao and Brandon W. Higgs, MedImmune, LLC, Gaithersburg, MD, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China, Cincinnati Children s Hospital Medical Center, cincinnati, OH 7. HLA-DRB*08:0 Is Associated With Bucillamine-Induced Proteinuria In Japanese Rheumatoid Arthritis Patients: A Case-Control Study. Hiroshi Furukawa, Shomi Oka, Kota Shimada, Shoji Sugii, Atsushi Hashimoto, Akiko Komiya, Naoshi Fukui, Taiichiro Miyashita, Kiyoshi Migita, Akiko Suda 4, Shouhei Nagaoka 5, Naoyuki Tsuchiya 6 and Shigeto Tohma, Sagamihara Hospital, National Hospital Organization, Sagamihara, Japan, Tokyo Metropolitan Tama Medical Center, Tokyo, Japan, Nagasaki Medical Center, National Hospital Organization, Omura, Japan, 4 Yokohama City University, Mecical Center, Yokohama, Japan, 5 Yokohama Minami Kyousai Hospital, Yokohama, Japan, 6 University of Tsukuba, Tsukuba, Japan 74. Genetic Association On Disease Severity In Rheumatoid Arthritis: A Validation Study In Japanese Patients. Shinji Yoshida, Katsunori Ikari, Koichiro Yano, Yoshiaki Toyama, Atsuo Taniguchi, Hisashi Yamanaka and Shigeki Momohara, Institute of Rheumatology, Tokyo Women s Medical University, Tokyo, Japan, Department of Orthopaedic Surgery, Keio University School of Medicine, Shinjuku, Japan, Tokyo Women s Medical University, Tokyo, Japan 75. Dynamics Of The Inflammatory Response In Rheumatoid Arthritis Patients Following Traumatic Injury: Insights From In Vivo,In Silico, and Single Nucleotide Polymorphism Studies. Rajaie Namas, Rami Namas, Harpreet Sagar, Felix Fernandez-Madrid, Timothy Billiar and Yoram Vodovotz, Wayne State University/ Henry Ford Health System, Detroit, MI, University of Pittsburgh, Pittsburgh, PA, Wayne State University, Detroit, MI 76. Identification Of Major Histocompatibility Complex Class II Alleles Associated With Systemic Sclerosis Through Imputation Strategy. Jose Ezequiel Martin, Carmen P. Simeón, Norberto Ortego-Centeno, Patricia Carreira 4, Miguel A. Gonzalez-Gay 5, Nicolas Hunzelmann 6, Shervin Assassi 7, Filemon K. Tan 7, Frank C. Arnett 7, Xiaodong Zhou 7, T.R.D.J. Radstake 8, Maureen D. Mayes 7, Paul de Bakker 9, Javier Martin 0 and B. P. C. Koeleman 8, Instituto de Parasitología y Biomedicina López-Neyra, IPBLN-CSIC, Granada, Spain, Hospital Valle de Hebron, Barcelona, Spain, Hospital Clínico San Cecilio, Granada, Spain, 4 Hospital Universitario de Octubre, Madrid, Spain, 5 Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, Rheumatology Division, IFIMAV, Santander, Spain, 6 University of Cologne, Cologne, Germany, 7 University of Texas Health Science Center at Houston, Houston, TX, 8 University Medical Center Utrecht, Utrecht, Netherlands, 9 Brigham and Women s Hospital, Harvard Medical School, Boston, MA, 0 Instituto de Parasitologia y Biomedicina López-Neyra, IPBLN-CSIC, Granada, Spain 77. Differences and Overlap Of Immunological Pathways Implicated In The Aetiology Of Anti-Citrullinated Peptide Antibody Positive and Negative Rheumatoid Arthritis. Sebastien Viatte, Paul Martin, Andrew Brass, Mark Lunt 4, Anne Barton 4 and Stephen Eyre 4, Arthritis Research UK Epidemiology Unit, Manchester Academic Health Science Centre, The University of Manchester, Manchester, United Kingdom, Arthritis Research UK Epidemiology Unit, Manchester Academic Health Sciences Centre, Institute of Inflammation and Repair, The University of Manchester, Manchester, United Kingdom, School of Computer Science, University of Manchester, Manchester, United Kingdom, Manchester, United Kingdom, 4 Arthritis Research UK Epidemiology Unit, University of Manchester, Manchester, United Kingdom 78. Fc-Gamma Receptor Genetic Variation In Kawasaki Disease. Carline E. Tacke, Willemijn B. Breunis, Long T. Hoang, Eileen Png, Judy Geissler, Sietse Nagelkerke, Justine Ellis 4, Sonia Davila, Chiea Chuen Khor, Michael Levin 5, David Burgner 4, Chisato Shimizu 6, Jane C. Burns 6, Martin L. Hibberd and Taco W. Kuijpers, Emma Children s Hospital/Academic Medical Center (AMC), Amsterdam, Netherlands, Sanquin Resarch and Landsteiner Laboratory (AMC), Amsterdam, Netherlands, Genome Institute of Singapore, Singapore, Singapore, 4 Murdoch Childrens Research Institute, Parkville, Australia, 5 Imperial College London, London, United Kingdom, 6 UC San Diego, School of Medicine, La Jolla, CA 79. The Association Between Single Nucleotide Polymorphism ABCG rs4 and Hyperuricemia: A Case-Control Study. Bingqing Zhang, Weigang Fang, Yun Zhang, Shufen Liu, Yuanjie Li and Xuejun Zeng, Peking Union Medical College, Beijing, China, Peking Union Medical College Hospital, Beijing, China 80. Familial Aggregation Of Female Premenopausal Gout --Monogenic, Polygenic Or Clinical Coincidence? Bingqing Zhang, Shufen Liu, Nuo Si, Yun Zhang and Xuejun Zeng, Peking Union Medical College, Beijing, China, Peking Union Medical College Hospital, Beijing, China, Chinese Academy of Medical Science & Peking Union Medical College, Beijing, China Health Services Research, Quality Measures and Quality of Care Rheumatoid Arthritis 8. Rheumatoid Arthritis Quality Measure Results In a Large Managed Care Population. Roxanne Meyer, Lorie A. 0 Program Book 67

170 ACR POSTER SESSION A Ellis, Susan C. Bolge, Andrew Howe and Yunping Zhou, Janssen Scientific Affairs, LLC, Horsham, NY, Janssen Scientific Affairs, LLC, Horsham, PA, Comprehensive Health Insights, Louisville, KY 8. National Quality Forum Measures Among Rheumatoid Arthritis Patients In a Large Managed Care Population. Roxanne Meyer, Lorie A. Ellis, Susan C. Bolge, Joseph Tkacz, Peter Kardel and Charles Ruetsch, Janssen Scientific Affairs, LLC, Horsham, NY, Janssen Scientific Affairs, LLC, Horsham, PA, Health Analytics, LLC, Columbia, MD 8. The Performance Of a Point Of Care Test For Detection Of Anti-Mutated Citrullinated Vimentin and Rheumatoid Factor In Early Rheumatoid Arthritis. Preeda Rojanasantikul, Prapa Pattrapornpisut, Kulvara Anuruckparadorn and Wanruchada Katchamart, Division of Rheumatology, Department of Internal Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand, Department of Internal Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand, Department of Transfusion Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand 84. Are Physician Gender, Age and Clinical Experience Associated With Discrepancy In Global Disease Score In Rheumatoid Arthritis, Ankylosing Spondylitis and Psoriatic Arthritis? Data From The Nationwide Danbio Registry. Cecilie Lindstrom Egholm, Niels Steen Krogh, Lene Dreyer, Torkell Ellingsen 4, Bente Glintborg 5, Marcin Kowalski 6, Tove Lorenzen 7, Ole Rintek Madsen 8, Henrik Nordin 9, Claus Rasmussen 0 and Merete L. Hetland, Regional Research Unit, Region Zealand, Roskilde, Denmark, ZiteLab ApS, Copenhagen, Denmark, Copenhagen University Hospital at Gentofte, Copenhagen, Denmark, 4 Diagnostic Centre Region Hospital Silkeborg Denmark, 8600 Silkeborg, Denmark, 5 Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Glostrup Hospital, Glostrup, Denmark, 6 Aalborg University Hospital, Aalborg, Denmark, 7 Department of Rheumatology, Region Hospital Silkeborg, Silkeborg, Denmark, 8 Copenhagen University Hospital in Gentofte, Copenhagen, Denmark, 9 Department of Infectious Diseases and Rheumatology, Rigshospitalet, Copenhagen, Denmark, 0 Vendsyssel Teaching Hospital/Aalborg University, Hjoerring, Denmark, Copenhagen University Hospital Glostrup, Copenhagen, Denmark 85. No Secular Trends In Real Live Radiographic Progression Of Rheumatoid Arthritis In Recent Year. Miriam Gärtner, Farideh Alasti, Gabriela Supp, Josef S. Smolen and Daniel Aletaha, Medical University of Vienna, Vienna, Austria, Medical University of Vienna and Hietzing Hospital, Vienna, Austria 86. Delay In Consultation and Starting Disease Modifying Anti- Rheumatic Drugs In Patients With Rheumatoid Arthritis In Argentina. How Early Arthritis Clinics Impact On Health Barriers? Natalia Zamora, Christian A. Waimann, Maria Florencia Marengo, Gustavo Citera, Amelia Granel, Ana Inés Marcos, Emilio Buschiazzo, Ricardo V. Juarez, Dora Pereira 4, Gisela Pendón 4, Andrea D Orazio 5, Mariana Salcedo 6, Judith Sarano 7, María Victoria Collado 7, Graciela Gómez 7, Alejandra Medina 8, María Eugenia Lara 9, Juan C. Barreira 9, María Alicia Lázaro 0, Alejandra Cusa 0, Luciana González Lucero, María Silvia Yacuzzi, Raúl Nicolas Martínez and Pablo Arturi, Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, Hospital San Roque de Gonnet, La Plata, La Plata, Argentina, Hospital Señor del Milagro, Salta, Argentina, 4 Hospital Ricardo Gutierrez, La Plata, La Plata, Argentina, 5 Hospital de la Asociacion Medica de Bahía Blanca, Bahía Blanca, Argentina, 6 Consultorio Privado, San Nicolás, Argentina, 7 Instituto de Investigaciones Medicas Alfredo Lanari, Buenos Aires, Argentina, 8 Hospital General de Agudos Dr. E. Tornu, Ciudad Autónoma de Buenos Aires, Argentina, 9 Buenos Aires British Hospital, Buenos Aires, Argentina, 0 Hospital central de San isidro Dr A. Posse, San Isidro, Argentina, Hospital Angel C. Padilla de San Miguel de Tucumán, San Miguel de Tucumán, Argentina, Hospital Italiano de La Plata, La Plata, Argentina 87. The Health and Economic Consequences Of Delay In Starting Disease-Modifying Anti-Rheumatic Drugs In Australian Patients With Early Rheumatoid Arthritis. Danny Liew, Mark Tacey and Sharon Van Doornum, The University of Melbourne, Melbourne, Australia 88. Can MDHAQ/RAPID Be Used In Usual Care Of Patients With Systemic Lupus Erythematosus? Narender Annapureddy, Theodore Pincus, Joel A. Block and Meenakshi Jolly, Rush University Medical Center, Chicago, IL, NYU Hospital for Joint Diseases and New York University School of Medicine, New York, NY 89. Implementation Of a Methotrexate Self-Injection Education Video Reducing Teaching Time While Maintaining Patient Confidence and Knowledge. Steven J. Katz and Sylvia Leung, University of Alberta, Edmonton, AB 90. A Meta-Analysis and Systematic Literature Review: Effect Of The Method Used To Measure Adherence In Rheumatoid Arthritis On Its Rate, and Evaluation Of Associated Factors. Anat Scheiman-Elazary, Cortney Shourt, M. Cameron Hay and Daniel Furst, Rheumatology UCLA, Los Angeles, CA, Anthropology Miami University, Oxford, OH, David Geffen School of Medicine, UCLA, Los Angeles, CA 9. Does Specific Joint Involvement In Rheumatoid Arthritis Patients Predict Patient Reported Outcomes? Implications For Clinical Practice. Regan Arendse, William G. Bensen, Andrew Chow, Jude F. Rodrigues 4, Sanjay Dixit 5, Dalton E. Sholter 6, Philip Baer 7, Milton F. Baker 8, Denis Choquette 9, Isabelle Fortin 0, Algis Jovaisas, Emmanouil Rampakakis, John S. Sampalis, Francois Nantel, Susan M. Otawa, May Shawi and Allen J. Lehman, University of Saskatchewan, Saskatoon, SK, St. Joseph s Hospital and McMaster University, Hamilton, ON, Credit Valley Rheumatology, Mississauga, ON, 4 Rheumatology, Windsor, ON, 5 McMaster University, Burlington, ON, 6 Rheumatology Associates, Edmonton, AB, 7 Rheumatology, Scarborough, ON, 8 University of Victoria, Victoria, BC, 9 Institut de Rhumatologie de Montréal, Montreal, QC, 0 Centre de Rhumatologie de l Est du Québec, Rimouski, QC, 68 0 Program Book

171 ACR POSTER SESSION A University of Ottawa, Ottawa, ON, JSS Medical Research, St-Laurent, QC, Janssen Canada Inc, Toronto, ON 9. Can Routine Assessment Of Patient Index Data (RAPID) Be Used As a Patient Reported Assessment Tool For Patients With Ankylosing Spondylitis? Muhammet Cinar, Sedat Yilmaz, Fatma Ilknur Cinar, Suleyman Serdar Koca, Hakan Erdem, Salih Pay, Yusuf Yazici 4, Ayhan Dinc 5 and Ismail Simsek, Gulhane School of Medicine, Ankara, Turkey, Gulhane Military Medical Academy, School of Nursing, Ankara, Turkey, Department of Rheumatology, Faculty of Medicine, Firat University, Elazig, Turkey, 4 NYU Hospital for Joint Diseases and New York University School of Medicine, New York, NY, 5 Patio Clinic, Ankara, Turkey 9. Physician Variability In Rheumatoid Patients Not Receiving Biologics Or Non-Biologic Dmards: Implications For Quality Reporting. Dimitrios A. Pappas, Lang Chen, Leslie R. Harrold, George W. Reed 4, Joel M. Kremer 5, Jeffrey D. Greenberg 6 and Jeffrey R. Curtis 7, Columbia University, College of Physicians and Surgeons, New York, NY, University of Alabama at Birmingham, Birmingham, AL, University of Massachusetts Medical School, Worcester, MA, 4 CORRONA, Inc., Worcester, MA, 5 Center for Rheumatology, Albany Medical College, Albany, NY, 6 NYU Hospital for Joint Diseases, New York, NY, 7 University of Alabama at Birmingham, Division of Clinical Immunology and Rheumatology, Birmingham, AL 94. Team Managed Care From a Patient s Perspective: A Study Of Biological Patients At a Canadian Centre. Dawn Heap, Margaret Saldanha, Melissa Deamude, Cynthia Mech, Helena Ross, Kathy Kislinsky, Lauri Vanstone, Arthur N. Lau and William G. Bensen 4, Rheumatology Health Team, St. Joseph s Hospital Hamilton, Hamilton, ON, Rheumatology Health Team, Hamilton, ON, McMaster University, Hamilton, ON, 4 St. Joseph s Hospital and McMaster University, Hamilton, ON 95. Major Cost Savings Associated With Reduced Biologic Dosing Frequency In Inflammatory Arthritis. Claire- Louise Murphy, Miriam O Sullivan, Sohail Awan, Shawn Chavrimootoo, Clara Bannon, Linzi Martin, Trevor Duffy, Eithne Murphy and Maurice Barry, Connolly hospital, Dublin 5, Dublin, Ireland, Connolly hospital, Dublin, Ireland 96. Uptake Of The American College Of Rheumatology s Rheumatology Clinical Registry: Quality Measure Summary Data. Jinoos Yazdany, Salahuddin Kazi, Rachel Myslinski and Melissa Francisco, University of California, San Francisco, San Francisco, CA, UT Southwestern Medical Center, Dallas, TX, American College of Rheumatology, Atlanta, GA 97. Discordance Of Patient-Physician Assessments Of General Health In a US Hispanic Population With Rheumatoid Arthritis. Leyda Díaz-Correa, Mariely Nieves-Plaza, Yesenia C. Santiago-Casas, Tania González-Rivera, Grissel Ríos and Luis M. Vilá, University of Puerto Rico Medical Sciences Campus, San Juan, PR, University of Pittsburgh, Pittsburgh, PA, University of Michigan School of Medicine, Ann Arbor, MI 98. Accuracy Of International Classification Of Diseases (Ninth Revision) Coding For Rheumatoid Arthritis In The Primary Care Setting. Sheena Ogando, Karolina M. Weiss and Harry D. Fischer, Albert Einstein College of Medicine at Beth Israel Medical Center, New York, NY 99. Overcoming The Barriers To Adequate Hydroxychloroquine Retinal Toxicity Screening. Cristina Arriens and Elizabeth Blair Solow, University of Texas Southwestern Medical Center at Dallas, Dallas, TX, UT Southwestern Medical Center, Dallas, TX 00. Hydroxychloroquine Use Among Systemic Lupus Erythematosus Patients In An Academic Rheumatology Practice. James G. Miceli and Harry D. Fischer, Beth Israel Medical Center, New York, NY, Albert Einstein College of Medicine at Beth Israel Medical Center, New York, NY 0. Comparison To Organisational Models For EARLY Rheumatoid Arthritis Management: Routine Care Versus EARLY Arthritis Clinic. Giovanni Ciancio, Ilaria Farina, Federica Pignatti and Marcello Govoni, Rheumatology Unit-Azienda Ospedaliera-Universitaria Sant Anna, Ferrara, Italy, Rheumatology Unit-Azienda Ospedaliera- Universitaria Sant Anna, Ferrara, Italy, ferrara, Italy 0. Analysis Of Non-Steroidal Anti-Inflammatory Drug Burden Among Rheumatoid Arthritis Patients Using The Dougados Algorithm. E Alemao, L Xie, R Wong, G Lltalien and O Baser, Bristol-Myers Squibb, Princeton, NJ, SATinMED Research, Ann Arbor, MI, STATinMED Research and University of Michigan, Ann Arbor, MI 0. Belief In Self-Adjustability Of Medication Dosing Is Negatively Correlated With Medication Adherence In Patients With Rheumatoid Arthritis. Wenxin Sun, Dianne Carrol Tan Bautista, Xiaohui Xin, Yu Ting Saw, Wee Boon Tan, Kanchanadevi Balasubramaniam, Wan Pin Lee, Steve Thein Htay Oo, Yin Bun Cheung and Julian Thumboo, Duke-NUS Graduate Medical School, Singapore, Singapore, Singapore General Hospital, Singapore, Singapore 04. Evaluation Of Hospitalizations and Costs In Patients With Rheumatoid Arthritis In United States Medicare Population. E Alemao, L Wang, G Lltalien, O Baser, H Yuce 4 and M Hochberg 5, Bristol-Myers Squibb, Princeton, NJ, STATinMED Research, Dallas, TX, STATinMED Research and University of Michigan, Ann Arbor, MI, 4 New York City College of Technology (CUNY), Brooklyn, NJ, 5 University of Maryland, Baltimore, MD 05. Temporal Trends In The Prescribing Of Disease Modifying Anti-Rheumatic Drugs For Rheumatoid Arthritis and The Impact Of Guidelines. Gemma L Wallace, C. J. Edwards, Nigel K. Arden, Daniel Prieto-Alhambra 4 and Andrew Judge 5, University of Oxford, Oxford, United Kingdom, University Hospital Southampton, Southampton, United Kingdom, Oxford NIHR Musculoskeletal Biomedical Research Unit, University of Oxford, Oxford, United Kingdom, 4 URFOA-IMIM, Parc de Salut Mar; Idiap Jordi Gol; University of Oxford; University of Southampton, Barcelona, Spain, 5 Oxford University, Oxford, United Kingdom 0 Program Book 69

172 ACR POSTER SESSION A American College Of Rheumatology s Rheumatology Informatics System For Effectiveness Registry Pilot. Peter J. Embi, William Stephens and Rachel Myslinski, The Ohio State University, Columbus, OH, Ohio State University, Columbus, OH, American College of Rheumatology, Atlanta, GA 07. Frequency and Predictors Of Hypertension Communication In Rheumatoid Arthritis Visits. Christie M. Bartels, Heather Johnson, Elizabeth A. Jacobs, Patrick McBride and Maureen Smith, University of Wisconsin School of Medicine and Public Health, Madison, WI 08. Three Approaches To Evaluating Step Therapy Policies For Immune Disorder Specialty Pharmaceuticals. Michael P. Ingham, Andrew Paris, Lorie A. Ellis and Chris Kozma, Janssen Scientific Affairs, LLC, Horsham, PA, Vigilytics, Victor, NY, CK Consulting, Saint Helena Island, SC 09. Focus on cardiovascular Risk Factor Recording In a Rheumatology Outpatient Clinic. Eirik Ikdahl, Silvia Rollefstad, Inge C. Olsen, Tore K. Kvien, Inger Johanne Widding Hansen, Dag Magnar Soldal 4, Glenn Haugeberg 4 and Anne Grete Semb, Diakonhjemmet Hospital, Oslo, Norway, University of Oslo, Oslo, Norway, Hospital of Southern Norway Trust, Kristiansand, Norway, Kristiansand, Norway, 4 Hospital of Southern Norway Trust, Kristiansand, Norway 0. Medication Adherence In Patients With Gout: A Systematic Review. Mary De Vera, Sharan Rai and Vidula Bhole, Arthritis Research Centre of Canada, Richmond, BC, EpiSolutions Consultancy Services, Thane, India. The Economic Burden Of Gout: A Systematic Review Of Direct and Indirect Costs. Sharan Rai, Aliya Haji, Lindsay C Burns and Hyon K. Choi, Arthritis Research Centre of Canada, Richmond, BC, University of British Columbia, Vancouver, BC, Boston University School of Medicine, Boston, MA Imaging of Rheumatic Diseases I: Imaging in Gout, Pediatric, Soft and Connective Tissue Diseases. Dual-Energy Computed Tomography for Monitoring of Urate Deposition in Tophaceous Gout: A Prospective Longitudinal Study Examining Sensitivity to Change. Ashwin Rajan, Opetaia Aati, Ramanamma Kalluru, Gregory Gamble, Anne Horne, Anthony Doyle, Fiona M. McQueen and Nicola Dalbeth, University of Auckland, Auckland, New Zealand, Department of Rheumatology, Auckland District Health Board, Auckland, New Zealand. Digital Tomosynthesis for Measurement of Bone Erosion in Gout: Comparison With Computed Tomography. Nicola Dalbeth, Anthony Doyle, Mark Roger, Angela Gao and Fiona M. McQueen, University of Auckland, Auckland, New Zealand, Auckland District Health Board, Auckland, New Zealand 4. Use Of Dual-Energy Computed Tomography In Evaluation Of Axial Gout. Kristin Logee, Ranadeep Mandhadi, William Traverse and Santhanam Lakshminarayanan, 0 Program Book University of Connecticut, Farmington, CT, Saint Francis Hospital and Medical Center, Hartford, CT, University of Connecticut School of Medicine, Farmington, CT 5. Relationship Between Structural Joint Damage and Urate Deposition In Gout: A Site-By-Site Analysis Using Plain Radiography and Dual Energy Computed Tomography. Nicola Dalbeth, Opetaia Aati, Ramanamma Kalluru, Anne Horne, Anthony Doyle and Fiona M. McQueen, University of Auckland, Auckland, New Zealand, Department of Rheumatology, Auckland District Health Board, Auckland, New Zealand 6. Systematic Staging For Uric Acid Deposits With Dual- Energy Computed Tomography and Ultrasound In Suspected Gout. Wolfgang A. Schmidt and Alexander Huppertz, Med Ctr Rheumatology Berlin Buch, Immanuel Krankenhaus Berlin, Berlin, Germany, Imaging Science Institute Charité, Berlin, Germany 7. Clinical Value Of 8 f-fluoro-dexoxyglucose Positron Emission Tomography In Patients With Adult-Onset Still s Disease. Hiroyuki Yamashita, Kazuo Kubota, Yuko Takahashi, Hiroshi Kaneko, Toshikazu Kano and Akio Mimori, National Center for Global Health and Medicine, Tokyo, Japan 8. The Role Of Salivary GLAND Ultrasound In Sjogren Syndrome: A Single Center Experience. Giuseppe Germanò, Niccolò Possemato, Olga Addimanda, Pierluigi Macchioni and Carlo Salvarani, Arcispedale S Maria Nuova, IRCCS, Reggio Emilia, Italy, Arcispedale S Maria Nuova-IRCCS, Reggio Emilia, Italy 9. Contrast-Enhanced Ultrasound Of The Sovraortic Arteries: The Potential Role In Monitoring Disease Activity and Response To Treatment In Large Vessel Vasculitis. Giuseppe Germanò, Pierluigi Macchioni, Niccolò Possemato and Carlo Salvarani, Arcispedale S Maria Nuova, IRCCS, Reggio Emilia, Italy, Arcispedale S Maria Nuova-IRCCS, Reggio Emilia, Italy 0. Asymptomatic Myocardial Ischemic Disease In Takayasu s Arteritis: Detection By Magnetic Resonance Imaging. Cloé Comarmond, Philippe Cluzel, Dan Toledano, Nathalie Costedoat-Chalumeau 4, Richard Isnard 5, Fabien Koskas 6, Patrice Cacoub Sr. 7 and David Saadoun 8, Hôpital Pitié Salpétrière, Paris, France, Pitié-Salpétrière, Paris, France, Hôpital Pitié-Salpêtrière, Paris, France, 4 Hopital Cochin, Paris, France, 5 CHU Pitié-Salpêtrière, 47-8 Boulevard de l hôpital, 7565 Paris Cedex, Paris, France, Paris, France, 6 Assistance Publique-Hôpitaux de Paris, Hopital Pitié-Salpétrière, Paris, France, 7 CHU Pitié-Salpêtrière, Paris, France, 8 Pitié-Salpêtrière Hospital, APHP, Paris, France. Detection Of Cerebral Microvascular Lesions In Patients With Acute Phase Neuropsychiatric Systemic Lupus Erythematosus By 7Tesla MRI. Nobuhito Sasaki, Okinori Murata, Yukari Ninomiya, Yuka Oikawa, Hitoshi Kobayashi, Kohei Yamauchi, Makoto Sasaki, Takashi Sawai and Yutaka Nakamura, Iwate Medical University School of Medicine, Morioka, Japan. Comparison Of Whole Body Versus Targeted Magnetic

173 ACR POSTER SESSION A Resonance Imaging For Assessing Disease Activity and Damage In Idiopathic Inflammatory Myopathies. Adam Schiffenbauer, Evrim Turkbey, Lisa G. Rider, Suvimol Hill, Irene Z. Whitt, Songtao Liu, David A. Bluemke and Frederick W. Miller, NIEHS, NIH, Bethesda, MD, NIH, Bethesda, MD, Duke, Durham, NC. Clinical Predictors For Subcutaneous Power Doppler Signals Detected By Ultrasound in Hands Of Scleroderma Patients. Anat Scheiman-Elazary, Ami Ben-Artzi, V.K. Ranganath, Nabeel Borazan, Philip J. Clements, Suzanne Kafaja and Daniel Furst, Rheumatology UCLA, Los Angeles, CA, David Geffen School of Medicine, UCLA, Los Angeles, CA 4. Ultrasound Evaluation Of Joints, Tendons and Subcutaneous Tissue Of Hands In 74 Scleroderma Patients. Anat Scheiman-Elazary, Ami Ben-Artzi, Suzanne Kafaja, V Ranganath, Nabeel Borazan, Philip J. Clements and Daniel Furst, Rheumatology UCLA, Los Angeles, CA, David Geffen School of Medicine, UCLA, Los Angeles, CA 5. Cardiovascular Involvement In Erdheim-Chester Disease: A Magnetic Resonance Imaging Study On Seven Patients. Enrica Rossi, Lorenzo Buttarelli, Augusto Vaglio, Davide Gianfreda, Chiara Martini and Massimo De Filippo, University of Parma, Parma, Italy 6. Omeract Definitions For The Sonographic Appearance Of The Normal Pediatric Joint. Johannes Roth, Sandrine Jousse-Joulin, Silvia Magni-Manzoni, Ana Narrodi 4, Nikolay Tzaribachev 5, Annamaria Iagnocco 6, Esperanza Naredo 7, Maria-Antonietta D Agostino 8 and Paz Collado 9, University of Ottawa, Ottawa, ON, C.H.U. La Cavale Blanche, Brest, France, Ospedale Pediatrico Bambino Gesù, Rome, Italy, 4 Rheumatology, Madrid, Spain, 5 Center for Rheumatic Diseases, Bad Bramstedt, Germany, 6 University La Sapienza, Rome, Italy, 7 Hospital General Universitario Gregorio Marañón, Madrid, Spain, 8 Ambroise Paré Hospital, and Versailles Saint Quentin en Yvelines University, Boulogne- Billancourt, France, 9 Severo Ochoa University Hospital, Madrid, Spain 7. Quantitative Image Analysis Of Articular Involvement In Blau Syndrome By Radiographic Calpal Length and Ultrasound Assessment. Tsuyoshi Yamatou, Tomohiro Kubota, Harumi Akaike, Yuichi Yamasaki, Yukiko Nonaka, Yasuhito Nerome, Tomoko Takezaki, Hiroyuki Imanaka, Kei Ikeda, Naotomo Kambe, Syuji Takei and Tomokazu Nagakura 4, Kagoshima University, Kagoshima, Japan, Chiba University Hospital, Chiba, Japan, Chiba University Graduate School of Medicine, Chiba, Japan, 4 House of Meguminoseibo, Usuki, Japan 8. The Composition and Structure Of Calcifications In Juvenile Dermatomyositis Differs From Calcified Aortic Valves Removed From Adults Without JDM. Lauren M. Pachman, Gabrielle A. Morgan, Patrick M. McCarthy, Anna Huskin, S. Chris Malaisrie, Lyudmila Spevak, Stephen Doty and Adele Boskey, Ann & Robert H. Lurie Children s Hospital of Chicago Research Center, Chicago, IL, Northwestern University Feinberg School of Medicine Bluhm Cardiovascular Institute, Chicago, IL, Hospital for Special Surgery, New York, NY 9. Positron Emission Tomography Assessment Of Children With Systemic-Onset Juvenile Idiopathic Arthritis. Taichi Kanetaka, Tomo Nozawa, Kenichi Nishimura, Masako Kikuchi, Tomomi Sato, Nodoka Sakurai, Ryoki Hara, Kazuko Yamazaki and Shumpei Yokota, Yokohama City University School of Medicine, Yokohama, Japan 0. An Examination Of Shoulder Pain Using Magnetic Resonance Imaging In Older People. Tiffany K. Gill, E. Michael Shanahan, Dale Allison, Daniel Alcorn and Catherine L. Hill 4, University of Adelaide, Adelaide, South Australia, Australia, Flinders University, Bedford Park, South Australia, Australia, Bensons Radiology, Adelaide, Australia, 4 The Queen Elizabeth Hospital, Woodville, Australia. Variable Imaging Characteristics Identified By Point-Of- Care Ultrasound For Greater Trochanteric Pain Syndrome. Minna J. Kohler, Naina Rastalsky and Liana Fraenkel, Massachusetts General Hospital / Harvard Medical School, Boston, MA, Yale University School of Medicine, Veterans Affairs Connecticut Healthcare System, New Haven, CT. Can Musculoskeletal Ultrasonography Examination (MSUS) Predict Outcome In Shoulder Impingement Syndrome (SIS)? A Prospective Blinded Study. Mumtaz Khan, Karen McCreesh, Aamir Saeed, Tomas Ahern and Alexander D. Fraser 4, Limerick University Hospital, Limerick, Ireland, University of Limerick, Limerick, Ireland, St. Vincent s University Hospital, Dublin, Ireland, 4 Limerick Univeristy Hospital, Limerick, Ireland. Ultrasonographic Evaluation Of Patellar Cartilage and Triangular Fibrocartilage In Patients With Familial Benign Hypercalcemia. Alberto Batticciotto, Diana Certan, Valentina Varisco, Marco Antivalle, Fabiola Atzeni, Maurizio Bevilacqua and Piercarlo Sarzi-Puttini, Rheumatology Unit, L. Sacco University Hospital, Milan, Italy, Endocrinology Unit, L. Sacco University Hospital, Milan, Italy 4. The Power Doppler Modalities Of 5 Ultrasound Machines Perform Very Differently, Ascertained By a Microvessel Flow Phantom. David F. Ten Cate, Jolanda J. Luime, Myrthe van der Ven, Johanna M.W. Hazes, Klazina Kooiman, Nico De Jong and Johannes G. Bosch, Erasmus University Medical Center, Rotterdam, Netherlands Osteoarthritis - Clinical Aspects I: Risk Factors for and Sequelae of Osteoarthritis 5. Meniscal Extrusion Is a Better Predictor Of Radiographic Osteoarthritis Change Over Ten Years Compared To Cartilage Volume Loss. Louisa Chou, Hussain Ijaz Khan, Andrew McBride, Dawn Aitken, Changhai Ding, Leigh Blizzard, Jean-Pierre Pelletier, Johanne martel-pelletier, Flavia Cicuttini and Graeme Jones, Menzies Research Institute Tasmania, University of Tasmania, Hobart, 7000, Australia, Osteoarthritis Research Unit, University of Montreal Hospital Research Centre (CRCHUM), Montreal, QC, Department of Epidemiology and Preventive 0 Program Book 7

174 ACR POSTER SESSION A Medicine, Monash University, Melbourne, 004, Australia 6. Hip Bone Marrow Lesions In Asymptomatic and Osteoarthritic Adults: Prevalence, Risk Factors and Significance. L Dawson, Yuanyuan Wang, Anita Wluka, Kim Bennell, Andrew Teichtahl and Flavia Cicuttini, Monash University, Melbourne, Australia, University of Melbourne, Melbourne, Australia, Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, 004, Australia 7. The Association Of Radiographic Disease With Lesions On MRI In Lateral Compartment Knee Osteoarthritis: The Osteoathritis Initiative. Barton L. Wise, Jingbo Niu, Felix Liu, John A. Lynch 4, Yuqing Zhang, Ali Guermazi 5, David T. Felson, C. Kent Kwoh 6 and Nancy E. Lane, UC Davis School of Medicine, Sacramento, CA, Boston University School of Medicine, Boston, MA, University of California at San Francisco, San Francisco, CA, 4 University of California-San Francisco, San Francisco, CA, 5 Boston University, Boston, MA, 6 University of Pittsburgh, Pittsburgh, PA 8. Structural Predictors Of Ten Year Knee Cartilage Volume Loss. Dawn Aitken, Hussain Ijaz Khan, Changhai Ding, Leigh Blizzard, Jean-Pierre Pelletier, Johanne Martel- Pelletier, Flavia Cicuttini and Graeme Jones, Menzies Research Institute Tasmania, University of Tasmania, Hobart, 7000, Australia, Osteoarthritis Research Unit, University of Montreal Hospital Research Centre (CRCHUM), Montreal, QC, Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, 004, Australia 9. A Family History Of Knee Joint Replacement Increases The Progression Of Knee Joint Radiographic Osteoarthritis and Cartilage Volume Loss Over Ten Years. Hussain Ijaz Khan, Dawn Aitken, Louisa Chou, Andrew McBride, Changhai Ding, Jean Pierre Pelletier, Johanne M. Pelletier, Leigh Blizzard, Flavia Cicuttini 4 and Graeme Jones, Menzies Research Institute Tasmania, University of Tasmania, Hobart, 7000, Australia, Institut de Rhumatologie de Montréal, Montreal, QC, Osteoarthritis Research Unit, University of Montreal Hospital Research Centre (CRCHUM), Notre-Dame Hospital, Montreal, QC, 4 Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, 004, Australia 40. Longitudinal Femorotibial Cartilage Thickness Increase In Young Athletes At The End Of Adolescence. Felix Eckstein, Heide Boeth, Gerd Diederichs, Wolfgang Wirth, Martin Hudelmaier, Sebastian Cotofana and Georg Duda, Paracelsus Medical University, Salzburg, Austria, Julius Wolff Institute, Charité Universitätsmedizin Berlin, Berlin, Germany, Department of Radiology, Charité - Universitätsmedizin Berlin, Berlin, Germany 4. Exploratory Factor Analysis Of a Parsimonious Medial Cartilage Damage Index Reveals One Factor Associated With Radiographic Severity and Symptoms: Data From The Osteoarthritis Initiative. Grace H. Lo, Lori Lyn Price, Ming Zhang, Jeffrey B. Driban, Daniel Harper and Timothy E. McAlindon, Michael E. DeBakey VA Medical Center, Baylor College of Medicine, Houston, TX, Tufts University, Boston, MA, Tufts Medical Center, Boston, MA 4. Elevated Systemic Blood Pressure Is Associated With Increased Prevalent Knee Osteoarthritis and Knee Pain: Data From The Osteoarthritis Initiative. Grace H. Lo, Timothy E. McAlindon, Jeffrey N. Katz, Jeffrey B. Driban, Lori Lyn Price 4, Charles Eaton 5, Nancy Petersen 6, Christie Ballantyne 7 and Maria E. Suarez-Almazor 8, Michael E. DeBakey VA Medical Center, Baylor College of Medicine, Houston, TX, Tufts Medical Center, Boston, MA, Brigham and Women s Hospital, Boston, MA, 4 Tufts University, Boston, MA, 5 Brown University, Providence, RI, 6 Michael E. DeBakey VA Medical Center Health Services Research and Development Center of Excellence, Houston, TX, 7 Baylor College of Medicine, Houston, TX, 8 University of Texas MD Anderson Cancer Center, Houston, TX 4. The Association Between Metabolic Syndrome and Hand Osteoarthritis - Data From The Framingham Study. Ida K. Haugen, Vasan Ramachandran, Devyani Misra, Tuhina Neogi, Jingbo Niu, Yuqing Zhang and David T. Felson, Diakonhjemmet Hospital, Oslo, Norway, Boston University School of Medicine, Boston, MA 44. Association Between Serum Adipokine Levels and Extent Of Symptomatic Joint Involvement In Hip and Knee Osteoarthritis. Anthony V. Perruccio, Vinod Chandran, Nizar N. Mahomed and Rajiv Gandhi 4, Toronto Western Hospital, Toronto Western Research Institute, and University of Toronto, Toronto, ON, University of Toronto, Toronto Western Hospital, Toronto, ON, University Health Network and University of Toronto, Toronto, ON, 4 University Health Network, Arthritis Program, Toronto, ON 45. C-Reactive Protein But Not Erythrocyte Sedimentation Rate Is Associated With Decrease In Muscle Strength In Patients With Knee Osteoarthritis: A Year Follow Up Study. Diana C Sanchez-Ramirez, Marike van der Leeden, Martin van der Esch, Leo D. Roorda, Sabine Verschueren 4, Jaap van Dieen 5, Joost Dekker 6 and Willem F. Lems 6, VU university Amsterdam, Amsterdam, Netherlands, Reade, Amsterdam, Netherlands, Reade, centre for rehabilitation and rheumatology, Amsterdam, Netherlands, 4 KU University of Leuven, Leuven, Belgium, 5 VU University, Amsterdam, Netherlands, 6 VU University Medical Center, Amsterdam, Netherlands 46. Bone Mineral Density and the Risk of Knee Osteoarthritis: The Johnston County Osteoarthritis Project. Kamil E. Barbour, Jennifer M. Hootman, Charles G. Helmick, Louise Murphy, Jordan B. Renner 4 and Joanne M. Jordan 5, Centers for Disease Control and Prevention, Atlanta, GA, Centers for Disease Control and Prevention, Kennesaw, GA, CDC, Atlanta, GA, 4 University of North Carolina at Chapel Hill, Chapel Hill, NC, 5 University of North Carolina Thurston Arthritis Research Center, Chapel Hill, NC 47. Associations Between Levels Of Urinary C-Telopeptide Fragments Of Type II Collagen and Knee Structure In Asymptomatic Middle-Aged Women. Binghui Wang, Hans Kurniawan Pramono, Flavia Cicuttini, Anita Wluka, Fahad Hanna, Susan Davis, Robin Bell, Andrew Teichtahl and Yuanyuan Wang, Monash University, Melbourne, 7 0 Program Book

175 ACR POSTER SESSION A Australia, Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, 004, Australia 48. Hand Osteoarthritis Is Associated With Increased Type II Collagen Degradation In Women: The Ofely Study. Jean-Charles Rousseau, Elisabeth Sornay-Rendu, Cindy Bertholon, Patrick Garnero and Roland Chapurlat, INSERM UMR 0, Lyon, France, INSERM, UMR 0, Lyon and Cisbio Bioassays, Bagnols/Cèze, France, INSERM UMR 0 and Université de Lyon, Hôpital Edouard Herriot, Lyon, France 49. Biomarkers Reflect Differences In Osteoarthritis Phenotypes Of The Lumbar Spine: The Johnston County Osteoarthritis Project. Adam P. Goode, Amanda E. Nelson, Virginia B. Kraus, Jordan B. Renner 4 and Joanne M. Jordan, Duke University, Durham, NC, University of North Carolina Thurston Arthritis Research Center, Chapel Hill, NC, Duke University Medical Center, Durham, NC, 4 University of North Carolina at Chapel Hill, Chapel Hill, NC 50. Synovial Inflammation In Meniscal Tear Patients: CCL9 mrna Expression Is Independently Associated With Knee Related Disability. Anjali Nair, Charles Bush-Joseph, Nikhil Verma, Matthew Tetreault, Kanta Saha, Arkady Margulis, Louis F. Fogg and Carla R. Scanzello, Rush University Medical Center, Chicago, IL 5. Physical Activity Is Associated With Reduced Incident Disability: Evidence From The Osteoarthritis Initiative. Dorothy D. Dunlop, Jing Song, Pamela A. Semanik, Leena Sharma, Joan M. Bathon, Charles Eaton, Marc C. Hochberg 4, Rebecca D. Jackson 5, C. Kent Kwoh 6, W, Jerry Mysiw 5, Michael C. Nevitt 7 and Rowland W. Chang 8, Northwestern University, Chicago, IL, Columbia University, New York, NY, Brown University, Providence, RI, 4 University of Maryland, Baltimore, MD, 5 Ohio State University, Columbus, OH, 6 University of Pittsburgh, Pittsburgh, PA, 7 University of California, San Francisco, San Francisco, CA, 8 Northwestern University Medical School, Chicago, IL 5. The Association Of Knee Buckling With Vibratory Perception and Muscle Strength: The Multicenter Osteoarthritis Study. Najia Shakoor, David T. Felson, Jingbo Niu, Neil A. Segal, Uyen Sa D.T. Nguyen, Jasvinder A. Singh 4 and Michael C. Nevitt 5, Rush University Medical Center, Chicago, IL, Boston University School of Medicine, Boston, MA, University of Iowa, Iowa City, IA, 4 University of Alabama, Tuscaloosa, AL, 5 University of California, San Francisco, San Francisco, CA 5. Higher Leg Extensor Muscle Power Output Is Associated With Reduced Pain and Better Quality Of Life In Patients With Symptomatic Knee Osteoarthritis. Kieran F. Reid, Lori Lyn Price, William F. Harvey, Jeffrey B. Driban, Roger A. Fielding and Chenchen Wang, Tufts University, Boston, MA, Tufts Medical Center, Boston, MA 54. The Relationship Of Foot Pronation During Walking To Risk Of Incident Medial Tibiofemoral and Lateral Patellofemoral Cartilage Damage: The Multicenter Osteoarthritis Study. K. Douglas Gross, Howard J. Hillstrom, Yuqing Zhang, Emily K. Quinn, Michael C. Nevitt 4, Neil A. Segal 5, Cora E. Lewis 6 and David T. Felson, Boston University, Boston, MA, Hospital Special Surgery (HSS), New York, NY, Boston University School of Medicine, Boston, MA, 4 University of California, San Francisco, San Francisco, CA, 5 University of Iowa, Iowa City, IA, 6 University of Alabama, Birmingham, Birmingham, AL 55. History Of Knee Injury Is Weakly Associated With Knee Structural Change In Middle Or Older Aged Adults. Hussain Ijaz Khan, Dawn Aitken, Changhai Ding, Leigh Blizzard, Jean Pierre Pelletier, Johanne M. Pelletier, Flavia Cicuttini 4 and Graeme Jones, Menzies Research Institute Tasmania, University of Tasmania, Hobart, 7000, Australia, Institut de Rhumatologie de Montréal, Montreal, QC, Osteoarthritis Research Unit, University of Montreal Hospital Research Centre (CRCHUM), Notre-Dame Hospital, Montreal, QC, 4 Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, 004, Australia 56. Classification Of Alignment By Self-Report Versus Radiograph Results In Unexpected and Discrepant Pain and Functional Outcomes. E Megan Erickson, Jeffrey B. Driban, Lori Lyn Price, Chenchen Wang, Timothy E. McAlindon and William F. Harvey, Tufts Medical Center, Boston, MA 57. The Association Of Proximal Tibia Shape With Sex: The Osteoarthritis Initiative. Barton L. Wise, Felix Liu, Neeta Parimi, John A. Lynch 4, Yuqing Zhang 5, Lisa Kritikos and Nancy E. Lane, UC Davis School of Medicine, Sacramento, CA, University of California at San Francisco, San Francisco, CA, California Pacific Medical Center Research Institute, San Francisco, CA, 4 University of California-San Francisco, San Francisco, CA, 5 Boston University School of Medicine, Boston, MA 58. Underdiagnosis and Undertreatment Of Knee Osteoarthritis In The Obese Population: The Need For Physician Education and Advocacy. Janice Lin, Ryan Flanagan, Jay Bhatia, Manish Parikh, Christine Ren-Fielding, Renata La Rocca Vieira, Steven B. Abramson and Jonathan Samuels, NYU Langone Medical Center, New York, NY 59. Examining Patient Reported Outcome Measurement Information System Measures In Community Dwelling Adults With Arthritis. Ana-Maria Orbai, Leigh F. Callahan, Rebecca J. Cleveland, Sharon R. Ghazarian, Susan J. Bartlett and Clifton O. Bingham III, Johns Hopkins University, Baltimore, MD, University of North Carolina, Chapel Hill, NC, University of North Carolina at Chapel Hill, Chapel Hill, NC 60. Pain, Functional Impairment and Ultrasound Detected Changes In Patients With Erosive and Non-Erosive Hand Osteoarthritis. Olga Sleglova, Olga Ruzickova, Karel Pavelka and Ladislav Senolt, Institute of Rheumatology, Prague, Prague, Czech Republic, Institute of Rheumatology and Department of Rheumatology, st Medical Faculty, Charles University Prague, Prague, Czech Republic, Institute of Rheumatology, Department of Rheumatology, st Faculty of Medicine, Charles University, Prague, Czech Republic 0 Program Book 7

176 ACR POSTER SESSION A Concordance Of Hip Pain With Radiographic Hip Osteoarthritis In An Urban US Community: The Framingham Osteoarthritis Study. Kyu Chan Kim, David T. Felson, Katherine D. Linsenmeyer, Ali Guermazi, Steven C. Vlad, Mary M. Clancy and Jingbo Niu, Boston Medical Center, Boston, MA, Boston University School of Medicine, Boston, MA, Boston University, Boston, MA 6. Is There a Role For Non-Mendelian Inheritance In Severe Osteoarthritis Of The Knee. Allen D. Sawitzke, Richard Pimentel, Jathine Wong, Helena Martinez, Marta Herrero 4, Josep Verges 5 and Daniel O. Clegg 6, University of Utah, Salt Lake City, UT, University of Utah, Salt Lake, UT, BIOIBERICA, S.A:,, Barcelona, Spain, 4 Bioiberica, Barcelona, Spain, 5 Pharmacological Research Unit, Scientific Medical Department, Bioibérica, S.A., Barcelona, Spain, 6 George Wahlen VA Medical Center/University of Utah, Salt Lake City, UT 6. Generalized Osteoarthritis : A Systematic Review. Amanda E. Nelson, Michael W. Smith and Yvonne M. Golightly, University of North Carolina Thurston Arthritis Research Center, Chapel Hill, NC, Saint Luke s Hospitals, Kansas City, MO, University of North Carolina at Chapel Hill, Chapel Hill, NC 64. The Proportion Of Knee Osteoarthritis Patients In Southern Sweden That Seek Medical Car. Aleksandra Turkiewicz, Maria Gerhardsson de Verdier, Gunnar Engström, Stefan Lohmander and Martin Englund, Department of Orthopedics, Clinical Sciences Lund, Lund University, Lund, Sweden, Astra Zeneca R&D Molndal, Molndal, Sweden, Molndal, Sweden, Dept of Cardiovascular epidemiology, Clinical Sciences, Lund University, Lund, Sweden 65. All-Cause Mortality and Incident Cardiovascular Disease In Knee Osteoarthritis: The Framingham Study. Devyani Misra, David T. Felson, Ida K. Haugen, Martin Englund and Tuhina Neogi, Boston University School of Medicine, Boston, MA, Diakonhjemmet Hospital, Oslo, Norway, Department of Orthopedics, Clinical Sciences Lund, Lund University, Lund, Sweden 66. Cardiovascular Disease In Osteoarthritis: Hip Versus Knee and The Influence Of Multiple Symptomatic Joint Involvement. Anthony V. Perruccio, Rita A. Kandel and Aileen M. Davis, Toronto Western Hospital, Toronto Western Research Institute, and University of Toronto, Toronto, ON, Mount Sinai Hospital and University of Toronto, Toronto, ON, Health Care and Outcomes Research, Toronto Western Research Institute; Departments of Rehabilitation Science and Health Policy, Management and Evaluation, University of Toronto, Toronto, ON 67. Risk Of Falls Increases With Additional Symptomatic Osteoarthritic Joints: The Johnston County Osteoarthritis Project. Adam Dore, Yvonne M. Golightly, Vicki Mercer, Jordan B. Renner, Xiaoyan A. Shi, Joanne M. Jordan and Amanda E. Nelson, University of North Carolina at Chapel Hill, Chapel Hill, NC, SAS Institute, Inc, Cary, NC, University of North Carolina Thurston Arthritis Research Center, Chapel Hill, NC 0 Program Book Pediatric Rheumatology - Clinical and Therapeutic Aspects I: Juvenile Idiopathic Arthritis 68. Inflammatory Bowel Disease In Juvenile Idiopathic Arthritis Patients Upon Biologics. Deborah Barthel and Gerd Horneff, Asklepios Clinic Sankt Augustin, Sankt Augustin, Germany, Centre of Pediatric Rheumatology, Sankt Augustin, Germany 69. Marked Improvement In Patient Reported Outcomes Of Children With Active Systemic Juvenile Idiopathic Arthritis With Canakinumab Treatment Results Of The Phase III Program. Rayfel Schneider, Hermine I. Brunner, Nicolino Ruperto, Nico Wulffraat, Pierre Quartier, Riva Brik, Liza McCann, Helen E. Foster, Michael Frosch, Valeria Gerloni, Liora Harel, Claudio Len, Kristin Houghton, Rik Joos, Ken Abrams 4, Karine Lheritier 5, Sophia Kessabi 5, Alberto Martini and Daniel J. Lovell, Pediatric Rheumatology Collaborative Study Group (PRCSG), Cincinnati, OH, Pediatric Rheumatology International Trials Organization (PRINTO)-Istituto Gaslini, Genova, Italy, Necker-Enfants Malades Hospital, Paris, France, 4 Novartis Pharmaceuticals Corporation, East Hanover, NJ, 5 Novartis Pharma AG, Basel, Switzerland 70. Canakinumab In The Treatment Of Systemic Juvenile Idiopathic Arthritis: Results From a -Week Pooled Post-Hoc Analysis For Efficacy. Hermine Brunner, Pierre Quartier, Tamas Constantin, Shai Padeh, Inmaculada Calvo, Muferet Erguven, Laurence Goffin, Michael Hofer, Tilmann Kallinich, Sheila Oliveira, Yosef Uziel, Stefania Viola 4, Kiran Nistala, Carine Wouters, Karine Lheritier 5, Josef Hruska 5, Ken Abrams 6, Alberto Martini, Nicolino Ruperto and Daniel J. Lovell, Pediatric Rheumatology Collaborative Study Group (PRCSG), Cincinnati, OH, Necker-Enfants Malades Hospital, Paris, France, Paediatric Rheumatology International Trials Organization (PRINTO), Genova, Italy, 4 Pediatria, Genova, Italy, 5 Novartis Pharma AG, Basel, Switzerland, 6 Novartis Pharmaceuticals Corporation, East Hanover, NJ 7. Baseline Characteristics Of Patients With Active Systemic JIA On Canakinumab Therapy Successfully Discontinuing Corticosteroids: Secondary Analyses From A Pivotal PHASE Study. Hermine Brunner, Nicolino Ruperto, Tamás Constantin, Nico Wulffraat, Gerd Horneff, Jordi Anton, Reinhard Berner, Fabrizia Corona, Rubén J. Cuttica, Marine Desjonqueres, Michel Fischbach, Maria Alessio, Alice Chieng, Wolfgang Emminger, Elie Haddad, Karine Lheritier, Ken Abrams 4, Josef Hruska, Daniel J. Lovell and Alberto Martini, Pediatric Rheumatology Collaborative Study Group (PRCSG), Cincinnati, OH, Pediatric Rheumatology International Trials Organization (PRINTO)- Istituto Gaslini, Genova, Italy, Novartis Pharma AG, Basel, Switzerland, 4 Novartis Pharmaceuticals Corporation, East Hanover, NJ 7. Predictive Markers Of Joint Damages Of Children With Systemic-Onset Juvenile Idiopathic Arthritis In Long-Term Course Of Treatment With Tocilizumab. Tomo Nozawa, Taichi Kanetaka, Kenichi Nishimura, Masako Kikuchi, Tomomi Sato, Nodoka Sakurai, Ryoki Hara, Kazuko Yamazaki and Shumpei Yokota, Yokohama City University School of Medicine, Yokohama, Japan

177 ACR POSTER SESSION A 7. Neutropenia With Tocilizumab Treatment Is Not Associated With Increased Infection Risk In Patients With Systemic Juvenile Idiopathic Arthritis. Fabrizio De Benedetti, Hermine I. Brunner, Eileen M. Baildam, Ruben Burgos-Vargas, Gerd Horneff 4, Hans-Iko Huppertz, Kirsten Minden 5, Barry L. Myones, Karen Onel, Jianmei Wang 6, Kamal N. Bharucha 7, Daniel J. Lovell, Alberto Martini 8 and Nicolino Ruperto, IRCCS Ospedale Pediatrico Bambino Gesú, Rome, Italy, PRCSG, Cincinnati, OH, PRINTO, Genoa, Italy, 4 Pediatric Rheumatology International Trials Organization (PRINTO)-Istituto Gaslini, Genova, Italy, 5 pediatric rheumatology, Berlin, Germany, 6 Roche, Welwyn Garden City, United Kingdom, 7 Genentech, South San Francisco, CA, 8 Istituto Giannina Gaslini, Genova, Italy 74. Reported Macrophage Activation Syndrome In Patients With Systemic-Onset Juvenile Idiopathic Arthritis Treated With Tocilizumab. Shumpei Yokota, Yasuhiko Itoh, Tomohiro Morio, Naokata Sumitomo and Seiji Minota, The Safety Evaluation Committee of Actemra for JIA, Tokyo, Japan 75. Changes In Serum IL-8 Level In Systemic Juvenile Idiopathic Arthritis Patients Who Attained Drug-Free Remission By Tocilizumab. Tomohiro Kubota, Syuji Takei, Yuichi Yamasaki, Junko Yasumura, Naomi Kuwada, Yukiko Nonaka, Tomoko Takezaki, Tsuyoshi Yamatou, Tomokazu Nagakura 4, Yasuhito Nerome, Hiroyuki Imanaka and Harumi Akaike, Kagoshima University, Kagoshima, Japan, Hiroshima University, Hiroshima City, Japan, Kumamoto University, Kumamoto City, Japan, 4 House of Meguminoseibo, Usuki, Japan 76. Assessment Of Radiographic Progression In Patients With Systemic Juvenile Idiopathic Arthritis Treated With Tocilizumab: -Year Results From The Tender Trial. Clara Malattia, Nicolino Ruperto, Elena Palmisani, Silvia Pederzoli, Angela Pistorio, Hermine I. Brunner, Rubén J. Cuttica 4, Inmaculada Calvo, Stella Maris Garay, Despina Eleftheriou, Carine Wouters, Jianmei Wang 5, Clare Devlin 5, Daniel J. Lovell, Alberto Martini 6, Fabrizio De Benedetti 7 and Angelo Ravelli 6, Pediatria, Genoa, Italy, PRINTO, Genoa, Italy, PRCSG, Cincinnati, OH, 4 Pediatric Rheumatology International Trials Organization (PRINTO)- Istituto Gaslini, Genova, Italy, 5 Roche, Welwyn Garden City, United Kingdom, 6 Istituto Giannina Gaslini, Genova, Italy, 7 IRCCS Ospedale Pediatrico Bambino Gesú, Rome, Italy 77. Childhood Arthritis and Rheumatology Research Alliance (CARRA) Standardized Consensus Treatment Plans for New Onset Polyarticular Juvenile Idiopathic Arthritis. Sarah Ringold, Pamela F. Weiss, Robert A. Colbert, Esi Morgan DeWitt 4, Tzielan C. Lee 5, Karen Onel 6, Sampath Prahalad 7, Rayfel Schneider 8, Susan Shenoi 9, Richard K. Vehe 0 and Yukiko Kimura, Seattle Children s Hospital, Seattle, WA, The Children s Hospital of Philadelphia, Philadelphia, PA, NIAMS NIH, Bethesda, MD, 4 Cincinnati Children s Hospital Medical Center, Cincinnati, OH, 5 Stanford University School of Medicine, Stanford, CA, 6 PRCSG, Cincinnati, OH, 7 Emory Children s Center, Atlanta, GA, 8 Pediatric Rheumatology Collaborative Study Group (PRCSG), Cincinnati, OH, 9 Seattle Children s Hospital, University of Washington, Seattle, WA, 0 University of Minnesota, Minneapolis, MN, Joseph M Sanzari Children s Hospital, Hackensack University Medical Center, Hackensack, NJ 78. Results Of a 4 Month Extension Study In Patients Who Participated In The Trial Of Early Aggressive Therapy In Polyarticular Juvenile Idiopathic Arthritis. Carol A. Wallace, John Bonsack, Steven J. Spalding, Hermine Brunner 4, Kathleen M. O Neil 5, Diana Milojevic 6, Sarah Ringold 7, Laura E. Schanberg 8, Gloria C. Higgins 9, Beth S. Gottlieb 0, Joyce J. Hsu, Marilynn G. Punaro, Yukiko Kimura and Audrey F. Hendrickson 4, Seattle Childrens Hosp & Research Institute, Seattle, WA, University of Utah Health Sciences Center, Salt Lake City, UT, The Cleveland Clinic, Cleveland, OH, 4 Cincinnati Children s Hospital Medical Center, Cincinnati, OH, 5 Riley Hospital for Children, Indianapolis, IN, 6 University of California, San Francisco, San Francisco, CA, 7 Seattle Children s Hospital, Seattle, WA, 8 Duke University Medical Center, Durham, NC, 9 Nationwide Childrens Hosp, Columbus, OH, 0 Cohen Children s Medical Center of New York, New Hyde Park, NY, Stanford University, Palo Alto, CA, Texas Scottish Rite Hospital, Dallas, TX, Joseph M Sanzari Children s Hospital, Hackensack University Medical Center, Hackensack, NJ, 4 Seattle Children s Research Institute, Seattle, WA 79. Safety and Effectiveness Of Adalimumab In Children With Polyarticular Juvenile Idiopathic Arthritis Aged To <4 Years Or 4 Years Weighing <5 Kg. Daniel J. Kingsbury, Pierre Quartier, Vipin Arora, Jasmina Kalabic 4, Hartmut Kupper 4 and Neelufar Mozaffarian, Legacy Emanuel Children s Hospital, Portland, OR, PRINTO, Genoa, Italy, AbbVie, North Chicago, IL, 4 AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany 80. Long-Term Safety and Efficacy Of Etanercept In Paediatric Subjects With Extended Oligoarticular Juvenile Idiopathic Arthritis, Enthesitis-Related Arthritis, Or Psoriatic Arthritis. Tamas Constantin, Ivan Foeldvari, Jelena Vojinovic, Gerd Horneff 4, Ruben Burgos-Vargas 5, Irina Nikishina 6, Jonathan Akikusa 7, Tadej Avcin 8, Jeffrey Chaitow 9, Elena Koskova 0, Bernard Lauwerys, Jack Bukowski, Chuanbo Zang, Joseph Wajdula, Deborah Woodworth, Bonnie Vlahos, Alberto Martini 4 and Nicolino Ruperto 5, Semmelweis University, Budapest, Hungary, Hamburger Zentrum für Kinder- und Jugendrheumatologie, Klinikum Eilbek, Hamburg, Germany, Dept Pediatric Rheumatology, Clinical Center, School of Medicine University of Nis, Nis, Serbia, 4 Asklepios Klinik Sankt Augustin, Sankt Augustin, Germany, 5 Hospital General de Mexico, Mexico DF, Mexico, 6 Scientific Research Institute of Rheumatology RAMS, Moskow, Moskow, Russia, 7 Royal Childrens Hospital, Parkville, Australia, 8 The Ljubljana University Medical Centre, Pediatric Clinic, Ljubljana, Slovenia, 9 Children s Hospital Westmead, Sydney, Australia, 0 National Institute of Rheumatic Diseases, Piestany, Slovakia, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain, Brussels, Belgium, Pfizer Inc, Collegeville, PA, Pfizer Inc., Collegeville, PA, 4 Istituto Giannina Gaslini, Genova, Italy, 5 PRINTO, Genoa, Italy 8. GO-Kids Imaging Substudy: MRI Treatment Response To 0 Mg/m 4-Weekly Subcutaneous injections Of Golimumab In Children With Polyarticular JIA Preliminary Results Of The Open Label Portion. Nikolay Tzaribachev, Catrin Tzaribachev and Bernd Koos, PRI - Pediatric Rheumatology Research Institute, Bad Bramstedt, Germany, University Medical Center Schleswig-Holstein, Campus Kiel, Kiel, Germany 0 Program Book 75

178 ACR POSTER SESSION A Rates Of Flare-Free Survival In Juvenile Idiopathic Arthritis When Tapering Individual Components Of Tumor Necrosis Factor Inhibitor and Methotrexate Combination Therapy. Caroline Y Chang, Rika Meyer and Andreas Reiff, Children s Hospital Los Angeles, Los Angeles, CA 8. Efficacy Of Biologic Treatments In Juvenile Idiopathic Arthritis With a Polyarticular Course: An Indirect Comparison. Laura Sawyer, Alex Diamantopoulos, Hermine I. Brunner, Fabrizio De Benedetti, Nicolino Ruperto 4, Fred Dejonckheere 5 and Caroline Keane 6, Symmetron Limited, London, United Kingdom, PRCSG, Cincinnati, OH, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy, 4 PRINTO, Genoa, Italy, 5 F. Hoffmann-La Roche Ltd, Basel, Switzerland, 6 Roche, Welwyn Garden City, United Kingdom 84. What Is the Relative Priority of the ACR Pediatric Core Set Measures for Youth With Juvenile Idiopathic Arthritis and Their Parents? Jaime Guzman, Oralia Gomez-Ramirez, Susanne M. Benseler, Roberta A. Berard 4, Rollin Brant, Ciaran M. Duffy 5, Roman Jurencak 6, Kiem Oen 7, Ross E. Petty 8, Natalie J. Shiff 9 and Lori B. Tucker, BC Children s Hospital and University of British Columbia, Vancouver, BC, University of British Columbia, Vancouver, BC, Hospital for Sick Children, Toronto, ON, 4 Children s Hospital of Western Ontario, London, ON, 5 Children s Hospital of Eastern Ontario and University of Ottawa, Ottawa, ON, 6 University of Ottawa, Ottawa, ON, 7 University of Manitoba, Winnipeg, MB, 8 BCs Children Hosptial, Vancouver, BC, 9 University of Saskatchewan, Saskatoon, SK 85. Juvenile Idiopathic Arthritis Patients Demonstrate Alterations In HDL Functionality Without Accelerated Subclinical Atherosclerosis. Preethi Mani, Kiyoko Uno, Katherine Wolski, Steven J. Spalding, Stephen J. Nicholls and M. Elaine Husni, Cleveland Clinic Lerner College of Medicine, Cleveland, OH, Cleveland Clinic Foundation, Cleveland, OH, The Cleveland Clinic, Cleveland, OH 86. Cardiovascular Risk In Adults With Juvenile Idiopathic Arthritis. Elizabeth Coulson, Wan-Fai Ng, Philip N. Platt and H. E. Foster 4, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom, Newcastle University, Newcastle upon Tyne, United Kingdom, Freeman Hospital, Newcastle upon Tyne, United Kingdom, 4 Musculoskeletal Research Group, Institute of Cellular Medicine, Newcastle University and Great North Children s Hospital, Newcastle Upon Tyne, United Kingdom 87. Long-Term Evaluation Of Cardiac Function In Juvenile Idiopathic Arthritis Under Anti-Tumor Necrosis Factor Therapy. Alessandro C. Lianza, Nadia E. Aikawa, Julio C. B. Moraes, Gabriela N. Leal, Samira S. Morhy, Eloisa Bonfa and Clovis A. Silva, University of São Paulo, Sao Paulo, Brazil, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, Faculdade de Medicina da Universidade de São Paulo, Sao Paulo, Brazil 88. MRI Findings In Juvenile Spondyloarthopathy and Effects Of Treatment On Subsequent MRI. Clara Lin and Diana Milojevic, University of California-San Francisco, San Francisco, CA, University of California, San Francisco, San Francisco, CA 0 Program Book 89. Development and Validation Of The Cutoff Values For Disease Activity States Of The Three-Item Version Of The Juvenile Arthritis Disease Activity Score. Alessandro Consolaro, Sara Verazza, Maria C. Gallo, Giulia Bracciolini, Giorgia Negro, Alessia Frisina, Nicolino Ruperto, Alberto Martini and Angelo Ravelli, Istituto Giannina Gaslini, Genova, Italy, University of Genova, Genova, Italy 90. Children With JIA Show Distinct Patterns Of Improvement In Their Health-Related Quality Of Life During The First Year On Treatment: Growth Mixture Modeling Of a Prospective Cohort Of Newly Diagnosed Patients. Bin Huang, Chen Chen, Stacey Niehaus, Hermine Brunner, Rina Mina and Michael Seid, Cincinnati Children s Hospital Medical Center/University of Cincinnati School of Medicine, Cincinnati, OH, Cincinnati Children s Hospital Medical Center, Cincinnati, OH 9. Growth In Children and Adolescents With Juvenile Idiopathic Arthritis (JIA) After Years Of Treatment With Etanercept: Results From The British Society For Paediatric and Adolescent Rheumatology (BSPAR) Etanercept Cohort Study. Lianne Kearsley-Fleet, Rebecca Davies, Mark Lunt, Kimme L. Hyrich, Taunton R. Southwood and on Behalf Of The BSPAR Etanercept Cohort Study, Arthritis Research UK Epidemiology Unit, University of Manchester, Manchester, United Kingdom, Arthritis Research UK Epidemiology Unit, Manchester Academic Health Sciences Centre, Institute of Inflammation and Repair, The University of Manchester, Manchester, United Kingdom, Institute of Child Health, University of Birmingham and Birmingham Children s Hospital, Birmingham, United Kingdom 9. Body Surface Area-Based Dosing Approach Produced Comparable Golimumab Exposure Across Different Age Ranges After Subcutaneous Administration Of Golimumab In Pediatric Patients With Juvenile Idiopathic Arthritis. Jocelyn H. Leu, Alan M. Mendelsohn, Joyce Ford, Hugh M. Davis and Zhenhua Xu, Janssen Research & Development, LLC., Spring House, PA, Janssen Research and Development, LLC., Spring House, PA 9. The Efficacy Of Etanercept In Patients With Juvenile Idiopathic Arthritis With Inadequate Response To Infliximab As a First TNF Inhibitor. Ekaterina Alekseeva, Tatyana Bzarova, Anna Fetisova, Tatyana Sleptsova, Saniya Valieva, Kseniya Isayeva, Rina Denisova, Elena Mitenko, Evgeniya Chistyakova and Nikolay Taybulatov, PRINTO, Genoa, Italy, Scientific Center of Children s Health of RAMS, Moscow, Russia 94. Physical Activity In Children With Juvenile Idiopathic Arthritis (JIA): The LEAP (Linking Exercise, Activity and Pathophysiology in Childhood Arthritis) Study. Lori B. Tucker, Heather A. McKay, Leanne M. Ward, Jaime Guzman, Adam Baxter-Jones 4, Kiem Oen 5, Alan M. Rosenberg 6, Johannes Roth, Elizabeth Stringer 7, Rae SM Yeung 8, Kristin M. Houghton, Heather Macdonald 9, Debbie Ehrmann Feldman 0, Ciaran M. Duffy and LEAP Study Investigators, University of British Columbia, Vancouver, BC, University of Ottawa, Ottawa, ON, BC Children s Hospital and University of British Columbia, Vancouver, BC, 4 College of Kinesiology, University of Saskatchewan,

179 ACR POSTER SESSION A Saskatoon, SK, 5 University of Manitoba, Winnipeg, MB, 6 Royal University Hospital, Saskatoon, SK, 7 IWK Health Centre and Dalhousie University, Halifax, NS, 8 The Hospital for Sick Children and University of Toronto, Toronto, ON, 9 The University of British Columbia, Vancouver, BC, 0 Université de Montréal, Montreal, QC, Children s Hospital of Eastern Ontario and University of Ottawa, Ottawa, ON, BC Children s Hospital, Vancouver, BC 95. Uveitis In The Nordic Juvenile Idiopathic Arthritis Cohort; High Incidence, Frequent Complications, and Gender Associated Risk Factors. Ellen Nordal, Lillemor Berntson, Kristiina Aalto, Suvi Peltoniemi, Susan Nielsen 4, Troels Herlin 5, Anders Fasth 6 and Marite Rygg 7, University of Tromsø, Tromsø, Norway, Uppsala University Hospital, Uppsala, Sweden, Helsinki University Children s Hospital, Helsinki, Finland, 4 Juliane Marie Centret, Rigshospitalet, Copenhagen, Denmark, 5 Aarhus University Hospital, Aarhus, Denmark, 6 University of Gothenburg, Gothenburg, Sweden, 7 St Olav University Hospital, Trondheim, Norway 96. Declines In Levels Of Disease Activity and Physical Disability In Children With Juvenile Idiopathic Arthritis Seen In Standard Clinical Care Over The Last 5 Years. Alessandro Consolaro, Stefano Lanni, Francesca Minoia, Sergio Davì, Sara Dalprà, Benedetta Schiappapietra, Rossana Pignataro, Cristina Ferrari, Alberto Martini and Angelo Ravelli, Istituto Giannina Gaslini, Genova, Italy, University of Genova, Genova, Italy 97. Plasma Nicotinamide Phosphoribosyltransferase Correlates With Markers Of Inflammation and May Predict Early Therapeutic Response To Low-Dose Methotrexate In Juvenile Idiopathic Arthritis. Ryan S. Funk, Leon van Haandel, Marcia Chan, Lanny J. Rosenwasser, Andrew Lasky, Maria F. Ibarra, Mark F. Hoeltzel, S.Q. Ye, J.S. Leeder and Mara L. Becker, Children s Mercy Hospital, Kansas City, MO 98. Preliminary Prospective Study Of Ultrasonography In Patients With Juvenile Idiopathic Arthritis In Clinical Remission: Subclinical Synovitis May Predict Flare? Vanessa B Miotto e Silva, Sônia A.V. Mitraud, Rita NV Furtado, Jamil Natour and Maria Teresa Terreri, Escola Paulista de Medicina/ Universidade Federal de São Paulo (EPM/UNIFESP), São Paulo, Brazil, Escola Paulista de Medicina/ Universidade Federal de São Paulo (EPM/ UNIFESP), Sao Paulo, Brazil 99. Phenotypic Cluster Analysis Of Juvenile Idiopathic Arthritis: Relationship To International Leagues Of Associations For Rheumatology Classification Criteria. Jay Mehta, Juan Lin, Norman T. Ilowite and for The CARRA Registry Investigators 4, Children s Hospital at Montefiore/ Albert Einstein College of Medicine, Bronx, NY, Albert Einstein College of Medicine, Bronx, NY, The Children s Hospital at Montefiore, Bronx, NY, 4 Multiple Affiliations, Palo Alto, CA Spondylarthropathies and Psoriatic Arthritis: Clinical Aspects and Treatment: Psoriatic Arthritis: Clinical Aspects and Treatment 00. Higher Disease Activity In Psoriatic Arthritis Is Associated With Elevated Total Cholesterol and Triglycerides. Monalyn Labitigan, Asha Shrestha, George W. Reed, Robert P. Magner, Nicole Jordan, Joel M. Kremer 4, Jeffrey D. Greenberg 5, Asena Bahce-Altuntas and Anna R. Broder, Albert Einstein College of Medicine, Bronx, NY, CORRONA, Inc., Southborough, MA, University of Massachusetts Medical School, Worcester, MA, 4 Center for Rheumatology, Albany Medical College, Albany, NY, 5 New York Hospital for Joint Diseases, New York, NY 0. Arthritis and Nail Involvement In Patients With Plaque- Type Psoriasis. Odirlei Andre Monticielo, Karen Regina Rosso Schons, Cristiane Faccin Knob, Walter Neumaier, Maristela de Oliveira Beck and André Avelino Costa Beber, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil, Universidade Federal de Santa Maria, Santa Maria, Brazil 0. Maintenance Of Efficacy and Safety Of Ustekinumab In Patients With Active Psoriatic Arthritis Despite Prior Conventional Nonbiologic and Anti-TNF Biologic Therapy: year Results Of a Phase, Multicenter, Double-Blind, Placebo-Controlled Trial. Christopher T. Ritchlin, Iain B. McInnes, Arthur Kavanaugh, Lluis Puig 4, Proton Rahman 5, Carrie Brodmerkel 6, Shu Li 6, Yaung- Kaung Shen 6, Mittie K. Doyle 6, Alan M. Mendelsohn 6 and Alice B. Gottlieb 7, University of Rochester, Rochester, NY, University of Glasgow, Glasgow, United Kingdom, University of California, San Diego, La Jolla, CA, 4 Universitat Autònoma de Barcelona, Barcelona, Spain, 5 Memorial University, St. Johns, NF, 6 Janssen Research & Development, LLC., Spring House, PA, 7 Tufts Medical Center, Boston, MA 0. Risk Of Cardiovascular Events In Patients With Psoriatic Arthritis, Psoriasis, and Rheumatoid Arthritis: A General Population-Based Cohort Study. Alexis Ogdie, Yiding Yu, Kevin Haynes, Samantha Maliha, Thorvardur Love 4, Andrea Troxel, Sean Hennessy, David Margolis, Stephen Kimmel, Nehal N. Mehta 5, Hyon K. Choi 6 and Joel Gelfand, University of Pennsylvania, Philadelphia, PA, Brigham and Women s Hospital, Boston, MA, University of Pennsylvania., Philadelphia, PA, 4 Faculty of Medicine, University of Iceland, Reykjavik, Iceland, 5 NHLBI, National Institutes of Health, Bethesda, MD, 6 Boston University School of Medicine, Boston, MA 04. Anti-Citrullinated Protein Antibodies In Patients With Psoriatic Arthritis: Clinical Relevance. Doquyen H. Huynh, Carol Etzel, Vanessa Cox, J. M. Kremer 4, Jeffrey D. Greenberg 5 and Arthur Kavanaugh 6, UC San Diego School of Medicine, San Diego, CA, CORRONA, Inc, Southborough, MA, UT MD Anderson Cancer Center, Houston, TX, 4 Albany Medical College and The Center for Rheumatology, Albany, NY, 5 NYU Hospital for Joint Diseases, New York, NY, 6 University of California San Diego, San Diego, CA 0 Program Book 77

180 ACR POSTER SESSION A 05. Incidence of Herpes Zoster in Patients with Psoriatic Arthritis. Devy Zisman, Haim Bitterman, Ilan Feldhamer, Doron Comanesther, Erez Battat, Sari Greenberg-Dotan, Sarit Cohen 4 and Arnon-Dov Cohen, The Ruth and Bruce Rappaport Faculty of Medicine, Haifa, Israel, Chief Physician s Office, Clalit Health Services, Haifa, Israel, Chief Physician s Office, Clalit Health Services, Tel Aviv, Israel, 4 Carmel Medical Center, Haifa, Israel 06. Responsiveness To Change Of a Global Ultrasound Assessment Score In Psoriatic Arthritis Patients. Maria Laura Acosta Felquer, Santiago Ruta, Javier Rosa, David A. Navarta, Carla Saucedo, Ricardo Garcia-Monaco, Mirtha Sabelli and Enrique R. Soriano, Rheumatology Unit, Internal Medical Services, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, Radiology and Imagenology Department, Hospital italiano de Buenos Aires, Buenos Aires, Argentina, Rheumatology Unit, Internal Medical Services, Hospital Italiano de Buenos Aires, Instituto Universitario Hospital Italiano de Buenos Aires, and Fundacion PM Catoggio, Buenos Aires, Argentina 07. Abnormal Imaging and Increased Osteoclast Precursors In a Psoriasis Cohort Are Associated with New Onset of Psoriatic Arthritis. Ralf G. Thiele, Yahui Grace Chiu, Francisco A. Tausk, Bethany A. Marston, Gregory Dieudonne, Vaseem Chengazi, Michelle Smith, Sharon Moorehead, Rick Barrett and Christopher T. Ritchlin, University of Rochester, Rochester, NY 08. Cross-Cultural Adaptation, Validation and Reliability Of The Brazilian Version Of The Psoriatic Arthritis Screening Evaluation Tool. Roberto Ranza, Claudia G Schainberg, Sueli Carneiro, Gladys Martins 4, Jose Joaquim Rodrigues 5, Jamille Carneiro 6, Ricardo Romiti 7, Thiago B. M. Barros 8, Ana Luiza Sampaio 9, Amanda Pedreira 9, Carolina Z Costa 0, Rogerio MC Pinto, M. Elaine Husni and Abrar A. Qureshi, Universidade Federal de Uberlandia, Uberlandia MG, Brazil, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil, Brazilian Registry of Spondyloarthritis, São Paulo, Brazil, 4 Dermatologia Hospital Universitario Universidade de Brasilia, Brasilia, Brazil, 5 Dermatologia, Universidade Federal de Uberlandia, Uberlandia, Brazil, 6 Reumatologia, Universidade de Brasilia, Brasilia, Brazil, 7 Dermatologia Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil, 8 Reumatologia Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, 9 Dermatologia Hospital Universitário e Faculdade de Medicina, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil, 0 Reumatologia, Universidade Federal de Uberlandia, Uberlandia, Brazil, Matematica, Universidade Federal de Uberlandia, Uberlandia, Brazil, Cleveland Clinic Foundation, Cleveland, OH, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 09. Diagnostic Delay Of Even More Than 6 Months Contributes To Poor Radiographic and Functional Outcome In Psoriatic Arthritis. Muhammad Haroon, Phil Gallagher and Oliver FitzGerald, Dublin Academic Medical Centre, St. Vincent s University Hospital, Dublin, Ireland 0. Long-Term Safety and Tolerability Of Apremilast, An Oral Phosphodiesterase 4 Inhibitor, In Patients With Psoriatic Arthritis: Pooled Safety Analysis Of Three Phase, Randomized, Controlled Trials. Philip J. Mease, Arthur Kavanaugh, Dafna D. Gladman, Adewale O. Adebajo 4, Juan J. Gomez-Reino 5, Jürgen Wollenhaupt 6, Maurizio Cutolo 7, Georg Schett 8, Eric Lespessailles 9, Kamal Shah 0, ChiaChi Hu 0, Randall M. Stevens 0, Christopher J. Edwards and Charles A. Birbara, Swedish Medical Center and University of Washington School of Medicine, Seattle, WA, University of California San Diego, San Diego, CA, University of Toronto, Toronto Western Hospital, Toronto, ON, 4 University of Sheffield, Sheffield, United Kingdom, 5 Hospital Clinico Universitario, Santiago, Spain, 6 Schön Klinik Hamburg Eilbek, Hamburg, Germany, 7 University of Genova, Genova, Italy, 8 University of Erlangen-Nuremberg, Erlangen, Germany, 9 University of Orléans, Orléans, France, 0 Celgene Corporation, Warren, NJ, University of Southampton, Southampton, United Kingdom, University of Massachusetts Medical School, Worcester, MA. Long-Term (5-Week) Results Of a Phase, Randomized, Controlled Trial Of Apremilast, An Oral Phosphodiesterase 4 Inhibitor, In Patients With Psoriatic Arthritis and Current Skin Involvement (PALACE ). Christopher J. Edwards, Francisco J. Blanco, Jeffrey Crowley, ChiaChi Hu 4, Randall M. Stevens 4 and Charles A. Birbara 5, University of Southampton, Southampton, United Kingdom, INIBIC-Hospital Universitario A Coruña, A Coruña, Spain, Bakersfield Dermatology, Bakersfield, CA, 4 Celgene Corporation, Warren, NJ, 5 University of Massachusetts Medical School, Worcester, MA. Effect Of Certolizumab Pegol Over 48 Weeks On Signs and Symptoms In Patients With Psoriatic Arthritis With and Without Prior Tumor Necrosis Factor Inhibitor Exposure. Philip J. Mease, Roy M. Fleischmann, Jürgen Wollenhaupt, Atul Deodhar 4, Dafna Gladman 5, Christian Stach 6, Bengt Hoepken 6, Luke Peterson 7 and Désirée van der Heijde 8, Swedish Medical Center and University of Washington, Seattle, WA, University of Texas Southwestern Medical Center, Dallas, TX, Schön Klinik, Hamburg, Germany, 4 Oregon Health & Science University, Portland, OR, 5 Toronto Western Hospital and University of Toronto, Toronto, ON, 6 UCB Pharma, Monheim, Germany, 7 UCB Pharma, Raleigh, NC, 8 Leiden University Medical Center, Leiden, Netherlands. The DC-STAMP + IL7A + Cell Subset Is Elevated In Psoriatic Arthritis (PsA) Patients and Declines Following Anti-TNFi Therapy. Yahui Grace Chiu, Edward M. Schwarz, Hua He, Francisco A. Tausk, Sharon Moorehead, Michelle Smith and Christopher T. Ritchlin, University of Rochester, Rochester, NY 4. Impact Of Low Infliximab Dose Regimen On Treatment Response and Drug Survival In 46 Patients With Psoriatic Arthritis. Results From The Nationwide Registries Danbio and Icebio. Bente Glintborg, Bjorn Gudbjornsson, Niels Steen Krogh, Emina Omerovic 4, Natalia Manilo 5, Mette Holland-Fischer 6, Hanne M. Lindegaard 7, Anne Gitte Loft 8, Henrik Nordin 9, Laura Johnsen 0, Sussi Flejsborg Oeftiger, Annette Hansen, Claus Rasmussen, 78 0 Program Book

181 ACR POSTER SESSION A Gerdur Grondal 4, Árni Jón Geirsson 4 and Merete Lund Hetland 5, The Danish Rheumatologic Database (DANBIO), Glostrup Hospital, Glostrup, Denmark, Faculty of Medicine, University of Iceland, Reykjavik, Iceland, ZiteLab ApS, Copenhagen, Denmark, 4 Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Glostrup Hospital, Glostrup, Denmark, 5 Department of Rheumatology, Frederiksberg Hospital, Copenhagen, Denmark, 6 Department of Rheumatology, Aalborg University Hospital, Aalborg, Denmark, 7 Odense University Hospital, Odense, Denmark, 8 Department of Rheumatology, Sygehus Lillebaelt, Vejle, Denmark, 9 Department of Infectious Diseases and Rheumatology, Rigshospitalet, Copenhagen, Denmark, 0 Department of Rheumatology, Helsingør and Hillerød Hospital, Hillerød, Denmark, Department of Rheumatology, Køge Hospital, Køge, East Timor, Department of Rheumatology, Gentofte University Hospital, Copenhagen, Denmark, Vendsyssel Teaching Hospital/Aalborg University, Hjoerring, Denmark, 4 Department of Rheumatology, Landspitali - The National University Hospital of Iceland, Reykjavik, Iceland, 5 The Danish Rheumatologic Database (DANBIO), Glostrup Hospital., Copenhagen, Denmark 5. Long Term Outcomes In Psoriatic Arthritis ; A Prospective Multicentre Observational Study Of Work Disability In Psoriatic Arthritis: First Report Of The Clinical and Socioeconomic Associations Of Work Disability In Psoriatic Arthritis. William Tillett, Gavin Shaddick, Ayman Askari, Annie Cooper 4, Paul Creamer 5, Gavin Clunie 6, Philip S. Helliwell 7, Lesley Kay 8, Eleanor Korendowych, Suzanne Lane 9, Jonathon Packham 0, Ragai Shaban, Lyn Williamson, Corinne devries and Neil McHugh, Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, University of Bath, Bath, United Kingdom, Robert Jones and Agnes Hunt Hospital, Shrophire, United Kingdom, 4 Royal Hampshire County Hospital, Winchester, United Kingdom, 5 North Bristol NHS foundation trust, Bristol, United Kingdom, 6 Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom, 7 NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds, United Kingdom, 8 Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom, 9 Ipswich Hospital NHS Trust, Ipswich, United Kingdom, 0 Haywood Rheumatology Centre, Stoke-on-Trent, United Kingdom, Queen Alexandra Hospital, Portsmouth, United Kingdom, Great Western Hospitals NHS Foundation Trust, Swindon, United Kingdom 6. Quantiferon-TB Test Can Be Usefull For Decision Of Anti- Tuberculosis Prophylaxis During Anti-TNF Treatment: Result Of Real Life. Umut Kalyoncu, Levent Kilic, Ahmet Cagkan Inkaya, Omer Karadag, Sule Apras Bilgen, Ali Akdogan, Sedat Kiraz and Ihsan Ertenli, Hacettepe University School of Medicine, Ankara, Turkey, Hacettepe University, Faculty of Medicine, Ankara, Turkey, Hacettepe University Faculty of Medicine, Ankara, Turkey 7. Apremilast, An Oral Phosphodiesterase 4 Inhibitor, Is Associated With Long-Term (5-Week) Improvement In Tender and Swollen Joint Counts In Patients With Psoriatic Arthritis: Results From Three Phase, Randomized, Controlled Trials. Maurizio Cutolo, Philip J. Mease, Dafna D. Gladman, Arthur Kavanaugh 4, Adewale O. Adebajo 5, Juan J. Gomez-Reino 6, Jürgen Wollenhaupt 7, Georg Schett 8, Eric Lespessailles 9, Kamal Shah 0, ChiaChi Hu 0, Randall M. Stevens 0, Christopher J. Edwards and Charles A. Birbara, University of Genova, Genova, Italy, Swedish Medical Center and University of Washington School of Medicine, Seattle, WA, University of Toronto, Toronto Western Hospital, Toronto, ON, 4 University of California San Diego, San Diego, CA, 5 University of Sheffield, Sheffield, United Kingdom, 6 Hospital Clinico Universitario, Santiago, Spain, 7 Schön Klinik Hamburg Eilbek, Hamburg, Germany, 8 University of Erlangen-Nuremberg, Erlangen, Germany, 9 University of Orléans, Orléans, France, 0 Celgene Corporation, Warren, NJ, University of Southampton, Southampton, United Kingdom, University of Massachusetts Medical School, Worcester, MA 8. Effect Of Brodalumab (AMG 87) On Pain and Physical Functioning In Patients With Psoriatic Arthritis. Mark C. Genovese, Philip J. Mease, Hema Viswanathan, Dina Chau, JingYuan Feng, Ngozi Erondu and Ajay Nirula, Stanford University, Palo Alto, CA, Swedish Medical Center and University of Washington School of Medicine, Seattle, WA, Amgen Inc, Thousand Oaks, CA 9. Secukinumab Shows Substantial Improvement In Both Psoriasis Symptoms and Physical Functioning In Moderate-To-Severe Plaque Psoriasis Patients With Psoriatic Arthritis: A Subanalysis Of a Phase, Multicenter, Double-Blind, Placebo-Controlled Study. Alice B. Gottlieb, Bardur Sigurgeirsson, Andrew Blauvelt, Shephard Mpfofu 4, Ruvie Martin 5 and Charis Papavassilis 4, Tufts Medical Center, Boston, MA, University of Iceland, Kópavogur, Iceland, Oregon Health and Sciences University, Portland, OR, 4 Novartis Pharma AG, Basel, Switzerland, 5 Novartis Pharma AG, East Hanover, Switzerland 0. Sustained Improvement In Health-Related Quality Of Life, Work Productivity, Employability, and Reduced Healthcare Resource Utilization Of Patients With Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis Treated With Golimumab: 5-Year Results From Phase III Studies. Chenglong Han, Arthur Kavanaugh, Mark C. Genovese, Benjamin Hsu 4, Atul A. Deodhar 5 and Elizabeth C. Hsia 6, Janssen Global Services, LLC., Malvern, PA, University of California, San Diego, La Jolla, CA, Stanford University, Palo Alto, CA, 4 Janssen Research & Development, LLC., Spring House, PA, 5 Oregon Health & Science University, Portland, OR, 6 Janssen Research & Development, LLC./U of Penn, Spring House/Philadelphia, PA. Evaluation and Comparison Of Performance Of Different Classification Criteria For Reactive Arthritis. Mariana Benegas, Rafael Chaparro, Oscar L. Rillo, Luciana Casalla, Emilce Schneeberger, Federico Ceccatto, Sergio Paira, Federico Zazzetti 4, Juan C. Barreira 5 and Emilio Busquiazzo 6, Hospital Gral. de Agudos Dr. E. Tornú, Buenos Aires, Argentina, Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, Hospital Jose María Cullen, Santa Fé, Argentina, 4 Hospital Británico, Buenos Aires, Argentina, 5 Buenos Aires British Hospital, Buenos Aires, Argentina, 6 Hospital del Milagro, Salta, Argentina 0 Program Book 79

182 ACR POSTER SESSION A. Ustekinumab Improves Physical Function, Quality Of Life, and Work Productivity Of Patients With Active Psoriatic Arthritis Who Were Methotrexate-naïve Or Previously Treated With Methotrexate Or Anti-Tumor Necrosis Factor Agent:Data From Phase, Randomized, Placebo- Controlled Trials. Proton Rahman, Lluis Puig, Alice B. Gottlieb, Arthur Kavanaugh 4, Iain B. McInnes 5, Christopher T. Ritchlin 6, Shu Li 7, Yuhua Wang 7, Ning Zhao 8, Rita Ganguly 8, Michael Song 7, Alan M. Mendelsohn 7 and Chenglong Han 8, Memorial University, St. Johns, NF, Universitat Autònoma de Barcelona, Barcelona, Spain, Tufts Medical Center, Boston, MA, 4 University of California, San Diego, La Jolla, CA, 5 University of Glasgow, Glasgow, United Kingdom, 6 University of Rochester, Rochester, NY, 7 Janssen Research & Development, LLC., Spring House, PA, 8 Janssen Global Services, LLC., Malvern, PA. Safety Of Ustekinumab From The Placebo-Controlled Periods Of Psoriatic Arthritis and Psoriasis Clinical Developmental Programs. Iain B. McInnes, Kim Papp, Lluis Puig, Kristian Reich 4, Christopher T. Ritchlin 5, Bruce Strober 6, Proton Rahman 7, Arthur Kavanaugh 8, Alan M. Mendelsohn 9, Michael Song 9, Daphne Chan 9, Yaung- Kaung Shen 9, Shu Li 9 and Alice B. Gottlieb 0, University of Glasgow, Glasgow, United Kingdom, Probity Research, Waterloo, ON, Universitat Autònoma de Barcelona, Barcelona, Spain, 4 Dermatologikum Hamburg, Hamburg, Germany, 5 University of Rochester, Rochester, NY, 6 University of Connecticut, Farmington, CT, 7 Memorial University, St. Johns, NF, 8 University of California, San Diego, La Jolla, CA, 9 Janssen Research & Development, LLC., Spring House, PA, 0 Tufts Medical Center, Boston, MA 4. Long-Term Safety Of Ustekinumab: 5 Years Of Follow- Up From The Psoriasis Clinical Development Program Including Patients With Psoriatic Arthritis. Kim Papp, Christopher E.M Griffiths, Kenneth B. Gordon, Mark Lebwohl 4, Philippe O. Szapary 5, Yasmine Wasfi 5, Daphne Chan 5, Yaung-Kaung Shen 5, Vincent Ho 6, Pierre-Dominique Ghislain 7, Bruce Strober 8 and Kristian Reich 9, Probity Research, Waterloo, ON, Dermatology Centre, University of Manchester, Manchester Academic Health Science Centre, Salford Royal NHS Foundation Trust, Manchester, United Kingdom, Northwestern University, Chicago, IL, 4 Mount Sinai Medical Center, New York, NY, 5 Janssen Research & Development, LLC., Spring House, PA, 6 University of British Columbia, Vancouver, BC, 7 7. Cliniques Universitaires Saint-Luc, Université Catholique de Louvain,, Brussels, Belgium, 8 University of Connecticut, Farmington, CT, 9 Dermatologikum Hamburg, Hamburg, Germany 5. Certain Class I HLA Alleles and Haplotypes Have Important Positive and Negative Associations With Psoriatic Arthritis Phenotype. Muhammad Haroon, Robert Winchester, Jon T. Giles and Oliver FitzGerald, Dublin Academic Medical Centre, St. Vincent s University Hospital, Dublin, Ireland, Columbia University, New York, NY, Columbia University, College of Physicians & Surgeons, New York, NY 6. Reduction Of Disease Burden On Workplace and Household Productivity In Psoriatic Arthritis Over 48 Weeks Of Treatment With Certolizumab Pegol. Arthur Kavanaugh, Dafna Gladman, Désirée M. van der Heijde, Oana Purcaru 4 and Philip J. Mease 5, University of California San Diego, San Diego, CA, University of Toronto, Toronto Western Hospital, Toronto, ON, Leiden University Medical Center, Leiden, Netherlands, 4 UCB Pharma, Brussels, Belgium, 5 Swedish Medical Center and University of Washington, Seattle, WA 7. Major Differences In The Pattern Of Joint Swelling and Tenderness In a Large Psoriatic Arthritis Cohort Results From An Exploratory Hierarchical Cluster Analysis. Burkhard Möller, Daniel Stekhoven and Peter M. Villiger, Inselspital, Bern, Switzerland, Swiss Clinical Quality Management in Rheumatic Diseases-SCQM Foundation, Zurich, Switzerland, Inselspital-University Hospital of Bern, Bern, Switzerland 8. Clinical Characteristics Of Patients Who Switch Biologic Therapy Within The First Two Years: Results From a Large US Registry Population. Philip J. Mease, Emily Edson- Heredia, Katherine C. Saunders, Catherine L. Shuler, Baojin Zhu, Monica Chaudhari 4 and Jeffrey D. Greenberg 5, Swedish Medical Center and University of Washington School of Medicine, Seattle, WA, Eli Lilly and Company, Indianapolis, IN, CORRONA, Inc., Southborough, MA, 4 Axio Research LLC, Seattle, WA, 5 New York Hospital for Joint Diseases, New York, NY 9. Health-Related Quality Of Life In Early Psoriatic Arthritis In Comparison With Early Rheumatoid Arthritis. A 5-Year Follow-Up Report From The Swedish Early Psoriatic Arthritis Registry and The Swedish Early Intervention In RA Registry. Lars Törnqvist, Tomas Husmark, Ulla R. C. Lindqvist, Gerd-Marie Alenius 4, Per Larsson 5, Annika Teleman 6, Mats Geijer 7, Lars Erik Kristensen 8, Ingrid Thyberg 9 and Elke Theander 0, Skåne University Hospital Malmö, Lund University, Sweden, Malmö, Sweden, Department of Rheumatology, Falu Hospital, Falun, Sweden, Department of Medical Sciences, Rheumatology, University Hospital, Uppsala university, Uppsala, Sweden, 4 Department of Public Health and Clinical Medicine, Rheumatology, Umeå University, Umeå, Sweden, 5 Karolinska University Hospital, Stockholm, Sweden, 6 Department of Rheumatology, Spenshult Hospital, Oskarstrom, Sweden, 7 Skåne University Hospital, Lund, Center for Medical Imaging and Physiology, Lund, Sweden, 8 Skåen University Hospital, Lund University, Lund, Sweden, 9 Linköping University Hospital, Linkoping, Sweden, 0 Lund University, Malmö, Sweden 0. Proteomic Profiling Of Synovial Fluid For The Identification Of Psoriatic Arthritis Soluble Biomarkers. Daniela Cretu, Fawnda Pellett, Rajiv Gandhi, Eleftherios Diamandis 4 and Vinod Chandran, University of Toronto, Department of Laboratory Medicine and Pathobiology, Toronto, ON, University of Toronto, Toronto Western Hospital, Toronto, ON, University Health Network, Arthritis Program, Toronto, ON, 4 Mount Sinai Hospital, Department of Pathology and Lab Medicine, Toronto, ON 80 0 Program Book

183 ACR POSTER SESSION A. Apremilast, An Oral Phosphodiesterase 4 Inhibitor, Is Associated With Long-Term (5-Week) Improvement In Physical Function In Patients With Psoriatic Arthritis: Results From Three Phase, Randomized, Controlled Trials. Georg Schett, Philip J. Mease, Dafna D. Gladman, Arthur Kavanaugh 4, Adewale O. Adebajo 5, Juan J. Gomez- Reino 6, Jürgen Wollenhaupt 7, Maurizio Cutolo 8, Eric Lespessailles 9, Kamal Shah 0, ChiaChi Hu 0, Randall M. Stevens 0, Christopher J. Edwards and Charles A. Birbara, University of Erlangen-Nuremberg, Erlangen, Germany, Swedish Medical Center and University of Washington School of Medicine, Seattle, WA, University of Toronto, Toronto Western Hospital, Toronto, ON, 4 University of California San Diego, San Diego, CA, 5 University of Sheffield, Sheffield, United Kingdom, 6 Hospital Clinico Universitario, Santiago, Spain, 7 Schön Klinik Hamburg Eilbek, Hamburg, Germany, 8 University of Genova, Genova, Italy, 9 University of Orléans, Orléans, France, 0 Celgene Corporation, Warren, NJ, University of Southampton, Southampton, United Kingdom, University of Massachusetts Medical School, Worcester, MA. Risk Of Cardiovascular Disease Among Patients With Psoriatic Arthritis Compared To Ankylosing Spondylitis (retrospective cohort study). Zohair Abbas and Marina N. Magrey, Case Western Reserve University at Metrohealth Medical Center, Cleveland, OH, Case Western Reserve University School of Medicine at MetroHealth Medical Center, Cleveland, OH. Changes In Weight Associated With Tumour Necrosis Factor Inhibition In Psoriatic Arthritis. Barry J. Sheane, Arane Thavaneswaran, Dafna D. Gladman and Vinod Chandran, University of Toronto, Toronto Western Hospital, Toronto, ON 4. The Joint Effect Of Carotid Ultrasound and Preventive Cardiology Referral On Cardiovascular Risk Factor Modification in Psoriatic Arthritis Patients. Michael Lucke, Soo Hyun Kim and M. Elaine Husni, Cleveland Clinic, Cleveland, OH, Cleveland Clinic Foundation, Cleveland, OH 5. Comparing Adalimumab and Etanercept As First Line Agents In Patients With Psoriatic Arthritis. Data From The Rhumadata Clinical Database and Registry. Sabrina Hoa, Denis Choquette, Louis Bessette, Diane Sauvageau, Boulos Haraoui, Jean Pierre Pelletier, Jean- Pierre Raynauld, Edith Villeneuve and Louis Coupal, Centre hospitalier de l université de Montréal (Hôpital Notre-Dame), Montréal, QC, Institut de Rhumatologie de Montréal, Montreal, QC, Centre Hospitalier Universitaire de Québec, pavillon CHUL, Sainte-Foy, QC 6. Cluster Analysis Of Psoriatic Arthritis Patients At Follow- Up. Arane Thavaneswaran, Vinod Chandran and Dafna Gladman, University of Toronto, Toronto Western Hospital, Toronto, ON 7. Fatigue and Work Disability In Psoriatic Arthritis. Jessica Walsh, Molly McFadden, Gerald G. Krueger, Allen D. Sawitzke and Daniel O. Clegg, University of Utah, Salt Lake City, UT, University of Utah, SLC, UT, George Wahlen VA Medical Center/University of Utah, Salt Lake City, UT 8. Tailored Approach To Early Psoriatic Arthritis Patients: Ultrasonographic Predictors For Structural Joint Damage. Yasser El Miedany, Maha El Gaafary, Sally Youssef and Annie Nasr, Medway Hospital, Gillingham, United Kingdom, Ain Shams University, Cairo, Egypt 9. The Association Between Obesity and Radiographic Progression Of Joint Damage Among Patients With Psoriatic Arthritis. Lihi Eder, Arane Thavaneswaran, Vinod Chandran, Richard J. Cook and Dafna D. Gladman, University of Toronto, Toronto Western Hospital, Toronto, ON, University of Waterloo, Waterloo, ON 40. Baseline Characteristics and Treatment Outcomes In Psoriasis Patients With Polyarthritis Or Oligoarthritis. Philip S. Helliwell, Philip Mease, Eustratios Bananis, Heather Jones, Annette Szumski and Lisa Marshall, NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds, United Kingdom, University of Washington School of Medicine, Seattle, WA, Pfizer Inc., Collegeville, PA 4. Impact Of Persistent Minimal Disease Activity On Long- Term Outcomes In Psoriatic Arthritis: Results From 5 Years Of The Long Term Extension Of a Randomized, Placebo-Controlled, Study. Arthur Kavanaugh, Iain B. McInnes, Philip J. Mease, Gerald G. Krueger 4, Dafna D. Gladman 5, Stephen Xu 6, Linda Tang 7 and Katrien van Beneden 8, University of California, San Diego, La Jolla, CA, University of Glasgow, Glasgow, United Kingdom, Swedish Medical Center and University of Washington, Seattle, WA, 4 University of Utah, Salt Lake City, UT, 5 University of Toronto, Toronto Western Hospital, Toronto, ON, 6 Janssen Research & Development, LLC., Spring House, PA, 7 Janssen Research & Development, LLC., Horsham, PA, 8 Janssen Biologics Europe, Leiden, Netherlands 4. TNF Blockage In Psoriatic Arthritis: Long-Term Effect On Lipid Profile. Julio C. B. Moraes, Carla G.S. Saad, Ana Cristina Ribeiro, Claudia G Schainberg, Celio R. Gonçalves, Percival D Sampaio-Barros and Eloisa Bonfá, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil 4. Conventional Dmards For Psoriatic Arthritis: Data On 5 Treatment Courses With Methotrexate, Sulfasalazine and Leflunomide. Elisabeth Lie, Karen M. Fagerli, Erik Rødevand, Synnøve Kalstad, Knut Mikkelsen 4, Ada Wierød 5, Désirée van der Heijde 6 and Tore K. Kvien, Diakonhjemmet Hospital, Oslo, Norway, St. Olavs Hospital, Trondheim, Norway, University Hospital of Northern Norway, Tromsø, Norway, 4 Lillehammer Hospital for Rheumatic Diseases, Lillehammer, Norway, 5 Vestre Viken Hospital Drammen, Drammen, Norway, 6 Leiden University Medical Center, Leiden, Netherlands 44. Clinical Phenotype Of Patients With Arthritis Mutilans Has Important Differences Compared To Other Patients With Psoriatic Arthritis. Muhammad Haroon, Phil Gallagher and Oliver FitzGerald, Dublin Academic Medical Centre, St. Vincent s University Hospital, Dublin, Ireland 0 Program Book 8

184 ACR POSTER SESSION A Prevalence Of Peri-Articular Manifestations (Enthesitis and Dactylitis) and Disease Activity In Psoriatic Arthritis Patients: Impact Of Treatment With TNF Inhibitors In a Real-World Canadian Population. Proton Rahman, Denis Choquette, William G. Bensen, Majed M. Khraishi 4, Isabelle Fortin 5, Andrew Chow 6, Maqbool K. Sheriff 7, Julie Vaillancourt 8, John S. Sampalis 9, Susan M. Otawa 0, Allen J. Lehman 0 and May Shawi 0, Memorial University, St. Johns, NF, Institut de Rhumatologie de Montréal, Montreal, QC, St. Joseph s Hospital and McMaster University, Hamilton, ON, 4 MD, Memorial University of Newfoundland, Nexus Clinical Research, St Johns, NF, 5 Centre de Rhumatologie de l Est du Québec, Rimouski, QC, 6 Credit Valley Rheumatology, Mississauga, ON, 7 Nanaimo Regional General Hospital, Nanaimo, BC, 8 JSS Medical Research, Montreal, QC, 9 JSS Medical Research, St-Laurent, QC, 0 Janssen Canada Inc, Toronto, ON 46. Rheumatoid Arthritis, a More Severe Disease Than Psoriatic Arthritis? A Comparison Of Disease Activity In Patients With Psoriatic Arthritis and Rheumatoid Arthritis From The Swedish Early Psoriatic Arthritis Registry (SwePsA) and The Swedish Rheumatology Registry For Early RA (SRR). Gerd-Marie Alenius, Tomas Husmark, Elke Theander, Per Larsson 4, Mats Geijer 5, Annika Teleman 6 and Ulla R. C. Lindqvist 7, Department of Public Health and Clinical Medicine, Rheumatology, Umeå University, Umeå, Sweden, Department of Rheumatology, Falu Hospital, Falun, Sweden, Lund University, Malmö, Sweden, 4 Karolinska University Hospital, Stockholm, Sweden, 5 Skåne University Hospital, Lund, Center for Medical Imaging and Physiology, Lund, Sweden, 6 Department of Rheumatology, Spenshult Hospital, Oskarstrom, Sweden, 7 Department of Medical Sciences, Rheumatology, University Hospital, Uppsala university, Uppsala, Sweden 47. Factors Explaining The Discrepancy Between Patient and Physician Global Assessment Of Disease Activity In Psoriatic Arthritis. Lihi Eder, Arane Thavaneswaran, Vinod Chandran, Richard J. Cook and Dafna Gladman, University of Toronto, Toronto Western Hospital, Toronto, ON, University of Waterloo, Waterloo, ON 48. Laboratory Abnormalities In Patients With Psoriatic Arthritis Receiving Apremilast, An Oral Phosphodiesterase 4 Inhibitor: Pooled Safety Analysis Of Three Phase, Randomized, Controlled Trials. Philip J. Mease, Arthur Kavanaugh, Adewale O. Adebajo, Juan J. Gomez-Reino 4, Jürgen Wollenhaupt 5, Dafna D. Gladman 6, Maurizio Cutolo 7, Georg Schett 8, Eric Lespessailles 9, Kamal Shah 0, ChiaChi Hu 0, Randall M. Stevens 0, Christopher J. Edwards and Charles A. Birbara, Swedish Medical Center and University of Washington School of Medicine, Seattle, WA, University of California San Diego, San Diego, CA, University of Sheffield, Sheffield, United Kingdom, 4 Hospital Clinico Universitario, Santiago, Spain, 5 Schön Klinik Hamburg Eilbek, Hamburg, Germany, 6 University of Toronto, Toronto Western Hospital, Toronto, ON, 7 University of Genova, Genova, Italy, 8 University of Erlangen-Nuremberg, Erlangen, Germany, 9 University of Orléans, Orléans, France, 0 Celgene Corporation, Warren, NJ, NIHR Wellcome Trust Clinical Research Facility, University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom, University of Massachusetts Medical School, Worcester, MA 0 Program Book 49. Serum CTX-I Predicts Systemic Bone Loss At The Hip Over Year In Patients With Early Psoriatic Arthritis. Agnes Szentpetery, Mark Kilbane, Myra P. O Keane, Muhammad Haroon, Phil Gallagher, Susan van der Kamp, Malachi McMenna and Oliver FitzGerald, Dublin Academic Medical Centre, St. Vincent s University Hospital, Dublin, Ireland 50. Cortical Bone Density As Measured By Digital X-Ray Radiogrammetry Correlates with Radiographic Joint Damage In The Hands Within Year In Psoriatic Arthritis. Agnes Szentpetery, Muhammad Haroon, Phil Gallagher, Eric J. Heffernan and Oliver FitzGerald, Dublin Academic Medical Centre, St. Vincent s University Hospital, Dublin, Ireland 5. Psoriatic Arthritis Mutilans: Clinical and Radiographic Definitions. A Systematic Review. Amir Haddad, Mansour Somaily, Sindhu R. Johnson, Rouhi Fazelzad, Amie T. Kron 4, Cathy Chau 5 and Vinod Chandran, University of Toronto, Toronto Western Hospital, Toronto, ON, Toronto Western Hospital, Toronto General Hospital, Mount Sinai Hospital, and University of Toronto, Toronto, ON, University Health Network, Toronto, ON, 4 Toronto Scleroderma Research Program, Toronto Western Hospital, Mount Sinai Hospital, and University of Toronto, Toronto, ON, 5 Toronto Scleroderma Research Program, Toronto Western Hospital, Mount Sinai Hospital, University of Toronto, Toronto, ON 5. Efficacy and Safety Of Vaccination Against seasonal 0 Influenza Virus Among Patients With Psoriatic Arthritis and Psoriasis. Arik Polackek, Yuri Korobko, Noa Madar- Balakirski, Uri Arad, David Levartovsky, Ilana Kaufman 4, Marina Anouk 5, Irena Litinsky 6, Ella Mendelson 7, Daphna Paran 8, Hagit Matz 9, Dan Caspi 9, Michal Mandelbaum 0 and Ori Elkayam, Tel Aviv Medical Center, Tel Aviv, Israel, Tel Aviv Sourasky Medical Center and the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel, Tel Aviv Medical Ctr, Tel Aviv, Israel, 4 Tel Aviv Sourasky Medical Center and the Sackler Faculty of Medicine, Tel Aviv University, Tel-aviv, Israel, 5 Tel Aviv Sourasky Medical Ctr, Tel-Aviv University, Tel Aviv, Israel, 6 Department of Rheumatology, Tel Aviv Sourasky Medical Center and the Sackler Faculty of Medicine Tel Aviv University, Tel Aviv, Israel, 7 Sheba Medical Center, Ramat Gan, Israel, 8 Tel Aviv Sourasky Medical Ctr, Tel-Aviv university, Tel Aviv, Israel, 9 Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, 0 Sheba Medical Center, Tel Aviv, Israel 5. Time Interval Between The Onset Of Psoriasis and The Onset Of Psoriatic Arthritis May Define Disease Subsets. Arane Thavaneswaran, Vinod Chandran and Dafna Gladman, University of Toronto, Toronto Western Hospital, Toronto, ON 54. Disease Burden Among Patients With Psoriatic Arthritis Who Have Experienced First Line Tumor Necrosis Factor Inhibitor Regimen Failure In The European Union. Siva Narayanan, Yao Lu, Richard Hutchings and Amanda Baskett, Ipsos Healthcare, Columbia, MD, Ipsos Healthcare, London, United Kingdom

185 ACR POSTER SESSION A 55. Response To Etanercept With Or Without Methotrexate Combination Therapy In Patients With Psoriatic Arthritis. Bernard Combe, Urs Kerkmann, Fiona Brock and Gaia Gallo, Hôpital Lapeyronie-Service d Immunorhumatologie, Montpellier, France, Pfizer Europe, Rome, Italy, Quanticate, Hitchin, Hertfordshire, United Kingdom Rheumatoid Arthritis - Clinical Aspects I: Comorbidities in Rheumatoid Arthritis 56. Outcomes Of Patients With Rheumatoid Arthritis and Comorbid Hyperlipidemia. L Rosenblatt, JR Curtis, G Yang and T Hebden, Bristol-Myers Squibb, Plainsboro, NJ, University of Alabama at Birmingham, Birmingham, AL, Formerly of Bristol-Myers Squibb, Plainsboro, NJ 57. Predictive Value Of Anti Cyclic Citrullinated Peptide and Rheumatoid Factor To The Development Of Rheumatoid Arthritis In a Cohort Of Healthy Relatives Of Patients With Rheumatoid Arthritis. Jose Dionisio Castillo-Ortiz and Cesar Ramos-Remus, Maastricht University Medical Center, Maastricht, Netherlands, Unidad de Investigacion en Enfermedades Cronico-Degenerativas, Guadalajara, Mexico 58. Inflammatory Burden Predicts Carotid Plaque Progression and Subsequent Cardiovascular Events In Rheumatoid Arthritis: The -Year Prospective Cohort Study. Churl Hyun Im, Sang Hoon Kwon, Jeong Soo Eun, Na Ri Kim, Eon Jeong Nam and Young Mo Kang, Kyungpook National University School of Medicine, Daegu, South Korea 59. Tocilizumab Treatment Increases Left Ventricular Ejection Fraction and Decreases Left Ventricular Mass Index In Rheumatoid Arthritis Patients Without Cardiac Symptoms : Assessment By Cardiac Magnetic Resonance Imaging At.0 Tesla. Hitomi Kobayashi, Isamu Yokoe, Hiroshi Sato, Yasuyuki Kobayashi, Kihei Yoneyama, Masaharu Hirano 4 and Masami Takei, NIhon University School of Medicine, Tokyo, Japan, Itabashi Chuo Medical Center, Tokyo, Japan, St.Marianna University School of Medicine, Kawasaki, Japan, 4 Tokyo Medical Colleage, Tokyo, Japan 60. Visit-To-Visit Variability In Blood Pressure In Patients With Rheumatoid Arthritis (RA) Vs General Population, and Its Impact On Cardiovascular Events and All-Cause Mortality In RA. Elena Myasoedova, Cynthia S. Crowson, Abigail B. Green, Eric L. Matteson and Sherine E. Gabriel, Mayo Clinic, Rochester, MN 6. Risk Of Venous Thromboembolism and Use Of Disease- Modifying Antirheumatic Drugs For Rheumatoid Arthritis. Seoyoung C. Kim, Daniel H. Solomon, Jun Liu, Jessica M. Franklin 4, Robert J. Glynn and Sebastian Schneeweiss, Brigham and Women s Hospital, Boston, MA, Harvard Medical School, Brigham and Women s Hospital, Division of Rheumatology, Division of Pharmacoepidemiology, Boston, MA, Brigham and Women s Hospital, Harvard Medical School, Boston, Boston, MA, 4 Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women s Hospital, Boston, MA 6. Management Of Hyperlipidemia In Patients With RA: Results From The Corrona Certain Study. Dimitrios A. Pappas, Ani John, Joel M. Kremer, George W. Reed 4, Tanya Sommers 4, Jeffrey D. Greenberg 5, Ashwini Shewade and Jeffrey R. Curtis 6, Columbia University, New York, NY, Genentech Inc., South San Francisco, CA, Albany Medical College and The Center for Rheumatology, Albany, NY, 4 CORRONA, Inc., Southborough, MA, 5 NYU Hospital for Joint Diseases, New York, NY, 6 7University of Alabama at Birmingham Division of Clinical Immunology and Rheumatology, Birmingham, AL 6. Comparing Myocardial Infarction Risks Associated With Biologics Of Varying Mechanisms Of Action Among Older RA Patients. Jeffrey R. Curtis, Huifeng Yun, Jie Zhang, Fenglong Xie, Lang Chen, Emily Levitan, James Lewis, Timothy Beukelman, Kenneth G. Saag and Iris Navarro- Millan, University of Alabama at Birmingham, Division of Clinical Immunology and Rheumatology, Birmingham, AL, University of Alabama at Birmingham, Birmingham, AL, University of Pennsylvania, Philadelphia, PA 64. Hyperuricemia As a Risk Factor for Cardiovascular Disease in Patients With Rheumatoid Arthritis. Daniel Kuo, Cynthia S. Crowson, Sherine E. Gabriel and Eric L. Matteson, Mayo Clinic, Rochester, MN 65. Oral Calcium Supplementation Is Associated With Subclinical Atherosclerosis In Rheumatoid Arthritis. Shanthi Dhaduvai, Laura Geraldino-Pardilla, Jon T. Giles and Joan M. Bathon, Columbia University Medical Center, New York, NY, Columbia University, College of Physicians & Surgeons, New York, NY, Columbia University, New York, NY 66. Traditional Cardiac Risk Factors Predict Significant Coronary Plaque Burden In Asymptomatic Patients With Rheumatoid Arthritis. George A. Karpouzas, Jennifer Malpeso, Tae-Young Choi, Youngju Pak and Matthew Budoff, Harbor-UCLA Medical Center, Torrance, CA 67. Cytomegalovirus-Related Immunity Correlates With Myocardial Disease In Rheumatoid Arthritis. John M. Davis III, Cynthia S. Crowson, Michael A. Strausbauch, Terry M. Therneau, Eric L. Matteson, Keith L. Knutson and Sherine E. Gabriel, Mayo Clinic, Rochester, MN 68. Detrimental Impact Of Long-Term Cumulative Burden Of Rheumatoid Arthritis (RA) Disease Severity On Cardiovascular Outcomes In RA. Elena Myasoedova, Birkan Ilhan, Helen Khun, Eric L. Matteson and Cynthia S. Crowson, Mayo Clinic, Rochester, MN, Marmara University, School of Medicine, Istanbul, Turkey 69. Prolongation Of QT Interval In Patients With Rheumatoid Arthritis and Its Impact On Mortality: Results From a Population-Based Study. Krati Chauhan, Michael Ackerman, Cynthia S. Crowson, Eric L. Matteson and Sherine E. Gabriel, Mayo Clinic, Rochester, MN, Mayo Clinic, Rochester Minnesota, Rochester, MN 0 Program Book 8

186 ACR POSTER SESSION A Shift In Cardiovascular Risk and Lipid Levels In Rheumatoid Arthritis Patients Using ATP- Guidelines: Corrona Certain Study. Dimitrios A. Pappas, Ani John, Jeffrey R. Curtis, George W. Reed 4, Tanya Sommers 4, Jeffrey D. Greenberg 5, Ashwini Shewade and Joel M. Kremer 6, Columbia University, New York, NY, Genentech Inc., South San Francisco, CA, University of Alabama at Birmingham, Division of Clinical Immunology and Rheumatology, Birmingham, AL, 4 CORRONA, Inc., Southborough, MA, 5 New York Hospital for Joint Diseases, New York, NY, 6 Albany Medical College and The Center for Rheumatology, Albany, NY 7. Inflammatory Cell Infiltrates In The Heart Of Patients With Coronary Artery Disease With and Without Inflammatory Rheumatic Disease: A Biopsy Study. Jacqueline Kirsti Andersen, Ingvild Oma, Ingjerd Lien Kveldstad, Knut Mikkelsen, Terje Veel 4, Sven M. Almdahl 5, Matthew H. Liang 6, Øystein T. Førre 7, Morten Fagerland 7 and Ivana Hollan, Gjøvik University College, Gjøvik, Norway, Innlandet Hospital Trust, Lillehammer, Norway, Lillehammer Hospital for Rheumatic Diseases, Lillehammer, Norway, 4 Feiringklinikken, Feiring, Norway, 5 University Hospital of North Norway, Tromsø, Norway, 6 Harvard Medical School, Boston, MA, 7 Oslo University Hospital, Oslo, Norway 7. Cardiovascular Risk In Intensively Treated Rheumatoid Arthritis: Comparison To An Osteoarthritis Population. First Prospective Analysis Of The ACT-CVD Cohort. Inger L. Meek, Harald E. Vonkeman and Mart A.F.J. van de Laar, Rheumatology Center Twente, Medisch Spectrum Twente & Twente University, Enschede, Netherlands, Medisch Spectrum Twente & University of Twente, Enschede, Netherlands 7. Menopause Occurs Earlier and Is An Independent Risk Factor For Osteoporosis In Women With Rheumatoid Arthritis. Michael Cocker, Alexander Oldroyd and Marwan Bukhari, Royal Lancaster Infirmary, Lancaster, United Kingdom, Lancaster University, Lancaster, United Kingdom 74. Effect Of Age At Menopause In Women With Early Rheumatoid Arthritis. Lauren Wong, Wei-Ti Huang, Juan Xiong, Gilles Boire, Boulos Haraoui 4, Janet E. Pope 5, J. Carter Thorne 6, Carol A. Hitchon 7, Diane Tin 6, Edward Keystone 8 and Vivian P. Bykerk, Hospital for Special Surgery, New York, NY, Mount Sinai Hospital, University of Toronto, Toronto, ON, Centre Hospitalier Universitaire de Sherbrooke, Université de Sherbrooke, Sherbrooke, QC, 4 Institut de Rhumatologie de Montréal, Montreal, QC, 5 St. Joseph s Health Care, University of Western Ontario, London, ON, 6 Southlake Regional Health Centre, Newmarket, ON, 7 University of Manitoba, Winnipeg, MB, 8 Mount Sinai Hospital, Toronto, ON 75. Systemic Inflammation Contributes To Depression In Patients With Rheumatoid Arthritis. Mary Margaretten, Laura Trupin, Patricia P. Katz, Gabriela Schmajuk, Jinoos Yazdany, Chris Tonner, Jennifer Barton and Edward H. Yelin, University of California, San Francisco, San Francisco, CA 0 Program Book 76. The Risk Of Pneumococcal Infections After Immunisation With Pneumococcal Conjugate Vaccine Compared To Non-Vaccinated Inflammatory Arthritis Patients. Johanna Bengtsson, Pierre Geborek, Tore Saxne, Martin Englund, Ingemar F. Petersson, Jan-Åke Nilsson 4, Göran Jönsson 5 and Meliha C. Kapetanovic 6, Section of Rheumatology, Lund University and Skåne University Hospital, Lund, Sweden, Lund, Sweden, Lund University, Lund, Sweden, Department of Orthopedics, Clinical Sciences Lund, Lund University, Lund, Sweden, 4 Lund University, Malmö, Sweden, 5 Dept of Clinical Sciences Lund, Section of Infectious Diseases, Lund, Sweden, 6 Dept of Clinical Sciences Lund, Section of Rheumatology, Lund University, Lund, Sweden 77. Risk Factors For Stroke In Patients With Rheumatoid Arthritis. Anja Strangfeld, Yvette Meißner, Adrian Richter, Matthias Schneider, Hans Peter Tony 4, Kerstin Gerhold, Angela Zink 5 and Joachim Listing 6, German Rheumatism Research Center, a Leipniz Institute, Berlin, Germany, German Rheumatism Research Center Berlin, Berlin, Germany, University of Duesseldorf, Duesseldorf, Germany, 4 University of Würzburg, Würzburg, Germany, 5 German Rheumatism Research Centre and Charité University Medicine, Berlin, Germany, 6 German Rheumatism Research Center, Berlin, Germany 78. HBV Reactivation and Consequent Hepatitis In Rheumatoid Arthritis Patients With Different HBV Carring State: A Clinical Observation Follow-Up. Lie Dai, An Qi Liang, Ying Qian Mo, Jian Da Ma, Le Feng Chen, Dong Hui Zheng and Lang Jing Zhu, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China 79. Osteoporotic Fracture and Post-Operative Clinical and Cost Outcomes In Rheumatoid Arthritis: Results From Two UK Inception Cohorts. Elena Nikiphorou, Lewis Carpenter, Josh Dixey, Peter Williams 4, Patrick D. Kiely 5, David Walsh 6, Richard Williams 7 and Adam Young 8, ERAS, St Albans City Hospital & University College London (UCL), London, United Kingdom, University of Hertfordshire, Hatfield, United Kingdom, New Cross Hospital, Wolverhampton, United Kingdom, 4 Medway Maritime Hospital, Gillingham, United Kingdom, 5 St George s Hospital, London, United Kingdom, 6 University of Nottingham, Nottingham, United Kingdom, 7 County Hospital, Hereford, United Kingdom, 8 St Albans City Hospital, St Albans, United Kingdom 80. Active Rheumatoid Arthritis Is An Independent Risk Factor Of Chronic Kidney Disease. Ryosuke Hanaoka, Kazuhiro Kurasawa, Ayae Tanaka and Harutsugu Okada 4, Kamitsuga General Hospital, Kanuma, Tochigi, Japan, Dokkyo Medical University, Mibu-machi, Shimotsuga-gun, Tochigi-ken, Japan, Dokkyo Medical University, Mibu, Tochigi, Japan, 4 Dokkyo Medical University, Mibu-machi, Tochigi-ken, Japan 8. Coronary Endothelial Dysfunction Directly Measured By N Positron Emission Tomography (PET) Is Detected In Established Rheumatoid Arthritis (RA), But Not Early RA. OM Troum, OL Pimienta, B Hidalgo and WA Hsueh, Keck School of Medicine, University of Southern California, Los Angeles, CA, University of Alabama, Birmingham, AL, Weill Cornell Medical College, Houston, TX

187 ACR POSTER SESSION A 8. Effect Of Biologic Disease Modifiers On Cardiovascular Risk Of Patients With Rheumatoid Arthritis Years Prospective Cohort Study. Majed M. Khraishi and Rana Aslanov, MD, Memorial University of Newfoundland, Nexus Clinical Research, St Johns, NF, MD, MSc, Memorial University of Newfoundland, St.John s, NF 8. Increased Incidence Of Low-Energy Fractures In Rheumatoid Arthritis Patients. Kristina Wiberg, Marie- Louise Öhman, Ulrika Bergström and Solbritt M. Rantapaa-Dahlqvist, Umeå University, Umeå, Sweden, Institution of Public health and clinical medicine/ Rheumatology, University of Umeå, Umeå, Sweden, Umea, Sweden 84. Carotid Artery Plaques Are Associated With Coronary Atherosclerosis In Patients With Inflammatory Joint Diseases Independent Of Several Cardiovascular Risk Calculators. Silvia Rollefstad, Eirik Ikdahl, Inge C. Olsen, Tore K. Kvien, Anne S. Eirheim, Terje R. Pedersen and Anne G. Semb, Diakonhjemmet Hospital, Oslo, Norway, University of Oslo, Oslo, Norway 85. Systemic Inflammation In Patients With Inflammatory Joint Disease Does Not Influence Statin Dose Needed To Obtain Low Density Lipoprotein Cholesterol Goal In Cardiovascular Prevention. Silvia Rollefstad, Eirik Ikdahl, Tore K. Kvien, Terje R. Pedersen, Ingar Holme and Anne G. Semb, Diakonhjemmet Hospital, Oslo, Norway, University of Oslo, Oslo, Norway, Oslo University Hospital-Ullevaal, Oslo, Norway 86. Rheumatoid Arthritis Is Associated With Systemic Inflammation In Coronary Vessels. Inge A.M. van den Oever, Alper M. van Sijl, Umit Baylan, Michael. T. Nurmohamed, Alexandre E. Voskuyl, Hans W. Niessen and Suat Simsek, VU University Medical Center, Amsterdam, Netherlands, Medical Center Alkmaar (MCA), Alkmaar, Netherlands 87. Left Ventricular Myocardial Tissue In Rheumatoid Arthritis Shows Systemic Inflammation After Fatal Myocardial Infarction. Inge A.M. van Den Oever, Alper M. van Sijl, Umit Baylan, Michael. T. Nurmohamed, Alexandre E. Voskuyl, Hans W. Niessen and Suat Simsek, VU University Medical Center, Amsterdam, Netherlands, Medical Center Alkmaar (MCA), Alkmaar, Netherlands 88. Vitamin D Levels and Inflammation In The Aortic Wall Of Patients With Inflammatory Rheumatic Disease and Coronary Artery Disease. Ingvild Oma, Jacqueline Kirsti Andersen, Torstein Lyberg, Øyvind Molberg 4, Jon Elling Whist, Ingjerd Lien Kvelstad, Terje Veel 5, Morten Fagerland, Sven M. Almdahl 6, Knut Mikkelsen 7 and Ivana Hollan 7, Innlandet Hospital Trust, Lillehammer, Norway, Gjøvik University College, Gjøvik, Norway, Oslo University Hospital, Oslo, Norway, 4 University of Oslo, Oslo, Norway, 5 Feiringklinikken, Feiring, Norway, 6 University Hospital of North Norway, Tromsø, Norway, 7 Lillehammer Hospital for Rheumatic Diseases, Lillehammer, Norway 89. Small Intestine Enteropathy In Patients With Rheumatoid Arthritis and Osteoarthritis, Taking Regularly Non- Steroidal Antirheumatic Drugs. Has The Basic Disease Effect On Incidence and Degree Of Damage? Petr Bradna, Ilja Tachecí, Drahomira Bastecka, Stanislav Rejchrt, Jan Bures and Marcela Kopacova 4, Charles University Prague Faculty of Medicine Hradec Kralove and University Hospital, Hradec Králové, Czech Republic, Charles University Prague Faculty of Medicine Hradec Kralove and University Hospital, Hradec Kralove, Czech Republic, Charles University Prague,Medical Faculty Hradec Kralove and University Hospital, Hradec Kralove, Hradec Kralove, Czech Republic, 4 Charles University Prague, Medical Faculty Hradec Kralove and University Hospital, Hradec Kralove, Czech Republic 90. Autonomic Dysfunction In Rheumatoid Arthritis Improves With Disease Modifying Anti Rheumatic Drugs. Ashit Syngle, Inderjeet Verma, Pawan Krishan and Nidhi Garg, Healing Touch City Clinic, Fortis Multispeciality Hospital, Chandigarh, India, Punjabi University Patiala, India, Chandigarh, India, Punjabi University Patiala, India, Patiala, India 9. Insulin Resistance As A Risk Factor For Subclinical Atherosclerosis In Rheumatoid Arthritis. Adel M. Elsayed, Samah A. El Bakry, S. A. M. Hassan, Rehab A. Rahman, Rania A. Abo-Shady and Nouran Abaza, Ain Shams University, Cairo, Egypt, Lecturer of Physical medicine, Rheumatology and Rehabilitation, Faculty of Medicine, Ain Shams University, Cairo, Egypt 9. Prevalence Of Cardiovascular Risk Factors and Cardiovascular Disease In Rheumatoid Arthritis Patients Across International Regions: A Comparison Of The Corrona International and Corrona United States Registries. Dimitrios A. Pappas, Kathy Lampl, Joel M. Kremer, Sebastião C. Radominski 4, Janos Gal 5, Fredrik Nyberg 6, Anand N. Malaviya 7, Aimée Whitworth 8, Oscar Luis Rillo 9, Allan Gibofsky 0, Tatiana Popkova, Meilien Ho, Ieda Laurindo, George W. Reed 8, Eduardo Mario Kerzberg 4, Laura Horne, Roman Záhora 5, Katherine C. Saunders 8, Bernado Pons-Estel 6, Alina U. Onofrei 7 and Jeffrey D. Greenberg 8, Columbia University, New York, NY, AstraZeneca R&D Wilmington, Wilmington, DE, Center for Rheumatology, Albany Medical College, Albany, NY, 4 Universidade Federal do Paraná, Curitiba, Brazil, 5 County Hospital, Kecskemet, Hungary, 6 AstraZeneca R&D, Mölndal, Sweden, 7 Consultant Rheumatologist, ISIC Superspeciality Hospital, New Delhi-007-, India, 8 CORRONA, Inc., Southborough, MA, 9 CONAART - Hospital Tornú, Buenos Aires, Argentina, 0 Hospital for Special Surgery, New York, NY, Research Institute of Rheumatology -Russian Academy of Medical Science, Moscow, Russia, AstraZeneca R&D Alderley Park, Macclesfield, United Kingdom, Universidade de São Paulo, São Paulo, Brazil, 4 J. M. Ramos Mejía Hospital, School of Medicine, University of Buenos Aires, Buenos Aires, Argentina, 5 Revmatologická ambulance, Terezin, Czech Republic, 6 Hospital Provincial de Rosario, Rosario, Argentina, 7 University of Massachusetts Medical School, Worcester, MA, 8 NYU Hospital for Joint Diseases, New York, NY 0 Program Book 85

188 ACR POSTER SESSION A Survival In Rheumatoid Arthritis Associated Pulmonary Arterial Hypertension Is Comparable To Idiopathic Pulmonary Arterial Hypertension. Saghar Sadeghi, John T. Granton, Pooneh Akhavan and Sindhu R. Johnson 4, Toronto Scleroderma Research Program, Toronto Western Hospital, Mount Sinai Hospital, and University of Toronto, Toronto, ON, Toronto Pulmonary Hypertension Programme, Toronto General Hospital and University of Toronto, Toronto, ON, Early Rheumatoid Arthritis Program, Mount Sinai Hospital and University of Toronto, Toronto, ON, 4 Toronto Western Hospital, Toronto General Hospital, Mount Sinai Hospital, and University of Toronto, Toronto, ON 94. Vitamin D Deficiency In Patients With Early Inflammatory Arthritis. Seung-Geun Lee, Guen-Tae Kim, Joung-Wook Lee, Seong-Ho Kim 4 and Seung-Hoon Baek 5, Divsion of Rheumatology, Department of Internal Medicine, Pusan National University School of Medicine, Pusan National University Hospital, Busan, South Korea, Division of Rheumatology, Department of Internal Medicine, Kosin University College of Medicine, Busan, South Korea, Divsion of Rheumatology, Department of Internal Medicine, Busan St. Mary s Medical Center, Busan, South Korea, 4 Division of Rheumatology, Inje University College of Medicine, Haeundae Paik Hospital, Busan, South Korea, 5 Divsion of Rheumatology, Department of Internal Medicine, Ilsin Christian Hospital, Busan, South Korea 95. Sex Differences In Lean Mass Deficits In Rheumatoid Arthritis. Joshua Baker, David I. Daikh and Patricia P. Katz, University of Pennsylvania, Philadelphia, PA, University of California, San Francisco, San Francisco, CA 96. The Dosage Of Prednisolone Is a Risk Factor For Falls In Rheumatoid Arthritis Patients -The Third Year Results Of The Tomorrow Study-. Yuko Sugioka, Tatsuya Koike, Kenji Mamoto, Tadashi Okano, Masahiro Tada, Kentaro Inui and Hiroaki Nakamura, Osaka City University Graduate School of Medicine, Osaka, Japan 97. Does Elevated Disease Activity Or Medication Use Influence The Bone Density Of The Prepubertal Offspring In Pregnant Women With Rheumatoid Arthritis? Florentien D.O. de Steenwinkel, Anita C.S. Hokken- Koelega, Johanna Hazes and Radboud J.E.M. Dolhain, Erasmus Medical Center, Rotterdam, Netherlands, Erasmus Medical Center- Sophia Children s Hospital, Rotterdam, Netherlands 98. Does Elevated Disease Activity Or Medication Use Influence The Body Composition Of The Prepubertal Offspring In Pregnant Women With Rheumatoid Arthritis? Florentien D.O. de Steenwinkel, Radboud J.E.M. Dolhain, Johanna M.W. Hazes and Anita C.S. Hokken-Koelega, Erasmus Medical Center, Rotterdam, Netherlands, Erasmus University Medical Center, Rotterdam, Netherlands, Erasmus Medical Center- Sophia Children s Hospital, Rotterdam, Netherlands 99. Nausea and Vomiting During Pregnancy and Spontaneous Abortion In Women With Rheumatoid Arthritis. Balambal Bharti, Diana L. Johnson and Christina D. Chambers, University of California San Diego, La Jolla, CA, University of California, San Diego, La Jolla, CA 0 Program Book 400. Parotid Ultrasound Abnormalities Among Rheumatoid Arthritis Patients: Prevalence and Clinical Correlates. Hong Yang, Doquyen H. Huynh, Arnold Ceponis and Arthur Kavanaugh 4, UCSD, San Diego, CA, UC San Diego School of Medicine, San Diego, CA, University of California San Diego, La Jolla, CA, 4 University of California San Diego, San Diego, CA 40. Chest Pain Is Not Associated With Coronary Atherosclerosis In Patients With Rheumatoid Arthritis and Ankylosing Spondylitis. Silvia Rollefstad, Eirik Ikdahl, Inge C. Olsen, Jonny Hisdal, Tore K. Kvien, Anne S. Eirheim, Terje R. Pedersen and Anne G. Semb, Diakonhjemmet Hospital, Oslo, Norway, Uslo University Hospital-Aker, Oslo, Norway, University of Oslo, Oslo, Norway 40. Can Modulators Of Inflammation Serve As Biomarkers For Subclinical Atherosclerosis In Rheumatoid Arthritis? Kimberly P. Liang, Douglas P. Landsittel, Suresh R. Mulukutla, Steven E. Reis, Marc C. Levesque, Donald M. Jones, Rachel Gartland, Ali Shoushtari, Flordeliza S. Villanueva, Hunter C. Champion and Larry W. Moreland, University of Pittsburgh, Pittsburgh, PA 40. Peripheral Blood Biomarkers Of Rheumatoid Arthritis- Associated Interstitial Lung Disease. Juan Chen and Dana P. Ascherman, The First Afflicted Hospital of Xiamen University,, Xiamen,, China, University of Miami, Miami, FL 404. Arterial Stiffness Is Associated With Abnormal Left Ventricular Geometry In Patients With Rheumatoid Arthritis. Helga Midtbø, Eva Gerdts, Inge C. Olsen, Tore K. Kvien, Einar Davidsen and Anne Grete Semb, Haukeland University Hospital, Bergen, Norway, University of Bergen, Bergen, Norway, Diakonhjemmet Hospital, Oslo, Norway 405. Gout and RA: Not Such a Rare Coexistence After All. Christina Petsch, Elizabeth Araujo, Matthias Englbrecht, Axel J. Hueber, Georg Schett, Bernhard Manger and Juergen Rech, University of Erlangen-Nuremberg, Erlangen, Germany 406. Cardiovascular Case Fatality In Rheumatoid Arthritis Is Decreasing; Results From a Current Low Disease Activity Rheumatoid Arthritis Cohort and Review Of The Literature. Inger L. Meek, Harald E. Vonkeman and Mart A.F.J. van de Laar, Rheumatology Center Twente, Medisch Spectrum Twente & Twente University, Enschede, Netherlands, Medisch Spectrum Twente & University of Twente, Enschede, Netherlands 407. Association Between Anti-Cyclic Citrullinated Peptide Antibodies Titres and The Presence and Severity Of Diffuse Interstitial Lung Disease Secondary To Rheumatoid Arthritis. Juan Manuel Ponce-Guarneros, Alberto Daniel Rocha Muñoz, Jorge Ivan Gámez Nava, Soraya Amalí Zavaleta Muñíz 4, Miriam Lizette Díaz Toscano 5, Mario Salazar Paramo 6, Liliana Faviola De La Cerda Trujillo 7, Norma Guadalupe González Montoya, Ernesto German Cardona Muñoz 8, Monica Vazquez del Mercado 9 and Laura González López, Hospital General Regional 0, Instituto Mexicano del Seguro Social. Guadalajara., Guadalajara, Jalisco, Mexico, Departamento de Medicina Interna- Reumatología, Hospital General Regional 0, Instituto Mexicano del Seguro Social., Guadalajara, Jalisco, Mexico,

189 ACR POSTER SESSION A Unidad de Investigación en Epidemiología Clínica, Hospital de Especialidades Centro Médico Nacional de Occidente., Guadalajara, Jalisco, Mexico, 4 Universidad de Guadalajara, Guadalajara, Jalisco, México, Mexico, 5 Doctorado en Farmacología, Centro Universitario de Ciencias de la Salud, Guadalajara, Jalisco, Mexico, 6 Instituto Mexicano Del SS, Guadalajara, Mexico, 7 Unidad de Investigación en Epidemiología Clínica del Hospital de Especialidades Centro Médico Nacional de Occidente, IMSS, Guadalajara, Jalisco, Mexico, 8 Departamento de Fisiología, Universidad de Guadalajara, Guadalajara, México, Guadalajara, Jalisco, Mexico, 9 Universidad de Guadalajara, Guadalajara, Mexico 408. Comorbidity In Early Rheumatoid Arthritis.Does Inflammation Matter? Lena Innala, Clara Sjöberg, Ewa H. Berglin, Anna Södergren, Bozena Möller, Solbritt M. Rantapaa-Dahlqvist and Solveig Wållberg-Jonsson, Institution of Public health and clinical medicine/ Rheumatology, University of Umeå, Umeå, Sweden, Department of Rheumatology, Sunderby Hospital, Luleå, Sweden, Institution of Public health and clinical medicine/ Rheumatology, University of Umeå, Umeå, Sweden, Umea, Sweden 409. Rheumatoid Arthritis-Associated Interstitial Lung Disease: Lung Inflammation Evaluated With High Resolution Computed Tomography Scan Is Correlated To Rheumatoid Arthritis Disease Activity. Jorge Rojas-Serrano, Renzo Perez-Dorame, Heidegger Mateos-Toledo and Mayra Mejia, Instituto Nacional de Enfermedades Respiratorias, Mexico City, Mexico, Instituto Nacional de Enfermedades Respiratorias, Mexico, Mexico, Instituto Nacional de Enfermedades Respiratorias Dr. Ismael Cosío Villegas. México DF., México, D.F., Mexico 40. Correlation of Carotid Intima Media Thickness With Interleukin-6, Tumor Necrosis Factor-α and Anti-Cyclic Citrullinated Peptides In Rheumatoid Arthritis. Lourdes Nuñez Atahualpa, Mauricio Figuroa Sanchez, Daniel Alberto Rocha Muñoz, Raul Vargas Ramirez, Beatriz Teresita Martin Marquez 4, Jorge Ivan Gamez Nava 5, Laura González López 6, Erika Martínez García, Esther Sanchez Corona, Marcelo Petri 4, Rosa Navarro Hernandez, Veronica Gonzalez Diaz, Jorge Aguilar Arreola 7, Ana Guisllaine Bernard Medina, Alejandra Nuñez Atahualpa 8, Javier Andrade Garduño 8, Eduardo Gomez Bañuelos and Monica Vazquez Del Mercado 7, Hospital Civil Fray Antonio Alcalde, Guadalajara, Mexico, Unidad de Investigación en Epidemiología Clínica del Hospital de Especialidades Centro Médico Nacional de Occidente, IMSS, Guadalajara, Jalisco, Mexico, Instituto de Investigación en Reumatología y del Sistema Músculo Esquelético,, Guadalajara, Mexico, 4 Universidad de Guadalajara, Guadalajara, Mexico, 5 Unidad de Investigación en Epidemiología Clínica, Hospital de Especialidades Centro Médico Nacional de Occidente., Guadalajara, Jalisco, Mexico, 6 Departamento de Medicina Interna-Reumatología, Hospital General Regional 0, Instituto Mexicano del Seguro Social., Guadalajara, Jalisco, Mexico, 7 Hospital Civil Dr Juan I Menchaca, Guadalajara, Mexico, 8 Universidad Autónoma de Guadalajara, Guadalajara, Mexico 4. Differential Effects of biologics On The Removal Of Amyloid Deposition Between The Kidney and Gastric Tract Of Amyloid A Amyloidosis Patients With Rheumatoid Arthritis. Hiroshi Uda, Tamaki Harada, Ayumi Matsumoto, Aya Mizumoto, Toshirou Takama and Osamu Saiki, Higashiosaka City General Hospital, Higashiosaka, Japan 4. Clinical Characterization Of Extensive Interstitial Lung Disease In Rheumatoid Arthritis Patients. Masaomi Yamasaki, Shin-Yokohama Yamasaki Clinic, Yokohama, Japan 4. A Multiple Cause-Of-Death Study In Rheumatoid Arthritis. Frederico A. G. Pinheiro, Deborah C. C. Souza and Emilia I. Sato, Universidade Federal de São Paulo, São Paulo, Brazil, Escola Paulista de Medicina - Universidade Federal de São Paulo, Sao Paulo, Brazil 44. High Prevalence Of Obesity Among Early and Established Rheumatoid Arthritis. Ines Colmegna, Maria Celia Bazan Bardales, Susan J. Bartlett and Carol A. Hitchon, McGill University Health Centre, Montreal, QC, McGill University, Montreal, QC, University of Manitoba, Winnipeg, MB 45. Stability Of Carotid Intima Media Thickness and No Plaque Formation In Inflammatory Arthritis Patients On Biologics Over One Year. Stephanie O. Keeling, Asvina Bissonauth, Jeff Odenbach, Quazi Ibrahim and Michael Sean McMurtry, University of Alberta, Edmonton, AB, EPICORE, Edmonton, AB 46. Changes In Body Composition On Two Different Glucocorticoid Regimens In Early RA: Experience From The Cobra-Light Trial. Nicole P.C. Konijn, Karin Britsemmer, Marieke M. ter Wee, Debby den Uyl, Birgit S. Blomjous, Maarten Boers, Dirkjan van Schaardenburg, Willem F. Lems and Michael T Nurmohamed, VU University Medical Center, Amsterdam, Netherlands, Jan van Breemen Research Institute/Reade, Amsterdam, Netherlands 47. Consensus Statement On The Diagnosis and Management Of Comorbidity In Rheumatoid Arthritis. Cristina Lajas, José Luis Andreu, Alejandro Balsa, Manuel Crespo 4, Carlos M. Gonzalez 5, Oscar Illera 6, Juan A. Jover, Isabel Mateo 7, Javier Orte 8, Javier Rivera 9, Jose M Rodriguez-Heredia 0, Fredeswinda I. Romero, Juan A Martínez-López, Ana M. Ortiz, Esther Toledano, Virginia Villaverde, Estibaliz Loza 4, Loreto Carmona 4 and Santos Castañeda 5, Hospital Clínico San Carlos, Madrid, Spain, HU Puerta de Hierro Majadahonda, Madrid, Spain, La Paz University Hospital, Rheumatology, Madrid, Spain, 4 Hospital universitario Severo Ochoa, Madrid, Spain, 5 Gregorio Marañon Hospital, Madrid, Spain, 6 Hospital Infanta Sofía, Madrid, Spain, 7 Servicio De Reumatología, Hospital De Octubre,, Madrid, Spain, 8 Hospital Universitario Ramón y Cajal, Madrid, Spain, 9 Instituto Provincial de Rehabilitación, Madrid, Spain, 0 Hospital Universitario de Getafe, Getafe, Spain, Jiménez Díaz Foundation University Hospital, Madrid, Spain, Hospital Universitario de La Princesa. IIS Princesa, Madrid, Spain, Hospital Universitario de Móstoles, Mostoles, Spain, 4 Institute for Musculoskeletal Health, Madrid, Spain, 5 Hospital Universitario de La Princesa, IIS Princesa, Madrid, Spain 0 Program Book 87

190 ACR POSTER SESSION A 48. Assessment Of Treatment Effect Over Insulin Resistance and Adipokines In Patients With Early Rheumatoid Arthritis: A 6 Months Longitudinal Observational Study. Sara Manrique-Arija, José Rioja, Pedro Valdivielso, María América López-Lasanta, Pilar Espiño 4, Inmaculada Ureña 4, Francisco G. Jiménez-Núñez 4, Carmen M. Romero-Barco 4 and Antonio Fernández-Nebro, Hospital Carlos Haya. University of Malaga. IBIMA, Malaga, Spain, Department of Medicine. University of Malaga, Malaga, Spain, Vall d Hebron Hospital Research Institute, Barcelona, Spain, 4 Hospital Carlos Haya. University of Malaga, Malaga, Spain 49. A Long Term Observation Of Rheumatoid Arthritis Who Developed Methotrexate Related Lymphoproliferative Disorders. Yukiko Kamogawa, Kyohei Nakamura, Ryu Watanabe, Tsuyoshi Shirai, Yoko Fujita, Yuko Shirota, Noriko Fukuhara, Hiroshi Fujii, Shinichiro Saito, Tomonori Ishii and Hideo Harigae, Tohoku University, Sendai, Japan 40. Lean Body Mass (LBM) Distribution Negatively Impacts On Health Related Quality Of Life (HRQoL) In Patients With Rheumatoid Arthritis (RA). Rocio V. Gamboa- Cardenas, Manuel F. Ugarte-Gil, Erika Noriega, Mariela Medina-Chinchon, Francisco Zevallos-Miranda, J. Mariano Cucho-Venegas, Jose L. Alfaro-Lozano, Zoila Rodriguez- Bellido, Risto A. Perich-Campos, Karim E. Diaz-Deza and Cesar A. Pastor-Asurza, Hospital Almenara, Lima, Peru, Universidad Nacional Mayor de San Marcos, Lima, Peru 4. Enhanced Cardiovascular Risk Factor Screening In Rheumatoid Arthritis: Does This Have a Sustained Impact? Mark J Ponsford, Jennifer K. Cooney, Bethany Anthony, Fflur A. Huws, Lauren Evans, Jeanette Thom and Yasmeen Ahmad, Peter Maddison Research Centre, Llandudno, United Kingdom, School of Sport, Health and Exercise Sciences, Bangor University, George Building, Bangor, Gwynedd, LL57 PZ, UK., Bangor, United Kingdom 4. Disease Activity In Rheumatoid Arthritis Is Associated With Abnormal Left Ventricular Geometry. Helga Midtbø, Eva Gerdts, Inge C. Olsen, Tore K. Kvien, Einar Davidsen and Anne Grete Semb, Haukeland University Hospital, Bergen, Norway, University of Bergen, Bergen, Norway, Diakonhjemmet Hospital, Oslo, Norway 4. Serological Biomarkers For The Development Of Rheumatoid Arthritis Related Interstitial Lung Disease. Elena Nikiphorou, Esther Chan, Vadivelu Saravanan, Julie Dawson, Navtej Sathi 4, Felix Woodhead 5, Mohamed Nisar 6, Subhashini Arthanari 6, Yasmeen Ahmad 7, Adam Young 8 and Clive Kelly, ERAS, St Albans City Hospital & University College London (UCL), London, United Kingdom, Queen Elizabeth Hospital, Gateshead, United Kingdom, St Helens Hospital, St Helens, United Kingdom, 4 Wrightington Hospital, Wigan, United Kingdom, 5 University Hospitals Coventry and Warwickshire, Coventry, United Kingdom, 6 Burton Hospital, Burton-on-Trent, United Kingdom, 7 Peter Maddison Research Centre, Bangor, United Kingdom, 8 St Albans City Hospital, St Albans, United Kingdom Rheumatoid Arthritis Treatment - Small Molecules, Biologics and Gene Therapy: I 44. -Year Results From The Ample (Abatacept versus Adalimumab Comparison in Biologic-Naïve RA Patients with Background Methotrexate) Trial: Changes In Patient- Reported Outcomes In Response To Subcutaneous Abatacept Or Adalimumab In Rheumatoid Arthritis. R Fleischmann, ME Weinblatt, M Schiff, D Khanna 4, MA Maldonado 5, A Nadkarni 5 and D E Furst 6, University of Texas Southwestern Medical Center, Dallas, TX, Rheumatology & Immunology, Brigham & Women s Hospital, Boston, MA, University of Colorado, Denver, CO, 4 University of Michigan, Ann Arbor, MI, 5 Bristol-Myers Squibb, Princeton, NJ, 6 University of California at Los Angeles, Los Angeles, CA 45. Efficacy, Pharmacokinetics, and Safety of Different Doses of Methotrexate in Combination With Adalimumab: Results From the Concerto Trial. Gerd R. Burmester, Alan J. Kivitz, Hartmut Kupper, Udayasankar Arulmani 4, Stefan Florentinus 5, Sandra Goss 4, Suchitrita S. Rathmann 4 and Roy Fleischmann 6, Charité - Universitätsmedizin Berlin, Berlin, Germany, Altoona Center for Clinical Research, Duncansville, PA, AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany, 4 AbbVie Inc., North Chicago, IL, 5 AbbVie, Rungis, France, 6 University of Texas Southwestern Medical Center, Dallas, TX 46. Characteristics of Protocol-Specified Responders/Non- Responders Treated With Etanercept Plus Methotrexate in Period of the Prize Study. Paul Emery, Annette Szumski, Jack Bukowski, Eustratios Bananis and Lisa Marshall, Institute Rheumatic and Musculoskeletal Medicine University of Leeds, Leeds, United Kingdom, Pfizer Inc., Collegeville, PA, Pfizer Inc, Collegeville, PA 47. US Veterans With Rheumatoid Arthritis Who Switch Among Tumor Necrosis Factor Blocking Agents Have No Additional Clinical Benefit With The Change In Therapy and Incur Higher Costs. Grant W. Cannon, Scott L. DuVall, Candace L. Hayden, Liron Caplan, Jeffrey R. Curtis 4, Kaleb Michaud 5, Ted R. Mikuls 6, Andreas M. Reimold 7, David H. Collier 8, George Joseph 8, David J. Harrison 8 and Brian C. Sauer 9, Salt Lake City VA and University of Utah, Salt Lake City, UT, VA Salt Lake City Health Care System and University of Utah School of Medicine, Salt Lake City, UT, Denver Veterans Affairs Medical Center, Denver, CO, 4 University of Alabama at Birmingham, Birmingham, AL, 5 National Data Bank for Rheumatic Diseases & University of Nebraska Medical Center, Omaha, NE, 6 Omaha VA and University of Nebraska Medical Center, Omaha, NE, 7 Dallas VA and University of Texas Southwestern, Dallas, TX, 8 Amgen Inc., Thousand Oaks, CA, 9 George E. Wahlen Veteran Affairs Medical Center, Salt Lake City, UT 48. Correlation Between Objective and Patient Self-Reported Clinical Improvement After Multiple Courses of Rituximab in Rheumatoid Arthritis Patients With Inadequate Response to Tumour Necrosis Factor Inhibitors: Data From Repeat Study. Ioan Ancuta, Catalin Codreanu, Ruxandra Ionescu, Magda Parvu 4, Dan Nemes 5, Rodica Chirieac 6, Paulina Ciurea 7, Maria Suta 8, Andra Balanescu 9, Eugenia 88 0 Program Book

191 ACR POSTER SESSION A Mociran 0 and Elena Rezus, Dr. I. Cantacuzino Hospital, Bucharest, Romania, Dr. I. Stoia Center for Rheumatic Diseases, Bucharest, Romania, Clinic Hospital Sf. Maria, Bucharest, Romania, 4 N.Gh. Lupu Clinical Hospital, Bucharest, Romania, 5 Victor Babes University of Medicine and Pharmacy, Timisoara, Romania, 6 C.M.I. Rodica Chirieac, Iasi, Romania, 7 Emergency County Hospital, Craiova, Romania, 8 Emergency County Hospital, Constanta, Romania, 9 University of Medicine and Pharmacy, Bucharest, Romania, 0 Emergency County Hospital Dr Constantin Opis, Maramures, Romania, Recovering Clinical Hospital, Iasi, Romania 49. Sustained Clinical Efficacy After Multiple Courses of Rituximab in Rheumatoid Arthritis Patients With Inadequate Response to Tumour Necrosis Factor Inhibitors: -Year Data From the Repeat (Repeated Courses in Routine Clinical Practice) Study. Catalin Codreanu, Ioan Ancuta and Ruxandra Ionescu, Dr. I. Stoia Center for Rheumatic Diseases, Bucharest, Romania, Dr. I. Cantacuzino Hospital, Bucharest, Romania, Clinic Hospital Sf. Maria, Bucharest, Romania 40. Comparing abatacept to Adalimumab, Etanercept and Infliximab As First Or Second Line Agents in Patients With Rheumatoid arthritis: Experience From the rhumadata Clinical Database and Registry. Denis Choquette, Diane Sauvageau, Louis Bessette, Boulos Haraoui, Jean Pierre Pelletier, Jean-Pierre Raynauld, Edith Villeneuve and Louis Coupal, Institut de Rhumatologie de Montréal, Montreal, QC, Centre Hospitalier Universitaire de Québec, pavillon CHUL, Sainte-Foy, QC 4. Prediction Of Week 5 Treatment Response Based On A Week Assessment In Rheumatoid Arthritis Patients Receiving Certolizumab Pegol: Comparison Of A Patient-Reported Instrument Versus Physician-Based Disease Activity Assessment. Jeffrey R. Curtis, Willem Koetse, Jeymi Tambiah, Lucian Ionescu 4 and Yusuf Yazici 5, University of Alabama at Birmingham, Birmingham, AL, UCB Pharma, Raleigh, NC, UCB Pharma, Smyrna, GA, 4 UCB Pharma, Brussels, Belgium, 5 New York University Hospital for Joint Diseases, New York, NY 4. Use Of Rituximab As Second Line Biologic Agent Compared With Adalimumab, Etanercept and Infliximab In Patients With Rheumatoid Arthritis. a Report From The Rhumadata Clinical Database and Registry. Louis Bessette, Denis Choquette, Diane Sauvageau, Boulos Haraoui, Jean Pierre Pelletier, Jean-Pierre Raynauld, Edith Villeneuve and Louis Coupal, Centre Hospitalier Universitaire de Québec, pavillon CHUL, Sainte-Foy, QC, Institut de Rhumatologie de Montréal, Montreal, QC 4. Retrospective Analysis Of Certolizumab Pegol Use During Pregnancy: Update Of Impact On Birth Outcomes. Megan E. B. Clowse, Douglas C. Wolf, Frauke Förger, John J. Cush 4, Christian Stach 5, Gordana Kosutic 6, Susan Williams 6, Chidi Maduka 6 and Uma Mahadevan 7, Duke University Medical Center, Durham, NC, Atlanta Gastroenterology Associates, Atlanta, GA, University of Bern, Bern, Switzerland, 4 Baylor Research Institute and Baylor University Medical Center, Dallas, TX, 5 UCB Pharma, Monheim, Germany, 6 UCB Pharma, Raleigh, NC, 7 UCSF Medical Center, San Francisco, CA 44. Results Of 64 Weeks Of Treatment With An Anti-IL-7 Antibody, Ixekizumab, In Patients With Rheumatoid Arthritis In a Phase Study. Mark C. Genovese, Hilde Carlier, Janelle Erickson, Daniel Braun and Subhashis Banerjee, Stanford University, Palo Alto, CA, Eli Lilly & Company, Indianapolis, IN 45. Final 5-Year Safety and Efficacy Results Of a Phase, Randomized, Placebo-Controlled Trial Of Golimumab In Methotrexate-naïve Patients With Rheumatoid Arthritis. Paul Emery, Roy M. Fleischmann, Ingrid Strusberg, Patrick Durez 4, Peter Nash 5, Eric Amante 6, Melvin A. Churchill 7, Won Park 8, Bernardo Pons-Estel 9, Chenglong Han 0, Timothy A. Gathany 0, Yiying Zhou, Stephen Xu and Elizabeth C. Hsia, University of Leeds, Leeds Institute of Molecular Medicine and NIHR LMBRU, Leeds, United Kingdom, University of Texas Southwestern Medical Center at Dallas, Dallas, TX, Instituto Reumatológico Strusberg, Cordoba, Argentina, 4 Pôle de Recherche en Rhumatologie, Institut de Recherche Expérimentale et Clinique, Université Catholique de Louvain, Brussels, Belgium, 5 University of Queensland, Brisbane, Australia, 6 University of Phillipines General Hospital, Manila, Philippines, 7 Arthritis Center of Nebraska, Lincoln, NE, 8 Inha University Hospital, Incheon, South Korea, 9 Sanatorio Parque, Rosario, Argentina, 0 Janssen Global Services, LLC., Malvern, PA, Janssen Research & Development, LLC., Spring House, PA, Janssen Research & Development, LLC./U of Penn, Spring House/ Philadelphia, PA 46. Efficacy and Safety Study Of a Sequential Therapy Of Tocilizumab and, If Initially Inadequately Responded To Tocilizumab, Followed By Rituximab In Patients With Rheumatoid Arthritis and Inadequate Response To Traditional Disease Modifying Anti-Rheumatic Drugs (MIRAI)-Interim Analysis. Thomas Doerner, Hans Peter Tony, Hendrik Schulze-Koops, Jörg Kaufmann 4, Peter Kaestner 5, Herbert Kellner 6, Reiner Kurthen 7, S. Wagner 8, Marvin A. Peters 9 and Christof Iking-Konert 0, Humdoldt Univ, Berlin, Germany, University of Würzburg, Würzburg, Germany, University of Munich, Munich, Germany, 4 Rheumatologist, Ludwigsfelde, Germany, 5 Ambulantes Rheumazentrum Erfurt, Germany,, Erfurt, Germany, 6 Centre for Inflammatory Joint Diseases, Munich, Germany, 7 Rheumapraxis, Aachen, Germany, 8 Internistische Schwerpunktpraxis für Rheumatologie, Halle, Germany, 9 Roche Pharma AG, Grenzach-Wyhlen, Germany, 0 University Hospital Hamburg Eppendorf, Hamburg, Germany 47. Patterns Of Use Of Oral and Subcutaneous Methotrexate Use In Rheumatoid Arthritis Patients Enrolled In The U.S. Medicare Program. Jeffrey R. Curtis, Fenglong Xie, Jie Zhang, Lang Chen, Huifeng Yun, Michael H. Schiff, David Mackey and Seth Ginsberg, University of Alabama at Birmingham, Birmingham, AL, University of Colorado, Denver, CO, Creaky Joints, New York, NY 48. Tofacitinib, An Oral Janus Kinase Inhibitor, In A Rheumatoid Arthritis Open-Label Extension Study Following Adalimumab Therapy In A Phase Randomised Clinical Trial. M. C. Genovese, R. F. van Vollenhoven, B. Wilkinson, L. Wang, S. H. Zwillich, D. Gruben, B. Benda 4 and T. V. Jones 4, Stanford University, Palo Alto, CA, The Karolinska Institute, Stockholm, Sweden, Pfizer Inc, Groton, CT, 4 Pfizer Inc, Collegeville, PA 0 Program Book 89

192 ACR POSTER SESSION A Tofacitinib, An Oral Janus Kinase Inhibitor: Analysis Of Gastrointestinal Adverse Events Across The Rheumatoid Arthritis Clinical Program. E. B. Lee, J. R. Curtis, R. Riese, C. A. Connell, R. Chew, M.G. Boy, E. Maller 4, C. Su 4 and L. Wang, Seoul National University, Seoul, South Korea, University of Alabama at Birmingham, Birmingham, AL, Pfizer Inc, Groton, CT, 4 Pfizer Inc, Collegeville, PA 440. Cardiovascular Safety Findings In Rheumatoid Arthritis Patients Treated With Tofacitinib, A Novel, Oral Janus Kinase Inhibitor. C. Charles-Schoeman, P Wicker, M. A. Gonzalez-Gay, S. P. Wood 4, M.G. Boy 4, J. Geier 5, D. Gruben 4, K. Soma 4 and R. Riese 4, University of California, Los Angeles, CA, PW Consulting LLC, Mystic, CT, Hospital Marques De Valdecilla, Santander, Spain, 4 Pfizer Inc, Groton, CT, 5 Pfizer Inc, New York, NY 44. Tofacitinib, An Oral Janus Kinase Inhibitor: Safety Comparison In Patients With Rheumatoid Arthritis and An Inadequate Response To Nonbiologic Or Biologic Disease Modifying Anti-Rheumatic Drugs. G. R. Burmester, C Charles-Schoeman, J. D. Isaacs, T. Hendrikx 4, K. Kwok 5, S. H. Zwillich 6 and R. Riese 6, Charité University Medicine Berlin, Berlin, Germany, University of California, Los Angeles, CA, Newcastle University, Newcastle-upon- Tyne, United Kingdom, 4 Pfizer Inc, Capelle aan den IJssel, Netherlands, 5 Pfizer Inc, New York, NY, 6 Pfizer Inc, Groton, CT 44. Tolerability and Non-Serious Adverse Events In Rheumatoid Arthritis Patients Treated With Tofacitinib As Monotherapy Or In Combination Therapy. A. Dikranian, K. Soma, R. Riese, D. Gruben and T. V. Jones, San Diego Arthritis Medical Clinic, San Diego, CA, Pfizer Inc, Groton, CT, Pfizer Inc, Collegeville, PA 44. Efficacy and Safety Analyses Of Tofacitinib From Pooled Phase, Phase and Long-Term Extension Rheumatoid Arthritis Studies: US Compared With Non-US Populations. S. B. Cohen, R. M. Fleischmann, J. M. Kremer, A. Koenig, K. Kwok 4, L. Wang 5, C. A. Mebus 5, R. Riese 5 and T. Robinson, Metroplex Clinical Research Center, Dallas, TX, Albany Medical College and The Center for Rheumatology, Albany, NY, Pfizer Inc, Collegeville, PA, 4 Pfizer Inc, New York, NY, 5 Pfizer Inc, Groton, CT 444. Reversibility Of Pharmacodynamic Effects After Short- and Long-Term Treatment With Tofacitinib In Patients With Rheumatoid Arthritis. M. C. Genovese, T. Kawabata, K. Soma, S. Menon, J.D. Clark, J. Hodge 4, L. Takiya 4, R. Riese and S. Krishnaswami, Stanford University, Palo Alto, CA, Pfizer Inc, Groton, CT, Pfizer Inc, Cambridge, MA, 4 Pfizer Inc, Collegeville, PA 445. Post-Hoc Analysis Of Serious Infection Events and Selected Clinical Factors In Rheumatoid Arthritis Patients Treated With Tofacitinib. J. J. Gomez-Reino, A. Hazra, C. Fosser, S. Menon, S. H. Zwillich, R. Riese and S. Krishnaswami, Hospital Clinico Universitario de Santiago, Santiago de Compostela, Spain, Pfizer Inc, Groton, CT 0 Program Book 446. Remission Rates During Golimumab Treatment For Rheumatoid Arthritis Are Associated With Differences In Baseline Disease States Across Geographic Regions. P Durez, K Pavelka, M Lazaro, A Garcia Kutzbach 4, R Moots 5, H Amital 6, R Yao 7, M Govoni 8, N Vastesaeger 9 and HH Weng 7, Université Catholique de Louvain and Cliniques Universitaires Saint-Luc, Brussels, Belgium, Revmatologicky Ustav, Praha, Czech Republic, Instituto de Asistencia Reumatológica Integral, San Fernando, San Fernando, Argentina, 4 Universidad Francisco Marroquin Guatemala School of Medicine, Guatemala City, Guatemala, 5 University Hospital Aintree, Liverpool, United Kingdom, 6 Sheba Medical Center, Tel-Hashomer, Israel, 7 Merck Sharp & Dohme, Kenilworth, NJ, 8 Merck Sharp & Dohme, Rome, Italy, 9 Merck Sharp & Dohme, Brussels, Belgium 447. High Levels Of Memory B CELLS ARE Associated With Response To A First ANTI-TNF Drug In Patients With Rheumatoid Arthritis. Claire I. Daien, Sarah Gailhac, Thibault Mura, Bernard Combe, Michael Hahne 4 and Jacques Morel, Lapeyronie Hospital, Montpellier, France, CNRS, Montpellier, France, Hopital Gui De Chauliac, Montpellier, France, 4 IGMM, CNRS UMR555, Montpellier, Montpellier, France Effectiveness Of Tocilizumab In Monotherapy and In Combination With Different Synthetic Dmards: A Registry-Based Comparison Study. Cem Gabay, Myriam Riek, Merete L. Hetland, Ulrik Tarp 4, K. Pavelka 5, Matija Tomsic 6, Helena Canhao 7, Katerina Chatzidionysiou 8, R.F. van Vollenhoven 9, Galina Lukina 0, E. Nasonov, Dan C. Nordström, Elisabeth Lie, Ioan Ancuta 4, Estibaliz Loza Santamaria 5, Piet Van Riel 6 and Tore K. Kvien, Geneva University Hospitals, Geneva, Switzerland, SCQM Registry, Zurich, Switzerland, DANBIO, Center for Rheumatology and Spine Diseases, Glostrup Univ Hospital, Glostrup, Denmark, 4 Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark, 5 Department of Clinical and Experimental Rheumatology, Charles University, Prague, Czech Republic, 6 University Medical Centre Ljubjana, Ljubljana, Slovenia, 7 Instituto de Medicina Molecular, Rheumatology Research Unit, Rheumatology Research Unit, on behalf of the Rheumatic Diseases Portuguese Register, Lisbon, Portugal, 8 Unit for Clinical Research Therapy. Inflammatory Diseases (ClinTrid), Karolinska Institute, Stockholm, Sweden, 9 Karolinska Institute, Stockholm, Sweden, 0 ARBITER, Institute of Rheumatology, Moscow, Russia, Institute of Rheumatology, Moscow, Russia, ROB-FIN, Helsinki University Central Hospital, Helsinki, Finland, Diakonhjemmet Hospital, Oslo, Norway, 4 Dr. I. Cantacuzino Hospital, Bucharest, Romania, 5 Instituto de salud Musculoesqueletica, Madrid, Spain, 6 Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands 449. Work Instability In Early Rheumatoid Arthritis With Elevated Risk Of Employment Loss: Effects Of Adalimumab/Methotrexate Combination Therapy Versus Methotrexate In a Randomized Clinical Trial. Arthur Kavanaugh, Josef S. Smolen, Arijit Ganguli, Hartmut Kupper, Mary Cifaldi, Naijun Chen and Dennis Revicki 4, University of California, San Diego, La Jolla, CA, Medical University of Vienna, Vienna, Austria, AbbVie Inc., North Chicago, IL, 4 United BioSource, Bethesda, MD

193 ACR POSTER SESSION A 450. Tocilizumab Monotherapy Compared With Adalimumab Monotherapy In Patients With Rheumatoid Arthritis: An Evaluation Of High-Density Lipoprotein Composition. Cem Gabay, Katie Tuckwell, Jennifer Green, Micki Klearman and Arthur Kavanaugh 4, SCQM registry, University Hospitals of Geneva, Geneva, Switzerland, Roche, Welwyn Garden City, United Kingdom, Roche, South San Francisco, CA, 4 University of California, San Diego, La Jolla, CA 45. Evaluation Of Disease Activity By The Routine Assessment Of Patient Index Data In Patients With Rheumatoid Arthritis Receiving Tocilizumab. Yu F. Asanuma, Takashi Maruyama, Maiko Yanagisawa, Kazuhiro Yokota, Yoshihiro Yoshida, Hiroshi Kajiyama, Kojiro Sato, Yuji Akiyama and Toshihide Mimura, Saitama Medical University, Saitama, Japan 45. What Are The Implications Of Concomitant and Pre- Medication On Infusion Reactions To Infliximab: Results From RemiTRAC Infusion, a Prospective Real-World Community Registry. Denis Choquette, Rafat Y. Faraawi, Merlin Njoya, Andrew Chow 4, William G. Bensen 5 and Francois Nantel 6, Institut de Rhumatologie de Montréal, Montreal, QC, Rheumatologist, KW Musculoskeletal Research Inc., Kitchener, ON, McKesson Canada, Toronto, ON, 4 Credit Valley Rheumatology, Mississauga, ON, 5 St. Joseph s Hospital and McMaster University, Hamilton, ON, 6 Janssen Canada Inc, Toronto, ON 45. Impact Of Inadequate Adherence On Clinical Outcomes: Results From The Biologics In Rheumatoid Arthritis Genetics and Genomics Study Syndicate Cohort. James Bluett, Catharine Morgan, Layla Thurston, Darren Plant, Ann W. Morgan, Anthony G. Wilson 4, John Isaacs 5, Kimme L. Hyrich, Lis Cordingley and Anne Barton, Arthritis Research UK Epidemiology Unit, The University of Manchester, Manchester, United Kingdom, Manchester Medical School, The University of Manchester, Manchester, United Kingdom, NIHR-Leeds Musculoskeletal Biomedical Research Unit and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, 4 Department of Infection and Immunity, University of Sheffield, Sheffield, United Kingdom, 5 National Institute for Health Research, Newcastle Biomedical Research Centre, Newcastle Hospitals Foundation Trust and Newcastle University, Newcastle Upon Tyne, United Kingdom 454. Antibody Response To Pneumococcal and Influenza Vaccination In Patients With Rheumatoid Arthritis Receiving Subcutaneous Abatacept. MC Genovese, CO Bingham rd, S Cohen, L Calabrese 4, JR Curtis 5, A Block 6, J Fay 6, S Kelly 6, A Luo 6, D Wong 6 and R Alten 7, Stanford University, Palo Alto, CA, Johns Hopkins University, Baltimore, MD, Metroplex Clinical Research Center, Dallas, TX, 4 Cleveland Clinic, Cleveland, OH, 5 University of Alabama at Birmingham, Birmingham, AL, 6 Bristol-Myers Squibb, Princeton, NJ, 7 Schlosspark-Klinik, University Medicine Berlin, Berlin, Germany 455. Oskira-: A Phase III, Multicenter, Randomized, Double- Blind, Placebo-Controlled Parallel-Group Study Of Dosing Regimens Of Fostamatinib In Rheumatoid Arthritis Patients With An Inadequate Response To Disease-Modifying Antirheumatic Drugs. Peter Dawes, Aleksandar Dimic, Mark C. Genovese, Désiréé van der Heijde 4, Martin Jenkins 5, Chris O Brien 6, Barry Oemar 7, Jiri Vencovsky 8 and Michael Weinblatt 9, University of North Staffordshire NHS Trust, Stoke-on-Trent, United Kingdom, Rheumatology Institute, Niška Banja, Serbia, Stanford University, Palo Alto, CA, 4 Leiden University Medical Center, Leiden, Netherlands, 5 AstraZeneca R&D Alderley Park, Macclesfield, United Kingdom, 6 AstraZeneca R&D Wilmington, Wilmington, DE, 7 AstraZeneca R&D Boston, Boston, MA, 8 Institute of Rheumatology, Prague, Czech Republic, 9 Division of Rheumatology, Brigham & Women s Hospital, Boston, MA 456. Oskira-: A Phase III, Multicenter, Randomized, Double- Blind, Placebo-Controlled Parallel-Group Study Of Dosing Regimens Of Fostamatinib In Rheumatoid Arthritis Patients With An Inadequate Response To a Tumor Necrosis Factor -á Antagonist. Mark Genovese, Désiréé van der Heijde, Edward Keystone, Alberto Spindler 4, Claude-Laurent Benhamou 5, Arthur Kavanaugh 6, Edward Fudman 7, Kathy Lampl 8, Chris O Brien 8, Emma Duffield 9, Jeffrey Poiley 0 and Michael Weinblatt, Stanford University, Palo Alto, CA, Leiden University Medical Center, Leiden, Netherlands, University of Toronto, Toronto, ON, 4 Centro Medico Privado de Reumatologia, Tucuman, Argentina, 5 Centre Hospitalier Régional d Orléans, Orleans, France, 6 University of California San Diego, San Diego, CA, 7 Austin Rheumatology Research PA, Austin, TX, 8 AstraZeneca R&D Wilmington, Wilmington, DE, 9 AstraZeneca R&D Alderley Park, Macclesfield, United Kingdom, 0 Arthritis Associates, Orlando, FL, Division of Rheumatology, Brigham & Women s Hospital, Boston, MA 457. Pharmacodynamic Effect Of Intravenous Golimumab By Messenger Ribonucleic Acid Expression Profiling. Yauheniya Cherkas, Carrie Brodmerkel, Mark Curran and Sarah Lamberth, Janssen Research & Development, LLC., Spring House, PA 458. High Levels Of Natural Killer CELLS ARE Associated With Response To Tocilizumab In Patients With Severe Rheumatoid Arthritis. Claire I. Daien, Sarah Gailhac, Rachel Audo, Thibault Mura 4, Michael Hahne, Bernard Combe and Jacques Morel, Lapeyronie Hospital, Montpellier, France, CNRS, Montpellier, France, IGMM, CNRS UMR555, Montpellier, Montpellier, France, 4 Hopital Gui De Chauliac, Montpellier, France 459. Transaminase Levels and Hepatic Events Observed During Tocilizumab Treatment: Pooled Analysis Of Long-Term Clinical Trial Safety Data In Patients With Rheumatoid Arthritis. Mark C. Genovese, Joel M. Kremer, Ronald F. van Vollenhoven, Rieke Alten 4, Juan José Scali 5, Ariella Kelman 6, Lucy Rowell 7 and Laura Pitts 7, Stanford University Medical Center, Palo Alto, CA, Center for Rheumatology, Albany Medical College, Albany, NY, Karolinska Institute, Stockholm, Sweden, 4 University of Berlin, Berlin, Germany, 5 Durand University Hospital, Buenos Aires, Argentina, 6 Genentech, South San Francisco, CA, 7 Roche, Welwyn Garden City, United Kingdom 0 Program Book 9

194 ACR POSTER SESSION A Comparative Efficacy Of Novel Disease-Modifying Antirheumatic Drugs As Monotherapy and In Combination With Methotrexate In Rheumatoid Arthritis Patients With An Inadequate Response To Traditional Disease-Modifying Antirheumatic Drugs: A Network Meta-Analysis. Felicity Buckley, Axel Finckh, Thomas W.J. Huizinga, Fred Dejonckheere 4 and Jeroen P. Jansen, MAPI Consultancy, Boston, MA, University of Geneva, Geneva, Switzerland, Leiden University Medical Center, Leiden, Netherlands, 4 F. Hoffmann-La Roche Ltd, Basel, Switzerland 46. Higher TNFi Dosing Is Not Associated With More Serious Infectious Events (SIE), Elevated AST/ALT Or WBC<.5 In The US Corrona Database. Daniel Furst, Mei Liu, Jeffrey D. Greenberg and Joel M. Kremer 4, David Geffen School of Medicine, UCLA, Los Angeles, CA, CORRONA, Inc, Southborough, MA, NYU Hospital for Joint Diseases, New York, NY, 4 Albany Medical College and The Center for Rheumatology, Albany, NY 46. Reduced Response To Biologic Treatments in Rheumatoid Arthritis Patients Affected By Arterial Hypertension. Marco Antivalle, Michel Chevallard, Michele Battellino, Alberto Batticciotto, Maria Chiara Ditto, Alessandra Mutti, Federica Rigamonti, Valentina Varisco, Sara Bongiovanni, Fabiola Atzeni and Piercarlo Sarzi-Puttini, Rheumatology Unit, L. Sacco University Hospital, Milan, Italy, Rheumatology Unit, L. Sacco University Hospital, Milano, Italy, Rheumatology Unit, L. Sacco University Hospital, MiIano, Italy 46. An Indirect Comparisons Analysis Between Biologic Disease Modifiers in The Treatment Of Rheumatoid Arthritis To Evaluate For Efficacy and Safety. Aaron C. Garza Romero, Elie Donath, Hernan Osorno and Suresh Kumar, University of Miami Miller School of Medicine Palm Beach Regional Campus, Atlantis, FL 464. The Efficacy and Safety Of Tocilizumab Subcutaneous Versus Tocilizumab Intravenous, In Combination With Traditional Dmards In Patients With RA At 49 Weeks (SUMMACTA). Gerd R. Burmester, Andrea Rubbert-Roth, Alain G. Cantagrel, Stephen Hall 4, Piotr Leszczynski 5, Daniel Feldman 6, Madura J. Rangaraj 7, Georgia Roane 8, Charles L. Ludivico 9, Eduardo F. Mysler 0, Chris Wells, Melanie Bennett and Ivana Vranic, Charité - Universitätsmedizin Berlin, Berlin, Germany, Klinikum der Universität zu Köln, Köln, Germany, Centre Hospitalier Universitaire de Toulouse, Toulouse, France, 4 Cabrini Medical Centre, Malvern, Australia, 5 J. Strus Poznan Municipal Hospital, Poznan University of Medical Sciences, Poznan, Poland, 6 Universidade Federal de São Paulo, Sao Paulo, Brazil, 7 Arthritis & Diabetes Clinic, Inc., Monroe, LA, 8 Rheumatology Associates of South Carolina, Charleston, SC, 9 East Penn Rheumatology Associates, PC, Bethleham, PA, 0 Organización Médica de Investigación, Buenos Aires, Argentina, Roche, Welwyn Garden City, United Kingdom, Roche Products Ltd., Welwyn Garden City, United Kingdom 0 Program Book 465. Higher Titer Of Anti-Citrullinated Protein Antibodies In Biologic-Naïve Rheumatoid Arthritis Patients Are Candidate Biomarkers To Predict Sensitivity Leading To Clinical Remission With Abatacept; Data From The Abroad Study. Takao Fujii, Masahiro Sekiguchi, Kiyoshi Matsui, Masayasu Kitano, Motomu Hashimoto, Koichiro Ohmura, Aihiro Yamamoto, Hideko Nakahara 4, Keiji Maeda 4, Akira Yokota 5, Kenji Miki 6, Naoki Shimmyo 7, Takanori Kuroiwa 8, Kosaku Murakami, Yoshio Ozaki 9, Kenshi Higami 0, Ichiro Yoshii, Yuji Nozaki, Takashi Ikawa, Satoshi Morita 4, Yutaka Kawahito, Norihiro Nishimoto 5, Tsuneyo Mimori and Hajime Sano, Graduate School of Medicine, Kyoto University, Kyoto, Japan, Hyogo College of Medicine, Nishinomiya-city, Japan, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan, 4 NTT West Osaka Hospital, Osaka, Japan, 5 Yokota Clinic for Rheumatology, Osaka, Japan, 6 Amagasaki Central Hospital, Amagasaki, Japan, 7 Kashiba Asahigaoka Hospital, Kashiba, Japan, 8 Yukioka Hospital, Osaka, Japan, 9 Kansai Medical University Hirakata Hospital, Hirakata, Japan, 0 Higami Hospital, Nara, Japan, Yoshii Hospital, Shimanto, Japan, Kinki University Faculty of Medicine, Sayama, Japan, Osaka Rehabilitation Hospital, Hannan, Japan, 4 Yokohama City University, Kanagawa, Japan, 5 Osaka Rheumatology Clinic, Osaka, Japan 466. Biologic Monotherapy in French Rheumatoid Arthritis (RA) Patients From a Real-Life Clinical Practice Compared To Patients Treated with a Combination Therapy (Biologic + DMARD). Philippe Dieude, Chantal Deslandre, Emilie Desfleurs, Jeanne Antheaume and Jean-Charles Balblanc 4, Rheumatology departement & INSERM U699, Paris Diderot university, APHP, Bichat hospital, Paris, France, Cochin Hospital, Paris, France, Roche SAS, Boulogne- Billancourt, France, 4 Centre Hospitalier Général de Belfort, Belfort, France 467. Adherence To Conventional Disease Modifying Anti- Rheumatic Drugs (cdmards) In Rheumatoid Arthritis (RA) Patients Treated In Association With a Biologic: A French Cross-Sectional Survey. Jean-Charles Balblanc, Philippe Dieude, Emilie Desfleurs, Jeanne Antheaume and Chantal Deslandre 4, Centre Hospitalier Général de Belfort, Belfort, France, Rheumatology departement & INSERM U699, Paris Diderot university, APHP, Bichat hospital, Paris, France, Roche SAS, Boulogne-Billancourt, France, 4 Cochin Hospital, Paris, France 468. The Differential Role Of T Helper Cells In The Pathogenesis and Responsiveness To Abatacept Therapy In Rheumatoid Arthritis. Shunsuke Fukuyo, Shingo Nakayamada, Kunihiro Yamaoka, Satoshi Kubo, Shigeru Iwata, Kazuyoshi Saito and Yoshiya Tanaka, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, University of Occupational and Environmental Health, Kitakyushu, Japan, Kitakyushu, Japan 469. Anti-TNF Therapy Induces Positive Changes In The Lipoprotein Profile Of RA Patientes. Results Of a Prospective Study. Jaime Calvo-Alén, Carmela Baamonde, Ignacio Villa, Víctor Martínez-Taboada, Mario Agudo and Juan Gómez-Gerique, Hospital Universitario Sierrallana, Torrelavega, Spain, Hospital Universitario Marqués de Valdecilla, Santander, Spain, Hospital Universitario Marqués de Valdecilla. IFIMAV, Santander, Spain

195 ACR POSTER SESSION A 470. Sarilumab, a Subcutaneously Administered, Fully Human Monoclonal Antibody Inhibitor Of The IL-6 Receptor Alpha: Relationship Between Inflammation Suppression and Changes In Cholesterol Levels. Christina Charles- Schoeman, Steven P. Weinstein, Janet van Adelsberg, Tanya Momtahen 4, Richard Wu 5, Neil Graham 5 and Stefano Fiore 4, UCLA David Geffen School of Medicine, Los Angeles, CA, Regeneron Pharmaceuticals Inc, Tarrytown, NY, Regeneron Pharmaceutials, Inc., Tarrytown, NY, 4 Sanofi, Bridgewater, NJ, 5 Regeneron Pharmaceuticals, Inc., Tarrytown, NY 47. Etanercept 5 Mg Once Weekly Program For Rheumatoid Arthritis, Psoriatic Arthropathy and Ankylosing Spondylitis Patients In Sustained Clinical and Radiological Remission. Joaquín Borrás-Blasco, Antonio Gracia-Pérez, Dolores- Elvira Casterá, J. Dolores Rosique-Robles, Javier Abad and Alejandro González Álvarez, Hospital de Sagunto, Sagunto, Spain, Hospital Obispo Polanco, Teruel, Spain 47. Clinical Efficacy Rate Of The Non-Specific Effect (the placebo effect) In The Tumour Necrosis Factor Inhibitors For Rheumatoid Arthritis Treatment After Methotrexate Failure: Meta-Analysis. Julie Azaïs, Thomas Barnetche, Pascale Vergne-Salle, Christine Bonnet, Carine Dufauret- Lombard, Richard Treves and Philippe Bertin, CHU Dupuytren Limoges, Limoges, France, CHU Bordeaux Pellegrin, Bordeaux, France, CHU Dupuytren Limoges, limoges, France 47. Real-World Effectiveness and Safety Of Infliximab In The Treatment Of Rheumatoid Arthritis Over 5 Years: The Canadian Experience. Denis Choquette, William Bensen, Andrew Chow, John T. Kelsall 4, Maqbool K. Sheriff 5, Jude F. Rodrigues 6, Emmanouil Rampakakis 7, John S. Sampalis 7, May Shawi 8, Francois Nantel 8, Susan M. Otawa 8 and Allen J. Lehman 8, Institut de Rhumatologie de Montréal, Montreal, QC, St. Joseph s Hospital and McMaster University, Hamilton, ON, Credit Valley Rheumatology, Mississauga, ON, 4 Mary Pack Arthritis Centre, Vancouver, Vancouver, BC, 5 Nanaimo Regional General Hospital, Nanaimo, BC, 6 Rheumatology, Windsor, ON, 7 JSS Medical Research, St- Laurent, QC, 8 Janssen Canada Inc, Toronto, ON 474. HM-05, a Novel Syk Inhibitor Significantly Ameliorates The Severity Of Arthritis In Rodents. Yu Cai, Zhong Cui Sun, Ping Ren, Lei Fang, Xiaoming Dai, Zhipeng Wu, Qianqian Dong, Xinrong Wang, Jian Wang, Yang Sai, Xiong Li and Weiguo Su, Hutchison Medipharma Limited, Shanghai, China 475. Alteration Of Aortic Distensibility Within 6 Months Of Treatment In RA Patients: An Observational Comparison Of Infliximab and Synthetic Dmards. Birgul Ay, Dilek Keskin, Goksal Keskin and Ayhan Dinc, DYB Research and Training Hospital, Ankara, Turkey, Patio Clinic, Ankara, Turkey 476. Two-Year Results From The Ample Trial: Low Disease Activity and Association Between Remission and Changes In Physical Function and Radiographic Outcomes With Subcutaneous Abatacept Or Adalimumab. R Fleischmann, M Schiff, M E Weinblatt, M Maldonado 4, E Massarotti 5 and Y Yazici 6, University of Texas Southwestern Medical Center, Dallas, TX, University of Colorado, Denver, CO, Brigham & Women s Hospital, Boston, MA, 4 Bristol-Myers Squibb, Princeton, NJ, 5 Brigham and Women s Hospital, Boston, MA, 6 New York University Hospital for Joint Diseases, New York, NY 477. Golimumab Improves Patient-Reported Outcomes In Patients With Active Rheumatoid Arthritis. B Dasgupta, P Bertin, L Settas, JE Fonseca 4, V Wolff 5, R Yao 6, M Govoni 7, N Vastesaeger 8 and HH Weng 6, Southend University Hospital, Westcliff-on-Sea, United Kingdom, Hôpital Dupuytren, Limoges, France, AHEPA University Hospital of Thessaloniki, Thessaloniki, Greece, 4 Lisbon Academic Medical Centre, Lisboa, Portugal, 5 Hospital del Salvador, Santiago, Chile, 6 Merck Sharp & Dohme, Kenilworth, NJ, 7 Merck Sharp & Dohme, Rome, Italy, 8 Merck Sharp & Dohme, Brussels, Belgium 478. Analysis Of The JAK Selectivity Of GLPG064 and Its Main Metabolite In Different Species, Healthy Volunteers and Rheumatoid Arthritis Patients. René Galien, Béatrice Vayssière, Steve de Vos, Marielle Auberval, Nick Vandeghinste, Sonia Dupont, Philippe Clément-Lacroix, Philippe Delerive, Frédéric Vanhoutte, Reginald Brys, Annegret Van der Aa, Luc Van Rompaey and Gerben van t Klooster, Galapagos SASU, Romainville, France, Galapagos NV, Mechelen, Belgium 479. Attainment Of Remission, Functional, and Quality Of Life Improvements With Golimumab Treatment In Rheumatoid Arthritis Are Associated With Patient Expectations. B Dasgupta, B Combe, I Louw, J Wollenhaupt 4, C Zerbini 5, A Beaulieu 6, H Schulze-Koops 7, P Durez 8, V Wolff 9, R Yao 0, HH Weng 0, M Govoni and N Vastesaeger, Southend University Hospital, Westcliff-on-Sea, United Kingdom, Hôpital Lapeyronie, Montpellier, France, Panorama Medical Centre, Cape Town, South Africa, 4 Schön-Klinik, Hamburg, Germany, 5 Hospital Heliópolis, Serviço de Reumatologia, São Paulo, Brazil, 6 Centre de Rhumatologie, St-Louis, QC, 7 University of Munich, Munich, Germany, 8 Université Catholique de Louvain and Cliniques Universitaires Saint-Luc, Brussels, Belgium, 9 Hospital del Salvador, Santiago, Chile, 0 Merck Sharp & Dohme, Kenilworth, NJ, Merck Sharp & Dohme, Rome, Italy, Merck Sharp & Dohme, Brussels, Belgium 480. Levels Of Circulating Mirnas Before and After Months Therapy With Dmards In Patients With Early Rheumatoid Arthritis. Mária Filková, Borbala Aradi, Ladislav Senolt, Klara Prajzlerova 4, Serena Vettori, Herman F. Mann 5, Jiri Vencovsky 4, K. Pavelka 6, Beat A. Michel 7, Renate E Gay, Steffen Gay and Astrid Jüngel, Institute of Rheumatology and Department of Rheumatology of the First Faculty of Medicine, Charles University in Prague, Czech Republic, Prague, Czech Republic, Center of Experimental Rheumatology, University Hospital Zurich and Zurich Center of Integrative Human Physiology (ZIHP), Zurich, Switzerland, Institute of Rheumatology, Department of Rheumatology, st Faculty of Medicine, Charles University, Prague, Czech Republic, 4 Institute of Rheumatology, Department of Clinical and Experimental Rheumatology, st Faculty of Medicine, Charles University, Prague, Czech 0 Program Book 9

196 ACR POSTER SESSION A Republic, 5 Institute of Rheumatology, Prague, Prague, Czech Republic, 6 Department of Clinical and Experimental Rheumatology, Charles University, Prague, Czech Republic, 7 Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland 48. Down-Titration of Biological Therapies In Rheumatoid Arthritis In Daily Clinical Practice. Miguel Arredondo, Iciar Cañamares, Esther Ramírez-Herráiz, Isidoro Gonzalez- Alvaro, Alberto Garcia-Vadillo, Alberto Morell, Rosario Garcia-Vicuña and Jose María Alvaro-Gracia, Hospital Universitario de La Princesa, Madrid, Spain 48. Methotrexate Use At Infliximab Initiation and Impact On Treatment Outcomes: An Analysis From A Canadian Registry. Denis Choquette, J. Carter Thorne, John T. Kelsall, Michel Zummer 4, Michael Starr 5, Maqbool K. Sheriff 6, William G. Bensen 7, Andrew Chow 8, Philip Baer 9, Emmanouil Rampakakis 0, John S. Sampalis 0, Francois Nantel, Allen J. Lehman, Susan M. Otawa and May Shawi, Institut de Rhumatologie de Montréal, Montreal, QC, Southlake Regional Health Centre, Newmarket, ON, Mary Pack Arthritis Centre, Vancouver, Vancouver, BC, 4 Ch Maisonneuve-Rosemont, Montreal, QC, 5 Montreal General Hospital, Montreal, QC, 6 Nanaimo Regional General Hospital, Nanaimo, BC, 7 St. Joseph s Hospital and McMaster University, Hamilton, ON, 8 Credit Valley Rheumatology, Mississauga, ON, 9 Rheumatology, Scarborough, ON, 0 JSS Medical Research, St-Laurent, QC, Janssen Canada Inc, Toronto, ON 48. Adalimumab and Methotrexate Pharmacokinetics Following Combination Therapy With Different Methotrexate Doses in Methotrexate and Biologic-Naïve Rheumatoid Arthritis Patients: Concerto Study. Sandra L Goss, Cheri E Klein, Hartmut Kupper, Gerd R Burmester and Walid Awni, AbbVie Inc., North Chicago, IL, AbbVie Deutschland GmBH & Co KG, Ludwigshafen, Germany, Charité-Universitätsmedizin Berlin, Free University and Humboldt University of Berlin, Berlin, Germany 484. Response To Biologic Disease-Modifying Anti-Rheumatic Drugs After Discontinuation Of Anti-Tumor Necrosis Factor Alpha Agents In Rheumatoid Arthritis Patients. Eric Elkin, Max I. Hamburger, Tripthi Kamath, Sarika Ogale, Adam Turpcu, Jae Oh 4, Kristin King 4, Monarch Shah and Martin J. Bergman 5, ICON Clinical Research, San Francisco, CA, Rheumatology Associates, Melville, NY, Genentech, South San Francisco, CA, 4 ICON Late Phase and Outcomes Research, San Francisco, CA, 5 Taylor Hospital, Ridley Park, PA 485. WITHDRAWN 486. Safety Of Biologic Therapy In Veterans With Rheumatoid Arthritis and Chronic Hepatitis B Infection. Jeffrey R. Curtis, Mary J. Burton, Shuo Yang, Lang Chen, Ted R. Mikuls 4, Kevin L. Winthrop 5 and John Baddley, University of Alabama at Birmingham, Division of Clinical Immunology and Rheumatology, Birmingham, AL, VA Hospital, Jackson, MS, University of Alabama at Birmingham, Birmingham, AL, 4 Omaha VA and University of Nebraska Medical Center, Omaha, NE, 5 Oregon Health & Science University, Portland, OR 487. The Cost Savings Associated With a Departmental Etanercept Dose Reduction Pathway For Patients With Rheumatic Diseases and Maintained Low Disease Activity. Richard CJ Campbell, Emma Sanders, Francesca Leone, Emma Gilgeours, Margaret Sibley and Patrick D. Kiely, St George s Hospital, London, United Kingdom 488. The Effect Of Methotrexate On Adalimumab Pharmacokinetics: Pooled Analysis Of Adalimumab Pharmacokinetics In Patients With Rheumatoid Arthritis After Subcutaneous Administration. Walid Awni, Sabine Pilari, Ghada Ahmed and Peter Noertersheuser, AbbVie Inc., North Chicago, IL, AbbVie Deutschland GmbH & Co KG, Ludwigshafen, Germany, AbbVie, North Chicago, IL 489. Combining Methotrexate To Etanercept Does Not Improve Its Retention Rate In Rheumatoid Arthritis Patients When Compared To Etanercept Monotherapy. A Report From The Rhumadata Clinical Data Base and Registry. Denis Choquette, Louis Bessette, Boulos Haraoui, Diane Sauvageau, Jean Pierre Pelletier, Jean-Pierre Raynauld, Edith Villeneuve and Louis Coupal, Institut de Rhumatologie de Montréal, Montreal, QC, Centre Hospitalier Universitaire de Québec, pavillon CHUL, Sainte- Foy, QC 490. Does Low Disease Activity At Six Months Predict Remission At Months In Rheumatoid Arthritis Patients Treated With Biologics In a Real World Setting? Philip Baer, William G. Bensen, Andrew Chow, Rafat Y. Faraawi 4, Denis Choquette 5, Isabelle Fortin 6, John T. Kelsall 7, Dalton E. Sholter 8, Emmanouil Rampakakis 9, John S. Sampalis 9, Francois Nantel 0, Allen J. Lehman 0, May Shawi 0 and Susan M. Otawa 0, Rheumatology, Scarborough, ON, St. Joseph s Hospital and McMaster University, Hamilton, ON, Credit Valley Rheumatology, Mississauga, ON, 4 Rheumatologist, KW Musculoskeletal Research Inc., Kitchener, ON, 5 Institut de Rhumatologie de Montréal, Montreal, QC, 6 Centre de Rhumatologie de l Est du Québec, Rimouski, QC, 7 Mary Pack Arthritis Centre, Vancouver, Vancouver, BC, 8 Rheumatology Associates, Edmonton, AB, 9 JSS Medical Research, St-Laurent, QC, 0 Janssen Canada Inc, Toronto, ON 49. Infection Risk Among Patients Receiving Concurrent Denosumab and Biologic Or Non-Biologic DMARD Therapy: An Analysis Of The Consortium Of Rheumatology Researchers Of North America (CORRONA) Registry. Vance J. Bray, Adam W. Bagley, Sterling G. West, Carol J. Etzel, Joel M. Kremer 4 and Jason R. Kolfenbach, Denver Arthritis Clinic, Denver, CO, University of Colorado School of Medicine, Aurora, CO, UT MD Anderson, Houston, TX, 4 Albany Medical College and The Center for Rheumatology, Albany, NY 49. Distinction Between Glucocorticoid-Responders and Non-Responders In Rheumatoid Arthritis: A New Role For Endoplasmic Reticulum Aminopeptidase. Ruth Fritsch-Stork, Sandra Cardoso, Jasper Broen, Marian Groot- Koerkamp, Arno Concepcion, Floris Lafeber and Johannes W.J. Bijlsma, University Medical Center Utrecht, Utrecht, Netherlands 94 0 Program Book

197 ACR POSTER SESSION A 49. A Real-World Risk Analysis Of Biological Treatment (Adalimumab and Etanercep) In Country With High Prevalence Of Tuberculosis and Hepatitis B/C. Ying-Ming Chiu, Chao-Hsiung Tang, Sheng-Tzu Hung, Ya-Wen Yang 4, Chi-Hui Fang 4 and Hsiao-Yi Lin 5, Changhua Christian Hospital, Changhua City, Taiwan, Taipei Medical University, Taipei, Taiwan, Formosa Biomedical Technology Corp., Taipei, Taiwan, 4 Pfizer Limited, Taipei, Taiwan, 5 Taipei Veterans General Hospital, Taipei, Taiwan 494. Autoantibody Profiles Predict Responsiveness To Methotrexate and Anti-TNF Therapy In Early Rheumatoid Arthritis. Petra Budde, Angelika Lueking, Carmen Theek, Peter Schulz-Knappe, Jacqueline Detert, Gerd R Burmester and Matthias Schneider 4, Protagen AG, Dortmund, Germany, Charité - Universitätsmedizin Berlin, Berlin, Germany, Charité-Universitätsmedizin Berlin, Free University and Humboldt University of Berlin, Berlin, Germany, 4 Heinrich-Heine-University, Duesseldorf, Germany 495. The Impact Of Inadequate Response To Prior Biologic Agents On Abatacept Drug Retention In Rheumatoid Arthritis Patients. A Pan-European Analysis Of RA Registries. Axel Finckh, Florenzo Iannone, Juan Gomez Reino, David Neto, Elisabeth Lie 4, Piet van Riel 5, Merete Lund Hetland 6, Karel Pavelka 7, Carl Turesson 8, Xavier Mariette 9 and Jacques-Eric Gottenberg 0, University of Geneva, Geneva, Switzerland, D.I.M.I.M.P, Rheumatology Unit - University of Bari, Bari, Italy, Hospital Clínico de Santiago, Santiago de Compostela, Spain, 4 Diakonhjemmet Hospital, Oslo, Norway, 5 Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, 6 The Danish Rheumatologic Database (DANBIO), Glostrup Hospital., Copenhagen, Denmark, 7 Department of Clinical and Experimental Rheumatology, Charles University, Prague, Czech Republic, 8 Lund University, Malmö, Sweden, 9 Bicêtre University Hospital, Le Kremlin Bicetre, France, 0 Strasbourg University Hospital, Strasbourg, France 496. Effectiveness Of Repeated Courses Of Rituximab In RA Results From The Cererra Collaboration. Katerina Chatzidionysiou, Elisabeth Lie, Evgeny Nasonov, Galina Lukina, Merete Hetland 4, Ulrik Tarp 5, Karel Pavelka 6, Cem Gabay 7, Dan Nordström 8, Helena Canhao 9, Matija Tomsic 0, Piet van Riel, Juan Gomez-Reino, Ioan Ancuta, Tore Kvien and Ronald van Vollenhoven, Unit for Clinical Research Therapy. Inflammatory Diseases (ClinTrid), Karolinska Institute, Stockholm, Sweden, Diakonhjemmet Hospital, Oslo, Norway, ARBITER, Institute of Rheumatology, Moscow, Russia, 4 DANBIO, Department of Rheumatology, Copenhagen University Hospital at Glostrup, Copenhagen, Denmark, 5 Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark, 6 Department of Clinical and Experimental Rheumatology, Charles University, Prague, Czech Republic, 7 SCQM registry, University Hospitals of Geneva, Geneva, Switzerland, 8 ROB-FIN, Helsinki University Central Hospital, Helsinki, Finland, 9 Instituto de Medicina Molecular, Rheumatology Research Unit, Rheumatology Research Unit, on behalf of the Rheumatic Diseases Portuguese Register, Lisbon, Portugal, 0 BioRx.si, University Medical Centre Ljubjana, Ljubljana, Slovenia, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, Hospital Clinico Universitario de Santiago, Santiago de Compostela, Spain, Cantacuzino Hospital, Bucharest, Romania 497. Development Of a Novel Bispecific Therapeutic For Arthritic Diseases. Mathieu Ferrari, Shimobi Onuoha, Tahereh Kamalati, Daniele Sblattero and Costantino Pitzalis 4, William Harvey Research Institute, Barts and the London School of Medicine and Dentistry Queen Mary University of London, London, United Kingdom, University College of London, London, United Kingdom, University of Eastern Piedmont, Novara, Italy, 4 William Harvey Research Institute, QMUL, London, United Kingdom 498. A Systematic Review and Meta-Analysis Comparing Low- Versus High-Dose Rituximab For Rheumatoid Arthritis. Markus Bredemeier, Fernando K. de Oliveira and Claúdia M. Rocha, Hospital Nossa Senhora da Conceição - Grupo Hospitalar Conceição, Porto Alegre, Brazil 499. Efficacy and Safety Of Infliximab Or Adalimumab Vs Abatacept In Patients With Rheumatoid Arthritis and An Inadequate Response To Methotrexate: Attest-Ample Network Randomized Trial. Robin Christensen, Simon Tarp, Daniel E. Furst, Lars E. Kristensen and Henning Bliddal, Musculoskeletal Statistics Unit, The Parker Institute, Department of Rheumatology, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Denmark, David Geffen School of Medicine, University of California, Los Angeles, CA, Department of Clinical Sciences, Lund, Section of Rheumatology, Lund University, Lund, Sweden 500. Fixed Versus On-Flare Retreatment With Rituximab In RA Results From The Cererra Collaboration. Katerina Chatzidionysiou, Elisabeth Lie, Evgeny Nasonov, Galina Lukina, Merete Hetland 4, Ulrik Tarp 5, Karel Pavelka 6, Cem Gabay 7, Dan Nordström 8, Helena Canhao 9, Matija Tomsic 0, Piet van Riel, Juan Gomez-Reino, Ioan Ancuta, Tore Kvien and Ronald van Vollenhoven, Unit for Clinical Research Therapy. Inflammatory Diseases (ClinTrid), Karolinska Institute, Stockholm, Sweden, Diakonhjemmet Hospital, Oslo, Norway, ARBITER, Institute of Rheumatology, Moscow, Russia, 4 DANBIO, Department of Rheumatology, Copenhagen University Hospital at Glostrup, Copenhagen, Denmark, 5 Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark, 6 Department of Clinical and Experimental Rheumatology, Charles University, Prague, Czech Republic, 7 SCQM registry, University Hospitals of Geneva, Geneva, Switzerland, 8 ROB-FIN, Helsinki University Central Hospital, Helsinki, Finland, 9 Instituto de Medicina Molecular, Rheumatology Research Unit, Rheumatology Research Unit, on behalf of the Rheumatic Diseases Portuguese Register, Lisbon, Portugal, 0 BioRx.si, University Medical Centre Ljubjana, Ljubljana, Slovenia, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, Hospital Clinico Universitario de Santiago, Santiago de Compostela, Spain, Cantacuzino Hospital, Bucharest, Romania 0 Program Book 95

198 ACR POSTER SESSION A 50. A Randomized Placebo-Controlled Phase Study To Evaluate Efficacy, Safety and Tolerability Of Two Secukinumab Loading Dose Regimens In Subjects With Active Rheumatoid Arthritis Despite Treatment With Methotrexate. Silvano Adami, André Beaulieu, Proton Rahman, Bruno Seriolo 4, Janet S. Lee 5, Gerhard Krammer 6, Brian Porter 6, Anuradha Thulasiraman 6 and Hanno B. Richards 6, Rheumatology Clinic, University of Verona, Verona, Italy, Faculty of Medicine, Laval University, Quebec, QC, Memorial University, St. Johns, NF, 4 Research Laboratory and Academic Unit of Clinical Rheumatology, Department of Internal Medicine, University of Genova, Genoa, Italy, 5 Novartis Pharma AG, East Hanover, NJ, 6 Novartis Pharma AG, Basel, Switzerland 50. Early Introduction Of Biologic Treatment Is An Important Predictor Of Sustained Favorable Outcome Including Clinical Remission In Early Arthritis But Not Of Sustained Favorable Outcome On Structure and Function Only: Results From The Espoir Cohort. Cécile Gaujoux-Viala, Laure Gossec, Maxime Dougados, Francis Guillemin 4 and Bruno Fautrel, EA 45, Montpellier I University, Nîmes University Hospital, Rheumatology Department, Nîmes, France, Paris 6 Pierre et Marie Curie University; AP-HP, Rheumatology, Pitié-Salpêtrière Hospital, - GRC-UPMC 08 EEMOIS, Paris, France, Paris-Descartes University, APHP, Cochin Hospital, Paris, France, 4 CHU Nancy, Clinical Epidemiology and Evaluation, Université de Lorraine, Paris Descartes University, APEMAC, EA 460, Nancy, France Sjögren s Syndrome: Clinical Aspects 50. Sjögren s Syndrome In American Ethnic and Racial Minorities. Ann Igoe, Christopher J. Lessard, Juan- Manuel Anaya, Astrid Rasmussen, Kiely Grundahl, Biji T. Kurien 4, Jacen S Maier-Moore 5, Lida Radfar 6, John A. Ice, Glen D. Houston 6, David M. Lewis 6, Donald U. Stone 6, Kimberly S. Hefner 7, Kathy L. Sivils and R. Hal Scofield 8, Oklahoma Medical Research Foundation, Oklahoma City, OK, School of Medicine and Health Sciences, Universidad del Rosario, Bogotá, Colombia, Oklahoma Medical Research Foundation, oklahoma CIty, OK, 4 U.S. Department of Veterans Affairs Medical Center, Oklahoma City, OK, 5 University of Oklahoma Health Sciences Center, Oklahoma Medical Research Foundation, Department of Veterans Affairs, Oklahoma City, OK 704, Oklahoma City, OK, 6 University of Oklahoma Health Sciences Center, Oklahoma City, OK, 7 Hefner Eye Care and Optical Center, Oklahoma City, OK, 8 US Department of Veterans Affairs Medical Center, Oklahoma City, OK 504. Raynaud s Phenomenon and African American Race Are Independently Associated With Non-Hodgkin s Lymphoma In Sjogrens Syndrome Patients: Findings From a United States National Study. Bella Mehta, Neville Jadeja, Marjan Mujib and Petros V. Efthimiou 4, Westchester Medical Center at New York Medical College, valhalla, NY, Jacobi Medical Center, New York, NY, New York Medical College, Valhalla, NY, 4 LM&MHC/Weill Cornell MC, New York, NY 505. Damage Accrual In a Single Centre Cohort Of Patients With Primary Sjögren s Syndrome Followed Up For Over 0 Years. Chiara Baldini, Francesco Ferro, Pasquale Pepe, Nicoletta Luciano, Francesca Sernissi, Carlotta Cacciatore, Daniela Martini, Antonio Tavoni, Marta Mosca 4 and Stefano Bombardieri, Rheumatology Unit, Pisa, Italy, Institute of Clinical Physiology, National Research Council, Pisa, Italy, Immunoallergology unit, Pisa, Italy, 4 Rheumatology Unit, University of Pisa, Pisa, Italy 506. Hospitalization In Patients With Primary Sjögren s Syndrome. Yemil Atisha-Fregoso, Yahaira Rivera and Gabriela Hernandez-Molina, Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubirán, Mexico City, Mexico 507. Level Of Agreement Of The AECG 00 and ACR 0 Classification Criteria For Sjögren s Syndrome In The Brittany Cohort: Clues To Understand Discrepancies. Divi Cornec, Alain Saraux, Jacques-Olivier Pers, Sandrine Jousse-Joulin, Yves Renaudineau, Beatrice Cochener, Thierry Marhadour 4 and Valerie Devauchelle-Pensec 5, Brest Occidentale University, Brest, France, CHU Brest et Université Bretagne Occidentale, Brest, France, Brest university medical school, EA 6, UBO and CHU de la Cavale Blanche,, Brest, France, 4 CHU de la Cavale Blanche, Brest, France, 5 Brest Occidentale university, Brest, France 508. Is Ultrasonography Of Salivary Gland a Validate Tool In Sjögren Syndrome? Study : Interobserver Reliability Between International Group Of Experts. Sandrine Jousse- Joulin, Vera Milic, Elke Theander, Malin V. Jonsson 4, Wan- Fai Ng 5, Chiara Baldini 6, Marina Carotti 7, Alan N. Baer 8, Joel Fradin 9, Pascale Rachele 0, Hendrika Bootsma, Jacqueline Brown, Nicoletta Luciano 6, S Bombardieri, Roland Jonsson 4, Salvatore De Vita 4, Alojzija Hocevar 5, Matija Tomsic 6, Alain Saraux 7, Emmanuel Nowak 8, Alessandro Ciapetti Sr. 9, Arjan Vissink, John Rout 0, Thomas Mandl, Simon J. Bowman and Valerie Devauchelle-Pensec, Brest university medical school, EA 6, UBO and CHU de la Cavale Blanche,, Brest, France, belgrade university, belgrade, Serbia, Lund University, Malmö, Sweden, 4 University of Bergen, Bergen, Norway, 5 Departement of rheumatology, New-Castle University Hospital, UK, Newcastle, England, 6 Rheumatology Unit, Pisa, Italy, 7 Ospedali Riuniti, Ancona, Italy, 8 Johns Hopkins University, Baltimore, MD, 9 John Hopkins Universirty, Baltimore, MD, 0 university of Pisa, Pisa, Italy, University Medical Center Groningen, Groningen, Netherlands, Tower Wing Guy s hospital, london, United Kingdom, Department of Rheumatology, University of Pisa, Pisa, Pisa, Italy, 4 Rheumatology Clinic, DSMB, University of Udine, Udine, Italy, 5 University Medical Centre Ljubljana, Ljubljana, Slovenia, 6 BioRx.si, University Medical Centre Ljubjana, Ljubljana, Slovenia, 7 CHU Brest et Université Bretagne Occidentale, Brest, France, 8 CHU Brest, Brest, France, 9 Department of Rheumatology, Politechnic University of the Marche, Ancona, Ancona, Italy, 0 Birmingham Dental Hospital, Birmingham, United Kingdom, Skåne University Hospital Malmo, Lund University, Sweden, Malmö, Sweden, Queen Elizabeth Hospital Birmingham, Birmingham, United Kingdom, Brest Occidentale university, Brest, France 96 0 Program Book

199 ACR POSTER SESSION A 509. A Novel Screening Tool Indicative Of Primary Sjogren s Syndrome Versus Sicca Symptoms. Gerard Dumancas, Michael Brown, Indra Adrianto, Christopher J. Lessard, Jennifer A. Kelly, Kiely Grundahl, Astrid Rasmussen, R. Hal Scofield, Courtney Montgomery and Kathy L. Sivils, Oklahoma Medical Research Foundation, Oklahoma City, OK, Oklahoma Medical Research Foundation, oklahoma CIty, OK, US Department of Veterans Affairs Medical Center, Oklahoma City, OK 50. Multicentric Analysis Of Inter and Intra Observer Reliabilities For Histopathological Abnormalities In Salivary Gland Biopsy In Primary Sjögren Syndrome. Sebastian Costa, Isabelle Quintin Roue, Agnes Lesourd, Sandrine Jousse-Joulin, Pascale Marcorelles 4, Eric Hachulla 5, Vincent Goeb 6, Marie-Christine Copin 7, Jean-Marie Berthelot 8, Jacques-Olivier Pers 9, Olivier Vittecoq 0, Emmanuel Nowak, Alain Saraux and Valerie Devauchelle-Pensec, Brest university hospital, Brest, France, Morvan hospital, Brest, France, Brest university medical school, EA 6, UBO and CHU de la Cavale Blanche,, Brest, France, 4 Brest university hospital, CHU Morvan, Brest, France, 5 Internal Medicine, Lille CEDEX, France, 6 Amiens University Hospital, Amiens, France, 7 Lille university, Lille, France, 8 Nantes University Hospital, Nantes, France, 9 Brest Occidentale University, Brest, France, 0 Rouen University Hospital & Inserm905, University of Rouen, Rouen Cedex, France, CHU Brest, Brest, France, Université Brest Occidentale, Brest, France, Brest Occidentale university, Brest, France 5. Salivary Gland Lymphocyte Pattern Associated With Response To Belimumab In Primary sjogren ssyndrome: Results Of The Beliss Study. Raphaèle Seror, Thierry Lazure, Frederic Desmoulins, Stephan Pavy 4, Corinne Miceli-Richard 5, Gabriel Baron 6, Philippe Ravaud 7 and Xavier Mariette 8, Université Paris Sud, Le Kremlin Bicêtre, France, INSERM U0 - Université Paris XI, Le Kremlin Bicêtre, France, Université Paris-Sud, Le Kremlin Bicêtre, Le Kremlin Bicetre, France, 4 Hopital Bicetre, Paris, France, 5 Université Paris-Sud, Bicêtre Hospital,, Kremlin Bicêtre, France, 6 Epidemiology, Paris, France, 7 Hopital Hotel Dieu, Paris Descartes University, Paris, France, 8 Bicêtre University Hospital, Le Kremlin Bicetre, France 5. The Significance Of Ectopic Germinal Center In Minor Salivary Gland Of Patients With Sjögren s Syndrome. Kyung-Eun Lee, Dong-Jin Park, Jeong-Won Lee, Ji-Hyoun Kang, Lihui Wen, Tae-Jong Kim, Yong-Wook Park and Shin-Seok Lee, Chonnam National University Medical School, Gwangju, South Korea, Chonnam National University Medical School and Hospital, Gwangju, South Korea 5. Diagnostic Value Of Labial Minor Salivary Gland Biopsy For Primary Sjögren s Syndrome. Raquel Altoe, Valeria Valim, Maria Carmem S. Santos, Erica V. Serrano and Samira T. Miyamoto, Universidade Federal do Espírito Santo, Vitória, Brazil, Universidade de Vila Velha, Vitória, Brazil, Universidade Federal do Espírito Santo, Vitoria, Brazil 54. EULAR Sjögren s Syndrome Patient Reported Index (ESSPRI) Is Increased In Sjögren s Syndrome Patient With Fibromyalgia. Valeria Valim, Samira T. Miyamoto, Mauricio Paganotti, Erica V. Serrano and Raquel Altoe, Universidade Federal do Espírito Santo, Vitória, Brazil, Universidade Federal do Espírito Santo, Vitoria, Brazil, Universidade de Vila Velha, Vitória, Brazil 55. Does Multiplex Flow Immunoassay Underdetect SSA and SSB Antibodies? An Evaluation Of The Sjogren s International Collaborative Clinical Alliance (SICCA) Cohort. Alan N. Baer, Laura Gutierrez, Mara McAdams DeMarco, Mi Y. Lam, Livia Casciola-Rosen, Stephen Shiboski 4, Caroline Shiboski and Lindsey A. Criswell 5, Johns Hopkins University, Baltimore, MD, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, University of California San Francisco, San Francisco, CA, 4 University of California, San Francisco, San Francisco, CA, 5 University of California, San Francisco, Rosalind Russell Medical Research Center for Arthritis, San Francisco, CA 56. Prevalence Of Seronegative Sjogren s Syndrome: A Comparative Study From The Sjogren s International Collaborative Clinical Alliance (SICCA) Cohort. Alan N. Baer, Laura Gutierrez, Mara McAdams DeMarco, Mi Y. Lam, Livia Casciola-Rosen, Stephen Shiboski 4, Caroline Shiboski and Lindsey A. Criswell 5, Johns Hopkins University, Baltimore, MD, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, University of California San Francisco, San Francisco, CA, 4 University of California, San Francisco, San Francisco, CA, 5 University of California, San Francisco, Rosalind Russell Medical Research Center for Arthritis, San Francisco, CA 57. Antibody Responses To Oral Bacteria In Patients With Primary Sjögren s Syndrome and Comparison With Rheumatoid Arthritis and Periodontitis. Bozo Lugonja, Michael Milward, Diana Pearson, Thomas Dietrich, Iain Chapple, John Hamburger, Francesca Barone, Saaeha Rauz, Lorraine Yeo, Ana Povedo-Gallego, Geraint Williams, Paola de Pablo, Andrea Richards, Christopher D. Buckley, Dagmar Scheel-Toellner and Simon J. Bowman, University of Birmingham, Birmingham, United Kingdom, Birmingham Dental Hospital, Birmingham, United Kingdom, Queen Elizabeth Hospital Birmingham, Birmingham, United Kingdom 58. Vitamin D In Sjogren s Syndrome. Suneet Grewal, Judith A. James, R. Hal Scofield, Kathy L. Sivils, Michael H. Weisman and Swamy Venuturupalli, Cedars-Sinai Medical Center, Los Angeles, CA, Oklahoma Medical Research Foundation, Oklahoma City, OK 59. Identification Of IgG4-Related Disease and Analysis Of IgG4 Serum Levels In Different Subgroups Of Patients With Sjögren s Syndrome. Antónia Szántó, Gábor Nagy, Csaba Molnár and Margit Zeher, University of Debrecen, Medical and Health Science Center, Institute for Medicine, Debrecen, Hungary, University of Debrecen, Medical and Health Science Center, Institute for Pathology, Debrecen, Hungary 0 Program Book 97

200 ACR POSTER SESSION A 50. Chronic Obstructive Pulmonary Disease Is Very Common in Primary Sjögren s Syndrome. Anna M. Nilsson, Elke Theander, Roger Hesselstrand, Eeva Piitulainen 4, Sandra Diaz 5, Olle Ekberg 5, Per Wollmer 6 and Thomas Mandl 7, Skane University Hospital Malmo, Lund University, Malmo, Sweden, Lund University, Malmö, Sweden, Skane University Hospital Lund, Lund University, Lund, Sweden, 4 Lund University & Skåne University Hospital, Malmö, Sweden, 5 Skåne University Hospital Malmo, Lund University, Malmö, Sweden, 6 Skane University Hospital Malmo, Lund University, Malmö, Sweden, 7 Skåne University Hospital Malmo, Lund University, Sweden, Malmö, Sweden 5. Respiratory Compromise In Patients With Primary Sjögren Syndrome. Evangelina Maria Miretti, Maria Haye Salinas, Francisco Caeiro, Anastasia Secco, Antonio Catalan Pellet, Paula Pucci 4, Cecilia Asnal 5, Catherine Crow 6, Cristina Amitrano 7, Alejandro Nitsche 7, Silvia Papassidero 8, Oscar L. Rillo 9, Federico Zazzetti 0, Juan C. Barreira, Mariano Rivero, Damián Duartes Noé, Hugo A. Laborde, Natalia Tamborenea, Eduardo Albiero, Maria Renata Seisdedos 4, Carla Gobbi 5, Paula Alba 6, Pablo Astesana 7, Gabriela Salvatierra 8 and Veronica Saurit, Hospital Privado Centro Médico de Córdoba, Córdoba, Argentina, Rivadavia Hospital, Buenos aires, Argentina, Hospital Rivadavia, Buenos Aires, Argentina, 4 Aleman Hospital, Argentina, buenos Aires, Argentina, 5 Argerich, Buenos Aires, Argentina, 6 Hospital Alemán, Buenos aires, Argentina, 7 Hospital Alemán, Buenos Aires, Argentina, 8 Hospital Tornú, Buenos Aires, Argentina, 9 Hospital Gral. de Agudos Dr. E. Tornú, Buenos Aires, Argentina, 0 Hospital Británico, Buenos Aires, Argentina, Buenos Aires British Hospital, Buenos Aires, Argentina, OMI, Buenos Aires, Argentina, Sanatorio Allende de Córdoba, Córdoba, Argentina, 4 Rivadavia Hospital, Buenos Aires, Argentina, 5 Sanatorio Allende de Córdoba, Cordoba, Argentina, 6 Hospital Córdoba, Córdoba, Argentina, 7 Sanatorio Allende, cordoba, Argentina, 8 Centro de enfermedades Reumaticas, Santiago Del Estero, Argentina 5. Abatacept Reduces Disease Activity In Early Primary Sjögren s Syndrome:One Year Results From a Phase II Open-Label Study. PM Meiners, A Vissink, Fkl Spijkervet, EA Haacke, WH Abdulahad, E Brouwer, MG Huitema, N Sillevis Smitt-Kamminga, FGM Kroese, S Arends and H Bootsma, University Medical Center Groningen, Groningen, Netherlands Spondyloarthropathies and Psoriatic Arthritis: Pathogenesis, Etiology, Animal Models I 5. Association Between The Presence Of Amyloidosis In Patients With Ankylosing Spondylitis and Polymorphisms In Type /Type Serum Amyloid A Protein Genes, Mediterranean Fever Genes. Gozde Yildirim Cetin, Eda Ganiyusufoglu, Dilek Solmaz, Yonca Cagatay 4, Sibel Yilmaz Oner 5, Burak Erer 6, Hasan Sabit Sagliker 7, Ali Berkant Avci 8, Servet Akar, Omer Nuri Pamuk 9, Metin Kilinc, Timucin Kasifoglu 0, Haner Direskeneli 5 and Mehmet Sayarlioglu, Sutcu Imam University, School of Medicine, Department of Internal Medicine, Division of Rheumatology, Kahramanmaras, Turkey, Sutcu Imam University, School of Medicine, Department of Biochemistry Research Laboratory, Kahramanmaras, Turkey, Dokuz Eylul University School of Medicine, Izmir, Turkey, 4 Bilim University, Faculty of Medicine, Rheumatology Department, Istanbul, Turkey, 5 Marmara University, School of Medicine, Istanbul, Turkey, 6 Istanbul University, Istanbul Faculty of Medicine,, Istanbul, Turkey, 7 Sutcu Imam University, School of Medicine, Department of Internal Medicine, Kahramanmaras, Turkey, 8 Antalya University, School of Medicine, Department of Internal Medicine, Division of Rheumatology, Antalya, Turkey, 9 Trakya University Medical Faculty, Edirne, Turkey, 0 Eskisehir Osmangazi University School of Medicine, Eskisehir, Turkey, Ondokuz Mayis University School of Medicine, Samsun, Turkey 54. Expansion Of DC-STAMP + IL-7 + Cells In Bone Marrow From Psoriasis and Psoriatic Arthritis Patients. Yahui Grace Chiu, Edward M. Schwarz, Jamie Biear, Debbie Campbell, Jennifer Hossler, Jennifer H. Anolik, R. John Looney and Christopher T. Ritchlin, University of Rochester, Rochester, NY, Univerity of Rochester, Rochester, NY, University of Rochester Medical Center, Rochester, NY 55. Evidence For Enhanced Induction Of Unfolded Protein Response Target Genes In Peripheral Blood Mononuclear Cells From Spondyloarthritis Patients. Grace Kwon, Eva Yang, Keith A. Sikora, Hemalatha Srinivasalu, Gerlinde Layh- Schmitt and Robert A. Colbert, NIAMS NIH, Bethesda, MD 56. Endochondral Bone Formation and Advanced Enthesitis Are Key Features Of Proteoglycan Induced Spondylitis Mouse Model Of Ankylosing Spondylitis. Gethin P Thomas, Hsu-Wen Tseng, Allison Pettit, Tibor T. Glant, Allan McRae and Matthew A. Brown 4, University of Queensland Diamantina Institute, Woolloongabba, Australia, University of Queensland Centre for Clinical Research, Herston, Australia, Rush University Medical Center, Chicago, IL, 4 University of Queensland Diamantina Institute, Brisbane, Australia 57. Presence Of Gastrointestinal Symptoms and Autoantibodies In Patients With Spondyloarthritis In A Colombian Population. Consuelo Romero-Sanchez, Wilson Bautista-Molano, Diana M Munoz C, Viviana Parra I, Alejandro Escobar, Carlos Martínez, Ferney Garcia, Daniel Herrera 4, Sebastían Segura, Juliette De Ávila, Ana MAría Mesa, Haroldo Juliao 5, John Londono and Rafael Valle- Oñate, UIBO Institute (Oral Basic Research Unit),School of Dentistry, Universidad El Bosque, Bogotá, Colombia, Spondyloarthropathy Group, Rheumatology Department, Hospital Militar Central/Universidad de La Sabana, Bogotá, Colombia, Coloproctology Deparment, Hospital Militar Central, Bogotá, Colombia, 4 Instituto de Genética Humana, Facultad de Medicina, Pontificia Universidad Javeriana, Bogotá, Colombia, 5 Gastroenterology Deparment, Hospital Militar Central, Bogotá, Colombia 58. Upregulated Th7 and Innate Pathways Are More Characteristic Of The Skin Than The Synovium In Psoriatic Arthritis. Jennifer Belasco, Hiroshi Mitsui, Mayte Suarez- Farinas, James S. Louie, N. Wei, Nicholas Gulati and James G. Krueger, The Rockefeller University, New York, NY, UCLA School of Medicine, Los Angeles, CA, Arthritis Treatment Center, Frederick, MD 98 0 Program Book

201 ACR POSTER SESSION A 59. Ankylosing Spondylitis and Dysfunctional Dkk. Rajbir Gulati, Maripat Corr, Michael H. Weisman and David Hallegua 4, Cedars Sinai Medical Center, Los Angeles, CA, Univ of California-San Diego, La Jolla, CA, Cedars-Sinai Medical Center, Los Angeles, CA, 4 Cedars-Sinai/UCLA, Beverly Hills, CA 50. Pattern Recognition Receptor Stimulated Cytokine Expression By Spondyloarthritis Patient Macrophages. Yi-Ping Liu, Ashley Bomkamp, Jens Eickhoff, Jack Schneck, Mike Khan and Judith Smith, University of Wisconsin- Madison, Madison, WI 5. Influenza Infection Of MHC-I Transgenic Mice Reveals That Erap Is Necessary and Sufficient For Generation Of The B7-Specific Immunodominant Epitope. Ali Akram and Robert Inman, University of Toronto and University Health Network (UHN), Toronto, ON, University of Toronto and Toronto Western Hospital, Toronto, ON 5. Role Of Baseline C-Reactive Protein In Response To Infliximab Plus Naproxen Vs Naproxen Alone In Patients With Axial Spondyloarthritis. J Sieper, M Rudwaleit, J Lenaerts, J Wollenhaupt, L Myasoutova 4, S Park 5, Y Song 6, R Yao 7, M Govoni 8, D Chitkara 7 and N Vastesaeger 9, University Clinic Benjamin Franklin, Berlin, Germany, Practice Rheumatology, Hasselt, Belgium, Schön-Klinik, Hamburg, Germany, 4 Kazan State Medical University, Kazan, Russia, 5 Catholic University of Korea, Seoul, South Korea, 6 Seoul National University, Seoul, South Korea, 7 Merck Sharp & Dohme, Kenilworth, NJ, 8 Merck Sharp & Dohme, Rome, Italy, 9 Merck Sharp & Dohme, Brussels, Belgium 5. WITHDRAWN 54. Peripheral Blood Gene Expression Profiling Of Psoriatic Arthritis Patient. Bidisha Dasgupta, Yauheniya Cherkas, Sarah Lamberth and Carrie Brodmerkel, Janssen Research & Development, LLC., Spring House, PA 55. Death Receptor Increases Region-Specific, Osteoblast- Dependent Aberrant New Bone Formation In The Axial Skeleton Of Mice In a Spontaneous Model Of Ankylosing Enthesopathy. Fraser L. Collins, Jessica O Williams, Anja C. Bloom, Michael D. Stone, Ernest Choy, Edward C. Wang and Anwen S. Williams, Cardiff University, Institute of Infection and Immunity, Cardiff, United Kingdom, University Hospital Llandough, Cardiff & Vale University Health Board, Cardiff, United Kingdom 56. Membrane-Bound TNF Drives Axial and Peripheral Inflammation and Pathologic New Bone Formation. Leonie M. van Duivenvoorde, Melissa N. van Tok and Dominique L. Baeten, Academic Medical Center / University of Amsterdam, Amsterdam, Netherlands, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands 57. Investigating a Novel Locus For Psoriatic Arthritis. Ashley Budu-Aggrey, John Bowes, Pauline Ho, James Bluett, Harry Hébert, Helena Marzo-Ortega 4, Ann W. Morgan 4, Matthew A. Brown 5, Ross McManus 6, Neil McHugh 7, Oliver M. FitzGerald 8, Ian N. Bruce and Anne Barton, NIHR Manchester Musculoskeletal Biomedical Research Unit, Manchester Academy of Health Sciences, Manchester, United Kingdom, Arthritis Research UK Epidemiology Unit, Centre for Musculoskeletal Research, Institute of Inflammation and repair, Manchester Academic Health Science Centre, The University of Manchester, Manchester, United Kingdom, The Dermatology Centre, Salford Royal NHS Foundation Trust, University of Manchester, Manchester Academic Health Science Centre, Manchester, United Kingdom, 4 NIHR-Leeds Musculoskeletal Biomedical Research Unit and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, 5 The University of Queensland Diamantina Insititute, Brisbane, Australia, 6 Department of Clinical Medicine, Institute of Molecular Medicine, Trinity College Dublin, Ireland, Dublin, Ireland, 7 Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, 8 St.Vincent s University Hospital, Dublin, Ireland 58. Ankylosing Spondylitis Associated Endoplasmic Reticulum Aminopeptidase Variants Alter The Unfolded Protein Response. Nigil Haroon and Zhenbo Zhang, Toronto Western Research Institute, Toronto, ON 59. Effects Of ERAP Knockdown On HLA Class I and HLA-B7 Expression In Human Monocytic U97 Cells. Tri M. Tran, Sohee Hong and Robert A. Colbert, NIAMS/NIH, Bethesda, MD, NIAMS NIH, Bethesda, MD Systemic Lupus Erythematosus - Animal Models 540. Exploration Of a Novel Therapeutic Target In a Murine Model Of Systemic Lupus Erythematosus: Targeting Sphingosine--Phosphate (SP) Receptors. Christopher Tracy, Jess Edison, S. Frattalone and C. Moratz, Walter Reed National Military Medical Center, Bethesda, MD, Uniformed Services University of Health Sciences, Bethesda, MD 54. An Essential Role For Caspase- In The Induction Of Murine Lupus and Its Associated Vascular Damage. J. Michelle Kahlenberg, Srilakshmi Yalavarthi, Wenpu Zhao, Jeffrey Hodgin, Tamra J. Reed, Noriko M. Tsuji and Mariana J. Kaplan, University of Michigan, Ann Arbor, MI, University of Michigan Rheumatology, Ann Arbor, MI, Biomedical Research Institute, National Institute of Advanced Industrial Science and Technology, Tsukuba, Japan 54. Evidence For Involvement Of C5a Receptor in Human and Murine Lupus Nephritis. Constanze Hess, Ditte Tornehave, Peter Helding Kvist, Yvonne Sundström, Louise Berg, Iva Gunnarsson 4, Søren Jacobsen 5, Claus Haase and Lars Hornum, Department of Immunopharmacology, Novo Nordisk A/S, Måløv, Denmark, Department of Histology, Novo Nordisk A/S, Måløv, Denmark, Rheumatology Unit, Karolinska Institutet, Stockholm, Sweden, 4 Karolinska Institutet, Stockholm, Sweden, 5 Department of Rheumatology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark 0 Program Book 99

202 ACR POSTER SESSION A 54. Inhibiting TWEAK (TNF-like weak inducer of apoptosis) Signaling Improves Blood Brain Barrier Integrity and Protects From Neuronal Damage In Murine Neuropsychiatric Lupus. Jing Wen, Jessica Doerner, Ariel Stock, Jennifer Michaelson, Linda Burkly, Maria Gulinello and Chaim Putterman, Albert Einstein College of Medicine, Bronx, NY, Biogen Idec, Cambridge, MA 544. Ultraviolet-B Induced Plasmacytoid Dendritic Cell Migration and Type Interferon Signaling In The Skin. Clayton Sontheimer, Thomas H. Teal, Nalini Agrawal, Denny Liggitt and Keith B. Elkon, University of Washington, Seattle, WA 545. Preferential Infiltration Of Double-Negative (DN) T Cells Into The Glomeruli Of NZM 8 Lupus Mice. Ning Yu, Shunhua Guo, William Stohl and Chaim O. Jacob, University of Southern California Keck School of Medicine, Los Angeles, CA 546. The Survival Of Gr + CDb + cells Is Differentially Regulated In Male and Female Lupus-Prone Mice. Elena Gonzalez, Trine Jorgensen and Abhishek Trigunaite, Lerner Research Institute, Cleveland Clinic Foundation, Cleveland, OH 547. Anti Ribosomal P Antibodies Accelerate Lupus Glomerulonephritis and Induce Lupus Nephritis In Naive Mice. Dana Ben-Ami Shor, Miri Blank, Sandra Reuter, Torsten Matthias 4, Alexander Volkov 5, Iris Barshack 6 and Yehuda Shoenfeld 7, Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center affiliated to Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Tel-Aviv, Israel, Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center, affiliated to Sackler Faculty of Medicine,Tel Aviv University, Tel-Aviv, Tel-Aviv, Israel, AIRA e.v., AESKU.KIPP Institute, Wendelsheim, Germany, 4 AESKU. Diagnostics GmbH & Co. KG, Wendelsheim, Germany, 5 Institute of Pathology, Sheba Medical Center, affiliated to Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Tel-Aviv, Israel, 6 Institute of Pathology, Sheba Medical Center, affiliated to Sackler Faculty of Medicine, Tel-Aviv University,Tel-Aviv, Tel-Aviv, Israel, 7 Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center, Affiliated to Sackler Faculty of Medicine, Tel-Aviv University,Tel-Aviv, Tel-Aviv, Israel 548. Characterizing The Role Of The Granulocyte Colony Stimulating Factor Pathway In a Mouse Model Of Systemic Lupus Erythematosus. Laurence Morel and Ramya Sivakumar, University of Florida, Gainesville, FL 549. Augmented Megakaryopoiesis Supports Accumulation Of Plasma Cells In Lupus-Prone Mice. Oliver Winter, Niels-Peter Becker, Stephanie Musiol, Katrin Moser, Falk Hiepe and Rudolf A. Manz 4, Charité - University Medicine Berlin, Berlin, Germany, German Arthritis Research Center (DRFZ Berlin), Berlin, Germany, Charité University Hospital Berlin, Berlin, Germany, 4 University of Lübeck, Lübeck, Germany 550. Neutrophil Gelatinase Associated Lipocalin (NGAL/ Lipocalin-) Regulates the Onset Of Serum Autoantibodies In Pristane Induced Lupus. Rahul Pawar, Beatrice Goilav, Yumin Xia, Haoyang Zuang, Leal Herlitz 4, Westley H. Reeves and Chaim Putterman, Albert Einstein College of Medicine, Bronx, NY, Children s Hospital at Montefiore, Bronx, NY, University of Florida, Gainesville, FL, 4 Columbia University Medical Center, New York, NY 55. Different Cell Death Programs Contribute To Severity Of Lupus Glomerulonephritis In Males and Females. Neelakshi Jog and Roberto Caricchio, Temple University, Philadelphia, PA, Temple Univ Med Office Bldg, Philadelphia, PA 55. Inhibitor Of Differentiation, A Transcription Factor Regulates Susceptibility To Kidney Disease. Dominika Nackiewicz, Ani Manichaikul, Barbara Szczerba, Paromita Dey, Stephen Rich, Coleen McNamara, Umesh Deshmukh and Harini Bagavant, University of Virginia, Charlottesville, VA 55. Estrogen Receptor Alpha Deficiency Protects Against Development Of Cognitive Impairment In Murine Lupus. Melissa A. Cunningham, Jena Wirth, Heather A. Boger, Ann-Charlotte Granholm-Bentley and Gary S. Gilkeson, MUSC, Charleston, SC, Medical University of SC, Charleston, SC, Medical University of South Carolina, Charleston, SC 554. Identification Of Stage Specific Genes Associated With Lupus Nephritis and Response To Remission induction In NZB/W Mice. Ramalingam Bethunaickan, Celine C. Berthier, Hong-dong Li, Weijia Zhang, Yuanfang Guan, Matthias Kretzler and Anne Davidson, Feinstein Institute for Medical Research, Manhasset, NY, University of Michigan, Ann Arbor, MI, Mount Sinai School of Medicine, New York, NY 555. Therapeutic Inhibition Of Anti-Apoptotic BCL- Family Proteins In a Murine Model Of Lupus Nephritis. Li Chun Wang, Stuart Perper, Danise Perron, Edit Tarcsa, Philip Bardwell, Neelufar Mozaffarian, Andrew Souers, Steven Elmore, Tariq Ghayur and Lisa Olson, AbbVie Bioresearch Center, Inc, Worcester, MA, AbbVie Bioresearch Center, Worcester, MA, AbbVie, North Chicago, IL 556. Depletion Of The Gut Microbiota Prevents β -Glycoprotein I Antibody Production and Mortality In a Model Of Antiphospholipid Syndrome. Silvio M. Vieira, Andrew Yu, Odelya E. Pagovich, Eleni Tiniakou, John Sterpka and Martin A. Kriegel, Yale University School of Medicine, New Haven, CT 557. Inhibition of Calcium/Calmodulin-Dependent Protein Kinase 4 Ameliorates Th7 Related Autoimmune Disorder. Tomohiro Koga, Christian Hedrich, Masayuki Mizui, Nobuya Yoshida, Linda Lieberman, José C. Crispin and George C. Tsokos, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 00 0 Program Book

203 ACR POSTER SESSION A 558. Fli- Regulates Immune Cell Infiltration Through Affecting Local Chemokine Expression and IL-6 Expression In The Kidney Of Lupus Prone Mice. Shuzo Sato, Sarah Williams, Eva Karam and Xian Zhang, Medical University of South Carolina, Charleston, SC, Ralph H. Johnson VA Medical Center, Charleston, SC, Medical University of South Carolina and Ralph H. Johnson VA Medical Center, Charleston, SC 559. Effects Of In Vivo Treatment With Hydroxychloroquine On Endothelial Function In a Murine Model Of Systemic Lupus Erythematosus. Marta Mosca, Chiara Tani, Sabrina Vagnani, Linda Carli, Rosaria Talarico, Chiara Baldini, Stefano Bombardieri and Agostino Virdis 4, Rheumatology Unit, University of Pisa, Pisa, Italy, GenOMeC PhD, University of Siena, Siena, Italy, Rheumatology Unit, Pisa, Italy, 4 Hypertension Unit, University of Pisa, Pisa, Italy 560. Purified IgG From Patients With Systemic Lupus Erythematosus Enhances Apoptosis In Neonatal Rat Cardiomyocytes Exposed To Simulated Myocardial Ischaemic/Reperfusion Injury. Lauren Bourke, James McCormick, Vera Ripoll, Charis Pericleous, Anna Radziszewska, Anastasis Stephanou and Yiannis Ioannou, University College London, London, United Kingdom, Arthritis Research UK Centre for Adolescent Rheumatology at University College London, Great Ormond Street Hospital and UCLH, University College London, London, United Kingdom 56. Acyl-CoA Synthetase Expression Is Increased In Murine Models Of Lupus As Well As In Human Systemic Lupus Erythematosus. Eyal Kedar, Shelley Barnhart, Keith B. Elkon and Karin Bornfeldt, University of Washington, Seattle, WA, Division of Rheumatology, Department of Medicine, University of Washington, Seattle, WA 56. The Knock-Out Of TWEAK Receptor/Fn4 Ameliorates Lupus Nephritis In MRL/Lpr Mice. Yumin Xia, Leal Herlitz, Simona Gindea, Jing Wen, Rahul Pawar, Alexander Misharin, Harris R. Perlman, Ping Wu 4, Jennifer Michaelson 4, Linda Burkly 4 and Chaim Putterman, Albert Einstein College of Medicine, Bronx, NY, Columbia University Medical Center, New York, NY, Northwestern University, Chicago, IL, 4 Biogen Idec, Cambridge, MA 56. Hold The Rituximab: Neuropsychiatric Disease In Murine Lupus Is Not B-Cell Dependent. Jing Wen, Ariel Stock, Haowei Wang, Mark Shlomchik, Maria Gulinello and Chaim Putterman, Albert Einstein College of Medicine, Bronx, NY, Yale University School of Medicine, New Haven, CT 564. Role of TLR and dsrna Hyper-Responsiveness in the Generation of the Lupus-Like Phenotype of New Zealand Black Congenic Mice. Gillian Minty, Nan-Hua Chang, Kieran Manion, Yuriy Baglaenko, Evelyn Pau and Joan E. Wither, Toronto Western Hospital, University of Toronto, Toronto, ON, Toronto Western Hospital, Toronto, ON, Toronto Western Research Institute, Toronto Western Hospital, University of Toronto, Toronto, ON 565. Differential Efficacy Of Human Mesenchymal Stem Cells On Disease In Murine Lupus Based On Source Of Origin. Erin Collins, Fei Gu, Osama S. Naga, Phil Ruiz and Gary S. Gilkeson, Medical University of South Carolina, Charleston, SC, Division of Rheumatology and Immunology,Medical University of South Carolina, Charleston, SC, University of Miami, Miami, FL 566. A Human Monoclonal Antibody Against Domain I Of β- Glycoprotein I prevents Clotting and Fetal Loss Induced By Polyclonal Anti-Phospholipid Antibodies In Animal Models. Chiara Agostinis, Paolo Durigutto, Daniele Sblattero, Maria Orietta Borghi, Claudia Grossi 4, Roberta Bulla, Paolo Macor, Pier Luigi Meroni 5 and Francesco Tedesco, Institute for Maternal and Child Health, IRCCS Burlo Garofolo, Trieste, Italy, Department of Life Sciences, University of Trieste, Trieste, Italy, Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy, 4 Laboratory of Immuno-rheumatology, IRCCS Istituto Auxologico Italiano, Milan, Italy, 5 Division of Rheumatology, Istituto G. Pini, Milan, Italy 567. Contribution Of Marginal Zone B Cells To Autoimmunity In The B6.Sle.Sle.Sle Lupus Prone Mouse. Ying Yi Zheng and Laurence Morel, University of Florida, Gainesville, FL 568. Pneumococcal Polysaccharide Vaccination Regulates T and B Lymphocyte Cytokine Responses and Decreases Kidney Stat Levels In MRL/Lpr Mice In Vivo. Victor Gazivoda, Shikha Mehta, Luhan Wang, Julia Ash, Kirk E. Sperber and Ioannis Tassiulas, New York Medical College, Valhalla, NY 569. Hydroxycholorquine Is Cardioprotective In Neonatal Rat Cardiomyocytes Exposed To Simulated Myocardial Ischaemic/Reperfusion Injury.-An Effect Mediated Through ERK Phosphorylation. Lauren Bourke, James McCormick, Anastasis Stephanou and Yiannis Ioannou, University College London, London, United Kingdom, Arthritis Research UK Centre for Adolescent Rheumatology at University College London, Great Ormond Street Hospital and UCLH, University College London, London, United Kingdom 570. In Vivo Therapeutic Success Of Microrna-55 (mir-55) Antagomir In a Mouse Model Of Lupus Pulmonary Hemorrhage. Shiyu Zhou, Dong Liang, Xinfang Huang, Chunyuan Xiao, Yuanjia Tang, Qian Jia, John B. Harley and Nan Shen, Shanghai Institutes for Biological Sciences Chinese Academy of Sciences & Shanghai Jiao Tong University School of Medicine, Shanghai, China, Cincinnati Children s Hospital Medical Center, Cincinnati, OH, Shanghai Institute of Rheumatology,Renji Hospital, Shanghai JiaoTong University School of Medicine, Shanghai, China 57. Protective Effect Of Inducible Adeno-Associated Virus Mediated IL- Gene Therapy On Tissue Damages In Lupus-Prone Mice. Masayuki Mizui, Tomohiro Koga, Linda Lieberman, Jessica Beltran, Mark C. Johnson, José C. Crispin, Roland Tisch and George C. Tsokos, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, University of North Carolina at Chapel Hill, Chapel Hill, NC 0 Program Book 0

204 ACR POSTER SESSION A 57. Immunization With Hepatitis B Vaccine Accelerates SLE-Like Disease In An Animal Model. Nancy Agmon- Levin, María Teresa Arango, Shaye Kivity, Aviva Katzav 4, Boris Gilburd 5, Miri Blank 6, Juan-Manuel Anaya 7, Gisele Zandman-Goddard 8, Joab Chapman 9 and Yehuda Shoenfeld 0, The Zabludowicz Center for Autoimmune Diseases, Tel-Hashomer, Israel, Doctoral Program in Biomedical Sciences Universidad del Rosario, Bogota, Colombia;Center for Autimmune Diseases Research CREA, Universidad del Rosario,, Bogota, Colombia, Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center, affliated to Sackler Faculty of Medicine, Tel-Aviv University Israel, Tel-Aviv, Israel, 4 Department of. Neurology and Sagol Neuroscience Center, Sheba Medical Center,Tel-Hashomer, Ramat Gan, Israel, 5 The Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center, Tel-Hashomer, Ramat-Gan, Israel, 6 Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center, affiliated to Sackler Faculty of Medicine,Tel Aviv University, Tel-Aviv, Tel-Aviv, Israel, 7 School of Medicine and Health Sciences, Universidad del Rosario. Center for Autoimmune Diseases Research (CREA), Bogotá, Colombia, 8 Wolfson Medical Center;Sackler Faculty of Medicine, Tel-Aviv University, Holon, Israel, 9 Department of. Neurology and Sagol Neuroscience Center, Sheba Medical Center, Tel-Hashomer, Ramat Gan, Israel, 0 Sheba Medical Center, Ramat Gan, Israel Absence Of Estrogen Receptor Alpha Reduces The Number and Function Of Bone Marrow Derived Plasmacytoid Dendritic Cells In Lupus Prone Mice. Jennifer Scott, Osama S. Naga, Melissa A. Cunningham, Jena Wirth, Jackie G. Eudaly and Gary S. Gilkeson, Medical University of South Carolina, Charleston, SC, MUSC, Charleston, SC Systemic Lupus Erythematosus - Clinical Aspects I - Renal, Malignancy, Cardiovascular Disease 574. Oral Candidiasis in Systemic Lupus Erythematosus. Monthida Fangtham, Hong Fang and Michelle Petri, Johns Hopkins University School of Medicine, Baltimore, MD 575. Association Of Psoriasis and Psoriatic Arthritis With Systemic Lupus Erythematosus. Ashwini Shadakshari, Jianghong Yu and Andras Perl, SUNY Upstate Medical University, Syracuse, NY 576. Monitoring Of Opportunistic Virus Infections In Systemic Lupus Erythematosus. Lorenzo Cavagna, Sandra Calarota, Eva Scorletti, Roberto Caporali, Francesca Rovida 4, Carlomaurizio Montecucco 5 and Fausto Baldanti 4, University and IRCCS Foundation Policlinico S. Matteo, Pavia, Italy, IRCCS Foundation Policlinico S. Matteo, Pavia, Italy, Division of Rheumatology, IRCCS Policlinico San Matteo Foundation and University of Pavia, Pavia, Italy, 4 IRCCS Foundation Policlinico S. Matteo,, Pavia, Italy, 5 University and IRCCS Policlinico S. Matteo Foundation, Pavia, Italy 577. Is An Excess Risk Of Attention Deficit Hyperactivity Disorder In Children Born To Women With SLE Mediated By In Utero Drug Exposures? Preliminary Data From The O S L E R Cohort. Evelyne Vinet, Susan Scott, Christian A. Pineau, Lawrence Joseph, Ann E. Clarke, Eric Fombonne 4, Robert W. Platt and Sasha Bernatsky 5, McGill University Health Center, Montreal, QC, McGill University Health Centre, Montreal, QC, McGill University, Montreal, QC, 4 Oregon Health and Sciences University, Portland, OR, 5 Research Institute of the McGill University Health Ctre, Montreal, QC 578. Ultrasonographic Findings and Inter-Observer Reliability In Danish Patients With Systemic Lupus Erythematosus - a Comparison With Clinical Examination Of Wrist and Hand Joints. Lene Dreyer, Søren Jacobsen, Lars Juul and Lene Terslev 4, Copenhagen University Hospital at Gentofte, Copenhagen, Denmark, Department of Rheumatology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark, Copenhagen University Hospital at Gentofte, Copenhagen, Denmark, 4 Copenhagen University Hospital at Glostrup, Copenhagen, Denmark 579. Switching Treatment Between Mycophenolate Mofetil and Azathioprine In Lupus Patients The Reasons and The Effect. Hesham Al Maimouni, Dafna Gladman, Dominique Ibanez and Murray B. Urowitz, University of Toronto, Toronto Western Hospital, Toronto, ON 580. Lupus Nephritis Flares Precipitated By Switching From Mycophenolate Mofetil to Azathioprine in Pre-Pregnancy Planning. Natasha Jordan and David D Cruz, Louise Coote Lupus Unit, St Thomas Hospital, London, United Kingdom 58. Predictive Value Of The Autoantibody Triad Of Anti-Ro, Anti-Sm and Anti-RNP For The Future Development Of Lupus Nephritis. Natasha Jordan and David D Cruz, Louise Coote Lupus Unit, St Thomas Hospital, London, United Kingdom 58. A Real-World Survey Of Clinical Practice Among Rheumatologists and Nephrologists In The United States Reveals Differences In Care Of Non-Nephritis Systemic Lupus Erythematosus and Lupus Nephritis As Compared With American College Of Rheumatology Treatment Guidelines. Neelufar Mozaffarian, Steve Lobosco and Adam Roughley, AbbVie, North Chicago, IL, Adelphi Real World Ltd., Macclesfield, United Kingdom 58. Prognostic Significance Of Visit-To-Visit Variability, Maximum Systolic Blood Pressure, and Episodic Hypertension In Sytemic Lupus Erythematosus. George Stojan, Hong Fang, Laurence S. Magder and Michelle Petri, Johns Hopkins University School of Medicine, Baltimore, MD, University of Maryland, Baltimore, MD 584. The Effect Of Ramipril On Endothelial Function and Endothelial Progenitor Cells In Patients With Systemic Lupus Erythematosus. Emilia I. Sato, Luiz Samuel G. Machado and Ana Cecilia Machado, Escola Paulista de Medicina - Universidade Federal de São Paulo, Sao Paulo, Brazil, Universidade Federal de São Paulo, São Paulo, Brazil 0 0 Program Book

205 ACR POSTER SESSION A 585. Breast Cancer In Systemic Lupus (SLE): Do Demographic and Clinical Factors, Including DNA serology, Influence Risk? Sasha Bernatsky, Rosalind Ramsey-Goldman, Michelle Petri, Murray B. Urowitz 4, Dafna D. Gladman 5, Christine Peschken 6, William Foulkes, Yvan St. Pierre 7, Patrice Chrétien Raymer 7, Basile Tessier Cloutier, Guillermo Ruiz-Irastorza 8, Ann E. Clarke and Systemic Lupus International Collaborating Clinics (SLICC) 9, McGill University, Montreal, QC, Northwestern University Feinberg School of Medicine, Chicago, IL, Johns Hopkins University School of Medicine, Baltimore, MD, 4 University of Toronto, Toronto Western Hospital, Toronto, ON, 5 Toronto Western Hospital and University of Toronto, Toronto, ON, 6 University of Manitoba, Winnipeg, MB, 7 McGill University Health Centre, Montreal, QC, 8 Hospital de Cruces, UPV/EHU, Barakaldo, Spain, Bizkaia, Spain, 9 Toronto Western Hospital, Toronto, ON 586. Blood Pressure Variability and Age-Related Blood Pressure Patterns In Systemic Lupus Erythematosus. George Stojan, Laurence S. Magder and Michelle Petri, Johns Hopkins University School of Medicine, Baltimore, MD, University of Maryland, Baltimore, MD 587. Low-Dose Aspirin Has An Anti-Platelet Effect In Systemic Lupus Erythematosus. Michelle Petri, Laurence S. Magder and Thomas Kickler, Johns Hopkins University School of Medicine, Baltimore, MD, University of Maryland, Baltimore, MD 588. Efficacy Of Rituximab In Patients With Refractory Lupus Nephritis, a Post-Hoc Analysis From Phase II Trial In Japan. Yoshiya Tanaka, Kazuhiko Yamamoto, Tsutomu Takeuchi, Nobuyuki Miyasaka 4, Takayuki Sumida 5, Tsuneyo Mimori 6, Takao Koike 7 and Kazuhiro Endo 8, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan, Keio University School of Medicine, Tokyo, Japan, 4 Tokyo Medical and Dental University, Tokyo, Japan, 5 University of Tsukuba, Tsukuba, Japan, 6 Graduate School of Medicine, Kyoto University, Kyoto, Japan, 7 NTT Sapporo Medical Center, Sapporo, Japan, 8 Zenyaku Kogyo Co., Ltd., Tokyo, Japan 589. A Survey Of Physician and Patient Satisfaction With Control Of Systemic Lupus Erythematosus and Lupus Nephritis. Neelufar Mozaffarian, Steve Lobosco and Adam Roughley, AbbVie, North Chicago, IL, Adelphi Real World Ltd., Macclesfield, United Kingdom 590. Candidate Urinary Biomarkers May Predict The Future Development Of Renal Functional Loss With Lupus Nephritis In Children and Adults. Khalid Abulaban, Brad H. Rovin, Shannen Nelson, Huijuan Song, Paul Kimmel 4, John Kusek 4, Harold Feldman 5, Vasan Ramachandran 6, Michael Bennett, Jun Ying 7 and Hermine Brunner 8, Cincinnati Children s Hospital Medical Center, Cincinnati, OH, Ohio State University Medical Center, Columbus, OH, Cincinnati Children s Hospital, Cincinnati, OH, 4 NIDDK, National Institutes of Health, Bethesda, MD, 5 The University of Pennsylvania, Philadelphia, PA, 6 Boston University School of Medicine, Boston, MA, 7 University of Cincinnati, Cincinnati, OH, 8 Cincinnati Children s Hospital Medical Center, Cincinnati, OH 59. Elevated Level Of cfdna Mainly Derive From Netosis Of Common Neutrophils As Well As Low-Density Granulocytes In Systemic Lupus Erythematosus and Is Associated With Lupus Nephritis Severity. Sigong Zhang, Guochun Wang and Xin Lu, China-Japan Friendship Hospital, Beijing, China, Beijing, China 59. Analysis Of Relationship Between Clinical Manifestations and Autoantibody Profile In ISN/RPS Class V Lupus Nephritis. Masanori Hanaoka, Takahisa Gono, Yasushi Kawaguchi, Hisashi Yamanaka, Yasuhiro Katsumata, Kae Takagi, Hirotaka Kaneko, Hisae Ichida, Yuko Ota, Hidenaga Kawasumi, Sayumi Baba, Yuko Okamoto and Sayuri Kataoka, Tokyo Women s Medical University, Tokyo, Japan, Institute of Rheumatology, Tokyo Women s Medical University, Tokyo, Japan 59. Urinary Prostaglandin D Synthetase As a Biomarker Of Lupus Nephritis Activity: One Year Longitudinal Study. Ranjan Gupta, Akhilesh Yadav, Ramnath Misra and Amita Aggarwal, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India 594. Renal Biopsy Findings In Lupus Patient With Insignificant Proteinuria : Relation To Disease Activity and Clinical Manifestations. Abdel Azeim M. Al-Hefny, Samah Elbakry, Sameh A. Mobasher, Ola H. Nada 4 and Nouran Abaza 5, Professor of Internal Medicine and Rheumatology, Faculty of Medicine, Ain Shams University, Cairo, Egypt, Cairo, Egypt, Assistant professor of Internal Medicine and Rheumatology, Faculty of Medicine, Ain Shams University, Cairo, Egypt, Lecturer of Internal Medicine and Rheumatology, Faculty of Medicine, Ain Shams University, Cairo, Egypt, 4 Lecturer of Pathology, Faculty of Medicine, Ain Shams University, Cairo, Egypt, 5 Lecturer of Physical medicine, Rheumatology and Rehabilitation, Faculty of Medicine, Ain Shams University, Cairo, Egypt 595. WITHDRAWN 596. Extended Follow-Up Of a Investigator-Initiated trial Comparing Two Sequential Induction and Maintenance Treatment Regimens For Proliferative Lupus Nephritis Based Either On Cyclophosphamide Or Cyclosporine A. Jakub Zavada, Satu Pesickova, Romana Rysava, Pavel Horak, Zbynek Hrncir 4, Jozef Rovensky 5, Jozef Lukac 5, Jirina Vitova 6, Jana Böhmova 7, Marta Olejarova, Dana Tegzova 8 and Vladimir Tesar, Institute of Rheumatology, Prague, Prague, Czech Republic, General University Hospital and First Faculty of Medicine, Charles University, Prague, Czech Republic, rd Department of Internal Medicine University Hospital Olomouc, Olomouc, Czech Republic, 4 Faculty of Medicine and University Hospital, Hradec Kralove, Czech Republic, 5 National Institute of Rheumatology, Piestany, Slovakia, 6 Hospital, Ceske Budejovice, Czech Republic, 7 Faculty Hospital St. Anna, Brno, Czech Republic, 8 Institute of Rheumatology, Prague, Czech Republic 597. Low Complement (C), Male Gender and Methotrexate Use Are Associated With Noncalcified Plaque In Systemic Lupus Erythematosus. Adnan Kiani, Armin Zadeh, Jens Vogel-Claussen, Joao Lima, Laurence S. Magder and Michelle Petri, Johns Hopkins University School of Medicine, Baltimore, MD, Johns Hopkins University, Baltimore, MD, University of Maryland, Baltimore, MD 0 Program Book 0

206 ACR POSTER SESSION A 598. Gender Influence On Lupus Nephritis Outcomes In An Urban, Multiethnic Population. Cindy Johnston, Catarina Vila-Inda and Irene Blanco, Albert Einstein College of Medicine, Bronx, NY 599. Association Between Serum Leptin and Adiponectin Levels With The Severity Of Proteinuria In Lupus Nephritis. Valeria Diaz-Rizo, Nicte Selene Fajardo-Robledo, Alan Joel Ruiz-Padilla, Dalia Sanchez-Mosco, Tania Marlene Rodriguez-Hernandez 4, Xochitl Trujillo 5, Miguel Huerta 5, Monica Vazquez del Mercado 6, Laura Gonzalez-Lopez 4 and Jorge Ivan Gamez-Nava 7, Doctorado en Ciencias Médicas, Centro Universitario de Investigación Biomédica, Universidad de Colima; UMAE, Hospital de Especialidades, Centro Médico Nacional de Occidente, IMSS, Guadalajara, Jalisco, Mexico, Doctorado en Farmacología, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara, Jalisco, Mexico, Centro Universitario de Investigación Biomédica, Universidad de Colima; Hospital General Regional 0 IMSS, Guadalajara, Jalisco, Mexico, 4 Hospital General Regional 0, Instituto Mexicano del Seguro Social (IMSS), Guadalajara, Jalisco, Mexico, 5 Centro Universitario de Investigación Biomédica, Universidad de Colima, Colima, Mexico, 6 Universidad de Guadalajara, Guadalajara, Mexico, 7 UMAE, Centro Médico Nacional de Occidente, IMSS; Doctorado en Farmacología, Universidad de Guadalajara, Jalisco, Mexico 600. Factors Associated With Long-Term Renal Function Deterioration In Lupus Nephritis Treated Initially With Combined Prednisolone and Mycophenolate Mofetil (MMF) Or Tacrolimus (Tac). Chi Chiu Mok, Chi Hung To, King Yee Ying, Cheuk-Wan Yim and Woon Leung Ng, Tuen Mun Hospital, Hong Kong, Hong Kong, Princess Margaret Hospital, Hong Kong, Hong Kong, United Christian Hospital, Hong Kong, Hong Kong 60. Hypovitaminosis D and The Metabolic Syndrome In Patients With Systemic Lupus Erythematosus (SLE). Chi Chiu Mok, Ling Yin Ho and Daniel Birmingham, Tuen Mun Hospital, Hong Kong, Hong Kong, Ohio State University Medical Center, Columbus, OH 60. Repeat Biopsy In Lupus Nephritis: A Single-Center Experience. Josefina Marin, Marina Scolnik, Eliana Lancioni, Gustavo Greloni, Cristian Quiroz, Johana Zacariaz, Carla Saucedo, Luis J. Catoggio and Enrique R. Soriano, Rheumatology Unit, Internal Medical Services, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, Nephrology Service, Buenos Aires, Argentina, Rheumatology Unit, Internal Medical Services, Hospital Italiano de Buenos Aires, Instituto Universitario Hospital Italiano de Buenos Aires, and Fundacion PM Catoggio, Buenos Aires, Argentina 60. Factors Associated With a Double Increase In Serum Creatinine In Biopsy Proven Lupus Nephritis From a Single Center In Spain. Raúl Menor Almagro, M. H. Cardiel, Javier Rubio Garrido, J. Luis de la Iglesia, José Javier Perez Venegas, María Mar Ruiz Tudela, José Javier Salaberri and Manuel Paez-Camino, Hospital de Jerez, Jerez de la Frontera, Spain, Centro de Investigacion Clinica de Morelia, Morelia, Mexico 604. Mycophenolate Mofetil Is Not Associated With Reduced Cardiovascular Or Lupus Damage Accumulation In a Cross- Sectional Lupus Cohort Study. Maureen A. McMahon, Maria Dall era, Eliza Chakravarty, Joseph E. Craft 4, Gary S. Gilkeson 5, Kenneth C. Kalunian 6, R. John Looney 7, Gerald McGwin Jr. 8 and Meggan Mackay 9, UCLA David Geffen School of Medicine, Los Angeles, CA, University of California, San Francisco, San Francisco, CA, Oklahoma Medical Research Foundation, Oklahoma City, OK, 4 Yale University School of Medicine, Internal Medicine, Section of Rheumatology, New Haven, CT, 5 Medical University of South Carolina, Charleston, SC, 6 UCSD School of Medicine, La Jolla, CA, 7 University of Rochester, Rochester, NY, 8 University of Alabama at Birmingham, Birmingham, AL, 9 Feinstein Institute for Medical Research, Manhasset, NY 605. Childhood Lupus Nephritis: Long Term Outcome Of 9biopsy Proven Cases From India. Puja Srivastava, Bonnie Abujam, Ramnath Misra, Able Lawrence, Vikas Agarwal and Amita Aggarwal, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India 606. Characteristics Of Lupus Nephritis: Data From a Large Multicenter Registry Of Patients With Systemic Lupus Erythematosus. Diane L. Kamen, Graciela S. Alarcon, Jill P. Buyon, Mary Anne Dooley 4, Richard A. Furie 5, David S. Pisetsky 6 and Tammy O. Utset 7, Medical University of South Carolina, Charleston, SC, University of Alabama at Birmingham, Birmingham, AL, NYU School of Medicine, New York, NY, 4 University of North Carolina at Chapel Hill, Chapel Hill, NC, 5 The Feinstein Institute for Medical Research and North Shore-Long Island Jewish Health System, Lake Success, NY, 6 Duke University Medical Center, Durham, NC, 7 University of Chicago Department of Medicine, Chicago, IL 607. Venous Thromboembolic Disease Is Associated With Increased Length Of Stay and In-Hospital Mortality In Hospitalized SLE Patients: A Multi-State, Population-Based Study. Matthew Cascino, Laura Trupin, Sara Murray, Mary Margaretten, Edward H. Yelin and Jinoos Yazdany, University of California, San Francisco, San Francisco, CA, UC San Francisco, San Francisco, CA 608. Effect Of Renal Damage On Extra-Renal Organ Damage and Mortality In Patients With Systemic Lupus Erythematosus (SLE): A Longitudinal Cohort Study Of 756 Patients. Chi Chiu Mok, Ling Yin Ho, Kar Li Chan and Chi Hung To, Tuen Mun Hospital, Hong Kong, Hong Kong 609. Increased Arterial Stiffness In Systemic Lupus Erythematosus (SLE) Patients At Low Risk For Cardiovascular Disease: A Cross-Sectional Controlled Study. Karim Sacre, Brigitte Escoubet, Maria Chauchard, Antoine Dossier, Marie-Paule Chauveheid and Thomas Papo, University Paris-7, INSERM U699, APHP, Bichat Hospital, Paris, France, University Paris-7, INSERM U87, APHP, Bichat Hospital, Paris, France, University Paris-7, APHP, Bichat Hospital, Paris, France 04 0 Program Book

207 ACR POSTER SESSION A 60. Disease Specific Quality Of Life Domains Are Impaired In Patients With Lupus Nephritis? Meenakshi Jolly, Zineb Aouhab, Sergio Toloza, Ana M. Bertoli 4, Ivana Blazevik 5, Luis M. Vila 6, Ioana Moldovan 7, Karina Marianne D. Torralba 8, Arif Kaya 9, Berna Goker 0, Mehmet E. Tezcan, Seminur Haznedaroglu 9, Josiane Bourré-Tessier, Ann E. Clarke, D.J. Wallace 4, Michael H. Weisman 4 and Graciela S. Alarcon 5, Rush University Medical Center, Chicago, IL, John H Stroger Hospital, Chicago, IL, Hospital San Juan Bautista, Catamarca, Argentina, 4 Instituto Reumatológico Strusberg, Cordoba, Cordoba, Argentina, 5 University of Buenos Aires, Buenos Aries, Argentina, 6 University of Puerto Rico Medical Sciences Campus, San Juan, PR, 7 Loma Linda Univ Medical Center, Loma Linda, CA, 8 USC Keck Schl of Medicine, Los Angeles, CA, 9 Gazi University Medical School, Ankara, Turkey, 0 Gazi University, Ankara, Turkey, Dr. Lutfi Kirdar Kartal EA Hastanesi, Istanbul, Turkey, McGill University, Montréal, QC, McGill University Health Center, Montreal, QC, 4 Cedars-Sinai Medical Center, Los Angeles, CA, 5 University of Alabama at Birmingham, Birmingham, AL 6. Efficacy and Safety Of Transjugular Renal Biopsy In Systemic Lupus Erythematosus and Antiphospholipid Syndrome: A Retrospective Monocentric Study Of 9 Procedures. Alexis Mathian, Maud Cazenave, Laurent Arnaud, Nathalie Costedoat-Chalumeau 4, Du Boutin-LE Thi Huong, Ahlem Chaib, Fleur Cohen-Aubart 5, Julien Haroche, Miguel Hié, Makoto Miyara, Philippe Rouvier 6, Jean-Charles Piette 7, Philippe Cluzel 8 and Zahir Amoura 7, Hôpital Pitié-Salpêtrière, AP-HP, UPMC Univ Paris 06 & French National Reference Center For Systemic Lupus and Antiphospholipid Syndrome, Internal Medicine, Paris, France, Service de médecine interne, Centre de référence National pour le Lupus et le Syndrome des antiphospholipides, CHU Pitié-Salpêtrière, APHP, Paris, France, Paris, France, Hôpital Pitié-Salpêtrière, AP-HP, UPMC Univ Paris 06 & French National Reference Center For Systemic Lupus and Antiphospholipid Syndrome, Paris, France, 4 Assistance Publique-Hôpitaux de Paris, Hopital Pitié-Salpétrière, Paris, France, 5 Pitié-Salpêtrière Hospital, APHP, Paris, France, 6 Service d anatomie pathologie, CHU Pitié-Salpêtrière, APHP, Paris, France, Paris, France, 7 CHU Pitié-Salpêtrière, Paris, France, 8 Pitié-Salpétrière, Paris, France 6. Increased Expression Of Membrane Endothelial Protein C Receptor Associates With Poor Response In Lupus Nephritis Independent Of Chronicity Index. Barbara Mendez, Ming Wu, Dominick Santoriello, Laura Barisoni, Peter M. Izmirly, Jill P. Buyon and Robert M. Clancy, New York University School of Medicine, New York, NY, University of Miami Hospital, Miami, FL 6. The Influence Of Cumulative Dose Of Corticosteroids On The Presence Of Carotid Atherosclerosis In Patients With Longstanding Systemic Lupus Erythematosus. Maria Rubino, Ellie Aghdassi, Sun Makosso-Kallyth, Stacey Morrison 4, Lihi Eder 5 and Paul R. Fortin 6, Université Laval, Quebéc, QC, University Health Network Research Institute and Department of Public Health, University of Toronto, Toronto, ON, Centre de Recherche CHU de Québec, Québec, QC, 4 The Toronto Western Hospital, Toronto, ON, 5 University of Toronto, Toronto Western Hospital, Toronto, ON, 6 Division of Rheumatology, Université Laval, Québec, QC 64. Causes Of Mortality In Lupus Patients Followed Prospectively At a Large Single-Centre Lupus Clinic. Barry J. Sheane, Dominique Ibanez, Dafna D. Gladman and Murray B. Urowitz, University of Toronto, Toronto Western Hospital, Toronto, ON 65. Relationship Between 5-Hydroxyvitamin D [5(OH) D] and Risk For Cardiovascular Events In Systemic Lupus Erythematosus Over Years In An Inception Cohort. Apinya Lertratanakul, Peggy Wu, Alan Dyer, Dafna D. Gladman, Murray B. Urowitz, Paul R. Fortin 4, Dominique Ibanez, Rosalind Ramsey-Goldman and for the Systemic Lupus International Collaborating Clinics (SLICC) 5, Northwestern University, Chicago, IL, Northwestern University Feinberg School of Medicine, Chicago, IL, University of Toronto, Toronto Western Hospital, Toronto, ON, 4 Centre de Recherche du Chu de Québec et Université Laval, Quebec City, QC, 5 University of Toronto, Toronto Western Hospital (Coordinating Center), Toronto, ON 66. Trends Of Mortality Associated To Systemic Lupus Erythematosus At The Nation Level: A Multiple Cause-Of- Death Analysis In France. Laurent Chiche Sr., Guillemette Thomas, Albetine Aouba, Julien Mancini, Gabrielle Sarlon 4, Noémie Jourde, Eric Jougla and Jean-Robert Harle, Internal Medicine, CHU Marseille, Marseille, France, APHM, Marseille, France, inserm CépiDc, paris, France, 4 APHM, marseille, France 67. The Potentiality Of Multi-Target Therapy With Cyclophosphamide and Tacrolimus For Lupus Nephritis. Ryota Sakai, Akiko Shibata, Kentaro Chino, Tsuneo Kondo, Ayumi Okuyama, Eiko Nishi, Hirofumi Takei, Hayato Nagasawa and Koichi Amano, Saitama Medical Center, Saitama Medical University, Kawagoe, Japan 68. Active Renal Disease Is Associated With The Presence Of The Metabolic Syndrome (MetS) In Peruvian Patients With Systemic Lupus Erythematosus (SLE). Manuel F. Ugarte-Gil, Rocio V. Gamboa-Cardenas, Mariela Medina- Chinchon, Francisco Zevallos-Miranda, Karim E. Diaz- Deza, J. Mariano Cucho-Venegas, Zoila Rodriguez-Bellido, Jose L. Alfaro-Lozano, Risto A. Perich-Campos, Erika Noriega, Hugo Torrealva and Cesar A. Pastor-Asurza, Hospital Almenara, Lima, Peru, Universidad Nacional Mayor de San Marcos, Lima, Peru 69. Survival and Prognostic Factors In Patients With Connective Tissue Disease Associated Pulmonary Arterial Hypertension: Results From Korean Nationwide Registry. Kwi Young Kang, Chan Hong Jeon, Sung Jae Choi, Seung- Ki Kwok 4, Seong-Kyu Kim 5, Hyoun-Ah Kim 6, Eon Jeong Nam 7, Yong-Beom Park 8, Kichul Shin 9, Jaejoon Lee 0, Chang-Hoon Lee, Chan-Bum Choi, Shin-Seok Lee and Dae-Hyun Yoo 4, Catholic University of Korea, Incheon St. Mary s Hospital, Seoul, South Korea, Soonchunhyang University College of Medicine, Bucheon, South Korea, Korea University Medical Center, Seoul, South Korea, 4 The Catholic University of Korea, Seoul St. Mary s Hospital, Seoul, South Korea, 5 Catholic University of Daegu School of Medicine, Daegu, South Korea, 6 Ajou University School of Medicine, Suwon, South Korea, 7 Kyungpook National University School of Medicine, Daegu, South Korea, 0 Program Book 05

208 ACR POSTER SESSION A 06 8 Yonsei University College of Medicine, Seoul, South Korea, 9 College of Medicine, Seoul National University, Seoul, South Korea, 0 Sungkyunkwan University School of Medicine, Samsung Medical Center, Seoul, South Korea, Department of Internal Medicine, School of Medicine, Wonkwang University, Iksan, Chonbuk, South Korea, Hanyang University Hospital for Rheumatic Diseases, Clinical Research Center for Rheumatoid Arthritis (CRCRA), Seoul, South Korea, Chonnam National University Medical School, Gwangju, South Korea, 4 Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea 60. Human Papillomavirus and Precancerous Lesions In Patients With Systemic Lupus Erythematosus. Eleonora Lucero, Laura Juarez, Veronica Bellomio, Francisco Colombres, Maximiliano Machado Escobar, Raúl Nicolás Martínez, Teresita Alvarellos, Agustina Lacaze, Ariel Sanchez, Pablo Agustín Apas Perez de Nucci, Guillermo Cohen Imach, Sonia Marcela Ortiz Mayor, Iris Aybar Odstrcil, Ana Cerón, Ricardo V. Juárez, Mirta Santana and Alberto Berman, Padilla Hospital, Tucumán, Argentina, Córdoba Private Hospital, Córdoba, Argentina, Hospital Señor del Milagro, Salta, Argentina 6. Baseline Characteristics That Predict a Short-Term Response To Immunosuppressive Treatment In Patients With Pulmonary Arterial Hypertension Associated With Connective Tissue Disease. Hidekata Yasuoka, Yuichiro Shirai, Yuichi Tamura, Toru Satoh, Tsutomu Takeuchi and Masataka Kuwana, Keio University School of Medicine, Tokyo, Japan, Kyorin University School of Medicine, Tokyo, Japan 6. Serum Anti-Apolipoprotein Antibodies Are Present In a Quarter Of Patients With Systemic Lupus Erythematosus At The Time Of Diagnosis and Are Associated With Earlier Mortality. Sara Croca, Maria Davari, D.A. Isenberg and Anisur Rahman, University College London, London, United Kingdom 6. Lupus Patients Have a High Prevalence Of Abnormalities On Resting Electrocardiogram That Are Associated With Increased Risk For Cardiovascular Events. Zahi Touma, Paula Harvey, Dafna Gladman, Arthy Sabapathy and Murray B. Urowitz, University of Toronto, Toronto Western Hospital, Toronto, ON, Women s College Hospital, Toronto, ON 64. Extremely High Coronary Artery Calcium Scores Among Patients With Systemic Lupus Erythematosus. Susan Due Kay, Anne Voss, Axel Cosmus Pyndt Diederichsen and Mikael Kjær Poulsen 4, University of Southern Denmark, Odense , Denmark, Odense University Hospital, Odense C, Denmark, Odense University Hospital, Odens-5000, Denmark, 4 Odense University Hospital, Odense , Denmark 65. Smoking and Secondhand Smoke Exposure Among Patients With Systemic Lupus Erythematosus and Controls: Associations With Disease and Disease Damage. Samantha J. Minkin, Stephanie N. Slan, Gary S. Gilkeson and Diane L. Kamen, Medical University of South Carolina, Charleston, SC 0 Program Book 66. Ultrasound Assessment Of Both Carotid and Femoral Arteries In Patients With Systemic Lupus Erythematosus Increases Sensitivity For Detecting Asymptomatic Atherosclerosis. Sara Croca, D.A. Isenberg and Anisur Rahman, University College London, London, United Kingdom Systemic Lupus Erythematosus - Human Etiology and Pathogenesis: Mechanisms and Biomarkers 67. Exome Scan Analysis Of Rare Variants Implicates XKR6 In Early Age Of Onset Systemic Lupus Erythematosus. Indra Adrianto, Graham B. Wiley, Stuart B. Glenn, Adam Adler, Shaofeng Wang, James Robertson, Jennifer A. Kelly, Christopher J. Lessard, Kathy L. Sivils, Courtney G. Montgomery and Patrick M. Gaffney, Oklahoma Medical Research Foundation, Oklahoma City, OK 68. Estrogen Modulates The Expression Of Endosome- Associated Toll-Like Receptor 8 Through Estrogen Receptor-α Which May Contribute To Sex-Bias In Systemic Lupus Erythematosus. Nicholas A. Young, Lai-Chu Wu, Craig Burd, Alexandra Friedman, Benjamin Kaffenberger, Murugesan Rajaram, Larry S. Schlesinger, Hayley James, Margaret Shupnik and Wael N. Jarjour, The Ohio State University Wexner Medical Center, Columbus, OH, University of Virginia School of Medicine, Charlottesville, VA 69. Altered ER Stress-Induced Autophagic Reactions Are Associated With Increased Apoptosis of T Lymphocytes in Systemic Lupus Erythematosus. Won Seok Lee, Myung- Soon Sung, Eun-Gyeong Lee, Chang-Hoon Lee, Myeung Su Lee, Yun-Hong Cheon 4, Sang-il Lee 4, Yun Kyoung Hong 5 and Wan-Hee Yoo, Department of Internal Medicine, Chonbuk National University Medical School and Research Institute of Clinical Medicine, Jeonju, South Korea, Department of Internal Medicine, School of medicine, Wonkwang university, Iksan, Chonbuk, South Korea, Department of Internal Medicine, School of Medicine, Wonkwang University, Iksan, Chonbuk, South Korea, 4 Gyeongsang National University School of Medicine, Jinju, South Korea, 5 Department of internal medicine, Presbyterian medical center, Jeonju, South Korea 60. Galectin--Binding Protein Is Highly Increased On Circulating Microparticles In SLE Patients and Co-Localizes With IgG In Glomerular Deposits In Human Lupus Nephritis. Christoffer T. Nielsen, Ole Østergaard, Ole Petter Rekvig, Gunnar K. Sturfelt 4, Søren Jacobsen 5 and Niels H. H. Heegaard 6, University Hospital Rigshospitalet, Copenhagen, Denmark, Statens Serum Institute, Copenhagen S, Denmark, University Hospital, Tromsø, Norway, 4 Lund University, Lund, Sweden, 5 Department of Rheumatology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark, 6 Statens Serum Institut, Copenhagen, Denmark 6. Type I IFN Regulation Of IL-0 Is Detrimental To Endothelial Cell Differentiation and May Enhance Cardiovascular Risk In Systemic Lupus Erythematosus. J. Michelle Kahlenberg, Alyssa Cates, Victoria Holden, Carolyne K. Smith and Mariana J. Kaplan, University of Michigan, Ann Arbor, MI, University of Michigan Rheumatology, Ann Arbor, MI

209 ACR POSTER SESSION A 6. Anti-Ribosomal-Phosphoprotein Autoantibodies Penetrate Into Neuronal Cells Via Neuron Growth Associated Protein (GAP4). Shaye Kivity, Yehuda Shoenfeld, Margalit Zusev, Inna Slutsky 4, Dolores J Cahill 5, Sara Louise O Kane 6, Michal Harel-Meir 7, María Teresa Arango 8, Juan-Manuel Anaya 9, Joab Chapman 0 and Miri Blank, Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center, affliated to Sackler Faculty of Medicine, Tel-Aviv University Israel, Tel-Aviv, Israel, Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center, Affiliated to Sackler Faculty of Medicine, Tel-Aviv University,Tel-Aviv, Tel-Aviv, Israel, Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center, Affiliated to Sackler Faculty of Medicine, Tel-Aviv University, Israel, Ramat Gan, Israel, 4 Department of Physiology and Pharmacology, Sackler Faculty of Medicine,, Tel-Aviv, Israel, 5 School of Medicine and Medical Sciences, Conway Institute of Biomolecular & Biomedical Research, University College, Dublin, Ireland, 6 School of Medicine and Medical Sciences, Conway Institute of Biomolecular & Biomedical Research, University College, Dublin, Ireland, 7 Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center, affiliated to Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Tel-Aviv, Israel, 8 Doctoral Program in Biomedical Sciences Universidad del Rosario, Bogota, Colombia;Center for Autimmune Diseases Research CREA, Universidad del Rosario,, Bogota, Colombia, 9 School of Medicine and Health Sciences, Universidad del Rosario, Bogotá, Colombia, 0 Department of. Neurology and Sagol Neuroscience Center, Sheba Medical Center, Tel-Hashomer, Ramat Gan, Israel, Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center, affiliated to Sackler Faculty of Medicine,Tel Aviv University, Tel-Aviv, Tel-Aviv, Israel 6. Reduced PD- Signaling Promotes Suppressive Function Of CD4 + Regulatory T Cells In Patients With Systemic Lupus Erythematosus. Maida Wong, Jennifer M. Grossman, Antonio La Cava and Bevra H. Hahn, UCLA David Geffen School of Medicine, Los Angeles, CA 64. IL-/IL-R Interaction On Lymphocyte Subsets From Lupus Patients. Vinh Nguyen, Horea Rus, Cosmin Tegla and Violeta Rus, University of Maryland School of Medicine, Baltimore, MD, University of Maryland School of Medicine and Veteran Affairs Medical Center, Baltimore, MD 65. Multiple Altered Soluble Inflammatory Mediators Correlate With Disease Activity and Mark Impending Disease Flare In European-American Lupus Patients. Melissa E. Munroe, Jourdan R. Anderson, Krista M. Bean, Joan T. Merrill, Joel M. Guthridge, Virginia C. Roberts, Linda F. Thompson and Judith A. James, Oklahoma Medical Research Foundation, Oklahoma City, OK, University of Oklahoma Health Sciences Center, Oklahoma City, OK 66. Neutrophil-Mediated Interferon Activation In Systemic Lupus Erythematosus Bone Marrow. Anna Bird, Nida Meednu, Javier Rangel-Moreno, Srilakshmi Yalavarthi, Jennifer Barnard, Teresa Owen, Jason S. Knight, Alfred Rabinovich, Arumugam Palanichamy, Jane Liesveld, Jason W Bauer, Emily Baechler, Mariana J. Kaplan and Jennifer H. Anolik, University of Rochester Medical Center, Rochester, NY, University of Michigan Rheumatology, Ann Arbor, MI, University of Minnesota, Minneapolis, MN 67. Proteomic Approach and Validation Of Urinary Biomarkers In Lupus Nephritis. Joo Youn Lee, Sung Hae Chang, Hye Jin Oh, Yong Yook Lee, Min Jueng Kang, Eun Young Lee 4, Eun Bong Lee 4, Eugene C. Yi and Young Wook Song, Department of Molecular Medicine and Biopharmaceutical Sciences, Seoul National University, Seoul, South Korea, Seoul National University Bundang Hospital, Seongnamsi, South Korea, Seoul National University, Seoul, South Korea, 4 Division of Rheumatology, Department of Internal Medicine, Seoul National University, Seoul, South Korea 68. Estrogen-Induced STAT and STAT4 Expression Is Estrogen Receptor α Dependent and IFNα Independent: A Novel Mechanism For Sex-Bias In Systemic Lupus Erythematosus Pathogenesis? Nicholas A. Young, Giancarlo R. Valiente, Lai-Chu Wu, Michael Bruss, Craig Burd and Wael N. Jarjour, The Ohio State University Wexner Medical Center, Columbus, OH, The Ohio State University College of Medicine, Columbus, OH 69. Examination Of The Cytokine Profile Of The Cerebrospinal Fluid In Neuropsychiatric Systemic Lupus Erythematosus. Kunihiro Ichinose, Takeshi Ushigusa, Yoshikazu Nakashima, Takahisa Suzuki, Yoshiro Horai, Shin-ya Kawashiri, Naoki Iwamoto, Mami Tamai, Kazuhiko Arima, Hideki Nakamura, Tomoki Origuchi and Atsushi Kawakami, Unit of Translational Medicine, Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan 640. Systemic Lupus Erythematosus Patients With Atherosclerosis Are Characterised By a Distinct Invariant Natural Killer T Cell Phenotype and Altered CDd- Mediated Lipid Antigen Presentation. Edward Smith, Sara Croca, Andrew Pitcher, D.A. Isenberg, Anisur Rahman and Elizabeth C. Jury, University College London, London, United Kingdom 64. Vitamin D Increases The Number and Function Of Myeloid Angiogenic Cells In Systemic Lupus Erythematosus. John A. Reynolds, David W. Ray, Terence O Neill, M. Yvonne Alexander and Ian N. Bruce, Arthritis Research UK Epidemiology Unit and NIHR Manchester Musculoskeletal Biomedical Research Unit, The University of Manchester, Manchester, United Kingdom, Institute of Human Development, The University of Manchester, Manchester, United Kingdom, Healthcare Science Research Institute, Manchester Metropolitan University, Manchester, United Kingdom 64. Serum Concentrations Of Type I Interferon-Regulated Chemokines Are Associated With Disease Activity In Systemic Lupus Erythematosus. Eric F. Morand, Kathryn Connelly and Alberta Y. Hoi, Monash University, Melbourne, Australia 64. Potential Immunopathological Roles Of The Novel Anti- Inflammatory Cytokine Interleukin-5 In Patients With Systemic Lupus Erythematous. Zhe Cai, Chun-Kwok Wong and Lai Shan Tam, The Chinese University of Hong Kong, Hong Kong, Hong Kong, The Chinese University of Hong Kong, Hong Kong, China 0 Program Book 07

210 ACR POSTER SESSION A 644. Expansion Of CD4 + CXCR + T Cells In Patients With Systemic Lupus Erythematosus (SLE) Correlates With Subclinical Atherosclerosis. Karim Sacre, Brigitte Escoubet, Nicolas Charles, Antoine Dossier 4, Marie-Paule Chauveheid 4 and Thomas Papo, University Paris-7, INSERM U699, APHP, Bichat Hospital, Paris, France, University Paris-7, INSERM U87, APHP, Bichat Hospital, Paris, France, INSERM U699, Paris, France, 4 University Paris-7, APHP, Bichat Hospital, Paris, France 645. Transcript Profiling Of Blood and Kidney Biopsies From Chinese Patients With Lupus Nephritis Reveals Concordant Activation Of Type I IFN Signaling In The Blood and Kidney, Reduced B Cell Presence In The Blood, and Increased Macrophages In The Kidney. Zheng Liu, Chris, A. Morehouse, Xinfang Huang, Philip Brohawn, Nan Shen, Yihong Yao and Brandon W. Higgs, MedImmune, LLC, Gaithersburg, MD, Shanghai Ren Ji Hospital, Shanghai, China 646. Expression Of Interferon-Inducible Gene (Lymphocyte Antigen 6 Complex Locus E) In Systemic Lupus Erythematosus Patients and Its Association With Disease Activity. Eman Omran, Tayseer M Khidre, Eman Alkady, Eman Mosaad 4 and Mona Hussein Abd Elsamea, Assiut University- Faulty of Medicne, Assiut, Egypt, Assiut University, Faculty of Medicine, Assiut, Egypt, Assiut University- Faculty of Medicine, Assiut, Egypt, 4 AssiutUniversity- Faculty of Medicine, Assiut, Egypt Systemic Sclerosis, Fibrosing Syndromes and Raynaud s I 647. Enhanced Expression of CCR Receptors in Healthy AA and SSc ILD Monocytes. Rebecca Lee, Charles Reese, Beth Perry, Jonathan Heywood, Michael Bonner, Richard P. Visconti, Richard M. Silver, Stanley Hoffman and Elena Tourkina, Medical University of SC, Charleston, SC 648. A Possible Contribution of Inducible Costimulator to the Development of Skin Sclerosis and Interstitial Lung Disease in Systemic Sclerosis. Koichi Yanaba, Yoshihide Asano and Shinichi Sato, The University of Tokyo, Tokyo, Japan, University of Tokyo Graduate School of Medicine, Tokyo, Japan 649. Altered BMP Signalling In a TGFβ Dependent Murine Model Of Scleroderma May Contribute To Development Of Pulmonary Arterial Hypertension. Adrian J Gilbane, Emma C. Derrett-Smith, Sarah Trinder, Andrew Pearce, Christopher P. Denton and Alan M. Holmes, UCL Medical School, London, United Kingdom, Novartis, London, United Kingdom 650. Parental Influence On Systemic Sclerosis. Tracy M. Frech, Richard Pimentel, Allen D. Sawitzke, Gopi Penmetsa 4 and Jathine Wong, Salt Lake City VAMC, Salt Lake, UT, University of Utah, Salt Lake, UT, University of Utah Medical Ctr, Salt Lake City, UT, 4 University Of Utah Hospital, Salt lake City, UT 65. Growth Differentation Factor-5, a Marker Of lung disease In Systemic Sclerosis, Is Involved In Fibrosis Development But Does Not Impair Fibrosis Development. Stijn Lambrecht, Vanessa Smith, Katelijne De wilde, Julie Coudenys, Filip De Keyser and Dirk Elewaut 4, Laboratory for Molecular Immunology and Inflammation, Ghent University, Ghent, Belgium, Department of Rheumatology, Ghent University Hospital, Ghent, Belgium, Ghent University, Ghent, Belgium, 4 Department of Rheumatology Ghent University Hospital, Ghent, Belgium 65. Pirfenidone and BIBF0 Suppress Collagen Synthesis In Skin Fibroblast From Patients With Systemic Sclerosis. Yuko Ota, Yasushi Kawaguchi, Kae Takagi, Hisae Ichida, Yasuhiro Katsumata, Takahisa Gono, Yuko Okamoto, Tomoaki Higuchi, Hidenaga Kawasumi and Hisashi Yamanaka, Tokyo Women s Medical University, Tokyo, Japan 65. Norepinephrine-Induced IL-6 Regulates Fibrosis In Systemic Sclerosis. Sei-ichiro Motegi, Akihito Uehara, Kazuya Yamada, Akihiko Uchiyama, Sachiko Ogino, Yoko Yokoyama, Yuko Takeuchi and Osamu Ishikawa, Gunma University Graduate School of Medicine, Gunma, Japan 654. Effects Of Macitentan and Its Active Metabolite In Modulating Extracellular Matrix Synthesis In Cultured Human Systemic Sclerosis and Normal Skin Fibroblasts. Maurizio Cutolo, Paola Montagna, Renata Brizzolara, Elisa Alessandri, Pietro Paolo Tavilla 4, Aurora Parodi 4, Alberto Sulli and Stefano Soldano, University of Genova, Genova, Italy, Research Laboratory and Academic Unit of Clinical Rheumatology, Department of Internal Medicine, University of Genova, Genova, Italy, Research Laboratory and Academic Unit of Clinical Rheumatology, Department of Internal Medicine, University of Genova, Genoa, Italy, 4 Department of Endocrinologial and Medical Science, Unit of Dermatology, University of Genova, Genova, Italy 655. DNA Methylation and Systemic Sclerosis. Gloria Salazar, Khurshida Begum, Xinjian Guo, Minghua Wu, Shervin Assassi, Maureen D. Mayes, John D. Reveille and Xiaodong Zhou, University of Texas Health Science Center at Houston, Houston, TX, Baylor College of Medicine, Houston, TX, The University of Texas Medical School at Houston, Houston, TX 656. Gene Expression Variation and The Role Of Interferon In Patients With Morphea From The Morphea In Adults and Children Cohort. Daniel Grabell, Andrew Kim, Virginia Pascual, Shervin Assassi 4 and Heidi Jacobe, UT Southwestern Medical Center at Dallas, Dallas, TX, Lenox Hill Hospital, New York, NY, Baylor University, Dallas, TX, 4 University of Texas Health Science Center at Houston, Houston, TX 657. Lipoic Acid Plays a Crucial Role In Scleroderma Dermal Fibroblasts. Pei-Suen Tsou, Beatrix Balogh, Adam J. Pinney, George Zakhem, Ann Kendzicky, Elena Schiopu, Dinesh Khanna, David A. Fox and Alisa E. Koch, Division of Rheumatology, University of Michigan Medical Center, Ann Arbor, MI, University of Michigan Medical School, Ann Arbor, MI 08 0 Program Book

211 ACR POSTER SESSION A 658. Elevated 8-Isoprostane In Scleroderma: Implications Of Its Role In Inhibiting Vascular Endothelial Growth Factor- Induced Angiogenesis. Pei-Suen Tsou, George Zakhem, Beatrix Balogh, M. Asif Amin, Phillip Campbell, Gautam Edhayan, Ray Ohara, Elena Schiopu, Dinesh Khanna, Alisa E. Koch and David A. Fox, Division of Rheumatology, University of Michigan Medical Center, Ann Arbor, MI, University of Michigan Medical School, Ann Arbor, MI, University of Michigan, Ann Arbor, MI 659. Circulating Cell-free micrornas in Systemic Sclerosis. Samantha Steen, Anting L. Carlsen, Line V. Iversen, Christoffer T. Nielsen, Christian Lood, Anders A. Bengtsson and Niels H. H. Heegaard, Statens Serum Institut, Copenhagen, Denmark, University Hospital Rigshospitalet, Copenhagen, Denmark, Lund University, Lund, Sweden 660. Bleomycin Delivery By Mini-Osmotic Pump: A Novel Multi-Organ Murine Model For Fibrosis. Rebecca Lee, Elena Tourkina, Richard P. Visconti and Stanley Hoffman, Medical University of SC, Charleston, SC 66. Topoisomerase- Specific T Cells Exhibit a Proinflammatory Th7 Phenotype and Are Associated With Interstitial Lung Disease In Scleroderma. Andrea Fava, Raffaello Cimbro, Antony Rosen, Qing-Rong Liu, Fredrick M. Wigley and Francesco Boin, Johns Hopkins University, Baltimore, MD, NIH/NIDA, Baltimore, MD, Johns Hopkins University School of Medicine, Baltimore, MD 66. Oxidative Stress-Dependent Activation Of Collagen Synthesis Is Induced In Human Pulmonary Vascular Smooth Muscle Cells By Scleroderma Sera and Predicts Pulmonary Vascular Disease. Francesco Boin, Anna Maria Posadino, Annalisa Cossu, Roberta Giordo, Ami A. Shah, Gaia Spinetti, Gian Luca Erre, Costanza Emanueli 4, Giuseppe Passiu, Fredrick M. Wigley and Gianfranco Pintus, Johns Hopkins University School of Medicine, Baltimore, MD, University of Sassari, Sassari, Italy, Istitituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Multi Medica, Milan, Italy, 4 University of Bristol, Bristol, United Kingdom 66. Propylthiouracil Attenuates Aortic Vasculopathy In An Animal Model Of Systemic Sclerosis. Gianluca Bagnato, Alessandra Bitto, Gabriele Pizzino, Neal Roberts, Domenica Altavilla, Francesco Squadrito, Gianfilippo Bagnato and Antonino Saitta, University of Messina, Messina, Italy, University of Louisville, Louisville, KY 664. Formate, Acetate and Acetone: News Biomarkers in Systemic Sclerosis identified by Metabolomics. Emmanuel Chatelus, Francois Marie Moussallieh, Christelle Sordet, Arnaud Theulin, Alain Meyer, Karim El Bayed, Jean Francois Kleinmann, Jean Sibilia, Jacques- Eric Gottenberg and Izzie Jacques Namer, Strasbourg University Hospital, Strasbourg, France, UMR 777 CNRS/ Strasbourg University, Strasbourg, France 665. DNA hypermethylation of Forkhead box protein (FOXP) locus leads to quantitative defects of regulatory T cells in systemic sclerosis. Yaoyao Wang, Ye Shu, Qing Wang, Ming Zhao, Gongping Liang, Qianjin Lu and Rong Xiao, Second Xiangya Hospital, Central South University, Changsha, China, Hunan Children s Hospital, Changsha, China 666. Involvement Of TCR Vdelta + NKT Cells In Systemic Sclerosis: Association With Interstitial Pneumonia. Seiji Segawa, Daisuke Goto, Masanobu Horikoshi, Yuya Kondo, Naoto Umeda, Shinya Hagiwara, Masahiro Yokosawa 4, Tomoya Hirota, Haruka Miki, Hiroto Tsuboi, Hiroshi Ogishima, Takeshi Suzuki 4, Isao Matsumoto and Takayuki Sumida, University of Tsukuba, Ibaraki, Japan, University of Tsukuba, Tsukuba City, Japan, University of Tsukuba, Tsukuba, Japan, 4 University of Tsukuba, Tsukuba, Ibaraki, Japan 667. IL6 and CCL Co-Regulate Fibroblast Dependent Trans- Endothelial Migration Of Mononuclear Cells and Fibrotic Response In Scleroderma. Rebecca Alade, Korsa Khan, Xu Shiwen, Christopher P. Denton and Voon Ong 4, UCL Medical School, London, United Kingdom, UCL medical School, London, United Kingdom, Royal Free Hospital, London, United Kingdom, 4 UCL Medical School, London, England 668. Enhanced Expression Of The Cold-Sensing Receptor- TRPM8 In Scleroderma Endothelial Cells and Skin and Endothelial Dysfunction Following TRPM8 Activation. Yongqing Wang, David R. Giovannucci and Bashar Kahaleh, University of Toledo, Toledo, OH 669. Up-Regulated Expression Of CXCL5 In Circulating Platelets From Patients With Systemic Sclerosis: A Role In Fibrosis. Hidekata Yasuoka, Ken Stern, Yuka Okazaki, Tetsuya Nishimoto, Tsutomu Takeuchi and Masataka Kuwana, Keio University School of Medicine, Tokyo, Japan Systemic Sclerosis, Fibrosing Syndromes, and Raynaud s - Clinical Aspects and Therapeutics I 670. Serum Proteins and Whole Blood Transcripts Suppressed By An Anti-Type I Interferon Receptor Monoclonal Antibody In Subjects With Systemic Sclerosis. Xiang Guo, Brandon W. Higgs, Christopher Kane, Chris, A. Morehouse, Zheng Liu, Liangwei Wang, Stephen Yoo, Yihong Yao, Lorin Roskos and Wendy White, MedImmune, LLC, Gaithersburg, MD, MedImmune, Gaithersburg, MD 67. Autoantibody Diversity In Scleroderma Patients With Antinucleolar Antibodies and Negative For Three Major Disease-Specific Markers. Sarada Nandiwada, Troy Jaskowski, Maureen D. Mayes, Minoru Satoh 4 and Anne E. Tebo, University of Utah, Salt Lake City, UT, ARUP Laboratories, Salt Lake City, UT, University of Texas Health Science Center at Houston, Houston, TX, 4 University of Florida, Gainesville, FL 0 Program Book 09

212 ACR POSTER SESSION A Anti-Th/To Antibodies In Various Systemic Rheumatic Diseases Screened By Anti-Rpp5 ELISA. Ann D. Chauffe, Eric S. Sobel, Michael R. Bubb, Westley H. Reeves, Michael Mahler, Cristina Gascon, Jason Y.F. Chan, S. John Calise, Edward K.L. Chan and Minoru Satoh, University of Florida, Gainesville, FL, INOVA Diagnostics, San Diego, CA, INOVA Diagnostics, Inc., San Diego, CA 67. Anti-Fibrillarin Antibodies Are Associated With More Severe Gastrointestinal Involvement and Poorer Survival. Shervin Assassi, Marie Hudson, Maureen D. Mayes, Jennifer Walker, Murray Baron, Wendy Stevens 4, Karen Patterson 5, Tiffany Graham, Solene Tatibouet, James Wick 6, Matt Stephenson 6 and Marvin J. Fritzler 6, University of Texas Health Science Center at Houston, Houston, TX, McGill University, Montreal, QC, Flinders Medical Centre, Adelaide, Australia, 4 St Vincent s Hospital, Melbourne, Australia, 5 Institute of Medical and Veterinary Science, North Adelaide, Australia, 6 University of Calgary, Calgary, AB 674. Systemic Sclerosis Disease Subset Is a Better Predictor Of Long Term Outcome Than Autoantibody Profile. Svetlana I. Nihtyanova, Voon H. Ong and Christopher P. Denton, Royal Free and University College Medical School, London, United Kingdom, The Royal Free and University College Medical School, London, United Kingdom 675. Impact Of Male Sex On Survival In Systemic Sclerosis. Haseena Hussein, Peter Lee, Cathy Chau and Sindhu R. Johnson 4, Toronto Scleroderma Research Program, Mount Sinai Hospital, Toronto Western Hospital, University of Toronto, Toronto, ON, Mt. Sinai Hospital, Toronto, ON, Toronto Scleroderma Research Program, Toronto Western Hospital, Mount Sinai Hospital, University of Toronto, Toronto, ON, 4 Division of Rheumatology, Toronto Western Hospital, University Health Network Pulmonary Hypertension Programme, Toronto General Hospital, Mount Sinai Hospital and University of Toronto, Toronto, ON 676. Early Systemic Sclerosis: Marker Autoantibody Positive Patients Have A Faster Pace Of The Disease. Gabriele Valentini, Antonella Marcoccia, Michele Iudici, Serena Vettori and Giovanna Cuomo, Rheumatology Unit, Second University of Naples, Naples, Italy, Angiology Unit, Sandro Pertini Hospital, Rome, Italy 677. Effect Of Menopause On Skin Thickening In Systemic Sclerosis. Evelyne Vinet, Sasha Bernatsky, Christian A. Pineau, Marie Hudson, Murray Baron and the Canadian Scleroderma Research Group, McGill University Health Center, Montreal, QC, McGill University, Montreal, QC, McGill University Health Centre, Montreal, QC 678. Quantifying Change In Pulmonary Function As a Prognostic Marker In Systemic Sclerosis-Related Interstitial Lung Disease. Owen Moore, Susanna Proudman, Nicole Goh, Tamera Corte 4, Hannah Rouse, Oliver Hennessy, Vivek Thakkar 5, Joanne Sahhar 6, Janet E. Roddy 7, Peter Youssef 4, Eli Gabbay 7, Peter Nash 8, Jane Zochling 9, Wendy Stevens 5 and Mandana Nikpour 0, St. Vincent s Hospital, Melbourne, Australia, Royal Adelaide Hospital, Adelaide, Australia, Alfred Hospital, Melbourne, 0 Program Book 679. Australia, 4 Royal Prince Alfred Hospital, Sydney, Australia, 5 St Vincent s Hospital, Melbourne, Australia, 6 Monash Medical Centre, Clayton, Australia, 7 Royal Perth Hospital, Perth, Australia, 8 Nambour Hospital, Sunshine Coast, Australia, 9 Menzies Research Institute Tasmania, Hobart, Australia, 0 University of Melbourne, Fitzroy, Australia 680. Validation Of a Novel Radiographic Scoring System For Calcinosis Affecting The Hands Of Patients With Systemic Sclerosis. Lorinda Chung, Antonia Maria Valenzuela Vergara, David Fiorentino, Kate Stevens, Shufeng Li, Jonathan Harris 4, Charles E. Hutchinson 5, Shervin Assassi 6, Lorenzo Beretta 7, Santhanam Lakshminarayanan 8, Tatiana Rodriguez Reyna 9, Christopher P. Denton 0, Rebecca G. Taillefer, Solene Tatibouet, Ariane Herrick and Murray Baron 4, Stanford Univ Medical Center, Palo Alto, CA, Stanford University School of Medicine, Stanford, CA, Stanford University School of Medicine, Redwood City, CA, 4 Salford Royal Hospital, Manchester, United Kingdom, 5 University of Warwick, Coventry, United Kingdom, 6 University of Texas Health Science Center at Houston, Houston, TX, 7 Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico, Milan, Italy, 8 University of Connecticut School of Medicine, Farmington, CT, 9 Instituto Nacional de Ciencias Médicas y Nutrición, Mexico City, Mexico, 0 Royal Free and University College Medical School, London, United Kingdom, University of Montreal, Montreal, QC, McGill University, Montreal, QC, University of Manchester, Salford, United Kingdom, 4 Jewish General Hospital, Montreal, QC 68. Diastolic Dysfunction Amongst Autoantibody Subgroups Of Patients With Diffuse Scleroderma. Cory Perugino, John Stephens, Colin O Rourke and Soumya Chatterjee, Cleveland Clinic, Cleveland, OH 68. Survival After Lung Transplantation In Systemic Sclerosis. A Systematic Review. Irfan Y. Khan, Lianne G. Singer, Marc de Perrot, John T. Granton 4, Shaf Keshavjee, Cathy Chau 5, Amie T. Kron 6 and Sindhu R. Johnson 7, Pulmonary Hypertension Programme, University Health Network, University of Toronto, Toronto, ON, Division of Respirology, University of Toronto; and Toronto Lung Transplant Program, University Health Network, Toronto, ON, Toronto Lung Transplant Program, Division of Thoracic Surgery, University Health Network, University of Toronto, Toronto, ON, 4 Toronto Pulmonary Hypertension Programme, Toronto General Hospital and University of Toronto, Toronto, ON, 5 Toronto Scleroderma Research Program, Toronto Western Hospital, Mount Sinai Hospital, University of Toronto, Toronto, ON, 6 Toronto Scleroderma Research Program, Toronto Western Hospital, Mount Sinai Hospital, and University of Toronto, Toronto, ON, 7 Division of Rheumatology, Toronto Western Hospital, University Health Network Pulmonary Hypertension Programme, Toronto General Hospital, Mount Sinai Hospital and University of Toronto, Toronto, ON 68. Effects Of Extracoporeal Shock Wave Therapy To The Digital Ulcers Of Scleroderma:a Pilot Study. Shinichiro Saito, Yukiko Kamogawa, Kyohei Nakamura, Ryu Watanabe, Tsuyoshi Shirai, Yoko Fujita, Hiroshi Fujii, Yuko Shirota, Tomonori Ishii, Hideo Harigae, Katsuko Kikuchi and Yasushi Kawaguchi, Tohoku University, Sendai, Japan, Tokyo Women s Medical University, Tokyo, Japan

213 ACR POSTER SESSION A 684. HRCT Predictors Of Decline In FVC% predicted Implications For Cohort Enrichment For Scleroderma Lung Disease (SLD) Trials. Dinesh Khanna, Chi-hong Tseng, Robert D. Suh, Fereidoun Abtin 4, Athol U. Wells 5, Donald Tashkin 6 and Jonathan Goldin 7, University of Michigan, Ann Arbor, MI, University of California Los Angeles, David Geffen School of Medicine, Los Angeles, CA, Ronald Reagan UCLA Medical Center, Los Angeles, CA, 4 University of California Los Angeles Medical Center, Santa Monica, CA, 5 Department of Radiology, London, United Kingdom, 6 David Geffen School of Medicine at UCLA, Los Angeles, CA, 7 David Geffen School of Medicine at UCLA, Santa Monica, CA 685. Clinical Characteristics Of Scleroderma Patients With Calcinosis In a Single-Center Cohort. Danielle Velez and Vivien M. Hsu, RWJMS, South Plainfield, NJ, RWJ Med Schl Scleroderma Prog, New Brunswick, NJ 686. Lung Function and Survival In Systemic Sclerosis Associated Interstitial Lung Disease. Samar M. Shadly, Sindhu R. Johnson, Cathy Chau and Theodore K. Marras 4, University Health Network Interstitial Lung Diseases Program, University Health Network and Mount Sinai Hospital, Toronto, ON, Division of Rheumatology, Toronto Western Hospital, University Health Network Pulmonary Hypertension Programme, Toronto General Hospital, Mount Sinai Hospital and University of Toronto, Toronto, ON, Toronto Scleroderma Research Program, Toronto Western Hospital, Mount Sinai Hospital, University of Toronto, Toronto, ON, 4 University Health Network Interstitial Lung Diseases Program, University Health Network and Mount Sinai Hospital, University of Toronto, Toronto, ON 687. Blood Flow In The Hands Of a Predefined Homogeneous Systemic Sclerosis Population: The Presence Of Digital Ulcers and The Improvement With Bosentan. Jessica Meijs, Annemie J.M. Schuerwegh, Alexandre E. Voskuyl, Joanne P.J. Bloemsaat-Minekus and Madelon C. Vonk 4, Leiden University Medical Center, Leiden, Netherlands, VU University Medical Center, Amsterdam, Netherlands, Actelion, Woerden, Netherlands, 4 Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands 688. Role Of Class II Human Leukocyte Antigens In The Progression From Early To Definite Systemic Sclerosis. Barbara Vigone, Alessandro Santaniello, Maurizio Marchini, Gaia Montanelli, Monica Caronni, Adriana Severino, Stefania Celeste and Lorenzo Beretta, Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico, Milan, Italy 689. Minimal Clinically Important Investigations In Systemic Sclerosis. Jessica Meijs, Anne A. Schouffoer, Nina Ajmone Marsan, Maarten K. Ninaber and Tom W.J. Huizinga, Leiden University Medical Center, Leiden, Netherlands 690. Subclinical Biventricular Systolic Function Is Impaired In Patients With Systemic Sclerosis: A Speckle Tracking- Based Echocardiographic Study. Sukru Taylan Sahin, Selen Yurdakul, Neslihan Yilmaz, Yonca Cagatay, Saide Aytekin and Sule Yavuz, Istanbul Florence Nightingale Hospital, Cardiology, Istanbul, Turkey, Bilim University, Faculty of Medicine, Cardiology Department, Istanbul, Turkey, Bilim University, Faculty of Medicine, Rheumatology Department, Istanbul, Turkey 69. Assessment Of The New American and European Classification Criteria For Systemic Sclerosis In The Norwegian Systemic Connective Tissue Disease and Vasculitis Registry. Anna-Maria Hoffmann-Vold, Torhild Garen, Oyvind Midtvedt and Øyvind Molberg, Oslo University Hospital, Oslo, Norway, Oslo University Hospital Rikshospitalet, Oslo, Norway 69. Descriptive Review Of Morphea Subjects From a Single Cohort Center. Lesley Portugal, Muneera Naeem, Lakshmi N. Moorthy and Vivien M. Hsu 4, Robert Wood Johnson Medical School, New Brunswick, NJ, Mountainside Hospital, Montclair, NJ, Robert Wood Johnson Medical School-UMDNJ, New Brunswick, NJ, 4 RWJ Med Schl Scleroderma Prog, New Brunswick, NJ 69. Characterization Of Lower Limb Cutaneous Ulcers In Systemic Sclerosis: The Analysis of 44 Lesions. Jelena Blagojevic, Guya Piemonte, Laura Benelli, Francesca Braschi, Ginevra Fiori, Felice Galluccio, Francesca Bartoli, Lorenza Busco, Alberto Pignone, Giulia Carnesecchi, Gemma Lepri, Serena Guiducci and Marco Matucci Cerinic, University of Siena, Siena, Italy, University of Florence, Florence, Italy 694. Pulmonary Involvement In Mixed Connective Tissue Disease: Slow Progression After 0 Years Of Follow-Up. Leticia Kawano-Dourado, Olivia M Dias, Fernando U Kay, Thais E H Gripp, Paula S Gomes, Ricardo Fuller, Bruno G Baldi, Ronaldo A Kairalla, Carlos R R Carvalho and M.Teresa C. Caleiro, University of Sao Paulo, Sao Paulo, Brazil, Hospital do Servidor do Estado de Sao Paulo, São Paulo, Brazil, University of Sao Paulo, São Paulo, Brazil 695. Peripheral Bone Marrow-Derived Endothelial Progenitor Cells and N-Terminal Probrain Natriuretic Peptide in Scleroderma Mexican Patients With and Without Diastolic Dysfunction: A Preliminary Report. Jesús Sepúlveda, Olga Vera-Lastra, Maria Pilar Cruz-Dominguez, Laura Montiel- Cervantes, Joaquín Gómez-León, Luis Robles-Espinoza, Ramón Lozano-Morales, Sergio Mendoza-Alvarez, Rubiraida Molina-Aguilar, Gabriela Medina 4, Jorge Vela- Ojeda and Luis J. Jara 5, Instituto Mexicano del Seguro Social, Mexico City, Mexico, MD, Mexico City, Mexico, Hospital de Especialidades Centro Medico Nacional La Raza., Mexico, DF, Mexico, 4 Seris/Zachila s/n La Raza, Mexico City, Mexico, 5 Hospital de Especialidades Centro Medico La Raza, México City, Mexico 696. Combined Pulmonary Fibrosis and Emphysema (CPFE) In Systemic Sclerosis. Nicolas Champtiaux, Vincent Cottin, Eric Hachulla, Dominique Valeyre 4, Hilario Nunes 4, David Launay 5, Alice Berezne 6, Bruno Crestani 7, Loic Guillevin 8, Jean-Francois Cordier and Luc Mouthon 9, Service de Médecine Interne, hôpital Cochin, Assistance Publique- Hôpitaux de Paris (AP-HP), Paris, France, Division of Pneumology, Hôpital Louis-Pradel, Hospices Civils de Lyon, Lyon, Lyon, France, Internal Medicine, Lille CEDEX, France, 4 Avicenne Hospital (AP-HP), Bobigny, France, 5 Claude Huriez University Hospital, Lille, France, 6 Paris Descartes University, Internal Medicine department, Cochin Hospital, Paris, France, 7 Hôpital Bichat, Paris, France, 8 Cochin University Hospital, Paris, France, 9 Department of Internal Medicine, Referral Center for Rare Autoimmune and Systemic Diseases, Hôpital Cochin, AP HP, Université Paris Descartes, Paris, France, Paris, France 0 Program Book

214 ACR POSTER SESSION A 697. Chronic Periaortitis With Thoracic Aorta Involvement: A New Subtype Of Large Vessel Vasculitis. Alessandra Palmisano, Maria Letizia Urban, Domenico Corradi, Federico Alberici, Carlo Salvarani 4, Carlo Buzio and Augusto Vaglio, University of Parma, Parma, Italy, Nephrology University of Parma, Parma, Italy, Pathology University of Parma, Parma, Italy, 4 Arcispedale S Maria Nuova-IRCCS, Reggio Emilia, Italy 698. Longitudinal Assessment Of Pulmonary Function In 04 Norwegian Patients With Systemic Sclerosis. Anna-Maria Hoffmann-Vold, Torhild Garen, Oyvind Midtvedt, May- Brit Lund, Jan Tore Gran and Øyvind Molberg, Oslo University Hospital, Oslo, Norway, Oslo University Hospital Rikshospitalet, Oslo, Norway, Oslo University Hospital, Rikshopitalet, Oslo, Norway 699. Adverse Events With The Use Of Radiotherapy In Patients With Connective Tissue Diseases and Cancer: A Systematic Review and Meta-Analysis. Maria A. Lopez- Olivo, Juan A Martínez-López, Jean H. Tayar, Mahesh Bavineni 4 and Maria E. Suarez-Almazor 5, University of Texas. M.D Anderson Cancer Center, Houston, TX, Jiménez Díaz Foundation University Hospital, Madrid, Spain, University of Texs, MD Anderson Cancer Center, Houston, TX, 4 Louisiana State University Lafayette, Lafayette, LA, 5 University of Texas MD Anderson Cancer Center, Houston, TX 700. Severity Of Muscle Weakness Predicts Disability In Scleroderma. Julie J. Paik, Fredrick M. Wigley, Amanda Mejia and Laura K. Hummers, Johns Hopkins University School of Medicine, Baltimore, MD, Johns Hopkins Bloomberg School of Publich Health, Baltimore, MD 70. Osteoporosis and Fracture Risk In Outpatients With Systemic Sclerosis. Veronica Codullo, Flora Inverardi, Silvia Breda, Laura Bogliolo 4, Francesca De Nard 5, Giovanni Cagnotto 5, Roberto Caporali 6 and Carlomaurizio Montecucco 7, IRCCS Policlinico San Matteo Foundation, Pavia, Italy, Division of Rheumatology, IRCCS Policlinico San Matteo Foundation and University of Pavia, Pavia, Italy, University of Pavia, IRCCS Foundation Policlinico San Matteo, 700, Italy, 4 IRCCS Foundation Policlinico San Matteo, Pavia, Italy, 5 University of Pavia/ IRCCS Policlinico San Matteo Foundation, Pavia, Italy, 6 Rheumatology, IRCCS Policlinico San Matteo Foundation and University of Pavia, Pavia, Italy, 7 University and IRCCS Policlinico S. Matteo Foundation, Pavia, Italy 70. Extension Of Cardiac Damage Through The Delayed Enhancement Of Cardiac Magnetic Resonance: Predictive Value Of a Combined Approach Based On Clinical and Laboratory Findings, EKG-Holter and Cardiac Magnetic Resonance. Silvia Laura Bosello, Giacomo De Luca, Agostino Meduri, Giorgia Berardi, Manuela Rucco, Giovanni Canestrari, Federico Parisi and Gianfranco Ferraccioli, Division of Rheumatology, Institute of Rheumatology and Affine Sciences, Catholic University of the Sacred Heart, Rome, Italy, INSTITUTE OF RADIOLOGY - Catholic University of the Sacred Heart, ROME, Italy 70. Prediction Of Worsening Of Skin Fibrosis In Patients With Diffuse Systemic Sclerosis Using The EULAR Scleroderma Trials and Research (EUSTAR) Registry. Britta Maurer, Nicole Graf, Beat A. Michel, Carola Metzig, Vivian Lanius, Dinesh Khanna 4 and Oliver Distler, Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland, graf biostatistics, Winterthur, Switzerland, Bayer Pharma AG, Berlin, Germany, 4 Division of Rheumatology, University of Michigan Medical Center, Ann Arbor, MI 704. Correlation Between Patient Self-Report Of Symptoms Of Raynaud s Phenomenon and Objective Assessment Of Digital Microvascular Perfusion Using Infrared Thermography. Marina Scolnik, Bhavisha Vasta, Darren Hart, Jacqueline A. Shipley, Sue Brown, Eleanor Korendowych, Neil J McHugh and John D. Pauling, Rheumatology Section, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, Department of Pharmacy and Pharmacology, University of Bath, Bath, United Kingdom 705. Evaluating The Effects Of Combination Aspirin and Dipyridamole (asasantin retard) On Platelet Function, Oxidative Stress and Peripheral Vascular Function In Primary Raynaud s Phenomenon and Systemic Sclerosis. John D. Pauling, Jacqueline A. Shipley, Darren Hart, Ginger L. Milne and Neil J McHugh, Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, Vanderbilt University, Nashville, TN, Department of Pharmacy and Pharmacology, University of Bath, Bath, United Kingdom 706. Treatment With Rituximab Reduces Activation Of Scleroderma Dermal Fibroblasts. Paolo Fraticelli, Salvatore De Vita, Nicoletta Franzolini, Silvia Svegliati 4, Cecilia Tonnini 4, Barbara Gabrielli 4, Cathryn Anne Scott 5, Giovanni Pomponio 6, Gianluca Moroncini 4 and Armando Gabrielli 4, Istituto di Clinica Medica, Università Politecnica delle Marche, Ancona, Italy, Rheumatology Clinic, DSMB, University of Udine, Udine, Italy, Presidio Ospedaliero di San Daniele del Friuli, ASS 4 Medio Friuli, Udine, Italy, 4 Università Politecnica delle Marche, Ancona, Italy, 5 Università degli studi di Udine, Udine, Italy, 6 Ospedali Riuniti, Ancona, Italy 707. Effect Of Aminaftone On Raynaud s Phenomenon Secondary To Systemic Sclerosis: A Double-Blind Prospective, Randomized, Placebo-Controlled Pilot Study. Alessandro Santaniello, Barbara Vigone, Monica Caronni and Lorenzo Beretta, Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico, Milan, Italy 708. Different Location and Extent Of Impaired Perfusion Of The Choroid Plexus In Primary and Secondary Raynaud s Phenomenon. Francesca Ingegnoli, Roberta Gualtierotti, Luisa Pierro, Elisabetta Miserocchi 4, Giulio Modorati 5, Claudia Del turco, Marco Gagliardi, Giuseppe Parrinello, Tommaso Schioppo and Pier Luigi Meroni 6, Rheumatology, Istituto G. Pini, University of Milan, Milano, Italy, Division of Rheumatology, Istituto G. Pini, University of Milan, Milano, Italy, Vita-Salute University, San Raffaele Scientific 0 Program Book

215 ACR POSTER SESSION A Institute, Milano, Italy, 4 Scientific Institute San Raffaele, University Vita-Salute, Milan, Italy, 5 Ocular immunology and uveitis service, Milano, Italy, 6 Division of Rheumatology, Gaetano Pini Institute, Milano, Italy 709. Intravenous Immunoglobulin May Be An Effective Therapy In Scleroderma Patients With Refractory Active Diffuse Cutaneous Disease. Corrie Poelman, Laura K. Hummers, Fredrick M. Wigley, Cynthia Anderson, Francesco Boin and Ami A. Shah, Johns Hopkins University School of Medicine, Baltimore, MD 70. Nilotinib (Tasigna ) In The Treatment Of Early Diffuse Systemic Sclerosis: A Single Group, Open Label Pilot Clinical Trial One Year Results. Jessica K. Gordon, Cynthia Magro, Uzunma Udeh, Daniele Lerner, Horatio F. Wildman, Wei-Ti Huang, Mary K. Crow and Robert F. Spiera, Hospital for Special Surgery, New York, NY, Weill- Cornell Medical Center, New York, NY T-cell Biology and Targets in Autoimmune Disease: Signaling Pathways in T-cell Differentiation 7. Interleukin-6 Driven STAT Phosphorylation In Circulating Lymphocytes Is Specific For CD4 + T Cells In Early Rheumatoid Arthritis. Amy E. Anderson, Christine Routledge, Philip Mawson, John D. Isaacs and Arthur G. Pratt, Newcastle University, Newcastle upon Tyne, United Kingdom, The Freeman Hospital, Newcastle upon Tyne, United Kingdom 7.,5(OH) D Inhibits Th7 Cytokine Production and RORγt Expression Through GATA/IL4-Dependent and -Independent Mechanisms. Wendy Dankers, Jan Piet van Hamburg, Anne-Marie Mus, Patrick S. Asmawidjaja, Johannes van Leeuwen, Rudi W. Hendriks, Louis Boon, Edgar Colin 4 and Erik Lubberts, Erasmus MC, University Medical Center, Rotterdam, Netherlands, Erasmus Medical Center, Rotterdam, Netherlands, Bioceros, Utrecht, Netherlands, 4 ZGT, Almelo, Netherlands 7. Increased IL- Receptor Expression Is Observed On KIRDL+ CD4+ T Cells In Ankylosing Spondylitis and Correlates With IL-R Polymorphisms. A. Ridley, C. Cohen, T. Karaderi, S. Kollnberger, I. Wong-Baeza, J. Shaw, P. Wordsworth and P. Bowness, University of Oxford, Oxford, United Kingdom 74. Interferon Regulatory Factor Haploinsufficiency Deteriorates Imiquimod-Induced Psoriasis-Like Skin Inflammation. Takayuki Kimura, Makoto Sugaya, Makiko Kawaguchi, Sohshi Morimura, Hiraku Suga and Shinichi Sato, The University of Tokyo, Tokyo, Japan 75. Combination Blocking Of Interleukin-6 and Interleukin- In Experimental Arthritis Inhibits Their Redundant Role In T Helper 7-Driven Joint Pathology. Debbie M. Roeleveld, Marije I. Koenders, Renoud J. Marijnissen, Cheryl L. Nickerson-Nutter, Fons A. van de Loo and Wim B. van den Berg 4, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, Rheumatology Research and Advanced Therapeutics, Radboud University Nijmegen Medical Center, Nijmegen, Netherlands, Pfizer, Cambridge, MA, 4 Rheumatology Research and Advanced Therapeutics, Department of Rheumatology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands 76. Protein Phosphatase 5 (PP5) Regulates Methylation Sensitive Gene Expression In CD4+ T Cells. Dipak R. Patel, Gabriela Gorelik and Bruce C. Richardson, University of Michigan, Ann Arbor, MI 77. The Active Metabolite Of Spleen Tyrosine Kinase Inhibitor Fostamatinib Abrogates The T Cell Priming Capacity Of Dendritic Cells. Andrew Platt, Ross McQueenie, Robert Benson, John Butcher, Martin Braddock, James M. Brewer, Iain B. McInnes and Paul Garside, University of Glasgow, Glasgow, United Kingdom, Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom, AstraZeneca R&D Alderley Park, Macclesfield, United Kingdom 78. Patients With Rheumatoid Arthritis Have Impaired Candida Albicans Specific Th7 Responses But Preserved Oral Candida Albicans Protective Immunity. Shrinivas Bishu, E. Wern Su, Erich Wikerson, Donald M. Jones, Kelly A. Reckley, Sarah L. Gaffen and Marc C. Levesque, University of Pittsburgh, Pittsburgh, PA, University of Pittsburgh School of Medicine, Pittsburgh, PA 79. Mesenchymal Stem Cells and Skin Fibroblasts Both Suppress Early Steps In T Cell Activation In a Nitric-Oxide Dependent Manner. Runsheng Wang, Francoise Meylan, Jizhong Zou, Mahendra Rao and Richard M. Siegel 4, NIH/ NIAMS, Rheumatology fellowship and training branch, Bethesda, MD, NIH/NIAMS, autoimmunity branch, Bethesda, MD, NIH/NIAMS, center for regenerative medicine, Bethesda, MD, 4 National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD 70. Mammalian Target Of Rapamycin (mtor) Skews T Cell Lineage Development In Systemic Lupus Erythematosus (SLE). Hiroshi Kato and Andras Perl, SUNY Upstate Medical University, Syracuse, NY 7. Abatacept Efficacy Is Overruled By IL-7 In TSLP-Primed Myeloid Dendritic cell driven T Cell Activation From Rheumatoid Arthritis Patients. F.M. Moret, T.R.D.J. Radstake, J.W.J. Bijlsma, F.P.J.G. Lafeber and J.A.G. van Roon, University Medical Center Utrecht, Utrecht, Netherlands 7. T Cell Activation Induces Increased mrna Expression Of The Splicing Factor SF/ASF But Simultaneous Protein Downregulation Via Proteasome Mediated Degradation. Vaishali R. Moulton, Andrew R. Gillooly and George C. Tsokos, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 7. BAFF Promotes T Follicular Helper Cell Development and Germinal Center Generation In Mice. Song Guo Zheng, Maogeng Chen, Qiang Li and William Stohl, University of Southern California Keck School of Medicine, Los Angeles, CA 0 Program Book

216 ACR POSTER SESSION A 74. Abatacept Is Highly Effective At Inhibiting T Cell Priming and Induces a Unique Transcriptional Profile In CD4 + t Cells. Agapitos Patakas, Rui-Ru Ji, William Weir, Sean Connolly, Steven G. Nadler, James M. Brewer, Iain B. McInnes and Paul Garside, University of Glasgow, Glasgow, United Kingdom, Bristol Myers Squibb Co. Research and Development, Princeton, NJ 75. Dose-Dependent Suppression Of Cytokine Production From T Cells By a Novel Phosphoinositide -Kinase Delta Inhibitor. Emily E. Way, Kong Chen, Kamal D. Puri and Jay K. Kolls, Children s Hospital of Pittsburgh of UPMC, Pittsburgh, PA, Gilead Sciences, Inc., Seattle, WA 76. Localization At The Immunological Synapse Of Adaptor Protein Grb and PLC Gamma- In Non-Stimulated Peripheral Blood T Lymphocytes From Patients With Systemic Lupus Erythematosus Suggests An In Vivo dysregulated Activation State. Nursamaa Abdoel, Mireyma Sanchez, Hector Rojas, Martin Rodriguez and Ana M. Blasini, Hospital Universitario de Caracas, Caracas, Venezuela, Instituto de Inmunologia, Escuela de Medicina, Universidad Central de Venezuela, Caracas, Venezuela 77. Tofacitinib Does Not Inhibit Dendritic Cell Maturation and T Cell Proliferation In Vitro. Emmanuelle Le Bras, Dagmar Halbritter and Martin Fleck, University Medical Center of Regensburg, Regensburg 905, Germany, University Medical Center of Regensburg, 904 Regensburg, Germany, Asklepios Clinic Bad Abbach, Bad Abbach, Germany 78. Adiponectin Promotes The Differentiation Of naïve T Cell To Th7 Cell and Aggravates Collagen-Induced Arthritis. Miaojia Zhang, Xiaoxuan Sun, Wenfeng Tan, Xiaoke Feng 4 and Ke Gan, the First Affiliated Hospital of Nanjing Medical University, Nanjing, CHINA., Nanjing, China, the First Affiliated Hospital of Nanjing Medical University, Nanjing, CHINA, Nanjing, China, the First Affiliated Hospital of Nanjing Medical University, Nanjing, China, 4 the First Affiliated Hospital of Nanjing Medical University, China, Nanjing, China Vasculitis I 79. Unraveling The Identity Of FoxP + Regulatory T-Cells In Gpa-Patients. WH Abdulahad, Coen A. Stegeman, MG Huitema, Pieter C. Limburg, Abraham Rutgers, Peter Heeringa and Cees G.M. Kallenberg, University Medical Center Groningen, Groningen, Netherlands 70. Role Of Innate Immunity In The Pathogenesis Of ANCA-Associated Vasculitis. Angelica Gattamelata, Giovanna Peruzzi, Rossana Scrivo, Roberta Priori, Stefania Morrone, Angela Santoni and Guido Valesini, Department of Internal Medicine and Medical Specialties, Sapienza University, Rome, Italy, Department of Molecular Medicine, Sapienza University, Rome, Italy, Department of Experimental Medicine, Sapienza University, Rome, Italy 7. Cell-Mediated Immune Responses To Influenza and Herpesvirus Antigen Stimulation Are Conserved But Adversely Impacted By Immunosuppressive Therapy and Active Infection In Patients With Granulomatosis With Polyangiitis. John McKinnon, Robbie Mailliard, Dawn McClemens-McBride, Donald Jones, Charles Rinaldo Jr. and Kathleen Maksimowicz-McKinnon, Henry Ford Hospital, Detroit, MI, University of Pittsburgh, Pittsburgh, PA 7. C Activation Is Associated With The Disease Activity Of Microscopic Polyangiitis. Dan Liu, Jin-song Zhou, Qingping Chen, Chao-yang Duan, Li Wang, Yuan Jia and Ke Li, Peking University People s Hospital, Beijing, China, The Fifth Hospital of Xi an, Xi an, China, The Second Affiliated Hospital, Xi an Jiaotong University, Xi an, China 7. Expansion Of IgA-Plasma Cells As a Sign For Ear-Nose- Throat-Involvment In Granulomatosis With Polyangiitis? Bimba F. Hoyer, Adriano Taddeo, Qingyu Cheng, Laleh Khodadadi, Gerd Burmester and Falk Hiepe, Charité University Medicine, Department of Medicine/ Rheumatology and Clinical Immunology and German Rheumatism Research Centre Berlin (DRFZ), Germany, Berlin, Germany, Deutsches Rheumaforschungszentrum, Berlin, Germany 74. Plasma Levels Of Fibrin/Fibrinogen Degradation Products Might Be a Useful Indicator Of Disease Activity, Classification and Nephritis Complications In Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. Kuninobu Wakabayashi, Nao Oguro, Yoko Miura, Sho Ishii, Shinya Seki, Masayu Umemura, Takahiro Tokunaga, Hiroyuki Tsukamoto, Sakiko Isojima, Hidekazu Furuya, Ryo Yanai, Kumiko Otsuka, Ryo Takahashi, Takeo Isozaki, Nobuyuki Yajima, Yusuke Miwa and Tsuyoshi Kasama, Showa University School of Med, Shinagawa-ku Tokyo, Japan 75. The Significance Of Anti-Myeloperoxidase and Anti- Proteinase Antibodies In The Absence Of Anti- Neutrophil Cytoplasmic Antibody Immunofluorescence Positivity. Deepak A. Rao, Joseph F. Merola, William R. O Brien, Kevin Wei, Samuel U. Takvorian, Paul F. Dellaripa and Peter H. Schur, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 76. Clinical Research Of Microscopic Polyangiitis Combined With Autoimmune Hemolytic Anemia. Dan Liu, Qing-ping Chen, Hai-hong Yao, Ru Li, Yin Su, Jie Zhang, Yu Chen, Ke Li and Yuan Jia, Peking University People s Hospital, Beijing, China, The Fifth Hospital of Xi an, Xi an, China, The Second Affiliated Hospital, Xi an Jiaotong University, Xi an, China 77. Antineutrophil Cytoplasmic Antibody-Associated Vasculitis Associated With Systemic Sclerosis In Japan: A Review Of The Literature. Natsumi Nagao, Yuri Sadanaga, Satoko Tashiro, Rie Suematsu, Syuichi Koarada, Akihide Ohta and Yoshifumi Tada, Saga University, Saga, Japan 4 0 Program Book

217 ACR POSTER SESSION A 78. Home Heating Sources May Be Important In The Etiology Of Granulomatosis With Polyangiitis Results Of An Epidemiological Study. Lisa K. Stamp, Peter T. Chapman, Richard Watts, Christopher Frampton, Janine Francis and John L. O Donnell 4, University of Otago, Christchurch, Christchurch, New Zealand, Christchurch Hospital, Christchurch, New Zealand, Ipswich Hospital, Ipswich, United Kingdom, 4 Canterbury Health Laboratories, Christchurch, New Zealand 79. Pulmonary Fibrosis In ANCA-Associated Vasculitis. Cloé Comarmond, Bruno Crestani, Abdellatif Tazi, Baptiste Hervier 4, Sylvain Adam-Marchand 5, Hilario Nunes 6, Fleur Cohen-Aubart 4, Marie Wislez 7, Jacques Cadranel 7, Bruno Housset 8, Célia Lloret-Linares 9, Pascal Sève 0, Christian Pagnoux, Sébastien Abad, Juliette Camuset, Boris Bienvenu 4, Michael Duruisseaux 5, Eric Hachulla 6, Jean- Benoît Arlet 7, Mohamed Hamidou 8, Alfred Mahr 9, Anne- Laure Brun 0, Philippe Grenier 0, Patrice Cacoub and David Saadoun, Hôpital Pitié Salpétrière, Paris, France, Hôpital Bichat, Paris, France, Hôpital Saint-Louis, Paris, France, 4 Pitié-Salpêtrière Hospital, APHP, Paris, France, 5 Centre Hospitalier Universitaire de Tours, Tours, France, 6 Avicenne Hospital (AP-HP), Bobigny, France, 7 Hôpital Tenon, Paris, France, 8 Centre Hospitalier Intercommunal de Créteil, Créteil, France, 9 Hôpital Lariboisière, Paris, France, 0 CHU Lyon, Lyon, France, Rheumatology, Mount Sinai Hospital, Toronto, Canada, Toronto, ON, Avicenne Hospital, Bobigny, France, Centre Hospitalier Victor Dupouy, Argenteuil, France, 4 Division of Internal Medicine, Centre Hospitalier Régional Universitaire de Caen, Côte de Nacre, Caen, France, Caen, France, 5 CHU de Grenoble, Grenoble, France, 6 Internal Medicine, Lille CEDEX, France, 7 HEGP, Paris, France, 8 Nantes University Hospital, Nantes, France, 9 Department of Internal Medicine, Hospital Saint-Louis, Paris, France, 0 Hôpital Pitié-Salpêtrière, Paris, France, Hopital Pitié-Salpétrière, Paris, France, Department of Internal Medicine and Laboratory I Immunology, Immunopathology, Immunotherapy, UMR CNRS 7, INSERM U959, Groupe Hospitalier Pitié-Salpetrière, Université Pierre et Marie Curie, Paris 6, Paris, France, Paris, France 740. Cardiac Involvement In Granulomatosis With Polyangiitis. Lucy McGeoch, Simon Carette, David Cuthberston, Gary S. Hoffman 4, Nader A. Khalidi 5, Curry L Koening 6, Carol A. Langford 7, Paul A. Monach 8, Larry W. Moreland 9, Philip Seo 0, Ulrich Specks, Steven R. Ytterberg, Carol McAlear, Peter A Merkel, Christian Pagnoux 4 and The Vcrc, Mount Sinai Hospital, University Health Network, University of Toronto, Toronto, ON, UHN/MSH, Toronto, ON, University of South Florida, Tampa, FL, 4 Cleveland Clinic Foundation, Cleveland, OH, 5 McMaster University, Hamilton, ON, 6 George E. Wahlen Department of Veterans Affairs Medical Center Salt Lake City and University of Utah, University of Utah School of Medicine, Salt Lake City, UT, 7 Cleveland Clinic, Cleveland, OH, 8 Boston University, Boston, MA, 9 University of Pittsburgh, Pittsburgh, PA, 0 Johns Hopkins Vasculitis Center, Baltimore, MD, Mayo Clinic, Rochester, MN, University of Pennsylvania, Philadelphia, PA, University of Pennsylvania and VA Medical Center, Philadelphia, PA, 4 Division of Rheumatology, Mount Sinai Hospital, Toronto, ON 74. Clinically Apparent Arterial Thrombosis In Persons With Systemic Vasculitis. Alexander Tsoukas, Christian A. Pineau, Sasha Bernatsky, Lawrence Joseph and Patrick Belisle, McGill University, Montreal, QC, McGill University Health Center, Montreal, QC, Research Institute of the McGill University Health Centre, Montreal, QC 74. Granulomatosis With Polyangiitis Central Nervous System Involvement: Presentation and Management. Gonzalo De Luna, Benjamin Terrier, Pierre Kaminsky, Francois Maurier, Roser Solans 4, Raphaèle Seror 5, Xavier Puéchal 6, Luc Mouthon 7 and Loic Guillevin, Cochin University Hospital, Paris, France, Université de Lorraine, Nancy, F-54000, France; CHU de Nancy, Orphan disease unit, Nancy, F-54000, France;, Nancy, France, Division of internal Medicine, CHR Metz, Metz, Metz, France, 4 Hospital Vall d Hebron, Barcelona, Spain, 5 Bicetre university hospital, LE Kremlin-Bicetre, France, 6 Hôpital Cochin, AP-HP, Université Paris Descartes, Sorbonne Paris Cité, Paris, France, 7 Department of Internal Medicine, Referral Center for Rare Autoimmune and Systemic Diseases, Hôpital Cochin, AP HP, Université Paris Descartes, Paris, France, Paris, France 74. Safety Of Remission Induction With Rituximab Versus Cyclosphosphamide In Patients 65 and Older With Severe ANCA-Associated Vasculitis. Eli Miloslavsky, Ulrich Specks, Peter A Merkel, Philip Seo 4, Robert F. Spiera 5, Carol A. Langford 6, Gary S. Hoffman 7, Cees G.M. Kallenberg 8, E. William St. Clair 9, Nadia Tchao 0, Linna Ding, David Ikle, Brett Jepson, Paul Brunetta and John H. Stone 4, Massachusetts General Hopsital, Boston, MA, Mayo Clinic, Rochester, MN, University of Pennsylvania and VA Medical Center, Philadelphia, PA, 4 Johns Hopkins Vasculitis Center, Baltimore, MD, 5 Hospital for Special Surgery, New York, NY, 6 Cleveland Clinic, Cleveland, OH, 7 Cleveland Clinic Foundation, Cleveland, OH, 8 University Medical Center Groningen, Groningen, Netherlands, 9 Duke University Medical Center, Durham, NC, 0 Immune Tolerance Network, Bethesda, MD, NIAID, Bethesda, MD, Rho, Chapel Hill, NC, Genentech, So San Francisco, CA, 4 Massachusetts General Hospital, Boston, MA 744. Efficacy Of Rituximab For Otolaryngologic (ENT) Manifestations Of Granulomatosis With Polyangiitis (GPA, Wegener s granulomatosis). Lindsay Lally, Robert Lebovics, Wei-Ti Huang and Robert F. Spiera, Hospital for Special Surgery, New York, NY, St. Luke s-roosevelt Hospital Center, New York, NY 745. Relationship Between Infectious Side Effects and Immunoglobulin Levels In The Maintenance Rituximab Vs Azathioprine For ANCA-Associated Vasculitides Trial. Loic Guillevin, Christian Pagnoux, Alexandre Karras, Chahera Khouatra 4, Olivier Aumaître 5, Pascal Cohen 6, Olivier Decaux 7, Hélène Desmurs-Clavel 8, Pierre Gobert 9, Thomas Quemeneur 0, Claire Blanchard-Delaunay, Pascal Godmer, Xavier Puechal, Pierre-Louis Carron 4, Pierre- Yves Hatron 5, Nicolas Limal 6, Mohamed Hamidou 7, Francois Maurier 8, Thomas Papo 9, Matthias Büchler 0, Bernard Bonnotte, Philippe Ravaud and Luc Mouthon, Division of Internal Medicine, Hôpital Cochin, University Paris Descartes, Paris, France, Hôpital Cochin, PARIS, France, Hôpital Européen Georges Pompidou, APHP, 0 Program Book 5

218 ACR POSTER SESSION A 6 Paris, France, 4 CHU Lyon, Lyon, France, 5 Division of internal Medicine, Centre Hospitalier Universitaire, Hôpital Gabriel Montpied, Clermont Ferrand, Clermont Ferrand, France, 6 Cochin University Hospital, Paris, France, 7 Rennes University Hospital, Rennes, France, 8 University of Lyon, LYON, France, 9 Centre Hospitalier d Avignon, Avignon, France, 0 CHR de Valenciennes, Valenciennes, France, Hôpital de Niort, Niort, France, Department of Internal Medicine, Centre Hospitalier Bretagne Atlantique de Vannes, Vannes, France, Department of Internal Medicine, Referral Center for Rare Autoimmune and Systemic Diseases, Hôpital Cochin, AP HP, Université Paris Descartes, Paris, France, Paris, France, 4 Centre Hospitalier de Grenoble, Grenoble, France, 5 Claude Huriez University Hospital, Lille, France, 6 Hôpital Henri Mondor, APHP, Creteil, France, 7 Nantes University Hospital, Nantes, France, 8 Division of internal Medicine, CHR Metz, Metz, Metz, France, 9 University Paris-7, INSERM U699, APHP, Bichat Hospital, Paris, France, 0 University Hospital of Tours, TOURS, France, Centre Hospitalier de Dijon, Dijon, France, Hopital Hotel Dieu, Paris Descartes University, Paris, France 746. Rate Of Infection and Development Of Malignancy In Patients With ANCA-Associated Vasculitis Treated With Rituximab: A Meta-Analysis From Randomized Trials. Carolina Mejia-Otero, Carlos J. Lozada and Luis Arias- Urdaneta, Mount Sinai Medical Center, Miami, FL, University of Miami Miller School of Medicine, Miami, FL, Mount Sinai Medical Center, Miami Beach, FL 747. Glucocorticoid Treatment and Damage In The Antineutrophil- Cytoplasm Antibody Associated Vasculitides. Joanna Robson, Helen Doll, Ravi Suppiah, Oliver Flossmann 4, Lorraine Harper 5, Peter Hoglund 6, David Jayne 7, Alfred Mahr 8, Kerstin Westman 9 and Raashid A. Luqmani 0, Nuffield Department of Orthopaedics Rheumatology and Musculoskeletal Sciences, Botnar Research Centre, University of Oxford, Oxford, United Kingdom, University of East Anglia, Norwich, United Kingdom, Auckland District Health Board, Auckland, New Zealand, 4 Royal Berkshire Hospital, Reading, United Kingdom, 5 University of Birmingham, Birmingham, United Kingdom, 6 Skane University Hospital, Lund, Sweden, 7 Addenbrookes Hospital University of Cambridge, Cambridge, United Kingdom, 8 Department of Internal Medicine, Hospital Saint-Louis, Paris, France, 9 Skåne University Hospital Malmö, Lund University, Malmö, Sweden, 0 University of Oxford, Oxford, United Kingdom 748. Efficacy Of Glucocorticoids To Treat Limited Flares In ANCA-Associated Vasculitis. Eli Miloslavsky, Ulrich Specks, Peter A. Merkel, Philip Seo 4, Robert F. Spiera 5, Carol A. Langford 6, Gary S. Hoffman 7, Cees G.M. Kallenberg 8, E. William St. Clair 9, Nadia Tchao 0, Linna Ding, David Ikle, Brett Jepson, Paul Brunetta and John H. Stone 4, Massachusetts General Hopsital, Boston, MA, Mayo Clinic, Rochester, MN, University of Pennsylvania, Philadelphia, PA, 4 Johns Hopkins Vasculitis Center, Baltimore, MD, 5 Hospital for Special Surgery, New York, NY, 6 Cleveland Clinic, Cleveland, OH, 7 Cleveland Clinic Foundation, Cleveland, OH, 8 University Medical Center Groningen, Groningen, Netherlands, 9 Duke University Medical Center, Durham, NC, 0 Immune Tolerance Network, 0 Program Book Bethesda, MD, NIAID, Bethesda, MD, Rho, Chapel Hill, NC, Genentech, So San Francisco, CA, 4 Massachusetts General Hospital, Boston, MA 749. Efficacy Of Methotrexate For Remission Induction and Maintenance In Granulomatosis With Polyangiitis In Routine Clinical Practice. Megan L. Krause, Misbah Baqir, Rodrigo Cartin-Ceba, Tobias Peikert, Karina Keogh and Ulrich Specks, Mayo Clinic, Rochester, MN 750. High Clinical Remission Rate With Relatively High Incidence Of Serious Infection In Newly-Onset ANCA- Associated Vasculitides In Japan - A Report From The Nationwide Prospective Cohort Study. Masayoshi Harigai, Ken-ei Sada, Takao Fujii, Masahiro Yamamura 4, Yoshihiro Arimura 5 and Hirofumi Makino, Tokyo Medical and Dental University, Tokyo, Japan, Okayama University, Okayama, Japan, Graduate School of Medicine, Kyoto University, Kyoto, Japan, 4 Okayama Saiseikai Hospital, Okayama, Japan, 5 Kyorin University School of Medicine, Tokyo, Japan 75. Maintenance Treatment In Childhood Granulomatosis With Polyangiitis. Marinka Twilt, Rayfel Schneider, Diane Hebert, Elizabeth Harvey, Ronald M. Laxer, Sharon Dell, Christoph Licht and Susanne M. Benseler, The Hospital for Sick Children, Toronto, ON, Hospital for Sick Children, Toronto, ON 75. Fatigue, Pain, and Functional Disability Among Patients With Vasculitis. Antoine G. Sreih, Narender Annapureddy and Osama Elsallabi, The University of Pennsylvania, Philadelphia, PA, Rush University Medical Center, Chicago, IL, Creighton University, Omaha, NE 75. Cardiovascular Outcomes Are Worse In Microscopic Polyangiitis Compared To Granulomatosis With Polyangiitis: Data From An Inception Cohort Of Patients With Anti-Neutrophil Cytoplasm Antibody Associated Systemic Vasculitis. Anna Mistry, Joanna Robson, Susan L Hogan, Caroline Poulton, Yichun Hu, Ronald Falk 4 and Raashid A. Luqmani 5, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, UK, Oxford, United Kingdom, Nuffield Department of Orthopaedics Rheumatology and Musculoskeletal Sciences, Botnar Research Centre, University of Oxford, Oxford, United Kingdom, UNC Kidney Centre, University of North Carolina, Chapel Hill, North Carolina, Chapel Hill, NC, 4 UNC Kidney Center, Chapel Hill, NC, 5 Nuffield Orthopaedic Centre, Oxford, United Kingdom 754. Validation Of The New Histopathological Classification Of ANCA Glomerulonephritis and Its Association With Renal Outcomes In a Paediatric Population. Marinka Twilt, Damien Noone, Wesley Hayes, Paul Thorner, Susanne M. Benseler, Ronald M. Laxer, Rulan Parekh and Diane Hebert, The Hospital for Sick Children, Toronto, ON, Hospital for Sick Children, Toronto, ON 755. Outcome Of Kidney Transplantation In Paediatric Patients With ANCA Associated Glomerulonephritis: A Single- Center Experience. Marinka Twilt, Damien Noone, Wesley Hayes, Paul Thorner, Susanne M. Benseler, Ronald M. Laxer, Rulan Parekh and Diane Hebert, The Hospital for Sick Children, Toronto, ON, Hospital for Sick Children, Toronto, ON

219 ACR POSTER SESSION A 756. Survival Of Patients With ANCA-Associated Vasculitides In Chronic Dialysis In France From 00 To 0: Data From The National Rein Registry. Manon Romeu, Cécile Couchoud Sr., Jean-Christophe Delarozière, Laurent Chiche Sr. 4, Jean-Robert Harle, Bertrand Gondoin, Stéphane Burtey, Philippe Brunet, Yvon Berland and Noémie Jourde-Chiche Sr. 5, Aix-Marseille Universite, APHM, Marseille, France, agence de la biomédecine, paris, France, APHM, Marseille, France, 4 Internal Medicine, CHU Marseille, Marseille, France, 5 Aix-Marseille Université - APHM, Marseille, France 757. Clinical Value Of Commonly-Measured Laboratory Tests In Eosinophilic Granulomatosis With Polyangiitis (Churg- Strauss). Peter C. Grayson, Paul A. Monach, David Cuthbertson, Simon Carette 4, Gary S. Hoffman 5, Nader A. Khalidi 6, C. L. Koening 7, Carol A. Langford 8, Kathleen Maksimowicz-McKinnon 9, Christian Pagnoux 0, Philip Seo, Ulrich Specks, Steven R. Ytterberg and Peter A. Merkel, National Institutes of Health, Bethesda, MD, Boston University, Boston, MA, University of South Florida, Tampa, FL, 4 UHN/MSH, Toronto, ON, 5 Cleveland Clinic Foundation, Cleveland, OH, 6 McMaster University, Hamilton, ON, 7 Salt Lake City Veterans Administration, Salt Lake City, UT, 8 Cleveland Clinic, Cleveland, OH, 9 Henry Ford Hospital, Detroit, MI, 0 Rheumatology, Mount Sinai Hospital, Toronto, Canada, Toronto, ON, Johns Hopkins Vasculitis Center, Baltimore, MD, Mayo Clinic, Rochester, MN, University of Pennsylvania, Philadelphia, PA 758. Impact Of Cardiac Magnetic Resonance Imaging On Eosinophilic Granulomatosis With Polyangiitis Outcomes: A Long-Term Retrospective Study On 4 Patients. Bertrand Dunogué, Pascal Cohen, Benjamin Terrier, Julien Marmursztejn, Denis Duboc, Olivier Vignaux and Loic Guillevin, Cochin University Hospital, Paris, France 760. Eosinophilic Granulomatosis With Polyangiitis (Churg Strauss Syndrome): Comparison Of The Independent French Vasculitis Study Group and Italian Pisa Patient Cohorts and Cross-Validation Of Cluster Analysis. Chiara Baldini, Pascal N. Tyrrell, Manuela Latorre, Simon Carette 4, Nader A. Khalidi 5, Veronica Seccia 6, Loic Guillevin 7 and Christian Pagnoux 8, Rheumatology Unit, Pisa, Italy, University of Toronto, Toronto, ON, Pneumology Unit, Pisa, Italy, 4 UHN/MSH, Toronto, ON, 5 McMaster University, Hamilton, ON, 6 Unit of Otorhinolaryngology, Department of Neuroscience, University of Pisa, Pisa, Italy, Pisa, Italy, 7 Department of Internal Medicine, Referral Center for Rare Autoimmune and Systemic Diseases, Hôpital Cochin, AP HP, Université Paris Descartes, Paris, France, Paris, France, 8 Division of Rheumatology, Mount Sinai Hospital, Toronto, ON 760. Cluster Analysis To Explore Clinical Subclassification Of Eosinophilic Granulomatosis With Polyangiitis (Churg Strauss). Thomas Neumann, Frank Moosig, Augusto Vaglio, Jochen Zwerina 4, Renato Alberto Sinico 5, Wojciech Szczeklik 6, Paolo Bottero 7, Phillip Bremer, Andrea Gioffredi, Barbara Sokolowska 6, Luca Di Toma 5, Federica Maritati, Julian Großkreutz, Claus Kroegel, Matthieu Resche-Rigon 8 and Alfred Mahr 9, Jena University-Hospital, Jena, Germany, University Hospital Schleswig Holstein and Klinikum Bad Bramstedt, Bad Bramstedt, Germany, University of Parma, Parma, Italy, 4 Hanusch Hospital, Vienna, Austria, 5 Azienda Ospedaliera Ospedale San Carlo Borromeo, Milan, Italy, 6 Jagiellonian University Medical College, Krakow, Poland, 7 Magenta Hospital, Magenta, Italy, 8 Hopital Saint-Louis, Paris, France, 9 Department of Internal Medicine, Hospital Saint-Louis, Paris, France 759. Eosinophilic Granulomatosis With Polyangiitis (Churg- Strauss Syndrome) Re-Analysis Of The French Vasculitis Study Group Cohort Using Different Disease Definitions and Cluster Analysis. Christian Pagnoux, Pascal N. Tyrrell, Chiara Baldini, Simon Carette 4, Jean-Francois Cordier 5, Loic Guillevin 6 and French Vasculitis Study Group FVSG 7, Division of Rheumatology, Mount Sinai Hospital, Toronto, ON, University of Toronto, Toronto, ON, Rheumatology Unit, Pisa, Italy, 4 UHN/MSH, Toronto, ON, 5 Division of Pneumology, Hôpital Louis-Pradel, Hospices Civils de Lyon, Lyon, Lyon, France, 6 Department of Internal Medicine, Referral Center for Rare Autoimmune and Systemic Diseases, Hôpital Cochin, AP HP, Université Paris Descartes, Paris, France, Paris, France, 7 Service de médecine interne, Centre de Références des Vascularites, Université Paris Descartes, APHP, Hôpital Cochin, Paris, France., Paris, France 0 Program Book 7

220 ACR POSTER SESSION B MONDAY, OCTOBER 8, 0 Exhibit Hall B-C-D B cells in Human and Animal Arthritis 909. Diagnostic Autoantibody Signatures Of Rheumatoid Arthritis Patients Identified With a Bead-Based Assay Approach. Angelika Lueking, Petra Budde, Stefan Vordenbäumen, Carmen Theek, Heike Goehler, Martin Gamer, Peter Schulz-Knappe and Matthias Schneider, Protagen AG, Dortmund, Germany, Univ. Duesseldorf, Düsseldorf, Germany, Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany 90. Anti-Carbamylated Protein Antibodies (Anti-CarP) Precede The Onset Of Rheumatoid Arthritis. Jing Shi, Lotte A. van de Stadt, E.W.Nivine Levarht, Tom W. J. Huizinga, Dörte Hamann, Dirkjan van Schaardenburg, René E.M. Toes and Leendert A. Trouw, Leiden University Medical Center, Leiden, Netherlands, Jan van Breemen Research Institute Reade, Amsterdam, Netherlands, Sanquin Diagnostic Services, Amsterdam, Netherlands 9. Neutralization Of Anti-Citrullinated Protein Antibodies - a Way To Go? Catia Cerqueira, Elena Ossipova, Monika Hansson, Linda Mathsson, Lars Klareskog, Johan Rönnelid and Per Johan Jakobsson, Rheumatology unit, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden, Uppsala University, Uppsala, Sweden 9. B-Cell Responses To De Novo Identified Citrullinated Fibrinogen Peptides Are Associated With PTPN Risk Allele. Vijay Joshua, Loes Schobers, Lena Israelsson, Johan Rönnelid, Monika Hansson 4, Anca I Catrina 5, Ger JM Pruijn and Vivianne Malmström 6, Rheumatology unit, Karolinska University Hospital, Karolinska Institute, Stockholm, Sweden, Department of Biomolecular Chemistry, Radboud University, Nijmegen, Netherlands, Uppsala University, Uppsala, Sweden, 4 Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden, 5 Rheumatology Unit, Department of Medicine, Karolinska Institute, Stockholm, Sweden, 6 Rheumatology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden 9. High Throughput Epitope Mapping Of Autoantibodies In BXD Mice Reveals The Generation Of Autoantibodies Against Citrullinated Antigens At The Predicted Major Immunogenic Sites. Jennie Hamilton, Qi Wu, PingAr Yang, Hui-Chen Hsu and John D. Mountz, University of Alabama at Birmingham, Birmingham, AL 94. Accentuated Expression Of RANKL In Switched Memory B Cells From Patients With Rheumatoid Arthritis. Yuri Hirosaki, Hiroaki Niiro, Shun-ichiro Ota, Naoko Ueki, Hirofumi Tsuzuki, Siamak Jabbarzadeh-Tabrizi, Kumiko Noda, Naoyasu Ueda, Naoyasu Ueda, Atsushi Tanaka, Masahiro Ayano, Sho Ueda, Satomi Hisamoto, Daisuke Oryoji, Mitsuteru Akahoshi, Yojiro Arinobu, Hiroshi Tsukamoto, Takahiko Horiuchi and Koichi Akashi, Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan 95. IL-6R Inhibition Reduces Activation Of Different Peripheral Memory B Cell Subsets In RA. Zafar Mahmood, Khalid Muhammad, Marc Schmalzing, Petra Roll, Kathrina Eckert, Thomas Dörner and Hans-Peter Tony, University of Würzburg, Würzburg, Germany, University Hospital Würzburg, Würzburg, Germany, Charité university medecine/ German Rheumatism Research Centre Berlin (DRFZ), Berlin, Germany 96. Role Of CD0+ B Cells As Antigen-Presenting Cells In Arthritis. Estefania Armas-Gonzalez, Ana Diaz-Martin, María Jesús Dominguez-Luis, Maria Teresa Arce-Franco, Ada Herrera-Garcia, Vanesa Hernandez, Alicia Usategui, Jose L. Pablos, Sagrario Bustabad and Federico Diaz- Gonzalez, Hospital Universitario de Canarias, La Laguna. Tenerife, Spain, Instituto de Investigación Hospital de Octubre, Madrid, Spain, University of La Laguna, Hospital Universitario de Canarias, La Laguna, Spain 97. B-Regulatory-, CD9 + CD0 + CD4 high CD8 high -Cells Are Functionally Impaired In Patients With Rheumatoid Arthritis and Healthy First Degree Relatives Compared With Controls. Mikael Brink, Kristina Lejon, Lisbeth Ärlestig and Solbritt Rantapää Dahlqvist 4, Umeå University, Umea, Sweden, Umeå Universitet, Umeå, Sweden, Umeå University, Umeå, Sweden, 4 Umeå University Hospital, Umeå, Sweden 98. Regulatory B Cells Suppress Skin Inflammation in a Murine Model of Psoriasis. Koichi Yanaba and Shinichi Sato, The University of Tokyo, Tokyo, Japan, University of Tokyo Graduate School of Medicine, Tokyo, Japan 99. B Cell Derived IFN-γ Contributes To The Negative Regulation Of T-Regulatory Cell Differentiation In Arthritis. Susan Olalekan, Yanxia Cao and Alison Finnegan, Rush University Medical Center, Chicago, IL 90. Fms-Like Tyrosine Kinase Signaling Is Essential For Differentiation Of Antigen Specific Plasma Cells During Experimental Arthritis. Mattias Svensson, Kersti Månsson, Karin Andersson, Mats Bemark, Mikael Brisslert and Maria Bokarewa, University of Gothenburg, Gothenburg, Sweden 9. Blocking The Complement Receptor (CR) Ligand- Receptor Interaction With a Novel Mouse Anti-Mouse CR Monoclonal Antibody Decreases Antigen-Specific Humoral Immune Responses and The Evolution Of Collagen- Induced Arthritis. Rosa Rodriguez, Liudmila Kulik, Joshua Thurman, Jonathan Hannan, Steve Tomlinson and V. Michael Holers, University of Colorado School of Medicine, Aurora, CO, Medical University of South Carolina, Charleston, NC 9. Role Of B Cells and/or Autoantibodies In Pulmonary Manifestations Of Inflammatory Arthritis. Lisa K. Peterson, Jeremy Sokolove, Paul Jedlicka, Lauren J. Lahey, William H. Robinson 4 and Leonard L. Dragone, National Jewish Health, Denver, CO, VA Palo Alto Health Care System and Stanford University, Palo Alto, CA, University of Colorado Denver, Aurora, CO, 4 Stanford University, Palo Alto, CA 8 0 Program Book

221 ACR POSTER SESSION B 9. Redox Dependent Conformational Changes Of The Autoantigen La Are Responsible For Its Shuttling, Translocation and a Pathophysiological Role Of Anti- La Autoantibodies. Irene Michalk, Nicole Berndt, Claudia C. Bippes, Holger Bartsch, Stefanie Koristka, Claudia Arndt, Anja Feldmann, Biji T. Kurien, Robert Hal Scofield, A. Darise Farris 4, Judith A. James 5, Marc Cartellieri and Michael Bachmann, Carl Gustav Carus TU-Dresden, Dresden, Germany, University of Oklahoma Health Sciences Center, Oklahoma City, OK, Arthritis & Clinical Immunology Program, Oklahoma Medical Research Foundation; Department of Medicine, University of Oklahoma Health Sciences Center; US Department of Veterans Affairs Medical Center, Oklahoma City, OK, 4 Oklahoma Medical Research Foun, Oklahoma City, OK, 5 Oklahoma Medical Research Foundation, Oklahoma City, OK 94. B Cell Subsets and Dysfunction Of Regulatory B Cells In IgG4-Related Diseases and Primary Sjögren Syndrome: The Similarities and Differences. Wei Lin, Lixia Jin, Wen Zhang, Hua Chen, QingJun Wu, Yunyun Fei, Yan Zhao, Xiaofeng Zeng and Fengchun Zhang, Peking Union Medical College Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Beijing, China, Tsinghua University, Beijing, China 95. B Cell Subset Phenotypes In Patients With Granulomatosis With Polyangiitis (Wegener s). Atul A. Khasnis, Carol A. Langford, L Calabrese, Julia M. Sugalski, Michael Lederman and Donald D. Anthony 4, Cleveland Clinic Foundation, Cleveland, OH, Cleveland Clinic, Cleveland, OH, Case Western Reserve University, Cleveland, OH, 4 Case Western Reserve University, Cleveland VA Medical Center, University Hospitals of Cleveland, Cleveland, OH 96. Autoantibodies to the Th/To Complex Are the Most Common Antibodies in Systemic Sclerosis (SSc) Patients Without Other Autoantibodies. Michael Mahler, Jason Y.F. Chan, Edward K.L. Chan, Minoru Satoh, Marie Hudson, Murray Baron 4, James Wick 5 and Marvin J. Fritzler 5, INOVA Diagnostics, San Diego, CA, University of Florida, Gainesville, FL, McGill University, Montreal, QC, 4 Jewish General Hospital, Montreal, QC, 5 University of Calgary, Calgary, AB Cytokines, Mediators, Cell-cell Adhesion, Cell Trafficking and Angiogenesis I 97. The Role of HIF- and HIF- During Angiogenesis and Metabolic Adaptation of Human Microvascular Endothelial Cells Towards Hypoxia. Martin Hahne, Cindy Strehl, Manuela Jakstadt, Paula Hoff, Timo Gaber, Gerd-Rüdiger Burmester and Frank Buttgereit, Charité University Medicine, Berlin, Germany, Charite University Hospital, Berlin, Germany, Charité - Universitätsmedizin Berlin, Berlin, Germany 98. The Bioenergetic Role of HIF- and HIF- During Angiogenesis of Human Microvascular Endothelial Cells. Martin Hahne, Cindy Strehl, Manuela Jakstadt, Paula Hoff, Timo Gaber, Gerd-Rüdiger Burmester and Frank Buttgereit, Charité University Medicine, Berlin, Germany, Charite University Hospital, Berlin, Germany, Charité - Universitätsmedizin Berlin, Berlin, Germany 99. Blockade Of TNFα Produced By TSLP-Primed CDc Myeloid Dendritic Cells Skews T Cell Response To Th Activity In Rheumatoid Arthritis Patients. F.M. Moret, T.R.D.J. Radstake, J.W.J. Bijlsma, F.P.J.G. Lafeber and J.A.G. van Roon, University Medical Center Utrecht, Utrecht, Netherlands 90. The Endocannabinoid Anandamide Modulates Adhesion, Proliferation and The Production Of Inflammatory Mediators In Rheumatoid Arthritis Synovial Fibroblasts By Activating CB, TRPV, TRPA and Non-Cannabinoid Receptor Targets. Torsten Lowin, Angelika Graeber and Rainer H. Straub, Laboratory of Exp. Rheumatology and Neuroendocrino-Immunology, University Hospital of Regensburg, Regensburg, Germany 9. Effect Of Neutralizing IL-7A and IL-7F Antibodies On Host Resistance To Acute Mycobacterium Tuberculosis Infection In Mice In Comparison With Neutralizing TNF-α Treatment. Michael Kammüller, Franco Di Padova, Christian Antoni, Salah-Dine Chibout, Timothy Wright, Marie-Laure Bourigault 4, Noria Segueni 4, Stephanie Rose 4, Bernhard Ryffel 4 and Valerie Quesniaux 4, Novartis Institutes for Biomedical Research, Basel, Switzerland, Novartis Pharmaceuticals Corporation, East Hanover, NJ, Novartis Pharma AG, Basel, Switzerland, 4 UMR755 CNRS and University of Orleans, Orleans, France 9. Hypoxia and Signal Transducer and Activator Of Transcription Signalling Interactions Regulate Pro- Inflammatory Pathways In Rheumatoid Arthritis. Wei Gao, Jennifer McCormick, Mary Connolly, Emese Balogh, Douglas J. Veale and Ursula Fearon, Translational Rheumatology Research Group, Dublin, Ireland, St. Vincent s University Hospital, Dublin 4, Ireland, Translation Research Group, Dublin Academic Medical Centre, St. Vincent s University Hospital, Dublin, Ireland 9. Characterizing The Expression and Function Of CCL8 and Its Corresponding Receptor CCR0 In The Pathogenesis Of RA. Zhenlong Chen, Seung-jae Kim, Michael V. Volin, Suncica Volkov, William Swedler, Nadera J. Sweiss and Shiva Shahrara, University of Illinois at Chicago, Chicago, IL, Chicago College of Osteopathic Medicine Midwestern University, Downers Grove, IL 94. Interleukin-B Is Up-Regulated By Decoy Receptor In Specifically Rheumatoid Synovial Fibroblasts. Koji Fukuda, Yasushi Miura, Toshihisa Maeda, Shinya Hayashi and Masahiro Kurosaka, Kobe University Graduate School of Medicine, Kobe, Japan, Kobe University Graduate School of Health Sciences, Kobe, Japan 95. Adenosine AA Receptor Activates The Pro-Fibrotic Wnt / β-catenin Signaling In Human Dermal Fibroblasts. Miguel Perez-Aso and Bruce N. Cronstein, New York University School of Medicine, New York, NY, NYU School of Medicine, Division of Rheumatology, New York, NY 0 Program Book 9

222 ACR POSTER SESSION B Decreased Plasma Levels Of Soluble CD8 Link Leukocyte Migration and Disease Activity In Spondyloarthritis. Tue W. Kragstrup, Babak Jalilian, Malene Hvid, René Østgård, Berit Schiøttz-Christensen, Anne G. Jurik 4, William H. Robinson, Thomas Vorup-Jensen and Bent Deleuran 4, Stanford University School of Medicine, Stanford, CA, Aarhus University, Aarhus, Denmark, Private practice, Aarhus, Denmark, 4 Aarhus University Hospital, Aarhus, Denmark 97. Inhibitor Of DNA Binding Mediates Angiogenesis In Rheumatoid Arthritis By Recruitment Of Endothelial Progenitor Cells. Takeo Isozaki, Alisa E. Koch, M. Asif Amin, Ali S. Arbab, Gautam Edhayan, Christine M. Ha, Pei-Suen Tsou, Sean C. Friday, David A. Fox and Jeffrey H. Ruth, University of Michigan Medical School, Ann Arbor, MI, Henry Ford Hospital and Medical Centers, Detroit, MI, Division of Rheumatology, University of Michigan Medical Center, Ann Arbor, MI 98. A Disintegrin and Metalloprotease-7 (ADAM-7) Is Expressed In Rheumatoid Arthritis and Mediates Monocyte Migration. Takeo Isozaki, Nao Oguro, Shinya Seki, Yoko Miura, Sho Ishii, Hiroyuki Tsukamoto, Takahiro Tokunaga, Masayu Umemura, Hidekazu Furuya, Ryo Yanai, Sakiko Isojima, Kuninobu Wakabayashi, Nobuyuki Yajima, Yusuke Miwa and Tsuyoshi Kasama, Showa University School of Med, Shinagawa-ku Tokyo, Japan 99. Reduction Of Circulating Blood Neutrophils In Mice By Anti-IL-6R Alpha Monoclonal Antibody is Not Due To Apoptosis Or Blockade Of Neutrophil Differentiation. Ludmila Kelly, Vilma Decman and Dimitris Skokos, Regeneron Pharmaceuticals, Inc., Tarrytown, NY 940. Novel Function Of Soluble Interleukin-6 Receptor As An Antagonist Of Interleukin-7-Mediated Anti-Inflammatory Responses. Misato Hashizume, Keiko Esaki, Keiko Yoshimoto, Hideto Kameda, Tsutomu Takeuchi and Yoshihiro Matsumoto, Chugai Pharmaceutical Co., Ltd., Gotemba, Japan, Keio University School of Medicine, Tokyo, Japan 94. Mir-4a In Rheumatoid Arthritis: Characterisation Of Elevated Synovial Expression and Association With Treatment Resistance. Clare E Tange, Stefano Alivernini, Derek S. Gilchrist, Lynn Crawford, Ashleigh-Ann Rainey, Derek Baxter, Iain B. Mcinnes and Mariola Kurowska-Stolarska, University of Glasgow, Glasgow, United Kingdom, Division of Rheumatology, Institute of Rheumatology and Affine Sciences, Catholic University of the Sacred Heart, Rome, Italy 94. CXCL Is a Marker Of Joint Involvement In Early Rheumatoid Arthritis. Stinne Greisen, Tue Rasmussen, Karen Schelde, Kristian Stengaard-Pedersen, Merete Lund Hetland, Kim Hørslev-Petersen 4, Bent Deleuran 5 and Malene Hvid, Aarhus University, Aarhus, Denmark, Arhus University Hospital, Aarhus, Denmark, The Danish Rheumatologic Database (DANBIO), Glostrup Hospital., Copenhagen, Denmark, 4 University of Southern Denmark, Graasten, Denmark, 5 Aarhus University Hospital, Aarhus, Denmark 0 Program Book 94. Synergism Between Granulocyte-Macrophage Colony Stimulating Factor and Interleukin-7 Causes Joint Damage Via The Production Of Interleukin-, Receptor Activator Of NF-κB Ligand and S00A8. Annemarie E.M. Van Nieuwenhuijze, Fons A.J. Van de Loo, Birgitte Walgreen, Miranda B. Bennink, Monique M. Helsen, Liduine Van den Bersselaar, Ian P. Wicks, Wim B. Van den Berg 4 and Marije I. Koenders 4, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, Rheumatology Research and Advanced Therapeutics, Department of Rheumatology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, Walter & Eliza Hall Institute of Medical Research, Melbourne, Australia, 4 Rheumatology Research and Advanced Therapeutics, Radboud University Nijmegen Medical Center, Nijmegen, Netherlands 944. Mir-5a: A Novel Regulator Of IL-6 and TLR Driven Pathways In RA Pathogenesis. Ashleigh-Ann Rainey, Derek S. Gilchrist, Clare E Tange, Marina Frleta, Lynn Crawford, Derek Baxter, Iain B. Mcinnes and Mariola Kurowska- Stolarska, University of Glasgow, Glasgow, United Kingdom 945. Non-Canonical NF-Kappa B Signaling Enhances Angiogenesis In a Novel D Spheroid Model Of Rheumatoid Arthritis Synovial Inflammation. Chrissta X. Maracle, Ae-Ri Noort, Katinka P.M. van Zoest and Sander W. Tas, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands 946. Interleukin-4 Regulates Angiogenesis and Cell Proliferation In Inflammatory Arthritis, This Effect Is Potentiated By Hypoxia. Emese Balogh, Mary Connolly, Monika Biniecka, Jennifer McCormick, Douglas J. Veale and Ursula Fearon, Translation Research Group, Dublin Academic Medical Centre, St. Vincent s University Hospital, Dublin, Ireland, St. Vincent s University Hospital, Dublin 4, Ireland 947. The Interleukin /mir9 Axis Regulates Differential Collagen Production In Tendinopathy. Dr Neal L Millar, Derek S. Gilchrist, Mariola Kurowska-Stolarska, Prof George AC Murrell and Prof Iain B. McInnes, University of Glasgow, Glasgow, United Kingdom, Institute of Infection,Immunity and Inflammation, College of Medical, Veterinary and Life Sciences University of Glasgow,, Glasgow, United Kingdom, Orthopaedic Research Institute, Sydney, Australia 948. Dual Neutralization Of TNF and IL-7 Provides Greater Efficacy In Collagen Induced Arthritis Through Regulation Of a Gene Transcription Program That Includes CXCL and CXCL5. Carolyn Cuff, Chung-Ming Hsieh, Suzanne Mathieu, Anwar Murtaza, Margaret Hugunin, Shaughn Bryant, Robert O brien, Lisa Olson and Jeffrey Voss, AbbVie Pharmaceuticals, Worcester, MA, Broad Institute, Cambridge, MA 949. Targeting CDc-Expressing Mdcs To Inhibit Tcell Activation and Thymus and Activation Regulated Chemokine (TARC)- Dependent Chemotaxis In RA. M.R. Hillen, F.M. Moret, F.P.J.G. Lafeber, C.E. Hack, T.R.D.J. Radstake and J.A.G. van Roon, University Medical Center Utrecht, Utrecht, Netherlands

223 ACR POSTER SESSION B 950. Changes In Circulating Visfatin Levels By Different Anti- Rheumatic Treatments: A Comparison Among Synthetic Disease Modifying Anti-Rheumatic Drugs, Tumor Necrosis Factor Blockade and B-Cell Depletion For Rheumatoid Arthritis. Hana Hulejová, Markéta Kuklová, Herman F. Mann, Mária Filková 4, Olga Kryštufková 5, Karel Pavelka 6, Ondrej Sglunda 4, Jiri Vencovsky and Ladislav Senolt, Institute of Rheumatology, Prague, Czech Republic, Institute of Rheumatology, Department of Experimental Rheumatology, st Faculty of Medicine, Charles University in Prague, Prague, Czech Republic, Institute of Rheumatology, Prague, Prague, Czech Republic, 4 Institute of Rheumatology and Department of Rheumatology of the First Faculty of Medicine, Charles University in Prague, Czech Republic, Prague, Czech Republic, 5 Institute of Rheumatology, and Dept. of Rheumatology, st Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic, 6 Department of Clinical and Experimental Rheumatology, Charles University, Prague, Czech Republic 95. The Anti-IL-7A Monoclonal Antibody Secukinumab (AIN457) Inhibits Pro-Inflammatory Mediator Release From Human Primary Synoviocytes Costimulated With IL-7 and TNF. Christine Huppertz, Marija Curcic Djuric, Robert Hennze and Frank Kolbinger, Autoimmunity, Transplantation and Inflammatory Disease, Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, SWITZERLAND, Basel, Switzerland 95. CXCR Deficiency Attenuates Imiquimod-Induced Psoriasis-Like Skin Inflammation By Predominant Infiltration Of M Macrophages. Sohshi Morimura, Makoto Sugaya and Shinichi Sato, The University of Tokyo, Tokyo, Japan 95. Baseline Serum Interleukin-4 Levels Predict Radiographic Progression In Rheumatoid Arthritis Patients. Sung Hae Chang, Byoung Youg Choi, Hyon Joung Cho, Hye Jin Oh, Eun Ha Kang, Yeong Wook Song and Yun Jong Lee, Seoul National University Bundang Hospital, Seongnam-si, South Korea, Seoul National University Hospital, Seoul, South Korea, Seoul National University College of Medicine, Seoul, South Korea 954. Correlating The In Vivo Production Of IFNγ To Disease Parameters In TLR9-Induced Macrophage Activation Syndrome (MAS) In Mice. Vanessa Buatois, Laurence Chatel, Laura Cons, Sabrina Lory, Maureen Deehan, Jennifer Sims, Cristina de Min, Marie Kosco-Vilbois and Walter Ferlin, NovImmune S.A., Geneva, Switzerland, Integrated Biologix GmBH, Basel, Switzerland 955. Myeloid Deletion Of SIRT Aggravates Serum Transfer Arthritis But Ameliorate Collagen-Induced Arthritis. Sang- Il Lee, Yun-Hong Cheon, Won Seok Lee and Ji-Min Kim, Gyeongsang National University School of Medicine, Jinju, South Korea, Department of Internal Medicine, Chonbuk National University Medical School and Research Institute of Clinical Medicine, Jeonju, South Korea, Division of Rheumatology, Department of Internal Medicine, Keimyung University School of Medicine, Daegu, South Korea 956. WITHDRAWN 957. The Role Of S00A4 As a Biological Marker Of Immune Response In Early Rheumatoid Arthritis. Lucie Andrés Cerezo, Klára Prajzlerová, Martina Remáková, Herman F. Mann, Michal Tomcík, Karel Pavelka, Jiri Vencovsky and Ladislav Senolt, Institute of Rheumatology, Prague, Czech Republic, Institute of Rheumatology, Prague, Prague, Czech Republic 958. Serum Cytokine Changes In Rituximab-Treated Rheumatoid Arthritis Patients. Tamarah D. de Jong, Saskia Vosslamber, Wilco de Jager, Hennie G. Raterman, Alexandre E. Voskuyl, Kyra A. Gelderman and Cornelis L. Verweij, VU University Medical Center, Amsterdam, Netherlands, University Medical Center Utrecht, Utrecht, Netherlands 959. Interleukin 0 Negatively Correlates With Glycoprotein VI- Related Platelet Activation In Rheumatoid Arthritis (RA): A Novel Potential Target Of Cardiovascular Morbidity In RA. Leann Bell, Anne M. Madigan, Paul A. MacMullan, Eimear Dunne, Paola M. Bagaglia, Laura J. Durcan, Dermot Kenny and Geraldine M. McCarthy, Mater Misericordiae University Hospital, Dublin 7, Ireland, RCSI, Dublin, Ireland Education: Medical Education 960. Self-Perceived Efficacy of a Workshop On Musculoskeletal Clinical Anatomy. Miguel A. Saavedra, José E. Navarro- Zarza, J. Alvarez-Nemegyei, Juan J. Canoso 4, Robert A. Kalish 5, Pablo Villaseñor-Ovies 6 and Cristina Hernández- Díaz 7, Hospital de Especialidades, Centro Medico La Raza Instituto Mexicano del Seguro Social Mexico D.F., México D.F., Mexico, Mexican Taskforce for the Advancement of Clinical Anatomy, Mexico, Mexico, Instituto Mexicano del Seguro Social, Merida, Mexico, 4 ABC Medical Center and Tufts University, Mexico City, Mexico, 5 Tufts Medical Center, Boston, MA, 6 Hospital Angeles Tijuana, Tijuana, Mexico, 7 Instituto Nacional de Rehabilitación, Mexico City, Mexico 96. Assessment and Promotion of a National Immunology Curriculum for Adult Rheumatology Residents. Dharini Mahendira, Shirley L. Chow, Sari Herman-Kideckel and Heather McDonald-Blumer 4, St Michael s Hospital, University of Toronto, Toronto, ON, University of Toronto, Toronto, ON, University of Toronto, North York, ON, 4 Division of Rheumatology, Mount Sinai Hospital; Osteoporosis Program, Toronto General Hospital, Toronto, ON 96. Electronic Learning Module Enhances Rheumatology Education. Malini Juyal, Avis Ware, John Houk and Rina Mina, University of Cincinnati, Cincinnati, OH, Cincinnati Children s Hospital Medical Center/University of Cincinnati School of Medicine, Cincinnati, OH 96. Impact Of a Nurse-Led Program On Comorbidity Management In Rheumatoid Arthritis (RA): Results Of a Prospective, Multicenter, Randomized, Controlled Trial. Martin Soubrier, Elodie Perrodeau, Melanie Gilson, Alain G. Cantagrel 4, Xavier le Loet 5, René-Marc Flipo 6, Sandrine 0 Program Book

224 ACR POSTER SESSION B Guis 7, Gael Mouterde 8, Liana E. Euller-Ziegler 9, Thierry Schaeverbeke 0, Bruno Fautrel, Alain Saraux, Isabelle Chary-Valckenaere, Gérard Chales 4, Emmanuelle Dernis 5, Pascal Richette 6, Xavier Mariette 7, Francis Berenbaum 8, Jean Sibilia 9, Philippe Ravaud 0 and Maxime Dougados, CHU CLERMONT-FERRAND, Clermont-Ferrand, France, Epidemiologist, Paris, France, CH Grenoble Hopital Sud, Grenoble, France, 4 Hopital Purpan, Toulouse CEDEX 9, France, 5 CHU de ROUEN, Rouen, France, 6 Hôpitaux Universitaires de Lille, France, France, 7 Aix Marseille Univ; AP-HM, Marseille, France, 8 Montpellier University, Lapeyronie Hospital, Montpellier, France, 9 L Archet Hospital (University), Nice CEDEX, France, 0 Groupe Hospitalier Pellegrin, Bordeaux, France, UPMC - Paris 6 University, Paris, France, CHU de la Cavale Blanche, Brest Cedex, France, Nancy Teaching Hospital, Nancy, France, 4 CHU RENNES, Rennes, France, 5 Centre Hospitalier, Le Mans, France, 6 Hôpital Lariboisière, Paris, France, 7 Bicêtre University Hospital, Le Kremlin Bicetre, France, 8 AP-HP, St Antoine Hospital, Paris, France, 9 CHU Hautepierre, Strasbourg, France, 0 Hopital Hotel Dieu, Paris Descartes University, Paris, France, Cochin Hospital, Paris, France 964. Redesign Of a Rheumatology Curriculum For Internal Medicine Residents: Results Of Needs Assessment Survey. Susan F. Kroop, Cecilia P. Chung and Charlene M. Dewey, Vanderbilt University Medical School, Nashville, TN, Vanderbilt University, Nashville, TN, Vanderbilt University School of Medicine, Nashville, TN 965. The Mini-Residency In Musculoskeletal Care: An Efficient and Effective Mixed Method Model For Continuing Professional Education. Michael J. Battistone, Andrea M. Barker, Marissa Grotzke, J Peter Beck, Robert Z. Tashjian, Timothy A. Huhtala, Grant W. Cannon and Patrice Kennedy, Salt Lake City VA and University of Utah, Salt Lake City, UT, Salt Lake City VA, Salt Lake City, UT 966. Less Is More? A Targeted Intervention Results In Substantial Improvement In rheumatologists Ordering Of Anti Nuclear Antibodies (ANA) In Patients With Rheumatic Complaints. Nienke Lesuis, Ester Piek, Hatice Demirel, Ronald F. van Vollenhoven and Alfons A. den Broeder, Sint Maartenskliniek, Nijmegen, Netherlands, Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID), the Karolinska Institute, Stockholm, Sweden 967. Bending Ethical Norms To Serve Patients Interests: Tensions In Medical Professionalism. C. Ronald MacKenzie, Inmaculada de Melo-Martin, Michele Meltzer and Elizabeth A. Kitsis 4, Hospital for Special Surgery, New York, NY, Weill Cornell Medical College, New York, NY, Jefferson Universtiy, Philadelphia, PA, 4 Albert Einstein College of Med, Bronx, NY 968. Success Of Educational Intervention In Improving The Management Of Rheumatoid Arthritis. Nimish Mehta and Ronald Viggiani, Medscape, LLC, New York, NY 969. Increasing Rheumatology Exposure To Internal Medicine Residents: Year Analysis Of A Web-Based Image Of The Month. Steven J. Katz, University of Alberta, Edmonton, AB 0 Program Book 970. Incorporating The Health Literacy Universal Precautions Toolkit Quick Start In Academic Rheumatology Practices: Carolina Fellows Collaborative. Adam Dore, John Dye, Lara Hourani, Betsy Hackney, Lisa G. Criscione- Schreiber, Faye N. Hant 4, Kenneth S. O Rourke 5, Beth L. Jonas and Leigh F. Callahan 6, University of North Carolina at Chapel Hill, Chapel Hill, NC, Duke University School of Medicine, Durham, NC, Medical University of South Carolina, Charleston, SC, 4 Medical Univ of South Carolina, Charleston, SC, 5 Wake Forest School of Medicine, Winston- Salem, NC, 6 University of North Carolina, Chapel Hill, NC 97. A Needs Assessment and Review Curriculum Of Content Of Teaching On Systemic Lupus Erythematosus. Mo Yin Mok, Yi Lo and Chak Sing Lau, University of Hong Kong, Hong Kong, Hong Kong 97. Retrospective Self-Assessment Of Pre-Course Competency: A Useful Tool For Musculoskeletal Curriculum Assessment In a Multi-Center, Interprofessional Cohort. Michael J. Battistone, Andrea M. Barker, J Peter Beck, Marissa Grotzke, Timothy A. Huhtala, Jorie Butler, Amy C. Cannella, David I. Daikh 4, Meika A Fang 5, Antonio A. Lazzari 6, Pedro Roldan 7, Joan Marie Von Feldt 8 and Grant W. Cannon, Salt Lake City VA and University of Utah, Salt Lake City, UT, Salt Lake City VA, Salt Lake City, UT, Omaha Veterans Affairs Hospital and University of Nebraska Medical Center, Omaha, NE, 4 University of California, San Francisco, San Francisco, CA, 5 VA Greater Los Angeles Healthcare System, Los Angeles, CA, 6 Boston VA Medical Center, Boston, MA, 7 Leesburg VA CBOC, Leesburg, FL, 8 Univ of Pennsylvania/Philadelphia VAMC, Philadelphia, PA 97. Basic Musculoskeletal Ultrasound Curriculum Among Internal Medicine Residents: A Pilot Study. Gaurav Gulati and David George, University of Cincinnati College of Medicine, Cincinnati, OH, The Reading Hospital and Medical Center, West Reading, PA 974. Medical Student Perceptions Of Point-Of-Care Ultrasound In Musculoskeletal Education. Minna J. Kohler, Joshua Rempell and Margaret Seton, Massachusetts General Hospital / Harvard Medical School, Boston, MA, Brigham and Women s Hospital, Boston, MA 975. Outcomes-Based Program Evaluation Of a Musculoskeletal Ultrasound Curriculum. Hitasha Singh and Karina D. Torralba, University of Southern California, Los Angeles, CA, University of Southern California Keck School of Medicine, Los Angeles, CA 976. Experiential Learning In Musculoskeletal Ultrasound. Hitasha Singh and Karina D. Torralba, University of Southern California, Los Angeles, CA, University of Southern California Keck School of Medicine, Los Angeles, CA 977. Development Of a Tool To Assess Internal Medicine Residents Confidence In Their Musculoskeletal Examination Skills. Lisa G. Criscione-Schreiber, Eric Schreiber, Murat Arcasoy and Kenneth S. O Rourke 4, Duke University Health System, Durham, NC, University of North Carolina at Chapel Hill, Chapel Hill, NC, Duke University School of Medicine, Durham, NC, 4 Wake Forest School of Medicine, Winston-Salem, NC

225 ACR POSTER SESSION B 978. Inter-Professional Training Programs For Primary Care Providers Can Successfully Educate Practitioners With Dramatically Different Educational and Training Background Through a Common Mini-Residency Training Program. David I. Daikh, Michael J. Battistone, Andrea M. Barker, Andy L. Avins, Marissa Grotzke, Meika A Fang 4, Antonio A. Lazzari 5, Amy C. Cannella 6, Pedro Roldan 7, Joan Marie Von Feldt 8 and Grant W. Cannon, San Francisco VA Medical Center and University of California, San Francisco, San Francisco, CA, Salt Lake City VA and University of Utah, Salt Lake City, UT, San Francisco VA Medical Center, San Francisco, CA, 4 VA Greater Los Angeles Healthcare System, Los Angeles, CA, 5 Boston VA Medical Center, Boston, MA, 6 Omaha Veterans Affairs Hospital and University of Nebraska Medical Center, Omaha, NE, 7 Leesburg VA CBOC, Leesburg, FL, 8 Univ of Pennsylvania/Philadelphia VAMC, Philadelphia, PA 979. Southern Hemisphere Educational Partnership For Pediatric Arthritis and Rheumatological Diseases (SHEPPARD): An International Educational Program. Ricardo A. G. Russo, Marìa M. Katsicas, Kate Webb and Christiaan Scott, Hospital de Pediatria Garrahan, Buenos Aires, Argentina, Hospital de Pediatrìa Garrahan, Buenos Aires, Argentina, Red Cross War Memorial Children s Hospital, Cape Town, South Africa 980. Promoting Critical Appraisal Self-Efficacy and Peer Connectivity With An Epidemiology Curriculum For Rheumatology Trainees. Juliet Aizer, Jessica Berman, Anne R. Bass, Stephen A. Paget and Lisa A. Mandl, Hospital for Special Surgery Weill Cornell Medical College, New York, NY, Hospital for Special Surgery, Weill Cornell Medical College, New York, NY, Hospital for Special Surgery, New York, NY 98. Competency and Confidence In Musculoskeletal Medicine For The First Graduating Class Of a New Medical School. Shazia Bég, University of Central Florida, Orlando, FL 98. Preferred Strategies For Delivering Treatment Information To People With Rheumatoid Arthritis, Osteoarthritis and Osteoporosis. Maria A. Lopez-Olivo, Robert Volk, Maria Jibaja-Weiss and Maria E. Suarez-Almazor 4, University of Texas. M.D Anderson Cancer Center, Houston, TX, UT MD Anderson Cancer Center, Houston, TX, Baylor College of Medicine, Houston, TX, 4 University of Texas MD Anderson Cancer Center, Houston, TX 98. Teaching Musculoskeletal Care Through An Inter- Disciplinary and Inter-Professional Clinical Training Program Successfully Provides Trainees With Knowledge and Skills Required To Deliver Excellent Musculoskeletal Care. Grant W. Cannon, Andrea Barker, J Peter Beck, Jeffery Berdan, Marissa Grotzke, Timothy A. Huhtala, Patrice Kennedy, Phillip Lawrence, JoAnn Rolando and Michael J. Battistone, Salt Lake City VA and University of Utah, Salt Lake City, UT, Salt Lake City VA, Salt Lake City, UT ARHP Education/Community Programs 984. Development and Usability Testing Of The Arthritis Health Journal: An Online Tool To Promote Self-Monitoring In People With Rheumatoid Arthritis. Erin Carruthers, Paul M Adam, Hilary Horlock, Linda C. Li 4, Anne F. Townsend, Charles H Goldsmith 5, Beverly Mitchell and Diane Lacaille 6, Arthritis Research Centre of Canada, Richmond, BC, Mary Pack Arthritis Centre, Vancouver, BC, Provincial Health Services Authority, Vancouver, BC, 4 University of British Columbia, Vancouver, BC, 5 Simon Fraser University, Burnaby, BC, 6 Arthritis Research Centre of Canada, University of British Columbia, Richmond, BC 985. Efficacy Study Of Multimedia To Educate Rheumatoid Arthritis Patients. Julie A. Unk, Washington Univ School of Med, St. Louis, MO 986. Participant and Educator Feedback Informs Delivery Of An Interprofessional Inflammatory Arthritis Education Program Using Telemedicine In Rural Communities. Carol Kennedy, Kelly Warmington, Carol Flewelling, Rachel Shupak, Angelo Papachristos 4, Caroline Jones 4, Dorcas Beaton 5, Sydney C. Lineker 6 and Denise Linton, St. Michael s Hospital, Toronto, ON, Hospital for Sick Children, Toronto, ON, St. Michaels Hospital, Toronto, ON, 4 St Michael s Hospital, Toronto, ON, 5 Scientist, Institute for Work & Health, Toronto, ON, 6 The Arthritis Society, Toronto, ON 987. Improving Access To Subspecialty Care For Underserved Communities: A Rheumatology Patient Navigator Pilot Intervention. Candace H. Feldman, Gregory A. Culley, Erika Brown, Chanele R. Assencoa, LeRoi S. Hicks 4 and Daniel H. Solomon 5, Brigham and Women s Hospital,Harvard Medical School, Boston, MA, Family Health Center of Worcester, Inc., Worcester, MA, Brigham and Women s Hospital, Boston, MA, 4 UMass Memorial Medical Center, Worcester, MA, 5 Harvard Medical School, Brigham and Women s Hospital, Division of Rheumatology, Division of Pharmacoepidemiology, Boston, MA 988. Lupus Education For Providers Serving The Asian American Community: Hospital For Special Surgery s LANtern (Lupus Asian Network) Initiative. My-Lan N. Tran, Roberta Horton, Michael D. Lockshin and Arthur Yee, Hospital for Special Surgery, New York City, NY, Hospital for Special Surgery, New York, NY 989. Reproductive Counseling Program For Lupus Patients At The Systemic Lupus Erythematosus-Antiphospholipid Syndrome Center Of Excellence At Hospital For Special Surgery. Katherine Kim, Alana B. Levine, Monica C. Richey, Nadine H. Spring, Elizabeth Schulman, Lisa R. Sammaritano, Shari E. Gelber 4 and Jane E. Salmon, Hospital for Special Surgery, New York, NY, Hospital for Special Surgery, New York, NY, Hospital for Special Surgey, New York, NY, 4 New York Presbyterian Hospital, New York, NY 990. Utilizing Facebook Chats To Convey Health Information To Lupus Patients At The Systemic Lupus Erythematosus - Antiphospholipid Syndrome Center Of Excellence At Hospital For Special Surgery. Nadine H. Spring, Elyse Bernstein, Su Jin Kim, Monica C. Richey, Jessica Rowshandel and Jane E. Salmon, Hospital for Special Surgery, New York, NY, SLE Lupus Foundation, New York, NY 0 Program Book

226 ACR POSTER SESSION B 99. Utilization Of An Informational Needs Assessment To Develop An Education Program For Patients With Ankylosing Spondylitis (AS) and Related Axial Spondyloarthritis (SpA). Rita Kang, Rebecca Morton, Christopher Hawke, Laura A. Passalent, Robert D. Inman, Dinny Wallis, Joan Blair, Alison Lake, Heather Sloman, Marc Doucet 4, Debra MacGarvie and King Wong 4, University Health Network- Toronto Western Hospital, Toronto, ON, Toronto Western Hospital, University of Toronto, Toronto, ON, Toronto Western Research Institute, University Health Network and University of Toronto, Toronto, ON, 4 University Health Network, Toronto, ON Epidemiology and Health Services II 99. Promise Of Behavioral Economics: Delay Discounting and Physical Activity In Patients With Musculoskeletal Diseases. Elena Losina, Yan Dong, Stephanie Chen, Ran Schwarzkopf, Laurel Donnell-Fink, David Lerner and Jeffrey N. Katz, Brigham and Women s Hospital, Boston, MA, University of California Irvine Medical Center, Orange, CA 99. An Analysis Of Healthcare Resource Utilization Among Patients Undergoing Total Knee Arthroplasty In The United Kingdom. Mireia Raluy, Michael Schoenfeld, Dimitra Lambrelli, Meng Wang, Ning Wu, Shih-Yin Chen and Russel Burge, United BioSource Corporation, London, United Kingdom, Eli Lilly and Company, Indianapolis, IN, United BioSource Corporation, Lexington, MA 994. The Economic Burden Of Osteoarthritis In Americans: Analysis From a Privately Insured Population. Susanne X. Wang, Arijit X. Ganguli, Dendy Macaulay, William Reichmann, Jeroen Medema and Mary A. Cifaldi, AbbVie Inc., North Chicago, IL, Analysis Group, Inc., New York, NY, Analysis Group, Inc., Boston, MA 995. Quality Of Life, Productivity Impairment, Disease Severity and Health Care Costs In Relation To Functional Impairment In Psoriatic Arthritis Patients In The Czech Republic. Jiri Stolfa, Liliana Sedova, David Suchy, Jiri Klimes, Milan Vocelka and Tomas Dolezal, Charles University Prague, Prague, Czech Republic, University hospital Plzen, Plzen, Czech Republic, Charles University, Prague, Czech Republic 996. Predictors and Modeling of Costs in Rheumatoid Arthritis. Jonas Eriksson, Thomas Frisell, Johan Askling and Martin Neovius, Clinical Epidemiology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden, Karolinska Institutet, Stockholm, Sweden, Karolinska University Hospital, Stockholm, Sweden 997. Does Biologic Treatment For Rheumatoid Arthritis Offset Health Care Costs In Patients With Rheumatoid Arthritis? An Instrumental Variable Approach Using Administrative Data. Nick Bansback, Eric Fu, Daphne Guh, Huiying Sun, Wei Zhang, Diane Lacaille and Aslam H. Anis, University of British Columbia, Vancouver, BC, Centre for Health Evaluation and Outcome Sciences, Vancouver, BC, Arthritis Research Centre of Canada, University of British Columbia, Richmond, BC 998. Adequacy Of Drug Coverage and Cost-Sharing For Medicare Beneficiaries With Rheumatoid Arthritis. Jinoos Yazdany, R. Adams Dudley, Randi Chen and Chien- Wen Tseng 4, University of California, San Francisco, San Francisco, CA, University of California San Francisco Philip R. Lee Institute for Health Policy Studies, San Francisco, CA, Pacific Health Research and Education Institute, Honolulu, HI, 4 University of Hawaii and Pacific Health Research and Education Institute, Honolulu, HI 999. Cost Consideration For Biologics For Patients With Rheumatoid Arthritis In a Pharmacy Benefit Management Setting. Ning Wu, Yuan-Chi Lee, Neel Shah and David J. Harrison, United BioSource Corporation, Lexington, MA, Amgen Inc., Thousand Oaks, CA 000. Comparison Of The Cost-Effectiveness Of The Treatment Strategies With and Without Biological Response Modifiers For Patients With Recently Diagnosed Rheumatoid Arthritis Following A Clinical Guideline For Treatment Selection. An Tran-Duy, Annelies Boonen, Wietske Kievit, Piet L.C.M. van Riel, Mart A.F.J. van de Laar and Johan L. Severens 4, Maastricht University Medical Center, Maastricht, Netherlands, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, Medisch Spectrum Twente & University of Twente, Enschede, Netherlands, 4 Erasmus University Rotterdam, Rotterdam, Netherlands 00. Long-Term Effectiveness and Cost Per Effectively Treated Patient With Biologics Used In Rheumatoid Arthritis. Vernon F. Schabert, Jason Yeaw, Jonathan Korn, Caroleen Quach, David J. Harrison 4, Huifeng Yun 5, George Joseph 6, David H. Collier 4 and Jeffrey R. Curtis 7, IMS Health, Alexandria, VA, IMS Consulting Group, Alexandria, VA, University of North Carolina at Chapel Hill, Gillings School of Public Health, Chapel Hill, NC, 4 Amgen Inc., Thousand Oaks, CA, 5 University of Alabama at Birmingham, Birmingham, AL, 6 Former Amgen Employee, Thousand Oaks, CA, 7 University of Alabama at Birmingham, School of Public Health, Birmingham, AL 00. WITHDRAWN 00. Measuring Economic Value of Morning Stiffness; Consistency Over Year. Risto Tuominen, University of Turku, Turku, Finland 004. Cost-Effectiveness Analysis Of Two Rituximab Based Therapeutic Regimens For Longstanding Rheumatoid Arthritis. Luca Quartuccio, Rossella Di Bidino, Matteo Ruggeri, Domenico Biasi 4, Franco Schiavon 5, Leonardo Punzi 6, Silvano Adami 4, Americo Cicchetti and Salvatore De Vita, Rheumatology Clinic, DSMB, University of Udine, Udine, Italy, HTA Unit, A.Gemelli Teaching Hospital, Rome, Italy, Faculty of Economics, Catholic University of the Sacred Heart, Rome, Italy, 4 Rheumatology Clinic, University of Verona, Verona, Italy, 5 Rheumatology Clinic, University of Padova, Padova, Italy, 6 University of Padova, Rheumatology Unit, Padova, Italy 4 0 Program Book

227 ACR POSTER SESSION B 005. Generalization and Extrapolation Of Treatment Effects From Clinical Studies In Rheumatoid Arthritis. Sandhya C. Nair, Wietske Kievit, R W Janse, Johannes WJ Bijlsma 4, Floris Lafeber 5, Jaap Fransen and P.M.J. Welsing, University Medical Center Utrecht, Utrecht, Netherlands, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, Medical student, Utrecht, Netherlands, 4 University Medical Centre Utrecht, Utrecht, Netherlands, 5 UMC Utrecht, Utrecht, Netherlands 006. One-Year Change Of Employment and Work Productivity In Patients With Systemic Lupus Erythematosus From The Southeastern United States. Deepak Sree, S. Sam Lim, Hong Kan, Priti M. Jhingran, Charles T. Molta, Gaobin Bao and Cristina Drenkard, Emory University, Atlanta, GA, GlaxoSmithKline, Research Triangle Park, NC, GlaxoSmithKline, King of Prussia, PA 007. Dose Of Corticosteroid, Risk Of Adverse Events and Healthcare Resource Utilization In Systemic Lupus Erythematosus. Wei-Shi Yeh, Shih-Yin Chen, Kathleen McCarty, Qian Li, Yuan-Chi Lee and Nathalie Franchimont, Biogen Idec Inc., Weston, MA, United BioSource Corporation, Lexington, MA 008. Longitudinal Analysis Of Direct Medical Costs For Systemic Sclerosis Patients: A Population-Based Study. Natalie McCormick, Carlo A. Marra, Eric C. Sayre and J. Antonio Avina-Zubieta 4, University of British Columbia, Vancouver, BC, Univ of British Columbia, Vancouver, BC, Arthritis Research Centre of Canada, Richmond, BC, 4 Arthritis Research Centre of Canada, University of British Columbia, Richmond, BC 009. Association Of Depressive Symptomatology and Life and Job Satisfaction In Patients With Rheumatoid Arthritis. Jutta G. Richter, Dr. Ralph Brinks, Thomas Muth, Mia Vidakovic, Tobias Koch, Peter Angerer and Matthias Schneider, Heinrich-Heine-University, Duesseldorf, Germany, Univ. Duesseldorf, Duesseldorf, Germany, Heinrich-Heine-University Duesseldorf, Duesseldorf, Germany 00. Association Of Depressive Symptomatology and Life and Job Satisfaction In Patients With Systemic Lupus Erythematosus. Jutta G. Richter, Thomas Muth, Ralph Brinks, Mia Vidakovic, Tobias Koch, Peter Angerer and Matthias Schneider, Heinrich-Heine-University, Duesseldorf, Germany, Univ. Duesseldorf, Duesseldorf, Germany, Heinrich-Heine-University Duesseldorf, Duesseldorf, Germany 0. Psychiatric and Cardiovascular Comorbidities As Causes Of Work Disability Among Individuals With Rheumatoid Arthritis. Anne M. Kerola, Tuomo Nieminen, Markku J. Kauppi, Hannu Kautiainen 4, Tuomas Kerola, Lauri J. Virta 5, Timo Pohjolainen 6 and Kari Puolakka 7, Medical School, University of Helsinki, Helsinki, Finland, Division of Cardiology, Helsinki University Central Hospital, Helsinki, Finland, Department of Internal Medicine, Päijät-Häme Central Hospital, Lahti, Finland, 4 Unit of Primary Health Care, Helsinki University Central Hospital, Helsinki, Finland, 5 Research Department, the Social Insurance Institution, Turku, Finland, 6 ORTON Rehabilitation Centre, ORTON Foundation, Helsinki, Finland, 7 Department of Medicine, South Karelia Central Hospital, Lappeenranta, Finland 0. Disease Severity, Quality Of Life, and Productivity Loss Among Patients With Ankylosing Spondylitis In Germany. Jürgen Braun, Herbert Kellner, Regina Max, Markus Rihl 4, Elmar Schmitz-Bortz 5, Hendrik Schulze-Koops 6, Silke Zinke 7, Tao Fan 8, Qian Ding 8 and Ramon Lyu 8, Rheumazentrum Ruhrgebiet, Herne, Germany, Centre for Inflammatory Joint Diseases, Munich, Germany, University of Heidelberg, Heidelberg, Germany, 4 German Society for Rheumatology Association, Traunstein, Germany, 5 Rheumatism Practice in Hattingen, Hattingen, Germany, 6 University of Munich, Munich, Germany, 7 Rheumatological Office, Berlin, Germany, 8 Merck & Co., Inc, Whitehouse Station, NJ 0. Estimating the Monetary Value of annual Productivity Gained in Early Active RA Patients Receiving Etanercept Plus Methotrexate: Results From the Prize Study. Wei Zhang, Nick Bansback, Huiying Sun, Ronald Pedersen, Sameer Kotak 4 and Aslam H. Anis, Centre for Health Evaluation and Outcome Sciences, Vancouver, BC, University of British Columbia, Vancouver, BC, Pfizer Inc, Collegeville, PA, 4 Pfizer Inc., New York, NY 04. Test-Retest Reliability Of Five Global Measures Addressing At Work Limitations/Productivity Loss In Patients With Rheumatological Conditions. Sarah Leggett, Annelies Boonen, Diane Lacaille, Dorcas Beaton 4, Bruno Fautrel 5, Ailsa Bosworth 6, Catherine Hoffstetter 7, Sabrina Dadoun 5, Carlo Alberto Scirè 8, Sofia Hagel 9, Mihai Bojinca 0, Carina Mihai, Antje Neuen, Pam Rogers, Denise Linton 4, Ingemar Petersson 5 and Suzanne Verstappen 6, Arthritis Research UK Epidemiology Unit, Manchester Academic Health Science Centre,The University of Manchester, Manchester, United Kingdom, Maastricht University Medical Center, Maastricht, Netherlands, Arthritis Research Centre of Canada, University of British Columbia, Richmond, BC, 4 Scientist, Institute for Work & Health, Toronto, ON, 5 APHP, Pitié-Salpêtrière University Hospital, Paris, France, 6 National Rheumatoid Arthritis Society, Maidenhead, United Kingdom, 7 Patient partner, Toronto, ON, 8 Epidemiology Unit -Italian Society for Rheumatology, Milano, Italy, 9 Lund University and Skåne University Hospital, Lund, Sweden, 0 Dr. I. Cantacuzino Hospital, Bucharest, Romania, Carol Davila University of Medicine and Pharmacy & Cantacuzino Hospital, Bucharest, Romania, University Hospital Maastricht, Internal Medicine, Division of Rheumatology, Maastricht, Netherlands, Arthritis Research Centre, Vancouver, BC, 4 St. Michael s Hospital, Toronto, ON, 5 Lund University, Department of Orthopedics, Clinical Sciences Lund, Lund, Sweden, 6 Arthritis Research UK Epidemiology Unit, The University of Manchester, Manchester, United Kingdom 05. Quality Of Life, Productivity Impairment, Disease Severity and Health Care Costs In Relation To Functional Impairment In Ankylosing Spondylitis Patients In The Czech Republic. Liliana Sedova, Jiri Stolfa, David Suchy, Andrea Smrzova, Jiri Klimes 4, Milan Vocelka 4 and Tomas Dolezal 4, Charles University Prague, Prague, Czech Republic, University hospital Plzen, Plzen, Czech Republic, University hospital Olomouc, Olomouc, Czech Republic, 4 Charles University, Prague, Czech Republic 0 Program Book 5

228 ACR POSTER SESSION B Presenteeism Predicts Sick Leave Better Than Basdai and/or BASFI In A Longitudinal Cohort Of Patients With Ankylosing Spondylitis (EASIC). Thien Thi Vinh Nguyen, An Tran-Duy, Frank Heldmann, Juergen Braun, Herbert Thijs and Annelies Boonen, Hasselt University, Hasselt, Belgium, Maastricht University Medical Center, Maastricht, Netherlands, Rheumazentrum Ruhrgebiet, Herne, Germany 07. WITHDRAWN 08. Methodology Of Determining An Appropriate Look-Back Period To Identify Autoimmune Rheumatic Disease In a Study Of Post-Myocardial Infarction Mortality. Mark Tacey, Megan Bohensky and Sharon Van Doornum, The University of Melbourne, Melbourne, Australia 09. Comparison Of Comorbidity Indexes In a Clinical and Administrative Rheumatoid Arthritis Cohort: A Case For The Rheumatic Diseases Comorbidity Index. Bryant R. England, Harlan Sayles, Ted R. Mikuls, Dannette S. Johnson and Kaleb Michaud 4, University of Nebraska Medical Center, Omaha, NE, Omaha VA and University of Nebraska Medical Center, Omaha, NE, Jackson VA and University of Mississippi Medical Center, Jackson, MS, 4 National Data Bank for Rheumatic Diseases & University of Nebraska Medical Center, Omaha, NE 00. The Impact Of Diagnostic Decision Rules Used In Administrative Healthcare Databases On The Frequency Of Rheumatoid Arthritis and Systemic Lupus Erythematosus. John G. Hanly, Kara Thompson and Chris Skedgel, Dalhousie University and Capital Health, Halifax, NS 0. Application Of a Novel Measure Of Socioeconomic Status Using Individual Housing Data In Rheumatology Research. Young Juhn, Sherine E. Gabriel, Cynthia S. Crowson, Jennifer Rand-Weaver and Elizabeth Krusemark, Mayo Clinic, Rochester, MN 0. Initiation Of Biologic Therapy: The Patient Perspective. Amir Goren, Susan C. Bolge, Duncan Brown, Roxanne Meyer 4 and Seth Ginsberg 5, Kantar Health, New York, NY, Janssen Scientific Affairs, LLC, Horsham, PA, Kantar Health, New york, NY, 4 Janssen Scientific Affairs, LLC, Horsham, NY, 5 Creaky Joints, New York, NY 0. Openness To and Preference For Biologic Therapy Among Patients With Rheumatoid Arthritis Prior To Biologic Initiation: Patient and Prescriber Perspectives. Susan C. Bolge, Duncan Brown, Amir Goren, Roxanne Meyer 4 and Seth Ginsberg 5, Janssen Scientific Affairs, LLC, Horsham, PA, Kantar Health, New york, NY, Kantar Health, New York, NY, 4 Janssen Scientific Affairs, LLC, Horsham, NY, 5 Creaky Joints, New York, NY 04. Modeling The Benefit Risk Profiles Of a New Janus Kinase Inhibitor Tofacitinib Compared Tottumour Necrosis Factor Inhibitor Biologic Treatments Incorporating Conjoint Derived Patient Preference Weights. Michael P. Ingham, Shannon Cartier, Raphael J. DeHoratius, Jack McGowan and Eric Sabot, Janssen Scientific Affairs, LLC, Horsham, PA, Optum, Eden Prairie, MN, Janssen Services, LLC, Horsham, PA 0 Program Book 05. Mapping The Health Assessment Questionnaire On a Preference Based Utility Measure In a Large Canadian Rheumatoid Arthritis Cohort: Results From The Ontario Best Practices Research Initiative. Mark Tatangelo, George A. Tomlinson and Claire Bombardier, University of Toronto, Toronto, ON, Toronto General Hospital, Toronto, ON 06. Impact Of Basing Rheumatoid Arthritis Disease Activity Measurement and Treatment Recommendations On Patient Instead Of Physician Joint Assessments. Yomei Shaw, Daisy Bang, Heather Eng, Stephen R. Wisniewski, Mark S. Roberts and Marc C. Levesque, University of Pittsburgh, Graduate School of Public Health, Pittsburgh, PA, University of Pittsburgh, Pittsburgh, PA 07. Factors Associated With Decisions To Adjust Therapy For Rheumatoid Arthritis Patients In Moderate To High Disease Activity. Yomei Shaw, Chung-Chou H. Chang, Heather Eng, Ilinca D. Metes, Stephen R. Wisniewski, Mark S. Roberts and Marc C. Levesque, University of Pittsburgh, Graduate School of Public Health, Pittsburgh, PA, University of Pittsburgh, Pittsburgh, PA 08. Development Of Patient-Reported Outcomes Measurement Information System (PROMIS ) Gastrointestinal (GI) Symptoms Item Bank. Dinesh Khanna, Lin Chang, Gil Y. Melmed, Roger Bolus 4, Puja Khanna, Ron Hays 5 and Brennan Spiegel 5, University of Michigan Medical Center, Ann Arbor, MI, David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, CA, Cedar-Sinai Medical Center, Los Angeles, CA, 4 Research Solutions Group, Encinitas, CA, 5 University of California, Los Angeles, Los Angeles, CA 09. Quality Of Life In Rheumatoid Arthritis: Cross-National Comparison Study Between US and South Korea. Yoon- Kyoung Sung, Kazuki Yoshida, Femke H.M. Prince, Michelle A. Frits, Jung-Yoon Choe, Won Tae Chung, Jisoo Lee 4, Eun-Mi Koh 5, Dae-Hyun Yoo 6, Simon M. Helfgott, Nancy A. Shadick, Michael E. Weinblatt, Sang-Cheol Bae 6 and Daniel H. Solomon, Brigham and Women s Hospital, Boston, MA, Catholic University of Daegu School of Medicine, Daegu, South Korea, Dong-A University Hospital, Busan, South Korea, 4 Ewha Womans University Mokdong Hospital, Seoul, South Korea, 5 Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea, 6 Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea 00. Readability of Participant Information and Consent Forms for Rheumatology Clinical Trial Participants. Stephen Hall, Gail Grant and Christina Meyer, Melbourne Rheumatology, Melbourne, Australia, emeritus research, melbourne, Australia 0. Health Literacy Predicts Discrepancies Between Traditional Written Rheumatoid Arthritis Patient Assessments and Verbally-Administered Assessments. Joel M. Hirsh, Lisa A. Davis, Itziar Quinzanos, Angela Keniston and Liron Caplan 4, Denver Health and Hospital Authority, Denver, CO, Univ. of Colorado Sch. of Medicine, Aurora, CO, University of Colorado School of Medicine, Aurora, CO, 4 Denver Veterans Affairs Medical Center, Denver, CO

229 ACR POSTER SESSION B 0. Shared Decision-Making In The Choice Of Biologic Medication: The Patient Perspective. Susan C. Bolge, Helen Eldridge and Michael P. Ingham, Janssen Scientific Affairs, LLC, Horsham, PA, Janssen Services, LLC., Titusville, NJ Epidemiology and Health Services III 0. Psychological status correlates of disease activity and sleep quality in patients with Ankylosing Spondylitis: A case-control study. Mingcan Yang, Yutong Jiang, Zhiming Lin, Zetao Liao, Qiuxia Li 4, Yanli Zhang and Jieruo Gu 5, Third affiliated hospital of Sun Yat-sen University, Guangzhou, China, third affiliated hospital of Sun Yatsen Universtiy, Guangzhou, China, THIRD AFFILIATED HOSPITAL OF SUN YAT-SEN UNIVERSIT, Guangzhou, China, 4 The Affiliated Third Hospital of Sun Yat-san University, Rheumatology, Guangzhou, China, 5 Third Affiliated Hospital of Sun Yat-sen University, GuangZhou, China 04. The Part Of Function (Health assessment Questionnaire) In The SF-6D and EQ-5D Utility Measures Varies Over Time In Early Arthritis (ESPOIR cohort): Questionable Validity Of Deriving Quality Adjusted Life Years From HAQ. Cécile Gaujoux-Viala, Anne-Christine Rat, Kossar Hosseini, Rene-Marc Flipo 4, Francis Guillemin and Bruno Fautrel 5, EA 45, Montpellier I University, Nîmes University Hospital, Rheumatology Department, Nîmes, France, Université de Lorraine, Nancy, F-54000, France; Inserm, CIC-EC CIE6, Nancy, F-54000, France; CHU de Nancy, Clinical Epidemiology and Evaluation Department, Nancy, F-54000, France; CHU de Nancy, Rheumatology department, Nancy, France, CHU Nancy, Clinical Epidemiology and Evaluation, Université de Lorraine, Paris Descartes University, APEMAC, EA 460, Nancy, France, 4 Hopital R Salengro CHRU Lille, Lille, France, 5 Paris 6 Pierre et Marie Curie University; AP- HP, Rheumatology, Pitié-Salpêtrière Hospital, - GRC-UPMC 08 EEMOIS, Paris, France 05. Psoriatic Arthritis and Mortality - a Nationwide Study. Thorvardur Jon Love, Thor Aspelund, Alexis Ogdie, Joel M. Gelfand 4, Hyon K. Choi 5, Vilmundur Gudnason and Bjorn Gudbjornsson 6, Landspitali University Hospital, Reykjavik, Iceland, The Icelandic Heart Association, Kopavogur, Iceland, University of Pennsylvania, Philadelphia, PA, 4 University of Pennsylvania., Philadelphia, PA, 5 Boston University School of Medicine, Boston, MA, 6 Faculty of Medicine, University of Iceland, Reykjavik, Iceland 06. The Independent Impact Of Depression On Incident Myocardial Infarction In Psoriatic Disease: A Population- Based Cohort Study. Lindsay C Burns, Jan P. Dutz and Hyon K. Choi, University of British Columbia, Vancouver, BC, Arthritis Research Centre of Canada, Richmond, BC 07. Incidence Of Malignancy In Patients With Rheumatoid Arthritis From a Japanese Large Observational Cohort (NinJa). Atsushi Hashimoto, Noriyuki Chiba, Jinju Nishino, Toshihiro Matsui 4 and Shigeto Tohma, Sagamihara Hospital, National Hospital Organization, Sagamihara, Japan, Morioka National Hospital, NHO, Iwate, Japan, Nishino Clinic, Orthopedics and Rheumatology, Tokyo, Japan, 4 National Hospital Organization Sagamihara Hospital, Kanagawa, Japan 08. Impact Of Biological Treatment On Overall Mortality and On Incidence Of Second Cancers In Arthritis Patients - A Follow-Up Study From The Danish Danbio Registry. Lene Dreyer, Lene Mellemkjær, Inger Marie Jensen Hansen and Merete Lund Hetland 4, Copenhagen University Hospital at Gentofte, Copenhagen, Denmark, Danish Cancer Society Research Center, Copenhagen, Denmark, OUH Svendborg Hospital, Svendborg, Denmark, 4 The Danish Rheumatologic Database (DANBIO), Glostrup Hospital., Copenhagen, Denmark 09. Risk Of High-Grade Cervical Dysplasia In Women With Systemic Inflammatory Diseases. Seoyoung C. Kim, Robert J. Glynn, Edward Giovannucci, Sonia Hernandez-diaz, Jun Liu, Sarah Feldman, Elizabeth W. Karlson 4, Sebastian Schneeweiss and Daniel H. Solomon 5, Brigham and Women s Hospital, Boston, MA, Harvard School of Publich Health, Boston, MA, Harvard School of Public Health, Boston, MA, 4 Brigham and Women s Hospital, Harvard Medical School, Boston, MA, 5 Harvard Medical School, Brigham and Women s Hospital, Division of Rheumatology, Division of Pharmacoepidemiology, Boston, MA 040. Use Of TNF Inhibitors Is Associated With a Reduced Risk Of Diabetes In RA Patients. Siri Lillegraven, Jeffrey D. Greenberg, George W. Reed, Katherine C. Saunders 4, Jeffrey R. Curtis 5, Leslie R. Harrold 6, Marc C. Hochberg 7, Dimitrios A. Pappas 8, Joel M. Kremer 9 and Daniel H. Solomon 0, Diakonhjemmet Hospital, Oslo, Norway, NYU Hospital for Joint Diseases, New York, NY, CORRONA, Inc., Worcester, MA, 4 CORRONA, Inc., Southborough, MA, 5 University of Alabama at Birmingham, Birmingham, AL, 6 University of Massachusetts Medical School, Worcester, MA, 7 University of Maryland, Baltimore, MD, 8 Columbia University, College of Physicians and Surgeons, New York, NY, 9 Center for Rheumatology, Albany Medical College, Albany, NY, 0 Harvard Medical School, Brigham and Women s Hospital, Division of Rheumatology, Division of Pharmacoepidemiology, Boston, MA 04. Non-Differential Reporting Of Myocardial Infarction To a National Observational Drug Safety Study Using Linked Data: Linkage Of The British Society For Rheumatology Biologics Register For Rheumatoid Arthritis and The Myocardial Ischaemia National Audit Project. Audrey SL Low, Deborah P. Symmons, Mark Lunt, Louise K. Mercer, Christopher Gale 4, Kath Watson, British Society for Rheumatology Biologics Registers (BSRBR) Control Centre Consortium, William G. Dixon 5, Kimme L. Hyrich 6 and On behalf of the BSRBR 7, Arthritis Research UK Epidemiology Unit, The University of Manchester, Manchester, United Kingdom, NIHR Manchester Musculoskeletal Biomedical Research Unit, Manchester Academic Health Science Centre, Manchester, United Kingdom, Arthritis Research UK Epidemiology Unit, University of Manchester, Manchester, United Kingdom, 4 Department of Cardiology,York Teaching Hospital NHS Foundation Trust, York, United Kingdom, 5 The University of Manchester, Manchester, United Kingdom, 6 Arthritis Research UK Epidemiology Unit, Manchester Academic Health Sciences Centre, Institute of Inflammation and Repair, The University of Manchester, Manchester, United Kingdom, 7 British Society for Rheumatology, London, United Kingdom 0 Program Book 7

230 ACR POSTER SESSION B 04. Comparison Of Medication Usage Following Myocardial Infarction In Patients With Autoimmune Rheumatic Disease Versus Controls. Sharon Van Doornum, Mark Tacey, Megan Bohensky, Caroline Brand, Vijaya Sundararajan and Ian Wicks 4, The University of Melbourne, Melbourne, Australia, The Royal Melbourne Hospital, Melbourne, Australia, University of Melbourne, Melbourne, Australia, 4 Royal Melbourne Hospital, Melbourne, Australia Musculoskeletal Hospital Admissions Among Patients Treated For Rheumatoid Arthritis Between 999 and 00 Compared With The General Population In The Netherlands. I D Bezemer, L M A Houweling, E Alemao, F J A Penning-van Beest and M Hochberg, PHARMO Institute for Drug Outcomes Research, Utrecht, Netherlands, Bristol-Myers Squibb, Princeton, NJ, University of Maryland, Baltimore, MD 044. Temporal Associations Of Prevalent Depression With The Different Domains Of Rheumatoid Arthritis Disease Activity. Alan Rathbun, Leslie R. Harrold and George Reed, University of Massachusetts Medical School, Worcester, MA 045. Under Reporting Of Cataracts In Randomised Controlled Trials Investigating The Use Of Systemic Glucocorticoids In Patients With Rheumatoid Arthritis. Rachel J. Black and William G. Dixon, The University of Manchester, Manchester, United Kingdom 046. Comparison Of The Incidence Of Influenza Like Illness In Pregnant Women With Rheumatoid Arthritis and Women Without Rheumatoid Arthritis Who Receive An Influenza Vaccination. Yunjun Luo, Diana L. Johnson, Ronghui Xu and Christina D. Chambers, University of California, San Diego, La Jolla, CA 047. Rates Of Hospitalized Infections In Rheumatoid Arthritis Patients From 5 Rheumatoid Arthritis Registries Across The World. Hisashi Yamanaka, Johan Askling, Niklas Berglind, Stefan Franzén, Thomas Frisell, Christopher Garwood 4, Jeffrey D. Greenberg 5, Meilien Ho 6, Marie Holmqvist, Laura Horne 7, Eisuke Inoue, Kathy Lampl 7, Kaleb Michaud 8, Dimitrios A. Pappas 9, George Reed 0, Deborah Symmons 4, Eiichi Tanaka, Trung Tran, Suzanne Verstappen 4 and Fredrik Nyberg, Tokyo Women s Medical University, Tokyo, Japan, Karolinska Institutet, Stockholm, Sweden, AstraZeneca R&D Mölndal, Mölndal, Sweden, 4 Arthritis Research UK Epidemiology Unit, The University of Manchester, Manchester, United Kingdom, 5 New York Hospital for Joint Disease, New York, NY, 6 AstraZeneca R&D Alderley Park, Macclesfield, United Kingdom, 7 AstraZeneca R&D Wilmington, Wilmington, DE, 8 University of Nebraska Medical Center, Omaha, NE, 9 Columbia University, New York, NY, 0 University of Massachusetts Medical School, Worcester, MA, MedImmune LLC, Gaithersburg, MD, AstraZeneca R&D, Mölndal, Sweden 048. Generalizability Of a U.S. Rheumatoid Arthritis Registry: A Comparison Of Participants Vs. Non-Participants Characteristics. Jeffrey R. Curtis, Lang Chen, Huifeng Yun, Leslie R. Harrold, Jeffrey D. Greenberg 4 and Joel M. Kremer 5, University of Alabama at Birmingham, Division of Clinical Immunology and Rheumatology, Birmingham, AL, University of Alabama at Birmingham, Birmingham, AL, University of Massachusetts Medical School, Worcester, MA, 4 New York Hospital for Joint Diseases, New York, NY, 5 Center for Rheumatology, Albany Medical College, Albany, NY 049. Formal Education Level Explains Variation In Rheumatoid Arthritis (RA) Core Data Set Measures and Indices In Korean Patients At Higher Levels Of Significance Than Age, Sex, and Duration Of Disease. Sung-Hoon Park, Isabel Castrejón, Jung-Yoon Choe, Seong-Kyu Kim, Hwajeong Lee, Sang Gyu Kwak and Theodore Pincus, Catholic University of Daegu School of Medicine, Daegu, South Korea, NYU Hospital for Joint Diseases and New York University School of Medicine, New York, NY 050. Population-Based Analysis Of Treatment Patterns For Recently Diagnosed Rheumatoid Arthritis Patients In The United States. Martin M. Crane, Boyka Stoykova, Julie Priest, Nasha Wang, Henry Krzywy and Rahul Ganguly, GlaxoSmithKline, Durham, NC, GlaxoSmithKline, Uxbridge, United Kingdom 05. Sociodemographic, Health System, and Community Characteristics Associated With Initiation Of Biological Dmards In RA. Edward H. Yelin, Chris Tonner, Seoyoung C. Kim, Jeffrey N. Katz, John Z. Ayanian and Daniel H. Solomon 4, UC San Francisco, San Francisco, CA, University of California, San Francisco, San Francisco, CA, Brigham and Women s Hospital, Boston, MA, 4 Harvard Medical School, Brigham and Women s Hospital, Division of Rheumatology, Division of Pharmacoepidemiology, Boston, MA 05. Glucocorticosteroids and Mortality Risk In Rheumatoid Arthritis - Results Of a Population Based Study. Diane Lacaille, J. Antonio Avina-Zubieta, Eric C. Sayre, Michal Abrahamowicz and John Esdaile, Arthritis Research Centre of Canada, University of British Columbia, Richmond, BC, Arthritis Research Centre of Canada, Richmond, BC, McGill University, Montreal, QC 05. Physician Proclivity To Use Oral Glucocorticoids Among Rheumatoid Arthritis Patients. Huifeng Yun, Fenglong Xie, Elizabeth S. Delzell, Lang Chen, Emily Levitan, James Lewis, Kenneth G. Saag, Timothy Beukelman, Kevin L. Winthrop, John Baddley and Jeffrey R. Curtis 4, University of Alabama at Birmingham, Birmingham, AL, University of Pennsylvania, Philadelphia, PA, Oregon Health & Science University, Portland, OR, 4 University of Alabama at Birmingham, Division of Clinical Immunology and Rheumatology, Birmingham, AL 054. Use Of Oral and Subcutaneous MTX In a Commercially Insured Rheumatoid Arthritis Population. Jeffrey R. Curtis, Fenglong Xie, Jie Zhang, Lang Chen, Huifeng Yun, Michael H. Schiff, Timothy Beukelman and Seth Ginsberg, University of Alabama at Birmingham, Birmingham, AL, University of Colorado, Denver, CO, Creaky Joints, New York, NY 8 0 Program Book

231 ACR POSTER SESSION B 055. Discontinuation Rates In Patients With RA Of Triple Disease Modifying Antirheumatic Therapy. Sofia Pedro, Frederick Wolfe, Hawre Jalal and Kaleb Michaud, National Data Bank for Rheumatic Diseases, Wichita, KS, University of Minnesota, Minneapolis, MN, National Data Bank for Rheumatic Diseases & University of Nebraska Medical Center, Omaha, NE 056. Adherence To Methotrexate Therapy Among Patients With Rheumatoid Arthritis In Denmark: A Registry Based Cohort Study. Henning Bliddal, Robin Christensen, Mikkel Østergaard, Tove Lorenzen, Michael Sejer Hansen 4, Peter Vestergaard 5 and Stine A Eriksen 5, The Parker Institute, Department of Rheumatology, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Denmark, Frederiksberg, Denmark, Copenhagen University Hospital Glostrup, Copenhagen, Denmark, Department of Rheumatology, Region Hospital Silkeborg, Silkeborg, Denmark, 4 Gildhøj Privathospital, Copenhagen, Denmark, 5 Aalborg University, Aalborg, Denmark 057. Regional Variations In Rheumatoid Arthritis Treatment and Health Outcomes Across The United States. Susan C. Bolge, Roxanne Meyer and Kathy Annunziata, Janssen Scientific Affairs, LLC, Horsham, PA, Janssen Scientific Affairs, LLC, Horsham, NY, Kantar Health, Princeton, NJ 058. Concomitant Methotrexate Use and The Risk Of Drug Discontinuation For Adalimumab Compared With Etanercept In Anti-TNF-Naïve Rheumatoid Arthritis Patients: A Nationwide Population-Based Cohort Study. Hsin-Hua Chen, Der-Yuan Chen, Chao-Hsiung Tang, Ya- Wen Yang 4, Chi-Hui Fang 4 and Nicole Huang, National Yang-Ming University, Taipei, Taiwan, Taichung Veterans General Hospital, Taichung, Taiwan, Taipei Medical University, Taipei, Taiwan, 4 Pfizer Limited, Taipei, Taiwan 059. Perinatal and Early Life Risk Factors For Systemic Lupus Erythematosus In a National Cohort Of Women. Christine G. Parks, Aimee D Aloisio and Dale Sandler, NIH/NIEHS, Research Triangle Park, NC 060. Perinatal Risk Factors For Systemic Lupus: A Register- Based Case-Control Study. Elizabeth V. Arkema and Julia F. Simard, Karolinska Institutet, Stockholm, Sweden, Stanford University School of Medicine, Stanford, CA 06. Clinical Phenotypes and Disease Burden Of Discoid Lupus Erythematosus In a Sample Of Systemic Lupus Erythematosus Patients In The Southeastern United States. Leslie Anne Cassidy, Gaobin Bao, Charmayne M. Dunlop-Thomas, S. Sam Lim and Cristina Drenkard, Emory University, Atlanta, GA 06. The Brief Index Of Lupus Damage As a Predictor Of Mortality In a Cohort Of Patients With Systemic Lupus Erythematosus. Stephanie Rush, Laura Trupin, Jinoos Yazdany and Patricia P. Katz, University of California, San Francisco, San Francisco, CA 06. The Influence Of Socioeconomic and Race In Damage Score In Patients With Systemic Lupus Erythematosus. Roberto Teixeira, Eduardo F. Borba, Georges Christopoulos Sr. and Emilia Sato 4, UNIVERSIDADE FEDERAL DE SÃO PAULO, SAO PAULO, Brazil, Rheumatology Division; University of São Paulo, São Paulo, Brazil, SANTA CASA DE MISERICORDIA DE MACEIO, MACEIO, Brazil, 4 Universidade Federal de São Paulo, São Paulo, Brazil 064. Trends In Hospitalizations Due To Organ Damage In Patients With Systemic Lupus Erythematosus In Canada, Amyn Sayani, Neerav Monga, Marni Freeman and Jorge Alfonso Ross Terres, GlaxoSmithKline, Inc., Mississauga, ON 065. Acute Myocardial Infarction Variation Among U.S. Medicaid Recipients With Systemic Lupus Erythematosus By Race and Ethnicity, Medha Barbhaiya, Candace H. Feldman, Jessica M. Franklin, Jun Liu, Joanne M. Foody 4, Michael A. Fischer, Daniel H. Solomon and Karen H. Costenbader, Division of Rheumatology, Immunology and Allergy, Brigham and Women s Hospital, Harvard Medical School, Boston, MA, Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women s Hospital, Boston, MA, Brigham and Women s Hospital, Boston, MA, 4 Division of Cardiovascular Medicine, Brigham and Women s Hospital, Boston, MA 066. Depression Screening In Patients With Systemic Lupus Erythematosus From The Southeastern United States: Missing Opportunities For Early Diagnosis and Treatment. Cristina Drenkard, Charmayne M. Dunlop-Thomas, Gaobin Bao and S. Sam Lim, Emory University, Atlanta, GA 067. Incidence and Prevalence Of Systemic Lupus Erythematosus: A 00 Nation-Wide Population-Based Study Using French National Administrative Databases. Laurent Arnaud, Jean-Paul Fagot, Michel Païta, Alexis Mathian, Anne Fagot-Campagna and Zahir Amoura, Hôpital Pitié-Salpêtrière, AP-HP, UPMC Univ Paris 06 & French National Reference Center For Systemic Lupus and Antiphospholipid Syndrome, Paris, France, Caisse Nationale d Assurance Maladie des Travailleurs Salariés, Paris, France, Pitié-Salpêtrière Hospital, APHP, Paris, France 068. An In-Depth Analysis Of The Prevalence and Socio- Demographic Factors Associated With Lupus Nephritis In Major Industrialized Countries. Guiping Yang and Anne Tuomari, Teva Pharmaceuticals, Inc., Frazer, PA 069. Racial Differences In Systemic Lupus Erythematosus Patients Treatment Preferences: A Two-Site Study. Ernest R. Vina, Tammy O. Utset, Michael J. Hannon, Nicole Roberts, Christopher M. Masi 4 and C. Kent Kwoh 5, University of Pittsburgh and VA Pittsburgh Healthcare System, Pittsburgh, PA, University of Chicago Department of Medicine, Chicago, IL, University of Pittsburgh School of Medicine, Pittsburgh, PA, 4 NorthShore University Health System, Evanston, IL, 5 University of Pittsburgh, Pittsburgh, PA 0 Program Book 9

232 ACR POSTER SESSION B 070. Characteristics and Medication Use Patterns Among Belimumab Users In a Commercially Insured Population With Systemic Lupus Erythematosus. Xuehua Ke, Jeetvan Patel, Hong Kan, Debra F Eisenberg and Alan Oglesby, HealthCore Inc, Wilmington, DE, GlaxoSmithKline, Research Triangle Park, NC 07. Prevalence Of Systemic Lupus Erythematosus and Lupus Nephritis In The United States: Analysis Of Commercial and Public Insurance Billing Data. Kunal Gandhi, Evo Alemao, Hugh Kawabata and Jan L. Hillson, Bristol-Myers Squibb, Princeton, NJ, Bristol-Myers Squibb, Seattle, WA ARHP Epidemiology and Public Health 07. Gene-Environment Interaction Between HLA-DRB Shared Epitope and Occupational Textile Dust Exposure In The Risk Of ACPA-Positive Rheumatoid Arthritis In Female Patients: Evidence From The Malaysian Epidemiological Investigation Of Rheumatoid Arthritis Case-Control Study. Chun Lai Too, Nor Asiah Muhamad, Leonid Padyukov, Lars Alfredsson, Camilla Bengtsson 4, Lars Klareskog and Shahnaz Murad 5, Institute for Medical Research, Jalan Pahang.Kuala Lumpur, Malaysia, Kuala Lumpur, Malaysia, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden, Institute of Environmental Medicine, Karolinska Institute, Stockholm, Sweden, 4 Karolinska Institutet, Stockholm, Sweden, 5 Institute for Medical Research, Jalan Pahang, Kuala Lumpur, Malaysia 07. Longitudinal Decline In Steps/Day In Older Adults With Or At High Risk Of Knee OA. Daniel K. White, Roger Fielding, K. Douglas Gross, Michael C. Nevitt 4, Cora E. Lewis 5, James Torner 6 and Tuhina Neogi, Boston University School of Medicine, Boston, MA, Tufts University, Boston, MA, MGH Institute of Health Professions, Boston, MA, 4 University of California, San Francisco, San Francisco, CA, 5 University of Alabama, Birmingham, Birmingham, AL, 6 University of Iowa, Iowa City, Iowa City, IA 074. Obesity and Life-Space Mobility Among Older Mexican Americans With and Without Arthritis. Soham Al Snih, Rafael Samper-Ternent, Amit Kumar and Kenneth J. Ottenbacher, University of Texas Medical Branch, Galveston, TX, Universidad Javeriana. Hospital San Ignacio, Bogota, Colombia 075. Patient Characteristics Associated With Insomnia and Sleep Apnea In Knee and Hip OA. Kelli D. Allen, Hayden B. Bosworth, Cynthia Coffman, Amy Jeffreys, Eugene Z. Oddone, William S. Yancy Jr. and Christi Ulmer, Duke and Durham VA Medical Center, Durham, NC 076. Individuals With Knee Or Hip OA and Low SES Are Likely To Be Physically Active. Rebecca J. Cleveland, Kamil E. Barbour, Jordan B. Renner, Joanne M. Jordan and Leigh F. Callahan 4, University of North Carolina at Chapel Hill, Chapel Hill, NC, Centers for Disease Control and Prevention, Atlanta, GA, University of North Carolina Thurston Arthritis Research Center, Chapel Hill, NC, 4 University of North Carolina, Chapel Hill, NC 077. Less Time Spent In Sedentary Behavior Is Associated With Better Future Physical Function: Objective Data From The Osteoarthritis Initiative. Jungwha Lee, Jing Song, Rowland W. Chang, Linda S. Ehrlich-Jones, Pamela A. Semanik, Min-Woong Sohn and Dorothy D. Dunlop, Northwestern University Medical School, Chicago, IL, Northwestern University, Chicago, IL, Rehabilitation Institute Chicago, Chicago, IL 078. Trends In Prevalence Of Knee Pain Among US Adults, National Health Interview Survey Jennifer M. Hootman, Charles G. Helmick and Yvonne M. Golightly, Centers for Disease Control and Prevention, Kennesaw, GA, Centers for Disease Control and Prevention, Atlanta, GA, University of North Carolina at Chapel Hill, Chapel Hill, NC 079. Physical Activity and Rheumatoid Arthritis: State Of The Art. Jasper van Kuijk, Sanne van Dartel and Han Repping- Wuts, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands 080. Incidence Of Coronary Heart Disease Associated With Arthritis: A Canadian Population-Based Cohort Study. Orit Schieir, S. Hogg-Johnson, Richard H Glazier and Elizabeth M. Badley 4, University of Toronto, Toronto, ON, Institute for Work and Health, and Dalla Lana School of Public Health, University of Toronto, Toronto, ON, nstitute for Clinical Evaluative Sciences, Sunnybrook Health Sciences Centre, Toronto, ON, 4 Division of Health Care and Outcomes Research, Toronto Western Research Institute; Dalla Lana School of Public Health, University of Toronto, Toronto, ON Fibromyalgia, Soft Tissue Disorders and Pain II 08. The Effects of Coexisting Cervical Myofascial Pain Syndromes On Pain and Disability of the Computer Users With Cumulative Trauma Disorders. Hakan Genc, Ozgul Bozkurt Tuncer, Hatice Rana Erdem, Baris Nacir, Aynur Karagoz and Burcu Duyur Cakit, Ministry of Health, Ankara Training and Research Hospital, Ankara, Turkey, Ministry of Health, Yuksekova Public Hospital, Hakkari, Turkey, Ahi Evran University, Kirsehir, Turkey 08. The Effects of Prolotherapy in Patients With Subacromial Impingement Syndrome. Eylem Akcan Hannan, Akyuz Gulseren Sr. and Nertila Hysenaj, Marmara Univesrsity School of Medicine, Istanbul, Turkey, Marmara University School of Medicine, Istanbul, Turkey, Private Vital Hospital, Istanbul, Turkey 08. Something Ventured, Something Gained: Alternative Therapies For FMS and RA. Robert S. Katz, Hannah Bond, Jessica L. Polyak, Lauren Kwan, Alexandra Small and Susan Shott 4, Rush Medical College, Chicago, IL, Rheumatology Associates, Chicago, IL, University of Illinois Medical School, Chicago, IL, 4 Rush University Medical Center, Chicago, IL 084. Age Distribution of Women With Idiopathic and Traumatic Fibromyalgia. Robert S. Katz and Frank Leavitt, Rush Medical College, Chicago, IL, Rush University Medical Center, Chicago, IL 0 0 Program Book

233 ACR POSTER SESSION B 085. I Work Out: Exercise Appears To Increase FMS Pain. Robert S. Katz, Ben J. Small and Susan Shott, Rush Medical College, Chicago, IL, Rush University Medical School, Chicago, IL, Rush University Medical Center, Chicago, IL 086. The Straight Neck in Fibromyalgia. Robert S. Katz and Anthony Farkasch, Rush Medical College, Chicago, IL, Rheumatology Associates, Chicago, IL 087. Abnormalities Of Central Processing Mechanisms In Fibromyalgia. Robert S. Katz and Bhagwan T. Shahani, Rush Medical College, Chicago, IL, University of Illinois College of Medicine, Chicago, IL 088. Fibromyalgia and Parental Medical Histories Of Depression and Alcoholism. Robert S. Katz, Ben J. Small, Sharon M. Ferbert and Susan Shott 4, Rush Medical College, Chicago, IL, Rush University Medical School, Chicago, IL, Advocates for Funding Fibromyalgia Treatment, Education and Research(AFFTER), Libertyville, IL, 4 Rush University Medical Center, Chicago, IL 089. Synergistic Effects Of Transcranial Direct Current Stimulation and Trigger Point Injection For Treatment Of Myofascial Pain Syndrome: A Pilot Study With Randomized, Single-Blinded Trial. Shi-Uk Lee, Chang Han Lee and Yoon-Hee Choi, Seoul National University Boramae Medical Center, Seoul, South Korea, Seoul National University Bundang Hospital, Seoul, South Korea 090. Suprascapular Nerve Block For Shoulder Pain In The First Year After Stroke: A Randomised Controlled Trial. Zoe Adey-Wakeling, Maria Crotty and E. Michael Shanahan, Flinders University, Adelaide, Australia, Flinders University, Bedford Park, South Australia, Australia 09. Altered Intrinsic Brain Connectivity In The Salience Network Of Fibromyalgia Patients At Rest. Seong-Ho Kim, Division of Rheumatology, Inje University College of Medicine, Haeundae Paik Hospital, Busan, South Korea 09. Low Dose Naltrexone In The Treatment Of Fibromyalgia. Samy Metyas, Karen Yeter, John Solyman and D. Arkfeld, Assistant clinical professor Of Rheumatology at USC, covina, CA, University of Southern California Keck School of Medicine, Los Angeles, CA, Research Associate, Covina, CA 09. SPA Therapy In The Treatment Of Chronic Shoulder PAIN Due To Rotator Cuff Tendinopathy: Rotatherm, A Large Randomized Multicentre Trial. Isabelle Chary-Valckenaere, Damien Loeuille, Nicolas Jay, François Kohler, Christian F Roques, Michel Boulange and Gérard Gay, Nancy University Hospital, Nancy, France, Université Paul Sabatier, Toulouse, France 094. Hyperbaric Oxygen Ameliorates Fibromyalgia Symptoms and Functional Impairment A Randomized Prospective Trial. Shai Efrati, Jacob N. Ablin, Yair Bechor, Shir Daphna- Tekoah, Gregory Fishlev 4, Yifat Faran, Jacob Bergan, Mony Friedman and Dan Buskila 5, Asaf-Harofeh medical center, Beer Yaacov, Zerifin, Israel, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, Ashkelon Academic College, Ashkelon, Israel, 4 Assaf Harofeh Medical Center, Beer Yaacov, Zerifin, Israel, 5 Ben-Gurion University, Beer-Sheva, Israel 095. Pooled Safety Data From Randomized, Controlled Trials Of Diclofenac Sodium Topical Gel % In Subjects With Acute Pain. Roy D. Altman, Helmut Pabst, Hans-Georg Predel, Bruno Giannetti 4, Ian Burnett 5, Morris Gold 6 and Evan F. Ekman 7, UCLA, Los Angeles, CA, Independent Physician, Gilching, Germany, German Sports University, Cologne, Germany, 4 CRM clinical trials GmbH, Rheinbach, Germany, 5 Novartis Consumer Health, Nyon, Switzerland, 6 Novartis Consumer Health, Parsippany, NJ, 7 Southern Orthopaedic Sports Medicine, Columbia, SC 096. Is Vitamin D Deficiency a Risk Factor For The Development Of Statin Induced Myalgia, In Patients Treated With Statin? Ozlem Tasoglu, Yesim Kutsal, Irfan Tasoglu, Oya Ozdemir and Yildiz Erdoganoglu, Hacettepe University Faculty of Medicine, Ankara, Turkey, Türkiye Yuksek Ihtisas Training and Research Hospital, Ankara, Turkey, Hacettepe University, Ankara, Turkey 097. A Potential Use Of Neurotropin TM, a Novel Neuro- Modulating Medication, For The Treatment Of Chronic Pain and Fibromyalgia. Kenji Miki, Ryota Hashimoto, Kenrin Shi and Masao Yukioka, Yukioka Hospital, Osaka, Japan, Osaka University Graduate School of Medicine, Suita, Japan, Osaka University Hospital, Suita, Japan 098. Safety and Efficacy Of Influenza Vaccination In Patients Suffering From Fibromyalgia. Jacob N. Ablin, Valerie Aloush, Ayelet Brill, Mark Berman, Merav Barzilai, Dan Caspi, Michal Mandelboim, David Levartovsky 4, Ari Polachek 5, Yonatan Wolman, Daphna Paran 6, Michael Barkagan and Ori Elkayam, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, Tel Aviv Sourasky Medical Center and the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel, Sheba Medical Center, Ramat Gan, Israel, 4 Tel Aviv Medical Ctr, Tel Aviv, Israel, 5 Tel Aviv Medical Center, Tel Aviv, Israel, 6 Tel Aviv Sourasky Medical Ctr, Tel-Aviv university, Tel Aviv, Israel 099. IgG Autoantibodies Against p9ing4 In Early-Stage Type I Complex Regional Pain Syndrome (CRPS) and In Other Inflammatory Diseases Involving The Joints. Niklas T. Baerlecken, Torsten Witte, Reinhold E. Schmidt, Christina Lansche, Michael Bernateck and Nils Pursche, Medical University Hannover, Hannover, Germany, Medical University Hannover, Hanover, Germany, Medical University of Hannover, Hannover, Germany 00. Relationship Between Body Mass Index, Fat Mass and Muscle Mass Withmusculoskeletal Pain In Community Residents. Young-Il Seo, Hyun Ah Kim, Nam H. Cho and Jong Jin Yoo 4, Hallym university sacred heart hospital, Kyunggi, South Korea, Hallym University Sacred Heart Hospital, Kyunggi, South Korea, Ajou University School of medicine, Suwon, South Korea, 4 Armed Forces Capital Hospital Seongnam Republic of Korea, Seongnam si, South Korea 0. Neuromuscular Taping On Patients With Fibromyalgia May Be a Useful Tool To Relief Muscular Pain. Camillo Giacomelli, Antonino Santagati, Arianna Consensi, Alessandra Rossi, Stefano Bombardieri and Laura Bazzichi, Rheumatology Unit, Pisa, Italy 0 Program Book

234 ACR POSTER SESSION B 0. The Correlation Among Macromastia, Spinal Pain, Thoracic Kyphosis and Fall Risk. Ulku Akarirmak, Hidayet Sari, Murat Uludag, Sibel Ozbayrak, Hasan Battal, Hasan Huseyin Gokpinar and Sukru Aras, Istanbul University Cerrahpasa Medical School, Istanbul, Turkey, Private Capa Hospital, Istanbul, Turkey 0. Brain Derived Neurotrophic Factor Is Elevated In Patients With Rheumatoid Arthritis and Secondary Fibromyalgia. Able Lawrence, Venkatesh Pai, Rajni Srivastava, Vikas Agarwal, Ramnath Misra and Amita Aggarwal, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India 04. Quality Of Life and Burden Of Ehlers-Danlos Syndrome (EDS) Type III. Marion Geoffroy, Christelle Guillaume, Amélie Servettaz, Violaine Laurant-Noel, Christine Serratrice Sr., Jacques Serratrice, Boris Bienvenu 4 and Roland Jaussaud, Hôpital Robert Debré. CHU de Reims, Reims, France, Foundation Hopital Saint Joseph, Marseille, France, Hôpital de la Timone, Marseille, France, 4 Division of Internal Medicine, Centre Hospitalier Régional Universitaire de Caen, Côte de Nacre, Caen, France, Caen, France 05. New and Not Improved? The Efficacy Of FMS Medications. Robert S. Katz, Hannah Bond, Lauren Kwan, Jessica L. Polyak and Susan Shott, Rush Medical College, Chicago, IL, Rheumatology Associates, Chicago, IL, Rush University Medical Center, Chicago, IL 06. Effectiveness Of Interdisciplinary Program For Fibromyalgia. Dianne Whiting, Debbi Huskey, Emily Rosario and Samy Metyas, Casa Colina Centers for Rehabilitation, Pomona, CA 07. A Randomized Trial Of a Physical Self-Management Program For Fibromyalgia Syndrome. Aline Ranzolin, Suélem S. Barros, Vanessa M. Fernandes, Eduardo A. S. Pimentel, Claudia Diniz L. Marques and Angela Luzia B. Pinto Duarte, Hospital das Clínicas - Universidade Federal de Pernambuco, Recife, Brazil, Programa de Pós- Graduação em Ciências da Saúde da Universidade Federal de Pernambuco, Recife, Brazil, Centro Universitário Maurício de Nassau, Recife, Brazil 08. Methylphenidate Improves Concentration, Energy and Mood In Fibromyalgia. Robert S. Katz, Hannah Bond and Frank Leavitt, Rush Medical College, Chicago, IL, Rheumatology Associates, Chicago, IL, Rush University Medical Center, Chicago, IL 09. Which Baseline Characteristics Influence The Response To Milnacipran In Patient With Fibromyalgia? Olivier Vitton, Olivier Vitton, Pierre Bunouf, Lilia Abtroun and Frederic Bonfils, Pierre Fabre, Castres, France, Pierre Fabre, Toulouse, France, Ariana Pharma, Paris, France Imaging of Rheumatic Diseases II: Imaging in Spondyloarthritis and Osteoarthritis 0. Onychopathy: When Ultrasound Can Help The Dermatologist. Andrea Delle Sedie, Valentina Dini, Linda Carli, Sabrina Barbanera, Lucrezia Riente, Stefano Bombardieri and Marco Romanelli, Rheumatology Unit, University of Pisa, Pisa, Italy, Dermatology Unit, University of Pisa, Pisa, Italy, GenOMeC PhD, University of Siena, Siena, Italy. Utility Of An Ultrasound Enthesitis Score As a Complementary Diagnostic Tool To Detect Psoriatic Arthritis In Patients With Psoriasis. Tomas Cazenave, Christian A. Waimann, Gustavo Citera and Marcos G. Rosemffet, Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina. Examining Phenotypes Of Patients With Psoriasis In The Prepare Study For Similarities Between Diagnosed Psoriatic Arthritis and Those With Signs Of Subclinical Psoriatic Arthritis Detected By Imaging. Philip J. Mease, Javier Coindreau, Lotus Mallbris, Annette Szumski and Heather Jones, Swedish Medical Center and University of Washington, Seattle, WA, Pfizer Inc., Collegeville, PA. Scintigraphic Detection Of TNFα With a Radiolabeled Anti- TNFα In Patients With Active Peripheral Spondyloarthritis and Rheumatoid Arthritis. Philippe Carron, Bieke Lambert, Filip De Vos, Gust Verbruggen, Dirk Elewaut and Filip van Den Bosch, Department of Rheumatology Ghent University Hospital, Ghent, Belgium, Department of Nuclear Medicine Ghent University Hospital, Ghent, Belgium, Department of Radiopharmacy Ghent University, Ghent, Belgium 4. Entheses Ultrasound In Patients With Ankyosing Spondylitis: A Controlled Study With Healthy Subjects. Suellen Narimatsu, Andre Rosenfeld, Germana. B. Q. Estrela, Jorge E. P. Proglhof, Rita N.V. Furtado and Jamil Natour, Universidade Federal de São Paulo, São Paulo, Brazil 5. Prevalence Of Structural and Inflammatory Sacroiliitis, Assessed Using Computed Tomography and MR Imaging, In Inflammatory Bowel Disease: A Retrospective Study In 78 Patients. Sophie Leclerc-Jacob, Guillaume Lux, Anne Christine Rat, Valérie Laurent, Alain Blum, Isabelle Chary-Valckenaere, Laurent Peyrin-Biroulet and Damien Loeuille, Nancy Teaching Hospital, Nancy, France, CHU Brabois, Vandoeuvre les Nancy, France 6. A Prospective Evaluation Of The Diagnostic Value Of Conventional Radiography, Ultrasound and MRI In Comparison To Clinical Examination For The Assessment Of Heel and Knee Enthesitis In Patients With Peripheral Spondyloarthritis and Controls. Xenofon Baraliakos, Uta Kiltz, Frank Heldmann, Heiner Appel, Friedrich Dybowski 4, Manfred Igelmann 5, Ludwig H. Kalthoff 6, Claudia Klink 7, Dietmar MJ Krause 8, Ertan Saracbasi, Elmar Schmitz-Bortz 9 and Jügen Braun, Rheumazentrum Ruhrgebiet, Herne, Germany, Ruhr-University Bochum, Herne, Germany, Rheumatology and Nephrology Practice, 0 Program Book

235 ACR POSTER SESSION B Hamm, Germany, 4 Rheumatology Practice, Herne, Germany, 5 Private Rheumatology office, Bochum, Germany, 6 Private rheumatology office, Herne, Germany, 7 Private rheumatology office, Gladbeck, Germany, 8 Internistische und rheumatologische Gemeinschaftspraxis, Gladbeck, Germany, 9 Rheumatism Practice in Hattingen, Hattingen, Germany 7. Integrated 8 f-fluoride Positron Emission Tomography and Magnetic Resonance Imaging Of The Spine a Pilot Study and Comparison Of Signals In Patients With Axial Spondyloarthritis. Xenofon Baraliakos, Dr. Christian Buchbender, Ben Ostendorf, Verena Hartung, MD 4, Thorsten Poeppel, MD 4 and Juergen Braun, Rheumazentrum Ruhrgebiet, Herne, Germany, Univ. Duesseldorf, Düsseldorf, Germany, Heinrich-Heine- University, Duesseldorf, Germany, 4 University Duisburg- Essen, Duisburg, Germany 8. Assessment Of Structural Damage In Patients With Ankylosing Spondylitis Using 8F-Fluoride Positron Emission Tomography-Magnetic Resonance Imaging. GeunTae Kim, Seung-Geun Lee, Seong-Ho Kim, Joung- Wook Lee 4 and Seung-Hoon Baek 5, Kosin University College of Medicine, Busan, South Korea, Divsion of Rheumatology, Department of Internal Medicine, Pusan National University School of Medicine, Pusan National University Hospital, Busan, South Korea, Division of Rheumatology, Inje University College of Medicine, Haeundae Paik Hospital, Busan, South Korea, 4 Divsion of Rheumatology, Department of Internal Medicine, Busan St. Mary s Medical Center, Busan, South Korea, 5 Divsion of Rheumatology, Department of Internal Medicine, Ilsin Christian Hospital, Busan, South Korea 9. Quantification Of Inflammatory Disease Of Spine In Ankylosing Spondylitis Using Volumetric Magnetic Resonance Imaging Analysis. Ejaz Pathan, Adrian Lim, Andy Graham, Keshthra Satchithananda, Dobrina Hull 4, Sonya Abraham 5, Anshul Rastogi 6, Andrew Keat 7, Mark Hinton 8, Olga Kubassova 9, Peter C. Taylor 0 and J.V. Hajnal, Kennedy Institute of Rheumatology, London W6 8RF, United Kingdom, Imperial College Healthcare NHS Trust, London, United Kingdom, Image Analysis, London, United Kingdom, 4 The Kennedy Institute of Rheumatology, London, United Kingdom, 5 Charing Cross Hospital, Imperial college NHS trust London UK, London W6 8RF, United Kingdom, 6 Barts and the London NHS Trust, London, United Kingdom, 7 Northwick Park Hospital, Harrow, United Kingdom, 8 Image Analysis Ltd, London, United Kingdom, 9 Image Analysis Ltd., Leeds, United Kingdom, 0 University of Oxford, Oxford, United Kingdom, King s College London, London, United Kingdom 0. Concordance Between a Positive MRI Of The Sacroiliac joints Based On The Local Reading Versus a Centralised Reading: Experience From The DESIR-Cohort. Rosaline van den Berg, Fabrice Thévenin, Antoine Feydy, Pascal Claudepierre, Monique Reijnierse, Alain Saraux 4 and Désirée van der Heijde, Leiden University Medical Center, Leiden, Netherlands, Paris Descartes University, Côchin Hospital, APHP, Paris, France, Henri Mondor Teaching Hospital, AP-HP, Créteil, France, 4 Université Brest Occidentale, Brest, France. Volatility Of The Site and Type Of Lesions In The Spine In Patients With Recent Onset Spondyloarthritis and Possible Spondyloarthritis Over a -Month Period. Rosaline van den Berg, Manouk de Hooge, Victoria Navarro-Compán, Monique Reijnierse, Floris van Gaalen, Karen Fagerli, Robert Landewé, Maikel van Oosterhout 4, Roberta Ramonda 5, Tom Huizinga and Désirée van der Heijde, Leiden University Medical Center, Leiden, Netherlands, Diakonhjemmet Hospital, Oslo, Norway, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands, 4 GHZ Hospital, Gouda, Netherlands, 5 University of Padova, Padova, Italy. How Reliable Is The Scoring Of Msasss In Clinical Practice In Centers Participating In DESIR? Comparison With The Gold Standard Central Reading. Pascal Claudepierre, Manouk de Hooge, Antoine Feydy, Monique Reijnierse, Alain Saraux 4, Maxime Dougados 5 and Désirée van der Heijde, Henri Mondor Teaching Hospital, AP-HP, Créteil, France, Leiden University Medical Center, Leiden, Netherlands, Paris Descartes University, Côchin Hospital, APHP, Paris, France, 4 CHU de la Cavale Blanche, Brest Cedex, France, 5 Rheumatology B Department, Paris- Descartes University, Cochin Hospital, Paris, France. Comparison Of The Performance Of The BASRI and Msasss In Patients With Early Inflammatory Back Pain From The DESIR Cohort. Manouk de Hooge, Pascal Claudepierre, Antoine Feydy, Monique Reijnierse, Alain Saraux 4, Maxime Dougados 5 and Désirée van der Heijde, Leiden University Medical Center, Leiden, Netherlands, Henri Mondor Teaching Hospital, AP-HP, Créteil, France, Paris Descartes University, Côchin Hospital, APHP, Paris, France, 4 CHU de la Cavale Blanche, Brest Cedex, France, 5 Rheumatology B Department, Paris-Descartes University, Cochin Hospital, Paris, France 4. Lumbar Degenerative Changes In The Spondyloartritis Caught Early Cohort. F. de Bruin, S. ter Horst, Karen Fagerli, R. Landewe, M. van Oosterhout 4, J.L Bloem 5, D. van der Heijde 5 and M. Reijnierse 5, LUMC, Leiden, Netherlands, Diakonhjemmet Hospital, Oslo, Norway, Academic Medical Center / University of Amsterdam, Amsterdam, Netherlands, 4 Groene Hartziekenhuis, Gouda, Netherlands, 5 Leiden University Medical Center, Leiden, Netherlands 5. Fatigue In Ankylosing Spondylitis Is Associated With The Brain Networks Of Sensory Salience and Attention. Robert Inman, Q. Wu and Karen Davis, University of Toronto and Toronto Western Hospital, Toronto, ON, Toronto Western Research Institute, Toronto, ON 6. Opportunistic Computed Tomography Screening For Determining Osteoporosis In Patients With Ankylosing Spondylitis and Spine Fractures. Amanda Cagan, Osa Emohare, Robert Morgan, David Polly and Elie Gertner, Regions Hospital, Saint Paul, MN, University of Minnesota, Minneapolis, MN, Regions Hospital and University of Minnesota Medical School, St. Paul, MN 0 Program Book

236 ACR POSTER SESSION B 7. Semiquantitative MRI Features Of Knee Osteoarthritis Show Compartment-Specific Relationships With Quantitative Cartilage Thickness Loss: The Multicenter Osteoarthritis Study. Ali Guermazi, Felix Eckstein, Daichi Hayashi, Frank Roemer, Wolfgang Wirth, Tianzhong Yang, Jingbo Niu, Leena Sharma 4, Michael C. Nevitt 5, Cora E. Lewis 6, James Torner 7 and David T. Felson, Boston University, Boston, MA, Paracelsus Medical University, Salzburg, Austria, Boston University School of Medicine, Boston, MA, 4 Northwestern University, Chicago, IL, 5 University of California, San Francisco, San Francisco, CA, 6 University of Alabama, Birmingham, Birmingham, AL, 7 University of Iowa, Iowa City, Iowa City, IA 8. Validation Of a Rapid, Quantitative Method Of Magnetic Resonance Imaging-Detected Osteoarthritis-Related Bone Marrow Lesions In The Patellofemoral Joint. Charles Ratzlaff and Jeffrey W. Duryea, Harvard Medical School / Brigham and Women s Hospital, Boston, MA, Brigham & Women, Boston, MA 9. Development and Validation Of a Rapid Knee Cartilage Quantification Method. Ming Zhang, Jeffrey B. Driban, Lori Lyn Price, Daniel Harper, Grace H. Lo, Eric Miller, Robert J. Ward and Timothy E. McAlindon, Tufts Medical Center, Boston, MA, Michael E. DeBakey VA Medical Center, Baylor College of Medicine, Houston, TX, Tufts University, Medford, MA 0. Change In Knee Osteophyte Volume By Semi-Automated Method In Knee Osteoarthritis Over Four Years Using T DESS D MRI. Michael Hakky, Charles Ratzlaff, Ali Guermazi, Mohamed Jarraya 4 and Jeffrey W. Duryea 5, Lahey Clinic, Burlington, MA, Harvard Medical School / Brigham and Women s Hospital, Boston, MA, Boston University, Boston, MA, 4 Boston University School of Medicine, Boston, MA, 5 Brigham and Women s Hospital, Boston, MA. Peri-Articular Fractal Signature Analysis and Bone Mineral Density Measure Different Aspects Of Bone: Cross-Sectional Data From The Osteoarthritis Initiative. Jeffrey B. Driban, Felix Liu, Alina O Brien, Lori Lyn Price, Grace H. Lo, Michael C. Nevitt 4, Charles Eaton 5, Timothy E. McAlindon and John A. Lynch 6, Tufts Medical Center, Boston, MA, University of California at San Francisco, San Francisco, CA, Michael E. DeBakey VA Medical Center, Baylor College of Medicine, Houston, TX, 4 University of California, San Francisco, San Francisco, CA, 5 Brown University, Providence, RI, 6 University of California-San Francisco, San Francisco, CA. Sensitivity To Change Of Radiographic Fixed-Location and Magnetic Resonance Imaging-Based Cartilage Thickness Measures In The Lateral Compartment Of Knees With Radiographic Osteoarthritis Data From The Osteoarthritis Initiative. Wolfgang Wirth, Jeffrey W. Duryea, Michael C. Nevitt, Robert J. Buck 4, David Hunter 5 and Felix Eckstein, Paracelsus Medical University, Salzburg, Austria, Brigham and Women s Hospital, Boston, MA, University of California, San Francisco, San Francisco, CA, 4 StatAnswers Consulting, Minneapolis, MN, 5 Royal North Shore Hospital, St. Leonards, Australia. Sensitivity To Change Of a New Method Of Computer Measurement Of Hip Joint Space Width: Performance Of Location-Specific Measures Obtained At a 48 Month Interval. Charles Ratzlaff and Jeffrey W. Duryea, Harvard Medical School / Brigham and Women s Hospital, Boston, MA, Brigham and Women s Hospital, Boston, MA 4. More Evidence For Breaking The law Of valgus : Imaging Evidence For Higher Prevalence and Volume Of Bone Marrow Lesions In The Medial Patellofemoral Joint. Charles Ratzlaff and Jeffrey W. Duryea, Harvard Medical School / Brigham and Women s Hospital, Boston, MA, Brigham and Women s Hospital, Boston, MA 5. Synovial Fluid Vascular Endothelial Growth Factor Could Predict Progression Of Osteoarthritis According To Radiological and Ultrasonographic Findings. Sang-Heon Lee, Hae-Rim Kim and Ho-Youn Kim, Konkuk University Medical Center, Seoul, South Korea 6. MR Tρ and T Of Meniscus After Acute Anterior Cruciate Ligament Injuries. Elijah Abramson, Michael Hoppe, Toran MacLeod, Lorenzo Nardo, Julien Rivoire, Richard Souza, Thomas M Link, C. Benjamin Ma and Xiaojuan Li, University of California, San Francisco, San Francisco, CA Infection Related Rheumatic Diseases 7. Evaluating Indeterminate Quantiferon-TB Gold In-Tube Results in Patients With Chronic Inflammatory Diseases On Immunosuppressive Therapy. Cassandra Calabrese, Robert A. Overman, Stacie Dusetzina and Rula Hajj-Ali, Cleveland Clinic, Cleveland, OH, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Raleigh-Durham, NC, Cleveland Clinic Foundation, Cleveland, OH 8. Tuberculin Skin Test and Booster Phenomenon In a Rheumatoid Arthritis Population. Differences Between Early and Established Disease. Lorena Perez-Barbosa, David Vega-Morales, Janett Carmen Luzmilla Riega-Torres, Octavio Ilizaliturri-Guerra and Mario Alberto Garza- Elizondo, Early Arthritis Clinic, Rheumatology Service, Hospital Universitario, Monterrey, Mexico, Rheumatology Service, Hospital Universitario, Monterrey, Mexico 9. Pyogenic Arthritis: Clinical and Epidemiological Features Of 0 Cases At a University Hospital. Anne Riveros-Frutos, Lourdes Mateo, Melania Martínez-Morillo, Beatriz Tejera, Samantha Rodriguez-Muguruza, Juana Sanint, Susana Holgado, Jerónima Cañellas, Xavier Tena, Alejandro Olivé and Montserrat Gímenez, Hospital Universitario Germans Trias i Pujol, Badalona, Spain 40. Study Of The Antibody Titer By Influenza Vaccination In Rheumatoid Arthritis Patients Treated With Biologics In JAPAN. Hisato Ishikawa, Daihei Kida, Yosuke Hattori, Atsushi Kaneko and Tomotaro Sato, Nagoya Medical Center, nagano, Japan, Nagoya Medical Center, Nagoya, Japan 4 0 Program Book

237 ACR POSTER SESSION B 4. Response To H. Pylori Treatment and Autoantibody In Chronic Thrombocytopenia. Mitsuyo Kinjo and Kensuke Nakanishi, Okinawa Chubu Hospital, Uruma City Okinawa, Japan, Okinawa Chubu Hospital, Uruma, Japan Innate Immunity and Rheumatic Disease 4. Distinct Pathways Of Ly6C hi Monocyte Development Identified By a Novel Dual-Reporter Murine Myeloid Progenitor Cell Line. Pui Lee, David Sykes, Sarah Ameri, Demetrios Kalaitzidis, Peter A. Nigrovic and Astrid Cardona 4, Boston Children s Hospital, Boston, MA, Massachusetts General Hospital, Boston, MA, Brigham and Women s Hospital, Boston, MA, 4 University of Texas - San Antonio, San Antonio, MA 4. Increased Frequency Of Pratroling Monocytes In Experimental Arthritis and Rheumatoid Arthritis Patients In Response To IL6-R Blockade. Julie Quentin, Jessy Presumey, Florence Apparailly, Yves-Marie Pers, Pascale Louis Plence 4 and Christian Jorgensen, Inserm U844, Montpellier, France, Inserm, Montpellier, France, Inserm U844, CHU saint-eloi, Université Montpellier, CHU Lapeyronie, Montpellier, France, 4 INSERM U844 Montpellier, Montpellier, France 44. Wnt Signaling Pathway Regulates Multi-Unconventional Differentiation and Function Of Human Dendritic Cells. Jia Wang, Yi Liu and Yi Zhao, Sichuan Provincial People s Hospital, Chengdu, China, West China Hospital of Sichuan University, Chengdu, China 45. Regulation Of Plasmacytoid Dendritic Cells By Prostaglandin E. Alice E. Wiedeman and Keith B. Elkon, University of Washington, Seattle, WA 46. WITHDRAWN 47. Human Dendritic Cells Produce Thymic Stromal Lymphopoietin In Response To Pattern Recognition Receptor Ligation and This Secretion Is Augmented By Endoplasmic Reticulum Stress. Matthew J Elder, Anthony YKC Ng, Steven J Webster, Michael J Bacon, JS Hill Gaston and Jane C Goodall, University of Cambridge, Cambridge, United Kingdom, University of Cambridge/Clin Med, Cambridge, United Kingdom 48. Autologous Tolerogenic Dendritic Cells In Rheumatoid and Inflammatory Arthritis. Gillian Bell, Amy Anderson, Julie Diboll, Rachel Harry, Elaine McColl, Anne Dickinson, Catharien Hilkens and John Isaacs, Newcastle University, Newcastle upon Tyne, United Kingdom, National Institute for Health Research, Newcastle Biomedical Research Centre, Newcastle Hospitals Foundation Trust and Newcastle University, Newcastle Upon Tyne, United Kingdom 49. Phenotypic and Molecular Profile Of Innate Lymphoid Cells In Chronic Synovial Inflammation. Hulda S. Hreggvidsdottir, Maureen C. Turina, Troy Noordenbos, Marius Munneke, Charlotte Peters, Jochem Bernink, Jenny Mjosberg, Dominique L. Baeten and Hergen Spits, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, Karolinska Institutet, Stockholm, Sweden 50. Differential Regulation Of IL-0 and Dusp Production By Kinases In The p8 MAPK Pathway. Deepa Hammaker, Katharyn Topolewski and G. S. Firestein, UCSD School of Medicine, La Jolla, CA 5. Snapin Is Required For Functional Autophagy and Is Critical For Monocyte To Macrophage Differentiation. Bo Shi, Qiquan Huang, Robert Birkett, Renee E. Koessler, Andrea Dorfleutner, Christian Stehlik and Richard M. Pope, Northwestern University Feinberg School of Medicine, Chicago, IL, Northwestern University, Chicago, IL, Northwestern Univ Med School, Chicago, IL 5. Ligation Of TLR5 Promotes Myeloid Cell Infiltration and Differentiation Into Mature Osteoclasts In RA Patients and Experimental Arthritis. Seung-jae Kim, Zhenlong Chen, Nathan D. Chamberlain, Michael V. Volin, Suncica Volkov, William Swedler, Shiva Arami, Anjali Mehta, Nadera J. Sweiss and Shiva Shahrara, University of Illinois at Chicago, Chicago, IL, Chicago College of Osteopathic Medicine Midwestern University, Downers Grove, IL 5. Rheumatoid Arthritis Synovial Fibroblasts Lack Tolerization Of Inflammatory Cytokines and Matrix Degrading Enzymes After Repeated LPS Stimulation. Kerstin Klein, Renate E. Gay, Christoph Kolling, Adrian Ciurea, Beat A. Michel 4, Lih-Ling Lin 5, Steffen Gay and Caroline Ospelt, Center of Experimental Rheumatology, University Hospital Zurich and Zurich Center of Integrative Human Physiology (ZIHP), Zurich, Switzerland, Schultess Clinic, Zurich, Switzerland, University Hospital of Zurich, Zurich, Switzerland, 4 Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland, 5 Pfizer, Cambridge, MA 54. Poly(I:C)-Induced Cell Death Of Synovial Fibroblasts via an Unknown dsrna Receptor. Jörg Hamann, Paul P. Tak and Olga N. Karpus, Academic Medical Center, Amsterdam, Netherlands, GlaxoSmithKline U.K. and Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands 55. WITHDRAWN 56. Suppression Of Immune Responses and Joint Inflammation By Myeloid-Derived Suppressor Cells In a T Cell-Dependent Mouse Model Of Rheumatoid Arthritis. Katalin Mikecz, Julia Kurko, Timea Ocsko, Andras Vida, Beata Tryniszewska, Tibor A. Rauch, Joel A. Block, Robert S. Katz, Anjali Nair, Carla R. Scanzello and Tibor T. Glant, Rush University Medical Center, Chicago, IL, Rush Medical College, Chicago, IL 57. Peptidylarginine Deiminase Inhibition Prevents Neutrophil Extracellular Trap Formation, Modulates Innate Immune Responses, and Reduces Vascular Damage In Mice. Jason S. Knight, Wei Luo, Alexander A. O Dell, Wenpu Zhao, Venkataraman Subramanian, Chiao Guo, Robert C. Grenn, Paul Ryan Thompson, Daniel T. Eitzman and Mariana J. Kaplan, University of Michigan Rheumatology, Ann Arbor, MI, University of Michigan Cardiology, Ann Arbor, MI, The Scripps Research Institute, Jupiter, FL 0 Program Book 5

238 ACR POSTER SESSION B Decreased NK-Cell Numbers and Upregulation Of Markers Of Systemic Inflammation In Autoantibody Positive Arthralgia Patients and Early Rheumatoid Arthritis Patients But Not In Autoantibody-Negative Rheumatoid Arthritis Patients. Paulina Chalan, Johan Bijzet, Kornelis S.M. van der Geest, Bart-Jan Kroesen, Annemieke M.H. Boots and Elisabeth Brouwer, University Medical Center Groningen, Groningen, Netherlands 59. Exercise Suppresses Systemic Inflammation Via Inhibition Of NF-κB Activation In Monocytes. Alisa Blazek, Derrick Knapik, Lai-Chu Wu, Nicholas A. Young, Wael N. Jarjour and Sudha Agarwal, The Ohio State University, Columbus, OH, The Ohio State University Wexner Medical Center, Columbus, OH 60. Oxidative Stress As a Disease Marker and Therapeutic Target In Patients With Tumor Necrosis Factor Receptor Associated Periodic Fever Syndrome. Cornelia Cudrici, Ariel Bourla, Martin Pelletier, Leah Billingham, Amanda K. Ombrello, Michael Murphy, Daniel L. Kastner 4 and Richard M. Siegel 5, Immunoregulation Section, Autoimmunity Branch, Bethesda, MD, National Human Genome Research Institute,National Institute of Health, Bethesda, MD, Medical research council mitochondria biology unit Cambridge,UK, Cambridge, United Kingdom, 4 National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, 5 National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD 6. Microrna-55 As a Proinflammatory Regulator via SHIP- Down-Regulation In Acute Gouty Arthritis. Hye Mi Jin, Young-Nan Cho, Seung-Jung Kee, Dong-Jin Park, Yong- Wook Park, Shin-Seok Lee and Tae-Jong Kim, Chonnam National University Medical School and Hospital, Gwangju, South Korea, Chonnam National University Medical School, Gwangju, South Korea 6. The Role Of Microrna 55 In Innate Immunity and Arthritis. Antonia Puchner, Victoria Saferding, Eliana Goncalves-Alves, Josef S. Smolen, Kurt Redlich and Stephan Blueml, Medical University of Vienna, Vienna, Austria 6. The Receptor For Advanced Glycation End Products (RAGE) As a Modulator Of Inflammatory Responses and Its Contribution To Gender-Specific Effects During Arthritis. Timo Wirth, Christoph Kessel, Philipp Becker, Toni Weinhage, Nadine Nippe and Dirk Foell, University of Muenster, Muenster, Germany, University of Muenster, Münster, Germany 64. Both Endosomal and Surface Toll-Like Receptors Can Act As Biomarkers In Lupus. Maria Perez-Ferro, Cristina Serrano, Fredeswinda I. Romero, María J Martínez-Becerra, Jorge E Rojas, María Sanchez-Blazquez, Raquel Largo, Juan A Martínez-López, Gabriel Herrero-Beaumont and Olga Sanchez-Pernaute, Jiménez Díaz Foundation University Hospital, Madrid, Spain 65. Systems Approach To The Study Of the Microbiome and Inflammatory Pathways In Oral Ulcer Tissue From Patients With Active Behςet s Syndrome (BS). Cailin Sibley, Gulen Hatemi, Yusuf Yazici, Yin Liu 4, Steve Brooks, Hasan Yazici 5 and Raphaela Goldbach-Mansky 6, NIH / NIAMS, Bethesda, MD, Cerrahpasa Medical Faculty, University of Istanbul, Istanbul, Turkey, NYU Hospital for Joint Diseases and New York University School of Medicine, New York, NY, 4 NIAMS / NIH, Bethesda, MD, 5 Istanbul University, Cerrahpasa Medical Faculty, Rheumatology, Istanbul, Turkey, 6 National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH, Bethesda, MD 66. Anti-Inflammatory Property Of HDL In NOD Ligand Induced Kawasaki Arteritis In Mice. Hajime Kono, Tamiko Yanagida, Kurumi Asako, Toshihiro Nanki, Hirotoshi Kikuchi, Akiko Okamoto, Akiko Onda and Maki Takayama, Teikyo University School of Medicine, Tokyo, Japan 67. A Possible Mechanism Of NLRP Inflammasome Hypersensitivity In Cryopyrin-Associated Periodic Syndrome. Sayaka Ito, Chie Tagami, Yukichi Hara and Tetsuo Kubota, Tokyo Medical and Dental University, Tokyo, Japan 68. Innate Immune Cell Production Of Interleukin- Drives CpG-Induced Macrophage Activation Syndrome. Lehn K. Weaver and Edward M. Behrens, Children s Hospital of Philadelphia, Philadelphia, PA 69. A Novel Pro-Inflammatory Signaling Pathway Regulated By Follistatin-Like Protein. Yury Chaly, Anthony Marinov, Yu Fu, Brian Campfield, John Kellum, Bruce Hostager, Daniel Bushnell, Yudong Wang, Jerry Vockley and Raphael Hirsch, University of Iowa Carver College of Medicine, Iowa City, IA, Children s Hospital of Pittsburgh of UPMC, Pittsburgh, PA, University of Pittsburgh School of Medicine, Pittsburgh, PA 70. Expression and Function Of Human Mfg-E8 In The Clearance Of Apoptotic Cells and Suppression Of Inflammation. Lucrezia Colonna, Jie An, Xizhang Sun, Nalini Agrawal, Alice Wiedeman and Keith B. Elkon, University of Washington, Seattle, WA 7. Treatment Of Psoriasis Patients With IMO-00 Shows Improvement In Gene Expression Patterns Of Meta- Analysis Derived- Transcriptome and IL-7 Pathway. Mayte Suarez-Farinas, Jennifer Belasco, Tim Sullivan, Robert Arbeit and James G. Krueger, The Rockefeller University, New York, NY, Idera Pharmaceuticals, Inc., Cambridge, MA 7. Molecular Characterisation Of The Killer Cell Immunoglobulin-Like Receptor DL Binding To Aberrant HLA-B7 Heavy Chains In Spondyloarthritis. H. Hatano, J. Shaw, K McHugh, P. Bowness and S. Kollnberger, University of Oxford, Oxford, United Kingdom Metabolic and Crystal Arthropathies I 6 0 Program Book 7. A Clinically Significant Interaction Between Furosemide and Allopurinol: Potential Implications for Clinical Practice. Lisa K. Stamp, Claudia Knake and Andrew Bahn, University of Otago, Christchurch, Christchurch, New Zealand, University of Otago, Dunedin, New Zealand

239 ACR POSTER SESSION B 74. Impact Of Bariatric Surgery On Serum Urate Targets in People With Morbid Obesity and Diabetes: A Prospective Longitudinal Study. Nicola Dalbeth, Peggy Chen, Marie White, Gregory Gamble, Caran Barratt-Boyes, Peter J. Gow 4 and Brandon Orr-Walker, University of Auckland, Auckland, New Zealand, Counties Manukau District Health Board, Auckland, New Zealand, CCRep, Auckland, New Zealand, 4 Middlemore Hospital, Auckland, New Zealand 75. ABCG May Influence Risk Of Gout Through Extra-Renal Metabolic Pathways: Analysis Of The Effects Of The Q4K Variant On Serum Urate Responses To a Fructose Load. Nicola Dalbeth, Meaghan House, Gregory Gamble, Bregina Pool, Anne Horne, Lauren Purvis, Angela Stewart, Marilyn E. Merriman, Murray Cadzow, Amanda Phipps-Green and Tony R. Merriman, University of Auckland, Auckland, New Zealand, University of Otago, Dunedin, New Zealand 76. Pharmacokinetics and Pharmacodynamics Of Pegloticase In Patients With End-Stage Renal Failure Receiving Hemodialysis. Anthony J. Bleyer, David E. Wright and Alan Glicklich, Wake Forest University School of Medicine, Winston-Salem, NC, Savient Pharmaceuticals, Inc., San Diego, CA, Savient Pharmaceuticals, Inc., Bridgewater, NJ 77. Efficacy and Safety Of Canakinumab Pre-Filled Syringe Versus Triamcinolone Acetonide In Acute Gouty Arthritis Patients. Prashanth Sunkureddi, Edith Toth, Jacques P. Brown, Rüdiger Möricke 4, Jan Michael Nebesky 5, Gerhard Krammer 5, Aiyang Tao 6, Markus John 5 and Alan Kivitz 7, Clear Lake Rheumatology, Nassau Bay, TX, Flór Francis Hospital Rheumatology Department, Kistarcsa, Hungary, CHU de Québec Research Centre and Laval University, Quebec City, QC, 4 Institut für Präventive Medizin & Klinische Forschung GbR, Magdeburg, Germany, 5 Novartis Pharma AG, Basel, Switzerland, 6 Novartis Pharmaceuticals Corporation, East Hanover, NJ, 7 Altoona Center for Clinical Research, Duncansville, PA 78. Effect Of Febuxostat On Serum Urate Levels In Gout Subjects With Hyperuricemia and Moderate-To- Severe Renal Impairment: A Randomized Controlled Trial. Kenneth G. Saag, Michael A. Becker, Andrew Whelton, Patricia A. MacDonald 4, Yun Zhou 5 and Lhanoo Gunawardhana 5, University of Alabama at Birmingham, Birmingham, AL, University of Chicago, Chicago, IL, The Johns Hopkins University and Universal Clinical Research Center, Inc., Baltimore, MD, 4 Takeda Pharmaceuticals USA, Inc., Deerfield, IL, 5 Takeda Global Research & Development Center, Inc., Deerfield, IL 79. Colchicine Use and The Risk Of Myocardial Infarction Among Gout Patients: Interim Results From a VA Retrospective Cohort Study. Daria B. Crittenden, Jessica N. Kimmel, Virginia C. Pike, Daniel Diaz, Avni Shah, Cilian J. White, Michael DeBerardine, Grace Kim, Binita Shah, Christopher J. Swearingen, Jeffrey D. Greenberg 4, Steven P. Sedlis, Craig T. Tenner 5, Bruce N. Cronstein and Michael H. Pillinger, NYU School of Medicine, Division of Rheumatology, New York, NY, NYU School of Medicine, Division of Cardiology, New York, NY, Pediatric Biostatistics, University of Arkansas for Medical Sciences, Little Rock, AR, 4 NYU Hospital for Joint Diseases, New York, NY, 5 NYU School of Medicine, Department of Internal Medicine, New York, NY 80. Rising Burden Of Gout and Poor Management Of The Disease In The United Kingdom: A Nationwide Population Study. Chang-Fu Kuo, Michael Doherty, Matthew J. Grainge and Weiya Zhang, Chang Gung Memorial Hospital, Taipei, Taiwan, University of Nottingham, Nottingham, United Kingdom 8. The Effect Of Uric Acid Lowering Therapy In Preventing Comorbidity and Acute Attack Of Gout; A Retrospective Study. Kowoon Joo, Won Park, Seong-Ryul Kwon, Mie-Jin Lim, Kyong-Hee Jung, Hoyeon Joo and Sung-Soo Kim, Inha University Hospital, Incheon, South Korea, Ulsan Univ College of Medicine and Gangneung Asan Hospital, Gangneung, South Korea 8. The Performance Of a Diagnostic Rule For Acute Gouty Arthritis Without Joint Fluid Analysis: a Validation Study. Laura Kienhorst, Hein Janssens, Jaap Fransen and Matthijs Janssen, Rijnstate Hospital, Arnhem, Netherlands, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands 8. The Treatment Of Gout In Relation To The 0 Uric Acid Target Guidelines In The US Population. Stephen Juraschek, Lara Kovell, Edgar Miller III and Allan C. Gelber, Johns Hopkins University, Baltimore, MD 84. High Mobility Group Box Plays a Role In Gouty Arthritis. Kiwon Moon, Jinhyun Kim and Yun Jong Lee, Kangwon National University Hospital, Chuncheon city, Kangwon province, South Korea, Chungnam National University School of Medicine, Daejeon, South Korea, Seoul National University Bundang Hospital, Seongnam-si, South Korea 85. More Than One-Third Of Patients Reach Serum Urate Target and Continue To Report Multiple Flares. Dinesh Khanna, Puja Khanna, Chris Storgard, Scott Baumgartner 4 and Robert Morlock, University of Michigan, Ann Arbor, MI, University of Michigan Medical Center, Ann Arbor, MI, Ardea Bioscience, San Diego, CA, 4 Ardea Biosciences, San Diego, CA 86. Use Of High-Dose Allopurinol To Reach Serum Uric Acid Targets In Patients With Gout Across Multiple Countries. Jasvinder A. Singh, Chris Storgard, Scott Baumgartner and Robert Morlock, University of Alabama, Tuscaloosa, AL, Ardea Bioscience, San Diego, CA, Ardea Biosciences, San Diego, CA 87. A Large-Scale, Multicenter, Prospective, Open-Label, 6-Month Study To Evaluate The Safety Of Allopurinol Monotherapy In Patients With Gout. Michael A. Becker, David Fitz-Patrick, Chris Storgard, Matt Cravets 4 and Scott Baumgartner 5, University of Chicago, Chicago, IL, East- West Medical Research Institute, Honolulu, HI, Ardea Bioscience, San Diego, CA, 4 Ardea Biosciences, Inc., San Diego, CA, 5 Ardea Biosciences, San Diego, CA 88. An Assessment Of The Response Of Chronic, Occult, Synovial-Based Inflammation Of Gout To Serum Urate Lowering Therapy. John D. Carter, Michelle Patelli, Scott Anderson, Neelish Prakash, Robyn Aydelott, Ernesto Rodriguez, Helen E. Bateman, Ashley G. Sterrett, Joanne Valeriano-Marcet and Louis R. Ricca 4, University of South Florida, Tampa, FL, James A Haley VA Hospital USF, Tampa, FL, JAHVA, Tampa, FL, 4 University of South Florida College of Medicine, St Petersburg, FL 0 Program Book 7

240 ACR POSTER SESSION B 89. Allopurinol Dose Titration and Efficacy: A Large- Scale, 6-Month, Multicenter, Prospective Study. Scott Baumgartner, Hyon Choi, Nicola Dalbeth, David Fitz-Patrick 4, Matt Cravets 5 and Chris Storgard 6, Ardea Biosciences, San Diego, CA, Boston University School of Medicine, Boston, MA, Auckland District Health Board, Auckland, New Zealand, 4 East-West Medical Research Institute, Honolulu, HI, 5 Ardea Biosciences, Inc., San Diego, CA, 6 Ardea Bioscience, San Diego, CA 90. The Synergistic Effects Of Metabolic Syndrome Indicators and Hyperuricemia In Contributing To Cardiac Event Risk: A Cross-Sectional Examination Of The Nhanes III Data. Daniel A. Albert and Sayyad Kyazimzade, The Dartmouth Institute for Health Policy and Clinical Practice, Lebanon, NH, The Dartmouth Institute for Health Policy & Clinical Practice, Lebanon, NH, Lebanon, NH 9. Low-Dose Anakinra Is Effective For The Prophylaxis Of Acute Episodes Of Inflammation In Severe Tophaceous Gout. Fernando Perez-Ruiz, Ana M. Herrero-Beites, Monike de Miguel and Joana Atxotegi, BioCruces Health Institute, Baracaldo, Spain, Hospital de Gorliz, Gorliz, Spain, Hospital Universitario Cruces, Baracaldo, Spain 9. Pharmacovigilance Update On Pegloticase For Treatment Refractory Gout: United States Clinical Experience Demonstrates The Value Of Serum Uric Acid Monitoring As a Biomarker Of Risk and Efficacy. Robert T. Keenan, Raymond L. Malamet, Tina L. Howson and Kenneth M. Bahrt, Duke University, Durham, NC, Savient Pharmaceuticals, Inc., Bridgewater, NJ 9. Target Tophus Size and Complete Response Rates In Patients Treated With Open-Label Pegloticase For Chronic Gout Refractory To Conventional Therapy. Robert T. Keenan, Nicola Dalbeth and Herbert S. B. Baraf, Duke University, Durham, NC, University of Auckland, Auckland, New Zealand, Arthritis & Rheumatism Associates, PC, Wheaton, MD 94. Enhanced IL-β and IL-6 Production In Gout Patients Upon Stimulation With Mono Sodium Urate Crystals and Synergizing Agents Compared To Healthy Volunteers. Tania O. Crisan, Maartje Cleophas, Mihai G. Netea, Tim L. Jansen and Leo A. Joosten, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, Department of Medicine, Radboud University Nijmegen Medical Center, Nijmegen, Netherlands 95. Sex Differences In Gout Evaluation and Management. Leslie R. Harrold, Carol Etzel, Allan Gibofsky, Joel M. Kremer 4, Michael H. Pillinger 5, Kenneth G. Saag 6, Naomi Schlesinger 7, Robert Terkeltaub 8, Vanessa Cox and Jeffrey D. Greenberg 9, University of Massachusetts Medical School, Worcester, MA, CORRONA, Inc, Southborough, MA, Hospital for Special Surgery, New York, NY, 4 Center for Rheumatology, Albany Medical College, Albany, NY, 5 NYU School of Medicine, Division of Rheumatology, New York, NY, 6 University of Alabama at Birmingham, Birmingham, AL, 7 UMDNJ-Robert Wood Johnson Medical School, New Brunswick, NJ, 8 VA Medical Ctr/University of California San Diego, San Diego, CA, 9 New York Hospital for Joint Diseases, New York, NY 96. Chronic Renal Injury Does Not Prevent Achievement Of Target Serum Uric Acid In Tophaceous Gout. Mireille Aujero, J. Steuart Richards, Carl A. Nunziato, David D. Maron 4 and Gail S. Kerr 5, Washington DC VA Medical Center and Georgetown University, Washington, DC, Washington DC VA and Georgetown University, Washington, DC, Howard University Hospital, Washington, DC, 4 Washington DC VA Medical Center, Washington, DC, 5 Washington DC VAMC, Georgetown and Howard University, Washington, DC 97. Gout Medications and The Risk For Incident Coronary Heart Disease and Stroke: The Framingham Heart Study. Weiqi Wang, Vidula Bhole and Eswar Krishnan, stanford university, palo alto, CA, EpiSolutions Consultancy Services, Thane, India, Stanford University, Palo Alto, CA 98. Allopurinol Dose Above Creatinine Clearance Based Dose Is Safe and Effective in Gout - Compliance, Efficacy and Safety At and Years. Nicole Coman-Wright, Peter T. Chapman, John L. O Donnell and Lisa K. Stamp, University of Otago, Christchurch, Christchurch, New Zealand, Christchurch Hospital, Christchurch, New Zealand, Canterbury Health Laboratories, Christchurch, New Zealand 99. The Performance Of a Novel Scoring System In The Differential Diagnosis Between Acute Gout and Septic Arthritis. Jung-Soo Song, Kwang-Hoon Lee, Sang Tae Choi, Eun-Jin Kang and You-Jung Ha 4, Chung-Ang University College of Medicine, Seoul, South Korea, Dongguk University Ilsan Hospital, Goyang, South Korea, Busan Medical Center, Busan, South Korea, 4 Yonsei University College of Medicine, Seoul, South Korea 00. Proportion Of Patients Achieving Serum Urate Target In a Longitudinal Veterans Administration (VA) Gout Registry: Crystal Registry. Puja Khanna, Andreas M. Reimold, Gail S. Kerr, J. Steuart Richards 4, Elizabeth Chang 5, Jasvinder A. Singh 6, H. Ralph Schumacher 7, Tanima Bannerjee 8 and Dinesh Khanna 9, Ann Arbor VA, Ann Arbor, MI, Dallas VA and University of Texas Southwestern, Dallas, TX, Washington DC VAMC, Georgetown and Howard University, Washington, DC, 4 Washington DC VAMC and Georgetown University, Washington, DC, 5 Phoenix VAHCS, Phoenix, AZ, 6 University of Alabama, Tuscaloosa, AL, 7 Department of Medicine, University of Pennsylvania and VA Medical Center, Philadelphia, PA, 8 University of Michigan, Ann Arbor, MI, 9 Division of Rheumatology, University of Michigan Medical Center, Ann Arbor, MI Miscellaneous Rheumatic and Inflammatory Diseases I: Autoinflammatory Syndromes 0. A Progress Report On An Emerging Disease: NOD- Associated Autoinflammatory Disease. Qingping Yao, Cleveland Clinic, Cleveland, OH 0. Two Family Kindreds With Blau s Syndrome Associated With Unusual NOD Mutations. Qingping Yao, Cleveland Clinic, Cleveland, OH 8 0 Program Book

241 ACR POSTER SESSION B 0. An Escalating Dose Of Anakinra In Patients With Autoinflammatory Disease Is a Safe and Reasonable Therapeutic Option. Amanda K. Ombrello, Karyl S Barron, Patrycja M. Hoffmann, Anne Jones, Deborah Stone and Daniel L. Kastner, National Human Genome Research Institute,National Institute of Health, Bethesda, MD, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD 04. Model-Based Pharmacokinetics Of Canakinumab and Pharmacodynamics Of IL-Beta Binding In Cryopyrin Associated Periodic Syndromes, a Step Towards Personalized Medicine. Aurélie Gautier, Phil Lowe, Andrej Skerjanec, Phil McKernan, Wenping Wang and Olivier Luttringer, Novartis Pharma AG, Basel, Switzerland, Novartis Pharmaceuticals Corporation, East Hanover, NJ 05. Effectiveness Of Canakinumab In a Cryopyrin-Associated Periodic Syndrome Cohort.A Single Center Experience. Virginia Moreira-Navarrete, Francisco Javier Toyos Saenz de Miera, Carmen Vargas Lebrón and F. Navarro Sarabia 4, University Hospital Virgen Macarena, Sevilla, Spain, Hospital Virgen de la Macarena, Sevilla, Spain, Hospital Virgen Macarena, SEVILLA, Spain, 4 Hospital Universitario Virgen Macarena, Sevilla, Spain 06. Canakinumab Treatment Regimens In CAPS Patients. Ferdinand Hofer, Theresa Endres, Birgit Kortus-Goetze, Norbert Blank, Elisabeth Weissbarth-Riedel 4, Catharina Schuetz 5, Tilmann Kallinich 6, Karoline Krause 7, Christoph Rietschel 8, Gerd Horneff 9 and Jasmin B. Kuemmerle- Deschner, University Hospital Tuebingen, Tuebingen, Germany, Klinikum der Philipps-Universität Marburg, Marburg, Germany, University of Heidelberg, Heidelberg, Germany, 4 Universitätsklinikum Eppendorf, Hamburg, Germany, 5 Klinik für Kinder und Jugendmedizin, Universitätsklinikum Ulm, Ulm, Germany, 6 Charite, University Hospital Berlin, Berlin, Germany, 7 Dept. of Dermatology and Allergy, Allergie-Centrum-Charité, Charité Universitätsmedizin Berlin, Germany, Berlin, Germany, 8 Clementine-Kinderhospital, Frankfurt, Germany, 9 Asklepios Klinik Sankt Augustin, Sankt Augustin, Germany 07. Efficacy Of Tocilizumab In Patients With AA Amyloidosis Secondary To Familial Mediterranean Fever: A Single Centre Experience. Sedat Yilmaz, Muhammet Cinar, Ismail Simsek, Hakan Erdem and Salih Pay, Gulhane School of Medicine, Ankara, Turkey 08. Canakinumab In Patients With FMF. Serdal Ugurlu, Emire Seyahi, Gulen Hatemi, Ayse Hacioglu and Huri Ozdogan, Cerrahpasa Medical Faculty, University of Istanbul, Istanbul, Turkey 09. Starting Time Of Inflammatory Attacks In Patients With Familial Mediterranean Fever. Feyza Berktas, Nilufer Alpay Kanitez, Bahtiyar Toz, Oguz Kaan Bakkaloglu, Burak Erer and Ahmet Gul, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey 0. Epicardial Adipose Tissue and Atherosclerosis In Patients With Familial Mediterranean Fever. Adem Kucuk, Yalcin Solak, Hakan Akilli, Oguzhan Yildirim, Ibrahim Guler 4, Ramazan Ucar 5, Alpay Aribas, Orhan Ozbek 6, Mehmet Kayrak and Recep Tunc 7, Necmettin Erbakan University, Division of Rheumatology, Konya, Turkey, Karaman State Hospital, Division of Nephrology, Karaman, Turkey, Necmettin Erbakan University, Division of Cardiology, Konya, Turkey, 4 Konya Research and Education Hospital, Division of Radiology, Konya, Turkey, 5 Konya Education and Research Hospital, Department ofinternal Medicine, Konya, Turkey, 6 Necmettin Erbakan University, Division of Radiology, Konya, Turkey, 7 Selçuk University, Konya, Turkey. Adult Autoinflammatory Phenotypes Associated With Heterozygous MEFV Mutations: A Continuum of Familial Mediterranean Fever? Qingping Yao, Cleveland Clinic, Cleveland, OH. Are Different Disease Subtypes With Distinct Clinical Expression Present In Familial Mediterranean Fever: Results Of a Cluster Analysis. Servet Akar, Timucin Kasifoglu, Dilek Solmaz, Sule Yasar Bilge, Ismail Sari and Mehmet Tunca, Dokuz Eylul University School of Medicine, Izmir, Turkey, Eskisehir Osmangazi University School of Medicine, Eskisehir, Turkey. Low-Penetrance NLRP-Variants. Theresa Endres, Ferdinand Hofer, Raphaela T. Goldbach-Mansky, Hal M. Hoffman, Norbert Blank 4, Karoline Krause 5, Christoph Rietschel 6, Gerd Horneff 7, Peter Lohse 8 and Jasmin B. Kuemmerle-Deschner, University Hospital Tuebingen, Tuebingen, Germany, National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH, Bethesda, MD, University of California at San Diego, La Jolla, CA, 4 University of Heidelberg, Heidelberg, Germany, 5 Dept. of Dermatology and Allergy, Allergie-Centrum-Charité, Charité Universitätsmedizin Berlin, Germany, Berlin, Germany, 6 Clementine-Kinderhospital, Frankfurt, Germany, 7 Asklepios Klinik Sankt Augustin, Sankt Augustin, Germany, 8 Institut für Laboratoriumsmedizin und Humangenetik, Singen, Germany 4. Resistant Or Recurrent Acute Pericarditis: A New Therapeutic Opportunity? Claire Massardier, Claire Dauphin, Romain Eschalier, Jean-René Lusson and Martin Soubrier, CHU CLERMONT-FERRAND, Clermont-ferrand, Colombia, CHU CLERMONT-FERRAND, Clermont-ferrand, France, CHU CLERMONT-FERRAND, Clermont-Ferrand, France Osteoporosis and Metabolic Bone Disease: Clinical Aspects and Pathogenesis 5. Human Immunodeficiency Virus Infection and Fracture Risk-a Meta-analysis. Sian Yik Lim, Ana Marcella Rivas and Kenneth Nugent, Texas Tech University Health Sciences Center, Lubbock, TX 0 Program Book 9

242 ACR POSTER SESSION B Risk Factors Associated With Fracture Occurrence Appear to Differ Between Distal Radius, Clinical Vertebral, and Hip Fractures in Japanese Patients With Rheumatoid Arthritis: A Prospective Observational Cohort Study. Kensuke Ochi, Takefumi Furuya, Yuki Go, Eisuke Inoue, Katsunori Ikari, Atsuo Taniguchi, Hisashi Yamanaka and Shigeki Momohara, Institute of Rheumatology, Tokyo Women s Medical University, Tokyo, Japan, Tokyo Women s Medical University, Tokyo, Japan 7. Determination Of Vitamin D Level Prior To The Initiation Of Bisphosphonate Therapy. Chris T. Derk, Ruchika Patel, Rennie L. Rhee, Yiu Tak Leung, R. Michelle Koolaee, Shiv Sehra and Ashwini Komarla, University of Pennsylvania, Philadelphia, PA 8. Incidence Of and Risk Factors For Clinical Fractures In Patients With Systemic Lupus Erythematosus and Matched Controls: A Population-Based Study In The United Kingdom. Irene Bultink, Nicholas Harvey, Arief Lalmohamed, Cyrus Cooper 4, Willem Lems, Tjeerd Van Staa 5 and Frank de Vries 6, VU University Medical Center, Amsterdam, Netherlands, MRC Lifecourse Epidemiology Unit, Southampton, United Kingdom, University Medical Center Utrecht, Utrecht, Netherlands, 4 University of Oxford; Southampton General Hospital, Southampton, United Kingdom, 5 Utrecht University, Utrecht, Netherlands, 6 Care and Public Health Research Institute, Maastricht, Netherlands 9. Phase Fracture Trial Of Odanacatib For Osteoporosis Baseline Characteristics and Study Design. Socrates Papapoulos, Henry G. Bone, David W. Dempster, John Eisman 4, Susan Greenspan 5, Michael McClung 6, Toshitaka Nakamura 7, Joseph Shih 8, Albert Leung 9, Arthur Santora 9, N. Verbruggen 0 and Antonio Lombardi, Leiden University Medical Center, Leiden, Netherlands, Michigan Bone and Mineral Clinic, Detroit, MI, Helen Hayes Hospital, West Haverstraw, NY, 4 The Garvan Institute of Medical Research, Sydney, Australia, 5 University of Pittsburgh, Pittsburgh, PA, 6 Oregon Osteoporosis Center, Portland, OR, 7 University of Occupational & Environmental Health, Kitakyushu, Japan, 8 Robert Wood Johnson Medical School, Piscataway, NJ, 9 Merck Sharp & Dohme Corp., Whitehouse Station, NJ, 0 MSD Belgium, Brussels, Belgium, Merck Sharp and Dohme Corp, Whitehouse Station, NJ 0. Rheumatoid Arthritis Characteristics and Fracture Risk: A Population-Based Study. Shreyasee Amin, Sherine E. Gabriel, Sara J. Achenbach, Elizabeth J. Atkinson, Terry M. Therneau and L. Joseph Melton III, Mayo Clinic, Rochester, MN. The Effects Of Hyperthyroidism On Bone Mineral Density At Different Sites- An Observational Case-Control Study. Christopher Varley, Alexander Oldroyd and Marwan Bukhari, Lancaster University, Lancaster, United Kingdom, Royal Lancaster Infirmary, Lancaster, United Kingdom. Analysis Of Corelation Of Bone Mineral Density Of Spine With Other Sites In Ankylosing Spondylitis As Compared To Rheumatoid Arthritis and Control Populations. Janie Bruce and Vikas Majithia, University of Mississippi School of Medicine, Jackson, MS, G.V. Sonny Montogomery VA Medical Center, Jackson, MS 0 Program Book. Monitoring Osteoporosis Therapy: Can FRAX Help To Assess Success Or Failure In Achieving Treatment Goals? Yasser El Miedany, Ahmed Elyassaki, Sally Youssef, Annie Nasr, Mohammed Hegazi and Ihab Ahmed 4, Medway Hospital, Gillingham, United Kingdom, Ain Shams University, Cairo, Egypt, Al Adan Hospital, Kuwait, Kuwait, 4 Cairo University, Cairo, Egypt 4. Prednisone Has No Effect On Odanacatib Pharmacokinetics In Healthy Subjects. Gene Marcantonio, Chengcheng Liu, Stefan Zajic, Chantal Mahon, David Hreniuk, Anish Mehta, Kate Mostoller, Denise Morris 4, Hongwei Xue 4 and S. Aubrey Stoch, Merck Sharp & Dohme Corp., Whitehouse Station, NJ, Merck Sharp & Dohme Corp, Whitehouse Station, NJ, Merck Sharp & Dohme Corp.,, Whitehouse Station, NJ, 4 Covance, Madison, WI 5. FRAX 0-Year Fracture Risk In Women With a Fracture Of The Distal Forearm: Agreement Between Assessments With and Without Bone Mineral Density and Influence Of Measurement Side In Individual Patients. Emilie Egsmose, Mette Birkvig, Thora Buhl and Ole Rintek Madsen, Copenhagen University Hospital Hvidovre, Copenhagen, Denmark, Copenhagen University Hospital Gentofte, Copenhagen, Denmark 6. Adherence With Current Osteoporosis Treatment Guidelines Among Rheumatologists Caring For Patients With Rheumatoid Arthritis Using Items From The Fracture Risk Assessment Tool Score. Jennifer Watt, Andrew E. Thompson, Nicole G. H. Le Riche and Janet E. Pope 4, University of Western Ontario, London, ON, St. Josephs Health Ctr, London, ON, St. Joseph s Hospital, London, ON, 4 Schulich School of Medicine and Dentistry, Western University, London, ON 7. WITHDRAWN 8. Trabecular BONE Score In Rheumatoid Arthritis and Ankylosing Spondylitis and Changes During LONG TERM Treatment With TNFA Blocking Agents. Eric Toussirot, Laurent Mourot, Daniel Wendling, Gilles Dumoulin 4 and CIC BT 5, CIC Biotherapy 506 and Rheumatology and EA 466 Pathogens and Inflammation, Besançon, France, University of Franche Comté, Besançon, France, University Hospital, Besancon, France, 4 Department of Endocrine and Metabolic Biochemistry, Besançon, France, 5 University Hospital, Besançon, France 9. A Before and After Comparison Of The Effects Of Monitoring On a Quality Indicator For glucocorticoid induced Osteoporosis In a Japanese Hospital. Yasuhiro Suyama, Mitsumasa Kishimoto, Chisun Min, Yoichiro Haji, Yuri Ohara, Ryo Rokutanda, Hisanori Shimizu, Ken-ichi Yamaguchi, Yukio Matsui and Masato Okada, St. Luke s International Hospital, Tokyo, Japan 0. Analysis Of Fracture Risk Assessment Score (FRAX) Correlation With Bone Mineral Density (BMD) In Males and Post-Menopausal Females. Vikas Majithia and Khush Aujla, University of Mississippi Medical Center, Jackson, MS, University of Mississippi School of Medicine, Jackson, MS

243 ACR POSTER SESSION B. The Quality Of Life and Resource Use Related To Hip Fractures Based On Data From The International Costs and Utilities Related To Osteoporotic Fractures Study. Moa Ivergård, Viktor Wintzell, László B Tankó, Victoria Barghout, Axel Svedbom, Vidmantas Alekna, Maria Luisa Bianchi 4, Patricia Clark 5, Manuel Díaz Curiel 6, Hans Peter Dimai 7, Mikk Jürisson 8, Olga Lesnyak 9, Eugene McCloskey 0, Kerrie M Sanders, Thierry Thomas, Fredrik Borgström and John A Kanis 4, OptumInsight, Stockholm, Sweden, Novartis Pharma AG, Basel, Switzerland, Vilnius University, Faculty of Medicine, Vilnius, Lithuania, 4 Bone Metabolism Unit, Istituto Auxologico Italiano IRCCS, Milan, Italy, 5 Clinical Epidemiology Unit, Hospital Infantil Federico Gómez and Faculty of Medicine UNAM, Mexico City, Mexico, 6 Catedra de Enfermedades Metabolicas Óseas, Universidad Autonoma, Madrid, Spain, 7 Department of Internal Medicine, Division of Endocrinology and Metabolism, Medical University of Graz, Graz, Austria, 8 Faculty of Medicine, Tartu University, Tartu, Estonia, 9 Ural State Medical Academy, Yekaterinburg, Russia, 0 Academic Unit of Bone Metabolism, Metabolic Bone Centre, University of Sheffield, Sheffield, United Kingdom, Department of Medicine, NorthWest Academic Centre, The University of Melbourne, Melbourne, Australia, INSERM U059, CHU- St-Etienne, Saint Etienne, France, LIME/MMC, Karolinska Institutet, Stockholm, Sweden, 4 WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield, Sheffield, United Kingdom. Osteoporosis In Rheumatoid Arthritis Still a Threat In The Biologic Era? Glenn Haugeberg, Torhild Garen, Hege Sommerseth, Anne Prøven and Knut Helgetveit, Hospital of Southern Norway Trust, Kristiansand, Norway, Oslo University Hospital Rikshospitalet, Oslo, Norway, Martina Hansens Hospital, Bærum, Norway. Strontium Ranelate Uncouples Bone Resorption From Bone Formation In Osteoporotic Patients With Or Without Clinical Risk Factors. Olivier Bruyere, Julien Collette and Jean-Yves Reginster, University of Liège, Liège, Belgium, Labo RIA, CHU Sart Tilman, Liege, Belgium 4. Effects Of Biological Therapy In Bone Metabolism In Patients With Chronic Inflammatory Arthropathies. Maria Victoria Hernández, Andrea Cuervo, Pilar Peris, Ana Monegal, Raimon Sanmarti, Juan D. Cañete and Nuria Guañabens, Hospital Clínic of Barcelona. IDIBAPS. University of Barcelona, Barcelona, Spain 5. Predictors Of Fracture In Patients With Osteopenia: Data From An Observational Cohort. Kathryn Mitchell, Peter Diggle and Marwan Bukhari, Faculty of Health and Medicine, Lancaster, United Kingdom 6. Outcomes and Costs Of Sacral Insufficiency Fractures. Shahryar Hadavi, Sanam Kia, Christian Dejaco, Bhaskar Dasgupta and Frances Borg, Southend University Hospital, Westcliff-on-Sea, United Kingdom, Southend University Hospital, Westcliff-on-sea, United Kingdom 7. Denosumab Leads To Significantly Greater Increases In Bone Mineral Density Than Ibandronate and Risedronate In Postmenopausal Women At High Risk For Fracture Who Were Previously Treated With An Oral Bisphosphonate. Jacques P. Brown, Michael A. Bolognese, Pei-Ran Ho, Jesse Hall, Christian Roux 4, Henry G. Bone 5, Sydney Bonnick 6, Joop van den Bergh 7, Irene Ferreira 8, Prayashi Ghelani 9, Paula Dakin, Rachel B. Wagman and Chris Recknor 0, CHU de Québec Research Centre and Laval University, Quebec City, QC, Bethesda Health Research Center, Bethesda, MD, Amgen Inc., Thousand Oaks, CA, 4 Paris Descartes University, Paris, France, 5 Michigan Bone and Mineral Clinic, Detroit, MI, 6 Clinical Research Center of North Texas, Denton, TX, 7 VieCuri Medical Centre and Maastricht University, Venlo, Netherlands, 8 Amgen Inc., Cambridge, United Kingdom, 9 Ovatech Solutions, London, United Kingdom, 0 United Osteoporosis Centers, Gainesville, GA 8. Persistence At Months With Denosumab (Prolia ) In Postmenopausal Women With Osteoporosis: Interim Results From a Prospective Observational Study. Stuart L. Silverman, Ethel Siris, David L. Kendler, Dea Belazi 4, Jacques P. Brown 5, Deborah T. Gold 6, E. Michael Lewiecki 7, Alexandra Papaioannou 8, Christine Simonelli 9, Irene Ferreira 0, Paula Dakin, Suresh Siddhanti, Bradley Stolshek and Christopher Recknor, Cedars-Sinai Medical Center, UCLA Center of Excellence, Beverly Hills, CA, Columbia University, New York, NY, University of British Columbia, Vancouver, BC, 4 AlchemiPharma LLC, Wayne, PA, 5 CHU de Québec Research Centre and Laval University, Quebec City, QC, 6 Duke University Medical Center, Durham, NC, 7 University of New Mexico School of Medicine, Albuquerque, NM, 8 McMaster University, Hamilton, ON, 9 Health East Osteoporosis Care, Woodbury, MN, 0 Amgen Inc., Cambridge, United Kingdom, Amgen Inc., Thousand Oaks, CA, United Osteoporosis Centers, Gainesville, GA 9. The Effects Of Hyperparathyroidism On Body Mass Index and Bone Mineral Density- An Observational Case- Control Study. Chris Varley, Alexander Oldroyd and Marwan Bukhari, Lancaster University, Llandudno, United Kingdom, Lancaster University, Lancaster, United Kingdom, Royal Lancaster Infirmary, Lancaster, United Kingdom 40. Study On The Relationship Between The Preoperative Stay and Morbimortality In Patients With Hip Fracture. Irene Martin, Maria Aparicio, Laura López-Vives, Montserrat Jordana, Antoni Coscujuela, Abelardo Montero and Carmen gomez-vaquero, Hospital Universitari de Bellvitge, Barcelona, Spain 4. A Low Serum 5(OH) Vitamin D Level As a Risk Factor For Incidence and Severity Of Vertebral Fracture In Glucocorticoid-Induced Osteoporosis In Japan. Mari Ushikubo, Harumi Kuda, Sayaka Kubo, Keisuke Izumi, Kumiko Akiya and Hisaji Oshima, National Tokyo Medical Center, Tokyo, Japan, Keio University School of Medicine, Tokyo, Japan 0 Program Book 4

244 ACR POSTER SESSION B 4. A Prospective Randomized Open Label Trial To Evaluate The Effect Of Food On Vitamin D Absorption. Lucas Grisanti, Zeenat Ali, Joseph M. Grisanti, James Hatem, Mary Brennan, Michael Grisanti, Mary Margaret O Neil, Linda Burns and Kostas Botsoglou 4, College of Wooster, Wooster, OH, Mercy Hospital of Buffalo, Buffalo, NY, Buffalo Rheumatology, Orchard Park, NY, 4 Sisters Hospital, Buffalo, NY 4. Osteoporosis Medication Adherence: Reasons For Stopping and Not Starting. Amy H. Warriner, Ryan C. Outman, Allison Wyman, Fred H. Hooven, Jonathan D. Adachi 4, Roland Chapurlat 5, Juliet E. Compston 6, Cyrus Cooper 7, Jeffrey R. Curtis 8, Adolfo Díez-Pérez 9, Robert Lindsay 0, Lyn March, Jeri W. Nieves 0 and Kenneth G. Saag, University of Alabama at Birmingham, Birmingham, AL, Center for Outcomes Research, UMass Medical School, Worcester, MA, University of Massachusetts, Worcester, MA, 4 McMaster University, Hamilton, ON, 5 INSERM UMR 0 and Université de Lyon, Hôpital Edouard Herriot, Lyon, France, 6 University of Cambridge School of Clinical Medicine, Cambridge, United Kingdom, 7 MRC Lifecourse Epidemiology Unit, Southampton, United Kingdom, 8 University of Alabama at Birmingham, Division of Clinical Immunology and Rheumatology, Birmingham, AL, 9 Hospital del Mar-IMIM, Universitat Autònoma de Barcelona, Barcelona; and RETICEF, ISCIII Madrid; Spain, Barcelona, Spain, 0 Helen Hayes, West Haverstraw, NY, University of Sydney Institute of Bone and Joint Research, Royal North Shore Hospital, St Leonards, Australia 44. Low Bone Mineral Density In African-American Males May Be More Prevalent Than Previously Reported and Exhibits Association With Low BMI But Not Older Age - Results Of a Retrospective Cohort Analysis. Khush Aujla and Vikas Majithia, University of Mississippi School of Medicine, Jackson, MS, University of Mississippi Medical Center, Jackson, MS 45. The Differential Effect Of Smoking On Bone Mineral Density At The Lumbar Spine and Neck Of Femur In Each Gender: An Observational Study. William Hedges, Alexander Oldroyd and Marwan Bukhari, Royal Lancaster Infirmary, University Hospitals of Morecambe Bay NHS Foundation Trust, Lancaster, United Kingdom, Lancaster University, Lancaster, United Kingdom, Royal Lancaster Infirmary, Lancaster, United Kingdom 46. Efficacy Of a 6-Month Treatment With Strontium Ranelate g/day In The Improvement Of Long Bone Fractures With Delayed-Union Or Non-Union. Jean-Marc Feron, Vaclav Vyskocil, Carlina Albanese, Luis Augusto Tavares Russo 4 and Jean-Denis Laredo 5, Hôpital Saint Antoine, GHU Est, AP-HP, Paris, France,. interní klinika, Všeobecná fakultní nemocnice, U Nemocnice, Praha, Czech Republic, Università degli studi, ROMA, Italy, 4 CCBR Brasil, Rua Mena Barreto, Botofogo, 7, Rio de Janeiro, Brazil, 5 Hopital Lariboisière,, rue Ambroise Paré, 75475, Paris, France 47. Association Between Bisphosphonate Switching Behavior and Cost Outcomes In Postmenopausal United States Veterans. Joanne Lafleur, Scott L. DuVall, Jeffrey R. Curtis, Robert A Adler 4, Tina Willson 5, Irene Agodoa 6, Bradley Stolshek 7 and Richard E. Nelson 8, University of Utah College of Pharmacy, Salt Lake City, UT, VA Salt Lake City Health Care System and University of Utah School of Medicine, Salt Lake City, UT, University of Alabama at Birmingham, Birmingham, AL, 4 Hunter Holmes McGuire VA Medical Center, Richmond, VA, 5 University of Utah, Salt Lake City, UT, 6 Amgen Inc, Thousand Oaks, CA, 7 Amgen, Inc., Thousand Oaks, CA, 8 Salt Lake City VA and University of Utah, Salt Lake City, UT 48. Prevalence Of Vitamin D Inadequacy In European Postmenopausal Women Aged Over 80 Years. Olivier Bruyere, Justine Slomian, Charlotte Beaudart, Fanny Buckinx, Etienne Cavalier, Sophie Gillain, Jean Petermans and Jean-Yves Reginster, University of Liège, Liège, Belgium, CHU de Liege, Liege, Belgium Pain - Basic Mechanisms 49. Contrasting Pathophysiology and Behavioural Responses Associated With Osteoarthritis and An Inflammatory Arthropathy. Sanaa Zaki, Margaret M. Smith, Susan Smith, Mark Connor and Christopher B. Little, University of Sydney, St Leonards, Australia, Macquarie University, North Ryde, Australia 50. Serological Markers Of Structural Integrity and Inflammation Is Associated With Pain In Osteoarthritis. Anne Sofie Siebuhr, Lars Arendt-Nielsen, Thomas Navndrup Eskehave, Morten Asser Karsdal, Kristian Kjaer Petersen, Ole Simonsen 4 and Anne C. Bay-Jensen, Nordic Bioscience, Biomarkers and Research, Herlev, Denmark, Center for Sensory-Motor Interaction, Aalborg, Denmark, Center for Clinical and Basic Research and C4Pain, Aalborg, Denmark, 4 Frederikshavn Hospital, Frederikshavn, Denmark 5. Collagen Antibodies Induce Pain-Like Behavior In Mice Without Signs Of Inflammation. Gustaf Wigerblad, Katalin Sandor, Kutty Selva Nandakumar, Rikard Holmdahl and Camilla Svensson, Karolinska Institutet, Stockholm, Sweden 5. The Effect of Pretreatment With Resiniferatoxin On Dynamic Weight Bearing Measures and Evoked Pain Responses in An Acute Arthritis Murine Model. Mishal Abdullah, Christopher W. Dorman, Sandra Frizelle, Sonia C. Funkenbusch, Maren L. Mahowald and Hollis E. Krug 4, University of Minnesota Medical School, Minneapolis, MN, Minneapolis VA Health Care System, Minneapolis, MN, University of Minnesota Medical School and Minneapolis VA Health Care System, Minneapolis, MN, 4 VA Health Care System, Minneapolis, MN 5. Studies On The Relationship Between Intraplantar Carrageenan-Induced Bradykin B Receptor Messenger Ribonucleic Acid Expression and Oedema and Hyperalgesia In Rats: Effects Of Dexamethasone and a B Receptor Antagonist, BI-8. Guy Kennett, Jessica Arlott, Phil Butler, Mike Comer, Andrew Clarkson, Alex Coulthard, Sean Lightowler, Rachel Upcott-Gill, Rebecca Upton, Louise Wray, Philipp Wabnitz, Sven Kühnert and Simon Cruwys, Saretius Ltd, Reading, United Kingdom, Cyprotex Ltd, Macclesfield, United Kingdom, Grunenthal GmbH, Aachen, Germany 4 0 Program Book

245 ACR POSTER SESSION B Pediatric Rheumatology - Clinical and Therapeutic Aspects II: Pediatric Systemic Lupus Erythematosus, Pediatric Vasculitis and Pediatric Myositis 54. Prevalence Of Antinuclear Antibodies In Schoolchildren Across Puberty and Possible Relationship With Musculoskeletal Pain. A Longitudinal Study. Francesca Sperotto, Sara Brachi, Mara Seguso, Fabio Vittadello and Francesco Zulian, University of Padua, Padua, Italy, University of Ferrara, Ferrara, Italy 55. Ovarian Dysfunction In Adult Childhood-Onset Systemic Lupus Erythematosus Patients: A Possible Role Of Methotrexate? Daniel B. Araujo, Lucas Yamakami, Eloisa Bonfá, Vilma S. T. Viana, Sandra G. Pasoto, Rosa M. Pereira, Paulo C. Serafin, Eduardo F. Borba 4 and Clovis A. Silva 5, Faculdade de Medicina da Universidade de São Paulo (FMUSP), São Paulo, Brazil, Faculdade de Medicina da Universidade de São Paulo, Sao Paulo, Brazil, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, 4 Rheumatology Division; University of São Paulo, São Paulo, Brazil, 5 University of São Paulo, São Paulo, Brazil 56. Depression, Anxiety and Suicidal Thoughts In a Cohort Of Pediatric Lupus and Mixed Connective Tissue Disease Patients. Andrea Knight, Pamela F. Weiss, Knashawn Morales and Ron Keren, Children s Hospital of Philadelphia, Philadelphia, PA, The Children s Hospital of Philadelphia, Philadelphia, PA, University of Pennsylvania, Philadelphia, PA 57. Feasibility and Clinical Implications Of The Pediatric Automated Neuropsychological Assessment Metrics for Screening Of Childhood-Onset Neuropsychiatric Systemic Lupus Erythematosus. Patricia Vega-Fernandez, Natasha M. Ruth, Deborah M. Levy, Frank Zelko 4, Eyal Muscal 5, Marisa S. Klein-Gitelman 4, HaiMei Liu 6, Adam Huber 7, Jiha Lee 8, Jessica Hummel 8, Lori B. Tucker 9, Tresa Roebuck-Spencer 0 and Hermine Brunner, Cincinanti Children s Hospital Medical Center, Cincinnati, OH, Medical University of South Carolina, Charleston, SC, The Hospital for Sick Children, University of Toronto, Toronto, ON, 4 Children s Memorial Hospital, Chicago, IL, 5 Baylor College of Medicine, Houston, TX, 6 Children s Hospital of Fundan University, Shanghai, China, 7 IWK Health Centre, Halifax, NS, 8 Cincinnati Children s Hospital Medical Center, Cincinnati, OH, 9 University of British Columbia, Vancouver, BC, 0 University of Oklahoma, Norman, OK, Pediatric Rheumatology Collaborative Study Group (PRCSG), Cincinnati, OH 58. Cognitive Functions In Childhood-Onset Systemic Lupus Erythematosus. Bruna Bellini, Cleonice de Souza, Mariana Postal, Nailu A. Sinicato, Paula T Fernandes, Roberto Marini and Simone Appenzeller, State University of Campinas, Campinas, Brazil, Faculty of Medical Science, State University of Campinas Unicamp, São Paulo, Brazil 59. Cognitive Dysfunction In Childhood Systemic Lupus Erythematosus: Comparison Of Different Classification Criteria. Bruna Bellini, Cleonice de Souza, Mariana Postal, Nailu A. Sinicato, Roberto Marini, Paula T Fernandes and Simone Appenzeller, State University of Campinas, Campinas, Brazil, Faculty of Medical Science, State University of Campinas Unicamp, São Paulo, Brazil 60. Serum S00β Is Associated With Neuropsychiatric Manifestations In Childhood-Onset Systemic Lupus Erythematosus. Aline T. Lapa, Mariana Postal, Nailu A. Sinicato, Bruna Bellini, Paula T Fernandes, Roberto Marini and Simone Appenzeller, State University of Campinas, Campinas, Brazil, Faculty of Medical Science, State University of Campinas Unicamp, São Paulo, Brazil 6. The Usefulness Of Traditional Neurocognitive Testing and N-Methyl-D-Aspartate Receptor Antibodies In Pediatric Lupus Patients. Natasha M. Ruth, Mary C. Kral, Tamara K. Nowling, Stephanie Slan, Murray H. Passo and Gary S. Gilkeson, Medical University of South Carolina, Charleston, SC, MUSC, Charleston, SC, Medical University of South Carolina and Ralph H. Johnson VA Medical Center, Charleston, SC 6. Comparison Of Remission Rates For Pediatric Membranous Plus Proliferative Lupus Nephritis Versus Isolated Proliferative Lupus Nephritis: An Analysis Of The Childhood Arthritis and Rheumatism Research Alliance Registry. Alexis Boneparth, Norman T. Ilowite and The CARRA Registry Investigators, The Children s Hospital at Montefiore, Bronx, NY, Duke Clinical Research Institute, Durham, NC 6. Childhood-Onset Systemic Lupus Erythematosus In Ontario: Long Term Outcomes In a Population-Based Cohort With Universal Health Care Coverage. Deborah M. Levy, Nadia Gunraj, Janet E. Pope, J. Carter Thorne 4, Wesley Fidler 5, Peter B. Dent 6, Johannes Roth 7, Roberta A. Berard 8, Murray Berall 9, Astrid Guttmann 0 and Earl D. Silverman, The Hospital for Sick Children and University of Toronto, Toronto, ON, Institute for Clinical Evaluative Sciences, Toronto, ON, St. Joseph s Health Care, University of Western Ontario, London, ON, 4 Southlake Regional Health Centre, Newmarket, ON, 5 St. Joseph s Hospital, Thunder Bay, ON, 6 McMaster University, Hamilton, ON, 7 University of Ottawa, Ottawa, ON, 8 Children s Hospital of Western Ontario, London, ON, 9 Humber River Regional Hospital, Toronto, ON, 0 Institute for Clinical Evaluative Sciences, The Hospital for Sick Children and University of Toronto, Toronto, ON, The Hospital for Sick Children, University of Toronto, Toronto, ON 64. Evaluation Of Quality Indicators and Disease Damage In Childhood-Onset Systemic Lupus Erythematosus Patients. Julia G. Harris, Kristyn I. Maletta, Evelyn M. Kuhn and Judyann C. Olson, Children s Hospital of Wisconsin, Milwaukee, WI, National Outcomes Center, Children s Hospital of Wisconsin, Milwaukee, WI, Medical College of Wisconsin, Milwaukee, WI 65. Initial Benchmarking Of The Quality Of Medical Care Of Children and Adolescents With Lupus. Ahmad I. Zaal, Julia G. Harris, Clovis A. Silva, Marco F. Sliva, Jiha Lee, Alexandria J. Greenler, Simone Appenzeller 4, Maraisa Centeville 4, HaiMei Liu 5, Joshua D. Pendl, Jennifer L. Huggins, Jessica M. Sage and Hermine Brunner, Cincinnati Children s Hospital Medical Center, Cincinnati, OH, Children s Hospital of Wisconsin, Milwaukee, WI, Faculdade de Medicina da Universidade de São Paulo, Sao Paulo, Brazil, 4 Faculty of Medical Science, State University of Campinas Unicamp, São Paulo, Brazil, 5 Children s Hospital of Fundan University, Shanghai, China 0 Program Book 4

246 ACR POSTER SESSION B 66. WITHDRAWN 67. Impact Of Disease Duration On Vascular Surrogates Of Early Atherosclerosis In Childhood-Onset Systemic Lupus Erythematosus. Julie Barsalou, Timothy J. Bradley, Cameron Slorach, Lawrence W.K. Ng, Deborah M. Levy and Earl D. Silverman, The Hospital for Sick Children, University of Toronto, Toronto, ON 68. Long-Term Follow-Up Of a Pediatric Lupus Cohort: Transition Of Care and Health Related Outcomes. Susanna Felsenstein, Anusha Ramanathan, Beatriz Gonzalez and Andreas Reiff, Children s Hospital Los Angeles, Los Angeles, CA 69. The Development Of a Mobile Application For Adolescents and Young Adults With Lupus. Natasha M. Ruth, Deborah M. Levy, Andrea Regina, Christy Taberner 4, Edith M. Williams 5 and Miriam Kaufman, Medical University of South Carolina, Charleston, SC, The Hospital for Sick Children, University of Toronto, Toronto, ON, The Hospital for Sick Children, Toronto, ON, 4 Mohawk College, Toronto, ON, 5 University of South Carolina, Columbia, SC 70. Risk Factors For The Development Of Avascular Necrosis In Pediatric Systemic Lupus Erythematosus Patients. Reut Gurion, Howard Yang, Hong Li, Stephanie Frenkian, Kathleen A. Haines, Jennifer E. Weiss, Yukiko Kimura, Andrew S. Zeft 4, Angela B. Robinson, Suzanne C. Li and for The CARRA Registry Investigators 5, Rainbow Babies and Children s Hospital / Case Medical Center, Cleveland, OH, Joseph M Sanzari Children s Hospital, Hackensack University Medical Center, Hackensack, NJ, Case Western Reserve University, Cleveland, OH, 4 The Cleveland Clinic, Cleveland, OH, 5 Duke Clinical Research Institute, Durham, NC 7. Longitudinal Disease Trajectory Of Juvenile Dermatomyositis. Lily Siok Hoon Lim, Eleanor Pullenayegum, Dafna Gladman, Earl D. Silverman 4 and Brian M. Feldman 5, University of Toronto, Toronto, ON, The Hospital for Sick Children, Toronto, ON, University of Toronto, Toronto Western Hospital, Toronto, ON, 4 The Hospital for Sick Children, University of Toronto, Toronto, ON, 5 Hospital for Sick Children, Toronto, ON 7. Whole-Body Versus Thigh Magnetic Resonance Imaging In The Assessment Of Juvenile Dermatomyositis. Clara Malattia, Annalisa Madeo, Marta Dellepiane, Diliana Beleva, Stefania Viola, Alessandro Consolaro 4, Nicolino Ruperto 4 and Alberto Martini 5, Pediatria, Genoa, Italy, Istituto G Gaslini, Pediatria II, Reumatologia, Genova, Italy, Pediatria, Genova, Italy, 4 Istituto Giannina Gaslini, Genova, Italy, 5 Istituto Giannina Gaslini, Pediatria II, Reumatologia, Paediatric Rheumatology International Trials Organisation (PRINTO) Coordinating Center, Genoa, Italy, Genoa, Italy 7. Granulomatosis With Polyangiitis In Children Is More Severe Than In Adults. A Long-Term, Single Center, Follow Up Study. Francesco Zulian, Grazia Minardo, Valeria Carraro, Franco Schiavon and Giorgia Martini, University of Padua, Padua, Italy, Rheumatology Clinic, University of Padova, Padova, Italy 74. Maternal Vitamin D, Fetal C-Reactive Protein and Brain Natriuretic Peptide Associate With The Development and Morbidity Of Cardiac Neonatal Lupus. Amit Saxena, Peter M. Izmirly, Joanne H. Reed, Sara Sahl, Deborah Friedman, Robert M. Clancy and Jill P. Buyon, New York University School of Medicine, New York, NY, New York Medical College, Valhalla, NY 75. Prenatal Exposure To Fluorinated Steroids Does Not Affect Long Term Morbidity In Cardiac Neonatal Lupus. Amit Saxena, Peter M. Izmirly, Sara Sahl, Deborah Friedman and Jill P. Buyon, New York University School of Medicine, New York, NY, New York Medical College, Valhalla, NY 76. Immunologic Monitoring and Infectious Complications In Pediatric Rheumatology Patients Treated With Rituximab. Alysha Taxter, Kathleen E. Sullivan and Jon Burnham, The Children s Hospital of Philadelphia, Philadelphia, PA, The Children s Hospital of Philadelphia and the Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA 77. A Pilot Study Of Young Adults With Juvenile Dermatomyositis With Decreased Nailfold Capillary End Row Loops: Brachial Artery Reactivity and Oxidized Lipids. Lauren M. Pachman, Maureen A. McMahon, Tamar Polonsky, Gabrielle A. Morgan, Maria Amoruso and Chiang-Ching Huang 4, Ann & Robert H. Lurie Children s Hospital of Chicago Research Center, Chicago, IL, UCLA David Geffen School of Medicine, Los Angeles, CA, University of Chicago Medicine, Chicago, IL, 4 Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL Rheumatoid Arthritis - Animal Models I 78. The Arthritis Severity and Joint Damage Locus Cia5/Pia4 Is a New Genetic Regulator of the Invasive Properties of Synovial Fibroblasts. Max Brenner, Teresina Laragione and Percio Gulko, Hosftra North Shore-LIJ School of Medicine, Manhasset, NY 79. Anti-IL-6 Receptor Antibody Is Effective In Arthritis Regardless Of Obesity In Mouse Model. Miho Suzuki, Hiroto Yoshida and Yoshihiro Matsumoto, Chugai Pharmaceutical Co., Ltd., Gotemba, Japan 80. The Role of Sphingosine--Phosphate Receptor Signaling in Murine Collagen-Induced Arthiritis. Hidetake Nagahara, Masataka Kohno, Ken Murakami, Aihiro Yamamoto, Takahiro Seno, Wataru Fujii, Kazuki Fujioka, Yuji Kukida, Ryo Oda, Hiroyoshi Fujiwara and Yutaka Kawahito, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, kyoto, Japan 8. Inadequate Glucocorticoid Secretion in Experimental Arthritis in Rats Is Closely Linked to Impaired Mitochondria and Reduced Lipid Breakdown in the Adrenal Cortex. Christine Wolff, Katharina Krinner, Josef Schröder and Rainer H. Straub, Laboratory of Exp. Rheumatology and Neuroendocrino-Immunology, Department of Internal Medicine I, University Hospital, Regensburg, Germany, Department of Phatology, University Hospital, Regensburg, Germany, Laboratory of Exp. Rheumatology and Neuroendocrino-Immunology, University Hospital of Regensburg, Regensburg, Germany 44 0 Program Book

247 ACR POSTER SESSION B 8. Effect of RC-095, An Antagonist of Gastrin-Releasin Peptide Receptor, Regulating Synovial Fibroblasts in Experimental Arthritis. Patricia Oliveira, Lidiane Filippin, Mirian Farinon, Vanessa Clarimundo, Gilberto Schwartsmann and Ricardo M. Xavier, Hospital de Clinicas de Porto Alegre, Porto Alegre, Brazil, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil 8. Power Doppler Ultrasound Phenotyping of Expanding Versus Collapsed Popliteal Lymph Nodes in Murine Inflammatory Arthritis. Echoe M. Bouta, Yawen Ju, Homaira Rahimi, Ronald Wood, Lianping Xing and Edward M. Schwarz, University of Rochester, Rochester, NY, University of Rochester Medical Center, Rochester, NY 84. Nuclear Receptor 4A Is Differentially Expressed In Animal Models Of RA During Inflammation and Resolution. Jordan Everett, Fiona E. McCann, Andrew C. Palfreeman, Anita T. Shaw, Ellen M. Gravallese 4 and Kimberlee S. Mix, Loyola University New Orleans, New Orleans, LA, The Kennedy Institute of Rheumatology, University of Oxford, London, United Kingdom, UMass Memorial Medical Center and University of Massachusetts Medical School, Worcester, MA, 4 UMass Memorial Medical Center, Worcester, MA 85. Choline Kinase: A Novel Target For Rheumatoid Arthritis. Monica Guma, Elsa Sanchez-Lopez, Alessia Lodi, Stefano Tiziani, Juan Carlos Lacal, Michael Karin and Gary S. Firestein, UCSD School of Medicine, La Jolla, CA, University of Texas at Austin, Austin, TX, University Hospital Fundacion Jimenez Diaz, Madrid, Spain 86. Anti-Inflammatory Effects Of Tyrosine-Hydroxylase(TH)- Positive Catecholamine Producing Cells In Chronic Arthritis. Zsuzsa Jenei-Lanzl, Silvia Capellino, Frieder Kees and Rainer H. Straub 4, Laboratory of Experimental Rheumatology and Neuroendocrine Immunology, Regensburg, Germany, Department of Pediatrics, Division of Endocrinology, Johns Hopkins University School of Medicine, Baltimore, Maryland 87, USA., Baltimore, MD, University of Regensburg, Regensburg, Germany, 4 Laboratory of Exp. Rheumatology and Neuroendocrino- Immunology, University Hospital of Regensburg, Regensburg, Germany 87. Pre-Clinical Proof-Of-Concept Of ALX-076, a Nanobody Neutralizing Both IL-7A and F In a Cynomolgus Monkey Collagen Induced Arthritis Model. Katrien Vanheusden, Laurent Detalle, Alex Hemeryck, Alain Vicari, Roland Grenningloh, Sofie Poelmans, Heidi Wouters and Thomas Stöhr, Ablynx NV, Gent, Belgium, Calypso Biotech, Geneva, Switzerland, Merck-Serono, Darmstadt, Germany 88. Development Of Antibodies Specific For Carbamylated Protein Precedes Disease Onset In Mice With Collagen- Induced Arthritis. Leendert A. Trouw, Bisheng Liu, Jing Shi, Diahann T.S.L. Jansen, Martin Hegen, Tom W.J. Huizinga, Jeroen N. Stoop and René E. M. Toes, Leiden University Medical Center, Leiden, Netherlands, Pfizer, Cambridge, MA 89. IL-6 Is Required For Th- and Th7- Mediated Arthritis. Alison Finnegan, Yanxia Cao and Susan Olalekan, Rush University Medical Center, Chicago, IL 90. Pro-Inflammatory and Anti-Inflammatory Roles Of Interferon Regulatory Factor 5 In The Development Of Collagen-Induced Arthritis. Yoshifumi Tada, Syuichi Koarada, Rie Suematsu, Satoko Tashiro, Natsumi Nagao and Akihide Ohta, Saga University, Saga, Japan 9. COVA: Overcoming Limitations Of Current Biologics In Rheumatoid Arthritis By a Novel, Bispecific Tumor- Necrosis-Factor-Alpha / Interleukin-7A (TNF/IL-7A) Inhibitor Moving Towards The Clinic. Dragan Grabulovski, Michela Silacci, Nadja Baenziger-Tobler, Wibke Lembke, Wenjuan Zha, Richard Woods, Isabella Attinger-Toller, Roger Santimaria, Susann Koenig-Friedrich, Ulrike von der Bey, Mathias Locher and Julian Bertschinger, Covagen AG, Schlieren, Switzerland 9. The Spatial Energy Expenditure Configuration and Possible Applications In An Experimental Model Of Arthritis. Susanne Klatt and Rainer H. Straub, Laboratory of Exp. Rheumatology and Neuroendocrine Immunology, University Hospital Regensburg, Regensburg, 9055, Germany, Laboratory of Exp. Rheumatology and Neuroendocrino-Immunology, University Hospital of Regensburg, Regensburg, Germany 9. Serum Matrix Metalloproteinase As a Translational Marker For Efficacy Of Anti-Arthritic Treatments In Rat Collagen Induced Arthritis and Mouse Model Of Lipopolysaccharide-Induced Bone Resorption. Ines Glojnaric, Snjezana Cuzic, Boska Hrvacic, Vanesa Ivetic Tkalcevic, Miroslava Dominis Kramaric and Vesna Erakovic Haber, Fidelta Ltd., Zagreb, Croatia 94. Anti-Inflammatory Effect Of Resveratrol As a Dietary Supplement In An Antigen-Induced Arthritis Rat Model. Romina R. Riveiro-Naveira, Jesus Loureiro, Alberto Centeno-Cortés, Eduardo López-Peláez, Carlos Vaamonde- García, M. Noa Valcárcel-Ares, Francisco J. Blanco and Maria J. López-Armada, Aging and Inflammation Research Lab, INIBIC-CHU A Coruña, A Coruña, Spain, Experimental Surgery Unit, CHU A Coruña, A Coruña, Spain, Osteoarticular and Aging Research Laboratory, Proteomics Unit-Associated Node to ProteoRed-ISCIII, INIBIC-CHUAC, A Coruña, Spain 95. Mechanisms For Fostamatinib-Induced Blood Pressure Elevation. Matthew Skinner, Karen Philp, David Lengel, Lucy Coverley, Eva Lamm Bergstroem, Philip Glaves, Helen Musgrove, Helen Prior, Martin Braddock, Russell Huby, Jon O Curwen, Paul Duffy and Alex Harmer, AstraZeneca R&D Alderley Park, Macclesfield, United Kingdom, AstraZeneca R&D Waltham, Waltham, MA, AstraZeneca R&D Mölndal, Mölndal, Sweden 96. Deletion Of RBP-J In a Murine Model Of Inflammatory Arthritis Reveals Pro-Inflammatory Cytokine Expression and Immunophenotypic Differences. Soumya D. Chakravarty, Karmen Au, Lionel B. Ivashkiv and Xiaoyu Hu, Hospital for Special Surgery, New York, NY 0 Program Book 45

248 ACR POSTER SESSION B 97. Human IL-alpha Conditional Transgenic Mice Mimic Autoinflammatory Syndromes In Human. Hiroya Kanagawa, Yasuo Niki, Yoshiaki Toyama and Takeshi Miyamoto 4, Department of Orthopaedic Surgery, Keio University, Shinjuku-ku, Tokyo, Japan, Department of Orthopaedic Surgery, Keio University, Tokyo, Japan, Department of Orthopaedic Surgery, Keio University School of Medicine, Shinjuku, Japan, 4 Department of Orthopaedic Surgery, Keio University, Shinjuku-ku,Tokyo, Japan 98. Statin Alleviates Rheumatoid Arthritis Progression Through Diminishing Inflammation Or Oxidative Stress- Induced Cyr6 Synthesis. Kuo Liang Hou and Sze Kwan Lin, School of Dentistry, College of Medicine National Taiwan University, Taipei, Taiwan 99. PTEN Controls Osteoclastogenesis and Inflammatory Bone Destruction In a TNF-Driven Model Of Arthritis. Stephan Blueml, Gernot Schabbauer, Antonia Puchner, Victoria Saferding, Emine Sahin, Julia Brunner, Tobias Lohmeyer, Josef S. Smolen and Kurt Redlich, Medical University of Vienna, Vienna, Austria, Medical University Vienna, Vienna, Austria 00. The Role Of Celastrol On Osteoclastogenesis and Bone Erosion In Collagen-Induced Arthritis. Ke Gan, Wenfeng Tan, Miaojia Zhang, Xiaoke Feng and Lingxiao Xu, Nanjing University of Chinese Medicine, nanjing, China, the First Affiliated Hospital of Nanjing Medical University, Nanjing, CHINA., Nanjing, China, the First Affiliated Hospital of Nanjing Medical University, China, Nanjing, China 0. The Tumor Necrosis Factor Stimulated Gene-6 Promoter Reporter Can Monitor The Disease Activity In Rheumatoid Arthritis. Mathijs G.A. Broeren, Eline A. Vermeij, Onno J. Arntz, Miranda B. Bennink, Emma Sterken, Calin Popa, Tim L. Jansen, Wim B. van den Berg and Fons A.J. Van de Loo, Rheumatology Research and Advanced Therapeutics, Department of Rheumatology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands 0. Application of Cytostatic Agent Kinesin Eg5 Inhibitor Litronesib (KF8967) On Rat Adjuvant-Induced Arthritis and Mouse Type II Collagen-Induced Arthritis. Ichiro Miki and Masako Uchii, Kyowa Hakko Kirin, Co., Ltd., Shizuoka, Japan, Kyowa Hakko Kirin Co., Ltd., Shizuoka, Japan Rheumatoid Arthritis - Clinical Aspects II: Predictors of Disease Course in Rheumatoid Arthritis - Treatment Approaches 0. Variations In Disease Activity and Therapeutic Management Of Rheumatoid Arthritis In Different International Regions: A Comparison Of Data From The Corrona International and Corrona United States Registries. Dimitrios A. Pappas, Kathy Lampl, Joel M. Kremer, Sebastião C. Radominski 4, Janos Gal 5, Fredrik Nyberg 6, Anand N. Malaviya 7, Aimée Whitworth 8, Oscar Luis Rillo 9, Allan Gibofsky 0, Tatiana Popkova, Meilien Ho, Ieda Laurindo, George W. Reed 8, Eduardo Mario Kerzberg 4, Laura Horne, Roman Záhora 5, Katherine C. Saunders 8, Bernado Pons-Estel 6, Alina U. Onofrei 7 and Jeffrey D. Greenberg 8, Columbia University, New York, NY, AstraZeneca R&D Wilmington, Wilmington, DE, Center for Rheumatology, Albany Medical College, Albany, NY, 4 Universidade Federal do Paraná, Curitiba, Brazil, 5 County Hospital, Kecskemet, Hungary, 6 AstraZeneca R&D, Mölndal, Sweden, 7 Consultant Rheumatologist, ISIC Superspeciality Hospital, New Delhi-007-, India, 8 CORRONA, Inc., Southborough, MA, 9 CONAART - Hospital Tornú, Buenos Aires, Argentina, 0 Hospital for Special Surgery, New York, NY, Research Institute of Rheumatology -Russian Academy of Medical Science, Moscow, Russia, AstraZeneca R&D Alderley Park, Macclesfield, United Kingdom, Universidade de São Paulo, São Paulo, Brazil, 4 J. M. Ramos Mejía Hospital, School of Medicine, University of Buenos Aires, Buenos Aires, Argentina, 5 Revmatologická ambulance, Terezin, Czech Republic, 6 Hospital Provincial de Rosario, Rosario, Argentina, 7 University of Massachusetts Medical School, Worcester, MA, 8 NYU Hospital for Joint Diseases, New York, NY 04. Anti-Carbamylated Antibody Positivity Is Associated With More Severe Radiological Progression In Patients With Recent Onset ACPA Negative Rheumatoid Arthritis: Results From The Norfolk Arthritis Register (NOAR). Jenny H. Humphreys, Suzanne M. Verstappen, Kimme L. Hyrich, Tarnya Marshall, Anne Barton, René E.M. Toes 4, Leendert A. Trouw 4 and Deborah P. Symmons 5, Arthritis Research UK Epidemiology Unit, University of Manchester, Manchester, United Kingdom, Arthritis Research UK Epidemiology Unit, Manchester Academic Health Sciences Centre, Institute of Inflammation and Repair, The University of Manchester, Manchester, United Kingdom, Norfolk and Norwich University Hospitals Trust, Norwich, United Kingdom, 4 Leiden University Medical Center, Leiden, Netherlands, 5 NIHR Manchester Musculoskeletal Biomedical Research Unit, Manchester Academic Health Science Centre, Manchester, United Kingdom 05. Clinical Joint Involvement Is Decisive For Radiographic Progression. Miriam Gärtner, Farideh Alasti, Gabriela Supp, Josef S. Smolen and Daniel Aletaha, Medical University of Vienna, Vienna, Austria, Medical University of Vienna and Hietzing Hospital, Vienna, Austria 06. Do Sustained Clinical Remission and Sustained Low Disease Activity Equally Predict Functional Status In Early Rheumatoid Arthritis? Bindee Kuriya, Juan Xiong, Gilles Boire, Boulos Haraoui, Carol A. Hitchon 4, Janet E. Pope 5, J. Carter Thorne 6, Diane Tin 6, Edward C. Keystone, Cheryl Barnabe 7, Pooneh Akhavan 8 and Vivian P. Bykerk 9, Mount Sinai Hospital, University of Toronto, Toronto, ON, Centre Hospitalier Universitaire de Sherbrooke, Université de Sherbrooke, Sherbrooke, QC, Institut de Rhumatologie de Montréal, Montreal, QC, 4 University of Manitoba, Winnipeg, MB, 5 St Joseph Health Centre, London, ON, 6 Southlake Regional Health Centre, Newmarket, ON, 7 University of Calgary, Calgary, AB, 8 Early Rheumatoid Arthritis Program, Mount Sinai Hospital and University of Toronto, Toronto, ON, 9 Hospital for Special Surgery, New York, NY 46 0 Program Book

249 ACR POSTER SESSION B 07. Synovial Subset Derived Baseline Serum Biomarkers Segregate Rheumatoid Arthritis Patients Into Subgroups With Distinct Serum Protein and Clinical Characteristics. A. Francesca Setiadi, Nicholas Lewin-Koh, Sarah Kummerfeld, David F. Choy, Cécile T.J. Holweg, Sally Fischer, An Song and Michael J. Townsend, Genentech, South San Francisco, CA 08. Low Accuracy Of Radiograph Reports In Identifying Patients With Rheumatoid Arthritis In The Veterans Affairs Rheumatoid Arthritis Registry. Maria P. Martes, Alan R. Erickson, Ted R. Mikuls and Grant W. Cannon 4, Salt Lake City VA Medical Center and University of Utah, Salt Lake City, UT, Omaha VA and University of Nebraska Medical Center, LaVista, NE, Omaha VA and University of Nebraska Medical Center, Omaha, NE, 4 Salt Lake City VA and University of Utah, Salt Lake City, UT 09. Prognosis Of Seronegative Patients In a Large Prospective Cohort Of Patients With Early Inflammatory Arthritis. Lillian J. Barra, Janet E. Pope, Boulos Haraoui, Carol A. Hitchon, J. Carter Thorne 4, Edward C. Keystone 5, Diane Tin 4, Gilles Boire 6 and Vivian P. Bykerk 7, Schulich School of Medicine and Dentistry, Western University, London, ON, Centre Hospitalier de l Université de Montréal, Montreal, QC, University of Manitoba, Winnipeg, MB, 4 Southlake Regional Health Centre, Newmarket, ON, 5 Mount Sinai Hospital, University of Toronto, Toronto, ON, 6 Centre Hospitalier Universitaire de Sherbrooke, Université de Sherbrooke, Sherbrooke, QC, 7 Hospital for Special Surgery, Weill Cornell Medical College, New York, NY 0. Evaluation Of The Japanese Patients With Rheumatoid Arthritis (RA) Of Rapid Radiographic Progression (RRP) Treated With Synthetic Disease Modifying Anti-Rheumatic Drugs (DMARDs) In Daily Practice: A Large-Scale Prospective Longitudinal Cohort Study (an interim report of Apple Survey). Akitomo Okada, Atsushi Kawakami, Takaaki Fukuda, Toshihiko Hidaka 4, Tomonori Ishii 5, Yukitaka Ueki 6, Takao Kodera 7, Munetoshi Nakashima 8, Yuichi Takahashi 9, Seiyo Honda 0, Yoshiro Horai, Tomohiro Koga, Mami Tamai, Kiyoshi Aoyagi, Ryu Watanabe 5, Hiroshi Okuno and Katsumi Eguchi, Japanese Red Cross Nagasaki Genbaku Hospital, Nagasaki, Japan, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, Kurume University Medical Center, Kurume, Japan, 4 Zenjinkai Shimin-No-Mori-Hospital, Miyazaki, Japan, 5 Tohoku University, Sendai, Japan, 6 Sasebo Chuo Hospital, Sasebo, Japan, 7 Tohoku Kosei Nenkin Hospital, Sendai, Japan, 8 Japanese Red Cross Nagasaki Genbaku Hospital, Nagasahi, Japan, 9 Yu Family Clinic, Sendai, Japan, 0 Kurume University School of Medicene, Kurume, Japan, Center for Health & Community Medicine, Nagasaki University, Nagasaki, Japan, Tohoku University Hospital, Sendai, Japan, Sasebo City General Hospital, Sasebo, Nagasaki, Japan. Aiming Simple Disease Activity Score Remission At One Year Leads To Better -Year Radiographic and Functional Outcomes Than aiming low Disease activity in Early Rheumatoid Arthritis Patients Treated In Routine Practice. Data From Espoir Cohort. Adeline Ruyssen- Witrand, Gregory Guernec, Delphine Nigon, Gabriel Tobon 4, Bénédicte Jamard 5, Anne-Christine Rat 6, Olivier Vittecoq 7, Alain G. Cantagrel 8 and Arnaud L. Constantin, Purpan University Hospital, Toulouse, France, Inserm, Toulouse, France, Purpan University Hospital, Toulouse Cedex 9, France, 4 Unit of immunology, Brest, France, 5 Toulouse University Hospital, Toulouse, France, 6 Université de Lorraine, Nancy, F-54000, France; Inserm, CIC-EC CIE6, Nancy, F-54000, France; CHU de Nancy, Clinical Epidemiology and Evaluation Department, Nancy, F-54000, France; CHU de Nancy, Rheumatology department, Nancy, France, 7 Rouen University Hospital & Inserm905, University of Rouen, Rouen Cedex, France, 8 Centre Hospitalier Universitaire de Toulouse, Toulouse, France. A Multi-Biomarker Disease Activity Score Correlates With Radiographic Progression In Early Rheumatoid Arthritis: Results From a Randomized Trial. Karen Hambardzumyan, Rebecca Bolce, Scott E. Cruickshank, Eric H. Sasso, David Chernoff, Kristina Forslind 4, Saedis Saevarsdottir, Ingemar F. Petersson 5, Pierre Geborek 5, Sofia Ernestam 6 and Ronald F van Vollenhoven, Karolinska Institutet, Stockholm, Sweden, Crescendo Bioscience Inc., South San Francisco, CA, Scott E. Cruickshank and Associates, Inc., Santa Barbara, CA, 4 Section of Rheumatology, Department of Medicine, Helsingborg General Hospital, Helsingborg, Sweden, 5 Lund University, Lund, Sweden, 6 Karolinska University Hospital, Huddinge, Sweden. Tobacco Exposure Is Associated With Radiographic Damage In Hispanic and African American Rheumatoid Arthritis Patients. Rodolfo Perez Alamino, Luis R. Espinoza, Gail S. Kerr, Christopher Swearingen 4, Chunqiao Luo 4, Yusuf Yazici 5, Yvonne R. S. Sherrer 6, Edward L. Treadwell 7, Angelia D. Mosley-Williams 8, Sharon Dowell 9, Ignacio Garcia-Valladares 0, Theresa Lawrence-Ford, Adrian Godoy 9, Akgun Ince and Cindy Flower, Lousiana State University and LSU Medical Center, New Orleans, LA, LSU Medical Center, New Orleans, LA, Washington DC VAMC and Georgetown University and Howard University Hospital, Washington, DC, 4 University of Arkansas for Medical Sciences, Little Rock, AR, 5 New York University Hospital for Joint Diseases, New York, NY, 6 Centre Rheum Immunol Arthritis, Fort Lauderdale, FL, 7 East Carolina University, Greenville, NC, 8 John Dingell VAMC, Detroit, MI, 9 Howard University, Washington, DC, 0 Guadalajara, Guadalajara, Mexico, North Georgia Rheumatology Group, PC, Lawrenceville, GA, Saint Louis University, St. Louis, MO, University of the West Indies, Bridgetown, Barbados 4. Synovial Ectopic Lymphoneogenesis Predicts Clinical Response To Certolizumab Pegol In Patients With Rheumatoid Arthritis. Maria Di Cicco, Stephen Kelly, Frances Humby, Nora Ng, Sabrina Dadoun, Rebecca Hands, Vidalba Rocher, Alessandra Nerviani, Michele Bombardieri and Costantino Pitzalis, Centre for Experimental Medicine and Rheumatology, Queen Mary University of London, London, United Kingdom, APHP, Pitié-Salpêtrière University Hospital, Paris, France, William Harvey Research Institute, QMUL, London, United Kingdom 0 Program Book 47

250 ACR POSTER SESSION B η and Its Auto-Antibodies Predict Response To Anti-TNF Therapy. Walter P. Maksymowych and Anthony Marotta, University of Alberta, Edmonton, AB, Augurex Life Sciences Corp, North Vancouver, BC 6. MMP As a Predictor Identifying a Subgroup Of Rheumatoid Patients Who Are Successfully Treated With Methotrexate (MTX) Alone But Still Subject To Radiographic Progression. Shunichi Shiozawa, Yasushi Tanaka, Ryosuke Yoshihara, Miki Murata, Takashi Yamane, Chihiro Tanaka, Noriaki Yo and Kazuko Shiozawa, Kyushu University Beppu Hospital, Beppu, Japan, Kohnan Kakogawa Hospital, Kakogawa, Japan 7. Methotrexate Optimization (ie introduction during the first months and with dose escalation at 6 months at least at 0mg/w or 0.mg/kg/w) Is Associated With Better Clinical Outcomes In Daily Practice: Results From The Espoir Cohort. Cécile Gaujoux-Viala, Simon Paternotte, Bernard Combe, Maxime Dougados 4 and Bruno Fautrel 5, EA 45, Montpellier I University, Nîmes University Hospital, Rheumatology Department, Nîmes, France, Paris- Descartes University, Cochin hospital, Paris, France, Lapeyronie Hospital, Montpellier I university, Montpellier, France, 4 Paris-Descartes University, APHP, Cochin Hospital, Paris, France, 5 Paris 6 Pierre et Marie Curie University; AP-HP, Rheumatology, Pitié-Salpêtrière Hospital, - GRC-UPMC 08 EEMOIS, Paris, France 8. Prevalence and Impact Of Soft Tissue Manifestations In Early Inflammatory Arthritis: Results From The Canadian Early Arthritis Cohort. Mihaela Popescu, Edith Villeneuve, Boulos Haraoui, Gilles Boire 4, Carol A. Hitchon 5, Edward C. Keystone 6, Janet E. Pope 7, J. Carter Thorne 8, Diane Tin 8 and Vivian P. Bykerk 6, University of Montreal, Montreal, QC, Institut de Rhumatologie de Montréal, Montreal, QC, Centre Hospitalier de l Université de Montréal, Montreal, QC, 4 Centre Hospitalier Universitaire de Sherbrooke, Université de Sherbrooke, Sherbrooke, QC, 5 University of Manitoba, Winnipeg, MB, 6 Mount Sinai Hospital/University of Toronto, Toronto, ON, 7 St Joseph Health Care, London, ON, 8 Southlake Regional Health Centre, Newmarket, ON 9. Diagnostic Value Of Anti-Citrullinated Proteins Antibodies In Rheumatoid Arthritis. Claudia L. Giraldo, Rafael Chaparro del Moral, Mercedes Ciancio, Oscar L. Rillo, Emilia Saint Martin 4, Emilce Schneeberger 5, Gustavo Citera 5, Federico Zazzetti 6, Amalia Schiel 7 and Juan C. Barreira 7, Hospital General de Agudos, Buenos Aires, Argentina, Hospital General de Agudos Dr. E. Tornu, Buenos Aires, Argentina, Hospital General de Agudos Dr. E. Tornú, Buenos Aires, Argentina, 4 Instituto de Rehabilitacion Psicofisica, Buenos Aires, Argentina, 5 Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, 6 Buenos Aires Hospital Britanico, Buenos Aires, Argentina, 7 Buenos Aires British Hospital, Buenos Aires, Argentina 0. Categorization Of Rheumatoid Arthritis Subjects By Rheumatoid Factor and Anti-Cyclic Citrullinated Autoantibody Status Identifies Rheumatoid Arthritis Subjects With Different Characteristics. Swati Modi, Mariely Nieves-Plaza, Donald M. Jones, Erich R Wilkerson, Christine L. Amity, Kelly A. Reckley, Ilinca D. Metes, Jason Lyons, Heather Eng 4, Stephen R. Wisniewski 4 and Marc C. Levesque, University of Pittsburgh, Pittsburgh, PA, Univ of Pittsburgh, Pittsburgh, PA, University of Pittsburgh School of Medicine, Pittsburgh, PA, 4 University of Pittsburgh, Graduate School of Public Health, Pittsburgh, PA. Vasoactive Intestinal Peptide Serum Levels As a Marker Of Prognosis In Rheumatoid Arthritis. Rosario Garcia-Vicuña, Ana M. Ortiz, Iria Valino-Seoane, Amalia Lamana, Javier Leceta, Yasmina Juarranz, Isidoro González-Alvaro, Rosa P Gomariz and Carmen Martinez-Mora 4, Hospital Universitario de La Princesa. IIS Princesa, Madrid, Spain, School of Biology. Universidad Complutense de Madrid, Madrid, Spain, Hospital Universitario de La Princesa, IIS Princesa, Madrid, Spain, 4 School of Medicine. Universidad Complutense de Madrid, Madrid, Spain. Osteoprotegerin and TNF-Related Apoptosis Inducing Ligand Are Respectively Predictive Factors Of Remission and Erosion In Early Rheumatoid Arthritis Patients Included In The French Cohort Espoir. Rachel Audo, Laura Papon, Claire I. Daien, Cédric Lukas, Bernard Combe, Olivier Vittecoq, Michael Hahne and Jacques Morel, IGMM, CNRS UMR555, Montpellier, Montpellier, France, Lapeyronie Hospital, Montpellier, France, Rouen University Hospital & Inserm905, University of Rouen, Rouen Cedex, France. Plasma Leucine-Rich Alpha- Glycoprotein Is a Useful Disease Activity Biomarker In Rheumatoid Arthritis. Jung- Soo Song, You-Jung Ha, Eun-Jin Kang, Kwang-Hoon Lee 4, Sang-Won Lee, Yong-Beom Park, Soo-Kon Lee and Sang Tae Choi, Chung-Ang University College of Medicine, Seoul, South Korea, Yonsei University College of Medicine, Seoul, South Korea, Busan Medical Center, Busan, South Korea, 4 Dongguk University Ilsan Hospital, Goyang, South Korea 4. Evaluation Of The Usefulness Of Interferon-Gamma Release Assays and Tuberculin Skin Test For Detection Of Latent Mycobacterium Tuberculosis Infection In Korean Rheumatic Patients With Biologic Agents. Jae-Hoon Kim, Soyoung Won, Chan-Bum Choi, Yoon-Kyoung Sung, Gwan Gyu Song and Sang-Cheol Bae, Korea Univ College of Med, Seoul, South Korea, Clinical Research Center for Rheumatoid Arthritis (CRCRA), Seoul, South Korea, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea 5. A Novel Index To Identify Interstitial Lung Disease In Rheumatoid Arthritis Patients. Jose Felix Restrepo, Inmaculada Del Rincon, Roy W. Haas, Daniel F. Battafarano and Agustin Escalante, University of Texas Health Science Center, San Antonio, TX, San Antonio Military Medical Center, San Antonio, TX 6. Discriminative Metabolite Profiling Of Synovial Fluid In Rheumatoid Arthritis Compared To Osteoarthritis. Jiwon Hwang, Joong Kyong Ahn, Jaejoon Lee, Inyoung Kim, Seulkee Lee, Chan Hong Jeon 4, Eun-Mi Koh and Hoon-Suk Cha, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea, Kangbuk Samsung hospital, Sungkyunkwan University School of Medicine, Seoul, South Korea, Sungkyunkwan University School of Medicine, Samsung Medical Center, Seoul, South Korea, 4 Soonchunhyang University College of Medicine, Bucheon, South Korea 48 0 Program Book

251 ACR POSTER SESSION B 7. Autoantibodies To Citrullinated Proteins Associate With Bone Destruction Marker and Are Modulated By First Anti Rheumatic Treatment In Early Rheumatoid Arthritis. Aase Haj Hensvold, Vijay Joshua, Saedis Saevarsdottir, Michaela Larkin, Lena Israelsson, Ferhan Qureshi, Per- Johan Jakobsson, Nadine A. Defranoux 4, Lars Klareskog, Vivianne Malmström 5 and Anca I Catrina, Rheumatology unit, Karolinska University Hospital, Karolinska Institut, Stockholm, Sweden, Rheumatology unit, Karolinska University Hospital, Karolinska Institute, Stockholm, Sweden, Crescendo Bioscience, Inc., South San Francisco, CA, 4 Crescendo Bioscience Inc., South San Francisco, CA, 5 Rheumatology unit, Karolinska University Hospital, Karolinska Institutet, STockholm, Sweden, Stockholm, Sweden 8. Incidence Trends and Predictors Of Orthopedic Surgery In Patients With Rheumatoid Arthritis Results From a Well Defined Population. Korosh Hekmat, Lennart Jacobsson, Jan-Åke Nilsson, Minna Willim, Martin Englund, Ingemar F. Petersson and Carl Turesson, Lund University, Malmö, Sweden, Lund University, Lund, Sweden 9. Physician Global Assessment At Three Months Is Strongly Predictive Of Remission At Months In Early Rheumatoid Arthritis. Results From The Canadian Early Arthritis Cohort. Tommy Choy, Vivian P. Bykerk, Gilles Boire, Boulos Haraoui 4, Carol A. Hitchon 5, J. Carter Thorne 6, Edward C. Keystone 7 and Janet E. Pope 8, University of Western Ontario, London, ON, Hospital for Special Surgery, New York, NY, Centre Hospitalier Universitaire de Sherbrooke, Université de Sherbrooke, Sherbrooke, QC, 4 Institut de Rhumatologie de Montréal, Montreal, QC, 5 University of Manitoba, Winnipeg, MB, 6 Southlake Regional Health Centre, Newmarket, ON, 7 Mount Sinai Hospital, University of Toronto, Toronto, ON, 8 Schulich School of Medicine and Dentistry, Western University, London, ON 0. Prednisone Use Associated With Worse Outcomes In Rheumatoid Arthritis Pregnancies. Prateek Chaudhary and M. E. B. Clowse, Duke University Medical Center, Durham, NC. Mathematical Model To Predict The Early Responders In a Monocentric Cohort Of Patients With Rheumatoid Arthritis Treated By Anti TNF-Alpha. Camillo Giacomelli, Claudia Ferrari, Chiara Stagnaro, Rosaria Talarico, Arianna Consensi, Francesca Sernissi, Laura Bazzichi and Stefano Bombardieri, Rheumatology Unit, Pisa, Italy. Metaflammation, PEDF and Chemerin: Potential Systemic Factors Which Link Obesity To Response To Therapy In Early Rheumatoid Arthritis. Elisa Gremese, Barbara Tolusso, Anna Laura Fedele, Maria Rita Gigante, Angela Carbonella, Silvia Canestri, Clara Di Mario and Gianfranco Ferraccioli, Division of Rheumatology, Institute of Rheumatology and Affine Sciences, Catholic University of the Sacred Heart, Rome, Italy. The Impact Of Menopause In Rheumatoid Arthritis Activity. Sofia Pedro, Eliza Chakravarty, Megan E. B. Clowse, Rebecca Schumacher and Kaleb Michaud, National Data Bank for Rheumatic Diseases, Wichita, KS, Oklahoma Medical Research Foundation, Oklahoma City, OK, Duke University Medical Center, Durham, NC 4. Predicted Versus Observed Radiographic Progression In a Rheumatoid Arthritis Randomized Trial. Adrian Levitsky, Kristina Forslind and Ronald F. van Vollenhoven, Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID), the Karolinska Institute, Stockholm, Sweden, Department of Clinical Sciences, Section of Rheumatology, Skåne University Hospital, Lund, Sweden 5. Sarcopenia Is Associated With Joint Damage In Rheumatoid Arthritis patients a Cross Sectional Study In a Peruvian Population. Erika Noriega, Rocio V. Gamboa- Cardenas, Manuel F. Ugarte-Gil, Mariela Medina- Chinchon, Francisco Zevallos-Miranda, J. Mariano Cucho- Venegas, Risto A. Perich-Campos, Jose L. Alfaro-Lozano, Zoila Rodriguez-Bellido and Cesar A. Pastor-Asurza, Hospital Almenara, Lima, Peru, Universidad Nacional Mayor de San Marcos, Lima, Peru 6. The Safety and Feasibility Of a Treat-To-Target Strategy Aimed At Achieving a Simplified Disease Activity Index Of Ü. While Administering Entecavir In Rheumatoid Arthritis Complicated By Hepatitis B Virus. Yukitomo Urata, Yoshihide Nakamura and Ken-ichi Furukawa, Seihoku Central Hospital, United Municipalities of Tsugaru, Gosyogawara, Japan, Hirosaki University Graduate School of Medicine, Hirosaki, Japan 7. Nearly Pain Free Self-Administration Of Methotrexate Using An Investigational Auto-Injector: Results Of a Phase- Clinical Trial In Rheumatoid Arthritis Patients With Mild-To-Severe Functional Limitations. Alan J. Kivitz, David McLain, John Hill, Bruce Freundlich 4, Jonathan Jaffe 5 and Kaushik J. Dave 5, Altoona Center for Clinical Research, Duncansville, PA, Rheumatology, McLain Medical Associates, PC, Birmingham, AL, Avail Clinical Research, DeLand, FL, 4 University of Pennsylvania, Philadelphia, PA, 5 Antares Pharma Inc, Ewing, NJ Time To Institution Of Disease Modifying Anti- Rheumatic Drugs In Australian Patients With Early Rheumatoid Arthritis. Sharon Van Doornum, Joanne Tropea, Mark Tacey and Danny Liew, The University of Melbourne, Melbourne, Australia, Royal Melbourne Hospital, Melbourne, Australia 9. Efficacy and Safety Of Biologics Agents For Patients With Rheumatoid Arthritis and Hepatitis B Carrier. Masahiro Tada, Tatsuya Koike, Akihiro Tamori, Tadashi Okano, Yuko Sugioka, Kenji Mamoto, Kentaro Inui and Hiroaki Nakamura, Osaka City University Graduate School of Medicine, Osaka, Japan 40. Functional Disability and Quality Of Life Are More Likely Improved In Patients With Rheumatoid Arthritis Who Achieved The New ACR/EULAR Remission Criteria Compared To DAS8 Remission In Daily Practice. Yoko Shimizu, Ayako Nakajima, Eisuke Inoue, Eiichi Tanaka, Akiko Kobayashi, Yohei Seto, Shigeki Momohara, Atsuo Taniguchi and Hisashi Yamanaka, Institute of Rheumatology, Tokyo Women s Medical University, Tokyo, Japan, Tokyo Women s Medical University, Tokyo, Japan 0 Program Book 49

252 ACR POSTER SESSION B Significantly Less Glucocorticoids and Better Patient- Reported Outcomes In Women With Early Inflammatory Arthritis Using Oral Contraceptives Compared To Never Users. Gisela Westhoff, Rainer H. Straub, Frank Buttgereit, Johanna Callhoff 4 and Angela Zink 5, German Rheumatism Research Center Berlin, Berlin, Germany, Laboratory of Exp. Rheumatology and Neuroendocrino- Immunology, University Hospital of Regensburg, Regensburg, Germany, Charité - Universitätsmedizin Berlin, Berlin, Germany, 4 German Rheumatism Research Center, Berlin, Germany, 5 German Rheumatism Research Centre and Charité University Medicine, Berlin, Germany 4. Prognosis In Espoir Rheumatoid Arthritis Cohort At 4 Months According To Remission Status At Months: No Differences In Radiographic Scores According To Prior Remission Status, But Significant Differences In HAQ Scores, Highest For Boolean and RAPIDRJ Criteria. Isabel Castrejón, Maxime Dougados, Bernard Combe, Francis Guillemin 4, Bruno Fautrel 5 and Theodore Pincus, NYU Hospital for Joint Diseases and New York University School of Medicine, New York, NY, Cochin Hospital, Paris, France, CHU Lapeyronie, Montpellier, France, 4 Hopitaux de Brabois, Nancy, France, 5 APHP, Pitié-Salpêtrière University Hospital, Paris, France 4. Are There Differences Between Young and Older Onset Early Rheumatoid Arthritis and Does This Impact Outcomes? An Analysis From The Canadian Early Arthritis Cohort. Michael Arnold, Vivian P. Bykerk, Gilles Boire, Boulos Haraoui 4, Carol A. Hitchon 5, J. Carter Thorne 6, Edward Keystone 7 and Janet E. Pope 8, University College Dublin, Ireland, Dublin, Ireland, Hospital for Special Surgery, New York, NY, Centre Hospitalier Universitaire de Sherbrooke, Université de Sherbrooke, Sherbrooke, QC, 4 Institut de Rhumatologie de Montréal, Montreal, QC, 5 University of Manitoba, Winnipeg, MB, 6 Southlake Regional Health Centre, Newmarket, ON, 7 University of Toronto, Toronto, ON, 8 Schulich School of Medicine and Dentistry, Western University, London, ON 44. Optimal Rheumatoid Arthritis Patient Selection For Biological Treatment From Pharmacoeconomic Perspectives Based On The Institute Of Rheumatology, Rheumatoid Arthritis (IORRA) Cohort. Eiichi Tanaka, Eisuke Inoue, Yoko Shimizu, Akiko Kobayashi, Naoki Sugimoto, Daisuke Hoshi, Kumi Shidara, Eri Sato, Yohei Seto, Ayako Nakajima, Shigeki Momohara, Atsuo Taniguchi and Hisashi Yamanaka, Tokyo Women s Medical University, Tokyo, Japan, Institute of Rheumatology, Tokyo Women s Medical University, Tokyo, Japan 45. Retinal Vascular Calibre a Novel Biomarker Of Inflammation and Treatment Response In Rheumatoid Arthritis. John HY Moi, Lauren AB Hodgson, Ian P Wicks, Tien Yin Wong and Sharon Van Doornum, The University of Melbourne, Melbourne, Australia, Centre for Eye Research Australia, Melbourne, Australia, Walter & Eliza Hall Institute of Medical Research, Parkville, Australia 46. Drug Free Holiday In Patients With Rheumatoid Arthritis (RA): patients Opinion. I.M. Markusse, G. Akdemir, T.W.J. Huizinga and C.F. Allaart, Leiden University Medical Center, Leiden, Netherlands 0 Program Book 47. A Multi-Biomarker Disease Activity Score For Rheumatoid Arthritis Predicts Radiographic Damage In The BeSt Study. I.M. Markusse, L. Dirven, M. van den Broek, K.H. Han, M.F. van Lieshout, N. Riyazi 4, R.J. Bolce 5, E.H. Sasso 5, P.J.S.M. Kerstens 6, W.F. Lems 7, T.W.J. Huizinga and C.F. Allaart, Leiden University Medical Center, Leiden, Netherlands, Maasstad Hospital, Rotterdam, Netherlands, Spaarne Hospital, Hoofddorp, Netherlands, 4 Haga Hospital, The Hague, Netherlands, 5 Crescendo Bioscience Inc., South San Francisco, CA, 6 Jan van Breemen Research Institute Reade, Amsterdam, Netherlands, 7 VU University Medical Center, Amsterdam, Netherlands 48. Initial Combination Therapy In Early Rheumatoid Arthritis: Which Patients Benefit? I.M. Markusse, K.H. Han, A.J. Peeters, H.K Ronday 4, P.J.S.M. Kerstens 5, T.W.J. Huizinga, W.F. Lems 6 and C.F. Allaart, Leiden University Medical Center, Leiden, Netherlands, Maasstad Hospital, Rotterdam, Netherlands, Reinier de Graaf Gasthuis, Delft, Netherlands, 4 Haga Hospital, The Hague, Netherlands, 5 Jan van Breemen Research Institute Reade, Amsterdam, Netherlands, 6 VU University Medical Center, Amsterdam, Netherlands 49. High Rate Of Improvement In Serum Matrix Metalloproteinase- Levels At 4 Weeks Predict Remission At 5 Weeks In RA Patients With Adalimumab Therapy. Yosuke Hattori, Atsushi Kaneko, Daihei Kida, Hisato Ishikawa, Toshihisa Kojima and Naoki Ishiguro 4, Nagoya Medical Center, Nagoya, Japan, Nagoya Medical Center, nagano, Japan, Nagoya University Hospital, Nagoya, Japan, 4 Nagoya Univeristy Graduate School of Medicine, Nagoya, Japan 50. Factors Influencing Selection Of Biologic Therapy and Comparative Effectiveness In Patient Reported Outcomes Among Patients With Rheumatoid Arthritis. Iris Navarro- Millan, Lang Chen, Leslie R. Harrold, Lisa Herrinton, Liyan Liu and Jeffrey R. Curtis 4, University of Alabama at Birmingham, Birmingham, AL, University of Massachusetts Medical School, Worcester, MA, Kaiser Permanente, Oakland, CA, 4 University of Alabama at Birmingham, Division of Clinical Immunology and Rheumatology, Birmingham, AL 5. A Comparison Of The Clinical Effectiveness Of Treatment Strategies For Active RA Patients : Using a Prospective Biologic Registry (BIOPSY) and an RA Specific Cohort (KORONA). Yoon-Kyoung Sung, Soo-Kyung Cho, Chan- Bum Choi, Soyoung Won, So-Young Bang, Hoon-Suk Cha 4, Jung-Yoon Choe 5, Won Tae Chung 6, Seung-Jae Hong 7, Jae-Bum Jun, Hyoun Ah Kim 8, Jinseok Kim 9, Seong-Kyu Kim 5, Tae-Hwan Kim, Hye-Soon Lee, Jaejoon Lee 4, Jisoo Lee 0, Shin-Seok Lee, Sung Won Lee 6, Yeon-Ah Lee 7, Seong-Su Nah, Chang-Hee Suh 8, Dae-Hyun Yoo, Bo Young Yoon and Sang-Cheol Bae, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, Clinical Research Center for Rheumatoid Arthritis (CRCRA), Seoul, South Korea, Hanyang University Guri Hospital, Guri, South Korea, 4 Sungkyunkwan University School of Medicine, Samsung Medical Center, Seoul, South Korea, 5 Catholic University of Daegu School of Medicine, Daegu, South Korea, 6 Dong-A University Hospital, Busan, South Korea, 7 Kyung Hee University, Seoul, South Korea, 8 Ajou

253 ACR POSTER SESSION B University Hospital, Suwon, South Korea, 9 Jeju National University Hospital, Jeju, Korea, South Korea, 0 Ewha Womans University Mokdong Hospital, Seoul, South Korea, Chonnam National University Medical School and Hospital, Gwangju, South Korea, Soonchunhyang University Cheonan Hospital, Cheonan, South Korea, Inje University Ilsan Paik Hospital, Goyang, South Korea 5. What Factors Lead To Achieve and Sustain Remission In Rheumatoid Arthritis Patients With Moderate To High Disease Activity? Soo-Kyung Cho, Yoon-Kyoung Sung, Jeeseon Shim, Chan-Bum Choi, Jung-Yoon Choe, Won Tae Chung 4, Seung-Jae Hong 5, Jae-Bum Jun, Tae-Hwan Kim, Tae-Jong Kim 6, Eun-Mi Koh 7, Jisoo Lee 8, Shin-Seok Lee 6, Sung Won Lee 4, Dae-Hyun Yoo and Sang-Cheol Bae, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, Clinical Research Center for Rheumatoid Arthritis (CRCRA), Seoul, South Korea, Catholic University of Daegu School of Medicine, Daegu, South Korea, 4 Dong-A University Hospital, Busan, South Korea, 5 Kyung Hee University, Seoul, South Korea, 6 Chonnam National University Medical School and Hospital, Gwangju, South Korea, 7 Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea, 8 Ewha Womans University Mokdong Hospital, Seoul, South Korea 5. Remission After Twelve Month Of Treatment In The Prague Early Rheumatoid Arhritis Cohort. Herman F. Mann, Olga Ruzickova, Olga Sleglova, Marketa Fojtikova, Dana Tegzova 4, Sarka Forejtova and Ladislav Senolt 4, Institute of Rheumatology, Prague, Prague, Czech Republic, Institute of Rheumatology and st faculty of medicine, Charles University, Prague, Czech Republic, Institute and Clinic of Rheumatology, Charles University, Prague, Czech Republic, 4 Institute of Rheumatology, Prague, Czech Republic Successful Self-Administration Of Methotrexate In Rheumatoid Arthritis Patients Using a Prefilled Autoinjector Pen. Jaime Pachon, Alan Kivitz, Kay-Uwe Heuer and Uwe Pichlmeier, Miami Research Associates, South Miami, FL, Altoona Center for Clinical Research, Duncansville, PA, medac GmbH, Wedel, Germany 55. Subcutaneous Administration Of Methotrexate With a Prefilled Autoinjector Pen Results In a Higher Relative Bioavailability Compared To Oral Administration Of Methotrexate. Uwe Pichlmeier and Kay-Uwe Heuer, medac GmbH, Wedel, Germany 56. Disease Activity Of Rheumatoid Arthritis Is Influenced By Seasonal Change, As Analyzed Based On a Nationwide Japanese Cohort Database. Tetsuji Sawada, Hiroaki Mori, Kota Shimada, Haeru Hayashi, Koichiro Tahara, Jinju Nishino 4 and Shigeto Tohma 5, Tokyo Medical University, Tokyo, Japan, Tokyo Meidical University, Tokyo, Japan, Tokyo Metropolitan Tama Medical Center, Tokyo, Japan, 4 Nishino Clinic, Orthopedics and Rheumatology, Tokyo, Japan, 5 Sagamihara Hospital, National Hospital Organization, Sagamihara, Japan 57. Coping Style Is An Independent Predictor For Disease Activity At Three Months In Early Arthritis Patients Initiating Therapy With Disease Modifying Anti-Rheumatic Drugs. T. Martijn Kuijper, Hong Xiong, A.E.A.M. Weel, A.H. Gerards, Jendé van Zeben 4, P.H.P. de Jong 5, Ilja Tchetverikov 6, P.B.J. de Sonnaville 7, M.V. Krugten 8, B.A. Grillet 9, Jolanda J. Luime and Johanna M.W. Hazes, Erasmus Medical Center, Rotterdam, Netherlands, Maasstad Hospital, Rotterdam, Netherlands, Vlietland Hospital, Schiedam, Netherlands, 4 Sint Franciscus Gasthuis, Rotterdam, Netherlands, 5 Erasmus University Medical Center, Rotterdam, Netherlands, 6 Albert Schweitzer Ziekenhuis, Dordrecht, Netherlands, 7 Admiraal de Ruyter Ziekenhuis, Goes, Netherlands, 8 Admiraal de Ruyter Hospital, Vlissingen, Netherlands, 9 Zorgsaam Hospital, Terneuzen, Netherlands 58. No Differences In Patient-Reported Outcomes By Methotrexate Dose Among Early Rheumatoid Arthritis Patients Treated Concomitantly With Adalimumab: Results From The Concerto Trial. Roy M Fleischmann, Alan Kivitz, Ronald F van Vollenhoven, James W. Shaw 4, Stefan Florentinus 5, Piyalal M. Karunaratne 4, Hartmut Kupper 6, Maxime Dougados 7 and Gerd R Burmester 8, University of Texas Southwestern Medical Center, Dallas, TX, Altoona Center for Clinical Research, Duncansville, PA, Karolinska Institutet, Stockholm, Sweden, 4 AbbVie Inc., North Chicago, IL, 5 AbbVie, Rungis, France, 6 AbbVie Deutschland GmBH & Co KG, Ludwigshafen, Germany, 7 René Descartes University, Paris, France, 8 Charité-Universitätsmedizin Berlin, Free University and Humboldt University of Berlin, Berlin, Germany 59. Does Rheumatoid Arthritis Disease Activity Correlate With Weather Conditions? Eimear Savage, David McCormick, Stephen McDonald, Michael Stevenson, Owen Moore and Andrew Cairns 4, Belfast Hospitals Trust, Musgrave Park Hospital, Belfast BT9 7JB, Northern Ireland, Queens University, Belfast. School of Medicine, Dentistry and Biomedical Sciences., Belfast BT 6BJ, Northern Ireland, St. Vincent s Hospital, Melbourne, Australia, 4 Belfast Hospitals Trust, Musgrave Park Hospital, Belfast, United Kingdom 60. Evaluation Of Biomarkers Involved In Periondontal Disease Including Porphyromonas Gingivalis Antibodies To Predict Response To Infliximab In Rheumatoid Arthritis Patients. Mélanie Rinaudo-Gaujous, Pierre Miossec, Vincent Blasco-Baque, Philippe Gaudin 4, Christian Genin, Thierry Thomas 5, Stéphane Paul and Hubert Marotte 6, Laboratory of Immunology and immunomonitoring, CIC CIE Inserm Vaccinology, GIMAP EA064, Hôpital Nord, Saint-Etienne, France, Immunogenomics and inflammation research unit, Lyon, France, Institute of Cardiovascular and Metabolic Diseases, CHU Rangueil, Toulouse, France, 4 CHU Hôpital Sud, Grenoble Teaching Hospital, Echirolles, France, 5 INSERM U059 and University Hospital, Saint-Etienne, France, 6 LBTO INSERM U059 University Jean Monnet, Saint-Etienne, France 0 Program Book 5

254 ACR POSTER SESSION B 6. Stringent Therapies Improve Clinical, Radiographic and Magnetic Resonance Imaging Outcome In Early-Stage Rheumatoid Arthritis Patients From Japanese Population: Longitudinal Study From Nagasaki Early Arthritis Cohort. Mami Tamai, Yoshikazu Nakashima, Junko Kita, Ayuko Takatani, Ayako Nishino, Takahisa Suzuki, Yoshiro Horai, Akitomo Okada, Shin-ya Kawashiri, Naoki Iwamoto, Kunihiro Ichinose, Kazuhiko Arima, Hideki Nakamura, Tomoki Origuchi, Masataka Uetani, Katsumi Eguchi 4 and Atsushi Kawakami, Center for Health & Community Medicine, Nagasaki University, Nagasaki, Japan, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, Japanese Red Cross Nagasaki Genbaku Hospital, Nagasaki, Japan, 4 Sasebo City General Hospital, Sasebo, Nagasaki, Japan 6. Isymind Significantly Reduces MTX-Induced Nausea In a Pilot Trial. Eva Ostermeier, Hans Ulrich Koetter, Hans- Peter Tony and Ruth Pfister, University of Würzburg, Würzburg, Germany, isymind Institut, Giessen, Germany, University Hospital Würzburg, Würzburg, Germany 6. Active Tuberculosis Risk With Tumor Necrosis Factor Inhibitors After Treating Latent Tuberculosis -a 7-Year Retrospective Observational Study. Minkyung Kwon, Mindong Sung, Yong-Jin Kwon, Young Goo Song, Sang-Won Lee, Min-Chan Park, Yong-Beom Park, Soo-Kon Lee and Jason Jungsik Song, Yonsei University College of Medicine, Seoul, South Korea 64. Detection of Latent Tuberculosis Infection in Rheumatologic Diseases Before Anti-TNFα Therapy: Tuberculin Skin Test Versus IFN-γ Assay. Suleyman Ozbek, Ismail Hanta, Sedat Kuleci, Gulsah Seydaoglu and Ezgi Ozyilmaz, Cukurova University Faculty of Medicine, Adana, Turkey, Cukurova University, Adana, Turkey 65. Incidence Of Hepatitis B Virus Reactivation In Patients With Rheumatoid Arthritis During Treatment With Biologics. Jun Nakamura, Takao Nagashima, Katsuya Nagatani, Taku Yoshio, Masahiro Iwamoto and Seiji Minota 4, Jichi Medical University, Tochigi, Japan, Jichi Medical University, School of Medicine, Shimotsuke-shi, Tochigi-ken, Japan, Jichi Medical University, Shimotsuke, Tochigi, Japan, 4 The Safety Evaluation Committee of Actemra for JIA, Tokyo, Japan 66. Abdominal Adiposity and Body Composition In Rheumatoid Arthritis: Relation With Disease Characteristics In A Case-Control Study. Ivan Ferraz- Amaro, Esmeralda Delgado-Frías, Vanesa Hernandez- Hernandez, Jose Ramon Muñiz, Antonieta Gonzalez-Diaz 4, Angeles Gomez Rodriguez-Bethencourt 4 and Federico Diaz- Gonzalez 5, Hospital Universitario de Canarias, La Laguna, Spain, Rheumatology Service, Santa Cruz de Tenerife, Spain, Resonancia Magnetica IMETISA, Santa Cruz de Tenerife, Spain, 4 Servicio de Medicina Nuclear, Santa Cruz de Tenerife, Spain, 5 University of La Laguna, Hospital Universitario de Canarias, La Laguna, Spain 67. Performance Of a Two-Step Latent Tuberculosis Screening Algorithm In Patients With Rheumatoid Arthritis, Psoriatic Arthritis Or Ankylosing Spondylitis Prior To Treatment With Tumor Necrosis Alpha Inhibitors: Prospective Observational Data From The Biorx.Si Registry. ŽIga Rotar and Matija Tomsic, University Medical Centre Ljubljana, 000 Ljubljana, Slovenia, University Medical Centre Ljubjana, Ljubljana, Slovenia 68. The Effect Of Vitamin D On Early Rheumatoid Arthritis: A Retrospective Cohort Analysis. Faye A H Cooles, Arthur G Pratt, Wan-Fai Ng, Terry J Aspray and John D Isaacs, Newcastle University, Newcastle upon Tyne, United Kingdom, The Freeman Hospital, Newcastle upon Tyne, United Kingdom, National Institute for Health Research, Newcastle Biomedical Research Centre, Newcastle Hospitals Foundation Trust and Newcastle University, Newcastle Upon Tyne, United Kingdom 69. Evaluation Of Porphyromona Gingivalis Serology In Rheumatoid Arthritis and Non-Rheumatoid Inflammatory Disease. Mélanie Rinaudo-Gaujous, Adeline Moreau, Vincent Blasco-Baque, Xavier Roblin, Christian Genin, Thierry Thomas 4, Stéphane Paul and Hubert Marotte 5, Laboratory of Immunology and immunomonitoring, CIC CIE Inserm Vaccinology, GIMAP EA064, Hôpital Nord, Saint-Etienne, France, Institute of Cardiovascular and Metabolic Diseases, CHU Rangueil, Toulouse, France, Department of gastroenterology, Hôpital Nord, Saint- Etienne, France, 4 INSERM U059 and University Hospital, Saint-Etienne, France, 5 INSERM U059 and University Hospital, Hôpital Nord, Saint-Etienne, France 70. Prednisone Is a Risk Factor For Pneumocystis Jirovecii Pneumonia In Patients With Rheumatic Diseases: A Case-Control Study With 6 Cases. Wieneke van den Hombergh, Annelies van Ede, J. Fransen, Femke BG lamers-karnebeek, Saskia Kuipers and Matthijs Janssen 4, UMC st. Radboud, Nijmegen, Netherlands, UMC st Radboud, Nijmegen, Netherlands, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, 4 Rijnstate Hospital, Arnhem, Netherlands 7. Tuberculosis Infection In Patients With Tumor Necrosis Factor α Antagonists In South Korea;retrospective Analysis Using By National Health Insurance Review and Assessment Service. Jong Wook Beom, Eun-Jung Park, Jinseok Kim, Se Chang Park and Gi Hyeon Seo 4, Medicine, Jeju National University Hospital, Jeju, South Korea, Jeju National University Hospital, Jeju, South Korea, Seoul National University, Seoul, South Korea, 4 Health Insurance Review and Assessment Service, Seoul, South Korea 7. Do We Really Identify Latent Tuberculosis? Comparison Of The Performance Of Tuberculin Skin Test and Interferon Gamma Release Assay Before Biologics: A Systematic Review and Meta-Analysis. Marie Locci, Françoise Barchechath-Flaisler, Jean-Louis Leroux and Cécile Gaujoux-Viala, Nîmes University Hospital, Rheumatology Department, Nîmes, France, EA 45, Montpellier I University, Nîmes University Hospital, Rheumatology Department, Nîmes, France 5 0 Program Book

255 ACR POSTER SESSION B Rheumatoid Arthritis - Human Etiology and Pathogenesis 7. Connective Tissue Growth Factor Promotes Angiogenesis Through Increased Notch- Signaling in Rheumatoid Arthritis. Kazuhisa Nozawa, Maki Fujishiro, Ayako Yamaguchi, Mikiko Kawasaki, Kazuhisa Iwabuchi, Mitsuaki Yanagida, Keigo Ikeda, Shinji Morimoto 4, Yoshinari Takasaki 5 and Iwao Sekigawa, Juntendo University School of Medicine, Tokyo, Japan, Juntendo University Graduate School of Medicine, Chiba, Japan, Juntendo University Urayasu Hospital, Tomioka, Urayasu, Chiba, Japan, 4 Juntendo University Urayasu Hospital, Tokyo, Japan, 5 Division of Rheumatology, Department of Internal Medicine, Juntendo University, Tokyo, Japan 74. NRD Is a New Suppressor of Rheumatoid Arthritis Fibroblast-Like Synoviocyte Invasion. Teresina Laragione and Percio Gulko, Hosftra North Shore-LIJ School of Medicine, Manhasset, NY 75. Synergistic Enhancement Of Aggregated IgG-Induced Tumor Necrosis Factor α In Human Synovial Mast Cells By Interleukin. Hyunho Lee, Jun-ichi Kashiwakura, Masahiko Yanagisawa, Yuki Okamura, Takao Ishii, Masayuki Seki, Shu Saito, Yasuaki Tokuhashi, Chisei Ra and Yoshimichi Okayama, Nihon University School of Medicine, Tokyo, Japan, RIKEN Center for Integrateive Medical Sciences, Kanagawa, Japan 76. Low Vitamin D Level Is Not Associated With Increased Incidence Of Rheumatoid Arthritis. Jonida Cote, Androniki Bili, H. Lester Kirchner and Xiaoqin Tang, Geisinger Medical Center, Danville, PA, Geisinger Health System, Danville, PA, Geisinger Center for Health Research, Danville, PA 77. Decoy Receptor Regulates the Expression of Tryptophan Hydroxylase TPH in Rheumatoid Synovial Fibroblasts. Toshihisa Maeda, Yasushi Miura, Koji Fukuda, Shinya Hayashi and Masahiro Kurosaka, Kobe University Graduate School of Medicine, Kobe, Japan, Kobe University, Kobe, Japan 78. Associations Of Periodontitis (PD) With Established Seropositive Rheumatoid Arthritis are Independent of Smoking and Other Risk Factors. Ted R. Mikuls, Jeffrey Payne, Fang Yu, Geoffrey M. Thiele, Richard J. Reynolds 4, Grant W. Cannon 5, Jeffrey Markt 6, David McGowan 7, Gail S. Kerr 8, Robert Redman 9, Andreas M. Reimold 0, Garth Griffiths 0, Mark Beatty, Shawneen Gonzalez, Debra Bergman 6, Bartlett C. Hamilton III, Alan R. Erickson and James R. O Dell 6, Omaha VA and University of Nebraska Medical Center, Omaha, NE, University of Nebraska Medical Center, Lincoln, NE, Univ of Nebraska Med Ctr, Omaha, NE, 4 University of Alabama at Birmingham, Birmingham, AL, 5 Salt Lake City VA and University of Utah, Salt Lake City, UT, 6 University of Nebraska Medical Center, Omaha, NE, 7 George E. Wahlen VA Medical Center, Salt Lake City, UT, 8 Washington DC VAMC, Georgetown and Howard University, Washington, DC, 9 Washington DC VA, Georgetown and Howard University, Washington, DC, 0 Dallas VA and University of Texas Southwestern, Dallas, TX, University of Nebraska Medical Center and Omaha VA Medical Center, Omaha, NE, Omaha VA and University of Nebraska Medical Center, LaVista, NE 79. Differential Effects Of TNF Inhibitors, Anti-IL-6 Receptor Antibody and CTLA4-Ig On Human Monocytes. Toshihiro Tono, Yoshiyuki Arinuma, Tatsuo Nagai, Sumiaki Tanaka and Shunsei Hirohata, Kitasato University school of medicine, sagamihara, Japan, Kitasato University School of Medicine, Sagamihara, Japan 80. Histone Modifications In The Interluekin-6 Gene Promoter Region Of Rheumatoid Arthritis Synovial Fibroblasts. Takuma Tsuzuki Wada, Yasuto Araki, Kazuhiro Yokota, Fumihiko Miyoshi, Kojiro Sato and Toshihide Mimura, Saitama Medical University, Saitama, Japan, Research Center for Genomic Medicine, Saitama Medical University, Saitama, Japan 8. The ZCHC rs55694 Polymorphism Is Associated With Increased Carotid Intima-Media Thickness In Patients With Rheumatoid Arthritis. Raquel lopez Mejias, Fernanda Genre, Mercedes García-Bermúdez, Alfonso Corrales 4, Carlos González-Juanatey 5, J. Llorca 6, Encarnación Amigo 7, Jose A. Miranda-Filloy 8, Javier Rueda-Gotor, Ricardo Blanco, Santos Castañeda 9, Javier Martin 0 and Miguel A. Gonzalez-Gay, Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, Rheumatology Division, IFIMAV, Santander, Spain., Santander, Spain, Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, Rheumatology Division, IFIMAV, Santander, Spain, Instituto de Parasitologia y Biomedicina López-Neyra, IPBLN-CSIC, Granada, Spain, 4 Hospital Universitario Marqués de Valdecilla. IFIMAV, Santander, Spain, 5 Cardiology Division, Hospital Lucus Augusti, Lugo, Spain, 6 Department of Epidemiology and Computational Biology, School of Medicine, University of Cantabria, and CIBER Epidemiología y Salud Pública (CIBERESP), Santander, Spain, 7 Division of Rheumatology, Hospital Lucus Augusti, Lugo, Spain, 8 Hospital Xeral-Calde, Lugo, Spain, 9 Hospital Universitario de La Princesa, IIS Princesa, Madrid, Spain, 0 Instituto de Parasitologia y Biomedicina Lopez-Neyra (IPBLN-CSIC), Granada, Spain 8. The q. Genomic Region - rs Is Associated With Cardiovascular Disease In Patients With Rheumatoid Arthritis. Raquel lopez Mejias, Fernanda Genre, Mercedes García-Bermúdez, Santos Castañeda 4, Carlos González-Juanatey 5, J. Llorca 6, Encarnación Amigo 7, Alfonso Corrales 8, Jose A. Miranda-Filloy 9, Javier Rueda-Gotor, Carmen Gomez vaquero 0, Luis Rodriguez Rodriguez, Benjamin Fernandez Gutierrez, Alejandro Balsa, Dora Pascual-Salcedo, Francisco Javier López-Longo, Patricia Carreira 4, Ricardo Blanco, Isidoro González-Alvaro 4, Javier Martin 5 and Miguel A. Gonzalez-Gay, Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, Rheumatology Division, IFIMAV, Santander, Spain., Santander, Spain, Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, Rheumatology Division, IFIMAV, Santander, Spain, Instituto de Parasitologia y Biomedicina López-Neyra, IPBLN-CSIC, Granada, Spain, 4 Hospital Universitario de La Princesa, IIS Princesa, Madrid, Spain, 5 Cardiology Division, Hospital Lucus Augusti, Lugo, Spain, 6 Department of Epidemiology and Computational Biology, School of Medicine, University of Cantabria, and CIBER Epidemiología y Salud Pública (CIBERESP), Santander, 0 Program Book 5

256 ACR POSTER SESSION B 54 Spain, 7 Division of Rheumatology, Hospital Lucus Augusti, Lugo, Spain, 8 Hospital Universitario Marqués de Valdecilla. IFIMAV, Santander, Spain, 9 Hospital Xeral-Calde, Lugo, Spain, 0 Department of Rheumatology, Hospital Universitario Bellvitge, Barcelona, Spain, Department of Rheumatology, Hospital Clínico San Carlos, Madrid, Spain, La Paz University Hospital, Rheumatology, Madrid, Spain, Hospital General Universitario Gregorio Marañón, Madrid, Spain, 4 Hospital Universitario de Octubre, Madrid, Spain, 5 Instituto de Parasitologia y Biomedicina Lopez- Neyra (IPBLN-CSIC), Granada, Spain 8. Validation Of Popliteal Lymph Node Phenotype and Bin Expansion As Biomarkers Of Rheumatoid Arthritis Knee Flare. Homaira Rahimi, Ronald Wood, Igor Kuzin, Wakenda Tyler, Gregory Dieudonne, Stephen Kates, Christopher T. Ritchlin and Edward M. Schwarz, University of Rochester, Rochester, NY, University of Rochester Medical Center, Rochester, NY Estimation Of The Effect Of Denosumab On Bone Loss From The Results Of The -Month Phase II Study In Patients With Rheumatoid Arthritis (RA) On Background Methotrexate (MTX). Yoshiya Tanaka, Tsutomu Takeuchi, Naoki Ishiguro, Hisashi Yamanaka 4, Toshiyuki Yoneda 5, Harry K. Genant 6 and Désiréé van der Heijde 7, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, Keio University, Tokyo, Japan, Nagoya Univeristy Graduate School of Medicine, Nagoya, Japan, 4 Tokyo Women s Medical University, Tokyo, Japan, 5 Indiana University School of Medicine, Indianapolis, IN, 6 University of California, San Francisco, CCBR-Synarc, Newark, Tiburon, CA, 7 Leiden University Medical Center, Leiden, Netherlands 85. A Study Of Natural Killer Cell Subfractions In Abatacept Therapy For Rheumatoid Arthritis. Masao Sato, Masao Takemura, Ryuki Shinohe, Yasuko Yamamoto and Kuniaki Saito, Gifu University, Gifu, Japan, Kyoto University, Kyoto, Japan 86. Intracellular Concentration Of Methotrexate Is Influenced By Polymorphisms Of Gamma-Glutamyl Hydrolase Gene In Japanese Patients With Rheumatoid Arthritis. Tatsuhiro Yamamoto, Mai Kawazoe, Emiko Shindo, Natsuki Fujio, Kotaro Shikano, Kanako Kitahara, Sei Muraoka, Makoto Kaburaki, Nahoko Tanaka, Kaichi Kaneko, Natsuko Kusunoki, Yoshie Kusunoki, Kenji Takagi, Tomoko Hasunuma, Hirahito Endo and Shinichi Kawai, School of Medicine, Faculty of Medicine, Toho University, Tokyo, Japan 87. Reversing Vascular Dysfunction In Rheumatoid Arthritis: Peroxisome Proliferator-Activated Receptor Gamma Agonist Therapy Improves Augmentation Index But Not Endothelial Function. Michelle J. Ormseth, Aihua Bian, Annette M. Oeser, Andrew Cunningham, Ayumi Shintani, S. Bobo Tanner and C. Michael Stein, Vanderbilt Medical Center, Nashville, TN 88. Multiplex Cytokine Analyses In Patients With Rheumatoid Arthritis Require Use Of Agents Blocking Heterophilic Antibody Activity. Peter Olsson, Elke Theander, Ulf Bergström, Stefan Jovinge, Lennart Jacobsson and Carl Turesson, Lund University, Malmö, Sweden, Lund University, Lund, Sweden 0 Program Book 89. Serum 4--η Precedes and Independently Predicts The Development Of RA. Dirkjan van Schaardenburg, Reetinder Dhaliwal, Walter P. Maksymowych and Anthony Marotta, Jan van Breemen Research Institute Reade, Amsterdam, Netherlands, University of Alberta, Edmonton, AB, Augurex Life Sciences Corp, North Vancouver, BC 90. Chaperonin Protein 4--n (eta) In Rheumatoid Arthritis and Arthritogenic Viral Infections. Stanley J. Naides, Olga S Zhukov, Rania W Abolhosn and Joanna M Popov, Quest Diagnostics Nichols Institute, San Juan Capistrano, CA 9. Transporters As Drug Gateway Into The Cell For Specific Targeting Of Tyrosine Kinase Signaling Pathway In Rheumatoid Arthritis. Saliha Harrach, Christian Schmidt- Lauber, Bayram Edemir, Eberhard Schlatter, Thomas Pap, Giuliano Ciarimboli and Jessica Bertrand, University Hospital Münster, Münster, Germany, University Hospital Münster, Muenster, Germany 9. The Expression Of Proto-Oncogene Survivin Splicing Variant B In Synovial Tissues and Blood From Patients With Rheumatoid Arthritis. Sho Mokuda, Tatsuhiko Miyazaki, Junya Masumoto, Masamoto Kanno and Kiyoshi Takasugi 4, Center for Rheumatic Diseases, Dohgo Spa Hospital, Matsuyama, Japan, Ehime University Graduate School of Medicine, Toon, Japan, Graduate School of Biomedical Sciences, Hiroshima University, Hirosima, Japan, 4 Dohgo Spa Hospital, Matsuyama, Japan 9. Survivin But Not Fms-Like Tyrosine Kinase Ligand Is Up-Regulated Before Onset Of Rheumatoid Arthritis. Mikael Brink, Maria Bokarewa, Malin Erlandsson and Solbritt Rantapää Dahlqvist, Umeå University, Umea, Sweden, Göteborgs University, Göteborg, Sweden, Umeå University Hospital, Umeå, Sweden 94. Self Reported Dental Symptoms Do Not Predict Periodontal Status In Patients With Rheumatoid Arthritis. Gurpal Buttar, Anastasia Zelekis-Cholakis, Robert Schroth, Hani S. El-Gabalawy, Christine A. Peschken and Carol A. Hitchon, University of Manitoba, Winnipeg, MB 95. CXCL Is Elevated In Early and In Established Seropositive Rheumatoid Arthritis and Correlates With Rheumatoid Factor Levels. Jonathan D. Jones, B. JoNell Hamilton, Greg Challener, Artur Fernandes, Pierre Cossette, Patrick Liang, Ariel Masetto, HA Menard, Nathalie Carrier, Gilles Boire and William Rigby, Geisel School of Medicine at Dartmouth, Lebanon, NH, Centre Hospitalier Universitaire de Sherbrooke, Université de Sherbrooke, Sherbrooke, QC, McGill University, Montréal, QC 96. Survivin positivity Increases Risk For RA and Has a Strong Additive Effect On The Shared Epitope Alleles and Antibodies To Citrullinated Peptides In Patients Of The Malaysian Epidemiological Investigation Of Rheumatoid Arthritis (MyEIRA) Study Group. Chun Lai Too, Shahnaz Murad, Malin Erlandsson, Heselynn Hussein 4, Wahinuddin Sulaiman 5, Jasbir Singh Dhaliwal and Maria Bokarewa 6, Institute for Medical Research, Allergy and Immunology Research Center, Jalan Pahang, Kuala Lumpur, Malaysia, Institute for Medical Research, Jalan Pahang, Kuala Lumpur, Malaysia, Göteborgs University, Göteborg, Sweden, 4 Putrajaya Hospital, Putrajaya, Malaysia, 5 Tengku Bainun Hospital, Ipoh, Perak, Malaysia, 6 University of Gothenburg, Gothenburg, Sweden

257 ACR POSTER SESSION B 97. Changes In MMP In Fibroblast-Like Synoviocytes Following Adipogenesis. Satoshi Yamasaki, Kazuhiko Kumagai, Kouji Endo, Takaki Nojima and Eiji Sugiyama, Hiroshima University Hospital, Hiroshima, Japan 98. Comparison Of Atherogenicity Of Plasma From Patients With Rheumatoid Arthritis and Psoriatic Arthritis. Beenish Hafiz, Iryna Voloshyna, Michael J. Littlefield, Steven E. Carsons, Elise Belilos, Kristina Belostocki, Lois A. Bonetti, Gary C. Rosenblum and Allison B. Reiss, Winthrop University Hospital, Mineola, NY 99. Citrullinated Proteoglycan (Aggrecan) Present In Human Cartilage Is Recognized By Serum Antibodies From Rheumatoid Arthritis Patients. Timea Ocsko, Beata Tryniszewska, Andras Vida, Janos Gal, Gyorgyi Soos, Zoltan Szekanecz, Tibor A. Rauch, Joshua Jacobs, Tibor T. Glant and Katalin Mikecz, Rush University Medical Center, Chicago, IL, Bacs-Kiskun County Hospital, Kecskemet, Hungary, University of Debrecen Medical and Health Sciences Center, Debrecen, Hungary 400. Dipeptidyl Peptidase IV (DPP-IV, CD6) Levels In Patients With Rheumatoid Arthritis Treated With Biologic Therapies and Correlation With The Activity Of The Disease. José M. Pego-Reigosa, Oscar Cordero, Tania López-González, Coral Mouriño-Rodríguez, Bruno Aspe 4, Juan Viñuela-Roldán 5, Rubén Varela-Calviño 6, Cristina Calviño 6, Marina Rodríguez-López 4, Íñigo Hernández- Rodríguez 4 and Víctor del Campo-Pérez 4, Instituto de Investigación Biomédica de Vigo (IBIV), Vigo, Spain, Universidade de Santiago de Compostela, Santiago de Compostela, Spain, Meixoeiro Hospital, Vigo, Spain, 4 University Hospital Complex of Vigo, Vigo, Spain, 5 University Hospital Complex of Santiago, Santiago de Compostela, Spain, 6 Faculty of Pharmacy, University of Santiago de Compostela, Santiago de Compostela, Spain 40. Reduced Oral Glucose Tolerance Is Associated With a Lower Risk Of Rheumatoid Arthritis. Carl Turesson, Ulf Bergström, Mitra Pikwer, Jan-Åke Nilsson and Lennart Jacobsson, Lund University, Malmö, Sweden 40. Regulatory B0 CELLS ARE Decreased In Patients With Rheumatoid Arthritis and Inversely Correlated With Disease Activity. Claire I. Daien, Sarah Gailhac, Thibault Mura, Bernard Combe, Michael Hahne 4 and Jacques Morel, Lapeyronie Hospital, Montpellier, France, CNRS, Montpellier, France, Hopital Gui De Chauliac, Montpellier, France, 4 IGMM, CNRS UMR555, Montpellier, Montpellier, France 40. Protein Tyrosine Phosphatase Non-Receptor Type (PTPN) Is Expressed In a TNF-Dependent Manner In RA Synovial Tissues. Borbala Aradi, Masaru Kato, Mária Filková, Stephanie Kasper, Kerstin Klein, Michael Bader, Michael Scharl, Beat A Michel 4, Renate E Gay, Edit I Buzas 5, Steffen Gay and Astrid Jüngel, Center of Experimental Rheumatology, University Hospital Zurich and Zurich Center of Integrative Human Physiology (ZIHP), Zurich, Switzerland, Institute of Rheumatology and Department of Rheumatology of the First Faculty of Medicine, Charles University in Prague, Czech Republic, Prague, Czech Republic, Division of Gastroenterology and Hepatology, University Hospital Zürich and Zürich Center for Integrative Human Physiology, Zurich, Switzerland, 4 Rheumatology, University Hospital Zurich, Switzerland, Zurich, Switzerland, 5 Department of Genetics, Cell- and Immunobiology, Budapest, Hungary 404. Effects Of Smoking On Joint Physiology In Men and Mice. Caroline Ospelt, Giovanni Camici, Anna Engler, Christoph Kolling, Renate E. Gay, Beat A. Michel 4 and Steffen Gay, Center of Experimental Rheumatology, University Hospital Zurich and Zurich Center of Integrative Human Physiology (ZIHP), Zurich, Switzerland, Institute of Physiology, University of Zurich, Zurich, Switzerland, Schultess Clinic, Zurich, Switzerland, 4 Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland 405. Expression Of High Mobility Group Protein B and Its Receptors In Heart Of Patients With Coronary Artery Disease With and Without Inflammatory Rheumatic Disease: A Biopsy Study. Mei Zong, Ivana Hollan, Huiyuan Xiao, Cecilia Grundtman 4, Eva Lindroos 5, Helena E. Harris 6, Knut MIkkelsen 7, Stein E. Rynning 7, Sven M. Almdahl 8 and Ingrid E. Lundberg, Rheumatology Unit, Department of Medicine, Karolinska University Hospital in Solna, Karolinska Institutet, Stockholm, Sweden, Lillehammer Hospital for Rheumatic Diseases, Lillehammer, Norway, University of Oxford, Oxford, United Kingdom, 4 Innsbruck Medical University, Innsbruck, Austria, 5 Rheumatology Unit, Karolinska University Hospital in Solna, Karolinska Institutet, Stockholm, Sweden., Stockholm, Sweden, 6 Karolinska University Hospital, Solna, Karolinska Institutet, Stockholm, Sweden, 7 Feiring Heart Clinic, Feiring, Norway, 8 University Hospital of North Norway, Tromsø, Norway 406. The Scaffold Protein p6 Is Involved In NF-κB Signaling, Caspase- Dependent and -Independent Cell Death and Autophagy In Rheumatoid Arthritis Synovial Fibroblasts. Masaru Kato, Caroline Ospelt, Christoph Kolling, Beat A. Michel, Renate E. Gay 4, Steffen Gay 4 and Kerstin Klein, University Hospital Zurich, Zurich, Switzerland, Schultess Clinic, Zurich, Switzerland, Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland, 4 Center of Experimental Rheumatology, University Hospital Zurich and Zurich Center of Integrative Human Physiology (ZIHP), Zurich, Switzerland 407. High Serum Cholesterol Predicts Rheumatoid Arthritis In Women. Carl Turesson, Ulf Bergström, Mitra Pikwer, Jan-Åke Nilsson and Lennart Jacobsson, Lund University, Malmö, Sweden 408. High Body Mass Index Is Associated With a Reduced Long Term Risk Of Rheumatoid Arthritis In Men. Carl Turesson, Ulf Bergström, Mitra Pikwer, Jan-Åke Nilsson and Lennart Jacobsson, Lund University, Malmö, Sweden 0 Program Book 55

258 ACR POSTER SESSION B 56 Rheumatoid Arthritis Treatment - Small Molecules, Biologics and Gene Therapy II 409. Long-Term Impact of Delaying Combination Therapy With Adalimumab Plus Methotrexate By Years in Patients With Early Rheumatoid Arthritis: Final 0-Year Results of the Premier Trial. Edward C. Keystone, Ferdinand C. Breedveld, Désiréé van der Heijde, Robert Landewe, Stefan Florentinus 4, Udayasankar Arulmani 5, Shufang Liu 5, Hartmut Kupper 6 and Arthur Kavanaugh 7, University of Toronto, Toronto, ON, Leiden University Medical Center, Leiden, Netherlands, Academic Medical Center, Amsterdam, Netherlands, 4 AbbVie, Rungis, France, 5 AbbVie Inc., North Chicago, IL, 6 AbbVie Deutschland GmBH & Co KG, Ludwigshafen, Germany, 7 University of California San Diego, San Diego, CA 40. Tocilizumab Improves Left Ventricular Mass and Cardiac Output in Patients With Rheumatoid Arthritis. A Cohort Study. Kensuke Kume, Kanzo Amano, Susumu Yamada, Toshikatsu Kanazawa, Hiroshi Komori, Hiroyuki Ohta, Kuniki Amano 4 and Noriko Kuwaba 5, Hiroshima Clinic, Hiroshima, Japan, hiroshima clinic, hiroshima, Japan, hiroshima clinic, Hiroshima, Japan, 4 Sky Clinic, Hiroshima, Japan, 5 Sanki Clinical Link, Hiroshima, Japan 4. The Peroxisome Proliferator Activated Receptorgamma pioglitazone Decreases Cardiovascular Risk and Disease Activity In Patients With Rheumatoid arthritis. Wendy Marder, Shokoufeh Khalatbari, James D. Myles, Rita Hench, Susan Lustig, Srilakshmi Yalavarthi 4, Aishwarya Parameswaran, Robert Brook and Mariana J. Kaplan 4, University of Michigan, Ann Arbor, MI, University of Michigan at Ann Arbor, Ann Arbor, MI, Michigan Institute for Clinical and Health Research, University of Michigan, Ann Arbor, MI, 4 University of Michigan Rheumatology, Ann Arbor, MI 4. Use Of a Biologic Marker For An Integrated Pharmacodynamic and Clinical Analysis To Inform Further Clinical Development, Including Dose Selection For The Phase b Trial - Treat b - Of Tregalizumab In Rheumatoid Arthritis. Eva Dokoupilova, Slawomir Jeka, Jiri Vencovsky, Janusz Badurski 4, Klaas Prins 5, Vibeke Strand 6, Edward C. Keystone 7, Ronald F van Vollenhoven 8, Jurgen Wollenhaupt 9, Andrea Wartenberg-Demand 0, Gabriele Niemann 0, Ahmed Abufarag 0, Silke Aigner 0, Sibylle Kaiser 0, Faiza Rharbaoui 0, Niklas Czeloth 0, Ralf Wolter 0, Benjamin Dälken 0 and Thorsten Holzkämper 0, Medical Plus s.r.o, Uherske Hradiste, Czech Republic, Clinic of Rheumatology and Connective Tissue Diseases University Hospital No in Bydgoszcz Collegium Medicum UMK in Torun, Bydgoszcz, Poland, Institute of Rheumatology, Department of Clinical and Experimental Rheumatology, st Faculty of Medicine, Charles University, Prague, Czech Republic, 4 Center of Osteoporosis and Osteo-articular Diseases, Bialystock, Poland, 5 qpharmetra, Nijmegen, Netherlands, 6 Stanford University, Portola Valley, CA, 7 Mount Sinai Hospital, University of Toronto, Toronto, ON, 8 Karolinska Institutet, Stockholm, Sweden, 9 Schoen- Klinik Hamburg-Eilbek Teaching Hospital of the University of Hamburg, Hamburg, Germany, 0 Biotest AG, Dreieich, Germany 0 Program Book 4. Long-Term Safety and Efficacy Of Certolizumab Pegol In Combination With Methotrexate In The Treatment Of Rheumatoid Arthritis: 5-Year Results From a 5-Week Randomized Controlled Trial and Open-Label Extension Study. Edward Keystone, Robert Landewé, Ronald van Vollenhoven, Bernard Combe 4, Vibeke Strand 5, Philip J. Mease 6, Laura Shaughnessy 7, Brenda VanLunen 7 and Désirée van der Heijde 8, University of Toronto, Toronto, ON, Academic Medical Center Amsterdam & Atrium Medical Center, Heerlen, Netherlands, The Karolinska Institute, Stockholm, Sweden, 4 Montpellier University Hospital, Montpellier, France, 5 Stanford University, Palo Alto, CA, 6 Swedish Medical Center and University of Washington School of Medicine, Seattle, WA, 7 UCB Pharma, Raleigh, NC, 8 Leiden University Medical Center, Leiden, Netherlands 44. Final 5-Year Safety and Efficacy Results Of a Phase, Randomized Placebo-Controlled Trial Of Golimumab In Patients With Active Rheumatoid Arthritis Despite Prior Treatment With Methotrexate. Edward Keystone, Mark C. Genovese, Stephen Hall, Pedro Miranda 4, Sang-Cheol Bae 5, Chenglong Han 6, Timothy A. Gathany 6, Yiying Zhou 7, Stephen Xu 7 and Elizabeth C. Hsia 8, University of Toronto/ Mount Sinai Hospital, Toronto, ON, Stanford University, Palo Alto, CA, Cabrini Medical Centre, Melbourne, Australia, 4 Universidad de Chile and Centro de Estudios Reumatologicos, Santiago de Chile, Chile, 5 Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, 6 Janssen Global Services, LLC., Malvern, PA, 7 Janssen Research & Development, LLC., Spring House, PA, 8 Janssen Research & Development, LLC./U of Penn, Spring House/ Philadelphia, PA 45. Safety and Effectiveness Of Abatacept In 985 Japanese Patients With Rheumatoid Arthritis; Japan All-Cases Post-Marketing Surveillance. Takao Koike, Masayoshi Harigai, Naoki Ishiguro, Shigeko Inokuma 4, Junnosuke Ryu 5, Syuji Takei 6, Tsutomu Takeuchi 7, Y. Tanaka 8, Masahiko Watanabe 9 and Hisashi Yamanaka 0, NTT Sapporo Medical Center, Sapporo, Japan, Tokyo Medical and Dental University, Tokyo, Japan, Nagoya Univeristy Graduate School of Medicine, Nagoya, Japan, 4 Japanese Red Cross Medical Center, Tokyo, Japan, 5 Nihon University School of Medicine, Tokyo, Japan, 6 Kagoshima University, Kagoshima, Japan, 7 Keio University School of Medicine, Tokyo, Japan, 8 University of Occupational and Environmental Health, Kitakyushu, Japan, 9 Bristol-Myers K.K, Tokyo, Japan, 0 Tokyo Women s Medical University, Tokyo, Japan 46. Safety and Efficacy Of Subcutaneous Golimumab In Chinese Patients With Active Rheumatoid Arthritis Despite MTX Therapy: Results From a Randomized, Placebo-Controlled, Phase Trial. Zhanguo Li, Fengchun Zhang, Jonathan Kay, Kaiyin Fei 4, Chenglong Han 5, Yanli Zhuang 4, Zhong Wu 4 and Elizabeth C. Hsia 6, Peking University People s Hospital, Beijing, China, Peking Union Medical College Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Beijing, China, University of Massachusetts Medical School, Worcester, MA, 4 Janssen Research & Development, LLC., Spring House, PA, 5 Janssen Global Services, LLC., Malvern, PA, 6 Janssen Research & Development, LLC./U of Penn, Spring House/ Philadelphia, PA

259 ACR POSTER SESSION B 47. Lack Of Correlation Between Golimumab Exposure and Selected Safety Events Following Intravenous Or Subcutaneous Administration In An Integrated Analysis Of Phase Data Of Patients With Rheumatoid Arthritis, Psoriatic Arthritis, Or Ankylosing Spondylitis. Jocelyn H. Leu, Anna Beutler, Alan M. Mendelsohn, Sam Liao, Hugh M. Davis, Honghui Zhou and Zhenhua Xu, Janssen Research & Development, LLC., Spring House, PA, PharMax Research, Inc., Newport Beach, CA 48. Effects Of Smoking Status On Response To Treatment With Tofacitinib In Patients With Rheumatoid Arthritis. J. M. Kremer, J. D. Greenberg, C. Turesson, D. Gruben 4, C. A. Mebus 4, E. Bananis 5 and T. Robinson 5, Albany Medical College and The Center for Rheumatology, Albany, NY, NYU Hospital for Joint Diseases, New York, NY, Lund University, Malmö, Sweden, 4 Pfizer Inc, Groton, CT, 5 Pfizer Inc, Collegeville, PA 49. Mode Of Action Change Not Necessary After Failing The First Tumornecrosisfactor Inhibitor: Preliminary Results Of a Randomized Controlled Trial. Sofie H.M. Manders, Wietske Kievit, Herman L.M. Brus, Hein J. Bernelot Moens, Andre Hartkamp 4, Reinhard Bos 5, Elisabeth Brouwer 6, Henk Visser 7, Harald E. Vonkeman 8, Rene Westhovens 9, Mart A.F.J. van de Laar 8 and Piet LCM Van Riel, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, TweeSteden Ziekenhuis, Tilburg, Netherlands, Ziekenhuisgroep Twente, Almelo, Netherlands, 4 Jeroen Bosch Hospital, s-hertogenbosch, Netherlands, 5 Medical Center Leeuwarden, Leeuwarden, Netherlands, 6 University of Groningen, University Medical Center Groningen, Groningen, Netherlands, 7 Rijnstate, Arnhem, Netherlands, 8 Medisch Spectrum Twente & University of Twente, Enschede, Netherlands, 9 University Hospital KU Leuven, Leuven, Belgium 40. Induction Therapy With Adalimumab On Top Of An Aggressive Treat-To-Target Strategy With Methotrexate and Intraarticular Corticosteroid Reduces Radiographic Erosive Progression In Early Rheumatoid Arthritis, Even After Withdrawal Of Adalimumab. Results Of a -Year Trial (OPERA). Kim Hørslev-Petersen, Lykke Midtbøll Ørnbjerg, Merete L. Hetland, Peter Junker 4, Jan Pødenphant 5, Torkell Ellingsen 6, Palle Ahlqvist 7, Hanne M. Lindegaard 8, Asta Linauskas 9, Annette Schlemmer 0, Mette Y. Dam, Ib Hansen, Tine Lottenburger 7, Anette Jørgensen, Sophine B. Krintel, Johnny Raun, Christian G. Ammitzbøll, Julia Johansen, Mikkel Østergaard and Kristian Stengaard- Pedersen, University of Southern Denmark, Graasten, Denmark, Copenhagen University and Glostrup Hospital, Copenhagen, Denmark, DANBIO, Center for Rheumatology and Spine Diseases, Glostrup Univ Hospital, Glostrup, Denmark, 4 University of Southern Denmark, Odense, Denmark, 5 Copenhagen University at Gentofte, Hellerup, Denmark, 6 Silkeborg Regional Hospital, Silkeborg, Denmark, 7 University of Southern Denmark, Vejle, Denmark, 8 Odense University Hospital, Odense, Denmark, 9 Vendsyssel Hospital, Hjørring, Denmark, 0 Aalborg University Hospital, Aalborg, Denmark, Arhus University Hospital, Aarhus, Denmark, Viborg Hospital, Viborg, Denmark, Copenhagen University Hospital Glostrup, Copenhagen, Denmark 4. Treatment Responses and Their Predictors Of Abatacept In Biologic naïve Patients With Rheumatoid Arthritis; Data Form Abroad Study. Yutaka Kawahito, Takao Fujii, Akira Yokota, Hideo Hashimoto 4, Kiyoshi Matsui 5, Kenji Miki 6, Masayasu Kitano 5, Naoki Shinmyo 7, Aihiro Yamamoto, Koichiro Ohmura, Takanori Kuroiwa 8, Toshihiko Hidaka 9, Ichiro Yoshii 0, Hideko Nakahara, Takashi Fujimoto, Kosaku Murakami, Satoshi Morita 4, Masahiro Sekiguchi 5, Norihiro Nishimoto 5, Tsuneyo Mimori and Hajime Sano 5, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan, Graduate School of Medicine, Kyoto University, Kyoto, Japan, Yokota Clinic for Rheumatology, Osaka, Japan, 4 Rinku Hashimoto Rheumatology Orthopaedics, Osaka, Japan, 5 Hyogo College of Medicine, Nishinomiya-city, Japan, 6 Amagasaki Central Hospital, Amagasaki, Japan, 7 Kashiba Asahigaoka Hospital, Kashiba, Japan, 8 Yukioka Hospital, Osaka, Japan, 9 Zenjinkai Shimin-No-Mori-Hospital, Miyazaki, Japan, 0 Yoshii Hospital, Shimanto, Japan, NTT West Osaka Hospital, Osaka, Japan, Nara Medical University, Kashihara, Japan, Osaka Red Cross Hospital, Osaka, Japan, 4 Yokohama City University, Kanagawa, Japan, 5 Osaka Rheumatology Clinic, Osaka, Japan 4. Efficacy and Safety Of a Novel Disease-Modifying Antirheumatic Drug, Iguratimod, As Add-On Therapy For Patients With Rheumatoid Arthritis. Daisuke Kobayashi, Satoshi Ito, Akira Murasawa, Ichiei Narita and Kiyoshi Nakazono, Niigata Rheumatic Center, Shibata, Japan, Niigata Rheumatic Center, Niigata, Japan, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan 4. The Influence Of Body Mass Index On The Efficacy Of Tumor Necrosis Factor Blocking Therapy For Rheumatoid Arthritis. Ingrid M. Visman, Inge A.M. van den Oever, Charlotte L. M. Krieckaert, Gertjan Wolbink and Michael T. Nurmohamed, Jan van Breemen Research Institute Reade, Amsterdam, Netherlands, VU University Medical Center & Jan van Breemen Research Institute, Amsterdam, Netherlands 44. Persistence On Single Disease Modifying Anti-Rheumatic Drug Therapy In US Veterans With Rheumatoid Arthritis Is Extremely Rare. Jonathan Kruger, Ted R. Mikuls and Grant W. Cannon, Salt Lake City VA and University of Utah, Salt Lake City, UT, Omaha VA and University of Nebraska Medical Center, Omaha, NE 45. Discontinuation Of Tumor Necrosis Factor Inhibitors In Rheumatoid Arthritis Patients In Low Disease Activity: Persistent Benefits. Arthur Kavanaugh, Susan J. Lee, Daniel H. Solomon, Jeffrey D. Greenberg 4, Joel M. Kremer 5, Lilian Soto 6, Carol J. Etzel 7 and George W. Reed 8, University of California, San Diego, La Jolla, CA, University of California San Diego, La Jolla, CA, Harvard Medical School, Brigham and Women s Hospital, Division of Rheumatology, Division of Pharmacoepidemiology, Boston, MA, 4 NYU Hospital for Joint Diseases, New York, NY, 5 Center for Rheumatology, Albany Medical College, Albany, NY, 6 University of California San Diego, San Diego, CA, 7 CORRONA, Inc., Houston, TX, 8 CORRONA, Inc., Worcester, MA 0 Program Book 57

260 ACR POSTER SESSION B Inhibition Of Spermidine/Spermine N-Acetyltransferase Activity a New Therapeutical Concept In Rheumatoid Arthritis. Emmanuel Karouzakis, Astrid Jungel, Beat A. Michel, Renate E. Gay, Steffen Gay and Michel Neidhart, Center of Experimental Rheumatology, University Hospital Zurich and Zurich Center of Integrative Human Physiology (ZIHP), Zurich, Switzerland, Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland 47. Discovery and Characterization Of ABT-, An Anti- TNF/IL-7 DVD-Ig Molecule As a Potential Therapeutic Candidate For Rheumatoid Arthritis. Chung-Ming Hsieh, Carolyn Cuff, Edit Tarcsa and Margaret Hugunin, AbbVie Pharmaceuticals, Worcester, MA, AbbVie Bioresearch Center, Worcester, MA 48. The Safety and Efficacy Of Tocilizumab Subcutaneous In Combination With Traditional Dmards In Patients With Moderate To Severe Rheumatoid Arthritis Up To 48 Weeks (BREVACTA). Alan Kivitz, Ewa Olech, Michael A. Borofsky, Beatriz M. Zazueta 4, Federico Navarro-Sarabia 5, Sebastião C. Radominski 6, Joan T. Merrill 7, Chris Wells 8, Sunethra Wimalasundera 8, Wendy Douglass 8 and Janet E. Pope 9, Altoona Center for Clinical Research, Duncansville, PA, University of Nevada School of Medicine, Las Vegas, NV, Clinical Research Center of Reading, Reading, PA, 4 Centro de Investigacion en Enfermedades Reumaticas, Mexicali, Mexico, 5 Hospital Virgen Macarena, Serv. de Reumatología, Sevilla, Spain, 6 Universidade Federal do Paraná, Curitiba, Brazil, 7 Oklahoma Medical Research Foundation, Oklahoma City, OK, 8 Roche, Welwyn Garden City, United Kingdom, 9 St Joseph Health Centre, London, ON 49. Adiponectin Levels Are Increased After Tocilizumab Therapy Among Adults With Rheumatoid Arthritis: Results From The Measure Study. Hoda Mirjafari, Micki Klearman, Jianmei Wang, Naveed Sattar 4 and Jon T. Giles 5, Arthritis Research UK Epidemiology Unit, Institute of Inflammation and Repair, Manchester Academic Health Science Centre; The University of Manchester; and Roche;, Manchester, United Kingdom, Roche, South San Francisco, CA, Roche, Welwyn Garden City, United Kingdom, 4 University of Glasgow, Glasgow, United Kingdom, 5 Columbia University, College of Physicians & Surgeons, New York, NY 40. Safety and Efficacy Of Subcutaneous Tocilizumab Monotherapy In a Long-Term Extension Study In Japanese Rheumatoid Arthritis Patients. Atsushi Ogata, Osaka University Graduate School of Medicine, Suita, Japan 4. Algorithms Using Genome-Wide SNP Analysis For Prediction Of Efficacy and Adverse Events Of Abatacept Using Two Population Samples From Multiple Medical Cohorts. Tsukasa Matsubara, Satoru Koyano, Keiko Funahashi, Takako Miura, Kosuke Okuda, Takeshi Nakamura, Mitsuyoshi Iwahashi, Tomomi Tsuru 4, Shoichi Uchimura 5, Shigeru Honjo 6, Akira Sagawa 7, Takeo Sakurai 8, Hiroaki Matsuno 9, Tomomaro Izumihara 0, Eisuke Shono, Kou Katayama, Toyomitsu Tsuchida and Motohiro Oribe 4, Matsubara Mayflower Hospital, Kato, Japan, Research Institute of Joint Diseases, Kobe, Japan, Higashi- Hiroshima Memorial Hospital, Higashi-hiroshima, Japan, 4 PS Clinic, Fukuoka, Japan, 5 Kanzaki Municipal General Hospital, Kanzaki, Japan, 6 Honjo Rheumatism Clinic, Takaoka, Japan, 0 Program Book 7 Sagawa Akira Rheumatology Clinic, Sapporo, Japan, 8 Inoue Hospital, Takasaki, Japan, 9 Matsuno Clinic for Rheumatic Diseases, Toyama, Japan, 0 Izumihara Rheumatic and Medical Clinic, Kagoshima, Japan, Shono Rheumatology Clinic, Fukuoka, Japan, Katayama Orthopedic Rheumatology Clinic, Asahikawa, Japan, Tsuchida Clinic, Chiba, Japan, 4 Oribe Rheumatism and Internal Medicine Clinic, Oita, Japan 4. The Rate Of Serious Infections Remains Stable In Patients With Multiple Retreatments In Real life : Data From The Auto Immunity and Rituximab (AIR) Registry. Jacques- Eric Gottenberg, Philippe Ravaud, Patrice Cacoub Sr., Thomas Bardin 4, Alain G. Cantagrel 5, Bernard Combe 6, Maxime Dougados 7, Rene-Marc Flipo 8, Bertrand Godeau 9, Loic Guillevin 0, Xavier Le Loet, Eric Hachulla, Thierry Schaeverbeke, Jean Sibilia 4, Isabelle Pane 5, Gabriel Baron 6 and Xavier Mariette 7, Strasbourg University Hospital, Strasbourg, France, Hopital Hotel Dieu, Paris Descartes University, Paris, France, CHU Pitié-Salpêtrière, Paris, France, 4 Hôpital Lariboisière, Paris, France, 5 Purpan University Hospital, Toulouse Cedex 9, France, 6 Lapeyronie Hospital, Montpellier, France, 7 Paris-Descartes University, APHP, Cochin Hospital, Paris, France, 8 Hopital R Salengro CHRU, Lille, France, 9 University of Paris, AP-HP, Hôpital Mondor Créteil, Creteil, France, 0 Referral Center for Rare Autoimmune and Systemic Diseases, Hôpital Cochin, AP HP, Université Paris Descartes, Paris, France, CHU of ROUEN, Rouen, France, Claude Huriez University Hospital, Lille, France, Groupe Hospitalier Pellegrin, Bordeaux, France, 4 CHU Hautepierre, Strasbourg, France, 5 Hotel Dieu University Hospital Paris, Paris, France, 6 Groupe Hospitalier Bichat-Claude Bernard, Paris, France, 7 Bicêtre University Hospital, Paris, France 4. Lack Of Early Clinical Response To Treatment With Baricitinib Predicts Low Probability Of Achieving Long Term DAS8-ESR Low Disease Activity Or Remission In Patients With Rheumatoid Arthritis. Edward Keystone, Mark C. Genovese, Peter Taylor, Baojin Zhu 4, Scott D. Beattie 4, Stephanie de Bono 4, Terence Rooney 4, Douglas E. Schlichting 4 and William Macias 4, University of Toronto, Toronto, ON, Stanford University Medical Center, Palo Alto, CA, University of Oxford, Oxford, United Kingdom, 4 Eli Lilly and Company, Indianapolis, IN 44. Assessing Janus Kinase inhibitor s Place In Therapy In Established Rheumatoid Arthritis Patients From a Simplified Indirect Comparison Versus Tumor Necrosis Factor Inhibitors To a Bayesian Probability Of Response The Value Of Transparency. Michael P. Ingham, Paul Song, Shannon Cartier, Karin Lawson-Remer and Erin Murray, Janssen Scientific Affairs, LLC, Horsham, PA, Doctor Evidence LLC, Santa Monica, CA, Optum, Eden Prairie, MN 45. Effectiveness Of TNF-á Inhibitor Therapy Does Not Differ Between Elderly and Younger Patients With Rheumatoid Arthritis: Results From The Corrona Registry. Aviva C. Hopkins, Melisa Martinez-Marti, George W. Reed, Ping He, Jeffrey D. Greenberg 4, Carlos J. Lozada, Ozlem Pala, Joel M. Kremer 5 and Dimitrios A. Pappas 6, University of Miami Miller School of Medicine, Miami, FL, CORRONA, Inc., Southborough, MA, UMASS Medical School, Worcester, MA, 4 New York Hospital for Joint Disease, New York, NY, 5 Albany Medical College and The Center for Rheumatology, Albany, NY, 6 Columbia University, New York, NY

261 ACR POSTER SESSION B 46. Early Changes In a Multi-Biomarker Disease Activity Score After Starting Adalimumab Treatment Predict Change In MRI Inflammation At 6 Months. Simon Krabbe, R.J. Bolce, Cecilie Heegaard Brahe, Uffe Møller Døhn, Scott Cruickshank, Bo J. Ejbjerg 4, Merete L. Hetland, E.H. Sasso, D. Chernoff 5, Michael Sejer Hansen 6, Lene Surland Knudsen 7, Annette Hansen 8, Ole Rintek Madsen 8, Maria Hasselquist 9, Jakob M. Møller 9 and Mikkel Østergaard, Copenhagen University Hospital Glostrup, Copenhagen, Denmark, Crescendo Bioscience Inc., South San Francisco, CA, Scott Cruickshank and Associates, Inc., Santa Barbara, CA, 4 Slagelse Sygehus, Slagelse, Denmark, 5 Crescendo Bioscience, Inc., South San Francisco, CA, 6 Gildhøj Privathospital, Copenhagen, Denmark, 7 Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark, 8 Copenhagen University Hospital Gentofte, Copenhagen, Denmark, 9 Copenhagen University Hospital Herlev, Copenhagen, Denmark 47. Clinical and Radiographic Outcomes At Two Years and The Effect Of Tocilizumab Discontinuation Following Sustained Remission In The Second Year Of The ACT-RAY Study. Thomas W.J. Huizinga, Philip G. Conaghan, Emilio Martin-Mola, Georg Schett 4, Howard Amital 5, Ricardo M. Xavier 6, Orrin Troum 7, Maher Aassi 8, Corrado Bernasconi 8 and Maxime Dougados 9, Leiden University Medical Center, Leiden, Netherlands, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, Hospital Universitario La Paz, Madrid, Spain, 4 University of Erlangen-Nuremberg, Erlangen, Germany, 5 Sheba Medical Center,Tel-Hashomer, Tel-Aviv University, Tel-hashomer, Israel, 6 Faculdade de Medicina, Universidade Federal do Rio Grande do Sul - Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil, 7 University of Southern California School of Medicine, Santa Monica, CA, 8 F. Hoffmann-La Roche Ltd, Basel, Switzerland, 9 Cochin Hospital, Paris, France 48. Comparative Effectiveness Of Rituximab Vs. Subsequent Anti-Tumor Necrosis Factor In Patients With Rheumatoid Arthritis With Prior Exposure To TNFi. Leslie R. Harrold, George W. Reed, Robert P. Magner, Ashwini Shewade, Ani John, Jeffrey D. Greenberg 4 and Joel M. Kremer 5, University of Massachusetts Medical School, Worcester, MA, CORRONA, Inc., Southborough, MA, Genentech Inc., South San Francisco, CA, 4 NYU Hospital for Joint Diseases, New York, NY, 5 Albany Medical College and The Center for Rheumatology, Albany, NY 49. Safety, Pharmacokinetics, and Pharmacodynamics Of SAN-00, a Novel Monoclonal Antibody Against Very Late Antigen-: Results Of a Phase Study In Healthy Volunteers and Patients With Active Rheumatoid Arthritis. Charles Inderjeeth, Andrew Redfern, Michael Huang, Yun Hardiman, Theresa Grant, Lawrence C. Fritz, David Fuller, David Haughey 4 and Mark C. Totoritis, Linear Clinical Research Ltd, Perth, Australia, Santarus, Inc., San Diego, CA, INC Research, Inc., New South Wales, Australia, 4 ICON Development Solutions, Whitesboro, NY 440. Effects Of Tocilizumab On Serum Cytokines In Rheumatoid Arthritis With An Inadequate Response To Disease- Modifying Antirheumatic Drugs. Sang Jin Lee, Kyung Rok Kim, Sang Hyun Joo, Jae Myung Lee, In Ah Choi, Joo Youn Lee, Hyun Jung Yoo, Eun Young Lee, Eun Bong Lee, Won Park 4, Sung Hwan Park 5, Seung-Cheol Shim 6, Dae-Hyun Yoo 7, Han Joo Baek 8, Hyun Ah Kim 9, Soo Kon Lee 0, Yun Jong Lee, Young Eun Park, Hoon-Suk Cha and Yeong Wook Song, Department of molecular medicine and biophamaceutical sciences,seoul National University, Seoul, South Korea, Division of Rheumatology, Department of Internal Medicine, Seoul National University, Seoul, South Korea, Rheumatology, Seoul National University, Seoul, South Korea, 4 Inha University Hospital, Incheon, South Korea, 5 Rheumatology, The Catholic University, Seoul, South Korea, 6 Rheumatology, Eulji University, Daejeon, South Korea, 7 Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, 8 Rheumatology, Gachon University, Incheon, South Korea, 9 Hallym university, Kyunggi, South Korea, 0 Yonsei University College of Medicine, Seoul, South Korea, Rheumatology, Pusan Nationl University, Pusan, South Korea, Sungkyunkwan University School of Medicine, Samsung Medical Center, Seoul, South Korea 44. Predictive Factors Of Response To Tocilizumab In Patients With Active Rheumatoid Arthritis. Maria Victoria Hernández, Javier Narvaez, Raimon Sanmarti, Delia Reina 4, Cesar Diaz-Torne 5, Berta Magallares 5, Arturo Rodriguez de la Serna 5, José María Llobet 5, Hector Corominas 4 and Joan Miquel Nolla 6, Hospital Clínic of Barcelona. IDIBAPS. University of Barcelona, Barcelona, Spain, Hospital Universitario de Bellvitge, Barcelona, Spain, Hospital Clínic of Barcelona, Barcelona, Spain, 4 Hospital de Sant Joan Despí Moisès Broggi, Barcelona, Spain, 5 Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, 6 Hospital Universitari de Bellvitge, Barcelona, Spain 44. Three-Year Drug Survival and Effectiveness Of Abatacept and Tocilizumab In Patients with Rheumatoid Arthritis Treated In Routine Care. Results From The Nationwide Danish Danbio Registry. HCB Leffers, Mikkel Østergaard, Bente Glintborg, Niels Steen Krogh 4, Ulrik Tarp 5, Tove Lorenzen 6, Annette Hansen 7, Lene Dreyer 8 and Merete L. Hetland, Department of Rheumatology, Frederiksberg Hospital, Frderiksberg, Denmark, Copenhagen University Hospital Glostrup, Copenhagen, Denmark, Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Glostrup Hospital, Glostrup, Denmark, 4 ZiteLab ApS, Copenhagen, Denmark, 5 Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark, 6 Department of Rheumatology, Region Hospital Silkeborg, Silkeborg, Denmark, 7 Department of Rheumatology, Gentofte University Hospital, Copenhagen, Denmark, 8 Copenhagen University Hospital at Gentofte, Copenhagen, Denmark 44. Is The Risk Of Tumor Necrosis Factor Inhibitor-Induced Lupus The Same With Monoclonal Antibodies and Soluble Receptor? A Case/Non-Case Study In a Nationwide Pharmacovigilance Database. Guillaume Moulis, Agnès Sommet, Maryse Lapeyre-Mestre and Jean-Louis Montastruc, Toulouse University Hospital, Clinical Pharmacology Department, University of Toulouse, UMR INSERM-UPS 07, Toulouse, France, Toulouse University Hospital, INSERM U07, University of Toulouse, France, Toulouse, France 0 Program Book 59

262 ACR POSTER SESSION B Immunogenicity Induced By Tumor Necrosis Factor Antagonists In Chronic Inflammatory Arthropathies: Retrospective Study In Clinical Practice Conditions. Jose Inciarte-Mundo, Maria Victoria Hernández, Sonia Cabrera, Virginia Ruiz-Esquide 4, Julio Ramirez, Juan D. Cañete, Jordi Yague 5 and Raimon Sanmarti, Hospital Clínic of Barcelona, Barcelona, Spain, Hospital Clínic of Barcelona. IDIBAPS. University of Barcelona, Barcelona, Spain, Hospital Clínic, Barcelona, Spain, 4 Hospital Clinic, Barcelona, Spain, 5 Hospital Clínic / IDIBAPS, Barcelona, Spain 445. GEMS Audit: An Evaluation Of Routine Use Of Subcutaneous Methotrexate In Rheumatoid Arthritis. Esme Roads, Scot Buchan and Charles Li, Royal Surrey County Hospital, Guildford, United Kingdom, Strategen Ltd, Basingstoke, United Kingdom 446. The Efficacy Of Etanercept In Combination With Methotrexate In Moderate To Severe Rheumatoid Arthritis Is Not Dependent On The Dosage Of Methotrexate. T.W.J. Huizinga, Fiona Brock, Urs Kerkmann and Gaia Gallo, Leiden University Medical Center, Leiden, Netherlands, Quanticate, Hitchin, Hertfordshire, United Kingdom, Pfizer Europe, Rome, Italy 447. Success Rate Of 5-Or-More-Week Extended-Interval Therapy With Tocilizumab In Rheumatoid Arthritis Patients In Routine Practice. Masahiro Minoda, Kazuki Yoshida, Hideto Oshikawa, Hiroto Nakano, Naoho Takizawa, Kenichiro Tokunaga, Tatsuo Kobayashi, Mitsumasa Kishimoto and Kazuo Matsui, Kameda Medical Center, Kamogawa, Japan, Harvard School of Public Health, Boston, MA, St. Luke s International Hospital, Tokyo, Japan 448. Drug Retention Rates Of Biologic Monotherapies For Patients With Rheumatoid Arthritis In Daily Clinical Practice; Using Multicenter Registry In Japan. Hiroyuki Matsubara, Toshihisa Kojima, Masatoshi Hayashi and Naoki Ishiguro 4, Handa Municipal Hospital, Handa, Japan, Nagoya University Hospital, Nagoya, Japan, Nagano Red Cross Hospital, Nagano, Japan, 4 Nagoya Univeristy Graduate School of Medicine, Nagoya, Japan 449. Comparison Of Effects Of Standard- and Low-Dose Etanercept On Inflammatory Synovitis In Rheumatoid Arthritis Patients As Assessed By Ultrasonography. Kenji Mamoto, Tatsuya Koike, Tadashi Okano, Yuko Sugioka, Masahiro Tada, Kentaro Inui and Hiroaki Nakamura, Osaka City University Graduate School of Medicine, Osaka, Japan 450. Safety Of Resuming The Tumor Necrosis Factor Antagonists Therapy In Patients Who Developed Tuberculosis After Use Of Tumor Necrosis Factor Antagonists. Seokchan Hong, You Jae Kim, Bon San Koo, Kyung joo Ahn, Wook Jang Seo, Yong-Gil Kim, Chang-Keun Lee and Bin Yoo, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea, KEPCO medical center, Seoul, South Korea, Seoul Veterans Hospital, Seoul, South Korea 0 Program Book 45. Comparison Of Clinical Characteristics Of Patients With Rheumatoid Arthritis Receiving Their First Biologic and Biologic-Naïve Patients Considered Biologic-Suitable In The United States. Siva Narayanan, Yao Lu, Richard Hutchings and Amanda Baskett, Ipsos Healthcare, Columbia, MD, Ipsos Healthcare, London, United Kingdom 45. An Early Economic Evaluation Of Personalized Treatment With Rituximab By Prediction Of Effectiveness Using The Interferon Type I Signature In Rheumatoid Arthritis. Sandhya C. Nair, P.M.J. Welsing, Saskia Vosslamber, A.E. Voskuyl, M. T. Nurmohamed, J.W.J. Bijlsma, Floris Lafeber 4 and Cornelis L. Verweij, University Medical Center Utrecht, Utrecht, Netherlands, VU University Medical Center, Amsterdam, Netherlands, VU University Medical Center/Jan van Bremen Research Institute, Amsterdam, Netherlands, 4 UMC Utrecht, Utrecht, Netherlands 45. Repeated High Or Low Multi-Biomarker Disease Activity (VECTRA DA Algorithm) Scores Associated With Radiographic Outcomes In Patients with Rheumatoid Arthritis Treated with Tumor Necrosis Factor Inhibitors. Shintaro Hirata, Wanying Li, Nadine A. Defranoux, Rebecca Bolce, Eric H. Sasso, Satoshi Kubo, Shunsuke Fukuyo, Kentaro Hanami, Kunihiro Yamaoka, Kazuyoshi Saito and Yoshiya Tanaka, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, Crescendo Bioscience Inc., South San Francisco, CA 454. The Effects Of The Spleen Tyrosine Kinase Inhibitor Fostamatinib On Ambulatory Blood Pressure In Patients With Active Rheumatoid Arthritis Results Of The Oskira Ambulatory Blood Pressure Monitoring Trial. G Kitas, G Abreu, K Jedrychowicz-Rosiak, J Miller 4, R Nakov, S Panfilov, J Vencovsky 5, M Wang 6, M Weinblatt 7 and WB White 8, The Dudley Group of Hospitals NHS Foundation Trust, Dudley, United Kingdom, AstraZeneca, Molndal, Molndal, Sweden, MCBK SC, Grodzisk Mazowiecki, Poland, 4 S.W. Florida Clinical Research Center, Florida, FL, 5 Institute of Rheumatology, Prague, Czech Republic, 6 AstraZeneca, Alderley Park, Macclesfield, United Kingdom, 7 Brigham and Women s Hospital, Boston, MA, 8 Calhoun Cardiology Center, University of Connecticut School of Medicine, Farmington, CT 455. Comparison Of Serum Matrix Metalloproteinase- Levels In Rheumatoid Arthritis After Treatment With Adalimumub Or Abatacept For 4 Weeks. Yosuke Hattori, Atsushi Kaneko, Daihei Kida, Hisato Ishikawa, Toshihisa Kojima and Naoki Ishiguro 4, Nagoya Medical Center, Nagoya, Japan, Nagoya Medical Center, nagano, Japan, Nagoya University Hospital, Nagoya, Japan, 4 Nagoya Univeristy Graduate School of Medicine, Nagoya, Japan 456. Golimumab Levels, Anti-Drug Antibodies and Clinical Response In Rheumatoid Arthritis Patients At 8 Week Of Follow-Up. Eva L. Kneepkens, Dora pascual-salcedo, Chamaida Plasencia, Charlotte L. M. Krieckaert, Desiree van der Kleij, Michael T. Nurmohamed, Maria Teresa lópez-casla, Theo Rispens 4 and Gertjan Wolbink 4, Jan van Breemen Research Institute Reade, Amsterdam, Netherlands, La Paz University Hospital, Madrid, Spain, Sanquin Diagnostic Services, Amsterdam, Netherlands, 4 Sanquin Research, Amsterdam, Netherlands

263 ACR POSTER SESSION B 457. Inhibitory Effect Of Abatacept On Joint Damage In Rheumatoid Arthritis Patients With Or Without Concomitant Methotrexate: A Retrospective Multicenter Analysis Of Months Of Abatacept Treatment In Routine Clinical Practice. Isao Matsushita, Hiraku Motomura, Eiko Seki and Tomoatsu Kimura, Faculty of Medicine, University of Toyama, Toyama, Japan 458. Rates Of Switching and Healthcare Costs Associated With Switching Biologic Disease-Modifying Antirheumatic Drugs In a Commercial Population: Evidence From Real- World Observational Studies. A Nadkarni, F Lobo and T Juday, Bristol-Myers Squibb, Princeton, NJ, Bristol-Myers Squibb, Plainsboro, NJ 459. Multiple Cytokine Profiling Predicts The Effectiveness Of Switching Biologics In Rheumatoid Arthritis. Kensuke Koyama, Katsunori Ikari, Atsuo Taniguchi, Shigeki Momohara and Hisashi Yamanaka, Institute of Rheumatology, Tokyo Women s Medical University, Tokyo, Japan Years Of Treat-To-Target Therapy In Rheumatoid Arthritis Patients (the BeSt study): Clinical and Radiological Outcomes. I.M. Markusse, G. Akdemir, M. van den Broek, L. Dirven, R.J. Goekoop, K.H. Han, M. van Oosterhout 4, P.J.S.M. Kerstens 5, W.F. Lems 6, T.W.J. Huizinga and C.F. Allaart, Leiden University Medical Center, Leiden, Netherlands, Haga Hospital, The Hague, Netherlands, Maasstad Hospital, Rotterdam, Netherlands, 4 Groene Hart Hospital, Gouda, Netherlands, 5 Jan van Breemen Research Institute Reade, Amsterdam, Netherlands, 6 VU University Medical Center, Amsterdam, Netherlands 46. Corticosteroid Use In Rheumatoid Arthritis Patients On Infliximab: Treatment Implications Based On A REAL-WORLD Canadian Population. Boulos Haraoui, Algis V Jovaisas, William G. Bensen, Rafat Y. Faraawi 4, John T. Kelsall 5, Sanjay Dixit 6, Emmanouil Rampakakis 7, John S. Sampalis 7, Francois Nantel 8, Susan M. Otawa 8, Allen J. Lehman 8 and May Shawi 8, Centre Hospitalier de l Université de Montréal, Montreal, QC, University of Ottawa, Ottawa, ON, St. Joseph s Hospital and McMaster University, Hamilton, ON, 4 Rheumatologist, KW Musculoskeletal Research Inc., Kitchener, ON, 5 Mary Pack Arthritis Centre, Vancouver, Vancouver, BC, 6 McMaster University, Burlington, ON, 7 JSS Medical Research, St- Laurent, QC, 8 Janssen Canada Inc, Toronto, ON 46. Unmasking The Tolerability Of Methotrexate In Patients With Rheumatoid and Psoriatic Arthritis: A Retrospective Review Of Discontinuation From a Large UK Cohort. Andra Negoescu, Elena Nikiphorou, Anshuman P. Malaviya, Andrew Badcock, John D. Fitzpatrick, Calum T. Goudie and Andrew J. Ostor, Rheumatology Research Unit, Addenbrooke s Hospital, Cambridge, United Kingdom, Addenbrooke s Hospital, Cambridge, United Kingdom 46. Dietary Impact On Treatment Results Of Methotrexate In Patients With Rheumatoid Arthritis. Cecilia Lourdudoss, Alicja Wolk, Camilla Bengtsson, Lena Nise 4, Lars Alfredsson and Ronald van Vollenhoven 5, Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID), Karolinska institutet, Stockholm, Sweden, Institute of Environmental Medicine (IMM), Karolinska institutet, Stockholm, Sweden, Karolinska Institutet, Stockholm, Sweden, 4 Karolinska institutet, Stockholm, Sweden, 5 Unit for Clinical Research Therapy. Inflammatory Diseases (ClinTrid), Karolinska Institute, Stockholm, Sweden 464. Clinical and Radiographic Outcomes With Etanercept and Etanercept and Methotrexate In Patients With Rheumatoid Arthritis: Two-Year Results From The Canadian Methotrexate and Etanercept Outcome Study (CAMEO). Boulos Haraoui, J. Carter Thorne, Edward C. Keystone, Melanie Poulin-Costello 4, Eric Trottier 5, Andrew Vieira 4 and Janet E. Pope 6, Osteoarthritis Research Unit, University of Montreal Hospital Research Centre (CRCHUM), Montreal, QC, Southlake Regional Health Centre, Newmarket, ON, Mount Sinai Hospital/University of Toronto, Toronto, ON, 4 Amgen Canada Inc., Mississauga, ON, 5 Amgen Canada, Mississauga, ON, 6 St Joseph Health Care, London, ON 465. Adherence To The Recommended Dosing Regimen Of Abatacept In The Real-World Setting In The Action Study: Is There a Dose-Creep In Overweight Patients? H Nüßlein, R Alten, M Galeazzi, H M Lorenz 4, D Boumpas 5, M T Nurmohamed 6, W G Bensen 7, G R Burmester 8, H-H Peter 9, F Rainer 0, K Pavelka, M Chartier, C Poncet, C Rauch 4 and M Le Bars 5, University Erlangen, Nürnberg, Germany, Schlosspark-Klinik, University Medicine Berlin, Berlin, Germany, University of Siena, Siena, Italy, 4 University Hospital Heidelberg, Heidelberg, Germany, 5 Panepistimio Kritis, Rethymnon, Greece, 6 VU University Medical Center/Jan van Breeman Research Institute, Amsterdam, Netherlands, 7 St. Joseph s Hospital/McMaster University, Hamilton, ON, 8 Charité-Universitätsmedizin, Berlin, Germany, 9 University Medical Center Freiburg, Freiburg, Germany, 0 Hospital Barmherzige Brueder, Graz, Austria, Institute of Rheumatology, Prague, Czech Republic, Chiltern International, Neuilly, France, Docs International, Sèvres, France, 4 Bristol-Myers Squibb, Munich, Germany, 5 Bristol-Myers Squibb, Rueil Malmaison, France 466. Survival On Treatment Of The Second Line Biologic Therapy: Switch Or Swap Strategy? Ennio G. Favalli, Martina Biggioggero, Antonio Marchesoni and Pier Luigi Meroni, Chair and Division of Rheumatology, Gaetano Pini Institute, University of Milan, Milan, Italy, Milan, Italy, UOC Day Hospital Rheumatology, Gaetano Pini Institute, Milan, Italy, Milano, Italy, Division of Rheumatology, Gaetano Pini Institute, Milan, Italy, Milan, Italy 467. Adalimumab In Combination With High and Low Dose- Methotrexate In Rheumatoid Arthritis Patients With Inadequate Response To Methotrexate: Pharmacokinetic Results From The Musica Study. Ghada Ahmed, Sandra L Goss, Cheri E Klein, Neelufar Mozaffarian, Gurjit S. Kaeley and Walid Awni, AbbVie Inc., North Chicago, IL, Eli Lilly, San Diego, CA, University of Florida, Jacksonville, FL 0 Program Book 6

264 ACR POSTER SESSION B 468. Reasons For Discontinuation Of Biologic Agents In Rheumatoid Arthritis Patients. Eric Elkin, Martin J. Bergman, Tripthi Kamath, Sarika Ogale, Adam Turpcu, Kristin King 4, Jae Oh 4, Monarch Shah and Max I. Hamburger 5, ICON Clinical Research, San Francisco, CA, Taylor Hospital, Ridley Park, PA, Genentech, South San Francisco, CA, 4 ICON Late Phase and Outcomes Research, San Francisco, CA, 5 Rheumatology Associates, Melville, NY 469. Therapeutic Strategy In Patients With Rheumatoid Arthritis and Insufficient Response To a st Anti-TNF: Results of the Multicenter Randomized Controlled ROC Trial. Jacques- Eric Gottenberg, Olivier Brocq, Aleth Perdriger, Slim Lassoued 4, Jean-Marie Berthelot 5, Daniel Wendling 6, Liana E. euller-ziegler 7, Martin Soubrier 8, Christophe Richez 9, Bruno Fautrel 0, Arnaud L. Constantin, Xavier Mariette, Jacques Morel, Melanie Gilson 4, Grégoire Cormier 5, Jean Hugues Salmon 6, Stephanie Rist 7, Frédéric Liote 8, Hubert Marotte 9, Christine Bonnet 0, Christian Marcelli, Jeremie Sellam, Olivier Meyer, Elisabeth Solau-Gervais 4, Sandrine Guis 5, Jean-Marc Ziza 6, Charles Zarnitsky 7, Isabelle Valckenaere 8, Olivier Vittecoq 9, Alain Saraux 0, Yves-Marie Pers, Martine Gayraud, Gilles Bolla, Pascal Claudepierre 4, Marc Ardizzone 5, Emmanuelle Dernis 6, Maxime A. Breban 7, Olivier Fain 8, Jean-Charles Balblanc 9, Ouafaa Aberkane, Marion Vazel, Christelle Back, Elodie Perrodeau 40, Philippe Ravaud 4 and Jean Sibilia 4, Strasbourg University Hospital, Strasbourg, France, Hospital of Princesse Grâce de Monaco, Monaco, France, Hôpital Sud, Rennes, France, 4 Cahors Hospital, Cahors, France, 5 Nantes University Hospital, Nantes, France, 6 University Hospital, Besancon, France, 7 L Archet Hospital (University), Nice CEDEX, France, 8 CHU CLERMONT-FERRAND, Clermont-Ferrand, France, 9 Pellegrin Hospital, Bordeaux, France, 0 UPMC - Paris 6 University, Paris, France, Purpan University Hospital, Toulouse, France, Bicêtre University Hospital, Le Kremlin Bicetre, France, Montpellier University Hospital, Montpellier, France, 4 CH Grenoble Hopital Sud, Grenoble, France, 5 CHD Les Oudairies, LA ROCHE SUR YON, France, 6 Reims Hospital, Reims, France, 7 Orleans Hospital, Orleans, France, 8 Hôpital Lariboisière, Paris, France, 9 INSERM U059 and University Hospital, Hôpital Nord, Saint-Etienne, France, 0 CHU Dupuytren Limoges, Limoges, France, Rheumatology Department, Caen University Hospital, CAEN, France, Hopital Saint-Antoine, Pierre et Marie Curie University Paris 6, AP-HP, 750, France, Hopital Bichat, Paris, France, 4 Poitiers University Hospital, Poitiers, France, 5 Aix Marseille Univ; AP-HM, Marseille, France, 6 Croix Saint Simon Hospital, Paris, France, 7 CH du Havre, Le Havre, France, 8 Nancy University Hospital, Nancy, France, 9 RouenUniversity Hospital, Rouen, France, 0 CHU de la Cavale Blanche, Brest Cedex, France, CHU Lapeyronie, Montpellier, France, Institut Montsouris, Paris, France, Cannes Hospital, Cannes, France, 4 Henri Mondor Teaching Hospital, AP-HP, Créteil, France, 5 Mulhouse Hospital, Mulhouse, France, 6 Le Mans Hospital, Le Mans, France, 7 Ambroise Paré Hospital (AP-HP), and Versailles Saint Quentin en Yvelines University, Boulogne-Billancourt, France, 8 Internal Medicine, Jean Verdier Hospital, Bondy, France, 9 Centre Hospitalier Général de Belfort, Belfort, France, 40 Epidemiology, Hotel Dieu, Paris, France, 4 Hopital Hotel Dieu, Paris Descartes University, Paris, France, 4 CHU Hautepierre, Strasbourg, France 470. Anti-Tumour Necrosis Factor Alpha Therapy Reduces Platelet Reactivity and Is Associated With Improved Insulin Sensitivity In Patients With Inflammatory Arthritis. Paul A. MacMullan, Anne M. Madigan, Laura J. Durcan, Karl Egan, Paola M. Bagaglia, Dermot Kenny 4 and Geraldine M. McCarthy, RCSI, Dublin, Ireland, Mater Misericordiae University Hospital, Dublin 7, Ireland, Mater Misercordiae University Hospital, Dublin 7, Ireland, 4 RCSI, Dublin, Ireland 47. Tofacitinib For Rheumatoid Arthritis: A Systematic Review and Meta-Analysis. Maria A. Lopez-Olivo, Maria E. Suarez- Almazor and Mahesh Bavineni, University of Texas. M.D Anderson Cancer Center, Houston, TX, University of Texas MD Anderson Cancer Center, Houston, TX, Louisiana State University Lafayette, Lafayette, LA 47. Discontinuation Rates Of Tocilizumab Therapy In Rheumatoid Arthritis Patients In a Nonacademic Clinical Setting. Jaishree Manohar and Charles H. Pritchard, Drexel University College of Medicine, Sarasota, FL, Drexel University College of Medicine, Willow Grove, PA 47. Anti-Tumor Necrosis Factor α Therapy (Etanercept) Plus Methotrexate Lowers Serum Amyloid A Levels To a Greater Extent Than Triple Oral Disease Modifying Anti- Rheumatic Drug Therapy In Early Rheumatoid Arthritis Subjects. Ilinca D. Metes, Douglas W. Chew, Aarat M. Patel, G.K. Balasubramani, S. Louis Bridges Jr., Jeffrey R. Curtis, Stephen R. Wisniewski, Larry W. Moreland and Marc C. Levesque, University of Pittsburgh, Pittsburgh, PA, University of Pittsburgh, Graduate School of Public Health, Pittsburgh, PA, University of Alabama at Birmingham, Birmingham, AL 474. WITHDRAWN 475. Subcutaneous Delivery Of Methotrexate Is Associated With Improved Treatment Survival Compared To Oral Administration For The Initial Treatment Of Patients With Early Rheumatoid Arthritis. Glen S. Hazlewood, J. Carter Thorne, Janet E. Pope, Juan Xiong 4, Gilles Boire 5, Boulos Haraoui 6, Carol A. Hitchon 7, Edward C. Keystone 8, Diane Tin and Vivian P. Bykerk 9, University of Calgary, Calgary, AB, Southlake Regional Health Centre, Newmarket, ON, St Joseph Health Care, London, ON, 4 Mount Sinai Hospital, Toronto, ON, 5 Centre Hospitalier Universitaire de Sherbrooke, Université de Sherbrooke, Sherbrooke, QC, 6 Institut de Rhumatologie de Montréal, Montreal, QC, 7 University of Manitoba, Winnipeg, MB, 8 Mount Sinai Hospital/University of Toronto, Toronto, ON, 9 Hospital for Special Surgery, Weill Cornell Medical College, New York, NY 476. Effectiveness Of Etanercept In Elderly Patients With Rheumatoid Arthritis: A Single Center Retrospective Study. Arthur N. Lau, Alpesh Shah, Melissa Deamude, Cynthia Mech, Robert Bensen and William G. Bensen 4, McMaster University, Hamilton, ON, Rheumatology Health Team, Dr. Bensen s Rheumatology Clinic, Hamilton, ON, Rheumatology Health Team, St. Joseph s Hospital Hamilton, Hamilton, ON, 4 St. Joseph s Hospital and McMaster University, Hamilton, ON 6 0 Program Book

265 ACR POSTER SESSION B 477. A Novel Method Predicting Good Response Using Only Background Clinical Data In RA Patients Treated With Infliximab. Fumihiko Miyoshi, Kyoko Honne, Seiji Minota, Masato Okada 4, Noriyoshi Ogawa 5 and Toshihide Mimura 6, Saitama Medical University, Saitama, Japan, Jichi Medical University, Shimotsuke, Tochigi, Japan, Jichi Medical University, Shimotsuke,Tochigi, Japan, 4 St. Luke s International Hospital, Tokyo, Japan, 5 Hamamatsu University School of Medicine, Hamamatsu, Japan, 6 Research Center for Genomic Medicine, Saitama Medical University, Saitama, Japan 478. The Prevalence Of Biological Monotherapy Among Rheumatoid Arthritis Patients In Denmark: Results From The Danish Nationwide Danbio Registry. Tanja Schjoedt Joergensen, Lars-Erik Kristensen, Tove Lorenzen, Jørgen Jensen 4, Lida Zanjani 5, Toke Laursen 6, Sheraz Butt 7, Mette Y. Dam 8, Hanne M. Lindegaard 9, Jakob Espesen 0, Oliver Hendricks, Prabhat Kumar, Anita Kincses, Line H. Larsen 4, Marlene Andersen 5, Esben K. Næser 6, Dorte V. Jensen 7, Jolanta Grydehøj 8, Barbara Unger 9, Ninna Dufour 0, Vibeke N. Sørensen, Sara Vildhøj, Inger Marie J. Hansen, Johnny Raun 4 and Merete Hetland 5, The Parker Institute, Department of Rheumatology, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Copenhagen F, Denmark, Department of Clinical Sciences, Section of Rheymatology, University Hospital of Skåne, Lund, Sweden, Department of Rheumatology, Region Hospital Silkeborg, Silkeborg, Denmark, 4 Department of Rheumatology, Køge, Denmark, 5 Department of Rheumatology, Glostrup, Denmark, 6 Department of Rheumatology, Gentofte, Denmark, 7 Department of Rheumatology, Frederiksberg, Denmark, 8 Department of Rheumatology, Aarhus, Denmark, 9 Department of Rheumatology, Odense, Denmark, 0 Department of Rheumatology, Vejle, Denmark, Department of Rheumatology, Gråsten, Denmark, Department of Rheumatology, Esbjerg, Denmark, Department of Rheumatology, Copenhagen, Denmark, 4 Department of Rheumatology, Aalborg, Denmark, 5 Department of Rheumatology, Hjørring, Denmark, 6 Department of Rheumatology, Silkeborg, Denmark, 7 Department of Rheumatology, Rønne, Denmark, 8 Department of Rheumatology, Viborg, Denmark, 9 Department of Rheumatology, Horsens, Denmark, 0 Department of Rheumatology, Helsingør, Denmark, Department of Rheumatology, Randers, Denmark, Department of Rheumatology, Holstebro, Denmark, Department of Rheumatology, Svendborg, Denmark, 4 Department of Rheumatology, Fredericia, Denmark, 5 The Danish Rheumatologic Database (DANBIO), Glostrup Hospital., Copenhagen, Denmark 479. Relationship Between physicians Decision To Use Concomitant Glucocorticoid and Remission During Treatment With Tocilizumab In Patients With Background Of Limited Dose Of MTX. Toshihisa Kojima, Nobunori Takahashi, Koji Funahashi, Shuji Asai, Masahiro Hanabayashi, Shinya Hirabara, Nobuyuki Asai and Naoki Ishiguro, Nagoya University Hospital, Nagoya, Japan, Nagoya Univeristy Graduate School of Medicine, Nagoya, Japan 480. Prevalance Of Rare Variants In Methotrexate Pathway Genes: Implications From The National Heart Lung Blood Institute (NHLBI) Exome Sequencing Project. Fardina Malik, Alton Memorial Hospital, Alton, IL 48. Negative Effect Of Glucocorticoids Persistence Therapy On Porosity In Rheumatoid Arthritis Patients Treated With TNFα Blockers. Hubert Marotte, Sara Djemouai, Béatrice Pallot-Prades, Hervé Locrelle and Thierry Thomas 4, LBTO INSERM U059 University Jean Monnet, Saint-Etienne, France, University Hospital, Saint-Etienne, France, INSERM U059 and University Hospital, Hôpital Nord, Saint-Etienne, France, 4 INSERM U059 and University Hospital, Saint- Etienne, France 48. Survival Of Biological Treatment In Chronic Inflammatory Arthritis: A Preliminary Analysis Of Years Of Follow Up In Clinical Practice. Gabriela Ávila, Sara Marsal, Arnald Alonso, Carolina Diaz, Estefanía Quesada-Masachs, María López-Lasanta and Isabel Acosta, Vall d Hebron Hospital Research Institute, Barcelona, Spain, University Hospital Vall d Hebron, Barcelona, Spain 48. Physician and Patient Characteristics Associated With The Decision To Treat Rheumatoid Arthritis Patients With Biologic Monotherapy In Usual Care Settings. Mariely Nieves-Plaza, Heather Eng, Ilinca D. Metes, Ashwini Shewede 4, Stephen R. Wisniewski, Ani John 4 and Marc C. Levesque, Univeristy of Pittsburgh, Pittsburgh, PA, University of Pittsburgh, Graduate School of Public Health, Pittsburgh, PA, University of Pittsburgh, Pittsburgh, PA, 4 Genentech Inc., South San Francisco, CA 484. Treatment With The Glucagon-Like Peptide- Analogue Liraglutide Is Associated With Amelioration Of Disease Activity In a Prospective Cohort Study Of Patients With Inflammatory Arthritis. Catherine Sullivan, Gadintshware Gaoatswe, James Gibney, Marie Louise Healy 4, Michele Doran 5, David Kane, Donal O Shea and Ronan Mullan, Department of Rheumatology, Tallaght Hospital, TCD, Dublin 4, Ireland, Obesity Immunology Group, Education and Research Centre, St Vincent s University Hospital, UCD, Dublin 4, Ireland, Department of Endocrinology, Tallaght Hospital, TCD, Dublin 4, Ireland, 4 Department of Endocrinology, St James Hospital, TCD, Dublin 8, Ireland, 5 St James s Hospital, Dublin, Ireland 485. RNA Transcripts From Peripheral Blood Mononuclear Cells As Predictors Of Clinical Responsiveness In Rheumatoid Arthritis Subjects Treated With Abatacept. Matthew Henkel, Fang Du, Donald M. Jones, Erich R Wilkerson, William Horne, Jay K. Kolls, Marc C. Levesque and Mandy McGeachy, Univeristy of Pittsburgh, Pittsburgh, PA, University of Pittsburgh, Pittsburgh, PA, Children s Hospital of Pittsburgh of UPMC, Pittsburgh, PA Sjögren s Syndrome: Pathogenesis 486. High Resolution HLA Analysis In Primary and Secondary Sjögren s Syndrome. Gabriela Hernandez-Molina, Jose Manuel Rodriguez-Perez, Nancy Martínez-Rodríguez, Guadualupe Lima, Gilberto Vargas-Alarcon and Jorge Sanchez-Guerrero, Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubirán, Mexico City, Mexico, Instituto Nacional de Cardiologia Ignacio Chavez, Mexico City, Mexico, Mount Sinai Hospital, University Health Network, Toronto, ON 0 Program Book 6

266 ACR POSTER SESSION B WITHDRAWN 488. Gene Expression Profile According To Systemic Disease Activity In Primary Sjögren s Syndrome: Results From The Assessment Of Systemic Signs and Evolution Of Primary Sjögren s Syndrome (ASSESS) Cohort. Nawal Rahal, Nicolas Cagnard, Ghada Alsaleh, Raphaèle Seror 4, Corinne Miceli-Richard 5, Joelle Benessiano 6, Philippe Dieude 7, Jean Jacques Dubost 8, Anne-Laure Fauchais 9, Vincent Goeb 0, Eric Hachulla, Pierre-Yves Hatron, C. Larroche, Véronique le Guern 4, Jacques Morel 5, Aleth Perdriger 6, Xavier Puechal 7, Stephanie Rist 8, Alain Saraux 9, Damien Sene 0, Jean Sibilia, Olivier Vittecoq, Philippe Ravaud, Xavier Mariette 4 and Jacques-Eric Gottenberg, Strasbourg University Hospital, STRASBOURG, France, Institut Cochin, 7504 Paris, France, Univerity of Strasbourg, STRASBOURG, France, 4 Bicetre university hospital, LE Kremlin-Bicetre, France, 5 Université Paris-Sud, Bicêtre Hospital,, Kremlin Bicêtre, France, 6 Rheumatology, Paris Unervisity Hospital BICHAT, Paris, France, 7 Rheumatology departement & INSERM U699, Paris Diderot university, APHP, Bichat hospital, Paris, France, 8 CHU G.-Montpied, Clermont-Ferrand, France, 9 Department of Internal Medicine A, Dupuytren Hospital, Limoges University Hospital, Limoges, France, 0 Amiens University Hospital, Amiens, France, Internal Medicine, Lille CEDEX, France, Claude Huriez University Hospital, Lille, France, Hospital University Bobigny, bobigny, France, 4 Cochin Hospital, Paris, France, 5 Montpellier University Hospital, Montpellier, France, 6 Hôpital Sud, Rennes, France, 7 Department of Internal Medicine, Referral Center for Rare Autoimmune and Systemic Diseases, Hôpital Cochin, AP HP, Université Paris Descartes, Paris, France, Paris, France, 8 Orleans Hospital, Orleans, France, 9 CHU de la Cavale Blanche, Brest Cedex, France, 0 Hopital Lariboisière, Paris, France, Strasbourg University Hospital, Strasbourg, France, Rouen University Hospital & Inserm905, University of Rouen, Rouen Cedex, France, Hopital Hotel Dieu, Paris Descartes University, Paris, France, 4 Bicêtre University Hospital, Le Kremlin Bicetre, France 489. RNA-Sequencing Identifies Novel Differentially Expressed Coding and Non-Coding Transcripts In Sjögren s Syndrome. Indra Adrianto, Mikhail G. Dozmorov, Graham B. Wiley, John A. Ice, He Li, Jennifer A. Kelly, Astrid Rasmussen, Donald U. Stone, Juan-Manuel Anaya, Barbara M. Segal 4, Nelson L. Rhodus 5, Lida Radfar, John B. Harley 6, Judith A. James 7, Courtney G. Montgomery, R. Hal Scofield 8, Patrick M. Gaffney, Jonathan D. Wren, Kathy L. Sivils and Christopher J. Lessard, Oklahoma Medical Research Foundation, Oklahoma City, OK, University of Oklahoma Health Sciences Center, Oklahoma City, OK, School of Medicine and Health Sciences, Universidad del Rosario, Bogotá, Colombia, 4 Hennepin County Medical Center, Minneapolis, MN, 5 University of Minnesota, Minneapolis, MN, 6 Cincinnati Children s Hospital Medical Center, Cincinnati, OH, 7 Oklahoma Medical Research Foundation and University of Oklahoma Health Sciences Center, Oklahoma City, OK, 8 US Department of Veterans Affairs Medical Center, Oklahoma City, OK 0 Program Book 490. Comparative Study Of The Transcriptome Of Minor Salivary Gland Of Sjögren s Syndrome Patients Versus Healthy Controls Based On RNA-Seq. Alessia Gallo, Shih- Ing Jang, Stamatina Danielides, Ana Paola Cotrim and Ilias Alevizos, NIDCR, Bethesda, MD, NIH, Bethesda, MD, NIDCR/ NIH #0 N0, Bethesda, MD 49. Discovery and Validation Of Novel Micrornas In Minor Salivary Glands Of Sjögren s Syndrome Patients. Alessia Gallo, Mayank Tandon, Stamatina Danielides, Ana Paola Cotrim and Ilias Alevizos, NIDCR, Bethesda, MD, NIH, Bethesda, MD, NIDCR/ NIH #0 N0, Bethesda, MD 49. Histone Deacetylase But Not Is Highly Expressed In The Lymphocyte Foci In The Labial Glands Of Patients With Sjogren s Syndrome. Juan Guo and Wei Zhou, Peking University First Hospital, Beijing, China 49. WITHDRAWN 494. Increased Expression Of Interleukin In Sera and Salivary Gland From Patients With Sjögren Syndrome. Seung Min Jung, Young Sun Suh, Jung Hee Koh, Jae Ho Lee, Jennifer Lee, Soo Young Lee, Ji Hyeon Ju, Kyung-Su Park, Dae Chul Jeong, Sung Hwan Park and Seung-Ki Kwok, The Catholic University of Korea, Seoul St. Mary s Hospital, Seoul, South Korea, The Catholic University of Korea, Incheon St. Mary s Hospital, Incheon, South Korea 495. Lesional Intereukin- Expression Correlates With Functional Germinal Center Formation and T Follicular Helper Cell Infiltration In The Salivary Glands Of Sjogren s Syndrome. William Murray-Brown, Cristina Croia, Nurhan Sutcliffe, Anwar Tappuni, Costantino Pitzalis and Michele Bombardieri, William Harvey Research Institute, QMUL, London, United Kingdom, Queen Mary University of London, London, United Kingdom, Institute of Dentistry, Queen Mary University of London, London, United Kingdom 496. DNA Methylation In Six Cell and Tissue Types In Sjögren s Syndrome Reveals Distinct Patterns Across Samples and Clustering Based On Disease Status. Alice Baker, Diana Quach, Hong L. Quach, Emon Elboudwarej, Lisa F. Barcellos and Lindsey A. Criswell, University of California, Berkeley, Berkeley, CA, University of California, San Francisco, Rosalind Russell Medical Research Center for Arthritis, San Francisco, CA 497. Endosomal TLR Triggering Of B Cells In Sjögren s Syndrome Induces Increased Plasma Cells Differentiation, Ig Class Switch and Immunoglobulin Production. Marie Wahren- Herlenius, Susanna Brauner, Marika Kvarnström, Lasse Folkersen, Sabrina Görgen, Christina Trollmo, Vivianne Malmström and Gunnel Nordmark 4, Karolinska Institutet, Stockholm, Sweden, Karolinska Institutet, Stochkolm, Sweden, Rheumatology unit, Karolinska University Hospital, Karolinska Institutet, STockholm, Sweden, Stockholm, Sweden, 4 Uppsala University, Uppsala, Sweden 498. Hypofunction In Intact Cell Lobules Reflect Salivary Flow Rates In Sjogren s Patients. Leyla Y Teos, Bill Swaim, Ana Paola Cotrim, Margaret Grisius, Lolita Bebris, Indu Ambudkar 4, Gabor G. Illei 5 and Ilias Alevizos 6, NIH, Bethesda, MD, NIH/NIDCR, Bethesda, MD, NIDCR/NIH, Bethesda, MD, 4 NIDCR, Bethesda, MD, 5 MedImmune, LLC, Gaithersburg, MD, 6 NIDCR/ NIH #0 N0, Bethesda, MD

267 ACR POSTER SESSION B 499. Detection Of CD4 + CD5 low GITR + T Lymphocytes In Sjogren s Syndrome-Interstitial Lung Disease. Wu Zhenbiao and Chen Lina, First Affiliated Hospital, Fourth Military Medical University, Xi An, China, First Affiliated Hospital, Fourth Military Medical University, Xi an, China 500. Use Of B Lymphocyte Stimulator Inhibitor Belimumab May Be Associated With a Decrease In the Serum Concentration Of Endothelial Growth Factor In Patients With Primary Sjögren s Syndrome. Slavica Bobic, Sabeeda Kadavath, Linda Gerber, Ekaterini Zapantis and Petros V. Efthimiou, Lincoln Medical and Mental Health Center, New York, NY, Weill Cornell Medical College, New York, NY, LM&MHC/Weill Cornell MC, New York, NY 50. Umbilical Cord Mesenchymal Stem Cells Inhibit The Generation Of T Follicular Helper Cell In Sjogren s Syndrome. Rui Liu, Min Zhou, Dinglei Su, Xia Li and Lingyun Sun, Department of Rheumatology and Immunology, the Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China 50. Antibodies To Anti-Type - Muscarinic Acetylcholine Receptor Are Highly Prevalent To Rabbits Immunized With 4-Hydroxy--Noneal-Modified and 60-Kda Ro. Valerie Harris, Biji T. Kurien, R. Hal Scofield, Timothy Gross and Mary Girton, University of Oklahoma Health Science Center, Oklahoma City, OK, University of Oklahoma Health Sciences Center, Oklahoma City, OK, Oklahoma Medical Research Foundation, Oklahoma City, OK 50. The Suppressive Ability Of Altered Peptide Ligands To MR Reactive T Cells In MR Induced Autoimmune Sialadenitis. Hiromitsu Asashima, Hiroto Tsuboi, Naomi Matsuo, Chihiro Hagiya, Tomoya Hirota, Mana Iizuka, Yuya Kondo, Isao Matsumoto and Takayuki Sumida, Department of Internal Medicine, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan, University of Tsukuba, Tsukuba, Japan 504. Anti-Inflammation Effect Of Peroxisome Proliferator- Activated Receptor-ã (PPAR-ã) In Non-Obese Diabetic Mice With Sjogren s Syndrome. Bei Xu and Xiaomei Li, The third Affiliated Hospital of Anhui Medical University, The First Hospital of Hefei, Hefei, China, Anhui Medical University Affiliated Provincial Hospital, Hefei, Anhui, China Spondylarthropathies and Psoriatic Arthritis: Clinical Aspects and Treatment II 505. Evaluation Of a Case Ascertainment Tool For Ankylosing Spondylitis and Axial Spondylarthritis Among All Referrals To General Rheumatology Clinics. Eswar Krishnan, Michael H. Weisman, Atul A. Deodhar, Linjun Chen and Lianne S. Gensler 4, Stanford University, Palo Alto, CA, Cedars-Sinai Medical Center, Los Angeles, CA, Oregon Health & Science University, Portland, OR, 4 University of California, San Francisco, San Francisco, CA 506. Total Hip Replacement Outcomes in Ankylosing Spondylitis. Susan M. Goodman, Rebecca Zhu, Wei-Ti Huang, Mark P. Figgie, Michael Alexiades and Lisa A. Mandl, Hospital for Special Surgery, New York, NY 507. Infection Risk in Ankylosing Spondylitis: Results From a Longitudinal Observational Cohort. Dinny Wallis, Arane Thavaneswaran, Nigil Haroon, Renise Ayearst and Robert D. Inman, Toronto Western Hospital, University of Toronto, Toronto, ON, University of Toronto, Toronto Western Hospital, Toronto, ON 508. How Well Are The Assessment Of Spondyloarthritis International Society (ASAS) / Outcome Measures In Rheumatology (OMERACT) Core Outcome Sets For Ankylosing Spondylitis Implemented In Randomized Clinical Trials? A Systematic Literature Review. Wilson Bautista-Molano, Victoria Navarro-Compán, Robert Landewé and Désirée van der Heijde, Leiden University Medical Center, Leiden, Netherlands, Academic Medical Center, Amsterdam, Netherlands 509. Immunogenicity, Adalimumab Levels and Clinical Response In Ankylosing Spondylitis Patients During 4 Weeks Of Follow-Up. Eva L. Kneepkens, James C. Wei, Michael T. Nurmohamed, Kai-Jieh Yeo, CY Chen, Irene E. van der Horst-Bruinsma, Desiree van der Kleij 4, Theo Rispens 5, Gertjan Wolbink 5 and Charlotte L. M. Krieckaert, Jan van Breemen Research Institute Reade, Amsterdam, Netherlands, Chung Shan Med Univ Hospital, Taichung, Taiwan, VU University Medical Center, Amsterdam, Netherlands, 4 Sanquin Diagnostic Services, Amsterdam, Netherlands, 5 Sanquin Research, Amsterdam, Netherlands 50. Disease Activity In Male Smokers Has A >0-Fold Amplified Effect On Radiographic Damage In Comparison With Female NON-Smokers In Ankylosing Spondylitis. Sofia Ramiro, A.M. van Tubergen, Robert Landewé, Carmen Stolwijk, Maxime Dougados 4, Filip Van den Bosch 5 and Désirée van der Heijde 6, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands, Maastricht University Medical Center, Maastricht, Netherlands, Academic Medical Center Amsterdam & Atrium Medical Center, Heerlen, Netherlands, 4 Rheumatology B Department, Paris-Descartes University, Cochin Hospital, Paris, France, 5 Gent University Hospital, Gent, Belgium, 6 Leiden University Medical Center, Leiden, Netherlands 5. What Impairs Balance In Ankylosing Spondylitis? Posture Or Disease Activity? Osman Hakan Gunduz, Emel Ece Ozcan, Esra Giray and Ilker Yagci, Marmara University School of Medicine, Istanbul, Turkey 5. Smoking and Its Relationship With Clinical, Radiological and Functional Status In Patients With Ankylosing Spondylitis. Fernando Andres Sommerfleck, Emilce Edith Schneeberger, Natalia Zamora, Luis Alejandro Cayetti and Gustavo Citera, Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina 5. Human Leukocyte Antigen Tag Single Nucleotide Polymorphisms in Turkish Population: Polymerase Chain Reaction Restriction Fragment Length Polymorphism May Not Be Appropriate Genotyping Method For These Single Nucleotide Polymorphisms Due To Presence Of Complicating Polymorphism. Servet Akar, Yusuf Ziya Igci, Ismail Sari, Elif Pala, Esra Geyik, Dilek Solmaz, Pinar Cetin, Mehmet Nedim Tas and Nurullah Akkoc, Dokuz Eylul University School of Medicine, Izmir, Turkey, Gaziantep University School of Medicine, Gaziantep, Turkey 0 Program Book 65

268 ACR POSTER SESSION B 54. Drug Survival In Patients Receiving Golimumab Treatment Results From The Swedish Rheumatology Quality Register. Saedis Saevarsdottir, Michele Santacatterina, Leszek Stawiarz, Carl Turesson 4, Helena Forsblad 5, Lennart T.H. Jacobsson 6 and Staffan Lindblad 7, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden, Biostatistics Core Facility, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden, Dept. of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden, 4 Lund University, Malmö, Sweden, 5 Dept of Rheumatology & Inflammation Research, Institute of Medicine, The Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden, 6 Department of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden, 7 Dept. of Learning, Informatics, Management and Ethics; Karolinska Institutet, Stockholm, Sweden 55. Influence Of Taking Structural Lesions Into Account In Addition To Inflammatory Lesions On MRI Of The Sacroiliac Joints On The Classification Of Patients With Possible Axial Spondyloarthritis. Rosaline van den Berg, Manouk de Hooge, Floris van Gaalen, Victoria Navarro-Compán, Monique Reijnierse, Karen Fagerli, Robert Landewé, Maikel van Oosterhout 4, Roberta Ramonda 5, Tom Huizinga and Désirée van der Heijde, Leiden University Medical Center, Leiden, Netherlands, Diakonhjemmet Hospital, Oslo, Norway, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands, 4 GHZ Hospital, Gouda, Netherlands, 5 University of Padova, Padova, Italy 56. Safety and Efficacy Of Etanercept In Early Non- Radiographic Axial Spondyloarthritis: A Randomized, Double-Blind, Placebo-Controlled Trial At 4 Weeks. Maxime Dougados, Désirée van der Heijde, Joachim Sieper, Jügen Braun 4, Walter P. Maksymowych 5, Gustavo Citera 6, James Cheng-Chung Wei 7, Jan Lenaerts 8, Ronald Pedersen 9, Randi Bonin 9, Ehab Y. Mahgoub 9, Bonnie Vlahos 9 and Jack Bukowski 9, Rheumatology B Department, Paris-Descartes University, Cochin Hospital, Paris, France, Leiden University Medical Center, Leiden, Netherlands, Charité Universitätsmedizin Berlin, Berlin, Germany, 4 Rheumazentrum Ruhrgebiet, Herne, Germany, 5 University of Alberta, Edmonton, AB, 6 Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, 7 Chung Shan Medical University Hospital, Taichung, Taiwan, 8 Reuma Instituut, Hasselt, Belgium, 9 Pfizer Inc, Collegeville, PA 57. Different Imaging Abnormalities Suggestive Of Spondyloarthritis Are Present In Early Axial Spondyloarthritis. Data From The DESIR Cohort. Anna Moltó, Simon Paternotte, Désirée van der Heijde, Pascal Claudepierre 4, Martin Rudwaleit 5 and Maxime Dougados, Paris- Descartes University, Paris, France, Paris- Descartes University, Cochin hospital, Paris, France, Leiden University Medical Center, Leiden, Netherlands, 4 Paris-Est University; LIC EA49; APHP, Henri Mondor Hospital, Creteil, France, 5 Endokrinologikum Berlin, Berlin, Germany 58. Prevalence Of Spondylarthritis In Individuals Needing To Purchase An Orthopedic Mattress Because Of Chronic Back Pain. Ahmet Eftal Yucel, Muzeyyen Temel, Muhtesem Agildere and Mustafa Agah Tekindal, Baskent University Faculty of Medicine, Ankara, Turkey 59. Meeting The ACR 00 Fibromyalgia Criteria Worsens Disease Activity and Quality Of Life In Patients With Axial Spondyloarthritis Treated With Infliximab. Mathieu Verdet, Clément Guillou, Julien Michaud, Christopher Banse, Sandra Desouches, Gilles Avenel, Quentin Bréhier, Aurélia Bisson-Vaivre, Sophie Pouplin and Olivier Vittecoq 4, Rouen University Hospital, Rouen, France, Inserm 905 & Institute for Biomedical Research, University of Rouen, Rouen, France, Le Havre Hospital, Le Havre, France, 4 Department of Rheumatology, Rouen University Hospital & Inserm 905, Institute for Biomedical Research, University of Rouen, Rouen Cedex, France 50. Reduction Of Disease Burden On Workplace and Household Productivity In Axial Spondyloarthritis, Including Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis, Over 48 Weeks Of Treatment With Certolizumab Pegol. Désirée M. van der Heijde, Jürgen Braun, Martin Rudwaleit, Oana Purcaru 4 and Arthur Kavanaugh 5, Leiden University Medical Center, Leiden, Netherlands, Rheumazentrum Ruhrgebiet, Herne, Germany, Endokrinologikum Berlin, Berlin, Germany, 4 UCB Pharma, Brussels, Belgium, 5 University of California San Diego, San Diego, CA 5. Latent Tuberculosis Screening and Treatment In Ankylosing Spondylitis Patients Eligible For Anti-TNF Therapy In Endemic Area. Renata Miossi, Karina Rossi Bonfiglioli, Carla G.S. Saad, Ana Cristina Ribeiro, Julio C. B. Moraes and Eloisa Bonfá, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil 5. Remission In Spondyloarthritis : ASDAS and Basdai Thresholds From a Prospective Real Life Study. Marie Godfrin-Valnet, Marc Puyraveau and Daniel Wendling, Minjoz University Hospital, Besancon, France, CHU, Besançon, France 5. Presence Of Peripheral Arthritis Delays Spinal Radiographic Progression In Ankylosing Spondylitis: Observation Study Of Korean Spondyloarthropathy Registry (OSKAR) Over 5 Years. Tae-Jong Kim, Seunghun Lee, Kyung-Bin Joo, Dong-Jin Park 4, Yong-Wook Park 4, Shin-Seok Lee 4 and Tae-Hwan Kim 5, Chonnam National University Medical School and Hospital, Gwangju, South Korea, Hanyang University College of Medicine, Seoul, South Korea, Hanynag University, Seoul, South Korea, 4 Chonnam National University Medical School, Gwangju, South Korea, 5 Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea 54. Lower Etanercept Levels Are Associated With High Disease Activity In Ankylosing Spondylitis Patients At 4 Weeks Of Follow-Up. Eva L. Kneepkens, Charlotte L. M. Krieckaert, Desiree van der Kleij, Michael T. Nurmohamed, Irene E. van der Horst-Bruinsma, Theo Rispens 4 and Gertjan Wolbink 4, Jan van Breemen Research Institute Reade, Amsterdam, Netherlands, Sanquin Diagnostic Services, Amsterdam, Netherlands, VU University Medical Center, Amsterdam, Netherlands, 4 Sanquin Research, Amsterdam, Netherlands 66 0 Program Book

269 ACR POSTER SESSION B 55. Measurement Of Lateral Spinal Flexion and Schober Is Sufficient To Be Informed About Spinal Mobility In Patients With Ankylosing Spondylitis: -Year OASIS Results. Sofia Ramiro, Robert Landewé, Désirée van der Heijde, Carmen Stolwijk 4, Maxime Dougados 5, Filip Van den Bosch 6 and A.M. van Tubergen 4, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands, Academic Medical Center Amsterdam & Atrium Medical Center, Heerlen, Netherlands, Leiden University Medical Center, Leiden, Netherlands, 4 Maastricht University Medical Center, Maastricht, Netherlands, 5 Rheumatology B Department, Paris-Descartes University, Cochin Hospital, Paris, France, 6 Gent University Hospital, Gent, Belgium 56. Stable Clinical and MRI Response In Patients With Early Axial Spondyloarthritis After Years Of Continuous Treatment With Etanercept, Data Of The Esther Trial. In- Ho Song, Kay-Geert A. Hermann, Hildrun Haibel, Christian Althoff, Denis Poddubnyy 4, Joachim Listing 5, Anja Weiss 6, Ekkehard Lange 7, Bruce Freundlich 8, Martin Rudwaleit 9 and Joachim Sieper 4, Charité Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin, Germany, Charité Universitätsmedizin Berlin, Campus Mitte, Berlin, Germany, Charite Universitätsmedizin Berlin, Campus Mitte, Berlin, Germany, 4 Charité Universitätsmedizin Berlin, Berlin, Germany, 5 German Rheumatism Research Center, Berlin, Germany, 6 German Rheumatism Research Centre, Berlin, Germany, 7 Pfizer Pharma AG, Berlin, Germany, 8 University of Pennsylvania, Philadelphia, PA, 9 Endokrinologikum Berlin, Berlin, Germany 57. Routine Assessment Of Patient Index Data Scores Correlate Well With Bath Ankylosing Spondylitis Disease Activity Index In The Assessment Of Disease Activity and Monitoring Progression Of Ankylosing Spondylitis. Abhijeet Danve, Kiana Vakil-Gilani, Anusha Reddy, Annan Sheffield, Alexis Dinno and Atul Deodhar, Oregon Health and Science University, Portland, OR, Portland State University, Portland, OR 58. Patient-Tailored Dose Reduction Of Tumor Necrosis Factor-Alpha Blocking Agents In Ankylosing Spondylitis Patients With Stable Low Disease Activity. Suzanne Arends, Eveline van der Veer, Fleur B.S. Kamps, Monique Efde, Martha K. Leijsma, Hendrika Bootsma, Elisabeth Brouwer and Anneke Spoorenberg, University Medical Center Groningen, Groningen, Netherlands, Medical Center Leeuwarden, Leeuwarden, Netherlands 59. Patients With Imaging Abnormalities Of The Sacroiliac Joints Are More Likely To Respond To TNF Alpha Inhibitors In Early Axial Spondyloarthritis. Data From The DESIR Cohort. Anna Moltó, Simon Paternotte, Pascal Claudepierre and Maxime Dougados, Paris- Descartes University, Paris, France, Paris- Descartes University, Cochin hospital, Paris, France, Paris-Est University; LIC EA49; APHP, Henri Mondor Hospital, Creteil, France 50. Vitamin D Deficiency Is Associated With a More Active and Severe Disease In Early Axial Spondyloarthritis: Data From The DESIR Cohort. Ihsane Hmamouchi, Simon Paternotte, Didier Borderie and Maxime Dougados 4, Paris Descartes University, Cochin Hospital, Paris, France, Paris- Descartes University, Cochin hospital, Paris, France, Paris Descartes UNiversity, Pris, France, 4 Paris-Descartes University, APHP, Cochin Hospital, Paris, France 5. Agreement Between Disease Activity States and Improvement Scores As Defined by Bath Ankylosing Spondylitis Disease Activity Index and Ankylosing Spondylitis Disease Activity Score Cut-Off Values. Dilek Solmaz, Pinar Cetin, Ismail Sari, Merih Birlik, Servet Akar, Fatos Onen and Nurullah Akkoc, Dokuz Eylul University School of Medicine, Izmir, Turkey, Dokuz Eylul University School of Medicine, izmir, Turkey 5. Anti-Tumor Necrosis Fator Therapy Is Associated With Resolution Of Erosion In The Sacroiliac Joints Of Patients With Spondyloarthritis. Susanne Juhl Pedersen, Stephanie Wichuk, Praveena Chiowchanwisawakit, Robert GW Lambert and Walter P. Maksymowych, Copenhagen University Hospital at Glostrup, Copenhagen, Denmark, University of Alberta, Edmonton, AB, Mahidol University, Bangkok, Thailand 5. Work Outcome In Patients With Ankylosing Spondylitis: -Year Results From OASIS. Jose Dionisio Castillo-Ortiz, Sofia Ramiro, R. Landewe, D. van der Heijde 4, Maxime Dougados 5, Filip van Den Bosch 6 and Annelies Boonen 7, Unidad de Investigacion en Enfermedades Cronico- Degenerativas, Guadalajara, Mexico, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands, Academic Medical Center / University of Amsterdam, Amsterdam, Netherlands, 4 Leiden University Medical Center, Leiden, Netherlands, 5 Rheumatology B Department, Paris-Descartes University, Cochin Hospital, Paris, France, 6 Department of Rheumatology Ghent University Hospital, Ghent, Belgium, 7 Maastricht University Medical Center, Maastricht, Netherlands 54. Safety and Efficacy Of Golimumab, a Human Anti- Tumor Necrosis Factor Monoclonal Antibody Injected Subcutaneously Every 4 Weeks, In Chinese Patients With Active Ankylosing Spondylitis: -Year Results Of a Phase, Randomized, Placebo-Controlled Study. Chunde Bao, Feng Huang, Muhammad Asim Khan, Kaiyin Fei 4, Zhong Wu 4, Yanli Zhuang 4, Timothy A. Gathany 5, Chenglong Han 5 and Elizabeth C. Hsia 6, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China, Chinese PLA General Hospital, Beijing, China, Case Western Reserve University Hospital, Cleveland, OH, 4 Janssen Research & Development, LLC., Spring House, PA, 5 Janssen Global Services, LLC., Malvern, PA, 6 Janssen Research & Development, LLC./U of Penn, Spring House/Philadelphia, PA 55. Phenotype Of Patients and Impact Of The Disease In Early Spondyloarthritis Are Similar Regardless The Arm Of The Assessment In Spondyloarthritis International Society Criteria ( imaging or clinical ) Fulfilled By The Patients. Data From The DESIR Cohort. Anna Molto, Simon Paternotte, Désirée van der Heijde, Pascal Claudepierre 4, Martin Rudwaleit 5 and Maxime Dougados, Paris-Descartes University, APHP, Cochin Hospital, Paris, France, Paris- Descartes University, Cochin hospital, Paris, France, Leiden University Medical Center, Leiden, Netherlands, 4 Henri Mondor Teaching Hospital, AP-HP, Créteil, France, 5 Endokrinologikum Berlin, Berlin, Germany 0 Program Book 67

270 ACR POSTER SESSION B 56. Do Patients With Ankylosing Spondylitis Have An Excess Prevalence Of Chronic Widespread PAIN?: Results From The Scotland and Ireland Registry For Ankylosing Spondylitis (SIRAS) and The Musician Study. Fabiola Azeni, Marcus Beasley, Linda E. Dean, Gareth T Jones, Jane Gibson, Piercarlo Sarzi-Puttini 4 and Gary J. Macfarlane on behalf of SIRAS and MUSICIAN study investigators, Rheumatology Unit, L.Sacco University Hospital, Milan, Italy, University of Aberdeen, Aberdeen, United Kingdom, Fife Rheumatic Diseases Unit, Kircaldy, United Kingdom, 4 Rheumatology Unit, L. Sacco University Hospital, Milan, Italy 57. Primary & Subsequent Orthopedic Surgeries More Common In Juvenile Vs. Adult-Onset Ankylosing Spondylitis. Deepak R. Jadon, Ramani Arumugam, Gavin Shaddick, Alison L Nightingale, Athimalaipet V Ramanan and Raj Sengupta, Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, University of Bath, Bath, United Kingdom, University of Bristol Hospital Trust, Bristol, United Kingdom 58. The Age At Onset Of Symptoms Influence The Clinical Expression Of The Disease In Patients With Ankylosing Spondylitis. Natalia Zamora, Emilce Edith Schneeberger, Luis Alejandro Cayetti, Fernando Sommerfleck and Gustavo Citera, Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina 59. Inflammation In The Posterior Elements Of The Spine Is Infrequent In Patients With Recent Onset Axial Spondyloarthritis, Especially If No Inflammation In The Vertebral Bodies Is Observed. Rosaline van den Berg, Manouk de Hooge, Monique Reijnierse, Victoria Navarro- Compán, Karen Fagerli, Maureen Turina, Maikel van Oosterhout 4, Roberta Ramonda 5, Floris van Gaalen, Tom Huizinga and Désirée van der Heijde, Leiden University Medical Center, Leiden, Netherlands, Diakonhjemmet Hospital, Oslo, Norway, Academic Medical Center/ University of Amsterdam, Amsterdam, Netherlands, 4 GHZ Hospital, Gouda, Netherlands, 5 University of Padova, Padova, Italy 540. Sustained Clinical Remission In Patients With Non- Radiographic Axial Spondyloarthritis After Two Years Of Adalimumab Treatment. Joachim Sieper, Dominique L. Baeten, Filip Van den Bosch, Suchitrita S. Rathmann 4, Jaclyn K. Anderson 5 and Aileen L. Pangan 4, Charité Universitätsmedizin Berlin, Campus Benjamin-Franklin, Berlin, Germany, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, Gent University Hospital, Gent, Belgium, 4 AbbVie Inc., North Chicago, IL, 5 AbbVie, North Chicago, IL 54. Spinal Mobility Gets Impaired In a Fixed Order In Patients With Ankylosing Spondylitis: -Year OASIS Results. Sofia Ramiro, Robert Landewé, Désirée van der Heijde, Carmen Stolwijk 4, Maxime Dougados 5, Filip Van den Bosch 6 and A.M. van Tubergen 4, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands, Academic Medical Center Amsterdam & Atrium Medical Center, Heerlen, Netherlands, Leiden University Medical Center, Leiden, Netherlands, 4 Maastricht University Medical Center, Maastricht, Netherlands, 5 Rheumatology B Department, Paris-Descartes University, Cochin Hospital, Paris, France, 6 Gent University Hospital, Gent, Belgium 54. Regular Exercise Is Associated With Better Functional Outcomes In Ankylosing Spondylitis. Lianne S. Gensler, John D. Reveille, MinJae Lee, Mohammad Rahbar, Manouchehr Ardjomand-Hessabi 4, Matthew A. Brown 5, Michael H. Weisman 6 and Michael M. Ward 7, University of California, San Francisco, San Francisco, CA, University of Texas Health Science Center at Houston, Houston, TX, The University of Texas Health Science Center at Houston, Houston, TX, 4 The University of Texas, Health Science Center at Houston, Houston, TX, 5 University of Queensland Diamantina Institute, Brisbane, Australia, 6 Cedars-Sinai Med Ctr, Los Angeles, CA, 7 NIAMS/NIH, Bethesda, MD 54. Patients With Ankylosing Spondylitis Are Substantially Undertreated For Hypertension and Hypercholesterolemia. Sjoerd C. Heslinga, Inge A.M. van den Oever, Alper M. van Sijl, Irene E. Van der Horst-Bruinsma and Michael. T. Nurmohamed, VU University Medical Center, Amsterdam, Netherlands, Jan van Breemen Research Institute Reade, Amsterdam, Netherlands 544. Good Agreement Between The Ankylosing Spondylitis Disease Activity Scores Based On C-Reactive Protein and Erythrocyte Sedimentation Rate. Dilek Solmaz, Pinar Cetin, Ismail Sari, Merih Birlik, Servet Akar, Fatos Onen and Nurullah Akkoc, Dokuz Eylul University School of Medicine, Izmir, Turkey, Dokuz Eylul University School of Medicine, izmir, Turkey 545. Serum Periostin: a New Marker Of Local Bone Formation In Early Inflammatory Back Pain: results From The DESIR Cohort. Karine Briot, Simon Paternotte, Didier Borderie, Corinne Miceli-Richard, Maxime Dougados and Christian Roux, Paris Descartes University, Paris, France, Paris Descartes UNiversity, Pris, France, Université Paris-Sud, Bicêtre Hospital,, Kremlin Bicêtre, France 546. Patient-Reported Outcomes of Etanercept in Early Non-Radiographic Axial Spondyloarthritis: A -Week, Randomized, Double-Blind, Placebo-Controlled Trial. Maxime Dougados, Wen-Chan Tsai, Diego Luis Saaibi, Randi Bonin 4, Jack Bukowski 4, Ronald Pedersen 4, Bonnie Vlahos 5 and Sameer Kotak 6, Paris-Descartes University, APHP, Cochin Hospital, Paris, France, Chung-Ho Memorial Hospital, Kaohsiung, 807, Taiwan, MEDICITY S.A.S, Bucaramanga, Santander 6800, Colombia, 4 Pfizer Inc, Collegeville, PA, 5 Pfizer Inc., Collegeville, PA, 6 Pfizer Inc., New York, NY 547. How The Delay In Diagnosis Impacts On The Clinical, Functional and Radiographic Status Of Patients With Ankylosing Spondylitis. Is There a Window Of Opportunity? luis Alejandro Cayetti, Emilce Schneeberger, Natalia Zamora, Fernando Sommerfleck and Gustavo Citera, Instituto de Rehabilitacion Psicofisica, Buenos Aires, Argentina, Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina 548. Effect Of TNF Inhibitors On Bone Mineral Density In Patients With Ankylosing Spondylitis- a Systematic Review and Meta-Analysis. Nisha Nigil Haroon, Jeevitha Srighanthan, Nayef AL Ghanim, Robert D. Inman and Angela Cheung, University of Toronto, Toronto, ON, University of Toronto, Ontario, ON, Toronto Western Hospital, Toronto, ON 68 0 Program Book

271 ACR POSTER SESSION B 549. Prevalence Of Syndesmophytes In Patients With Chronic Back Pain Suspected Of Axial Spondyloarthritis (axspa) Not Fulfilling The Modified New York (mny) Criteria. Manouk de Hooge, Rosaline van den Berg, Floris van Gaalen, Monique Reijnierse, Victoria Navarro-Compán, Karen Fagerli, Maureen C. Turina, Maikel van Oosterhout 4, Roberta Ramonda 5, Tom Huizinga and Désiréé van der Heijde, Leiden University Medical Center, Leiden, Netherlands, Diakonhjemmet Hospital, Oslo, Norway, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, 4 GHZ Hospital, Gouda, Netherlands, 5 University of Padova, Padova, Italy 550. Validation Of The Ankylosing Spondylitis Disease Activity Score and Effectiveness Of Infliximab In The Treatment Of Ankylosing Spondylitis Over 4 Years: The Canadian Experience. Proton Rahman, Denis Choquette, Majed M. Khraishi, William G. Bensen 4, Saeed A. Shaikh 5, Dalton E. Sholter 6, Maqbool K. Sheriff 7, Emmanouil Rampakakis 8, John S. Sampalis 8, Francois Nantel 9, Susan M. Otawa 9, Allen J. Lehman 9 and May Shawi 9, Memorial University, St. Johns, NF, Institut de Rhumatologie de Montréal, Montreal, QC, MD, Memorial University of Newfoundland, Nexus Clinical Research, St Johns, NF, 4 St. Joseph s Hospital and McMaster University, Hamilton, ON, 5 McMaster University, St Catharines, ON, 6 Rheumatology Associates, Edmonton, AB, 7 Nanaimo Regional General Hospital, Nanaimo, BC, 8 JSS Medical Research, St-Laurent, QC, 9 Janssen Canada Inc, Toronto, ON 55. The Minimum Clinically Important Improvement and Patient Acceptable Symptom State In Basdai and BASFI For Patients With Ankylosing Spondylitis. Milla Kviatkovsky, Sofia Ramiro, Robert Landewé, Florence Tubach, Maxime Dougados 4 and D. van der Heijde 5, Nova Southeastern University, Miami, FL, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands, Universite Paris Diderot, Paris, France, 4 Rheumatology B Department, Paris-Descartes University, Cochin Hospital, Paris, France, 5 Leiden University Medical Center, Leiden, Netherlands 55. Effective Prevention Of New Osteitis On Magnetic Resonance Imaging In Patients With Early Axial Spondyloarthritis During Years Of Continous Treatment With Etanercept - Data Of The Esther Trial. In-Ho Song, Kay-Geert A. Hermann, Hildrun Haibel, Christian Althoff 4, Denis Poddubnyy, Joachim Listing 5, Anja Weiss 6, Ekkehard Lange 7, Bruce Freundlich 8, Martin Rudwaleit 9 and Joachim Sieper 0, Charité Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin, Germany, Charité Universitätsmedizin Berlin, Campus Mitte, Berlin, Germany, Charité Universitätsmedizin Berlin, Berlin, Germany, 4 Charite Universitätsmedizin Berlin, Campus Mitte, Berlin, Germany, 5 German Rheumatism Research Center, Berlin, Germany, 6 German Rheumatism Research Centre, Berlin, Germany, 7 Pfizer Pharma AG, Berlin, Germany, 8 University of Pennsylvania, Philadelphia, PA, 9 Endokrinologikum Berlin, Berlin, Germany, 0 Charité Universitätsmedizin Berlin, Campus Benjamin-Franklin, Berlin, Germany 55. Responsiveness Of Health Related Quality Of Life Questionnaires To Treatment With Anti-TNF Therapy In Psoriatic Arthritis. Zahi Touma, Arane Thavaneswaran, Vinod Chandran and Dafna D. Gladman, University of Toronto, Toronto Western Hospital, Toronto, ON 554. Real-World Effectiveness Of Infliximab In The Treatment Of Psoriatic Arthritis Over Months: The Canadian Experience. Proton Rahman, Majed M. Khraishi, William Bensen, John T. Kelsall 4, Brian D. Hanna 5, Craig Watts 6, Emmanouil Rampakakis 7, John S. Sampalis 7, May Shawi 8, Susan M. Otawa 8 and Allen J. Lehman 8, Memorial University, St. Johns, NF, MD, Memorial University of Newfoundland, Nexus Clinical Research, St Johns, NF, St. Joseph s Hospital and McMaster University, Hamilton, ON, 4 Mary Pack Arthritis Centre, Vancouver, Vancouver, BC, 5 McMaster University, Ontario, Kitchener, ON, 6 McGill University and Montreal General Hospital, Sainte-Annede-Bellevue, QC, 7 JSS Medical Research, St-Laurent, QC, 8 Janssen Canada Inc, Toronto, ON 555. Anti-TNF Drug Survival In Psoriatic Arthritis Patients Treated In Ordinary Clinical Practice. Glenn Haugeberg, Andreas P. Diamantopoulos, Agnete Gulati, Mari Hoff and Arthur Kavanaugh 4, Hospital of Southern Norway Trust, Kristiansand, Norway, St.Olavs Hospital, Trondheim, Norway, St Olavs Hospital, Trondheim, Norway, 4 University of California San Diego, San Diego, CA 556. Paradoxical Psoriasis: Experience Of a Biological Therapy Monographic Unit. Maria Luz Garcia Vivar, Silvia Perez Barrio, EVA Galindez Agirregoikoa, Catalina Gomez Arango 4, Jose Francisco Garcia Llorente 5, Rosa Izu Belloso 6, Esther Ruiz Lucea 5, Ignacio Torre Salaberri 7 and Jesus Maria Careaga Alzaga 8, Rheumatology department, Basurto University Hospital., BILBAO, Spain, Dermatology Department.Basurto University Hospital., BILBAO, Spain, Rheumatology Department. Basurto University Hospital., BILBAO, Spain, 4 Rheumatology Department, Basurto University Hospital., Bilbao, Spain, 5 Rheumatology department. Basurto University Hospital., BILBAO, Spain, 6 Dermatology Department. Basurto University Hospital. Bilbao, BILBAO, Spain, 7 Rheumatology Department. Basurto University Hospital., Bilbao, Spain, 8 Dermatology department. Basurto University Hospital., BILBAO, Spain 557. Assessing The Real Life Impact Of Psoriatic Arthritis On Disability, Quality Of Life, and Provider Satisfaction. M. Elaine Husni, Daniel Duch and Neil J. Korman, Cleveland Clinic Foundation, Cleveland, OH, Curatio CME Institute, Exton, PA, University Hospitals Dermatolo, Cleveland, OH 558. Drug Trends In Psoriatic Arthritis. Arane Thavaneswaran, Gideon Kalman-Lamb, Teneille Loo, Vinod Chandran and Dafna Gladman, University of Toronto, Toronto Western Hospital, Toronto, ON, University of Toronto, Toronto, ON Systemic Lupus Erythematosus - Clinical Aspects II: Central Nervous System Manifestations, Therapeutics 559. Cyclophosphamide and Rituximab Combination Treatment For Severe Systemic Lupus erythematosus is Effective and Well Tolerated. Ali Shahzad, Farheen Jafri, Bisharah Rizvi, Xiongce Zhao, Meryl Waldman and Sarfaraz A. Hasni 4, NIAMS/NIH, Bethesda, MD, R-Research, Hamilton, NJ, NIDDK/NIH, Bethesda, MD, 4 National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD 0 Program Book 69

272 ACR POSTER SESSION B 560. Clinical Characterization Of Anti-CCP+Ve Systemic Lupus Erythematosus Patients. Samera Vaseer and Eliza Chakravarty, University Of Oklahoma, Oklahoma City, OK, Oklahoma Medical Research Foundation, Oklahoma City, OK 56. Treat-To-Target In Systemic Lupus Erythematosus: Report From the TT/SLE Working Party. Ronald F. van Vollenhoven, Marta Mosca, George Bertsias, Annegret Kuhn 4, Kirsten Lerstrøm 5, Josef S. Smolen 6, David A. Isenberg 7, Matthias Schneider 8 and the TT/SLE Working Party 9, Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID), the Karolinska Institute, Stockholm, Sweden, Rheumatology Unit, Internal Medicine, University of Pisa, Pisa, Italy, University of Crete, Iraklion, Greece, 4 University of Münster, Münster, Germany, 5 Lupus Europe, Farum, Denmark, 6 Medical University of Vienna, Vienna, Austria, 7 University College London, London, United Kingdom, 8 Heinrich-Heine-University, Duesseldorf, Germany, 9 the Karolinska Institute, Stockholm, Sweden 56. Elevated Serum B-Cell Activating Factor (BAFF/BlyS) Characterises Disease Relapse Following Rituximab In Systemic Lupus Erythematosus. Lucy M. Carter, David A. Isenberg and Michael R. Ehrenstein, University College London, London, United Kingdom 56. Differential Expression Of B-Cell Activating factor and Its receptors in Discoid Lupus Erythematosus Subjects. Benjamin Chong, Lin-chiang Tseng, Andrew Kim, Rodney Miller, Kim Yancey and Gregory Hosler, University of Texas Southwestern Medical Center, Dallas, TX, Propath, Dallas, TX 564. Efficacy Of Influenza Vaccination Is Strongly Decreased In Systemic Lupus Erythematosus: A Meta-Analysis Of Literature Data. Laurent Arnaud, Alexis Mathian, Hervé Devilliers, Du Boutin-LE Thi Huong, Ahlem Chaib, Fleur Cohen-Aubart, Julien Haroche, Miguel Hié, Makoto Miyara and Zahir Amoura, Hôpital Pitié-Salpêtrière, AP-HP, UPMC Univ Paris 06 & French National Reference Center For Systemic Lupus and Antiphospholipid Syndrome, Paris, France, Internal medicine and systemic disease unit, Dijon University Hospital, Dijon, France 565. RNA-Sequencing Confirms Clinical Safety Of Herpes Zoster Vaccine. Christopher J. Lessard, Indra Adrianto, Joel M. Guthridge, John A. Ice, Graham B. Wiley, Stuart B. Glenn, Judith A. James, Joan T. Merrill, Patrick M. Gaffney, Courtney G. Montgomery, Kathy L. Sivils and Eliza Chakravarty, Oklahoma Medical Research Foundation, Oklahoma City, OK 566. Consensus Definition and Preliminary Validation Of a Low Disease Activity State In Systemic Lupus Erythematosus. Eric F. Morand, Kate Franklyn, Chak S. Lau, Sandra V. Navarra, Worawit Louthrenoo 4, Aisha Lateef 5, Laniyati Hamijoyo 6, Singgih Wahono 7, Shun-Le Chen 8, Jinou Ou 9, Alberta Y. Hoi and Mandana Nikpour 0, Monash University, Melbourne, Australia, Queen Mary Hospital, Hong Kong, Hong Kong, University of Santo Tomas Hospital, Manila, Philippines, 4 Faculty of Medicine, Chiang Mai, Thailand, 5 National University of Singapore, Singapore, Singapore, 6 Hasan Sadikin Hospital, Bandung, Indonesia, 7 Universitas Brawijaya, Malang, Indonesia, 8 Shanghai Jiao Tong University School of Medicine, Shanghai, China, 9 rd Hospital of Sun Yat-san University, Guang Zhou, China, 0 University of Melbourne, Fitzroy, Australia 567. Desensitization To Trimethoprim/Sulfamethoxazole In Systemic Lupus Erythematosus Patients : A Retrospective Cohort Study. Yasuhiro Suyama, Mitsumasa Kishimoto, Hiroto Nakano, Chisun Min, Yoichiro Haji, Ryo Rokutanda, Yuri Ohara, Hisanori Shimizu, Ken-ichi Yamaguchi, Yukio Matsui, Kazuo Matsui and Masato Okada, St. Luke s International Hospital, Tokyo, Japan, Kameda Medical Center, Kamogawa, Japan 568. A Comparative Study For High Prevalence Of A Positive Family History Of Systemic LUPUS Erythematosus In Juvenile-Onset Systemic LUPUS Erythematosus Versus Adult-Onset Disease. Maumer Durrani, Shirish Sangle, Natasha Jordan and David P. D Cruz, Louise Coote Lupus Unit, St Thomas Hospital, London, United Kingdom 569. The Accuracy Of The ICD-9 Code 70.0 To Identify a Cohort Of SLE Patients From The Electronic Medical Record. Arshad Mustafa, Jennifer Cai, Teresa Bosler, Nancy J. Olsen and David R. Karp, UT Southwestern Medical Center, Dallas, TX, Penn State MS Hershey Medical Center, Hershey, PA 570. Maintenance Therapy With Taclorimus and Mizoribine Pulse In SLE. Hiroshi Kajiyama, Daisuke Ikuma, Muneo Ota, Yuki Shimada, Kazuhiro Yokota, Yasuto Araki, Kojiro Sato, Yu F. Asanuma, Yuji Akiyama and Toshihide Mimura, Saitama Medical University, Saitama, Japan 57. Efficacy Of Tacrolimus Combination Therapy During The Maintenance Phase Of Systemic Lupus Erythematosus. Kumiko Ohtsuka, Yusuke Miwa, Nao Oguro, Yoko Miura, Sho Ishii, Shinya Seki, Hidekazu Furuya, Ryo Yanai, Ryo Takahashi, Kuninobu Wakabayashi, Nobuyuki Yajima and Tsuyoshi Kasama, Showa University School of Med, Shinagawa-ku Tokyo, Japan 57. High Type I Interferon In Systemic Lupus Erythematosus Plasma Predicts Future Renal Disease. Kyriakos A. Kirou, Mikhail Olferiev, Elzbieta E. Jacek, Mari Lliguicota, Margaret Robotham, Wei-Ti Huang, Elena Gkrouzman and Mary K. Crow, Hospital for Special Surgery, New York, NY 70 0 Program Book

273 ACR POSTER SESSION B 57. Longer Duration Of B Cell Depletion In Patients With Systemic Lupus Erythematosus Is Associated With a Better Outcome. Sofia Dias, Veronica Rodriguez, Hanh Nguyen, Charis Pericleous 4 and David A. Isenberg 4, Hospital de Santa Maria, Lisbon, Portugal, Hospital Regional Universitario Carlos Haya, Malaga, Spain, University College of London Hospital, london, United Kingdom, 4 University College London, London, United Kingdom 574. Favorable Clinical Response To Belimumab At Three Months. Anca Askanase, Arthi Reddy, Jill P. Buyon, Andrew G. Franks Jr., Richard A. Furie 4, Diane L. Kamen 5, Susan Manzi 6, Michelle Petri 7, Rosalind Ramsey-Goldman 8, Chung-E Tseng, Ronald F. van Vollenhoven 9 and Daniel J. Wallace 0, New York University School of Medicine, New York, NY, NYU School of Medicine, New York, NY, New York University, New York, NY, 4 The Feinstein Institute for Medical Research and North Shore-Long Island Jewish Health System, Lake Success, NY, 5 Medical University of South Carolina, Charleston, SC, 6 West Penn Allegheny Health System, Pittsburgh, PA, 7 Johns Hopkins University School of Medicine, Baltimore, MD, 8 Northwestern University Feinberg School of Medicine, Chicago, IL, 9 The Karolinska Institute, Stockholm, Sweden, 0 Cedars-Sinai Medical Center, Los Angeles, CA 575. Identification Of Novel Distinct Autoantigen Clusters Reflecting The Heterogeneity Of Systemic Lupus Erythematosus. Petra Budde, Angelika Lueking, Stefan Vordenbäumen, Heike Göhler, Martin Gamer, Klaus Marquardt, Anna Telaar, Daniel Chamrad, Carmen Theek, Peter Schulz-Knappe and Matthias Schneider, Protagen AG, Dortmund, Germany, Heinrich-Heine- University Duesseldorf, Duesseldorf, Germany 576. Type I Interferon-Mediated Skewing Of The Serotonin Synthesis In Systemic Lupus Erythematosus Is Associated To Cardiovascular Disease. Christian Lood, Helena Tydén, Birgitta Gullstrand, Cecilia Klint, Christina Wenglén, Christoffer T. Nielsen, Niels H. H. Heegaard 4, Andreas Jönsen and Anders A. Bengtsson, Lund University, Lund, Sweden, AnaMar AB, Lund, Sweden, Statens Serum Institut, Copenhagen S, Denmark, 4 Statens Serum Institut, Copenhagen, Denmark 577. Comparison Of Clinical and Serological Manifestations Among Juvenile-, Adult-, and Late-Onset Systemic Lupus Erythematosus Patients In Korea. Dong-Jin Park, Ji-Hyoun Kang, Kyung-Eun Lee, Jeong-Won Lee, Lihui Wen, Tae- Jong Kim, Yong-Wook Park and Shin-Seok Lee, Chonnam National University Medical School, Gwangju, South Korea, Chonnam National University Medical School and Hospital, Gwangju, South Korea 578. Decreased Sensitivity Of a Commercial Anti-dsDNA Assay In Patients With Moderately To Severely Active Systemic Lupus Erythematosus. Munther A. Khamashta, Gabor G. Illei, Stephen Yoo, Liangwei Wang and Warren Greth, Lupus Research Unit, The Rayne Institute, Kings College London School of Medicine, London, United Kingdom, MedImmune, LLC, Gaithersburg, MD 579. Novel Risk Factors For Thrombotic Thrombocytopenic Purpura In Systemic Lupus Erythematosus patients. Javier Merayo-Chalico, Diana Gómez-Martín, Roberta Demichelis- Gómez, Sandra Rajme-Lopez, Luis Aparicio-Vera and Jorge Alcocer-Varela, Instituto Nacional de Ciencias Médicas y Nutrición, Salvador Zubirán, Mexico city, Mexico 580. Drug-Resistant Bloodstream Infections In Systemic Lupus Erythematosus Patients: A Clinical Perspective. Ana Barrera-Vargas, Diana Gómez-Martín, Alfredo Ponce de León and Jorge Alcocer-Varela, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico 58. Lipid Lowering Medication Use Is Associated With Reduced Muscle Strength In Systemic Lupus Erythematosus. James S. Andrews and Patricia P. Katz, University of California San Francisco, San Francisco, CA, University of California, San Francisco, San Francisco, CA 58. The Accrual Of Damage In Corticosteroid-Naïve Patients With Systemic Lupus Erythematosus. Barry J. Sheane, Dominique Ibanez, Dafna D. Gladman and Murray B. Urowitz, University of Toronto, Toronto Western Hospital, Toronto, ON 58. Serositis In Systemic Lupus Erythematosus: Prevalence, Recurrence, Treatment and Outcome. Mansour Somaily, Dafna D. Gladman, Dominique Ibanez and Murray B. Urowitz, University of Toronto, Toronto Western Hospital, Toronto, ON 584. Clinical Correlates Of Chronic Isolated Thrombocytopenia In Patients With Systemic Lupus Erythematosus. Amanda J. Steiman, Dafna D. Gladman and Murray B. Urowitz, University of Toronto, Toronto Western Hospital, Toronto, ON 585. Corticosteroid Use Across 5 Weeks Of Belimumab Therapy In Patients With Systemic Lupus Erythematosus: Combined Analyses From The BLISS Trials. Ronald F. van Vollenhoven, Michelle Petri, Daniel J. Wallace, David Roth 4, Charles T. Molta 4, Anne Hammer 5, Tom Tang 5 and April Thompson 5, The Karolinska Institute, Stockholm, Sweden, Johns Hopkins University School of Medicine, Baltimore, MD, Cedars-Sinai Medical Center, Los Angeles, CA, 4 GlaxoSmithKline, King of Prussia, PA, 5 GlaxoSmithKline, Research Triangle Park, NC 586. Defining Hand Arthritis In Systemic Lupus Erythematosus, From An Ultrasound, Magnetic Resonance Imaging and Antibody Status Perspective. Elisabeth M.A Ball, Arthur Grey, Ai Lyn Tan, Eiji Fukuba 4, Gunter Steiner 5, Dennis McGonagle, Aubrey Bell and Madeleine Rooney 6, Queens University/Musgrave Park Hospital, Belfast, United Kingdom, Musgrave Park Hospital, Belfast, United Kingdom, University of Leeds, Leeds, United Kingdom, 4 Shimane University, Izuma, Japan, 5 Medical University of Vienna, Vienna, Austria, 6 Queens University Belfast, Belfast, United Kingdom 0 Program Book 7

274 ACR POSTER SESSION B 587. Continuous Variables Of Treatment Interventions In Patients Diagnosed With Systemic Lupus Erythematosus Among Commercially and Medicaid Insured Populations In The U.S. Hong Kan, Saurabh Nagar, Jeetvan Patel, Anna Oh, Daniel J. Wallace and Charles T. Molta 4, GlaxoSmithKline, Research Triangle Park, NC, University of California San Francisco, San Francisco, CA, Cedars- Sinai Medical Center, Los Angeles, CA, 4 GlaxoSmithKline, Philadelphia, PA 588. Poor Adherence To Medications For Systemic Lupus Erythematosus Among U.S. Medicaid Beneficiaries. Jinoos Yazdany, Jun Liu, Graciela S. Alarcon, Karen H. Costenbader 4 and Candace H. Feldman 5, University of California, San Francisco, San Francisco, CA, Brigham and Women s Hospital, Boston, Massachusetts, Boston, CA, University of Alabama at Birmingham, Birmingham, AL, 4 Division of Rheumatology, Immunology and Allergy, Brigham and Women s Hospital, Harvard Medical School, Boston, MA, 5 Brigham and Women s Hospital, Boston, MA 589. Obesity and Vascular Factors May Play a Role In Persistent Depression Among Individuals With Systemic Lupus Erythematosus. Patricia P. Katz, Chris Tonner, Laura Trupin, Edward H. Yelin and Jinoos Yazdany, University of California, San Francisco, San Francisco, CA, UC San Francisco, San Francisco, CA 590. A CD8 T Cell-IFN-γ-IDO Axis Is Required For Mesenchymal Stem Cell Suppression Of Human SLE. Dandan Wang, Lin Lu, Xuebing Feng, Xia Li and Lingyun Sun, Department of Rheumatology and Immunology, the Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China 59. Efficacy and Safety Of Atacicept For Prevention Of Flares In Subjects With Moderate To Severe Systemic Lupus Erythematosus (SLE). David Wofsy, David A. Isenberg, Daiana Licu, Yong Li 4, Claudia Pena Rossi and Caroline Gordon 5, University of California San Francisco and NIAID Autoimmunity Centers of Excellence, San Francisco, CA, University College London, London, United Kingdom, Merck Serono S.A., Geneva, Switzerland, 4 EMD Serono, Rockland, MA, 5 University of Birmingham, Birmingham, United Kingdom 59. Lupus Headache : Results From a Prospective, International, Inception Cohort Study. John G. Hanly, Murray B. Urowitz, Aidan o Keeffe, Caroline Gordon 4, Sang-Cheol Bae 5, Jorge Sanchez-Guerrero 6, Juanita Romero-Diaz 7, Ann E. Clarke 8, Sasha Bernatsky 9, Daniel J. Wallace 0, E.M. Ginzler, David A. Isenberg, Anisur Rahman, Joan T. Merrill, Michelle A. Petri 4, Paul R. Fortin 5, D. D. Gladman 6, Barri J. Fessler 7, Graciela S. Alarcon 7, Ian N. Bruce 8, Mary Anne Dooley 9, Kristjan Steinsson 0, Munther A. Khamashta, Rosalind Ramsey- Goldman, Susan Manzi, Gunnar K. Sturfelt 4, Ola Nived 5, Asad A. Zoma 6, R. F. van Vollenhoven 7, Manuel Ramos-Casals 8, Cynthia Aranow 9, Meggan Mackay 0, Guillermo Ruiz-Irastorza, Kenneth C. Kalunian, S. Sam Lim, Murat Inanc 4, Diane L. Kamen 5, Christine Peschken 6, Søren Jacobsen 7, Chris Theriault 8, Kara Thompson and Vernon Farewell 9, Dalhousie University and Capital Health, Halifax, NS, University of Toronto, Toronto Western Hospital, Toronto, ON, MRC Biostatistics Unit, Institute of Public Health, University Forvie Site, Cambridge, United Kingdom, 4 University of Birmingham, Birmingham, United Kingdom, 5 Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, 6 Mount Sinai Hospital, University Health Network, Toronto, ON, 7 Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, 8 McGill University Health Center, Montreal, QC, 9 Research Institute of the McGill University Health Ctre, Montreal, QC, 0 Cedars-Sinai Medical Center, Los Angeles, CA, SUNY- Downstate Medical Center, Brooklyn, NY, University College London, London, United Kingdom, Oklahoma Medical Research Foundation, Oklahoma City, OK, 4 Johns Hopkins University School of Medicine, Baltimore, MD, 5 Centre de Recherche du Chu de Québec et Université Laval, Quebec City, QC, 6 Toronto Western Hospital and University of Toronto, Toronto, ON, 7 University of Alabama at Birmingham, Birmingham, AL, 8 Arthritis Research UK Epidemiology Unit and NIHR Manchester Musculoskeletal Biomedical Research Unit, The University of Manchester, Manchester, United Kingdom, 9 University of North Carolina at Chapel Hill, Chapel Hill, NC, 0 Landspital Univ Hospital, Reykjavik, Iceland, Lupus Research Unit, The Rayne Institute, Kings College London School of Medicine, London, United Kingdom, Northwestern University Feinberg School of Medicine, Chicago, IL, West Penn Allegheny Health System, Pittsburgh, PA, 4 Lund University, Lund, Sweden, 5 Rheumatology, Lund, Sweden, 6 Hairmyres Hospital, East Kilbride, United Kingdom, 7 The Karolinska Institute, Stockholm, Sweden, 8 Hospital Clínic, Barcelona, Spain, 9 The Feinstein Institute, Manhasset, NY, 0 Feinstein Institute for Medical Research, Manhasset, NY, Hospital de Cruces, UPV/EHU, Barakaldo, Spain, Bizkaia, Spain, UCSD School of Medicine, La Jolla, CA, Emory University, Atlanta, GA, 4 Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey, 5 Medical University of South Carolina, Charleston, SC, 6 University of Manitoba, Winnipeg, MB, 7 Department of Rheumatology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark, 8 Capital Health, Halifax, NS, 9 MRC Biostatistics Unit, Cambridge, United Kingdom 59. Blood-Brain Barrier Damages and Intrathecal Synthesis Of Anti-NMDA Receptor NR Antibodies In Diffuse Psychiatric/Neuropsychological Syndromes In Systemic Lupus Erythematosus. Shunsei Hirohata, Yoshiyuki Arinuma and Taku Yoshio, Kitasato University School of Medicine, Sagamihara, Japan, Jichi Medical University, School of Medicine, Shimotsuke-shi, Tochigi-ken, Japan 594. Cognitive Dysfunction, Depression and Anti N-Methyl- D-Aspartate Receptor Antibodies and Anti- Ribosomal P In Systemic Lupus Erythematosus Patients In Argentina. Graciela Gómez, Judith Sarano, Maria de los Angeles Gargiulo, María Victoria Collado, Lorena Suarez, Daniel Fadel, Alexandra Panopulos and Marina Khoury, Instituto de Investigaciones Medicas Alfredo Lanari, Buenos Aires, Argentina 7 0 Program Book

275 ACR POSTER SESSION B 595. Electroclinical Correlates and Outcome Of Status Epilepticus In Systemic Lupus Erythematosus. Jamal Mikdashi, Tricia Ting and Allan Krumholz, University of Maryland School of Medicine, Baltimore, MD, University of Maryland. School of Medicine, Baltimore, MD, University fo Maryland school of Medicine, Baltimore, MD 596. Relationship Between IgG Anti-NR Glutamate Receptor Antibodies and Depressive / Anxiety Symptoms In Patients With Systemic Lupus Erythematosus. Chi Chiu Mok, Kar Li Chan and Betty Diamond, Tuen Mun Hospital, Hong Kong, Hong Kong, Feinstein Institute for Medical Research, Manhasset, NY 597. Autonomic Dysfunction In Systemic Lupus Erythematosus Patients With Previous Neuropsychiatric Involvement. Yang Gao, Sheung Wei Li, Lai Heung Chau, Chak Sing Lau and Mo Yin Mok, University of Hong Kong, Hong Kong, Hong Kong 598. Cognitive Dysfunction, a Non-Inflammatory Neuropsychiatric Syndrome In Systemic Lypus Erythematosus. Juanita Romero-Díaz, Alí Duarte-García, Sandra Juarez-Arellano, Alba Cicero-Casarrubias, Hilda Fragoso-Loyo 4, Luis Llorente 5 and Jorge Sánchez-Guerrero 6, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, Tufts Medical Center, Boston, MA, Instituto Nacional de Ciencias Medicas y Nutricion S.Z., Mexico city, Mexico, 4 Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico, Mexico, 5 Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubirán, Mexico City, Mexico, 6 Mount Sinai Hospital and University Health Network, Toronto Canada, Toronto, ON 599. High Proportion Of Intrathecal Ro5 SSA Antibodies In Neuropsychiatric Lupus Patients Relations To Neuropsychiatric Manifestations. Johanna Estelius, Liisa Hopia, Vijole Dzikaite-Ottosson, Magnus LA. Andersson, Elisabet Svenungsson and Jon Lampa, Karolinska Institutet, Stockholm, Sweden 600. Anti-Ribosomal P Protein Antibodies Exacerbate Long- Term Prognosis In Patients With Diffuse Neuropsychiatric/ Neuropsychological Syndromes In Systemic Lupus Erythematous. Yoshiyuki Arinuma, Hirotoshi Kikuchi, Eisuke Ogawa, Tatsuhiko Wada, Tatsuo Nagai, Sumiaki Tanaka and Shunsei Hirohata, Kitasato University School of Medicine, Sagamihara, Japan, Teikyo University School of Medicine, Tokyo, Japan 60. The Presence Of IgG-Immune Complexes In The Cerebrospinal Fluids Is Associated With Central Neurocychiatric Manifestatin But Not With Intrathecal Production Of Proimmflammatory Cytokines/Chemokines Such as Interferon-α In Systemic Lupus Erythematosus. Taku Yoshio, Hiroshi Okamoto, Kazuhiro Kurasawa, Yoshiaki Dei 4, Shunsei Hirohata 5 and Seiji Minota 6, Jichi Medical University, School of Medicine, Shimotsuke-shi, Tochigi-ken, Japan, Minami-Otsuka Clinic, Tokyo, Japan, Dokkyo Medical University, Mibu-machi, Shimotsugagun, Tochigi-ken, Japan, 4 Saiseikai Utsunomiya Hospital, Utsunomiya-shi, Tochigi-ken, Japan, 5 Kitasato University School of Medicine, Sagamihara, Japan, 6 Jichi Medical University, Shimotsuke,Tochigi, Japan 60. Autoantibodies, Cytokines and Chemokines In Serum and Cerebrospinal Fluid Of SLE Patients With Cognitive Dysfunction. Hilda Fragoso-Loyo, Alí Duarte-García, Sandra Juárez-Arellano, Alba Cicero-Casarrubias 4, Juanita Romero-Díaz 4, Luis LLorente-Peters and Jorge Sánchez- Guerrero 5, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico, Mexico, Tufts Medical Center, Boston, MA, Instituto Nacional de Ciencias Medicas y Nutricion S.Z., Mexico city, Mexico, 4 Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, 5 Mount Sinai Hospital and University Health Network, Toronto Canada, Toronto, ON 60. Sustained Reductions In Circulating B Cell Populations and Immunoglobulin G Levels With Long-Term Belimumab Treatment In Patients With Systemic Lupus Erythematosus. Herbert Struemper, William Freimuth, Christi Kleoudis, Thi-Sau Migone 4, David Roth and William Stohl 5, GlaxoSmithKline, Research Triangle Park, NC, Human Genome Sciences, Inc., Rockville, MD, GlaxoSmithKline, King of Prussia, PA, 4 Igenica, Burlingame, CA, 5 University of Southern California Keck School of Medicine, Los Angeles, CA 604. Effects Of Chronic Treatment With Blisibimod, An Inhibitor Of B Cell Activating Factor, On Renal and Inflammation Biomarkers In Patients With Systemic Lupus Erythematosus: Observations From The Placebo- Controlled Pearl-SC and Open-Label Extension Studies. Richard A. Furie, Matthew Thomas, Alvina Chu, Renee S. Martin, Colin Hislop and Morton A. Scheinberg 4, The Feinstein Institute for Medical Research and North Shore- Long Island Jewish Health System, Lake Success, NY, Health and Research Centre, Trivandrum, Kerala, India, Anthera Pharmaceuticals Inc, Hayward, CA, 4 Rheumatology Hospital Abreu Sodre Pesquisa Clínica, São Paulo, Brazil 605. Post-Marketing Experience With Belimumab In U.S. Lupus Centers: Data From The Lupus Clinical Trials Consortium, Inc. (LCTC) National Patient Registry. Jinoos Yazdany, Doruk Erkan, Jorge sanchez-guerrero, Bevra H. Hahn 4, Alana B. Levine, Galina Marder 5, W. Joseph McCune 6 and Ellen M. Ginzler 7, University of California, San Francisco, San Francisco, CA, Hospital for Special Surgery, New York, NY, Mount Sinai Hospital and University Health Network, Toronto Canada, Toronto, ON, 4 UCLA David Geffen School of Medicine, Los Angeles, CA, 5 North Shore Long Island Health System, Great Neck, NY, 6 University of Michigan, Ann Arbor, MI, 7 SUNY-Downstate Medical Center, Brooklyn, NY 0 Program Book 7

276 ACR POSTER SESSION B Overview Of The Safety Of Epratuzumab In Systemic Lupus Erythematosus. Daniel J. Wallace, Josep Ordi- Ros, C. Michael Neuwelt, Kenneth Kalunian 4, Michelle A. Petri 5, Slawomir Jeka 6, Ronald F. van Vollenhoven 7, Brian Kilgallen 8, Sabine Bongardt 9, Caroline Gordon 0 and Vibeke Strand, Cedars-Sinai Medical Center, Los Angeles, CA, Vall De Hebron General Hospt, Barcelona, Spain, East Bay Rheumatology Research Institute, San Leandro, CA, 4 UCSD School of Medicine, La Jolla, CA, 5 Johns Hopkins University School of Medicine, Baltimore, MD, 6 nd University Hospital in Bydgoszcz Medical College of Nicolaus Copernicus University, Bydgoszcz, Poland, 7 The Karolinska Institute, Stockholm, Sweden, 8 UCB Pharma, Raleigh, NC, 9 UCB Pharma, Brussels, Belgium, 0 University of Birmingham, Birmingham, United Kingdom, Stanford University, Palo Alto, CA 607. Two Year Follow-Up On Biologics Use In Centers- Data From The International Registry For Biologics In Systemic Lupus Erythematosus. Ronald F. van Vollenhoven, Melinda Mild, Søren Jacobsen, S. Bernatsky 4, Daniel J. Wallace 5, Sang-Cheol Bae 6, Manuel Ramos-Casals 7, Francisco J. García-Hernández 8, R. Ramsey-Goldman 9, Andrea Doria 0, Marta Mosca, Michelle A. Petri, M Ayala-Gutiérrez, J.G. Hanley 4 and for The SLICC group 5, Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID), the Karolinska Institute, Stockholm, Sweden, Karolinska Institutet, Stockholm, Sweden, Department of Rheumatology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark, 4 McGill UHC/RVH, Montreal, QC, 5 Cedars-Sinai Medical Center, Los Angeles, CA, 6 Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, 7 Hospital Clínic, Barcelona, Spain, 8 Hospital Virgen del Rocío, Sevilla, Spain, 9 Northwestern University Feinberg School of Medicine, Chicago, IL, 0 University of Padova, Padova, Italy, Rheumatology Unit, University of Pisa, Pisa, Italy, Johns Hopkins University School of Medicine, Baltimore, MD, Hospital Carlos Haya, Malaga, Spain, 4 Division of Rheumatology, Halifax, NS, 5 Department of Medicine, the Karolinska Institute, Stockholm, Sweden 608. A Phase I Single-Dose Crossover Study To Evaluate The Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Efficacy Of AMG 8 (anti-ifn-gamma) In Subjects With Discoid Lupus Erythematosus. Victoria P. Werth, David Fiorentino, Stanley B. Cohen, David Fivenson 4, Chris Hansen 5, Steve Zoog 6, Greg Arnold 6, Christine Wang 6, Michael Boedigheimer 6, Andrew Welcher 6, James Chung 6, Barbara Sullivan 6 and David A. Martin 7, Philadelphia Veterans Affairs Medical Center, Philadelphia, PA, Stanford University School of Medicine, Redwood City, CA, Metroplex Clinical Research Center, Dallas, TX, 4 David Fivenson, MD, Dermatology, PLLC, Ann Arbor, MI, 5 University of Utah School of Medicine, Salt Lake City, UT, 6 Amgen, Thousand Oaks, CA, 7 Amgen, Seattle, WA 0 Program Book 609. AMG 8 (anti-ifn-gamma) Treatment Leads To a Reduction In The Whole Blood IFN-Signature and Serum CXCL0 In Subjects With Systemic Lupus Erythematosus: Results Of Two Phase I Studies. David A. Martin, Andrew Welcher, Michael Boedigheimer, Zahir Amoura, Alan Kivitz 4, Jill P. Buyon 5, Jorge Sanchez- Guerrero 6, Juanita Romero-Diaz 7, Alla Rudinskaya 8, Kevin M. Latinis 9, S Cohen 0, Cynthia Aranow, Mike Damore, Winnie Sohn, Kit Chiu, Christine Wang, Naren Chirmule, Barbara Sullivan and James Chung, Amgen, Seattle, WA, Amgen, Thousand Oaks, CA, CHU Pitié-Salpêtrière, Paris, France, 4 Altoona Center for Clinical Research, Duncansville, PA, 5 NYU School of Medicine, New York, NY, 6 Mount Sinai Hospital, University Health Network, Toronto, ON, 7 Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, 8 Danbury Hospital, Danbury, CT, 9 Latinis Rheumatology, Leawood, KS, 0 Metroplex Clinical Research Center, Dallas, TX, The Feinstein Institute, Manhasset, NY 60. Lymphoablation Including B Cell Depletion and Autologous Hematopoietic Stem Cell Transplantation Leads To Long Remissions In Treatment-Resistant Systemic Lupus Erythematosus Patients. Sarfaraz A. Hasni, Gabor G. Illei, Nikolay P. Nikolov, Francis Hakim 4, Susan Leitman 4, James E. Balow 5, Howard A. Austin 6, Juan Gea-Banacloche 4, Unsong Oh 7, Paulo Muraro 8, Claude Sportes 9, Peter E. Lipsky 0, Ronald Gress 9, Steve Pavletic 9 and Amrie Grammer 0, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, NIDCR/ NIH, Bethesda, MD, NIDCR, NIH, Bethesda, MD, 4 NCI, NIH, Bethesda, MD, 5 National Institutes of Health, Bethesda, MD, 6 NIDDK/NIH, Bethesda, MD, 7 NINDS, NIH, Bethesda, MD, 8 NINDS/NIH, Bethesda, MD, 9 NCI/NIH, Bethesda, MD, 0 NIAMS/NIH, Bethesda, MD 6. Off-Label Use Of Rituximab For Systemic Lupus Erythematosus in Europe: Limited Use Mostly In Refractory Patients. Ronald F. van Vollenhoven, Melinda Mild, Andrea Doria, T. Dörner 4, Gianfranco Ferraccioli 5, Frederic Houssiau 6, T.W.J. Huizinga 7, David A. Isenberg 8, László Kovács 9, Guillermo Ruiz-Irastorza 0, Danilo Squatrito, Alexandre Voskuyl, Marta Mosca, G D Sebastiani 4, Murat Inanç 5, Gabriella Szücs 6, Søren Jacobsen 7, A. Castro 8 and for The IRBIS-EMA group 9, Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID), the Karolinska Institute, Stockholm, Sweden, Karolinska Institutet, Stockholm, Sweden, University of Padova, Padova, Italy, 4 Charité University Medicine Berlin, Berlin, Germany, 5 Division of Rheumatology, Institute of Rheumatology and Affine Sciences, Catholic University of the Sacred Heart, Rome, Italy, 6 Université catholique de Louvain, Brussels, Belgium, 7 Leiden University Medical Center, Leiden, Netherlands, 8 University College London, London, United Kingdom, 9 University of Szeged, Szeged, Hungary, 0 Hospital de Cruces, UPV/EHU, Barakaldo, Spain, Bizkaia, Spain, Careggi Hospital- Florence, Florence, Italy, VU University Medical Center, Amsterdam, Netherlands, Rheumatology Unit, University of Pisa, Pisa, Italy, 4 Rheumatology Unit, San Camillo-Forlanini Hospital, Rome, Rome, Italy, 5 Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey, 6 University of Debrecen Medical and Health Sciences Center, Debrecen, Hungary, 7 Department of Rheumatology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark, 8 Hospital Universitari de Reus, Spain, Reus, Spain, 9 ClinTRID, Department of Medicine, Karolinska Institute, Stockholm, Sweden

277 ACR POSTER SESSION B 6. Rituximab For Treatment Of Refractory Auto-Immune Hepatitis. Chadi Rakieh, Edward M. Vital, Paul Emery and Michael Martin, Division of Rheumatic and Musculoskeletal Disease, Leeds Institute of Molecular Medicine, University of Leeds and NIHR Leeds Musculoskeletal Biomedical Research Unit, LTHT, Leeds, United Kingdom, Leeds, United Kingdom 6. Anti-Malarial Drugs (hydroxychloroquine and quinacrine) Decrease The Production Of Interferon-Alfa Initiated By TLR-9 Agonist. Ou Jin, Xi Zhang, Qiuxia Li, Lingkai Fang, Hongyue Huang, Chengcheng Hou, Zetao Liao 4, Qiujing Wei, Zhiming Lin, Dongfang Lin and Jieruo Gu 5, third affiliated hospital of Sun Yat-sen Universtiy, Guangzhou, China, The Affiliated Third Hospital of Sun Yat-san University, Guangzhou, China, The Affiliated Third Hospital of Sun Yat-san University, Rheumatology, Guangzhou, China, 4 THIRD AFFILIATED HOSPITAL OF SUN YAT-SEN UNIVERSIT, Guangzhou, China, 5 Third Affiliated Hospital of Sun Yat-sen University, GuangZhou, China 64. Hydroxychloroquine Reverse The Elevation Of Interferon- Alfa Initiated By TLR-9 Agonist Which Irresponsive To Glucocorticoid. Ou Jin, Xi Zhang, Lingkai Fang, Qiuxia Li, Hongyue Huang, Zhiming Lin, Zetao Liao 4, Dongfang Lin, Chengcheng Hou and Jieruo Gu 5, third affiliated hospital of Sun Yat-sen Universtiy, Guangzhou, China, The Affiliated Third Hospital of Sun Yat-san University, Guangzhou, China, The Affiliated Third Hospital of Sun Yat-san University, Rheumatology, Guangzhou, China, 4 THIRD AFFILIATED HOSPITAL OF SUN YAT-SEN UNIVERSIT, Guangzhou, China, 5 Third Affiliated Hospital of Sun Yat-sen University, GuangZhou, China Systemic Lupus Erythematosus - Human Etiology and Pathogenesis: Genetics and Genomics 65. Type I Interferons As a Serum Biomarker Of Subclinical Atherosclerosis In Pediatric Systemic Lupus Erythematosus Patients. Smriti Mohan, Julie Barsalou, Timothy J. Bradley, Cameron Slorach, Lawrence Ng, Deborah M. Levy 4, Earl D. Silverman and Mariana J. Kaplan 5, University of Michigan, Ann Arbor, MI, The Hospital for Sick Children, University of Toronto, Toronto, ON, The Hospital for Sick Children, Toronto, ON, 4 The Hospital for Sick Children and University of Toronto, Toronto, ON, 5 University of Michigan Rheumatology, Ann Arbor, MI 66. Interferon Regulatory Factors and 5 As Key Elements Of The Interferon Signature On Plasmacytoid Dendritic Cells From Systemic Lupus Erythematosus Patients. Diana Gómez-Martín, Karina Santana-de Anda, Adriana Elizabeth Monsivais-Urenda, Sandra Rajme-Lopez 4, Luis Aparicio-Vera 4, Jorge Alcocer-Varela and Roberto González- Amaro, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, Instituto Nacional de Ciencias Médicas y Nutrición, Salvador Zubirán, Mexico City, Mexico, Facultad de Medicina. UASLP, San Luis Potosí, Mexico, 4 Instituto Nacional de Ciencias Médicas y Nutrición, Salvador Zubirán, Mexico city, Mexico 67. Toll-Like Receptor Plays a Role In Loss Of Tolerance To The Ro/SSA Auto-Antigen In Systemic Lupus Erythematosus. Julie Ducreux, Christine Galant, Julie Verbeeck, Pierre Coulie, Benoît Van den Eynde, Frédéric A. Houssiau and Bernard Lauwerys, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain, Brussels, Belgium, Institut de Duve, Université catholique de Louvain, Brussels, Belgium 68. Chromatin Binding In SLE Patients Correlates With The Intensity Of Apoptotic Binding By 9G4+ B Cells. Asiya Seema Chida, Quan-Zhen Li, Chandra Mohan, Youliang Wang, Scott Jenks, Louise Hartson and Ignacio Sanz 4, Emory University Medical Center, Atlanta, GA, University of Texas Southwestern Medical Center, Dallas, TX, Emory University School of Medicine, Atlanta, GA, 4 Emory University, Atlanta, GA 69. In Vitro Assessments Of Mesenchymal Stem Cells From Lupus Patients To Predict Suppressive Function In Vivo. Erin Collins, Fei Gu and Gary S. Gilkeson, Medical University of South Carolina, Charleston, SC, Division of Rheumatology and Immunology,Medical University of South Carolina, Charleston, SC 60. Characterization Of a Jamaican Lupus Cohort: Proinflammatory Biomarkers and Disease Activity. Rohan Willis, Monica Smikle, Karel de Ceulaer and Silvia S. Pierangeli, University of Texas Medical Branch, Galveston, TX, University of the West Indies, Kgn 7, Jamaica, University of the West Indies, KIngston, Jamaica 6. T Helper 7 Cells and Interferon Type I: Partners In Crime In SLE? Odilia B.J. Corneth, Zana Brkic, Cornelia G. van Helden-Meeuwsen, Radboud J.E.M. Dolhain, Naomi I. Maria, Sandra M.J. Paulissen, Nadine Davelaar, Jan Piet van Hamburg, Paul L. Van Daele, Virgil A. Dalm, Martin van Hagen, Marjan A. Versnel and Erik Lubberts, Erasmus Medical Center, Rotterdam, Netherlands 6. Deep-Sequencing Reveals Class-Specific Urinary Micrornas In Human Lupus Nephritis. Beatrice Goilav, Iddo Z. Ben- Dov, Irene Blanco, Olivier Loudig, Dawn M. Wahezi 4 and Chaim Putterman, Children s Hospital at Montefiore, Bronx, NY, The Rockefeller University, New York, NY, Albert Einstein College of Medicine, Bronx, NY, 4 Children s Hospital Montefiore, Bronx, NY 6. Differential Methylation Of Interferon-Related Genes Is Associated With Anti-dsDNA Autoantibody Production In Systemic Lupus Erythematosus. Sharon A. Chung, Joanne Nititham, Kimberly E. Taylor, Emon Elboudwarej, Hong L. Quach, Lisa F. Barcellos and Lindsey A. Criswell, University of California, San Francisco, San Francisco, CA, University of California, San Francisco, Rosalind Russell Medical Research Center for Arthritis, San Francisco, CA, University of California, Berkeley, Berkeley, CA 64. Lupus Risk Alleles With High Ethnic Variability Worldwide Are Associated With Renal Disease In Hispanic Patients. Belinda Waltman, Kimberly E. Taylor, Joanne Nititham and Lindsey A. Criswell, University of California, San Francisco, San Francisco, CA, University of California, San Francisco, Rosalind Russell Medical Research Center for Arthritis, San Francisco, CA 0 Program Book 75

278 ACR POSTER SESSION B 65. Prolactin-Induced Interferon Regulatory Factor Activation and Histone H4 Hyperacetylation In Monomac-6 Cells Correlating With Changes Seen In Monocytes From Systemic Lupus Erythematosus Patients. Yiu Tak Leung, Lihua Shi, Kelly Maurer, Li Song, Michelle Petri and Kate Sullivan, University of Pennsylvania, Philadelphia, PA, The Children s Hospital of Philadelphia, Philadelphia, PA, Johns Hopkins University School of Medicine, Baltimore, MD 66. Genetic Alterations In Abnormal Neutrophils Isolated From Human Systemic Lupus Erythematosus Patients. Namrata Singh, Kayla Martin, Mariana J. Kaplan, Philip L. Cohen and Michael F. Denny, Temple University, Philadelphia, PA, University of Michigan Rheumatology, Ann Arbor, MI, Temple University School of Medicine, Philadelphia, PA 67. Typing TREX Gene In Patients With Systemic Lupus Erythematosus. Micaela Fredi, Marika Bianchi, Laura Andreoli, Gaetano Grieco, Ivana Olivieri 4, Simona Orcesi 4, Elisa Fazzi 5, Cristina Cereda and Angela Tincani, Rheumatology Chair, University of Brescia and Pavia, Brescia, Italy, Laboratory of Experimental Neurobiology, C. Mondino National Institute of Neurology Foundation, Pavia, Italy, Rheumatology Unit, University of Brescia, Brescia, Italy, 4 Child Neurology and Psychiatry Unit C. Mondino National Institute of Neurology Foundation, Pavia, Italy, 5 Child Neurology and Psychiatry Unit, Mother-Child Department, Civil Hospital, University of Brescia, Brescia, Italy 68. Decreased Levels Of Splicing Factor / Alternative Splicing Factor (SF/ASF) Correlate With Lower Transcript Levels Of The RasGRP Normal Isoform In Lupus T Cells. Takashi Kurita, Shinsuke Yasuda, Vaishali R. Moulton, Michihito Kono, Hideyuki Koide, Kenji Oku, Toshiyuki Bohgaki, Olga Amengual, Tetsuya Horita, George C. Tsokos and Tatsuya Atsumi, Hokkaido University Graduate School of Medicine, Sapporo, Japan, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 69. Functional Effect Of NRH (LXRA) Promoter Polymorphisms In Korean Patients With Systemic Lupus Erythematosus. Ja-Young Jeon, Hyoun-Ah Kim, Ju-Yang Jung and Chang-Hee Suh, Ajou University School of Medicine, Suwon, South Korea, Ajou University Hospital, Suwon, South Korea 60. Association Of TREM-Like Transcript- With Systemic Lupus Erythematosus. Yerania Rodríguez-Navedo, Karina Vilá -Rivera, Mariely Nieves-Plaza, Martha Ricaurte, A. Valance Washington and Luis M. Vilá, University of Puerto Rico Medical Sciences Campus, San Juan, PR, University of Pittsburgh, Pittsburgh, PA, University of Puerto Rico, Río Piedras Campus, San Juan, PR 6. Transcription Activation-Like Effector Nuclease-Mediated Enhancer Knockout Influences TNFAIP Gene Expression and Mimics a Functional Phenotype Associated With Systemic Lupus Erythematosus. Shaofeng Wang, Feng Wen, Bo He and Patrick M. Gaffney, Oklahoma Medical Research Foundation, Oklahoma City, OK, The University of Oklahoma Health Sciences Center, Oklahoma City, OK 6. Identification Of a Novel Systemic Lupus Erythematosus Risk Locus Between FCHSD and PRY In Koreans. Christopher J. Lessard, Satria Sajuthi, So-Young Bang, Hye-Soon Lee, Young Mo Kang 4, Chang-Hee Suh 5, Won Tae Chung 6, Soo-Kon Lee 7, Jung-Yoon Choe 8, Seung-Cheol Shim 9, Shin-Seok Lee 0, Ji Hee Oh, Young Jin Kim, Jong- Young Lee, Bok-Ghee Han, Patrick M. Gaffney, Timothy J. Vyse for SLEGEN, John B. Harley 4, Carl D. Langefeld, Sang-Cheol Bae 5, Kathy L. Sivils 6 and Betty P. Tsao 7, Oklahoma Medical Research Foundation, Oklahoma City, OK, Wake Forest School of Medicine, Winston-Salem, NC, Hanyang University Guri Hospital, Guri, South Korea, 4 Kyungpook National University School of Medicine, Daegu, South Korea, 5 Ajou University Hospital, Suwon, South Korea, 6 Dong-A University Hospital, Busan, South Korea, 7 Yonsei University College of Medicine, Seoul, South Korea, 8 Catholic University of Daegu School of Medicine, Daegu, South Korea, 9 Daejeon Rheumatoid & Degenerative Arthritis Center, Chungnam National University Hospital, Daejeon, South Korea, 0 Chonnam National University Medical School and Hospital, Gwangju, South Korea, Center for Genome Science, Korea National Institute of Health, Osong, South Korea, Korea National Institute of Health, Osong, South Korea, King s College London, Guy s Hospital, London, United Kingdom, 4 Cincinnati Children s Hospital Medical Center, Cincinnati, OH, 5 Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, 6 University of Oklahoma Health Sciences Center, Oklahoma City, OK, 7 David Geffen School of Medicine University of California Los Angeles, Los Angeles, CA 6. Sub-Phenotype Mapping In Systemic Lupus Erythematosus Identifies Multiple Novel Loci Associated With Circulating Interferon Alpha. Silvia Kariuki, Yogita Ghodke, Jessica M. Dorschner, Beverly Chrabot, Jennifer A. Kelly, Betty P. Tsao 4, Robert P. Kimberly 5, Marta E. Alarcon-Riquelme 6, Chaim O. Jacob 7, Lindsey A. Criswell 8, Kathy L. Sivils, Carl D. Langefeld 9, John B. Harley 0, Andrew D. Skol and Timothy B. Niewold, University of Chicago, Chicago, IL, Mayo Clinic, Rochester, MN, Oklahoma Medical Research Foundation, Oklahoma City, OK, 4 David Geffen School of Medicine University of California Los Angeles, Los Angeles, CA, 5 University of Alabama at Birmingham, Birmingham, AL, 6 Oklahoma Medical Research Foundation, Center for Genomics and Oncological Research Pfizer-University of Granada-Junta de Andalucia, Oklahoma City, OK, 7 University of Southern California Keck School of Medicine, Los Angeles, CA, 8 University of California, San Francisco, Rosalind Russell Medical Research Center for Arthritis, San Francisco, CA, 9 Wake Forest University Health Sciences, Winston-Salem, NC, 0 Cincinnati Children s Hospital Medical Center, Cincinnati, OH 64. Genome-Wide Transcriptional Profiling Of Isolated Immune Cell Populations From SLE Patients With Different Ancestral Backgrounds. Shruti Sharma, Zhongbo Jin, Elizabeth Rosenzweig, Swapna Rao, Kichul Ko and Timothy B. Niewold, University of Chicago, Chicago, IL, Mayo Clinic, Rochester, MN 76 0 Program Book

279 ACR POSTER SESSION B 65. Identification Of Novel Genetic Associations Within Major Histocompatibility Complex (MHC) Class I and Class II In Systemic Lupus Erythematosus (SLE) Patients: An Examination Of Epitopes Of Early Autoimmunity. Gerard Dumancas, Chee Paul Lin, Indra Adrianto, Jennifer A. Kelly, Stuart B. Glenn, Jourdan Anderson, John B. Harley, Timothy J. Vyse, Robert P. Kimberly 4, Marta E. Alarcon-Riquelme 5, Carl D. Langefeld 6, Betty P. Tsao 7, Lindsey A. Criswell 8, Chaim O. Jacob 9, Patrick M. Gaffney, Kathy Sivils, Judith A. James and Courtney Montgomery, Oklahoma Medical Research Foundation, Oklahoma City, OK, Cincinnati Children s Hospital Medical Center, Cincinnati, OH, Divisions of Genetics and Molecular Medicine and Immunology, King s College London, London, United Kingdom, 4 University of Alabama at Birmingham, Birmingham, AL, 5 Oklahoma Medical Research Foundation, Center for Genomics and Oncological Research Pfizer- University of Granada-Junta de Andalucia, Oklahoma City, OK, 6 Wake Forest University Health Sciences, Winston- Salem, NC, 7 David Geffen School of Medicine University of California Los Angeles, Los Angeles, CA, 8 University of California, San Francisco, Rosalind Russell Medical Research Center for Arthritis, San Francisco, CA, 9 University of Southern California Keck School of Medicine, Los Angeles, CA 66. Pro-Inflammatory HDL and Subclinical Atherosclerosis Are Associated With Altered Expression Of Epigenetic and Oxidative Stress-Related Gene Transcripts In SLE. Brian Skaggs, Bevra H. Hahn, Jennifer M. Grossman, Elaine Lourenco, Isao Matsuura, Lori Sahakian and Maureen A. McMahon, UCLA David Geffen School of Medicine, Los Angeles, CA 67. IKZF Modulates PPAc Expression Through An Intronic Binding Site. Kamalpreet Nagpal, Katsue S. Watanabe and George C. Tsokos, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama, Japan 68. Concurrent Autoimmune Disease and Autoantibodies In a Large, Multi-Racial Cohort Of First Degree Blood Relatives Of SLE Patients. Julie M. Robertson, Benjamin F. Bruner, Rufei Lu, Joel M. Guthridge, John B. Harley and Judith A. James 4, Oklahoma Medical Research Foundation, Oklahoma City, OK, Harding University, Searcy, AR, Cincinnati Children s Hospital Medical Center, Cincinnati, OH, 4 Oklahoma Medical Research Foundation and University of Oklahoma Health Sciences Center, Oklahoma City, OK 69. GWAS In Hispanic and Latin American Individuals Enriched For Amerindian Ancestry Identifies a New Locus Associated With Systemic Lupus Erythematosus. Marta Eugenia Alarcon Riquelme, Julie T. Ziegler, Mary E. Comeau, Elena Sanchez 4, Bernado Pons-Estel 5, Eduardo Acevedo 6, Jorge Mariano Cucho 6, Ignacio Garcia de la Torre 7, Mario H. Cardiel 8, Pedro Miranda 9, Luis Cattogio 0, Marco Maradiaga, Jorge Esquivel-Valerio, Jose F Moctezuma, Mercedes Garcia 4, Guillermo Berbotto 5, Alejandra Babini 6, Hugo Scherbarth 7, Sergio Toloza 8, Judith A James, Teresa Tusie-Luna 9, John B Harley 0, Raphael Zidovetski, Carl Langefeldt and Chaim O. Jacob, Oklahoma Medical Research Foundation, Oklahoma City, OK, Wake Forest School of Medicine, Winston-Salem, NC, Wake Forest University Health Sciences, Winston-Salem, NC, 4 King s College London, London, United Kingdom, 5 Hospital Provincial de Rosario, Rosario, Argentina, 6 Hospital Nacional Guillermo Almenara Irigoyen, Lima, Peru, 7 Hospital General de Occidente, Zapopan, Mexico, 8 Hospital General, Morelia, Mexico, 9 Universidad de Chile and Centro de Estudios Reumatologicos, Santiago de Chile, Chile, 0 Hospital Italiano, Buenos Aires, Argentina, Hospital General de Culiacán, Culiacan, Sinaloa, Mexico, Hospital Universitario Dr. José Eleuterio González, Universidad Autonoma de Nuevo León, Nuevo Leon, Mexico, Hospital General de Mexico, Mexico, Mexico, 4 Hospital San Martin, La Plata, Argentina, 5 Hospital Eva Peron, Granadero Baigorria, Argentina, 6 Hospital Privado de Cordoba, Cordoba, Argentina, 7 H.I.G.A. Oscar E. Alende, Mar del Plata, Argentina, 8 Hospital San Juan Bautista, Catamarca, Argentina, 9 Instituto de Investigaciones Biomédicas de la Universidad Nacional Autónoma de México, and Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico, Mexico, 0 Childrens Hospital, Cincinnati, OH, University of Southern California, Los Angeles, CA, University of Southern California Keck School of Medicine, Los Angeles, CA T cell Biology in Autoimmune Diseases 640. Methotrexate Treatment Affects Effector, But Not Regulatory T Cells in Juvenile Idiopathic Arthritis. Maja Bulatovic Calasan, S.J. Vastert, Rianne C. Scholman, Frederik Verweij, Mark Klein, Nico M. Wulffraat, Berent J. Prakken and Femke van Wijk, University Medical Center Utrecht, Utrecht, Netherlands 64. Bispecific Antibodies For Redirection Of Human Regulatory T Cells To Surface-Inducible Autoantigen La/ SS-B. Stefanie Koristka, Marc Cartellieri, Claudia Arndt, Anja Feldmann, Irene Michalk, Claudia C. Bippes, Nicole Berndt, Anne Hermsdorf, Slava Stamova, Biji T. Kurien, Robert Hal Scofield, A. Darise Farris 4, Judith A. James 5, Holger Bartsch and Michael Bachmann, Carl Gustav Carus TU-Dresden, Dresden, Germany, University of Oklahoma Health Sciences Center, Oklahoma City, OK, Arthritis & Clinical Immunology Program, Oklahoma Medical Research Foundation; Department of Medicine, University of Oklahoma Health Sciences Center; US Department of Veterans Affairs Medical Center, Oklahoma City, OK, 4 Oklahoma Medical Research Foun, Oklahoma City, OK, 5 Oklahoma Medical Research Foundation, Oklahoma City, OK 64. CD5+CD9+ Regulatory T Cells Are Enriched At The Site Of Inflammation Of Patients With Rheumatoid Arthritis and Impaired In Suppressing IL-7A Secretion. Jessica Herrath, Karine Chemin, Inka Albrecht, Anca Catrina and Vivianne Malmström, Karolinska University Hospital, Department of Medicine, Solna, Unit of Rheumatology, Stockholm, Sweden, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden, Rheumatology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden 0 Program Book 77

280 ACR POSTER SESSION B 64. Ex Vivo Suppression Of RA Effector T Cells (Teff) By Mapc Media Is Synergistic With Treg. Gali Malul, David Soler, Donald D. Anthony, Hillard M. Lazarus, Nicholas Lehman 4, Thomas McCormick, Julia M. Sugalski 5, Anthony E. Ting 4 and Nora G. Singer 6, MetroHealth Medical Center, Cleveland, OH, Case Medical Center, Cleveland, OH, Case Western Reserve University, Cleveland VA Medical Center, University Hospitals of Cleveland, Cleveland, OH, 4 Athersys, Inc., Cleveland, OH, 5 Case Western Reserve University, Cleveland, OH, 6 Director, Division of Rheumatology, MetroHealth Medical Center, Case Western Reserve University, Cleveland, OH 644. WITHDRAWN 645. Circulating CD4+CD6+ T Lymphocytes Are Increased In Seropositive Arthralgia Patients But Decreased In Patients With Newly Diagnosed Rheumatoid Arthritis. Paulina Chalan, Bart-Jan Kroesen, Kornelis S.M. van der Geest, Minke G. Huitema, Wayel H. Abdulahad, Elisabeth Brouwer and Annemieke M.H. Boots, University Medical Center Groningen, Groningen, Netherlands 646. Alterations In Circulating T Follicular Helper Cells and T Regulatory Cells In Autoimmune Rheumatic Diseases Treated With B Cell Depletion Therapy: Rituximab. Pamela M.K Lutalo, Yuan Zhao, Lee Meng Choong, Shirish Sangle, Jo Spencer and David P. D Cruz, Peter Gorer Department of Immunobiology, School of Medicine, King s College London, London, United Kingdom, Louise Coote Lupus Unit, St Thomas Hospital, London, United Kingdom 647. An Altered Frequency Of Circulating Follicullar T Helper Cell Counterparts and Their Subsets Is Associated With Increased Circulating Plasmablasts In Seropositive RA Patients. Irene Arroyo-Villa, M. Belén Bautista-Caro, Alejandro Balsa, Pilar Aguado, Alejandro Villalba, Chamaida Plasencia, Amaya Puig-Kröger, Emilio Martín- Mola and Maria Eugenia Miranda-Carus, Hospital La Paz- IdiPaz, Madrid, Spain, Hospital Gregorio Marañon, Madrid, Spain 648. PD- + CD45RB lo lo Autoantibody-Inducing CD4 T Cells (aicd4 T cells) As a Key In The Pathogenesis Of Systemic Lupus Erythematosus (SLE). Yumi Miyazaki, Ken Tsumiyama and Shunichi Shiozawa, Kyushu University Beppu Hospital, Beppu, Japan 649. Assessment Of Cytomegalovirus-Specific T Cell Responses Upon Initiation Of Immunosuppression In Patients Suffering From Rheumatic Diseases As Novel Approach For Functional Immune Monitoring. Emmanuelle Le Bras, Sandra Weigand, Ludwig Deml, Dagmar Halbritter 4, Boris P. Ehrenstein, Wolfgang Hartung and Martin Fleck, University Medical Center of Regensburg, Regensburg 905, Germany, Asklepios Clinic Bad Abbach, Bad Abbach, Germany, Lophius Biosciences GmbH, Regensburg 905, Germany, 4 University Medical Center of Regensburg, 904 Regensburg, Germany 65. WITHDRAWN 65. Autophagy May Contribute To Glucocorticoid Resistance In Patients With Myositis By Maintaining T Lymphocytes Homeostasis In The Muscles. Mei Zong, John Jörholt, Julia Winter, Eva Lindroos, Helena E. Harris and Ingrid E. Lundberg, Rheumatology Unit, Department of Medicine, Karolinska University Hospital in Solna, Karolinska Institutet, Stockholm, Sweden, Karolinska University Hospital, Solna, Karolinska Institutet, Stockholm, Sweden, Rheumatology Unit, Karolinska University Hospital in Solna, Karolinska Institutet, Stockholm, Sweden., Stockholm, Sweden 65. Rheumatoid Arthritis Synovial IL-+CD4+ T Cells Specifically Induce Matrix Metalloproteinase Production By Fibroblast-Like Synoviocytes. Maria C. Lebre, Pedro L. Vieira, Saïda Aarrass, Thomas Newsom-Davis, Paul Peter Tak and Gavin R. Screaton, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands, Imperial College London, London, United Kingdom, Academic Medical Center / University of Amsterdam, Department of Clinical Immunology and Rheumatology & GlaxoSmithKline, Amsterdam, Netherlands 654. Characterization Of T Cell Phenotype and Function In a Double Transgenic (Collagen-Specific TCR /HLA-DR) Humanized Model Of Arthritis. Seunghyun Kim, Bo Tang, Sarah Hammond, DL Cullins, David Brand, EF Rosloniec, John M. Stuart 4, Arnold E. Postlethwaite, AH Kang and Linda Myers, University of Tennessee Health Science Center, Memphis, TN, St. Jude Children s Research Hospital, Memphis, TN, VA Medical Center, Memphis, TN, 4 VA Medical Center, University of Tennessee Health Science Center, Memphis, TN 655. HLA-B7 and KIRDL Interactions Promote The Differentiation and Survival Of Proinflammatory T Cells In Spondyloarthritis. A. Ridley, I. Wong-Baeza, H. Hatano, J. Shaw, H. Al-Mossawi, P. Bowness and S. Kollnberger, University of Oxford, Oxford, United Kingdom 656. Interferon Type I and T Helper 7: A Dangerous Liaison In Primary Sjögren s Syndrome? Zana Brkic, Sandra M.J. Paulissen, Cornelia G. van Helden-Meeuwsen, Naomi I. Maria, Odilia B.J. Corneth, Nadine Davelaar, Jan Piet van Hamburg, Paul L. Van Daele, Virgil A. Dalm, Martin van Hagen, Erik Lubberts and Marjan A. Versnel, Erasmus Medical Center, Rotterdam, Netherlands Vasculitis II 657. Enothelin- Plays a Role In The Pathogenesis Of Reversible Cerebral Vasoconstriction Syndrome. Tariq Hammad, Leonard H. Calabrese, Ken Uchino, Seby John, Mark Stillman, Stewart Tepper, Colin O Rourke, Allison Janocha, Serpil Erzurum and Rula Hajj-Ali, Cleveland Clinic, Cleveland, OH, Cleveland Clinic Foundation, Cleveland, OH 650. The Route Of T Cell Priming Determines The Requirement For IL- In The Development Of Arthritis. Alison Finnegan, Yanxia Cao and Susan Olalekan, Rush University Medical Center, Chicago, IL 78 0 Program Book

281 ACR POSTER SESSION B 658. Vessel Wall Characteristics Using High Resolution Magnetic Resonance Imaging In Reversible Cerebral Vasoconstriction Syndrome and Central Nervous System vasculitis. Rula Hajj-Ali, Seby John, Tariq Hammad, Emmanuel Obusez, Ken Uchino, Stephen Jones, Ferdinand Hui, Russell Cerejo and Leonard H. Calabrese, Cleveland Clinic Foundation, Cleveland, OH, Cleveland Clinic, Cleveland, OH, Clevalnd Clinic, Cleveland, OH 659. Systematic Review Of Amyloid Beta-Related Angiitis: A Treatable Cause Of Vasculitis Affecting Central Nervous System. Abhijeet Danve and Atul Deodhar, Oregon Health and Science University, Portland, OR 660. Primary Central Nervous System Vasculitis: Treatment and Course. Carlo Salvarani, Robert D. Brown Jr., Teresa J. H. Christianson, John Huston III, Kenneth Calamia, Caterina Giannini and Gene G. Hunder, Arcispedale S Maria Nuova-IRCCS, Reggio Emilia, Italy, Mayo Clinic, Rochester, MN, Mayo Clinic, Jacksonville, FL 66. The Spectrum of childhood Inflammatory Brain Diseases; An Increasingly Recognised Field. Marinka Twilt, Eyal Muscal, Tania Cellucci, Pavla Dolezalova 4, Rob Forsyth 5, Susan Kim 6, David A. Cabral 7, Johannes Roth 8, Adam Kirton 9, Rolando Cimaz 0, Jasmin Kummerle-Deschner, Annet van Royen-Kerkhof, Jürgen Brunner, Gaelle Chedeville 4, Jordi Anton 5, Angela Robinson 6, Mary Toth 7, Tilmann Kallinich 8, Claudia Bracaglia 9, Alexis Boneparth 0, Shehla Sheikh and Susanne M. Benseler, The Hospital for Sick Children, Toronto, ON, Baylor College of Medicine, Houston, TX, Hamilton Health Sciences, McMaster, Hamilton, ON, 4 First Faculty of Medicine and General Faculty Hospital, Prague, Czech Republic, 5 Newcastle upon Tyne s NHS foundation Trust, Newcastle upon Tyne, United Kingdom, 6 Children s Hospital Boston, Boston, MA, 7 BC Children s Hospital, Vancouver, BC, 8 University of Ottawa, Ottawa, ON, 9 Alberta Children s Hospital, Calgary, AB, 0 A. Meyer Children s Hospital, Florence, Italy, University Childrens Clinic Tuebingen, Tuebingen, Germany, Wilhelmina Children s Hospital, Utrecht, Netherlands, University Children s Hospital, Innsbruck, Austria, 4 Montreal Children s Hospital, Montreal, QC, 5 Hospital Sant Joan de Deu, Barcelona, Spain, 6 University Hospital, Rainbow babies & Children s Hospital, Cleveland, OH, 7 Akron Children s Hospital, Akron, OH, 8 Charite, University Hospital Berlin, Berlin, Germany, 9 Division of Rheumatology, Department of Pediatric Medicine, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy, 0 The Children s Hospital at Montefiore, Bronx, NY, Hospital for Sick Children, Toronto, ON 66. Developing Guideline For Polymyalgia Rheumatica: Prioritisation Of Outcome Measures Perspective Of Patients, General Practitioners and Rheumatologists. Yogesh Singh, Christian Dejaco, Sarah Mackie, Daniel Ching 4, Artur Bachta 5, Ajesh Maharaj 6, Alexandre Wagner 7, Manuela Lima 8, David Jayne 9, Kevin Barraclough 0, Christian D Mallen, Stephen P. Merry, Jane Hollywood, Madeline Whitlock 4, Kate Gilbert 5, Pamela Hildreth 5, Jennifer Nott 5, Hannah Padbury 5, Jean Miller 5, Lorna Neill 5, David Tronnier 6, Pablo Perel 7, Andrew Hutchings 8, Dario Camellino 9, Steven E. Carsons 0, William Docken, Christina Duftner, Andy Abril, Robert F. Spiera 4, Colin T. Pease 5, Andreas P. Diamantopoulos 6, Frank Buttgereit 7, Peter V. Balint 8, Elisabeth Nordborg 9, Lina Bianconi 0, Billy Fashanu 4, Shunsuke Mori, Víctor M. Martínez- Taboada, Maria C. Cid, Wolfgang A. Schmidt 4, Marco A. Cimmino 5, Michael Schirmer 6, Carlo Salvarani 7, Eric L. Matteson and Bhaskar Dasgupta 8, Southend university hospital, Westcliff-on-sea, United Kingdom, Southend University Hospital, Westcliff-on-sea, United Kingdom, University of Leeds, Leeds, United Kingdom, 4 Timaru Hospital, Timaru, New Zealand, 5 Military Medical Institute, Warsaw, Poland, 6 Prince Mshiyeni Memorial Hospital, Durban, South Africa, 7 Universidade Federal de São Paulo, Sao Paulo, Brazil, 8 Universidade dos Açores, Azores, Portugal, 9 Addenbrookes Hospital University of Cambridge, Cambridge, United Kingdom, 0 Hoyland House General Practice, Painswick, United Kingdom, University of Keele, Keele, United Kingdom, Mayo Clinic, Rochester, MN, Southend Hospital, Southend, United Kingdom, 4 Southend University Hospital, Southend, United Kingdom, 5 PMRGCAUK, Southend, United Kingdom, 6 patients representative, Rochester, MN, 7 London School of Hygiene & Tropical Medicine, London, United Kingdom, 8 London School of Hygiene and Tropical Medicine, London, United Kingdom, 9 Clinica Reumatologica, Genova, Italy, 0 Winthrop University Hospital, Mineola, NY, Brigham Orth & Arthritis Center, Chestnut Hill, MA, Hopital Kufstein, Kufstein, Austria, Mayo Clinic, Jacksonville, FL, 4 Hospital for Special Surgery, New York, NY, 5 Leeds Teaching Hospitals NHS Trust, Harrogate, United Kingdom, 6 Hospital of Southern Norway Trust, Kristiansand, Norway, 7 Charité - Universitätsmedizin Berlin, Berlin, Germany, 8 National Institute of Rheumatology and Physiotherapy, Budapest, Hungary, 9 Sahlgenska University Hospital, Goteborg, Sweden, 0 Ambulatorio Medicina Generale, Bibbiano, Italy, NHO Kumamoto Saishunsou National Hospital, Kumamoto, Japan, Hospital Universitario Marqués de Valdecilla. IFIMAV., Santander, Spain, Hospital Clínic. University of Barcelona. IDIBAPS, Barcelona, Spain, 4 Med Ctr Rheumatology Berlin Buch, Immanuel Krankenhaus Berlin, Berlin, Germany, 5 University of Genoa, Genova, Italy, 6 Innsbruck Medical University, Innsbruck, Austria, 7 Arcispedale S Maria Nuova-IRCCS, Reggio Emilia, Italy, 8 Southend University Hospital, Essex, United Kingdom 0 Program Book 79

282 ACR POSTER SESSION B 66. Obese Polymyalgia Rheumatica Patients Experience More Pain and Disability and Need Higher Doses Of Glucocorticoids. Marco A. Cimmino, Bhaskar Dasgupta, Cynthia S. Crowson, Michael Schirmer 4, Christian Dejaco 5, Carlo Salvarani 6 and Eric L. Matteson, University of Genoa, Genova, Italy, Southend University Hospital, Westcliffon-Sea, United Kingdom, Mayo Clinic, Rochester, MN, 4 Innsbruck Medical University, Innsbruck, Austria, 5 Medical University Graz, Graz A-806, Austria, 6 Arcispedale S Maria Nuova-IRCCS, Reggio Emilia, Italy 664. Lower Tissue Expression Of IL 6 In Patients With Giant Cell Arteritis Presenting With a Cranial Ischaemic Compication. Lorraine O Neill, Jennifer McCormick, Danielle Molloy, Douglas J. Veale, Conor Murphy, Geraldine M. McCarthy, Ursula Fearon and Eamonn S. Molloy, St. Vincent s University Hospital, Dublin 4, Ireland, Royal Victoria Eye and Ear Hospital, Dublin, Ireland, Mater Misericordiae University Hospital, Dublin 7, Ireland 665. B Cells Revisited In Giant Cell Arteritis. Kornelis S.M. van der Geest, Wayel H. Abdulahad, Gerda Horst, Caroline Roozendaal, Abraham Rutgers, Annemieke M.H. Boots and Elisabeth Brouwer, University Medical Center Groningen, Groningen, Netherlands 666. Negative Temporal Artery Biopsies: Pathologic Findings Of Patients With Biopsy-Negative Giant Cell Arteritis Compared To Those Of Patients Without Arteritis. Francesco Muratore, Alberto Lo Gullo, Alberto Cavazza, Giuseppe Germanò, Luigi Boiardi and Carlo Salvarani, Arcispedale S Maria Nuova, IRCCS, Reggio Emilia, Italy, Arcispedale S Maria Nuova-IRCCS, Reggio Emilia, Italy 667. Serum S00A8/S00A9 and S00A As a Marker Of Disease Activity In Giant Cell Arteritis. Jason Springer, Dirk Holzinger, Gary S. Hoffman, Paul A. Monach 4, Thomas Hamilton 5, Carol A. Langford 5, Dirk Foell 6, David Cuthbertson 7, Colin O Rourke 5, Simon Carette 8, Nader A. Khalidi 9, Carol McAlear 0, Christian Pagnoux, Philip Seo, Kenneth J. Warrington, Steven R. Ytterberg, Thomas Vogl 4, Peter A. Merkel 0, Johannes Roth 4 and Rula Hajj- Ali, University of Kansas Medical Center, Kansas City, KS, University Muenster, Muenster, Germany, Cleveland Clinic Foundation, Cleveland, OH, 4 Boston University, Boston, MA, 5 Cleveland Clinic, Cleveland, OH, 6 Department of Pediatric Rheumatology and Immunology, University of Münster, Münster, Germany, 7 University of South Florida, Tampa, FL, 8 UHN/MSH, Toronto, ON, 9 McMaster University, Hamilton, ON, 0 University of Pennsylvania, Philadelphia, PA, Division of Rheumatology, Mount Sinai Hospital, Toronto, ON, Johns Hopkins Vasculitis Center, Baltimore, MD, Mayo Clinic, Rochester, MN, 4 University of Muenster, Muenster, Germany 668. Does Fibrinogen Have a Role In The Assessment Of Patients With Giant Cell Arteritis? Lorraine O Neill, Eoghan M. McCarthy, Anne M. Madigan, Geraldine M. McCarthy, Eamonn S. Molloy, Ursula Fearon, Douglas J. Veale and Conor Murphy, St. Vincent s University Hospital, Dublin 4, Ireland, Mater Misericordiae University Hospital, Dublin 7, Ireland, Royal Victoria Eye and Ear Hospital, Dublin, Ireland 669. The Birmingham Vasculitis Activity Score As a Measure Of Disease Activity In Patients With Giant Cell Arteritis. Tanaz A. Kermani, David Cuthbertson, Simon Carette, Gary S. Hoffman 4, Nader A. Khalidi 5, Curry L. Koening 6, Carol A. Langford 7, Kathleen McKinnon-Maksimowicz 8, Carol McAlear 9, Paul A. Monach 0, Philip Seo, Kenneth J. Warrington, Steven R. Ytterberg, Peter A Merkel and Eric L. Matteson, University of California Los Angeles, Los Angeles, CA, University of South Florida, Tampa, FL, UHN/ MSH, Toronto, ON, 4 Cleveland Clinic Foundation, Cleveland, OH, 5 McMaster University, Hamilton, ON, 6 Salt Lake City Veterans Administration, Salt Lake City, UT, 7 Cleveland Clinic, Cleveland, OH, 8 University of Pittsburgh, Pittsburgh, PA, 9 University of Pennsylvania, Philadelphia, PA, 0 Boston University, Boston, MA, Johns Hopkins Vasculitis Center, Baltimore, MD, Mayo Clinic, Rochester, MN, University of Pennsylvania and VA Medical Center, Philadelphia, PA 670. Large Vessel Vasculitis: Estimating Disease Activity In Patients With Inflammatory Thoracic Aortic Aneurysms. Alison Clifford, Tiffany M. Clark, Douglas Johnston, Gosta Pettersson, Eric Roselli, E. Rene Rodriguez, Edward Soltesz, Lars Svensson, Carmela Tan and Gary S. Hoffman, Cleveland Clinic Foundation, Cleveland, OH 67. Cardiovascular Risk At Incidence Of Giant Cell Arteritis: A Population Based Retrospective Cohort Study. P. Deepak Udayakumar, Arun K. Chandran, Cynthia S. Crowson, Kenneth J. Warrington and Eric L. Matteson, Mayo Clinic, Rochester, MN 67. Serious Cardiovascular Events Risk Factors In Giant Cell Arteritis. A Population-Based Study In The French Apogee Cohort. Grégory Pugnet, Laurent Sailler, Guillaume Moulis, Jean-Pascal Fournier 4, Robert Bourrel 5, Jean- Louis Montastruc 6 and Maryse lapeyre-mestre 6, Toulouse University Hospital, University of Toulouse, INSERM UMR 07, Toulouse, France, Toulouse University Hospital, Toulouse, France, Toulouse University Hospital, Clinical Pharmacology Department, University of Toulouse, UMR INSERM-UPS 07, Toulouse, France, 4 Toulouse University, INSERM UMR 07, Toulouse, France, 5 Caisse Nationale de l Assurance Maladie échelon régional, Midi-Pyrénées, Toulouse, France, 6 Toulouse University Hospital, INSERM U07, University of Toulouse, France, Toulouse, France 67. Risk Of Myocardial Infarction In Patients With Giant Cell Arteritis: A Population-Based Study. Neda Amiri, Hyon K. Choi, Eric C. Sayre, Kamran Shojania and J. Antonio Avina-Zubieta, University of British Columbia, Vancouver, BC, Arthritis Research Centre of Canada, Richmond, BC, Arthritis Research Centre of Canada, University of British Columbia, Richmond, BC 80 0 Program Book

283 ACR POSTER SESSION B 674. Acute Coronary Syndromes In Patients With Giant Cell Arteritis: A Population Based Retrospective Cohort Study. P. Deepak Udayakumar, Arun K. Chandran, Cynthia S. Crowson, Kenneth J. Warrington and Eric L. Matteson, Mayo Clinic, Rochester, MN 675. Infections Requiring Or Acquired During Hospitalizations In Patients With Giant Cell Arteritis - a Population Based Retrospective Cohort Study. P. Deepak Udayakumar, Arun K. Chandran, Cynthia S. Crowson, Kenneth J. Warrington and Eric L. Matteson, Mayo Clinic, Rochester, MN 676. Statins Do Not Influence Occurrence Or Prednisone Requirement Of Giant Cell Arteritis. A French Population- Based Cohort Study. Grégory Pugnet, Laurent Sailler, Robert Bourrel, Jean-Louis Montastruc 4 and Maryse Lapeyre-Mestre 4, Toulouse University Hospital, University of Toulouse, INSERM UMR 07, Toulouse, France, Toulouse University Hospital, Toulouse, France, Caisse Nationale de l Assurance Maladie échelon régional, Midi- Pyrénées, Toulouse, France, 4 Toulouse University Hospital, INSERM U07, University of Toulouse, France, Toulouse, France 677. May Giant Cell Arteritis Be Characterized By Different Clinical Entity and Long-Term Outcome? Rosaria Talarico, Chiara Stagnaro, Claudia Ferrari, Anna d Ascanio, Chiari Tani, Chiara Baldini, Marta Mosca and Stefano Bombardieri, Rheumatology Unit, Pisa, Italy, Rheumatology Unit, University of Pisa, Pisa, Italy 678. How Similar Are Extracranial Giant Cell Arteritis and Takayasu Arteritis? Tanaz A. Kermani, Cynthia S. Crowson, Francesco Muratore, Jean Schmidt 4, Eric L. Matteson and Kenneth J. Warrington, University of California Los Angeles, Los Angeles, CA, Mayo Clinic, Rochester, MN, Arcispedale S Maria Nuova, IRCCS, Reggio Emilia, Italy, 4 CHU Nord, Amiens, France 679. Clinical Implications Of Antiphospholipid Antibodies In Takayasu s Arteritis. Natasha Jordan, Holy Bezanahary and David P. D Cruz, Louise Coote Lupus Unit, St Thomas Hospital, London, United Kingdom 680. Predictivity Of Serum Biomarkers For Disease Activity In a Prospectively Followed-Up Takayasu Arteritis Cohort: Is Serum Amyloid A Protein Better Than Conventional Acute Phase Markers? Ahmet Omma, Burak Erer, Nilufer Alpay, Nuray Gurel Polat, Ahmet Gul, Murat Inanc, Lale Ocal and Sevil Kamali, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey 68. Assessment of Patients With Takayasu s Arteritis in Routine Clinical Follow-Up With Indian Takayasu Clinical Activity Score 00(ITAS00). Fatma Alibaz-Oner and Haner Direskeneli, Marmara University, School of Medicine, Istanbul, Turkey 68. Patients With TAKAYASU S Arteritis Having Persistent ACUTE PHASE Response Usually Have An Increased MAJOR Vessel Uptake By 8F-FDG-PET/CT. Fatma Alibaz- Oner, Fuat Dede, Tunc Ones, H.Turgut Turoglu and Haner Direskeneli, Marmara University, School of Medicine, Istanbul, Turkey, Marmara University, School of Medicine, ISTANBUL, Turkey 68. High Prevalence Of Metabolic Syndrome In Takayasu Arteritis: An Increased Cardiovascular Risk and Lower Adiponectin Serum Levels. Thiago Silva, Mauricio Levy- Neto, Rosa M. R. Pereira and Eloisa Bonfa 4, Faculdade de Medicina da Universidade de Sao Paulo, Sao Paulo, Brazil, Faculdade de Medicina da Universidade de São Paulo, Sao Paulo, Brazil, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, 4 Universidade de Sao Paulo, São Paulo, Brazil 684. Early Combination Immunosuppression and Serial Non- Invasive Imaging Improves Outcome In Takayasu Arteritis. Taryn Youngstein, Michael Quinn, James Peters and Justin C. Mason, Hammersmith Hospital, Imperial College London, London, United Kingdom 685. Long-Term Use Of Tocilizumab For The Treatment Of Giant Cell Arteritis. Sebastian Unizony, John Stone and Brian Keroack, Massachusetts General Hospital, Harvard Medical School, Boston, MA, Maine Medical Center, Tufts University Medical School, Maine, ME 686. Tocilizumab In Refractory Takayasu Arteritis: a Case Series and Updated Literature Review.². Noemie Abisror, Arsene Mekinian, Christian Lavigne, Marie Anne Vandenhende, Michael Soussan 4 and Olivier Fain, Internal Medicine, Jean Verdier Hospital, Bondy, France, Internal Medicine, Angers, France, Internal Medicine, Bordeaux, France, 4 Nuclear Medicine, Avicennes Hospital, Bobigny, France 687. Tocilizumab In Refractory Aortitis: A Multicenter Study Of Patients. Javier Loricera, Ricardo Blanco, Santos Castañeda, Alicia Humbría, Sheila Melchor 4, Jaime Calvo- Alen 5, Elena Aurrecoechea 5, Íñigo Rúa-Figueroa 6, Norberto Ortego 7, Mauricio Mínguez 8, Gabriel Herrero-Beaumont 9, Beatriz Bravo 0, Jose Rosas, Javier Narvaez, Javier Calvo, Rafael Ariza 4, Mercedes Freire 5, M. Enriqueta Peiró, Vanesa Calvo-Río, Francisco Ortiz-Sanjuán and Miguel A. González-Gay, Hospital Universitario Marqués de Valdecilla. IFIMAV. Santander. Spain, Santander, Spain, Hospital Universitario de La Princesa, IIS Princesa, Madrid, Spain, Hospital Universitario de La Princesa. IIS Princesa. Madrid, Madrid, Spain, 4 Hospital Universitario de Octubre. Madrid, MADRID, Spain, 5 Hospital Sierrallana. Torrelavega, Torrelavega, Spain, 6 Hospital Universitario Dr Negrín. Las Palmas, Las Palmas de Gran Canaria, Spain, 7 Hospital Clínico San Cecilio. Granada, Granada, Spain, 8 Hospital Universitario San Juan. Alicante, Alicante, Spain, 9 IIS-Fundación Jiménez Díaz, Madrid, Spain, 0 Hospital Virgen de las Nieves. Granada, Granada, Spain, Hospital Marina Baixa. Villajoyosa, Villajoyosa, Spain, Hospital Universitario de Bellvitge, Barcelona, Spain, Consorcio Hospital General Universitario. Valencia, Valencia, Spain, 4 University Hospital Virgen Macarena.Sevilla, Sevilla, Spain, 5 Hospital Universitario Juan Canalejo. La Coruña, La Coruña, Spain 0 Program Book 8

284 ACR POSTER SESSION B 688. Does The Treatment With Anti-Coagulants and Anti- Platelets Protect Giant Cell Arteritis Patients From Visual Manifestations? Andreas P. Diamantopoulos, Helene Hetland, Glenn Haugeberg, Dag Magnar Soldal and Geirmund Myklebust, Hospital of Southern Norway Trust, Kristiansand, Norway 689. Antiplatelet Agents Decrease Ischemic Complications In Systemic Large Vessel Vasculitides: A Meta-Analysis. James Jeong and Lillian J. Barra, Schulich School of Medicine & Dentistry, Western University, London, ON, Schulich School of Medicine and Dentistry, Western University, London, ON 8 0 Program Book

285 ACR/ARHP POSTER SESSION C TUESDAY, OCTOBER 9, 0 Exhibit Hall B-C-D Biology and Pathology of Bone and Joint (Bone and Arthritis) 8. Oleanolic Acid Acetate Inhibits Osteoclast Differentiation By Downregulating Phospholipase Cγ calcium ion oscillation-nuclear Factor Of Activated T Cell c Signaling, and Suppresses Bone Loss In Mice. Chang- Hoon Lee, Myeung Su Lee, Won Seok Lee, Wan-Hee Yoo, Ju-Young Kim, Jae-Min Oh and Yong-Geun Jeong 4, Department of Internal Medicine, School of Medicine, Wonkwang University, Iksan, Chonbuk, South Korea, Department of Internal Medicine, Chonbuk National University Medical School and Research Institute of Clinical Medicine, Jeonju, South Korea, Department of Anatomy, School of Medicine, Wonkwang University, Iksan, South Korea, 4 Division of Rheumatology, Department of Internal Medicine, Changwon Fatima Hospital, Changwon, South Korea 8. IL-6 Suppresses Osteoblast Differentiation Through The SHP/MEK and SHP/Akt Pathways In Vitro. Shoichi Kaneshiro, Kosuke Ebina, Kenrin Shi, Chikahisa Higuchi, Hideki Yoshikawa, Jun Hashimoto and Makoto Hirao, Osaka University Graduate School of Medicine, Suita, Japan, Osaka-Minami Medical Center, Kawachinagano City, Japan, Osaka Minami Medical Center, Osaka, Japan 84. ONO A Novel Small Molecule Dual Inhibitor Of Bruton s Tyrosine Kinase (Btk) and Tec Kinase- Suppresses Osteoclastic Bone Resorption and Inflammation. Yuko Ariza, Toshio Yoshizawa, Yoshiko Ueda, Shingo Hotta, Tomoko Yasuhiro, Masami Narita, Yutaka Shichino and Kazuhito Kawabata, Ono Pharmaceutical Co., Ltd., Osaka, Japan 85. Osteoclast Progenitors, Fibroblast-Like Cells and Draining Lymph Node Cells Induce Catecholaminergic- To-Cholinergic Transition Of Sympathetic Nerve Fibers Under Healthy Conditions But Not In Highly Inflamed Arthritic Tissue. Hubert Stangl, Dominique Muschter, Susanne Graessel and Rainer H. Straub, Laboratory of Exp. Rheumatology and Neuroendocrino-Immunology, University Hospital of Regensburg, Regensburg, Germany, Division of Experimental Orthopedic Surgery, University Hospital of Regensburg, Regensburg, Germany 86. Immune Complex Formation By Adalimumab Contributes Significantly To Its Inhibitory Effect On TNF-Enhanced Human Osteoclast Development Even In The Absence Of Fc Receptor Binding. Bohdan P. Harvey and Zehra Kaymakcalan, AbbVie Bioresearch Center, Worcester, MA 87. The Intraarticular Injection Of An Inhibitor Of Complex V Of Mitochondrial Respiratory Chain Induces a Pathological Response In Rat Knee Joints. Carlos Vaamonde-García, Jesus Loureiro, Eduardo López-Peláez, Alberto Centeno- Cortés, Romina R. Riveiro-Naveira, M. Noa Valcárcel-Ares, Francisco J. Blanco and Maria J. López-Armada, Aging and Inflammation Research Lab, INIBIC-CHU A Coruña, A Coruña, Spain, Experimental Surgery Unit, CHU A Coruña, A Coruña, Spain, Osteoarticular and Aging Res. Lab. CIBER- BBN. INIBIC- University of A Coruña, A Coruña, Spain 88. In Vivo Cartilage-Specific Deletion Of Ephrin-B In Mice Results In Developmental Locomotory Defects Associated With Hip Bone Abnormality. Gladys Valverde-Franco, Bertrand Lussier, David Hum, Jiangping Wu, Jean-Pierre Pelletier, Mohit Kapoor and Johanne Martel-Pelletier, Osteoarthritis Research Unit, University of Montreal Hospital Research Centre (CRCHUM), Montreal, QC, Department of Clinical Sciences, Faculty of Veterinary Medicine, University of Montreal, Saint-Hyacinthe, QC, Laboratory of Immunology, University of Montreal Hospital Research Centre (CRCHUM), Montreal, QC 89. Carboxypeptidase B Down-Regulates Osteoclast Activation In Inflammation. Jason Jungsik Song, Sang-Won Lee, Yong-Beom Park, Soo Kon Lee, Lawrence Leung and William H. Robinson, Yonsei University College of Medicine, Seoul, South Korea, Stanford University School of Medicine, Stanford, CA 80. Adenosine A A Receptor (AAR) Diminishes Wear Particle (UHMWPE)-Mediated Osteolysis, Increases Bone Formation and Regulates Expression Of Axonal Guidance Proteins (AGP) By Macrophages, Osteoclasts (OC) and Osteoblasts (OB). Aranzazu Mediero, Tuere Wilder, Miguel Perez-Aso and Bruce N. Cronstein, NYU School of Medicine, New York, NY, New York University School of Medicine, New York, NY, NYU School of Medicine, Division of Rheumatology, New York, NY 8. Study Of Serum Levels Of Osteocalcin (s-oc) On Patients With Diffuse Idiopathic Skeletal Hyperostosis (DISH) and Ankylosing Spondilitis (AS). Mariela Geneva-Popova, Stojan Andreev, Pavel Pavlov, Daniel Ilev and Stanislava Popova, Medical University, Plovdiv, Plovdiv, Bulgaria, MHAT Tokuda, Sofia, Bulgaria 8. Discovery of MicroRNAs in the Regulation of Inflammation and Bone Erosion in Rheumatoid Arthritis. Ellen M. Gravallese, Yukiko Maeda, Nicholas Farina, Paul Fanning and Jane Lian, University of Massachusetts Medical School, Worcester, MA, University of Vermont College of Medicine, Burlington, VT, University of Massachusetts Medical School, worcester, MA 8. Combination Of TNF and IL-6 Induces Osteoclast-Like Cells With Bone-Resorption Activity Both In Vitro and In Vivo. Kazuhiro Yokota, Kojiro Sato and Toshihide Mimura, Saitama Medical University, Saitama, Japan 84. Abnormal Collagen Fibers Deposition In The Synovial Joints Is a Characteristic Of The Temporal Evolution Of The Diabetic rats Model Induced By Streptozotocin. Priscila C Andrade, Ana Paula P. Velosa, Jymenez Morais, Edwin R. Parra, Cláudia Goldeinstein-Schainberg, Vera L. Capelozzi and Walcy R. Teodoro, University of Sao Paulo School of Medicine, São Paulo, Brazil, University of Sao Paulo School of Medicine, Sao Paulo, Brazil 0 Program Book 8

286 ACR POSTER SESSION C Dynamic Visualization Of Monocyte Migration In D Synovial Micromass Tissue Cultures. Clemens Scheinecker, Ruth Byrne, Karolina Dalwigk, Anastasiya Hladik, Gunter Steiner, Josef S. Smolen and Hans Peter Kiener, Medical University of Vienna, Vienna, Austria, Medical University of Vienna and Hietzing Hospital, Vienna, Austria 86. Suppression Of HDAC5 Expression By Inflammatory Cytokines Is Required To Promote CXCL Chemokine Production In RA FLS. Chiara Angiolilli, A.M. Grabiec, P.A. Kabala, Paul-Peter Tak, D. Baeten and Kris A. Reedquist, Department of Clinical Immunology and Rheumatology Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands, Academic Medical Center / currently also GlaxoSmithKline, Amsterdam, Netherlands 87. Three-Dimension Culture Of Mesenchymal Stem Cells With Nano-Fiber Scaffold Induces Chondrogenesis and Osteogenesis. Kunihiro Yamaoka, Koshiro Sonomoto, Xiangmei Zhang, Masahiro Kondo, Shunsuke Fukuyo, Makoto Satake, Hiroaki Kaneko, Kazuhisa Nakano, Yosuke Okada and Yoshiya Tanaka, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, Integrative Technology Research Institute, Teijin Limited, Tokyo, Japan 88. The Use Of Three-Dimensionally Printed β-tricalcium Phosphate/Hydroxyapatite To Understand The Regulation Of Adenosine Receptors In Osteoclast Formation and Promotion In Bone Regeneration. Stephanie Ishack, Aranzazu Mediero, Tuere Wilder, John Ricci and Bruce N. Cronstein, NYU School of Medicine, New York, NY, NYU Dental School, New York, NY, NYU School of Medicine, Division of Rheumatology, New York, NY 89. Osteoclastogenesis Is Enhanced By Synovial Fluid Derived Anti-Citrullinated Proteins Antibodies In Rheumatoid Arthritis. Akilan Krishnamurthy, Heidi Wähämaa, Vijay Joshua, Catia Cerqueira, Elena Ossipova, Nancy Vivar Pomiano, Karin Lundberg, Vivianne Malmström 4, Per-Johan Jakobsson, Lars Klareskog, Georg Schett 5, Jimmy Ytterberg 6 and Anca I Catrina, Rheumatology unit, Karolinska University Hospital, Karolinska Institute, Stockholm, Sweden, Rheumatology unit, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden, Stockholm, Sweden, Rheumatology unit, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden, 4 Rheumatology unit, Karolinska University Hospital, Karolinska Institutet, STockholm, Sweden, Stockholm, Sweden, 5 University of Erlangen- Nuremberg, Erlangen, Germany, 6 Rheumatology Unit, Karolinska University Hospital, Karolinska Institute, Stockholm, Sweden 0 Program Book Cytokines, Mediators, Cell-cell Adhesion, Cell Trafficking and Angiogenesis II 840. Increased Expression of BAFF Receptor On Monocytes Is a Contributory Factor of Hypergammaglobulinemia in Patients With Primary Sjögren s Syndrome. Keiko Yoshimoto, Maiko Tanaka, Masako Kojima, Hideko Ogata, Eriko Ishioka, Ayumi Nishikawa, Katsuya Suzuki, Hideto Kameda, Tohru Abe and Tsutomu Takeuchi, Keio University School of Medicine, Tokyo, Japan, Saitama Medical School, Kawagoe-shi Saitama, Japan 84. BAFF Induces Production of Matrix Metalloproteinase-9 By Peripheral Monocytes in Patients With Primary Sjögren s Syndrome Through a Signaling Pathway That Involves NF-Kb and PI Kinase. Keiko Yoshimoto, Maiko Tanaka, Masako Kojima, Hideko Ogata, Eriko Ishioka, Ayumi Nishikawa, Katsuya Suzuki, Hideto Kameda, Tohru Abe and Tsutomu Takeuchi, Keio University School of Medicine, Tokyo, Japan, Saitama Medical School, Kawagoe-shi Saitama, Japan 84. Pathophysiological Effects Of Free Fatty Acids On Key Cells Of Arthritis. Klaus W. Frommer, Andreas Schäffler, Stefan Rehart, Angela Lehr, Ulf Müller-Ladner and Elena Neumann, Justus-Liebig-University of Gießen, Kerckhoff- Klinik, Bad Nauheim, Germany, Justus-Liebig-University of Giessen, Giessen, Germany, Markus-Hospital, Frankfurt, Germany 84. Treatment With Staphyloccocal Protein A Which Is Immuno-Modulatory In The Murine Collagen Arthritis Model, Does Not Increase Infection Severity In Murine Listeria Or Candida Challenge Models, In Contrast To Anti-TNF Treatment. Edward Bernton and Valerie Lowe, Protalex Inc., Summit, NJ, Washington Biotechnology, Inc., Baltimore, MD 844. Rheumatoid Arthritis, Sjogren s Syndrome and Systemic Lupus Erythematosus Patients Have a Distinct Spectrum Of Serum Anticytokine Autoantibodies. Sarthak Gupta, Ioanna P. Tatouli, Lindsey B. Rosen, Sarfaraz A. Hasni, Richard M. Siegel, Steven M. Holland, Haralampos M. Moutsopopoulos and Sarah K. Browne, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, School of Medicine, National University of Athens, Athens, Greece, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 845. Soluble Type I Interferon Receptor Is Elevated By Interferon Treatment and In Certain Autoimmune Diseases. Taher Fatakdawala, Michael Skawinski, Jonathan Ferriera, Tara Stauffer and Thomas Lavoie, PBL Assay Science, Piscataway, NJ 846. Mitochondrial Dysfunction Induces An Inflammatory, Tissue-Degrading, and Angiogenic Response In Normal Human Synoviocytes. M. Noa Valcárcel-Ares, Romina R. Riveiro-Naveira, Jesus Loureiro, Carlos Vaamonde-García, Laura Hermida-Carballo, Francisco J. Blanco and Maria J. López-Armada, Aging and Inflammation Research Lab, INIBIC-CHU A Coruña, A Coruña, Spain, Osteoarticular and Aging Res. Lab. CIBER-BBN. INIBIC- University of A Coruña, A Coruña, Spain

287 ACR POSTER SESSION C 847. Certolizumab-Pegol Induces Reverse Signaling Through Membrane TNF Via Calcineurin Activation In Human Monocytes. Relevance In Inflammation. Jean-Frederic Boyer, Michel Baron, Delphine Nigon, Arnaud L. Constantin, Alain G. Cantagrel and Jean-Luc Davignon, INSERM CNRS UMR 04, Paul Sabatier University Toulouse, Toulouse, France, Purpan University Hospital, Toulouse Cedex 9, France 848. Human Gingiva-Derived Mesenchymal Stromal Cells Inhibit Graft-Versus-Host Disease Through CD9 and IDO. Song Guo Zheng, Maogeng Chen, Dong Dong Chen, Jian Gu and Yi Shen, University of Southern California Keck School of Medicine, Los Angeles, CA, Zhoushan Hospital at Zhejiang Province, Zhoushan, China, Shanghai East Hospital at Tongji University, Shanghai, China 849. Proteomic Analysis Of Connexin 4 Reveals Association With Proteins Dysfunctional Related With Osteoarthrosis. Patricia Fernández-Puente, Raquel Gago-Fuentes, Paula Carpintero-Fernández, Jesús Mateos, Maria Dolores Mayan and Francisco J. Blanco, Osteoarticular and Aging Research Group. Rheumatology Division, Biomedical Research Center (INIBIC). Hospital Universitario A Coruña, Xubias de Arriba 84, 5006, A Coruña, Spain, Correspondence to: Ma.Dolores.Mayan.Santos@sergas. es and [email protected], A Coruña, Spain, Osteoarticular and Aging Res. Lab. CIBER-BBN. INIBIC- University of A Coruña, A Coruña, Spain 850. The Bromodomain Protein Inhibitor I-BET5 Suppresses Inflammatory and Matrix Degrading Properties Of Rheumatoid Arthritis Synovial Fibroblasts. Kerstin Klein, Renate E. Gay, Christoph Kolling, Lih-Ling Lin, Steffen Gay and Caroline Ospelt, Center of Experimental Rheumatology, University Hospital Zurich and Zurich Center of Integrative Human Physiology (ZIHP), Zurich, Switzerland, Schultess Clinic, Zurich, Switzerland, Pfizer, Cambridge, MA 85. Adenosine A Receptor Promotes Collagen Production By Human Fibroblasts Via Smad/-Independent Pathways Involving Cyclic AMP and AKT. Miguel Perez-Aso, Patricia Fernandez, Aranzazu Mediero, Edwin SL Chan and Bruce N. Cronstein 4, New York University School of Medicine, New York, NY, National Cancer Institute, NIH, Bethesda, MD, NYU School of Medicine, New York, NY, 4 NYU School of Medicine, Division of Rheumatology, New York, NY 85. Adenosine AA Receptors (AAR) Promote Scarring By Repressing Mir-9a. Ross C. Radusky, Miguel Perez-Aso, Andrew G. Franks Jr., Bruce N. Cronstein and Edwin SL Chan, New York University School of Medicine, New York, NY, New York University, New York, NY, NYU School of Medicine, Division of Rheumatology, New York, NY 85. Functions Of Aminopeptidase N/CD In Vitro On Rheumatoid Arthritis Synovial Cells. Rachel Morgan, Nilofar Behbahani-Nejad, Judith Endres and David A. Fox, University of Michigan, Ann Arbor, MI, University of Michigan Medical Center, Ann Arbor, MI, Division of Rheumatology, University of Michigan Medical Center, Ann Arbor, MI 854. The Involvement Of Mast Cells In The Development Of Lung Fibrosis Via Modulating Pulmonary Fibroblast Immune Function. Shinjiro Kaieda, Morihisa Tajiri, Masaki Okamoto, Naomi Yoshida, Hiroaki Ida, Tomoaki Hoshino and Takaaki Fukuda, Kurume University School of Medicine, kurume, Japan, Kurume University School of Medicine, Kurume, Japan, Kurume University Medical Center, Kurume, Japan 855. IL-6 Promotes Systemic Bone Loss Via Upregulation Of SPR In Osteoclast Precursors In a Mouse Collagen- Induced Arthritis Model. Keisuke Tanaka, Misato Hashizume, Hiroto Yoshida, Miho Suzuki and Yoshihiro Matsumoto, Chugai Pharmaceutical Co., Ltd., Gotemba, Japan 856. Potentiating Effects Of IL-7A, IL-7AF, IL-7F In Combination With TNF But Not With IL-beta In Human Primary Fibroblast-Like Synoviocytes From Rheumatoid Arthritis Patients. Christine Huppertz, Marija Curcic Djuric, Robert Hennze, Friedrich Raulf, Frank Kolbinger, Anis Mir and David Lee, Autoimmunity, Transplantation and Inflammatory Disease, Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, SWITZERLAND, Basel, Switzerland, Novartis Pharma AG, Basel, Switzerland 857. Identification Of SOX5 and SOX6 As Potent Regulators Of RANKL Expression Contributing To Bone Erosion In Rheumatoid Arthritis and Experimental Arthritis Model. Wenfeng Tan, Xiaoke Feng, Lingxiao Xu, Ke Gan, Fang Wang, Miaojia Zhang 4, Hui Wu 5 and Betty P. Tsao 6, the First Affiliated Hospital of Nanjing Medical University, Nanjing, China, the First Affiliated Hospital of Nanjing Medical University, China, Nanjing, China, the First Affiliated Hospital of Nanjing Medical University, Nanjing, CHINA., Nanjing, China, 4 Department of Rheumatology, Jiangsu Provincial People s Hospital, Nanjing, China, 5 David Geffen School of Medicine University of California Los Angeles, Los Angeles, CA, 6 UCLA School of Medicine, Los Angeles, CA 858. Investigating The Role Of IL- In The Pathogenesis Of Familial Mediterranean FEVER. Dilek Keskin, Goksal Keskin, Ali Inal and Lale Ozisik, DYB Research and Training Hospital, Ankara, Turkey, MD, Ankara, Turkey 859. OX40 + T Cells and OX40L + B Cells Accumulate In The Inflamed Joints and OX40 Signalling Is Skewed Towards Autoreactivity. Julie Kristine Laustsen, Tue Rasmussen, Malene Hvid and Bent Deleuran, Aarhus University, Aarhus N, Denmark, Aarhus University, Aarhus, Denmark, Aarhus University Hospital, Aarhus, Denmark 860. Novel Proinflammatory Microvesicles That Carry LL-7 In Patients With Cutaneous Lupus. Ming-Lin Liu, Muhammad Bashir, Meena Sharma, Honghui Xu, Kevin Williams, Cynthia O. Anyanwu 4, Joyce Okawa and Victoria P. Werth 5, University of Pennsylvania, Philadelphia, PA, Philadelphia V.A. Hospital, Philadelphia, PA, Temple University School of Medicine, Philadelphia, PA, 4 Philadelphia Veterans Affairs Medical Center, Philadelphia, PA, 5 University of Pennsylvania School of Medicine, Philadelphia, PA 0 Program Book 85

288 ACR POSTER SESSION C Neurotrophins Are Involved In Vascular Remodeling Of Giant Cell Arteritis. Kim Heang Ly, Alexis Régent, Elsa Molina, Sofiane Saada, Philippe Sindou, Claire Le Jeunne 4, Antoine Brezin 5, Veronique witko-sarsat, Philippe Bertin 6, Francois Labrousse, Pierre-Yves Robert, Anne- Laure Fauchais 7, Elisabeth Vidal 7, Luc Mouthon 8 and Marie- Odile Jauberteau, Limoges University Hospital, Limoges, France, Institut Cochin, INSERM U06, CNRS UMR 804, Université Paris Descartes, Paris, France, Limoges Medical School, Limoges, France, 4 Hotel-Dieu Hospital, AP-HP, Paris, Paris, France, 5 Service d ophtalmologie, hôpital Cochin, AP-HP, Paris, France, 6 Hôpital Dupuytren, Limoges, France, 7 Department of Internal Medicine A, Dupuytren Hospital, Limoges University Hospital, Limoges, France, 8 Department of Internal Medicine, Referral Center for Rare Autoimmune and Systemic Diseases, Hôpital Cochin, AP HP, Université Paris Descartes, Paris, France, Paris, France 86. Target-Directed Development Of a Proposed Biosimilar Etanercept, GP05: Comparability Of In Vitro Target Binding and Pre-Clinical Efficacy and Pharmacokinetics. Antonio da Silva, Ulrich Kronthaler, Cornelius Fritsch, Johann Poetzl, Adelheid Rohde 4, Anastassia Papandrikopoulou, Hans-Peter Hofmann 5 and Jan Marinus Visser, Sandoz Biopharmaceuticals / HEXAL AG, Holzkirchen, Germany, Novartis Pharma AG, Basel, Switzerland, Sandoz Biopharmaceuticals/Hexal AG, Oberhaching, Germany, 4 Sandoz Biopharmaceuticals/Hexal AG, Kundl, Austria, 5 Sandoz Biopharmaceuticals/Hexal AG, Holzkirchen, Germany 86. SLE Disease Activity In The Mucocutaneus, Vascular and Hematologic Systems Is Associated With An Increase In Plasma Type I Interferon Activity. Elena Gkrouzman, Mikhail Olferiev, Margaret Robotham, Mari Lliguicota, Wei- Ti Huang, Elzbieta E. Jacek, Kyriakos A. Kirou and Mary K. Crow, Hospital for Special Surgery, New York, NY 864. Immunologic Markers and Molecular Mechanisms Associated With Increased Systemic Lupus Erythematosus Activity In Patients Not Taking Immunosuppressive Medications. Mikhail G. Dozmorov, Cory Giles, Krista M. Bean, Nicolas Dominguez, Jonathan D. Wren, Joan T. Merrill, Judith A. James and Joel M. Guthridge, Oklahoma Medical Research Foundation, Oklahoma City, OK, Oklahoma Medical Research Foundation and University of Oklahoma Health Sciences Center, Oklahoma City, OK 865. Complement Activation and Anaphylatoxin Generation In Response To Staphylococcal Protein A Exposure: Ex Vivo and In Vivo Human Studies. Edward Bernton, Antonio Polley, Susan Zondlo, Lynne Mitchell and Dennis Hourcade, Protalex Inc., Summit, NJ, QPS Holdings LLC, Newark, DE, Washington University School of Medicine, St. Louis, MO 0 Program Book 866. Primary Human Cell BioMAP Profiling Of Methotrexate, Tocilizumab, Adalimumab, and Tofacitinib Reveals Different Mechanisms Of Action With Distinct Phenotypic Signatures. Seng-Lai Tan, Alison O Mahony, Ellen L. Berg, Kandeepan Ganeshalingam and Ernest H. Choy 4, Hoffmann-La Roche, Nutley, NJ, BioSeek, South San Francisco, CA, F. Hoffmann-La Roche, Basel, Switzerland, 4 Cardiff University School of Medicine, Cardiff, United Kingdom 867. Profiling Cytokine Production Of B Cells From SLE Patients Upon TLR9 Stimulation. Julia Sieber, Capucine Daridon, Simon Fillatreau and Thomas Dörner 4, Charité University Medicine, Berlin, Germany, Charité University Medicine / German Rheumatism Research Centre Berlin (DRFZ), Berlin, Germany, German Rheumatism Research Center Berlin (DRFZ), Berlin, Germany, 4 Charité university medecine/ German Rheumatism Research Centre Berlin (DRFZ), Berlin, Germany 868. Chemokine Expression In Systemic Lupus Erythematosus. Eoghan M. McCarthy, Joan Ní Gabhann, Siobhán Smith, Ruth Lee, Gaye Cunnane 4, Michele Doran 4, Donough G. Howard, Paul G. O Connell, Grainne M. Kearns and Caroline Jefferies, Mater Misericordiae University Hospital, Dublin 7, Ireland, Royal College of Surgeons in Ireland, Dublin, Ireland, Beaumont Hospital, Dublin 9, Ireland, 4 St James s Hospital, Dublin, Ireland 869. Serum Cytokine/Chemokine Profiles Are Useful For Evaluating Pathological Conditions Of Rheumatoid Arthritis and Diagnosing Anti-CCP Antibody-Negative Patients. Hitoshi Uga, Takahiro Okazawa, Yoshiaki Miyamoto, Takehiro Hasegawa, Jun Saegusa, Goh Tsuji, Sho Sendo, Akio Morinobu, Shunichi Kumagai and Hirokazu Kurata, Sysmex Corporation, Kobe, Japan, Kobe University Graduate School of Medicine, Kobe, Japan, Shinko Hospital, Kobe, Japan 870. B-Cell Activating Factor (BAFF) and Pregnancy Outcomes. Hindi E. Stohl, Lisa Korst, Richard H. Lee and William Stohl, University of Southern California Keck School of Medicine, Los Angeles, CA 87. Progranulin Directly Binds To The CRD and CRD Of TNFR Extracellular Domains. Jinlong Jian, Shuai Zhao, Qingyun Tian, Elena Gonzalez Gugel, Jyoti Mundra, Sardar MZ Uddin, Ben Liu, Brendon Richbourgh, Ryan Brunetti, Gerald Chan, Carolyn Green 4 and Chuanju Liu, NYU Hospital for Joint Diseases, New York, NY, NYU Hospital for Joint Diseases, New York Univerity, NY, Atreaon, Boston, MA, 4 Atreaon, Boston, NY Genetics and Genomics of Rheumatic Disease II 87. Gene-Body Mass Index Interactions Are Associated With Methotrexate Toxicity in Rheumatoid Arthritis. Stella Aslibekyan, Jin Sha, David T. Redden, Larry W. Moreland, James R. O Dell, Jeffrey R. Curtis, Ted R. Mikuls 4, S. Louis Bridges Jr. and Donna K. Arnett, University of Alabama at Birmingham, Birmingham, AL, University of Pittsburgh, Pittsburgh, PA, University of Nebraska Medical Center, Omaha, NE, 4 Omaha VA and University of Nebraska Medical Center, Omaha, NE

289 ACR POSTER SESSION C 87. Use Of Mendelian Randomization Associates Increased Serum Urate Caused By Genetic Variation In Uric Acid Transporters With Improved Renal Function. Tony R. Merriman, Tanya Flynn, Janak de Zoysa, Nicola Dalbeth and Kim Hughes, University of Otago, Dunedin, New Zealand, Waitemata District Health Board, Auckland, New Zealand, University of Auckland, Auckland, New Zealand 874. Genome-Wide Profiling Identifies Significant Differences Between The T-Lymphocyte and B-Lymphocyte Methylomes In Healthy Individuals. John Glossop, Nicola Nixon, Richard Emes, Kim Haworth, Jonathon Packham, Peter Dawes, Anthony Fryer, Derek Mattey and William Farrell, Haywood Rheumatology Centre, Stoke-on- Trent, United Kingdom, University of Nottingham, Sutton Bonnington, United Kingdom, Keele University, Stoke-on- Trent, United Kingdom 875. A Dense Mapping Of Human Leukocyte Antigen Region For Study Of Interaction With Smoking In The Development Of Rheumatoid Arthritis. Xia Jiang, Henrik Källberg, Lisbeth Ärlestig, Solbritt M. Rantapää-Dahlqvist, Lars Klareskog, Leonid Padyukov and Lars Alfredsson 4, Karolinska Institutet, Stockholm, Sweden, Umeå University, Umeå, Sweden, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden, 4 Institute of Environmental Medicine, Karolinska Institute, Stockholm, Sweden 876. Potential Chondrogenic Biomarkers For Cell-Based Therapy Monitoring In Osteoarthritis. Beatriz Rocha, Valentina Calamia, Vanessa Casas, Lucia Lourido, Carolina Fernandez-Costa, Patricia Fernandez-Puente, Jesus Mateos, Montserrat Carrascal, Francisco J. Blanco and Cristina Ruiz-Romero, Osteoarticular and Aging Research Laboratory, Proteomics Unit-Associated Node to ProteoRed-ISCIII, INIBIC-CHUAC, A Coruña, Spain, Laboratorio de Proteómica CSIC/UAB, Barcelona, Spain 877. A Neutrophil Signature Comprised Of Low Density Granulocyte (LDG)-Enriched Genes Is Associated With Organ-Specific Disease Activity In Systemic Lupus Erythematosus. Michelle Petri, Hong Fang, Jadwiga Bienkowska, Andrea Dearth, Norm Allaire and Ann Ranger, Johns Hopkins University School of Medicine, Baltimore, MD, Biogen Idec Inc., Cambridge, MA, Biogen Idec Inc, Cambridge, MA 878. Proteomics Analysis Of Cartilage Secretome: A Powerful Tool For The Discovery Of OA Biomarkers. Lucía Lourido, Valentina Calamia, Patricia Fernández-Puente, Jesus Mateos, Beatriz Rocha, Carolina Fernández-Costa, Francisco J. Blanco and Cristina Ruiz-Romero, Osteoarticular and Aging Research Laboratory, Proteomics Unit-Associated Node to ProteoRed-ISCIII, INIBIC-CHUAC, A Coruña, Spain 879. Major Histocompatibility Complex Class I Molecules Contribute To Behçet s Disease Risk Through Both Innate and Adaptive Immune Interactions. Michael J. Ombrello, Yohei Kirino, Paul de Bakker, Ahmet Gül 4, Elaine F. Remmers and Daniel L. Kastner, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, University Medical Center Utrecht, Utrecht, Netherlands, 4 Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey 880. Global Gene Expression Profiles Reveal Genetic Signatures Of Kawasaki Disease and Disease Outcome. Long Truong Hoang, Chiea Chuen Khor, Ahmad Nazri Mohamed Naim, Ling Ling, Chisato Shimizu, Martin L. Hibberd and Jane C. Burns, Genome Institute of Singapore, Singapore, Singapore, UC San Diego, School of Medicine, La Jolla, CA 88. HLA-DRB Rheumatoid Arthritis Susceptibility Amino Acids Define Haplotypes Associated With Radiological Outcome. Sebastien Viatte, Annie Yarwood, Buhm Han, Soumya Raychaudhuri, Deborah P. M. Symmons 4, Jane Worthington 5 and Anne Barton 6, Arthritis Research UK Epidemiology Unit, Manchester Academic Health Science Centre, The University of Manchester, Manchester, United Kingdom, Arthritis Research UK Epidemiology Unit, Centre for Musculoskeletal Research, Institute of Inflammation and repair, Manchester Academic Health Science Centre, The University of Manchester, Manchester, United Kingdom, Brigham and Women s Hospital, Harvard Medical School, Boston, MA, 4 Arthritis Research UK Epidemiology Unit, The University of Manchester, Manchester, United Kingdom, 5 Arthritis Research UK Epidemiology Unit, The University of Manchester and Rheumatoid Arthritis Consortium for Immunochip (RACI), International Consortium, United Kingdom, 6 Arthritis Research UK Epidemiology Unit, University of Manchester, Manchester, United Kingdom 88. Characterizing The C-Type Lectin Domain Family 4, Member C Gene (CLEC4C) Expression In Peripheral Blood From Rheumatoid Arthritis Patients. Annie Yarwood, Joanna Cobb, Kate McAllister, Joanne Barnes, Ernst R. Dow, Michelle A. Penny, Robert W. Hoffman and Anne Barton 4, Arthritis Research UK Epidemiology Unit, Centre for Musculoskeletal Research, Institute of Inflammation and repair, Manchester Academic Health Science Centre, The University of Manchester, Manchester, United Kingdom, NIHR Manchester Musculoskeletal Biomedical Research Unit, Manchester Academic Health Science Centre, Central Manchester Foundation Trust, Manchester, United Kingdom, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, 4 Arthritis Research UK Epidemiology Unit, University of Manchester, Manchester, United Kingdom 0 Program Book 87

290 ACR POSTER SESSION C 88. Fine Mapping and Expression Of a Locus Overlapping Types Of Inflammatory Arthritis. Kathryn J. A Steel, Anne Hinks, Annie Yarwood, Stephen Eyre, Edward Flynn, Paul Martin, Anne Barton and Wendy Thomson 4, Arthritis Research UK Epidemiology Unit, Manchester Academic Health Sciences Centre, Institute of Inflammation and Repair, The University of Manchester, Manchester, United Kingdom, Arthritis Research UK Epidemiology Unit, Centre for Musculoskeletal Research, Institute of Inflammation and repair, Manchester Academic Health Science Centre, The University of Manchester, Manchester, United Kingdom, Arthritis Research UK Epidemiology Unit, University of Manchester, Manchester, United Kingdom, 4 NIHR Manchester Musculoskeletal Biomedical Research Unit, Manchester Academic Health Science Centre, Manchester, United Kingdom 884. Autoantibody Specificities and Type I Interferon Pathway Activation In Idiopathic Inflammatory Myopathies. Saskia Vosslamber, Louise Ekholm, Anna Tjarnlund, T.D. de Jong, Lenka Plestilova, Martin Klein 4, Peter J. Charles 5, A.E. Voskuyl, Irene Bultink, Michiel Pegtel, J Vencovsky 6, Ingrid E. Lundberg and Cornelis L. Verweij, VU University Medical Center, Amsterdam, Netherlands, Rheumatology Unit, Department of Medicine, Karolinska University Hospital in Solna, Karolinska Institutet, Stockholm, Sweden, Institute of Rheumatology, st Faculty of Medicine, Charles University, Prague, Czech Republic, 4 Institute of Rheumatology, Prague, Prague, Czech Republic, 5 Kennedy Institute of Rheumatology, Oxford, United Kingdom, 6 Institute of Rheumatology, Prague, Czech Republic 885. A Weighted Genetic Risk Score Using All Known Susceptibility Variants To Predict Rheumatoid Arthritis Risk. Annie Yarwood, Buhm Han, Soumya Raychaudhuri, John Bowes, Mark Lunt, Dimitrios A. Pappas 4, Joel M. Kremer 5, Jeffrey D. Greenberg 6, Robert M. Plenge, Jane Worthington, Anne Barton 7 and Stephen Eyre, Arthritis Research UK Epidemiology Unit, Centre for Musculoskeletal Research, Institute of Inflammation and repair, Manchester Academic Health Science Centre, The University of Manchester, Manchester, United Kingdom, Brigham and Women s Hospital, Harvard Medical School, Boston, MA, Arthritis Research UK Epidemiology Unit, University of Manchester, Manchester, United Kingdom, 4 Columbia University, College of Physicians and Surgeons, New York, NY, 5 Center for Rheumatology, Albany Medical College, Albany, NY, 6 New York Hospital for Joint Diseases, New York, NY, 7 NIHR Manchester Musculoskeletal BRU, Central Manchester Foundation Trust and University of Manchester, Manchester Academic Health Science Centre, Manchester, United Kingdom 886. Differential Methylation Related To Response To Etanercept In Patients With Rheumatoid Arthritis. Amy Webster, Darren Plant, Mark Lunt, Stephen Eyre, Edward Flynn, Paul Martin, A. G. Wilson 4, A. W. Morgan 5, John Isaacs 6, Jane Worthington and Anne Barton, Arthritis Research UK Epidemiology Unit, University of Manchester, Manchester, United Kingdom, NIHR Manchester Musculoskeletal BRU, Central Manchester Foundation Trust and University of Manchester, Manchester Academic Health Science Centre, Manchester, United Kingdom, Arthritis Research UK Epidemiology Unit, Manchester Academic Health Sciences Centre, Institute of Inflammation and Repair, The University of Manchester, Manchester, United Kingdom, 4 Genomic Medicine, The University of Sheffield, Sheffield, United Kingdom, 5 Leeds Institute of Molecular Medicine, University of Leeds, Leeds, United Kingdom, 6 National Institute for Health Research, Newcastle Biomedical Research Centre, Newcastle Hospitals Foundation Trust and Newcastle University, Newcastle Upon Tyne, United Kingdom 887. Interleukin- Receptor Antagonist (IL-Ra) Plasma Levels Predict Radiographic Progression Of Symptomatic Knee Osteoarthritis Over 4 Months. Mukundan Attur, Alexander Statnikov, Jonathan Samuels, Svetlana Krasnokutsky, Jeffrey D. Greenberg, Zhiguo Li, Leon Rybak, Constantin F. Aliferis and Steven B. Abramson, NYU Hospital for Joint Diseases, New York, NY, NYU Langone Medical Center, New York, NY 888. Transcriptional Regulation Of Peptidylarginine Deiminase Type IV: Implications For Rheumatoid Arthritis. Ali Abbas, Kevin Le, Virginia Pimmett, David A. Bell, Ewa Cairns and Rodney P. DeKoter, Schulich School of Medicine and Dentistry, Western University, London, ON 889. Genome-Wide Association Study Of Knee Radiographic Osteoarthritis In African-American Populations. Youfang Liu, Michelle S. Yau, Laura Yerges-Armstrong, M C. Hochberg, Braxton D. Mitchell, Rebecca D. Jackson 4, Jordan B. Renner 5, David Duggan 6 and Joanne M. Jordan 7, Thurston Arthritis Research Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, University of Maryland School of Medicine, Baltimore, MD, University of Maryland, Baltimore, MD, 4 Ohio State University, Columbus, OH, 5 University of North Carolina at Chapel Hill, Chapel Hill, NC, 6 TGen, Pheonix, AZ, 7 University of North Carolina Thurston Arthritis Research Center, Chapel Hill, NC 890. Chemokine Receptor Polymorphisms On Chromosome Are Associated With Anticitrullinated Protein Antibody Specificities In African Americans With Rheumatoid Arthritis. Richard J. Reynolds, Maria I. Danila, Jeremy Sokolove, William H. Robinson 4, Doyt L. Conn 5, Beth L. Jonas 6, Leigh F. Callahan 7, Larry W. Moreland 8, Richard D. Brasington 9, Edwin A. Smith 0, Peter K. Gregersen and S. Louis Bridges Jr., University of Alabama at Birmingham, Birmingham, AL, Univ of Alabama-Birmingham, Birmingham, AL, VA Palo Alto Health Care System and Stanford University, Palo Alto, CA, 4 Stanford University School of Medicine, Stanford, CA, 5 Emory Univ School of Medicine, Atlanta, GA, 6 University of North Carolina at Chapel Hill, Chapel Hill, NC, 7 University of North Carolina, Chapel Hill, NC, 8 University of Pittsburgh, Pittsburgh, PA, 9 Washington Univ School of Med, St. Louis, MO, 0 Med Univ of South Carolina, Charleston, SC, Feinstein Institute for Medical Research, Manhasset, NY 88 0 Program Book

291 ACR POSTER SESSION C 89. Proteomic Profile Of Tears: Can It Help To Diagnose Juvenile Arthritis - Associated Uveitis Prior To The Clinical Signs Of Joints Inflammation. Vyacheslav Chasnyk, Sergei Nekhai, Alla Hynes, Tatiana Ammosova, Yuri Obukhov, Ekaterina Gaidar 4, Anatolyi Kononov 4, Margarita Dubko, Elena Serogodskaia 4 and Tatiana Nikitina 4, Saint-Petersburg State Pediatric Medical University, Saint-Petersburg, Russia, Howard University, Washington, DC, Eye Care Physicians and Surgeons, Winchester, VA, 4 Saint-Petersburg State Pediatric Medical University, St. Petersburg, Russia 89. High-Throughput Immunoglobulin G Fab Glycosylation Profiling Reveals Differential Glycosylation On Fab and Fc. Albert Bondt, Yoann Rombouts, Maurice H.J. Selman, Radboud JEM Dolhain and Manfred Wuhrer, Leiden University Medical Center, Leiden, Netherlands, Erasmus University Medical Center, Rotterdam, Netherlands 89. Altered DNA Methylation Profiles In Individuals With Osteoarthritis. Kathryn A Bailey, Daniel Rojas, Nikhil Umesh, Lisa Smeester, Tristan De Buysscher, Jordan B. Renner 4, Joanne M. Jordan 5 and Rebecca C. Fry, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC, Curriculum in Toxicology, Univeristy of North Carolina at Chapel Hill, Chapel Hill, NC, Center for Bioinformatics, University of North Carolina at Chapel Hill, Chapel Hill, NC, 4 University of North Carolina at Chapel Hill, Chapel Hill, NC, 5 University of North Carolina Thurston Arthritis Research Center, Chapel Hill, NC 894. Association Of Alleles and Amino Acids Of The Major Histocompatibility Complex Class I Chain-Related Gene A With Psoriatic Disease. Remy Pollock, Fawnda Pellett, Renise Ayearst, Fatima Abji, Dafna Gladman and Vinod Chandran, University of Toronto, Toronto Western Hospital, Toronto, ON 895. Identification Of Aberrant Pathways In Osteoarthritis Using RNA-Seq. Kathleen M. Fisch, Masahiko Saito, Ryuichiro Akagi, Stuart Duffy, Andrew I. Su and Martin K. Lotz, The Scripps Research Institute, La Jolla, CA, Toho University Sakura Medical Center, Sakura, China 896. Arthritis Associated Sequence Alterations Within a Genetic Susceptibility Region Of Mouse Chromosome ; A Genomic Region Which Is Syntenic With a Prominent Non-MHC Locus In Rheumatoid Arthritis. Andras Vida, Timea Besenyei, Beata Tryniszewska, Timea Ocsko, Zoltan Szekanecz, Tibor A. Rauch, Katalin Mikecz and Tibor T. Glant, Rush University Medical Center, Chicago, IL, University of Debrecen, Debrecen, Hungary, University of Debrecen Medical and Health Sciences Center, Debrecen, Hungary 897. Algorithms Using Genome-Wide SNP Analysis For Prediction Of Progression Of Joint Space Narrowing Or Erosion In Rheumatoid Arthritis Patients Using Data From Multiple Medical Cohorts. Tsukasa Matsubara, Satoru Koyano, Yoshitada Sakai, Keiko Funahashi, Takako Miura, Kosuke Okuda, Takeshi Nakamura, Akira Sagawa 4, Takeo Sakurai 5, Hiroaki Matsuno 6, Tomomaro Izumihara 7 and Eisuke Shono 8, Matsubara Mayflower Hospital, Kato, Japan, Research Institute of Joint Diseases, Kobe, Japan, Kobe University, Kobe, Japan, 4 Sagawa Akira Rheumatology Clinic, Sapporo, Japan, 5 Inoue Hospital, Takasaki, Japan, 6 Matsuno Clinic for Rheumatic Diseases, Toyama, Japan, 7 Izumihara Rheumatic and Medical Clinic, Kagoshima, Japan, 8 Shono Rheumatology Clinic, Fukuoka, Japan 898. Repression Of Wolf-Hischhorn Syndrome Candidate- (WHSC) Contributes To The Osteoarthritis-Inducing Cartilage Loss Of Functions. Francisco Espinoza, Yves- Marie Pers, Paul Chuchana, Jean Marc Brondello 4 and Christian Jorgensen, INSERM U844, MONTPELLIER, France, Inserm U844, CHU saint-eloi, Université Montpellier, CHU Lapeyronie, Montpellier, France, INSERM U844, Montpellier, France, 4 UM, Montpellier, France 899. Interferon Regulatory Factor 5 Gene Variant rs Is Associated With Carotid Intimal Medial Thickness In Rheumatoid Arthritis Patients. Saskia Vosslamber, Alper M. van Sijl, Carina Bos, A.E. Voskuyl, Michael T. Nurmohamed and Cornelis L. Verweij, VU University Medical Center, Amsterdam, Netherlands 900. Mass Spectrometry-Based Salivary Proteomics For The Discovery Of Novel Diagnostic Biomarkers For Primary Sjögren s Syndrome and Its Clinical Subsets. Camillo Giacomelli, Chiara Baldini, Francesca Sernissi, Daniela Martini, Pasquale Pepe, Nicoletta Luciano, Francesco Ferro, Chiara Tani, Marta Mosca and Stefano Bombardieri, Rheumatology Unit, Pisa, Italy, Institute of Clinical Physiology, National Research Council, Pisa, Italy, Rheumatology Unit, University of Pisa, Pisa, Italy 90. Genetic Variants In OPG and ANKH Are Associated With Severity Ofankylosis In Ankylosing Spondylitis In a Korean Cohort. Il-Hoon Sung, Tae-Hwan Kim, Young Bin Joo, So-Young Bang, Seunghun Lee, Kyung-Bin Joo 4, Proton Rahman 5, Darren D. O Rielly 5 and Robert Inman 6, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, Hanyang University Guri Hospital, Guri, South Korea, Hanyang University College of Medicine, Seoul, South Korea, 4 Hanynag University, Seoul, South Korea, 5 Memorial University, St. Johns, NF, 6 University of Toronto and Toronto Western Hospital, Toronto, ON 90. Characterization Of HLA-DRB Distribution By rd Hypervariable Region Sequence In Systemic Sclerosis and Control Populations. Coline, A. Gentil, Hilary S. Gammill, Christine, T. Luu and J. Lee Nelson, Fred Hutchinson Cancer Research Center, SEATTLE, WA, Fred Hutchinson Cancer Rsch, Seattle, WA 90. PIKCD Overexpression In The Synovial Membrane Of Rheumatoid Arthritis Patients Is Associated With Response To Anti-TNF Therapy. Antonio Julià, Gabriela Ávila, Raquel Celis, Raimon Sanmarti, Julio Ramirez 4, Sara Marsal and Juan D. Cañete 5, Vall d Hebron Hospital Research Institute, Barcelona, Spain, Hospital Clínic, Barcelona, Spain, Hospital Clínic of Barcelona, Barcelona, Spain, 4 Hospital Clinic, Barcelona, Spain, 5 Hospital Clínic de Barcelona, Barcelona, Spain 0 Program Book 89

292 ACR POSTER SESSION C 904. Gene Expression In Whole Blood Predicts The Abatacept Methotrexate Combination Responsiveness In Rheumatoid Arthritis: Preliminary Results From The Power Doppler Ultrasonography IM0-79 Study. T Lequerré, C Derambure, MA D Agostino, M Hiron, P Gaudin 4, C Gaillez 5, M Le Bars 5 and O Vittecoq, Rouen University Hospital & Inserm U905, Rouen, France, AP-HP Ambroise Paré Hospital, Boulogne-Billancourt, France, Rouen University Hospital & Inserm, Rouen, France, 4 CHU Hôpital Sud, Grenoble, France, 5 Bristol-Myers Squibb, Rueil Malmaison, France 905. Protein Profiles Of Peripheral Blood Mononuclear Cells As a Biomarker For Behcet s Disease. Manae Kurokawa, Takuya Yoshioka, Toshiyuki Sato, Kouhei Nagai, Nobuko Iizuka, Mitsumi Arito, Yukiko Takakuwa, Hiromasa Nakano, Seido Ooka, Naoya Suematsu, Kazuki Okamoto, HIroshi Nakamura, Noboru Suzuki, Shoichi Ozaki and Tomohiro Kato, St. Marianna University Graduate School of Medicine, Kawasaki, Japan, St. Marianna University School of Medicine, Kawasaki, Japan, Nippon Medical School, Bunkyo-ku, Japan Health Services Research, Quality Measures and Quality of Care Innovations in Health Care Delivery 906. Comparison Of Decision Rules For Identifying Patients With Systemic Lupus Erythematosus (SLE) In Administrative Healthcare Databases. John G. Hanly, Kara Thompson and Chris Skedgel, Dalhousie University and Capital Health, Halifax, NS 907. Acceptability Of Various Technology-Based Communication Modalities In a Rheumatology Clinic. Lisa A. Davis, Phat Luong, Sushmitha Bobba, Hannah Dischinger, Itziar Quinzanos and Liron Caplan, Denver Veterans Affairs Medical Center, Denver, CO, University of Colorado School of Medicine, Aurora, CO 908. Quality Of Life and Adherence To Treatment In Patients Managed In Nursing Clinics In Rheumatology. Santiago Muñoz-Fernández, Pablo Lazaro, Antonio Javier Blasco, Sandra Fortea Gracia, Laura Cano-García 4, Jose A. Roman Ivorra 5, Raquel Almodóvar González 6, José Santos Rey Rey 7, Teresa Navío-Marco 8 and Mercedes Cabañas, Hospital Universitario Infanta Sofía, San Sebastián de los Reyes (Madrid), Spain, Advanced Techniques in Health Services Research (TAISS), Madrid, Spain, Hospital de Sagunto, Sagunto, Spain, 4 Hospital Regional Universitario Carlos Haya, Málaga, Spain, 5 Hospital Universitario y Politécnico La Fe, Valencia, Spain, 6 Hospital Universitario Fundación Alcorcón, Madrid, Spain, 7 Complejo Hospitalario de Toledo, Toledo, Spain, 8 Hospital Universitario Infanta Leonor, Madrid, Spain 909. Interpretation Of Patient Reported Outcomes Measurement Information System (PROMIS) By Rheumatologists. Vivek Nagaraja, David A. Fox, Sheeja Francis, Ora Singer, Puja Khanna, Timothy Laing, Rory Marks, Seetha U. Monrad, Vladimir M. Ognenovski, Kristine Phillips and Dinesh Khanna, University of Michigan Medical Center, Ann Arbor, MI 90. Validation Of The Mayo Hip Questionnaire: Validity and Sensitivity To Change. Jasvinder A. Singh, Cathy Schleck, W. Scott Harmsen and David Lewallen 4, University of Alabama, Tuscaloosa, AL, Mayo Clinic College of Medicine, Rochester, MN, Mayo Clinic, Rochester, MN, 4 Mayo Clinic college of medicine, Rochester, MN 9. How Are Actual Patterns Of Care For a Health System In Rheumatology In Comparison With Validated Quality Measures? Susan Mathew, Tarun S. Sharma, Oscar Quintero, Olga Bailey, Debra Webb, Eric D. Newman and Androniki Bili, Geisinger Medical Center, Danville, PA 9. Do Persons With SLE In Poverty Rate Interactions With Providers and Health Plans Differently? Edward H. Yelin, Chris Tonner, Laura Trupin and Jinoos Yazdany, UC San Francisco, San Francisco, CA, University of California, San Francisco, San Francisco, CA 9. Expectations RA Patients Have For Their Treatment - A Comparison Of Clinical Results For Biologic and Disease- Modifying Anti-Rheumatic Drug Treated Patients Using Multiple Medical Cohorts. Tsukasa Matsubara, Hiroaki Matsuno, Tomomaro Izumihara, Yuichi Takahashi, Akira Sagawa, Motohiro Oribe, Eisuke Shono, Kensuke Kume, Masanori Adachi, Yuichi Nishioka, Nobumasa Miyake, Keisuke Hashimoto, Toshikaki Miyamoto, Shigeto Kiyokawa, Tomohiko Yoshida, Syoichi Kondo, Yoshiki Shiohira, Takanori Azuma, Yukio Sato, Masaaki Yoshida, Kenji Mannami, Akihiko Nakamura, Yasuhiko Hirabarashi, Keiko Funahashi and James E. Middleton, Japanese Clinician s Biologic Research Group, Kobe, Japan, Matsubara Mayflower Hospital, Kato, Japan, Research Institute of Joint Diseases, Kobe, Japan 94. Patient and Physician Perspectives On Family Planning and Pregnancy Issues In Systemic Inflammatory Diseases: Mind The Gap! Megan E. B. Clowse, Eliza Chakravarty, Daphnee S. Pushparajah, Sarah Mertens and Caroline Gordon 4, Duke University Medical Center, Durham, NC, Oklahoma Medical Research Foundation, Oklahoma City, OK, UCB Pharma, Brussels, Belgium, 4 University of Birmingham, Birmingham, United Kingdom 95. WITHDRAWN 90 0 Program Book

293 ACR POSTER SESSION C 96. Approaches and Challenges To Reducing Wait Times For Total Hip and Knee Replacement. Aileen M. Davis, Cheryl Cott, Rose Wong, Michel Landry 4, Linda C. Li 5, Allyson Jones 6, Cy Frank 7, Sydney C. Lineker 8, Louise Bergeron 9, Rhona McGlasson 0, Gillian A. Hawker, Dianne P. Mosher, Susan B. Jaglal, Richard Birtwhistle 4, Sherry Bar 5 and Elizabeth M. Badley 6, Division of Health Care and Outcomes Research, Toronto Western Research Institute, University Health Network, Ontario, ON, Divison of Health Care and Outcomes Research, Toronto Western Research Institute, University Health Network, Toronto, ON, Division of Health Care & Outcomes Research, Toronto Western Research Institute, University Health Network, Toronto, ON, 4 Department of Community and Family Medicine, Physical Therapy Division, Duke University Medical Center, Durham, NC, 5 Arthritis Centre of Canada, Richmond, BC, 6 University of Alberta, Edmonton, AB, 7 Alberta Bone and Joint Institute and Department of Surgery, University of Calgary, Calgary, AB, 8 The Arthritis Society, Toronto, ON, 9 Canadian Arthritis Patient Alliance, Ottawa, ON, 0 Bone and Joint Canada, Toronto, ON, Women s College Research Institute, University of Toronto, Toronto, ON, University of Calgary, Calgary, AB, Department of Physical Therapy, University of Toronto, Toronto, ON, 4 Centre for Studies in Primary Care and Family Medicine and Community Health and Epidemiology, Queen s University, Kingston, ON, 5 British Columbia Ministry of Health Services, Victoria, BC, 6 Toronto Western Research Institute, University Health Network, Toronto, ON 97. Falls Among Hospitalized Orthopedic Patients: A Prospective Case-Control Study. Lisa A. Mandl, Wei-Ti Huang, Jaimie Lee, Tina Bailey, Danielle Edwards, Patricia Quinlan, Mayu Sasaki and Steven K. Magid, Hospital for Special Surgery, New York, NY 98. Adoption Of New Electronic Medical Records May Inhibit Documentation Of Physician Quality Reporting System. Minzi Chen, William E. Davis, Austin Fraser, Jerald M. Zakem, Eve Scopelitis, Kismet Collins, MD, Tamika A. Webb- Detiege and Robert Quinet, Ochsner Medical Center, New Orleans, LA 99. Rheumatology-Ophthalmology Collaborative Uveitis Units May Improve The Diagnostic Approach Of This Pathology: Experience From a Uveitis Unit In a Secondary Spanish Hospital. Elena Aurrecoechea, Ana Diez del Corral, Angel de la Mora, Jaime Calvo-Alén and Ernesto Romera 4, Hospital Sierrallana. Torrelavega, Torrelavega, Spain, Ophthalmology Unit Hospital Sierrallana, Torrelavega, Spain, Hospital Universitario Sierrallana, Torrelavega, Spain, 4 Hospital Sierrallana Torrelavega, Torrelavega, Spain 90. Determining The Vaccination Rates Of American College Of Rheumatology Recommended Vaccines Among Veterans With Rheumatoid Arthritis A Quality Indicator. Puneet Bajaj, Melinda Collins and Ranjan Roy, VA Medical Center, Northport, NY 9. Ask The Rheumatologist: Evaluating The Use Of a Patient Centered Web Based Service. Steven J. Katz, University of Alberta, Edmonton, AB 9. Determinants Of Patient Satisfaction In An Academic Rheumatology Practice. Abhijeet Danve, Jennifer H. Ku, Helena Pang, Thien Hoang, Alana Ralston, Dongseok Choi and James T. Rosenbaum, Oregon Health and Science University, Portland, OR 9. A Study To Determine Patient Satisfaction With a Nurse- Led Injection Clinic In Rheumatology. Margaret Saldanha, Kathleen Brown, Dawn Heap, Cynthia Mech, Melissa Deamude, Kathy Kislinsky, Debbie McClory, Alpesh Shah and William G. Bensen 4, Rheumatology Health Team, St. Joseph s Hospital Hamilton, Hamilton, ON, Rheumatology Health Team Hamilton, Hamilton, ON, Rheumatology Health Team, Dr. Bensen s Rheumatology Clinic, Hamilton, ON, 4 St. Joseph s Hospital and McMaster University, Hamilton, ON 94. Cleveland Clinic Dual Energy X-Ray Absorptiometry Registry, A Web-Based Tool Designed For Efficient Collection Of Bone Density and Osteoporosis Related Clinical Risk Factor Data. Chad L. Deal, Gregory J. Strnad, Robert A. Overman and Boris Bershadsky, Cleveland Clinic, Cleveland, OH 95. Patient Satisfaction with an Associate Teaching Hospital Clinical Trial Unit In North-East London. Genevieve Casey, Carey Tierney, Hasan Tahir, Simon Donnelly and Judith Bubbear, Barts and the London Medical School, London, United Kingdom, Barts Health NHS Trust, London, United Kingdom 96. Validation Of The Hospital For Special Surgery Knee Questionnaire: Convergent Validity, Responsiveness and Sensitivity To Change. Jasvinder A. Singh, Cathy Schleck, W. Scott Harmsen and David Lewallen 4, University of Alabama, Tuscaloosa, AL, Mayo Clinic College of Medicine, Rochester, MN, Mayo Clinic, Rochester, MN, 4 Mayo Clinic college of medicine, Rochester, MN 97. Assessing Adherence To Choosing Wisely Recommendations Regarding Antinuclear Antibody and Antinuclear Antibody Subserology Testing In An Urban Community Health System. Adam Carlson, Jinoos Yazdany, Kara Lynch and Laura Trupin, UC San Francisco, San Francisco, CA, San Francisco General Hospital, San Francisco, CA 98. Outcomes Of The Fast-Track Pathway In Giant Cell Arteritis: A Sight Saver. Pravin Patil, Win Win Maw, Katerina Achilleos, Christian Dejaco, Mark Williams, Tochukwu Adizie 4, Dimitrios Christidis 5, Frances Borg and Bhaskar Dasgupta 4, Southend University Hospital, Westcliff-on-sea, United Kingdom, Medical University Graz, Graz A-806, Austria, Southend University Hospital, Westcliff on sea, United Kingdom, 4 Southend University Hospital, Westcliff-on-Sea, United Kingdom, 5 Southend University Hospital, Westcliffe on sea, United Kingdom 99. Timing Of Total Knee Arthroplasty: A Decision Analysis. Darena Tulanont, Haily Vora, Roopa Akkineni and Daniel A. Albert, The Dartmouth Institute for Health Policy and Clinical Practice, Lebanon, NH, Dartmouth-Hitchcock Medical Center, Lebanon, NH 0 Program Book 9

294 ACR POSTER SESSION C Patients Response To a Sleep Question and Disease Activity In Multiple Rheumatic Conditions. Sapna Sangani and Martin J. Bergman, Mercy Catholic Medical Center, Lansdowne, PA, Drexel University College of Medicine, Philadelphia, PA 9. Models Of Care For Arthritis: Drivers, Facilitators and Barriers To Their Development and Implementation. Aileen M. Davis, Cheryl Cott, Rose Wong, Michel Landry 4, Linda Li 5, Allyson Jones 6, Cy Frank 7, Sydney C. Lineker 8, Louise Bergeron 9, Gillian A. Hawker 0, Dianne P. Mosher, Vandana Ahluwalia, Michel Zummer, Susan B. Jaglal 4, Rhona McGlasson 5, Richard Birtwhistle 6, Sherry Bar 7 and Elizabeth M. Badley 8, Division of Health Care and Outcomes Research, Toronto Western Research Institute, University Health Network, Ontario, ON, Divison of Health Care and Outcomes Research, Toronto Western Research Institute, University Health Network, Toronto, ON, Division of Health Care & Outcomes Research, Toronto Western Research Institute, University Health Network, Toronto, ON, 4 Department of Community and Family Medicine, Physical Therapy Division, Duke University Medical Center, Durham, NC, 5 Arthritis Centre of Canada and Department of Physical Therapy, University of British Columbia, Vancouver, BC, 6 University of Alberta, Edmonton, AB, 7 Alberta Bone and Joint Institute and Department of Surgery, University of Calgary, Calgary, AB, 8 The Arthritis Society, Toronto, ON, 9 Canadian Arthritis Patient Alliance, Ottawa, ON, 0 Women s College Research Institute, University of Toronto, Toronto, ON, University of Calgary, Calgary, AB, Past President, Ontario Rheumatology Association, Brampton, ON, Ch Maisonneuve-Rosemont, Montreal, QC, 4 Department of Physical Therapy, University of Toronto, Toronto, ON, 5 Bone and Joint Canada, Toronto, ON, 6 Centre for Studies in Primary Care and Family Medicine and Community Health and Epidemiology, Queen s University, Kingston, ON, 7 British Columbia Ministry of Health Services, Victoria, BC, 8 Toronto Western Research Institute, University Health Network, Toronto, ON 9. Shared Decision Making In Early Knee Osteoarthritis: Perspectives Of Older Adults With Overweight and Obesity and Health Care Providers. Alicia Zbehlik, Mary Meinke and Stephen Bartels, Dartmouth-Hitchcock Medical Center, Lebanon, NH, The Dartmouth Institute for Health Policy and Clinical Practice, Lebanon, NH, The Center for Aging Research, The Dartmouth Institute for Health Policy and Clinical Practice, Lebanon, NH 9. Crowdsourcing Using The Audience Response System To Solve Medical Problems: A Pilot Study. Antoine G. Sreih and Fadi Aldaghlawi, The University of Pennsylvania, Philadelphia, PA, Weiss Memorial Hospital, chicago, IL 94. Scores On The Multidimensional Health Assessment Questionnaire (MDHAQ) For Walk Miles Or Kilometers, Poor Sleep, and Participate In Recreation, Are Higher, Indicating Poorer Status, Than Scores For 8 Activities Derived From The Health Assessment Questionnaire (HAQ). Kathryn Gibson, Sung-Hoon Park and Theodore Pincus, Liverpool Hospital and University of New South Wales, Sydney, Australia, NYU Hospital for Joint Diseases and New York University School of Medicine, New York, NY 0 Program Book 95. Validation Of The Cutaneous Dermatomyositis Disease Area and Severity Index: Characterizing Severity and Assessing Responsiveness To Clinical Change. Cynthia O. Anyanwu, David Fiorentino, Lorinda Chung, Yanli Wang 4, Kathleen J. Propert 4 and Victoria P. Werth 5, Philadelphia Veterans Affairs Medical Center, Philadelphia, PA, Stanford University School of Medicine, Redwood City, CA, Stanford University Medical Center, Palo Alto, CA, 4 University of Pennsylvania, Philadelphia, PA, 5 University of Pennsylvania School of Medicine, Philadelphia, PA 96. Quality Of Care In Patients At Risk For Pulmonary Involvement: Assessment Of Pulmonary Screening In Systemic Sclerosis and Myositis Patients In a General Rheumatology Clinic. Michael G. Indelicato, Janet E. Lewis, Vincent J. Giuliano and Donald L. Kimpel, University of Virginia, Charlottesville, VA, University of Virginia School of Medicine, Charlottesville, VA ARHP Health Services Research 97. The Role Of Rural Residence In Low Back Pain. Elizabeth G. Salt, Yevgeniya Gokun, Heather Bush and Leslie J. Crofford, University of Kentucky, Lexington, KY, Vanderbilt University, Nashville, TN 98. A Description Of Therapies Used For Low Back Pain. Elizabeth G. Salt, Yevgeniya Gokun and Jeffery Talbert, University of Kentucky, Lexington, KY 99. Assessing The Increasing Costs To Manage Patients With Gout By State. Aaron Davis and Jason Wreath, Goutchoices.com, San Clemente, CA, Symphony Health, Phoenix, AZ 940. The Development Of A National Systemic Sclerosis Service In Ireland Incorporating A National Registry. Mairead Murray, Emese Balogh and Douglas J. Veale, Dublin Academic Medical Centre, St. Vincent s University Hospital, Dublin, Ireland, Translation Research Group, Dublin Academic Medical Centre, St. Vincent s University Hospital, Dublin, Ireland, St. Vincent s University Hospital, Dublin 4, Ireland Imaging in Rheumatoid Arthritis 94. Imaging Atherosclerotic Plaque Inflammation In RA: Methodology and Initial Findings In a Single Centre Cohort. Sarah Skeoch, Penny Hubbard, Heather Williams, Dongxiang Xu, Sun Jie, Niranjan Balu, Wei Zhang, Jacqueline James 4, Thomas Hatsukami, Chun Yuan, M. Yvonne Alexander 5, Paul Hockings 6, John Waterton 7 and Ian N. Bruce 4, Arthritis Research UK Epidemiology Unit and NIHR Manchester Musculoskeletal Biomedical Research Unit, Manchester Academic Health Science Centre, The University of Manchester, Manchester, United Kingdom, University of Manchester, Manchester, United Kingdom, University of Washington, Seattle, WA, 4 Central Manchester University Hospitals Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom, 5 Healthcare Science Research Institute, Manchester Metropolitan University, Manchester, United Kingdom, 6 Astra Zeneca, Mölndal, Sweden, 7 Astra Zeneca, MACCLESFIELD, United Kingdom

295 ACR POSTER SESSION C 94. Ultrasound Shows Tenosynovitis to be Frequently Present as Well As Sensitive to Change in RA Patients On Biologic Medication. Hilde B. Hammer, Diakonhjemmet Hospital, Oslo, Norway 94. Results of a Reliability Exercise for the Grading of Tendon Rupture in Patients With Rheumatoid Arthritis, using a Consensus-Based Ultrasound Score. George A. W. Bruyn, Petra Hanova, Annamaria Iagnocco, Maria-Antonietta d Agostino 4, Lene Terslev 5, I. Moller 6, Peter V. Balint 7, E. Filippucci 8, Carlos Pineda 9, Marina Backhaus 0, Richard van Vugt, Richard J. Wakefield, Paul Baudoin, Kei Ikeda, Artur Bachta 4, Helen I. Keen 5, Levent Oczakar 6, Sibel Z. Aydin 7, Marwin Gutierrez 8, Peter Mandl 9 and Esperanza Naredo 0, MC Groep hospitals, Lelystad, Netherlands, Institute of Rheumatology, Prague, Prague, Czech Republic, University La Sapienza, Rome, Italy, 4 Versailles-Saint Quentin en Yvelines University- APHP, Ambroise-Paré Hospital, Boulogne-Billancourt, France, 5 The Parker Institute, Copenhagen, Denmark, 6 Instituto Poal, Barcelona, Spain, 7 National Institute of Rheumatology and Physiotherapy, Budapest, Hungary, 8 University Politecnica delle Marche, Ancona, Italy, 9 Instituto Nacional de Rehabilitacion, Mexico City, Mexico, 0 Charite University Hospital, Berlin, Germany, VU Medisch Centrum, Amsterdam, Netherlands, University of Leeds and NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds, United Kingdom, Chiba University Hospital, Chiba, Japan, 4 Military Medical Institute, Warsaw, Poland, 5 UWA, Perth, Australia, 6 Hacettepe University Medical School, Ankara, Turkey, 7 Medeniyet University, Goztepe Training and Research Hospital, Istanbul, Turkey, 8 Università Politecnica delle Marche, Ancona, Italy, 9 Medical University of Vienna, Vienna, Austria, 0 Hospital General Universitario Gregorio Marañón, Madrid, Spain 944. Ultrasound Characteristics Of Extensor Tendon Abnormalities and Peritendinous Fluid In Rheumatoid Arthritis. Laurie Ann Ramrattan and Gurjit S. Kaeley, University of Florida, Jacksonville, FL 945. Comparison Of Selected Joint Evaluation With Comprehensive Assessment In Musculoskeletal Ultrasonography For Detection Of Synovitis In Rheumatoid Arthritis. Ryusuke Yoshimi, Atsushi Ihata, Yosuke Kunishita, Daiga Kishimoto, Reikou Kamiyama, Kaoru Minegishi, Maasa Hama, Yohei Kirino, Yukiko Asami, Atsuhisa Ueda, Mitsuhiro Takeno, Ichiro Aoki and Yoshiaki Ishigatsubo, Yokohama City University Graduate School of Medicine, Yokohama, Japan 946. Can Satisfactory Reliability Of The 7-Joint Ultrasound Score Be Attained By Inexperienced Readers In a Single Calibration Exercise? Results From The Biodam Program. Marina Backhaus, Stephanie G. Werner, Sarah Ohrndorf, Shafeeq Alraqi, Sean Crowther, Sukhvinder Dhillon, Navjot Dhindsa 4, Arthur J. Fernandes 5, Oliver M. FitzGerald, Hilde B. Hammer 6, Christophe Hudry 7, Sandrine Jousse-Joulin 8, Robert GW Lambert, Maggie Larche 9, Anouck Remy-Moulard 0, Lene Terslev, Ramin Yazdani, Rana Dadashova, Joel Paschke and Walter P. Maksymowych, Charite University Hospital, Berlin, Germany, St.Vincent s University Hospital, Dublin, Ireland, University of Alberta, Edmonton, AB, 4 University of Manitoba, Winnipeg, MB, 5 Universite de Sherbrooke, Sherbrooke, QC, 6 Diakonhjemmet Hospital, Oslo, Norway, 7 Hopital Cochin, Paris, France, 8 CHU de la Cavale Blanche, Brest, France, 9 McMaster University, Hamilton, ON, 0 Hopital Peyronie, Montpellier, France, Copenhagen University Hospital at Glostrup, Copenhagen, Denmark, St.Clare s Mercy Hospital, St.John s, NF, CaRE Arthritis, Edmonton, AB 947. The 7-Joint Ultrasound Score Is a Feasible Tool For Evaluating Joint Inflammation In Rheumatoid Arthritis Patients. Experience Among Rheumatologists With Basic Or Intermediate Level Of Ultrasound Training. Jana Hurnakova, Jakub Zavada, Herman F. Mann, Ladislav Senolt, Martin Klein, Petra Hanova, Sarka Forejtova, Marta Olejarova, Olga Ruzickova, Olga Sleglova and Karel Pavelka, Institute of Rheumatology, Prague, Prague, Czech Republic 948. Power Doppler Ultrasound 7-Joint Score Vs. Simplified Disease Activity Index In Rheumatoid Arthritis Associated With Fibromyalgia. Rafael Chakr, Marina Behar, José A. Mendonça, Daniela Cervantes, Nizele Calegaro, Nicole Andrade, Iuri Siqueira, Daniel Zanchet, Andrese Gasparin, Penélope Esther Palominos, Charles Kohem, Odirlei Andre Monticielo, Claiton Brenol 4, Ricardo M. Xavier and João Carlos T. Brenol, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil, Pontifical Catholic University of Campinas / Institute of Clinical Research IPECC, Campinas, Brazil, Brazilian Registry of Spondyloarthritis, São Paulo, Brazil, 4 Universidade Federal do Rio Grande do Sul, Porto Alegre RS, Brazil 949. Assessment Of Wrist Joint Inflammation In Patients With Rheumatoid Arthritis By Quantitative Two- and Three- Dimensional Power Doppler Ultrasonography. Hsin-Hua Chen, National Yang-Ming University, Taipei, Taiwan 950. Relationship Between Radiographic Joint Space Narrowing, Sonographic Cartilage Thickness and Anatomy In Rheumatoid Arthritis and Control Joints. Peter Mandl, Gabriela Supp, Gabor Baksa, Daniel Aletaha, Reka Kurucz 4, Dora Niedermayer, Helga Radner, Paul Studenic, Peter V. Balint 4 and Josef S. Smolen 5, Medical University of Vienna, Vienna, Austria, Semmelweis University, Budapest, Hungary, Medical University Vienna, Vienna, Austria, 4 National Institute of Rheumatology and Physiotherapy, Budapest, Hungary, 5 Medical University of Vienna and Hietzing Hospital, Vienna, Austria 0 Program Book 9

296 ACR POSTER SESSION C 95. The Spring Ligament Window: A Unique Sonoanatomic View Into a Complex Rheumatoid Joint. Joanne Kitchen, I. Moller, Maribel Miguel-Perez and David A. Bong 4, Instituto Poal de Reumatolgia, Barcelona, Spain, Instituto Poal, Barcelona, Spain, University of Barcelona, Barcelona, Spain, 4 Instituto Poal de Reumatologia, Barcelona, Spain 95. The Value Of An Automated Ultrasound System In The Detection Of Synovitis. Ruediger Mueller, Mathias Gruenke, Joerg Wendler, Florian Schuch, Karina Hofmann-Preiss 4, Ina Boettger 4, Ruediger Jakobs 5, Hendrik Schulze-Koops 6 and Johannes von Kempis, Kantonsspital St. Gallen, St. Gallen, Switzerland, Medizinische Klinik IV, University of Munich, Munich, Germany, Schwerpunktpraxis Rheumatologie, Erlangen, Germany, 4 Institut für bildgebende Diagnostik und Therapie, Erlangen, Germany, 5 Siemens AG, Erlangen, Germany, 6 University of Munich, Munich, Germany 95. The Progression of Cartilage Damage in Rheumatoid Arthritis: A Three Year Prospective T- Magnetic Resonance Imaging Study Examining Predictive Factors. Fiona M. McQueen, Alexandra McHaffie, Andrew Clarke, Arier Lee, Quentin Reeves, Barbara Curteis and Nicola Dalbeth, University of Auckland, Auckland, New Zealand, Auckland District Health Board, Auckland, New Zealand 954. Advantages Of a Combined Rheumatoid Arthritis Magnetic Resonance Imaging Score (RAMRIS) For Hand and Feet: Does The Ramris Of The Hand Alone Underestimate Disease Activity and Progression? Dr. Philipp Sewerin, Dr. Christian Buchbender, Dr. Stefan Vordenbäumen, Dr. Axel Scherer, Dr. Falk Miese, Dr. Ralph Brinks, Dr. Hans-Jörg Wittsack, Prof. Dr. Gerald Antoch, Prof. Dr. Matthias Schneider and Prof. Dr. Benedikt Ostendorf, Univ. Duesseldorf, Düsseldorf, Germany, Univ. Duesseldorf, Duesseldorf, Germany 955. Biochemical MRI With Gagcest (Glycosaminoglycan Chemical Exchange Saturation Transfer Imaging) Of Finger Joint Cartilage In Rheumatoid Arthritis. Dr. Philipp Sewerin, Dr. Christoph Schleich, Prof. Dr. Benedikt Ostendorf, Dr. Stefan Vordenbäumen, Prof. Dr. Gerald Antoch, Prof. Dr. Matthias Schneider and Dr. Falk Miese, Univ. Duesseldorf, Düsseldorf, Germany, Univ. Duesseldorf, Duesseldorf, Germany 956. The Effect Of Initial Methotrexate Therapy On Cartilage Composition In Early Rheumatoid Arthritis: Follow-Up With Biochemical MRI Of Finger Cartilage. Dr. Philipp Sewerin, Dr. Falk Miese, Dr. Hans-Jörg Wittsack, Dr. Stefan Vordenbäumen, Dr. Christoph Schleich, Prof. Dr. Gerald Antoch, Prof. Dr. Matthias Schneider and Prof. Dr. Benedikt Ostendorf, Univ. Duesseldorf, Düsseldorf, Germany, Univ. Duesseldorf, Duesseldorf, Germany 957. Correlation Of Structural Abnormalities Of The Wrist and Metacarpophalangeal Joints Evaluated By High-Resolution Peripheral Quantitative Computed Tomography, Tesla MRI and Conventional Radiographs In Rheumatoid Arthritis. Chan Hee Lee, Waraporn Srikhum, Andrew J. Burghardt, Warapat Virayavanich, Thomas M. Link, John B. Imboden and Xiaojuan Li, University of California, San Francisco, San Francisco, CA, Thammasat University, Pathumthani, Thailand 958. Does Evaluation Of Hand Bone Loss By Digital x-ray Radiogrammetry Within The First Months After Diagnosis Of Rheumatoid Arthrits Identify Patients At Risk For Radiological Progression? Ewa H. Berglin and Solbritt M. Rantapaa-Dahlqvist, Institution of Public health and clinical medicine/ Rheumatology, University of Umeå, Umeå, Sweden, Institution of Public health and clinical medicine/ Rheumatology, University of Umeå, Umeå, Sweden, Umea, Sweden 959. Extremity MRI Scans of the Hand and the Diagnosis of Inflammatory Arthritis: Findings in Patients With a Clinical Diagnosis of RA, Non-Inflammatory Arthritis and Fibromyalgia. Robert S. Katz, Hannah Bond and Anthony Farkasch, Rush Medical College, Chicago, IL, Rheumatology Associates, Chicago, IL 960. Combination Of Magnetic Resonance Imaging-Proven Osteitis With 00 RA Classification Criteria Improves The Diagnostic Probability Of Early Rheumatoid Arthritis Whose Disease Duration Less Than 6 Months. Mami Tamai, Junko Kita, Yoshikazu Nakashima, Ayako Nishino, Takahisa Suzuki, Yoshiro Horai, Akitomo Okada, Tomohiro Koga, Shin-ya Kawashiri, Naoki Iwamoto, Kunihiro Ichinose, Kazuhiko Arima, Satoshi Yamasaki 4, Hideki Nakamura, Tomoki Origuchi, Masataka Uetani, Aya Fukushima, Kiyoshi Aoyagi, Katsumi Eguchi 5 and Atsushi Kawakami, Center for Health & Community Medicine, Nagasaki University, Nagasaki, Japan, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, Japanese Red Cross Nagasaki Genbaku Hospital, Nagasaki, Japan, 4 Hiroshima University Hospital, Hiroshima, Japan, 5 Sasebo City General Hospital, Sasebo, Nagasaki, Japan 96. The Diagnostic Utility Of Musculoskeletal Ultrasound In Early Arthritis a Probabilistic (Bayesian) Approach. Hamed Rezaei, Erik af Klint, Yogan Kisten and Ronald F. van Vollenhoven, The Karolinska Institute, Stockholm, Sweden, Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID), the Karolinska Institute, Stockholm, Sweden 96. The Value Of the 00 ACR/EULAR Rheumatoid Arthritis Classification Criteria For The Prognosis Of Early Arthritis: Evaluation Of Erosion Development With Ultrasonography. Nevsun Inanc, Fatma Alibaz-Oner, Meryem Can, Pamir Atagündüz and Haner Direskeneli, Marmara University, School of Medicine, Istanbul, Turkey 94 0 Program Book

297 ACR POSTER SESSION C 96. Ultrasonography Is Helpful For Optimizing The Diagnosis Of Early Rheumatoid Arthritis. Maasa Hama, Darisuren Tsolmon, Kaoru Minegishi, Ryusuke Yoshimi, Yohei Kirino, Atsuhisa Ueda, Mitsuhiro Takeno, Ichiro Aoki and Yoshiaki Ishigatsubo, Yokohama City University Graduate School of Medicine, Yokohama, Japan 964. Quantitative Erosion Volume Measurement From Computed Tomography. Jeffrey W. Duryea, Daniel H. Solomon, Bing LU, Ruby Russell, Roger Han, Ellen M. Gravallese 4 and Jonathan Kay 5, Brigham and Women s Hospital, Boston, MA, Harvard Medical School, Brigham and Women s Hospital, Division of Rheumatology, Division of Pharmacoepidemiology, Boston, MA, Brigham & Women s Hospital and Harvard Medical School, Boston, MA, 4 UMass Memorial Medical Center, Worcester, MA, 5 UMass Memorial Medical Center and University of Massachusetts Medical School, Worcester, MA 965. Performance Of a Computer-Based Method To Measure Erosions In Rheumatoid Arthritis: A Longitudinal Study. Jeremy Wortman, Stacy Smith, Frederick Wolfe and Jeffrey W. Duryea, Brigham and Women s Hospital, Boston, MA, National Data Bank for Rheumatic Diseases, Wichita, KS 966. Longitudinal Quantification Of Bone Erosions In Patients With Rheumatoid Arthritis Using High-Resolution Computed Tomography. Dominique Toepfer, Stephanie Finzel, Oleg Museyko, Georg Schett and Klaus Engelke, University of Erlangen-Nuremberg, Erlangen, Germany 967. Computer-Aided and Manual Quantifications Of MRI Synovitis, Bone Edema, Erosion and Semi-Quantitative Cartilage Loss In Rheumatoid Arthritis. Haitao Yang, Julien Rivoire, Michael Hoppe, John B. Imboden, Thomas M Link and Xiaojuan Li, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China, University of California, San Francisco, San Francisco, CA 968. A Novel, Feasible and Reliable Method Of Radiographic Scoring Of Rheumatoid Arthritis. Priyanka Vashisht, Harlan Sayles, Ted R. Mikuls and Alan R. Erickson 4, Creighton University Medical Center, Omaha, NE, University of Nebraska Medical Center, Omaha, NE, Omaha VA and University of Nebraska Medical Center, Omaha, NE, 4 Omaha VA and University of Nebraska Medical Center, LaVista, NE 969. Ankle Joint Involvement In Rheumatoid Arthritis. An Ultrasound Study Using High Resolution- and Colour Doppler Ultrasound. Mohammed Alsuwaidi, Boris P. Ehrenstein, Martin Fleck and Wolfgang Hartung, Asklepios Clinic Bad Abbach, Bad Abbach, Germany, University Medical Center of Regensburg, Regensburg, Germany 970. The Utility Of Fluorescence Optical Imaging For Detecting Clinically Silent Synovitis Of The Hands and Wrists. Yogan Kisten, Noémi Györi, Hamed Rezaei, Anna Karlsson, Carolina Romanus, Ronald van Vollenhoven and Erik af Klint, The Karolinska Institute, Stockholm, Sweden, Unit for Clinical Therapy Research Inflammaroty Diseases (ClinTRID) Department of Medicine, the Karolinska Insitute, Stockholm, Sweden, Unit for Clinical Research Therapy. Inflammatory Diseases (ClinTrid), Karolinska Institute, Stockholm, Sweden 97. The Four Finger Examination Technique Is Superior To The Standard Two Finger Technique To Detect Metacarpal Phalangeal Joint Swelling In Rheumatoid Arthritis - A Validation By Power Doppler Ultrasound. Mohammed Omair, Pooneh Akhavan, Ali Naraghi, Deborah Weber, Shikha Mittoo, Melissa Weber, Juan Xiong and Edward C. Keystone, Mount Sinai Hospital/University of Toronto, Toronto, ON, Mount Sinai Hospital, Toronto, ON, Mount Sinai Hospital, University of Toronto, Toronto, ON 97. Erosion Case Definition and Scoring Reliability Exercise Using a New Outcome Measurement Tool, High-Resolution Peripheral Quantitative Computed Tomography, In Rheumatoid Arthritis. Cheryl Barnabe, Dominique Toepfer, Hubert Marotte, Ellen-Margrethe Hauge 4, Andrea Scharmga 5, Roland Kocijan 6, Sebastian Kraus, Kresten K. Keller 4, Joost de Jong 5, Jeroen Williams 5 and Stephanie Finzel, University of Calgary, Calgary, AB, University of Erlangen-Nuremberg, Erlangen, Germany, Inserm U059, Saint-Etienne, France, 4 Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark, 5 Maastricht University, Maastricht, Netherlands, 6 Academic Teaching Hospital of Medical University Vienna, Vienna, Austria 97. Importance Of Hand Positioning In D Joint Space Morphology Assessment. Stephanie Boutroy, Elodie Hirschenhahn, Emile Youssof, Hervé Locrelle, Thierry Thomas, Roland Chapurlat and Hubert Marotte, INSERM U0 and University of Lyon, Hôpital Edouard Herriot, Lyon, France, INSERM U059 and University Hospital, Hôpital Nord, Saint-Etienne, France, INSERM UMR 0 and University of Lyon, Hôpital Edouard Herriot, Lyon, France 974. Assessing Validity Of Low Field Magnetic Resonance Imaging (MRI) for Joint Inflammation and Damage In Wrist/Hand Rheumatoid Arthritis (RA) - A Systematic Literature Review (SLR). OM Troum, OL Pimienta, TG Woodworth, O Morgacheva, V Ranganath and D E Furst, Keck School of Medicine, University of Southern California, Los Angeles, CA, David Geffen School of Medicine, University of California, Los Angeles, CA, David Geffen School of Medicine, UCLA, Los Angeles, CA 0 Program Book 95

298 ACR POSTER SESSION C 975. Cardiovascular Risk Stratification In Rheumatic Diseases : Carotid Ultrasound Is More Sensitive Than Coronary Artery Calcification Score To Detect Subclinical atherosclerosis In Patients With Rheumatoid Arthritis. Francisco Ortiz-Sanjuán, Alfonso Corrales, José Antonio Parra, Carlos González-Juanatey 4, Montserrat Santos, Javier Rueda, Ricardo Blanco, Vanesa Calvo-Río, Javier Loricera, Javier Llorca 5 and Miguel A González-Gay, Hospital Universitario Marqués de Valdecilla. IFIMAV. Santander. Spain, Santander, Spain, Hospital Universitario Marqués de Valdecilla. IFIMAV, Santander, Spain, Radiology Division, Hospital Universitario Marqués de Valdecilla, Santander, Spain, 4 Cardiology Division, Hospital Lucus Augusti, Lugo, Spain, 5 School of Medicine, University of Cantabria, and CIBER Epidemiología y Salud Pública (CIBERESP), Santander, Spain 976. Magnetic Resonance Imaging-Assessment Of Early Response To Certolizumab Pegol In Rheumatoid Arthritis: A Randomized, Double-Blind, Placebo-Controlled Phase IIIb Study Applying Magnetic Resonance Imaging At Week 0,,, 4, 8 and 6. Mikkel Ostergaard, Lennart Jacobsson, Christopher Schaufelberger, Michael Sejer- Hansen 4, Johannes Bijlsma 5, Anna Dudek 6, Maria Rell- Bakalarska 7, Fabienne Staelens 8, Robert Haake 9, Britt Sundman-Engberg 0 and Henning Bliddal, Copenhagen Center for Arthritis Research, Glostrup, Denmark, Section of Rheumatology, Malmö, Sweden, Sahlgrens Hospital, Göteborg, Sweden, 4 Rheumatology Clinic, Copenhagen, Denmark, 5 University Medical Center, Utrecht, Netherlands, 6 Medica Pro Familia, Warsaw, Poland, 7 Rheuma Medicus, Warsaw, Poland, 8 UCB Pharma, Brussels, Belgium, 9 UCB Pharma, Raleigh, NC, 0 UCB Pharma, Stockholm, Sweden, Department of Rheumatology, Frederiksberg, Denmark 977. Remission At Or 6 Months and Radiographic Non- Progression At Months In Methotrexate-Naïve Rheumatoid Arthritis Patients Treated With Tofacitinib Or Methotrexate: A Post-Hoc Analysis Of The ORAL Start Trial. V. Strand, D. van der Heijde, R. Landewe, E. B. Lee 4, B. Wilkinson 5, S. H. Zwillich 5, J. Bradley 5, C. Mebus 5, B. Benda 6 and D. Gruben 5, Stanford University, Palo Alto, CA, Leiden University Medical Center, Leiden, Netherlands, Academic Medical Center / University of Amsterdam, Amsterdam, Netherlands, 4 Seoul National University, Seoul, South Korea, 5 Pfizer Inc, Groton, CT, 6 Pfizer Inc, Collegeville, PA 978. The Effect Of Certolizumab On Lymphatic Volume and Flow In Rheumatoid Arthritis Patients With Acute Flare. Homaira Rahimi, Vaseem Chengazi, Gregory Dieudonne, Edward M. Schwarz and Christopher T. Ritchlin, University of Rochester, Rochester, NY ARHP Imaging of Rheumatic Disease: Research Methodology 979. Occupational Balance Questionnaire: From People s Perspectives To A Patient Reported Outcome. Mona Dür, Gunter Steiner, Michaela Stoffer, Alexandra Kautzky- Willer, Veronika Fialka-Moser, Clemens Dejaco, Birgit Prodinger, Alexa Binder, Josef S. Smolen 4 and Tanja A. Stamm, Medical University of Vienna, Vienna, Austria, Swiss Paraplegic Group, Nottwil, Switzerland, Notwill, Switzerland, Hospital Goettlicher Heiland, Vienna, Austria, 4 Medical University of Vienna and Hietzing Hospital, Vienna, Austria 980. Validation Of The Fox-Walk Test In People With Rheumatoid Arthritis. Birgitta Nordgren, Cecilia Fridén, Eva Jansson, Ted Österlund, Wilhelmus Johannes Andreas Grooten, Christina H. Opava and Anette Rickenlund, Karolinska Institutet, SE 48 Huddinge, Sweden, Karolinska Institutet, Huddinge, Sweden, Karolinska University Hospital, Huddinge, Sweden 98. Developing International Consensus Definitions Of Improvement For Adult and Juvenile Dermatomyositis and Polymyositis. Saad Feroz, Nicolino. Ruperto, Jiri Vencovsky, Peter A. Lachenbruch, Brian Erman 4, Adam Huber 5, Brian M. Feldman 6, Ingrid E. Lundberg 7, Angela Pistorio 8, Howard Rockette 9, Frederick W. Miller, Rohit Aggarwal 9, Lisa G. Rider, for The ACR-EULAR Myositis Response Criteria Project Group, Angelo Ravelli 0, Clarissa Pilkington and Sheila K. Oliveira, NIEHS, NIH, Bethesda, MD, PRINTO, IRCCS G. Gaslini, Genoa, Italy, Institute of Rheumatology, Department of Clinical and Experimental Rheumatology, st Faculty of Medicine, Charles University, Prague, Czech Republic, 4 SRA International, Research Triangle Park, NC, 5 IWK Health Centre, Halifax, NS, 6 Hospital for Sick Children, Toronto, ON, 7 Rheumatology Unit, Department of Medicine, Karolinska University Hospital in Solna, Karolinska Institutet, Stockholm, Sweden, 8 PRINTO, Genoa, Italy, 9 University of Pittsburgh, Pittsburgh, PA, 0 Paediatric Rheumatology International Trials Organization (PRINTO), Istituto Giannina Gaslini, Genova, Italy, Great Ormond Street Hospital, London, United Kingdom, Instituto de Pediatria e Puericultura Martagão Gesteira (IPPMG) da Universidade Federal do Rio de Janeiro (UFRJ), Rio de Janeiro, Brazil 98. Development and Validation Of Medication Assessment Tools Specific For Rheumatoid Arthritis. Louise Grech, Bernard Coleiro, Anthony Serracino Inglott, Lilian M. Azzopardi, Victor Ferrito and Andrew A. Borg, Mater Dei Hospital, Msida, Malta, University of Malta, Msida, Malta Metabolic and Crystal Arthropathies II 98. Prevalence Of Birefringent Crystals In Three Inflammation- Prone Tissues. Jane Park, Divya Soman, Martine P. Roudier and Peter A. Simkin, University of Washington, Seattle, WA 984. Impact Of Educational Attainment On Health-Related Quality Of Life and Healthcare Utilization Among Veterans With Gout. Cleopatra Aquino-Beaton, Jay E. Persselin, Ari Weinreb, Meika A Fang, Jasvinder A. Singh, Erin Duffy, David Elashoff 4, Puja Khanna 5 and Dinesh Khanna 6, VA Greater Los Angeles Healthcare System, Los Angeles, CA, University of Alabama, Tuscaloosa, AL, University of California Los Angeles, Los Angeles, CA, 4 UCLA Department of Medicine Statistics Core, Los Angeles, CA, 5 Ann Arbor VA, Ann Arbor, MI, 6 University of Michigan Medical Center, Ann Arbor, MI 985. Prescription Patterns Of Colchicine Before and After Food and Drug Administration Approval. Eswar Krishnan, Jasvinder A. Singh and Linjun Chen, Stanford University, Palo Alto, CA, University of Alabama, Tuscaloosa, AL 96 0 Program Book

299 ACR POSTER SESSION C 986. Colchicine Use and The Risk Of Myocardial Infarction Among Gout Patients: Results From a Community-Based, Informatics-Driven Retrospective Cohort Study. Daria B. Crittenden, Binita Shah, Steven P. Sedlis, Christopher J. Swearingen, Eric S. Wagner 4, Yvette M. Henry 4, Peter B. Berger 4, Bruce N. Cronstein and Michael H. Pillinger, NYU School of Medicine, Division of Rheumatology, New York, NY, NYU School of Medicine, Division of Cardiology, New York, NY, Pediatric Biostatistics, University of Arkansas for Medical Sciences, Little Rock, AR, 4 Geisinger Health System, Cardiovascular Center for Clinical Research, Danville, PA 987. LIVER Outcomes In Gout Patients Treated With Febuxostat and Altered LIVER Function TESTS. Fernando Perez-Ruiz and Ana M. Herrero-Beites, BioCruces Health Institute, Baracaldo, Spain 988. Self-Reported Gout, Comorbidities and Healthcare Resource Utilization Data From The 0 United States National Health and Wellness Survey. Jasvinder A. Singh, Kathy Annunziata and Puja Khanna, University of Alabama, Tuscaloosa, AL, Kantar Health, Princeton, NJ, University of Michigan Medical Center, Ann Arbor, MI 989. Determinants Of Functional Disability In Patients With Gout: Longitudinal Analysis From a Multicentre Observational Study Of The Italian Society For Rheumatology. Carlo Alberto Scirè, Maria Manara, Greta Carrara, Marco A. Cimmino, Marcello Govoni, Fausto Salaffi 4, Leonardo Punzi 5, Carlomaurizio Montecucco 6, Marco Matucci-Cerinic 7 and Giovanni Minisola 8, Epidemiology Unit -Italian Society for Rheumatology, Milano, Italy, University of Genoa, Genova, Italy, Section of Rheumatology - Department of Clinical and Experimental Medicine - University of Ferrara, Ferrara, Italy, 4 Rheumatology Unit - Polytechnic University of the Marche, Jesi, Italy, 5 University of Padova, Padova, Italy, 6 University and IRCCS Policlinico S. Matteo Foundation, Pavia, Italy, 7 University of Florence, Azienda Ospedaliera Careggi, Florence, Italy, 8 Rheumatology Unit, San Camillo-Forlanini Hospital, Rome, Italy 990. Treatment Of ACUTE Gout In The Emergency Department Evaluated According To The 0 American College Of Rheumatology Guidelines. Naomi Schlesinger, Tina Chang Young, Diane C. Radvanski, Dirk Moore 4 and Robert Eisenstein 5, UMDNJ-Robert Wood Johnson Medical School, New Brunswick, NJ, UMDNJ/School of Public Health, Piscataway, NJ, Robert Wood Johnson Medical School, New Brunswick, NJ, 4 UMDNJ - School of Public Health, Piscataway, NJ, 5 UMDNJ- Robert Wood Johnson Medical School, New Brunswick, NJ 99. Gout In Ambulatory Care Settings In The US: Eswar Krishnan and Linjun Chen, Stanford University, Palo Alto, CA 99. Trends In Outpatient Treatment Of Gout In The US: From 99 To 009. Eswar Krishnan and Linjun Chen, Stanford University, Palo Alto, CA 99. Geographic Variations Of Gout Epidemiology In The United Kingdom: A Nationwide Population Study. Chang- Fu Kuo, Michael Doherty, Matthew J. Grainge and Weiya Zhang, Chang Gung Memorial Hospital, Taipei, Taiwan, University of Nottingham, Nottingham, United Kingdom 994. Performance Of Gout Impact Scale Of The Gout Assessment Questionnaire In a Longitudinal Observational Study Of Patients With Gout. Puja Khanna, Cleopatra Aquino-Beaton, Jasvinder A. Singh, Erin Duffy 4, David Elashoff 5 and Dinesh Khanna 6, University of Michigan Medical Center, Ann Arbor, MI, VA Greater Los Angeles Healthcare System, Los Angeles, CA, University of Alabama, Tuscaloosa, AL, 4 University of California Los Angeles, Los Angeles, CA, 5 UCLA Department of Medicine Statistics Core, Los Angeles, CA, 6 Division of Rheumatology, University of Michigan Medical Center, Ann Arbor, MI 995. Serum Homocysteine Related To Decreased Renal Function In Chronic Gouty Patients. Jung-Soo Song, Jin Su Kim and Sang Tae Choi, Chung-Ang University College of Medicine, Seoul, South Korea 996. Racial/Ethnicity Differences In Health-Related Quality Of Life (HRQOL), Functional Ability and Health Care Utilization In Gout Patients. Aseem Bharat, Jasvinder A. Singh, Puja Khanna, Cleopatra Aquino-Beaton 4, Jay E. Persselin 4, Erin Duffy 5, David Elashoff 6 and Dinesh Khanna 7, University of Alabama at Birmingham, Birmingham, AL, University of Alabama, Tuscaloosa, AL, University of Michigan Medical Center, Ann Arbor, MI, 4 VA Greater Los Angeles Healthcare System, Los Angeles, CA, 5 University of California Los Angeles, Los Angeles, CA, 6 UCLA Department of Medicine Statistics Core, Los Angeles, CA, 7 University of Michigan, Ann Arbor, MI 997. Health Care Utilization In Gout Patients: A Prospective Multicenter Cohort Study. Jasvinder A. Singh, Aseem Bharat, Puja Khanna, Cleopatra Aquino-Beaton 4, Jay E. Persselin 4, Erin Duffy 5, David Elashoff 6 and Dinesh Khanna 7, University of Alabama, Tuscaloosa, AL, University of Alabama at Birmingham, Birmingham, AL, University of Michigan Medical Center, Ann Arbor, MI, 4 VA Greater Los Angeles Healthcare System, Los Angeles, CA, 5 University of California Los Angeles, Los Angeles, CA, 6 UCLA Department of Medicine Statistics Core, Los Angeles, CA, 7 University of Michigan, Ann Arbor, MI 998. The Risk Of Subsequent Attacks In Patients With Incident Gout: A Population-Based Study. Nour Zleik, Clement J. Michet, Helen Khun, Cynthia S. Crowson, Eric L. Matteson and Tim Bongartz, Mayo Clinic, Rochester, MN 999. Hospitalization and Flare Risk In Patients With Established Gout: A Population-Based Study. Nour Zleik, Clement J. Michet, Helen Khun, Cynthia S. Crowson, Eric L. Matteson and Tim Bongartz, Mayo Clinic, Rochester, MN 000. Changes In The Prevalence Of Gout In The United States General Population Between 960 and 00: The National Health and Nutrition Examination Surveys. Eswar Krishnan and Linjun Chen, Stanford University, Palo Alto, CA 0 Program Book 97

300 ACR POSTER SESSION C 00. Kaiser Permanent Pyramid In Patients With Gout: The Most Severe Gout Is Associated To The Most Complex Patients. Fernando Perez-Ruiz, Ana M. Herrero-Beites and Amaya Martinez-Galarza, BioCruces Health Institute, Baracaldo, Spain 00. Prophylactic Duration and Serum Uric Acid Level Are Associated With Gout Flare During Urate Lowering Treatment. Hyo-Jin Choi, Chan Hee Lee, Sang Tae Choi, Jung-Soo Song, Hyoun-Ah Kim 4, Chang-Hee Suh 5, Hoyeon Joo 6, Ki Chul Shin 7 and Hanjoo Baek, Gachon University Gil Hospital, Incheon, South Korea, NHIC Ilsan Hospital, Goyang-si, South Korea, Chung-Ang University College of Medicine, Seoul, South Korea, 4 Ajou University School of Medicine, Suwon, South Korea, 5 Ajou University Hospital, Suwon, South Korea, 6 Inha University Hospital, Incheon, South Korea, 7 Seoul National University College of Medicine, Seoul, South Korea 00. Outcome Of Gout Patients Placed On Febuxostat After Failing To Reach Serum Urate Target With Allopurinol. Hind Hatoum, Dinesh Khanna, Aki Shiozawa, Swu-Jane Lin 4, Kasem Akhras 5 and Puja Khanna 6, University of Illinois at Chicago, chicago, IL, University of Michigan, Ann Arbor, MI, Takeda Pharmaceuticals International, Inc, Deerfield, IL, 4 University of Illinois at Chicago, Chicago, IL, 5 Formerly of Takeda Pharmaceuticals International, Inc, Deerfield, IL, 6 University of Michigan Medical Center, Ann Arbor, MI 004. Kidney Disease Is An Independent Risk Factor For Incident Gout. Weiqi Wang, Vidula Bhole and Eswar Krishnan, stanford university, palo alto, CA, EpiSolutions Consultancy Services, Thane, India, Stanford University, Palo Alto, CA 005. Predictors Of Outcomes In Tophaceous Gout- Results From a Prospective Cohort At The Veterans Affairs. Puja Khanna, Cleopatra Aquino-Beaton, Jasvinder A. Singh, Erin Duffy 4, David Elashoff 5 and Dinesh Khanna 6, Ann Arbor VA, Ann Arbor, MI, VA Greater Los Angeles Healthcare System, Los Angeles, CA, University of Alabama, Tuscaloosa, AL, 4 University of California Los Angeles, Los Angeles, CA, 5 UCLA Department of Medicine Statistics Core, Los Angeles, CA, 6 Division of Rheumatology, University of Michigan Medical Center, Ann Arbor, MI 006. Uric Acid Level Is Not An Independent Predictor Of Cardiovascular Diseases In Gout Patients With Treatment; Long-Term Follow-Up Data In Single Tertiary Center In South Korea. Seulkee Lee, Eun-Jung Park, Jinseok Kim, Chan Hong Jeon, Hyungjin Kim, Jaejoon Lee 4, Eun-Mi Koh and Hoon-Suk Cha 4, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea, Jeju National University Hospital, Jeju, South Korea, Soonchunhyang University College of Medicine, Bucheon, South Korea, 4 Sungkyunkwan University School of Medicine, Samsung Medical Center, Seoul, South Korea 007. Using Natural Language Processing and Machine Learning To Identify Gout Flares From Electronic Clinical Notes. Chengyi Zheng, Nazia Rashid, T. Craig Cheetham, Yi-Lin Wu and Gerald D. Levy 4, Kaiser Permanente Southern California, Pasadena, CA, Kaiser Permanente Southern California, Downey, CA, Kaiser Permanente, Downey, CA, 4 Southern California Permanente Medical Group, Downey, CA 008. Assessing Treat To Target In Gout Patients With and Without Tophi. Leslie R. Harrold, Carol Etzel, Bruce Schechter, Raymond L. Malamet, Vanessa Cox and Jeffrey D. Greenberg 4, University of Massachusetts Medical School, Worcester, MA, CORRONA, Inc, Southborough, MA, Savient Pharmaceuticals, Inc., Bridgewater, NJ, 4 NYU Hospital for Joint Diseases, New York, NY 009. Outcome Of Allopurinol Or Febuxostat Treatment In Gout Patients Naïve To Urate-Lowering Therapy. Puja Khanna, Hind Hatoum, Swu-Jane Lin, Aki Shiozawa 4, Kasem Akhras 5 and Dinesh Khanna, University of Michigan Medical Center, Ann Arbor, MI, University of Illinois at Chicago, chicago, IL, University of Illinois at Chicago, Chicago, IL, 4 Takeda Pharmaceuticals International, Inc, Deerfield, IL, 5 Formerly of Takeda Pharmaceuticals International, Inc, Deerfield, IL Miscellaneous Rheumatic and Inflammatory Diseases II: Miscellaneous Rheumatic Diseases 00. Erdheim-Chester Disease: A Monocentric Series Of 96 Patients. Julien Haroche, Laurent Arnaud, Fleur Cohen- Aubart, Baptiste Hervier, David Saadoun, Nathalie Costedoat-Chalumeau, Sophie Besnard, Kim Heang Ly 4, Michel Pavic 5, Jean-Gabriel Fuzibet 6, Loic Raffray 7, Laurent Aaron 8, Pascal Bindi 9, António Marinho 0, Bjorn Blomberg, Juan Salvatierra, Claudia Dechant, Aude Rigolet 4, François Lifermann 5, Jo Caers 6, Catherine Veyssier- Belot 7, Bertrand Wechsler, Lucienne Michaux 8, Giorgio Graziani 9 and Zahir Amoura, Hôpital Pitié-Salpêtrière, AP-HP, UPMC Univ Paris 06 & French National Reference Center For Systemic Lupus and Antiphospholipid Syndrome, Paris, France, Hopital Cochin, Paris, France, Pontchaillou University Hospital, Rennes, Rennes, France, 4 Limoges University Hospital, Limoges, France, 5 HIA Desgenettes, Lyon, France, Lyon, France, 6 Internal Medicine, Hôpital de l Archet, CHU de Nice, Nice, France, 7 CHU de Bordeaux, Bordeaux, France, 8 Hôpital Jacques Coeur, Bourges, Bourges, France, 9 Department of medicine A, Centre Hospitalier de Verdun, Verdun, France, 0 Unidade de Imunologia Clínica, Porto, Portugal, University of Bergen, Norway, Bergen, France, University Hospital San Cecilio, Granada, Spain, University of Munich, Munich, Germany, 4 Pitie-Salpetriere Hospital, Paris, France, 5 CH de Dax, Dax, France, 6 Centre Hospitalier Universitaire de Liège Domaine Universitaire du Sart Tilman, Liège, Belgium, 7 CHI Poissy Saint-Germain-en-Laye, Saint-Germain-en-Laye, France, 8 Cliniques Universitaires Saint-Luc UCL Bruxelles, Bruxelles, Belgium, 9 Istituto Clinico Humanitas IRCCS, Rozzano- Milano, Italy, Milan, Italy 98 0 Program Book

301 ACR POSTER SESSION C 0. Osseous Sarcoidosis: Clinical Presentation, Treatment, and Outcomes. Experience From a Large Tertiary Care Academic Hospital. Jeffrey A. Sparks, Jakob I. McSparron, Christopher H. Fanta and Jonathan S. Coblyn, Brigham and Women s Hospital, Harvard Medical School, Boston, MA, Brigham and Women s Hospital, Boston, MA 0. Gender Influences On Organ Manifestations In a New Orleans Sarcoidosis Population. Adam Janot, McCall Walker, Mary Yu, Harmanjot K. Grewal, Matthew R. Lammi 4 and Lesley Ann Saketkoo 5, Louisiana State University Health Sciences Center, New Orleans, LA, LSUHSC School of Medicine, New Orleans, LA, Lousiana State University Health Sciences Center, New Orleans, LA, 4 Louisiana State University Health Sciences Center, Pulmonary and Critical Medicine, New Orleans, LA, 5 LSU HSC - New Orleans, Sections of Rheumatology and Pulmonary Medicine, New Orleans, LA 0. Biologic Therapy In Refractory Uveitis Of Sarcoidosis. Multicenter Study Of 6 Patients. Javier Loricera, Vanesa Calvo-Río, Ricardo Blanco, Marina Mesquida, Alfredo M. Adan, JM Herreras 4, A Aparicio 5, MJ Moreno Ramos 6, MJ Moreno Martínez 6, LF Linares Ferrando 6, M Hernández Martínez 6, D Peitado-Lopez 7, Miguel Cordero- Coma 8, Jl García Serrano 9, Norberto Ortego 9, O Maíz 0, A Blanco 0, Juan Sánchez-Bursón, S González-Suárez, Alejandro Fonollosa, Montserrat Santos-Gómez, F. Ortiz-Sanjuán and Miguel Angel González-Gay, Hospital Universitario Marqués de Valdecilla. IFIMAV. Santander. Spain, Santander, Spain, Hospital Universitario Marqués de Valdecilla. IFIMAV, Santander, Spain, Hospital Clínic of Barcelona, Barcelona, Spain, 4 Hospital Universitario, IOBA. Valladolid, Valladolid, Spain, 5 Hospital de Toledo., Toledo, Spain, 6 Hospital Clínico Universitario Virgen de la Arrixaca. Murcia, Murcia, Spain, 7 Hospital Universitario La Paz Madrid, Madrid, Spain, 8 Hospital de León, León, Spain, 9 Hospital San Cecilio. Granada, Granada, Spain, 0 Hospital Donosti San Sebastian, San Sebastián, Spain, Hospital de Valme. Sevilla, Sevilla, Spain, Hospital Cabueñes, Gijón, Gijón, Spain, Hospital de Cruces. Bilbao, Bilbao, Spain 04. Cigarette Smoking and Male Sex Are Independent Risk Factors For Ocular Sarcoidosis. Adam Janot, Dörte Huscher, McCall Walker, Harmanjot K. Grewal 4, Mary Yu, Matthew R. Lammi 5 and Lesley Ann Saketkoo 6, Louisiana State University Health Sciences Center, New Orleans, LA, Charité University Hospital and German Rheumatism Research Centre, a Leibniz Institute, Berlin, Germany, LSUHSC School of Medicine, New Orleans, LA, 4 Lousiana State University Health Sciences Center, New Orleans, LA, 5 Louisiana State University Health Sciences Center, Pulmonary and Critical Medicine, New Orleans, LA, 6 LSU HSC - New Orleans, Sections of Rheumatology and Pulmonary Medicine, New Orleans, LA 05. Sarcoid Arthritis In World Trade Center Exposed New York City Firefighters Presenting As a Unique Clinical Subset. Konstantinos Loupasakis, Jessica Berman, Michelle S Glaser, Nadia Jaber 4, Rachel Zeig-Owens, Mayris P Webber 4, Michael D Weiden 4, Anna Nolan 4, Kerry J Kelly 4 and David J Prezant 4, Hospital for Special Surgery Weill Cornell Medical College, New York, NY, Hospital for Special Surgery, Weill Cornell Medical College, New York, NY, Montefiore Medical Center, Bronx, NY, 4 Bureau of Health Services Fire Department of New York, Brooklyn, NY 06. Inflamamatory Myositis-Increased Incidence In Fire Department Of New York Firefighters After World Trade Center Exposure. Basit Qayyum, Michelle S Glaser, Nadia Jaber, Rachel Zeig-Owens, Mayris P Webber, Anna Nolan, Kerry J Kelly and David J Prezant, New York University School of Medicine, New York, NY, Montefiore Medical Center, Bronx, NY, Bureau of Health Services Fire Department of New York, Brooklyn, NY 07. Hyper Ferritinemia Suggests a High Frequency Of Macrophage Activation Syndrome In a Large Adult Severe Sepsis Cohort: A Role For Anakinra? Bita Shakoory, Joseph A. Carcillo and Steven Opal, Temple University, Philadelphia, PA, University of Pittsburg Medical Center, Pittsburgh, PA, Brown University, Providence, RI 08. Hemophagocytic Lymphohistiocytosis As a Clinical Syndrome Of Autoimmune Diseases, Haematology, Oncology and Infectious Diseases. César Antonio Egües Dubuc, Vicente Aldasoro Cáceres, Miren Uriarte Ecenarro, Carlos Meneses Villalba, Nerea Errazquin Aguirre, Iñaki Hernando Rubio, Olga Maiz Alonso, Jorge Cancio Fanlo, Esther Uriarte Isacelaya and Joaquin Belzunegui Otano, Donostia University Hospital, San Sebastián, Spain 09. Kikuchi-Fujimoto disease : Features and Outcome Of 9 Patients In France. Guillaume Dumas, Virginie Prendki, Julien Haroche, Patrice Cacoub 4, Zahir Amoura, Lionel Galicier 5, Olivier Meyer 6, Christophe Rapp, Christophe Deligny 7, Bertrand Godeau 8, Elisabeth Aslangul 9, Olivier Lambotte 0, Thomas Papo, Jacques Pouchot, Mohamed Hamidou, Gilles Grateau 4, Eric Hachulla 5, Thierry Carmoi 6, Robin Dhote 7, Magdalena Gerin 8, Arsene Mekinian 8, Fréderique Charlotte 4, Dominique Farge 5, Thierry Molina 9 and Olivier Fain 8, Hôpital d Instruction des Armées Bégin, Saint Mandé, France, Hôpitaux Universitaires de Genève, Genève, Switzerland, Hôpital Pitié-Salpêtrière, AP-HP, UPMC Univ Paris 06 & French National Reference Center For Systemic Lupus and Antiphospholipid Syndrome, Paris, France, 4 Hopital Pitié- Salpétrière, Paris, France, 5 Hopital St Louis, AP-HP, Paris, France, 6 Bichat University Hospital, Paris, France, 7 Centre hospitalier Universitaire de Fort de France, Fort de France, Martinique, 8 University of Paris, AP-HP, Hôpital Mondor Créteil, Creteil, France, 9 hôpital Hotel Dieu, AP-HP, Paris, France, 0 Hopital Kremlin Bicêtre, Kremlin Bicêtre, France, University Paris-7, INSERM U699, APHP, Bichat Hospital, Paris, France, Hôpital Européen Georges Pompidou, AP- HP, Paris, France, Nantes University Hospital, Nantes, France, 4 Hopital Tenon, Paris, France, 5 University Hospital Lilles, Lille CEDEX, France, 6 Hôpital d Instrcution des Armées du Val de Grace, Paris, France, 7 Avicenne University Hospital, Bobigny, France, 8 Hôpital Jean Verdier, AP-HP, Bondy, France 0 Program Book 99

302 ACR POSTER SESSION C 00. Clinical Characteristics In Japanese Patients With IgG4- Related Disease. Kazu Hamada, Yoshinori Taniguchi, Yoshiko Shimamura, Koji Ogata, Kosuke Inoue, Taro Horino, Yoshitaka Kumon, Kahori Hirose, Masamitsu Hyodo and Yoshio Terada, MD, Nankoku, Japan 0. The Proportion Of IgG4-Related Aortitis In Patients Diagnosed As Chronic Inflammation Of Aorta In Pathology. Bon San Koo, Bin Yoo, Chang-Keun Lee, You Jae Kim, Seokchan Hong, Yong-Gil Kim, Wook Jang Seo and Kyung joo Ahn, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea, Seoul Veterans Hospital, Seoul, South Korea, KEPCO medical center, Seoul, South Korea 0. The Comparison Between IgG4-Related Retroperitoneal Fibrosis and Idiopathic Retroperitoneal Fibrosis. Bon San Koo, Bin Yoo, Chang-Keun Lee, Yong-Gil Kim, You Jae Kim, Seokchan Hong, Wook Jang Seo and Kyung joo Ahn, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea, Seoul Veterans Hospital, Seoul, South Korea, KEPCO medical center, Seoul, South Korea 0. IgG4-Related Midline Destructive Lesion: Expanding The Spectrum Of Organ Involvement In IgG4-Related Disease. Emanuel Della Torre, Donald Krause, Vikram Deshpande, Vinay Mahajan, Hamid Mattoo, Shiv Pillai and John Stone, Massachusetts General Hospital, Boston, MA, St. Joseph s Hospital, Bangor, ME, Massachusetts General Hospital, Harvard Medical School, Boston, MA 04. Elevated IgG4+ Plasmablasts In Patients With Active, Untreated IgG4-Related Disease. Zachary S. Wallace, Vinay Mahajan, Mollie Carruthers, Hamid Mattoo, Shiv Pillai and John H. Stone, Massachusetts General Hospital, Boston, MA, Massachusetts General Hospital, Harvard Medical School, Boston, MA 05. Distinctive Expression Profiles Of Long Intergenic Non- Coding RNA Between Polymyalgia Rheumatica and Rheumatoid Arthritis Might Contains Helpful Suggestions For Understanding and Discriminating These Diseases. Yoshinobu Koyama, Motohiko Tanino, Hirokazu Shiraishi, Shuji Nagano, Toshiyuki Ota and Toshie Higuchi, Okayama Red Cross General Hospital, Okayama, Japan, DNA Chip Research Inc., Yokohama, Japan, Iizuka Hospital, Iizuka, Japan 06. Initial Dose Of Prednisolone For Japanese Patients With Polymyalgia Rheumatica. Akiko Aoki, Hiroshi Oka and Mitsuyuki Nakamura, Tokyo Medical University Hachioji Medical Center, Tokyo, Japan 07. Treatment Of Refractory Adult-Onset Still s Disease With Abatacept : Report Of Five Cases. Hye Jin Oh, Myung Jae Yun, Kyong Rok Kim, Sang Hyun Joo, Jae Myung Lee, Jin Kyun Park, Eun Bong Lee, Yeong Wook Song and Eun Young Lee, Seoul National University Hospital, Seoul, South Korea, Division of Rheumatology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, South Korea 08. Efficacy and Safety Of Biologic Agents In Adult-Onset Still s Disease: A Long-Term Follow-Up Of 9 Patients At a Single Referral Center. Giulio Cavalli, Stefano Franchini, Alvise Berti, Corrado Campochiaro, Barbara Guglielmi, Maria Grazia Sabbadini, Elena Baldissera and Lorenzo Dagna, Vita-Salute San Raffaele University, Milan, Italy, Vita- Salute San Raffaele University, Milano, Italy 09. Exposure-Response Modeling Of Canakinumab In The Avoidance Of Flares In Children With Systemic Juvenile Idiopathic Arthritis. Yuan Xiong, Wenping Wang, William Ebling, Haiying Sun, Olivier Luttringer, Ken Abrams, Nicola Ruperto and Hermine Brunner 4, Novartis Pharmaceuticals Corporation, East Hanover, NJ, Novartis Pharma AG, Basel, Switzerland, Istituto Gaslini, Genova, Italy, 4 Cincinnati Children s Hospital Medical Center, Cincinnati, OH 00. Comparative Immunogenicity Of Tumor Necrosis Factor Inhibitors: Impact On Clinical Efficacy and Tolerability In The Management Of Autoimmune Diseases: A Systematic Review and Meta-Analysis. Sarah Thomas, Nabeel Borazan, Lewei Duan, Nashla Barroso, Sara Taroumian, Banjamin Kretzmann 4, Ricardo Bardales 4 and Daniel E. Furst, University of California, Los Angeles, Los Angeles, CA, Rheumatology UCLA, Los Angeles, CA, David Geffen School of Medicine, University of California School of Medicine, Los Angeles, CA, 4 University of California Los Angeles, los angeles, CA 0. GRAID Interim Analysis Of The Retrospective German Register In Autoimmune Diseases. Thomas Dörner, Enno Schmidt, Christoph Fiehn, Frank Behrens 4, Rebecca Fischer-Betz 5, Martin Fleck 6, Julia Holle 7, Joerg C. Henes 8, Annett M. Jacobi 9, Christian Kneitz 0, Esther Wittenborn, Fabian Proft, Hendrik Schulze- Koops and Christof Iking-Konert 4, Charité university medecine/ German Rheumatism Research Centre Berlin (DRFZ), Berlin, Germany, University of Lübeck, Lübeck, Germany, ACURA Centre for Rheumatic Diseases, Baden-Baden, Germany, 4 CIRI/Div. Rheumatology, J.W. Goethe-University, Frankfurt/Main, Germany, 5 University of Düsseldorf, Düsseldorf, Germany, 6 University Medical Center of Regensburg, Regensburg, Germany, 7 Hospital Bad Bramstedt, Bad Bramstedt, Germany, 8 University Hospital Tuebingen, Tuebingen, Germany, 9 University Hospital Münster, Münster, Germany, 0 Hospital Südstadt, Rostock, Germany, Roche Pharma AG, Grenzach-Wyhlen, Germany, Medizinische Klinik und Poliklinik IV, Klinikum der Universität München, Munich, Germany, University of Munich, Munich, Germany, 4 University Hospital Hamburg Eppendorf, Hamburg, Germany 0. How Does Age At Onset Influence Autoimmune Rheumatic Diseases? Jenny Amaya-Amaya, Juan-Camilo Sarmiento-Monroy, Nicolás Molano-González, Mónica Rodríguez-Jiménez, Rubén-Darío Mantilla, Adriana Rojas- Villarraga and Juan-Manuel Anaya, School of Medicine and Health Sciences, Universidad del Rosario. Center for Autoimmune Diseases Research (CREA), Bogotá, Colombia 00 0 Program Book

303 ACR POSTER SESSION C 0. Mortality Prognostic Factors Of Patients With Systemic Autoimmune Diseases Admitted To An Intensive Care Unit. Pamela Inés Doti, Sara Fernandez, Emmanuel Coloma, Ona Escoda, Ignasi Rodiguez-Pintó, Pedro Castro, Gerard Espinosa and José María Nicolás, Department of Autoimmune Diseases, Hospital Clínic, Barcelona, Barcelona, Spain, Medical Intensive Care Unit, Hospital Clínic, Barcelona, Barcelona, Spain 04. Does Mixed Connective Tissue Disease Or Sharp s Syndrome Really Exist? Anne Barbarini, Christelle Sordet, Emmanuel Chatelus, Rose-Marie Javier, Joelle Goetz, Francois Lefebvre, Jacques-Eric Gottenberg, Thierry Martin and Jean Sibilia, Strasbourg University Hospital, Strasbourg, France, Strasbourg University Hospital, strasbourg, France, IBMC, Strasbourg, France 05. Description Of 4 Cases Of Relapsing Polychondritis Followed In a Single Center Since 000. Jeremie Dion, Nathalie Costedoat-Chalumeau, Damien Sene, Judith Cohen-Bittan, Gaëlle Leroux, Camille Francès 4 and Jean- Charles Piette, Hopital Cochin, Paris, France, Hopital Lariboisière, Paris, France, CHU Pitié-Salpêtrière, Paris, France, 4 Hopital Tenon, Paris, France 06. Biologic Therapy For Relapsing Polychondritis: Old and New Efficacy Indices. Mattia Baldini, Patrizia Aiello, Mirta Tiraboschi, Maria Grazia Sabbadini and Elena Baldissera, Ospedale San Raffaele and Università Vita-Salute San Raffaele, Milano, Italy 07. Isolated Anti-Ro5 Antibody Significance and Clinical Association. Yogesh Singh, Pravin Patil, Hilary Longhurst, Garry Clarke and Bhaskar Dasgupta 4, Southend university hospital, Westcliff-on-sea, United Kingdom, Southend University Hospital, Westcliff-on-sea, United Kingdom, Southend University Hospital, Westcliff on sea, United Kingdom, 4 Southend University Hospital, Westcliff-on-Sea, United Kingdom 08. Congenital Heart Block Related With Maternal Autoimmune Diseases: Descriptive Analysis Of a Series Of 7 Cases. Pamela Inés Doti, Ona Escoda, Sergi Cesar-Diaz, Narcís Masoller, Irene Teixidó, Josep Maria Martinez, Georgia Sarquella-Brugada and Gerard Espinosa, Department of Autoimmune Diseases, Hospital Clínic, Barcelona, Barcelona, Spain, Arrhythmia Unit, Cardiology Section, Hospital Sant Joan de Déu, Barcelona, Barcelona, Spain, Maternal Fetal Medicine Department, Hospital Clínic, Bacelona, Barcelona, Spain 09. Micro and Nanoparticles As Possible Causative-Prognostic Co-Factors Of Mixed Cryoglobulinemia Syndrome. Erica Artoni, Gian Luca Sighinolfi, Daniele Campioli, Marco Sebastiani, Dilia Giuggioli and Clodoveo Ferri, University of Modena and Reggio Emilia, Modena, Italy, Azienda Ospedaliera - Policlino di Modena, Modena, Italy 040. Pilot Study Of Abatacept In Patients With Refractory Autoimmune Chronic Urticaria. Clifton O. Bingham III, Marilyn Towns and Susan J. Bartlett, Johns Hopkins University, Baltimore, MD, McGill University, Montreal, QC 04. Pregnancy Outcomes In Women Exposed To Golimumab. Amy G. Lau, Michael Clark, Diane D. Harrison, Anja Geldhof, Riikka Nissinen and Marilyn Sanders, Janssen Research & Development, LLC., Horsham, PA, Janssen Biologics Europe, Leiden, Netherlands 04. Pregnancy Outcomes In Women With Rheumatologic Conditions Exposed To Infliximab. Sirisha Kalari, Fredrik Granath, Chun-Yuan Guo, Diane D. Harrison, Gabriella Bröms, Anja Geldhof, Riikka Nissinen, Marilyn Sanders, Mika Gissler 4, Lars Pedersen 5, Henrik Toft Sorensen 5 and Helle Kieler, Janssen Research & Development, LLC., Horsham, PA, Karolinska Institutet, Stockholm, Sweden, Janssen Biologics Europe, Leiden, Netherlands, 4 National Institute for Health and Welfare, Helsinki, Finland, 5 Aarhus University Hospital, Aarhus, Denmark 04. Perinatal Exposure To Traditional and Biologic Disease Modifying Antirheumatic Drugs In Rheumatic Diseases: A Systematic Review Of Congenital Outcomes. Corisande Baldwin, Sharan Rai, J. Antonio Avina-Zubieta and Mary De Vera, University of British Columbia, Vancouver, BC, Arthritis Research Centre of Canada, Richmond, BC, Arthritis Research Centre of Canada, University of British Columbia, Richmond, BC 044. Birth Outcomes In Childbearing Women Treated With Thiopurines: A Meta-Analysis. Zeinab F. Saleh, Raveendhara R. Bannuru, William F. Harvey and Timothy E. McAlindon, Tufts Medical Center, Boston, MA 045. Long QT and Hydroxychloroquine; A Poorly Recognised Problem In Rheumatology Patients. Andra Negoescu, Andrew Thornback, Eugene Wong and Andrew J. Ostor, Rheumatology Research Unit, Addenbrooke s Hospital, Cambridge, United Kingdom, Addenbrooke s Hospital, Cambridge, United Kingdom 046. Lower-Dose Indomethacin Submicron Particle Capsules Efficacy In Acute Pain: Results From Two Phase Studies. Roy D. Altman, Allan Gibofsky, Mark Jaros and Clarence Young 4, UCLA, Los Angeles, CA, Hospital for Special Surgery, New York, NY, Summit Analytical, Denver, CO, 4 Iroko Pharmaceuticals, Philadelphia, PA 047. Lower-Dose Indomethacin Submicron Particle Capsules Combined Safety From Two Phase Studies In Patients With Acute Pain Following Elective Surgery. Allan Gibofsky, Roy D. Altman, Clarence Young, Daniel Solorio 4 and Jennifer Nezzer 5, Hospital for Special Surgery, New York, NY, UCLA, Los Angeles, CA, Iroko Pharmaceuticals, Philadelphia, PA, 4 Iroko Pharmaceuticals, LLC, Philadelphia, PA, 5 Premier Research, Philadelphia, PA 048. Risk Factors For Glucocorticoids-Induced Diabetes In Patients With Rheumatic Diseases. Takayuki Katsuyama, Sayaka Aoki, Ken-ei Sada, Yuriko Yamamura, Haruki Watanabe, Eri Katsuyama, Mariko Narazaki, Noriko Tatebe, Koichi Sugiyama, Katsue S. Watanabe, Hiroshi Wakabayashi, Tomoko Kawabata, Jun Wada and Hirofumi Makino, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama, Japan, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan 0 Program Book 0

304 ACR POSTER SESSION C 049. Comparison Of Corticosteroid Plus Lidocaine Or Lidocaine Alone In Patients Receiving Celecoxib For The Treatment Of Acute Shoulder Or Trochanteric Bursitis: A Randomized, Double-Blind, Placebo Controlled Trial. Muhammad Imran, Haritha Narla, Jo A. Wick and Herbert B. Lindsley, Kansas University Medical center, Kansas city, MO, Kansas university Medical Center, kansas city, MO, Kansas University Med Ctr, Kansas City, KS 050. Arthralgia Occurring Under Aromatase Inhibitor Treatment For Breast Cancer. A Prospective Study. Daniel Wendling, Helene Letho-Gyselinck, Xavier Guillot, Clément Prati and Xavier Pivot, Minjoz University Hospital, Besancon, France, CHRU Besançon, Besançon, France, CHU J Minjoz, Besancon, France 05. Characteristics and Comparison Of Patients With Cystic Fibrosis With and Without Arthritis. Heather O. Tory, Karen Herlyn, David Zurakowski, Angela S. Pizzo 4, Robert P. Sundel 5 and Peter A. Merkel 6, Boston Children s Hospital, Boston, MA, University Hospital Schleswig-Holstein, Lübeck, Germany, Boston Children s Hospital, Boston, MA, 4 Mercy Hospital, Portland, ME, 5 Boston Children s Hospital and Harvard Medical School, Boston, MA, 6 University of Pennsylvania, Philadelphia, PA 05. The Prevalence and Pattern Of Self Reported Joint Symptoms In Cystic Fibrosis. Carl Orr, Cormac McCarthy, Johan Meurling, Paul G. O Connell, Cedric Gunaratnam and Noel G McElvaney, Royal College of Surgeons in Ireland, Dublin, Ireland, Beaumont Hospital, Dublin 9, Ireland Muscle Biology, Myositis and Myopathies: Advances in the Epidemiology, Immunology and Therapy of Myositis 05. Efficacy Of Intermittent Intra-Venous Cyclophosphamide and Cyclosporin A Combination Therapy For Rapidly Progressive Interstitial Lung Disease With Dermatomyositis Associated With Anti-Melanoma Differentiation-Associated Gene 5 Autoantibody Titer. Noriko Sasaki, Shinji Sato, Shinichi Nogi, Naofumi Chinen, Kiri Honda, Eiko Saito, Chiho Yamada and Yasuo Suzuki, Tokai University School of Medicine, Isehara, Japan 054. Efficacy and Safety Of Low-Intensity Resistance Training Combined With Vascular Occlusion In Polymyositis and Dermatomyositis. Melina Mattar, Luiz A. Perandini, Thalita Dassouki, Samuel K. Shinjo, Bruno Gualano, Hamilton Roschel, Fernanda R. Lima 4 and Ana Lucia S. Pinto, University of Sao Paulo, Rheumatology Division, LACRE, Sao Paulo, Brazil, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil, University of Sao Paulo, School of Physical Education and Sport, Sao Paulo, Brazil, 4 University of Sao Paulo, Rheumatology Division, Sao Paulo, Brazil 055. Killer T Cell Inhibition By CD6 Blockade For Treatment Of Inflammatory Myopathy. Hitoshi Kohsaka, Nao Tateishi, Shinya Hirata, Kazuko Shibuya, Akira Shibuya and Nobuyuki Miyasaka 4, Department of Medicine and Rheumatology, Tokyo Medical and Dental University, Tokyo, Japan, Kumamoto University School of Medicine, Kumamoto, Japan, Department of Immunology, University of Tsukuba, Ibaraki, Japan, 4 Tokyo Medical and Dental University, Tokyo, Japan 056. Use Of Biologics In Polymyositis and Dermatomyositis A National Register Study. John Svensson, Anna Tjärnlund, Balsam Hanna, Sara Magnusson Bucher 4, Johan Askling, Ingrid E. Lundberg 5 and Maryam Dastmalchi 6, Karolinska Institutet, Stockholm, Sweden, Rheumatology Unit, Department of Medicine, Karolinska University Hospital, Solna, Karolinska Institutet, Stockholm, Stockholm, Sweden, Sahlgrenska University Hospital, Gothenburg, Sweden, 4 Örebro University Hospital, Örebro, Sweden, 5 Rheumatology Unit, Department of Medicine, Karolinska University Hospital in Solna, Karolinska Institutet, Stockholm, Sweden, 6 Karolinska University Hospital in Solna, Karolinska Institutet, Stockholm, Sweden 057. Biomarker and Serologic Predictors Of Clinical Improvement After B Cell Depletion In Refractory Adult and Juvenile Dermatomyositis (DM) and Adult Polymyositis (PM) - The RIM (Rituximab in Myositis) Trial. Ann M. Reed, Cynthia S. Crowson, Molly S. Hein, Consuelo Lopez de Padilla, Helen Khun, Rohit Aggarwal, Dana P. Ascherman, Marc C. Levesque and Chester V. Oddis, Mayo Clinic, Rochester, MN, University of Pittsburgh, Pittsburgh, PA, University of Miami Miller School of Medicine, Miami, FL 058. Evidence For Immunotherapy In Polymyositis and Dermatomyositis: A Systematic Review. Erin Vermaak and Neil J McHugh, Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, Department of Pharmacy and Pharmacology, University of Bath, Bath, United Kingdom 059. Mortality In Polymyositis and Dermatomyositis: A Single Centre Study. Erin Vermaak, Gavin Shaddick and Neil J McHugh, Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, University of Bath, Bath, United Kingdom, Department of Pharmacy and Pharmacology, University of Bath, Bath, United Kingdom 060. Influence Of Anti-Ro/SSA Autoantibodies On Cinical Characteristic Of a Cohort Of Myositis Patients. Simone Barsotti, Rossella Neri, Valentina Iacopetti, Chiara Baldini, Nicoletta Luciano, Antonio Tavoni, Anna d Ascanio and Stefano Bombardieri, Rheumatology Unit, Pisa, Italy, Internal medicine, Barga, Italy, Immunoallergology unit, Pisa, Italy 06. Good Inter-Rater Reliability Of Myositis Experts In Assessing Clinical Improvement. Rohit Aggarwal, Nicolino. Ruperto, Brian Erman, Saad Feroz 4, Jiri Vencovsky 5, Adam Huber 6, Sheila K. Oliveira 7, Angela Pistorio 8, Clarissa Pilkington 9, Angelo Ravelli 0, Brian M. Feldman, Howard Rockette, Frederick W. Miller 4, Peter A. Lachenbruch 4 and Lisa G. Rider 4, University of Pittsburgh, Pittsburgh, PA, PRINTO, IRCCS G. Gaslini, Genoa, Italy, National Institute of Health, Bethesda, DC, 4 NIEHS, NIH, Bethesda, MD, 5 Institute of Rheumatology, Prague, Czech Republic, 6 IWK Health Centre, Halifax, NS, 7 Instituto de Pediatria e Puericultura Martagão Gesteira (IPPMG) da Universidade Federal do Rio de Janeiro (UFRJ), Rio de Janeiro, Brazil, 8 PRINTO, Genoa, Italy, 9 Great Ormond Street Hospital, London, United Kingdom, 0 Istituto Giannina Gaslini, Genova, Italy, Hospital for Sick Children, Toronto, ON 0 0 Program Book

305 ACR POSTER SESSION C 06. Clinical Features and Outcome In Polymyositis Vs. Dermatomyositis Patients With The Anti-Jo- Autoantibody. Rohit Aggarwal, Diane Koontz, Zengbiao Qi and Chester V. Oddis, University of Pittsburgh, Pittsburgh, PA 06. Identification Of Autoantibodies To Tyrosyl Transfer RNA Synthetase Associated With Anti-Synthetase Syndrome. Yuko Okamoto, Yasuhiro Katsumata, Yasushi Kawaguchi, Koji Tahara, Kaori Ito, Hiroaki Hattori, Takahisa Gono, Kae Takagi, Masanori Hanaoka, Yuko Ota, Hidenaga Kawasumi and Hisashi Yamanaka, Tokyo Women s Medical University, Tokyo, Japan, BML, Saitama, Japan 064. An Autoimmune Myositis-Overlap Syndrome Associated With Autoantibodies To Nuclear Pore Complexes Description and Long-Term Follow-Up Of The Anti- Nup Syndrome. Catherine Isabelle, Marie-Christine Dabauvalle, Marvin J. Fritzler, Ira N. Targoff 4, Rose Goldstein 5, Yves Troyanov, Michel Gagné, Jean- Pierre Raynauld and Jean-Luc Senécal, Division of Rheumatology, Centre Hospitalier de l Université de Montréal, Montreal, QC, University of Würzburg, Würzburg, Germany, University of Calgary, Calgary, AB, 4 Oklahoma Medical Research Foun, Oklahoma City, OK, 5 McGill University, Montreal, QC 065. The Prevalence and Clinical Usefulness Of Anti-NXP- Autoantibodies In Chinese Patients With Idiopathic Inflammatory Myopathies. Xin Lu, Guochun Wang, Qinglin Peng, Kai Yuan and Hanbo Yang, China-Japan Friendship Hospital, Beijing, China, Beijing, China, China- Japan Friendship Hospital, Beijing, China 066. Distinct Arthropaties In Patients With Anti-Aminoacyl trna Synthetase Antibodies: Utility Of Autoantibody Profiles In Discrimination. Yuko Kaneko, Hironari Hanaoka, Michito Hirakata, Tsutomu Takeuchi and Masataka Kuwana, Keio University School of Medicine, Tokyo, Japan 067. Autoantibodies Associated With Inflammatory Myopathy and Other Systemic Autoimmune Rheumatic Diseases In Sera From Breast Cancer Patients. Monica Vázquez-Del Mercado, Adrian Daneri-Navarro, Beatriz Teresita Martín- Márquez, Raul Vargas Ramirez 4, Diego Velasco-Sanchez 5, Jason Y.F. Chan 6, S. John Calise 6, Edward K.L. Chan 6 and Minoru Satoh 6, Universidad de Guadalajara, Guadalajara, Jalisco, México, Mexico, Laboratorio de Inmunología, CUCS, Universidad de Guadalajara, Guadalajara, Mexico, Instituto de Investigación en Reumatología y del Sistema Músculo Esquelético, Guadalajara, Mexico, 4 Instituto de Investigación en Reumatología y del Sistema Músculo Esquelético,, Guadalajara, Mexico, 5. Instituto de Investigación en Reumatología y del Sistema Músculo Esquelético, CUCS, Universidad de Guadalajara, Guadalajara, Mexico, 6 University of Florida, Gainesville, FL 068. Comparison Of Radioimmunoprecipitation Versus Antigen Specific Assays For Identification Of Myositis Specific Autoantibodies In Dermatomyositis Patients. Eun Ha Kang, Eun Young Lee, Yun Jong Lee, Eun Bong Lee 4 and Yeong Wook Song, Seoul National University Bundang Hospital, Seongnam-si, South Korea, Division of Rheumatology, Department of Internal Medicine, Seoul National University, Seoul, South Korea, Rheumatology, Seoul National University, Seoul, South Korea, 4 Seoul National University College of Medicine, Seoul, South Korea 069. Serum Interferon-α Is a Biomarker To Reflect The Disease Activity In Patients With Anti-Melanoma Differentiation-Associated Gene 5 (MDA5) Antibody- Positive Dermatomyositis. Yoshiro Horai, Tomohiro Koga, Keita Fujikawa, Ayuko Takatani, Ayako Nishino, Yoshikazu Nakashima, Takahisa Suzuki, Shin-ya Kawashiri, Naoki Iwamoto, Kunihiro Ichinose, Mami Tamai, Hideki Nakamura, Hiroaki Ida 4, Yuji Ishimatsu 5, Hiroshi Mukae 6, Yasuhito Hamaguchi 7, Manabu Fujimoto 7, Masataka Kuwana 8, Tomoki Origuchi, Shigeru Kohno 5 and Atsushi Kawakami, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, Isahaya Health Insurance General Hospital, Isahaya, Japan, Unit of Translational Medicine, Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, 4 Kurume University School of Medicine, Kurume, Japan, 5 Department of Molecular Microbiology and Immunology, Nagasaki University School of Medicine, Nagasaki, Japan, Nagasaki, Japan, 6 Department of Respiratory Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan, Kitakyushu, Japan, 7 Kanazawa University Graduate School of Medical Sciences, Kanazawa, Japan, 8 Keio University School of Medicine, Tokyo, Japan 070. Cytokine Profiles In Polymyositis and Dermatomyositis Complicated With Anti-Melanoma Differentiation- Associated Gene 5 Antibody-Associated Interstitial Lung Disease Or Anti-Aminoacyl trna Synthetase Antibody- Associated Interstitial Lung Disease. Takahisa Gono, Yasushi Kawaguchi, Hirotaka Kaneko, Yasuhiro Katsumata, Masanori Hanaoka, Sayuri Kataoka, Hidenaga Kawasumi, Kae Takagi, Hisae Ichida, Sayumi Baba, Yuko Okamoto, Yuko Ota and Hisashi Yamanaka, Tokyo Women s Medical University, Tokyo, Japan 07. Adipokines Contribute To The Inflammatory Response In Adult and Juvenile Myositis. Molly S. Hein, Cynthia S. Crowson, Helen Khun, Consuelo Lopez de Padilla, Erik J. Peterson, Emily Baechler and Ann M. Reed, Mayo Clinic, Rochester, MN, University of Minnesota Medical School, Minneapolis, MN, University of Minnesota, Minneapolis, MN 07. Decreased Number Of Circulating NK Cells and Dramatic Lack Of IFN-Gamma Production In Patients With Antisynthetase Syndrome. Baptiste Hervier, Yves Allenbach, Fleur Cohen-Aubart, Micheline Pha, Lenaig Mescam-Mancini, David Saadoun, Alexis Mathian, Olivier Benveniste and Vincent Vieillard, Pitié-Salpêtrière Hospital, APHP, Paris, France, INSERM UMR-S 945, UPMC, Paris, France, University hospital, Grenoble, France 0 Program Book 0

306 ACR POSTER SESSION C 07. Clinical and Prognostic Factors Associated With Survival In Mexican Patients With Idiopathic Inflammatory Myopathies. Angeles Shunashy Galindo-Feria, Jorge Rojas-Serrano and Andrea Hinojosa-Azaola, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, Instituto Nacional de Enfermedades Respiratorias, Mexico City, Mexico 074. The Analysis Of Prognostic Factors In Patients With Inflammatory Myopathies and Amyopathic Dermatomiositis Complicated With Interstitial Lung Disease. Maasa Hama, Yumiko Sugiyama, Yohei Kirino, Yosuke Kunishita, Daiga Kishimoto, Reikou Kamiyama, Kaoru Minegishi, Ryusuke Yoshimi, Yukiko Asami, Atsuhisa Ueda, Mitsuhiro Takeno, Ichiro Aoki and Yoshiaki Ishigatsubo, Yokohama City University Graduate School of Medicine, Yokohama, Japan 075. Analysis Of The Associations Between Serum Ferritin and Cytokines In Pulmonary Disease Activity With Polymyositis/Dermatomyositis. Hidenaga Kawasumi, Takahisa Gono, Yasushi Kawaguchi, Yasuhiro Katsumata, Masanori Hanaoka, Sayuri Kataoka, Kae Takagi, Hisae Ichida, Sayumi Baba, Yuko Okamoto, Yuko Ota and Hisashi Yamanaka, Tokyo Women s Medical University, Tokyo, Japan 076. Oxidation Products Of Arachidonic Acid and Linoleic Acid Are Increased In High Density Lipoprotein From Patients With Dermatomyositis and Polymyositis. Christina Charles-Schoeman, Yuen Yin Lee, Ani Shahbazian, David Meriwether, Geraldine Navarro, John D. FitzGerald and Srinivasa T. Reddy, UCLA David Geffen School of Medicine, Los Angeles, CA 077. Inflammatory Lung Disease a Potential Risk Factor For Onset Of Inflammatory Myopathies. Ingrid E. Lundberg, Sevim Barbasso Helmers and Lars Alfredsson, Rheumatology Unit, Department of Medicine, Karolinska University Hospital in Solna, Karolinska Institutet, Stockholm, Sweden, Institute of Environmental Medicine, Unit of Cardiovascular Epidemiology, Karolinska Institutet, Stockholm, Sweden, Karolinska Institutet, Stockholm, Sweden 078. Pulmonary Hypertension In Anti-Jo Syndrome. Nilofar Syed, Ruchi Yadav, Colin O Rourke and Soumya Chatterjee, Cleveland Clinic, Cleveland, OH 079. Serum Interferon α, β and Interleukin-8 Are Associated With Disease Activity Of Rapidly Progressive Interstitial Lung Disease In Patients With Clinical Amyopathic Dermatomyositis. Shinji Sato, Noriko Sasaki, Shinichi Nogi, Naofumi Chinen, Kiri Honda, Eiko Saito, Chiho Yamada and Yasuo Suzuki, Tokai University School of Medicine, Isehara, Japan 080. Pregnancy Outcomes In Adult Patients With Dermatomyositis and Polymyositis. Lorinda Chung, David Fiorentino, Shufeng Li and Eliza Chakravarty 4, Stanford Univ Medical Center, Palo Alto, CA, Stanford University School of Medicine, Redwood City, CA, Stanford University School of Medicine, Stanford, CA, 4 Oklahoma Medical Research Foundation, Oklahoma City, OK 08. Role Of Muscle Persistent CD8null T Cells In Glucocorticoid Therapy Resistance In Myositis Patients. Jayesh Pandya, Ingela M. Loell, Mohammad Shahadat Hossain, Mei Zong, Sukanya Raghavan, Ingrid E. Lundberg and Vivianne Malmström, Rheumatology Unit, Department of Medicine, Karolinska University Hospital in Solna, Karolinska Institutet, Stockholm, Sweden 08. Interferon-Regulated Chemokine and Innate Cytokine Scores Identify Refractory Myositis Patients That Respond Better To Rtuximab Therapy. Consuelo Lopez de Padilla, Cynthia S. Crowson, Molly S. Hein, Helen Khun, Rohit Aggarwal, Marc C. Levesque, Dana P. Ascherman, Chester V. Oddis and Ann M. Reed, Mayo Clinic, Rochester, MN, University of Pittsburgh, Pittsburgh, PA, University of Miami, Miami, FL 08. Environmental Factors Associated With Disease Flare In Juvenile and Adult Dermatomyositis. Gulnara Mamyrova, Lisa G. Rider, Olcay Jones, Alison Ehrlich 4, Lauren M. Pachman 5, Robert Nickeson 6, Lisa G. Criscione-Schreiber 7, Frederick W. Miller, Lawrence K. Jung 8 and James D. Katz, George Washington University, Washington, DC, NIEHS, NIH, Bethesda, MD, Walter Reed National Military Medical Center, Bethesda, MD, 4 The George Washington University, Washington, DC, 5 Division of Pediatric Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, IL, 6 All Children s Hospital, St Petersburg, FL, 7 Duke University School of Medicine, Durham, NC, 8 Children s National Medical Center, Washington, DC 084. Increasing Incidence Of Immune Mediated Necrotizing Myopathy In A Single Center. Martin Klein, Herman F. Mann, Josef Zámecník and Jiri Vencovsky, Institute of Rheumatology, Prague, Prague, Czech Republic, nd Medical School and University Hospital Motol, Charles University, Prague, Czech Republic, Prague, Czech Republic, Institute of Rheumatology, Prague, Czech Republic 085. Identification Of Clinical Features and Risk Factors Associated With Calcinosis In Adult Patients With Dermatomyositis. Antonia Valenzuela, Lorinda Chung, Livia Casciola-Rosen, Antony Rosen and David Fiorentino 4, Stanford University School of Medicine, Palo Alto, CA, Stanford University Medical Center, Palo Alto, CA, Johns Hopkins University, Baltimore, MD, 4 Stanford University School of Medicine, Redwood City, CA 086. Defining The Prevalence and Associated Risk Factors For Calcinosis In Adult Dermatomyositis Patients. Jessie Werner, Jason Liebowitz, Andrew L. Mammen and Lisa Christopher-Stine 4, University of Maryland School of Medicine, Baltimore, MD, Johns Hopkins University School of Medicine, Baltimore, MD, Johns Hopkins, Baltimore, MD, 4 Johns Hopkins University, Baltimore, MD 087. Utility and Reliability Of Digital Nailfold Capillaroscopy In Children With Juvenile Dermatomyositis: Three Methods. Gabrielle A. Morgan, Adam Ostrower, Chiang-Ching Huang and Lauren M. Pachman, Ann & Robert H. Lurie Children s Hospital of Chicago Research Center, Chicago, IL, Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL 04 0 Program Book

307 ACR POSTER SESSION C 088. The Percentage Of Th7 Cells Correlates with the Expression Of Microrna-06 In Patients With Dermatomyositis. Xinyi Tang and Shengjun Wang, Department of Immunology, Jiangsu University, Zhenjiang, China 089. Downregulation Of Mir-0a Is Associated With Increased Von Willebrand Factor Antigen, Disease Activity Score and Earlier Diagnosis In Children With Untreated Juvenile Dermatomyositis. Dong Xu, Akadia Kachaochana, Gabrielle A. Morgan, Chiang-Ching Huang and Lauren M. Pachman, Ann & Robert H. Lurie Children s Hospital of Chicago Research Center, Chicago, IL, Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL ARHP Orthopedics, Low Back Pain and Rehabilitation: Rehabilitation Sciences 090. The Effects of Commercially Available Footwear On Foot Pain and Disability in People With Gout: A Feasibility Study. Keith Rome, Sarah Stewart, Alain Vandal, Peter J. Gow, Peter J. McNair and Nicola Dalbeth 4, AUT University, Auckland, New Zealand, Counties Manukau District Health Board, Auckland, New Zealand, Middlemore Hospital, Auckland, New Zealand, 4 University of Auckland, Auckland, New Zealand 09. Adaptation and Preliminary Testing of An Arthritis Walking Program to Reduce Joint Pain for Elderly Breast Cancer Survivors On Aromatase Inhibitor Therapy. Kirsten A. Nyrop, Betsy Hackney, Rebecca J. Cleveland, Mary Altpeter, Hyman Muss and Leigh F. Callahan, University of North Carolina at Chapel Hill, Chapel Hill, NC, University of North Carolina at Chapel Hill, Chapel Hill, NC, University of North Carolina, Chapel Hill, NC 09. Strengthening Exercises Using A Swiss Ball Improve Symptoms and Muscle Performance Of Patients With Fibromyalgia: A Randomized Controlled Study. Josiander Arakaki Sr., UNIFESP, sao paulo, Brazil 09. A Comparison Of Performance On The Keital Functional Test By Persons With Rheumatoid Arthritis and Systemic Sclerosis. Janet L. Poole, Amy New and Christina Garcia, University of New Mexico, Albuquerque, NM 094. Do Exercise Interventions For Total Hip Arthroplasty Have Therapeutic Validity? A Sensitivity Analysis Of Trials Included In a Cochrane Systematic Review. Marie D. Westby, Shirin Kazemi and Dina L. Jones, University of Alberta, Edmonton, AB, Mary Pack Arthritis Program, Vancouver, BC, West Virginia University, Morgantown, WV 095. Hand Exercises Significantly Improved Activity Performance, Grip Strength and Pain In Women With Hand Osteoarthritis - Results From a Randomised Controlled Trial. Toril Hennig, Liv Haehre, Vivian Tryving Hornburg, Petter Mowinckel, Ellen Sauar Norli and Ingvild Kjeken, Martina Hansens Hospital, Gjettum, Norway, Diakonhjemmet Hospital, Oslo, Norway 096. Impaired Shoulder-Arm Mobility and Muscle Function In Patients With Systemic Sclerosis. Helene Alexanderson, Fia Bringby, Annica Nordin, Lena Björnådal, Elisabet Svenungsson 4 and Carina Boström 5, Division of Physiotherapy, Karolinska Institutet, Huddinge, Stockholm, Sweden, Capio Arthro Clinic, Stockholm, Sweden, Rheumatology Unit, Karolinska Institutet, Stockholm, Sweden, 4 Karolinska Institutet, Stockholm, Sweden, 5 Division of Physiotherapy, Karolinska Institutet Huddinge, Stockholm, Sweden 097. Evaluation Of An Advanced Practice Physiotherapist Role in Rheumatology. Chandra Farrer, University of Toronto, Toronto, ON 098. What Elements Of Physical Therapy Interventions Contribute To Improved Outcomes Following Total Knee Arthroplasty. Joshua K Johnson, Traci E DeWan, Kelly L Donahue, Wenjun Li, Patricia D. Franklin and Carol A. Oatis, Arcadia University, Glenside, PA, University of Massachusetts Medical School, Worcester, MA 099. Global Postural Reeducation To TREAT Chronic LOW Back PAIN: Randomized, Controlled Trial. Priscila Almeida Lawand, Imperio Lombardi Jr, Carla Caires Sardim, Luiza H. C. Ribeiro, Anamaria Jones and Jamil Natour, Universidade Federal de Sao Paulo, Sao Paulo, Brazil, Universidade Federal de Sao Paulo, Santos, Brazil, Universidade Federal de São Paulo, São Paulo, Brazil 00. A Scoping Review On Leisure Activity Expectations After Total Hip Or Knee Arthroplasty Due To Arthritis. Dina L. Jones and Nirupama Semmalidinne, West Virginia University, Morgantown, WV 0. Barriers To Improving Physical Activity In Patients With Systemic Lupus Erythematosus: The Activity and Nutrition Trial In Lupus To Energize and Renew (ANTLER) Pilot Study. Linda S. Ehrlich-Jones, Grace E. Ahn, Christine Pellegrini and Rosalind Ramsey-Goldman, Rehabilitation Institute Chicago, Chicago, IL, Northwestern University, Chicago, IL, Northwestern University Feinberg School of Medicine, Chicago, IL 0. The Effect Of a Novel System Of Insoles Using Styrene Foam Beads On Foot Deformities In RA Patients. Yoshitada Sakai, Akira Hashiramoto, Yoshiko Kawasaki, Takaichi Okano, Takahiro Takeda, Naomi Yagi and Yutaka Hata, Kobe University Graduate School of Medicine, Kobe, Japan, Kobe University Hospital, Kobe, Japan, Graduate School of Engineering, University of Hyogo, Himeji, Japan 0. Relationships Between Self-Efficacy, Outcome Expectancy, and Outcomes In Older Adults With Osteoarthritis Of The Knee and Hypertension: Baseline Results. Elizabeth A. Schlenk, Deborah Crowley-Lisowski, Sarah Twerski, Alice Fallon, Alyssa Sartore, Susan Sereika, Joan Rogers, G. Kelley Fitzgerald and C. Kent Kwoh, University of Pittsburgh, Pittsburgh, PA 0 Program Book 05

308 ACR POSTER SESSION C Exercise For Ankylosing Spondylitis: It s Still Important. Janet Millner, John Barron, Kirsty Beinke, Rachael Butterworth 4, Briony Chasle 5, Lindsay Dutton 6, Margaret Lewington 7, Errol Lim 4, Tony Morley 8, Jennie O Reilly 9, Kathryn Pickering 0 and Jane Zochling, Menzies Research Institute Tasmania, Hobart, Australia, Eastwood Physiotherapy, Adelaide, Australia, Adelaide West Pilates Physiotherapy, Adelaide, Australia, 4 BJC Health, Sydney, Australia, 5 South East Sydney Area Health Service, Sydney, Australia, 6 Royal Perth Hospital, Perth, Australia, 7 Hydrohealth, Brisbane, Australia, 8 Physio Plus, Lismore, Australia, 9 Physiotherapy, Melbourne, Australia, 0 Curtin University, Perth, Australia 05. Differences In Spinal Mobility Measures In Relation To Disease Duration and Between Subgroups With Axial Spondyloarthritis. Elisabeth.A Mogard, Elisabet Lindqvist, Stefan Bergman and Ann B. I. Bremander, Lund University, Lund, Sweden, Spenshult Research and Development Center, Halmstad, Sweden 06. Aquatic Exercise Training For Fibromyalgia: A Systematic Review. Julia Bidonde, Angela J. Busch, Sandra Webber, Candice Schachter, Adrienne Danyliw, Tom Overend 4, Rachel Richards 5 and Tamara Rader 6, University of Saskatchewan, Saskatoon, SK, University of Manitoba, Winnipeg, MB, Health Quality Council, Saskatoon, SK, 4 Western Universtiy, London, ON, 5 North Shore Sports Medicine Clinic, North Vancouver, BC, 6 University of Ottawa, Ottawa, ON 07. Benefitial Effects Of a Simple Stretching Exercise Program For Patients With Ankylosing Spondylitis: A Randomized Controlled Trial. Andréa L. Gallinaro, Carla G.S. Saad, Claudia Goldenstein-Schainberg, Percival D sampaio- Barros, Julio C. B. Moraes, Hamilton Roschel, Ana Lucia S. Pinto and Celio R. Gonçalves, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil, Universidade de São Paulo, Faculdade de Educação Física e Esporte, São Paulo, Brazil 08. Pre- and Postoperative Physical Therapy In Total Hip and Knee Replacement Surgery: A Multi Center Study. Wilfred FH Peter, Claire Tilbury, Rutger Tordoir, Suzan Verdegaal, Ron Onstenk 4, Menno Benard 5, Stephan Vehmeijer 5, Enrike van der Linden-van der Zwaag, Eric Vermeulen, Rob Nelissen and Thea VlietVlieland 6, Reade, center for rehabilitation and rheumatology, Amsterdam, Nicaragua, Leiden University Medical Center, Leiden, Netherlands, Rijnland Hospital, Leiderdorp, Netherlands, 4 Het Groene Hart Hospital, Gouda, Netherlands, 5 Reinier de Graaf Hospital, Delft, Netherlands, 6 Leids University Medical Center, Leiden, Netherlands 09. Quality Indicators For Physical Therapy Management In Hip and Knee Osteoarthritis and Rheumatoid Arthritis. Wilfred FH Peter, Emalie Hurkmans, Philip van der Wees, Erik Hendriks 4, Rob de Bie 4, Leti van Bodegom-Vos and Theodora P.M. Vliet Vlieland, Leiden University Medical Center, Leiden, Netherlands, University of Applied Sciences, Vienna, Austria, Radboud University, Nijmegen, Netherlands, 4 University of Maastricht, Maastricht, Netherlands 0 Program Book 0. Who Will Achieve Individually Set Goals After Arthritis Team Rehabilitation? Sofia Hagel, Elisabet Lindqvist and Ann B. I. Bremander, Lund University and Skåne University Hospital, Lund, Sweden, Lund University, Lund, Sweden Orthopedics, Low Back Pain, and Rehabilitation. The Impact Of Centralized Pain On Long-Term Analgesic Response To Lower Extremity Joint Arthroplasty: A Prospective, Observational Cohort Study. Chad M. Brummett, Andrew Urquhart, Brian Hallstrom, Alex Tsodikov, David A. Williams 4 and Daniel J. Clauw 5, University of Michigan Medical School, Ann Arbor, MI, University of Michigan Health System, Ann Arbor, MI, School of Public Health, University of Michigan, Ann Arbor, MI, 4 Univ of MI Hlth System-Lobby M, Ann Arbor, MI, 5 University of Michigan, Ann Arbor, MI. Hip and Knee Arthroplasty In Patients With Rheumatoid Arthritis: Results From The Australian Orthopaedic Association National Joint Replacement Registry: 00 To 0. Andrew Lim, Stephen Graves, Yen Liu, Lionel Schachna and Russell R. Buchanan, Austin Health, Melbourne, Australia, Australian Orthopaedic Association National Joint Replacement Registry, Adelaide, Australia. Glucosamine Chondroitin Sulfate Reduces Pain, Disability and Non-Steroidal Anti-Inflammatory Drug consumption In Patients With Chronic Low Back Pain: A Large, Community-Based, Pilot, Open Prospective Study. Gurkirpal Singh, Liudmila Alekseeva, Valeriy Alekseev and Evgeny Nasonov 4, ICORE, Woodside, CA, State Institute of Rheumatology of Russian Academy of Medical Sciences, Moscow, Russia, First Moscow State Medical University, Moscow, Russia, 4 State NII of Rheumatology of Russian Academy of Sciences, Moscow, Russia 4. Hip Fracture Risk Factors To One Year and In-Hospital Mortality, a Prospective Cohort In South Brazil. Tiango Aguiar Ribeiro, Melissa Orlandin Premaor, João Alberto Larangeira, Michel Luft, Luiz Giulian Brito, Leonardo Waihrich Guterres and Odirlei Andre Monticielo, Federal University of Santa Maria (UFSM), Santa Maria, Brazil, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil 5. Social Networks and Hip Replacement Outcomes In Rheumatoid Arthritis and Osteoarthritis. Danielle Ramsden-Stein, Wei-Ti Huang, Rebecca Zhu, Susan M. Goodman, Mark P. Figgie, Michael Alexiades and Lisa A. Mandl, Hospital for Special Surgery, New York, NY 6. Diabetes: A Risk Factor For Poor Function Outcome After Total Knee Arthroplasty. Jasvinder A. Singh and David Lewallen, University of Alabama, Tuscaloosa, AL, Mayo Clinic college of medicine, Rochester, MN 7. The Effect Of Statin Therapy On Venous Thromboembolism After Hip Or Knee Arthroplasty. Anne R. Bass, Yuo-Yu Lee, Stephen Lyman, Geoffrey H. Westrich and Brian F. Gage, Hospital for Special Surgery Weill Cornell Medical College, New York, NY, Hospital for Special Surgery, New York, NY, Washington University School of Medicine in St. Louis, St. Louis, MO

309 ACR POSTER SESSION C 8. Pregnancy Does Not Adversely Affect Post-Operative Pain and Function In Women With Total Hip Arthroplasty. Lindsay Lally, Lisa A. Mandl, Rebecca Zhu, Wei-Ti Huang, Mark P. Figgie, Michael Alexiades and Susan M. Goodman, Hospital for Special Surgery, New York, NY 9. Higher Mortality In Males Compared To Females Undergoing Total Knee Or Total Hip Arthroplasty: A Study Of National Time Trends, Jasvinder A. Singh and Rekha Ramachandaran, University of Alabama, Tuscaloosa, AL, University of Alabama at Birmingham, Birmingham, AL 0. Total Knee Replacement Outcomes In Patients With Psoriatic Arthritis, Osteoarthritis With Cutaneous Psoriasis, and Osteoarthritis. Lisa A. Mandl, Rebecca Zhu, Wei-Ti Huang, Michael Alexiades, Mark P. Figgie and Susan M. Goodman, Hospital for Special Surgery, New York, NY. Total Hip Arthroplasty Outcomes In Patients With Psoriatic Arthritis, Osteoarthritis With Cutaneous Psoriasis, and Osteoarthritis. Lisa A. Mandl, Rebecca Zhu, Wei-Ti Huang, Michael Alexiades, Mark P. Figgie and Susan M. Goodman, Hospital for Special Surgery, New York, NY. Mechanical Back Pain Demonstrates Better Response To Celecoxib Than Acetaminophen Despite Lack Of MRI- Defined Inflammatory Changes In The Spine. Dinny Wallis, Finbar (Barry) D. O Shea, David Salonen, Nigil Haroon, Ammepa Anton 4, Laura A. Passalent, Rebecca Morton 5, Christopher Hawke, Joan Blair and Robert D. Inman, Toronto Western Hospital, University of Toronto, Toronto, ON, St James s Hospital, Dublin, Ireland, University Health Network, Toronto, ON, 4 Toronto Western Research Institute, Toronto, ON, 5 University Health Network- Toronto Western Hospital, Toronto, ON. Assessment Of Gesture Behavior and Knowledge On Low Back Pain Among Nurses. Hisa Morimoto, Anamaria Jones and Jamil Natour, Universidade Federal de Sao Paulo, Sao Paulo, Brazil, Universidade Federal de São Paulo, São Paulo, Brazil 4. Piriformis Muscle Syndrome: Diagnostic Criteria and Treatment Of a Monocentric Series Of 50 Cases. Fabrice Michel, Pierre Decavel, Laurent Tatu, Etienne Aleton, Guy Monnier, Bernard Parratte and Eric Toussirot, University Hospital, Besançon, France, CIC Biotherapy 506 and Rheumatology and EA 466 Pathogens and Inflammation, Besançon, France 5. Comparison Of The Effectiveness Of Local Anesthetic and Corticosteroid Injections For The Treatment Of Piriformis Syndrome. Tugce Ozekli Misirlioglu, Kenan Akgun, Meryem Gul Erden and Tuba Erbilir, Istanbul University Cerrahpasa Medical Faculty, Istanbul, Turkey 6. Time Trends In Total Ankle Arthroplasty: A Study Of The U.S. National Inpatient Sample. Jasvinder A. Singh and Rekha Ramachandaran, University of Alabama, Tuscaloosa, AL, University of Alabama at Birmingham, Birmingham, AL 7. Recurrences Of Hallux Valgus Deformity After Implant Surgery For Greater Toe In Rheumatoid Arthritis. Yuichi Mochida, Katsushi Ishii, Yuji Yamada, Naoto Mitsugi and Tomoyuki Saito, Yokohama City University Medical Center, Yokohama, Japan, Yokohama City University School of Medicine, Yokohama, Japan Osteoarthritis - Clinical Aspects II: Symptoms and Therapeutics in Osteoarthritis 8. Longitudinal Relation Of Sensitization To Incident Knee Pain, Incident Symptomatic Knee Osteoarthritis and Increase In Pain Severity: The Multicenter Osteoarthritis Study. Tuhina Neogi, Michael C. Nevitt, Joachim Scholz, Lars Arendt-Nielsen 4, Clifford Woolf 5, Laurence A. Bradley 6, Emily Sisson and Laura Frey-Law 7, Boston University School of Medicine, Boston, MA, University of California, San Francisco, San Francisco, CA, Columbia University, New York, NY, 4 Center for Sensory-Motor Interaction, Aalborg, Denmark, 5 Children s Hospital Boston, Boston, MA, 6 Univ of Alabama-Birmingham, Birmingham, AL, 7 University of Iowa, Iowa City, IA 9. The Diagnostic Utility Of Anterior Knee Pain and Pain With Activities In Identifying Knees With MRI-Detected Structural Damage In The Patellofemoral Joint: The Multicenter Osteoarthritis Study. Joshua J. Stefanik, Tuhina Neogi, Jingbo Niu, Neil A. Segal, Cora E. Lewis 4, Michael C. Nevitt 5, Frank Roemer 6, Ali Guermazi and David T. Felson, Boston University, Boston, MA, Boston University School of Medicine, Boston, MA, University of Iowa, Iowa City, IA, 4 University of Alabama, Birmingham, Birmingham, AL, 5 University of California, San Francisco, San Francisco, CA, 6 Klinikum Augsburg, Augsburg, Germany 0. Factors Associated With Two-Year Pain Experience Outcome In Knee Osteoarthritis. Jamie E. Rayahin, Joan S. Chmiel, Orit Almagor, Laura Belisle, Alison H. Chang, Kirsten Moisio, Karen W. Hayes, Yunhui Zhang and Leena Sharma, University of Illinois, Chicago, Chicago, IL, Northwestern University, Chicago, IL, Northwestern University Medical School, Chicago, IL. Osteoarthritis Pain: Variability and Clinical Correlations. Thomas J. Schnitzer, Renita Yeasted, Leijan Huang, Jennifer Duffecy, Mark Begale and A. Vania Apkarian, Northwestern University, Chicago, IL. Short-Run Transitions In Pain States: Reflections Of Multiple Outcome Clinical Measures of Inadequate Pain Relief among Patients With Knee Osteoarthiritis. Stephanie Taylor, Christopher Black, Paul M. Peloso, Philip G. Conaghan 4, Leah Stokes, Mart A.F.J. van de Laar 5, François Rannou 6, Nigel K. Arden 7 and Panagiotis Mavros, Merck & Co., Inc., Whitehouse Station, NJ, Merck, Whitehouse Station, NJ, Merck Sharp & Dohme Corp., Rahway, NJ, 4 Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, 5 University of Twente & Medisch Spectrum Twente, Enschede, Netherlands, 6 Physical Medicine and Rehabilitation Service, Paris-Descartes University, Cochin Hospital, Paris, France, 7 Oxford NIHR Musculoskeletal Biomedical Research Unit, University of Oxford, Oxford, United Kingdom 0 Program Book 07

310 ACR POSTER SESSION C 08. Neuropathic Pain After Primary Total Hip and Knee Arthroplasty. Anne Lubbeke, Gabor J. Puskas, Domizio Suva, Sylvette Bas, Cem Gabay, Axel Finckh and Pierre Hoffmeyer, Geneva University Hospitals, Geneva, Switzerland, Geneva University Hospital, Geneva, Switzerland 4. Responsiveness and Predictive Ability Of The Knee Society Scale (KSS) Score. Jasvinder A. Singh, Cathy Schleck, W. Scott Harmsen and David Lewallen 4, University of Alabama, Tuscaloosa, AL, Mayo Clinic College of Medicine, Rochester, MN, Mayo Clinic, Rochester, MN, 4 Mayo Clinic college of medicine, Rochester, MN 5. Musculoskeletal Pain Explains Differences In Function At Time Of Surgery In Black TKR and THR Patients. Anthony Porter, Wenjun Li, Leslie R. Harrold, Milagros Rosal, Philip Noble, David Ayers, Patricia D. Franklin and Jeroan Allison, University of Massachusetts Medical School, Worcester, MA, Baylor College of Medicine, Houston, TX 6. Does Functional Gain and Pain Relief After TKR and THR Differ By Patient Obese Status? Wenjun Li, Leslie R. Harrold, Jeroan Allison, Courtland Lewis, Thomas Bowen, Patricia D. Franklin and David Ayers, University of Massachusetts Medical School, Worcester, MA, Hartford Hospital, Hartford, CT, Geisinger, Danville, PA 7. Important Predictors Of Patient-Reported Outcomes After TKR and THR Are Not Included In Risk Models Based On Administrative Data. Patricia D. Franklin, Leslie R. Harrold, Wenjun Li, Jeroan Allison, David Ayers and Courtland Lewis, University of Massachusetts Medical School, Worcester, MA, Hartford Hospital, Hartford, CT 8. The Impact Of Arthritis Type On Post-TJR Functional Gain: Outcomes In RA Vs. OA Patients. Leslie R. Harrold, David Ayers, Brian Curtin, George Reed and Patricia D. Franklin, University of Massachusetts Medical School, Worcester, MA, Virginia Commonwealth University Medical Center, Richmond, VA 9. Do Hyaluronic Acid Injections Delay Total Knee Replacement Surgery? Thomas Abbott, Roy D. Altman, Robert Dimeff, Michael Fredericson 4, Vijay Vad 5, Peter Vitanzo Jr. 6, Sashi Yadalam, Ronald Levine, Brad Bisson 7 and Samir Bhattacharyya 7, Johnson & Johnson, New Brunswick, NJ, UCLA, Los Angeles, CA, UT Southwestern Medical Center, Dallas, TX, 4 Stanford University School of Medicine, Menlo Park, CA, 5 Weill Cornell Medical College, NY, NY, 6 Rothman Institute, Philadelphia, PA, 7 DePuy Synthes Mitek Sports Medicine, Raynham, MA 40. Effects Of Intra-Articular Hyaluronic Acid Injections On Gait Pattern In Patients With Knee Osteoarthritis. Bilal Uysal, Aysegul Ketenci, Sina Esmaeilzadeh and Dilsad Sindel, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey 0 Program Book 4. Interphalangeal Intra-Articular Injection With Triamcinolone Hexacetonide: Assessment Of effectiveness In Hand Osteoarthritis. Natalia de Oliva Spolidoro, Jamil Natour, Rita N.V. Furtado, Flavia S. Machado and Hilda A. Oliveira, Universidade Federal de São Paulo - Unifesp, São Paulo, Brazil, Universidade Federal de Sao Paulo, Sao Paulo, Brazil, Universidade Federal de São Paulo, São Paulo, Brazil 4. Long-Term Safety and Efficacy Of Subcutaneous Tanezumab In Patients With Knee Or Hip Osteoarthritis (NCT ). Leslie Tive, Eugene J. Dabezies, Robert J. Fountaine, Mark T. Brown, Michael D. Smith, Kenneth M. Verburg and Christine R. West 4, Pfizer Inc, New York, NY, Pensacola Research Consultants, Pensacola, FL, Pfizer, Inc., Groton, CT, 4 Pfizer, Williamston, MI 4. Strontium Ranelate Significantly Decreases Radiological Progression Using a New Definition For Radiological Progression In Patients With Primary Knee Osteoarthritis Treated With Strontium Ranelate. Olivier Bruyere, Roland Chapurlat, Cyrus Cooper and Jean-Yves Reginster, University of Liège, Liège, Belgium, INSERM UMR 0 and University of Lyon, Hôpital Edouard Herriot, Lyon, France, MRC Lifecourse Epidemiology Unit, Southampton, United Kingdom 44. Prevention Of Radiological Progression In Patients With Primary Knee Osteoarthritis With Strontium Ranelate. Jean-Yves Reginster, Roland Chapurlat, Francis Berenbaum, P. Nash 4, O. Zamani 5, Martine Cohen-Solal 6, Gerolamo Bianchi 7, Jaime Branco 8, F. Navarro 9 and Cyrus Cooper 0, University of Liège, Liège, Belgium, INSERM UMR 0 and University of Lyon, Hôpital Edouard Herriot, Lyon, France, AP-HP, St Antoine Hospital, Paris, France, 4 University of Queensland, Brisbane, Australia, 5 Rheumazentrum Favoriten, Wien, Austria, 6 INSERM U606 Hôpital Lariboisière, Centre Viggo Petersen, Paris, France, 7 ASL Genovese, Genoa, Italy, 8 Centro Hospitalar de Lisboa Ocidental, Hospital Egas Moniz, Lisboa, Portugal, 9 University Hospital Virgen Macarena, Sevilla, Spain, 0 MRC Lifecourse Epidemiology Unit, Southampton, United Kingdom 45. Impact On Cartilage Volume Changes Over Time Of Conventional Treatment and Of Glucosamine and Chondroitin Sulfate In Knee Osteoarthritis Patients: Data From The Osteoarthritis Initiative Cohort. Johanne Martel-Pelletier, Camille Roubille, Jean-Pierre Raynauld, François Abram, Pierre Dodin, Marc Dorais, Philippe Delorme and Jean-Pierre Pelletier, Osteoarthritis Research Unit, University of Montreal Hospital Research Centre (CRCHUM), Montreal, QC, Imaging Research & Development, ArthroLab Inc., Montreal, QC, StatSciences Inc., Notre-Dame de l Île Perrot, QC 46. Effects Of Chondroitin Sulfate On Brain Response To Painful Stimulation In Knee Osteoarthritis Patients: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial. Jordi Monfort, Jesús Pujol, O Contreras-Rodriguez, Jone Llorente-Onaindia, M López-Solà, Laura Blanco- Hinojo, J Deus, H Ortiz, Francisco Montañés, M Campillo, Pere Benito, Laura Sánchez, Marta Herrero and Josep Vergés, Hospital del Mar, Barcelona, Spain, Bioiberica, Barcelona, Spain, Pre-Clinical and Clinical R&D Area, Pharmascience Division, BIOIBERICA S.A., Barcelona, Spain

311 ACR POSTER SESSION C 47. Effect Of Fish Oil On Structural Progression In Knee Osteoarthritis: A Two Year Randomized, Double-Blind Clinical Trial Comparing High Dose With Low Dose. Catherine L. Hill, Graeme Jones, Susan Lester, Ruth Battersby, Tanya Fedorova 4, Kristen Hynes 5, Susanna Proudman 6, Leslie G. Cleland 6 and Lyn March 7, The Queen Elizabeth Hospital, Woodville, Australia, Menzies Research Institute Tasmania, University of Tasmania, Hobart, 7000, Australia, Queen Elizabeth Hospital, Woodville South, Australia, 4 University of Sydney, St Leonards, Australia, 5 University of Tasmania, Hobart, Australia, 6 Royal Adelaide Hospital, Adelaide, Australia, 7 University of Sydney Institute of Bone and Joint Research, Royal North Shore Hospital, St Leonards, Australia 48. Use Of Low Dose Aspirin Is Associated With Reduced Medial Tibial Cartilage Loss In Symptomatic Osteoarthritis: DATA From A Cohort Study. Anita Wluka, Changhai Ding, Yuanyuan Wang, Graeme Jones, Andrew Teichtahl and Flavia Cicuttini 4, Monash University, Melbourne, Australia, Menzies Research Institute Tasmania, University of Tasmania, Hobart, 7000, Australia, Menzies Research Institute, Tasmania, Australia, 4 Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, 004, Australia 49. Safety Of Lower-Dose Diclofenac Submicron Particle Capsules Dosed Up To Weeks In Patients With Osteoarthritis. Clarence Young and Marc C. Hochberg, Iroko Pharmaceuticals, Philadelphia, PA, University of Maryland, Baltimore, MD 50. Comparative Effectiveness Of Pharmacological Interventions For Knee Osteoarthritis: A Network Meta- Analysis. Raveendhara R. Bannuru, Timothy E. McAlindon, John B. Wong, David Kent and Christopher Schmid, Tufts Medical Center, Boston, MA, Brown University, Providence, RI 5. Synergistic Effect of Combining BioniCare in an Unloading Brace for Osteoarthritis of the Knee. Thomas Zizic, David S. Hungerford, Edmund J. MacLaughlin, Craig Mines 4, Shaili Deveshwar 5, Theresa Lawrence Ford 6, Cynthia Elliott 6, John R. Principe 7, Jack S. Tuber 8 and Joy Schechtman 9, The Johns Hopkins University School of Medicine, Baltimore, MD, Johns Hopkins University, Baltimore, MD, The Johns Hopkins University School of Medicine, Cambridge, MD, 4 East Side OrthoCare, Snellville, GA, 5 Sports Medicine and Orthopedic Center, Greensboro, NC, 6 North Georgia Rheumatology, Lawrenceville, GA, 7 WellBeingMD, Palos Heights, IL, 8 The Johns Hopkins University, Baltimore, Maryland, Baltimore, MD, 9 SunValley Arthritis Center, Peoria, AZ 5. Predicting Benefit From Lateral Wedge Orthotics Using Radiographic Parameters In Medial Knee Osteoarthritis. Berna Goker, Roy H. Lidtke, Laura E. Thorp, Markus A. Wimmer and Joel A. Block, Gazi University, Ankara, Turkey, Rush University Medical Center, Chicago, IL 5. Arrest Of Progressive Loss Of Vibratory Perception In Knee Osteoarthritis: Effects Of a 48 Week Biomechanical Intervention. Najia Shakoor, Roy H. Lidtke, Louis F. Fogg, Laura E. Thorp, Markus A. Wimmer, Rachel A. Mikolaitis and Joel A. Block, Rush University Medical Center, Chicago, IL 54. Improvement In Clinical Symptoms After 48 Weeks Of Wearing Flexible Footwear In Osteoarthritis Of Knee: A Randomized Placebo-Controlled Study. Najia Shakoor, Roy H. Lidtke, Louis F. Fogg, Laura E. Thorp, Markus A. Wimmer, Rachel A. Mikolaitis and Joel A. Block, Rush University Medical Center, Chicago, IL 55. Beneficial Effect Of Long-Term Use Of a Low-Cost Minimalist Footwear On Joint Load, Clinical, and Functional Aspects Of Elderly Women With Knee Osteoarthritis. Francis Trombini-Souza, Alessandra Matias, Mariane Yokota, Marco Butugan, Ivye Pereira, Claudia Goldenstein-Schainberg, Ricardo Fuller and Isabel C.N. Sacco, School of Medicine, University of São Paulo, São Paulo, Brazil, Reumatologia, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil, University of Sao Paulo, São Paulo, Brazil 56. Weight Change Has A Disease Modifying Effect On Knee Structure and Symptoms In Obese Individuals Without Diagnosed Knee Osteoarthritis. Andrew Teichtahl, Anita Wluka, Stephanie Tanamas, Yuanyuan Wang, Boyd Strauss, Joseph Proietto, John Dixon, Graeme Jones 4, Andrew Forbes and Flavia Cicuttini 5, Monash University, Melbourne, Australia, University of Melbourne, Melbourne, Australia, Baker Institute, Melbourne, Australia, 4 Menzies Research Institute, Tasmania, Australia, 5 Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, 004, Australia ARHP Osteoarthritis - Clinical Aspects: Psychology/Social Sciences 57. Understanding Differences Between Black and White Patients Reactions to New Treatment. Liana Fraenkel, Richard L. Street Jr. and Ellen Peters, Yale University School of Medicine, Veterans Affairs Connecticut Healthcare System, New Haven, CT, Texas A&M University, College Station, TX, Ohio State University, Columbus, OH 58. Do Numbers Make a Difference? Liana Fraenkel, Evan Wilhelms and Valerie Reyna, Yale University School of Medicine, Veterans Affairs Connecticut Healthcare System, New Haven, CT, Cornell University, Ithica, NY 59. Understanding the Preference to Stay With the Status Quo. Liana Fraenkel, Meaghan Cunningham and Ellen Peters, Yale University School of Medicine, Veterans Affairs Connecticut Healthcare System, New Haven, CT, Yale University School of Medicine, New Haven, CT, Ohio State University, Columbus, OH 60. The Journey to Diagnosis in As/Axial Spondyloarthritis - the Psychological Impact of Delay. Jane Martindale and Lynne Goodacre, Lancaster University, Lancaster, United Kingdom 0 Program Book 09

312 ACR POSTER SESSION C 6. Biopsychosocial Typologies of Pain in a Cohort of Patients With Systemic Sclerosis. Erin L. Merz, Vanessa L. Malcarne, Shervin Assassi, Deepthi Nair, Tiffany Graham, Brayden Yellman, Rosa M. Estrada-Y-Martin and Maureen D. Mayes, SDSU/UCSD Joint Doctoral Program in Clinical Psychology, San Diego, CA, University of Texas Health Science Center at Houston, Houston, TX 6. Physical, Psychological, and Social Impacts Of Restricting Back Pain: The Older Person s Perspective. Una E. Makris, Trisha V. Melhado, Simon C. Lee, Heidi A. Hamann, Lisa M. Walke, Thomas M. Gill and Liana Fraenkel 4, UT Southwestern Medical Center, VA Medical Center, Dallas, TX, UT Southwestern Medical Center, Dallas, TX, Yale University, New Haven, CT, 4 Yale University School of Medicine, Veterans Affairs Connecticut Healthcare System, New Haven, CT 6. Predictors Of No Improvement In Subjective Health Perception In Newly Diagnosed Rheumatoid Athritis Patients With a Good DAS8 Response At Months In The Dutch Rheumatoid Arthritis Monitoring Tight Control Cohort. Martijn Oude Voshaar, Erik Taal, Peter M. ten Klooster, Harald E. Vonkeman and Mart A.F.J. van De Laar, University of Twente, Enschede, Netherlands, Medisch Spectrum Twente, Enschede, Netherlands, Medisch Spectrum Twente & University of Twente, Enschede, Netherlands Pediatric Rheumatology - Clinical and Therapeutic Aspects III: Juvenile Idiopathic Arthritis and Other Pediatric Rheumatic Diseases 64. Rituximab In The Treatment Of Children With Systemic LUPUS Erythematosus: ONE Year Analysis Of Patients. Ekaterina Alexeeva, Rina Denisova, Saniya Valieva, Tatyana Bzarova, Kseniya Isayeva, Tatyana Sleptsova, Elena Mitenko, Evgeniya Chistyakova, Anna Fetisova and Elena Semikina, I.M.Sechenov First Moscow State Medical University, Moscow, Russia, Scientific Center of Children s Health of RAMS, Moscow, Russia, Scientific Center of Children s Health of RAMS, Moscw, Russia 65. Efficacy and Safety Of Biologic Agents In Patients With Poly-Articular Juvenile Idiopathic Arthritis: Network Meta- Analysis Of Randomized Controlled Withdrawal Trials. Gil Amarilyo, Simon Tarp, Ivan Foeldvari, Neta Cohen, Tracy D. Pope 4, Jennifer M.P. Woo 5, Robin Christensen and Daniel E. Furst 4, Dana-Dwek Children s hospital, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, Musculoskeletal Statistics Unit, The Parker Institute, Department of Rheumatology, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Denmark, Hamburger Zentrum für Kinderund Jugendrheumatologie, Klinikum Eilbek, Hamburg, Germany, 4 David Geffen School of Medicine, University of California, Los Angeles, CA, 5 Mattel Children s Hospital, University of California, Los Angeles, Los Angeles, CA 66. Infection Risk With Tumor Necrosis Factor Inhibitor Use In Polyarticular Juvenile Idiopathic Arthritis. Caroline Y Chang, Rika Meyer and Katherine AB Marzan, Children s Hospital Los Angeles, Los Angeles, CA 67. -Valent Polysaccharide Pneumococcal Vaccine in Juvenile Idiopathic Arthritis Patients: Anti-Tumor Necrosis Factor Therapy Role in Short and Long-Term Immunogenicity. Nadia E. Aikawa, Ivan L.A. França, Ana C. M. Ribeiro, Adriana M. Sallum, Eloisa Bonfa and Clovis A. Silva, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil, University of São Paulo, São Paulo, Brazil, University of São Paulo, Sao Paulo, Brazil 68. Temporomandibular Joint Involvement and Quality Of Life In Juvenile Idiopathic Arthritis. Paula Frid, Ellen Nordal, Francesca Bovis, Denise Marafon, Donato De Angelis, Sheila Oliveira, Fabrizia Corona, Gabrieli Simonini, Joyce Davidson, Helen Foster, Rik Joos, Ivan Foeldvari, Michel Steenks, Pekka Lahdenne, Pavla Dolezalova, Elena Palmisani, Alberto Martini, Angela Pistorio and Nicolino Ruperto, University Hospital North Norway, Tromso, Norway, University of Tromsø, Tromsø, Norway, Istituto Giannina Gaslini, Pediatria II, Reumatologia, Paediatric Rheumatology International Trials Organisation (PRINTO) Coordinating Center, Genoa, Italy, Genoa, Italy 69. Short Term Efficacy Of Biologic Agents In Patients With Systemic Juvenile Idiopathic Arthritis: Network Meta- Analysis Of Randomized Trials. Simon Tarp, Gil Amarilyo, Ivan Foeldvari, Neta Cohen, Tracy D. Pope 4, Jennifer M.P. Woo 5, Robin Christensen and Daniel E. Furst 4, Musculoskeletal Statistics Unit, The Parker Institute, Department of Rheumatology, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Denmark, Dana- Dwek Children s hospital, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, Hamburger Zentrum für Kinder- und Jugendrheumatologie, Klinikum Eilbek, Hamburg, Germany, 4 David Geffen School of Medicine, University of California, Los Angeles, CA, 5 Mattel Children s Hospital, University of California, Los Angeles, Los Angeles, CA 70. Efficacy and Safety Of Long-Term Rituximab Use In Patients With Systemic Juvenile Idiopathic Arthritis: The Results Of 5-Year Follow-Up In Real Clinical Practice. Ekaterina Alexeeva, Alexander Baranov, Saniya Valieva, Tatyana Bzarova, Rina Denisova, Kseniya Isayeva, Tatyana Sleptsova, Elena Mitenko, Evgeniya Chistyakova, Anna Fetisova, Elena Semikina and Svetlana Akulova, Scientific Center of Children s Health of RAMS, Moscow, Russia, I.M.Sechenov First Moscow State Medical University, Moscow, Russia, Scientific Center of Children s Health of RAMS, Moscw, Russia 7. Identification Of Best Cutoff Points and Clinical Signs Specific For Early Recognition Of Macrophage Activation Syndrome In Active Systemic Juvenile Idiopathic Arthritis. Mikhail Kostik, Margarita Dubko, Ludmila Snegireva, Vera Masalova, Tatyana Kornishina, Natalya Abramova, Irina Chikova, Natalya Glebova, Ekaterina Kuchinskaya, Eugenia Balbotkina, Olga Kalshnikova and Vyacheslav Chasnyk, Saint-Petersburg State Pediatric Medical University, Saint- Petersburg, Russia 0 0 Program Book

313 ACR POSTER SESSION C 7. Single MVK Mutation and Recurrent Fevers. Karyl S. Barron, Amanda K. Ombrello, Donald P. Goldsmith, Ivona Aksentijevich, Anne Jones and Daniel L. Kastner, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, St Christopher s Hospital for Children/ Drexel College of Medicine, Philadelphia, PA 7. The Interleukin- Receptor Antagonist Anakinra Is Effective In The Treatment Of Undifferentiated Periodic Fever Syndromes. Daniella M. Schwartz, Runsheng Wang, Karyl S Barron, Daniel L. Kastner 4 and Amanda K. Ombrello 5, National Institutes of Health, National Institute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, MD, NIH/NIAMS, Rheumatology fellowship and training branch, Bethesda, MD, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, 4 National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, 5 National Human Genome Research Institute,National Institute of Health, Bethesda, MD 74. Urinalysis Monitoring In Children With Henoch-Schönlein Purpura: Is It Time To Revise? Hao Wang, Manasita Tanya, Justin Hung Tiong Tan, Sook Fun Hoh, Lena Das and Thaschawee Arkachaisri, Duke-NUS Graduate Medical School, Singapore, Singapore, KK Women s and Children s Hospital, Singapore, Singapore, KK Women s and Children s Hospital and Duke-NUS Graduate Medical School, Singapore, Singapore 75. Systematic Analysis and Pathologic Findings In Young Adults With Sudden Death Attributed To Kawasaki Disease In Childhood. Chisato Shimizu, Alka Sood, Hubert Lau, Steven Campman and Jane C. Burns, UC San Diego, School of Medicine, La Jolla, CA, San Diego County Medical Examiner Office, La Jolla, CA 76. Relationships Between Physician and Patient Scored Clinical Outcome Measures In Pediatric Localized Scleroderma. Kaveh Ardalan, Christina Kelsey and Kathryn S. Torok, Children s Hospital of Pittsburgh of UPMC, Pittsburgh, PA 77. A Pilot Study Of Juvenile Localized Scleroderma (jls) Consensus Treatment Plans. Suzanne C. Li, Kathryn S. Torok, Mara L. Becker, Fatma Dedeoglu 4, Robert C. Fuhlbrigge 5, Gloria C. Higgins 6, Sandy D. Hong 7, Maria F. Ibarra, Ronald M. Laxer 8, Thomas G. Mason II 9, Elena Pope 8, Marilynn G. Punaro 0, C. Egla Rabinovich, Katie G. Stewart, Christina Kelsey, Brian Feldman 4, Themba Nyrienda 5 and Knut M. Wittkowski 6, Joseph M Sanzari Children s Hospital, Hackensack University Medical Center, Hackensack, NJ, Children s Hospital of Pittsburgh of UPMC, Pittsburgh, PA, Children s Mercy Hospital, Kansas City, MO, 4 Boston Childrens Hosp, Boston, MA, 5 Childrens Hospital, Boston, MA, 6 Nationwide Childrens Hosp, Columbus, OH, 7 U of Iowa Children s Hosp, Iowa City, IA, 8 The Hospital for Sick Children, Toronto, ON, 9 Mayo Clinic Rochester, Rochester, MN, 0 University of Texas Southwestern Medical Center, Dallas, TX, Duke Univ Med Ctr, Durham, NC, Texas Scottish Rite Hospital, Dallas, TX, Univ of Pittsburgh Med Ctr, Pittsburgh, PA, 4 Hospital for Sick Kids, Toronto, ON, 5 Hackensack University Medical Center, Hackensack, NJ, 6 Rockefeller University, New York, NY 78. Juvenile Onset Systemic Sclerosis: Clinical and Serological Features, and Mortality In Comparison With Adult Onset Disease. Juan G. Ovalles-Bonilla, Francisco Javier López-Longo, Indalecio Monteagudo, Esperanza Naredo, Carlos Gonzalez Fernandez, María Montoro Alvarez, Lina Martínez-Estupiñán, Juan C. Nieto, Julia Martínez-Barrio, Michelle Hinojosa, Natalia Bello, Belen Serrano, Carmen Mata and Luis Carreño, Hospital General Universitario Gregorio Marañón, Madrid, Spain 79. Consensus: What Agent To Use When First-Line Vasodilatadors Fail In Raynaud s Phenomenon Or Digital Ulcers Secondary To Juvenile Systemic Sclerosis? Marìa M. Katsicas, Mariana Gonzalez and Ricardo A. G. Russo, Hospital de Pediatrìa Garrahan, Buenos Aires, Argentina, Hospital de Pediatría Garrahan, Buenos Aires, Argentina, Hospital de Pediatria Garrahan, Buenos Aires, Argentina 80. Presentation, Diagnosis, and Treatment Of Chronic Recurrent Multifocal Osteomyelitis. Colin Anderson, Erin Wylie, Travis Heare, Jamie Stewart, Kelley Capocelli, Shelley Dell Orfano and Jennifer Soep, The University of Colorado, Aurora, CO, Children s Hospital Colorado, Aurora, CO 8. Methotrexate and Infliximab With Or Without Zoledronic Acid Improve Disease Activity and Prevent Damage Progression In Chronic Nonbacterial Osteomyelitis. Yongdong (Dan) Zhao, Nancy Chauvin, Diego Jaramillo and Jon Burnham, Children s Hospital of Philadelphia, PHILADELPHIA, PA, The Children s Hospital of Philadelphia and the Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA 8. Spectrum Of Musculoskeletal Inpatient Diagnoses At The Largest Pediatric Center In East Africa In 0. Angela Migowa, Ines Colmegna, Evelyne Ng ang a, John Wachira 4, Thomas Ngwiri 4, Carol A. Hitchon 5, Sasha Bernatsky 6 and Rosie Scuccimarri 7, Aga Khan University Hospital, Nairobi, Kenya, McGill University Health Centre, Montreal, QC, University of Nairobi, Nairobi, Kenya, 4 Gertrude s Children Hospital, Nairobi, Kenya, 5 University of Manitoba, Winnipeg, MB, 6 McGill University Health Center, Montreal, QC, 7 Montreal Children s Hospital and McGill University, Montréal, QC 8. Spectrum Of Outpatient Musculoskeletal Visits At The Largest Pediatric Center In East Africa In 0. Laurel Broten, Angela Migowa, Rosie Scuccimarri, Evelyne Ng ang a 4, John Wachira 5, Thomas Ngwiri 5, Sasha Bernatsky 6, Carol A. Hitchon 7 and Ines Colmegna 8, McGill University, Montreal, QC, Aga Khan University Hospital, Nairobi, Kenya, Montreal Children s Hospital and McGill University, Montréal, QC, 4 University of Nairobi, Nairobi, Kenya, 5 Gertrude s Children Hospital, Nairobi, Kenya, 6 McGill University Health Center, Montreal, QC, 7 University of Manitoba, Winnipeg, MB, 8 McGill University Health Centre, Montreal, QC 0 Program Book

314 ACR POSTER SESSION C 84. Application Of The Bonexpert Method For Bone Age and Bone Health Assessment In Patients With Juvenile Idiopathic Arthritis. Charlotte M. Nusman, Janneke Anink, Lisette W.A. van Suijlekom-Smit, Marion A.J. van Rossum, Mario Maas and Rick R. van Rijn, Academic Medical Center, Amsterdam, Netherlands, Erasmus MC Sophia Children s Hospital, Rotterdam, Netherlands, Emma Children s Hospital / Academic Medical Center and Reade Institute, Amsterdam, Netherlands 85. Three Middle Finger Width Correlates With Maximum Mouth Opening and Is a New Reliable Parameter To Identify Joint Hypermobility In Schoolchildren. Francesca Sperotto, Gabriella La Falce, Fabio Vittadello, Lorenzo Favero and Francesco Zulian, University of Padua, Padua, Italy, Gnatology Unit, Department of Dentistry, Padua, Italy 86. Lower Extremity Strength Is Related To Diminished Quality Of Life In Obese Children. Sharon M. Bout-Tabaku, Matt Briggs, Tom Best, Colleen Spees, Ajit Chaudhari and Laura Schmitt, The Ohio State University, Columbus, OH, The Ohio State Universtiy, Columbus, OH 87. Inter-Rater Reliability Of Jumping Mechanography In Healthy Children and Adults. Johannes Roth, Ciaran M. Duffy, Tania Bennett, Marta Erlandson, Michele Gibbon, Heather Macdonald 4, Douglas Race 5, Leanne M. Ward and Lori B. Tucker 5, University of Ottawa, Ottawa, ON, Children s Hospital of Eastern Ontario and University of Ottawa, Ottawa, ON, University of Toronto, Toronto, ON, 4 The University of British Columbia, Vancouver, BC, 5 University of British Columbia, Vancouver, BC Pediatric Rheumatology - Pathogenesis and Genetics 88. Role of Interleukin- in Abnormal Monocyte Phenotype in Systemic Onset Juvenile Idiopathic Arthritis. Yujuan Zhang, Claudia Macaubas, Clarissa Klein, M. Virginia Pascual, Arielle Hay, Susan D. Thompson 4, Christy I. Sandborg, Norman T. Ilowite and Elizabeth D. Mellins, Stanford University Med Ctr, Stanford, CA, Baylor Institue for Immunology Research, Dallas, TX, The Children s Hospital at Montefiore, Bronx, NY, 4 Cincinnati Children s Hospital Medical Center, Cincinnati, OH 89. TLR 4 Endogenous Ligand MRP8/4 Levels in Enthesitis Related Arthritis (ERA) and Its Association With Disease Activity and TLR 4 Expression. Amita Aggarwal, Mujeeb Rahman, Arpita Myles, Priyanka Gaur and Ramnath Misra, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India 90. Clinical and Immunologic Description Of Pediatric Conditions With Interferon-Regulated Gene Signatures (Chronic Atypical Neutrophilic Dermatosis Lipodystrophy Elevated Tempature, Aicardi Goutieres Syndrome, Juvenile Dermatomyositis, Juvenile Systemic Lupus Erythematosus). Hanna Kim, Adriana Almeida de Jesus, Yin Liu, Yan Huang, Gina Montealegre, Dawn Chapelle, Nicole Plass, Wanxia Tsai, Massimo Gadina, Lisa G. Rider 4, Adeline Vanderver 5 and Raphaela Goldbach-Mansky, National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH, Bethesda, MD, NIAMS / NIH, Bethesda, MD, National Institute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, MD, 4 NIEHS, NIH, Bethesda, MD, 5 Children s National Medical Center, Washington, DC 9. Intestinal Microbiome In Polyarticular Juvenile Idiopathic Arthritis: A PILOT Study. Petra C.E. Hissink Muller, A.E. Budding, Cornelia F. Allaart, Danielle M.C. Brinkman, Taco W. Kuijpers 4, Michiel Westedt, J. Merlijn van den Berg 5, Lisette W.A. Van Suijlekom-Smit 6, Marion A.J. Van Rossum 7, Tim G.J. de Meij and Rebecca Ten Cate, Reade Institute, Amsterdam, Netherlands, VU University Medical Center, Amsterdam, Netherlands, Leiden University Medical Center, Leiden, Netherlands, 4 Emma Children s Hospital/ Academic Medical Center (AMC), Amsterdam, Netherlands, 5 Emma Children s Hospital / Academic Medical Center (AMC), Amsterdam, Netherlands, 6 Erasmus MC Sophia Children s Hospital, Rotterdam, Netherlands, 7 Emma Children s Hospital / Academic Medical Center and Reade Institute, Amsterdam, Netherlands 9. Vitamin D Receptor Polymorphisms In A Cohort Of Italian Patients With Juvenile Idiopathic Arthritis. Fernanda Falcini, Francesca Marini, Donato Rigante, Federico Bertini 4, Gemma Lepri 5, Stefano Stagi, Marco Matucci Cerinic 5 and Maria Luisa Brandi 5, Department of Biomedicine, Division of Rheumatology AOUC, Excellence Centre for Research, Florence, Italy, University of Florence, Firenze, Italy, Università Cattolica Sacro Cuore, Rome, Italy, 4 Department of Internal Medicine, Rheumatology Section, University of Florence, Florence, Italy, 5 University of Florence, Florence, Italy 9. Altered Apoptosis Profile and Associated Soluble Factors In Patients With Juvenile-Onset Systemic Lupus Erythematosus. Bernadete Liphaus, Maria H. B. Kiss, Solange Carrasco and Cláudia Goldenstein-Schainberg, Instituto da Criança, Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil, University of Sao Paulo School of Medicine, São Paulo, Brazil, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil 94. RNA-Sequencing In Peripheral Blood Mononuclear Cells Identifies Novel Differentially Expressed Coding and Non-Coding Transcripts In Juvenile Idiopathic Arthritis. Kaiyu Jiang, Xiaoyun Sun, Yanmin Chen, Yufeng Shen and James N. Jarvis, The University at Buffalo, Buffalo, NY, Columbia University, New York, NY 95. Expanding The Spectrum Of Recombination Activating Gene- Deficiency To Include Early Onset Autoimmunity. Lauren A. Henderson, Francesco Frugoni, Gregory Hopkins, Helen de Boer, Sung-Yun Pai, Yu Nee Lee, Jolan E. Walter, Melissa M. Hazen and Luigi D Notarangelo, Boston Children s Hospital, Boston, MA, Dana-Farber Cancer Institute, Boston, MA, Massachusetts General Hospital for Children, Boston, MA 96. Aberrant IgG Glycosylation Is Associated With Active Disease In Juvenile Idiopathic Arthritis Patients. Esperanza Cleland, Brooke Gilliam and Terry L. Moore, Saint Louis University, Saint Louis, MO 97. High Titer IgG Anti-Cyclic Citrullinated Peptide Antibodies Are Associated With Joint Destruction In Juvenile Idiopathic Arthritis Patients. Brooke Gilliam, Lance Feller and Terry L. Moore, Saint Louis University, Saint Louis, MO 0 Program Book

315 ACR POSTER SESSION C 98. Genome Wide Association Meta-Analysis Implicates HLA-DRB, The BTNL/HLA-DRA region, and a Novel Susceptibility Locus On Chromosome In Systemic Juvenile Idiopathic Arthritis. Michael J. Ombrello, Elaine F. Remmers, Ioanna Tachmazidou, Alexei A. Grom 4, Dirk Föll 5, Alberto Martini 6, Marco Gattorno 7, Seza Ozen 8, Sampath Prahalad 9, John F. Bohnsack 0, Norman T. Ilowite, Elizabeth D. Mellins, Ricardo A. G. Russo, Claudio A. Len 4, Sheila K. Oliveira 5, Rae SM Yeung 6, Lucy R. Wedderburn 7, Jordi Anton 8, Carl D. Langefeld 9, Susan D. Thompson 4, Eleftheria Zeggini, Wendy Thomson 0, Daniel L. Kastner, Patricia Woo and on Behalf Of the International Childhood Arthritis Genetics Consortium, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, The Wellcome Trust Sanger Institute, Cambridge, United Kingdom, 4 Cincinnati Children s Hospital Medical Center, Cincinnati, OH, 5 University of Muenster, Muenster, Germany, 6 Istituto Giannina Gaslini, Genova, Italy, 7 G. Gaslini Institute, Genova, Italy, 8 Hacettepe University, Ankara, Turkey, 9 Emory Children s Center, Atlanta, GA, 0 University of Utah, Salt Lake City, UT, Albert Einstein College of Medicine, Bronx, NY, Stanford University Med Ctr, Stanford, CA, Hospital de Pediatria Garrahan, Buenos Aires, Argentina, 4 Universidade Federal de São Paulo/UNIFESP, São Paulo, Brazil, 5 Instituto de Pediatria e Puericultura Martagão Gesteira (IPPMG) da Universidade Federal do Rio de Janeiro (UFRJ), Rio de Janeiro, Brazil, 6 The Hospital for Sick Children and University of Toronto, Toronto, ON, 7 Arthritis Research UK Centre for Adolescent Rheumatology at University College London, Great Ormond Street Hospital and UCLH, University College London, London, United Kingdom, 8 Hospital Sant Joan de Deu, Barcelona, Spain, 9 Wake Forest School of Medicine, Winston-Salem, NC, 0 Arthritis Research UK Epidemiology Unit, Manchester Academic Health Sciences Centre, Institute of Inflammation and Repair, The University of Manchester, Manchester, United Kingdom, University College London, London, United Kingdom, INCHARGE, London, United Kingdom 99. Analysis Of The MHC Region In a Large Cohort Of Juvenile Idiopathic Arthritis Cases Identifies Independent Effects At HLA-DRB. Anne Hinks, Joanna Cobb, Buhm Han, Miranda C. Marion, Marc Sudman 4, Paul Martin, John F. Bohnsack 5, Lucy R. Wedderburn 6, Johannes Peter Haas 7, Paul de Bakker, Carl D. Langefeld, Soumya Raychaudhuri, Sampath Prahalad 8, Susan D. Thompson 4 and Wendy Thomson, Arthritis Research UK Epidemiology Unit, Manchester Academic Health Sciences Centre, Institute of Inflammation and Repair, The University of Manchester, Manchester, United Kingdom, Brigham and Women s Hospital, Harvard Medical School, Boston, MA, Wake Forest University Health Sciences, Winston-Salem, NC, 4 Cincinnati Children s Hospital Medical Center, Cincinnati, OH, 5 University of Utah, Salt Lake City, UT, 6 Arthritis Research UK Centre for Adolescent Rheumatology at University College London, Great Ormond Street Hospital and UCLH, University College London, London, United Kingdom, 7 German Centre for Rheumatology in Children and Young People, Garmisch-Partenkirchen, Germany, 8 Emory Children s Center, Atlanta, GA 00. Fatty Acid Profiling In Juvenile Idiopathic Arthritis: The Balance Between Pro-Inflammatory and Pro-Resolving Prostanoids. Weng Tarng Cham, Enzo Ranieri, Janice Fletcher and Christina A. Boros, Women s and Children s Hospital, North Adelaide, SA 5006, Australia, SA Pathology, North Adelaide, SA 5006, Australia, University of Adelaide/ Women s and Children s Hospital, Adelaide, Australia 0. Exon and mirna Arrays Reveal Complexity and Specificity Of The Juvenile Idiopathic Arthritis Neutrophil Transcriptome. Zihua Hu, Kaiyu Jiang, Mark B. Frank, Yanmin Chen and James N. Jarvis, University at Buffalo, Buffalo, NY, The University at Buffalo, Buffalo, NY, Oklahoma Medical Research Foundation, Oklahoma City, OK 0. TNF-α Is Associated With Cognitive Impairment In Childhood-Onset Systemic Lupus Erythematosus. Mariana Postal, Nailu A. Sinicato, Aline T. Lapa, Karina Peliçari, Bruna Bellini, Paula T Fernandes, Roberto Marini and Simone Appenzeller, State University of Campinas, Campinas, Brazil, Faculty of Medical Science, State University of Campinas Unicamp, São Paulo, Brazil 0. DEK s Autoantigenicity In Juvenile Idiopathic Arthritis Resides In Its C-Terminal 5 Amino Acids. Barbara S. Adams, Miguel Rivas, Yuanfan Ye, Lili Zhao, Maureen Legendre and Nirit Mor-Vaknin, University of Michigan, Ann Arbor, MI 04. Early Treatment With Methotrexate Is Associated With Extensive Re-Ordering Of The Neutrophil Transcriptome In Juvenile Idiopathic Arthritis. Zihua Hu, Kaiyu Jiang, Mark B. Frank, Yanmin Chen and James N. Jarvis, University at Buffalo, Buffalo, NY, The University at Buffalo, Buffalo, NY, Oklahoma Medical Research Foundation, Oklahoma City, OK 05. Galectin- and Transforming Growth Factor-β Signaling In The Pathogenesis Of Coronary Artery Aneurysms In Kawasaki Disease. Fujito Numano, Matthew Vejar, Chisato Shimizu, Susan Jimenez-Fernandez, Adriana H. Tremoulet, Jane C. Burns and Lori B. Daniels, UC San Diego, School of Medicine, La Jolla, CA 06. Detection Of State-Specific RNA Transcripts In Juvenile Idiopathic Arthritis Neutrophils Using RNA Sequencing. Kaiyu Jiang, Xiaoyun Sun, Yanmin Chen, Yufeng Shen and James N. Jarvis, The University at Buffalo, Buffalo, NY, Columbia University, New York, NY 07. Plasma Cytokine Concentrations Are Associated With Folate Perturbations and Methotrexate Polyglutamate Accumulation In The Peripheral Blood Of Juvenile Idiopathic Arthritis Patients Treated With Low-Dose Methotrexate. Ryan S. Funk, Leon van Haandel, Marcia Chan, Lanny J. Rosenwasser, Andrew Lasky, Maria F. Ibarra, Mark F. Hoeltzel, J.S. Leeder and Mara L. Becker, Children s Mercy Hospital, Kansas City, MO 0 Program Book

316 ACR POSTER SESSION C 4 ARHP Pediatrics 08. Psychological Condition Of JIA Patients Treated With Biologic Agents. - A Nation-Wide Survey In Japan. Yuki Osako, Yukiko Nonaka, Harumi Akaike, Tomohiro Kubota, Tsuyoshi Yamatou, Tomokazu Nagakura, Junko Yasumura 4, Hiroyuki Imanaka and Syuji Takei, Kagoshima University, Kagoshima city, Japan, Kagoshima University, Kagoshima, Japan, House of Meguminoseibo, Usuki, Japan, 4 Hiroshima University, Hiroshima City, Japan 09. Transition From The Pediatric Rheumatologist To The Adult Rheumatologist: Outcomes Of 5 Years Of Experience Between Two Institutions. Elizabeth C. Ortiz, Agarwal Arunima, Sandra Mintz and Bracha Shaham 4, University of Southern California, Los Angeles, CA, Childrens Hospital Los Angeles, Los Angeles, CA, Children s Hospital of LA, Los Angeles, CA, 4 Children s Hospital Los Angeles, Los Angeles, CA 0. Involvement In Leisure Activities Among Children and Youth With Juvenile Idiopathic Arthritis. Sabrina Cavallo, Annette Majnemer, Ciaran M. Duffy and Debbie Ehrmann Feldman, Université de Montréal, Montreal, QC, McGill university, Montreal, QC, Children s Hospital of Eastern Ontario and University of Ottawa, Ottawa, ON. Hospital For Special Surgery s Charla De Lupus ( Lupus Chat) Teen/Young Adult/ Parent Group: Holistic Support For Lupus Patients and Their Families. Erica Sandoval, Lillian Mendez, Roberta Horton, Josephine Isgro 4 and Jillian A. Rose, Hospital For Special Surgery, New York, NY, Hospital for Speical Surgery, New York, NY, Hospital for Special Surgery, New York, NY, 4 Morgan Stanley Children s Hospital of New-York Presbyterian, Columbia University Medical Center, New York, NY. Development Of Tools To Facilitate Shared Decision Making About Medications For Juvenile Idiopathic Arthritis A Project Of The Pediatric Rheumatology Care and Outcomes Improvement Network. Esi Morgan DeWitt, Ellen A. Lipstein, Katie Staun, Linda Scherer, Janalee Taylor, Carole M. Lannon and William B. Brinkman, Cincinnati Children s Hospital Medical Center, Cincinnati, OH, University of Cincinnati, Cincinnati, OH Rheumatoid Arthritis - Animal Models II. Anti-IL-6 Receptor Antibody Normalizes Both DKK- and Sclerostin As Wnt Inhibitors In a Mouse Model Of Collagen-Induced Arthritis. Hiroto Yoshida, Mika Yagoto, Miho Suzuki, Keisuke Tanaka, Isao Matsumoto, Takayuki Sumida and Yoshihiro Matsumoto, Chugai Pharmaceutical Co., Ltd., Gotemba, Japan, University of Tsukuba, Tsukuba, Japan 4. STAT Blockade Suppresses Autoimmune Arthritis In Mice Via The Reciprocal Regulation Of Treg and Th7 Cells. Jennifer Lee, Jae Ho Lee, Seung Min Jung, Young Sun Suh, Jung Hee Koh, Soo Young Lee, Dae Chul Jeong, Mi-La Cho, Seung-Ki Kwok, Ji Hyeon Ju, Kyung-Su Park and Sung-Hwan Park, The Catholic University of Korea, Seoul St. Mary s Hospital, Seoul, South Korea, The Catholic University of Korea, Incheon St. Mary s Hospital, Incheon, South Korea, Catholic University of Korea, Seoul, South Korea 0 Program Book 5. Apoptotic Cell-Based Therapy To Treat Collagen-Induced Experimental Arthritis. Rationale For The Use Of Apoptotic Cells In The Treatment Of Rheumatoid Arthritis. Sylvain Perruche, Amandine Clauzon, Francis Bonnefoy, Eric Toussirot and Philippe Saas, EFS Bourgogne Franche Comté, Besançon, France, CIC Biotherapy 506 and Rheumatology and EA 466 Pathogens and Inflammation, Besançon, France, INSERM UMR098 / Plateforme de Biomonitoring, Besançon, France 6. Tubastatin A, a Selective Histone Deacetylase-6 Inhibitor, Suppresses Synovial Inflammation and Joint Destruction In a Collagen Antibody-Induced Arthritis Mouse Model. Joong Kyong Ahn, Jaejoon Lee, Hyemin Jeong, Jiwon Hwang, Seulkee Lee, Ji Young Chai 4, Inyoung Kim, Eun Chung Hong 5, Eun-Kyung Bae 5, Hoon-Suk Cha and Eun- Mi Koh, Kangbuk Samsung hospital, Sungkyunkwan University School of Medicine, Seoul, South Korea, Sungkyunkwan University School of Medicine, Samsung Medical Center, Seoul, South Korea, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea, 4 Jesang Hospital, Seongnam-si Gyeonggi-do, South Korea, 5 Samsung Biomedical Research Institute, Seoul, South Korea 7. Experimental Arthritis Exacerbates Periodontal Disease But Periodontal Infection Does Not Exacerbated Experimental Arthritis. John Butcher, Jessica Oliver-Bell, Robert Benson, James Brewer, Paul Garside, Iain B. McInnes and Shauna Culshaw, Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom, Dental School, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom 8. Gingival Stem Cells Suppress Osteoclast Formation and Bone Erosion In CIA Through CD9 Signal. Song Guo Zheng, Jian Gu, Maogeng Chen and Yi Shen, University of Southern California Keck School of Medicine, Los Angeles, CA, Shanghai East Hospital at Tongji University, Shanghai, China 9. Active Immunization Against VEGF-Derived Oligopeptides Improves Joint Inflammation and Destruction In Collagen- Induced Arthritis. Emilie Duvallet, Laure Foulboeuf, Luca Semerano, Nadia Belmellat, Marc Lecouvey, Eric Assier, Sylviane Muller 4 and Marie-Christophe Boissier, EA4, LiP, University Paris, Sorbonne Paris Cité, Bobigny, France, EA4, LiP, University Paris, Sorbonne Paris Cité and Rheumatology Department, Avicenne Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Bobigny, 9009, France, Bobigny, France, CSPBAT Paris University, Bobigny, France, 4 CNRS, Strasbourg, France 0. The Role Of CDc+ Dendritic Cells In Inflammatory Arthritis. Antonia Puchner, Stephan Blüml, Victoria Saferding, Harald Leiss, Josef S. Smolen and Kurt Redlich, Medical University of Vienna, Vienna, Austria. The Histamine H 4 Receptor Drives Inflammation In Preclinical Models Of Arthritis. Paul J. Dunford, Jeffery Cowden, Fuqu Yu, Homayon Banie, Mandana Farahani, Ping Ling, Steven Nguyen, Jason Riley, Mai Zhang, Jian Zhu and Robin L. Thurmond, Janssen R&D, LLC, San Diego, CA

317 ACR POSTER SESSION C. Positive Allosteric Modulation Of The Adenosine A a Receptor Alters Inflammatory Cytokine Production and Alleviates Chronic Arthritis In Rats. Ajith A. Welihinda, Jordan A. Mechanic and Edward P. Amento, Molecular Medicine Research Institute, Sunnyvale, CA. Monitoring Of Active Matrix Metalloproteinase- Using. Sung Jae Choi, Young Ho Seo, Young Ho Lee, Jong Dae Ji, Gwan Gyu Song, Aeju Lee and Jae-Hoon Kim, Korea University Medical Center, Seoul, South Korea, Korea University Medical center, Seoul, South Korea, Korea Univ College of Med, Seoul, South Korea 4. Tumor Necrosis Factor Alpha Induces Anti-Citrullinated Protein Antibodies and Arthritis In Part Through Peptidyl Arginine Deiminase 4. Miriam A. Shelef, Jeremy Sokolove, Catriona Wagner, Eric Sackmann 4, Thomas Warner 4, David Beebe 4, William H. Robinson 5 and Anna Huttenlocher, Univ of Wisconsin Schl of Med, Madison, WI, VA Palo Alto Health Care System and Stanford University, Palo Alto, CA, VA Palo Alto Heatlh Care System and Stanford University, Palo Alto, CA, 4 University of Wisconsin, Madison, WI, 5 Stanford University, Palo Alto, CA 5. COVA: A Novel, Bispecific Tumor-Necrosis-Factor-Alpha / Interleukin-7A (TNF/IL-7A) Inhibitor With Excellent Pharmacokinetic Properties In Mice and Cynomolgus Monkeys. Mathias Locher, Dragan Grabulovski, Isabella Attinger-Toller, Susann Koenig-Friedrich, Ulrike von der Bey and Julian Bertschinger, Covagen AG, Schlieren, Switzerland 6. Involvement Of Suppressor Of Cytokine Signaling In Anti- Arthritic Effect Induced By Anti-IL-6 Receptor Antibody. Miho Suzuki, Hiroto Yoshida, Keisuke Tanaka, Isao Matsumoto, Takayuki Sumida and Yoshihiro Matsumoto, Chugai Pharmaceutical Co., Ltd., Gotemba, Japan, University of Tsukuba, Tsukuba, Japan 7. The Anti-Proliferative Function of RSK in Synovial Fibroblasts Protects Against TNF-á-Induced Joint Destruction in Inflammatory Arthritis. Anja Derer, Christina Boehm, Bettina Groetsch, Michael Stock, Kirsten Neubert, Sybille Boehm, Bettina Sehnert, Georg Schett, Axel J. Hueber and Jean-Pierre David, University of Erlangen-Nuremberg, Erlangen, Germany, University Medical Center Hamburg-Eppendorf, Hamburg, Germany 8. FMS-Like Tyrosine Kinase Ligand -Dependent CD0+DC Are Crucial For The Initiation Of Collagen-Induced Arthritis. Maria Ines Ramos, Samuel Garcia, Saïda Aarrass, Boy Helder, Kris A. Reedquist, Paul-Peter Tak and Maria C. Lebre, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands 9. Alleviation Of Collagen-Induced Arthritis By Multifunctional Nanoparticle Containing Methotrexate. You-Jung Ha, Sun-Mi Lee, Ji-Hee Lim, Hyung-Joon Kim, Sang-Won Lee, Soo Kon Lee, Kyung-Hwa Yoo and Yong- Beom Park, Yonsei University College of Medicine, Seoul, South Korea, Yonsei University, Seoul, South Korea 0. Specific Angiotensin Type II Receptor Stimulation Attenuates Collagen-Induced Arthritis Via Enhancement Of FoxP Regulatory T Cells. Bettina Sehnert, Veronica Valero-Esquitino, Georg Schett, Ulrika Muscha Steckelings and Reinhard E. Voll, University Hospital Freiburg, Freiburg, Germany, Medical Faculty Berlin, Berlin, Germany, University of Erlangen-Nuremberg, Erlangen, Germany. The Actin-Crosslinking Protein Lasp- Regulates Synovial Fibroblast Migration and Cartilage Destruction In Arthritis. Denise Beckmann, Jan Hillen, Marianne Heitzmann, Catherine S. Chew, Stefan Butz, Dietmar Vestweber, Hermann Pavenstädt, Thomas Pap 4 and Adelheid Korb- Pap, University Hospital Muenster, Muenster, Germany, Medical College of Georgia, Augusta, GA, Max Planck Institute of Molecular Biomedicine, Muenster, Germany, 4 University Hospital Münster, Münster, Germany. Neutralization of Angiopoietin- Enhances the Efficacy of Anti-Tumor Necrosis Factor-Alpha Treatment in a Mouse Model of Rheumatoid Arthritis by Decreasing Cellular Infiltration into the Joint and Protecting Bone. Brian Naiman, Sean Turman, William Iverson, Ronald Herbst, Tomas Mustelin and Jane Connor, MedImmune, LLC, Gaithersburg, MD. Porphyromonas Gingivalis peptidylarginine Deiminase Exacerbates Collagen-Induced Arthritis In C57BL/6 mice. Saba Alzabin, Anne-Marie Quirke, Elena B. Lugli, Muslima Choudhury, Peter J. Charles, Richard O. Williams and Patrick Venables, Epistem Ltd., Manchester, United Kingdom, Kennedy Institute of Rheumatology, Oxford, United Kingdom 4. Targeting Therapy Of Citrullinated Antigen-Specific B Cells Ameliorates Collagen-Induced Arthritis. Kazuya Michishita, Kimito Kawahata, Takeyuki Kanzaki, Lisa Akahira, Toshiki Eri and Kazuhiko Yamamoto, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan, Yamanashi Prefectural Central Hospital, Yamanashi, Japan 5. Fas Signaling In Macrophages Promotes Chronicity In K/ BxN Serum Transfer Induced Arthritis. Qi Quan Huang, Robert Birkett, Renee E. Koessler, Carla M. Cuda, J.-P. Jin 4, Harris R. Perlman and Richard M. Pope 5, Northwestern University, Chicago, IL, Northwestern University Medical School, Chicago, IL, Northwestern University Feinberg School of Medicine, Chicago, IL, 4 Wayne State University, Detroit, MI, 5 Northwestern Univ Med School, Chicago, IL 6. Articular Inflammation Is Protected By Fat- During The Acute Phase Of Arthritis In Mice. Sang-Il Lee, Yun-Hong Cheon, Ji-Min Kim and Won Seok Lee, Gyeongsang National University School of Medicine, Jinju, South Korea, Division of Rheumatology, Department of Internal Medicine, Keimyung University School of Medicine, Daegu, South Korea, Department of Internal Medicine, Chonbuk National University Medical School and Research Institute of Clinical Medicine, Jeonju, South Korea 0 Program Book 5

318 ACR POSTER SESSION C Rheumatoid Arthritis - Clinical Aspects III: Outcome Measures, Socioeconomy, Screening, Biomarkers in Rheumatoid Arthritis 7. Assessment Of Wage and Salary Growth In Patients With Rheumatoid Arthritis (RA). Martin J. Bergman, Gourab De, Arijit Ganguli, James Signorovitch 4 and Yanjun Bao 5, Taylor Hospital, Ridley Park, PA, Analysis Group, Inc., New York, NY, AbbVie, Inc., North Chicago, IL, 4 Analysis Group, Inc., Boston, MA, 5 AbbVie Inc., North Chicago, IL 8. Comparison Of The Long-Term Outcome For Rheumatoid Arthritis Patients With persistent Moderate Disease Activity Or Disease Remission During The First Year After Diagnosis: Data From The Espoir Cohort. Bernard Combe, Isabelle Logeart, M. Belkacemi, S Dadoun 4, Jean-Pierre Daurès 5 and Maxime Dougados 6, Lapeyronie Hospital, Montpellier I university, Montpellier, France, Pfizer, Paris, France, CHRU Montpellier, Montpellier, France, 4 Paris-Pitié Salpêtrière University Hospital, Paris, France, 5 CHU, Nimes, France, 6 Rheumatology B Department, Paris-Descartes University, Cochin Hospital, Paris, France 9. Validation Of a Patient Reported Experience Measure In Patients With Rheumatoid Arthritis. Marwan Bukhari, Peter Jones, Ifeanyi Sargeant, Maureen Cox 4, Alison Elliott 5, Suzanne Bullock 6, Anne O Brien and Ailsa Bosworth 7, Royal Lancaster Infirmary, Lancaster, United Kingdom, Keele University, Keele, United Kingdom, IS medical communications, Stafford, United Kingdom, 4 Nuffield Orthopaedic centre, Oxford, United Kingdom, 5 Roche Pharmaceuticals, Welwyn Garden City, United Kingdom, 6 Lancaster University, Lancaster, United Kingdom, 7 National Rheumatoid Arthritis Society, Maidenhead, United Kingdom 40. Correlative Analysis Of Swollen Joints Between Clinical Examination and Musculoskeletal Ultrasound For Rheumatoid Arthritis. Kenta Misaki, Takashi Nakazawa, Shunichi Fujita, Hirotaka Yamada and Toshihiko Yokota, Kurashiki Central Hospital, Kurashiki, Japan, Osaka Saiseikai Nakatsu Hospital, Osaka, Japan 4. Assessing Significant Flares In Rheumatoid Arthritis: Validity Of The Outcome Measures In Rheumatology Preliminary Flare Questions In The Canadian Early Arthritis Cohort. Susan J. Bartlett, Clifton O. Bingham III, Ernest Choy, Juan Xiong, Gilles Boire 4, Boulos Haraoui 5, Janet E. Pope 6, J. Carter Thorne 7, Carol A. Hitchon 8, Diane Tin 7, Edward C. Keystone 9 and Vivian P. Bykerk 9, Johns Hopkins University, Baltimore, MD, Cardiff University, Institute of Infection and Immunity, Cardiff, United Kingdom, Mount Sinai Hospital, University of Toronto, Toronto, ON, 4 Centre Hospitalier Universitaire de Sherbrooke, Université de Sherbrooke, Sherbrooke, QC, 5 Centre Hospitalier de l Université de Montréal, Montreal, QC, 6 St Joseph Health Care, London, ON, 7 Southlake Regional Health Centre, Newmarket, ON, 8 University of Manitoba, Winnipeg, MB, 9 Mount Sinai Hospital/University of Toronto, Toronto, ON 4. Patient Versus Physician Joint Counts In Rheumatoid Arthritis Utilizing a Unique Self-Joint Examination Tool. Daisy Bang, Yomei Shaw, Christine L. Amity, Kelly A. Reckley 4, Ilinca D. Metes and Marc C. Levesque, University of Pittsburgh, Pittsburgh, PA, University of Pittsburgh, Graduate School of Public Health, Pittsburgh, PA, Univ of Pittsburgh, Pittsburgh, PA, 4 University of Pittsburgh School of Medicine, Pittsburgh, PA 4. How Well Do The Three Generic Patient Reported Outcomes Measurement Information System Fatigue Instruments Perform In Rheumatoid Arthritis? Susan J. Bartlett, Ana-Maria Orbai, Trisha Duncan and Clifton O. Bingham III, Johns Hopkins University, Baltimore, MD 44. Diagnostic Accuracy Of Anti-Ccp Testing For Detecting Prevalent Rheumatoid Arthritis: Results From Screening a Population Based Cohort. Aase Haj Hensvold, Patrik KE Magnusson, Lena Israelsson, Monika Hansson 4, Vijay Joshua, Rikard Holmdahl 5, Per-Johan Jakobsson, Johan Askling 5, Vivianne Malmström 6, Lars Klareskog and Anca I Catrina, Rheumatology unit, Karolinska University Hospital, Karolinska Institut, Stockholm, Sweden, Swedish Twin Registry Karolinska Institutet, Stockholm, Sweden, Rheumatology unit, Karolinska University Hospital, Karolinska Institute, Stockholm, Sweden, 4 Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden, 5 Karolinska Institutet, Stockholm, Sweden, 6 Rheumatology unit, Karolinska University Hospital, Karolinska Institutet, STockholm, Sweden, Stockholm, Sweden 45. Predictive Validity Of Low Disease Activity Using Patient Reported Measures On Long-Term Outcomes In Early Rheumatoid Arthritis- Results From Study Of New Onset Rheumatoid Arthritis and Ontario Best Practices Initiative. Pooneh Akhavan, Binu Jacob, Paul R. Fortin, George A. Tomlinson 4 and Claire Bombardier 5, Mount Sinai Hospital/ University of Toronto, Toronto, ON, University of Toronto, Toronto, ON, University of Laval, Quebec, QC, 4 Toronto General Hospital, Toronto, ON, 5 University Health Network, Toronto, ON 46. Patients Assessment of the Disease Greatly Influences the Determination of Disease Activity and Remission in Rheumatoid Arthritis. Kenrin Shi, Kenji Miki, Masao Yukioka, Kosuke Ebina, Shoichi Kaneshiro and Hideki Yoshikawa, Yukioka Hospital, Osaka, Japan, Amagasaki Central Hospital, Amagasaki, Japan, Osaka University Graduate School of Medicine, Suita, Japan 47. Response To a Sleep Query On The Multi-Dimensional Health Assessment Questionnaire (MDHAQ) Is Related To Levels Of Disease Activity. Martin J. Bergman, Sapna Sangani, Isabel Castrejón and Theodore Pincus, Drexel University College of Medicine, Philadelphia, PA, Mercy Catholic Medical Center, Lansdowne, PA, NYU Hospital for Joint Diseases and New York University School of Medicine, New York, NY 6 0 Program Book

319 ACR POSTER SESSION C 48. Difference Between The Two Versions Of Disease Activity Score Based On C-Reactive Protein and Erythrocyte Sedimentation Rate. Pinar Cetin, Dilek Solmaz, Hacer Gulluoglu, Ismail Sari, Merih Birlik, Servet Akar, Fatos Onen and Nurullah Akkoc, Dokuz Eylul University School of Medicine, Izmir, Turkey, Dokuz Eylul University School of Medicine, Ýzmir, Turkey, Dokuz Eylul University School of Medicine, izmir, Turkey 49. What Proportion Of Patients With Rheumatoid Arthritis Fail To Achieve Remission Based On The Patient Global? An Analysis From The Prospective, Observational Biologic Treatment Registry Across Canada. Andrew Chow, Philip Baer, William G. Bensen, Isabelle Fortin 4, Majed M. Khraishi 5, Dalton E. Sholter 6, May Shawi 7, Allen J. Lehman 7, Susan M. Otawa 7, Emmanouil Rampakakis 8 and John S. Sampalis 8, Credit Valley Rheumatology, Mississauga, ON, Rheumatology, Scarborough, ON, St. Joseph s Hospital and McMaster University, Hamilton, ON, 4 Centre de Rhumatologie de l Est du Québec, Rimouski, QC, 5 MD, Memorial University of Newfoundland, Nexus Clinical Research, St Johns, NF, 6 Rheumatology Associates, Edmonton, AB, 7 Janssen Canada Inc, Toronto, ON, 8 JSS Medical Research, St-Laurent, QC 50. What Is The Real World Relationship Between Patient- Reported Pain Or Patient Global Assessment and Disease Activity Indices In Rheumatoid Arthritis? An Analysis From The Prospective, Observational, Biologic Treatment Registry Across Canada. Regan Arendse, Michael Starr, Proton Rahman, John T. Kelsall 4, Milton F. Baker 5, William Bensen 6, J. Carter Thorne 7, Philip Baer 8, Denis Choquette 9, Isabelle Fortin 0, Emmanouil Rampakakis, John S. Sampalis, Susan M. Otawa, May Shawi, Francois Nantel and Allen J. Lehman, University of Saskatchewan, Saskatoon, SK, Montreal General Hospital, Montreal, QC, Memorial University, St. Johns, NF, 4 Mary Pack Arthritis Centre, Vancouver, Vancouver, BC, 5 University of Victoria, Victoria, BC, 6 St. Joseph s Hospital and McMaster University, Hamilton, ON, 7 Southlake Regional Health Centre, Newmarket, ON, 8 Rheumatology, Scarborough, ON, 9 Institut de Rhumatologie de Montréal, Montreal, QC, 0 Centre de Rhumatologie de l Est du Québec, Rimouski, QC, JSS Medical Research, St-Laurent, QC, Janssen Canada Inc, Toronto, ON 5. Variability in the Classification of Remission Among Disease Activity Indices and Their Correlation: An Analysis From a Prospective, Observational Registry. William G. Bensen, Algis V Jovaisas, J. Carter Thorne, Philip Baer 4, Majed M. Khraishi 5, Sanjay Dixit 6, Denis Choquette 7, Michael Starr 8, Isabelle Fortin 9, Dalton E. Sholter 0, Emmanouil Rampakakis, John S. Sampalis, Francois Nantel, Allen J. Lehman, May Shawi and Susan M. Otawa, St. Joseph s Hospital and McMaster University, Hamilton, ON, University of Ottawa, Ottawa, ON, Southlake Regional Health Centre, Newmarket, ON, 4 Rheumatology, Scarborough, ON, 5 MD, Memorial University of Newfoundland, Nexus Clinical Research, St Johns, NF, 6 McMaster University, Burlington, ON, 7 Institut de Rhumatologie de Montréal, Montreal, QC, 8 Montreal General Hospital, Montreal, QC, 9 Centre de Rhumatologie de l Est du Québec, Rimouski, QC, 0 Rheumatology Associates, Edmonton, AB, JSS Medical Research, St- Laurent, QC, Janssen Canada Inc, Toronto, ON 5. Assessment Of Rheumatoid Arthritis Disease Activity By Patients and Physicians: Do Physicians Detect Improvement Before The Patient Does? William G. Bensen, J. Carter Thorne, Philip Baer, Andrew Chow 4, Regan Arendse 5, Isabelle Fortin 6, Milton F. Baker 7, Boulos Haraoui 8, Algis Jovaisas 9, John S. Sampalis 0, Emmanouil Rampakakis 0, Allen J. Lehman, Francois Nantel, May Shawi and Susan M. Otawa, St. Joseph s Hospital and McMaster University, Hamilton, ON, Southlake Regional Health Centre, Newmarket, ON, Rheumatology, Scarborough, ON, 4 Credit Valley Rheumatology, Mississauga, ON, 5 University of Saskatchewan, Saskatoon, SK, 6 Centre de Rhumatologie de l Est du Québec, Rimouski, QC, 7 University of Victoria, Victoria, BC, 8 Institut de Rhumatologie de Montréal, Montreal, QC, 9 University of Ottawa, Ottawa, ON, 0 JSS Medical Research, St-Laurent, QC, Janssen Canada Inc, Toronto, ON 5. How Often Are Core Variables Reported To Calculate Common Disease Activity Scores Measured In Routine Care Of Rheumatoid Arthritis Patients? Bindee Kuriya, Jessica Widdifield, Claire Bombardier, Xiuing Li 4, Binu Jacob, Pooneh Akhavan 5, J. Carter Thorne 6, Janet E. Pope 7, Edward C. Keystone, William G. Bensen 8 and Vandana Ahluwalia 9, Mount Sinai Hospital, University of Toronto, Toronto, ON, Institute for Clinical Evaluative Sciences, Toronto, ON, University of Toronto, Toronto, ON, 4 University of Toronto, University Health Network, Toronto, ON, 5 Mount Sinai Hospital/University of Toronto, Toronto, ON, 6 Southlake Regional Health Centre, Newmarket, ON, 7 St Joseph Health Care, London, ON, 8 St. Joseph s Hospital and McMaster University, Hamilton, ON, 9 William Osler Health Center, Mississauga, ON 54. Complementary and Alternative Medicine in Rheumatoid Arthritis - Persistently High Use Over the Past Decade Despite Advent of Biologics. Dana DiRenzo, Haiyan Sun, H. Lester Kirchner and Eric D. Newman, University of Maryland Medical Center, Baltimore, MD, Geisinger Health System, Danville, PA, Geisinger Medical Center, Danville, PA 55. Threshold Analysis of Patient Reported Morning Stiffness Where Delayed-Release (DR) Prednisone Was Compared to, and Replaced, Immediate Release Prednisone in Rheumatoid Arthritis (RA) Patients Receiving Conventional Disease-Modifying Antirheumatic Drugs (DMARDs) Over Year. Frank Buttgereit, Jeffery Kent, Robert Holt, Amy Grahn, Patricia Rice, Rieke Alten 4 and Yusuf Yazici 5, Charité - Universitätsmedizin Berlin, Berlin, Germany, Horizon Pharma, Inc, Deerfield, IL, CliniRx Research, Naperville, IL, 4 University of Berlin, Berlin, Germany, 5 New York University, New York, NY 56. Analysis of the Factors That Contribute to the Differences Between DAS8-ESR and DAS8-CRP. Toshihiro Matsui, Hirotaka Tsuno, Jinju Nishino, Yoshiaki Kuga, Atsushi Hashimoto and Shigeto Tohma 4, National Hospital Organization Sagamihara Hospital, Kanagawa, Japan, Nishino Clinic, Orthopedics and Rheumatology, Tokyo, Japan, Wakaba Hospital, Saitama, Japan, 4 Sagamihara Hospital, National Hospital Organization, Sagamihara, Japan 0 Program Book 7

320 ACR POSTER SESSION C 57. Symptom Complexes At The Beginning Of Rheumatoid Arthritis: A Qualitative Exploration In At Risk Individuals and In New Patients Prior To Diagnosis. Rebecca J Stack, Lilian H.D. van Tuyl, Maurits Sloots, Lotte A. van de Stadt, Wijnanda Hoogland, Bertha Matt, Christian D Mallen 4, Rumandeep Tiwana, Karim Raza and Dirkjan van Schaardenburg, University of Birmingham, Birmingham, United Kingdom, VU University Medical Center, Amsterdam, Netherlands, Jan van Breemen Research Institute Reade, Amsterdam, Netherlands, 4 University of Keele, Keele, United Kingdom 58. Less Than 5% Of Ethnic Minority Rheumatoid Arthritis Patients Meet Inclusion Criteria For Randomized Controlled Clinical Trials. Gail S. Kerr, Yusuf Yazici, Christopher Swearingen, Chunqiao Luo, Yvonne R. S. Sherrer 4, Edward L. Treadwell 5, Angelia D. Mosley-Williams 6, Luis R. Espinoza 7, Rodolfo Perez Alamino 8, Sharon Dowell 9, Ignacio Garcia-Vallardes 0, Theresa Lawrence-Ford, Adrian Godoy 9, Akgun Ince and Cindy Flower, Washington DC VAMC, Georgetown and Howard University, Washington, DC, New York University Hospital for Joint Diseases, New York, NY, University of Arkansas for Medical Sciences, Little Rock, AR, 4 Centre Rheum Immunol Arthritis, Fort Lauderdale, FL, 5 East Carolina University, Greenville, NC, 6 John Dingell VAMC, Detroit, MI, 7 LSU Medical Center, New Orleans, LA, 8 Lousiana State University and LSU Medical Center, New Orleans, LA, 9 Howard University, Washington, DC, 0 Guadalajara, Gaudalajara, Mexico, North Georgia Rheumatology Group, PC, Lawrenceville, GA, Saint Louis University, St. Louis, MO, University of the West Indies, Bridgetown, Barbados 59. Does a Ratingen Score Of At Disease Onset Define RA In ACR/EULAR 00 Criteria Negative Patients? Ruediger Mueller, Toni Kaegi, Sarah Haile and Johannes von Kempis, Kantonsspital St. Gallen, St. Gallen, Switzerland 60. Smoking and Antibodies To Cyclic Citrullinated Peptides Predict Persistently High Levels Of Survivin In Early Rheumatoid Arthritis. Bjorn Svensson, Ingiäld Hafström, Malin Erlandsson, Kristina Forslind 4 and Maria Bokarewa 5, Lund University, Lund, Sweden, Karolinska University Hospital, Stockholm, Sweden, Göteborgs University, Göteborg, Sweden, 4 Section of Rheumatology, Department of Medicine, Helsingborg General Hospital, Helsingborg, Sweden, 5 University of Gothenburg, Gothenburg, Sweden 6. Motivations For Inadequate Persistence With Disease Modifying Anti-Rheumatic Drugs In Early Rheumatoid Arthritis: The Patient s Perspective. Virginia Pascual-Ramos and Irazú Contreras-Yáñez, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico 6. Antibody To Malondialdehyde-Acetaldehyde Adducts (MAA) Is a Biomarker Of Inflammation and Is Correlated With The Disease Activity In Rheumatoid Arthritis. Kathleen Young, Dathe Benissan-Messan, Michael J. Duryee, Daniel Anderson, Liron Caplan, Lisa A. Davis 4, Harlan Sayles, Carlos D. Hunter, Lynell W. Klassen 5, James R. O Dell, Ted R. Mikuls 6 and Geoffrey M Thiele 5, Univ of Nebraska Med Ctr, Omaha, NE, University of Nebraska Medical Center, Omaha, NE, Denver Veterans Affairs Medical Center, Denver, CO, 4 Univ. of Colorado Sch. of Medicine, Aurora, CO, 5 Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE, 6 Omaha VA and University of Nebraska Medical Center, Omaha, NE 6. ADAMTS5 Is a Biomarker For The Efficacy Prediction Of Tocilizumab In Rheumatoid Arthritis. Kensei Tsuzaka, Masako Takao and Jiro Nishida, Ichikawa General Hospital,TDC, Ichikawa, Chiba, Japan 64. An Assay Panel Combining Anticitrullinated Peptide Autoantibodies and Rheumatoid Factor Isotypes Has High Yield In The Diagnosis Of Rheumatoid Arthritis. Nirupa J. Patel, Ignacio Garcia-Valladares, Derren Barken, Luis R. Espinoza 4, Heena Sheth 5 and Thierry Dervieux, LSU Health Sciences Ctr, New Orleans, LA, Guadalajara, Guadalajara, Mexico, Exagen Diagnostics, Vista, CA, 4 LSU Medical Center, New Orleans, LA, 5 University of Pittsburgh, Pittsburgh, PA 65. Switching From Immediate Release (IR) Prednisone To Delayed Release (DR) Prednisone Improves Patient Reported Outcomes In Rheumatoid Arthritis (RA) Patients On Conventional Disease-Modifying Antirheumatic Drugs (DMARDs). Rieke Alten, Robert Holt, Amy Grahn, Patricia Rice, Jeffery Kent, Frank Buttgereit 4 and Allan Gibofsky 5, University of Berlin, Berlin, Germany, Horizon Pharma, Inc, Deerfield, IL, CliniRx Research, Naperville, IL, 4 Charité - Universitätsmedizin Berlin, Berlin, Germany, 5 Hospital for Special Surgery, New York, NY 66. Research On Factors Influenced For Bone Metabolic Markers In Rheumatoid Arthritis Patients From Prospective Cohort Study. Masahiro Tada, Tatsuya Koike, Tadashi Okano, Yuko Sugioka, Kenji Mamoto, Kentaro Inui and Hiroaki Nakamura, Osaka City University Graduate School of Medicine, Osaka, Japan 67. The Diagnostic Accuracy Of Rheumatoid Factor Testing In Primary Care. Anne Miller, Alison L Nightingale, Cormac J Sammon, Tim Holt, Kamal R Mahtani, Neil McHugh 4, Corinne S de Vries and Raashid A. Luqmani, Nuffield Orthopaedic Centre, Oxford, United Kingdom, University of Bath, Bath, United Kingdom, University of Oxford, Oxford, United Kingdom, 4 Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom 68. Patient-Reported Outcome Measures For Rheumatoid Arthritis: Minimal Important Differences Review. Helen Kitchen, Brian Bekker Hansen, Linda Abetz, Lise Højbjerre and Martin Strandberg-Larsen, Adelphi Values Ltd, Cheshire, United Kingdom, Novo Nordisk A/S, Søborg, Denmark 8 0 Program Book

321 ACR POSTER SESSION C 69. Patient Reported Pain: A Predictor Of Outcomes In Rheumatoid Arthritis From The Consortium Of Rheumatology Researchers Of North America Registry. Dimitrios A. Pappas, Chitra K. Karki, Chin Lee, George W. Reed, Ping He 4 and Sarah Al Sawah, Columbia University, New York, NY, CORRONA, Inc., Southborough, MA, Eli Lilly and Company, Indianapolis, IN, 4 UMASS Medical School, Worcester, MA 70. US Guided Treat-To-Target Approach In Early RA: Implications For Uncoupling Of Disease Activity and Structural Damage. Yasser El Miedany, Maha El Gaafary, Sally Youssef and Annie Nasr, Medway Hospital, Gillingham, United Kingdom, Ain Shams University, Cairo, Egypt 7. Dietary Sodium Increases The Risk For Rheumatoid Arthritis Among Smokers Results From a Nested Case- Control Study. Björn Sundström, Ingegerd Johansson and Solbritt Rantapää Dahlqvist, Umeå University, Umeå, Sweden, Umeå Universitet, Umeå, Sweden, Umeå University Hospital, Umeå, Sweden 7. Patient Survey Regarding Utility Of The Health Assessment Questionnaire Reveals An Unrecognized Aspect Of Disease Activity In Rheumatoid Arthritis: Consequences Of Physical Activity. Kelly O Neill Young, Dana M. Symons, Andrew T. Lumpe and Cynthia S. Crowson, Rheumatoid Patient Foundation, Cocoa, FL, Seattle Pacific University, Seattle, WA, Mayo Clinic, Rochester, MN 7. Patient Survey Challenges Conventional Notions Regarding Symptoms and Experiences Of People Living With Rheumatoid Arthritis. Kelly O Neill Young, Cynthia S. Crowson and Dana M. Symons, Rheumatoid Patient Foundation, Cocoa, FL, Mayo Clinic, Rochester, MN 74. Assessment Of The Diagnostic Accuracy Of Different Strategies For Health Fair Case-Finding For Undiagnosed Inflammatory Arthritis. Kaylynn Aiona, Christopher C. Striebich, M. Kristen Demoruelle, Julia J. Rhiannon, Stuart M. Weisman 4, Marie L. Feser 4, Lezlie A. Derber 4, James H. Goddard 5, Stacey Brake 5, Jill Lysengen 6, Laura Rosseisen 6, John E. Hokanson, Anna E. Baron, Jill M. Norris, V. Michael Holers and Kevin D. Deane, Colorado School of Public Health, Aurora, CO, University of Colorado Denver, Aurora, CO, University of Colorado School of Medicine, Aurora, CO, 4 University of Colorado School of Medicine, Division of Rheumatology, Aurora, CO, 5 9Health Fair, Denver, CO, 6 Arthritis Foundation, Great West Region, Denver Office, Denver, CO 75. Responsiveness Of The Outcomes Measures In Rheumatology Clinical Trials Initiative s Preliminary Flare Questions To Detect Flares Within Patients In The Canadian Early Arthritis Cohort. Vivian P. Bykerk, Karen Visser, Ernest Choy, Clifton O. Bingham III 4, Daming Lin 5, Juan Xiong 5, Gilles Boire 6, Boulos Haraoui 7, Carol A. Hitchon 8, Janet E. Pope 9, J. Carter Thorne 0, Diane Tin 0, Edward C. Keystone 5, Susan J. Bartlett, - CATCH Investigators and - OMERACT Flare Working Group, Hospital for Special Surgery, Weill Cornell Medical College, New York, NY, Leiden University Medical Center, Leiden, Netherlands, Cardiff University, Institute of Infection and Immunity, Cardiff, United Kingdom, 4 Johns Hopkins University, Baltimore, MD, 5 Mount Sinai Hospital, University of Toronto, Toronto, ON, 6 Centre Hospitalier Universitaire de Sherbrooke, Université de Sherbrooke, Sherbrooke, QC, 7 Institut de Rhumatologie de Montréal, Montreal, QC, 8 University of Manitoba, Winnipeg, MB, 9 St Joseph Health Care, London, ON, 0 Southlake Regional Health Centre, Newmarket, ON, McGill University, Montreal, QC, Canadian Collaboration, Toronto, ON, International Collaboration, Baltimore, MD 76. Does Socioeconomic Status Affect Outcomes In Early Rheumatoid Arthritis? Data From An Inception Cohort. Grace Yang, Vivian P. Bykerk, J. Carter Thorne, Gilles Boire 4, Diane Tin, Carol A. Hitchon 5, Edward Keystone 6, Boulos Haraoui 7 and Janet E. Pope 8, Western University of Canada, London, ON, Mount Sinai Hospital/University of Toronto, Toronto, ON, Southlake Regional Health Centre, Newmarket, ON, 4 Centre Hospitalier Universitaire de Sherbrooke, Université de Sherbrooke, Sherbrooke, QC, 5 University of Manitoba, Winnipeg, MB, 6 University of Toronto, Toronto, ON, 7 Centre Hospitalier de l Université de Montréal, Montreal, QC, 8 St Joseph Health Care, London, ON 77. Midcarpal Joint Effusion Is As Common As Radiocarpal Joint Effusion In Swollen Wrists Of Patients With Rheumatoid Arthritis. Jae Ho Lee, Young Sun Suh, Jung Hee Koh, Seung Min Jung, Jennifer Lee, Ji Yeon Lee, Soo Young Lee, Seung-Ki Kwok, Ji Hyeon Ju, Kyung-Su Park, Dae Chul Jeong and Sung Hwan Park, The Catholic University of Korea, Seoul St. Mary s Hospital, Seoul, South Korea, The Catholic University of Korea, Seoul St. Mary s Hospital, Seoul, South Korea, The Catholic University of Korea, Incheon St. Mary s Hospital, Incheon, South Korea 78. Ordering Of Serologic Markers Of Rheumatoid Arthritis Among Primary Care and Subspecialty Providers: Under- Utilization Of Anti-Citrullinated Peptide Antibody Tests By Non-Rheumatologists. Emily H. Glynn, Mark H. Wener and Michael Astion, University of Washington, Seattle, WA, Seattle Children s Hospital, Seattle, WA 0 Program Book 9

322 ACR POSTER SESSION C 79. Assessment Of Global Disease Activity In Rheumatoid Arthritis By Patients and Physicians: Cultural Differences Among Countries In The Meteor Database. E. Gvozdenovic, R. Wolterbeek, C.F. Allaart, Claiton Brenol, Arvind Chopra, Maxime Dougados 4, Paul Emery 5, D. van der Heijde, T.W.J. Huizinga, Jonathan Kay 6, Emilio Martín Mola 7, Robert J. Moots 8, José A. P. Da Silva 9, Josef S. Smolen 0, Douglas J. Veale and R. Landewe, Leiden University Medical Center, Leiden, Netherlands, Universidade Federal do Rio Grande do Sul, Porto Alegre RS, Brazil, Center for Rheumatic Diseases, Pune, India, 4 Rheumatology B Department, Paris-Descartes University, Cochin Hospital, Paris, France, 5 Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, 6 UMass Memorial Medical Center and University of Massachusetts Medical School, Worcester, MA, 7 Rheumatology. La Paz Hospital. IdiPaz, Madrid, Spain, 8 University of Liverpool, Liverpool, United Kingdom, 9 Centro Hospitalar e Universitário de Coimbra Hospitais da Universidade de Coimbra, E.P.E., Coimbra, Portugal, 0 Medical University of Vienna, Vienna, Austria, St. Vincent s University Hospital, Dublin 4, Ireland, Academic Medical Center / University of Amsterdam, Amsterdam, Netherlands 80. Stiffness From The Perspective Of People Living With Rheumatoid Arthritis. Ana-Maria Orbai, Katherine Clegg- Smith, Susan J. Bartlett, Elaine De Leon 4, Michelle Jones and Clifton O. Bingham III, Johns Hopkins University, Baltimore, MD, Johns Hopkins University School of Public Health, Baltimore, MD, McGill University, Montreal, QC, 4 Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 8. An Analysis Of Highly Discordant Erythrocyte Sedimentation and C Reactive Protein Levels In Rheumatoid Arthritis. Micha Abeles, Manuel Gomez- Ramirez and Aryeh M. Abeles, University of Connecticut Health Center, Farmington, CT, Johns Hopkins University, Baltimore, MD 8. Performance Of The 00 ACR/EULAR Classification Criteria For Rheumatoid Arthritis In a Group Of Elderly Onset Patients. Pierluigi Macchioni, Giovanni Barausse, Luigi Boiardi, Giulia Pazzola, Roberto Bortolotti, Giovanna Restuccia, Maria Grazia Catanoso, Giuseppe Paolazzi and Carlo Salvarani 4, Arcispedale S Maria Nuova, IRCCS, Reggio Emilia, Italy, Ospedale di Trento, Trento, Italy, Ospedale Santa Chiara, Trento, Italy, 4 Arcispedale S Maria Nuova- IRCCS, Reggio Emilia, Italy 8. The Evolving Use Of Biologic Monotherapy In Rheumatoid Arthritis and Its Impact On Patient Outcomes. Laurent Chanroux, Katrina Johnson and Joan Casellas, The Research Partnership, London, United Kingdom 84. How Well Do Generic Patient Reported Outcomes Measurement Information System Instruments Capture Health Status In Rheumatoid Arthritis? Susan J. Bartlett, Ana-Maria Orbai, Trisha Duncan and Clifton O. Bingham III, Johns Hopkins University, Baltimore, MD 85. Correlation Of Individual Health Assessment Questionnaire (HAQ) Questions With Outcome Measures In Rheumatoid Arthritis: Implications For Instrument Reduction. J. Carter Thorne, Majed M. Khraishi, Boulos Haraoui, Jude F. Rodrigues 4, Algis Jovaisas 5, Denis Choquette, Sanjay Dixit 6, Dalton E. Sholter 7, Philip Baer 8, Maqbool K. Sheriff 9, Emmanouil Rampakakis 0, John S. Sampalis 0, Francois Nantel, Allen J. Lehman, May Shawi and Susan M. Otawa, Southlake Regional Health Centre, Newmarket, ON, MD, Memorial University of Newfoundland, Nexus Clinical Research, St Johns, NF, Institut de Rhumatologie de Montréal, Montreal, QC, 4 Rheumatology, Windsor, ON, 5 University of Ottawa, Ottawa, ON, 6 McMaster University, Burlington, ON, 7 Rheumatology Associates, Edmonton, AB, 8 Rheumatology, Scarborough, ON, 9 Nanaimo Regional General Hospital, Nanaimo, BC, 0 JSS Medical Research, St-Laurent, QC, Janssen Canada Inc, Toronto, ON 86. Reliability and Smallest Detectable Difference Of The Patient Global Assessment, Pain and Fatigue In Rheumatoid Arthritis Patients. Paul Studenic, Josef S. Smolen and Daniel Aletaha, Medical University Vienna, Vienna, Austria, Medical University of Vienna, Vienna, Austria 87. What Is The Internal Consistency Of The Disease Activity Score (DAS)-8 In Rheumatoid Arthritis Patients Treated In a Real World Setting? Andrew Chow, J. Carter Thorne, Regan Arendse, Dalton E. Sholter 4, Denis Choquette 5, Isabelle Fortin 6, Boulos Haraoui 5, Emmanouil Rampakakis 7, John S. Sampalis 7, Francois Nantel 8, Allen J. Lehman 8, May Shawi 8 and Susan M. Otawa 8, Credit Valley Rheumatology, Mississauga, ON, Southlake Regional Health Centre, Newmarket, ON, University of Saskatchewan, Saskatoon, SK, 4 Rheumatology Associates, Edmonton, AB, 5 Institut de Rhumatologie de Montréal, Montreal, QC, 6 Centre de Rhumatologie de l Est du Québec, Rimouski, QC, 7 JSS Medical Research, St-Laurent, QC, 8 Janssen Canada Inc, Toronto, ON 88. Novel Biomarkers From Peripheral Blood Mononuclear Cells Indicate Disease Activity In Rheumatoid Arthritis Patients. Jason Ptacek, Rachael Hawtin, Brent Louie, Erik Evensen, James Cordeiro, Barbara Mittleman, Michelle Atallah, Alessandra Cesano, Clifton O. Bingham III, Stacey Cofield, Jeffrey R. Curtis 4, Maria I. Danila, Richard A. Furie 5, Mark C. Genovese 6, Marc C. Levesque 7, Larry W. Moreland 7, Peter A. Nigrovic 8, James R. O Dell 9, William H. Robinson 6, Nancy A. Shadick 8, E. William St Clair 0, Christopher C. Striebich, Geoffrey M Thiele 9, Peter K. Gregersen 5 and S. Louis Bridges Jr., Nodality, Inc., South San Francisco, CA, Johns Hopkins University, Baltimore, MD, University of Alabama at Birmingham, Birmingham, AL, 4 University of Alabama at Birmingham, School of Public Health, Birmingham, AL, 5 The Feinstein Institute for Medical Research and North Shore-Long Island Jewish Health System, Lake Success, NY, 6 Stanford University, Palo Alto, CA, 7 University of Pittsburgh, Pittsburgh, PA, 8 Brigham and Women s Hospital/Harvard University, Cambridge, MA, 9 Omaha VA and the University of Nebraska Medical Center, Omaha, NE, 0 Duke Unversity Medical Center, Durham, NC, University of Colorado Denver, Aurora, CO 0 0 Program Book

323 ACR POSTER SESSION C 89. Correlation Of Anti-Citrullinated Protein and Anti- Carp Antibodies With Disease Duration and Activity In Rheumatoid Arthritis. Michael Mahler, Gabriella Lakos, Tyler Webb, Alvin Yee, Leendert A. Trouw and Pier- Luigi Meroni, INOVA Diagnostics, San Diego, CA, Leiden University Medical Center, Leiden, Netherlands, University of Milan, Milano, Italy 90. Global Metabolite Profiling Of Synovial Fluids From Different Forms Of Inflammatory Arthritis For The Identification Of Putative Biomarker In Rheumatoid Arthritis. Jiwon Hwang, Joong Kyong Ahn, Jaejoon Lee, Inyoung Kim, Seulkee Lee, Chan Hong Jeon 4, Eun- Mi Koh and Hoon-Suk Cha, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea, Kangbuk Samsung hospital, Sungkyunkwan University School of Medicine, Seoul, South Korea, Sungkyunkwan University School of Medicine, Samsung Medical Center, Seoul, South Korea, 4 Soonchunhyang University College of Medicine, Bucheon, South Korea 9. Only Rheumatoid Factor-Positive Subset Of Anti- Citrullinated Peptide/Protein Antibody-Negative Rheumatoid Arthritis Seroconverts To Anti-Citrullinated Peptide/Protein Antibody-Positive. Ryosuke Hiwa, Koichiro Ohmura, Shuichiro Nakabo, Chikashi Terao, Ran Nakashima, Yoshitaka Imura, Naoichiro Yukawa, Hajime Yoshifuji, Motomu Hashimoto, Moritoshi Furu, Hiromu Ito, Takao Fujii and Tsuneyo Mimori, Graduate School of Medicine, Kyoto University, Kyoto, Japan 9. Factors Affecting The Discrepancy Between Physician and Patient Global Assessment Of Disease Activity In Early and Established Rheumatoid Arthritis Patients- Results From The Ontario Best Practices Initiative. Pooneh Akhavan, Binu Jacob, Edward C. Keystone, Xiuying Li 4, J. Carter Thorne 5 and Claire Bombardier, Early Rheumatoid Arthritis Program, Mount Sinai Hospital and University of Toronto, Toronto, ON, University of Toronto, Toronto, ON, Rebecca MacDonald Centre for Arthritis and Autoimmune Disease, Mount Sinai Hospital, Toronto, ON, 4 University Health Network, Toronto, ON, 5 Southlake Regional Health Centre, Newmarket, ON 9. Anti-Citrullinated Peptide/Protein Antibody Specificities and Subclinical Synovitis In Palindromic Rheumatism: Towards a Better Understanding Of The Relationship With Rheumatoid Arthritis. Sonia Cabrera-Villalba, Julio Ramirez, Georgina Salvador, Virginia Ruiz-Esquide, M. Victoria Hernández, José Inciarte, Celia Saura, J. D. Cañete and Raimon Sanmarti, Hospital Clinic, Barcelona, Spain, Hospital Mutua de Terrassa. Barcelona, Barcelona, Spain 94. The Role Of Patient Global Disease Activity Score In The Definition Of American College Of Rheumatology/ European League Against Rheumatism Remission In Very Early Rheumatoid Arthritis From The Norwegian Very Early Arthritis Clinic. Maria Dahl Mjaavatten, Anne Julsrud Haugen, Halvor Nygaard, Olav Bjørneboe 4, Patrik Stolt 5, Cathrine Thunem 6 and Tore Kristian Kvien, Diakonhjemmet Hospital, Oslo, Norway, Østfold Hospital Trust, Fredrikstad, Norway, Revmatismesykehuset Lillehammer, Lillehammer, Norway, 4 Martina Hansens Hospital, Gjettum, Norway, 5 Innlandet Hospital Trust, Brumunddal, Norway, 6 Betanien Hospital, Skien, Norway 95. Mortality In Early Rheumatoid Arthritis Comparing Lithuania and Finland. A -Year Follow Up. Tuulikki Sokka, Sigita Stropuviene, Hannu Kautiainen, Tuomas Rannio 4 and Jolanta Dadoniene, Jyvaskyla Central Hospital, Jyvaskyla, Finland, Vilnius Univ, Vilnius, Lithuania, Unit of Primary Health Care, Helsinki University Central Hospital, Helsinki, Finland, 4 Jyvaskyla Central Hospital, Jyväskylä, Finland 96. Are SDAI50 and DAS8 Response Measures Comparable In Early Rheumatoid Arthritis Patients? Mohammed Omair, Edward C. Keystone, Juan Xiong, Gilles Boire, Janet E. Pope 4, J. Carter Thorne 5, Carol A. Hitchon 6, Boulos Haraoui 7, Diane Tin 5, Deborah Weber, Vivian P. Bykerk and Pooneh Akhavan, Mount Sinai Hospital/University of Toronto, Toronto, ON, Mount Sinai Hospital, Toronto, ON, Centre Hospitalier Universitaire de Sherbrooke, Université de Sherbrooke, Sherbrooke, QC, 4 St Joseph Health Care, London, ON, 5 Southlake Regional Health Centre, Newmarket, ON, 6 University of Manitoba, Winnipeg, MB, 7 Institut de Rhumatologie de Montréal, Montreal, QC 97. Evaluating Depression Questionnaires In German Rheumatoid Arthritis Patients Preliminary Results From a Validation Study. Matthias Englbrecht, Rieke Alten, Martin Aringer, Christoph G. Baerwald 4, Harald Burkhardt 5, Nancy Eby 6, Gerhard Fliedner 7, Bettina Gauger 8, Ulf Henkemeier 9, Michael Hofmann 0, Stefan Kleinert, Christian Kneitz, Christoph Pohl, Georg Schett, Marc Schmalzing, Anne-Kathrin Tausche 4, Hans Peter Tony 5 and Joerg Wendler 6, University of Erlangen-Nuremberg, Erlangen, Germany, University of Berlin, Berlin, Germany, University Clinical Center Technical University of Dresden, Dresden, Germany, 4 University Hospital Leipzig, Leipzig, Germany, 5 CIRI /Div. of Rheumatology, Goethe-University, Frankfurt/Main, Germany, 6 AMS-Advanced Medical Services, Mannheim, Germany, 7 Praxis Osnabrück, Germany, Germany, Osnabrück, Germany, 8 Roche Pharma AG, Grenzach, Germany, 9 University Hospital Frankfurt, Frankfurt, Germany, 0 Chugai Pharma, Frankfurt, Germany, University Hospital Würzburg, Würzburg, Germany, Hospital Südstadt, Rostock, Germany, Schlosspark Klinik, Berlin, Germany, 4 Universitätsklinikum Carl Gustav Carus an der Technischen Universität Dresden, Dresden, Germany, 5 University of Würzburg, Würzburg, Germany, 6 Schwerpunktpraxis Rheumatologie, Erlangen, Germany 98. Upper-Half Serum IgA (0+ TU/ml) and IgM (0+ IU/ml) Levels Significantly Predicted The Long-Term (mean yrs) Onset Of Rheumatoid Arthritis When Combined, But Neither test Individually In Their Respective Full Ranges Of Values. Alfonse T. Masi, Azeem A. Rehman, Jean C. Aldag, Huaping Wang, Ned J. Goertzen and Marius C. Teodorescu, University of Illinois College of Medicine at Peoria, Peoria, IL, TheraTest Laboratories Inc, Lombard, IL 0 Program Book

324 ACR POSTER SESSION C 99. Disease Activity Scoring: Comparing Patient and Physician Global Assessment Of Disease Activity In Rhumatoid Arthritis Patients Starting a First Biologic Agent. Boulos Haraoui, Louis Bessette, Diane Sauvageau, Jean Pierre Pelletier, Jean-Pierre Raynauld, Edith Villeneuve, Louis Coupal and Denis Choquette, Institut de Rhumatologie de Montréal, Montreal, QC, Centre Hospitalier Universitaire de Québec, pavillon CHUL, Sainte-Foy, QC 00. Rheumatologists Who Are Consistently Using An Objective Outcome Instrument Do Not Treat To Target In a Real World Setting. Gary Craig, Howard Kenney, Keith Knapp and Sergio Schwartzman, Arthritis Northwest PLLC., Spokane, WA, T JointMan LLC., Spokane, WA, Hosp for Special Surgery, New York, NY 0. T Cell Proliferative Response To Type II Collagen In Patients With Rheumatoid Arthritis. Nida Saleem, Tahir Aziz Ahmed, Javaid Mahmood Malik, Mushtaq Ahmed 4 and Mukarram Bashir 5, Armed Forces Institute Of Pathology, RAWALPINDI, Pakistan, Armed Forces Institute of Pathology, Rawalpindi, Pakistan, Rahmat Noor Clinic and Arthritis Research Centre, Rawalpindi, Pakistan, 4 Military Hospital Rawalpindi, rawalpindi, Pakistan, 5 Armed Forces Institute Of Pathology, rawalpindi, Pakistan 0. Anti-Carbamylated Protein Antibody In Japanese Patients With Rheumatoid Arthritis. Shunichi Shiozawa, Leendert A. Trouw and Kazuko Shiozawa, Kyushu University Beppu Hospital, Beppu, Japan, Leiden University Medical Center, Leiden, Netherlands, Konan Kakogawa Hospital, Kakogawa, Japan 0. Clinical Characteristics Of Rheumatoid Factor-Positive Or Negative Subsets Of Anti-Citrullinated Peptide/Protein Antibody-Negative Rheumatoid Arthritis. Ryosuke Hiwa, Koichiro Ohmura, Noriyuki Yamakawa, Moritoshi Furu, Chikashi Terao, Ran Nakashima, Yoshitaka Imura, Naoichiro Yukawa, Hajime Yoshifuji, Motomu Hashimoto, Hiromu Ito, Takao Fujii and Tsuneyo Mimori, Graduate School of Medicine, Kyoto University, Kyoto, Japan 04. Follow-Up Of Patients With Preclinical Rheumatoid Arthritis Results Of a Telephone Survey. Pascal Klaus, Vivien Köhler, Hans Bastian, Tanja Braun, Eva Gremmelsbacher, Vera Höhne-Zimmer, Frank Buttgereit, Gerd R. Burmester and Jacqueline Detert, Charité - Universitätsmedizin Berlin, Berlin, Germany 05. Influence Of Disease Activity On The Physical Activity Of Rheumatoid Arthritis Patients. Vanesa Hernández- Hernández, Ivan Ferraz-Amaro, Esmeralda Delgado-Frías, Sagrario Bustabad-Reyes and Federico Diaz-Gonzalez, Hospital Universitario de Canarias, La Laguna, Spain ARHP Rheumatoid Arthritis - Clinical Aspects: Clinical Practice/ Patient Care 06. Comparative Study Of Patients With Peripheral Psoriatic Arthritis, Axial Psoriatic Arthritis and Axial Spondyloarthritis Without Psoriasis. Abhijeet Danve, Neha Garg and Atul Deodhar, Oregon Health and Science University, Portland, OR, Oregon Health and Sciences University, Portland, OR 07. Lifestyle Factors Were Seldom Discussed With Patients Visiting a Rheumatology Clinic. Ann B. I. Bremander and Stefan Bergman, Spenshult Research and Development Center, Halmstad, Sweden 08. Rheumatoid Arthritis Flares: Inflammatory Or Avalanche? Caroline A. Flurey, Marianne Morris, Jon Pollock, Rodney A. Hughes, Pamela Richards and Sarah Hewlett, University of the West of England, Bristol, United Kingdom, St. Peters Hospital, Chertsey Surrey, United Kingdom, University of Bristol, Bristol, United Kingdom 09. Quantifying The Gap Between General Population Guidelines and Expert Opinion For Cardiovascular Risk Management In Rheumatic Disease Patients. Katherine P. Liao, Jonathan Brown, Jonathan S. Coblyn, Paul Cohen, Jorge Plutzky and Daniel H. Solomon, Brigham and Women s Hospital, Boston, MA, Harvard Medical School, Brigham and Women s Hospital, Division of Rheumatology, Division of Pharmacoepidemiology, Boston, MA 0. Nurse Training; Confidence and Competence For Educating Patients Commencing Methotrexate Therapy. Sandra M. Robinson, Andrew Hassell, Sarah Ryan, Nicola Adams 4, Peta S. Heslop and David Walker 5, North Tyneside General Hospital, North Shields, United Kingdom, School of Medicine (Keele Campus), Keele, United Kingdom, Keele University, Staffordshire, United Kingdom, 4 Northumbria University, Newcastle Upon Tyne, United Kingdom, 5 Freeman Hospital, Newcastle Upon Tyne, United Kingdom. Impact Of Healing Architecture In a Rheumatology Outpatient Clinic. Gunhild Bukh, Erik Kehn Jensen, Anne Marie Munk Tommerup and Ole Rintek Madsen 4, Copenhagen University Hospital Gentofte, Hellerup, Denmark, Kehn & Warnøe, Copenhagen, Denmark, Danish Architecture Centre, Copenhagen, Denmark, 4 Copenhagen University Hospital Gentofte, Copenhagen, Denmark. Experiences Of Older People Living With Ankylosing Spondylitis. Jane Martindale, Elham Kashefi and Lynne Goodacre, Lancaster University, Lancaster, United Kingdom. Pain-Related Anxiety As a Barrier To Use Of Methotrexate In Rheumatoid Arthritis: Comparing Conventional Vial, Needles, and Syringe With An Investigational Auto- Injector In Healthy Volunteers. Victoria L. Ruffing and Kaushik J. Dave, Johns Hopkins University, Baltimore, MD, Antares Pharma Inc, Ewing, NJ 4. WITHDRAWN 5. Reducing The Need For Total Knee Arthroplasty: The Experience Of a Multidisciplinary Osteoarthritis Clinic. Caroline Jones, Angelo Papachristos and Laurence A. Rubin, St Michael s Hospital, Toronto, ON, St. Michael Hospital, Toronto, ON 0 Program Book

325 ACR POSTER SESSION C Rheumatoid Arthritis Treatment - Small Molecules, Biologics and Gene Therapy III 6. Anti-Human TNF-Alpha Domain Antibody Construct, CEP- 747/Placulumab, Is As Efficacious As Other Leading TNF-Alpha-Blockade Therapies in a Humanized Mouse Model of Rheumatoid Arthritis. Matthew M. Seavey, Linglong Zou, Adam Clarke, Anthony G. Doyle, Roberta Weiss 4, Aric Orbach 5, Brad McIntyre 6 and Merav Bassan 5, Teva Pharmaceuticals, Inc., West Chester, PA, Teva Biopharmaceuticals, Rockville, MD, Teva Pharmaceuticals, Inc., Sydney, Australia, 4 Teva Pharmaceuticals, Inc., Frazer, PA, 5 Teva Pharmaceuticals, Inc., Netanya, Israel, 6 Teva Pharmaceuticals, Inc., West Cheater, PA 7. Impact of PVA Coated Nanoparticles On Cellular Viability and Functionality of Immune Cells Obtained From Healthy Donors and Patients With Rheumatoid Arthritis Or Osteoarthritis. Cindy Strehl, Timo Gaber, Manuela Jakstadt, Martin Hahne, Saskia Schellmann, Barbara Szostak, Géraldine Coullerez, Heinrich Hofmann, Gerd-Rüdiger Burmester and Frank Buttgereit 4, Charité University Medicine, Berlin, Germany, École polytechnique fédérale de Lausanne, Lausanne, Switzerland, Charite University Hospital, Berlin, Germany, 4 Charité - Universitätsmedizin Berlin, Berlin, Germany 8. Disease Activity in Moderate and Severe Rheumatoid Arthritis At Discontinuation in 0-Year Open-Label Extension Studies With Etanercept. Michael E. Weinblatt, Joan M. Bathon, Michele Hooper, Bojena Bitman, Yue Yang 4, David H. Collier, James Chung 5 and Mark C. Genovese 6, Brigham and Women s Hospital, Boston, MA, Columbia University, New York, NY, Amgen Inc., Thousand Oaks, CA, 4 Assent Consulting, South San Francisco, CA, 5 Amgen, Thousand Oaks, CA, 6 Stanford University, Palo Alto, CA 9. Comparative Safety Of Biological Agents Among Medicare Rheumatoid Arthritis Patients. Huifeng Yun, Fenglong Xie, Elizabeth S. Delzell, Lang Chen, Emily Levitan, James Lewis, Kenneth G. Saag, Timothy Beukelman, Kevin L. Winthrop, John Baddley, Paul M. Muntner and Jeffrey R. Curtis, University of Alabama at Birmingham, Birmingham, AL, University of Pennsylvania, Philadelphia, PA, Oregon Health & Science University, Portland, OR 0. Ultrasonographic Monitoring Of Response To Infliximab In Patients With Rheumatoid Arthritis. Xiaomei Leng, Weiguo Xiao, Xiaochun Zhu, Zhonghui Xu, Wei Yu, Jing Lu, Jiakai Wang, Xiaoru Xia, Yongji Li, Yi Liu 4, Yi Zhao 4, Honghao Tang 4, Dongbao Zhao 5, Yeqing Shi 5, Huji Xu 6, Jun Bao 6, Lin Chen 6, Ling Lin 6, Ling Zhou 6, Guoqiang Chen 7, Weihong Zhang 7 and Yan Zhao, Peking Union Medical College Hospital, Beijing, China, The First Hospital of China Medical University, Shenyang, China, The First Hospital of Wenzhou Medical College, Wenzhou, China, 4 West China Hospital of Sichuan University, Chengdu, China, 5 Changhai Hospital of Shanghai, Shanghai, China, 6 Shanghai Changzheng Hospital, Shanghai, China, 7 The First People s Hospital of Foshan, Foshan, China. Long-Term Safety and Efficacy Of Certolizumab Pegol In Combination With Methotrexate In The Treatment Of Rheumatoid Arthritis: 5-Year Results From a 4-Week Randomized Controlled Trial and Open-Label Extension Study. Josef S. Smolen, Ronald van Vollenhoven, Arthur Kavanaugh, Vibeke Strand 4, Jiri Vencovsky 5, Michael H. Schiff 6, Robert Landewé 7, Boulos Haraoui 8, Susan Walker 9 and Désirée van der Heijde 0, Medical University of Vienna and Hietzing Hospital, Vienna, Austria, The Karolinska Institute, Stockholm, Sweden, University of California San Diego, San Diego, CA, 4 Stanford University, Palo Alto, CA, 5 Institute of Rheumatology, Department of Clinical and Experimental Rheumatology, st Faculty of Medicine, Charles University, Prague, Czech Republic, 6 University of Colorado, Denver, CO, 7 Academic Medical Center Amsterdam & Atrium Medical Center, Heerlen, Netherlands, 8 Centre Hospitalier de l Université de Montréal, Montreal, QC, 9 UCB Pharma, Raleigh, NC, 0 Leiden University Medical Center, Leiden, Netherlands. Post Hoc Analysis Showing Better Clinical Response With The Loading Dose Of Certolizumab Pegol In Japanese Patients With Active Rheumatoid Arthritis. Tsutomu Takeuchi, Kazuhiko Yamamoto, Hisashi Yamanaka, Naoki Ishiguro 4, Yoshiya Tanaka 5, Katsumi Eguchi 6, Akira Watanabe 7, Hideki Origasa 8, Mariko Kobayashi 9, Toshiharu Shoji 9, Nobuyuki Miyasaka 0 and Takao Koike, Department of Rheumatology, Keio University, Tokyo, Japan, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan, Institute of Rheumatology, Tokyo Women s Medical University, Tokyo, Japan, 4 Nagoya Univeristy Graduate School of Medicine, Nagoya, Japan, 5 University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, 6 Sasebo City General Hospital, Sasebo, Nagasaki, Japan, 7 Tohoku University, Sendai, Japan, 8 University of Toyama School of Medicine, Toyama, Toyama, Japan, 9 UCB Pharma, Tokyo, Japan, 0 Tokyo Medical and Dental University, Tokyo, Japan, NTT Sapporo Medical Center, Sapporo, Japan.. Comprehensive Disease Remission Achieved By Certolizumab Pegol Treatment, and Factors Associated With Certolizumab Pegol Comprehensive Disease Remission, In Rheumatoid Arthritis Patients With Predominantly High Disease Activity. Yoshiya Tanaka, Kazuhiko Yamamoto, Tsutomu Takeuchi, Hisashi Yamanaka 4, Naoki Ishiguro 5, Katsumi Eguchi 6, Akira Watanabe 7, Hideki Origasa 8, Tadao Okamoto 9, Yumiko Wada 9, Toshiharu Shoji 9, Nobuyuki Miyasaka 0 and Takao Koike, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, The University of Tokyo, Tokyo, Japan, Keio University, Tokyo, Japan, 4 Tokyo Women s Medical University, Tokyo, Japan, 5 Nagoya University, Nagoya, Japan, 6 Sasebo City General Hospital, Sasebo, Japan, 7 Tohoku University, Sendai, Japan, 8 University of Toyama School of Medicine, Toyama, Toyama, Japan, 9 UCB Pharma, Tokyo, Japan, 0 Tokyo Medical and Dental University, Tokyo, Japan, NTT Sapporo Medical Center, Sapporo, Japan 0 Program Book

326 ACR POSTER SESSION C 4. Persistence On Biologics Is Associated With Concomitant Methotrexate Use Among Rheumatoid Arthritis Patient. Jie Zhang, Fenglong Xie, Elizabeth S. Delzell, Huifeng Yun, James Lewis, Kevin Haynes, Lang Chen and Jeffrey R. Curtis, University of Alabama at Birmingham, Birmingham, AL, University of Pennsylvania, Philadelphia, PA, University of Pennsylvania., Philadelphia, PA 5. Final 5-Year Safety and Efficacy Results Of a Phase, Randomized, Placebo-Controlled Trial Of Golimumab In Patients With Active Rheumatoid Arthritis Despite Previous Anti-Tumor Necrosis Factor Therapy. Josef S. Smolen, Jonathan Kay, Robert Landewé, Eric L. Matteson 4, Norman B. Gaylis 5, Jürgen Wollenhaupt 6, Frederick T. Murphy 7, Chenglong Han 8, Timothy A. Gathany 8, Stephen Xu 9, Yiying Zhou 9, Elizabeth C. Hsia 0 and Mittie K. Doyle 9, Medical University of Vienna and Hietzing Hospital, Vienna, Austria, University of Massachusetts Medical School, Worcester, MA, Academic Medical Center, University of Amsterdam and Atrium Medical Center, Heerlen, Netherlands, 4 Mayo Clinic, Rochester, MN, 5 Arthritis & Rheumatic Disease Specialties, Aventura, FL, 6 Schön Klinik Hamburg Eilbek, Hamburg, Germany, 7 Altoona Ctr for Clinical Research, Duncansville, PA, 8 Janssen Global Services, LLC., Malvern, PA, 9 Janssen Research & Development, LLC., Spring House, PA, 0 Janssen Research & Development, LLC./U of Penn, Spring House/Philadelphia, PA 6. Head-To-Head Comparison Of Subcutaneous Abatacept Versus Adalimumab On Background Methotrexate In RA: Blinded Two Year Results From The Ample (Abatacept Versus Adalimumab Comparison in Biologic-Naive RA Subjectswith Background Methotrexate) study. Michael E. Weinblatt, Michael H Schiff, Robert Valente, Désirée M. van der Heijde 4, Gustavo Citera 5, Ayanbola Elegbe 6, Michael A Maldonado 6 and Roy M. Fleischmann 7, Brigham and Women s Hospital, Boston, MA, University of Colorado, Denver, CO, Arthritis Center of Nebraska, Lincoln, NE, 4 Leiden University Medical Center, Leiden, Netherlands, 5 Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, 6 Bristol-Myers Squibb, Princeton, NJ, 7 University of Texas Southwestern Medical Center, Dallas, TX 7. Dose Reduction Of Tocilizumab In Rheumatoid Arthritis Patients With Low Disease Activity Is Feasible. Noortje van Herwaarden, Susan Herfkens-Hol, Aatke van der Maas, Bart J.F. van Den Bemt, Ronald F. van Vollenhoven, Johannes W.J. Bijlsma and Alfons A. den Broeder, Sint Maartenskliniek, Nijmegen, Netherlands, Karolinska Institute, Stockholm, Sweden, University Medical Center Utrecht, Utrecht, Netherlands 8. Tofacitinib, An Oral Janus Kinase Inhibitor, In The Treatment Of Rheumatoid Arthritis: Open-Label, Long- Term Extension Safety and Efficacy Up To 5 Years. Jürgen Wollenhaupt, Joel Silverfield, Eun Bong Lee, Susan P. Wood 4, Ketti K. Terry 4, Hiroyuki Nakamura 5, Yukako Ohno 5, David Gruben 4, Birgitta Benda 6, Lisy Wang 4 and Richard Riese 4, Schoen-Klinik Hamburg-Eilbek Teaching Hospital of the University of Hamburg, Hamburg, Germany, Healthpoint Medical Group, Tampa, FL, Seoul National University, Seoul, South Korea, 4 Pfizer Inc, Groton, CT, 5 Pfizer Japan Inc, Tokyo, Japan, 6 Pfizer Inc, Collegeville, PA 9. Improvements In Physical Function Correlate With Improvements In Health Related Quality Of Life: Reported Outcomes In Rheumatoid Arthritis Patients Treated With Tofacitinib: Results From Randomized Phase Trials. V. Strand, R. E. Alten, C. I. Nduaka, R. Riese, D. Gruben, S. H. Zwillich, J. Andrews and G. Wallenstein, Stanford University, Palo Alto, CA, Schlosspark-Klinik, University Medicine, Berlin, Germany, Pfizer Inc, Groton, CT 0. Relationship Between Lymphocyte Count and Risk Of Infection In Rheumatoid Arthritis Patients Treated With Tofacitinib. R. F. van Vollenhoven, R. Riese, S. Krishnaswami, T. Kawabata, C. Fosser, S. Rottinghaus, M. Lamba and S. H. Zwillich, The Karolinska Institute, Stockholm, Sweden, Pfizer Inc, Groton, CT. Efficacy and Safety Of Tofacitinib In Older and Younger Patients With Rheumatoid Arthritis. J. R. Curtis, H. Schulze-Koops, L Takiya, C. A. Mebus 4, K. Terry 4, R. Chew 4 and T. V. Jones, University of Alabama at Birmingham, Birmingham, AL, University of Munich, Munich, Germany, Pfizer Inc, Collegeville, PA, 4 Pfizer Inc, Groton, CT. Assessment of Lipid Changes and Infection Risk In Diabetic and Nondiabetic Patients With Rheumatoid Arthritis Treated With Tofacitinib. W. F. C. Rigby, L. Takiya, S. P. Wood, H. Fan and T. V. Jones, Giesel School of Medicine at Dartmouth, Lebanon, NH, Pfizer Inc, Collegeville, PA, Pfizer Inc, Groton, CT. Association Of Mean Changes In Laboratory Safety Parameters With C-Reactive Protein At Baseline and Week In Rheumatoid Arthritis Patients Treated With Tofacitinib. V. Strand, J. D. Isaacs, S. Menon, J. Beal 4, C. I. Nduaka, S. Krishnaswami, R. Riese and M.G. Boy, Stanford University, Palo Alto, CA, Newcastle University, Newcastle-upon-Tyne, United Kingdom, Pfizer Inc, Groton, CT, 4 Pfizer Inc, Collegeville, PA 4. ORAL SCAN: Effects Of The Oral JAK Inhibitor Tofacitinib In Combination With Methotrexate On Patient Reported Outcomes In a 4-Month Phase Trial Of Active Rheumatoid Arthritis. V. Strand, D. van der Heijde, C. A. F. Zerbini, C. A. Connell 4, D. Gruben 4, R. Riese 4 and G. Wallenstein 4, Stanford University, Palo Alto, CA, Leiden University Medical Center, Leiden, Netherlands, Centro Paulista de Investigação Clinica, Sao Paulo, Brazil, 4 Pfizer Inc, Groton, CT 5. Epstein-Barr Virus In Peripheral Blood Of Rheumatoid Arthritis Patients Predicts Response To Rituximab Therapy. Heikki Valleala, Markku Korpela, Markku J. Kauppi and Yrjo T. Konttinen 4, Helsinki University Central Hospital, Helsinki, Finland, Tampere University Hospital, Tampere, Finland, Department of Internal Medicine, Päijät-Häme Central Hospital, Lahti, Finland, 4 Helsinki Univ Central Hospital, Helsinki, Finland 4 0 Program Book

327 ACR POSTER SESSION C 6. Phase Evaluation Of PF-0477, a Dissociated Agonist Of The Glucocorticoid Receptor, For The Treatment Of Rheumatoid Arthritis In Patients With An Inadequate Response To Methotrexate. Thomas Stock, Dona Fleishaker, Xin Wang, Arnab Mukherjee and Charles Mebus, Pfizer Inc., Collegeville, PA, Pfizer Inc., Groton, CT 7. Serious Adverse Events Associated With Using Biological Agents To Treat Rheumatic Diseases: Network Meta- Analysis From a National Guideline Panel. Simon Tarp, Ulrik Tarp, Lis S. Andersen, Tove Lorenzen 4, Hanne M. Lindegaard 5, Michael Stoltenberg 6, Hanne S. Jensen 7, Birgitte Brock 8, Camilla M. Mikkelsen 9, Dorte V. Jensen 0, Karsten Asmussen 7, Troels Herlin and Robin Christensen, Musculoskeletal Statistics Unit, The Parker Institute, Department of Rheumatology, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Denmark, Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark, Department of Rheumatology, Copenhagen University Hospital, Gentofte, Denmark, 4 Department of Rheumatology, Region Hospital Silkeborg, Silkeborg, Denmark, 5 Odense University Hospital, Odense, Denmark, 6 Department of Rheumatology, Copenhagen University Hospital, Køge, Denmark, 7 Department of Rheumatology, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Denmark, 8 Department of Clinical Biochemistry, Aarhus University Hospital, Aarhus, Denmark, 9 The Capital Region of Denmark Hospital Pharmacy, Medicine Information Centre, Copenhagen NV, Denmark, 0 The Danish Rheumatologic Database (DANBIO), Center of Rheumatology and Spine Diseases VRR, Copenhagen University Hospital, Glostrup, Denmark, Aarhus University Hospital, Aarhus, Denmark 8. Biologic Switching Rates Among Patients With Rheumatoid Arthritis. L Rosenblatt, F Lobo, P Cockrum, L Wang, E Alemao, O Baser 4 and H Yuce 5, Bristol-Myers Squibb, Plainsboro, NJ, Bristol-Myers Squibb, Princeton, NJ, STATinMED Research, Dallas, TX, 4 STATinMED Research and University of Michigan, Ann Arbor, MI, 5 New York City College of Technology (CUNY), Brooklyn, NJ 9. Patient Evaluations Of Subcutaneous Golimumab Delivery By Autoinjector (SmartJect ) For Treatment Of Rheumatoid Arthritis. H Schulze-Koops, R Giacomelli, W Samborski, S Rednic 4, M Herold 5, R Yao 6, M Govoni 7, N Vastesaeger 8 and HH Weng 6, University of Munich, Munich, Germany, Università degli Studi dell Aquila, L Aquila, Italy, Ortopedyczno-Rehabilitacyjny Szpital Kliniczny, Wielkopolskie, Poland, 4 University of Medicine & Pharmacy, Cluj-Napoca, Romania, 5 Medical University of Innsbruck, Innsbruck, Austria, 6 Merck Sharp & Dohme, Kenilworth, NJ, 7 Merck Sharp & Dohme, Rome, Italy, 8 Merck Sharp & Dohme, Brussels, Belgium 40. Persistent Use Of Biologic Therapies At Lower Than Recommended Dosing Among Rheumatoid Arthritis Patients Enrolled In The US Medicare Program. Jie Zhang, Fenglong Xie, Elizabeth S. Delzell, Huifeng Yun, James Lewis, Kevin Haynes, Lang Chen, Kenneth G. Saag and Jeffrey R. Curtis, University of Alabama at Birmingham, Birmingham, AL, University of Pennsylvania, Philadelphia, PA, University of Pennsylvania., Philadelphia, PA 4. Efficacy Of Adalimumab Plus Methotrexate Therapy In Rheumatoid Arthritis Non-Responders Receiving Methotrexate Monotherapy Or Adalimumab Combination Therapy: Results From The Optima Trial. Josef S. Smolen, Ronald F. van Vollenhoven, Roy Fleischmann, Paul Emery 4, Stefan Florentinus 5, Suchitrita S. Rathmann 6, Anabela Cardoso 7, Hartmut Kupper 8 and Arthur Kavanaugh 9, Medical University of Vienna and Hietzing Hospital, Vienna, Austria, The Karolinska Institute, Stockholm, Sweden, University of Texas Southwestern Medical Center, Dallas, TX, 4 Leeds Teaching Hospital, Leeds, United Kingdom, 5 AbbVie, Rungis, France, 6 AbbVie Inc., North Chicago, IL, 7 AbbVie, Amadora, Portugal, 8 AbbVie Deutschland GmBH & Co KG, Ludwigshafen, Germany, 9 University of California, San Diego, La Jolla, CA 4. Long-Term Safety Of Rituximab: Pooled Analysis Of The Rheumatoid Arthritis Global Clinical Trial Program Over Years. Ronald van Vollenhoven, Paul Emery, Clifton O. Bingham III, Edward Keystone 4, Roy M. Fleischmann 5, Daniel E. Furst 6, Eva W. Hessey 7, Abdul Mehbob 7 and Patricia B. Lehane 7, Karolinska Institute, Stockholm, Sweden, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, Johns Hopkins University, Baltimore, MD, 4 University of Toronto, Toronto, ON, 5 University of Texas Southwestern Medical Center, Dallas, TX, 6 University of California, Los Angeles, Los Angeles, CA, 7 Roche Products Ltd., Welwyn Garden City, United Kingdom 4. Assessment Of Subclinical Atherosclerosis (Flow Mediated Dilatation and arterial stiffness) After 4 Weeks Of a Tocilizumab Therapy In Patients With Rheumatoid Arthritis. Martin Soubrier, Thomas Frayssac, Bruno Pereira, Marion Couderc Sr. 4, Coline Daron, Jean Jacques Dubost 5, Sandrine Malochet-Guinamand 4, Anne Tournadre 4 and Sylvain Mathieu 4, CHU CLERMONT-FERRAND, Clermont-Ferrand, France, CHU CLERMONT-FERRAND, Clermont-ferrand, France, Clinical research department, Clermont-Ferrand, France, 4 Rheumatology CHU Gabriel Montpied, Clermont-Ferrand, France, 5 CHU G.-Montpied, Clermont-Ferrand, France 44. Effect Of Tocilizumab On Treatment Patterns, Effectiveness and Safety With Laboratory Values For Patients With Rheumatoid Arthritis: Analyses From The Corrona-Certain Study. Dimitrios A. Pappas, Ani John, Joel M. Kremer, Chitra Karki 4, Tanya Sommers 4, George W. Reed 4, Jeffrey R. Curtis 5, Ashwini Shewade and Jeffrey D. Greenberg 6, Columbia University, New York, NY, Genentech Inc., South San Francisco, CA, Albany Medical College and The Center for Rheumatology, Albany, NY, 4 CORRONA, Inc., Southborough, MA, 5 University of Alabama-Birmingham, Birmingham, AL, 6 NYU Hospital for Joint Diseases, New York, NY 45. Long-Term Targeted Safety Event Rates In RA Patients Following Initiation Of Rituximab: Interim Analysis From Sunstone Registry. Kenneth G. Saag, Kevin L. Winthrop, Kimberly Alexander, Steven Francom and Daniel E. Furst 4, University of Alabama at Birmingham, Birmingham, AL, Oregon Health & Science University, Portland, OR, Genentech, Inc., South San Francisco, CA, 4 UCLA, Los Angeles, CA 0 Program Book 5

328 ACR POSTER SESSION C 46. Effects Of Tofacitinib, An Oral Janus Kinase Inhibitor, On Work Limitations In Patients With Rheumatoid Arthritis. Vibeke Strand, Keith S. Kanik, Carol Connell, Bethanie Wilkinson, David Gruben and Gene Wallenstein, Stanford University, Palo Alto, CA, Pfizer Inc, Groton, CT 47. Functional Single Nucleotide Polymorphisms In The Interferon-γ and The NLRP (Cryopyrin) Genes Associated With Anti-TNF Response In Danish Rheumatoid Arthritis Patients. Jacob Sode, Niels H. H. Heegaard, Henning Locht, Ulla Vogel 4, Steffen Bank 5, Merete Lund Hetland 6 and Vibeke Andersen 7, University of Southern Denmark, Odense, Denmark, Statens Serum Institut, Copenhagen, Denmark, Frederiksberg Hospital, Frederiksberg, Denmark, 4 National Research Centre for the Working Environment, Copenhagen, Denmark, 5 University of Aarhus, Aarhus, Denmark, 6 The Danish Rheumatologic Database (DANBIO), Glostrup Hospital., Copenhagen, Denmark, 7 OPEN (Odense Patient data Explorative Network), Odense, Denmark 48. Long Term Safety Of Intravenous Golimumab and Comparisons With Subcutaneous Golimumab In Rheumatologic Conditions: Results From The 0- Day Safety Report Of a Phase Trial Of Intravenous Golimumab. Rene Westhovens, Clifton O. Bingham III, Michael E. Weinblatt, Roy M. Fleischmann 4, Edward C. Keystone 5, Elizabeth C. Hsia 6, Benjamin Hsu 7, Lilianne Kim 7, Surekha Mudivarthy 7, Michael Mack 8, Neil Goldstein 7, Jürgen Braun 9, Arthur Kavanaugh 0, Alan M. Mendelsohn 7 and Jonathan Kay, University Hospital KU Leuven, Leuven, Belgium, Johns Hopkins University, Baltimore, MD, Brigham and Women s Hospital, Boston, MA, 4 University of Texas Southwestern Medical Center, Dallas, TX, 5 Mount Sinai Hospital, University of Toronto, Toronto, ON, 6 Janssen Research & Development, LLC./U of Penn, Spring House/ Philadelphia, PA, 7 Janssen Research & Development, LLC., Spring House, PA, 8 Janssen Research & Development, LLC, Spring House, PA, 9 Rheumazentrum Ruhrgebiet, Herne, Germany, 0 University of California San Diego, San Diego, CA, UMass Memorial Medical Center and University of Massachusetts Medical School, Worcester, MA 49. Abatacept and Anti-Tumor Necrosis Factor Monoclonal Antibodies: Efficacy and Safety Comparisons. M Schiff, M Dougados, R Fleischmann, J Fay 4 and M Maldonado 4, University of Colorado, Denver, CO, Hopital Cochin, Descartes University, Paris, France, University of Texas Southwestern Medical Center, Dallas, TX, 4 Bristol-Myers Squibb, Princeton, NJ 50. Effects Of VX-509, An Investigational Oral Selective Janus Kinase (JAK) Inhibitor, On Patient-Reported Outcomes In a Phase A Study Of Patients With Active Rheumatoid Arthritis. Vibeke Strand, Ellison Suthoff, Roy M. Fleischmann, Montserrat Vera-Llonch 4, John Jiang, Yanqiong Zhang and Nils Kinnman 5, Stanford University, Palo Alto, CA, Vertex Pharmaceuticals Incorporated, Cambridge, MA, Metroplex Clinical Research Center, University of Texas Southwestern Medical Center, Dallas, TX, 4 Vertex Pharamceuticals Incorporated, Cambridge, MA, 5 Vertex Pharmaceuticals Incorporated, Geneva, Switzerland 5. Tocilizumab In Patients With Rheumatoid Arthritis and Rates Of Malignancy: Results From Long-Term Extension Clinical Trials. Ronald F. van Vollenhoven, Andrea Rubbert- Roth, Anthony Sebba, Benjamin Porter-Brown 4, Lucy Rowell 4, Pavel Napalkov 5 and Devi Smart 4, Karolinska Institute, Stockholm, Sweden, University of Cologne, Cologne, Germany, University of South Florida, Tampa, FL, 4 Roche, Welwyn Garden City, United Kingdom, 5 Genentech, South San Francisco, CA 5. Evaluation and Management Of Laboratory Abnormalities During Tocilizumab Treatment Either As Monotherapy Or In Combination With Dmards In RA Patients: Findings From The ACT-STAR Study. Michael Weinblatt, Dennis Preston, Josh Friedman, Natasha Singh, Jenny Devenport and Joel M. Kremer, Division of Rheumatology, Brigham & Women s Hospital, Boston, MA, Genentech, Inc., South San Francisco, CA, Albany Medical College and The Center for Rheumatology, Albany, NY 5. Evaluation Of An Irreversible Dual Target Inhibitor (AC005) Of Bruton s Tryosine Kinase and Janus Kinase As a Therapeutic Agent For Rheumatoid Arthritis. Xiao Xu, Long Mao, Biao Xi, Xiaoying Zhang, Che Fang, Jia Liu and Wanhong Xu, ACEA Biosciences Inc., San Diego, CA 54. Drug Survival Rates Of Anti-Tumor Necrosis Factor Therapies In Patients With Rheumatoid Arthritis and Ankylosing Spondylitis. Dong-Jin Park, Kyung-Eun Lee, Ji-Hyoun Kang, Jeong-Won Lee, Tae-Jong Kim, Yong-Wook Park and Shin-Seok Lee, Chonnam National University Medical School, Gwangju, South Korea, Chonnam National University Medical School and Hospital, Gwangju, South Korea 55. Sarilumab, a Subcutaneously-Administered, Fully- Human Monoclonal Antibody Against The IL-6 Receptor Alpha: Using Acute Phase Reactants, Efficacy and Safety Parameters To Inform Phase Dose Selection. Janet van Adelsberg, Steven P. Weinstein, Neil Graham, Tanya Momtahen 4, Chunpeng Fan 4 and Stefano Fiore 4, Regeneron Pharmaceutials, Inc., Tarrytown, NY, Regeneron Pharmaceuticals Inc, Tarrytown, NY, Regeneron Pharmaceuticals, Inc., Tarrytown, NY, 4 Sanofi, Bridgewater, NJ 56. Soluble Interleukin- Receptor Levels and The CD4/ CD8 Ratio As Predictors Of The Efficacy Of Abatacept In Biologics-naïve Rheumatoid Arthritis Patients. Hajime Sano, Masahiro Sekiguchi, Masayasu Kitano, Naoto Azuma, Shinichiro Tsunoda, Kiyoshi Matsui and Tsuyoshi Iwasaki, Hyogo College of Medicine, Nishinomiya-city, Japan, Hyogo University of Health Sciences, Kobe, Japan 57. Confounding By Indication Distorts The Relationship Between Steroid Use and Cardiovascular Disease In Rheumatoid Arthritis. Alper M. van Sijl, Maarten Boers, Alexandre E. Voskuyl and Mike T. Nurmohamed, VU University Medical Center, Amsterdam, Netherlands 6 0 Program Book

329 ACR POSTER SESSION C 58. Sarilumab, a Subcutaneously Administered, Fully Human Monoclonal Antibody Inhibitor Of The IL-6 Receptor Alpha: Week Infection Rates By Level Of Circulating Neutrophils In Rheumatoid Arthritis and Ankylosing Spondylitis. Kevin L. Winthrop, Tanya Momtahen, Stefano Fiore, Steven P. Weinstein, Janet van Adelsberg 4, Richard Wu 5 and Neil Graham 5, Oregon Health & Science University, Portland, OR, Sanofi, Bridgewater, NJ, Regeneron Pharmaceuticals Inc, Tarrytown, NY, 4 Regeneron Pharmaceutials, Inc., Tarrytown, NY, 5 Regeneron Pharmaceuticals, Inc., Tarrytown, NY 59. Impact Of Etanercept-Methotrexate Treatment Withdrawal On Patient-Reported Outcomes In Patients With Early Rheumatoid Arthritis (PRIZE Trial). Piotr Wiland, B Combe, Oliver M. FitzGerald, Hasan Tahir 4, Stefanie Gaylord 5, Theresa Williams 5, Ronald Pedersen 6, Jack Bukowski 6, Bonnie Vlahos 5 and Sameer Kotak 7, Medical University of Wroclaw, Wroclaw, Poland, Hôpital Lapeyronie, Montpellier, France, St.Vincent s University Hospital, Dublin, Ireland, 4 Barts Health NHS Trust, London, United Kingdom, 5 Pfizer Inc., Collegeville, PA, 6 Pfizer Inc, Collegeville, PA, 7 Pfizer Inc., New York, NY 60. Incidence Of Diabetes and Effect Of Etanercept and Adalimumab On HbAc Over Year: Data From a Randomised Trial In Patients With Rheumatoid Arthritis. Paola de Pablo, Fiona M. Maggs, David Carruthers, Abdul A. Faizal 4, Mark T. Pugh 5 and Paresh Jobanputra 6, University of Birmingham, College of Medical & Dental Sciences, Queen Elizabeth Hospital Birmingham, UK, Birmingham, United Kingdom, Queen Elizabeth Hospital Birmingham, UK, Birmingham, United Kingdom, Sandwell and West Birmingham Hospitals NHS Trust, UK, Birmingham, United Kingdom, 4 Heart of England NHS Foundation Trust, UK, Solihull, United Kingdom, 5 Saint Mary s Hospital, UK, Isle of Wight, United Kingdom, 6 Queen Elizabeth Hospital Birmingham, UK., Birmingham, United Kingdom 6. Pharmacokinetic and Pharmacodynamic Characterization Of a Dissociated Agonist Of Glucocorticoid Receptor, Following Multiple Dose Administration In Healthy Japanese Adult Subjects. Brinda Tammara, Sou Miyoshi and Judith Hey-Hadavi, Pfizer, Collegeville, PA, Pfizer, Tokyo, Japan, Pfizer, NewYork, NY 6. Incidence Of Adverse Events In Patients With Rheumatoid Arthritis and Spondyloarthritis Exposed To Anti- TNF Therapy. Data From The Brazilian Registry For Monitoring Of Biologic Therapies In Rheumatic Diseases (BiobadaBrasil). Roberto Ranza, David C Titton, Valeria Vallim, Ines Silveira 4, Aline Ranzolin 5, Andre Hayata 6, Mirhelen M. Abreu 7, Paulo Louzada-Jr 8, Angela LBP Duarte 5, Claiton Brenol 9, Geraldo C Pinheiro 0, Glaucio R Castro, Hellen M Carvalho, Isaias Costa, Jose C Macieira 4, Jose R Miranda 5, Julio CM Bertacini 6, Luis SG Barbosa 7, Manoel B Bertolo 8, Marcelo M. Pinheiro, Maria F Sauma 9, Marilia B Silva 0, Marlene Freire, Roberto A Toledo and Vander Fernandes, Universidade Federal de Uberlandia, Uberlandia MG, Brazil, Hospital de Clínicas da UFPR, Curitiba PR, Brazil, Universidade Federal do Espirito Santo, Vitoria ES, Brazil, 4 PUCRS, Porto Alegre RS, Brazil, 5 Universidade Federal de Pernambuco, Recife PE, Brazil, 6 CRO Osasco, Osasco SP, Brazil, 7 Universidade Federal de São Carlos, São Carlos SP, Brazil, 8 USP RP, Ribeirão Preto SP, Brazil, 9 Universidade Federal do Rio Grande do Sul, Porto Alegre RS, Brazil, 0 UERJ, Rio de Janeiro RJ, Brazil, Hospital Governador Celso Ramos, Florianopolis SC, Brazil, Brazilian Registry of Spondyloarthritis, São Paulo, Brazil, Universidade Federal MS, Campo Grande MS, Brazil, 4 UFS Aracaju, Aracaju SE, Brazil, 5 Artrocenter Clinica Medica, Taubate SP, Brazil, 6 USP SP CDMAC, São Paulo SP, Brazil, 7 Universidade Federal Mato Grosso, Cuiabá MT, Brazil, 8 UNICAMP, Campinas SP, Brazil, 9 UFPA, Belem PA, Brazil, 0 Hospital Universitario Evangelico, Curitiba PR, Brazil, UFTM, Uberaba MG, Brazil, FUNFARP, São José do Rio Preto SP, Brazil, Universidade de Cuiabá, Cuiaba MT, Brazil 6. Positivity Of Rheumatoid Factor and Anti-Cyclic Citrullinated Peptide Is Associated With The Response Rate Of Infliximab, But Not Tocilizumab, In Treatment Of Rheumatoid Arthritis. Masao Sato, Masao Takemura, Ryuki Shinohe, Yasuko Yamamoto and Kuniaki Saito, Gifu University, Gifu, Japan, Kyoto University, Kyoto, Japan 64. Baseline Procalcitonin Levels Are Predictive Marker Of Remission In Biologic naïve Patients With Rheumatoid Arthritis Treated With Tocilizumab: Result From 4 Weeks Of Follow-Up. Soichiro Tsuji, Akiko Yura, Michihito Katayama, Satoru Teshigawara, Maiko Yoshimura, Eriko Tanaka, Yoshinori Harada, Yoshinori Katada, Masato Matsushita, Shiro Ohshima, Jun Hashimoto and Yukihiko Saeki, Rheumatology,Osaka-Minami Medical Center, Kawachinagano City, Japan, Allergology,Osaka-Minami Medical Center, Kawachinagano City, Japan, Clinical Research,Osaka-Minami Medical Center, Kawachinagano City, Japan 65. Concomitant Methotrexate Did Not Affect Discontinuation Rate Of Etanercept Due To Ineffectiveness: Six-Year Results From Japanese Multicenter Registry System. Nobunori Takahashi, Toshihisa Kojima, Atsushi Kaneko, Yuji Hirano and Naoki Ishiguro 4, Nagoya University Hospital, Nagoya, Japan, Nagoya Medical Center, Nagoya, Japan, Toyohashi Municipal Hospital, Toyohashi, Japan, 4 Nagoya Univeristy Graduate School of Medicine, Nagoya, Japan 0 Program Book 7

330 ACR POSTER SESSION C 66. Economic Impact Of Adalimumab Treatment In Japanese Patients With Rheumatoid Arthritis: Analysis Of 4 Weeks Data From The Anouveau Study. Yoshiya Tanaka, Yasuhiko Shinmura, Ryo Nakajima, Takahiro Muramatsu, Shuichi Komatsu, Tadamichi Kubo, Aki Kuroki, Ataru Igarashi, Toshiro Tango 4 and Tsutomu Takeuchi 5, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, AbbVie GK, Tokyo, Japan, The University of Tokyo, Tokyo, Japan, 4 Center for Medical Statistics, Tokyo, Japan, 5 Keio University School of Medicine, Tokyo, Japan 67. Discontinuation Of Biological Therapy Due To Adverse Drug Reactions In Rheumatoid Arthritis Patients: Years Follow-Up. Luis Rodriguez-Rodriguez, Leticia Leon, Zulema Rosales, Cristina Lajas, Lucía Arietti, Ana B. Rodríguez- Cambrón, Cristina Martínez-Prada, Jose María Leal, Pilar Macarrón, Gloria Candelas, Juan A. Jover and Lydia Abásolo, Hospital Clínico San Carlos, Madrid, Spain 68. Tocilizumab Efficiently Halts Radiographic Progression In Patients With Rheumatoid Arthritis and Swollen Joint Counts Within a Year Predict Long-Term Radiographic Outcomes: Three Year Results From Michinoku Tocilizumab Study Group. Ryu Watanabe, Hiroshi Okuno, Tomonori Ishii, Yasuhiko Hirabayashi and Hideo Harigae, Tohoku University, Sendai, Japan, Tohoku University Graduate School of Medicine, Sendai, Japan, Hikarigaoka Spellman Hospital, Sendai, Japan 69. Long-Term Outcome Of Infliximab Therapy In Rheumatoid Arthritis Patients: Results From Japanese Multicenter Registry System. Nobunori Takahashi, Toshihisa Kojima, Atsushi Kaneko, Yuji Hirano and Naoki Ishiguro 4, Nagoya University Hospital, Nagoya, Japan, Nagoya Medical Center, Nagoya, Japan, Toyohashi Municipal Hospital, Toyohashi, Japan, 4 Nagoya Univeristy Graduate School of Medicine, Nagoya, Japan 70. The Effectiveness Of Biological Agents Concomitant With Tacrolimus In Rheumatoid Arthritis. Kenya Terabe, Toshihisa Kojima, Nobunori Takahashi, Koji Funahashi, Atsushi Kaneko, Daihei Kida, Yuichiro Yabe 4, Yuji Hirano 5, Masatoshi Hayashi 6 and Naoki Ishiguro, Nagoya Univeristy Graduate School of Medicine, Nagoya, Japan, Nagoya University Hospital, Nagoya, Japan, Nagoya Medical Center, Nagoya, Japan, 4 Tokyo KoseiNenkin Hospital, Tokyo, Japan, 5 Toyohashi Municipal Hospital, Toyohashi, Japan, 6 Nagano Red Cross Hospital, Nagano, Japan 7. Is a Single Variable, The Swollen Joint Count, Valid As An Outcome Measure Separate From Being In An Index Measure? An Analysis From The Prospective, Biologic Treatment Registry Across Canada. J. Carter Thorne, Boulos Haraoui, William G. Bensen, Algis Jovaisas 4, Jude F. Rodrigues 5, Denis Choquette, Alice V. Klinkhoff 6, Emmanouil Rampakakis 7, John S. Sampalis 7, Francois Nantel 8, Allen J. Lehman 8, May Shawi 8 and Susan M. Otawa 8, Southlake Regional Health Centre, Newmarket, ON, Institut de Rhumatologie de Montréal, Montreal, QC, St. Joseph s Hospital and McMaster University, Hamilton, ON, 4 University of Ottawa, Ottawa, ON, 5 Rheumatology, Windsor, ON, 6 The Mary Pack Arthritis Ctr, Vancouver, BC, 7 JSS Medical Research, St-Laurent, QC, 8 Janssen Canada Inc, Toronto, ON 7. Comparison Of Proposed Biosimilar PF With Rituximab: Nonclinical and Phase I Clinical Assessments. Dolca Thomas, Jean-Claude P. Becker and Chee-Keng Ng, Pfizer Inc., New York, NY, Pfizer Inc., Andover, MA 7. UK Clinical Practice Use Of Biologics In Monotherapy For The Treatment Of Patients With Rheumatoid Arthritis. Andrew J. Ostor, G. Chelliah, Theodoros Dimitroulas, Margaret-Mary Gordon 4, Nicola Hewson 5, JA Mitchell 5, Senam Beckley-Kartey 6, Hok Pang 6 and Jose Saraiva- Ribeiro 6, Department of Rheumatology, Addenbrookes Hospital, Cambridge, United Kingdom, Clinical Trials Unit, Wrightington Hospital, Wigan, United Kingdom, Department of Rheumatology, Research and Development, Dudley Group NHS Foundation Trust, Russell s Hall Hospital, Dudley, United Kingdom, 4 Rheumatology Department, Gartnavel General Hospital, Glasgow, United Kingdom, 5 Syne Qua Non Ltd., Diss, United Kingdom, 6 Medical Department, Roche, Welwyn Garden City, United Kingdom 74. Pharmacodynamics Of a Novel Jak Selective Inhibitor In Rat Arthritis and Anemia Models and In Healthy Human Subjects. Jeffrey Voss, Candace Graff, Annette Schwartz, Deborah Hyland, Maria Argiriadi, Heidi Camp, Lori Dowding, Michael Friedman, Kristine Frank, Jonathon George, Eric Goedken, Gloria Lo Schiavo, Michael Morytko, Robert o Brien, Robert Padley, Matthew Rosebraugh, Michael Rozema, Kent Stewart, Grier Wallace, Neil Wishart, Anwar Murtaza 4 and Lisa Olson, AbbVie Pharmaceuticals, Worcester, MA, Abbvie Pharmaceuticals, worcester, MA, abbvie pharmaceuticals, north chicago, IL, 4 Broad Institute, Cambridge, MA 75. Tocilizumab Glucocorticoids Sparing Effect: The Spare- Study. Alain Saraux, Stephanie Rouanet, Rene-Marc Flipo, Jean-Cyril Poncet 4, Patrice Fardellone 5, Pascal Hilliquin 6, Isabelle Idier 7 and Alain G. Cantagrel 8, CHU Brest et Université Bretagne Occidentale, Brest, France, Roche, Boulogne-Billancourt, France, Hopital R Salengro CHRU Lille, Lille, France, 4 General Hospital Gap, Gap, France, 5 Hôpital Nord, C.H.U. d Amiens, Amiens, France, 6 General Hospital Corbeil, Corbeil-Essonnes, France, 7 Chugai Pharma France, La Defense, France, 8 Purpan University Hospital Toulouse, Toulouse Cedex 9, France 76. A Novel and Effective Prediction Model Of Response To Rituximab In Rheumatoid Arthritis. Alper M. van Sijl, Michel W.P. Tsang-A-Sjoe, Hennie G. Raterman, Michael T. Nurmohamed and Alexandre E. Voskuyl, VU University Medical Center, Amsterdam, Netherlands 77. Biomarkers Associated With Rheumatoid Arthritis Disease Activity Including Joint Damage Correlate With Changes In Clinical Response In Subjects Treated With Mavrilimumab At Doses Above 0 Mg. Wendy White, Patricia Ryan, Xiang Guo, Dominic Sinibaldi, Gopi Ranganna, Alex Godwood, Didier Saurigny, David Close, Steve Eck, Dee Wilkins 4, Lorin Roskos 4, Matthew A. Sleeman, Wanying Li 5, Guy Cavet 5 and Nadine A. Defranoux 5, MedImmune, LLC, Gaithersburg, MD, MedImmune, LLC, Cambridge, United Kingdom, MedImmune, Ltd, Cambridge, United Kingdom, 4 MedImmune, Gaithersburg, MD, 5 Crescendo Bioscience Inc., South San Francisco, CA 8 0 Program Book

331 ACR POSTER SESSION C 78. Safety Of Mavrilimumab In Cynomolgus Monkeys: Relevance Of Nonclinical Findings In Lung To Human Safety. Patricia C. Ryan, Matthew A. Sleeman, Marlon Rebelatto, Bing Wang, Hong Lu, Chi-Yuan Wu, Dee Wilkins, Susan Spitz, Gopi Ranganna, Alex Godwood 4, Alex Michaels, Didier Saurigny 4, Lorin Roskos, David Close 4, Heidi Towers, Kathleen McKeever and Rakesh Dixit, MedImmune, Gaithersburg, MD, MedImmune, LLC, Cambridge, United Kingdom, MedImmune, Hayward, CA, 4 MedImmune, Ltd, Cambridge, United Kingdom 79. In Rheumatoid Arthritis Patients With Stable Low Disease Activity On Methotrexate Plus Etanercept, Continuation Of Etanercept Is Superior Both Clinically and Radiographically To Discontinuation: Results From a Randomized, -Armed, Double-Blind Clinical Trial. Mikkel Østergaard, Marjatta Leirisalo-Repo, Till Uhlig, Marita Jansson 4, Esbjörn Larsson 4, Fiona Brock 5 and Ronald F. van Vollenhoven 6, Copenhagen University Hospital Glostrup, Copenhagen, Denmark, Helsinki University Central Hospital, Helsinki, Finland, Diakonhjemmet Hospital, Oslo, Norway, 4 Pfizer AB, Sollentuna, Sweden, 5 Quanticate, Hitchin, Hertfordshire, United Kingdom, 6 The Karolinska Institute, Stockholm, Sweden 80. Is Isoniazid Treatment For LTBI Safe For RA Patients With TNF Inhibitor Therapy? Yoon-Kyoung Sung, Soo- Kyung Cho, Soyoung Won, Jeeseon Shim, Dam Kim, Ji-Young Choi, Chan-Nam Son, Chan-Bum Choi, Tae- Hwan Kim, Jae-Bum Jun, Dae-Hyun Yoo and Sang- Cheol Bae, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, Clinical Research Center for Rheumatoid Arthritis (CRCRA), Seoul, South Korea 8. The JAK-Selective Inhibitor GLPG064 Is Safe and Rapidly Reduces Disease Activity In Patients With Moderate To Severe Rheumatoid Arthritis; Results Of a 4-Week Dose Ranging Study. Chantal Tasset, Pille Harrison, Annegret Van der Aa, Luc Meuleners, Frédéric Vanhoutte and Gerben van t Klooster, Galapagos NV, Mechelen, Belgium 8. B Cell Analysis Is An Essential Tool To Anticipate Clinical Relapse In Rheumatoid Arthritis Patients Treated With Rituximab. Anne-Priscille Trouvin, Serge Jacquot, Sébastien Grigioni, Hélène Boulard, Ingrid Dutot, Olivier Vittecoq, Xavier Le Loët, Olivier Boyer and Vincent Goëb 4, Rouen University Hospital, Rouen, France, INSERM U905, University of Rouen, Rouen, France, Rouen University Hospital & Inserm905, University of Rouen, Rouen, France, 4 Amiens University Hospital, Amiens, France 8. A Useful Mathematical Model Able To Predict The Early Response To Tocilizumab In Rheumatoid Arthritis. Chiara Stagnaro, Claudia Ferrari, Rosaria Talarico, Camillo Giacomelli, Stefano Bombardieri and Laura Bazzichi, Rheumatology Unit, Pisa, Italy 84. Variability In Patient Characteristics and Outcomes In Rheumatoid Arthritis Upon Infliximab Treatment Based On The Size Of Biologic Treatment Registry Site. J. Carter Thorne, William G. Bensen, Sanjay Dixit, Rafat Y. Faraawi 4, Dalton E. Sholter 5, Maqbool K. Sheriff 6, Philip Baer 7, Denis Choquette 8, Boulos Haraoui 8, Algis Jovaisas 9, Emmanouil Rampakakis 0, John S. Sampalis 0, May Shawi, Francois Nantel, Allen J. Lehman and Susan M. Otawa, Southlake Regional Health Centre, Newmarket, ON, St. Joseph s Hospital and McMaster University, Hamilton, ON, McMaster University, Burlington, ON, 4 Rheumatologist, KW Musculoskeletal Research Inc., Kitchener, ON, 5 Rheumatology Associates, Edmonton, AB, 6 Nanaimo Regional General Hospital, Nanaimo, BC, 7 Rheumatology, Scarborough, ON, 8 Institut de Rhumatologie de Montréal, Montreal, QC, 9 University of Ottawa, Ottawa, ON, 0 JSS Medical Research, St-Laurent, QC, Janssen Canada Inc, Toronto, ON 85. Anti-IL-6 Antibody Clazakizumab Is More Potent Than Tocilizumab In Blocking In Vitro and Ex Vivo IL-6-Induced Functions. Q Zhao, J Pang, D Shuster, C Hung, S Baglino, R Dodge, H Sun, W Trigona and L Salter-Cid, Bristol-Myers Squibb Research and Development, Princeton, NJ 86. Survival Of Biological Therapy In Rheumatoid Arthritis: Years Follow-Up Cohort. Zulema Rosales, Cristina Vadillo, Leticia León, Rayma Peña, Margarita Blanco, Esperanza Pato, J.L. Fernández Rueda, Luis Rodriguez-Rodriguez, Benjamin Fernández-Gutiérrez, Lydia Abásolo and Juan A. Jover, Hospital Clínico San Carlos, Madrid, Spain 87. Change of serum Amyloid a predict The Effect Of Biological Treatment In Rheumatoid Arthritis Patient. Chisa Okura, Yukio Yonemoto, Koichi Okamura, Tetsuya Kaneko, Tsutomu Kobayashi and Kenji Takagishi, Gunma University Graduate School of Medicine, Maebashi, Gunma, Japan, Inoue Hospital, Takasaki, Gunma, Japan 88. Predictive Factors Of Relapse Or Persistent Stable Remission For Rheumatoid Arthritis (RA) Patients In Remission in a TNF Blocker-Spacing Strategy Trial (STRASS Trial). Thao Pham, Jacques Morel, Toni Alfaiate, Emmanuelle Dernis 4, Philippe Gaudin 5, Olivier Brocq 6, Elisabeth Solau-Gervais 7, Jean-Marie Berthelot 8, Jean- Charles Balblanc 9, Xavier Mariette 0, Florence Tubach and Bruno Fautrel, Sainte Marguerite Hospital, Marseille, France, Lapeyronie Hospital, Montpellier, France, AP-HP, Paris, France, 4 Le Mans Hospital, Le Mans, France, 5 CHU Hôpital Sud, Grenoble Teaching Hospital, Echirolles, France, 6 Hospital of Princesse Grâce de Monaco, Monaco, France, 7 University Hospital of Poitiers, Poitiers, France, 8 Nantes University Hospital, Nantes, France, 9 Centre Hospitalier Général de Belfort, Belfort, France, 0 Bicêtre University Hospital, Le Kremlin Bicetre, France, Universite Paris Diderot, Paris, France, Paris 6 Pierre et Marie Curie University; AP-HP, Rheumatology, Pitié-Salpêtrière Hospital, - GRC-UPMC 08 EEMOIS, Paris, France 89. Tocilizumab Survives Introducing The Hemadialysis Longer Than Oral Medicine In AA Amyloidosis Patients With Rheumatoid Arthritis Of Renal Insufficiency. Osamu Saiki, Hiroshi Uda, Ayumi Matsumoto, Aya Mizumoto, Tamaki Harada and Toshirou Takama, Higashiosaka City General Hospital, Higashiosaka, Japan 0 Program Book 9

332 ACR POSTER SESSION C 90. Low Dose Of Tocilizumab Can Be Effective In RA Patients Who Achieve Remission.. Cecilia Prieto- Candau, Virginia Moreira- Navarrete, Carmen Vargas-Lebrón, Juan M Prieto-Martinez, Dolores Ruiz-Montesinos, Javier Toyos-Saenz de Miera and Federico Navarro-Sarabia, Hospital Virgen Macarena, SEVILLE, Spain, Hospital Virgen Macarena, Seville, Spain, Hospital Virgen Macarena, Serv. de Reumatología, Sevilla, Spain 9. Pathogenic Pro-Inflammatory Cytokine Production Induced By Synovial Fluid From RA Patients Is Related To Levels Of Endogenous TLR4 Ligands and Is Blocked By a Novel Therapeutic Anti-Human TLR4 Monoclonal Antibody, NI-00. Limin Shang, Greg Elson, Jeremy Sokolove, Prof Iain B. McInnes, James Reilly, Eric Hatterer, Marie Kosco-Vilbois 4, Walter Ferlin 4, Emmanuel Monnet 4 and Cristina de Min 4, NovImmune S.A., Plan-Les- Ouates, Geneva, Switzerland, VA Palo Alto Health Care System and Stanford University, Palo Alto, CA, University of Glasgow, Glasgow, United Kingdom, 4 NovImmune S.A., Geneva, Switzerland 9. Impact Of CT-P and Originator Infliximab Treatment On Quality Of Life Derived From The Health Assessment Questionnaire (HAQ) and Short-Form 6 (SF-6) From a Randomized, Double-Blind Trial In Patients With Active RA. Dae-Hyun Yoo, Andriy Yagensky, Antoaneta Toncheva, Osca Ruiz Santacruz 4, Fidencio Cons Molina 5, Yunju Bae 6, Taek Kwon 6, SinHye Kim 6, Peter Lacouture 7, Teresa Kok 8 and Won Park 9, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, Lutsk City Hospital, Lutsk, Ukraine, National Multiprofile Transport Hospital, Sofia, Bulgaria, 4 Centro Integral de Reumatología e Inmunología - CIREI S.A.S, Bogotá, Colombia, 5 Centro de Investigacion en Artritis y Osteoporosis SC, Mexicali, Mexico, 6 Celltrion Inc., Incheon, South Korea, 7 Hospira Inc, Lake forest, IL, 8 Hospira Inc., Lake Forest, IL, 9 Inha University Hospital, Incheon, South Korea Rheumatoid Arthritis: Human Etiology and Pathogenesis II 9. Involvement Of Transitional T Follicular Like Helper Cells Bearing Triple Phenotypes Of Tfh/Th/Th7 In The Pathogenesis Of Rheumatoid Arthritis. Shingo Nakayamada, Satoshi Kubo, Naoki Yunoue, Maiko Yoshikawa, Shunsuke Fukuyo, Kazuyoshi Saito and Yoshiya Tanaka, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan 94. In Rheumatoid Arthritis, Smoking Is Not Primarily Associated With Anti-Citrullinated Protein Antibodies, But With The Presence Of Multiple Autoantibodies. Ammar Muhammad, Tineke van Wesemael, Yuta Kochi, Maria Mjaavatten, Kirsten Wevers-de-Boer, Cornelia F. Allaart, Leendert A. Trouw, Akari Suzuki, Kazuhiko Yamamoto 4, Annette H.M. van der Helm-van Mil, Tom W.J. Huizinga, René E.M. Toes and Diane van der Woude, Leiden University Medical Center, Leiden, Netherlands, RIKEN, Yokohama, Japan, Diakonhjemmet Hospital, Oslo, Norway, 4 Graduate School of Medicine, The University of Tokyo, Tokyo, Japan 95. Plasma Short-Talin Is a New Rheumatoid Arthritis Monitoring Biomarker Independent Of The Inflammatory Markers. Kensei Tsuzaka, Masako Takao and Jiro Nishida, Ichikawa General Hospital,TDC, Ichikawa, Chiba, Japan 96. PIKdelta Regulates Invadosome Formation and Invasiveness Of Fibroblast-Like Synoviocyte In Rheumatoid Arthritis. Beatrix Bartok and G. S. Firestein, UCSD School of Medicine, La Jolla, CA 97. To Which Extent May The Familial Risk Of Rheumatoid Arthritis Be Explained By Established Risk Factors? Xia Jiang, Thomas Frisell, Johan Askling, Lars Klareskog, Lars Alfredsson and Henrik Källberg, Karolinska Institutet, Stockholm, Sweden, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden 98. Redox Mediated Angiogenesis In The Hypoxic Joint Of Inflammatory Arthritis. Monika Biniecka, Chin Teck Ng, Emese Balogh, Douglas J. Veale and Ursula Fearon, Translation Research Group, Dublin Academic Medical Centre, St. Vincent s University Hospital, Dublin, Ireland, St. Vincent s University Hospital, Dublin 4, Ireland 99. Altered Histone Methylation Is Associated With IL-6 Dependent Matrix Metalloproteinases Gene Transcriptional Activation In Rheumatoid Arthritis Synovial Fibroblasts. Yasuto Araki, Takuma Tsuzuki Wada, Kojiro Sato, Kazuhiro Yokota, Fumihiko Miyoshi, Yu F. Asanuma, Yuji Akiyama and Toshihide Mimura, Research Center for Genomic Medicine, Saitama Medical University, Saitama, Japan, Saitama Medical University, Saitama, Japan 400. Targeted Exon Resequencing For Korean Rheumatoid Arthritis. So-Young Bang, Kwangwoo Kim, Young-Ji Na, Jaemoon Lee, Youngho Park, Sun Young Lee 4, Adnan Ahmad Ansari 4, Chan-Bum Choi, Yoon-Kyoung Sung, Tae-Hwan Kim, Jae-Bum Jun, Dae-Hyun Yoo, Junghee Jung 5, Hwanseok Rhee 6, Jong-Young Lee 7, Bok-Ghee Han 7, Sung-Min Ahn 4, Sungho Won, Hye-Soon Lee and Sang-Cheol Bae, Hanyang University Guri Hospital, Guri, South Korea, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, Chung-Ang University, Seoul, South Korea, 4 Gachon University, Incheon, South Korea, 5 Bioinfomatics Center, Macrogen Inc, Seoul, South Korea, 6 Bioinfomatics Center, Macrogen Inc, Seoul, South Korea, 7 Korea National Institute of Health, Osong, South Korea 40. Disease Activity (DAS-8CRP) In Rheumatoid Arthritis Correlates With Synovial Expression Of Tumor-Associated and IL-6-Dependent Genes. Bernard Lauwerys, Julie Ducreux, Adrien Nzeusseu Toukap, Valérie Badot, Frédéric A. Houssiau and Patrick Durez, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain, Brussels, Belgium, Hôpital Erasme, Université Libre de Bruxelles, Brussels, Belgium 0 0 Program Book

333 ACR POSTER SESSION C 40. Association Between Life Events and Rheumatoid Arthritis, Results From The EIRA Case Control Study. Annmarie Wesley, Camilla Camilla Bengtsson, Marie Holmqvist, Töres Theorell, Saedis Saevarsdottir 4, Eva Skillgate, Lars Klareskog 4, Lars Alfredsson and Sara Wedrén 4, Karolinska Insitutet, Stockholm, Sweden, Karolinska Institutet, Stockholm, Sweden, Public Health Sciences, Karolinska Insitutet, Stockholm, Sweden, 4 Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden 40. The Incidence Of Factor V Leiden A69G, Methylene Tetrahydrofolate Reductase C677T, and Prothrombin G00A Mutation In Patients With Rheumatoid Arthritis. Taskin Senturk, Zahit Bolaman, Sabri Batun, Irfan Yavasoglu and Gurhan Kadikoylu, Professor, Aydin, Turkey, Professor, Diyarbakır, Turkey, Associated Professor, Aydin, Turkey 404. CXCL-Producing CD4 T-Cells In Rheumatoid Synovitis Are a Distinct Subset. Shio Kobayashi, Koichi Murata, Hideyuki Shibuya, Masahiro Ishikawa, Moritoshi Furu, Hiromu Ito, Shuichi Matsuda, Takeshi Watanabe and Hiroyuki Yoshitomi, Kyoto University Graduate School of Medicine, Kyoto, Japan, Graduate School of Medicine, Kyoto University, Kyoto, Japan 405. Respiratory Diseases As Risk Factors For Rheumatoid Arthritis. Marie Holmqvist, Johan Askling, Lars Alfredsson, Camilla Bengtsson, Fredrik Nyberg and Göran Tornling, Karolinska Institutet, Stockholm, Sweden, AstraZeneca R&D, Mölndal, Sweden, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden 406. The Relationship Between Anti-Citrullinated Protein Antibodies and Radiographic Damage In African- Americans With Rheumatoid Arthritis. Maria I. Danila, Richard J. Reynolds, Stella Aslibekyan, Ashutosh Tamhane, Laura B. Hughes, Jeremy Sokolove, William H. Robinson 4, Doyt L. Conn 5, Beth L. Jonas 6, Leigh F. Callahan 7, Larry W. Moreland 8, Richard D. Brasington 9, Edwin A. Smith 0, Ted R. Mikuls, Désirée van der Heijde and S. Louis Bridges Jr., Univ of Alabama-Birmingham, Birmingham, AL, University of Alabama at Birmingham, Birmingham, AL, VA Palo Alto Health Care System and Stanford University, Palo Alto, CA, 4 Stanford University School of Medicine, Stanford, CA, 5 Emory Univ School of Medicine, Atlanta, GA, 6 University of North Carolina at Chapel Hill, Chapel Hill, NC, 7 University of North Carolina, Chapel Hill, NC, 8 University of Pittsburgh, Pittsburgh, PA, 9 Washington Univ School of Med, St. Louis, MO, 0 Med Univ of South Carolina, Charleston, SC, Omaha VA and University of Nebraska Medical Center, Omaha, NE, Leiden University Medical Center, Leiden, Netherlands 407. Rheumatoid Arthritis-Related Autoantibodies In The Lung Evolve Over Time In Subjects At Elevated Risk For Future Rheumatoid Arthritis. M. Kristen Demoruelle, Patrick R. Wood, Michael H. Weisman, Mark C. Parish, Isabel F. Pedraza, Jill M. Norris, V. Michael Holers and Kevin D. Deane, University of Colorado School of Medicine, Aurora, CO, Cedars-Sinai Medical Center, Los Angeles, CA, Colorado School of Public Health, Aurora, CO 408. Secretory Leukocyte Protease Inhibitor Released By Rheumatoid Synovial Fibroblasts Exerts a Negative Control Of BAFF-Dependent B Cell Activation In Vitro and In Vivo In The Collagen-Induced and Chimeric RA/SCID Arthritis Models. Yvonne NW Kam, Andrew Filer, Christopher D. Buckley, Costantino Pitzalis 4 and Michele Bombardieri 4, Centre for Experimental Medicine and Rheumatology, QMUL, London, United Kingdom, Rheumatology Department, Birmingham, United Kingdom, University of Birmingham, Birmingham, United Kingdom, 4 William Harvey Research Institute, QMUL, London, United Kingdom 409. Association Of High Serum Interleukin- Levels With Porphyromonas Gingivalis Antibodies In Patients With Early Rheumatoid Arthritis. Sheila L. Arvikar, Klemen Strle, Deborah S. Collier, Mark C. Fisher, Toshihisa Kawai, Jose U. Scher and Allen C. Steere, Massachusetts General Hospital, Boston, MA, Forsyth Institute, Cambridge, MA, NYU Hospital for Joint Diseases, New York, NY 40. Effects Of Leptin and Adiponectin On Proliferation and Activation Were Are Significantly Increased In CD4 + T Cells From Rheumatoid Arthritis Patients. Daniel Xibille- Friedmann, Carolina Bustos-Rivera Bahena, Marisol Sandoval-Rios and Jose Luis Montiel-Hernandez, Hospital General de Cuernavaca, Cuernavaca, Mexico, Facultad de Ciencias, Cuernavaca, Mexico, Facultad de Farmacia, Cuernavaca, Mexico 4. The Peripheral Blood T Cell Repertoire Before The Clinical Onset Of Rheumatoid Arthritis a Study Of Incident Cases and Controls. Carl Turesson, Ulf Bergström, Edgars Grins, Olle Melander, Lennart Truedsson, Lennart Jacobsson and Stefan Jovinge, Lund University, Malmö, Sweden, Lund University, Lund, Sweden 4. Anti-CCP Antibodies and Increased Cartilage Turnover In Patients Developing Rheumatoid Arthritis. Carl Turesson, Christina Book, Ulf Bergström, Lennart Truedsson, Lennart Jacobsson and Tore Saxne, Lund University, Malmö, Sweden, Lund University, Lund, Sweden 4. Expression and Function Of a YAP, a Novel Pathway In Fibroblast-Like Synoviocyte In Rheumatoid Arthritis. Beatrix Bartok, UCSD School of Medicine, La Jolla, CA 44. Elevated Serum Resistin Levels In Rheumatoid Arthritis With Periodontitis. Byoong Yong Choi, Jin-Hee Kim, Kyung Hwa Kim, Kyong Rok Kim, Sang Hyun Joo, Myeong Jae Yoon 4, Hye Jin Oh 5, Hye Won Kim, Sung Hae Chang, Eun Young Lee, Eun Bong Lee, Yong-Moo Lee and Yeong Wook Song, Seoul National University College of Medicine, Seoul, South Korea, Department of Periodontology, School of Dentistry, Seoul National University, Seoul, South Korea, Division of Rheumatology, Department of Internal Medicine, Seoul National University, Seoul, South Korea, 4 Division of Rheumatology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, South Korea, 5 Seoul National University, Seoul, South Korea 0 Program Book

334 ACR POSTER SESSION C 45. Phosphorylated Venous Endothelial Nitric Oxide Synthase Is Elevated In Rheumatoid Arthritis Subjects With High Disease Activity. Elizabeth Blair Solow, Wanpen Vongpatanasin and David R. Karp, UT Southwestern Medical Center, Dallas, TX 46. Discovery Of Novel Biomarkers In Rheumatoid Urine : Significance Of Urinary CD4. Yune-Jung Park, Hyun-Sook Kim, Seung-Ah Yoo, Susanna Choi, Dong-Ho Kim 4, Chul- Soo Cho 5 and Wan-Uk Kim 5, Division of Rheumatology, Department of Internal Medicine, The Catholic University of Korea, School of Medicine, Seoul, Korea, Suwon, South Korea, Division of Rheumatology, Department of Internal Medicine, Soonchunhyang University of Korea, Seoul, Korea, Seoul, South Korea, Research Institute of Immunobiology, The Catholic University of Korea, Seoul, South Korea, 4 Research Institute of Immunobiology, Catholic Research Institute of Medical Science, Seoul, Korea., Seoul, South Korea, 5 College of Medicine, The Catholic University of Korea, Seoul, South Korea 47. Antibodies To Porphyromonas Gingivalis Peptidylarginine Deiminase In Rheumatoid Arthritis Are Not Directed Against The Autocitrullinated Enzyme. Maximilian F. Konig, Alizay Paracha, Malini Moni, Clifton O. Bingham III and Felipe Andrade, Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, The University of Oklahoma, Norman, OK 48. The Transmembrane Protein Tyrosine Phosphatase Kappa Promotes Aggressiveness Of Rheumatoid Arthritis Fibroblast-Like Synoviocytes. Stephanie M. Stanford, William B. Kiosses, Amanda M. Campbell, Michael F. Maestre, David L. Boyle, Gary S. Firestein and Nunzio Bottini, La Jolla Institute for Allergy and Immunology, La Jolla, CA, The Scripps Research Institute, La Jolla, CA, UCSD School of Medicine, La Jolla, CA 49. CDK6 Transcripts Expression Control By The Synoviocyte Proliferation Gene, SPACIA. Rie Komatsu, Ryoji Fujii, Tomoo Sato, Yoshihisa Yamano, Kazuo Yudoh, Moroe Beppu, Kusuki Nishioka and Toshihiro Nakajima, St. Marianna University School of Medicine, Kanagawa, Japan, Tokyo Medical University, Tokyo, Japan, Misato Marine Hospital, Kohchi, Japan 40. Pleiotropic Roles Of Fcγ Receptors Upregulated On Circulating Monocytes In Rheumatoid Arthritis Patients. Masako Tsukamoto, Katsuya Suzuki, Keiko Yoshimoto, Hideto Kameda and Tsutomu Takeuchi, Keio University School of Medicine, Tokyo, Japan 4. Association Between Physical Work Load and Rheumatoid Arthritis, Results From The EIRA Case Control Study. Annmarie Wesley, Henrik Källberg, Camilla Bengtsson, Eva Skillgate, Johan Rönnelid, Mohammed Mullazehi, Lars Klareskog 4, Lars Alfredsson, Saedis Saevarsdottir 4 and Sara Wedren 5, Karolinska Insitutet, Stockholm, Sweden, Karolinska Institutet, Stockholm, Sweden, Uppsala University, Uppsala, Sweden, 4 Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden, 5 Rheumatology Unit, Department of Medicine, Karolinska University Hospital, Karolinska Institute, Stockholm, Sweden 4. Anti-P. Gingivalis antibody Is Correlated With Severity Of Periodontitis But Not With Rheumatoid Arthritis Disease Activity In RA. Joo Youn Lee, In Ah Choi, Jin-Hee Kim, Kyung-Hwa Kim 4, Hye Jin Oh 5, Myeong Jae Yoon 6, Eun Young Lee, Eun Bong Lee, Yong-Moo Lee and Young Wook Song, Department of Molecular Medicine and Biopharmaceutical Sciences, Seoul National University, Seoul, South Korea, Division of Rheumatology, Department of Internal Medicine, Seoul National University, Seoul, South Korea, Department of Periodontology, School of Dentistry, Seoul National University, Seoul, South Korea, 4 Department of Periodontology and Dental Research Institute, School of Dentistry, Seoul National University, Seoul, South Korea, 5 Seoul National University, Seoul, South Korea, 6 Division of Rheumatology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, South Korea 4. Mir-7b As Biomarker and Regulator Of IL-6R Pathway In Resistant Rheumatoid Arthritis Monocyte. Marina Frleta, Ashleigh-Ann Rainey, Derek S. Gilchrist, Lynn Crawford, Derek Baxter, Mariola Kurowska-Stolarska and Prof Iain B. McInnes, University of Glasgow, Glasgow, United Kingdom 44. Investigation Of The Role Of Histone Deacetylases In Rheumatoid Arthritis Synovial Fibroblasts. Sarah Hawtree, Munitta Muthana, Sarah Aynsley, J. Mark Wilkinson and Anthony G. Wilson, University of Sheffield, Sheffield, United Kingdom 45. Impaired TNFá Production By Dendritic Cells From Rheumatoid Arthritis Patients Upon Contact With Porphyromonas Gingivalis. Kim CM Santegoets, Mark H. Wenink, Wim B van den Berg and Timothy RDJ Radstake, University Medical Center Utrecht, Utrecht, Netherlands, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands 46. Signaling Abnormalities In Neutrophil Granulocytes Of Rheumatoid Arthritis Patients Are Associated With Increased Extracellular Trap Formation and Provide a Basis For The Induction Of Anti-Citrullinated Peptide Antibodies. Chanchal Sur Chowdhury, Stavros Giaglis, Ulrich A. Walker, Andreas Buser, Paul Hasler and Sinuhe Hahn, University Hospital Basel, Basel, Switzerland, Kantonsspital Aarau, Aarau, Switzerland 47. Enhanced Expression Of mrna For Triggering Receptor Expressed On Myeloid Cells In CD4+ Cells Of The Bone Marrow In Rheumatoid Arthritis. Tatsuo Nagai, Tetsuya Tomita, Hideki Yoshikawa and Shunsei Hirohata, Kitasato University School of Medicine, Sagamihara, Japan, Osaka University Graduate School of Medicine, Suita, Japan 48. Suppression Of Tumor Necrosis Factor Receptor Associated Factor (TRAF) 6 Attenuates The Proinflammatory Effect Of Rheumatoid Arthritis Fibroblast-Like Synoviocytes. Lang Jing Zhu, Jing Jing Zhou, Chan Juan Zou, Dong Hui Zheng, Xiu Ning Wei, Jian Da Ma, Ying Qian Mo and Lie Dai, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China 0 Program Book

335 ACR POSTER SESSION C 49. Enhanced Responsiveness To Stimulation and Increased Extrusion Of Extracellular Traps By Rheumatoid Arthritis Neutrophil Granulocytes and of Healthy Control Neutrophils to Serum and Synovial Fluid From Rheumatoid Arthritis Patients. Stavros Giaglis, Chanchal Sur Chowdhury, Ulrich A. Walker, Andreas Buser, Sinuhe Hahn and Paul Hasler, Kantonsspital Aarau, Aarau, Switzerland, University Hospital Basel, Basel, Switzerland 40. Antibodies To Porphyromonas Gingivalis as An Etiological Clue To The Development Of Anti-Citrullinated Protein Antibody Positive Rheumatoid Arthritis. Nastya Kharlamova, Natalia Sherina, Anne-Marie Quirke, Kaja Eriksson, Lena Israelsson 4, Jan Potempa 5, Patrick Venables, Tulay Yucel-Lindberg and Karin Lundberg 6, Rheumatology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden, Kennedy Institute of Rheumatology, Oxford, United Kingdom, Department of Dentistry, Karolinska Institutet, Stockholm, Sweden, 4 Rheumatology unit, Karolinska University Hospital, Karolinska Institute, Stockholm, Sweden, 5 Jagiellonian University, Krakow, Poland, 6 Rheumatology unit, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden 4. Association Of T Follicular Helper / Th7 T Cell and Memory B Cell Populations In Rheumatoid Arthritis With Disease Activity and Therapy With TNF Antagonists. Marc C. Levesque, Camilla Macedo, Lisa Boyette, Kevin Hadi, Erich R Wilkerson, Diana Metes, Larry W. Moreland and Mandy J. McGeachy, University of Pittsburgh, Pittsburgh, PA, Univeristy of Pittsburgh, Pittsburgh, PA 4. Characterization Of Lung Inflammation and Identification Of Shared Citrullinated Targets In The Lungs and Joints Of Early RA. Vijay Joshua, Gudrun Reynisdottir, Jimmy Ytterberg, Marianne Engström, Anders Eklund, Magnus Skold, Per-Johan Jakobsson, Johan Rönnelid 4, Vivianne Malmström 5, Lars Klareskog, Johan Grunewald and Anca I Catrina, Rheumatology unit, Karolinska University Hospital, Karolinska Institute, Stockholm, Sweden, Rheumatology Unit, Karolinska University Hospital, Karolinska Institute, Stockholm, Sweden, Division of Respiratory Medicine, Karolinska University Hospital, Karolinska Institute, Stockholm, Sweden, 4 Uppsala University, Uppsala, Sweden, 5 Rheumatology unit, Karolinska University Hospital, Karolinska Institutet, STockholm, Sweden, Stockholm, Sweden Spondylarthropathies and Psoriatic Arthritis: Clinical Aspects and Treatment III 4. Evaluation Of The Two-Step Referral Strategy For Axial Spondyloarthritis In The Spondyloarthritis Caught Early Cohort. Ozair Abawi, Rosaline van den Berg, Désirée van der Heijde, Manouk de Hooge, Pauline Bakker, Monique Reijnierse, Tom Huizinga, Juergen Braun and Floris van Gaalen, Leiden University Medical Center, Leiden, Netherlands, Rheumazentrum Ruhrgebiet, Herne, Germany 44. Syndesmophyte Distribution Along The Vertebral Rim In Ankylosing Spondylitis Is Non-Random. Sovira Tan, Abhijit Dasgupta, Jianhua Yao, John A. Flynn, Lawrence Yao and Michael M. Ward, NIAMS/NIH, Bethesda, MD, NIH Clinical Center, Bethesda, MD, Johns Hopkins University, Baltimore, MD 45. Prevalence Of Inflammatory Lesions MRI-Spine In Patients With Chronic Back Pain Of Years Duration Included In The SPACE-Cohort. Manouk de Hooge, Rosaline van den Berg, Monique Reijnierse, Victoria Navarro-Compán, Floris van Gaalen, Karen Fagerli, Maureen C. Turina, Maikel van Oosterhout 4, Roberta Ramonda 5, Tom Huizinga and Désirée van der Heijde, Leiden University Medical Center, Leiden, Netherlands, Diakonhjemmet Hospital, Oslo, Norway, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, 4 GHZ Hospital, Gouda, Netherlands, 5 University of Padova, Padova, Italy 46. Classification Of Axspa Based On Positive Imaging (Radiographs and/or MRI of the Sacroiliac Joints) By Local Rheumatologists Or Radiologists Versus Central Trained Readers In The DESIR-Cohort. Rosaline van den Berg, Grégory Lenczner, Fabrice Thévenin, Pascal Claudepierre, Antoine Feydy, Monique Reijnierse, Alain Saraux 4 and Désirée van der Heijde, Leiden University Medical Center, Leiden, Netherlands, Henri Mondor Teaching Hospital, AP-HP, Créteil, France, Paris Descartes University, Côchin Hospital, APHP, Paris, France, 4 Université Brest Occidentale, Brest, France 47. Prevalence Of Axial Spondyloarthritis In The United States Among Patients With Chronic Back Pain and Other Spondyloarthritis-Related Features. Atul Deodhar, Philip J. Mease, Jeffrey R. Curtis, Piyalal M. Karunaratne 4, Kailash Malhotra 4 and Aileen L. Pangan 4, Oregon Health & Science University, Portland, OR, University of Washington and Swedish Medical Center, Seattle, WA, University of Alabama at Birmingham, Birmingham, AL, 4 AbbVie Inc., North Chicago, IL 48. Effectiveness Of Exercise Program in Ankylosing Spondylitis: Meta-Analysis Of Randomized Controlled Trials. Virginie Pécourneau, Arnaud L. Constantin and Alain G. Cantagrel, CHU Toulouse, Toulouse, France, Purpan University Hospital, Toulouse Cedex 9, France, Hopital Purpan, Toulouse CEDEX 9, France 49. Smoking Was Not Associated With Response To Adalimumab Therapy In Patients With Non-Radiographic Axial Spondyloarthritis. Joachim Sieper, Denis Poddubnyy, Aileen L. Pangan, Suchitrita S. Rathmann and Jaclyn K. Anderson 4, Charité Universitätesmedizin, Berlin, Germany, Charité Universitätsmedizin Berlin, Berlin, Germany, AbbVie Inc., North Chicago, IL, 4 AbbVie, North Chicago, IL 0 Program Book

336 ACR POSTER SESSION C Is There a Role For Etoricoxib In Patients With Axial Ankylosing spondylitis Refractory To Traditional NSAID? Maria García Manrique, Pilar Font, Joan Calvet, María Cruz Fernandez 4, Carlos Montilla 5, Luis Linares 6, Elia Brito 7, Xavier Juanola 8, Juan Mulero 9, Rubén Queiro 0, Rosa M. Morla, Rosario Garcia-Vicuña, Alba Erra, Mireia Moreno 4, Marta Larrosa 5, Eduardo Collantes 6 and Jordi Gratacos 7, Hospital Parc Taulí, Sabadell, Spain, IMIBIC-Reina Sofia Hospital, Cordoba, Spain, Corporació Sanitària Parc Taulí, Sabadell, Spain, 4 Hospital General de Móstoles, Mostoles, Spain, 5 Hospital Universitario de Salamanca, Salamanca, Spain, 6 Hospital Universitario Virgen de la Arrixaca, Murcia, Spain, 7 Hospital Ramón y Cajal, Madrid, Spain, 8 Hospital Universitari de Bellvitge, Barcelona, Spain, 9 Hospital Universitario Puerta de Hierro Majadahonda, Majadahonda (Madrid), Spain, 0 Rheumatology Department. Hospital Universitario Central de Asturias, Oviedo, Spain, Hospital Sta Tecla, Tarragona, Spain, Hospital Universitario de La Princesa, Madrid, Spain, Hospital de Sant Rafael, Barcelona, Spain, 4 Hospital Universitari Parc Taulí, Sabadell, Spain, 5 Hospital Universitari Parc Tauli, Sabadell, Spain, 6 Hospital Reina Sofia, Cordoba, Spain, 7 Hospital Universitari Parc Taulí, Sabadell (Barcelona), Spain 44. Do Postural Deformities In Patients With Ankylosing Spondylitis Cause Balance Problems? M. Ece Cinar, Yesim Akkoc, Hale Karapolat and Gokhan Keser, Ege University School of Medicine, Izmir, Turkey 44. [8F]-Fluoride PET/CT Assessment In Patients Responding To The ASAS Criteria For Spondyloarthritis Despite Negative Sacroiliac Joint MRI. Cecile Caoduro, Orland Angoue, Hatem Boulahdour and Eric Toussirot, University Hospital, Besançon, France, CIC Biotherapy 506 and Rheumatology and EA 466 Pathogens and Inflammation, Besançon, France 44. Prevalence Of Coronary Heart Disease In Spondyloarthopathies may Be Increased Due To Higher Prevalence Of Risk Factors As Well As The Disease Itself- A Retrospective Analysis At Single VA Medical Center. Trayton Mains and Vikas Majithia, University of Mississippi Medical Center, Jackson, MS, G.V. Sonny Montogomery VA Medical Center, Jackson, MS 444. The Contribution Of Disease Activity On Function and Quality Of Life In Patients With Ankylosing Spondylitis; Investigating Causality By Using Structural Equation Model. Servet Akar, Sabri Erdem, Kivanc Akat, Dilek Solmaz and Ismail Sari, Dokuz Eylul University School of Medicine, Izmir, Turkey, Dokuz Eylul University Faculty of Business, Izmir, Turkey 445. Acute Phase Reactant As a Marker Of Anti-Drug Antibody Formation In Ankylosing Spondylitis. Seokchan Hong, Eun-Ju Lee, You Jae Kim, Bon San Koo, Wook Jang Seo, Kyung joo Ahn, Yong-Gil Kim, Chang-Keun Lee and Bin Yoo, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea, Seoul Veterans Hospital, Seoul, South Korea, KEPCO medical center, Seoul, South Korea 0 Program Book 446. Opiate Use In Patients With Ankylosing Spondylitis. John D. Reveille, Michael M. Ward, MinJae Lee, Mohammad Rahbar, Manouchehr Ardjomand-Hessabi, Laura A. Diekman, Matthew A. Brown 4, Lianne S. Gensler 5 and Michael H. Weisman 6, University of Texas Health Science Center at Houston, Houston, TX, NIAMS/NIH, Bethesda, MD, The University of Texas Health Science Center at Houston, Houston, TX, 4 University of Queensland Diamantina Institute, Brisbane, Australia, 5 University of California, San Francisco, San Francisco, CA, 6 Cedars-Sinai Medical Center, Los Angeles, CA 447. Disease Activity Is Associated With Development Of Inflammatory Bowel Disease In Ankylosing Spondylitis: -Year Results From OASIS. Ivette Essers, Sofia Ramiro, Carmen Stolwijk, Robert Landewé, Désirée van der Heijde, Filip van Den Bosch 4, Maxime Dougados 5 and Astrid Van Tubergen 6, Maastricht University, Maastricht, Netherlands, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands, Leiden University Medical Center, Leiden, Netherlands, 4 Department of Rheumatology Ghent University Hospital, Ghent, Belgium, 5 Rheumatology B Department, Paris-Descartes University, Cochin Hospital, Paris, France, 6 Maastricht University Medical Center, Maastricht, Netherlands 448. Cardiovascular Disease Is Associated With Worse Functional Outcomes In Ankylosing Spondylitis. Lianne S. Gensler, Michael M. Ward, MinJae Lee, Mohammad Rahbar, Matthew A. Brown 4, John D. Reveille 5 and Michael H. Weisman 6, University of California, San Francisco, San Francisco, CA, NIAMS/NIH, Bethesda, MD, The University of Texas Health Science Center at Houston, Houston, TX, 4 University of Queensland Diamantina Institute, Brisbane, Australia, 5 University of Texas Health Science Center at Houston, Houston, TX, 6 Cedars-Sinai Med Ctr, Los Angeles, CA 449. Patient-Reported Disease Activity and Outcome In Male Versus Female Patients Of The Groningen Leeuwarden Axial Spondyloarthritis (GLAS) Cohort. Suzanne Arends, Fiona Maas, Eveline van der Veer, Reinhard Bos, Monique Efde, Martha K. Leijsma, Hendrika Bootsma, Elisabeth Brouwer and Anneke Spoorenberg, University Medical Center Groningen, Groningen, Netherlands, Medical Center Leeuwarden, Leeuwarden, Netherlands 450. Differences and Similarities Of Spondyloarthritis Classification Subgroups Defined By The Assessment Of Spondyloarthritis International Society (ASAS). Jacqueline E. Paramarta, Maud Van de Schoot, Maureen C. Turina, Carmen A. Ambarus, Johannes W.J. Bijlsma, Leen de Rycke and Dominique L. Baeten, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, University Medical Center Utrecht, Utrecht, Netherlands 45. Work Instability Scores In Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis Are Equal and Higher Than In Psoriatic Arthritis. Sherry Rohekar, Robert D. Inman and Dafna D. Gladman, St. Joseph s Hospital, London, ON, Toronto Western Research Institute, University Health Network and University of Toronto, Toronto, ON, University of Toronto, Toronto Western Hospital, Toronto, ON

337 ACR POSTER SESSION C 45. Effects Of Smoking In Patients With Axial Spondyloarthritis - Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis - Receiving Anti- TNF therapy. Ozlem Pehlivan, Yasemin Yalcinkaya, Nihat Huseyinsinoglu, Nilufer Alpay Kanitez, Burak Erer, Sevil Kamali, Murat Inanç, Orhan Aral, Ahmet Gul and Lale Ocal, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey 45. Identification Of Determinants Of The Functional Outcome In Patients With Early Axial Spondyloarthritis: Results From The German Spondyloarthritis Inception Cohort. Denis Poddubnyy, Hildrun Haibel, Joachim Listing, Jürgen Braun, Martin Rudwaleit 4 and Joachim Sieper, Charité Universitätsmedizin Berlin, Berlin, Germany, German Rheumatism Research Center, Berlin, Germany, Rheumazentrum Ruhrgebiet, Herne, Germany, 4 Endokrinologikum Berlin, Berlin, Germany 454. High Prevalence Of Left Ventricular Diastolic Dysfunction In Patients With Ankylosing Spondylitis. Sjoerd C. Heslinga, Thelma C. Konings, Irene E. Van der Horst-Bruinsma and Michael T. Nurmohamed, VU University Medical Center, Amsterdam, Netherlands 455. The Lipid Profile Improves In Patients With Ankylosing Spondylitis Responding To TNF Blocking Therapy. Sjoerd C. Heslinga, Irene E. Van der Horst-Bruinsma, Alper M. van Sijl and Michael T Nurmohamed, VU University Medical Center, Amsterdam, Netherlands, Jan van Breemen Research Institute Reade, Amsterdam, Netherlands 456. Prevalence Of Overweight and Obesity and The Relation To Disease Activity, Physical Function and Quality Of Life In Patients With Axial Spondyloarthritis. Fiona Maas, Anneke Spoorenberg, Eveline van der Veer, Reinhard Bos, Monique Efde, Hendrika Bootsma, Elisabeth Brouwer and Suzanne Arends, University Medical Center Groningen, Groningen, Netherlands, Medical Center Leeuwarden, Leeuwarden, Netherlands 457. Ankylosing Spondylitis and a Diagnostic Dilemma: Coccydynia. Rabia Deniz, Gülsen Ozen, Sibel Yilmaz-Oner, Sibel Z. Aydin, Can Erzik, Osman Hakan Gunduz, Nevsun Inanc, Haner Direskeneli and Pamir Atagunduz, Marmara University School of Medicine, Istanbul, Turkey, Medeniyet University, Goztepe Training and Research Hospital, Istanbul, Turkey, Marmara University, School of Medicine, Istanbul, Turkey 458. Change Over Time In The Profile Of Ankylosing Spondylitis Patients Treated With Infliximab In Canadian Routine Care. Denis Choquette, Michael Starr, Majed M. Khraishi, William G. Bensen 4, Saeed A. Shaikh 5, Jude F. Rodrigues 6, Dalton E. Sholter 7, Maqbool K. Sheriff 8, Julie Vaillancourt 9, John S. Sampalis 0, Allen J. Lehman, Susan M. Otawa, Francois Nantel and May Shawi, Institut de Rhumatologie de Montréal, Montreal, QC, Montreal General Hospital, Montreal, QC, MD, Memorial University of Newfoundland, Nexus Clinical Research, St Johns, NF, 4 St. Joseph s Hospital and McMaster University, Hamilton, ON, 5 McMaster University, St Catharines, ON, 6 Rheumatology, Windsor, ON, 7 Rheumatology Associates, Edmonton, AB, 8 Nanaimo Regional General Hospital, Nanaimo, BC, 9 JSS Medical Research, Montreal, QC, 0 JSS Medical Research, St-Laurent, QC, Janssen Canada Inc, Toronto, ON 459. Improvement In Physical Function, Health-Related Quality Of Life, and Work Productivity With Adalimumab Treatment In Non-Radiographic Axial Spondyloarthritis. Désirée M. van Der Heijde, Philip J. Mease, Aileen L. Pangan, Sumati A Rao, Naijun Chen and Mary Cifaldi, Leiden University Medical Center, Leiden, Netherlands, Swedish Medical Center and University of Washington School of Medicine, Seattle, WA, AbbVie Inc., North Chicago, IL 460. Spondyloarthritis Epidemiology and Burden Phase [SPEED ] Study: Disease Progression In Axial Spondyloarthropathy (SpA). Eric Ruderman, Vibeke Strand, Avani Joshi, Yanjun Bao, Keith Betts 4, Pooja Chopra 4, Michael B. McGuire 5 and Sumati A Rao, Northwestern University, Chicago, IL, Stanford University, Palo Alto, CA, AbbVie Inc., North Chicago, IL, 4 Analysis Group, Inc., Boston, MA, 5 Medical Data Analytics, Parsippany, NJ 46. Quality Of Life, Physical Function and Symptoms In Non-Radiographic Axial Spondyloarthritis:The Patient Perspective. Philip J. Mease, Sumati A Rao, Avani D. Joshi, Sarah Clifford, Christina Vernon and Mary A. Cifaldi, Swedish Medical Center and University of Washington School of Medicine, Seattle, WA, AbbVie Inc., North Chicago, IL, United BioSource Corporation, Bethesda, MD 46. Comparison Of Tumor Necrosis Factor Inhibitor Use For Ankylosing Spondylitis At University Rheumatology Clinics In Scotland and Oregon. Anusha Reddy, Abhijeet Danve, Kiana Vakil-Gilani, Jennifer H. Ku, Sanjay Ganhasan, Alison Black and Atul Deodhar, Aberdeen Royal Infirmary, Aberdeen, United Kingdom, Oregon Health and Science University, Portland, OR 46. Tomosynthesis As a New Diagnostic Tool For Evaluation Of Ankylosing Spondylitis With Modified Stoke Ankylosing Spondylitis Spinal Score: A Comparison With Plain Radiographs. Seunghun Lee, Tae-Hwan Kim, Jae-Bum Jun, Kyung-Bin Joo, Young Bin Joo and Jina Park 4, Hanyang University College of Medicine, Seoul, South Korea, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, Hanynag University, Seoul, South Korea, 4 Hanyang University Hospital, Seoul, South Korea 464. Late-Onset Ankylosing Spondylitis Has Distinctive Presenting Symptoms and a Higher Inflammatory Burden. Yeon-Ah Lee, Sang-Hoon Lee, Ran Song, Hyung-In Yang and Seung-Jae Hong, Kyung Hee University, Seoul, South Korea, Hospital at GANGDONG, Kyung Hee University, Seoul, South Korea 465. Prevelance Of Inflammatory Back Pain and Axial Spondyloarthritis Among University Employees In Izmir, Turkey. Fatos Onen, Dilek Solmaz, Pinar Cetin, Ali Balci, Servet Akar and Nurullah Akkoc, Dokuz Eylul University School of Medicine, Izmir, Turkey, Dokuz Eylul University School of Medicine, izmir, Turkey 0 Program Book 5

338 ACR POSTER SESSION C 466. Long Term Efficacy Over Five Years Of Adalimumab In Patients With Active Non - Radiographic Axial Spondyloarthritis. Hildrun Haibel, Xenofon Baraliakos, Joachim Listing, Juergen Braun and Joachim Sieper, Charité Universitätsmedizin Berlin, Berlin, Germany, Rheumazentrum Ruhrgebiet, Herne, Germany, German Rheumatism Research Center, Berlin, Germany 467. Response to Tumor Necrosis Factor inhibitors In Axial Spondyloarthritis: Does Sacroiliitis Make Any Difference? Julien Girodon, Vianney Jouhet and Elisabeth Solau- Gervais, University Hospital of Poitiers, Poitiers, France, University hospital Bordeaux, Bordeaux, France 468. The Prevalence Of Sjogren s Syndrome In Patients With Ankylosing Spondylitis. Ayse Balkarli, Adem Kucuk, Sahin Temel, Tayfun Gungor 4, Ramazan Ucar 5 and Veli Cobankara 6, Pamukkale University, Division of Rheumatology, Denizli, Turkey, Necmettin Erbakan University, Division of Rheumatology, Konya, Turkey, Department of Internal Medicine, Pamukkale University, Denizli, Turkey, 4 Department of Physical medicine and Rehabilitation, Necmettin Erbakan University, Konya, Turkey, 5 Konya Education and Research Hospital, Department ofinternal Medicine, Konya, Turkey, 6 Division of Rheumatology, Pamukkale University, Denizli, Turkey 469. Radiographic Sacroiliitis Progression In An Early Spondyloarthritis Cohort. Concepcion Castillo-Gallego, Eugenio de Miguel, Carmen Martin-Hervas, Diana Peiteado, Leticia Lojo and Emilio Martin-Mola, Hospital Universitario La Paz, Madrid, Spain, Hospital Universitario La Paz, Spain, Spain 470. Combined Axial and Peripheral Involvement Is Associated With Miscegenation In A Large and Heterogeneous Brazilian Cohort Of 505 Patients With Spondyloarthritis. Percival D Sampaio-Barros, Mittermayer Santiago, Adriana B. Bortoluzzo, Antonio Carlos Ximenes, José Antonio Braga da Silva, Manoel B Bértolo, Sandra Lúcia Ribeiro, Mauro Keisermann, Rita Menin, Thelma L. Skare, Sueli Carneiro, Valderilio F. Azevedo, Walber P. Vieira, Elisa Albuquerque, Washington A. Bianchi, Rubens Bonfiglioli, Cristiano Campanholo, Hellen M Carvalho, Izaias P. Costa, Angela Luzia B. P. Duarte, Charles Kohem, Nocy Leite, Sonia Lima, Eduardo S. Meirelles, Ivânio A. Pereira, Marcelo M. Pinheiro, Elizandra Polito, Gustavo G. Resende, Francisco AC Rocha, Maria de Fátima L. C. Sauma, Valéria Valim and Celio R. Gonçalves, Brazilian Registry of Spondyloarthritis, São Paulo, Brazil 47. Prevalence Of Inflammatory Back Pain In Psoriatic Arthritis: The Prepare Study. Majed Khraishi, Dafna D. Gladman, Javier Coindreau, Lotus Mallbris, Annette Szumski, Eustratios Bananis and Heather Jones, Nexus Clinical Research, St John s, NF, University of Toronto, Toronto Western Hospital, Toronto, ON, Pfizer Inc., Collegeville, PA 47. Disease Burden Is Similar Between Non-Radiographic Axial Spondyloarthritis and Ankylosing Spondylitis and Independent Of Gender Influences. Salih Ozgocmen, Erkan Kilic, Gamze Kilic and Ozgur Akgul, Erciyes University, Faculty of Medicine, Kayseri, Turkey 47. Comparison Of The Two Subtypes Of Axial Spondyloarthritis Patients Fulfilling The Imaging Arm Based On Radiographic and MRI Findings. Dilek Solmaz, Servet Akar, Ismail Sari, Pinar Cetin, Fatos Onen and Nurullah Akkoc, Dokuz Eylul University School of Medicine, Izmir, Turkey 474. Fat Mass and Resistin: Predictive Factors For Anti-TNF Therapy Response In Ankylosing Spondylitis Patients. Carla G.S. Saad, Andressa Silva Abreu, Ana Cristina Medeiros Ribeiro, Julio C. B. Moraes, Luiz A. Perandini, Thalita Dassouki, Rosa M. R. Pereira, Eloisa Bonfa and Ana Lucia S. Pinto, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil 475. Relationship Between Extra-Articular Manifestations and Disease Activity In Patients Diagnosed With New- Onset Spondyloarthropathy In a Cohort In Spain. César Antonio Egües Dubuc, Maria Martin Martinez, Joaquin Belzunegui Otano, Miren Uriarte Ecenarro, Juan Mulero, Eugenio de Miguel 4, Santiago Muñoz 5, Pedro Zarco 6, Eduardo Collantes 7, Sabina Perez Vicente and Milena Gobbo, Donostia University Hospital, San Sebastián, Spain, Research Unit, Spanish Society of Rheumatology., Madrid, Spain, Hospital Universitario Puerta de Hierro Majadahonda, Majadahonda (Madrid), Spain, 4 Hospital Universitario La Paz, Madrid, Spain, 5 Hospital Infanta Sofia, Madrid, Spain, 6 Fundación Hospital Alcorcon, Alcorcon, Madrid, Spain, 7 Hospital Reina Sofia, Cordoba, Spain 476. Periodontal Disease Is Not Associated With Ankylosing Spondylitis and TNF-Alpha Blockers Usage In Korea. Sung Hae Chang, Jung Tae Lee, Byoung Youg Choi, Hyon Joung Cho, Jong Jin Yoo, Hye Jin Oh, Eun Ha Kang, Yeong Wook Song 4, Hyo Jung Lee and Yun Jong Lee, Seoul National University Bundang Hospital, Seongnam-si, South Korea, Armed Forces Capital Hospital Seongnam Republic of Korea, Seongnam si, South Korea, Seoul National University Hospital, Seoul, South Korea, 4 Seoul National University College of Medicine, Seoul, South Korea 477. Impact Of Stressful Life Events On Disease Activity In Spondyloarthritis: Results Of The Coenv- Prospective Cohort Study. Guanguan Luo, Pierre Yves Boelle, Clément Turbelin, Roula Said Nahal, Nadine Zeboulon, Maria- Antonietta D Agostino, Solen Kerneis, Thomas Hanslik and Maxime A. Breban, Faculté de Médecine Pierre et Marie Curie, Paris, France, Ambroise Paré Hospital, Boulogne-Billancourt, France, Ambroise Paré Hospital, and Versailles Saint Quentin en Yvelines University, Boulogne- Billancourt, France 478. Clinical Characteristics Of Patients With Early Spondyloarthritis. Results From a Specialized Consultation In a Clinical Hospital. Juan Jose Aznar Sánchez, Eugenio Chamizo Carmona, Adela Gallego Flores, Raul Veroz Gonzalez and Tamara Libertad Rodriguez Araya, Hospital de Mérida, Mérida, Spain 6 0 Program Book

339 ACR POSTER SESSION C 479. Adalimumab Significantly Reduces Inflammation In Active Ankylosing Spondylitis: An Ultrasound Study. Zaiying Hu, Manlong Xu, Zetao Liao, Zhiming Lin and Jieruo Gu 4, THIRD AFFILIATED HOSPITAL OF SUN YAT-SEN UNIVERSIT, Guangzhou, China, THIRD AFFILIATED HOSPITAL OF SUN YAT-SEN UNIVERSIT, Guangzho, China, third affiliated hospital of Sun Yat-sen Universtiy, Guangzhou, China, 4 Third Affiliated Hospital of Sun Yat-sen University, GuangZhou, China 480. Predicting Progression Of Non-Radiographic Axial Spondyloarthritis. Nigil Haroon, Lianne S. Gensler, Dinny Wallis, Ammepa Anton, Grace Yoon 4 and Robert Inman 5, Toronto Western Research Institute, Toronto, ON, University of California, San Francisco, San Francisco, CA, Toronto Western Hospital, University of Toronto, Toronto, ON, 4 UCSF, San Franciscao, CA, 5 University of Toronto and Toronto Western Hospital, Toronto, ON 48. External Validation Of The Spondyloarthritis Radiography Online Reference Module For Training Readers To Score The Modified Stoke Ankylosing Spondylitis Score. Praveena Chiowchanwisawakit, Susanne Juhl Pedersen and Walter P. Maksymowych, Mahidol University, Bangkok, Thailand, Copenhagen University Hospital at Glostrup, Copenhagen, Denmark, University of Alberta, Edmonton, AB 48. Which Contextual Factors Have An Important Influence On Work Outcome In Patients With Ankylosing Spondylitis. A Systematic Literature Review. Jose Dionisio Castillo- Ortiz, Carmen Stolwijk and Annelies Boonen, Maastricht University Medical Center, Maastricht, Netherlands, Maastricht University, Maastricht, Netherlands 48. Periarticular Bone Gain In Early Psoriatic Arthritis But Not In Rheumatoid Arthritis Following Anti-Rheumatic Treatment As Measured By Digital X-Ray Radiogrammetry. Agnes Szentpetery, Muhammad Haroon, Phil Gallagher, Eric J. Heffernan and Oliver FitzGerald, Dublin Academic Medical Centre, St. Vincent s University Hospital, Dublin, Ireland 484. Immunogenicity Of TNFα Blockers In Patients With Psoriatic Arthritis. Michael Zisapel Zisapel, Noa Madar- Balakirsi, Hagit Padova, Irena Wigler, Daphna Paran 4, Uri Arad, Dan Caspi 5 and Ori Elkayam, Tel Aviv Medical Centet, Tel Aviv, Israel, Tel Aviv Medical Center, Tel Aviv, Israel, Tel Aviv Sourasky Medical Center and the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel, 4 Tel Aviv Sourasky Medical Ctr, Tel-Aviv university, Tel Aviv, Israel, 5 Tel Aviv Sourasky Medical Center, Tel Aviv, Israel 485. High Incidence Of Disease Recurrence After Discontinuation Of Disease Modifying Anti-Rheumatic Drug Treatment In Patients With Psoriatic Arthritis In Remission. Elizabeth Araujo, Stephanie Finzel, Dominik A. Schreiber, Matthias Englbrecht, Axel J. Hueber, Francesca Faustini, Juergen Rech and Georg Schett, University of Erlangen-Nuremberg, Erlangen, Germany 486. Clinical Performance Of 4 Methods For Detecting Latent Tuberculosis Infection (LTbI) In Patients With Active Chronic Inflammatory Arthritis Taking TNFα Blockers. Carina M F Gomes, Maria Teresa Terreri, Maria Isabel Pinto, Karen Oseki, Fernanda Spina and Marcelo M. Pinheiro, Universidade Federal de São Paulo, Sao Paulo, Brazil, Universidade Federal de São Paulo / UNIFESP, Sao Paulo, Brazil, Brazilian Registry of Spondyloarthritis, São Paulo, Brazil 487. Role Of IL- In The Development Of Premature Atherosclerosis In Psoriatic Arthritis Patients. Priscilla Ching-han Wong, Qing Shang, Cheuk-Man Yu and Lai Shan Tam, Prince of Wales hospital, New Territories, Hong Kong, The Chinese University of Hong Kong, Hong Kong, Hong Kong Spondyloarthropathies and Psoriatic Arthritis: Pathogenesis, Etiology, Animal Models II 488. Elevated Serum Anti-Flagellin Antibodies Implicate Subclinical Bowel Inflammation in Ankylosing Spondylitis. Dinny Wallis, Arundip Asaduzzaman, Michael H. Weisman, Nigil Haroon, Ammepa Anton, Dermot P. B. McGovern 4, Stephan R. Targan 4 and Robert D. Inman, Toronto Western Hospital, University of Toronto, Toronto, ON, Cedars-Sinai Med Ctr, Los Angeles, CA, Toronto Western Research Institute, Toronto, ON, 4 Cedars-Sinai Medical Center, Los Angeles, CA 489. Spondyloarthritis-Associated Polymorphisms Of ERAP Are Correlated With Gene Expression, Protein Level and Enzymatic Activity Of The Amino-Peptidase. Félicie Costantino, Alice Talpin, Irini Evnouchidou, Amir Kadi, Roula Said-Nahal, Ariane Leboime, Nelly Bonilla, Franck Letourneur, Tifenn Leturcq, Zeyna Ka, Peter van Endert, Henri-Jean Garchon, Gilles Chiocchia and Maxime A. Breban, Institut Cochin - Université Paris Descartes - INSERM U06 - CNRS (UMR 804), Paris, France, INSERM U0 - Université Paris Descartes - Sorbonne Paris Cité, Paris, France, Ambroise Paré Hospital (AP-HP), and Versailles Saint Quentin en Yvelines University, Boulogne- Billancourt, France 490. WITHDRAWN 49. Serum Levels Of Novel Noggin- and Sclerostin-Immune Complexes Are Elevated In Ankylosing Spondylitis. Florence W. Tsui, Hing Wo Tsui and Robert D. Inman, Toronto Western Research Institute UHN and University of Toronto, Toronto, ON, Toronto Western Research Institute UHN, Toronto, ON, Toronto Western Research Institute, University Health Network and University of Toronto, Toronto, ON 49. Functionally Distinct ERAP Haplotype Combinations Distinguish Individuals With Ankylosing Spondylitis. Edward James, Emma Reeves, Alexandra Colebatch, Tim Elliott and Christopher J. Edwards, University of Southampton, Southampton, United Kingdom, University Hospital Southampton, Southampton, United Kingdom, NIHR Wellcome Trust Clinical Research Facility, University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom 0 Program Book 7

340 ACR POSTER SESSION C 49. Interleukin-7 Serum Levels Are Associated With Markers Of Systemic Inflammation In Patients With Active Ankylosing Spondylitis. Denis Poddubnyy, Alain Vicari, Hildrun Haibel, Jürgen Braun, Martin Rudwaleit 4 and Joachim Sieper, Charité Universitätsmedizin Berlin, Berlin, Germany, EMD Serono, Geneva, Switzerland, Rheumazentrum Ruhrgebiet, Herne, Germany, 4 Endokrinologikum Berlin, Berlin, Germany 494. Ankylosing Spondylitis Associated Endoplasmic Reticulum Aminopaptidase Variants In Antigen Presentaing Cells Affect HLA-B7 Free Heavy Chain Expression and Binding To NK-Cell Receptors. Nigil Haroon and Zhenbo Zhang, Toronto Western Research Institute, Toronto, ON 495. Ankylosing Spondylitis Protective Endoplasmic Reticulum Aminopeptidase Variants Lead To Decreased Natural Killer Cell Conjugation and Activation. Hasan Abdullah, Zhenbo Zhang, Robert Inman and Nigil Haroon 4, University of Toronto, Toronto, ON, Toronto Western Research Institute, Toronto, ON, University of Toronto and Toronto Western Hospital, Toronto, ON, 4 Toronto Western Research Institute, University Health Network and University of Toronto, Toronto, ON 496. HLA-B7 Influence On The Gut Microbiome. Robert D. Inman, Aifeng Lin, Phillip Sherman and Lee Pinnell, Toronto Western Research Institute, University Health Network and University of Toronto, Toronto, ON, Toronto Western Research Institute and University Health Network, Toronto, ON, Hospital for Sick Children, Toronto, ON 497. Evidence Of a Microbial Signature In The Intestinal Microbiome In Ankylosing Spondylitis. Mary-Ellen Costello, Francesco Ciccia, Brooke Gardiner, Mhairi Marshall, Dana Willner, Tony Kenna, Giovanni Triolo and Matthew A. Brown, University of Queensland Diamantina Institute, Brisbane, Australia, Rheumatology Unit, University of Palermo, Palermo, Italy, Australian Centre for Ecogenomics, School of Chemistry and Molecular Biosciences, University of Queensland, Brisbane, Australia 498. ERAP Functional Knockout In Humans Does Not Alter ER Stress Or Evidence Of HLA-B7 Misfolding In Ankylosing Spondylitis. Philip Robinson, Yang Wang, Eugene Lau, Patricia Keith, Tony Kenna and Matthew A. Brown, University of Queensland Diamantina Insititute, Brisbane, Australia, University of Queensland Diamantina Institute, Brisbane, Australia 499. Analysis Of Inflammatory Markers Within Facet Joints Of Patients Within Ankylosing Spondylitis. Uta Syrbe, Janine Bleil, Rene Maier, Heiner Appel and Joachim Sieper 4, Charité Medical University, Campus Benjamin Franklin, Berlin, Germany, Charité, Berlin, Germany, Charite, Berlin, Germany, 4 Charitè Campus Benjamin Franklin, Berlin, Germany 500. Mast Cells Are a Major Source Of IL-7 In Synovium and Extra-Articular Tissues In Spondyloarthritis Related Diseases. T. Noordenbos, I. Gofita, M. Alsina, E.W.M. Vogels, A. A. te Velde, J. D. Cañete 4, D. Baeten 5 and N. Yeremenko, Department of Clinical Immunology and Rheumatology and Department of Experimental Immunology, Academic Medical Centre/University of Amsterdam, Amsterdam, Netherlands, Department of Dermatology, Hospital Clinic de Barcelona, Barcelona, Spain, Tytgat Institute for Liver and Intestinal Research, Academic Medical Centre/University of Amsterdam, the Netherlands, Amsterdam, Netherlands, 4 Hospital Clinic, Barcelona, Spain, 5 Department of Clinical Immunology and Rheumatology Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands 50. Validation Of Gene Expression Biomarkers Of Psoriatic Arthritis. Fatima Abji, Remy Pollock, Fawnda Pellett, Kun Liang, Vinod Chandran and Dafna Gladman, University of Toronto, Toronto Western Hospital, Toronto, ON, University of Waterloo, Waterloo, ON 50. Contributions Of Skin and Joint Manifestations To The Parent-Of-Origin Effect In Psoriatic Disease. Remy Pollock, Arane Thavaneswaran, Vinod Chandran, Art Petronis, Al Amin P. Rahman and Dafna Gladman, University of Toronto, Toronto Western Hospital, Toronto, ON, Centre for Addiction and Mental Health, Toronto, ON, Memorial University, St Johns, NE 50. IL-7+ CD8+ T Cells Are Enriched In The Joints Of Patients With Psoriatic Arthritis and Correlate With Markers Of Disease Activity and Joint Damage Progression. Bina Menon, Nicola J. Gullick, Hayley G. Evans, Gina J. Walter, Megha Rajasekhar, Toby Garrood, Leonie S. Taams and Bruce W. Kirkham, Guy s and St. Thomas Foundation Hospital NHS Trust, London, United Kingdom, King s College Hospital Foundation NHS Trust, London, United Kingdom, King s College London, London, United Kingdom Systemic Lupus Erythematosus - Clinical Aspects III: Biomarkers, Quality of Life and Disease Indicators, Late Complications 504. Male Children With Higher SLE Disease Activity In An US Cohort. Lakshmi N. Moorthy, Elizabeth Roy, Margaret Peterson, Afton L. Hassett 4, Alexa B. Adams, Laura V. Barinstein 5, Elizabeth C. Chalom 6, Karen Onel 7, Linda Ray 8, Jorge Lopez-Benitez 9, Kathleen A. Haines 0, Philip Hashkes, Daniel J. Kingsbury, Victoria Cartwright, Nora G. Singer, Ingrid Tomanova-Soltys 4, Andreas Reiff 5, Sandy D. Hong 6 and Thomas J. A. Lehman, Robert Wood Johnson Medical School-UMDNJ, New Brunswick, NJ, RWJMS-UMDNJ, New Brunswick, NJ, Hospital for Special Surgery, New York, NY, 4 University of Michigan, Ann Arbor, MI, 5 Mount Sinai Med Ctr, New York, NY, 6 St. Barnabas Medical Center, Livingston, NJ, 7 PRCSG, Cincinnati, OH, 8 University of Mississippi Medical Center, Jackson, MS, 9 Pediatric Rheumatology Program Centro Medico La Costa, Asuncion, Paraguay, 0 Joseph M Sanzari Children s Hospital, Hackensack University Medical Center, Hackensack, NJ, Shaare Zedek Medical Center, Jerusalem, Israel, Legacy Emanuel Children s Hospital, Portland, OR, Director, Division of Rheumatology, MetroHealth Medical Center, Case Western Reserve University, Cleveland, OH, 4 Winthrop University Hospital, Mineola, NY, 5 Children s Hospital Los Angeles, Los Angeles, CA, 6 U of Iowa Children s Hosp, Iowa City, IA 8 0 Program Book

341 ACR POSTER SESSION C 505. Higher Disease Damage Among African Americans With Familial Versus Sporadic Systemic Lupus Erythematosus. April Barnado, Lee Wheless, Stephanie Slan, Gary S. Gilkeson and Diane L. Kamen, Medical University of South Carolina, Charleston, SC 506. Systemic LUPUS Erythematosus Patients Presenting With Immune Thrombocytopenia and The Association Between Two Diseases. Omer Nuri Pamuk, Gulsum Emel Pamuk and Mehmet Sevki Uyanik, Trakya University Medical Faculty, Edirne, Turkey 507. What Is The Risk Of Having a Total Hip Or Knee Replacement for Patients With Lupus? Sandeep Mukherjee, David Culliford, Nigel K. Arden and Christopher J. Edwards, NIHR Wellcome Trust Clinical Research Facility, University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom, University of Southampton, Southampton, United Kingdom, Oxford NIHR Musculoskeletal Biomedical Research Unit, University of Oxford, Oxford, United Kingdom 508. Clinical and Serological Discordance In The Systemic Lupus Erythematosus International Collaborating Clinics (SLICC) Cohort. Murray B. Urowitz, Dafna Gladman, Nicole Anderson and Systemic Lupus Erythematosus International Collaborating Clinics SLICC, University of Toronto, Toronto Western Hospital, Toronto, ON, Toronto Western Hospital, Toronto, ON 509. Long Term Natural History Of Asymptomatic Avascular Necrosis In a Cohort Of Patients With Systemic Lupus Erythematosus Treated With Corticosteroids. Eileen J. Lydon and H. Michael Belmont, NYUHJD, New York, NY, NYU School of Medicine, New York, NY 50. The Epidemiology Of Systemic LUPUS Erythematosus and Clinical Features Of Patients At A Single Center In Northwestern Turkey. Omer Nuri Pamuk, Salim Dönmez, Gokce Busra Calayir and Cigdem Mengus, Trakya University Medical Faculty, Edirne, Turkey, Yüzüncü Yıl University Medical Faculty, Edirne, Turkey 5. Multicenter Validation Of The Lupus Activity Scoring Tool (LAST) As Compared To The Selena Sledai (SS) Modification. Majed M. Khraishi, Rana Aslanov, Sanjay Dixit, Krista Fudge 4, Vandana Ahluwalia 5 and Sarah Khraishi 6, MD, Memorial University of Newfoundland, Nexus Clinical Research, St Johns, NF, MD, MSc, Memorial University of Newfoundland, St.John s, NF, McMaster University, Burlington, ON, 4 Western Memorial Hospital, Corner Brook, NF, 5 Past President, Ontario Rheumatology Association, Brampton, ON, 6 Memorial University of Newfoundland, St.John s, NF 5. Smoking Is Associated With More Severe Skin Disease In Subjects With Moderate To Severe Systemic Lupus Erythematosus (SLE). Victoria P. Werth, Munther A. Khamashta, Gabor G. Illei, Stephen Yoo, Liangwei Wang and Warren Greth, Philadelphia Veterans Affairs Medical Center, Philadelphia, PA, Lupus Research Unit, The Rayne Institute, Kings College London School of Medicine, London, United Kingdom, MedImmune, LLC, Gaithersburg, MD 5. Anti-Mullerian Hormone In Patients With Systemic Lupus Erythematosus. Chiara Tani, Sabrina Vagnani, Linda Carli, Giovanni Gallo, Maria Rita Sessa, Chiara Baldini, Alessandra Della Rossa, Rosaria Talarico, Francesca Strigini, Marco Maccheroni, Stefano Bombardieri and Marta Mosca, Rheumatology Unit, University of Pisa, Pisa, Italy, Rheumatology Unit, Pisa, Italy, S. Chiara Hospital, Pisa, Italy 54. The Brief Index of Lupus Damage, a Patient-Reported Measure of Lupus Damage, Is Sensitive to Change. Patricia P. Katz, Laura Trupin, Stephanie Rush and Jinoos Yazdany, University of California San Francisco, San Francisco, CA, University of California, San Francisco, San Francisco, CA 55. Social Capital: A Novel Platform For Understanding Social Determinants Of Health In Systemic Lupus Erythematosus. Susan Kim, Carol Mancuso, Wei-Ti Huang and Doruk Erkan, Hospital for Special Surgery, New York, NY, Hospital for Special Surgery, NY, NY 56. Plasma Microparticles Are Associated With Venous Thrombosis In Systemic Lupus Erythematosus. Michelle Petri, Melissa Nastacio, Hong Fang, Thomas Kickler, Jayesh Jani and Laurence S. Magder, Johns Hopkins University School of Medicine, Baltimore, MD, University of Maryland, Baltimore, MD 57. The Interferon-Alpha Signature In Patients With Serologically Active Clinically Quiescent Systemic Lupus Erythematosus. Amanda J. Steiman, Murray B. Urowitz, Dominique Ibanez, Carolina Landolt-Marticorena, Joan E. Wither and Dafna D. Gladman, University of Toronto, Toronto Western Hospital, Toronto, ON, Toronto Western Hospital, University of Toronto, Toronto, ON, Toronto Western Research Institute, Toronto Western Hospital, University of Toronto, Toronto, ON 58. Only BAFF mrna, Not BAFF Protein Level In Blood, Is Associated With SLE Activity Over One Year. Eric Zollars, Hong Fang, Jadwiga Bienkowska, Julie Czerkowicz, Ann Ranger, Norm Allaire, Alice Thai, Jeff Browning 4, Laurence S. Magder 5 and Michelle Petri, Johns Hopkins University School of Medicine, Baltimore, MD, Biogen Idec Inc., Cambridge, MA, Biogen Idec Inc, Cambridge, MA, 4 Boston University School of Medicine, Boston, MA, 5 University of Maryland, Baltimore, MD 59. A Systemic Lupus Erythematosus (SLE) Diagnostic Test Based On DNA Methylation Signatures From Peripheral Blood Mononuclear Cells. David W. Anderson, Robert Shoemaker, Kurt Krummel, Zachary Hornby and Jonathan E. Lim, IGNYTA, Inc., San Diego, CA 0 Program Book 9

342 ACR POSTER SESSION C 50. A Freely Accessible Toolbox For Patient-Reported Outcomes: Development and Systematic Literature Review For Lupus Instruments. Isabel Castrejón, Loreto Carmona, Robin Christensen, Till Uhlig 4, Birgit Prodinger 5, Francis Guillemin 6, Marieke Scholte-Voshaar 7 and Laure Gossec 8, NYU Hospital for Joint Diseases and New York University School of Medicine, New York, NY, Institute for Musculoskeletal Health, Madrid, Spain, Musculoskeletal Statistics Unit, The Parker Institute, Department of Rheumatology, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Denmark, 4 Diakonhjemmet Hospital, Oslo, Norway, 5 Swiss Paraplegic Group, Nottwil, Switzerland, Notwill, Switzerland, 6 CHU Nancy, Clinical Epidemiology and Evaluation, Université de Lorraine, Paris Descartes University, APEMAC, EA 460, Nancy, France, 7 EULAR Standing Committee of People with Arthritis/Rheumatism in Europe, Zurich, Switzerland, 8 PitiéSalpêtrière Hospital, Pierre et Marie Curie University, Paris, France 5. Correlation Of Anti Single and Double Stranded DNA Antibodies and Disease Activity In Systemic Lupus Erythematosus. Cecilia Catoggio, Cecilia Reimundes and Carlos Edgardo Perandones, CEMIC, Buenos Aires, Argentina 5. Novel Autoantibody Against CAF- Is a Biomarker For CNS Manifestation in patients With SLE. Kentaro Doe, Kazuhisa Nozawa, Kaori Hiruma, Yusuke Yamada, Yuko Matsuki, Soichiro Nakano, Michihiro Ogasawara and Yoshinari Takasaki, Juntendo University School of Medicine, Tokyo, Japan 5. Inflammatory Arthritis Activity During Pregnancy In Systemic Lupus Erythematosus. Sara K. Tedeschi, Bonnie L. Bermas and Karen H. Costenbader, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 54. Application of The 0 Systemic Lupus International Collaborating Clinics Classification Criteria On a Regional Swedish Systemic Lupus Erythematosus Register. Anna Ighe, Örjan Dahlström, Thomas Skogh and Christopher Sjöwall, Linköping University, Linköping, Sweden, Linneaus Centre HEAD, Swedish Institute for Disability Research, Linköping, Sweden 55. An Assay Panel Combining Cell Bound Complement Activation Products With Autoantibodies To Extractable Nuclear Antigens and Mutated Citrullinated Vimentin Helps With The Differential Diagnosis Of Systemic Lupus Erythematosus. Chaim Putterman, Richard Furie, R. Ramsey-Goldman, Anca Askanase 4, Jill P. Buyon 4, Kenneth C. Kalunian 5, W. Winn Chatham 6, Elena M. Massarotti 7, Emily C. Somers 8, Irene Blanco, Puja Chitkara 9, Nicole Jordan, Kyriakos A. Kirou 0, Arthur Weinstein, Susan Manzi, Joseph M. Ahearn, Claudia Ibarra, Derren Barken and Thierry Dervieux, Albert Einstein College of Medicine, Bronx, NY, North Shore-LIJ Health System, Lake Success, NY, Northwestern University Feinberg School of Medicine, Chicago, IL, 4 NYU School of Medicine, New York, NY, 5 UCSD School of Medicine, La Jolla, CA, 6 University of Alabama at Birmingham, Birmingham, AL, 7 Brigham and Women s Hospital, Harvard Medical School, Boston, MA, 8 University of Michigan, Ann Arbor, MI, 9 SDAMC, San Diego, CA, 0 Hospital for Special Surgery, New York, NY, Washington Hospital Center, Washington, DC, West Penn Allegheny Health System, Pittsburgh, PA, Exagen Diagnostics, Vista, CA 56. An Autoantibody Profile for The Diagnosis Of Systemic Lupus Erythematosus Using the IMMUNARRAY ichip. Chaim Putterman, Irene Blanco, Nicole Jordan, Yves Renaudineau, Vered Daniel Carmi, Rachel Sorek, Ornit Cohen-Gindi, Miriam Lerner, D. Scott Batty, Idan Tamir and Irun R Cohen 4, Albert Einstein College of Medicine, Bronx, NY, Brest Occidentale University, Brest, France, ImmunArray, Rehovot, Israel, 4 Weizmann Institute of Science, Rehovot, Israel 57. Association Of Nail Dystrophy With Capillaroscopic Abnormalities, Anti-Endothelial Cell Antibody, Endothelin-, Activity and Chronicity In Systemic Lupus Erythematosus. Violeta Higuera, Luis M. Amezcua-Guerra, Felipe Massó, Mariana Patlan, Hugo Montoya, Araceli Paez and Luis H. Silveira, Instituto Nacional de Cardiologia Ignacio Chavez, Mexico city, Mexico, Instituto Nacional de Cardiología Ignacio Chávez, Mexico City, Mexico, Instituto Nacional Cardiología Ignacio Chávez, Mexico City, Mexico 58. Pregnancy Outcome In 69 Pregnancies Of Multinational Population In Qatar With Systemic Lupus Erythematosus. Abdul Razzakh Poil, Mohammed Hammoudeh, Prem Chandra, Abdo Lutf and Samar AL Emadi, Hamad General Hospital, Doha, Qatar, Hamad Medical Corporation, Doha, Qatar, ASSISTANT proffesor of clinical medicine weill cornell medical school Qatar, Doha, Qatar 59. Improved Outcomes In High Risk Lupus Pregnancies: Usefulness Of a Protocol Based Multidisciplinary Approach In Kerala, India. Vinod Ravindran, S Bhadran, P Shyjus, M Divakaran 4 and V Reshma 5, MES Medical College, Kerala, INDIA, Perinthalmanna, India, Department of Obstetrics, National Hospital, Calicut, India, Department of Obstetrics, MES Medical College, Perinthalmanna, India, 4 Department of Obstetrics, PVS Hospital, Calicut, India, 5 Department of Obstetrics, Indira Gandhi Hospital, Thalassery, India 50. Sustained Improvements In Health-Related Quality Of Life In Patients With Systemic Lupus Erythematosus following Epratuzumab Treament: Results from a Phase IIb Trial and Its Open-Label Extension. Vibeke Strand, Joan T. Merrill, Enkeleida Nikaï, Brian Kilgallen 4, Antoine Regnault 5 and Caroline Gordon 6, Stanford University, Palo Alto, CA, Oklahoma Medical Research Foundation, Oklahoma City, OK, UCB Pharma, Brussels, Belgium, 4 UCB Pharma, Raleigh, NC, 5 Mapi HEOR & Strategic Market Access, Lyon, France, 6 University of Birmingham, Birmingham, United Kingdom 5. Elevated Combined Serum Free Light Chains Are Associated With Active Disease In Systemic Lupus Erythematosus. Lakhvir Kaur Assi, Larissa Lisnevskaia, Emma Ross, Richard G Hughes, Anisur Rahman and David A. Isenberg, The Binding Site Group Ltd, Birmingham, United Kingdom, Oshawa Clinic, Oshawa, ON, University College London, London, United Kingdom 40 0 Program Book

343 ACR POSTER SESSION C 5. Changes In Quality Of Life In The First 5 Years Of Disease In The Systemic Lupus Erythematosus International Collaborating Clinics (SLICC) Cohort. Murray B. Urowitz, Dominique Ibanez, Nicole Anderson, Dafna D. Gladman and Systemic Lupus SLICC, University of Toronto, Toronto Western Hospital, Toronto, ON, Toronto Western Hospital, Toronto, ON 5. Delta Neutrophil Index As a Marker For Differential Diagnosis Between Flare and Infection In Febrile Systemic Lupus Erythematosus Patients. You-Jung Ha, Jung Yoon Pyo, Jin Su Park, Hee-Jin Park, Jason Jungsik Song, Yong- Beom Park, Soo-Kon Lee and Sang-Won Lee, Yonsei University College of Medicine, Seoul, South Korea 54. Pregnancy Complications In Lupus: Retrospective Observational Analysis From a US Health Claims Database. Michelle. A. Petri, Paola Daly, Daphnee S. Pushparajah, David Friesen 4 and Lydia Makaroff, Johns Hopkins University School of Medicine, Baltimore, MD, Lupus Foundation of America, Washington DC, DC, UCB Pharma, Brussels, Belgium, 4 UCB Pharma, Slough, United Kingdom 55. Rare Autoantibodies To Cellular Antigens In Systemic Lupus Erythematosous. Micaela Fredi, Ilaria Cavazzana, Marzia Quinzanini, Mara Taraborelli, Stefania Cartella, Angela Tincani and Franco Franceschini, Rheumatology Chair, University of Brescia and Pavia, Brescia, Italy, Rheumatology Unit, Spedali Civili, Brescia, Italy, Rheumatology Unit, University of Brescia, Brescia, Italy 56. Lupus Impact Tracker Is Responsive To Changes In Physician Assessed Disease Status By Systemic Lupus Erythematosus Responder Index. Hervé Devilliers, Mark Kosinski, Cindy Garris and Meenakshi Jolly 4, Internal medicine and systemic disease unit, Dijon University Hospital, Dijon, France, QualityMetric Inc, Lincoln, RI, GlaxoSmithKline R&D, Research Triangle Park, NC, 4 Rush University Medical Center, Chicago, IL 57. Inactive Systemic Lupus Erythematosus: Cytokines and Soluble Tumor Necrosis Factor Receptors Response To Moderate/Intense Exercise. Luiz A. Perandini, Diego Sales-de-Oliveira, Suzana B.V. Mello, Niels O Camara, Fernanda R. Lima, Eduardo F. Borba, Eloisa Bonfa, Ana Lucia Sá-Pinto, Hamilton Roschel 4 and Bruno Gualano 5, University of Sao Paulo, Rheumatology Division, Sao Paulo, Brazil, University of Sao Paulo, Rheumatology Division, São Paulo, Brazil, University of Sao Paulo, Sao Paulo, Brazil, 4 Universidade de São Paulo, Faculdade de Educação Física e Esporte, São Paulo, Brazil, 5 University of Sao Paulo, School of Physical Education and Sport, Sao Paulo, Brazil 58. Impact Of Omega- Fatty Acids On Quality Of Life In Systemic Lupus Erythematosus. Cristina Arriens, Chandra Mohan and David R. Karp, University of Texas Southwestern Medical Center at Dallas, Dallas, TX, University of Texas Southwestern Medical Center, Dallas, TX, UT Southwestern Medical Center, Dallas, TX 59. The Reliability Of a Novel Automated System For ANA Immunofluorescence Analysis In Daily Clinical Practice. Mohammed Alsuwaidi, Margit Dollinger, Martin Fleck and Boris P. Ehrenstein, Asklepios Clinic Bad Abbach, Bad Abbach, Germany 540. Serum Mercury Level and Disease Activity Of Systemic Lupus Erythematosus (SLE): A Case-Control Study. Chi Chiu Mok, Becky Fong and Chris Wong, Tuen Mun Hospital, Hong Kong, Hong Kong, Baptist University Hong Kong, Hong Kong, Hong Kong 54. Disease Activity Does Not Improve Significantly In One System and Worsen In Another System. Zahi Touma, Dafna Gladman and Murray B. Urowitz, University of Toronto, Toronto Western Hospital, Toronto, ON 54. Validation Of The Revised Selena Flare Index In Systemic Lupus Erythematosus. Michelle Petri, Joan T. Merrill, R. Maciuca, John C. Davis Jr. and William P. Kennedy, Johns Hopkins University School of Medicine, Baltimore, MD, Oklahoma Medical Research Foundation, Oklahoma City, OK, Genentech, Inc, South San Francisco, CA 54. Patients Perception Of Their Lupus Disease Activity, But Not Overall Health, Correlates With Physician Assessments. Anca Askanase, Samrawit Abraha, Ummara Shah, Aleks Merkovich and Jill P. Buyon, New York University School of Medicine, New York, NY, New York University School of Medicine, NYC, NY, NYU School of Medicine, New York, NY 544. Serum Mediated Phagocytosis Of Necrotic Material By Polymorphonuclear Leukocytes May Be Used As a Tool To Predict Clinical Manifestations In Systemic Lupus Erythematosus. Michele Compagno, Birgitta Gullstrand, Andreas Jönsen, Lennart Truedsson, Gunnar Sturfelt and Anders A. Bengtsson, Lund University, Lund, Sweden 545. Active Systemic Lupus Erythematosus: Cytokines and Soluble Tumor Necrosis Factor Receptors Response To Moderate/Intense Exercise. Luiz A. Perandini, Diego Sales-de-Oliveira, Suzana B.V. Mello, Niels O Camara, Fernanda R. Lima, Eduardo F. Borba, Eloisa Bonfa, Ana Lucia Sá-Pinto, Hamilton Roschel 4 and Bruno Gualano 5, University of Sao Paulo, Rheumatology Division, Sao Paulo, Brazil, University of Sao Paulo, Rheumatology Division, São Paulo, Brazil, University of Sao Paulo, Sao Paulo, Brazil, 4 Universidade de São Paulo, Faculdade de Educação Física e Esporte, São Paulo, Brazil, 5 University of Sao Paulo, School of Physical Education and Sport, Sao Paulo, Brazil 546. Anti-Nucleosome Antibodies As a Predictor Factor For Relapses In Clinically Quiescent Systemic Lupus Erythematosus: Results Of a Prospective Cohort Study. Dalia Sanchez-Mosco, Nadia Alejandra Gandarilla- Martinez, Nicte Selene Fajardo-Robledo, Valeria Diaz-Rizo 4, Soraya Amali Zavaleta-Muñiz 5, Miguel Huerta 6, Xochitl Trujillo 6, Arnulfo Nava 7, Ernesto German Cardona-Muñoz 8, Jose Francisco Muñoz-Valle 9, Jorge Ivan Gamez-Nava 0 and Laura Gonzalez-Lopez, Centro Universitario de Investigación Biomédica, Universidad de Colima; Hospital General Regional 0 IMSS, Guadalajara, Jalisco, Mexico, Hospital General Regional 0, Instituto Mexicano del Seguro Social (IMSS), Guadalajara, Jalisco, Mexico, Doctorado en Farmacología, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara, Jalisco, Mexico, 4 Doctorado en Ciencias Médicas, Centro Universitario de Investigación Biomédica, 0 Program Book 4

344 ACR POSTER SESSION C Universidad de Colima; UMAE, Hospital de Especialidades, Centro Médico Nacional de Occidente, IMSS, Guadalajara, Jalisco, Mexico, 5 UMAE, Hospital de Especialidades Centro Médico Nacional de Occidente, IMSS; Doctorado en Ciencias con orientación en Inmunología, Guadalajara, Jalisco, Mexico, 6 Centro Universitario de Investigación Biomédica, Universidad de Colima, Colima, Mexico, 7 UMAE, Hospital de Especialidades Centro Médico Nacional de Occidente, IMSS, Guadalajara, Jalisco, Mexico, 8 Unidad de Investigación Cardiovascular, CUCS, Universidad de Guadalajara, Guadalajara, Jalisco, Mexico, 9 Doctorado en Ciencias Biomédicas. Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara, Jalisco, Mexico, 0 UMAE, Centro Médico Nacional de Occidente, IMSS; Doctorado en Farmacología, Universidad de Guadalajara, Jalisco, Mexico 547. Anti-Ribosomal P Antibody Has a Protective Role In The Development Of Chronic Kidney Disease In Patients With Lupus Nephritis. Kyung-Eun Lee, Dong-Jin Park, Tae-Jong Kim, Yong-Wook Park and Shin-Seok Lee, Chonnam National University Medical School, Gwangju, South Korea, Chonnam National University Medical School and Hospital, Gwangju, South Korea 548. Assessment Of Worsening In Lupus Clinical Trials: Do The Endpoints Reflect Medical Judgement? Aikaterini Thanou, Eliza Chakravarty, Stan Kamp, Fredonna C. Carthen and Joan T. Merrill, Oklahoma Medical Research Foundation, Oklahoma City, OK, Oklahoma Medical Research Foundation, Oklahoma CIty, OK 549. Can Biomarkers Provide An Objective Standard Against Which To Assess Lupus Clinical Endpoint Measures? Aikaterini Thanou, Melissa E. Munroe, Stan Kamp, Joel M. Guthridge, Judith A. James and Joan T. Merrill, Oklahoma Medical Research Foundation, Oklahoma City, OK, Oklahoma Medical Research Foundation, Oklahoma CIty, OK, Oklahoma Medical Research Foundation and University of Oklahoma Health Sciences Center, Oklahoma City, OK 550. Predictive Markers Of Preeclampsia During Pregnancy In Patients With Systemic Erithematosus LUPUS and / Or Antiphospholipid Syndrome. Esther Rodriguez- Almaraz, Elena Gonzalo-Gil, Ignacio Herráiz, Paula I Gómez-Arriaga, Paloma Vallejo, Elena A López-Jiménez, María Galindo Izquierdo and Alberto Galindo Izquierdo, Department of Rheumatology. Hospital Universitario de Octubre, Madrid, Spain, Fetal Medicine Unit, Department of Obstetrics and Gynecology. Hospital Universitario de Octubre., Madrid, Spain, Department of Biochemistry. Hospital Universitario de Octubre., Madrid, Spain 55. Pharmacodynamics and Predictive Biomarkers In Patients Treated With Atacicept: Data From The APRIL-SLE Trial. David A. Isenberg, David Wofsy, Yong Li, Daiana Licu 4, Stephen D. Wax, Caroline Gordon 5 and Claudia Pena Rossi 4, University College London, London, United Kingdom, University of California San Francisco and NIAID Autoimmunity Centers of Excellence, San Francisco, CA, EMD Serono, Rockland, MA, 4 Merck Serono S.A., Geneva, Switzerland, 5 University of Birmingham, Birmingham, United Kingdom 55. Predictive Significance Of ANTI-Prothrombin Antibodies For Second and Third Trimester Obstetric Complications In Patients With Systemic LUPUS Erythematosus and ANTI-Phospholipid Syndrome. Marta Mosca, Chiara Tani, Martina Fabris, Francesca Strigini, Linda Carli 4, Sabrina Vagnani, Rosaria Talarico 4, Chiara Baldini 4, Alessandra Della Rossa 4, Elio Tonutti 5 and Stefano Bombardieri, Rheumatology Unit, University of Pisa, Pisa, Italy, Institute of Clinical Pathology, Udine, Italy, University of Pisa, Pisa, Italy, 4 Rheumatology Unit, Pisa, Italy, 5 Santa Maria Hospital, Udine, Italy 55. The Clinical Value Of Testing For Aphl, a New ELISA Kit With a Unique Phospholipid Mixture In Patients With Systemic Lupus Erythematosus (SLE). Savino Sciascia, Giovanni Sanna, Veronica Murru, Munther A. Khamashta and Maria Laura Bertolaccini, Centro di Immunopatologia e Documentazione su Malattie rare, Torino, Italy, Louise Coote Lupus Unit, St. Thomas Hospital, London, United Kingdom, Lupus Research Unit, The Rayne Institute, Kings College London School of Medicine, London, United Kingdom 554. In Vitro Fertilization In Systemic Lupus Erythematosus and Antiphospholipid Syndrome: A Series Of 8 Cycles. Pauline Orquevaux, Agathe Masseau, Véronique le Guern, Vanessa Gayet, Danièle Vauthier-Brouzes 4, Du Boutin 5, Bertrand Wechsler 6, Nathalie Morel 7, Jean Loup Pennaforte, Jean-Charles Piette 8 and Nathalie Costedoat- Chalumeau 9, CHU Reims, Reims, France, Nantes University Hospital, Nantes, France, Cochin Hospital, Paris, France, 4 Pitié Salpétrière Hospital, Paris, France, 5 Assistance Publique-Hôpitaux de Paris, Hopital Pitié-Salpétrière, Paris, France, 6 Hôpital Pitié-Salpêtrière, AP-HP, UPMC Univ Paris 06 & French National Reference Center For Systemic Lupus and Antiphospholipid Syndrome, Paris, France, 7 COCHIN, Paris, France, 8 CHU Pitié-Salpêtrière, Paris, France, 9 Hopital Cochin, Paris, France 555. Development and Validation Of a Questionnaire To Screen For The Presence Of Autoimmune Disease. Alan Boroway, Aileen M. Davis, Carolina Landolt-Marticorena and Joan E. Wither, Toronto Western Hospital, University of Toronto, Toronto, ON, Toronto Western Research Institute, Toronto Western Hospital, University of Toronto, Toronto, ON 556. Concordance Of Indirect Immunofluorescence and Multiplex Immunoassay For Measurement Of Antinuclear Antibodies. Caroline D Souza, Donald L. Kimpel, Walter Oliveira and Janet E. Lewis, University of Virginia School of Medicine, Charlottesville, VA, University of Virginia, Department of Pathology, Medical Laboratories, Charlottesville, VA 4 0 Program Book

345 ACR POSTER SESSION C 557. Fluctuations In svcam- and Adiponectin Mirror Fluctuations In Disease Activity In Lupus, But Cannot Be Use To Accurately Predict Impending Changes In Disease State. Carolina landolt-marticorena, Stephenie Prokopec, Stacey Morrison, Heather Reich, James Scholey, Dafna Gladman 4, Murray B. Urowitz 4, Paul Boutros, Paul R. Fortin 5 and Joan E. Wither 6, Toronto Western Hospital, University of Toronto, Toronto, ON, Ontario Institute for Cancer Research, Toronto, ON, The Toronto Western Hospital, Toronto, ON, 4 University of Toronto, Toronto Western Hospital, Toronto, ON, 5 University of Laval, Quebec, QC, 6 Toronto Western Research Institute, Toronto Western Hospital, University of Toronto, Toronto, ON Systemic Sclerosis, Fibrosing Syndromes, and Raynaud s II 558. Bone Morphogenic Protein Receptor (BMPR) Gene Mutations Are Associated To The Development Of Isolated Pulmonary Arterial Hypertension (PAH) In Systemic Sclerosis (SSc) Patients. Tatiana Sofia Rodriguez-Reyna, Jose Luis Hernandez-Oropeza, Tomas Rene Pulido- Zamudio, Felipe Massó, Jessica Gutierrez-Manjarrez, Alexandra Rueda de Leon-Aguirre, Julio Sandoval-Zarate and Carlos Rodriguez-Osorio, Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico, Instituto Nacional de Cardiologia Ignacio Chavez, Mexico City, Mexico 559. Effect Of NOX4 Overexpression On The Levels Of Micro RNAs Relevant To Systemic Sclerosis Fibrotic Process. Sonsoles Piera-Velazquez, Alma Makul and Sergio A. Jimenez, Jefferson Institute of Molecular Medicine, Division of Connective Tissue Diseases and Scleroderma Center,Thomas Jefferson University, Philadelphia, PA 560. Analysis Of Global Gene Expression Of Pulmonary Endothelial Cells From Caveolin- Knock-Out Mice. Sonsoles Piera-Velazquez, Zhaodong Li, Sankar Addya, Peter J. Wermuth and Sergio A. Jimenez, Jefferson Institute of Molecular Medicine, Division of Connective Tissue Diseases and Scleroderma Center,Thomas Jefferson University, Philadelphia, PA, Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA 56. Multiplex Cytokine Analysis Of Dermal Interstitial Blister Fluid In Systemic Sclerosis Defines Potential Pathogenic Pathways and Differentiates Clinical Subsets. Kristina E.N. Clark, Henry Lopez, Joanna Nikotorowicz-Buniak, Xu Shiwen, Korsa Khan, George Martin, David J. Abraham, Christopher P. Denton and Richard J. Stratton, UCL Medical School, London, United Kingdom, Murigenics, Vallejo, CA, Aero Dap, Vallejo, CA 56. Inhibition Of SOX9 Phosphorylation Abrogates The Increased Expression Of Profibrotic Genes In Systemic Sclerosis Dermal Fibroblasts. Sonsoles Piera-Velazquez, Alma Makul and Sergio A. Jimenez, Jefferson Institute of Molecular Medicine, Division of Connective Tissue Diseases and Scleroderma Center,Thomas Jefferson University, Philadelphia, PA 56. Modulating Myofibroblast Transition Of Human Scleroderma Fibroblasts Through Inhibition Of Rho Guanine Nucleotidase-Regulated Gene Transcription. Andrew Haak, Pei-Suen Tsou, Dinesh Khanna, David A. Fox, Scott D. Larsen and Richard R. Neubig 4, Department of Pharmacology, University of Michigan Medical Center, Ann Arbor, MI, Division of Rheumatology, University of Michigan Medical Center, Ann Arbor, MI, Vahlteich Medicinal Chemistry Core, College of Pharmacy, University of Michigan, Ann Arbor, MI, 4 Department of Pharmacology & Toxicology, Michigan State University, East Lansing, MI 564. Functional Activation Of The TRPV and TRPV Non- Selective Cation Channels Potentiates TGF-β-Induced Endothelial-To-Mesenchymal Transition In Murine Pulmonary Endothelial Cells Suggest a Potential Role Of Trpv Channels In The Pathogenesis Of Systemic Sclerosis. Peter J. Wermuth and Sergio A. Jimenez, Jefferson Institute of Molecular Medicine, Division of Connective Tissue Diseases and Scleroderma Center,Thomas Jefferson University, Philadelphia, PA 565. Synergistic Effects Of Endothelin- On Transforming Growth Factor-β (TGF-β) Induced Endothelial-To- Mesenchymal Transition. A Novel Mechanism For The Fibrogenic Effects Of Endothelin. Peter J. Wermuth, Zhaodong Li and Sergio A. Jimenez, Jefferson Institute of Molecular Medicine, Division of Connective Tissue Diseases and Scleroderma Center,Thomas Jefferson University, Philadelphia, PA 566. Nilotinib Treatment Effect In The Skin As Measured By DNA Microarray In Patients With Diffuse Systemic Sclerosis. Jessica K. Gordon, Tammara A. Wood, Robert F. Spiera and Michael L. Whitfield, Hospital for Special Surgery, New York, NY, Dartmouth Medical School, Hanover, NH, Geisel School of Medicine at Dartmouth, Hanover, NH 567. Cadherin- Regulates Pulmonary Fibrosis In Bleomycin- Induced Lung Injury. Mesias Pedroza, Anuh T. George and Sandeep K. Agarwal, Baylor College of Medicine, Houston, TX Involvement Of Collagen-Binding Heat Shock Protein 47 In The Scleroderma-Associated Fibrosis. Haiyan Chu, Ting Wu, Wenyu Wu, Wenzhen Tu, Yanyun Ma, Qingmei Liu, Hejian Zou 4, Li Jin and Jiu-Cun Wang, Ministry of Education Key Laboratory of Contemporary Anthropology, School of Life Sciences, Fudan University, Shanghai, China, Division of Dermatology, Huashan Hospital, Fudan University, Shanghai, Shanghai, China, Shanghai Traditional Chinese Medicine-Integrated Hospital, Shang hai, China, 4 Huashan Hospital, Shanghai, China 0 Program Book 4

346 ACR POSTER SESSION C Serum S00A4 Levels Correlate With Skin Fibrosis and Lung Involvement In Systemic Sclerosis. Michal Tomcik, Lucie Andres Cerezo, Simona Skacelova, Martin Komarc, Radim Becvar, Mariam Grigorian, Joerg HW Distler 4 and Ladislav Senolt, Institute of Rheumatology, Department of Rheumatology, st Faculty of Medicine, Charles University, Prague, Czech Republic, Institute of Biophysics and Informatics of the First Faculty of Medicine, Charles University, Prague, Czech Republic, Institute of Cancer Biology, Danish Cancer Society, Copenhagen, Denmark, 4 Department of Internal Medicine III and Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany 570. Tenofovir But Not Adefovir Prevents Liver and Skin Fibrosis In Two Models Of Adenosine-Mediated Injury. Jessica L. Feig, Doreen Tivon, Miguel perez Aso, Timothy Cardozo and Bruce N. Cronstein, New York University School of Medicine, New York, NY, NYU Univ Medical Center, New York, NY, NYU School of Medicine, Division of Rheumatology, New York, NY 57. Pigment Epithelium Derived Factor Secreted By Activated Fibroblasts Can Contribute To Impaired Angio and Vasculogenesis In Scleroderma. Vasiliki Liakouli, Georgia Mavria, Justin Gillespie, Margherita Scarcia, Paola Cipriani, Roberto Giacomelli, Paul Emery 4 and Francesco Del Galdo 4, Rheumatology Unit, University of Aquila, L Aquila, IT, L Aquila, Italy, Signal Transduction and Angiogenesis group, Leeds Institute of Cancer and Pathology, University of Leeds, Leeds, UK, Leeds, United Kingdom, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, 4 Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom 57. An Atypical Cyclin-Dependent Kinase Mediates Fibrosis and Is a Novel Target In Scleroderma. Jun Wei, Roberta G. Marangoni, Wenxia Wang, Jingang Huang, Joerg H. W. Distler and John Varga, Northwestern University, Chicago, IL, Department of Internal Medicine III and Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, Northwestern University Medical School, Chicago, IL 57. The Role Of STAT- In The Development Of Pulmonary and Dermal Fibrosis. Mesias Pedroza, Sarah To, Anuh T. George, David J. Tweardy and Sandeep K. Agarwal, Baylor College of Medicine, Houston, TX Systemic Sclerosis, Fibrosing Syndromes, and Raynaud s - Clinical Aspects and Therapeutics II 574. Early Use of Prostacyclin Therapy Improves Transplant- Free Survival in Patients With Systemic Sclerosis-Related Pulmonary Arterial Hypertension Plus Interstitial Lung Disease. Elizabeth Volkmann, Rajan Saggar, Bryant Torres, Lynne Yoder, Robert Elashoff, Rajeev Saggar, Harsh Agrawal, Nabeel Borazan, Sarah Thomas and Daniel Furst, University of California, Los Angeles, Los Angeles, CA, St. Joseph s Hospital and Medical Center, Phoenix, AZ, Rheumatology UCLA, Los Angeles, CA 0 Program Book 575. Utility Of Autoantibody Testing For Predicting Risk Of Pulmonary Arterial Hypertension: A Retrospective Analysis In Routine Autoantibody Laboratory. Masataka Kuwana, Yuichiro Shirai, Hidekata Yasuoka, Tsutomu Takeuchi and Kenichi Masui, Keio University School of Medicine, Tokyo, Japan, National Defense Medical College, Tokorozawa, Japan 576. Epoprostenol Rescue Therapy In Systemic Sclerosis- Associated Pulmonary Arterial Hypertension and Idiopathic Pulmonary Arterial Hypertension. Adrienne M. Roos, Christopher Pasarikovski, Amie T. Kron, John T. Granton, Peter Lee, John Thenganatt 4 and Sindhu R. Johnson 5, Toronto Scleroderma Research Program, Toronto Western Hospital, Mount Sinai Hospital, and University of Toronto, Toronto, ON, Toronto Pulmonary Hypertension Programme, Toronto General Hospital and University of Toronto, Toronto, ON, Mt. Sinai Hospital, Toronto, ON, 4 University Health Network Pulmonary Hypertension Programme, Toronto General Hospital, Divisions of Respirology and Critical Care Medicine, Toronto, ON, 5 Division of Rheumatology, Toronto Western Hospital, University Health Network Pulmonary Hypertension Programme, Toronto General Hospital, Mount Sinai Hospital and University of Toronto, Toronto, ON 577. Sex Disparities In Survival Of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension and Idiopathic Pulmonary Arterial Hypertension Patients. Christopher Pasarikovski, John T. Granton, Peter Lee, Adrienne M. Roos, Amie T. Kron, Cathy Chau 4 and Sindhu R. Johnson 5, Toronto Scleroderma Research Program, Toronto Western Hospital, Mount Sinai Hospital, and University of Toronto, Toronto, ON, Toronto Pulmonary Hypertension Programme, Toronto General Hospital and University of Toronto, Toronto, ON, Mt. Sinai Hospital, Toronto, ON, 4 Toronto Scleroderma Research Program, Toronto Western Hospital, Mount Sinai Hospital, University of Toronto, Toronto, ON, 5 Toronto Western Hospital, Toronto General Hospital, Mount Sinai Hospital, and University of Toronto, Toronto, ON 578. Pulmonary Hypertension In Systemic Sclerosis: Clinical Classification and Pulmonary Hypertension Subtypes. Monica Mohile, Mary Lucas, Virginia D. Steen, Thomas A. Medsger Jr. and Robyn T. Domsic, University of Pittsburgh Medical Center, Pittsburgh, PA, University of Pittsburgh, Pittsburgh, PA, Georgetown University Medical Center, Washington, DC 579. Recommendations For Screening and Detection Of Connective-Tissue Disease Associated Pulmonary Arterial Hypertension. Dinesh Khanna, Heather Gladue, John D. Fitzgerald, Richard N. Channick 4, Lorinda Chung 5, Oliver Distler 6, Daniel Furst 7, Eric Hachulla 8, Marc Humbert 9, David Langleben 0, Stephen C. Mathai, Rajeev Saggar, Scott H. Visovatti and Vallerie McLaughlin, University of Michigan Medical Center, Ann Arbor, MI, University of Michigan, Ann Arbor, MI, UCLA School Med Rehab #- 59, Los Angeles, CA, 4 Massachusetts General Hospital, Boston, MA, 5 Stanford Univ Medical Center, Palo Alto, CA, 6 Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland, 7 University of California in Los Angeles, Los Angeles, CA, 8 Claude Huriez University Hospital, Lille,

347 ACR POSTER SESSION C France, 9 Centre Chirurgical Marie-Lannelongue, Le Plessis- Robinson, France, 0 Jewish General Hospital, Montreal, QC, Johns Hopkins University, Baltimore, MD, St. Joseph s Hospital and Medical Center, Phoenix, AZ, The University of Michigan, Ann Arbor, MI 580. Does Mycophenolate Mofetil (MMF) Have An Effect On Pulmonary Hemodynamics? Observations From The Pulmonary Hypertension Assessment and Recognition Of Outcomes In Scleroderma (PHAROS) Cohort. Lesley Ann Saketkoo, Matthew R. Lammi, Jessica K. Gordon, Paula Lauto and Virginia D. Steen 4, LSU Scleroderma and Sarcoidosis Patient Care and Research Center, New Orleans, LA, Hospital for Special Surgery, New York, NY, LSU Health Sciences Center, New Orleans, LA, 4 Georgetown University Medical Center, Washington, DC 58. Can Changes In NT-Probnp Predict Early Response To Therapy and Prognosis In Systemic Sclerosis Associated Pre-Capillary Pulmonary Hypertension? Vincent Sobanski, Bernadette Lynch, Benjamin E. Schreiber, Clive Handler, Christopher P. Denton 4 and John G. Coghlan 5, Royal Free Hospital, London, United Kingdom, The Royal Free Hospital, London, United Kingdom, National Pulmonary Hypertension Service, London, United Kingdom, 4 Royal Free and University College Medical School, London, United Kingdom, 5 The Royal Free Hospital NHS Foundation Trust, London, United Kingdom 58. Treatment Of Pulmonary Hypertension In Scleroderma Patients With Restricitive Lung Disease.Observations From The Pulmonary Hypertension Assessment and Recognition Of Outcomes In Scleroderma Cohort. Virginia D. Steen and Robyn T. Domsic, Georgetown University Medical Center, Washington, DC, University of Pittsburgh, Pittsburgh, PA 58. Long-Term Treatment With Endothelin Receptor Antagonist Increases Peripheral Blood Perfusion In Systemic Sclerosis Patients. Maurizio Cutolo, Barbara Ruaro, Elena Bernero, Francesca Ravera, Giuseppe Zampogna, Elisa Alessandri, Vanessa Smith and Alberto Sulli, Research Laboratory and Academic Unit of Clinical Rheumatology, Department of Internal Medicine, University of Genova, Genoa, Italy, Department of Rheumatology, Ghent University Hospital, Ghent, Belgium 584. Screening and Diagnostic Modalities For Systemic Sclerosis-Associated Pulmonary Arterial Hypertension: A Systematic Review. Heather Gladue, Nezam I. Altorok, Whitney Townsend, Vallerie McLaughlin and Dinesh Khanna, University of Michigan, Ann Arbor, MI, University of Michigan Medical Center, Ann Arbor, MI 585. Left Ventricular Dysfunction Reflected By Higher Serum Brain Natriuretic Peptide Accounts For Poorer Prognosis Of Pulmonary Arterial Hypertension Associated With Systemic Sclerosis. Sumiaki Tanaka, Yoshiyuki Arinuma, Tatsuhiko Wada, Tatsuo Nagai, Jun Okada and Shunsei Hirohata, Kitasato University School of Medicine, Sagamihara, Japan, Kitasato Junior Collage of health and Hygienic Sciences, Minami-Uonuma, Japan 586. Antinuclear Antibody Negative Systemic Sclerosis Patients Have Less Vasculopathic Disease Manifestations. Gloria Salazar, Shervin Assassi, Fredrick M. Wigley, Daniel E. Furst, Laura K. Hummers, Dinesh Khanna 4, John Varga 5, Elena Schiopu 6, Virginia D. Steen 7, Murray Baron 8, Marie Hudson 8, Janet E. Pope 9, Monique E. Hinchcliff 5, Marvin J. Fritzler 0, David B. Robinson, Robert W. Simms, Richard M. Silver, Tracy M. Frech 4, Barri J. Fessler 5, Jerry A. Molitor 6, Sara Zamanian, Niall Jones 7, John D. Reveille, Frank C. Arnett and Maureen D. Mayes, University of Texas Health Science Center at Houston, Houston, TX, Johns Hopkins University School of Medicine, Baltimore, MD, University of California at Los Angeles, Los Angeles, CA, 4 Division of Rheumatology, University of Michigan Medical Center, Ann Arbor, MI, 5 Northwestern University Medical School, Chicago, IL, 6 University of Michigan Medical School, Ann Arbor, MI, 7 Georgetown University Medical Center, Washington, DC, 8 McGill University, Montreal, QC, 9 St Joseph Health Care, London, ON, 0 University of Calgary, Calgary, AB, University of Manitoba, Winnipeg, MB, Boston University School of Medicine, Boston, MA, Medical University of SC, Charleston, SC, 4 University of Utah School of Medicine, SLC, UT, 5 University of Alabama at Birmingham, Birmingham, AL, 6 Univ of MN MMC08, Minneapolis, MN, 7 Rheumatology Clinic at 4th Street Medical Clinic, Edmonton, AB 587. The Clinical Utility Of Flow-Mediated Dilation In Systemic Sclerosis. Tracy M. Frech, Ashley Walker, Zachary Barrett- Okeefe, Russell Richardson, D. Walter Wray and Anthony Donato, Salt Lake City VAMC, Salt Lake, UT, University of Utah, Salt Lake, UT 588. Pulmonary Hypertension In Patients With Anti-U- RNP Antibodies. Vincent Sobanski, Bernadette Lynch, Benjamin E. Schreiber, Svetlana I. Nihtyanova 4, Jennifer Harvey, Clive Handler, Christopher P. Denton 4 and John G. Coghlan 5, Royal Free Hospital, London, United Kingdom, The Royal Free Hospital, London, United Kingdom, National Pulmonary Hypertension Service, London, United Kingdom, 4 Royal Free and University College Medical School, London, United Kingdom, 5 The Royal Free Hospital NHS Foundation Trust, London, United Kingdom 589. Scleroderma Patients With Pulmonary Hypertension and Increased Pulmonary Capillary Wedge Pressure In The Pulmonary Hypertension Assessment and Recognition Of Outcomes In Scleroderma (PHAROS) Cohort. Matthew R. Lammi, Lesley Ann Saketkoo, Jessica K. Gordon, Paula Lauto 4 and Virginia D. Steen 5, Louisiana State University Health Sciences Center, Pulmonary and Critical Medicine, New Orleans, LA, LSU HSC - New Orleans, Sections of Rheumatology and Pulmonary Medicine, New Orleans, LA, Hospital for Special Surgery, New York, NY, 4 LSU Health Sciences Center, New Orleans, LA, 5 Georgetown University Medical Center, Washington, DC 0 Program Book 45

348 ACR POSTER SESSION C 590. Laser Speckle Contrast Analysis A New Method To Evaluate Blood Perfusion in Different Skin Areas Of Systemic Sclerosis Patients: Comparison With Laser Doppler Flowmetry. Alberto Sulli, Barbara Ruaro, Giorgia Ferrari, Elena Bernero, Carmen Pizzorni, Vanessa Smith and Maurizio Cutolo, Research Laboratory and Academic Unit of Clinical Rheumatology, Department of Internal Medicine, University of Genova, Genoa, Italy, Department of Rheumatology, Ghent University Hospital, Ghent, Belgium 59. Scleroderma Renal Crisis and Pulmonary Arterial Hypertension Are Very Rare In The Same Patient. Bernadette Lynch, Vincent Sobanski, Clive Handler, Benjamin E. Schreiber, John G. Coghlan, Voon H. Ong 4, Aine Burns and Christopher P. Denton 5, The Royal Free Hospital, London, United Kingdom, National Pulmonary Hypertension Service, London, United Kingdom, The Royal Free Hospital NHS Foundation Trust, London, United Kingdom, 4 The Royal Free and University College Medical School, London, United Kingdom, 5 Department of Rheumatology, London, United Kingdom 59. Clinical Significance Of Endothelial Vasodilator Function Evaluated By Endopat In Patients With Systemic Sclerosis. Naohiko Aozasa, Yoshihide Asano, Masaru Hatano, Ryosuke Saigusa, Kouta Takakuwa, Takehiro Takahashi, Tetsuo Toyama, Hayakazu Sumida, Atsushi Yao, Koichiro Kinugawa, Hisataka Maki, Toshiro Inaba, Hironori Muraoka, Shun Minatsuki, Issei Komuro and Shinichi Sato, University of Tokyo Graduate School of Medicine, Tokyo, Japan 59. The Prognosis Of Scleroderma Renal Crisis In RNA- Polymerase III Antibody (ARA) Positive Compared To ARA Negative Patients. Bernadette Lynch, Henry Penn, Jennifer Harvey, Aine Burns and Christopher P. Denton 4, The Royal Free Hospital, London, United Kingdom, Northwick Park Hospital, Harrow, United Kingdom, Royal Free Hospital, London, United Kingdom, 4 UCL Medical School, London, United Kingdom 594. Stabilisation Of Microcirculation In Early Systemic Sclerosis Patients With Diffuse Skin Involvement Following Rituximab Treatment. Vanessa Smith, Carmen Pizzorni, Valeria Riccieri, Saskia Decuman 4, Yves P. Piette, Ellen Deschepper 5, Filip De Keyser and Maurizio Cutolo 6, Department of Rheumatology, Ghent University Hospital, Ghent, Belgium, Research Laboratory and Academic Unit of Clinical Rheumatology, Department of Internal Medicine, University of Genova, Genoa, Italy, Department of Internal Medicine and Medical Specialities, University Sapienza, Rome, Italy, 4 Department of Internal Medicine, Ghent University, Ghent, Belgium, 5 Biostatistics Unit, Department of Public Health, Ghent University, Ghent, Belgium, 6 University of Genova, Genova, Italy 595. Microvascular Abnormalities In Patients With Early Systemic Sclerosis: Less Severe Morphological Changes Compared To Patients With Definite Disease. Cintia Camargo, Juliana Sekiyama, Maria I. Arismendi and Cristiane Kayser, Universidade Federal de São Paulo, São Paulo, Brazil 596. Association Between Nail Fold Capillaroscopy Abnormalities and Thermographic Assessment Of Peripheral Microvascular Dysfunction In An Unselected Cohort Of Patients Under Investigation For Symptoms Of Raynaud s Phenomenon. Bhavisha Vasta, Marina Scolnik, Darren Hart, Jacqueline A. Shipley, Sue Brown, Eleanor Korendowych, Neil J McHugh and John D. Pauling, Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, Rheumatology Section, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, Department of Pharmacy and Pharmacology, University of Bath, Bath, United Kingdom 597. Acupressure For The Treatment Of Raynaud s Phenomenon: A Pilot Randomized Controlled Trial. Heather Gladue, Richard E. Harris, Veronica Berrocal, Pei-Suen Tsou, Gautam Edhayan, Ray Ohara and Dinesh Khanna 4, University of Michigan, Ann Arbor, MI, Division of Rheumatology, University of Michigan Medical Center, Ann Arbor, MI, University of Michigan Medical School, Ann Arbor, MI, 4 University of Michigan Medical Center, Ann Arbor, MI 598. Timing and Outcome Of Transition From Primary To Secondary Raynaud s Phenomenon: A Capillaroscopic Based Study. Alberto Sulli, Giorgia Ferrari, Elena Bernero, Carmen Pizzorni, Vanessa Smith, Barbara Ruaro and Maurizio Cutolo, Research Laboratory and Academic Unit of Clinical Rheumatology, Department of Internal Medicine, University of Genova, Genoa, Italy, Department of Rheumatology, Ghent University Hospital, Ghent, Belgium 599. Safety and Effectiveness Of Mycophenolate In Systemic Sclerosis: A Systemic Review. Mohammed Omair, Abdulaziz Alahmadi and Sindhu R. Johnson, Mount Sinai Hospital/University of Toronto, Toronto, ON, Toronto Scleroderma Research Program, Division of Rheumatology, Mount Sinai Hospital, Toronto Western Hospital, University Health Network, University of Toronto, Toronto, ON, Toronto Western Hospital, Toronto General Hospital, Mount Sinai Hospital, and University of Toronto, Toronto, ON 600. Shear Wave Elastography: A Novel Quantitative Approach For Evaluating Scleroderma Skin. Ingeborg Sacksen, Mark H. Wener, P. Scott Pollock and Manjiri K. Dighe, University of Washington, Seattle, WA 60. Modified Rodnan Ultrasound Skin Score: An Ultrasound Skin Scoring Approach In Systemic Sclerosis. Ingeborg Sacksen, P. Scott Pollock and Mark H. Wener, University of Washington, Seattle, WA 60. Reduced Frequencies Of Circulating CD8 T Cells In Early Diffuse Cutaneous Systemic Sclerosis Is Associated With Worse Skin Scores. Marie Hudson, Maximilien Lora, Christopher Di Ioia, Solene Tatibouet, Sasha Bernatsky and Ines Colmegna 4, McGill University, Montreal, QC, McGill University Health Centre, Montréal, QC, McGill University Health Center, Montreal, QC, 4 McGill University Health Centre, Montreal, QC 46 0 Program Book

349 ACR POSTER SESSION C 60. Are There Differences In Limited Systemic Sclerosis According To Extension Of Skin Involvement?. Marina Scolnik, Eliana Lancioni, Luis J. Catoggio, Mirtha Sabelli, Zaida Bedran, Carla Saucedo, Josefina Marin and Enrique Soriano, Rheumatology Section, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, Rheumatology Unit, Internal Medical Services, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina 604. Longitudinal Assessment Of Scleroderma Skin By Optical Coherence Tomography: Preliminary Validation Of Sensitivity To Change Over-Time. Giuseppina Abignano, Lesley-Anne Bissell, Jason Britton, Daniel Woods, Maya H. Buch, Dennis McGonagle, Paul Emery and Francesco Del Galdo, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, Medical Physics Department, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, Michelson Diagnostics Ltd, Kent, United Kingdom 605. Quality Of Life and Psychosocial Aspects In Juvenile Localized Scleroderma. Roberta Culpo, Marco Ricca, Fabio Vittadello, Giuseppina Sequi, Francesco Zulian and Giorgia Martini, University of Padua, Padua, Italy 606. Mortality, Recurrence, and Hospital Course of Patients With Systemic Sclerosis Related Acute Intestinal Pseudo- Obstruction. Chris T. Derk, Nora Sandorfi, Shivani Purohit and Christopher Mecoli, University of Pennsylvania, Philadelphia, PA, Thomas Jefferson Univ Med Coll, Philadelphia, PA, Rheumatology Division, Department of Medicine, Thomas Jefferson University, Philadelphia, PA 607. Evaluation Of The Construct Validity Of The Patient- Reported Outcomes Measurement Information System (PROMIS ) Gastrointestinal (GI) Symptoms Measures In Systemic Sclerosis (SSc). Dinesh Khanna, Puja Khanna, Brennan Spiegel, Lin Chang, Gil Y. Melmed 4, Roger Bolus 5 and Ron Hays, University of Michigan Medical Center, Ann Arbor, MI, University of California, Los Angeles, Los Angeles, CA, David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, CA, 4 Cedar-Sinai Medical Center, Los Angeles, CA, 5 Research Solutions Group, Encinitas, CA 608. Coeliac Disease In Scleroderma - Clinical Features, Frequency and Impact Of Screening In Scleroderma. Alfredo Guillén-Del Castillo, Vincent Sobanski, Jennifer Harvey, Christopher Denton and Voon H. Ong 4, Hospital Universitari Vall d Hebron, Barcelona, Spain, Royal Free Hospital, London, United Kingdom, Royal Free and University College Medical School, London, United Kingdom, 4 The Royal Free and University College Medical School, London, United Kingdom 609. Dutch Translation and Validation Of The University of California, Los Angeles scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument.0. Jessica Meijs, Daisy Pors, Theodora P.M. Vliet Vlieland, Tom W.J. Huizinga and Annemie J.M. Schuerwegh, Leiden University Medical Center, Leiden, Netherlands 60. A New Pathogenic Role Of BAFF As a Critical Mediator Of Skin and Lung Fibrosis In Experimental Bleomycin-Induced Pulmonary Fibrosis, Systemic Sclerosis and Idiopathic Pulmonary Fibrosis. Antoine Francois, Pascal Schneider, Anne Davidson, Emmanuel Chatelus 4, Jérôme Avouac 5, Yannick Allanore 5, Bérengère Villeret 6, Aurélie Gombault 6, Paméla Gasse 7, Sylvain Marchand Adam 8, Bernhard Ryffel 9, Siamak Bahram 0, Philippe Georgel, Jean Sibilia, Isabelle Couillin 7 and Jacques-Eric Gottenberg 4, University of Strasbourg, Illkirch-Strasbourg, France, University of Lausanne, Lausanne, Switzerland, Feinstein Institute for Medical Research, Manhasset, NY, 4 Strasbourg University Hospital, Strasbourg, France, 5 Paris Descartes University, Rheumatology A department, Cochin Hospital, Paris, France, 6 University of Orleans and National Center for Scientific Research, Orléans, France, 7 University of Orleans and National Center for Scientific Research, Orleans, France, 8 National institute of the health and the medical research, Tours, France, 9 University and CNRS, b rue de la Ferollerie, Orleans, France, 0 Immunorhumatology Molécular, Strasbourg, France, Laboratoire d ImmunoGénétique Moléculaire Humaine, Strasbourg, France, CHU Hautepierre, Strasbourg, France 6. WITHDRAWN 6. Epidemiology Of Cancer In Systemic Sclerosis. Systematic Review and Meta-Analysis Of Cancer Incidence, Predictors and Mortality. Tatiana Nevskaya, Shelly Chandran, Adrienne M. Roos, Christopher Pasarikovski, Amie T. Kron, Cathy Chau and Sindhu R. Johnson 4, Toronto Scleroderma Research Program, Toronto Western Hospital, Mount Sinai Hospital, and University of Toronto, Toronto, ON, Toronto Scleroderma Research Program, Toronto Western Hospital, University of Toronto, Toronto, ON, Toronto Scleroderma Research Program, Toronto Western Hospital, Mount Sinai Hospital, University of Toronto, Toronto, ON, 4 Toronto Western Hospital, Toronto General Hospital, Mount Sinai Hospital, and University of Toronto, Toronto, ON Vasculitis III 6. NF-κB Pathway Is Depleted In Phagocytes From Behçet s Disease Patients Secondarily To Constitutive Phosphorylation Of The p65 Subunit. Sandro F. Perazzio, Paulo Vitor Soeiro Pereira, Alexandre W.S. Souza, Antonio Condino-Neto and Luis Eduardo C. Andrade, Escola Paulista de Medicina - Universidade Federal de São Paulo, Sao Paulo, Brazil, ICB IV - Universidade de São Paulo, São Paulo, Brazil, University Medical Center Groningen, Groningen, Netherlands 64. Plasma Of Active Behçet s Disease Increases Oxidative Metabolism Profile Of Normal and Patients Phagocytes. Sandro F. Perazzio, Paulo Vitor Soeiro Pereira, Alexandre W.S. Souza, Antonio Condino-Neto and Luis Eduardo C. Andrade, Escola Paulista de Medicina - Universidade Federal de São Paulo, Sao Paulo, Brazil, ICB IV - Universidade de São Paulo, São Paulo, Brazil, University Medical Center Groningen, Groningen, Netherlands 0 Program Book 47

350 ACR POSTER SESSION C Serum Beta Microglobulin and Its Association With Disease Activity in Patients With Behcet s Disease. Meltem Alkan Melikoglu and Mehmet Melikoglu, Ataturk University Medical School, Rheumatology, Erzurum, Turkey, Health Ministry Erzurum Regional Training and Research Hospital, Dermatology, Erzurum, Turkey 66. Ischemia-Modified Albumin : A Novel Marker of Vascular Involvement in Behcet s Disease? Erhan Capkin, Murat Karkucak, Mehmet Kola, Adem Karaca, süleyman Caner Karahan 4, Aysegul Sumer 4, Arzu Aydin Capkin 5, Ferhat Gokmen and Refik Ali Sari 6, rheumatolgy, trabzon, Turkey, rheumatology, trabzon, Turkey, oftalmology, trabzon, Turkey, 4 biochemistry, trabzon, Turkey, 5 dermatology, trabzon, Turkey, 6 immunology and allergy, trabzon, Turkey 67. Clinical Features Of 7 Patients With Behcet s Disease In Japan. Keisuke Nishimura, Jun Saegusa, Sho Sendo, Yoshinori Kogata, Goichi Kageyama, Seiji Kawano, Shunichi Kumagai and Akio Morinobu, Kobe University Graduate School of Medicine, Kobe, Japan, Shinko hospital, Kobe, Japan 68. Bipolar Disorders May Represent a Primary Feature Of Behçet s Disease. Rosaria Talarico, Laura Palagini, Elena Elefante, Claudia Ferrari, Chiara Stagnaro, Chiara Baldini, Chiari Tani, Marta Mosca and Stefano Bombardieri, Rheumatology Unit, Pisa, Italy, Psychiatry Unit, Department of Neuroscience, Pisa, Italy, Rheumatology Unit, University of Pisa, Pisa, Italy 69. Suicidal Ideation Among Patients With Behcet s Syndrome. Didem Uzunaslan, Caner Saygin, Gulen Hatemi, Koray Tascilar, Hasan Yazici and Vedat Hamuryudan, Istanbul University, Cerrahpasa Medical Faculty, Rheumatology, Istanbul, Turkey 60. Development Of De Novo Major Involvement During The Follow-Up In Behçet s Disease. Claudia Ferrari, Rosaria Talarico, Chiara Stagnaro, Anna d Ascanio, Chiara Tani, Chiara Baldini, Marta Mosca and Stefano Bombardieri, Rheumatology Unit, Pisa, Italy, Rheumatology Unit, University of Pisa, Pisa, Italy 6. Venous Claudication Is A Severe and Frequent Symptom In BEHCET S Syndrome. SerdaL Ugurlu, Emire Seyahi, Veysel Oktay, Zerrin Yigit, Serdar Kucukoglu and Hasan Yazici, Cerrahpasa Medical Faculty, University of Istanbul, Istanbul, Turkey, Cardiology Institute, University of Istanbul, Istanbul, Turkey 6. Comparison Of Different Methods Of Skin Pathergy Test In Patients With Behçet s Syndrome. Aysegul Lacin, Cigdem Atan Uzun, Zafer Gunendi and Feride Gogus, Gazi University Faculty of Medicine, Ankara, Turkey 6. A CT Evaluation Of Pulmonary and Cardiac Lesions In BEHÇET S Syndrome Patients Without Pulmonary Symptoms. Emire Seyahi, Deniz Cebi Olgun, SerdaL Ugurlu, Idil Hanci, Reona Takahashi and Hasan Yazici, Cerrahpasa Medical Faculty, University of Istanbul, Istanbul, Turkey, Krankrenhaus Nordwest, Frankfurt am Main, Frankfurt, Germany 0 Program Book 64. Evaluation of Asymptomatic Venous Disease By Venous Doppler Ultrasonography in Patients With Behcet s Disease. Fatma Alibaz-Oner, Emrah Karatay, Ihsan Nuri Akpinar, Tülin Ergun and Haner Direskeneli, Marmara University, School of Medicine, Istanbul, Turkey 65. Biologic Therapy In Refractory Uveitis Of Behcet s Syndrome: Switching and Dose Modification. Multicenter Study Of 4 Patients. F. Ortiz-Sanjuán, Vanesa Calvo-Río, Ricardo Blanco, Emma Beltrán, Juan Sánchez-Bursón 4, Marina Mesquida 5, Alfredo M. Adan 5, M Hernandez Grafella, E Valls Pascual 6, L Martínez-Costa 6, A Sellas- Fernàndez 7, Miguel Cordero-Coma 8, Manuel Diaz-llopis 9, David Salom 9, Jl García Serrano 0, Norberto Ortego 0, JM Herreras, Alejandro Fonollosa, A Aparicio, O Maíz 4, A Blanco 4, I Torre 5, Cruz Fernández-Espartero 6, V Jovani 7, D Peitado-Lopez 8, Esperanza Pato 9, J Cruz 0, J. Carlos Fernandez-Cid 0, Elena Aurrecoechea, M García, M Caracuel, Carlos Montilla 4, A Atanes 5, F Francisco 6, S Insua 7, S González-Suárez 8, A Sánchez-Andrade 9, F Gamero 0, Luis Linares, F Romero-Bueno, J García, AJ García González, Raquel Almodovar 4, E Minguez 5, C Carrasco Cubero 6, Alejandro Olivé Marqués 7, J Vázquez 8, O Ruiz Moreno 9, F Jimenez-Zorzo 9, J Manero 9, Javier Loricera and Miguel Angel González-Gay, Hospital Universitario Marqués de Valdecilla. IFIMAV. Santander. Spain, Santander, Spain, Hospital Universitario Marqués de Valdecilla. IFIMAV, Santander, Spain, Hospital General Universitario, Valencia, Valencia, Spain, 4 Hospital de Valme. Sevilla, Sevilla, Spain, 5 Hospital Clínic of Barcelona, Barcelona, Spain, 6 Hospital Peset Valencia, Valencia, Spain, 7 Hospital Val d Hebron. Barcelona, Barcelona, Spain, 8 Hospital de León, León, Spain, 9 Hospital Universitario La Fe de Valencia, Valencia, Spain, 0 Hospital San Cecilio. Granada, Granada, Spain, Hospital Universitario, IOBA. Valladolid, Valladolid, Spain, Hospital de Cruces. Bilbao, Baracaldo, Spain, Hospital de Toledo., Toledo, Spain, 4 Hospital Donosti San Sebastian, San Sebastián, Spain, 5 Hospital Basurto. Bilbao, Bilbao, Spain, 6 Hospital Universitario de Móstoles. Madrid, Madrid, Spain, 7 Hospital General de Alicante., Alicante, Spain, 8 Hospital Universitario La Paz Madrid, Madrid, Spain, 9 Hospital Clínico San Carlos. Madrid, Madrid, Spain, 0 Hospital de Pontevedra, Pontevedra, Spain, Hospital Sierrallana. Torrelavega, Torrelavega, Spain, Hospital La Princesa. Madrid, Madrid, Spain, Hospital de Córdoba., Córdoba, Spain, 4 Hospital Universitario de Salamanca, Salamanca, Spain, 5 HUCA La Coruña., A Coruña, Spain, 6 Hospital Doctor Negrín Canarias., Canarias, Spain, 7 Hospital Universitario Santiago de Compostela, Santiago de Compostela, Spain, 8 Hospital Cabueñes, Gijón, Gijón, Spain, 9 Hospital Lucus Augusti Lugo, Lugo, Spain, 0 Hospital San Pedro Alcantara Caceres, Caceres, Spain, Hospital Universitario Virgen de la Arrixaca. Murcia, Murcia, Spain, Fundación Jimenez Díaz. Madrid, Madrid, Spain, Hospital de Octubre. Madrid, Madrid, Spain, 4 Hospital Universitario Fundación Alcorcón. Madrid, Alcorcon. Madrid, Spain, 5 Hospital Clínico de Zaragoza, Zaragoza, Spain, 6 Hospital de Mérida, Mérida, Spain, 7 Hospital Germans Trias i Pujol. Badalona, Barcelona, Spain, 8 Hospital de Ferrol. A Coruña, A Coruña, Spain, 9 Hospital Universitario Miguel Servet. Zaragoza, Zaragoza, Spain

351 ACR POSTER SESSION C 66. Infliximab For Sight-Threatening and Refractory Uveitis Of Behcet s Syndrome. Vedat Hamuryudan, Gulen Hatemi, Yilmaz Ozyazgan, Didar Ucar, Sebahattin Yurdakul, Emire Seyahi, Koray Tascilar, Serdal Ugurlu and Hasan Yazici, Istanbul University, Cerrahpasa Medical Faculty, Rheumatology, Istanbul, Turkey, Behcet s Syndrome Research Center, Cerrahpasa Medical Faculty University of Istanbul, Istanbul, Turkey 67. Prognostic Factors Of Visual Function In The Treatment With Infliximab For Uveitis Of Behçet s Disease. Akihiko Nakabayashi, Toru Hirano, Yoshihiro Hishitani, Keisuke Hagihara, Kei Nakai, Kouji Nishida and Atsushi Kumanogoh, Osaka University Graduate School of Medicine, Suita, Japan, Osaka University Graduate School of Medicine, suita, Japan 68. Immunogenicity Of Infliximab Modulates Efficacy and Safety In Behcet s Disease Patients With Uveitis. Mitsuhiro Takeno, Kayo Terauchi, Yohei Kirino, Ryusuke Yoshimi, Nobuhisa Mizuki, Etsuko Shibuya and Yoshiaki Ishigatsubo, Yokohama City University Graduate School of Medicine, Yokohama, Japan 69. Is Complete Remission a Realistic Target With Current Therapeutic Options in Behçet s Disease? Fatma Alibaz- Oner, Gonca Mumcu, Zeynep Kubilay, Gülsen Ozen, Gülce Celik, Aslı Karadeniz, Meryem Can, Sibel Yılmaz Oner, Nevsun Inanc 4, Pamir Atagunduz 4, Tülin Ergun and Haner Direskeneli, Marmara University, School of Medicine, Istanbul, Turkey, Marmara University, Faculty of Health Sciences, Istanbul, Turkey, Marmara University School of Medicine., Istanbul, Turkey, 4 Marmara University School of Medicine, Istanbul, Turkey 60. Low Medication Adherence Is Observed In Behcet s Disease. Gonca Mumcu, Ali Taze, Esra Kula, Semiha Yemez, Silay Eksi, Leyla Köksal, Fatma Alibaz-Oner, Sibel Yilmaz Oner, Pamir Atagündüz, Nevsun Inanc, Tülin Ergun and Haner Direskeneli, Marmara University, Faculty of Health Sciences, Istanbul, Turkey, Marmara University, School of Medicine, Istanbul, Turkey 6. Fertility In Behçet s Syndrome: Structured Interview In A Multidisciplinary Center. Caner Saygin, Didem Uzunaslan, Gulen Hatemi, Koray Tascilar and Hasan Yazici, Istanbul University, Cerrahpasa Medical Faculty, Rheumatology, Istanbul, Turkey 6. Long Term Outcome Of Neuro-Behçet s Disease. Nicolas Noel, Remy Bernard, Bertrand Wechsler, Matthieu Resche-Rigon, Du Boutin, Jean-Charles Piette, Aurélie Drier, Didier Dormont, Patrice P. Cacoub Sr. and David Saadoun, Assistance Publique-Hôpitaux de Paris, Hopital Pitié-Salpétrière, Paris, France, Hopital Saint-Louis, Paris, France, Pitié-Salpêtrière Hospital, APHP, Paris, France 6. Clinical Spectrum Of Cutaneous Vasculitis. Javier Loricera, Vanesa Calvo-Río, Francisco Ortiz-Sanjuan, Héctor Fernández-Llaca, Marcos A. González-López, Lino Álvarez, M. Carmen González-Vela, Domingo González-Lamuño, Cristina Mata, Javier Rueda-Gotor, Víctor M. Martínez- Taboada 4, Miguel Angel González-Gay and Ricardo Blanco, Hospital Universitario Marqués de Valdecilla. IFIMAV. Santander. Spain, Santander, Spain, Hospital Universitario Marqués de Valdecilla. IFIMAV. Santander, Santander, Spain, Hospital Universitario Marqués de Valdecilla. IFIMAV, Santander, Spain, 4 Hospital Universitario Marqués de Valdecilla. IFIMAV., Santander, Spain 64. Henoch-Schönlein Purpura: Clinical Spectrum Of The Disease In 47 Patients From A Single Center. F. Ortiz- Sanjuán, Vanesa Calvo-Río, Javier Loricera, C Mata, L Martín Penagos, L Alvarez, M. Carmen González-Vela, D González-Lamuño, Javier Rueda-Gotor, Héctor Fernández- Llaca, Marcos A. González-López, Susana Armesto, M. Enriqueta Peiró, M. Arias, Miguel Angel Gonzalez-Gay and Ricardo Blanco, Hospital Universitario Marqués de Valdecilla. IFIMAV. Santander. Spain, Santander, Spain, Hospital Universitario Marqués de Valdecilla. IFIMAV, Santander, Spain 65. IgA Vasculitis In Adults a Rare and Benign Disease? Alojzija Hocevar, Jaka Ostrovrsnik, Vesna Jurcic and Matija Tomsic, University Medical Centre Ljubljana, Ljubljana, Slovenia, University of Ljubljana, Faculty of Medicine, Ljubljana, Slovenia, University Medical Centre Ljubjana, Ljubljana, Slovenia 66. IgA Vasculitis The Second Most Common Systemic Vasculitis In Adults In Slovenia. Alojzija Hocevar, ŽIga Rotar, Jaka Ostrovrsnik, Vesna Jurcic, Jelka Lindic and Matija Tomsic 4, University Medical Centre Ljubljana, Ljubljana, Slovenia, University Medical Centre Ljubljana, 000 Ljubljana, Slovenia, University of Ljubljana, Faculty of Medicine, Ljubljana, Slovenia, 4 University Medical Centre Ljubjana, Ljubljana, Slovenia 67. Validation Study Of The International Classification Criteria For The Cryoglobulinemic Vasculitis. Luca Quartuccio, Miriam Isola, Laura Corazza, Soledad Retamozo 4, Manal Abdel-Moneim El-Menyawi 5, Elisa Gremese 6, Marco Sebastiani 7, Nicolo Pipitone 8, Teresa Urraro 9, Vincenza Conteduca 0, Christos Koutsianas, Benjamin Terrier, Mostafa Naguib Zoheir, Alessandra Ghinoi 4, Davide Filippini 5, Francesco Saccardo 6, Mohamed Nabil Salem 7, Salvatore Scarpato 8, Paolo Fraticelli 9, Antonio Tavoni 0, Eleonora Catarsi, Cesare Mazzaro, Pietro Pioltelli, Mervat Matar 5, Patrizia Scaini 4, Matija Tomsic 5, Norihiro Nishimoto 6, Dimitrios Vassilopoulos 7, Michael Voulgarelis 8, Gaafar M. Ragab 9, Carlo Salvarani 0, Armando Gabrielli, Patrice Cacoub, Loic Guillevin, Domenico Sansonno 4, Anna Linda Zignego 9, Gianfranco Ferraccioli 6, Athanasios G. Tzioufas 5, Manuel Ramos- Casals 6, Clodoveo Ferri 7, Maurizio Pietrogrande 7, Giuseppe Monti 6, Massimo Galli 8, Stefano Bombardieri 9 and Salvatore De Vita, Rheumatology Clinic, DSMB, 0 Program Book 49

352 ACR POSTER SESSION C University of Udine, Udine, Italy, Institute of Statistics, DSMB, University of Udine, Udine, Italy, Rheumatology Clinic, University of Udine, Udine, Italy, 4 Laboratorio de Enfermedades Autoinmunes Josep Font, IDIBAPS, Hospital Clínic, Barcelona, Spain, 5 Faculty of Medicine, Cairo, Egypt, 6 Division of Rheumatology, Institute of Rheumatology and Affine Sciences, Catholic University of the Sacred Heart, Rome, Italy, 7 University of Modena and Reggio Emilia, Modena, Italy, 8 Arcispedale S Maria Nuova, IRCCS, Reggio Emilia, Italy, 9 Center for Systemic Manifestations of Hepatitis Viruses (MASVE), Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy, 0 Department of Internal Medicine and Clinical Oncology, University of Bari, Bari, Italy, Department of Pathophysiology, Medical School of Athens, Athens, Greece, Cochin University Hospital, Paris, France, Faculty of Medicine, Cairo University, Cairo, Egypt, 4 Arcispedale S Maria Nuova, Reggio Emilia, Italy, 5 Rheumatology Unit, Ospedale Niguarda,, Milan, Italy, 6 Internal Medicine Unit, Saronno Hospital, Azienda Ospedaliera di Busto Arsizio, Saronno (VA), Italy, 7 Faculty of Medicine, Beni Swafe University, Beni Swafe, Egypt, 8 Rheumatology Unit, M. Scarlato Hospital, Scafati, Salerno, Italy, 9 Istituto di Clinica Medica, Università Politecnica delle Marche, Ancona, Italy, 0 Immunoallergology unit, Pisa, Italy, University of Pisa, Pisa, Italy, Department of Internal Medicine, Pordenone General Hospital, Pordenone, Italy, Hematology, S.Gerardo Hospital, Monza, Italy, 4 Nephrology, Spedali Civili di Brescia, Brescia, Italy, 5 University Medical Centre Ljubjana, Ljubljana, Slovenia, 6 Osaka Rheumatology Clinic, Osaka, Japan, 7 Athens University School of Medicine, Athens, Greece, 8 Department of Pathophysiology, Athens, Greece, 9 Faculty of Medicine, Cairo University, Giza, Egypt, 0 Arcispedale S Maria Nuova-IRCCS, Reggio Emilia, Italy, Università Politecnica delle Marche, Ancona, Italy, Hopital Pitié-Salpétrière, Paris, France, Division of Internal Medicine, Hôpital Cochin, University Paris Descartes, Paris, France, 4 Section of Internal Medicine and Clinical Oncology, Department of Biomedical Sciences and Human Oncology, University of Bari, Medical School, Bari, Italy, 5 School of Medicine, National University of Athens, Athens, Greece, 6 Hospital Clínic, Barcelona, Spain, 7 Internal Medicine Unit, Policlinico San Marco, Bergamo, Italy, 8 Istituto di Malattie Infettive e Tropicali, Università di Milano c/o Ospedale L. Sacco, Milano, Italy, 9 Rheumatology Unit, University of Pisa, Pisa, Italy 68. Cryoglobulinemia Vasculitis With Or Without Associated Cryofibrinogenemia: A Different Phenotype? Martin Michaud, Guillaume Moulis, Jacques Pourrat, Benedicte Puissant, Antoine Blancher and Laurent Sailler, Toulouse University Hospital, University of Toulouse, Toulouse, France, Toulouse University Hospital, Clinical Pharmacology Department, University of Toulouse, UMR INSERM-UPS 07, Toulouse, France, Toulouse University Hospital, Toulouse, France 69. Long-Term Outcome of Monoclonal (type ) Cryoglobulinemia. Antoine Néel, François Perrin, Olivier Decaux, Thomas Dejoie, Maxime Halliez, Béatrice Mahé, Thierry Lamy, Fadi Fakhouri, Patrick Jego, Christian Agard, Cécile Vigneau, Lucienne Guenet, Bernard Grosbois, Philippe Moreau and Mohamed Hamidou, Nantes University Hospital, Nantes, France, Rennes University Hospital, Rennes, France 640. VERY LONG-TERM Effects Of The 4 PLUS Infusion PROTOCOL Of Rituximabalone In Patients With HCV-Associatedmixed Cryoglobulinemia With Diffusemembranoproliferative Glomerulonephritis,Severe Polyneuropathy and Necrotic Ulcersof Skin. Dario Roccatello, Savino Sciascia, Simone Baldovino and Daniela Rossi, Centro di Immunopatologia e Documentazione su Malattie rare, Torino, Italy, Centro di Ricerche di Immunologia Clinica ed Immunopatologia e Documentazione su Malattie Rare (CMID), Università di Torino, Torino, Italy 64. Earlier Admission To Specialized Care, Intensified Treatment and Improved Outcome In Patients With Autoimmune Connective Tissue Disorders and Vasculitides In Germany 0 Compared To 995. Dörte Huscher, Katinka Albrecht, Katja Thiele, Sascha Bischoff, Jutta G. Richter, Ina Kötter 4, Wolfgang Ochs 5 and Angela Zink 6, Charité University Hospital and German Rheumatism Research Centre, a Leibniz Institute, Berlin, Germany, German Rheumatism Research Centre, Berlin, Germany, Heinrich-Heine-University, Duesseldorf, Germany, 4 ZIRS, Centre for Interdisciplinary Rheumatology Stuttgart, Stuttgart, Germany, 5 Rheumatology Practice Bayreuth, Bayreuth, Germany, 6 German Rheumatism Research Centre and Charité University Medicine, Berlin, Germany 50 0 Program Book

353 ACR POSTER SESSION C 64. A Novel Genetic Basis For Systemic Vasculitis: Polyarteritis Nodosa Caused By Recessive Mutations In An Immune- Related Gene. Reeval Segel, Pnina Elkan-Navon, Sarah B. Pierce, Tom Walsh, Judith Barash, Shay Padeh 4, Avraham Zlotogorski 5, Yackov Berkun 6, Isabel Voth 7, Philip Hashkes, Liora Harel 8, Eduard Ling 9, Fatos Yalcinkaya 0, Ozgur Kasapcopur 0, Paul F. Renbaum, Ariella Weinberg- Shukron, Barbara Schormair, Mordechai Shohat, Alan A. Rubinow, Elon Pras 4, Juliane Winkelmann 4, Mustafa Tekin 5, Yair Anikster 4, Mary-Claire King and Ephrat Levy- Lahad, Shaare Zedek Medical Center, Jerusalem, Israel, University of Washington, Seattle, WA, Kaplan Medical Center, Rehovot, Israel, 4 Sheba Medical Center, Ramat Gan, Israel, 5 Hadassah-Hebrew University Medical Center, Jerusalem, Israel, 6 Hadassah Medical Center, Mount Scopus, Jerusalem, Israel, 7 Technische Universitat Munchen Klinikum rechts der Isar, Munich, Germany, 8 Schneider Children s Medical Center, Tel Aviv University, Petach Tikvah, Israel, 9 Soroka University Medical Center and Ben- Gurion University, Beer-Sheva, Beer Sheva, Israel, 0 Ankara University, Ankara, Turkey, Helmholtz Zentrum Munchen, Munich, Germany, Rabin Medical Center, Beilinson Hospital, Petach Tikvah, Israel, Hadassah Medical Center, Jerusalem, Israel, 4 Stanford University, San Francisco, CA, 5 Miller School of Medicine, University of Miami, Miami, FL 64. Midkine Is a Novel Prognostic Factor In Patients With Vasculitis Syndrome. Yoshie Kusunoki, Yutaka Okano, Natsuko Kusunoki, Natsuki Fujio, Mai Kawazoe, Emiko Shindo, Kotaro Shikano, Makoto Kaburaki, Sei Muraoka, Kanako Kitahara, Kaichi Kaneko, Nahoko Tanaka, Tatsuhiro Yamamoto, Kenji Takagi, Tomoko Hasunuma, Hirahito Endo and Shinichi Kawai, Kawasaki Municipal Kawasaki Hospital, Kanagawa, Japan, School of Medicine, Faculty of Medicine, Toho University, Tokyo, Japan 0 Program Book 5

354 INNOVATION THEATER These non-cme accredited presentations have been planned and will be implemented in accordance with the requirements of the FDA and applicable standards of the PhRMA Code on Interactions with Healthcare Professionals. All Innovation Theater presentations will be held in the Exhibit Hall (Booth #7) at their designated time. SUNDAY, OCTOBER 7, 0 0:0 - :5 am CIMZIA (certolizumab pegol) in Rheumatology Presented by UCB, Inc. :0 - :5 pm XELJANZ Path to Discovery Presented by Pfizer, Inc. :00 - :45 pm Application of Clinical Trial Data in Rheumatoid Arthritis: New Insights From an Established Rheumatoid Arthritis Trial Presented by AbbVie TUESDAY, OCTOBER 9, 0 0:0 - :5 am Targeting IL-7 Pathways: A New Cytokine Axis Guiding Future Therapeutic Options in Psoriatic Arthritis Presented by Amgen, Inc. :0 - :5 pm SIMPONI ARIA (golimumab) for the Treatment of Adult Patients With Moderately to Severely Active Rheumatoid Arthritis (RA), in Combination With Methotrexate (MTX): A Fully Human, Monoclonal Antibody, Anti-TNF Infusion Presented by Janssen Biotech, Inc. MONDAY, OCTOBER 8, 0 0:0 - :5 am ACTEMRA (tocilizumab): Patient-Focused Treatment Options in Rheumatoid Arthritis Presented by Genentech, a Member of the Roche Group :0 - :5 pm Co-Management of Patients With Psoriatic Arthritis: A Rheumatology-Dermatology Cross-Clinical Program Presented by Amgen, Inc. :0 - :5 pm New Insights Into the Clinical Utility of Vectra DA Presented by Crescendo Bioscience 5 0 Program Book

355 INDUSTRY-SUPPORTED SYMPOSIA SUNDAY, OCTOBER 7, 0 6:0 pm Non-CME Symposium The event listed below is a non-cme program wholly sponsored and supported by the commercial entities listed. By holding the program, the commercial entity has represented that the program has been developed and will be implemented in accordance with the requirements of the FDA and applicable standards of the PhRMA Code on Interactions with Healthcare Professionals. The commercial entity is to observe all guidelines established by federal and state regulatory agencies regarding non-cme educational or promotional presentations throughout the duration of the program. The content and views expressed during the program are those of the commercial entities and presenters. The ACR by making this venue available does not guarantee, warrant or endorse the content of the program nor the products discussed and reviewed during the program. Celebrating the Past and Inspiring the Future of Rheumatologic Care Together Developed and offered by Amgen Waterfront Pier Learning Objectives Upon completion of this activity, participants should be able to: understand the changes in the treatment paradigm for moderate to severe rheumatoid arthritis over the past 5 years appreciate the clinical data supporting the use of biologics for the treatment of moderate to severe rheumatoid arthritis, idiopathic juvenile arthritis and psoriatic arthritis review the impact biologics have had on patients lives 6:0 7:0 pm Registration and Dinner 7:0 7:45 pm Welcome and Introductions Vanessa Broadhurst, VP and General Manager, Amgen, Inc. 7:45 8:45 pm 5 Years of Biologic Therapy in Moderate to Severe Rheumatoid Arthritis Stanley Cohen, MD, UT Southwestern Medical School and Director, Rheumatology Division, Presbyterian Hospital, Dallas, TX Retrospective on the Treatment of Idiopathic Juvenile Arthritis Daniel Lovell, MD, MPH, University of Cincinnati Medical Center, Cincinnati, OH Carol Wallace, MD, University of Washington and Seattle Children s Hospital and Research Institute, Seattle, WA Psoriatic Arthritis and Anti-TNF Therapy: A Unique Perspective Arthur Kavanaugh, MD, The University of California at San Diego, CA Amgen Research Update Brian Kotzin, MD, VP, Global Development, Amgen, Inc. 8:45 9:0 pm Dessert Reception 6:0 pm Non-CME Symposium The event listed below is a non-cme program wholly sponsored and supported by the commercial entities listed. By holding the program, the commercial entity has represented that the program has been developed and will be implemented in accordance with the requirements of the FDA and applicable standards of the PhRMA Code on Interactions with Healthcare Professionals. The commercial entity is to observe all guidelines established by federal and state regulatory agencies regarding non-cme educational or promotional presentations throughout the duration of the program. The content and views expressed during the program are those of the commercial entities and presenters. The ACR by making this venue available does not guarantee, warrant or endorse the content of the program nor the products discussed and reviewed during the program. XELJANZ: Treating Adult Patients With Rheumatoid Arthritis After an Inadequate Response to Methotrexate Developed and offered by Pfizer, Inc. Third-Party Organization: Acumed Hilton San Diego Bayfront, Sapphire Ballroom CDGH Learning Objectives This poster presentation will explore a treatment option for adults with RA. The aim is to bring together clinicians and Opinion Leaders in a thoughtprovoking atmosphere. The poster presentation is designed to allow ample time for participants to interact and discuss these clinical and scientific issues. 6:0 pm 7:0 pm Registration and Reception 6:45 pm 6:55 pm Welcome and Speaker Introductions 6:55 pm 7:0 pm Review Poster # 7:0 pm 7:5 pm Question and Answer for Poster # 7:5 7:0 pm Review Poster # 7:0 7:5 pm Question and Answer for Poster # 7:5 pm 7:50 pm Review Poster # 7:50 pm 7:55 pm Question and Answer for Poster # 7:55 pm 8:0 pm Review Poster #4 8:0 pm 8:0 pm Open Discussion and Conclusion 6:0 pm CME-Accredited Symposium For CME-accredited symposia, the sponsoring organization is responsible for planning and providing CME credit. Advances in Spondyloarthritis: Translational Biology, Classification, and Therapy Supported by an educational grant from UCB, Inc. Sponsored by Cleveland Clinic Marriott Marquis San Diego Marina, Marina Ballroom Physician (ACCME) Accreditation Statement The Cleveland Clinic Foundation Center for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. Credit Designation Statement The Cleveland Clinic Foundation Center for Continuing Education designates this live activity for a maximum of AMA PRA Category Credits TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Participants claiming CME credit from this activity may submit the credit hours to the American Osteopathic Association for Category credit. 0 Program Book 5

356 INDUSTRY-SUPPORTED SYMPOSIA 54 Needs Assessment Statement The study of SpA is a rapidly evolving area that had been stagnant for many years. Advances into the pathogenesis, clinical manifestations, diagnosis, and classification of SpA disorders has improved the identification of the disease and expanded treatment options for patients. Use of targeted biologic therapies, specifically the TNF inhibitors, has greatly improved QOL outcomes, though it is unclear that current agents significantly affect disease progression. Major shifts also have occurred in how to clinically define the spectrum of SpA, especially the nonradiographic forms, providing opportunities for earlier diagnosis of this high disease-burden stage. The pace and complexity of the research has altered the clinical standards for screening, diagnosis, and management, especially of nonradiographic forms of the disease, creating gaps in practitioners knowledge, competence, and practice regarding patients with SpA. Learning Objectives Upon completion of this activity, participants should be able to: identify critical pathways in the axis between bone biology and innate and adaptive immunity contributing to the pathology of spondyloarthritis (SpA) list criteria and describe the clinical significance of current classifications of radiographic and nonradiographic SpA describe and critically appraise benefits and risk of current therapies for SpA, as well as novel agents being investigated in clinical trials incorporate advances in declarative knowledge of the above domains into best practices for screening, diagnosing, and managing SpA 6:0 7:0 pm Registration and Dinner 7:0 7:45 pm History of Spondyloarthritis Leonard Calabrese, DO, Cleveland Clinic, Cleveland, OH 7:45 8:0 pm Advances in Bone Immunology in Spondyloarthritis Christopher Ritchlin, MD, MPH, University of Rochester Medical Center, Rochester, NY 8:0 8:5 pm Spondyloarthritis: Current Classification and the Implications for Clinical Practice Philip Mease, MD, University of Washington School of Medicine, Seattle, WA 8:5 9:00 pm Update on Trials and Novel Therapies in Spondyloarthritis Filip Van den Bosch, MD, PhD, Ghent University, Ghent, Belgium 9:00 9:0 pm Panel Discussion of Best Practices in Diagnosis and Management of Spondyloarthritis Moderators: Leonard Calabrese, DO, and Elaine Husni, MD, MPH, Cleveland Clinic, Cleveland, OH 0 Program Book TUESDAY, OCTOBER 9, 0 6:0 pm Non-CME Symposium The event listed below is a non-cme program wholly sponsored and supported by the commercial entities listed. By holding the program, the commercial entity has represented that the program has been developed and will be implemented in accordance with the requirements of the FDA and applicable standards of the PhRMA Code on Interactions with Healthcare Professionals. The commercial entity is to observe all guidelines established by federal and state regulatory agencies regarding non-cme educational or promotional presentations throughout the duration of the program. The content and views expressed during the program are those of the commercial entities and presenters. The ACR by making this venue available does not guarantee, warrant or endorse the content of the program not the products discussed and reviewed during the program. Spondyloarthritis: A New Perspective Developed and offered by AbbVie Hilton San Diego Bayfront, Sapphire Ballroom CDGH Learning Objectives Upon completion of this activity, participants should be able to: understand the evolving concept of spondyloarthritis and recent updates to classification criteria how to apply said criteria to earlier identification and optimal management of patients with spondyloarthritis understand the patient journey from the perspective of clinicians who are also spondyloarthritis patients 6:0 7:00 pm Registration and Dinner 7:00 8:0 pm Spondyloarthritis: A New Perspective 8:0 9:00 pm Question and Answer 9:00 9:0 pm Dessert 6:0 PM CME Symposium For CME-accredited symposia, the sponsoring organization is responsible for planning and providing CME credit. Shared Decision-Making: Live Patient Clinician Conversations About Psoriatic Arthritis Supported by an educational grant from Celgene Corporation Sponsored by Albert Einstein College of Medicine of Yeshiva University, Montefiore Medical Center, and Haymarket Medical Education, LP San Diego Marriott Marquis & Marina, Marina Ballroom E, F, G Physician (ACCME) Accreditation Statement Albert Einstein College of Medicine: This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through joint sponsorship of Albert Einstein College of Medicine of Yeshiva University and Haymarket Medical Education. Albert Einstein College of Medicine of Yeshiva University is accredited by the ACCME to provide continuing medical education for physicians. Montefiore Learning Network is an approved provider of continuing nursing education by New Jersey State Nurses Association, an accredited approver by the American Nurses Credentialing Center s Commission on Accreditation. P# NYP68-/-5 Credit Designation Statement Albert Einstein College of Medicine of Yeshiva University designates this educational activity for a maximum of.0 AMA PRA Category Credits(s). Physicians should only claim credit commensurate with the extent of their participation in the activity. Needs Assessment Statement Psoriatic arthritis (PsA) is a complex condition with multiple common comorbidities that include other autoimmune conditions believed to share an inflammation-based etiology. To ensure optimal outcomes for patients with PsA, clinicians must maintain a suitably high index of suspicion for these comorbidities and understand the role of the inflammatory cascade, both in disease progression and as a target of treatment. Clinicians must also be familiar with the efficacy and safety data, tolerability, and monitoring requirements associated with available and emerging PsA therapies, including biologic agents, and proactively foster communication and collaboration with other health care providers and with patients to provide comprehensive PsA care. In this symposium, patients with PsA will join their own health care providers on the podium to provide insight

357 INDUSTRY-SUPPORTED SYMPOSIA into patient perspectives on the challenges of managing PsA and to model effective counseling, shared decision-making, and other strategies that contribute to best practices in PsA management. Learning Objectives Upon completion of this activity, participants should be able to: Identify disease mechanisms related to the inflammatory process for psoriatic arthritis and comorbid autoimmune conditions and their potential impact on treatment selection Select appropriate therapy for patients with psoriatic arthritis to minimize disease progression, improve patient compliance to therapy, and enhance patient quality of life Implement practical strategies to engage with other health care providers to improve the management of patients with psoriatic arthritis and comorbid conditions Routinely screen patients with psoriatic arthritis for common comorbid conditions, including psoriasis, cardiovascular disease, diabetes, metabolic syndrome, obesity, gastrointestinal disorders, and depression 6:0 7:00 pm Registration and Buffet Dinner 7:00 7:05 pm Welcome and Introductions Philip J. Mease, MD, Swedish Hospital Medical Center, Seattle, WA (Faculty Chair) 7:05 7:5 pm Overview of Psoriatic Arthritis Pathophysiology and the Role of the Inflammatory Cascade Speaker Iain B. McInnes, PhD, FRCP, FRSE, University of Glasgow, Glasgow, Great Britain 7:5 7:45 pm Psoriatic Disease and Cardiometabolic Risk Joel Gelfand, MD, MSCE, University of Pennsylvania School of Medicine, Philadelphia, PA 7:45 8:05 pm Psoriatic Arthritis Assessment and Treatment Philip J. Mease, MD, Swedish Hospital Medical Center, Seattle, WA 8:05 8:5 pm Live Clinician-Patient Vignettes All faculty and patients 8:5 9:00 pm Panel Discussion, Question-and-Answer Session All faculty and patients 6:0 PM CME Symposium For CME-accredited symposia, the sponsoring organization is responsible for planning and providing CME credit. Clinical Updates in Systemic Lupus Erythematosus Improved Diagnostic and Management Strategies Supported by an educational grant from Eli Lilly and Company Sponsored by Global Education Group Marriott Marquis San Diego Marina, Marriott Hall 4-6 Physician (ACCME) Accreditation Statement This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditations Council for Continuing Medical Education (ACCME) through the joint sponsorship of Global Education Group (Global) and Integritas Communications. Global is accredited by the ACCME to provide continuing medical education for physicians. Credit Designation Statement Global Education Group designates this live activity for a maximum of.5 AMA PRA Category Credits. Physicians should claim only the credit commensurate with the extent of their participation in this activity. Needs Assessment Statement Systemic lupus erythematosus is a chronic, multisystem autoimmune disorder that affects as many as.5 million Americans., The disease is pathologically characterized by the generation of autoantibodies and generalized, multisystem inflammation. Patients may present with a broad range of clinical symptoms, which usually wax and wane over time and can potentially involve almost all organs and tissues.,4 The serious consequences of disease, including increased mortality risks, elevate the urgency of early diagnosis, ongoing monitoring, and aggressive management. 5,6 Yet nonspecific and varied symptomatology often leads to diagnostic delays, presenting an important opportunity to improve assessment approaches. 7 Additionally, clinicians must evaluate all treatment options when individualizing management strategies for systemic lupus erythematosus, a concept that will only become more complex and critical as therapies in intermediate or late stages of clinical development become available. 8- Learning Objectives Discuss the pathophysiologic mechanisms of systemic lupus erythematosus with an emphasis on the roles of various immune cell populations and the heterogeneity of disease manifestations. Differentially diagnose systemic lupus erythematosus by integrating patient demographics, clinical presentations, laboratory testing, and the relative specificities and sensitivities of published classification criteria. Describe the mechanisms of action and clinical profiles of emerging treatment strategies for systemic lupus erythematosus Construct individualized multimodal treatment regimens for patients with systemic lupus erythematosus to address disease activity levels, complete symptom profiles, and comorbid conditions. Employ standardized clinical approaches to longitudinally monitor patients with systemic lupus erythematosus for disease activity, organ system damage, and therapeutic responses. 6:0 6:5 pm Pre-activity Outcomes Assessment 6:5 6:45 pm Disease Management Primer: Scientific Insights into Systemic Lupus Erythematosus 6:45 7:5 pm Case Studies in Systemic Lupus Erythematosus: Diagnostic and Management Strategies 7:5 7:45 pm Build-a-Case Collaboration 7:45 8:00 pm Ask the Experts Q&A and Post-activity Outcomes Assessment WEDNESDAY, OCTOBER 0, 0 :00 pm CME-Accredited Symposium For CME-accredited symposia, the sponsoring organization is responsible for planning and providing CME credit. A Rational Approach to Treating Rheumatoid Arthritis: Optimizing Disease Control and Patient Outcomes Supported by an educational grant from Lilly Sponsored by Medical Learning Institute, Inc. and Center of Excellence Media, LLC San Diego Convention Center 4A 0 Program Book 55

358 INDUSTRY-SUPPORTED SYMPOSIA Physician (ACCME) Accreditation Statement Physician Accreditation Medical Learning Institute is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Registered Nurse Designation Medical Learning Institute, Inc. Provider approved by the California Board of Registered Nursing, Provider Number 506 for contact hours. Registered Pharmacy Designation Medical Learning Institute (MLI) is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. Completion of this activity provides for contact hours (CEUs) of continuing education credit. Physician Credit Designation The Medical Learning Institute Inc designates this live activity for a maximum of.5 AMA PRA Category Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of the Medical Learning Institute Inc and the Center of Excellence Media, LLC. The Medical Learning Institute Inc is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. Registered Nurse Designation Medical Learning Institute Inc Provider approved by the California Board of Registered Nursing, Provider Number 506, for.5 contact hours. Registered Pharmacy Designation The Medical Learning Institute Inc is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. Completion of this knowledge-based activity provides for.5 contact hours (0.5 CEUs) of continuing pharmacy education credit. The Universal Activity Number for this activity is L0-P. Needs Assessment Statement Practice Gap: Rheumatologists are unclear on how to achieve and maintain disease control in their patients with rheumatoid arthritis by providing evidence- and value-based, personalized therapy Learning Objectives Upon completion of this activity, participants should be able to: Describe the therapeutic approaches to achieving and maintaining disease control in patients with rheumatoid arthritis (RA) Discuss the data supporting the aggressive treatment of early RA, and the utility of objective measures of disease activity Outline the latest clinical data on existing and emerging biologic agents for the treatment of RA and indicate the optimal use of each agent based on patient and disease characteristics Assess the clinical value and economic advantages of biosimilars in treating patients with RA :00 :0 pm Lunch :0 :40 pm Welcome, Introductions and Program Overview :40 :55 pm Treatment Decisions in Rheumatoid Arthritis (RA): Targeting Early RA and Providing Personalized Therapy by Assessing Disease Activity :55 :0 pm Treating to Target and Achieving Remission: Essential Concepts for the Rheumatologist :0 :0 pm The Current and Future Arsenal of Biologics for Treating Rheumatoid Arthritis: Where Are We Now and Where Are We Going? :0 :45 pm Making Rheumatoid Arthritis Therapy Affordable: Are Biosimilars the Answer? :45 :00 pm Question and Answers Sessions and Panel Discussion :00 pm CME-Accredited Symposium For CME-accredited symposia, the sponsoring organization is responsible for planning and providing CME credit. SPARTAN GRAPPA ASAS Educational Symposium on Axial Spondyloarthritis and Psoriatic Arthritis Supported by an educational grant from AbbVie Sponsored by Oregon Health & Science University, SPARTAN, GRAPPA and ASAS San Diego Convention Center 4B Physician (ACCME) Accreditation Statement This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of Oregon Health & Science University School of Medicine and NW Arthritis & Osteoporosis Institute. The OHSU School of Medicine is accredited by the ACCME to provide continuing medical education for physicians. Credit Designation Statement OHSU School of Medicine, Division of CME, designates this live activity for a maximum of.5 AMA PRA Category CreditsTM. Physicians should only claim credit commensurate with the extent of their participation in the activity. Needs Assessment Statement There have been numerous new developments in our understanding of and approach to management of spondyloarthritides within the last few years. The Assessment of Spondyloarthritis Society (ASAS) has developed and validated new classification criteria for axial spondyloarthritis (axial SpA), which has made it possible to diagnose patients with ankylosing spondylitis (AS) before they develop x-ray changes of sacroiliitis. The concept of axial spondyloarthritis has added new disease vocabulary and has made ankylosing spondylitis a subset of this larger disease entity. New data on the epidemiology of axial spondyloarthritis from the SPARTAN-NHANES population-based study suggests that these diseases remain significantly under-recognized, since as high as 6% of the US population has chronic inflammatory back pain and.4% of the US population may have axial SpA. Learning Objectives Upon completion of this activity, participants should be able to: discuss the classification criteria for spondyloarthritis (SpA) and psoriatic arthritis (PsA) describe the new understanding in the pathogenesis of spondyloarthritis and psoriatic arthritis develop an evidence based treatment plan for the management of axial spondyloarthritis and psoriatic arthritis Program Chair: Atul Deodhar MD and Robert Landewe MD :00 :05 pm Welcome and Introductions Philip Mease, MD, Seattle Rheumatology Associates, Seattle, WA :05 :0 pm Audience Response System Questions Lianne Gensler, MD, University of California, San Francisco, San Francisco, CA :0 :45 pm Epidemiology, Genetics and Pathophysiology of Axial Spondyloarthritis John Reveille, MD, University of Texas - Houston Health Science Center, Houston, TX :45 :0 pm Clinical Assessment and Measurements in Axial Spondyloarthritis and Psoriatic Arthritis Dafna Gladman, MD, University Health Network, Toronto Western Hospital 56 0 Program Book

359 INDUSTRY-SUPPORTED SYMPOSIA :0 :5 pm Management of Axial Spondyloarthritis and Psoriatic Arthritis Robert Landewe, MD, PhD, Academic Medical Center/University of Amsterdam & Atrium Medical Center Heerlen, Netherlands :5 :00 pm Unmet Needs in the Management of Axial Spondyloarthritis Atul Deodhar, MD, Oregon Health & Science University, Portland, OR :00 :5 pm Audience Response System Questions Lianne Gensler, MD, University of California, San Francisco, San Francisco, CA :5 4:00 pm Breakout Session on Axial Spondyloarthritis and Psoriatic Arthritis Physical Exam ASAS Faculty TBD :00 pm CME-Accredited Symposium For CME-accredited symposia, the sponsoring organization is responsible for planning and providing CME credit. Individualizing the Treatment of Patients With Rheumatoid Arthritis: Translating Comparative Effectives Research in Clinical Practice Supported by an educational grant from Bristol-Myers Squibb Sponsored by Med Learning Group San Diego Convention Center 5 Physician (ACCME) Accreditation Statement Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. This CME activity was planned and produced in accordance with the ACCME Essentials. For CME questions, please contact: Med Learning Group at HYPERLINK mailto:[email protected] [email protected] Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at: Credit Designation Statement Med Learning Group will designate the symposium and simulcast event for a maximum of.5 AMA PRA Category credits TM. Nursing Credit Information Purpose: This program would be beneficial for nurses involved in the management of rheumatoid arthritis and help them to implement an individualized plan for their patients. Credits:.50 ANCC Contact Hour(s) Accreditation Statement Ultimate Medical Academy/CCM is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center s Commission on Accreditation. Awarded.50 contact hour(s) of continuing nursing education of RNs and APNs. Needs Assessment Statement The past decade has seen tremendous advances in rheumatoid arthritis (RA) diagnosis and treatment. Patients at high risk of RA can now be identified and treated earlier in the spectrum of the disease. A variety of outcomes measures, especially in terms of health related quality of life, can be incorporated into treatment targets, along with simplified disease activity scores. New treatments, along with innovative dosing and combination strategies, offer patients a good chance of remission, or at least of reduced disease activity. However, accumulating data has only recently been formally evaluated and used as evidence supporting revisions of the RA classification criteria and treatment algorithms into new guidelines. Although all these tools have the potential to dramatically improve outcomes among patients with RA, many new criteria and recommendations are still object of debate among rheumatologists and are not implemented in clinical practice. Comparative effectiveness research offers rheumatologists important data to evaluate the safety and efficiency of different treatment options. When these data are evaluated in the framework of the existing guidelines and in the contest of practical considerations linked to individual patient profiles, they create a strong foundation for a more evidence-based approach to the management of RA, with the goal of preventing disease progression and improve patients symptoms and quality of life. Learning Objectives Upon completion of this activity, participants should be able to: Review data supporting the classification of rheumatoid arthritis (RA) by ACR/EULAR and the ACR updated treatment guidelines Understand the basis of comparative-effectiveness research and review existing data on mono and combinations therapies for RA at subsequent lines of treatment Contrast and compare safety and efficacy data from direct head to head clinical trials of biologic therapies for RA and apply this information to case studies :00 :0 pm Registration and Lunch :0 :40 pm Treatment of Rheumatoid Arthritis: Overarching Concepts Marc C. Levesque, MD, PhD, University of Pittsburgh, Pittsburgh, PA :40 :00 pm Focus on Early-Stage Rheumatoid Arthritis Marc C. Levesque, MD, PhD, University of Pittsburgh, Pittsburgh, PA :00 :0 pm Treatment of Patients With Established Disease and Inadequate Response to Metatrexate Gregg J. Silverman, MD, NYU Langone Medical Center, New York, NY :0 :40 pm Conclusions :40 :00 pm Questions and Answers :00 pm CME-Accredited Symposium For CME-accredited symposia, the sponsoring organization is responsible for planning and providing CME credit. Prognosis and Treatment of Osteoarthritis of the Knee: Update 0 Supported by an educational grant from Bioiberica, S.A. Sponsored by Medical Education Resources San Diego Convention Center 6 Physician (ACCME) Accreditation Statement This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Medical Education Resources (MER) and Consensus Medical Communications. MER is accredited by the ACCME to provide continuing medical education for physicians. Credit Designation Statement MER designates this educational activity for a maximum of.5 AMA PRA Category Credit(s). Physicians should only claim credit commensurate with the extent of their participation in the educational activity. Needs Assessment Statement Effective treatment of OA must focus on addressing all aspects of pathophysiology, including identification, prevention and treatment of joint cartilage, synovial membrane and subchondral bone injuries. Current data support the use of chondroitin sulfate, alone or in combination with glucosamine, as an effective treatment for patients with OA of the knee. These substances may result in an improvement of quality of life for patients with OA as well as significantly reduce the costs this disease generates in society. This program will investigate the pathophysiology of osteoarthritis, review the pharmacologic actions and long term clinical 0 Program Book 57

360 INDUSTRY-SUPPORTED SYMPOSIA efficacy of chondroitin sulfate, glucosamine as well as recent evidence on oral hyaluronate. Strategies to effectively manage patients with OA will also be discussed. Learning Objectives Upon completion of this activity, participants should be able to: Identify the key components that contribute to the pathogenesis of knee osteoarthritis (OA) Discuss emerging means of predicting knee OA prognosis Describe the role of chondroitin sulfate as monotherapy or in combination with glucosamine in OA disease modification Discuss current clinical data and outcomes associated with the use of chondroitin sulfate, glucosamine and hyaluronic acid in OA treatment :00 :0 pm Registration and Lunch :0 :5 pm Welcome and Introduction Jean-Pierre Pelletier, MD, Montreal, Quebec, Cananda :5 :7 pm The Effects of Chondroitin Sulfate on Inflammasome Activation Virginia Byers Kraus, MD, PhD, Duke University Medical Center, Durham, NC :7 :49 pm Effects of Glucosamine and Chondroitin Sulfate on Knee Osteoarthritis Structural Changes over Time: data from the OAI Cohort Johanne Martel Pelletier, PhD, Montreal, Quebec, Cananda :49 :0 pm Oral Hyaluronic Acid for the Treatment of Osteoarthritis Knee Pain: Results from a Double-Blind Randomized Study C. William Wu, PhD, Henry Ford Hospital, Detroit, MI :0 : pm Co-morbidities and Drug Utilization in Osteoarthritis Patients: Data from a Population-based Cohort Studey Daniel Prieto-Alhambra, MD, PhD, Oxford, United Kingdom : :5 pm Does Chondroitin Sulfate affect the Co-morbidities of Patients with Osteoarthritis? Patrick Du Souich, MD, PhD, Montreal, Quebec, Canada :5 :7 pm Arthrotest : a Clinically Validated DNA-based Test to Predict Knee Osteoarthritis Progression Ingrid Möller, MD, PhD, Barcelona, Spain :7 :55 pm Question and Answer Sessions Marc C. Hochberg, MD, MPH, Baltimore, MD Jean-Pierre Pelletier, MD, Montreal, Quebec, Canada :55 :00 pm Concluding Remarks Marc C. Hochberg, MD, MPH, University of Maryland School of Medicine, Baltimore, MD :00 pm CME-Accredited Symposium For CME-accredited symposia, the sponsoring organization is responsible for planning and providing CME credit. Guided by Objective Measures: Challenging Case Scenarios in Rheumatoid Arthritis An interactive, case-based workshop for clinicians Supported by an educational grant from Bristol-Myers Squibb. Sponsored by Medscape, LLC San Diego Convention Center 7 Physician (ACCME) Accreditation Statement Medscape, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Credit Designation Statement Medscape, LLC designates this live activity for a maximum of.5ama PRA Category Credit(s). Physicians should claim only the credit commensurate with the extent of their participation in the activity. Needs Assessment Statement Many patients with rheumatoid arthritis (RA) are not adequately controlled and only a minority attain consistent remission.[prince 0] With the release of new American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) diagnostic and classification criteria for RA,[Aletaha 00] new ACR and EULAR treatment recommendations,[singh; 0; Smolen 00b] new ACR/EULAR definitions of remission,[felson 0] and the new goals of RA therapy that emerged from the treat-totarget initiative,[smolen 00a] there is a compelling need to re-engage and re-educate rheumatologists on these developments. Proper implementation of each of these recent recommendations and goals requires vigilant measurement and assessment of disease activity. While it is clear that systematic measurement of disease activity facilitates clinical decisionmaking in RA, until recently no recommendations [existed] on which measures should be applied in clinical practice in the US. [Anderson 0] Learning Objectives Upon completion of this activity, participants should be able to: interpret the ACR recommendations for disease activity measures and their characteristics suitable for implementation in practice apply effective strategies for frequent monitoring and assessment of patients for meeting the treat-to-target goals develop a plan for treating to target, selection of initial therapy, and advancing of biologic therapies to achieve remission in patients with RA :00 :00 pm Registration, Lunch, and Preparatory Activity :00 :05 pm Welcome and Introductions Susan Taylor, Executive Director, External Affairs Scripps Health, San Diego, CA :05 :40 pm Case Presentation, Breakout Session and Insights Part : Integrating Quantitative Measures of Disease Activity into the Treatment of RA Jeffrey Curtis, MD, University of Alabama at Birmingham, Birmingham, AL Kenneth Kalunian, MD, University of California, San Diego, San Diego, CA Michael Weisman, MD, Cedars-Sinai Medical Center, Los Angeles, CA :40 :5 pm Case Presentation, Breakout Session and Insights Part : Using Measures of Disease Activity to Help Guide Treatment Decisions in RA Jeffrey Curtis, MD, University of Alabama at Birmingham, Birmingham, AL Kenneth Kalunian, MD, University of California, San Diego, San Diego, CA Michael Weisman, MD, Cedars-Sinai Medical Center, Los Angeles, CA :5 :5 pm Test Your Knowledge Susan Taylor, Executive Director, External Affairs Scripps Health, San Diego, CA :5 :0 pm Summary and Conclusion Susan Taylor, Executive Director, External Affairs Scripps Health, San Diego, CA Jeffrey Curtis, MD, University of Alabama at Birmingham, Birmingham, AL 58 0 Program Book

361 CERTIFICATES OF CME CREDIT OR PARTICIPATION Accreditation Statement: The American College of Rheumatology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Designation Statement: The ACR designates this live educational activity for a maximum of 5.75 AMA PRA Category credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity. International Physicians: International physicians who register as part of a group and require AMA PRA Category Credit(s), must provide the following information to your tour leader: full name, mailing address, telephone and fax numbers, and address. The information will be used to verify your meeting attendance. The American Medical Association has an agreement of mutual recognition of continuing medical education credit with the European Union of Medical Specialties. International physicians interested in converting AMA PRA Category Credit to EACCME credit should contact the UEMS. Health Professionals: Participants may claim hours to receive a Certificate of Participation for an activity designated for AMA PRA Category Credit(s). For non-cme sessions, attendees may also request a certificate of participation. MEETING EVALUATIONS, CME CREDIT/ CERTIFICATES OF PARTICIPATION Use My Annual Meeting to complete your meeting and session evaluations online. Access My Annual Meeting at www. ACRannualmeeting.org to or print your CME certificate or certificate of participation. Computers are also available for you to complete your CME/ certificate of participation and session evaluations online during the meeting at the CME/Technology Center located in the Sails Pavilion. International physicians, requiring a Certificate of Attendance, can obtain one at the registration counter located in the Sails Pavilion or at the Discovery Center located in the center of the Exhibit Hall F-G, booth 4. If your country recognizes AMA PRA Category Credit(s) in accordance with AMA PRA requirements, please complete the session evaluations and CME application online using My Annual Meeting. Your evaluation of the meeting is very important. Therefore, all speakers and moderators participating in an ACR-sponsored activity are required to disclose to the planning committee and audience any financial or other relationships including, but not limited to: None: Nothing to disclose. Stock, stock options or bond holdings in a for-profit corporation or self-directed pension plan. Research grants. Employment (full or part-time) 4. Ownership or partnership 5. Consulting fees or other remuneration (payment) 6. Non-remunerative positions of influence such as officer, board member, trustee or public spokesperson 7. Receipt of royalties 8. Speakers bureau 9. Other Speakers, moderators and abstract authors submitted their disclosure online prior to publication. Disclosures for invited speakers are listed in the indices by presenters last name. Abstract author disclosures are in an online supplement to the October issue of Arthritis & Rheumatism. Disclosures for the late-breaking abstracts are published in the December issue of Arthritis & Rheumatism. Any individual who refuses to disclose relevant financial relationships will be disqualified from being a planning committee member, a presenter, an author of a CME activity, and cannot have control of, or responsibility for, the development, management, presentation or evaluation of the CME activity. Disclosure Policy It is the policy of the American College of Rheumatology to ensure that its CME activities are independent and free of commercial bias. To ensure content objectivity and balance, and guarantee that the content presented is in the best interest of its learners and the public, the ACR requires that everyone in a position to control content disclose all relevant financial relationships with any commercial interest if the relationship is financial and occurred within the past months. If there are relationships that create a conflict of interest, these must be resolved in accordance with the ACR s CME Resolution of Conflict policy prior to the participation of the individual in the development or presentation of CME content. Conflict of Interest/Disclosure Statements As an educational provider accredited by the Accreditation Council for Continuing Medical Education (ACCME), the American College of Rheumatology must ensure balance, independence, objectivity and scientific rigor in all its educational activities. 0 Program Book 59

362 0 ACR/ARHP ANNUAL MEETING LEADERSHIP THANK YOU! The ACR/ARHP board of directors extends its gratitude to the ACR/ARHP Annual Meeting Planning Subcommittee, ACR Abstract Oversight Committee, ACR Abstract Selection Committee, ARHP Abstract Review Panels, and ARHP Clinical Focus Task Force members for their leadership and volunteering their services to plan the 0 annual meeting. Their significant contributions and expertise make the annual meeting the premier event for specialists in the field of rheumatology. 60 ACR/ARHP Annual Meeting Planning Subcommittee Chester Oddis, MD, Chair Afton Hassett, PsyD, ARHP Chair Elect Mary Cronin, MD, Clinical Sub-chair Richard Loeser, MD, Basic Science Sub-chair Hazel Breland, PhD, ARHP Chair Elect Eric L. Matteson, MD, Abstract Selection Chair (Clinical) Richard Pope, MD, Abstract Selection Chair (Basic) Elizabeth G. Salt, ARNP, PhD, Abstract Selection Chair (ARHP) John Varga, MD, Basic Science Sub-chair Mary-Chester Wasko, MD, MSc, MTP/ Workshop/Study Group Sub-chair Shreyasee Amin, MDCM, MP Stacey Ardoin, MD Dana P. Ascherman, MD Alan N. Baer, MD Joan M. Bathon, MD, A&R Editor Thuy T. Beam, MD, ARHP Elana Bernstein, MD Marcy Bolster, MD S. Louis Bridges, MD, PhD Dominic Co, MD, PhD Andrew P. Cope, MD, PhD Lawrence Edwards, MD Judy L. Foxworth, PhD, PT, ARHP Mark F. Gourley, MD Laurie Hughell, Pa-C, MPH, ARHP Rula Hajj-Ali, MD Wael N. Jarjour, MD Meenakshi Jolly, MD Shelly P. Kafka, MD Dinesh Khanna, MD Robert A. Lafyatis, MD Kristine M. Lohr, MD William McClatchey, MD Zsuzsanna McMahan, MD Sandra J. Mintz, BSN, ARHP, Executive Committee Representative Uyen Sa D. Nguyen, DSc, MPH, ARHP Karen Onel, MD Kenneth O Rourke, MD Egla Rabinovich, MD Leonard H. Sigal, MD Gregg J. Silverman, MD Jasvinder Singh, MD Chokkalingam Siva, MD Christine Stamatos, ANP-C, ARHP Virginia Steen, MD George Stojan, MD, Fellows Representative Margaret R. Wilkes, MD Douglas White, MD, PhD 0 Program Book Ex Officio Members Joel A. Block, MD, Chair, Committee on Education Audrey B. Uknis, MD, ACR President ACR Abstract Oversight Committee Steven R. Ytterberg, MD, Chair Shreyasee Amin, MD Kathleen O Neil, MDEmily Somers, PhD, ScM ARHP Clinical Focus Task Force Patricia P. Katz, PhD, Chair Aileen Davis, PhD Adam Good, PT, DPT, PhD Kaleb Michaud, PhD Marie D. Westby, PT, PhD ACR and ARHP Abstract Selection Committees (including category chairs and reviewers) Eric L. Matteson, MD, Abstract Selection Chair (Clinical) Richard Pope, MD, Abstract Selection Chair (Basic) AD HOC REVIEWER Kent C. Kwoh, MD BASIC SCIENCE. B cell Biology and Targets in Autoimmune Disease Robert A. Eisenberg, MD, Co-chair William Stohl, MD, PhD, Co-chair Bevra H. Hahn, MD David A. Isenberg, MD Gregg J. Silverman, MD Philip L. Cohen, MD. Biology and Pathology of Bone and Joint Hiroshi Asahara, MD, Co-chair Mary C. Nakamura, MD, Co-chair Antonios O. Aliprantis, MD Frank Beier, PhD Di Chen, MD, PhD Edward M. Schwarz, PhD. Cytokines, Mediators, Cell-cell Adhesion, Cell Trafficking and Angiogenesis Shiva Shahrara, PhD, Co-chair Douglas J. Veale, MD, Co-chair David L. Boyle, MD Peter A. Nigrovic, MD Sujata Sarkar, MD Zoltan Szekanecz, MD, PhD 4. Genetics, Genomics and Proteomics John B. Harley, MD, PhD, Co-chair Betty P. Tsao, PhD, Co-chair Gary S. Gilkeson, MD Robert M. Plenge, MD, PhD Soumya Raychaudhuri, MD, PhD Nan Shen, MD 5. Innate Immunity and Rheumatic Disease Susan A. Boackle, MD, Co-chair Diego Kyburz, MD, Co-chair Edward K.L. Chan, PhD Costantino Pitzalis, MD, PhD Kris A. Reedquist, PhD Ranjeny Thomas, MBBS, MD 6. Pain - Basic Aspects Anne-Marie Malfait, MD, PhD, Co-chair Thomas J. Schnitzer, MD, PhD, Co-chair Martin K. Lotz, MD Jason J. McDougall, PhD Camilla Svensson, PhD David Walsh, MD 7. Pediatric Rheumatology - Pathogenesis and Genetics Polly J. Ferguson, MD, Co-chair Alexei A. Grom, MD, Co-chair Edward M. Behrens, MD Leonard L. Dragone, MD, PhD Anna Huttenlocher, MD Anne M. Stevens, MD, PhD 8. Rheumatoid Arthritis - Animal Models Harris R. Perlman, PhD, Co-chair Charles S. Via, MD, Co-chair Alison Finnegan, PhD Thomas Pap, MD Veena Taneja, PhD Adarichev Vyacheslav, MD 9. Rheumatoid Arthritis - Human Etiology and Pathogenesis Nancy J. Olsen, MD, Co-chair David S. Pisetsky, MD, PhD, Co-chair Maripat Corr, MD John M. Davis, MD T.W.J. Huizinga, MD, PhD Pierre Miossec, MD, PhD 0. Spondylarthropathies and Psoriatic Arthritis - Pathogenesis, Etiology Robert A. Colbert, MD, PhD, Co-chair Joachim Sieper, MD, Co-chair Maxime A. Breban, MD, PhD Dirk Elewaut, MD, PhD Rik J. Lories, MD, PhD Judith A. Smith, MD, PhD. Systemic Lupus Erythematosus - Animal Models Keith B. Elkon, MD, Co-chair Ram P. Singh, PhD, Co-chair Ann Marshak-Rothstein, PhD Chandra Mohan, MD Laurence Morel, PhD John D. Mountz, MD, PhD

363 0 ACR/ARHP ANNUAL MEETING LEADERSHIP. Systemic Lupus Erythematosus - Human Etiology and Pathogenesis Mary K. Crow, MD, Co-chair Vasileios C. Kyttaris, MD, Co-chair Jill P. Buyon, MD Judith A. James, MD, PhD Insoo Kang, MD Andras Perl, MD, PhD. Systemic Sclerosis, Fibrosing Syndromes and Raynaud s Pathogenesis, Animal Models and Genetics Arnold E. Postlethwaite, MD, Co-chair Richard M. Silver, MD, Co-chair Yannick Allanore, MD, PhD Christopher P. Denton, MD, PhD Carol A. Feghali-Bostwick, PhD John Varga, MD 4. T cell Biology and Targets in Autoimmune Disease Jorg J. Goronzy, MD, PhD, Co-chair Joseph Holoshitz, MD, Co-chair I-Cheng Ho, MD, PhD Terri M. Laufer, MD Linda K. Myers, MD Julie Zikherman, MD CLINICAL 5. Antiphospholipid Syndrome Pier Luigi Meroni, MD, Co-chair Joyce Rauch, PhD, Co-chair Roger A. Levy, MD, PhD Anisur Rahman, PhD Robert Roubey, MD Yehuda Shoenfeld, MD 6. Education Robert A. Kalish, MD, Co-chair Joan Marie Von Feldt, MD, MSEd, Co-chair Michael J. Battistone, MD Jessica Berman, MD Richard D. Brasington, MD John A. Flynn, MD Paulette C. Hahn, MD 7. Epidemiology and Health Services Research Cheryl Barnabe, MD, MSc, Co-chair Jeffrey R. Curtis, MD, MPH, MS, Co-chair Elena Losina, PhD, Co-chair Ted R. Mikuls, MD, MSPH, Co-chair Gabriela Schmajuk, MD, MS, Co-chair Jasvinder A. Singh, MD, MPH, Co-chair Liron Caplan, MD, PhD Cynthia S. Crowson, MS Dorothy D. Dunlop, PhD Jeffrey N. Katz, MD, MSc Nasim A. Khan, MD Seoyoung C. Kim, MD, MSCE Eswar Krishnan, MD Yvonne C. Lee, MD, MMedSc Lee S. Simon, MD Laura L. Tarter, MD Evelyne Vinet, MD Huifeng Yun, BS 8. Fibromyalgia, Soft Tissue Disorders and Pain Mary-Ann Fitzcharles, MBChB, MD, Co-chair Lisa G. Suter, MD, Co-chair Jacob N. Ablin, MD Laurence A. Bradley, PhD Terry H. Oh,MD Pier Carlo Sarzi-Puttini, MD 9. Health Services Research, Quality Measures and Quality of Care Gary L. Bryant, MD, Co-chair Salahuddin Kazi, MD, Co-chair Una E. Makris, MD Esi M. Morgan Dewitt, MD, MSCE Eric D. Newman, MD Catalina Orozco, MD 0. Imaging of Rheumatic Diseases Eugene Y. Kissin, MD, Co-chair Desiree van der Heijde, MD, PhD, Co-chair Maria-Antonietta d Agostino, MD, PhD Mikkel Østergaard, DMSc, PhD Burton Sack, MD Jonathan Samuels, MD. Infection-related Rheumatic Disease John D. Carter, MD, Co-chair Kathryn H. Dao, MD, Co-chair Ines Colmegna, MD James S. Louie, MD Chaim Putterman, MD Clement E. Tagoe, MD, PhD. Metabolic and Crystal Arthropathies N. Lawrence Edwards, MD, Co-chair Naomi Schlesinger, MD, Co-chair Leslie R. Harrold, MD, MPH Robert T. Keenan, MD, MPH Fernando Perez Ruiz,MD, PhD Lisa K. Stamp, PhD. Miscellaneous Rheumatic and Inflammatory Diseases Thomas Bardin, MD, PhD, Co-chair Laura Carbone, MD, Co-chair Loic Guillevin, MD Raymond M. Pertusi, DO Katherine K. Temprano, MD Benjamin W.E. Wang, MD 4. Muscle Biology, Myositis and Myopathies Frederick W. Miller, MD, PhD, Co-chair Lauren M. Pachman, MD, Co-chair Mary E. Cronin, MD Carol B. Lindsley, MD Nicola Ruperto, MD Steven R. Ytterberg, MD 5. Orthopedics, Low Back Pain, and Rehabilitation William F. Harvey, MD, MSc, Co-chair M. Elaine Husni, MD, MPH, Co-chair Lisa A. Mandl, MD, MPH Daniel J. Mazanec, MD Ernest R. Vina, MD, MSc Barton Wise, MD 6. Osteoarthritis - Clinical Aspects Grace H. Lo, MD, MSc, Co-chair Tuhina Neogi, MD, PhD, Co-chair Jolanda Cibere, MD, PhD Philip G. Conaghan, MD, PhD Martin Englund, MD, PhD Stephen P. Messier, PhD 7. Osteoporosis and Metabolic Bone Disease: Clinical Aspects and Pathogenesis Robin K. Dore, MD, Co-chair Anthony D. Woolf, MBBS, Co-chair Piet P. Geusens, MD, PhD Andrew J. Laster, MD Willem F. Lems, MD, PhD S. Bobo Tanner, MD 8. Pediatric Rheumatology - Clinical and Therapeutic Aspects C. Egla Rabinovich, MD, MPH, Co-chair Rayfel Schneider, MD, Co-chair Emily von Scheven, MD, Co-chair Andrew Zeft, MD, MPH, Co-chair Aimee O. Hersh, MD Bianca A. Lang, MD Eyal Muscal, MD, MS Murray H. Passo, MD Sarah Ringold, MD Ricardo A. G. Russo, MD Nora G. Singer, MD Robert P. Sundel, MD 9. Rheumatoid Arthritis - Clinical Aspects Jennifer Barton, MD, Co-chair Vivian P. Bykerk, MD, Co-chair Ernest Choy, MD, Co-chair Paul F. Dellaripa, MD, Co-chair Merete L. Hetland, DMSc, MD, PhD, Co-chair Eric M. Ruderman, MD, Co-chair Rieke Alten, MD Joshua Baker, MD, MSCE Clifton O. Bingham, MD Loreto Carmona, MD, PhD Kevin D. Deane, MD, PhD Kimme L. Hyrich, MD, PhD Shahin Jamal, MD, MSc Diane V. Lacaille, MD, MHSc Arthur M. Mandelin, MD, PhD Shikha Mittoo, MD, MHS Kristine Phillips, MD, PhD Piet L.C.M. van Riel, MD, PhD 0 Program Book 6

364 0 ACR/ARHP ANNUAL MEETING LEADERSHIP 0. Rheumatoid Arthritis - Small Molecules, Biologics and Gene Therapy Gerd R. Burmester, MD, PhD, Co-chair John J. Cush, MD, Co-chair Jonathan Kay, MD, Co-chair Joseph A. Markenson, MD, Co-chair Iain B. McInnes, PhD, Co-chair Daniel Solomon, MD, MPH, Co-chair S. Louis Bridges, MD, PhD Stanley B. Cohen, MD Bruce N. Cronstein, MD David T. Felson, MD, MPH Roy Fleischmann, MD Mark C. Genovese, MD Arthur Kavanaugh, MD Alan K. Matsumoto, MD William F. C. Rigby, MD Hendrik Schulze-Koops, MD, PhD Sergio Schwartzman, MD Ronald F. Van Vollenhoven, MD, PhD. Sjögren s Syndrome Alan N. Baer, MD, Co-chair Xavier Mariette, MD, PhD, Co-chair Simon J. Bowman, PhD Lindsey A. Criswell, MD, MPH Roland Jonsson, DMD, PhD Robert Hal Scofield, MD. Spondylarthropathies and Psoriatic Arthritis: Clinical Aspects and Treatment Jürgen Braun, MD, Co-chair Luis R. Espinoza, MD, Co-chair Robert D. Inman, MD, Co-chair Robert Landewé, MD, PhD, Co-chair Walter P. Maksymowych, MD, Co-chair Neil McHugh, MBChB, MD, Co-chair Daniel O. Clegg, MD Atul A. Deodhar, MD Oliver M. Fitzgerald, MD Philip S. Helliwell, MA, PhD Gail S. Kerr, MD Pedro Machado, MD Andreas M. Reimold, MD John D. Reveille, MD Christopher T. Ritchlin, MD, MPH Enrique R. Soriano, MD, MSc Rafael Valle-Onate, MD Filip van den bosch, MD, PhD Michael H. Weisman, MD. Systemic Lupus Erythematosus - Clinical Aspects and Treatment Maria Dall Era, MD, Co-chair Dafna D. Gladman, MD, Co-chair Kenneth C. Kalunian, MD, Co-chair S. Sam Lim, MD, MPH, Co-chair Victoria K. Shanmugam, MBBS, MRCP, Co-chair Daniel J. Wallace, MD, Co-chair Cynthia Aranow, MD Eliza F. Chakarvarty, MD Megan E. B. Clowse, MD, MPH Elizabeth D. Ferucci, MD, MPH Lindsy J. Forbess, MD Jennifer M. Grossman, MD Peter M. Izmirly, MD Diane L. Kamen, MD, MS Arezou Khosroshahi, MD Kevin M. Latinis, MD, PhD Matthew H. Liang, MD Maureen A. McMahon, MD 4. Systemic Sclerosis, Fibrosing Syndromes, and Raynaud s - Clinical Aspects and Therapeutics Murray Baron, MD, Co-chair Robyn T. Domsic, MD, MPH, Co-chair Mary Ellen Csuka, MD Aryeh Fischer, MD Svetlana I. Nihtyanova, MBBS Susanna Proudman, MBBS 5. Vasculitis Rula Hajj-Ali, MD, Co-chair Kenneth J. Warrington, MD, Co-chair Bhaskar Dasgupta, MD Tanaz A. Kermani, MD, MS Carlo Salvarani, MD Cornelia M. Weyand, MD, PhD ARHP 6. Clinical Practice/Patient Care Laurie A. Hughell, PA-C, MPH, Chair James G. Freeman, MD Beatriz Y. Hanaoka, MD Leonard H. Sigal, MD Barbara A. Slusher, PA-C, MSW Karen L. Smarr, PhD 7. Education/Community Programs Laura Wright, MBA, Chair Paul M. Adam, MSW Susan J. Blalock, PhD Sandra Mintz, BSN Yvonne van Eijk-Hustings, RN, MSc Deanna S. Yamamoto, NP 8. Epidemiology and Public Health Uyen Sa D.T. Nguyen, DSc, MPH, Chair Susan J. Bartlett, PhD Charles G. Helmick, MD Sunny Kim, PhD Robert R. McLean, DSc, MPH Emily C. Somers, PhD, ScM 9. Health Services Research Hazel L. Breland, PhD, OTR/L, Chair Helen Benham, MBBS Jennifer M. Hootman, ATC, PhD James A. Jenkins, PhD Linda C. Li, PhD, PT Benjamin J. Smith, PA-C 40. Pediatrics Thuy T. Beam, BSN, RN, Chair Nicole Carlson, NP Karla Jones, RN Norma L. Liburd, MN Kara M. Schmidt, MD Janalee Taylor, CNS, CPNP, MSN 4. Psychology/Social Sciences Christine A. Stamatos, ANP-C, Chair Vanessa L. Malcarne, PhD Perry M. Nicassio, PhD Elizabeth G. Salt, PhD Lisa Shelton, BSc, BSN, RN David A. Williams, PhD 4. Rehabilitation Sciences Judy Foxworth, PhD, PT, Chair Mary-Beth Coty, PhD, RN Nadine M. Fisher, EdD G. Kelley Fitzgerald, PhD, PT Janet L. Poole, OTR, PhD Mary Wright, BS, OT 4. Research Methodology Chokkalingam Siva, MD, Chair Kelli D. Allen, PhD Alyssa B. Dufour, PhD Michael P. Lavalley, PhD Kaleb Michaud, PhD Elizabeth A. Schlenk, PhD, RN BASIC RESEARCH CONFERENCE ABSTRACT REVIEWERS Robert M. Plenge, MD, PhD Katherine A. Siminovitch, MD CLINICAL RESEARCH CONFERENCE ABSTRACT REVIEWERS Karen H. Costenbader, MD Kevin D. Deane, MD 6 0 Program Book

365 0 Fellows Education Fund Through the Fellows Education Fund, the ACR is accelerating the education and training of the next generation of rheumatologists. The ACR Fellows Education Fund has a proven track record of successfully providing rheumatology fellows-in-training with outstanding educational opportunities to advance their knowledge and skills to treat an ever-changing patient population. The ACR thanks the following organizations for their support of the 0 Fellows Education Fund: Genentech, Inc. UCB, Inc. Janssen Biotech, Inc.

366 EXHIBITORS AbbVie Pharmaceuticals Booth #: 6 Actelion Pharmaceuticals Pharmaceuticals, Therapeutic/ Patient Aid Products Booth #: 4,47 Bioventus, LLC Diagnostic Equipment/Products, Medical Device Booth #: 4 Borgess Health Booth #: CESAS Medical Nonprofit Organization Booth #: Chugai Pharmaceutical Co., Ltd. Pharmaceuticals Booth #: 9 eclinicalworks Electronic Medical Records Booth #: 4 Elsevier Publisher Booth #: 56 Alpinion Medical Systems Diagnostic Equipment/Products Booth #: 4 Bristol-Myers Squibb Pharmaceuticals Booth #: 07 Cleveland Clinic Nonprofit Organization Booth #: 7 EMD Serono, Inc. Pharmaceuticals Booth #: 84 American College of Physicians/ Annals of Internal Medicine Nonprofit Organization, Publisher Booth #: 4 Amgen, Inc. Biotech Booth #: 00 APLAR Medical Conference Booth #: 44 Arthritis Foundation Nonprofit Organization Booth #: 66 Arthritis Introspecitve Nonprofit Organization Booth #: 4 Arthritis National Research Foundation Nonprofit Organization Booth #: 5 AstraZeneca Pharmaceuticals Booth #: 48 BioMed Central Publisher Booth #: 99 British Society for Rheumatology Nonprofit Organization Booth #: 58 California Rheumatology Alliance Nonprofit Organization Booth #: 9 Canadian Institutes of Health Research - Institute of Musculoskeletal Health and Arthritis Nonprofit Organization Booth #: 7 CarnaBio USA Biotech, Contract Research Booth #: 8 CEDARLANE Booth #: 67 Celgene Corporation Pharmaceuticals Booth #: 09 Celltrion Healthcare Co., LTD. Pharmacueticals, Therapeutic/ Patient Aid Products Booth #: Center for Medicine in the Public Interest Nonprofit Organization Booth #: Clinical and Experimental Rheumatology Publisher Booth #: 4 ContextMedia:Health s Rheumatoid Health Network Educational Materials for Patients Booth #: 07 Corinthian Reference Laboratory Laboratory Equipment/Products Booth #: com CORRONA, Inc. Biotech Booth #: 69 Crescendo Bioscience, Inc. Diagnostic Products Booth #: 9 CuraScript SD Distributor, Pharmaceuticals Booth #: 5 DePuy Mitek Medical Device Booth #: 6 DKBmed Booth #: 46 DynaMed/EBSCO Research Databases Booth #: Esaote North America Diagnostic Equipment/Products Booth #: 8 ESCEO asbl Nonprofit Organization Booth #: 55 Euroimmun US Diagnostic Products, Medical Device Booth #: 89 European League Against Rheumatism (EULAR) Nonprofit Organization Booth #: 4 Everidis Health Sciences Nutritional Products Booth #: 6 EXHIBITCHEK Market Research Booth #: 9 Ferring Pharmaceuticals Inc. Medical Device Booth #: 54 Fidia Pharma USA Biotech, Medical Device Booth #: 90 Forest Pharmaceuticals, Inc. Pharmceuticals Booth #: Program Book

367 EXHIBITORS GE Healthcare Diagnostic Equipment/Products Booth #: 9 Genentech and Roche Biotech, Pharmaceuticals Booth #: 60 Genzyme, a Sanofi company Biotech Booth #: 76 GlaxoSmithKline Pharmaceuticals Booth #: 47,4 Halozyme Therapeutics Pharmaceuticals Booth #: 9 Happy Feet Booth #: 45 Hologic Diagnostic Eqipment/Products, Medical Device Booth #: 4 Horizon Pharma, Inc. Pharmaceuticals Booth #: 9 Hospira Pharmaceuticals Booth #: 08 Hospital for Special Surgery Nonprofit Organization Booth #: Immuno Concepts Booth #: Inova Diagnostics, Inc. Biotech, Diagnostic Equipment/ Products Booth #: 05 inpractice Resources LLC Booth #: 00 Janssen Biotech, Inc. Pharmaceuticals Booth #: 09 Johns Hopkins Rheumatology Nonprofit Organization Booth #: 45 Journal of Rheumatology, The Publisher Booth #: 78 La Lettre Du Rhumatologue - EDIMARK SANTE Publisher Booth #: 80 LabCorp Booth #: Laclede Inc Booth #: Letter to Editor Rheumatology Digital Media, Publisher Booth #: 56 Lilly USA, LLC. Pharmaceuticals Booth #: 79A,79B LipoScience Diagnostic Products, Medical Device Booth #: 5 Lupus Initiative, The Nonprofit Organization Booth #: 74 Mayo Clinic Contract Research, Registry, Nonprofit Organization Booth #: 68 McKesson Specialty Health Distributor Booth #: 98 com medac pharma, Inc. Pharmaceuticals Booth #: 90 METEOR Nonprofit Organization Booth #: 47 Metro Medical Distributor Booth #: 09 Mother to Baby conducted by Organization of Teratology Information Specialists Nonprofit Organization Booth #: 6 National Death Index Nonprofit Organization Booth #: National Fibromyalgia Partnership Nonprofit Organization Booth #: 59 National Institute of Arthritis and Musculoskeletal and Skin Diseases Educational Materials for Patients, Government Agency Booth #: 5 National Scleroderma Core Centers Contract Research, Nonprofit Organization Booth #: 65 New Balance Athletic Shoe, Inc. Booth #: NOMID Alliance Educational Materials for Patients, Nonprofit Organization Booth #: 67 Northwestern University Division of Rheumatology Nonprofit Organization Booth #: 57 edu/divisions/rheumatology Novartis Pharmaceuticals Corporation Pharmaceuticals Booth #: 0, 77 NYU Langone Medical Center - NYU Hospital for Joint Diseases Nonprofit Organization Booth #: 48 rheumatology Ochsner Health System Recruitment Booth #: OMERACT Educational Materials for Patients, Nonprofit Organization Booth #: 54 One Source Immunology Booth #: 0 com Ossur Americas Medical Device Booth #: 8 Oxford University Press Publisher Booth #: 09 PANLAR Nonprofit Organization Booth #: 49 Patient Access Network Foundation Nonprofit Organization Booth #: 69 PatientPoint Educational Materials for Patients Booth #: 85 Pfizer, Inc. Pharmaceuticals Booth #: Program Book 65

368 EXHIBITORS QIAGEN Biotech, Diagnostic Products Booth #: Quest Diagnostics Diagnostic Products Booth #: 7 Questcor Pharmaceuticals, Inc. Pharmaceuticals Booth #: 47,645 Quidel Corporation Diagnostic Equipment/Products, Diagnostic Products Booth #: 4 R. J. Fasenmyer Center for Clinical Immunology Nonprofit Organization Booth #: 74 FasenmyerCenter RDL Reference Laboratory Diagnostic Products Booth #: 09 Regeneron Pharmaceuticals, Inc. Pharmaceuticals Booth #: 0 Rheumatoid Patient Foundation Educational Materials for Patients, Nonprofit Organization Booth #: 6 Rheumatology News Publisher Booth #: 5 Rheumatology Practice News Special Edition Publisher Booth #: 0 www. rheumatologypracticenews.com Rottapharm Ltd Nutritional Products, Pharmaceuticals Booth #: 89 RV Infusion Partners Booth #: RX Biotech Specialty Pharmacy Booth #: 08 Sanofi Biosurgery Biotech Booth #: 4 Saretius Contract Research Booth #: 9 Savient Pharmaceuticals Biotech Booth #: 47 Scandinavian Journal of Rheumatology Nonprofit Organization Booth #: 76 Scleroderma Foundation Educational Materials for Patients, Nonprofit Organization Booth #: 6 SI-BONE Medical Device Booth #: Sjogren s Syndrome Foundation Nonprofit Organization Booth #: 5 Sobi, Inc Biotech, Pharmaceuticals Booth #: 00 SonoSite Diagnostic Equipment, Medical Device Booth #: 7 Spondylitis Association of America Educational Materials for Patients, Nonprofit Organization Booth #: 50 Springer Publisher Booth #: 94 St. Peter s Hospital Nonprofit Organization Booth #: Takeda Pharmaceuticals U.S.A., Inc. Pharmaceuticals Booth #: 84 The Binding Site Booth #: The Gout & Uric Acid Education Society Educational Materials for Patients, Nonprofit Organization Booth #: 6 The JAMA Network Publisher Booth #: 56 The Myositis Association Nonprofit Organization Booth #: 60 TheraTest Laboratories, Inc. Diagnostic Equipment/Products Booth #: 08 Thomson Reuters Market Research, Publisher Booth #: 45 com TSI Healthcare Office Software/Equipment Booth #: 94 Turkish Journal of Rheumatology Nonprofit Organization Booth #: 64 UCB, Inc. Pharmaceuticals Booth #: 8 Value-Based Care in Rheumatology Publisher Booth #: com Vasculitis Foundation Educational Materials for Patients, Nonprofit Organization Booth #: 46 Vindico Medical Education Publisher Booth #: 7 VQ OrthoCare Educational Materials for Patients, Medical Device Booth #: Wake Forest Baptist Health Nonprofit Organization Booth #: 5 Warner Chilcott Pharmceuticals Booth #: 44 Wiley Publisher Booth #: Program Book

369 Leadership X $7,500,000 + Corporate Roundtable Pinnacle X $5,000,000 + As a direct result of the support of Corporate Roundtable donors, the Foundation continues to increase funding for research and training. Principal X $,500,000 + Participation in the Corporate Roundtable is a direct investment toward helping to: Ensure a highly trained workforce is available to provide competent clinical care to patients affected by rheumatic disease; Develop the next generation of researchers dedicated to rheumatic disease; Accelerate targeted inflammatory arthritis research. The Foundation thanks the Corporate Roundtable donors for their exemplary support. Partner X $,000,000 + * * Industry Roundtable members as of July, 0 Within Our Reach Partner Donor X Multi-year commitment * Steward $5,000 + Antares Pharma, Inc.

370 ACKNOWLEDGEMENTS The ACR, ARHP and the Foundation wish to thank the following organizations for providing support for the 0 ACR/ARHP Annual Meeting. AbbVie Exhibit Hall Networking Lounges Exhibit Hall Internet Centers Convention Center Banner Convention Center Escalator Clings Conference Shuttle Buses Amgen, Inc. Scientific Program Book Session Tracker Convention Center Column Clings Convention Center Escalator Clings and Elevator Banner Celgene Corporation Convention Technology Center Convention Center Banner Genentech, a Member of the Roche Group My Annual Meeting Hotel Key Cards Pfizer, Inc. Clinical Scenario Challenge Bristol-Myers Squibb Company Exhibit Hall Hanging Aisle Signs Exhibit Hall Wi-Fi Way 68 0 Program Book

371 ACKNOWLEDGEMENTS In addition to the support provided for the 0 ACR/ARHP Annual Meeting, the ACR, the ARHP and the Foundation wish to thank the following organizations for providing support for activities and programs throughout the year. AbbVie Corporate Roundtable, Leadership Level Fellows Education Fund Winter Rheumatology Symposium Rheumatology Maintenance of Certification Course Rheumatology Training Directors Conference Clinical Rheumatology for Health Professionals: ABC s of X-ray Reading State-of-the-Art Clinical Symposium CARE 0 ARHP Advanced Rheumatology Course Musculoskeletal Ultrasound Train-the-Trainer Pilot Program Hands-on Workshop Musculoskeletal Ultrasound Course for Rheumatologists Fundamentals (April and October) Musculoskeletal Ultrasound Course for Rheumatologists with Interventional Cadaver Workshop Intermediate Medical Student Clinical Preceptorship Medical Student Research Preceptorship Health Professional Research Preceptorship Medical and Pediatric Resident Research Award Student Achievement Award Annual Meeting Corporate Roundtable Symposium Annual Meeting Industry-Supported Post-Conference Symposium Amgen, Inc. Corporate Roundtable, Leadership Level Fellows Education Fund Winter Rheumatology Symposium Rheumatology Maintenance of Certification Course Rheumatology Training Directors Conference Clinical Rheumatology for Health Professionals: ABC s of X-ray Reading State-of-the-Art Clinical Symposium CARE 0 ARHP Advanced Rheumatology Course Amgen Fellowship Training Award Amgen Pediatric Visiting Professorship Award Amgen Pediatric Research Award ARHP Networking Forum Annual Meeting Corporate Roundtable Symposium Antares Pharma, Inc. Corporate Roundtable, Steward Level Bioiberica, S.A. Annual Meeting Industry-Supported Post-Conference Symposium Bristol-Myers Squibb Company Fellows Education Fund Annual Meeting Industry-Supported Post-Conference Symposium Celgene Corporation Corporate Roundtable, Principal Level Annual Meeting Corporate Roundtable Symposium Eli Lilly and Company Corporate Roundtable, Partner Level* Winter Rheumatology Symposium Rheumatology Maintenance of Certification Course Rheumatology Training Directors Conference Clinical Rheumatology for Health Professionals: ABC s of X-ray Reading State-of-the-Art Clinical Symposium CARE 0 ARHP Advanced Rheumatology Course Annual Meeting Corporate Roundtable Symposium Annual Meeting Industry-Supported Post-Conference Symposium GE Healthcare Musculoskeletal Ultrasound Course for Rheumatologists Fundamentals (April and October) Musculoskeletal Ultrasound Course for Rheumatologists with Interventional Cadaver Workshop - Intermediate Genentech, a Member of the Roche Group Corporate Roundtable, Principal Level Fellows Education Fund Winter Rheumatology Symposium Rheumatology Maintenance of Certification Course Rheumatology Training Directors Conference Clinical Rheumatology for Health Professionals: ABC s of X-ray Reading State-of-the-Art Clinical Symposium CARE 0 ARHP Advanced Rheumatology Course ARHP Networking Forum Janssen Biotech, Inc. Corporate Roundtable, Partner Level* Fellows Education Fund Scientist Development Award Pfizer, Inc. Corporate Roundtable, Pinnacle Level Rheumatology Maintenance of Certification Course State-of-the-Art Clinical Symposium Musculoskeletal Ultrasound Course for Rheumatologists Fundamentals (April and October) Musculoskeletal Ultrasound Course for Rheumatologists with Interventional Cadaver Workshop Intermediate Annual Meeting Corporate Roundtable Symposium UCB, Inc. Corporate Roundtable, Principal Level Fellows Education Fund Winter Rheumatology Symposium Rheumatology Maintenance of Certification Course Rheumatology Training Directors Conference Clinical Rheumatology for Health Professionals: ABC s of X-ray Reading State-of-the-Art Clinical Symposium CARE 0 ARHP Advanced Rheumatology Course Annual Meeting Corporate Roundtable Symposium *Industry Roundtable Member 0 Program Book 69

372 A Abdelrahman, Magdi, MRCP ACR Knowledge Bowl - Preliminary Round... 4 Aggarwal, Rohit, MD, MS Atypical Myopathies Myopathy: Issues in Diagnosis and Treatment (044) Myopathy: Issues in Diagnosis and Treatment (064)... 0 Rheumatic Disease Update: Myositis, An Overview and Differentiation From Metabolic Myopathies... 6 Albrecht, Inka, PhD ACR Plenary Session III: Discovery Aletaha, Daniel, MD, MSc Choosing and Monitoring Rheumatoid Arthritis Therapy in Disclosure: Abbvie, 8; Grünenthal, 5; Janssen Pharmaceutica Product, L.P., 8; Merck Pharmaceuticals, 8; Mitsubishi Tanabe, 8; Pfizer Inc, 5; Sanofi-Aventis Pharmaceutical, 5 Alevizos, Ilias, DMD ACR Basic Research Conference: Beyond Germline Genetics: New Perspectives on Rheumatic Disease Predisposition... 9 Allen, Kelli D., PhD Piloting Your Research to Success: The Why, What and How of Pilot Studies Alvaro-Gracia, JM, MD ACR Plenary Session III: Discovery Ancoli-Israel, Sonia, PhD Poor Sleep: Consequences and Cures Disclosure: Astra Zeneca, Ferring Pharmaceuticals Inc., GlaxoSmithKline, Hypnocore, Johnson & Johnson, Merck, NeuroVigil, Inc., Orphagen Pharmaceuticals, Pfizer, Philips, Purdue Pharma LP, sanofi-aventis, 5 Andersen, Renee, CHT, OTR/L Update on Orthotic Management for Rheumatic Diseases Through the Lifespan Annapureddy, Narender, MD ACR Knowledge Bowl - Preliminary Round... 4 Aranow, Cynthia, MD Systemic Lupus Erythematosus: Central Nervous System (08) Disclosure: Amgen, 5; Bristol-Myers Squibb, 5; Dynavax, ; Eli Lilly and Company, ; Genentech and Biogen IDEC Inc., ; GlaxoSmithKline,, 5; Human Genome Sciences, Inc., ; Pfizer Inc, ; UCB, Ardoin, Stacy P., MD, MS Pediatric Autoimmune and Inflammatory Skin Disease Winning at Clue: The Clinical Rheumatologist s Guide to Figuring out Who Killed Who, With What and Where in the Rheumatic Diseases.. 77 Arkachaisri, Thaschawee, MD International League of Associations for Rheumatology (ILAR) Pediatric Rheumatology in Developing Countries... 5 Arkfeld, Daniel, MD ACR Knowledge Bowl - Preliminary Round... 4 Disclosure: Keck School of Medicine at USC, Armanios, Mary, MD Telomeres, Telomerase and Age-Related Disease... 4 Arnold, Lesley M., MD Anxiety Disorders in Rheumatic Disease Disclosure: AstraZeneca, ; Daiichi Sankyo, 5; Dainippon Sumitomo Pharma, 5; Eli Lilly and Company, ; Forest Laboratories, ; Pfizer Inc,, 5, 8; Purdue Pharma L.P., 5; Takeda, ; Theravance,, 5 Rheumatic Disease and Pain Management in Special Needs Populations Disclosure: AstraZeneca, ; Daiichi Sankyo, 5; Dainippon Sumitomo Pharma, 5; Eli Lilly and Company, ; Forest Laboratories, ; Pfizer Inc,, 5, 8; Purdue Pharma L.P., 5; Takeda, ; Theravance,, 5 Arriens, Cristina, MD Thieves Market Posters - ACR/ARHP Poster Session C Asahara, Hiroshi, MD ACR Basic Research Conference: Beyond Germline Genetics: New Perspectives on Rheumatic Disease Predisposition... 9 Ascherman, Dana P., MD Animal Models in Rheumatic Disease How Useful Are They?... Molecular Mechanisms of Muscle Dysfunction in Inflammatory Myopathy and Muscular Dystrophy... 4 Protein Citrullination and Biological Response Modification: Rheumatoid Arthritis and Beyond Avery, Michael Thomas, DO Thieves Market Posters - ACR/ARHP Poster Session B B Backman, Catherine L., PhD ARHP Clinical Focus Course: Meeting the Challenges of Measuring Outcomes in Rheumatology Clinical Practice... 0 Baer, Alan N., MD Choosing and Monitoring Rheumatoid Arthritis Therapy in Controversies in Sjögren s Syndrome (0) Controversies in Sjögren s Syndrome (08).. 4 Current Management of Sjögren s Syndrome... 7 Baker, Nancy A., MPH, OTR, OTR/L Piloting Your Research to Success: The Why, What and How of Pilot Studies The Results Section in Medical Research Literature: The Appropriate and Inappropriate Use of Statistics... 0 Baraf, Herbert S. B., MD Contract Negotiations for Physicians... 0 Barker, Andrea, MPAS, PA-C Inter-professional Collaborative Practice and Education: A Review of the Field and Report of a New Center of Excellence in Musculoskeletal Care Barton, Greg M., PhD Cell Death and Toll-like Receptor (TLR) Recognition of Nucleic Acid Ligands... 5 Barton, Jennifer, MD ARHP Clinical Focus Course: Meeting the Challenges of Measuring Outcomes in Rheumatology Clinical Practice... 0 Disclosure: Pfizer, Bathon, Joan M., MD Good Reviewers Make Good Authors: A Guide to Conducting Excellent Manuscript Reviews Battafarano, Daniel F., DO Immunology Boot Camp Session : Biologic Logic, An Update Rheumatology Practice in the Age of the Affordable Care Act Battistone, Michael J., MD Inter-professional Collaborative Practice and Education: A Review of the Field and Report of a New Center of Excellence in Musculoskeletal Care Rheumatology Research Foundation Special Session: Clinician Scholar Educators Beam, Thuy T., BSN, RN Juvenile Systemic Lupus Erythematosus Beaton, Dorcas, PhD ARHP Clinical Focus Course: Meeting the Challenges of Measuring Outcomes in Rheumatology Clinical Practice... 0

373 Becker, Michael A., MD Crystal: Diagnosis and Management of Gout (00)... Disclosure: Ardea Biosciences, Inc, 5; AstraZeneca, 5; BioCryst Pharmaceuticals, Inc, 5; Metabolex Pharmaceuticals, Inc, 5; Regeneron, 5; Savient Pharmaceuticals, Inc, 5; Takeda Pharmaceuticals, Inc, 5; UpTo Date, Inc., 7 Crystal: Diagnosis and Management of Gout (06)... 0 Disclosure: Ardea Biosciences, Inc, 5; AstraZeneca, 5; BioCryst Pharmaceuticals, Inc, 5; Metabolex Pharmaceuticals, Inc, 5; Regeneron, 5; Savient Pharmaceuticals, Inc, 5; Takeda Pharmaceuticals, Inc, 5; UpTo Date, Inc., 7 Behrens, Edward M., MD Updated ACR Recommendations for the Treatment of Juvenile Idiopathic Arthritis Where s the Money? A Comprehensive Approach to Funding Your Research... 4 Bellido, Teresita M., PhD Bone is Hard or is it? Mechanisms Regulating Bone Qualities Bensler, Susa, MD, PhD Pediatric Inflammatory Brain Diseases... 5 Berman, Jessica, MD Assessment Tool Selection in Health Professions Education Bhardwaj, Nina, MD, PhD Sentinels of the Immune System: Dendritic cell and Plasmacytoid Dendritic Cells Disclosure: Crucell, 9 Bingham III, Clifton O., MD Choosing and Monitoring Rheumatoid Arthritis Therapy in Disclosure: AbbVie/Abbott, 5; Amgen, 5; BMS,, 5; Celgene, 5; Corrona, ; Genetech/Roche, ; Genetech/rRoche, 5; Janssen Pharmaceutica Product, L.P.,, 5; Mesoblast, ; Novartis Pharmaceutical Corporation, 5; Pfizer, ; Pfizer Inc, 5; UCB,, 5 ACR Review Course... 8 Vaccinations for Patients on Biologic Therapies (060) Disclosure: AbbVie/Abbott, 5; Amgen, 5; BMS,, 5; Celgene, 5; Corrona, ; Genetech/Roche, ; Genetech/rRoche, 5; Janssen Pharmaceutica Product, L.P.,, 5; Mesoblast, ; Novartis Pharmaceutical Corporation, 5; Pfizer, ; Pfizer Inc, 5; UCB,, 5 Vaccinations for Patients on Biologic Therapies (090)... 5 Disclosure: AbbVie/Abbott, 5; Amgen, 5; BMS,, 5; Celgene, 5; Corrona, ; Genetech/Roche, ; Genetech/rRoche, 5; Janssen Pharmaceutica Product, L.P.,, 5; Mesoblast, ; Novartis Pharmaceutical Corporation, 5; Pfizer, ; Pfizer Inc, 5; UCB,, 5 Birnbaum, Julius, MD, MHS Challenges in Systemic Lupus Erythematosus Management Curbside Consults - Ask the Experts Blanco V, Francisco J., MD OA-OMICS... 5 Disclosure: Bioiberica, ; Bristol-Myers Squibb, ; Celgene, ; Gebro Pharma, ; Grunenthal, ; Pfizer Inc, ; Roche Pharmaceuticals, Block, Joel A., MD Mechanisms of Pain in Osteoarthritis... 4 Disclosure: Ferring, Inc., 5; PL Pharma, Inc., 9 Boackle, Susan A., MD ACR Basic Research Conference: Beyond Germline Genetics: New Perspectives on Rheumatic Disease Predisposition... Boin, Francesco, MD Curbside Consults - Ask the Experts Bolster, Marcy B., MD ACR Special Session: Career Opportunities in Rheumatology: Making a Choice Bouxsein, Mary, PhD Bone is Hard or is it? Mechanisms Regulating Bone Qualities Disclosure: Amgen,, 9; Eli Lilly and Company, 9; Merck Pharmaceuticals,, 9 Bowe, Constance, MD Assessment Tool Selection in Health Professions Education Brady, Teresa J., PhD Enhancing Clinical Practice with Patient Engagement and Self-management Support Strategies... 6 Breland, Hazel L., PhD, OTR/L ARHP Moderators Orientation... 4 Health Literacy Universal Precautions for the Rheumatology Setting... 7 Bridges Jr., S. Louis, MD, PhD Functional Genomics: Approaches to Identifying Causal Variants Non-coding DNA: Signals, Switches, and Complex Regulation of Genes The Link Between Inflammation in the Joint and the Gut... 6 Bryan, Angela, MD Thieves Market: Show Me Your Best Cases Bucala, Richard J., MD, PhD Good Reviewers Make Good Authors: A Guide to Conducting Excellent Manuscript Reviews Buckner, Jane, MD Functional Genomics: Approaches to Identifying Causal Variants Burke, Allen, MD Histopathology of Rheumatic Lung Disease (0)... 4 Histopathology of Vasculitis ()... 0 Burns, Jane C., MD Kawasaki Disease: Putting Out the Fire Butte, Atul, MD, PhD Personalized Medicine: Transforming 00 Billion Points of Data Into Diagnostics, Therapeutics, and New Insights Into Disease... 7 Disclosure: Bristol Myers Squibb, 5; Carmenta, ; Genentech, 5; Johnson and Johnson, 5; NuMedii,, 5, 7; Personalis,, 5, 7; Samsung Advanced Institute of Technology, 5; Siemens, 5 Bykerk, Vivian P., MD ACR Clinical Research Conference: Preclinical Rheumatic Disease... 7 Disclosure: AMGEN, Antares, Astellas, Augurex, BMS, Genentech, Pfizer, Roche, UCB, 9 C Calabrese, Leonard H., DO Vaccinology and DMARD Use in Immunocompromised and High-Risk Populations... 5 Disclosure: BMS Genentec Jansen Pfizer Sanofi Horizon, 5 What is Not Central Nervous Angiitis: Making the Right Diagnosis (050) Disclosure: BMS Genentec Jansen Pfizer Sanofi Horizon, 5 Callahan, Leigh F., PhD Health Literacy Universal Precautions for the Rheumatology Setting... 7 Calonge, Ned, MD, MPH ACR Clinical Research Conference: Preclinical Rheumatic Disease... 7 Caminschi, Irina, PhD Cell Death and Toll-like Receptor (TLR) Recognition of Nucleic Acid Ligands... 4 Disclosure: Clec9A s owedby WEH, 7 Cannon, Grant W., MD Inter-professional Collaborative Practice and Education: A Review of the Field and Report of a New Center of Excellence in Musculoskeletal Care Carpenter, Melissa, PhD Regenerative and Stem Cell Medicine Catrina, Anca, MD, PhD ACR Clinical Research Conference: Preclinical Rheumatic Disease... 7 Chaichian, Yashaar, MD Thieves Market Posters - ACR/ARHP Poster Session B... 69

374 Chakarvarty, Eliza F., MD Pregnancy and Rheumatic Diseases (07) Disclosure: UCB, 9 Pregnancy and Rheumatic Diseases (066)... 0 Disclosure: UCB, 9 Vaccinology and DMARD Use in Immunocompromised and High-Risk Populations... 5 Disclosure: UCB, 9 Chan, Edward K.L., PhD ACR Basic Research Conference: Beyond Germline Genetics: New Perspectives on Rheumatic Disease Predisposition... Chang, Anthony, MD Renal Histopathology in Systemic Lupus Erythematosus and Vasculitis ()... 7 Disclosure: Abbott Laboratories, ; Roche Organ Transplantation Research Foundation, Renal Histopathology in Systemic Lupus Erythematosus and Vasculitis (9)... 4 Disclosure: Abbott Laboratories, ; Roche Organ Transplantation Research Foundation, Chauhan, Krati, MD, MPH Thieves Market Posters - ACR/ARHP Poster Session C Chawla, Ajay, Md, PhD Adipose Tissue and Inflammation... 4 Chen, Lan, MD, PhD Synovial Fluid Analysis and Crystal Identification (5)... 5 Synovial Fluid Analysis and Crystal Identification (5) Chen, Minzi, MD ACR Knowledge Bowl - Preliminary Round... 4 Chhakchhuak, Christine Rheumatic Disease Update: Myositis, An Overview and Differentiation From Metabolic Myopathies... 6 Chipeta, James, BSc, MBChB, PhD International League of Associations for Rheumatology (ILAR) Pediatric Rheumatology in Developing Countries... 5 Disclosure: Not a commercial grant but an Related ILAR grant, Chira, Peter, MD, MS Nonalcoholic Fatty Liver Disease Chretien, Katherine, MD Medical Education: The Year in Review... 4 Opportunities for Social Media in Medical Education Christenson, Mary E., PhD, PT Aerobic, Strength and Biomechanical Considerations for Treatment Progression in Osteoarthritis: What is the Evidence? Chrostowski, Susan, MS, ANP-C, RN The Risks, Screening and Management of Human Papillomavirus in Patients With Rheumatologic Disease... 7 Chung, Antanya, CPC, CPC-I, CRHC, CCS-P Policy Changes That Will Affect Your Practice in 04: Meaningful Use, Value-based Purchasing, PQRS, and ICD Ready or Not It s Coming: Implementation of ICD ACR Certified Rheumatology Coder Course: The Anatomy of Rheumatology Coding... Clauw, Daniel J., MD Fibromyalgia 0: Update on Management (04)... 4 Disclosure: Lilly, Pfizer, Forest, Nuvo, Cerephex, Purdue, 5; Nuvo, Merck, Cerephex, Pfizer, Persistent Pain: Mechanisms of Chronic Pain and Innovative Treatment Options Disclosure: Lilly, Pfizer, Forest, Nuvo, Cerephex, Purdue, 5; Nuvo, Merck, Cerephex, Pfizer, Clayburne, Gilda M., MLT Synovial Fluid Analysis and Crystal Identification (5)... 5 Synovial Fluid Analysis and Crystal Identification (5) Clowse, Megan E. B., MD, MPH ACR Review Course... 8 Disclosure: UCB, 5 Rheumatic Diseases in Women of Childbearing Years: Fertility, Pregnancy and Lactation Disclosure: UCB, 5 Co, Dominic, MD, PhD Autoimmunity Caused by Immune Deficiency: When Not Enough Is Too Much Coaxum, Audrey, CHI, CMCO, CMC, CMIS, CMOM ACR Practice Management Pre-meeting Course... Cohen, Stanley B., MD Rheumatoid Arthritis: Challenging Cases (07)... 6 Disclosure: Abbott,Amgen, Astellas,BMS, Merck, Lilly,Pfizer,UCB, 5 Rheumatoid Arthritis: Challenging Cases (058) Disclosure: Abbott,Amgen, Astellas,BMS, Merck, Lilly,Pfizer,UCB, 5 Colbert, Robert A., MD, PhD ACR Clinical Research Conference: Preclinical Rheumatic Disease... 4 Collins, Christopher E., MD Opportunities for Social Media in Medical Education Collins, Maxine, MBA, CPA, CMC, CMIS, CMCN ACR Practice Management Pre-meeting Course... Compton, Seth A., MD ACR Knowledge Bowl - Preliminary Round... 4 Conaghan, Philip G., MD, PhD Peripheral Magnetic Resonance Imaging in Rheumatology Practice (07)... 7 Peripheral Magnetic Resonance Imaging in Rheumatology Practice (4) Cooper Jr., Leslie T., MD Critical Care Rheumatology... 5 Cope, Andrew P., MD, PhD Interleukin-6 (IL-6), The Pleiotrophic Cytokine: New Clinical Roles and Therapeutic Opportunities Disclosure: Roche Pharmaceuticals, 8 Molecular and Cellular Profiling of the Immune Response... 8 The Role of B cells in Rheumatic Disease Corsiero, Elisa, PhD ACR Plenary Session III: Discovery Costenbader, Karen H., MD, MPH ACR Clinical Research Conference: Preclinical Rheumatic Disease... 7 Good Reviewers Make Good Authors: A Guide to Conducting Excellent Manuscript Reviews Crawford, Donah Z., BS, MA Highlights for the 0 ARHP Annual Scientific Meeting... 5 Crofford, Leslie J., MD Where s the Money? A Comprehensive Approach to Funding Your Research... 4 Cronin, Mary E., MD ACR Plenary Session II: Discovery Clinicopathologic Conference: A Patient with Rheumatoid Arthritis and Systemic Disease Microparticles: Real Effectors or Just Mini-Me.7 ACR Practice Management Pre-meeting Course... 0

375 Crowson, Cynthia S., MS Knowledge Is Power, But Sample Size Matters More: The Role of Sample Size in the Power and Precision of Study Results Disclosure: Genentech and Biogen IDEC Inc., ; Pfizer Inc, ; Roche Pharmaceuticals, The Results Section in Medical Research Literature: The Appropriate and Inappropriate Use of Statistics... 0 Disclosure: Genentech and Biogen IDEC Inc., ; Pfizer Inc, ; Roche Pharmaceuticals, Curtis, Jeffrey R., MD, MPH, MS Fine Tuning Your Skills in Utilizing Disease Activity Measurement Tools for Rheumatic Arthritis... 6 Disclosure: Roche/Genentech, UCB, Janssen, CORRONA, Amgen, Pfizer, BMS, Crescendo, AbbVie,, 5 Enhancing Clinical Practice with Patient Engagement and Self-management Support Strategies... 6 Disclosure: Roche/Genentech, UCB, Janssen, CORRONA, Amgen, Pfizer, BMS, Crescendo, AbbVie,, 5 Vaccinology and DMARD Use in Immunocompromised and High-Risk Populations... 5 Disclosure: Roche/Genentech, UCB, Janssen, CORRONA, Amgen, Pfizer, BMS, Crescendo, AbbVie,, 5 Curzan, Anne, PhD Keynote Address: Words that Heal... 6 Cush, John J., MD Rheumatology Roundup: Highlights from the 0 Annual Meeting... 7 Disclosure: Pfizer,, ; Abbvie, 5; Amgen,, 5; BMS, 5; Celgene, ; CORRONA, ; Genentech Inc., 5; IROKO pharmaceuticals, 5; Janssen Pharmaceutica Product, L.P.,, 5; Novartis Pharmaceutical Corporation, ; Pfizer Inc, 5; UCB,, 5; Vertex, 5 Still s Disease and Autoinflammatory Syndromes (086)... 4 Disclosure: Pfizer,, ; Abbvie, 5; Amgen,, 5; BMS, 5; Celgene, ; CORRONA, ; Genentech Inc., 5; IROKO pharmaceuticals, 5; Janssen Pharmaceutica Product, L.P.,, 5; Novartis Pharmaceutical Corporation, ; Pfizer Inc, 5; UCB,, 5; Vertex, 5 D D Spain, Linda, CMPE, CMCO, CMC, CMIS, CMOM ACR Practice Management Pre-meeting Course... Daikh, Brian E., MD Thieves Market: Show Me Your Best Cases Rheumatology Research Foundation Paul Klemperer, MD, Memorial Lectureship: Rheumatoid Arthritis and Autoimmunity: Good Genes, Elegant Mechanisms, Bad Results... 7 Dalbeth, Nicola, MBChB, MD Crystal Diseases: How Does Joint Damage Occur and Why Do Attacks Resolve Spontaneously?. 78 Gout and Pseudogout: What s New in Treatments and Diagnostic Modalities? Dall Era, Maria, MD Systemic Lupus Erythematosus: Difficult to Treat Systemic Lupus Erythematosus (049) Systemic Lupus Erythematosus: Difficult to Treat Systemic Lupus Erythematosus (088)... 4 Danve, Abhijeet, MD ACR Knowledge Bowl - Preliminary Round... 4 Dao, Kathryn H., MD Infections with Biologics (05) Disclosure: UCB, Celgene, Novartis, Pfizer, Amgen, Infections with Biologics (074)... Disclosure: UCB, Celgene, Novartis, Pfizer, Amgen, Dasgupta, Bhaskar, MD Large Vessel Vasculitis: What Should the Clinician Know... 4 Disclosure: Napp,Roche, Polymyalgia Rheumatica (055) Disclosure: Napp,Roche, Davidson, Anne, MBBS Rheumatology Research Foundation Special Session: Disease Targeted Research... 0 de Jong, Pascal, PhD ACR Plenary Session II: Discovery Deane, Kevin D., MD, PhD ACR Clinical Research Conference: Preclinical Rheumatic Disease... 6 Hereditary Angioedema Update (05)... 4 DeMarco, Paul J., MD ACR Musculoskeletal Ultrasound Course for Rheumatologists... Disclosure: Abbott Immunology Pharmaceuticals, Amgen, Auxilium, 8; Amgen, 8; Auxilium, Denay, Jane M., BSN, MSN, CFNP You Can Improve Hand Function in Scleroderma... Dennis, Gregory J., MD ACR Special Session: Career Opportunities in Rheumatology: Making a Choice Disclosure: UCB, Inc, Contract Negotiations for Physicians... 0 Disclosure: UCB, Inc, Mitigating Health Disparities in Rheumatologic Disease Disclosure: UCB, Inc, Deodhar, Atul A., MD Joint Injection Techniques ()... 5 Disclosure: American Regent, Joint Injection Techniques (7)... 4 Disclosure: American Regent, Rheumatoid Arthritis Management: Views from Around the World Disclosure: Abbott Laboratories, UCB, Novartis, Pfizer, ; UCB pharma, Abbott, 5 Selected Topics Related to Spondylarthropathies Disclosure: Abbott Laboratories, UCB, Novartis, Pfizer, ; UCB pharma, Abbott, 5 Devji, Ike, JD Risk Management-A Case Study Dewing, Kori A., DNP, ARNP Defining the Roles of the Rheumatology Nurse Internationally... Rheumatology Practice in the Age of the Affordable Care Act Dixit, Rajiv, MD Pain: Evaluation and Treatment of Back Pain (05)... 6 Pain: Evaluation and Treatment of Back Pain (05) Domsic, Robyn T., MD, MPH Systemic Sclerosis: Disease Staging and Subsetting in Clinical Practice (09)... 6 Systemic Sclerosis: Disease Staging and Subsetting in Clinical Practice (069)... 0 Dooley, Mary Anne, MD, MPH Systemic Lupus Erythematosus: Novel Treatments (00)... Disclosure: GSK 0, 8; GSK, UCB, HGS, Roche, Lily, ; HGS, GSK, 5; LFA, 6 Dorner, Thomas, MD The Role of B cells in Rheumatic Disease Disclosure: Roche/Chugai, UCB, Sanofi, Takeda, 8 Dua, Anisha B., MD, MPH Rheumatic Disease Update: Rheumatoid Arthritis... 7 Disclosure: Amgen Rheumatology National Advisory Board, 6 Thieves Market: Show Me Your Best Cases Disclosure: Amgen Rheumatology National Advisory Board, 6 Dufour, Alyssa B., PhD The Results Section in Medical Research Literature: The Appropriate and Inappropriate Use of Statistics... 0 Dugowson, Carin, MD, MPH Chart Etiquette: Creating Meaningful Notes. 0 Dunlop, Dorothy D., PhD Basic Statistical Concepts for the Medical Researcher (05)... 7 E Edrissian, Mohammadomid, MD ACR Knowledge Bowl - Preliminary Round... 4 Edwards, N. Lawrence, MD Curbside Consults - Ask the Experts Disclosure: Metabolex Pharmaceuticals; 5; Novartis Pharmaceutical Corporation, 5; SOBI Pharmaceuticals, 5; Takeda Pharmaceuticals, Thieves Market: Show Me Your Best Cases.. 04

376 Invited Speaker /Moderator Index Ekström, Tomas J., PhD ACR Basic Research Conference: Beyond Germline Genetics: New Perspectives on Rheumatic Disease Predisposition... El-Gabalawy, Hani S., MD ACR Clinical Research Conference: Preclinical Rheumatic Disease... 4 Elewaut, Dirk, MD, PhD The Link Between Inflammation in the Joint and the Gut... 6 Elist, Michael, DO ACR Knowledge Bowl - Preliminary Round... 4 Elson, Charles O., MD ACR Clinical Research Conference: Preclinical Rheumatic Disease... 6 Disclosure: Prometheus Laboratories, 7 Embi, Peter J., MD, MS Why Every U.S. Rheumatologist Should Join the National Rheumatology Registry (RISE)... 4 Erbil, Jen, MD ACR Knowledge Bowl - Preliminary Round... 4 Erkan, Doruk, MD Antiphospholipid Syndrome (00)... Disclosure: Alexion Pharmaceuticals, Inc., 5; APS ACTION Executive Committee Chair, 6; Eli Lilly and Company, ; GlaxoSmithKline, 8; Lupus Clinical Trials Consortium, ; New York Community Trust, Ernste, Floranne C., MD Thieves Market Posters - ACR/ARHP Poster Session C Esdaile, John, MD, MPH Pharmacist/Physician Partnership in Rheumatic Disease Management... 6 Disclosure: Shoppers Drug Mart, 5 Evangelisto, Amy M., MD Muscoloskeletal Ultrasound Course for Rheumatologists... Musculoskeletal Ultrasound (8) Disclosure: Abbott Laboratories,, 8; USSONAR, 6 Musculoskeletal Ultrasound (4) Disclosure: Abbott Laboratories,, 8; USSONAR, 6 Felix, Ioonna, PT, DPT, OCS Postural Changes: How to Improve Joint Protection, Strength and Gain Efficiency... 6 Felson, David T., MD, MPH ACR Plenary Session II: Discovery Ferguson, Polly J., MD ACR Pediatric Rheumatology Town Hall Meeting... Ferrante, Jr., Anthony W., MD, PhD Adipose Tissue and Inflammation... 4 Disclosure: AstraZeneca, ; Merck Pharmaceuticals, 5 Ferrer, Helga G., MD ACR Knowledge Bowl - Preliminary Round... 4 Fields, Theodore R., MD Crystal: Diagnosis and Management of Gout (0)... 6 Disclosure: Pfizer Pharmaceuticals, 8; Savient Pharmaceuticals, 8; Takeda Pharmaceuticals, 8, 9 Finckh, Axel, MD, PD ACR Clinical Research Conference: Preclinical Rheumatic Disease... 7 Fiorentino, David, MD, PhD Atypical Myopathies Firestein, Gary S., MD ACR Basic Research Conference: Beyond Germline Genetics: New Perspectives on Rheumatic Disease Predisposition... 8 Disclosure: Ignyta, Contract Negotiations for Physicians... 0 Disclosure: Ignyta, Fischer, Aryeh, MD Pulmonary Manifestations of Rheumatic Disease (045) Disclosure: Actelion Pharmaceuticals US, 5, 8; Gilead Pharmaceuticals,, 5, 8 Pulmonary Manifestations of Rheumatic Disease (08)... 4 Disclosure: Actelion Pharmaceuticals US, 5, 8; Gilead Pharmaceuticals,, 5, 8 Fisher, Edward, MD, PhD Macrophage Polarization Disclosure: Merck Pharmaceuticals, 5 Foxworth, Judy, PhD, PT Aerobic, Strength and Biomechanical Considerations for Treatment Progression in Osteoarthritis: What is the Evidence? Postural Changes: How to Improve Joint Protection, Strength and Gain Efficiency... 6 Francisco, Melissa Chart Etiquette: Creating Meaningful Notes. 0 Patient Engagement/Privacy and Security... Policy Changes That Will Affect Your Practice in 04: Meaningful Use, Value-based Purchasing, PQRS, and ICD Why Every U.S. Rheumatologist Should Join the National Rheumatology Registry (RISE)... 4 Franco, Alessandra, MD, PhD Kawasaki Disease: Putting Out the Fire Franklin, Patricia D., MD, MBA, MPH The Age of Information Technology: Registries, Administrative Databases, and the Role of the Internet in Rheumatic Disease Research... 6 Disclosure: NIAMS-NIH, NLM-NIH, AHRQ, Zimmer, Franks Jr., Andrew G., MD Challenges in Systemic Lupus Erythematosus Management Disclosure: Stiefel Pharmaceuticals, 5 Frey, Melissa, MSW, LCSW Navigating the System: The Key to Obtaining Medications for Your Patients... 7 Friedman, Emily, BA CORC FORUM: Disaster Planning: How to Prepare for a Catastrophe and Minimize your Liability. 5 Furst, Daniel, MD, MPH Systemic Sclerosis: How to Perform Skin Scores (4)... 4 Disclosure: AbbVie, Actelion, Amgen, BMS, BiogenIdec, Janssen, Gilead, GSK, NIH, Novartis, Pfizer, Roche/Genentech, UCB, 5; AbbVie, Actelion, Amgen, BMS, Gilead, GSK, NIH, Novartis, Pfizer, Roche/Genentech, UCB, ; AbbVie, Actelion, UCB, 8 F Falk, Ronald, MD Novel Insight Into the Pathogenesis of Systemic Vasculitis... 4 Feldman, Brian M., MD, MSc ACR Pediatric Rheumatology Town Hall Meeting... Disclosure: Bayer, Baxter, ; BMS, Pfizer, Novartis, 5; CRA, TAS, 6 Fitzcharles, Mary-Ann, MBChB, MD ARHP Clinical Focus Course: Meeting the Challenges of Measuring Outcomes in Rheumatology Clinical Practice... 0 Disclosure: Pfizer Inc, Valeant, Lilly, Purdue, 8 Medical Marijuana and the Rheumatologist.. 65 Disclosure: Pfizer Inc, Valeant, Lilly, Purdue, 8 Flemming, Donald J., MD X-ray Challenges in Rheumatic Diseases (8). 68 Disclosure: Elsevier, 7 G Gabriel, Sherine E., MD, MSc ACR Clinical Research Conference: Preclinical Rheumatic Disease... 7 Gamma, Frank, JD, MBA Contract Negotiations for Physicians... 0 Garber, Larry, MD Patient Engagement/Privacy and Security Program Book

377 Gardner, Gregory C., MD Best Practices for Diagnostic Imaging in Evaluating Rheumatologic Conditions... 5 Joint Injections (Knee, Ankle, Shoulder and Wrist) (0) Joint Injections (Knee, Ankle, Shoulder and Wrist) ()... 0 Gay, Steffen, MD ACR Basic Research Conference: Beyond Germline Genetics: New Perspectives on Rheumatic Disease Predisposition... 8 Gelber, Allan C., MD, PhD The Age of Information Technology: Registries, Administrative Databases, and the Role of the Internet in Rheumatic Disease Research... 6 Gershwin, Eric, MD ACR Basic Research Conference: Beyond Germline Genetics: New Perspectives on Rheumatic Disease Predisposition... Sex and Autoimmunity: Hormones and Beyond Giangreco, David, MD ACR Knowledge Bowl - Preliminary Round... 4 Gignac, Monique A., PhD Work, Health and Well-being: Arthritis and Employment Across the Life Course Gilek, Katarzyna, MD ACR Knowledge Bowl - Preliminary Round... 4 Gorman, Mark P., MD Pediatric Inflammatory Brain Diseases... 5 Gourley, Mark F., MD Behçet s Disease Janus Kinase (JAK) Inhibitors in Rheumatoid Arthritis Medical Marijuana and the Rheumatologist.. 65 Regenerative and Stem Cell Medicine Goyal, Janak R., MD Musculoskeletal Ultrasonography: Basic (4).. 5 Musculoskeletal Ultrasonography: Basic (7).. 68 Graf, Jonathan D., MD Rheumatic Manifestations of Endocrine Disorders... 7 Green, Douglas R., PhD Cell Death and Toll-like Receptor (TLR) Recognition of Nucleic Acid Ligands... 4 Greenfield, Meghan, MD Thieves Market Posters - ACR/ARHP Poster Session C Grg, Neha, MD ACR Knowledge Bowl - Preliminary Round... 4 Grom, Alexei A., MD Macrophage Activation Syndrome (04) Disclosure: Novartis Pharmaceutical Corporation, 5 Haining, W. Nicholas, BM, BCh Molecular and Cellular Profiling of the Immune Response... 8 Hajj-Ali, Rula, MD Curbside Consults - Ask the Experts Large Vessel Vasculitis: What Should the Clinician Know... 5 Novel Insight into the Pathogenesis of Systemic Vasculitis... 4 Thieves Market: Show Me Your Best Cases Hale, Elizabeth, BA(Hons); MSc Body Image With Rheumatic Conditions Disclosure: Bristol-Myers Squibb, 5 Designing a Qualitative Study and an Example of the Use of Qualitative Study Design in Patients With Rheumatologic Disease Disclosure: Arthritis Research UK, ; Bristol-Myers Squibb, 5 Hammoudeh, Mohammed, MD ACR Knowledge Bowl - Preliminary Round... 4 Rheumatoid Arthritis Management: Views From Around the World Hannan, Marian T., DSc, MPH Good Reviewers Make Good Authors: A Guide to Conducting Excellent Manuscript Reviews Inflammatory Arthropathies of the Foot and Ankle: Assessment and Non-pharmacological Foot Care Interventions... Obesity and Rheumatic Disease... 7 Invited Speaker /Moderator Index Gilkeson, Gary S., MD Sex and Autoimmunity: Hormones and Beyond Gold, Jeffrey I., PhD An Integrative Approach to Pediatric Wellness Goldbach-Mansky, Raphaela T., MD, MSc Adult Onset Still s Disease: A Clinical Review From Pathophysiology to Therapies... Goldring, Mary B. ACR Basic Research Conference: Beyond Germline Genetics: New Perspectives on Rheumatic Disease Predisposition... 9 Bone is Hard or is it? Mechanisms Regulating Bone Qualities Disclosure: Boehringer Ingelheim, ; Pfizer Inc, Bone Therapeutics, Fidia Pharma, Inc, Abbott Laboratories, 5 Goldring, Steven R., MD Year in Review... Disclosure: Boehringer Ingelheim, ; Pfizer Inc, Bone Therapeutics, Fidia Pharma, Inc, Abbott Laboratories, 5 Gruber, Barry, MD Rheumatic Disease Update Debate: Calcium and Vitamin D, What Does the Research Support? Disclosure: Amgen, 8; Lilly Pharmaceuticals, 8; Merck Pharmaceuticals, 9 Gul, Maryam, MD Thieves Market Posters - ACR/ARHP Poster Session B Gultekin, Sakir Humayun, MD Muscle Involvement in Rheumatic Diseases (0)... 4 H Hagman, James, PhD ACR Basic Research Conference: Beyond Germline Genetics: New Perspectives on Rheumatic Disease Predisposition... Hahn, Kristina, MHA ACR Practice Management Pre-meeting Course... 0 Hanson, Eric, MD ACR Plenary Session I: Discovery Hant, Faye N., DO, MSCR Scleroderma Mimics (08)... 4 Harley, John B., MD, PhD ACR Clinical Research Conference: Preclinical Rheumatic Disease... 4 Disclosure: Erba DIagnostice, 7; Erba Diagnostics,, 5; Genentech and Biogen IDEC Inc., 9; Genentech, Inc., 5, 9; Lilly Pharmaceuticals, 5, 9; Regeneron Pharmaceuticals, Inc., 9 Harrington, J. Timothy, MD Rheumatoid Arthritis: Outcome Measures in Clinical Practice (008)... Disclosure: Corrona, 5; Crescendo Bioscience, 5 Harrold, Leslie R., MD, MPH The Age of Information Technology: Registries, Administrative Databases, and the Role of the Internet in Rheumatic Disease Research... 6 Disclosure: Corrona, 5; Takeda, 0 Program Book 75

378 Invited Speaker /Moderator Index 76 Hassett, Afton L., PsyD Distinguished Lecturer: Integrating Concepts of Behavioral Change and Technology to Promote Health in Persons With Arthritis Disclosure: Brestol-Myers Squibb and Pfizer, Keynote Address: Words that Heal... 6 Disclosure: Brestol-Myers Squibb and Pfizer, Hatemi, Gulen, MD ACR Plenary Session I: Discovery Hays, Ron, PhD Patient-reported Outcome Measures for Rheumatologists... 8 Hayward, Kristen, MD, MS Proficiency in Teaching: Engaging Learners (4)... 4 Heaney, Robert P., MD Rheumatic Disease Update Debate: Calcium and Vitamin D, What Does the Research Support?. 87 Disclosure: Int l Dairy Foods Assoc., 8 Heath, Jonathon, MD Histopathology of Rheumatic Lung Disease (0)... 4 Histopathology of Vasculitis ()... 0 Hee, Frank Tay Sen, MBBS Thieves Market Posters - ACR/ARHP Poster Session C Hemmati, Iman, MD ACR Plenary Session I: Discovery Higgs, Jay B., MD Advanced Musculoskeletal Ultrasound (04).. 7 Advanced Musculoskeletal Ultrasound (0). 0 ACR Musculoskeletal Ultrasound Course for Rheumatologists... Hillstrom, Howard J., PhD Inflammatory Arthropathies of the Foot and Ankle: Assessment and Non-pharmacological Foot Care Interventions... Disclosure: JAK Tool, 5 Knee Braces and Foot Orthosis for Knee Osteoarthritis ()... 0 Disclosure: Ossur Generation II, Hoens, Alison, BSc(PT), MSc ARHP Clinical Focus Course: Meeting the Challenges of Measuring Outcomes in Rheumatology Clinical Practice... 9 Hoffman, Hal M., MD Inflammasomes in Health and Disease Disclosure: Novartis Pharmaceutical Corporation, 5, 8; Regeneron, 5; SOBI, 5 Holers, V. Michael, MD ACR Clinical Research Conference: Preclinical Rheumatic Disease... 4 Disclosure: Stanford Patent, 7 Emerging and Unexpected Regulatory Roles for Complement in the Rheumatic Diseases... 7 Disclosure: Alexion Pharmaceuticals, Inc., 5, 7 0 Program Book Hoppmann, Richard, MD Beyond Musculoskeletal Ultrasound for Rheumatologists (09)... 4 Disclosure: GE Healthcare, 9 Hordinsky, Maria, MD Alopecia 0 for the Rheumatologist... 4 Disclosure: Investigator initated studies supported by grants from Medicis and Allergan, 5; Am also a consultant to and member of the Pantene Institute affilitaed with Proctor & Gamble., Hudson, Marie, MD, MPH Vascular Disease in Scleroderma: A Multi-Organ Challenge Hughell, Laurie A., PA-C, MPH Rheumatic Diseases in Women of Childbearing Years: Fertility, Pregnancy and Lactation Hughes, Tudor, MD Clinicopathologic Conference: A Patient with Rheumatoid Arthritis and Systemic Disease Hummers, Laura K., MD, ScM Vascular Disease in Scleroderma: A Multi-Organ Challenge Disclosure: Actelion Pharmaceuticals US, ; medimmune, Humphrey, Mary Beth, MD, PhD Osteoporosis Treatment Strategies for Today and Tomorrow... 5 Hunter, David J., MBBS, PhD Osteoarthritis Pathophysiology, Diagnosis and Management: What Can I Tell my Osteoarthritis Patient to Do Other Than Weight Loss and Quadriceps Strengthening? Hunter, John C., MDD Best Practices for Diagnostic Imaging in Evaluating Rheumatologic Conditions... 5 Husni, M. Elaine, MD, MPH Psoriatic Arthritis (006)... Psoriatic Arthritis (076)... Huttenlocher, Anna, MD ACR Pediatric Rheumatology Town Hall Meeting... Huynh, Doquyen H., MD Clinicopathologic Conference: A Patient with Rheumatoid Arthritis and Systemic Disease I Iida, Masako Defining the Roles of the Rheumatology Nurse Internationally... Inman, Christi J. (C.J.), MD, MS ARHP Clinical Focus Course: Meeting the Challenges of Measuring Outcomes in Rheumatology Clinical Practice... 0 Spondylarthropathy: An Update (009)... Disclosure: Abbvie, Janssen, Pfizer, UCB, 5 Iraheta, Isa, MD ACR Knowledge Bowl - Preliminary Round... 4 Ivashkiv, Lionel, MD ACR Basic Research Conference: Beyond Germline Genetics: New Perspectives of Rheumatic Disease Predisposition... Iversen, Maura D., BSc, DPT, SD, MPH Aerobic, Strength and Biomechanical Considerations for Treatment Progression in Osteoarthritis: What is the Evidence? Distinguished Lecturer: Integrating Concepts of Behavioral Change and Technology to Promote Health in Persons With Arthritis J Jarjour, Wael N., MD Sex and Autoimmunity: Hormones and Beyond Johnson, Kiana, PhD Juvenile Systemic Lupus Erythematosus Johnson, Mark S., MD, MPH Mitigating Health Disparities in Rheumatologic Disease ACR-EULAR Scleroderma Classification Criteria Jolly, Meenakshi, MD, MS Body Image With Rheumatic Conditions Disclosure: GSK, 5; LupusPRO/LIT, 4; Med Immune, 7 Patient-reported Outcome Measures for Rheumatologists... 8 Disclosure: GSK, 5; LupusPRO/LIT, 4; Med Immune, 7 Jonas, Beth L., MD Health Literacy Universal Precautions for the Rheumatology Setting... 7 Jones, Karla B., CNP Immunology Boot Camp Session : Biologic Logic, An Update Jones, Kim D., PhD Influence of Cardiac Comorbidities on Exercise in Individuals With Rheumatic Diseases... 5

379 Jones, Simon A., BSC, PhD Interleukin-6 (IL-6), The Pleiotrophic Cytokine: New Clinical Roles and Therapeutic Opportunities... Disclosure: Ferring Pharmaceuticals, ; NovImmune SA,, 5; Roche Pharmaceuticals, ; Roche Pharmaceuticals/Chugai, 5 Jordan, Joanne M., MD, MPH Osteoarthritis: Update 0 (04)... 6 Disclosure: Algynomics, Inc., ; Chronic Osteoarthritis Management Initiative of US Bone and Joint Initiative, 6; Interleukin Genetics, Inc., 5; Osteoarthritis Research Society International, 6; Samumed, 5; Trinity Partners, Inc., 5 Osteoarthritis: Update 0 (08)... 4 Disclosure: Algynomics, Inc., ; Chronic Osteoarthritis Management Initiative of US Bone and Joint Initiative, 6; Interleukin Genetics, Inc., 5; Osteoarthritis Research Society International, 6; Samumed, 5; Trinity Partners, Inc., 5 ACR Review Course... 8 Disclosure: Algynomics, Inc., ; Chronic Osteoarthritis Management Initiative of US Bone and Joint Initiative, 6; Interleukin Genetics, Inc., 5; Osteoarthritis Research Society International, 6; Samumed, 5; Trinity Partners, Inc., 5 Juel, Vern, MD Critical Care Rheumatology... 5 Disclosure: FDA Orphan Product Development Program, 9; Jacobus Pharmaceuticals, 9 Jurisson, Mary, MD Tai Chi and Alternative Therapies in Rheumatic (5) K Kaeley, Gurjit S., MBBS, MRCP Musculoskeletal Ultrasonography: Basic (4). 5 Disclosure: Esaote, 9; Sonosite, 9 Musculoskeletal Ultrasonography: Basic (7). 68 Disclosure: Esaote, 9; Sonosite, 9 ACR Musculoskeletal Ultrasound Course for Rheumatologists... Kafka, Shelly P., MD Adult Onset Still s Disease: A Clinical Review from Pathophysiology to Therapies... Alopecia 0 for the Rheumatologist... 4 Inflammatory Eye Disease: An Update for Rheumatologists... Selected Topics Related to Spondylarthropathies Kahl, Leslie, MD You Can Improve Hand Function in Scleroderma... Kahr, Anthony, MD ACR Knowledge Bowl - Preliminary Round... 4 Kalaiah, Mudappa Karineravanda, MBBS Thieves Market Posters - ACR/ARHP Poster Session C Kalish, Robert A., MD Clinical Anatomy and Physical Exam: Essential Tools in Lower Extremity Regional Pain Syndromes (0)... 4 Clinical Anatomy and Physical Exam: Essential Tools in Upper Extremity Regional Pain Syndromes (6) Karasawa, Rie, MD, PhD ACR Plenary Session III: Discovery Karsenty, Gerard, MD, PhD Rheumatology Research Foundation Oscar S. Gluck, MD, Memorial Lectureship: The Contribution of Bone to Whole Organism Physiology... 6 Kastner, Daniel L., MD, PhD Pediatrics: Periodic Fevers in Children (06).. 67 Katz, Patricia P., PhD ARHP Clinical Focus Course: Meeting the Challenges of Measuring Outcomes in Rheumatology Clinical Practice... 9 Kavanaugh, Arthur, MD Clinicopathologic Conference: A Patient With Rheumatoid Arthritis and Systemic Disease New Therapies for Modulating Cell Signaling in Rheumatoid Arthritis... 5 Psoriatic Arthritis (056) Rheumatology Roundup: Highlights from the 0 Annual Meeting... 7 Kay, Jonathan, MD Rheumatoid Arthritis: Challenging Cases (007)... Disclosure: Abbott Laboratories, ; Amgen Inc., 5; Ardea Biosciences, ; Baxter Healthcare Corporation, 5; Bristol-Myers Squibb Company, 5; Celgene Corp., 5; Eli Lilly and Company, ; Fidia Farmacutici, SpA, ; fourteen Inc., 5; Genentech Inc., 5; Horizon Pharma, Inc., 5; Hospira, Inc., 5; Janssen Biotech, Inc., 5; medac pharma Inc., 5; PanGenetics, B.V., 5; Pfizer Inc, ; Pfizer Inc., 5; Roche Laboratories, ; Roche Laboratories, Inc., 5; sanofi-aventis, ; Savient Pharmaceuticals, Inc., 5; Sun Pharmaceutical Industries Ltd., 5; UCB, Inc., 5 Rheumatoid Arthritis: Challenging Cases (078)... Disclosure: Abbott Laboratories, ; Amgen Inc., 5; Ardea Biosciences, ; Baxter Healthcare Corporation, 5; Bristol-Myers Squibb Company, 5; Celgene Corp., 5; Eli Lilly and Company, ; Fidia Farmacutici, SpA, ; fourteen Inc., 5; Genentech Inc., 5; Horizon Pharma, Inc., 5; Hospira, Inc., 5; Janssen Biotech, Inc., 5; medac pharma Inc., 5; PanGenetics, B.V., 5; Pfizer Inc, ; Pfizer Inc., 5; Roche Laboratories, ; Roche Laboratories, Inc., 5; sanofi-aventis, ; Savient Pharmaceuticals, Inc., 5; Sun Pharmaceutical Industries Ltd., 5; UCB, Inc., 5 Kazi, Salahuddin, MD ARHP Clinical Focus Course: Meeting the Challenges of Measuring Outcomes in Rheumatology Clinical Practice... 9 Chart Etiquette: Creating Meaningful Notes. 0 Getting Electronic Health Records Right (6). 87 Quality Measures in Rheumatology: Developing and Implementing Meaningful Measures as Health Care Reform Advances Why Every U.S. Rheumatologist Should Join the National Rheumatology Registry (RISE)... 4 Keenan, Robert T., MD, MPH Ready or Not It s Coming: Implementation of ICD Keystone, Edward, MD Physical Examination Skills for Improved Detection of Synovitis and Cervical Thoracolumbar Disorders (08)... 7 Disclosure: Abbott Laboratories,, 5; Amgen,, 5; AstraZeneca,, 5; Biotest, 5; Bristol Myers- Squibb, ; Bristol-Myers Squibb, 5; F Hoffman La-Roche, 5; F. Hoffman La-Roche, ; Genentech and Biogen IDEC Inc., 5; Janssen Pharmaceutica Product, L.P.,, 5; Lilly Pharmaceuticals, ; Novartis Pharmaceutical Corporation, ; Pfizer Inc,, 5; UCB,, 5 Rheumatoid Arthritis: Biological Agents (047). 77 Disclosure: Abbott Laboratories,, 5; Amgen,, 5; AstraZeneca,, 5; Biotest, 5; Bristol Myers- Squibb, ; Bristol-Myers Squibb, 5; F Hoffman La-Roche, 5; F. Hoffman La-Roche, ; Genentech and Biogen IDEC Inc., 5; Janssen Pharmaceutica Product, L.P.,, 5; Lilly Pharmaceuticals, ; Novartis Pharmaceutical Corporation, ; Pfizer Inc,, 5; UCB,, 5 Rheumatoid Arthritis: Biological Agents (077)... Disclosure: Abbott Laboratories,, 5; Amgen,, 5; AstraZeneca,, 5; Biotest, 5; Bristol Myers- Squibb, ; Bristol-Myers Squibb, 5; F Hoffman La-Roche, 5; F. Hoffman La-Roche, ; Genentech and Biogen IDEC Inc., 5; Janssen Pharmaceutica Product, L.P.,, 5; Lilly Pharmaceuticals, ; Novartis Pharmaceutical Corporation, ; Pfizer Inc,, 5; UCB,, 5 Khamashta, Munther A., MD Antiphospholipid Syndrome (0) Antiphospholipid Syndrome (06)... 0 Khan, Omar, MD ACR Knowledge Bowl - Preliminary Round... 4 Invited Speaker /Moderator Index 0 Program Book 77

380 Invited Speaker /Moderator Index 78 Khanna, Dinesh, MD, MSc 0 ACR-EULAR Scleroderma Classification Criteria Disclosure: Actelion Pharmaceuticals US, 5, 8; BMS, 5; DIGNA, 5; Gilead, 5; Merck Pharmaceuticals, 5; NIH, ; Roche Pharmaceuticals, 5; Scleroderma Foundation, ; United Therapeutics, 5, 8 Patient-reported Outcome Measures for Rheumatologists... 8 Disclosure: Actelion Pharmaceuticals US, 5, 8; BMS, 5; DIGNA, 5; Gilead, 5; Merck Pharmaceuticals, 5; NIH, ; Roche Pharmaceuticals, 5; Scleroderma Foundation, ; United Therapeutics, 5, 8 Update on Thrombotic Microangiopathies... 6 Disclosure: Actelion Pharmaceuticals US, 5, 8; BMS, 5; DIGNA, 5; Gilead, 5; Merck Pharmaceuticals, 5; NIH, ; Roche Pharmaceuticals, 5; Scleroderma Foundation, ; United Therapeutics, 5, 8 Vascular Disease in Scleroderma: A Multi-Organ Challenge Disclosure: Actelion Pharmaceuticals US, 5, 8; BMS, 5; DIGNA, 5; Gilead, 5; Merck Pharmaceuticals, 5; NIH, ; Roche Pharmaceuticals, 5; Scleroderma Foundation, ; United Therapeutics, 5, 8 Kim, Alfred, MD, PhD Where s the Money? A Comprehensive Approach to Funding Your Research... 4 Disclosure: ACR/RRF, Kim, Seoyoung C., MD, MSCE The Risks, Screening and Management of Human Papillomavirus in Patients with Rheumatologic Disease... 7 Disclosure: Pfizer Inc, Kim, Susan, MD Juvenile Dermatomyositis (0)... 6 Kimel, Alexandru F., MD Rheumatology Practice 0: Starting Out in Practice for the Graduating Fellow (068)... 0 Kimura, Yuki, MD Updated ACR Recommendations for the Treatment of Juvenile Idiopathic Arthritis King II, Charles M., MD Enhancing Clinical Practice with Patient Engagement and Self-management Support Strategies... 6 Physician Profiling- It s Going to Cost You! Risk Management-A Case Study... 0 Kinjo, Mitsuyo, MD, MPH Thieves Market Posters - ACR/ARHP Poster Session B Kissin, Eugene Y., MD Musculoskeletal Ultrasound (8) Disclosure: SonoSite, 9; USSONAR Board Member, 6 Musculoskeletal Ultrasound (4) Disclosure: SonoSite, 9; USSONAR Board Member, 6 ACR Musculoskeletal Ultrasound Course for Rheumatologists...6 Rheumatology Research Foundation Special Session: Clinician Scholar Educators Disclosure: SonoSite, 9; USSONAR Board Member, 6 0 Program Book Klareskog, Lars, MD, PhD ACR Clinical Research Conference: Preclinical Rheumatic Disease... 7 Disclosure: No own commercial interests, Klepper, Susan, PhD, PT Update On Orthotic Management for Rheumatic Diseases Through the Lifespan Kohler, Minna J., MD Musculoskeletal Ultrasound Course for Rheumatolgists - Foot and Ankle... 6 ACR Musculoskeletal Ultrasound Course for Rheumatologists... Kolasinski, Sharon L., MD Contract Negotiations for Physicians... 0 Kolfenbach, Jason R., MD ACR Knowledge Bowl - Preliminary Round... 4 Krajci, Katherine, LCSW Navigating the System: The Key to Obtaining Medications for Your Patients... 7 Kremer, Joel M., MD Janus Kinase (JAK) Inhibitors in Rheumatoid Arthritis Disclosure: Pfizer, Lilly, ; Pfizer, Lilly, Vertex, 5 Krohn, Kelly D., MD Knee Braces and Foot Orthosis for Knee Osteoarthritis ()... 0 Disclosure: Eli Lilly employee, Kuchroo, Vijay K., MD, PhD The Role of Th7 Cells in Health and Disease. 05 Disclosure: Tempero Inc, ; Tempero Inc., 5 Kunkel, Gary A., MD ACR Musculoskeletal Ultrasound Course for Rheumatologists... 6 Kutzbach, Abraham G., MD ACR Knowledge Bowl - Preliminary Round... 4 L Lafyatis, Robert, MD Cell Death and Toll-like Receptor (TLR) Recognition of Nucleic Acid Ligands... 4 Disclosure: Actelion Pharmaceuticals US, ; Amira, 5; Biogen Idec,, 5; BMS, 5; Bristol- Myers Squibb, ; Celdara, 5; Celgene, 5; Celltex, 5; Dart Therapeutics, 5; Genentech and Biogen IDEC Inc., ; Human Genome Sciences, Inc., ; Idera, 5; Inception, 5; Intermune, 5; Lycera, 5; Medimmune,, 5; Novartis Pharmaceutical Corporation, 5; Precision Dermatology, 5; PRISM, 5; Promedior, 5; Regeneron,, 5; Roche/ Genentech, 5; Sanofi/Genzyme,, 5; Shire,, 5; Stromedix, ; UCB, ; Zwitter, 5 Laing, Timothy, MD Legislative Update From Capitol Hill... 4 Lane, Nancy E., MD Vitamin D and Bone Health (040) Langford, Carol A., MD, MHS ACR/ABIM Maintenance of Certification Learning Session 0 Update in Rheumatology... 5 Disclosure: Bristol-Myers Squibb, 9; Genentech and Biogen IDEC Inc., 9 How to Maintain Your Medical License and Certification After 0: Changes Will Impact All Physicians. Are You Prepared? Disclosure: Bristol-Myers Squibb, 9; Genentech and Biogen IDEC Inc., 9 Lasky, Andrew, MD Rheumatology Research Foundation Memorial Lecture: Pediatric Rheumatology - Where We ve Been, Where We re Going... 6 Lavalley, Michael P., PhD Good Reviewers Make Good Authors: A Guide to Conducting Excellent Manuscript Reviews Disclosure: Associate Editor, 6; Sunovion Pharmaceutical Company, 5 Knowledge Is Power, But Sample Size Matters More: The Role of Sample Size in the Power and Precision of Study Results Disclosure: Associate Editor, 6; Sunovion Pharmaceutical Company, 5 Lawry, George V., MD Musculoskeletal Exam Skills I: General Musculoskeletal Examination for Arthritis? ()... 5 Disclosure: McGraw-Hill Publishers, 7 Musculoskeletal Exam Skills II: Regional Musculoskeletal Examination of the Neck and Low Back ()... 7 Disclosure: McGraw-Hill Publishers, 7 Musculoskeletal Exam Skills III: Regional Musculoskeletal Examination of the Shoulder and Knee (7) Disclosure: McGraw-Hill Publishers, 7 Lazaro, Deana M., MD Inter-professional Collaborative Practice and Education: A Review of the Field and Report of a New Center of Excellence in Musculoskeletal Care Lee, Jungwha, PhD, MPH Basic Statistical Concepts for the Medical Researcher (05)... 7 Lehman, Thomas J. A., MD Pediatrics: Difficult to Treat Juvenile Idiopathic Arthritis (075)... Disclosure: Abbott Laboratories, 8; Amgen, 8; Genentech and Biogen IDEC Inc., 5; Genzyme Corporation, 5; Novartis Pharmaceutical Corporation, 5 Pediatrics: Spondylarthritis in Children (005).. Disclosure: Abbott Laboratories, 8; Amgen, 8; Genentech and Biogen IDEC Inc., 5; Genzyme Corporation, 5; Novartis Pharmaceutical Corporation, 5 Lemke, Greg, PhD Tyro/Axl/Mer (TAM) Receptors and Innate Immune Regulation Disclosure: Xetrios Therapeutics,

381 Leong, Amye L., MBA Fine Tuning Your Skills in Utilizing Disease Activity Measurement Tools for Rheumatic Arthritis... 6 Leslie, Christina, PhD ACR Basic Research Conference: Beyond Germline Genetics: New Perspectives on Rheumatic Disease Predisposition... Li, Jia, MD, PhD ACR Plenary Session I: Discovery Li, Linda C., PhD, PT Piloting Your Research to Success: The Why, What and How of Pilot Studies Lian, Jane, PhD ACR Basic Research Conference: Beyond Germline Genetics: New Perspectives on Rheumatic Disease Predisposition... 9 Lim, S. Sam, MD, MPH Mitigating Health Disparities in Rheumatologic Disease Disclosure: GlaxoSmithKline, Lipson, Aliza, MD Patient Engagement/Privacy and Security... Loeser, Richard F., MD Mechanics, Matrix Disruption, and the Development of Osteoarthritis OA-OMICS... 5 Lohr, Kristine M., MD, MS ACR/ABIM Maintenance of Certification Learning Session 0 Update in Rheumatology... 5 Atypical Myopathies Opportunities for Social Media in Medical Education ACR Review Course Loredo, Jose S., MD, MS, MPH Poor Sleep: Consequences and Cures Disclosure: Advance Sleep Medicine Inc., 5 Loughlin, John, PhD OA-OMICS... 5 Lovell, Daniel (D.J.) MD, MPH Pediatric Rheumatology for Adult Rheumatologists (054) Disclosure: AstraZeneca, 5; Centocor, Inc., 5; Forest Laboratories, 9; Hoffmann-La Roche, Inc., 5; Medimmune, 5; Novartis Pharmaceutical Corporation, 5; ucb, 5 Lundberg, Ingrid E., MD, PhD Molecular Mechanisms of Muscle Dysfunction in Inflammatory Myopathy and Muscular Dystrophy... 4 Disclosure: BMS, ; Novartis Pharmaceutical Corporation, 5 Lupien, Mathieu, PhD ACR Basic Research Conference: Beyond Germline Genetics: New Perspectives on Rheumatic Disease Predisposition... 9 Luqmani, Raashid A., DM Vasculitis: Update (00)... 6 Vasculitis: Update (080)... M Mackay, Meggan, MD, MS Systemic Lupus Erythematosus: Central Nervous System (087)... 4 Mackey, Sean, MD, PhD Persistent Pain: Mechanisms of Chronic Pain and Innovative Treatment Options Magalhaes, Claudia Saad, MD International League of Associations for Rheumatology (ILAR) Pediatric Rheumatology in Developing Countries... 5 Magid, Steven K., MD Chart Etiquette: Creating Meaningful Notes. 0 Mains, Trayton, DO ACR Knowledge Bowl - Preliminary Round... 4 Majithia, Vikas, MD, MPH ACR Knowledge Bowl - Preliminary Round... 4 Majka, Darcy S., MS ACR Clinical Research Conference: Preclinical Rheumatic Disease... 7 Maksymowych, Walter P., MD Magnetic Resonance Imaging in the Diagnosis and Management of Spondyloarthritis: A Clinician s Guide (0)... 4 Magnetic Resonance Imaging in the Diagnosis and Management of Spondyloarthritis: A Clinician s Guide () Malaviya, Anand N., MD Rheumatoid Arthritis Management: Views from Around the World Disclosure: Member Advisory Board Janssen Pharma, Roche Pharma,, 5; Pfizer Inc, 5; Reddy s., 5 Maldonado-Cocco, Jose Antonio, MD Rheumatoid Arthritis Management: Views from Around the World Malemud, Charles J., PhD ACR Basic Research Conference: Beyond Germline Genetics: New Perspectives on Rheumatic Disease Predisposition... 9 Disclosure: Genentech/Roche Group, Malfait, Anne-Marie, MD, PhD Mechanisms of Pain in Osteoarthritis... 4 Disclosure: Allergan, 5 Malik, Ashima, MD Thieves Market: Show Me Your Best Cases Mammen, Andrew L., MD, PhD Atypical Myopathies Disclosure: Inova Diagnostics, Inc., 7 Mandelin II, Arthur M., MD, PhD Fine Tuning Your Skills in Utilizing Disease Activity Measurement Tools for Rheumatic Arthritis... 6 The Rheumatologic Musculoskeletal Screening Exam, with Emphasis on Objective Diseasespecific Measurements (9) The Rheumatologic Musculoskeletal Screening Exam, with Emphasis on Objective Diseasespecific Measurements (6) Mandell, Brian F., MD, PhD Synovial Fluid Analysis and Crystal Identification (5)... 5 Synovial Fluid Analysis and Crystal Identification (5) Mandl, Lisa A., MD, MPH ACR Clinical Research Conference: Preclinical Rheumatic Disease... 7 Manno, Rebecca L., MD, MHS ACR Knowledge Bowl - Preliminary Round... 4 Manzi, Susan, MD, MPH Systemic Lupus Erythematosus: Novel Treatments (08)... 6 Disclosure: Bristol Myers Squibb, Exagen, Human Genome Sciences, 9; Intellectual Property, 9; NIH, 9; UCB S.A; NIH, Marcus, Don, MD Tai Chi and Alternative Therapies in Rheumatic (5) Margules, Kenneth R., MD Joint Injections (Knee, Ankle, Shoulder and Wrist). (0) Joint Injections (Knee, Ankle, Shoulder and Wrist). ()... 0 Maricic, Michael J., MD Osteoporosis Treatment Strategies for Today and Tomorrow... 5 Disclosure: Amgen, Rheumatology Research Foundation Oscar S. Gluck, MD, Memorial Lectureship: The Contribution of Bone to Whole Organism Physiology... 6 Invited Speaker /Moderator Index 0 Program Book 79

382 Invited Speaker /Moderator Index 80 Marra, Carlo A., PharmD, PhD Pharmacist/Physician Partnership in Rheumatic Disease Management... 6 Marston, Bethany A., MD ACR Musculoskeletal Ultrasound Course for Rheumatologists... 6 Marth, Jamey, PhD Glycoregulation of Autoimmunity... 7 Martinez, Joseph, MD ACR Knowledge Bowl - Preliminary Round... 4 Matteson, Eric L., MD, MPH ACR Plenary Session II: Discovery Disclosure: Ardea Biosciences, ; Celegene, ; Genentech and Biogen IDEC Inc., ; Hoffmann-La Roche, Inc., ; Janssen Pharmaceutica Product, L.P., ; Mesoblast, ; Novartis Pharmaceutical Corporation, ; Pfizer Inc, ; Rheumatology Research Foundation, ; UCB Pharma, Hench Lecture: Evolutionary Medicine and Chronic Inflammatory State - Known and New Concepts in Pathophysiology... Disclosure: Ardea Biosciences, ; Celegene, ; Genentech and Biogen IDEC Inc., ; Hoffmann-La Roche, Inc., ; Janssen Pharmaceutica Product, L.P., ; Mesoblast, ; Novartis Pharmaceutical Corporation, ; Pfizer Inc, ; Rheumatology Research Foundation, ; UCB Pharma, Large Vessel Vasculitis: What Should the Clinician Know... 5 Disclosure: Ardea Biosciences, ; Celegene, ; Genentech and Biogen IDEC Inc., ; Hoffmann-La Roche, Inc., ; Janssen Pharmaceutica Product, L.P., ; Mesoblast, ; Novartis Pharmaceutical Corporation, ; Pfizer Inc, ; Rheumatology Research Foundation, ; UCB Pharma, The Great Debate: Biologics or Triple Therapy for the Treatment of Rheumatoid Arthritis? Disclosure: Ardea Biosciences, ; Celegene, ; Genentech and Biogen IDEC Inc., ; Hoffmann-La Roche, Inc., ; Janssen Pharmaceutica Product, L.P., ; Mesoblast, ; Novartis Pharmaceutical Corporation, ; Pfizer Inc, ; Rheumatology Research Foundation, ; UCB Pharma, Mayes, Maureen D., MD, MPH You Can Improve Hand Function in Scleroderma... Disclosure: Actelion Pharmaceuticals US, ; Celgene, ; Roche Pharmaceuticals, Maynard, Janet W., MD Update on Safety Issues in the Treatment of Rheumatic Diseases From the FDA and Beyond... 5 McCarthy, Geraldine M., MD Crystal Diseases: How Does Joint Damage Occur and Why Do Attacks Resolve Spontaneously?. 78 McClung, Michael, MD Osteoporosis Treatment Strategies for Today and Tomorrow... 5 Disclosure: Amgen,, 5; Lilly, 5; Merck Pharmaceuticals,, 5; Novartis Pharmaceutical Corporation, 5; Warner-Chilcott, 8 0 Program Book McCurdy, Deborah K., MD Rheumatology Research Foundation Memorial Lecture: Pediatric Rheumatology - Where We ve Been, Where We re Going... 6 McDougall, Jason J., PhD Medical Marijuana and the Rheumatologist.. 65 Disclosure: Eli Lilly Co. USA, McGovern, Dermot P. B., MD The Link Between Inflammation in the Joint and the Gut... 6 McInnes, Iain B., PhD ACR Plenary Session II: Discovery Disclosure: Novartis, Janssen Research & Development, LLC., 8; UCB, 9 Janus Kinase (JAK) Inhibitors in Rheumatoid Arthritis Disclosure: Astra Zeneca,, 5; Pfizer Inc,, 5; Vertex, 5 McLean, Robert R., DSc, MPH Highlights for the 0 ARHP Annual Scientific Meeting... 5 Obesity and Rheumatic Disease... 7 Medsger Jr., Thomas A., MD 0 ACR-EULAR Scleroderma Classification Criteria Mehta, Puja, MBBS, MRCP Thieves Market Posters - ACR/ARHP Poster Session B Merkel, Peter A., MD, MPH Where s the Money? A Comprehensive Approach to Funding Your Research... 4 Disclosure: Actelion Pharmaceuticals US,, 5; Bristol-Myers Squibb, ; Celgene, ; Genentech and Biogen IDEC Inc., ; Roche Pharmaceuticals, Merriam, Sharan, EdD An Overview of Qualitative Research Designing a Qualitative Study and An Example of the Use of Qualitative Study Design in Patients With Rheumatologic Disease Michaud, Kaleb, PhD ACR Plenary Session III: Discovery Disclosure: National Data Bank for Rheumatic Diseases, ; University of Nebraska Medical Center, Michels, Aaron, MD ACR Clinical Research Conference: Preclinical Rheumatic Disease... 7 Disclosure: Novartis Pharmaceutical Corporation, Mikuls, Ted R., MD, MSPH ACR Clinical Research Conference: Preclinical Rheumatic Disease... 6 Disclosure: Roche/Genentech and Biogen IDEC Inc., Rheumatology Research Foundation Special Session: Disease Targeted Research... 0 Disclosure: Roche/Genentech and Biogen IDEC Inc., Millar, Audrey Lynn, PhD, PT Influence of Cardiac Comorbidities on Exercise in Individuals With Rheumatic Diseases... 5 Disclosure: Human Kinetics, 7 Miller, Daniel, MD Dermatopathology of Rheumatic Diseases (06)... 7 Dermatopathology of Rheumatic Diseases (9) Mintz, Sandra, BSN An Integrative Approach to Pediatric Wellness Misra, Devyani, MD Rheumatic Disease and Pain Management in Special Needs Populations Moldovan, Thais, MD ACR Knowledge Bowl - Preliminary Round... 4 Molloy, Eamonn, MD, MS Large Vessel Vasculitis: What Should the Clinician Know... 5 Disclosure: Merck Pharmaceuticals, 5; Pfizer Inc, 5; Roche Pharmaceuticals, Molnar, Joseph, MD, PhD Care of Chronic Non-Healing Wounds Disclosure: Healogics, 5; Integra Life Sciences, 8; Kinetic Concepts Inc., 9 Monach, Paul A., MD, PhD Understanding of Approach to the Care of Patients With Vasculitis (00)... 4 Disclosure: Genentech and Biogen IDEC Inc., Understanding of Approach to the Care of Patients With Vasculitis (089)... 4 Disclosure: Genentech and Biogen IDEC Inc., Monrad, Seetha U., MD ACR/ABIM Maintenance of Certification Learning Session 0 Update in Rheumatology... 5 Rheumatology Research Foundation Special Session: Clinician Scholar Educators Morgan DeWitt, Esi, MD, MSCE Patient-reported Outcome Measures for Rheumatologists... 8 Mosser, David M., MD, PhD Macrophage Polarization... Disclosure: LeukoSight, Inc, 4 Mukkera, Srikanth, MD ACR Knowledge Bowl - Preliminary Round... 4 Murphy, Claire-Louise, MB, BCH, BAO (MRCPI). Thieves Market Posters - ACR/ARHP Poster Session C Piloting Your Research to Success: The Why, What and How of Pilot Studies Mustafa, Arshad, MD ACR Knowledge Bowl - Preliminary Round... 4

383 N Nagaraju, Kanneboyina, DVM, PhD Molecular Mechanisms of Muscle Dysfunction in Inflammatory Myopathy and Muscular Dystrophy... 4 Namas, Rajaie, MD Thieves Market Posters - ACR/ARHP Poster Session B Neogi, Tuhina, MD, PhD ACR Special Session: Career Opportunities in Rheumatology: Making a Choice Crystal Diseases: How Does Joint Damage Occur and Why do Attacks Resolve Spontaneously?. 78 Newman, Eric D., MD Quality Measures in Rheumatology: Developing and Implementing Meaningful Measures as Health Care Reform Advances Nicassio, Perry M., PhD Anxiety Disorders in Rheumatic Disease Nigrovic, Peter A., MD ACR Review Course... 7 Disclosure: Baxter Healthcare, ; Momenta Pharmaceuticals, 5; Novartis Pharmaceutical Corporation, 5 Nikolov, Nikolay P., MD Update on Safety Issues in the Treatment of Rheumatic Diseases From the FDA and Beyond... 5 Nirmala, Nanguneri R., PhD ACR Plenary Session II: Discovery Disclosure: Novartis,, Nola, Kam, PharmD, MS Pharmacist/Physician Partnership in Rheumatic Disease Management... 6 Nolan, Garry, PhD Molecular and Cellular Profiling of the Immune Response... 8 Disclosure: Nodality, Norris, Jill M., MPH, PhD ACR Clinical Research Conference: Preclinical Rheumatic Disease... 4 O O Dell, James R., MD The Great Debate: Biologics or Triple Therapy for the Treatment of Rheumatoid Arthritis? O Neil, Kathleen M., MD Juvenile Systemic Lupus Erythematosus O Rourke, Kenneth S., MD Assessment Tool Selection in Health Professions Education Care of Chronic Non-Healing Wounds... 0 Inter-professional Collaborative Practice and Education: A Review of the Field and Report of a New Center of Excellence in Musculoskeletal Care Joint Injection Techniques ()... 5 Joint Injection Techniques (7)... 4 Medical Education: The Year in Review... 4 O Shea, John J., MD ACR Basic Research Conference: Beyond Germline Genetics: New Perspectives on Rheumatic Disease Predisposition... Disclosure: Pfizer Inc, ; US Patent, 9 Janus Kinase (JAK) Inhibitors in Rheumatoid Arthritis Disclosure: Pfizer Inc, ; US Patent, 9 Oatis, Carol A., PT, PhD ARHP Clinical Focus Course: Meeting the Challenges of Measuring Outcomes in Rheumatology Clinical Practice... 0 Oddis, Chester V., MD ACR Plenary Session I: Discovery Rheumatology Roundup: Highlights from the 0 Annual Meeting... 7 Year in Review... Ogdie, Alexis, MD, MSCE Where s the Money? A Comprehensive Approach to Funding Your Research... 4 Olefsky, Jerrold M. M., MD Adipose Tissue and Inflammation... 4 Onel, Karen, MD Kawasaki Disease: Putting Out the Fire Orris, Lindsay J., DO ACR Knowledge Bowl - Preliminary Round... 4 Osterberg, Lars, MD, MPH Gout and Pseudogout: What s New in Treatments and Diagnostic Modalities? Ostergaard, Mikkel, DMSc, MD, PhD Peripheral Magnetic Resonance Imaging in Rheumatology Practice (07)... 7 Peripheral Magnetic Resonance Imaging in Rheumatology Practice (4) P Padyukov, Leonid, MD, PhD ACR Clinical Research Conference: Preclinical Rheumatic Disease... 7 Papaliodis, George, MD Current Management of Sjögren s Syndrome. 7 Inflammatory Eye Disease: An Update for Rheumatologists... Parks, Christine G., PhD ACR Clinical Research Conference: Preclinical Rheumatic Disease... 4 Pascual, M. Virginia, MD Molecular and Cellular Profiling of the Immune Response... 8 Disclosure: Novartis Pharmaceutical Corporation, 5; Pfizer Inc, Patel, Nirupa J., MD ACR Knowledge Bowl - Preliminary Round... 4 Perkins, Elizabeth, MD ACR Practice Management Pre-meeting Course... 0 Perlman, Harris R., PhD Inflammation and Atherosclerosis: Autoimmunity and Cardiovascular Disease... 5 Macrophage Polarization... Peters, Kristin, PhD Body Image With Rheumatic Conditions Petretto, Enrico, PhD Functional Genomics: Approaches to Identifying Causal Variants Petri, Michelle, MD, MPH Challenges in Systemic Lupus Erythematosus Management Disclosure: Anthera, Gaxo, Medimmune, TEVA, UCB,Pfizer, ; Anthera, UCB, Genentech,Glaxo,Medimmune, Pfizer, 5 Pillinger, Michael H., MD ACR Special Session: Career Opportunities in Rheumatology: Making a Choice ACR Basic Research Conference: Beyond Germline Genetics: New Perspectives on Rheumatic Disease Predisposition... 9 Pincus, Theodore, MD Patient Questionnaires: Multi-Dimensional Health Assessment Questionnaire/Routine Assessment of Patient Index Data and Beyond Toward a Standard, Scientific, Quantitative Patient History (40)... 4 Disclosure: BMS, Janssen, Protalex, UCB, Amgen, 7 Pisetsky, David S., MD, PhD Microparticles: Real Effectors or Just Mini- Me... 7 Pittock, Sean J., MD Pediatric Inflammatory Brain Diseases... 5 Invited Speaker /Moderator Index 0 Program Book 8

384 Invited Speaker /Moderator Index 8 Plenge, Robert M., MD, PhD ACR Basic Research Conference: Beyond Germline Genetics: New Perspectives on Rheumatic Disease Predisposition... Disclosure: Corrona, 5; Ignyta, 4 Good Reviewers Make Good Authors: A Guide to Conducting Excellent Manuscript Reviews Disclosure: Corrona, 5; Ignyta, 4 Poil, Abdul Razzakh, MD ACR Knowledge Bowl - Preliminary Round... 4 Pollock, P. Scott, MD Best Practices for Diagnostic Imaging in Evaluating Rheumatologic Conditions... 5 Poole, Janet L., OTR, PhD You Can Improve Hand Function in Scleroderma... Pope, Janet E., MD, MPH 0 ACR-EULAR Scleroderma Classification Criteria Raynaud s and Digital Ischemia (046) Raynaud s and Digital Ischemia (084)... 4 Pope, Richard, MD ACR Plenary Session III: Discovery Inflammasomes in Health and Disease Inflammation and Atherosclerosis: Autoimmunity and Cardiovascular Disease... 5 Macrophage Polarization... The Role of Th7 Cells in Health and Disease Prescott, Kara H., MD ACR Knowledge Bowl - Preliminary Round... 4 Puck, Jennifer, MD Autoimmunity Caused by Immune Deficiency: When Not Enough Is Too Much Punaro, Marilynn G., MD Updated ACR Recommendations for the Treatment of Juvenile Idiopathic Arthritis Q Quinet, Robert, MD ACR Knowledge Bowl - Preliminary Round... 4 Quinzanos, Itziar, MD ACR Knowledge Bowl - Preliminary Round Program Book R Rabinovich, C. Egla, MD, MPH ACR Pediatric Rheumatology Town Hall Meeting... Disclosure: Jannsen; Abbott, UCB, Hoffmann-La Roche Inc., Pediatric Inflammatory Brain Diseases... 5 Disclosure: Jannsen; Abbott, UCB, Hoffmann-La Roche Inc., Rabinstein, Alejandro A., MD Critical Care Rheumatology... 5 Radstake, Timothy, MD, PhD ACR Basic Research Conference: Beyond Germline Genetics: New Perspectives on Rheumatic Disease Predisposition... 9 Rantapaa-Dahlqvist, Solbritt M., MD, PhD ACR Clinical Research Conference: Preclinical Rheumatic Disease... 4 Rao, Mahendra, MD, PhD Regenerative and Stem Cell Medicine Rao, Smita, PT, PhD Inflammatory Arthropathies of the Foot and Ankle: Assessment and Non-pharmacological Foot Care Interventions... Update on Orthotic Management for Rheumatic Diseases Through the Lifespan Raychaudhuri, Soumya, MD, PhD ACR Basic Research Conference: Beyond Germline Genetics: New Perspectives on Rheumatic Disease Predisposition... 8 Functional Genomics: Approaches to Identifying Causal Variants Raza, Karim, MD, PhD ACR Clinical Research Conference: Preclinical Rheumatic Disease... 4 Reimold, Andreas M., MD Rheumatology Update: Inflammatory Bowel Disease Disclosure: Ardea, ; Janssen Pharmaceutica Product, L.P., ; Lilly, ; Novartis, ; Pfizer, ; UCB, 5 Selected Topics Related to Spondylarthropathies Disclosure: Ardea, ; Janssen Pharmaceutica Product, L.P., ; Lilly, ; Novartis, ; Pfizer, ; UCB, 5 Resman-Targoff, Beth, PharmD Pharmacist/Physician Partnership in Rheumatic Disease Management... 6 Reveille, John D., MD Reactive Arthritis: An Update (07)... 4 Reactive Arthritis: An Update (085)... 4 Richardson, Bruce C., MD, PhD ACR Basic Research Conference: Beyond Germline Genetics: New Perspectives on Rheumatic Disease Predisposition... 9 Disclosure: IGNYTA, Highlights for the 0 ARHP Annual Scientific Meeting... 5 Ridgway, William, MD Animal Models in Rheumatic Disease How Useful Are They?... Riggs, Elizabeth, PhD, MSN, BSN, RN Enhancing Clinical Practice With Patient Engagement and Self-management Support Strategies... 6 Ringold, Sarah, MD Updated ACR Recommendations for the Treatment of Juvenile Idiopathic Arthritis Ritchlin, Christopher T., MD, MPH ACR Review Course Disclosure: Amgen, Janssen, UCB, Abbott, Boerhinger Ingleheim, Lilly, 5 Robbins, Mark L., MD, MPH ARHP Clinical Focus Course: Meeting the Challenges of Measuring Outcomes in Rheumatology Clinical Practice... 9 Quality Measures in Rheumatology: Developing and Implementing Meaningful Measures as Health Care Reform Advances Rome, Keith, PhD Inflammatory Arthropathies of the Foot and Ankle: Assessment and Non-pharmacological Foot Care Interventions... Ronnblom, Lars, MD, PhD Sentinels of the Immune System: Dendritic cell and Plasmacytoid Dendritic Cells Rosen, Antony, MD Basic Immunology for Clinical Rheumatologists (05) Disclosure: Bill and Melinda Gates Foundation, 5; Inova Diagnostics, Inc., 7; Sanofi-Aventis Pharmaceutical, 5 Basic Immunology for Clinical Rheumatologists (07)... Disclosure: Bill and Melinda Gates Foundation, 5; Inova Diagnostics, Inc., 7; Sanofi-Aventis Pharmaceutical, 5 Winning at Clue: The Clinical Rheumatologist s Guide to Figuring out Who Killed Who, With What and Where in the Rheumatic Diseases.. 77 Disclosure: Bill and Melinda Gates Foundation, 5; Inova Diagnostics, Inc., 7; Sanofi-Aventis Pharmaceutical, 5 Rosenthal, Ann K., MD Calcium Crystal Arthritis (0) Gout and Pseudogout: What s New in Treatments and Diagnostic Modalities?... 88

385 Rosove, Michael H., MD Update on Thrombotic Microangiopathies... 6 Roth, Johannes, MD ACR Musculoskeletal Ultrasound Course for Rheumatologists... Roubey, Robert, MD ACR Review Course... 8 Disclosure: Alexion Pharmaceuticals, Inc., 5 Rouster-Stevens, Kelly A., MD, MSc Pediatric Systemic Lupus Erythematosus (004). Rovin, Brad H., MD Systemic Lupus Erythematosus: Lupus Nephritis (09)... 4 Disclosure: Biogen Idec, 5; celtic, 9; lilly, 9; ONyx, 5; Questcor, ; Teva Pharmaceuticals, Systemic Lupus Erythematosus: Lupus Nephritis (079)... Disclosure: Biogen Idec, 5; celtic, 9; lilly, 9; ONyx, 5; Questcor, ; Teva Pharmaceuticals, Samuels, Jonathan, MD ACR Musculoskeletal Ultrasound Course for Rheumatologists... 5 Sandborg, Christy I., MD Rheumatology Research Foundation Memorial Lecture: Pediatric Rheumatology - Where We ve Been, Where We re Going... 6 Sandell, Linda, PhD OA-OMICS... 5 Schanberg, Laura E., MD ACR Pediatric Rheumatology Town Hall Meeting... Disclosure: Amgen, 9; BMS, 9; Lilly, 5; Novartis Pharmaceutical Corporation, 9; Pfizer Inc, 9; SOBI, 9; UCB, 5 Scher, Jose U., MD ACR Clinical Research Conference: Preclinical Rheumatic Disease... 6 Seibold, James R., MD Pulmonary Hypertension in the Rheumatic Diseases (057) Disclosure: Actelion Pharmaceuticals US, ; Aires, 5; Bayer, 5; Eiccose, 5; Eiger, 5; United Therapeutics,, 8 Sequeira, Winston, MD ACR Knowledge Bowl - Preliminary Round... 4 Shakoory, Bita, MD ACR Knowledge Bowl - Preliminary Round... 4 Sharma, Leena, MD Osteoarthritis Pathophysiology, Diagnosis and Management: What Can I Tell my Osteoarthritis Patient to Do Other Than Weight Loss and Quadriceps Strengthening? Sharma, Manisha, MBBS, MD Thieves Market Posters - ACR/ARHP Poster Session B Invited Speaker /Moderator Index Russell, Linda, MD Osteoporosis: Novel Treatments (065)... 0 S Saag, Kenneth G., MD, MSc Challenging Cases in Osteoporosis Management (04) Disclosure: Amgen,, 5; Eli Lilly and Company,, 5; Merck Pharmaceuticals,, 5 Safran, Dana G., ScD Physician Profiling- It s Going to Cost You! Saggar, Rajeev, MD Vascular Disease in Scleroderma: A Multi-Organ Challenge Sah, Robert L., MD, ScD Mechanics, Matrix Disruption, and the Development of Osteoarthritis Disclosure: GlaxoSmithKline, ; Johnson and Johnson, ; Medtronic, Salmon, Jane E., MD ACR Plenary Session I: Discovery Disclosure: Alexion Pharmaceuticals, Inc., Novartis, 5; Roche Pharmaceuticals, Salt, Elizabeth G., PhD An Overview of Qualitative Research Disclosure: I review grants for the Pfizer medical education group, 5; I have a grant with the ACR, ; Smithkline, Designing a Qualitative Study and An Example of the Use of Qualitative Study Design in Patients With Rheumatologic Disease Disclosure: I review grants for the Pfizer medical education group, 5; I have a grant with the ACR, ; Smithkline, Sammaritano, Lisa R., MD Rheumatic Diseases in Women of Childbearing Years: Fertility, Pregnancy and Lactation Schmajuk, Gabriela, MD, MS Rheumatology Research Foundation Special Session: Disease Targeted Research... 0 Schmidt, Thomas W., MD Thieves Market Posters - ACR/ARHP Poster Session B Schneider, Rayfel, MD Updated ACR Recommendations for the Treatment of Juvenile Idiopathic Arthritis Disclosure: Hoffmann-La Roche, Inc., 5; Innomar Strategies, 5; Novartis Pharmaceutical Corporation, 5 Schwab, Pascale, MD ACR Knowledge Bowl - Preliminary Round... 4 Schwartzman, Sergio, MD Inflammatory Eye Disease/Uveitis (06) Disclosure: Abbvie, Pfizer, Janssen, UCB, Genentech, 8; Abbvie, Pfizer, Janssen, UCB, Genentech, Hospira, Crecendo, 5 Inflammatory Eye Disease: An Update for Rheumatologists... Disclosure: Abbvie, Pfizer, Janssen, UCB, Genentech, 8; Abbvie, Pfizer, Janssen, UCB, Genentech, Hospira, Crecendo, 5 Schweitz, Michael, MD Rheumatology Practice in the Age of the Affordable Care Act Schwimmer, Jeffrey B, MD Nonalcoholic Fatty Liver Disease Sedghizadeh, Parish P., DDS, MS Oral Health in Rheumatologic Disease Sherry, David D., MD Rheumatology Research Foundation Special Session: Clinician Scholar Educators Sibley, Cailin H., MD Behçet s Disease Siegfried, Elaine, MD Pediatric Autoimmune and Inflammatory Skin Disease Disclosure: Amgen, ; Pierre Fabre, ; Valeant, 5 Sieper, Joachim, MD Ankylosing Spondylitis: Disease Modification (05) Disclosure: Abbott Immunology Pharmaceuticals, Merck, Pfizer, Janssen, ; Abbott Immunology Pharmaceuticals, Merck, Pfizer, UCB, 8; Abbott Immunology Pharmaceuticals, Merck, Pfizer, UCB, Lilly, Rche, Sanofi,Novartis, 5 Selected Topics Related to Spondylarthropathies Disclosure: Abbott Immunology Pharmaceuticals, Merck, Pfizer, Janssen, ; Abbott Immunology Pharmaceuticals, Merck, Pfizer, UCB, 8; Abbott Immunology Pharmaceuticals, Merck, Pfizer, UCB, Lilly, Rche, Sanofi,Novartis, 5 Sigal, Leonard H., MD Telomeres, Telomerase and Age-Related Disease... 4 Silver, Richard M., MD ACR Review Course... 7 Disclosure: Actelion Pharmaceuticals US, 9; Genentech and Biogen IDEC Inc., 8 Silverman, Gregg J., MD ACR Basic Research Conference: Beyond Germline Genetics: New Perspectives on Rheumatic Disease Predisposition... 8 Disclosure: Pfizer, Medimmune Genentech, Roche, Merck Serano, 5 0 Program Book 8

386 Invited Speaker /Moderator Index 84 Emerging and Unexpected Regulatory Roles for Complement in the Rheumatic Diseases... 7 Disclosure: Pfizer, Medimmune Genentech, Roche, Merck Serano, 5 Glycoregulation of Autoimmunity... 7 Disclosure: Pfizer, Medimmune Genentech, Roche, Merck Serano, 5 New Therapies for Modulating Cell Signaling in Rheumatoid Arthritis...44 Disclosure: Pfizer, Medimmune Genentech, Roche, Merck Serano, 5 Sentinels of the Immune System: Dendritic cell and Plasmacytoid Dendritic Cells Disclosure: Pfizer, Medimmune Genentech, Roche, Merck Serano, 5 Tyro/Axl/Mer (TAM) Receptors and Innate Immune Regulation Disclosure: Pfizer, Medimmune Genentech, Roche, Merck Serano, 5 Silverman, Stuart, MD Oral Health in Rheumatologic Disease Disclosure: Amgen, Genetech, Lilly, Novartis, Pfizer/Wyeth, 5; Amgen, Lilly, Medtronics and Pfizer/Wyeth, ; Amgen, Lilly, Pfizer/Wyeth, 8; Cedars-Sinai Medical Center, Osteoporosis: Interpreting Dual Energy X-ray Absorptiometry and Clinical Risk Factors: The New Fracture Risk Assessment Algorithm ()... 4 Disclosure: Amgen, Genetech, Lilly, Novartis, Pfizer/Wyeth, 5; Amgen, Lilly, Medtronics and Pfizer/Wyeth, ; Amgen, Lilly, Pfizer/Wyeth, 8; Cedars-Sinai Medical Center, Osteoporosis: Interpreting Dual Energy X-ray Absorptiometry and Clinical Risk Factors: The New Fracture Risk Assessment Algorithm (8)... 4 Disclosure: Amgen, Genetech, Lilly, Novartis, Pfizer/Wyeth, 5; Amgen, Lilly, Medtronics and Pfizer/Wyeth, ; Amgen, Lilly, Pfizer/Wyeth, 8; Cedars-Sinai Medical Center, Simon, Lee S., MD Rheumatoid Arthritis: Safety of Novel Therapies (048) Disclosure: Savient Pharma, ; Affinergy, Astrazeneca, Abraxxis, Alpha Rx, NuvoResearch, Roche, Pfizer, Novartis, PLx Pharma, Hisamatsu, Dr Reddys, Avanir, Cerimon, Leerink Swann, Alimera, Nomura, Luxor, Paraexel, Nitec, Bayer, Rigel, Chelsea, Regeneron, Cypress, Savient, Nicox, Fidel, 5 Rheumatoid Arthritis: Safety of Novel Therapies (067)... 0 Disclosure: Savient Pharma, ; Affinergy, Astrazeneca, Abraxxis, Alpha Rx, NuvoResearch, Roche, Pfizer, Novartis, PLx Pharma, Hisamatsu, Dr Reddys, Avanir, Cerimon, Leerink Swann, Alimera, Nomura, Luxor, Paraexel, Nitec, Bayer, Rigel, Chelsea, Regeneron, Cypress, Savient, Nicox, Fidel, 5 Singh, Hitasha, MD ACR Knowledge Bowl - Preliminary Round... 4 Singh, Jasvinder, MD Gout and Pseudogout: What s New in Treatments and Diagnostic Modalities? Disclosure: Savient, Takeda, Ardea, Regeneron, Allergan, URL pharmaceuticals and Novartis., 5; Takeda, Savient, Osteoarthritis Pathophysiology, Diagnosis and Management: What Can I Tell my Osteoarthritis Patient to Do Other Than Weight Loss and 0 Program Book Quadriceps Strengthening?... 4 Disclosure: Savient, Takeda, Ardea, Regeneron, Allergan, URL pharmaceuticals and Novartis., 5; Takeda, Savient, Vaccinology and DMARD Use in Immunocompromised and High-Risk Populations... 5 Disclosure: Savient, Takeda, Ardea, Regeneron, Allergan, URL pharmaceuticals and Novartis., 5; Takeda, Savient, Singh, Namrata, MD ACR Knowledge Bowl - Preliminary Round... 4 Singh, Ram Raj, MD Sex and Autoimmunity: Hormones and Beyond Siverling, Scott, PT, OCS Postural Changes: How to Improve Joint Protection, Strength and Gain Efficiency... 6 Slusher, Barbara A., PA-C, MSW Fine Tuning Your Skills in Utilizing Disease Activity Measurement Tools for Rheumatic Arthritis... 6 Best Practices for Diagnostic Imaging in Evaluating Rheumatologic Conditions... 5 Smith, Benjamin J, PA-C ARHP First-time Attendee Orientation... Smith, Kimberly C., BS, MD Thieves Market Posters - ACR/ARHP Poster Session B Smith, Melvin. PhD ACR Practice Management Pre-meeting Course... 0 Smolen, Josef S., MD Rheumatoid Arthritis: Biological Agents (06). 6 Disclosure: AbbVie, Astra-Zeneca, BMS, Celgene, Glaxo, Janssen, MSD, Medimmune, Novartis- Sandoz, Pfizer, Roche, UCB, 5; AbbVie, BMS, Celgene, Janssen, MSD, Medimmune, Novartis- Sandoz, Pfizer, Roche, UCB, 9; AbVie, BMS, MSD, Pfizer, Roche, UCB, ; Mosby-Elsevier, BMJ, 7 Solomon, Daniel, MD, MPH Rheumatology Practice in the Age of the Affordable Care Act Update on Safety Issues in the Treatment of Rheumatic Diseases From the FDA and Beyond... 5 Specks, Ulrich, MD Curbside Consults - Ask the Experts Spiera, Robert F., MD Temporal Arteritis (059) Disclosure: Roche Pharmaceuticals, g, Temporal Arteritis (070)... 0 Disclosure: Roche Pharmaceuticals, g, St. Clair, E. William, MD Current Management of Sjögren s Syndrome. 7 Disclosure: Biogen Idec, 9; Up-to-Date, 7 Stamatos, Christine A., ANP-C Immunology Boot Camp Session : The Basics of Targeted Therapies... 7 Immunology Boot Camp Session : The Basics of Autoimmunity and Immunodeficiency - When Good Cells Go Bad Persistent Pain: Mechanisms of Chronic Pain and Innovative Treatment Options Stamatoyannopoulos, John, MD Non-coding DNA: Signals, Switches, and Complex Regulation of Genes Steen, Virginia D., MD ACR Review Course... 7 Steere, Allen C., MD Rheumatology Research Foundation Special Session: Disease Targeted Research... 0 Stehlik, Christian, PhD Inflammasomes in Health and Disease Stein, Brady L., MD Challenges in Systemic Lupus Erythematosus Management ACR Basic Research Conference: Beyond Germline Genetics: New Perspectives on Rheumatic Disease Predisposition... Stinson, Jennifer N., PhD, RN, CPNP ARHP Clinical Focus Course: Meeting the Challenges of Measuring Outcomes in Rheumatology Clinical Practice... 0 Stojan, George, MD Challenges in Systemic Lupus Erythematosus Management Critical Care Rheumatology... 5 Update on Thrombotic Microangiopathies... 6 Stone, John, MD, MPH ACR Plenary Session III: Discovery Vasculitis Mimics (09) Disclosure: Genentech and Biogen IDEC Inc.,, 5; Roche Pharmaceuticals, Straub, Rainer H., MD Hench Lecture: Evolutionary Medicine and Chronic Inflammatory State - Known and New Concepts in Pathophysiology... Suarez-Almazor, Maria E., MD, PhD ARHP Clinical Focus Course: Meeting the Challenges of Measuring Outcomes in Rheumatology Clinical Practice... 0 Sullivan, Kate, MD, PhD Autoimmunity Caused by Immune Deficiency: When Not Enough Is Too Much Disclosure: Immune Deficiency Foundation, 5; Springer Publisher,

387 Sundel, Robert P., MD Kawasaki Disease: Putting Out the Fire Syed, Nilofar, MD Thieves Market: Show Me Your Best Cases T Tabas, Ira, MD, PhD Inflammation and Atherosclerosis: Autoimmunity and Cardiovascular Disease... 5 Disclosure: Merck Pharmaceuticals, 5; National Institutes of Health, Tabechian, Darren, MD ACR Musculoskeletal Ultrasound Course for Rheumatologists... 6 Terkeltaub, Robert, MD Crystal Diseases: How Does Joint Damage Occur and Why do Attacks Resolve Spontaneously? Disclosure: Novartis, Pfizer, Regeneron, Takeda, BioCryst, Ardea, Metabolex, UBC, 5 Thanarajasingam, Uma, MD, PhD Thieves Market: Show Me Your Best Cases Theis, Kristina A., MPH Work, Health and Well-being: Arthritis and Employment Across the Life Course Thomas, Ranjeny, MBBS, MD ACR Clinical Research Conference: Preclinical Rheumatic Disease... 7 Disclosure: Dendright Pty Ltd, 4 Thompson, Paul Ryan, PhD Protein Citrullination and Biological Response Modification: Rheumatoid Arthritis and Beyond Tidball, James, PhD Molecular Mechanisms of Muscle Dysfunction in Inflammatory Myopathy and Muscular Dystrophy... 4 Tillman, Melesia, CPC, CPC-I, CRHC, CHA ACR Certified Rheumatology Coder Course: The Anatomy of Rheumatology Coding... ACR Practice Management Pre-meeting Course... 0 Ting, Jenny, PhD Inflammasomes in Health and Disease Toder, Kiley Dru, MD Thieves Market: Show Me Your Best Cases Torgerson, Troy R., MD, PhD Autoimmunity Caused by Immune Deficiency: When Not Enough Is Too Much Immunodeficiency Syndromes (04) Immunology Boot Camp Session : The Basics of Targeted Therapies... 7 Immunology Boot Camp Session : The Basics of Autoimmunity and Immunodeficiency - When Good Cells Go Bad Trizuto, Jennifer L., MPT Rheumatology Update: Inflammatory Bowel Disease Tyndall, Alan G., MD Regenerative and Stem Cell Medicine U Uknis, Audrey B., MD ACR Business Meeting... 4 ACR Plenary Session I: Discovery International League of Associations for Rheumatology (ILAR) Pediatric Rheumatology in Developing Countries... 5 ACR/ARHP Opening Lecture and Awards... Utrie, Paul C., MD Musculoskeletal Exam Skills I: General Musculoskeletal Examination for Arthritis ()... 5 Musculoskeletal Exam Skills II: Regional Musculoskeletal Examination of the Neck and Low Back ()... 7 Musculoskeletal Exam Skills III: Regional Musculoskeletal Examination of the Shoulder and Knee (7) V Valen, Peter A., MD Influence of Cardiac Comorbidities on Exercise in Individuals With Rheumatic Diseases... 5 Valeri, Linda, PhD Mediation Analysis: Theory and Method for Causal Inference... 8 van den Hoogen, Frank H.J., MD, PhD 0 ACR-EULAR Scleroderma Classification Criteria van Eijk-Hustings, Yvonne JL, MSc, RN Defining the Roles of the Rheumatology Nurse Internationally... Van Mater, Heather, MD, MSc Pediatric Inflammatory Brain Diseases... 5 van Schaardenburg, Dirkjan, MD, PhD ACR Clinical Research Conference: Preclinical Rheumatic Disease... 7 Disclosure: Patent, 4 van Spil, Erwin (W.E.), MD Osteoarthritis Pathophysiology, Diagnosis and Management: What Can I Tell my Osteoarthritis Patient to Do Other Than Weight Loss and Quadriceps Strengthening? van Vollenhoven, Ronald, MD, PhD The Great Debate: Biologics or Triple Therapy for the Treatment of Rheumatoid Arthritis? Disclosure: AbbVie, BMS, GSK, MSD, Pfizer, Roche, UCB,, 5 Varga, John, MD ACR Plenary Session III: Discovery Adipose Tissue and Inflammation... 4 Personalized Medicine: Transforming 00 Billion Points of Data Into Diagnostics, Therapeutics, and New Insights Into Disease... 7 Venables, Patrick, MD Protein Citrullination and Biological Response Modification: Rheumatoid Arthritis and Beyond Venter, J. Craig, PhD ACR/ARHP Opening Lecture and Awards... Villasenor Ovies, Pablo, MD Clinical Anatomy and Physical Exam: Essential Tools in Lower Extremity Regional Pain Syndromes (0)... 4 Clinical Anatomy and Physical Exam: Essential Tools in Upper Extremity Regional Pain Syndromes (6) Vleugels, Ruth Ann, MD, MPH Cutaneous Vasculitis (0)... 4 Dermatological Manifestations of Rheumatic Diseases (00)... Dermatological Manifestations of Rheumatic Diseases (04) Von Feldt, Joan Marie, MD, MSEd How to Maintain Your Medical License and Certification After 0: Changes Will Impact All Physicians. Are You Prepared? Disclosure: American Board of Internal Medicine, 6 W Wallace, Daniel, MD Oral Health in Rheumatologic Disease ACR Review Course... 8 Invited Speaker /Moderator Index 0 Program Book 85

388 Invited Speaker /Moderator Index 86 Ward, Michael M., MD Mitigating Health Disparities in Rheumatologic Disease Warren, Robert, MD, PhD, MPH Patient Engagement/Privacy and Security... Policy Changes That Will Affect Your Practice in 04: Meaningful Use, Value-based Purchasing, PQRS, and ICD Warrington, Kenneth J., MD Large Vessel Vasculitis: What Should the Clinician Know... 5 Wasko, Mary Chester M., MD, MSc Rheumatic Disease Update: Rheumatoid Arthritis... 7 Disclosure: Astra-Zeneca, 9 Weisman, Michael H., MD Ankylosing Spondylitis: 0 Update (0)... 6 Disclosure: Cedars-Sinai, ; NIH, Ankylosing Spondylitis: 0 Update (06).. 0 Disclosure: ACR, ; ACR/EULAR, ; Cedars-Sinai Medical Center, ; FDA, ; NIH, ; Rigel, ; SanofiAventis, Weiss, Pamela F., MD, MSCE Updated ACR Recommendations for the Treatment of Juvenile Idiopathic Arthritis Wells, Alvin F., MD, PhD ACR Musculoskeletal Ultrasound Course for Rheumatologists... 6 Weyand, Cornelia M., MD, PhD ACR Plenary Session II: Discovery Novel Insight into the Pathogenesis of Systemic Vasculitis... 4 White, Daniel K., PT, ScD, MSc Knowledge Is Power, But Sample Size Matters More: The Role of Sample Size in the Power and Precision of Study Results Audits - Are You At Risk? White, Douglas, MD CORC FORUM: Disaster Planning: How to Prepare for a Catastrophe and Minimize your Liability. 5 Wilkes, Margaret R., MD Inflammatory Eye Disease: An Update for Rheumatologists... Osteoporosis Treatment Strategies for Today and Tomorrow... 5 Wilkie, Ross, BSc, PhD Work, Health and Well-being: Arthritis and Employment Across the Life Course Program Book Willard, Huntington F., PhD ACR Basic Research Conference: Beyond Germline Genetics: New Perspectives on Rheumatic Disease Predisposition... Williams, David A., PhD Anxiety Disorders in Rheumatic Disease Disclosure: Forest Laboratories, 5; Pfizer Inc, ARHP Clinical Focus Course: Meeting the Challenges of Measuring Outcomes in Rheumatology Clinical Practice... 0 Disclosure: Forest Laboratories, 5; Pfizer Inc, Winchester, Robert, MD Rheumatology Research Foundation Paul Klemperer, MD, Memorial Lectureship: Rheumatoid Arthritis and Autoimmunity: Good Genes, Elegant Mechanisms, Bad Results... 7 Winthrop, Kevin L., MD, MPH Vaccinology and DMARD Use in Immunocompromised and High-Risk Populations... 5 Disclosure: Genentech and Biogen IDEC Inc., 5; Pfizer Inc,, 5; UCB, 5 Wiseman, Michael, MD Update on Safety Issues in the Treatment of Rheumatic Diseases From the FDA and Beyond... 5 Disclosure: Amgen, Biogen, Cephalon, Centocor, Dynavax, Eli Lilly, Genentech, Human Genome Sciences, Pfizer, Rigel, Sanofi-Aventis, Teva, and UCB, 9; Astellas Pharma Global Development, Crescendo Bioscience, Inc., Abbvie, and UCB Pharma, 5, 9 Witter, James P., MD, PhD Patient-reported Outcome Measures for Rheumatologists... 8 Wofsy, David, MD Year in Review... Worthing, Angus, MD PCMH-Model and the Rheumatology Specialty Wortmann, Robert L., MD Adult Inflammatory Myopathy (0)... 4 Disclosure: Questcor, 5 Adult Inflammatory Myopathy (07)... 0 Disclosure: Questcor, 5 Rheumatic Disease Update: Myositis, An Overview and Differentiation from Metabolic Myopathies... 6 Disclosure: Questcor, 5 Wright, Laura, MBA Navigating the System: The Key to Obtaining Medications for Your Patients... 7 Wu, Ava, DDS Current Management of Sjögren s Syndrome. 7 Wu, Kim M., DD Thieves Market Posters - ACR/ARHP Poster Session B Wynn, Thomas, PhD Macrophage Polarization... Y Yamamoto, Deanna S., NP Defining the Roles of the Rheumatology Nurse Internationally... Yazdany, Jinoos, MD, MPH ARHP Clinical Focus Course: Meeting the Challenges of Measuring Outcomes in Rheumatology Clinical Practice... 0 Quality Measures in Rheumatology: Developing and Implementing Meaningful Measures as Health Care Reform Advances... 5 Why Every U.S. Rheumatologist Should Join the National Rheumatology Registry (RISE)... 4 Yazici, Yusuf, MD Behçet s Disease (0)... 4 Disclosure: BMS, Genentech, 5; Celgene, BMS, Genentech, Behçet s Disease (07)... Disclosure: BMS, Genentech, 5; Celgene, BMS, Genentech, Yee Jr., Hal, MD, PhD PCMH-Model and the Rheumatology Specialty Yelin, Edward H., PhD Work, Health and Well-being: Arthritis and Employment Across the Life Course Young, Kelly, BA Enhancing Clinical Practice With Patient Engagement and Self-management Support Strategies... 6 Z Zerr, Pawel, MSc ACR Plenary Session II: Discovery Zhang, Yuqing, DSc, MPH Mediation Analysis: Theory and Method for Causal Inference... 8 The Age of Information Technology: Registries, Administrative Databases, and the Role of the Internet in Rheumatic Disease Research... 6 Zhao, X. Frank, MD Clinicopathologic Conference: A Patient With Rheumatoid Arthritis and Systemic Disease Zupko, Karen, BS Audits - Are You At Risk? Disclosure: Karen Zupko and Associates, 5

389 A Achenbach, SJ 0 Ahmed, G 488, 467 Al Sawah, S 69 A. Rahman, R 9 Aalto, K 95 Aaron, L 00 Aarrass, S 65, 8 Aassi, M 47 Aati, O, 5 Abad, J 47 Abad, S 78 Abásolo, L 67, 86 Abawi, O 4 Abaza, N 9, 594 Abbas, A 888 Abbas, Z Abbey, S 8 Abbott, T 9 Abdoel, N 75 Abdollahi-Roodsaz, S 74, 740 Abdulahad, WH 645, 665 Abdulahad, W 5, 78, 88 Abdullah, H 495 Abdullah, M 5 Abe, T 840, 84 Abeles, AM 8 Abeles, M 8 Aberkane, O 469 Abetz, L 68 Abignano, G 604, 709 Abisror, N 686 Abji, F 894, 50 Ablin, JN 8, 88, 89, 094, 098 Abo-Shady, RA 9 Abolhosn, RW 90 AbouZahr, Z 807 Abraha, S 54 Abraham, DJ 7, 56, 90 Abraham, LJ 70 Abraham, S 9 Abrahamowicz, M 05, 758, 89 Abram, F 45, 669 Abramova, N 7 Abrams, K 69, 70, 7, 69, 78, 09, 748 Abrams, S 0 Abramson, E 6 Abramson, SB 58, 887 Abreu, AS 474 Abreu, G 454 Abreu, MM 6 Abril, A 66 Abtin, F 68 Abtroun, L 09 Abufarag, A 4 Abujam, B 605 Abujudeh, HH 904 Abulaban, K 590 Acevedo, E 69 Achilleos, K 98, 667 Ackerman, M 69 Acosta, I 48 Acosta Felquer, ML 06 ACR-EULAR Myositis Response Criteria Project Group, FT 98 Adachi, JD 864, 4 Adachi, M 9 Adam, P 78 Adam, PM 984, 708 Adam-Marchand, S 78 Adami, S 50, 004 Adams, AB 504 Adams, BS 0 Adams, EH, 7 Adams, N 0 Adan, AM 750, 0, 65 Addimanda, O 8 Addya, S 560 Adebajo, AO 0, 7,, 48, 86 Adeleke, GA 874 Adey-Wakeling, Z 090 Adizie, T 98 Adler, RA 47 Adrianto, I 509, 489, 565, 65, 770, 77 Aegerter, P 79 af Klint, E 96, 970 Agard, C 69 Agarwal, M 59 Agarwal, SK 567, 57 Agarwal, S 59 Agarwal, V 605, 0 Ager, J 85 Aggarwal, A 59, 605, 0, 89 Aggarwal, R 776, 98, 057, 06, 06, 08 Aghdassi, E 6 Agildere, M 58 Agmon-Levin, N, 57 Agnew-Blais, J Agodoa, I 47 Agostinis, C 566 Agrawal, H 574 Agrawal, N 544, 70 Aguado, P 647 Agudo, M 469 Aguilar Arreola, J 40 Aguirre, MA 887 Aguirre de Cárcer, D 695 Aguirre Zamorano, Ahearn, JM 55 Ahern, T Ahlberg, J 40 Ahlquist, P 80 Ahlqvist, P 875, 40, 687 Ahluwalia, V 9, 5, 5 Ahmad, Y 4, 4 Ahmed, I Ahmed, M 0 Ahmed, TA 0 Ahn, GE 0 Ahn, JK 6, 6, 90 Ahn, KJ 450, 0, 0, 445 Ahn, SM 400 Aiello, P 06 Aigner, S 4 Aikawa, NE 87, 904, 75, 67, 675 Aiona, K 87, 74 Aitken, D 5, 8, 9, 55, 755 Aizer, J 980, 8 Ajmone Marsan, N 688 Akagi, R 895 Akahira, L 4, 89 Akahoshi, M 5, 94 Akaike, H 7, 75, 08 Akamata, K 84, 706, 707 Akar, S 5,, 5, 5, 544, 48, 444, 465, 47, 749 Akarirmak, U 0 Akasaki, Y 59, 64 Akashi, K 5, 94 Akat, K 444 Akcan Hannan, E 08 Akdemir, G 799, 46, 460 Akdogan, A 6 Akgul, O 47 Akgun, K 5 Akhavan, P 9, 06, 787, 79, 97, 45, 5, 9, 96 Akhras, K 00, 009 Akhtar, N 767 Akikusa, J 80 Akilesh, S 795 Akilli, H 0 Akiya, K 4 Akiyama, Y 45, 570, 99 Akkineni, R 99 Akkoc, N 5, 5, 544, 48, 465, 47 Akkoc, Y 44 Akkurt, E 5 Akpinar, IN 64 Akram, A 5 Aksentijevich, I 894, 78, 7, 864 Aksu, K 749 Aktas, T 684 Akter, T 907 Akulova, S 70 Al Daabil, M 699 AL Emadi, S 58 AL Ghanim, N 548 Al Maimouni, H 579 AL Osaimi, N 708 Al Snih, S 074 Al-Hefny, AAM 594 Al-Mossawi, H 655 Alade, R 667 Alahmadi, A 599 Alarcon, GS 606, 60, 588, 59 Alarcon Riquelme, ME 69 Alarcon-Riquelme, ME 6, 65 Alasti, F 85, 05 Alba, P 5 Albanese, C 46 Albayrak, I 5 Alberici, F 696, 789 Albert, DA 90, 99 Albesa, R 8, 0, 654 Albiero, E 5 Albrecht, I 64, 648 Albrecht, K 64 Albuquerque, E 470 Alcaraz, MJ 84 Alcocer-Varela, J 579, 580, 66 Alcorn, D 0 Aldag, JC 98 Aldaghlawi, F 9 Aldasoro Cáceres, V 08 Alekna, V Alekseev, V Alekseeva, E 9, 79 Alekseeva, L Alemao, E 0, 04, 04, 8 Alemao, E 07 Alemo Munters, L 779 Alenius, GM 9, 46 Alessandri, E 654, 58 Alessio, M 7 Aletaha, D 85, 05, 950, 86 Aleton, E 4 Alevizos, I 490, 49, 498 Alexander, C 68 Alexander, K 45 Alexander, MY 64, 94 Alexanderson, H 779, 096 Alexeeva, E 64, 70 Alexiades, M 506, 5, 8, 0, Alfaiate, T 88, 69 Alfaro-Lozano, JL 40, 68, 5 Alfonso Ross Terres, J 064 Alfredsson, L, 4, 7, 80, 07, 46, 875, 077, 97, 40, 405, 4, 656 Algergawy, S 79 Alhajeri, H 80 Alheresh, R 845, 846 Ali, Z 4 Alibaz-Oner, F 68, 68, 96, 64, 69, 60 Aliferis, CF 887 Aliprantis, AO 7 abstract author Index 0 Program Book 87

390 Alivernini, S 94 Ambudkar, I 498 Angerer, P 009, 00 Ardalan, K 76 abstract author Index Alkady, E 646 Allaart, CF 09, 799, 46, 47, 48, 460, 79 Allaart, CF 9, 94 Allaire, N 0, 88, 74, 877, 58 Allaire, SH 845, 846 Allanore, Y 60 Allegri, F 9 Allen, KD 897, 075, 855 Allenbach, Y 07 Allison, D 0 Allison, D 70 Allison, J 5, 6, 7, 70 Almaden, Y 887 Almagor, O 0, 75 Almdahl, SM 7, 88, 405 Almeida, GJ 84, 86 Almeida de Jesus, A 78, 90, 864 Almodovar, R 750, 65 Almodóvar González, R 908 Alonso, A 644 Alonso, A 48 Aloush, V 8, 098 Alpay, N 680 Alpay Kanitez, N 09, 45 Alraqi, S 946 Alsaleh, G 488 Alshaar, O 79 Alsina, M 500 Alsuwaidi, M 969, 59 Altavilla, D 66 Altawil, R 80 Alten, R 454, 465 Alten, RE 9 Alten, R 459, 55, 65, 97 Althoff, C 56, 55, 88 Altman, RD 095, 046, 047, 9 Altoe, R 5, 54 Altorok, NI 584, 77 Altpeter, M 09 Alvarellos, T 60 Alvarez, L 64 Álvarez, L 6 Alvarez-Garcia, O 58 Alvarez-Nemegyei, J 960 Alvaro-Gracia, J 644 Alvaro-Gracia, JM 48 Alves, C 87 Alzabin, S Amano, K 40, 764 Amano, K 67 Amano, K 40 Amante, E 45 Amarilyo, G 65, 69 Amaya-Amaya, J 0 Ambarus, CA 450 Amengual, O 7, 68 Amento, EP Ameri, S 4 Amezcua-Guerra, LM 57 Amigo, E 8, 8 Amin, MA 658, 774, 777, 97 Amin, S 0, 85 Amiri, N 67 Amital, H 446 Amital, H 88, 89, 47, 89 Amitrano, C 5 Amity, CL 8, 0, 4 Ammitzbøll, CG 6, 875, 40, 687, 80 Ammosova, T 89 Amoruso, M 77 Amoura, Z 6, 85, 067, 564, 609, 00, 09, 84 An, J 70, 70 Anaya, JM 50, 57, 6, 489, 0, 770, 77 Ancuta, I 48, 49, 448, 496, 500 Andersen, JK 7, 88 Andersen, KK 875 Andersen, LS 7 Andersen, M 478 Andersen, M 805 Andersen, V 47 Anderson, A 48 Anderson, AE 70 Anderson, C 80 Anderson, C 708 Anderson, D 6 Anderson, DW 59 Anderson, JK 79, 540, 80, 49 Anderson, J 65 Anderson, JR 65 Anderson, N 508, 5 Anderson, S 88 Anderson, S 8 Andersson, K 90, 76 Andersson, ML 599 Andrade, F 47, 685 Andrade, LEC 6, 64 Andrade, N 948 Andrade, PC 84 Andrade Garduño, J 40 Andreev, S 8 Andreoli, L 9, 67, 65 Andres Cerezo, L 957, 569 Andrés-Bergós, J 57, 60 Andreu, JL 47 Andrew, M 74 Andrews, J 9 Andrews, J 766 Andrews, JS 58 Andrigueti, FV 8 Angele, P 78 Angermann, C 78 Angiolilli, C 7 Angiolilli, C 86 Angoue, O 44 Anikster, Y 64 Anink, J 84 Anis, AH 97, 997, 0 Annapureddy, N 88, 75 Annunziata, K 057, 988 Anolik, JH 54, 66, 890 Anouk, M 8, 5 Ansari, AA 400 Antheaume, J 466, 467 Anthony, B 4 Anthony, DD 95, 64 Antivalle, M, 46 Antoch, PDG 954, 955, 956 Anton, A, 480, 488 Anton, J 7, 66, 78, 98 Antoni, C 9 Anuruckparadorn, K 8 Anyanwu, CO 860, 95 Aoki, A 06 Aoki, I 945, 96, 074 Aoki, S 048 Aouba, A 750 Aouba, A 66 Aouhab, Z 60 Aoyagi, K 0, 960 Aozasa, N 59 Aparicio, A 750, 0, 65 Aparicio, M 40 Aparicio-Vera, L 579, 66 Apas Perez de Nucci, PA 60 Apkarian, AV Apostolidis, SA 74 Apparailly, F 4 Appel, H 6, 499 Appenzeller, S 58, 59, 60, 65, 0 Apras Bilgen, S 6 APS Action, OBO 65 Aquino-Beaton, C 984, 994, 996, 997, 005 Arad, U 5, 484 Aradi, B 480, 40 Arakaki, J Sr. 09 Araki, Y 80, 570, 99 Aral, O 45 Arami, S 5 Aranow, C 59, 609, 765, 900 Aras, S 0 Araujo, DB 55, 65 Araujo, E 405, 485 Arbab, AS 97 Arbeit, R 7 Arcasoy, M 977 Arce-Franco, MT 96 Arden, NK 05, 895,, 507 Ardizzone, M 469 Ardjomand-Hessabi, M 54, 446 Ardoin, SP 79 Arends, S 5 Arends, S 58, 449, 456 Arendse, R 9, 50, 5, 87 Arendt-Nielsen, L 50, 8, 79 Argiriadi, M 74 Arias, M 64 Arias-Urdaneta, L 745 Aribas, A 0 Arida, A 74, 767 Arietti, L 67 Arima, K 69, 6, 960 Arimura, Y 749 Aringer, M 806, 97 Arinobu, Y 5, 94 Arinuma, Y 79, 59, 600, 585 Arismendi, MI 8, 595 Arito, M 49, 905 Ariza, R 687 Ariza, Y 84 Arkachaisri, T 74 Arkema, EV 060, 697, 657 Arkfeld, D 09 Ärlestig, L 97, 875 Arlet, JB 78 Arlott, J 5 Armas-Gonzalez, E 96 Armbruster, C 75 Armesto, S 64 Armitage, C 696 Armstrong, R 800 Arnaud, L 6, 067, 564, 00 Arndt, C 9, 64 Arnett, DK 87 Arnett, FC 76, 586 Arnett, T 7 Arnold, G 608, 74 Arnold, LM 8, 850 Arnold, M 4 Arntz, OJ 0, 80 Aronow, WS 749 Arora, P 58 Arora, V 79 Aróstegui, JI 78 Arredondo, M 48 Arriens, C 99, 58 Arroyo-Villa, I 647 Arsenault, P 850 Arthanari, S 4 Artim-Esen, B ARTIS Study Group, T 804, 805 Artoni, E 09 Arts, EEA 86, Program Book

391 Arts, ICW 90, 74 Arturi, P 86 Arufe, MC 4 Arulmani, U 45, 409 Arumugam, R 57 Arunima, A 09 Arvikar, SL 409 Asaduzzaman, A 488 Asahara, H 6 Asai, N 479 Asai, S 479 Asako, K 66 Asami, Y 945, 074 Asano, Y 648, 84, 59, 706, 707 Asanuma, YF 45, 570, 99 Asashima, H 50 Ascherman, DP 40, 776, 778, 057, 08 Ascoli, BM 44 Ash, J 568, 749 Askanase, A 884, 574, 55, 54, 900 Askari, A 5 Askling, J, 78, 804, 805, 996, 047, 697, 056, 44, 97, 405, 759 Aslangul, E 09 Aslanov, R 8, 5 Aslibekyan, S 87, 406 Asmawidjaja, PS 7 Asmussen, K 7, 84 Asnal, C 5 Aspe, B 400 Aspelund, T 05 Aspray, TJ 68 Assaf, AR, 7 Assassi, S 76, 655, 656, 679, 747, 6, 586, 79, 840, 96 Assencoa, CR 987 Assi, LK 5 Assier, E 9 Astesana, P 5 Astion, M 78 Astudillo, L 750 Aszodi, A 75 Atagunduz, P 457, 69 Atagündüz, P 96, 60 Atallah, M 876, 88 Atanelishvili, I 907 Atanes, A 750, 65 Ateka, O 7 Atisha-Fregoso, Y 506 Atkinson, EJ 0 Atsumi, T 0, 7, 68 Attinger-Toller, I 9, 5 Attur, M 887 Atxotegi, J 9 Atzeni, F, 46, 84 Au, K 96 Auberval, M 478 Audo, R 458, Aujero, M 96 Aujla, K 0, 44 Aulie, H 677 Aulie, HA 676 Aumaître, O 744, 78 Aurrecoechea, E 750 Aurrecoechea, E 687, 99, 65 Austin, HA 60 Austin, M 86 Avci, AB 5 Avcin, T 80 Avenel, G 59 Ávila, G 48, 90 Avina-Zubieta, JA 76, 008, 05, 67, 84, 04, 897 Avins, AL 978 Avouac, J 60 Awale, A 90 Awan, S 95 Awni, W 48, 488, 467 Axelsen, MB 80 Ay, B 475 Ayala-Gutiérrez, M 607 Ayanian, JZ 05, 760 Ayano, M 5, 94 Aybar Odstrcil, I 60 Aydelott, R 88 Aydin, SZ 94, 457 Aydin Tufan, M 749 Ayearst, R 507, 894, 777 Ayers, D 5, 6, 7, 8, 70, 9 Aynsley, S 44 Aytekin, S 689 Azaïs, J 47 Azeni, F 56 Azevedo, VF 470 Aznar Sánchez, JJ 478 Azuma, N 56 Azuma, T 9 Azzopardi, LM 98 Baamonde, C 469 Baba, S 59, 070, 075 Babini, A 69 Bacchion, F 74 Bachmann, M 9, 64 Bachta, A 66, 94 Back, C 469 Backhaus, M 94, 946 Backman, CL 78 Bacon, MJ 47 Badcock, A 46 Baddley, J 486, 05, 9, 680, 76 B Bader, M 40 Badley, EM 907, 080, 96, 9, 84, 847 Badot, V 40 Badurski, J 4 Bae, EK 6 Bae, J 9 Bae, SC 6, 09, 4, 5, 5, 44, 59, 607, 6, 707, 80, 400 Bae, Y 9 Baechler, E 66, 07 Baecklund, E 697 Baek, HJ 440 Baek, H 00 Baek, IW 595 Baek, SH 94, 8 Baenziger-Tobler, N 9 Baer, AN 9, 9, 508, 55, 56 Baer, P 9, 48, 490, 49, 50, 5, 5, 85, 84 Baerlecken, NT 786, 099 Baerwald, CG 97 Baeten, D 86, 500 Baeten, DL 56, 49, 540, 450 Bagaglia, PM 959, 470 Bagavant, H 55, 775 Baglaenko, Y 564 Bagley, AW 49, 80 Baglino, S 85 Bagnato, G 66 Bagnato, G 66 Bahce-Altuntas, A 00 Bahn, A 7 Bahram, S 60 Bahrt, KM 9 Baier, C 6 Baildam, EM 7 Bailey, KA 89 Bailey, O 9 Bailey, T 97 Baillet, A 696 Bajaj, P 90 Baker, A 496 Baker, D 768 Baker, J 95, 8 Baker, K 88 Baker, MF 9, 50, 5 Bakkaloglu, OK 09 Bakker, P 4 Baksa, G 950 Balanescu, A 48 Balasubramani, GK 47, 7, 790 Balasubramaniam, K 0 Balblanc, JC 466, 467, 469, 88, 69 Balboni, I 86 Balbotkina, E 7 Balci, A 465 Baldanti, F 576 Baldi, BG 69 Baldi, C 74 Baldini, C 505, 508, 559, 758, 759, 850, 677, 900, 060, 5, 55, 68, 60 Baldini, M 06 Baldissera, E 08, 06 Baldovino, S 640 Baldwin, C 04 Balint, PV 66, 94, 950 Balkarli, A 468 Balkenhol, A 6 Ball, EMA 586 Ballantyne, C 4 Balog, A 74 Balogh, B 657, 658 Balogh, E 9, 946, 940, 98 Balow, JE 60 Balsa, A 47, 8, 647 Balu, N 94 Bananis, E 48 Bananis, E 40, 46, 47 Bandak, E 86 Bandholm, T 7 Banerjee, S 44 Bang, D 06, 4 Bang, SY 6, 5, 6, 90, 400 Banie, H Bank, S 47 Bannerjee, T 00 Bannon, C 95 Bannuru, RR 044, 50 Bansback, N 997, 0 Banse, C 59 Banzato, A 65 Bao, C 54, 705 Bao, G 006, 06, 066 Bao, J 0 Bao, Y 7, 460 Baqir, M 748 Bar, S 96, 9 Baracat, EC 65 Baraf, HSB 9 Baraliakos, X 6, 7, 800, 80, 466 Baranov, A 70 Barash, J 64 Barausse, G 8 Barbanera, S 0 Barbarash, O 7 Barbarini, A 04 Barbarot, S 750 Barbarroja, N, 887 Barbasso Helmers, S 077 Barber, M 98 Barbhaiya, M 065 Barbo, A 88, 80 Barbosa, LS 6 abstract author Index 0 Program Book 89

392 abstract author Index Barbour, KE 95, 46, 076 Barcellos, LF 496, 6 Barchechath-Flaisler, F 7 Bardales, R 00 Bardelli, M 74 Bardin, T 4 Bardwell, P 555 Barendregt, PJ 87, 77 Barghout, V Barinstein, LV 504 Barisoni, L 6 Barkagan, M 098 Barken, D 797, 64, 55 Barker, A 98 Barker, AM 965, 97, 978, 87 Barnabe, C 96, 06, 97 Barnado, A 505 Barnard, J 66 Barnes, J 88 Barnetche, T 47 Barnhart, S 56 Baron, AE 74 Baron, G 5, 4 Baron, M 847 Baron, M 679, 96, 80, 586, 95, 96 Baron for the Canadian Scleroderma Research Group, M 79 Barone, F 57 Barra, G 906 Barra, LJ 09, 689 Barraclough, K 66 Barratt-Boyes, C 74 Barreira, JC 86,, 5, 9 Barrera-Vargas, A 580 Barrett, R 07 Barrett-Okeefe, Z 99 Barron, J 04 Barron, KS 0, 78, 7 Barron, KS 7 Barros, SS 07 Barros, TBM 08 Barroso, N 00 Barry, M 95 Barsalou, J 67, 65, 8 Barshack, I 547 Barsotti, S 060 Bartels, CM 07, 709 Bartels, EM 805 Bartels, S 9 Barthel, D 68 Bartholby, C 7 Bartholdy, C 86 Bartholmai, B 775 Bartlett, SJ 59, 44, 040, 4, 4, 75, 80, 84, 867, 868, 869 Bartok, B 96, 4, 75 Bartoli, F 69 Barton, A 77, 45, 57, 04, 88, 88, 88, 885, 886, 877 Barton, B 70 Barton, J 75, 758, 774 Bartsch, H 9, 64 Barzilai, M 098 Bas, S Baser, O 0, 04, 8 Bashir, M 860 Bashir, M 0 Baskett, A 54, 45 Bass, AR 980, 7, 8 Bassan, M 6 Bastecka, D 89 Bastian, H 04 Bastick, AN 75 Basu, N 787 Bateman, HE 88 Bathon, JM 5, 65, 8, 685, 75 Battafarano, DF 5, 76 Battal, H 0 Battat, E 05 Battellino, M 46 Battersby, R 47 Batticciotto, A, 46, 806 Battistone, MJ 965, 97, 978, 98, 87 Batty, DS 56 Batun, S 40 Baudoin, P 94 Bauer, H 808 Bauer, JW 66 Baumgartner, S 85, 86, 87, 89 Bautista, DCT 0 Bautista-Caro, MB 647 Bautista-Molano, W 57, 508 Bavineni, M 698, 47 Baxter, D 94, 944, 4 Baxter-Jones, A 94 Bay-Jensen, AC 70, 7, 878, 879, 50, 79 Baylan, U 86, 87 Bayoumi, A 788 Bazan Bardales, MC 44 Bazzichi, L 74 Bazzichi, L 0,, 8 Beagley, K 696 Beal, J Bean, KM 65, 864, 77 Beasley, M 84, 56, 848 Beaton, D 907, 986, 04, 788 Beattie, SD 4 Beatty, M 8, 78 Beauchamp, ME 758 Beaudart, C 89, 48 Beaulieu, A 479 Beaulieu, A 50, 87 Beavers, D 757 Bebris, L 498 Becetti, K 84 Bechor, Y 094 Beck, JP 965, 97, 98, 87 Beck, KE 87 Beck, MDO 0 Becker, JCP 7 Becker, ML 97, 77, 07 Becker, MA 78, 87 Becker, NP 549 Becker, P 6 Beckley-Kartey, S 7 Beckmann, D Becvar, R 569 Bedoya, S 75 Bedran, Z 60 Beebe, D 4 Beer, J 8 Beeton, C 87 Bég, S 98 Begale, M Begum, K 655 Behar, M 948 Behbahani-Nejad, N 85 Behery, O 8 Behrens, EM 68 Behrens, F 0 Behrens, TW 808, 877 Beinke, K 04 Bek, S 69 Belamie, E 5 Belasco, J 58, 7 Belazi, D 8 Beleva, D 7 Belilos, E 98 Belisle, L 0 Belisle, P 740 Belkacemi, M 8 Bell, A 586 Bell, DA 888 Bell, G 48 Bell, L 959 Bell, R 47 Bellini, B 58, 59, 60, 0 Bello, N 78 Bellomio, V 60 Belmatoug, N 807 Belmellat, N 9 Belmont, HM 509 Belostocki, K 98 Beltrán, E 750, 65 Beltran, J 57 Belzunegui Otano, J 08, 475 Bemark, M 90 Ben-Ami Shor, D 547 Ben-Artzi, A, 4 Ben-Dov, IZ 6 Benard, M 08 Benda, B 48, 80, 977 Benda, B 8 Benegas, M Benelli, L 69 Benessiano, J 488 Bengtsson, AA 0, 659, 576, 769, 544 Bengtsson, C 7, 07, 46, 405, 4 Bengtsson, C 769 Bengtsson, J 76 Benham, H 695, 696 Benhamou, CL 456 Benissan-Messan, D 6 Benito, P 46 Bennell, K 6 Bennett, D 88 Bennett, M 464 Bennett, M 590 Bennett, S 800 Bennett, T 87 Bennink, MB 49, 94, 0, 80 Benseler, SM 84, 750, 75, 754, 66, 788 Bensen, R 476 Bensen, WG 465 Bensen, W 47, 554, 50 Bensen, WG 9, 94, 45, 45, 48, 490, 46, 476, 550, 9, 49, 5, 5, 5, 7, 84, 458 Benson, R 76, 7 Benveniste, O 07 Beom, JW 7 Beppu, M 49 Berahovich, R 79 Berall, M 6 Berard, RA 84, 6, 790 Berardi, G 70 Berbotto, G 69 Berclaz, PY 7 Berdan, J 98 Berenbaum, F 96, 44 Berenson, DF 58 Beretta, L 679, 687, 706 Berezne, A 695 Berg, EL 866 Berg, L 54 Bergan, J 094 Berger, PB 986 Bergeron, L 96, 9 Bergin, D 65, 8 Berglin, EH 408, 958 Berglind, N 78, 047, 759 Bergman, D 8, 78 Bergman, MJ 484, 468, 90, 7, 47 Bergman, S 05, 07 Bergstroem, EL 95 Bergstrom, L Program Book

393 Bergström, U 88, 40, 407, 408, 4, 4 Bergström, U 8 Berktas, F 09 Berkun, Y 78, 64 Berland, Y 755 Berman, A 75 Berman, A 60 Berman, J 980, 05, 8 Berman, M 8, 098 Bermas, BL 699, 5 Bernard, L 807 Bernard, R 6 Bernard Medina, AG 40 Bernasconi, C 47 Bernateck, M 099 Bernatsky, S 607 Bernatsky, S, 96, 577, 585, 740, 59, 756, 770, 8, 8, 60, 8, 8, 90, 95 Berndt, N 9, 64 Bernelot Moens, HJ 49 Berner, R 7 Bernero, E 58, 590, 598 Berninger, L 6 Bernink, J 49 Bernstein, EJ 746 Bernstein, E 990 Bernton, E 84, 865 Berntson, L 95 Berrocal, V 597 Bershadsky, B 94 Bertacini, JC 6 Berthelot, JM 50, 469, 88, 69, 750, 87, 880 Berthier, CC 554 Bertholon, C 48, 756 Berti, A 08 Bertin, P 477 Bertin, P 47, 86 Bertini, F 9 Bertolaccini, ML, 7, 887, 55 Bertoli, AM 60 Bertolo, MB 6, 470 Bertrand, J 50, 75, 9 Bertschinger, J 9, 5 Bertsias, G 56 Bes, C 749 Besancon-Bergelin, A 84 Besenyei, T 896 Besnard, S 00 Bessette, L 5, 40, 4, 489, 756, 99 Best, T 86 Bethunaickan, R 554, 796 Betts, K 460 Beukelman, T 6, 794, 05, 054, 9, 680, 76 Beutler, A 47 Bevilacqua, M Beyer, C 8, 85, 690, 704, 7 Bezanahary, H 84 Bezanahary, H 679 Bezemer, ID 04 Bhadran, S 59 Bhakta, N 59 Bharat, A 996, 997 Bharti, B 99 Bharucha, KN 7, 79 Bhatia, J 58 Bhattacharyya, S 9 Bhole, V 94, 0, 97, 004 Bian, A 87 Bianchi, G 44 Bianchi, ML Bianchi, M 67 Bianchi, WA 470 Bianconi, L 66 Biasi, D 004 Bidonde, J 06 Biear, J 54 Bienkowska, J 88, 88, 74, 877, 58 Bienvenu, B 78, 04, 784 Bierma-Zeinstra, SMA 75 Biggioggero, M 466 Bijlsma, JWJ 70, 99, 45, 879 Bijlsma, J 976 Bijlsma, JWJ 49, 7, 450, 75 Bijlsma, JW 005 Bijzet, J 58 Bili, A 76, 9, 76 Billiar, T 75 Billingham, L 60 Binder, A 979 Bindi, P 00 Bingham, CA 79 Bingham, CO III 59, 874, 876, 040, 4, 4, 75, 80, 84, 88, 4, 48, 47, 768, 866, 867, 868, 869 Bingham rd, C 454 Biniecka, M 946, 98 Binks, D 65, 8 Bippes, CC 9, 64 Birbara, CA 0,, 7,, 48, 86 Bird, A 66 Birkett, R 5, 5, 8 Birkvig, M 5 Birlik, M 5, 544, 48 Birmingham, D 60 Birmingham, JD 780 Birtwhistle, R 96, 9 Bischoff, S 64 Bishu, S 77 Bisig, S 5 Bissell, LA 604, 766 Bisson, B 9 Bisson-Vaivre, A 59 Bissonauth, A 45 Biswas, P 765 Bitman, B 8 Bitterman, H 05 Bitto, A 66 Bitton, A 908 Björnådal, L 096 Bjørneboe, O 87, 94 Black, A 46 Black, C Black, RJ 045 Blagojevic, J 69 Blair, H 66 Blair, J 99, Blalock, E Blanc, F 754 Blanchard-Delaunay, C 744, 78 Blancher, A 68 Blanco, A 750, 0, 65 Blanco, A 84 Blanco, FJ 4, 47, 68, 69, 77, 5, 5, 56, 64, 65,, 94, 87, 846, 849, 876, 878, 644 Blanco, I 598, 6, 55, 56 Blanco, M 86 Blanco, R 788, 89, 89, 8, 8, 687, 750, 975, 0, 65, 6, 64 Blanco-Hinojo, L 46 Blaney Davidson, EN 49, 56, 769 Blank, M 547, 57, 6, 655 Blank, N 06, Blanset, D 40 Blasco, AJ 908 Blasco-Baque, V 60, 69 Blasini, AM 75 Blauvelt, A 9 Blazek, A 59 Blazevik, I 60 Bleil, J 499 Bleyer, AJ 76 Bliddal, H 499, 056, 86, 976, 7, 805 Blizzard, L 5, 8, 9, 55 Bloch, DB 58 Bloch, EG 58 Block, A 454 Block, JA 88, 56, 5, 5, 54 Bloem, JL 4, 804 Bloemsaat-Minekus, JPJ 686 Blom, AB 46, 79, 48, 766, 769, 77 Blom, T 8 Blomberg, B 00 Blomjous, BS 46 Bloom, AC 55 Bluemke, DA Blueml, S 6, 99 Bluett, J 45, 57 Blum, A 5 Blüml, S 0 Boackle, SA 70 Bobba, S 907 Bobic, S 500 Bobrowska - Snarska, D 6 Bode, C 9 Bodick, N 668 Boedigheimer, M 608, 609, 74 Boehm, C 7 Boehm, M 894 Boehm, S 7 Boelle, PY 477 Boers, M 46, 786, 57 Boesen, M 805 Boeth, H 40 Boettger, I 95 Bogatkevich, GS 907 Boger, HA 55 Bogliolo, L 700 Bohensky, M 00, 78, 08, 04 Bohgaki, T 7, 68 Bohnsack, JF 98, 99 Boiardi, L 666, 8 Boin, F 66, 66, 708 Boire, G 74, 06, 09, 8, 9, 4, 95, 475, 756, 786, 79, 4, 75, 76, 96, 866, 868, 869 Boissier, MC 9 Bojinca, M 04 Bokarewa, M 90, 9, 96, 76, 60 Bolaman, Z 40 Bolce, RJ 47, 46 Bolce, R, 45, 789 Bolge, SC 8, 8, 0, 0, 0, 057 Bolla, G 469 Bolognese, MA 86 Bolognese, MA 7 Bolster, MB 765, 8 Bolus, R 08, 607 Bombardier, C 05, 770, 787, 45, 5, 9 Bombardieri, M 4, 495, 408, 647 Bombardieri, S 508, 74 Bombardieri, S 505, 559, 850, 0, 0,, 677, 900, 060, 8, 5, 55, 68, 60, 67 Bomkamp, A 50 Bond, H 4, 08, 05, 08, 959 Bondt, A 89 Bone, HG 9, 7 Boneparth, A 6, 66, 796 Bonetti, LA 98 abstract author Index 0 Program Book 9

394 abstract author Index Bonfa, E 87, 4, 55, 5, 68, 75, 67, 474, 57, 545, 65 Bonfiglioli, KR 5 Bonfiglioli, R 470 Bonfils, F 09 Bong, DA 95 Bongardt, S 606, 78, 79, 808 Bongartz, T 85, 998, 999 Bongiovanni, S 46 Bonilla, N 489 Bonin, R 56, 546 Bonnefoy, F 5 Bonner, M 647 Bonnet, C 47, 469 Bonnet, F 750 Bonnick, S 7 Bonnotte, B 744, 84 Bonsack, J 78 Book, C 4 Boon, L 7 Boonen, A 88, 90, 000, 04, 06, 5, 74, 48, 86 Boonen, S 86 Boots, AMH 58, 645, 665 Bootsma, H 5, 88 Bootsma, H 508, 58, 449, 456 Borazan, N, 4, 00, 574 Borba, EF 06, 55, 57, 545 Borderie, D 50, 545 Borg, AA 98 Borg, F 6, 98, 667 Borges, C 90 Borghi, M, 5 Borghi, MO 566 Borghi, MO 9 Borgström, F Bornfeldt, K 56 Borofsky, MA 48 Boros, CA 00 Boroway, A 555 Borrás-Blasco, J 47 Bortolotti, R 8 Bortoluzzo, AB 470 Bos, C 899 Bos, R 49, 449, 456 Bosch, JG 4 Bosello, SL 70 Boskey, A 8 Bosler, T 569 Boss, J Bossaller, L 904 Bossini-Castillo, L 808, 89 Bossini-Castillo for the Spanish Scleroderma Group, L 79 Bostan, C 86 Boström, C 096 Bosworth, A 04, 9 Bosworth, HB 075, 855 Botsoglou, K 4 Bottero, P 760 Bottini, N 48 Boudreau, RM 754 Boulahdour, H 44 Boulange, M 09 Boulard, H 8 Boumpas, D 465 Bourgeois, P 85 Bourigault, ML 9 Bourke, L 560, 569 Bourla, A 60 Bourré-Tessier, J 60 Bourrel, R 67, 676 Bout-Tabaku, SM 86 Bouta, EM 8 Boutin, D 554, 6 Boutin-LE Thi Huong, D 6, 564 Boutros, P 557 Boutroy, S 97 Bovis, F 68 Bowen, T 6 Bowers, B 709 Bowes, J 57, 704, 885, 877 Bowman, J 695 Bowman, SJ 508, 57 Bown, L 667 Bowness, P 7, 7, 655 Bowring, J 84, 847 Box, J 765 Boy, MG 49, 440, Boyden, S 864 Boyer, JF 847 Boyer, O 8 Boyette, L 4 Boyle, DL 794, 8 Boyle, DL 48, 75 Bozkurt Tuncer, O 08 Bracaglia, C 66 Bracciolini, G 89 Brachat, A 69 Brachi, S 54 Bracke, K 8 Braddock, M 76, 95 Bradley, J 977 Bradley, JD 794 Bradley, LA 8 Bradley, TJ 67, 65 Bradna, P 89 Braga da Silva, JA 470 Brahe, CH 46 Brake, S 87, 74 Branch, W 6 Branch, WD, 4, 765 Branco, J 44 Brand, C 00, 78, 04 Brand, D 654 Brandi, ML 9 Brandt, DF 890 Brant, R 84 Brar, A 90 Braschi, F 69 Brasington, RD 890, 406 Brass, A 77 Braun, D 44 Braun, J 06, 7, 4, 466, 86 Braun, J 6, 56, 80 Braun, J 0, 50, 799, 800, 48, 45, 49 Braun, N 89 Braun, T 04 Brauner, S 497 Bravo, B 687 Bray, VJ 49 Breban, MA 469, 477, 489 Breda, L 75 Breda, S 700 Bredemeier, M 44, 498 Breedveld, E 8 Breedveld, FC 409 Bréhier, Q 59 Bremander, ABI 05, 0, 07 Bremer, P 760 Brennan, M 4 Brennan, MT 770 Brenner, M 46, 78, 87 Brenol, C 948, 79, 6 Brenol, JCT 948 Brescia, AC 865 Bressollette, L 88 Breunig, M 78 Breunis, WB 78 Brewer, J 7 Brewer, JM 76, 7 Brezin, A 86 Briasouli, P 764 Bridges, SL Jr. 70, 876, 47, 790, 87, 890, 88, 406, 745 Brienza, V 79 Briggs, M 86 Briggs, TA 70 Brik, R 69, 69 Brill, A 098 Bringby, F 096 Brink, M 97, 9 Brink, P 69 Brinkman, DMC 9 Brinkman, WB Brinkmann, GH 87 Brinks, DR 009, 954 Brinks, R 00 Briot, K 866, 545 Brisslert, M 90 Brito, E 440 Brito, LG 4 Britsemmer, K 46 Britton, J 604 Brizard, G 696 Brizzolara, R 654 Brkic, Z 6, 656 Brock, B 7 Brock, F 55, 446, 79 Brock, M 775 Brocq, O 469, 88, 69 Broder, AR 00 Brodeur, S 40 Brodin, N 87 Brodmerkel, C 47, 0, 457, 54 Broen, J 49, 79 Broeren, MGA 0, 80 Brogan, P 78 Brohawn, P 50, 7, 645, 7, 77 Brondello, JM 898 Brook, R 4 Brookhart, MA 760 Brooks, P 87 Brooks, S 65 Broten, L 8 Brouwer, E 5 Brouwer, E 808, 58, 49, 58, 645, 665, 449, 456 Brouwer, J 68 Brown, D 78 Brown, D 0, 0 Brown, EE 70 Brown, E 987, 908 Brown, JP 86 Brown, J 508 Brown, JP 77, 7, 8 Brown, J 09 Brown, K 9 Brown, LE 88 Brown, MT 4 Brown, MA 56, 57, 54, 705, 706, 707, 80, 446, 448, 497, 498, 697 Brown, M 509 Brown, RD Jr. 660 Brown, S 84 Brown, SR 84 Brown, S 70, 596 Brown, V 40 Brown and the Immunochip Consortium, MA 79 Browne, SK 844 Browning, J 58 Brucato, A 75, 86 Bruce, IN 57, 64, 59, 94, 896 Bruce, J Bruchfeld, J 697 Bruckner, P 75 Brummett, CM Brun, AL 78 Bruner, BF 68 Brunet, P Program Book

395 Brunetta, P 74, 747, 808, 78 Brunetti, R 87 Brunner, H 70, 7, 78, 90, 590, 57, 65, 69, 09 Brunner, HI 69, 7, 76, 8, 790, 79, 844, 76, 675 Brunner, J 99 Brunner, J 66 Brus, HLM 49 Bruss, M 68 Brusselle, G 8 Bruyere, O 89,, 48, 4 Bruyn, GAW 94 Bryan, RL 768, 74 Bryant, S 948 Brys, R 478 Brzezicki, J 76 Brzosko, M 6 Bröms, G 04 BSPAR Etanercept Cohort Study, OBOT 9, 678 BSRBR, OBOT 80, 04, 760 BT, C 8 Buatois, V 954 Bubb, MR 67 Bubbear, J 95 Buch, MH 604 Buchan, S 445 Buchanan, RR Buchbender, DC 7, 954 Buchbinder, R 87, 84 Buck, RJ Buckinx, F 89, 48 Buckley, CD 57, 408, 875 Buckley, F 460 Buckner, J 8 Buckner, JH 659, 660 Buckner, T 5 Budde, P 494, 909, 575 Budding, AE 9 Budinger, GS 744 Budoff, M 66 Budu-Aggrey, A 57 Buffington, CAT 4 Buhl, T 5 Buisman, L 08 Buján, J 77 Bukh, G Bukhari, M 7,, 5, 9, 45, 9 Bukowski, J 80, 46, 56, 546, 59, 689 Bulatovic Calasan, M 79, 640 Bulbin, D 847 Bulla, R 566 Bullock, S 9 Bultink, I 8, 884 Bunouf, P 09 Burd, C 68, 68 Bures, J 89 Burge, R 99 Burgess, S 894 Burghardt, AJ 957 Burgner, D 78 Burgos-Vargas, R 7, 80, 79 Burguera, EF 47 Burkhardt, H 97 Burkly, L 54, 56 Burkly, LC 88 Burmester, GR 465 Burmester, GR 44 Burmester, G 7 Burmester, GR 48, 494, 58, 77 Burmester, GR 45, 464, 04, 688, 767 Burmester, GR 97, 98, 7, 7 Burnett, I 095 Burnham, J 76, 8 Burnham, JM 785 Burns, A 59, 59 Burns, JC 78, 880, 75, 05 Burns, L 4 Burns, LC, 06, 66 Burns, MB 79 Burska, A 766 Burtey, S 755 Burton, MJ 486 Busch, AJ 06 Buschiazzo, E 86 Busco, L 69 Buser, A 46, 49 Bush, H 97 Bush-Joseph, C 8, 50 Bushnell, D 66, 69 Buskila, D 88, 89, 094 Busquiazzo, E Bustabad, S 96 Bustabad-Reyes, S 05 Bustos-Rivera Bahena, C 40 Butcher, J 76, 7 Butler, J 97, 87 Butler, P 5 Butt, S 478 Buttar, G 94 Buttarelli, L 5 Butterworth, R 04 Buttgereit, F 97, 98, 4, 66, 55, 65, 04, 7 Butugan, M 55 Butz, S Buyon, JP 606, 6, 765, 74, 75, 574, 609, 764, 55, 54, 80, 86 Buzas, EI 40 Buzio, C 696, 789 Büchler, M 744 Bykerk, VP 74, 06, 09, 8, 9, 4, 475, 786, 79, 4, 75, 76, 96, 866, 868, 869 Bykowska-Sochacka, M 844 Byrjalsen, I 878 Byrne, R 85 Bzarova, T 9, 64, 70 Böhmova, J 596 C Cabañas, M 908 Cabral, AR 650 Cabral, DA 865, 66 Cabrera, S 0, 444, 870 Cabrera-Villalba, S 9 Cacciatore, C 505 Cacoub, P Sr. 0, 78, 4, 754, 766, 09, 67 Cacoub, PP Sr. 75, 6 Cador, B 750 Cadranel, J 78 Cadzow, M 75 Caeiro, F 5 Caers, J 00 Cagan, A 6 Cagatay, Y 5, 689 Caglar, E 75 Cagnard, N 488 Cagnoli, PC 884 Cagnotto, G 700 Cahill, DJ 6 Cai, J 569 Cai, Y 474 Cai, Z 64 Cairns, A 59 Cairns, E 888 Calabrese, C 7 Calabrese, L 454, 95 Calabrese, LH 657, 658 Calamia, K 76, 660 Calamia, V 56, 64, 876, 878 Calarota, S 576 Calayir, GB 50 Calegaro, N 948 Caleiro, MTC 69 Calise, SJ 7, 67, 067 Callaghan, M 694 Callahan, LF 59, 970, 076, 890, 09, 406 Callhoff, J 4, 798, 80 Calogeras, A 800 Calvet, J 440 Calviño, C 400 Calvo, I 70, 76, 79, 78 Calvo, J 687 Calvo-Alen, J 469, 687, 99 Calvo-Río, V 788, 687, 750, 975, 0, 65, 6, 64 Camara, NO 57, 545 Camargo, C 595 Cambridge, G 8 Camellino, D 66 Camici, G 404 Camilla Bengtsson, C 40 Camp, H 74 Campanholo, C 470 Campbell, AM 48 Campbell, D 54 Campbell, P 658 Campbell, PL 774 Campbell, RC 487 Campfield, B 66, 69 Campillo, M 46 Campioli, D 09 Campman, S 75 Campochiaro, C 08 Camuset, J 78 Can, M 96, 69 Canada, K 40 Canadian STOPP Consortium, T 865 Cañamares, I 48 Cancio Fanlo, J 08 Candelas, G 67 Candotti, F 894 Cañellas, J 9 Canestrari, G 70 Canestri, S Cañete, JD 0, 9, 500 Cañete, JD 4, 444, 90, 870 Canhao, H 448, 496, 500, 877 Cannan, S 40 Cannella, AC 97, 978, 85, 87 Cannon, GW 47, 8, 965, 97, 978, 98, 08, 78, 44, 778, 87 Cano-García, L 908 Canoso, JJ 960 Cantagrel, AG 464, 96,, 4, 847, 75, 48, 808 Cantarini, L 75 Cantu, M 807 Cao, X 84, 847 Cao, Y 99, 89, 650 Caoduro, C 44 Capellino, S 86 Capelo, JL 64 Capelozzi, VL 84, 90 Capkin, AA 66 Capkin, E 66 Caplan, L 47, 0, 907, 6 Capocelli, K 80 Capone, L 4, 4 Caporali, R 74 Caporali, R 576, 700, 806 Cappelleri, JC, 7 Caracuel, M 788, 750, 65 Caramella, D 850 Carames, B 68, 7 abstract author Index 0 Program Book 9

396 abstract author Index Carbonella, A Carceller, MC 84 Carcillo, JA 07 Cardiel, MH 60 Cardiel, MH 69 Cardona, A 4 Cardona Muñoz, EG 407 Cardona-Muñoz, EG 546 Cardoso, A 4 Cardoso, S 49 Cardozo, T 570 Careaga Alzaga, JM 556 Carette, S 79, 756, 758, 759, 667, 669 Carey, TS 897 Caricchio, R 55 Carli, L 559, 850, 0, 5, 55 Carlier, H 44 Carlotti, E 647 Carlsen, AL 659 Carlson, A 97 Carmoi, T 09 Carmona, FD 89, 89 Carmona, FD 79 Carmona, L 47, 50 Carneiro, J 08 Carneiro, S 08, 470 Carnesecchi, G 69 Caronni, M 687, 706 Carotti, M 508 Carpenter, L 79 Carpintero-Fernández, P 69, 849 Carr, D 74 CARRA Registry Investigators, FT 99, 70 CARRA Registry Investigators, T 6 Carrara, G 989 Carraro, V 7 Carrascal, M 876 Carrasco, S 9 Carrasco Cubero, C 750, 65 Carreira, P 76, 8 Carreño, L 78, 644 Carretero-Prieto, RM Carrier, N 95 Carron, P Carron, PL 744 Carruthers, D 60 Carruthers, E 984, 708, 80 Carruthers, M 784, 04, 649 Carson, DA 7 Carsons, SE 98, 66 Cartella, S 55 Cartellieri, M 9, 64 Carter, JD 88 Carter, LM 56 Carthen, FC 548 Cartier, S 04, 44 artin-ceba, R 748 Cartwright, V 504 Carty, A 777 Carvalho, C 90 Carvalho, CRR 69 Carvalho, HM 6, 470 Casalla, L Casas, V 876 Cascino, M 607, 774 Casciola-Rosen, L 55, 56, 085 Casellas, J 8 Casey, G 95 Casey, VA 899, 90 Caspi, D 8, 5, 098, 484 Cassidy, LA 06 Castañeda, S 47, 788, 89, 89, 8, 8, 687 Casterá, DE 47 Castillo-Gallego, C 469 Castillo-Ortiz, JD 57, 5, 48 Castrejón, I 049, 4, 47, 50 Castro, A 6 Castro, GR 6 Castro, P 0 Catalan Pellet, A 5 Catanoso, MG 8 Catarsi, E 67 Catay, E 859 CATCH Investigators, 75 Catelani, MB 86 Cates, A 6 Cathebras, P 84 Catoggio, C 5 Catoggio, LJ 60, 60 Catrina, A 64 Catrina, AI 9, 7, 89, 44, 4 Cats, H 48 Cattogio, L 69 Cauley, JA 95 Cavagna, L 576 Cavalcanti, FS 5 Cavalier, E 89, 48 Cavalli, G 08 Cavallo, S 0 Cavazza, A 666 Cavazzana, I 55 Caverzagie, KJ 85 Cavet, G 788, 77 Cayetti, LA 5, 58, 547 Cazenave, M 6 Cazenave, T Cazotti, LA 89 Cebi Olgun, D 6 Ceccatto, F Cedzik, D 4 Celeste, S 687 Celik, G 69 Celis, R 90, 870 Cellucci, T 66 Cengiz, AK 9 Centeno-Cortés, A 94, 87 Centers of Excellence, A 765 Centeville, M 65 Ceponis, A 400 Cerdó-Ráez, T 887 Cereda, C 67 Cerejo, R 658 Cerón, A 60 Cerqueira, C 9, 89 Certan, D Cervantes, D 948 Cervera, R Cesano, A 876, 88 Cesar-Diaz, S 08 Cetin, P 5, 5, 544, 48, 465, 47 Cha, HS 6, 5, 440, 006, 6, 90 Cha, S, Chae, JJ 894, 74 Chai, JY 6 Chaib, A 6, 564 Chaitow, J 80 Chakr, R 948 Chakravarty, E 604,, 560, 565, 94, 080, 548 Chakravarty, SD 96 Chalan, P 58, 645 Chales, G 96 Challener, G 95 Chalom, EC 504 Chaly, Y 66, 69 Cham, WT 00 Chamberlain, ND 5 Chambers, CD 99, 046 Chambers, R Chamizo Carmona, E 478 Champion, HC 40 Champtiaux, N 695 Chamrad, D 575 Chan, CH 84 Chan, D, 4 Chan, EKL 7, 67, 96, 067 Chan, ES 85, 85 Chan, E 4 Chan, G 87 Chan, JYF 67, 96, 067 Chan, KL 608, 596 Chan, M 97, 07 Chan, MO 790 Chan, S 89, 888 Chandra, P 58 Chandran, AB, 7 Chandran, AK 67, 674, 675 Chandran, S 6 Chandran, V 44, 0,, 6, 9, 47, 5, 5, 55, 558, 894, 50, 50, 780, 78 Chang, AH 0 Chang, A 890, 794 Chang, CY 8, 66 Chang, CCH 07 Chang, E 00 Chang, L 08, 607 Chang, NH 6, 564 Chang, RW 5, 778, 077 Chang, SH 67, 95, 44, 476 Chang Young, T 990 Channick, RN 579 Chanroux, L 8 Chaparro, R Chaparro del Moral, R 9 Chapelle, D 90 Chapelle, DC 78 Chapelle, JP 5 Chaperot, L 70 Chapman, B 60 Chapman, J 57, 6 Chapman, PT 98 Chapple, I 57 Chapurlat, R 48, 4, 97, 4, 44, 756 Chari, S 649 Charles, N 644 Charles, PJ 884, Charles-Schoeman, C 44 Charles-Schoeman, C 440 Charles-Schoeman, C 470, 076 Charlier, E 5, 55 Charlotte, F 09 Chartier, M 465 Chary-Valckenaere, I 96, 09, 5 Chasle, B 04 Chasnyk, V 79, 89, 7 Chatel, L 954 Chatelus, E 664, 04, 60 Chatham, WW 884, 55 Chatterjee, S 680, 078 Chatzidionysiou, K 448, 496, 500 Chau, C 5, 675, 685, 577, 6, 98 Chau, D 8 Chau, LH 597 Chauchard, M 609 Chaudhari, A 86 Chaudhari, M 8 Chaudhary, P 0 Chauffe, AD 67 Chauhan, K 69 Chausson, M 76 Chauveheid, MP 609, 644 Chauvin, N 75, 8 Chavez, J C 0 Program Book

397 Chavrimootoo, S 95 Chedeville, G 66 Cheetham, TC 857, 007 Chelliah, G 7 Chemin, K 64 Chen, A 665 Chen, C 90 Chen, CY, 77, 656 Chen, C 509 Chen, DY 5 Chen, DY 058 Chen, D 76 Chen, DD 848 Chen, G 0 Chen, HH 5, 058, 949 Chen, H 94 Chen, J 705 Chen, J 40 Chen, K 74 Chen, L 9, 6, 47, 486, 048, 05, 054, 50, 9, 4, 40, 680, 76, 866 Chen, LF 78 Chen, L 0 Chen, L 505, 985, 99, 99, 000 Chen, M 7, 848, 8 Chen, M 98 Chen, N 449, 459 Chen, P 74 Chen, QP 7, 75 Chen, R 998 Chen, SY 78 Chen, SY 99, 007 Chen, SL 566 Chen, S 86, 99 Chen, W 79 Chen, WM 5, 54 Chen, X 797 Chen, Y 94, 0, 04, 06 Chen, YW 779 Chen, Y 75 Chen, Z 9, 5 Cheng, D 809 Cheng, LI 05 Cheng, Q 7 Cheng-Chung Wei, J 56 Chengazi, V 07, 978 Cheon, YH 69, 955, 6 Cherkas, Y 457, 54 Cherkas, Z 47 Chernitskiy, V 77 Chernoff, D 46 Chernoff, D, 789 Cheung, A 548 Cheung, YB 0 Chevallard, M 46 Chew, CS Chew, DW 47, 790 Chew, ML 850 Chew, R 49, 80, Chiba, N 07 Chibout, SD 9 Chiche, L Sr. 66, 755, 880 Chida, AS 68 Chieng, A 7 Chighizola, CB 65 Chikova, I 7 Chin, D 894 Chindalore, VL 74 Chinen, N 05, 079 Ching, D 66 Chino, K 67 Chiocchia, G 489 Chiowchanwisawakit, P 5, 48, 69, 887 Chira, P 790, 78 Chirieac, R 48 Chirmule, N 609 Chistyakova, E 9, 64, 70 Chitkara, D 5 Chitkara, P 55 Chiu, K 609, 74 Chiu, YG 07,, 54 Chiu, YM 49 Chmiel, JS 0, 75 Cho, CS 595, 46 Cho, HJ 95, 476 Cho, ML 4 Cho, NH 00 Cho, SK 5, 5, 80 Cho, YN 6 Chodosh, J 77 Choe, JY 9, 09, 049, 5, 5, 6, 76 Choi, BY 44 Choi, BY 95, 476 Choi, CB 69, 4, 5, 5, 80, 400 Choi, D 9 Choi, HJ 00 Choi, H 856, 89 Choi, HK, 0, 76, 05, 06, 67, 84, 66 Choi, IA 440, 4 Choi, JY 80 Choi, JJ 595 Choi, ST 787, 99,, 995, 00 Choi, SJ 69, Choi, S 46 Choi, TY 66 Choi, YH 089 Choinière, M 8 Choong, LM 646 Chopra, A 79 Chopra, P 460 Chopra, R 4, 4 Choquette, D 9, 5, 45, 40, 4, 45, 47, 48, 489, 490, 550, 50, 5, 85, 87, 99, 7, 84, 458 Choromanski, TL 696 Chorus, AM 88 Chou, L 5, 9 Choudhry, N 70 Choudhury, M Chow, A 9, 45, 45, 47, 48, 490, 49, 5, 87 Chow, SL 96 Choy, DF 07 Choy, E 55, 4, 75, 868, 869 Choy, EH 866 Choy, T 9 Chrabot, B 6 Chrétien Raymer, P 585 Chris, A 668 Christensen, R 499, 056, 86, 65, 69, 7, 50, 7, 805 Christensen, TG 84 Christiansen, C 878, 879, 79 Christianson, TJH 660 Christidis, D 98 Christmann, R 90 Christopher-Stine, L 086 Christopoulos, G Sr. 06 Chu, A 604, 74 Chu, H 568 Chuchana, P 898 Chun, BY 9 Chung, C 877 Chung, CP 964, 84 Chung, C 8 Chung, J 608, 609, 74, 8 Chung, L 679, 8, 95, 080, 085, 579 Chung, SA 6 Chung, WT 09, 5, 5, 6 Churchill, MA 45 Ciancio, G 0 Ciancio, M 9 Ciapetti, A Sr. 508 Ciarimboli, G 9 Cibere, J 97, 98 Cicchetti, A 004 Ciccia, F 497 Cicero-Casarrubias, A 598, 60 Cicuttini, F 5, 6, 8, 9, 47, 55, 48, 56, 67, 755 Cid, MC 89, 89, 66 Cieza, A 86 Cifaldi, M 449, 459 Cifaldi, MA 994, 46 Cimaz, R 66, 75 Cimbro, R 66 Cimmino, MA 66, 66, 989 Cinar, FI 9 Cinar, ME 44 Cinar, M 9, 07, 749 Cipriani, P 57 Cisternas, M 909 Citera, G 86,, 9, 5, 56, 58, 547, 6 Ciurea, A 5, 5 Ciurea, P 48 Clair, A 9, 850 Clancy, MM 6 Clancy, RM 6, 74, 86 Clare-Salzler, MJ 660 Clarimundo, V 8 Clark, JD 444 Clark, KEN 56 Clark, MR 890, 794 Clark, M 04 Clark, P Clark, TM 670 Clarke, A 6 Clarke, A 95 Clarke, AE, 577, 585, 60, 59, 8, 8, 90 Clarke, G 07 Clarke, W 805 Clarkson, A 5 Claudepierre, P 0,,, 469, 57, 59, 55, 78, 46, 808 Clausen-Schaumann, H 75 Claushuis, D 705 Clauw, DJ, Clauzon, A 5 Clayman, M 668 Clegg, DO 6, 7, 778 Clegg-Smith, K 80 Cleland, E 96 Cleland, LG 47 Clément-Lacroix, P 478 Clements, PJ, 4, 87, 908 Cleophas, M 94 Cleveland, C 55 Cleveland, RJ 59, 076, 09 Clifford, A 670 Clifford, S 46 Close, D 7, 77, 78 Clowse, MEB 0 Clowse, MEB 4,, 78, 79, 94, 900 Clunie, G 5 Cluzel, P 0, 6 Coates, LC 84 Cobankara, V 468 Cobb, J 88, 99 Coblyn, JS 0, 09 Cobraiville, G 5 Cochener, B 507 abstract author Index 0 Program Book 95

398 abstract author Index Cocker, M 7 Cockrum, P 8 Codreanu, C 48, 49 Codullo, V 700 Coenen, MJH 808, 877 Coffman, C 075, 855 Cofield, S 876, 88, 646 Coghlan, JG 745, 58, 588, 59 Cohen, AD 05 Cohen, C 7 Cohen, IR 56 Cohen, N 65, 69 Cohen, P 744, 757, 78, 784 Cohen, P 09 Cohen, PL 66 Cohen, S 454, 609 Cohen, SB 44 Cohen, S 05 Cohen, SB 608 Cohen Imach, G 60 Cohen-Aubart, F 6, 78, 564, 00, 07 Cohen-Bittan, J 05 Cohen-Gindi, O 56 Cohen-Solal, M 44 Coindreau, J, 47 Coit, PS 70, 77 Colbert, RA 77, 55, 59, 75, 694, 74 Cole, B 856 Colebatch, A 49 Coleiro, B 98 Coleman, E 7 Colin, E 7 Collado, MV 86, 594 Collado, P 6 Collamer, AN 7 Collantes, E 887, 440, 475 Collantes-Estevez, E Collee, G 799 Collette, J Collier, DH 47, 00, 8 Collier, DS 409 Collier, H 84 Collins, CE 740 Collins, E 565, 69 Collins, FL 55 Collins, M 90 Collins, MD, K 98 Colmegna, I 44, 8, 8, 60 Coloma, E 0 Colombres, F 60 Colonna, L 70 Coman-Wright, N 98 Comanesther, D 05 Comarmond, C 0, 78, 766 Combe, B 479, 59 Combe, B 55, 447, 458, 870, 7,, 4, 40, 4, 4, 8 Comblain, F 8 Comeau, M 86 Comeau, ME 69 Comer, M 5 Compagno, M 544 Compston, JE 4 Conaghan, PG 84, 47,, 766 Concepcion, A 49 Conde-Jaldon, M 89 Condino-Neto, A 6, 64 Conn, DL 890, 406 Connell, CA 49, 4 Connell, C 46 Connelly, K 64, 76 Connolly, MK 55 Connolly, M 9, 946 Connolly, S 7 Connor, J Connor, M 49 Cons, L 954 Cons Molina, F 76, 9 Consensi, A 0, Consolaro, A 89, 96, 7 Constantin, AL, 469, 847, 48, 87 Constantin, T 70, 7, 80 Conteduca, V 67 Contreras, G 884 Contreras-Rodriguez, O 46 Contreras-Yáñez, I 6 Control Centre Consortium, BSFRBR 04, 760 Control Centre Consortium, B 80 Cook, RJ 9, 47, 780, 78 Cool, CD 80 Cooles, FAH 68 Cooney, JK 4 Cooper, A 5 Cooper, C 800, 8, 4, 4, 44 Cootes, TF 694 Copin, MC 50 Corazza, L 67 Cordazzo, C 708 Cordeiro, J 876, 88 Cordero, O 400 Cordero-Coma, M 750, 0, 65 Cordier, JF 695, 758 Cordingley, L 45 Coresh, J 9, 9 Cormier, G 469 Cornec, D 507, 85, 880, 88 Corneth, OBJ 6, 656 Corominas, H 44 Corona, F 7, 68, 75 Corr, M 59, 7, 8 Corradi, D 696 Corrales, A 8, 8, 975 Correia, R 8 Corrigan, N 84 Corsiero, E 647 Corte, T 678 Cortes, A 706 Cortés-Pereira, E 5, 5, 65 Coscujuela, A 40 Cossette, P 95 Cossu, A 66 Costa, CZ 08 Costa, I 6 Costa, IP 470 Costa, S 50 Costa Beber, AA 0 Costa-Reis, P 860 Costantino, F 489 Costedoat-Chalumeau, N, 0, 6, 85, 00, 05, 554, 80, 84, 86 Costello, ME 497 Costenbader, KH,, 780, 065, 588, 699, 77, 5, 656, 657, 679 Cote, J 76 Cotofana, S 40, 754 Cotrim, AP 490, 49, 498 Cott, C 96, 9 Cottam, H 7 Cottin, V 695 Couchoud, C Sr. 755 Coudenys, J 65 Couderc, M Sr. 4 Couillin, I 60 Coulie, P 67 Coullerez, G 7 Coulon, F 8 Coulson, E 86 Coulthard, A 5 Coupal, L 5, 40, 4, 489, 99 Covelli, M 806 Coverley, L 95 Cowden, J Cowen, E 894 Cox, M 9 Cox, V 04, 95, 008 Cozic, N 85 Craft, JE 604 Cragg, M 8 Craig, G 00 Crane, MM 050 Craven, A 786 Cravets, M 87, 89 Crawford, L 94, 944, 4 Creamer, P 5 Crema, M 75 Crespo, M 47 Crestani, B 695, 78 Cretu, D 0 Crisan, TO 94 Criscione-Schreiber, LG 970, 977, 08, 8 Crisostomo, M 5 Crispin, JC 557, 57, 74 Criswell, LA 55, 55, 56, 496, 6, 64, 6, 65, 77 Crittenden, DB 79, 986 Croca, S 6, 66, 640 Crofford, LJ 97 Croia, C 495 Croker, BA 770 Cronstein, BN 5, 95, 79, 80, 88, 85, 85, 986, 570, 70 Cross, M 87 Crotty, M 090 Crow, C 5 Crow, MK 709, 57, 86 Crow, YJ 70 Crowley, J Crowley-Lisowski, D 0 Crowson, CS 8, 60, 64, 67, 68, 69, 868, 0, 66, 67, 674, 675, 678, 775, 998, 999, 057, 07, 08, 7, 7, 85 Crowther, S 946 Cruickshank, S 46 Cruickshank, SE Crusius, JBA 808 Cruwys, S 5 Cruz, J 750, 65 Cruz-Dominguez, MP 694 CSRG 80 Cuadrado, MJ, 7, 887 Cucho, JM 69 Cucho-Venegas, JM 40, 68, 5 Cuda, CM 70, 5, 744, 89 Cudrici, C 60 Cuervo, A 4 Cuff, C 948, 47 Cui, J 6, 877 Cullen, P 74 Culley, GA 987 Culliford, D 895, 507 Cullins, D 654 Culpo, R 605 Culshaw, S 7 Cunnane, G 868 Cunningham, A 87 Cunningham, M 59 Cunningham, MA 55, 57 Cuomo, G 676, 906 Cuperus, N 87 Curcic Djuric, M 95, 856 Curhan, G 66 Curran, M 47, Program Book

399 Curteis, B 95 Dalprà, S 96 Davis, M 78 de Rycke, L 450 Curtin, B 8 Dalwigk, K 85 Davis, S 47 de Seny, D 5, 55 Curtis, JR 49, 80, Curtis, JR 9, 6, 6, 70, 47, 4, 47, 486, 794, 876, 00, 040, 048, 05, 054, 4, 47, 50, 47, 790, 87, 88, 9, 4, 40, 44, 47, 646, 680, 76, 87, 866 Curtis, J 56, 454 Curwen, JO 95 Cusa, A 86 Cush, JJ 4, 765 Cuthberston, D 79 Cuthbertson, D 756, 667, 669 Cutolo, M 0, 7,, 48, 654, 85, 86, 58, 590, 594, 598 Cuttica, RJ 7, 76, 79 Cuzic, S 9 Czeloth, N 4 Czerkowicz, J 74, 58 D D Agostino, M 904 D Agostino, MA 6, 79, 94, 477 D Aloisio, A 059 d Ascanio, A 677, 060, 60 D Cruz, D 580, 58 D Cruz, DP 568, 646, 679 D Orazio, A 86 D Souza, C 556 da Silva, A 86 Da Silva, JAP 79 Dabauvalle, MC 064 Dabezies, EJ 4 Dadashova, R 946 Dadoniene, J 95 Dadoun, S 8 Dadoun, S 04, 4 Dagna, L 08 Dagnelie, PC 90, 74 Dahlström, 54 Dai, L 78, 48 Dai, X 474 Daien, CI 447, 458,, 40 Daikh, DI 95, 97, 978, 7, 77, 87 Dailey, D 7 Dairaghi, D 79 Daizadeh, N 864 Dakin, P 7, 8 Dalbeth, N 60,,, 5, 860, 74, 75, 89, 9, 87, 95, 090 Dale, J 798 Dall Era, M 4, 604, 884, 740, 765 Dalm, VA 6, 656 Dalmau, P 84 Daly, P 808, 54 Dam, MY 875, 40, 478, 687 Damore, M 609 Daneri-Navarro, A 067 Dani, L 777 Daniel, S, 7 Daniel Carmi, V 56 Danielides, S 490, 49 Daniels, LB 05 Danila, MI 876, 890, 88, 406 Dankers, W 7 Danneskiold-Samsøe, B 86, 7, 805 Danoff, SK 685 Danve, A 57, 659, 9, 06, 46 Danyliw, A 06 Daphna-Tekoah, S 094 Darbie, LM 79 Daridon, C 9, 867 Daron, C 4 Darrah, E 685 Das, L 74 Dasgupta, A 44 Dasgupta, B 477, 479 Dasgupta, B 895, 6, 66, 66, 98, 07, 667 Dasgupta, B 54 Dassouki, T 054, 474 Dastmalchi, M 777, 779, 056, 648 Datta, SK 8 Dauphin, C 4 Daurès, JP 8 Davari, M 6 Dave, KJ 796, 7, Davelaar, N 6, 656 Davey, M 74 Davì, S 96 David, JP 7 Davidsen, E 404, 4 Davidson, A 554, 60, 765, 796, 8 Davidson, B 800 Davidson, J 68 Davidyock, T 744 Davies, H 874 Davies, R 9, 678 Davignon, JL 847 Davila, S 78 Davis, A 99 Davis, AM 66, 96, 9, 555 Davis, HM 9, 47 Davis, JC Jr. 54 Davis, JM III, 67, 868 Davis, K 5 Davis, L 894 Davis, LA 846, 0, 907, 6 Davis, WE 98 Dawes, P 455, 874 Dawson, J 4 Dawson, L 6 De, G 7 De Achaval, S 80 De Angelis, D 68 De Ávila, J 57 de Bakker, P 76, 89, 704, 706, 879, 99 De Bandt, M 87 De Benedetti, F 7, 76, 8, 79 de Bie, R 88, 09 de Boer, H 95 de Bono, S 4 de Bruin, F 4 de Buck, PDM 889 De Buysscher, T 89 de Ceulaer, K 9, 60 De Filippo, M 5 De Groof, A 7 de Groot, P 654 de Hooge, M,,, 55, 59, 549, 77, 80, 4, 45, 884, 886 de Jager, MH 87, 77 de Jager, W 958, 784 de Jong, J 97 De Jong, N 4 de Jong, PHP 57, 69, 77 de Jong, TD 884 de Jong, TD 958 De Jonge, R 79 De Keyser, F 65, 594 de Korwin, JD 750 de Kovel, C 808 De La Cerda Trujillo, LF 407 De la Fuente, A 4 de la Iglesia, JL 60 de la Mora, A 99 de Laat, B 654 De Leon, E 80 de Looze, F 668 De Luca, G 70 De Luna, G 74 de Meij, TGJ 9 de Melo-Martin, I 967 de Miguel, E 89, 469, 475 de Miguel, M 9 de Min, C 954, 9 de Munter, W 46, 766 De Nard, F 700 de Oliveira, FK 498 de Pablo, P 57, 60 De Palma, R 906 de Perrot, M 98 De Rotte, MCFJ 79 De Smet, M 76 de Sonnaville, PB 799, 69, 77 de Sonnaville, PBJ 87, 57 de Souza, C 58, 59 de Steenwinkel, FDO 97, 98 De Toro, FJ 77 De Vera, M 0, 04, 89 De Vita, S 508, 705, 004, 67 De Vos, F de Vos, S 478 de Vries, CS 67 de Vries, F 8 de Vries, N 808, 877 De Vries-Bouwstra, JK 809 De Wandele, I 84 De wilde, K 65 de Zoysa, J 87 Deal, CL 0, 94, 664 Deamude, M 94, 476, 9 Dean, LE 56, 776 Deane, KD 6, 80, 869, 87, 74, 407, 659, 660 Dearth, A 88, 88, 74, 877 DeBerardine, M 79 Decaux, O 744, 754, 69, 750, 78 Decavel, P 4 Dechant, C 00 Decman, V 99 Decuman, S 594 Dede, F 68 Dedeoglu, F 77 Deehan, M 954 Dees, C 8, 8, 85, 690, 708 DeFranco, A 4 Defranoux, NA 7, 45, 77 Degli-Esposti, M 696 Dehlendorff, C 875 DeHoratius, RJ 04 Dei, Y 60 Dejaco, C 6, 66, 66, 98, 667 Dejaco, C 979 Dejoie, T 69 Dejonckheere, F 8, 460 Dekker, J 45, 89 DeKoter, RP 888 del Campo-Pérez, V 400 Del Galdo, F 57, 604, 709 Del Rincon, I 5, 76 Del turco, C 707 Delarozière, JC 755 Delerive, P 478 Deleuran, B 96, 94, 859, 7 Delgado-Frías, E 66, 05 Deligny, C 09, 84 Dell, S 750 abstract author Index 0 Program Book 97

400 abstract author Index 98 Dell Orfano, S 80 Della Rossa, A 5, 55 Della Torre, E 0 Dellaripa, PF 74 Delle Sedie, A 0 Dellepiane, M 7 Delorme, P 45, 669 Delzell, ES 05, 9, 4, 40, 680, 76 Demichelis-Gómez, R 579 Demirel, H 966 Deml, L 649 Demoruelle, MK 6, 80, 87, 74, 407, 660 Dempster, DW 9 den Boer, E 79 den Broeder, AA 966, 7, 86, 88 den Uyl, D 46 Deng, X 868 Deng, Y 78 Deng, Z 864 Denio, AE 847 Denisova, R 9, 64, 70 Deniz, R 457 Dennison, EM 800 Denny, JC 707, 877 Denny, MF 66 Dent, PB 865, 6 Denton, C 608 Denton, CP 7, 649, 667, 674, 679, 745, 56, 58, 588, 59, 59, 79, 90 Deodhar, A, 87, 57, 659, 06, 47, 46 Deodhar, AA 0, 505, 799 Derambure, C 904 Derber, LA 87, 74 Derer, A 7 Derk, CT 7, 97 Dernis, E 96, 469, 88, 69 Derrett-Smith, E 90 Derrett-Smith, EC 649 Dervan, E 768 Dervieux, T 797, 64, 55 Desai, R 8 Desai, S 40 Deschepper, E 594 Desfleurs, E 466, 467 Deshmukh, U 55, 775 Deshpande, V 785, 0 Desjonqueres, M 7 Deslandre, C 466, 467 Desmoulins, F 5 Desmurs-Clavel, H 744, 78 Desouches, S 59 Detalle, L 87 Detert, J 494, 04 Deus, J 46 Devanarayan, V 57 0 Program Book Devauchelle-Pensec, V 507, 508, 50, 85, 880, 88 Devenport, J 5 Deveshwar, S 5 Devilliers, H 564, 56, 784 Devlin, C 76 devries, C 5 DeWan, TE 098 Dewey, CM 964 Dey, P 55, 775 Dhaduvai, S 65 Dhaliwal, JS 96 Dhaliwal, R 89 Dhar, JP 85 Dhar, R 85 Dhillon, S 946 Dhindsa, N 946 Dhote, R 09, 750 Di Bidino, R 004 Di Blasi Lo Cuccio, C 75 Di Cicco, M 4 Di Ioia, C 60 Di Mario, C Di Padova, F 9 Di Toma, L 760 Diamandis, E 0 Diamantopoulos, A 8 Diamantopoulos, AP 555, 66, 688 Diamond, B 596, 765 Dias, OM 69 Dias, S 57 Diaz, C 48 Diaz, D 79 Diaz, S 50 Díaz Curiel, M Díaz Toscano, ML 407 Díaz-Correa, L 97 Diaz-Deza, KE 40, 68 Díaz-González, F 85, 96, 66, 05, 644 Diaz-llopis, M 750, 65 Diaz-Martin, A 96 Díaz-Prado, S 77 Diaz-Rizo, V 599, 546 Diaz-Torne, C 44 Diboll, J 48 Dickerson, J 76 Dickinson, A 48 Diederichs, G 40 Diederichsen, ACP 64 Diekman, LA 446, 840 Diep, V 86 Dietrich, T 57 Dieude, P 466, 467, 870, 488 Dieudonne, G 07, 8, 978 Diez del Corral, A 99 Díez-Pérez, A 4 DiFrancesco, M 76 Diggle, P 5 Dighe, MK 600 Dijkmans, BAC 808 Dikranian, A 44 Dima, C 5 Dimai, HP Dimeff, R 9 Dimic, A 455 Dimitroulas, T 7 Dimonaco, S 767 Dinc, A 9, 475 Ding, C 5, 8, 9, 55, 48, 755 Ding, L 74, 747, 884, 78 Ding, Q 0 Ding, Y 7 Dinh, A 807 Dini, V 0 Dinno, A 57 Diogo, D 704, 877 Dion, J 05 Diot, E 84 DiRenzo, D 54 Direskeneli, H 5, 68, 68, 96, 457, 64, 69, 60, 749, 80 Direskeneli on behalf of the Turkish Takayasu Study Group, H 70 Dirven, L 47, 460 Dischinger, H 907 Dispenzieri, A 868 Distler, A 8, 690, 704, 7 Distler, JHW 8, 8, 85, 690, 57, 704, 708, 7 Distler, JH 569 Distler, JH 80 Distler, O 70, 8, 8, 690, 579, 704, 708, 7 Ditto, MC 46 Divakaran, M 59 Divers, J 5, 54 Dixey, J 79 Dixit, R 78 Dixit, S 9, 46, 5, 85, 84, 5 Dixon, J 56 Dixon, WG 04, 045, 758, 760 Djemouai, S 48 Dobson, C 667 Docken, W 66 Dodge, R 85 Dodin, P 45 Doe, K 5 Doerner, J 54 Doerner, T 46 Doherty, E 700 Doherty, M 80, 99, 658 Dohi, M 89 Dokoupilova, E 4 Dolezal, T 995, 05 Dolezalova, P 66, 68 Dolhain, RJEM 97, 98, 6 Dolhain, RJ 89, 68 Doll, H 746 Dollinger, M 59 Dominguez, N 864 Dominguez-Luis, MJ 96 Dominis Kramaric, M 9 Domsic, RT 578, 58 Donahue, KL 098 Donath, E 46 Donato, A 99 Dong, Q 474 Dong, Y 0, 86, 99, 768 Donica, H 766 Donnell-Fink, L 0, 86, 99, 856 Donnelly, S 95 Dooley, MA 606, 884, 59 Dorais, M 45, 669 Doran, M 484, 868 Dore, A 67, 900, 970, 76 Dorfleutner, A 5 Doria, A, 607, 6 Dorman, CW 5 Dormont, D 6 Dorrego, L 644 Dorschner, JM 6 Dossier, A 609, 644 Doti, PI 0, 08 Doty, S 8 Doucet, M 99 Dougados, M 49 Dougados, M 50, 866, 96,,, 7, 4, 58, 4, 47, 50, 56, 57, 55, 59, 50, 5, 55, 54, 545, 546, 55, 799, 8, 79, 447, 688, 87, 885 Douglas, D 797 Douglass, W 48 Dow, ER 88 Dowding, L 74 Dowell, S, 58 Doyle, A,, 5 Doyle, AG 6 Doyle, MK 0, 5 Dozmorov, MG 489, 864, 77, 770 Dragone, LL 9 Dreier, R 75 Drenkard, C 006, 06, 066 Drescher, E 75 Dreyer, L 84, 578, 08, 44 Driban, JB 4, 4, 5, 56, 9, Drier, A 6 Drion, P 8 Du, F 485 Du, Y 894 Duan, CY 7 Duan, L 00 Duarte, AL 6

401 Duarte, ALBP 470 Dvorkina, O 900 Eisman, J 9 Emoto, K 796 Duarte, ALBP 44, 07 Dwyer, E 8 Eitzman, DT 57 Endo, H 86, 64 Duarte-García, A 598, 60 Dybowski, F 6 Ejbjerg, BJ 46 Endo, K 588 Duartes Noé, D 5 Dye, J 970 Ekberg, O 50 Endo, K 97 Dubko, M 89, 7 Dyer, A 65 Ekholm, L 884 Endres, J 77, 85 Duboc, D 757 Dubost, JJ 488, 4, 880 Dubs, B 5 Dubuc, JE 76, 69, 7 Duch, D 557 Ducreux, J 67, 40 Duda, G 40 Dudek, A 976 Dudley, RA 998 Dufauret-Lombard, C 47 Duffecy, J Duffield, E 456 Duffy, CM 84, 94, 87, 0, 790 Duffy, E 984, 994, 996, 997, 005 Duffy, P 95 Duffy, S 895 Duffy, T 95 Dufour, AB 899, 900, 90, 76 Dufour, N 478 Duftner, C 66 Dugan, J 74 Duggan, D 889 Dulac, Y 84 Dumancas, G 509, 65 Dumas, G 09 Dumax-vorzet, A 70 Dumoulin, G 8 Duncan, T 4, 84, 867 Dunford, PJ Dunlop, DD 5, 778, 077, 75 Dunlop-Thomas, CM 06, 066 Dunne, E 959 Dunogué, B 757 Dupon, M 807 Dupont, S 478 Durcan, LJ 959, 470 Durden, E 05 Durez, P 446, 479 Durez, P 45, 77, 40 Durigutto, P 566 Durmaz, Y 9 Durrani, M 568 Duruisseaux, M 78 Duryea, JW 8, 0,,, 4, 964, 965 Duryee, MJ 6 Dusetzina, S 7 Dutot, I 8 Dutton, L 04 Dutz, JP 06 DuVall, SL 47, 47 Duvallet, E 9 Duyur Cakit, B 08 Dür, M 979 Dzikaite-Ottosson, V 599 Dälken, B 4 Dönmez, S 50 Dörner, T 6 Dörner, T 9, 95, 867, 0 Døhn, UM 46 E Eaton, C 4, 5, 778,, 75 Ebbing, PCC 8 Eberhard, BA 86 Eberl, H 766 Ebina, K 8, 46 Ebling, W 09 Ebsworth, K 79 Eby, N 97 Eck, S 77 Eckels, M 8 Eckert, K 95 Eckstein, F 40, 7,, 670, 754 Edberg, JC 70 Edelmann, E 806 Edemir, B 9 Eder, L 9, 47, 6, 780 Ederveen, T 74 Edhayan, G 658, 97, 597 Edison, J 540, 869 Edson-Heredia, E 8 Edwan, JH 74 Edwards, CJ 05 Edwards, CJ 0,, 7,, 48, 800, 86, 49, 507 Edwards, D 97 Efde, M 58, 449, 456 Efrati, S 094 Efthimiou, PV 504, 500 Egan, K 470 Egholm, CL 84 Egsgaard, L 79 Egsmose, E 5 Eguchi, K 0, 6, 960,, Egües Dubuc, CA 08, 475 Ehrenstein, BP 649, 969, 59 Ehrenstein, MR 56 Ehrlich, A 08 Ehrlich-Jones, LS 077, 0 Eickhoff, J 50 Eijkelkamp, N 857, 858 Eirheim, AS 84, 40 Eisenberg, DF 070 Eisenstein, R 990 Eklund, A 4 Ekman, EF 095 Eksi, S 60 El Bakry, SA 9 El Bayed, K 664 El Gaafary, M 8, 70 El Mansouri, FE 6 El Miedany, Y 8,, 70 El-bakry, S 594 El-Gabalawy, HS 94 El-Menyawi, MAM 67 Elashoff, D 984, 994, 996, 997, 005 Elashoff, R 574 Elboudwarej, E 496, 6 Elder, MJ 47 Elder, M 780 Eldridge, H 0 Elefante, E 68 Eleftheriou, D 76 Elegbe, A 6 Elewaut, D 65,, 69 Eliopoulos, E 5 Elkan-Navon, P 64 Elkayam, O 8, 5, 098, 484 Elkin, E 484, 468 Elkon, KB 8, 544, 56, 45, 70, 70 Ellegaard, K 7, 805 Ellingsen, T 6, 84, 875, 40, 687, 80 Elliott, A 9 Elliott, C 5 Elliott, T 49 Ellis, J 78 Ellis, LA 8, 8, 08 Ellsworth, JE 865 Elmore, S 555 Eloranta, ML 77 Elsallabi, O 75 Elsayed, AM 9 Elson, G 9 Elyassaki, A Emanueli, C 66 Embi, PJ 06 Emery, P 75 Emery, P 46, 45, 84, 6, 7, 79, 4, 4, 57, 604, 689, 709, 766 Emes, R 874 Emin, A 895 Emmetts, R 845 Emminger, W 7 Emmungil, H 749 Emohare, O 6 Endres, T 06, Eng, H 06, 07, 0, 48, 7 Engbers, A 889 Engelke, K 86 Engelke, K 966 England, BR 09 Englbrecht, M 405, 97, 485, 80 Engler, A 404 Englund, M 99, 64, 65, 76, 67, 68 Engström, G 99, 64 Engström, M 4 Enns, E 96 Epis, OM 870 Erakovic Haber, V 9 Erbilir, T 5 Erdem, H 9, 07 Erdem, HR 08 Erdem, S 444 Erden, MG 5 Erdoganoglu, Y 096 Erer, B 5, 09, 680, 45 Ergun, T 64, 69, 60 Erguven, M 70 Eri, T 4, 89 Erickson, AR 8, 08, 78, 968 Erickson, EM 56 Erickson, J 44 Eriksen, SA 056 Eriksson, H 77 Eriksson, J 996 Eriksson, K 40 Eriksson, P 77 Erkan, D 605, 55, 65 Erken, E 749 Erlandson, M 87 Erlandsson, M 9, 96, 76, 60 Erman, B 98, 06 Ernestam, S, 789 Ernste, FC 775 Erondu, N 8, 87 Erra, A 440 Errazquin Aguirre, N 08 Erre, GL 66 Ersozlu Bakirli, D 749 Erten, S 749 Ertenli, I 6 Ertl, G 78 Ertl, L 79 Erzik, C 457 Erzurum, S 657 abstract author Index 0 Program Book 99

402 Esaki, K 940 Falcini, F 9 Feist, E 786, 85 Ferrari, C 96 Esbjörnsson, M 779 Falk, R 75 Feldhamer, I 05 Ferrari, G 590, 598 abstract author Index 400 Escalante, A 5, 76 Eschalier, R 4 Escobar, A 57 Escoda, O 0, 08 Escoubet, B 609, 644 Esdaile, J 96, 98, 05 Esdaile, JM 897 Eshed, I 8, 80 Eskehave, TN 50, 79 Esmaeilzadeh, S 40 Espesen, J 478 Espiño, P 48 Espinosa, G, 0, 08 Espinoza, F 898 Espinoza, LR, 58, 64 Esquivel-Valerio, J 69 Essenmacher, L 85 Essers, I 447 Estelius, J 599 Estrada-Y-Martin, RM 6 Estrela, GBQ 4 Etzel, C 04, 95, 008 Etzel, CJ 49, 45 Eudaly, JG 57 euller-ziegler, LE 96, 469 Eun, JS 58 Evangelisto, AM 686 Evans, HG 50 Evans, L 4 Evans-Young, G 758 Evensen, E 876, 88 Everett, J 84 Evnouchidou, I 489 Eynullayeva, E 05 Eyre, S 77, 704, 88, 885, 886, 877 F van Delden, A 779 Fabre, S 808 Fabris, M 55 Facchini, A 54 Fadel, D 594 Fagerland, M 7, 88 Fagerli, K, 4, 55, 59, 549, 77, 80, 45, 884, 886 Fagerli, KM 4 Faggioni, R 50 Fagot, JP 067 Fagot-Campagna, A 067 Fahmi, H 6 Fain, O 469, 686, 09, 84 Fairley, J 67 Faizal, AA 60 Fajardo-Robledo, NS 599, 546 Fakhouri, F 69 F 0 Program Book Fallon, A 0 Faludi, M Fan, C 55 Fan, H Fan, T 0 Fang, C 5 Fang, CH 49, 058 Fang, G 8 Fang, H 9,, 574, 58, 88, 74, 804, 805, 877, 56, 58, 65 Fang, L 474 Fang, L 6, 64 Fang, MA 97, 978, 984, 87 Fang, W 79 Fangtham, M 574 Fanning, P 8 Fanta, CH 0 Faraawi, RY 45, 490, 46, 84 Farahani, M Faran, Y 094 Fardellone, P 75 Farewell, V 59, 896 Farge, D 09 Farhey, Y 79 Farina, I 0 Farina, N 8 Farinon, M 8 Farkasch, A 086, 959 Farley, J 8 Farrell, W 874 Farrer, C 097 Farris, AD 9, 64, 77 Fashanu, B 66 Fasth, A 95 Fatakdawala, T 845 Fathi, M 648 Fauchais, AL 488, 86 Faustini, F 485 Fautrel, B 50, 85, 96, 04, 04, 7, 4, 469, 88, 69, 87 Fava, A 66 Favalli, EG 466 Favero, L 85 Fawcett, PT 865 Fay, J 454, 49 Fazelzad, R 5 Fazzi, E 67 Fearon, U 9, 946, 664, 668, 98 Fedele, AL Fedorova, T 47 Feehan, C 80 Feehan, LM 80 Fei, K 46, 54 Fei, Y 94 Feig, JL 570 Feldman, B 77 Feldman, BM 7, 98, 06, 788 Feldman, CH 0, 780, 848, 987, 065, 588, 679 Feldman, D 464 Feldman, DE 94, 0 Feldman, H 590 Feldman, S 09 Feldmann, A 9, 64 Feller, L 97 Felsenstein, S 68 Felson, DT 7, 4, 5, 54, 6, 65, 85, 90, 7, 694, 88, 9, 67 Feltelius, N 697 Feng, J 8, 87 Feng, J 7 Feng, X 77, 00, 857 Feng, X 590, 698 Ferbert, SM 088 Ferlin, W 954, 9 Fernandes, AW 7 Fernandes, AJ 946 Fernandes, A 95 Fernandes, JK 5, 54 Fernandes, PT 58, 59, 60, 0 Fernandes, V 6 Fernandes, VM 07 Fernandez, G 86 Fernandez, I 778 Fernandez, MC 440 Fernandez, P 85 Fernandez, S 0 Fernandez Gutierrez, B 8 Fernández Rueda, JL 86 Fernandez-Cid, JC 750, 65 Fernández-Costa, C 56, 64, 876, 878 Fernández-Espartero, C 750, 65 Fernández-Gutiérrez, B 86 Fernández-Llaca, H 6, 64 Fernández-López, C 5, 5, 65 Fernandez-Madrid, F 75 Fernández-Moreno, M 5, 5, 65 Fernández-Nebro, A 48 Fernández-Pernas, P 4 Fernández-Puente, P 69, 56, 64, 849, 876, 878 Fernández-Tajes, J 5, 5, 65 Feron, JM 46 Feroz, S 98, 06 Ferraccioli, G 70,, 6, 67 Ferrándiz, ML 84 Ferrari, C, 677, 8, 68, 60 Ferrari, M 497 Ferrari, S 864 Ferraz-Amaro, I 66, 05 Ferreira, I 7, 8 Ferreira, I 74 Ferri, C 09, 67 Ferriera, J 845 Ferrito, V 98 Ferro, F 505, 850, 900 Fertig, N 748 Ferucci, ED 696 Feser, ML 87, 74 Feskens, EJM 74 Fessler, BJ 59, 586 Fetisova, A 9, 64, 70 Feuchtenberger, M 78 Feudtner, C 75 Feydy, A 0,,, 78, 46 Fialka-Moser, V 979 Fidelus-Gort, R 797 Fidler, W 6 Fiehn, C 0 Fielding, R 07 Fielding, RA 5 Fields, TR 8 Figgie, MP 506, 5, 8, 0, Figuroa Sanchez, M 40 Filer, A 408, 875 Filgueira-Fernandez, P 69 Filippin, L 8 Filippini, D 67 Filippucci, E 94 Filippucci, E 79 Filková, M 480, 950, 40 Fillatreau, S 867 Finckh, A 460, 495,, 90 Finnegan, A 99, 89, 650 Finzel, S 966, 97, 485, 80 Fior, R 750 Fiore, S 470, 55, 58 Fiorentino, D 679, 608, 8, 95, 080, 085 Fiori, G 69 Firestein, GS 50, 794, 96, 8 Firestein, GS 85, 48, 75, 876 Fisch, KM 895 Fischbach, M 7 Fischer, HD 98, 00 Fischer, MA 065, 679 Fischer, S 07 Fischer-Betz, R 0 Fisher, MC 409 Fishlev, G 094

403 Fitz-Patrick, D 87, 89 Fitzcharles, MA 8,, 4, 4, 6, 88, 89, 85 Fitzgerald, GK 0 Fitzgerald, JD 076, 579 Fitzgerald, KA 904 FitzGerald, O 09, 5, 44, 49, 50, 88, 48, 779 FitzGerald, OM 57, 946, 59 Fitzpatrick, JD 46 Fivenson, D 608 Flanagan, R 58 Flato, B 676 Flatø, B 677 Fleck, M 76, 649, 969, 0, 59 Fleischer, SJ 9 Fleischmann, R 44, 476, 49 Fleischmann, RM 44 Fleischmann, R 45, 4 Fleischmann, RM 58 Fleischmann, RM, 45, 85, 6, 4, 48, 50, 688 Fleishaker, D 6 Fleisher, TA 864 Flejsborg Oeftiger, S 4 Fletcher, J 00 Flewelling, C 986 Fliedner, G 97 Flipo, RM 96, 04, 4, 75 Florentinus, S 45, 58, 409, 4, 688 Flores, R 797 Flores-Suarez, LF 787 Flossmann, O 746 Flower, C, 58 Flurey, CA 08 Flynn, E 88, 886 Flynn, JA 44 Flynn, T 60, 87 Flüß, E 84 Foeldvari, I 80, 65, 68, 69 Foell, D 786, 6, 667 Fogal, S 40 Fogg, LF 50, 5, 54 Fojtikova, M 5 Folkersen, L 497 Foltz, V 85 Fombonne, E 577, 8 Fong, B 540 Fonollosa, A 750, 0, 65 Fonseca, J 477 Fonseca, JE 877 Font, P 440 Foody, JM 065 Foong, YC 755 Forbes, A 56 Ford, J 9 Ford, TL 5 Forejtova, S 5, 947 Forrester, JV 696 Forsblad, H 54 Forsblad-d Elia, H 77 Forslind, K, 4, 789, 60 Forsyth, R 66 Forsythe, L 694 Fortea Gracia, S 908 Fortin, I 9, 45, 490, 49, 50, 5, 5, 87 Fortin, PR 6, 6, 65, 59, 756, 45, 557 Fosser, C 445, 0 Foster, HE 86 Foster, H 68 Foster, HE 69 Foucher, KC 8 Foulboeuf, L 9 Foulkes, W 585 Fountaine, RJ 4 Fournier, JP 67 Fournier, S 808 Fox, DA 657, 658, 774, 777, 97, 77, 85, 909, 56 Fradin, J 508 Fraenkel, L, 57, 58, 59, 6, 854, 908 Fragoso-Loyo, H 884, 598, 60 França, ILA 67 Francès, C 05 Franceschini, F 55 Franchimont, N 007, 808 Franchini, S 08 Francis, S 909 Francisco, F 750, 65 Francisco, M 96 Francois, A 60 Francom, S 45 Frank, C 96, 9 Frank, K 74 Frank, MB 0, 04 Frank, S 78 Frank Bertoncelj, M 775, 76, 87 Franklin, JM 6, 780, 065, 679 Franklin, PD 098, 5, 6, 7, 8, 70, 9 Franklyn, K 566 Franks, AG Jr. 574, 85 Fransen, J 70 Fransen, J 005, 8, 66, 86, 88 Franzén, S 78, 047, 759 Franzolini, N 705 Fraser, AD Fraser, A 98 Fraticelli, P 705, 67 Frattalone, S 540 Frayssac, T 4 Frech, TM 650, 586, 765, 99 Fredericson, M 9 Fredi, M 67, 55 Freeman, M 064 Freemont, T 8 Freimuth, W 60 Freire, M 6 Freire, M 788, 687 Frenkian, S 70 Freundlich, B 796, 7, 56, 55, 88 Frey-Law, L 8 Freyne, B 797 Frid, P 68 Friday, SC 97 Fridén, C 980 Friedman, A 68 Friedman, D 74, 75, 80 Friedman, J 5 Friedman, M 74 Friedman, M 094 Friesen, D 54 Frisell, T 78, 996, 047, 97, 759 Frishman, WH 749 Frisina, A 89 Frits, MA 6, 09, 68, 88 Fritsch, C 86 Fritsch-Stork, R 49 Fritz, LC 49 Fritzler, MJ 96, 80, 064, 586, 96 Frizelle, S 5 Frleta, M 944, 4 Frobell, R 670 Frommer, KW 77, 84 Frosch, M 69 Frugoni, F 95 Fry, RC 89 Fryer, A 874 Fu, E 997 Fu, Q 705 Fu, YX 7 Fu, Y 69 Fucile, C 4, 798 Fudge, K 5 Fudman, E 456 Fuentes-Boquete, IM 77 Fuhlbrigge, RC 77 Fujieda, M 645 Fujii, H 49, 68, 70 Fujii, R 49 Fujii, T 465, 749, 89, 4, 9, 0 Fujii, W 80 Fujikawa, K 069 Fujimoto, M 748, 069 Fujimoto, T 4 Fujio, N 86, 64 Fujioka, K 80 Fujishiro, M 7 Fujita, S 40 Fujita, T 89 Fujita, Y 49, 68 Fujiu, K 707 Fujiwara, H 80 Fukuba, E 586 Fukuda, K 94, 77 Fukuda, T 0, 854 Fukuhara, N 49 Fukui, N 7 Fukushima, A 960 Fukuyo, S 468, 45, 87, 9 Fuller, D 49 Fuller, R 69, 55 Fulton, RS 877 Funahashi, K 4, 897, 9 Funahashi, K 479, 70 Funk, RS 97, 07 Funkenbusch, SC 5 Furie, R 808, 55 Furie, RA 606, 876, 574, 604, 74, 88 Furst, DE 44, 974 Furst, D 90,, 4, 46, 574, 579 Furst, DE 499, 87, 908, 00, 65, 69, 4, 45, 586 Furtado, RNV 4, 4 Furtado, RN 98 Furu, M 9, 0, 404 Furukawa, H 67, 7 Furukawa, KI 6 Furuya, H 7, 98, 57 Furuya, T 86, 6 Fusama, M 76 Fuzibet, JG 00 FVSG, FVSG 758 Föll, D 98 Förger, F 4 Førre, T 7 G Gabay, C 448, 450, 496, 500, Gabbay, E 678 Gaber, T 97, 98, 7 Gabler, NB 8 Gabriel, SE 60, 64, 67, 69, 868, 0, 0, 85 Gabrielli, A 705, 67 Gabrielli, B 705 Gabusi, A 54 Gaddy, J 696 Gadina, M 894, 78, 90 Gadola, S 800 Gaffen, SL 77 Gaffney, PM 88, 489, 565, 6, 6, 65, 70, 770 Gage, BF 7 Gagliardi, M 707 Gagné, M 064 Gago-Fuentes, R 69, 849 Gaidar, E 89 abstract author Index 0 Program Book 40

404 abstract author Index Gailhac, S 447, 458, 40 Gaillez, C 904 Gait, AD 694 Gal, J 9, 0, 99, 74 Galant, C 67 Galdos, RL 58 Gale, C 04, 760 Galeazzi, M 465 Galeazzi, M 74 Galetti, M 789 Galicier, L 09 Galien, R 478 Galindez Agirregoikoa, E 556 Galindo Izquierdo, A 550 Galindo Izquierdo, M 550 Galindo-Feria, AS 07 Gallagher, P 09, 44, 49, 50, 88, 48 Gallego Flores, A 788, 478 Galli, M 67 Gallinaro, AL 07 Gallo, A 490, 49 Gallo, G 55, 446 Gallo, G 5 Gallo, MC 89 Gallo, P 895 Gallucci, S 895 Galluccio, F 69 Gamache, P 756 Gamble, G, 74, 75 Gamboa-Cardenas, RV 40, 68, 5 Gamer, M 909, 575 Gamero, F 750, 65 Gamez Nava, JI 407, 40 Gamez-Nava, JI 599, 546 Gammill, HS 90 Gan, JB 8 Gan, K 77, 00, 857 Gan, RW 6, 869, 660 Gandarilla-Martinez, NA 546 Gandhi, K 07 Gandhi, R 44, 0 Gandjbakhch, F 85, 79 Ganeshalingam, K 866 Ganguli, A 449, 77, 7 Ganguli, AX 994 Ganguly, R 050 Ganguly, R Ganhasan, S 46 Ganiyusufoglu, E 5 Gao, A Gao, L 78 Gao, W 9 Gao, W 884 Gao, Y 597 Gaoatswe, G 484 Garay, SM 76 Garchon, HJ 489 Garcia, C 09 Garcia, F 57 García, J 65 García, M 750, 65 Garcia, M 69 Garcia, S 8 Garcia de la Torre, I 69 García González, A 750, 65 Garcia Kutzbach, A 446 Garcia Llorente, JF 556 García Manrique, M 440 García Serrano, J 750, 0, 65 Garcia Vivar, ML 556 García-Bermúdez, M 8, 8 García-Hernández, FJ 607 Garcia-Monaco, R 06, 855, 859 Garcia-Vadillo, A 48 Garcia-Valladares, I, 64 Garcia-Vallardes, I 58 Garcia-Vicuña, R 48,, 440, 644 García-Villanueva, MJ 89, 89 Gardiner, B 497 Garen, T 690, 697, Garg, N 06 Garg, N 90 Gargiulo, MDLA 594 Garnero, P 48, 756 Garrido, M 766 Garris, C 56 Garrood, T 50 Garside, P 76, 7, 7 Gartland, R 40 Garvey, WT 5, 54 Garwood, C 78, 047, 759 Garza Romero, AC 46 Garza-Elizondo, MA 8 Gascon, C 67 Gasparin, A 948 Gasse, P 60 Gaston, JH 47 Gatenby, P 787 Gathany, TA 45, 44, 54, 5 Gattamelata, A 79 Gatto, M Gattorno, M 98, 75 Gaudin, P 904 Gaudin, P 60, 88, 69, 87 Gaudric, J 766 Gauger, B 97 Gaujoux-Viala, C 50, 04, 7, 7 Gaur, P 89 Gautier, A 04 Gavin, I 84 Gawlak, S 88 Gay, G 09 Gay, RE 480, 40 Gay, RE 775, 5, 404, 406, 46, 850, 76, 87 Gay, S 480, 775, 5, 40, 404, 406, 46, 850, 76, 87 Gayet, V 554 Gaylis, NB 877, 5 Gaylord, S 59, 689 Gayraud, M 469 Gazivoda, V 568 Gea-Banacloche, J 60 Gebe, J 8 Geborek, P 76,, 789, 684 Geier, J 440, 80 Geijer, M 9, 46 Geirsson, J 4 Geissler, J 78 Gelber, AC 8 Gelber, SE 989 Gelderman, KA 958 Geldhof, A 04, 04 Gelfand, J 0 Gelfand, JM 05 Genant, HK 86 Genant, HK 84, 800 Genc, H 08 Geneva-Popova, M 8 Geng, L 698 Genin, C 60, 69 Genovese, MC 48, 444 Genovese, M 456 Genovese, MC 8, 0, 44, 455, 459, 87, 876, 44, 4, 7, 79, 88, 8 Genovese, M 454 Genre, F 8, 8 Gensler, LS 505, 54, 446, 448, 480, 840 Gentil, CA 90 Geoffroy, M 04 George, AT 567, 57 George, D 97 George, J 74 Georgel, P 60 Geppert, TD 74 Geraldino-Pardilla, L 65 Gerards, AH 87, 57, 69, 77 Gerber, L 500 Gerdts, E 404, 4 Gerhardsson de Verdier, M 99, 64 Gerhold, K 77 Gerin, M 09 Gerloni, V 69, 69 Germanò, G 8, 9, 666 Gerosa, M 9 Gertel, S 89 Gertner, E 6 Gestin, S 88 Geyer, M 6 Geyik, E 5 Ghasem-Zadeh, A 867 Ghayur, T 555 Ghazarian, SR 59 Ghelani, P 7 Ghinoi, A 67 Ghislain, PD 4 Ghodke, Y 6 Gholizadeh, S 87, 908 Ghosh, D 70 Ghout, I 807 Giacomelli, C 0,, 900, 8 Giacomelli, R 9 Giacomelli, R 57 Giaglis, S 46, 49 Gianfreda, D 5, 789 Giannetti, B 095 Giannini, C 660 Giannini, EH 790 Gibbon, M 87 Gibertini, P 806 Gibney, J 484 Gibofsky, A 9, 95, 0, 046, 047, 65 Gibson, J 56 Gibson, K 94 Gierut, AK 70 Gigante, MR Giger, ML 890 Gignac, MA 907, 84, 847 Gilbane, AJ 649 Gilbert, K 66 Gilburd, B, 57 Gilchrist, DS 94, 944, 947, 4 Giles, BM 70 Giles, C 864 Giles, G 67 Giles, I 4, 8,, Giles, JT 5, 65, 49, 685 Gilgeours, E 487 Gilkeson, GS 5, 54, 55, 565, 57, 604, 65, 6, 69, 767, 505 Gill, A 7 Gill, TM 6, 854 Gill, TK 0 Gillain, S 89, 48 Gillespie, J 57, 709 Gilliam, B 96, 97 Gilliland, WR 869 Gillis, BS 84 Gillooly, AR 7 Gilson, M 96, 469 Giltiay, NV 8 Gímenez, M 9 Gindea, S 56 Ginsberg, S 47, 0, 0, 054 Ginzler, EM 59 Ginzler, EM Program Book

405 Gioffredi, A 760 Giordo, R 66 Giovannoni, L 74 Giovannucci, DR 668 Giovannucci, E 09 Giraldo, CL 9 Giray, E 5 Girodon, J 467 Girton, M 50 Gissler, M 04 Gitelman, D 76 Giuggioli, D 09 Giuliano, VJ 96 Gjertsson, I 80 Gkrouzman, E 57, 86 Gladman, DD 59 Gladman, D, 6, 6, 47, 5, 579, 6, 7, 558, 807, 894, 50, 50, 508, 54, 557, 78 Gladman, DD 6, 0, 7,,, 9, 4, 48, 585, 64, 65, 86, 55, 58, 58, 584, 45, 47, 57, 5, 780 Gladue, H 579, 584, 597 Glant, TT 56, 56, 99, 896, 697, 74 Glas, CAW 9 Glaser, MS 05, 06 Glaves, P 95 Glazier, RH 080 Glebova, N 7 Glenn, SB 565, 65, 77 Glicklich, A 76 Glintborg, B 84, 4, 44 Glojnaric, I 9 Glossop, J 874 Glynn, EH 78 Glynn, RJ 6, 09, 70, 658 Go, Y 6 Gobbi, C 5 Gobbo, M 475 Gobert, P 744, 78 Godar, D 4 Goddard, JH 74 Godeau, B 4, 09 Godfrin-Valnet, M 5 Godmann, L 50 Godmer, P 744, 78 Godoy, A, 58 Godwood, A 7, 77, 78 Goeb, V 50, 488, 8, 880 Goedken, E 74 Goehler, H 909 Goekoop, RJ 460 Goemaere, S 86 Goertzen, NJ 98 Goetz, J 04 Goffin, L 70 Gogus, F 6 Goh, N 678 Goilav, B 550, 6 Goker, B 60, 5 Gokmen, F 66 Gokpinar, HH 0 Gokun, Y 97, 98 Gold, DT 8 Gold, KN 8 Gold, L 764 Gold, M 095 Goldbach-Mansky, R 764, 65, 90, 864 Goldbach-Mansky, RT, 78, 74 Goldberg, G 69 Goldeinstein-Schainberg, C 84 Goldenberg, DL 8, 85 Goldenstein-Schainberg, C 904, 07, 55, 9 Goldfine, A 658 Goldin, J 68 Goldmuntz, EA 765 Goldring, MB 60 Goldring, SR 70 Goldsmith, CH 97, 984, 708 Goldsmith, DP 7 Goldstein, BL 846 Goldstein, N 48 Goldstein, R 064 Golightly, YM 6, 67, 900, 078, 76 Gomariz, RP Gombault, A 60 Gomes, CMF 486 Gomes, PS 69 Gómez, G 86, 594 Gomez Arango, C 788, 556 Gomez Bañuelos, E 40 Gomez Reino, J 495 Gomez Rodriguez-Bethencourt, A 66 Gomez vaquero, C 8 Gómez-Arriaga, PI 550 Gómez-Gerique, J 469 Gómez-Hernández, G 650 Gómez-León, J 694 Gómez-Martín, D 579, 580, 66 Gomez-Ramirez, M 8 Gomez-Ramirez, O 84 Gomez-Reino, JJ 445 Gomez-Reino, J 496, 500 Gomez-Reino, JJ 0, 7,, 48, 86 gomez-vaquero, C 40 Goncalves, C 75 Gonçalves, CR 4, 07, 470 Goncalves-Alves, E 6 Gondoin, B 755 Gono, T 59, 65, 06, 070, 075 Gonullu, E 749 Gonzalez, B 68 Gonzalez, CM 47 Gonzalez, E 546 Gonzalez, M 79 Gonzalez, S 8, 78 González Álvarez, A 47 González Cano, R 857 Gonzalez Diaz, V 40 Gonzalez Fernandez, C 78 González López, L 407, 40 González Lucero, L 86 González Montoya, NG 407 González-Alvaro, I 48, 808,, 8 González-Amaro, R 66 gonzalez-conejero, R Gonzalez-Diaz, A 66 González-Escribano, MF 89 Gonzalez-Gay, MA 440 González-Gay, MA 788, 975 Gonzalez-Gay, MA 76, 89, 89, 8, 8, 687 González-Gay, MA 808, 750, 0, 65, 6, 64 González-Juanatey, C 8, 8, 975 González-Lamuño, D 64 González-Lamuño, D 6 Gonzalez-Lopez, L 599, 546 González-López, MA 6, 64 Gonzalez-Reyes, JA 887 González-Rivera, T 97 González-Rodríguez, C 0 González-Suárez, S 750, 0, 65 González-Vela, MC 6, 64 Gonzalo-Gil, E 550 Goodacre, L 60, Goodall, JC 47 Goode, AP 49, 897, 855 Goodman, SM 506, 5, 8, 0, Gopalakrishnan, R 77 Gordo, J 904 Gordon, C 59, 59, 606, 696, 78, 79, 94, 50, 55 Gordon, JK 709, 746, 566, 580, 589 Gordon, KB 4 Gordon, MM 7 Gorelik, G 75 Goren, A 0, 0 Gorlova, O 79 Goronzy, JJ 69, 70 Goss, S 45 Goss, SL 48, 467 Gossec, L 50, 50 Goto, D 666 Gottenberg, JE 495, 664, 4, 469, 488, 04, 60, 77, 808, 880, 90 Gottlieb, AB 0, 9,,, 695 Gottlieb, BS 78, 790, 780, 79 Goudie, CT 46 Gourlay, ML 0 Govoni, M 446, 477, 479, 5, 9 Govoni, M 0, 989 Gow, PJ 74, 090 Goyanes, N 69 Grabell, D 656 Grabiec, AM 86, 7 Grabulovski, D 9, 5 Gracia-Pérez, A 47 Graeber, A 90 Graessel, S 85 Graf, JD 665 Graf, N 70 Graff, C 74 Graham, A 9 Graham, N 470, 55, 58 Graham, RR 707, 877 Graham, T 6, 96 Grahn, A 55, 65 Grainge, MJ 80, 99 Gram, H 69 Grammatikos, AP 70 Grammer, A 60 Grams, M 9 Gran, JT 697 Granath, F 04 Granel, A 86 Granholm-Bentley, AC 55 Grant, G 00 Grant, T 49 Granton, JT 9, 576, 577, 98 Gratacos, J 440 Grateau, G 09 Grauer, A 86 Gravallese, EM 65, 84, 8, 964, 904 Graven-Nielsen, T 86 Graves, S Grayson, PC 756, 786 Graziani, G 00 Grech, L 98 Green, AB 60 Green, C 87 Green, C 74 Green, J 450 Greenberg, JD 48 abstract author Index Gofita, I 500 Gondaira, F Program Book 40

406 abstract author Index Greenberg, JD 9, 00, 04, 8, 6, 70, 9, 46, 78, 040, 047, 048, 79, 95, 0, 45, 45, 48, 707, 885, 887, 008, 44, 759, 87, 877 Greenberg-Dotan, S 05 Greenblatt, MB 7 Greenlees, L 50 Greenler, AJ 844, 65 Greenspan, S 9 Greenwald, MW 87, 877 Gregersen, PK 6, 47, 876, 704, 707, 890, 88, 659, 660, 79, 877 Gregory, C 05 Greisen, S 94, 7 Greloni, G 60 Gremese, E, 67 Gremmelsbacher, E 04 Grenier, P 78 Grenn, RC 57 Grenningloh, R 87 Gress, R 60 Greth, W 578, 5 Grewal, HK 0, 04 Grewal, S 58 Grey, A 586 Grieco, G 67 Griffin, N 79 Griffiths, CEM 4 Griffiths, E 74 Griffiths, G 8, 78 Grigioni, S 8 Grigorian, M 569 Grillet, BA 799, 87, 57, 77 Grimaldi, C 40 Grins, E 4 Gripp, TEH 69 Grisanti, JM 4 Grisanti, L 4 Grisanti, M 4 Grisius, M 498 Groetsch, B 7 Grom, AA 98 Gronau, T 75 Grondal, G 4 Groot-Koerkamp, M 49 Grooten, WJA 980 Grosbois, B 69 Gross, AJ 4 Gross, KD 54, 07, 67 Gross, T 50 Gross, WL 786 Grossi, C 9,, 5, 566 Grossman, JM 6, 885, 66, 78, 900 Grotzke, M 965, 97, 978, 98, 87 Großkreutz, J 760 Gruben, D 48, 440, 44, 48, 794, 977, 9, 4 Gruben, D 8, 46 Gruenke, M 95 Grundahl, K 50, 509 Grundtman, C 405 Grunewald, J 4 Grydehøj, J 478 Gu, F 565, 69 Gu, J 848, 8 Gu, J 0, 6, 64, 479 Gualano, B 054, 57, 545 Gualtierotti, R 707 Guan, Y 554 Guañabens, N 4 Gudbjornsson, B 4, 05 Gudman, NS 70, 879 Gudnason, V 05 Guenet, L 69 Guermazi, A 7, 6, 7, 0, 9, 75, 754, 856 Guernec, G Guerra, MM, 765 Guettrot-Imbert, G 84 Gugel, EG 87 Guglielmi, B 08 Guh, D 997 Guiducci, S 69 Guillaume, C 04 Guillemin, F 50, 04, 4, 50, 654, 87 Guillén-Del Castillo, A 608 Guillevin, L 695, 74, 744, 757, 758, 759, 4, 67, 78, 784, 84 Guillot, X 050 Guillou, C 59 Guis, S 96, 469 Gul, A 09, 680, 45 Gulati, A 555 Gulati, G 97 Gulati, N 58 Gulati, R 59 Guler, I 0 Gulinello, M 54, 56 Gulko, P 46, 78, 74, 87 Gullick, NJ 50 Gullstrand, B 0, 576, 544 Gulluoglu, H 48 Gulseren, A Sr. 08 Guma, M 85 Gunaratnam, C 05 Gunawardhana, L 78 Gunduz, OH 5, 457 Gunendi, Z 6 Gungor, T 468 Gunnarsson, I 54, 769, 797, 898 Gunraj, N 6 Guo, C 57 Guo, CY 04 Guo, J 49 Guo, S 545 Guo, X 77, 94 Guo, X 655 Gupta, A 668 Gupta, R 7 Gupta, R 59 Gupta, S 844 Gupta, S 667 Gurel Polat, N 680 Gurion, R 70, 674 Gustafsson, J 769, 898 Guterres, LW 4 Guthridge, JM 65, 565, 68, 70, 767, 809, 864, 549, 77 Gutierrez, L 55, 56 Gutierrez, M 94 Gutierrez-Manjarrez, J 558 Guttmann, A 6 Gutwein, F 749 Guzman, J 84, 94, 790 Gvozdenovic, E 09, 79 Gül, A 70, 879 Györi, N 970 Gärtner, M 85, 05 Göhler, H 575 Görgen, S 497 H Ha, CM 97 Ha, YJ 787, 99,, 9, 5 Haacke, E 5 Haak, A 56 Haake, R 976 Haas, JP 99 Haas, RW 5, 76 Haase, C 54 Haavardsholm, EA 9 Hachulla, E 50, 695, 78, 4, 488, 09, 579, 750, 84, 880 Hacioglu, A 08 Hack, CE 949, 76 Hack, E 858 Hackett, J 68 Hackney, B 970, 09 Hackshaw, KV 4 Hadavi, S 6 Haddad, A 5, 78 Haddad, E 7 Haddon, DJ 794 Haddon, D 86 Hadi, K 4 Hadigan, C 78 Haehre, L 095 Hafiz, B 98 Hafström, I 60 Hagedorn, TJ 90 Hagel, S 04, 0 Hagihara, K 67 Hagiwara, S 666 Hagiya, C 50 Hahn, BH 6, 885, 605, 66, 808 Hahn, S 46, 49 Hahne, M 97, 98, 7 Hahne, M 447, 458,, 40 Hai, T 85 Haibel, H 56, 55, 45, 466, 49, 88 Haile, S 59 Haines, GK III 70 Haines, KA 70, 504, 789 Haji, A Haji, Y 9, 567 Hajj-Ali, R 7, 657, 658, 667 Hajnal, JV 9 Hakim, F 60 Hakky, M 0 Halbritter, D 76, 649 Hall, J 7 Hall, S 464, 00, 44 Hallegua, D 59 Halliez, M 69 Hallstrom, B Halsall, D 667 Halushka, M 764 Hama, M 945, 96, 074 Hamada, K 00 Hamaguchi, Y 748, 069 Hamann, D 90 Hamann, HA 6 Hamann, J 54 Hambardzumyan, K, 789 Hamburger, J 57 Hamburger, MI 484, 86, 468 Hamidou, M 78, 744, 09, 69, 750, 84 Hamijoyo, L 566 Hamilton, BJ 95 Hamilton, BC III 8, 78 Hamilton, J 9 Hamilton, T 667 Hamilton, W 895 Hammad, T 657, 658 Hammaker, D 50 Hammer, A 585 Hammer, HB 79, 94, 946 Hammond, S 654 Hammoudeh, M 58 Hamuryudan, V 69, 66 Hamuza, M 77 Han, BG 6, 400 Han, B 704, 88, 885, 99 Han, C 0,, 45, 44, 46, 54, Program Book

407 Han, KH 47, 48, 460, 69 Harle, JR 66, 755 Hashizume, M 940, 855 Hazlewood, GS 475 Han, L 854 Han, R 964 Hanabayashi, M 479 Hanami, K 45 Hanaoka, H 066 Hanaoka, M 59, 06, 070, 075 Hanaoka, R 80 Hanci, I 6 Handler, C 58, 588, 59 Hands, R 4 Haney, D 788 Haney, DJ 789 Hanley, JG 607 Hanly, JG 00, 59, 906, 896 Hanna, B 056 Hanna, BD 554 Hanna, F 47 Hannaford, P 848 Hannan, J 9 Hannan, MT 899, 900, 90, 757, 76 Hannon, MJ 069, 754 Hanova, P 94, 947 Hanrahan, LM 808 Hansbro, P 695 Hansen, A 4, 46, 44 Hansen, BB 68 Hansen, C 608 Hansen, G 40 Hansen, I 875, 40, 687, 80 Hansen, IJW 09 Hansen, IMJ 478 Hansen, MS 056, 46 Hansen, NU 70 Hansen, R 8 Hansen, U 75 Hanslik, T 477 Hanson, E 764 Hanssen, AD 85 Hansson, M 9, 9, 44 Hant, FN 970 Hanta, I 64 Haqqi, TM 74, 767 Hara, M 880 Hara, R 9, 7 Hara, Y 67 Harada, T 4, 89 Harada, Y 64 Haraoui, B 5, 74, 40, 4, 489, 06, 09, 8, 9, 4, 46, 464, 475, 79, 4, 5, 75, 76, 85, 87, 96, 99,, 7, 84, 866, 868, 869 Hardiman, Y 49 Harel, L 69, 69, 64 Harel-Meir, M 6 Harigae, H 49, 68, 68 Harigai, M 749, 45 Harley, JB 69 Harley, JB 570, 489, 6, 6, 65, 68, 767, 70, 7, 77, 770, 77 Harlow, L 778 Harmer, A 95 Harmsen, WS 90, 96, 4 Haroche, J 6, 564, 00, 09 Haroon, M 09, 5, 44, 49, 50, 88, 48, 779 Haroon, N 58, 507,, 480, 488, 494, 495, 777 Harper, D 4, 9 Harper, J 860 Harper, L 746 Harrach, S 9 Harris, EN 9 Harris, HE 405, 65 Harris, J 679 Harris, JG 845, 64, 65, 79 Harris, RE 597 Harris, V 50 Harrison, DJ 47, 999, 00 Harrison, DD 04, 04 Harrison, H 847 Harrison, P 8 Harrold, LR 9, 040, 044, 048, 95, 50, 48, 008, 5, 6, 7, 8, 70, 9 Harry, R 48 Hart, D 70, 704, 596 Hart, P 649 Hartgring, S 76, 858 Hartkamp, A 49 Hartmann, A 676 Hartmann, B 69 Hartson, L 68 Hartung, W 649, 969 Hartung, MD, V 7 Harvey, BP 86 Harvey, E 750 Harvey, J 588, 59, 608 Harvey, N 8 Harvey, NC 800 Harvey, P 6 Harvey, WF 5, 56, 044 Harvie, M 696 Haseeb, A 74 Hasegawa, A 6, 64 Hasegawa, M 748 Hasegawa, T 869 Hashimoto, A 7, 07, 56 Hashimoto, H 4 Hashimoto, H 67 Hashimoto, J 8, 64 Hashimoto, K 9 Hashimoto, M 465, 9, 0 Hashimoto, R 097 Hashiramoto, A 0 Hashkes, P 504, 64 Hashkes, PJ 790 Hasler, P 46, 49 Hasnain, S 695 Hasni, SA 559, 60, 844 Hassan, SAM 9 Hassell, A 0 Hasselquist, M 46 Hassett, AL 504 Hasunuma, T 86, 64 Hata, Y 0 Hatano, H 7, 655 Hatano, M 59 Hatem, J 4 Hatemi, G 76, 65, 08, 69, 66, 6 Hatoum, H 00, 009 Hatron, PY 744, 488, 750 Hatsukami, T 94 Hatta, K 764 Hatterer, E 9 Hattori, H 06 Hattori, Y 40, 49, 455 Hauge, EM 97 Haugeberg, G 09,, 555, 688 Haugen, AJ 87, 94 Haugen, IK 4, 65 Haughey, D 49 Hawellek, T 50 Hawke, C 99, Hawker, GA 96, 9 Hawkins, PN 748 Hawley, J 8 Haworth, K 874 Hawtin, R 876, 88 Hawtree, S 44, 874 Hay, A 88 Hay, MC 90 Hayashi, D 7 Hayashi, H 56 Hayashi, M 448, 70 Hayashi, S 94, 77 Hayashi, T 7 Hayata, A 6 Hayden, CL 47 Haye Salinas, M 5 Hayem, G 880 Hayes, KW 0 Hayes, W 75, 754 Haynes, K 0, 4, 40 Hays, R 08, 607 Hazen, MM 95 Hazes, JMW 87, 69, 77, 889 Hazes, J 97 Hazes, JMW 08, 4, 98, 57 Hazes, JM 68 Haznedaroglu, S 60 Hazra, A 445 He, B 6 He, H He, P 45, 69 He, Y 70 Healy, ML 484 Heap, D 94, 9 Heare, T 80 Hebden, T 56 Hebert, D 750, 75, 754 Hébert, H 57 Hedges, W 45 Hedrich, C 557 Hedrich, CM 74 Heegaard, NHH 60, 659, 576, 47 Heeringa, P 78 Heffernan, EJ 50, 48 Hefner, KS 50, 77 Hegazi, M Hegen, M 88 Heijnen, C 857, 858 Heimans, L 799 Hein, MS 057, 07, 08 Heinz, DE 80 Heitzmann, M Hekmat, K 68 Helder, B 8 Heldmann, F 06, 6, 80 Helfgott, SM 09 Helgetveit, K Heller, T 78 Helliwell, PS 5, 40, 84 Helmick, CG 95, 46, 078, 696, 909 Helsen, MM 766, 94 Hemeryck, A 87 Hemmati, I 76, 84 Hemmelgarn, B 96 Hench, R 4 Henderson, LA 95 Henderson, S 794 Hendricks, O 478 Hendrickson, AF 78 Hendriks, E 09 Hendriks, RW 7 Hendrikx, J 66 Hendrikx, T 44 Henein, S 668 Henes, JC 0 Henkel, M 485 Henkemeier, U 97 Hennessy, O 678 Hennessy, S 0 Hennig, T 095 Henningsen, P 88, 89 Hennze, R 95, 856 abstract author Index 0 Program Book 405

408 abstract author Index 406 Henriksen, K 7 Henriksen, M 86, 7 Henrotin, Y 76, 8, 69, 7 Henry, B 750 Henry, YM 986 Henry Dunand, C 794 Hensor, E 766 Hensvold, AH 7, 44 Herbst, R Herfkens-Hol, S 7 Herlin, T 95, 7 Herlitz, L 550, 56 Herlitz-Lindberg, M 898 Herlyn, K 05 Herman-Kideckel, S 96 Hermann, KGA 56, 55, 800, 88 Hermida-Carballo, L 846 Hermida-Gómez, T 77 Hermiston, M 4 Hermsdorf, A 64 Hernáez, ML 60 Hernandez, JA 89 Hernández, MV 0, 788, 9, 870 Hernández, MV 4, 44, 444 Hernandez, V 96 Hernandez Grafella, M 750, 65 Hernández Martínez, M 0 Hernández-Díaz, C 960 Hernandez-diaz, S 09 Hernández-Hernández, V 66, 05 Hernandez-Molina, G 506, 486 Hernandez-Oropeza, JL 558 Hernández-Rodríguez, 400 Hernández-Rodríguez, J 89 Hernando Rubio, I 08 Herold, M 06, 9 Herráiz, I 550 Herrath, J 64, 648 Herrera, BM 55 Herrera, D 57 Herrera-Garcia, A 96 Herreras, J 750, 0, 65 Herrero, M 6, 46 Herrero-Beaumont, G 57, 60, 64, 687 Herrero-Beites, AM 9, 987, 00 Herrick, A 679 Herrinton, L 50 Hershfield, M 894 Hervier, B 78, 00, 07 Herzer, P 806 Heslinga, SC 54, 454, 455 Heslop, PS 0 Hess, C 54 Hesselstrand, R 50 Hessey, EW 4 0 Program Book Hetland, H 688 Hetland, M 496, 500, 478 Hetland, ML 84, 448, 875, 40, 46, 44, 687, 80, 90 Hetland, ML 07, 6, 4, 495, 94, 08, 47, 7 Heuer, KU 54, 55 Hewitt, A 705 Hewlett, S 08 Hewson, N 7 Hey-Hadavi, J 6 Heydt, PA 79 Heywood, J 647 Heywood, W 4 Hibberd, ML 78, 880 Hicks, LS 987 Hidaka, T 0, 4 Hidalgo, B 8 Hidalgo-Conde, A 89 Hié, M 6, 564 Hiepe, F 549, 7 Higami, K 465 Higashi, K 76 Higgins, GC 78, 790, 77, 675 Higgs, BW 50, 7, 645, 94 Higgs, JB 7, 85 Higuchi, C 8 Higuchi, T 65 Higuchi, T 05 Higuera, V 57 Hiki, Y 6 Hildreth, P 66 Hilkens, C 48 Hill, AA 809 Hill, CL 0, 47 Hill, E 7 Hill, J 7 Hill, S Hill, SC 78 Hillen, J Hillen, MR 949 Hilliquin, P 75 Hillmann, A 889 Hillson, JL 07, 808 Hillstrom, HJ 54, 76 Hinchcliff, ME 586 Hindrup, JS 84 Hinks, A 88, 99 Hinojosa, M 78 Hinojosa-Azaola, A 07 Hinton, M 9 Hirabara, S 479 Hirabarashi, Y 9 Hirabayashi, Y 68 Hirakata, M 066 Hiraki, LT, 780, 848, 77, 656, 657, 679 Hirano, D 6 Hirano, M 59 Hirano, T 67 Hirano, Y 65, 69, 70 Hirao, M 8 Hirata, S 45 Hirata, S 055 Hirayama, Y 880 Hirohata, S 67, 79, 59, 600, 60, 47, 585 Hiromura, K 880 Hiron, M 904 Hirosaki, Y 5, 94 Hirose, K 00 Hirota, T 666, 50 Hirsch, D 40 Hirsch, R 66, 69 Hirschenhahn, E 97 Hirschfield, G 88 Hirsh, JM 846, 0 Hiruma, K 5 Hisamoto, S 5, 94 Hisdal, J 40 Hishitani, Y 67 Hislop, C 604, 74 Hissink Muller, PCE 9 Hitchon, CA 74, 44, 06, 09, 8, 9, 4, 94, 475, 79, 8, 8, 4, 75, 76, 96, 866, 868, 869 Hiwa, R 9, 0 Hizmetli, S 9 Hjalte, F 769 Hladik, A 85 Hmamouchi, I 50 Ho, LY 60, 608 Ho, M 9, 78, 047, 0, 79, 759 Ho, P 699 Ho, P 57 Ho, PR 7 Ho, V 4 Hoa, S 5 Hoang, LT 78 Hoang, LT 880 Hoang, T 9 Hocevar, A 508, 65, 66 Hochberg, M 04, 04 Hochberg, MC 889 Hochberg, MC 95, 5, 040, 49, 75 Hockings, P 94 Hodge, J 444, 794 Hodgin, J 54 Hodgson, LA 45 Hodgson, RJ 65 Hoeck, HC 79 Hoeltzel, MF 97, 07 Hoepfner, M 786 Hoepken, B, 799 Hofer, F 06, Hofer, M 70 Hoff, M 555 Hoff, P 97, 98 Hoffman, GS 79, 74, 747, 756, 667, 669, 670, 78 Hoffman, H 748 Hoffman, HM Hoffman, RW 88 Hoffman, S 647, 660 Hoffmann, PM 0 Hoffmann-Vold, AM 690, 697 Hoffmeyer, P Hoffstetter, C 04 Hofmann, HP 86 Hofmann, H 7 Hofmann, M 97 Hofmann-Preiss, K 95 Hogan, SL 75 Hogg-Johnson, S 080 Hoglund, P 746 Hoh, SF 74 Hoi, AY 64, 566, 76 Hokanson, JE 74 Hokken-Koelega, ACS 97, 98 Holdaas, H 676 Holden, V 6 Holers, VM 6, 80, 869, 87, 9, 74, 407, 659, 660 Holgado, S 9 Hollan, I 7, 88, 405 Holland, SM 844 Holland-Fischer, M 4 Hollands, S 770 Holle, J 0 Hollis, S 79 Hollis-Moffatt, JE 60 Hollywood, J 66 Holmdahl, R 5, 44 Holme, I 85 Holmes, AM 649 Holmqvist, M 78, 047, 40, 405, 759 Holroyd, CR 800 Holt, R 55, 65 Holt, T 67 Holweg, CTJ 07 Holzinger, D 667, 784 Holzkämper, T 4 Hom, J 4, 798 Homik, J 96 Honda, K 05, 079 Honda, S 0 Hong, EC 6 Hong, F 57 Hong, SD 77, 504 Hong, S 450, 0, 0, 445 Hong, SJ 0, 5, 5, 464 Hong, S 59 Hong, YK 69 Honjo, S 4 Honne, K 477 Hoogeboom, T 87

409 Hoogland, W 57 Hreniuk, D 4 Hughes, P 77 Huynh, DH 04, 400 Hooper, M 8 Hrncir, Z 596 Hughes, RG 5 Hvid, M 96, 94, 859, 7 Hootman, JM 95, 46, 078 Hruska, J 70, 7 Hughes, RA 08 Hwang, J 6, 755, 6, 90 Hooven, FH 4 Hrvacic, B 9 Hughes, T 70, 77 Hyland, D 74 Hopia, L 599 Hopkins, AC 45 Hopkins, G 95 Hoppe, M 6, 967 Horai, Y 69, 0, 6, 960, 069 Horak, P 596 Horan, G 80 Horcajada, MN 8 Horikoshi, M 666 Horino, T 00 Horita, T 7, 68 Horiuchi, T 5, 94 Horlock, H 984 Horn, HC 875, 80 Hornburg, VT 095 Hornby, Z 59 Horne, A, 5, 75 Horne, L 9, 78, 047, 0, 759 Horne, W 485 Horneff, G 68, 7, 7, 80, 79, 79, 795, 06, Hornum, L 54 Horst, G 665 Horton, R 905, 988, Hoshi, D 44 Hoshino, K 748 Hoshino, T 854 Hosoya, T 79 Hossain, MS 08 Hosseini, K 04 Hossler, J 54 Hostager, B 69 Hot, A 750 Hotta, S 84 Hou, C 6, 64 Hou, KL 98 Houghton, K 69, 69 Houghton, KM 94, 865 Houk, J 96, 79 Hourani, L 970 Hourcade, D 865 House, M 75 Housset, B 78 Houssiau, F 6, 78, 79 Houssiau, FA 67, 40, 7 Houston, GD 50, 77 Houweling, LMA 04 Howard, DG 868 Howard, TD 86 Howe, A 8 Howson, TL 9 Hoy, D 87 Hoyer, BF 7 Hreggvidsdottir, HS 49 Hrycaj, P 76 Hsia, EC 0, 45, 44, 46, 54, 5, 48 Hsieh, CM 948, 47 Hsu, A 764 Hsu, B 0, 800, 48 Hsu, HC 7, 9, 7, 745 Hsu, JJ 78 Hsu, VM 684, 69 Hsueh, W 8 Hu, C 0,, 7,, 48, 85, 86 Hu, DZ 7 Hu, F Hu, X 96 Hu, Y Hu, Y 75 Hu, Z 479 Hu, Z 0, 04 Huang, B 90, 790 Huang, CC 77, 087, 089 Huang, F 54 Huang, H 6, 64 Huang, J 85, 690, 57 Huang, L Huang, M 49 Huang, N 5, 058 Huang, QQ 5, 8 Huang, Q 5 Huang, WT 74, 709, 74, 896, 506, 57, 746, 86, 97, 5, 8, 0,, 55 Huang, W 796 Huang, X 7, 570, 645, 705 Huang, Y 78, 90 Huang, Y 5, 54 Hubbard, P 94 Huber, A 57, 98, 06 Huber, AM 865, 790 Huber, LC 775 Hubert, J 50 Huby, R 95 Hudelmaier, M 40, 670 Hudry, C 946, 808 Hudson, M 96, 756, 80, 586, 60, 95, 96 Hueber, AJ 405, 7, 485 Hueber, W 77 Huebner, JL 7 Huerta, AA 90 Huerta, M 599, 546 Huffman, C 850 Huffman, KM 7 Huggins, JL 844, 65, 79 Hughes, K 87 Hughes, LB 406 Hughes-Austin, JM 6, 659 Hugunin, M 948, 47 Huhtala, TA 965, 97, 98, 87 Hui, F 658 Huisman, AM 69 Huitema, M 5, 78, 88 Huitema, MG 645 Huizinga, TWJ 799, 46, 47, 48, 446, 460, 6, 79, 804 Huizinga, TW 788 Huizinga, TWJ 460, 808, 47 Huizinga, T, 55, 59, 549, 77, 80, 4, 45, 884, 886 Huizinga, TWJ 869, 90 Huizinga, TWJ 68, 688, 88, 94, 609, 809 Hulejová, H 950 Hull, D 9 Hum, D 48, 88 Humbert, M 579 Humbría, A 687 Humby, F 4 Hummel, J 57 Hummers, LK 699, 708, 586 Humphreys, JH 04 Hunder, GG 660 Hung, C 85 Hung, ST 49 Hungerford, DS 5 Hunt, KJ 5, 54 Hunter, CD 6 Hunter, D, 668 Hunter, DJ 89, 754, 757 Hunzelmann, N 76 Huppertz, A 6 Huppertz, C 95, 856 Huppertz, HI 7, 795 Hurkmans, E 09 Hurnakova, J 947 Huscher, D 04, 64 Huseyinsinoglu, N 45 Huskey, D 06 Huskin, A 8 Husmark, T 9, 46 Husni, ME 85, 08, 4, 557 Hussein, H 675 Hussein, H 96 Hussein Abd Elsamea, M 646 Huston, J III 660 Hutchings, A 895, 66 Hutchings, R 54, 45 Hutchinson, CE 679, 694 Huttenlocher, A 4 Huws, FA 4 Hyndman, D 7 Hynes, A 89 Hynes, K 47 Hyodo, M 00 Hyrich, KL 9, 45, 80, 04, 04, 678, 760 Hysenaj, N 08 Häuser, W 88, 89, 840, 85 Höhne-Zimmer, V 04 Høiseth, A 867 Højbjerre, L 68 Hørslev-Petersen, K 875, 94, 40, 687, 7, 80 I abstract author Index Iacopetti, V 060 Iagnocco, A 6, 79, 94 Iannaccone, CK 6, 68, 88 Iannone, F 495, 90 Ibanez, D 579, 64, 65, 58, 58, 807, 57, 5 Ibarra, C 55 Ibarra, MF 97, 77, 07 Ibrahim, Q 45 Ice, JA 50, 489, 565, 770, 77 Ichida, H 59, 65, 070, 075 Ichikawa, HT 5 Ichimura, Y 84, 706, 707 Ichinose, K 69, 888, 6, 960, 069 Ida, H 854, 069 Idier, I 75 Idler, K 57 Ieong, M 744 Igarashi, A 66 (IGAS), IGOASC 706 Igci, YZ 5 Igelmann, M 6 Ighe, A 54 Igoe, A 50 Ihata, A 945 Iizuka, M 50 Iizuka, N 49, 905 Ikari, K 74, 86, 6, 459, 707 Ikawa, T 465 Ikdahl, E 09, 84, 85, 40 Ikeda, K 7, 94 Ikeda, K 7 Ikeuchi, H 880 Iking-Konert, C 46, 0 Ikle, D 74, 747, 78 Ikuma, D 880, 570 Ilev, D 8 Ilhan, B 68 Ilizaliturri-Guerra, O 8 0 Program Book 407

410 abstract author Index Illei, GG 7, 498, 578, 60, 5 Illera, O 47 Ilowite, NT 99, 790, 6, 780, 88, 98 Im, CH 58 Im, HJ 76 Imamura, M 89 Imanaka, H 7, 75, 08 Imazio, M 75 Imboden, JB 758, 957, 967, 665 Immermann, FW 809 Imran, M 049 Imundo, LF 780, 675 Imura, Y 9, 0 Inaba, T 59 Inal, A 858 Inanc, M 59, 6, 680, 45 Inanc, N 96, 457, 69, 60, 80 Ince, A, 58 Inciarte, J 0, 9 Inciarte-Mundo, J 444 Indelicato, MG 96 Inderjeeth, C 49 Infante, O 45 Ingegnoli, F 707 Ingham, MP 08, 04, 0, 44 Ingleshwar, A 88, 80 Inkaya, AC 6 Inman, R 5, 5, 705, 90, 480, 495 Inman, RD 99, 507, 548,, 45, 488, 49, 496, 777 Innala, L 408 Inokuma, S 45 Inoue, E 86, 047, 6, 40, 44, 759 Inoue, K 00 Inoue, M 76 Insalaco, A 75 Insua, S 750, 65 (International Consortium For The Genetics Of SLE), S 88 Inui, K 96, 9, 449, 66 Inverardi, F 700 Investigators, LS 94 Ioannidis, C 74 Ioannou, J 8 Ioannou, Y 4,,, 560, 569 Ionescu, L 4 Ionescu, R 48, 49 Iozzo, R 75 IRBIS-EMA group, FT 6 Isaacs, JD 44, Isaacs, J 45, 48, 886 Isaacs, JD 68 Isaacs, JD 70 Isabelle, C 064 Isayeva, K 9, 64, 70 Isenberg, DA, 8, 6, 66, 640 Isenberg, DA, 56, 56, 57, 59, 59, 6, 5, 55 Isgro, J 905, Ishack, S 88 Ishida, MA 75 Ishigatsubo, Y 70, 945, 96, 074, 68 Ishiguro, N 49, 84, 45, 448, 455, 479,,, 65, 69, 70, 769, 800 Ishii, K 7 Ishii, S 7, 98, 57 Ishii, T 75 Ishii, T 49, 68, 0, 68 Ishikawa, H 40, 49, 455 Ishikawa, M 404 Ishikawa, O 65 Ishimatsu, Y 069 Ishimori, ML 767 Ishioka, E 840, 84 Isnard, R 0 Isojima, S 7, 98 Isola, M 67 Isozaki, T 7, 777, 97, 98 Israelsson, L 9, 7, 44, 40 Issartel, B 807 Ito, H 9, 0, 404 Ito, K 06 Ito, S 67, 4 Ito, S 67 Itoh, Y 74 Iudici, M 676, 906 Ivashkiv, LB 776, 96 Ivergård, M Iversen, LV 659 Iverson, W Ivetic Tkalcevic, V 9 Iwabuchi, K 7 Iwahashi, M 4 Iwai, H 79 Iwamoto, M 65 Iwamoto, N 69, 6, 960, 069 Iwasaki, T 56 Iwata, S 468 Izmirly, PM 6, 74, 75, 80 Izu Belloso, R 556 Izumi, K 4 Izumihara, T 4, 897, 9 Jabbarzadeh-Tabrizi, S 5, 94 Jaber, B 877 Jaber, N 05, 06 Jacek, EE 57, 86 Jackson, RD 5, 889, 75 Jacob, B 787, 45, 5, 9 J Jacob, CO 545, 6, 65, 69 Jacobe, H 656 Jacobi, AM 889, 0 Jacobs, E 709 Jacobs, EA 07 Jacobs, J 99 Jacobsen, S 54, 578, 60, 59, 607, 6 Jacobsson, L 88, 40, 407, 408, 976, 4, 4, 68 Jacobsson, LTH 804, 805, 54 Jacques, P 69 Jacquot, S 8 Jadeja, N 504 Jadon, DR 57 Jaeggi, E 8 Jaen, JC 79 Jaffe, J 796, 7 Jafri, F 559 Jaglal, SB 96, 9 Jakobs, R 95 Jakobsson, PJ 9 Jakobsson, PJ 7, 89, 44, 4 Jakstadt, M 97, 98, 7 Jalal, H 055, 646 Jalilian, B 96 Jamal, S Jamard, B James, E 8, 648 James, E 49 James, H 68 James, J 94 James, JA 69 James, JA 6, 58, 65, 88, 9, 489, 565, 65, 68, 64, 70, 767, 809, 864, 549, 77 Jang, SI 490 Jani, J 56 Janocha, A 657 Janot, A 0, 04 Janow, GL 789 Janse, RW 005 Jansen, DTSL 88 Jansen, JP 460 Jansen, TL 94, 0 Janssen, M 8, 70 Janssens, H 8 Jansson, E 980 Jansson, M 79 Jara, LJ 7, 694 Jaramillo, D 75, 8 Jarjour, WN 68, 68, 59 Jaros, M 046 Jarraya, M 0 Jarrel, J 794 Jarvis, JN 94, 0, 04, 06 Jasey, G 668 Jaskal, K 5 Jaskowski, T 4, 6, 67 Jauberteau, MO 86 Jaussaud, R 04 Javier, RM 04 Jay, N 09 Jayne, D 746, 66 Jean, S 756 Jedlicka, P 9 Jedrychowicz-Rosiak, K 454 Jefferies, C 868 Jeffreys, A 075, 855 Jeffries, MA 6 Jego, P 69 Jeka, S 4, 606, 76, 844 Jenei-Lanzl, Z 78, 86 Jenkins, M 455 Jenks, S 4,,, 68 Jennings, F 8 Jensen, DV 478, 7 Jensen, EK Jensen, HS 7 Jensen, J 478 Jensen Hansen, IM 08 Jensen-Urstad, K 898 Jeon, CH 69, 6, 006, 90 Jeon, JY 69 Jeong, DC 494, 4, 77 Jeong, H 6 Jeong, J 689 Jeong, YG 8 Jepson, B 74, 747, 78 Jetha, A 907 Jhingran, PM 006 Ji, JD Ji, RR 7 Jia, Q 570 Jia, Y 7, 75 Jian, J 87 Jiang, J 50 Jiang, K 94, 0, 04, 06 Jiang, X, 875, 97, 656 Jiang, Y 0 Jiao, J, Jibaja-Weiss, M 98 Jie, S 94 Jimenez, SA 559, 560, 56, 564, 565 Jimenez-Fernandez, S 05 Jiménez-Núñez, FG 48 Jimenez-Zorzo, F 750, 65 Jin, HM 6 Jin, JP 5 Jin, L 568 Jin, L 94 Jin, O 6, 64 Jin, Z 64 Jindal, RM 90 Jobanputra, P 60 Joergensen, TS 478, Program Book

411 Jog, N 55 Johansen, J 6, 40, 687 Johansen, JS 875, 80 Johansson, I 7 John, A 6, 70, 48, 48, 44, 87 John, M 77, 754 John, S 657, 658 Johnsen, L 4 Johnson, A 790 Johnson, C 685 Johnson, DS 809, 09 Johnson, DL 99, 046 Johnson, H 07 Johnson, HM 75 Johnson, JK 098 Johnson, K 8 Johnson, MC 57 Johnson, P 8 Johnson, SR 5, 9, 675, 685, 576, 577, 599, 6, 98 Johnston, C 598 Johnston, D 670 Johnston, J 696 Jolly, M 88, 60, 884, 56 Jonas, BL 970, 890, 406, 8 Jones, A 96, 96, 9 Jones, A 89, 099, Jones, A 0, 78, 7 Jones, C 986, 5 Jones, DL 094, 00 Jones, D 70 Jones, DM 40, 77, 0, 485 Jones, GT 56 Jones, GT 84, 776 Jones, G 5, 8, 9, 55, 47, 48, 56, 755 Jones, H 40,, 47 Jones, H 7 Jones, JD 95 Jones, JT 844, 76 Jones, M 80 Jones, M 768, 856 Jones, N 586 Jones, O 08 Jones, P 9 Jones, S 658 Jones, TV 48, 44,, Jonsson, IM 76 Jonsson, J 697 Jonsson, MV 508, 878 Jonsson, R 508, 88, 770, 77, 878 Joo, H 8, 00 Joo, K 8 Joo, KB 5, 90, 46 Joo, SH 440, 07, 44 Joo, YB 90, 46 Joos, R 69, 69, 68 Joosten, LA 766, 94, 740 Jordan, JM 46, 49, 67, 897, 900, 076, 76, 889, 89 Jordan, N 580, 58, 568, 679 Jordan, N 00, 55, 56 Jordana, M 40 Jorgensen, C 5, 54, 79, 4, 898 Jorgensen, T 546 Joseph, G 47, 00 Joseph, L 577, 740, 8 Joshi, A 460 Joshi, AD 46 Joshua, V 9, 7, 89, 44, 4 Jou, IM 78 Jougla, E 66 Jouhet, V 467 Joung, CI 0, 755 Jourde, N 66 Jourde-Chiche, N Sr. 755 jousse-joulin, S 6, 507, 508, 50, 85, 946, 880, 88 Jovaisas, A 9, 5, 85, 7, 84 Jovaisas, AV 46, 5 Jovani, V 750, 65 Jover, JA 47, 67, 86, 644 Jovinge, S 88, 4 Ju, JH 494, 4, 77 Ju, Y 8 Juanola, X 440 Juarez, L 60 Juarez, RV 86, 60 Juárez-Arellano, S 598, 60 Juarranz, Y Juday, T 458 Judge, A 05 Juhn, Y 0 Julià, A 90 Juliao, H 57 Jun, JB 6, 5, 5, 80, 400, 46, 80 Jung, E 889 Jung, JY 69 Jung, J 400 Jung, KH 8 Jung, LK 08 Jung, SM 494, 4, 77 Jung, S 70 Jungel, A 46 Junker, P 6, 875, 40, 687, 80 Juraschek, S 8 Jurcic, V 65, 66 Jurencak, R 84, 865, 79 Jurik, AG 96, 84 Jury, EC 640 Justa, S 76 Jutkowitz, E 856 Juul, L 578 Juyal, M 96 Jüngel, A 480, 40 Jürisson, M 04, Jänne, OA 78 Jönsen, A 0, 576, 769, 544 Jönsson, G 76 Jörholt, J 65 Jørgensen, A 875, 40, 687, 80 K Ka, Z 489 Kabala, PA 7 Kabala, PA 86 Kaburaki, M 86, 64 Kachaochana, A 089 Kadavath, S 500 Kadi, A 489 Kadikoylu, G 40 Kaegi, T 59 Kaeley, GS 467, 944, 686, 85 Kaestner, P 46 Kafaja, S, 4, 87, 908 Kaffenberger, B 68 Kageyama, G 67 Kahaleh, B 668, 80 Kahlenberg, JM 54, 6 Kaieda, S 854 Kairalla, R 90 Kairalla, RA 69 Kaiser, S 4 Kaji, K 748 Kajiyama, H 45, 880, 570 Kalabic, J 79 Kalaitzidis, D 4 Kalari, S 04 Kalekar, L 7 Kalish, RA 960 Kaliyaperumal, A 74 Kallberg, H 808 Kalled, S 0 Kallenberg, CGM 78, 74, 747, 78 Kallikorm, R 04 Kallinich, T 70, 06, 66 Kalliolias, GD 776 Kalluru, R, 5 Kalman-Lamb, G 558 Kalra, S 775 Kalshnikova, O 7 Kalstad, S 4 Kalthoff, LH 6 Kalunian, K 884, 606, 78, 79 Kalunian, KC 604, 59, 808, 55 Kalyoncu, U 6, 749 Kam, YN 408 Kamalati, T 497 Kamali, S 680, 45 Kamath, T 484, 468 Kambe, N 7 Kameda, H 940, 840, 84, 40 Kamen, DL 5, 54, 606, 65, 884, 574, 59, 767, 505 Kaminsky, P 74, 654 Kamiyama, R 945, 074 Kammüller, M 9 Kamogawa, Y 49, 68 Kamp, S 809, 548, 549 Kamphuis, S 79 Kamps, FBS 58 Kan, H 006, 070, 587, 740 Kanagawa, H 97 Kanazawa, T 40, 764 Kandel, RA 66 Kane, C 94 Kane, D 484 Kaneko, A 40, 49, 455, 65, 69, 70 Kaneko, H 87 Kaneko, H 7 Kaneko, H 59, 070 Kaneko, K 86, 64 Kaneko, T 87 Kaneko, Y 066 Kaneshiro, S 8, 46 Kanetaka, T 9, 7 Kanetsuka, Y 7 Kang, A 654 Kang, EH 95, 068, 476 Kang, EJ 787, 99, Kang, J 8 Kang, JH 5, 577, 54 Kang, KY 69 Kang, MJ 67 Kang, R 99 Kang, SW 66 Kang, YM 58, 6 Kanik, KS 46 Kanis, JA Kanno, M 9 Kano, T 7 Kantarci, F 75 Kanzaki, T 4, 89 Kapczinski, F 44 Kapetanovic, MC 76, 684 Kaplan, I 80 Kaplan, MJ 54, 6, 66, 886, 57, 4, 65, 66 Kaplan, RA 797 Kapoor, M 48, 88 Kapoor, S 875 Kaptanoglu, E 9 Karaca, A 66 Karaca, G 5 Karadag, O 6 Karadeniz, A 69 Karaderi, T 7 Karagoz, A 08 Karahan, SC 66 0 Program Book 409 abstract author Index

412 abstract author Index 40 Karam, E 558 Karapolat, H 44 Karasawa, R 645 Karatay, E 64 Kardel, P 8 Karin, M 85 Kariuki, S 6 Karki, C 44 Karki, CK 69 Karkucak, M 66 Karlson, E Karlson, EW,, 09, 77, 656, 657 Karlsson, A 970 Karlsson, L 805 Karouzakis, E 46 Karp, DR 884, 569, 767, 45, 58 Karpenko, O 84 Karpouzas, GA 66 Karpus, ON 54 Karras, A 744, 754, 78 Karsdal, MA 70, 7, 878, 879, 50, 79 Karsh, J Karumanchi, SA 765 Karunaratne, PM 58, 47, 688 Kasama, T 7, 98, 57 Kasapcopur, O 64 Kashefi, E Kashiwakura, JI 75 Kasifoglu, T 5,, 749 Kasper, S 40 Kassem, M 70 Kast, M 5 Kastner, DL 894, 60, 0, 70, 78, 879, 7, 7, 98, 864 Kastning, J 90 Katada, Y 64 Kataoka, S 59, 070, 075 Katayama, K 4 Katayama, M 64 Katchamart, W 8 Kates, S 8 Kato, H 79 Kato, M 40, 406 Kato, T 49, 905 Katsicas, MM 979, 79 Katsumata, Y 59, 65, 06, 070, 075 Katsumoto, T 55 Katsuyama, E 048 Katsuyama, T 048 Katz, JD 08 Katz, JN 0, 0, 4, 86, 99, 05, 760, 768, 856, 908 Katz, PP 75, 95, 899, 90, 906, 06, 58, 589, 774, 54, 66, 77 0 Program Book Katz, RS, 9, 4, 840, 08, 084, 085, 086, 087, 088, 05, 08, 56, 959 Katz, SJ 89, 969, 9 Katzav, A 57 Katzmann, J 868 Kauffman, M 77, 890 Kaufman, I 5 Kaufman, KM 88, 70 Kaufman, M 69 Kaufmann, J 46 Kauppi, MJ 779, 0, 5 Kautiainen, H 779, 0, 95 Kautzky-Willer, A 979 Kavanaugh, A 794 Kavanaugh, A 57, 0, 04, 0, 7, 0,,, 6,, 4, 48, 400, 449, 450, 456, 86, 409, 45, 50, 555, 695, 79,, 4, 48 Kavelaars, A 857, 858 Kaverina, N 794 Kavernia, N 890 Kawabata, D 89 Kawabata, H 07 Kawabata, K 84 Kawabata, T 444, 0 Kawabata, T 048 Kawagoe, T 70 Kawaguchi, M 7 Kawaguchi, Y 59, 65, 68, 89, 06, 070, 075 Kawahata, K 4, 89 Kawahito, Y 465, 80, 4 Kawai, S 86, 64 Kawai, T 409 Kawakami, A 69, 888, 0, 6, 960, 069 Kawana, K 769 Kawano, S 67 Kawano-Dourado, L 69 Kawasaki, A 67 Kawasaki, M 7 Kawasaki, Y 0 Kawashiri, SY 69, 6, 960, 069 Kawasumi, H 59, 65, 06, 070, 075 Kawazoe, M 86, 64 Kawut, SM 8 Kay, FU 69 Kay, J 46, 964, 79, 5, 48, 767, 904 Kay, L 5 Kay, SD 64 Kaya, A 60 Kaymakcalan, Z 86 Kayrak, M 0 Kayser, C 8, 595 Kazemi, S 094 Kazi, S 96, 666 Ke, X 070 Keane, C 8, 79 Kearns, GM 868 Kearsley-Fleet, L 9, 678 Keat, A 9 Keating, RM 659, 660, 765 Keaveny, TM 785 Kedar, E 56 Kee, SJ 6 Keeley, P 848 Keeling, SO 45 Keen, HI 94, 766 Keenan, RT 9, 9 Kees, F 78, 86 Keisermann, M 470 Keith, P 498 Kelchtermans, H 654 Keller, KK 97 Kellner, H 46, 0 Kellum, J 69 Kelly, C 4 Kelly, JA 509, 489, 6, 65, 70, 77 Kelly, KJ 05, 06 Kelly, L 649 Kelly, L 99 Kelly, S 454 Kelly, S 4 Kelman, A 459, 767 Kelsall, JT 47, 48, 490, 46, 554, 50 Kelsey, C 76, 77 Kelsey, S 847 Kendler, DL 867 Kendler, DL 8 Kendzicky, A 657 Keniston, A 846, 0 Kenna, T 497, 498 Kennedy, C 986 Kennedy, P 965, 98 Kennedy, WP 54 Kennett, G 5 Kenney, H 00 Kenny, D 959, 470 Kent, D 50 Kent, J 55, 65 Keogh, K 748 Keren, R 56, 75 Kerkmann, U 55, 446 Kermani, TA 669, 678 Kerneis, S 477 Keroack, B 685 Kerola, AM 779, 0 Kerola, T 779, 0 Kerr, GS 8, 96, 00,, 78, 7, 58 Kerr, L 8 Kerr, S 78 Kersten, C 87 Kerstens, PJSM 47, 48, 460 Kerzberg, EM 9, 0 Keser, G 44 Keshavjee, S 98 Keskin, D 475, 858 Keskin, G 475, 858 Kessabi, S 69 Kessel, C 6 Keszei, AP 88 Ketenci, A 40 Keyes, K Keyes-Elstein, L 884 Keysor, JJ 88, 845, 846 Keystone, E 74, 456, 4, 4, 44, 4, 76, 4, 868, 869 Keystone, EC 06, 09, 8, 9, 409, 4, 464, 475, 786, 787, 79, 97, 4, 5, 75, 9, 96, 48, 866 Khalatbari, S 4 Khalidi, NA 79, 756, 759, 667, 669 Khamashta, MA, 7, 0, 887, 578, 59, 5, 55 Khan, HI 5, 8, 9, 55, 755 Khan, IY 98 Khan, K 667, 56 Khan, M 50 Khan, MA 54, 86 Khan, M Khanagavi, J 749 Khanna, D 44 Khanna, D 657, 658, 68, 70, 87, 908, 08, 85, 00, 909, 984, 994, 996, 997, 00, 005, 009, 56, 579, 584, 586, 597, 607 Khanna, P 08, 85, 00, 909, 984, 988, 994, 996, 997, 00, 005, 009, 607 Kharlamova, N 40 Khasnis, AA 95 Khawaja, K 77 Khera, S 749 Khetan, S 874 Khodadadi, L 7 Khor, CC 78, 880 Khosroshahi, A 649 Khouatra, C 744, 78 Khoury, M 594 Khraishi, M 47 Khraishi, MM 45, 8, 550, 554, 49, 5, 85, 458, 5 Khraishi, S 5 Khraiwesh, H 887 Khun, H 68, 775, 998, 999, 057, 07, 08 Kia, S 6 Kiani, A 597 Kickler, T 587, 56 Kida, D 40, 49, 455, 70 Kiel, DP 757

413 Kieler, H 04 Kiely, PD 79, 487 Kiener, HP 85 Kienhorst, L 8 Kievit, W 000, 005, 49 Kikuchi, H 66, 600 Kikuchi, K 68 Kikuchi, M 9, 7 Kilbane, M 49 Kilgallen, B 606, 78, 79, 50 Kilic, E 47 Kilic, G 47 Kilic, L 6, 749 Kilinc, M 5 Kiltz, U 6, 86 Kim, A 795 Kim, A 656 Kim, D 80 Kim, DH 46 Kim, G 8 Kim, G 79 Kim, GT 94 Kim, HR 5 Kim, H 78, 90 Kim, HY 5 Kim, HW 44 Kim, HA 0, 5 Kim, HA 69, 69, 00 Kim, HA 00, 440 Kim, HS 0, 46 Kim, HJ 9 Kim, H 006 Kim, I 6, 6, 90 Kim, JH 4, Kim, JM 955, 6 Kim, JS 995 Kim, JH 44, 4 Kim, J 66, 84 Kim, J 5, 7, 006 Kim, JY 8 Kim, J 6 Kim, K 989 Kim, KJ 595 Kim, K 400 Kim, KR 07, 44 Kim, KC 6 Kim, KH 44 Kim, KR 440 Kim, KH 4 Kim, L 874, 48, 768 Kim, M 765, 808 Kim, NR 58 Kim, SH 0 Kim, SY 760 Kim, SH 0, 94, 09, 8 Kim, SK 9, 0, 69, 049, 5, 8 Kim, SC 6, 780, 848, 09, 05, 70, 658, 679 Kim, SJ 9, 5 Kim, S 654 Kim, S 9 Kim, SH 4 Kim, SJ 990 Kim, SS 8 Kim, S 66, 55 Kim, TH 5, 5, 5, 90, 80, 400, 46, 80 Kim, TJ 5, 6, 5, 5, 577, 54, 547 Kim, WU 595, 46 Kim, YG 450, 0, 0, 445 Kim, YJ 450, 0, 0, 445 Kim, YJ 6 Kimberly, RP 6, 65, 70, 86 Kimmel, JN 79 Kimmel, P 590 Kimmel, S 0 Kimpel, DL 96, 556 Kimura, T 7 Kimura, T 457 Kimura, Y 77, 78, 790, 70, 780, 789 Kincses, A 478 King, K 484, 468 King, MC 64 Kingsbury, D 69 Kingsbury, DJ 79, 504 Kinjo, M 4 Kinloch, A 794 Kinnman, N 50 Kinugawa, K 59 Kiosses, WB 7, 48 Kiran, A 895 Kiraz, S 6 Kirchner, HL 847, 76, 54, 76 Kirino, Y 70, 879, 945, 96, 074, 68 Kirkham, BW 50 Kirou, KA 57, 86, 55 Kirton, A 66 Kisacik, B 749 Kishimoto, D 945, 074 Kishimoto, M 9, 447, 567 Kislinsky, K 94, 9 Kiss, MHB 9 Kissin, EY 85 Kisten, Y 96, 970 Kita, J 6, 960 Kitahara, K 86, 64 Kitano, M 465, 4, 56 Kitas, G 454 Kitas, G 86, 88 Kitchen, H 68 Kitchen, J 95 Kitsis, EA 967 Kivity, S 57, 6 Kivitz, A 77, 54, 58, 48, 609, 74, 765 Kivitz, AJ 45, 7, 799, 688 Kiyokawa, S 9 Kjeken, I 095 Klareskog, L, 4, 7, 80, 808, 8, 9, 07, 7, 704, 707, 89, 875, 44, 97, 40, 4, 4, 656 Klassen, LW 6 Klatt, S 9 Klaus, P 04 Klearman, M 450, 49 Klebanov, B 77, 890 Klein, CE 48, 467 Klein, C 88 Klein, JP 89 Klein, K 5, 40, 406, 850 Klein, M 640 Klein, M 884, 947, 084 Klein-Gitelman, MS 57, 76, 675, 86 Kleinert, S 78, 97 Kleinmann, JF 664 Kleoudis, C 60 Klepacka, M 844 Klimes, J 995, 05 Klink, AJ 75 Klink, C 6 Klinkhoff, AV 7 Klint, C 576 Klokker, L 86 Klotz, W 06 Kluger, E 84 Knake, C 7 Knapik, D 59 Knapp, K 00 Kneepkens, EL 456, 509, 54 Kneitz, C 78, 0, 97 Knight, A 56 Knight, JS 66, 886, 57 Knob, CF 0 Knoop, J 89 Knudsen, LS 46 Knutson, KL 67 Ko, G 8 Ko, K 64 Koarada, S 76, 90 Kobayashi, A 40, 44 Kobayashi, D 4 Kobayashi, H 59 Kobayashi, H Kobayashi, M Kobayashi, S 404 Kobayashi, T 447 Kobayashi, T 87 Kobayashi, Y 59 Koca, SS 9 Koch, AE 657, 658, 774, 777, 97 Koch, T 009, 00 Kochi, Y 707, 94 Kocijan, R 97, 80 Kodera, T 0 Koeleman, BPC 76 Koeleman, BPC 808, 89, 79 Koelsch, KA 77 Koenders, MI 74, 94, 74, 740 Koenen, K Koenig, A 44 Koenig-Friedrich, S 9, 5 Koening, CL 756 Koening, CL 79 Koening, CL 669 Koessler, RE 5, 5, 8 Koetse, W 4 Koetter, HU 6 Koevoets, R 09 Koga, T 557, 57, 888, 0, 960, 069, 74 Kogata, Y 67 Koh, EM 09, 6, 5, 006, 6, 90 Koh, JH 494, 4, 77 Kohane, I 877 Kohem, C 948, 470 Kohler, F 09 Kohler, MJ, 974 Kohno, M 80 Kohno, S 069 Kohsaka, H 79, 055 Koide, H 68 Koike, T 588, 45,, Koike, T 96, 9, 449, 66 Kojima, M 840, 84 Kojima, T 49, 448, 455, 479, 65, 69, 70 Kok, T 9 Kola, M 66 Kolbinger, F 95, 856 Kolfenbach, JR 49 Kollias, G 69 Kolling, C 775, 5, 404, 406, 850, 76, 87 Kollnberger, S 7, 7, 655 Kolls, JK 74, 485 Kolte, D 749 Komarc, M 569 Komarla, A 7 Komatsu, R 49 Komatsu, S 66 Komiya, A 7 Komocsar, WJ 7 Komori, H 40, 764 Komuro, I 59 Kondo, A 6 Kondo, M 87 Kondo, S 9 Kondo, T 67 Kondo, Y 67, 666, 50 Konig, MF 47 abstract author Index 0 Program Book 4

414 Konijn, NPC 46 Kraus, VB 49, 858 Kubo, S 468, 45, 9, 774 Kurreeman, F 877 Konings, TC 454 Kraus, VB 7 Kubo, S 4 Kurthen, R 46 Kono, H 66 Krause, A 85 Kubo, T 66, 769 Kurucz, R 950 Kono, M 68 Krause, DM 6 Kubota, K 7 Kusaoi, M 67 Kononov, A 89 Krause, D 0 Kubota, T 67 Kusek, J 590 Konttinen, YT 5 Krause, K 06,, 747 Kubota, T 7, 75, 08 Kusunoki, N 86, 64 Koo, BS 450, 0, 0, 445 Krause, ML 748 Kubzansky, L Kusunoki, Y 86, 64 abstract author Index Kooiman, K 4 Koolaee, RM 7 Koontz, D 776, 06 Koos, B 8 Kopacova, M 89 Kopec, JA 97, 98 Korb-Pap, A Korendowych, E 5, 70, 596 Korhonen, R 44 Koristka, S 9, 64 Korkmaz, C 76, 749 Korman, NJ 557 Korn, J 00 Kornishina, T 7 Korobko, Y 5 Koroleva, I 77 Korotkova, M 779 Korpela, M 5 Korshunov, NI 689 Korst, L 870 Kortekaas, MC 79 Kortus-Goetze, B 06 Kosco-Vilbois, M 954, 9 Kosek, J 4 Kosinski, M 56 Koskas, F 0 Koskinen, A 44 Koskova, E 80 Kostik, M 7 Kosutic, G 4 Kotak, S 0, 546, 59 Koth, L 59 Kottgen, A 9 Koutsianas, C 67 Kovács, L, 6 Kovalenko, V 76 Kovell, L 8 Kowalski, M 84 Koyama, K 459 Koyama, Y 05 Koyano, S 4, 897 Kozera, L 766 Kozma, C 08 Krabbe, S 46 Krabben, A 804 Kragstrup, TW 96, 7 Krajewska-Kulak, E 844 Kral, MC 6 Krammer, G 50, 77 Krasnokutsky, S 887 Krasnokutsky-Samuels, S 8 Kraus, S 97, 80 Kremer, JM 04, 44, 48 Kremer, JM 9, 00, 6, 70, 9, 459, 46, 49, 877, 040, 048, 95, 0, 45, 45, 48, 885, 44, 5, 87, 877 Kretzler, M 554 Kretzmann, B 00 Krieckaert, CLM 4, 456, 509, 54 Kriegel, MA 556 Krieger, R 904 Krinner, K 8 Krintel, SB 875, 40, 687, 80 Krishan, P 90 Krishnamurthy, A 89 Krishnan, E 94, 97, 505, 7, 8, 985, 99, 99, 000, 004 Krishnaswami, S 444, 445, 794, 0, Kristensen, LE 499 Kristensen, LE 9 Kristensen, LE 478, 684 Kritikos, L 57 Kroe-Barrett, R 40 Kroegel, C 760 Kroes, ACM 809 Kroese, F 5, 88 Kroesen, BJ 58, 645 Krogh, NS 84, 4, 44, 80 Kroin, J 76 Kron, AT 5, 576, 577, 6, 98 Kronthaler, U 86 Kroon, FPB 84 Kroop, SF 964 Krueger, GG 7, 4 Krueger, JG 58, 7 Krug, HE 5 Kruger, J 44 Krugten, MV 57, 69 Kruize, AA 879 Krumholz, A 595 Krummel, K 59 Krusemark, E 0 Krüger, K 75 Kryštufková, O 950 Krzywy, H 050 Kräft, T 50 Krönke, G 8 Ku, JH 9, 46 Kubassova, O 9 Kubilay, Z 69 Kuchinskaya, E 7 Kucuk, A 0, 468 Kucukoglu, S 6 Kuda, H 4 Kuehn, H 894 Kuemmerle-Deschner, JB 06,, 748 Kuga, Y 56 Kuhn, A 56 Kuhn, EM 64 Kuijper, TM 57 Kuijpers, TW 78, 9 Kuipers, S 70 Kuis, W 784 Kukida, Y 80 Kuklová, M 950 Kula, E 60 Kuleci, S 64 Kulik, L 9 Kumagai, K 97 Kumagai, S 869, 67 Kumanogoh, A 67 Kumar, A 074 Kumar, P 478 Kumar, S 46 Kume, K 40, 9, 764 Kummerfeld, S 07 Kummerle-Deschner, J 66 Kumon, Y 00 Kunishita, Y 945, 074 Kuntz, K 856 Kuo, CF 80, 99 Kuo, D 64 Kupper, H 57, 79, 45, 449, 48, 58, 409, 4, 686, 688 Kurasawa, K 80, 60 Kurata, H 869 Kurien, BT 50, 88, 9, 50, 64 Kurita, T 68 Kuritani, T 76 Kuriya, B 06, 770, 787, 79, 5 Kurko, J 56 Kurniawan Pramono, H 47 Kuroiwa, T 465, 4, 76 Kurokawa, M 49, 905 Kuroki, A 66, 769 Kurosaka, M 94, 77 Kurosawa, H 880 Kurosawa, Y 6 Kurowska-Stolarska, M 94, 944, 947, 4 Kutsal, Y 096 Kuwaba, N 40, 764 Kuwada, N 75 Kuwana, M 6, 669, 748, 066, 069, 575 Kuzin, I 8 Kuziora, M 50 Kvarnström, M 497 Kviatkovsky, M 55 Kvien, T 496, 500 Kvien, TK 09, 4, 84, 85, 40, 404, 4, 448, 87, 9 Kvien, TK 94 Kvist, PH 54 Kwak, SG 049 Kwan, L 08, 05 Kwoh, CK 7, 5, 778, 069, 0, 75, 754 Kwok, K 44, 44 Kwok, PY 55 Kwok, SK 69, 494, 4, 77 Kwon, G 55, 694 Kwon, MH 755 Kwon, M 6 Kwon, SH 58 Kwon, SR 8 Kwon, T 9 Kwon, YJ 6 Kyazimzade, S 90 Kyburz, D 5, 775 Kühnert, S 5 Kyle, RA 868 Kyndt, X 750 Kyttaris, VC 70, 74 Källberg, H 875, 97, 4 Köhler, V 04 Köksal, L 60 Köppert, S 77 Kötter, I 64 L. Severens, J 000 La Cava, A 6 La Falce, G 85 La Rocca Vieira, R 58 Labitigan, M 00 Laborde, HA 5 Labour, MN 5 Labrador-Horrillo, M 777 Labrousse, F 86 Lacaille, D 984, 997, 04, 05, 708, 89, 897 L 4 0 Program Book

415 Lacal, JC 85 Lacaze, A 60 Lachance, P 668 Lachenbruch, PA 98, 06 Lacin, A 6 Lacouture, P 9 Ladel, C 754 Lafeber, FPJG 70, 99, 949, 879 Lafeber, F 49, 005, 45, 76 Lafleur, J 47 Lafyatis, R 90 Lahdenne, P 68 Lahey, LJ 9 Laing, T 909 Lajas, C 47, 67 Lake, A 99 Lakos, G 8,, 5, 89 Lakshminarayanan, S 4, 679 Lally, L 74, 896, 8 Lalmohamed, A 8 Lam, MY 55, 56 Lamana, A Lamba, M 0 Lambert, B Lambert, C 69, 7 Lambert, R 80 Lambert, RG 89, 5, 946, 69, 89, 887, 888 Lamberth, S 47, 457, 54 Lambotte, O 754, 09 Lambrecht, S 65, 69 Lambrelli, D 99 Lambrianides, A 4 lamers-karnebeek, FB 70 Lammi, MR 0, 04, 580, 589 Lampa, J 80, 599 Lampertico, P 806 Lampl, K 9, 456, 78, 047, 0, 759 Lamy, T 69 Lancioni, E 60, 60 Landeira, A 4 Landesman, Y 77, 890 Landewe, R 09, 4, 5, 977, 79 Landewé, R, 409, 4, 508, 50, 55, 55, 54, 55, 77, 786,, 5, 447, 87, 885 Landewé, RBM 799 Landolt-Marticorena, C 6, 57, 555, 557 Landon, GC 88, 80 Landry, M 96, 9 Landsittel, DP 40 Lane, NE 95, 7, 57 Lane, S 5 Lang, BA 865 Lange, E 56, 55, 88 Langefeld, CD 5, 54, 6, 6, 65, 98, 99, 70, 86 Langefeldt, C 69 Langenhoff, J 09 Langford, CA 79, 74, 747, 756, 95, 667, 669, 78 Langleben, D 579 Laniosz, V 4 Lanius, V 70 Lanni, S 96 Lannon, CM Lansche, C 099 Lao, R 55 Lapa, AT 60, 0 Lapeyre-Mestre, M 44, 67, 676 Lara, ME 86 Laragione, T 46, 78, 74, 87 Larangeira, JA 4 Larche, M 865, 946 Laredo, JD 46 Largo, R 57, 60, 64 Larkin, J III 75 Larkin, M 7 Larranaga-Vera, A 57, 60 Larroche, C 488 Larrosa, M 440 Larsen, LH 478 Larsen, SD 56 Larson, DR 868 Larsson, A 898 Larsson, E 79 Larsson, P 9, 46 Laskin, CA 765 Lasky, A 97, 07 Lassoued, S 469 Lateef, A 566 Latinis, KM 609 Latorre, M 759 Latus, J 89 Latz, E 904 Lau, AG 04 Lau, AN 94, 476 Lau, CS 566 Lau, CS 97, 597 Lau, E 498 Lau, H 75 Launay, D 695, 750 Laurant-Noel, V 04 Laurent, V 5 Laurindo, I 9, 0 Laursen, T 478 Laustsen, JK 859 Lauto, P 580, 589 Lauwerys, B 80, 67, 40, 7 Lavalley, MP 88, 845, 846 Laven, JS 68 Lavigne, C 686 Lavoie, T 845 Law, A 9, 9 Law, J 84 Lawand, PA 099 Lawlor, KE 770 Lawrence, A 605, 0 Lawrence, P 98 Lawrence-Ford, T, 58 Lawson, EF 849 Lawson-Remer, K 44 Laxer, RM 750, 75, 754, 77, 79 Layh-Schmitt, G 55, 694 Lazaro, DM 8 Lazaro, M 446 Lázaro, MA 86 Lazaro, P 908 Lazarus, HM 64 Lazure, T 5 Lazzari, AA 97, 978, 87 Le, K 888 Le Bars, M 465, 904 Le Bras, E 76, 649 le Cessie, S 68 le Guern, V 488, 554, 880 Le Jeunne, C 86 Le Loet, X 96, 4, 8 Le Riche, NGH 6 Le Thi Huong, D 75 Leal, GN 87 Leal, JM 67 Leanderson, T 77 Leandro, M 8 Leavitt, F, 084, 08 Lebidois, J 84 Leblanc, CM 865 Leboime, A 489 Lebovics, R 74 Lebre, MC 65, 8 Lebwohl, M 4 Leceta, J Leclair, D 40 Leclerc-Jacob, S 5 Leclercq, S Lecompte, T 654 Lecouvey, M 9 Lederman, M 95 Ledingham, A 88 Lee, A Lee, A 776 Lee, AT 79, 877 Lee, A 95 Lee, CH 957, 00 Lee, CH 089 Lee, CH 69, 69, 8 Lee, CK 450, 0, 0, 445 Lee, C 7, 69 Lee, CC 894, 78 Lee, D 77, 856 Lee, DC 785 Lee, EB 49, 80, 977 Lee, EB 67, 440, 07, 068, 8, 44, 4 Lee, EY 67, 440, 76, 07, 068, 44, 4 Lee, EG 69 Lee, EJ 445 Lee, FEH 4, 798 Lee, H 049 Lee, HS 0, 5, 6, 400 Lee, HJ 476 Lee, H 75 Lee, I 884 Lee, JH 494, 4, 77 Lee, JM 440, 07 Lee, J 69, 6, 5, 006, 6, 90 Lee, J 400 Lee, J 97 Lee, JS 50 Lee, J 494, 4, 77 Lee, JW 5, 577, 54 Lee, JH 0 Lee, JY 77 Lee, J 57, 65 Lee, J 09, 5, 5 Lee, JY 6, 400 Lee, JY 67, 440, 4 Lee, JW 94, 8 Lee, JT 476 Lee, J 077 Lee, KH 99, Lee, KE 5, 577, 54, 547 Lee, M 54, 446, 448, 840 Lee, MS 69, 8 Lee, P 675, 576, 577 Lee, P 4 Lee, R 647, 660 Lee, RH 870 Lee, R 50 Lee, R 868 Lee, SJ 440 Lee, SH 5 Lee, SH 464 Lee, SI 69, 955, 6 Lee, SW 787,, 6, 89, 9, 5 Lee, S 6, 006, 6, 90 Lee, SG 94, 8 Lee, S 5, 90, 46 Lee, SU 089 Lee, SS 0, 5, 69, 6, 5, 5, 5, 577, 6, 54, 547 Lee, SC 6 Lee, SK 440, 89, 9 Lee, SY 494, 4, 77 Lee, SK 787,, 6, 6, 5 abstract author Index 0 Program Book 4

416 abstract author Index 44 Lee, SY 400 Lee, SM 9 Lee, SW 5, 5 Lee, SY 76 Lee, SJ 45 Lee, TC 77, 79 Lee, WP 0 Lee, WS 69, 955, 8, 6 Lee, YA 0, 5, 464 Lee, YY 67 Lee, YM 44, 4 Lee, YH Lee, YN 95 Lee, YC 999, 007 Lee, YY 076 Lee, YJ 95, 84, 440, 068, 476 Lee, YY 7 Lee, YC, 6, 68 Leeder, JS 97, 07 Leeming, DJ 7, 878 Leese, J 78 Lefebvre, F 04 Lefevre, G 808 Lefèvre, S 77 Leffers, H 44 Legendre, M 0 Leggett, S 04 Lehane, PB 4 Lehman, AJ 9, 45, 47, 48, 490, 46, 550, 554, 49, 50, 5, 5, 85, 87, 7, 84, 458 Lehman, N 64 Lehman, TJA 504 Lehmann, K 50 Lehmann, S 78 Lehr, A 84 Leijsma, MK 58, 449 Leirisalo-Repo, M 79 Leiss, H 0 Leite, N 470 Leitman, S 60 Lejon, K 97 Leleti, M 79 Lember, M 04 Lembke, W 9 Lemieux, J 79 Lems, WF 47, 48, 460 Lems, W 8 Lems, WF 45, 46, 89 Len, C 69 Len, CA 98 Lenaerts, J 5 Lenaerts, J 56 Lenczner, G 78, 46 Leng, X 0 Lengel, D 95 Lentle, B 865 Leo, P Program Book Leo-Summers, L 854 Leon, EP, 65 Leon, G 79 León, L 67, 86 Leonard, D 769 Leonard, MB 785 Leone, F 487 Lepri, G 69, 9 Lequerré, T 904 Lerma, C 45 Lerner, D 709 Lerner, D 99 Lerner, M 56 Leroux, G 05 Leroux, JL 7 Lerstrøm, K 56 Lertratanakul, A 65 Lesende-Rodríguez, I 4 Lesnyak, O Lesourd, A 50 Lespessailles, E 0, 7,, 48, 86 Lessard, CJ 50, 509, 88, 489, 565, 6, 770, 77, 77 Lessard, JA 77 Lester, S 47 Lesuis, N 966 Leszczynski, P 464, 844 Letho-Gyselinck, H 050 Letourneur, F 489 Leturcq, T 489 Leu, JH 9, 47 Leung, A 9 Leung, L 89 Leung, S 89 Leung, YT 7, 65 Levarht, EWN 90 Levartovsky, D 5, 098 Leveille, SG 757 Levesque, K 84, 86 Levesque, MC 40, 77, 8, 876, 884, 06, 07, 0, 47, 48, 485, 7, 765, 776, 790, 057, 08, 4, 88, 4 Levin, M 78 Levine, AB 989, 605 Levine, R 9 Levitan, E 6, 05, 9, 680, 76 Levitsky, A 4 Levy, B 856 Levy, DM 57, 6, 67, 69, 65, 790 Levy, GD 857, 007 Levy-Lahad, E 64 Levy-Neto, M 68 Lewallen, D 90, 96, 6, 4 Lewiecki, EM 864, 8 Lewin-Koh, N 07 Lewington, M 04 Lewis, CE 85 Lewis, CE 54, 07, 7, 9, 67 Lewis, C 6, 7, 9 Lewis, DM 50, 77 Lewis, J 6, 05, 9, 4, 40, 680, 76 Lewis, JE 96, 556 Lewitzky, S 77 Leyva, AL 666 Lheritier, K 69, 70, 7 Li, C 445 Li, H 7 Li, H 489, 770, 77 Li, H 70 Li, HD 554 Li, H 40 Li, J 76 Li, J 7, 7, 745 Li, K 7, 75 Li, L 9 Li, LC 98, 984, 96, 78 Li, M 59 Li, Q 007 Li, Q 7 Li, Q 0, 6, 64 Li, QZ 68, 77 Li, R 75 Li, S 76 Li, SW 597 Li, S 0,,, 695 Li, S 679, 080 Li, SC 70, 77, 789 Li, T 6 Li, W 45, 788, 77 Li, W 098, 5, 6, 7, 70 Li, X 50, 590, 698 Li, X 6, 957, 967 Li, X 504 Li, X 474 Li, X 5 Li, X 9 Li, Y 75 Li, Y 59, 55 Li, Y 0 Li, YT 78 Li, Y 79 Li, Y 77 Li, Z 46 Li, Z 560, 565 Li, Z 887 Liakouli, V 57 Lian, J 8 Liang, AQ 78 Liang, D 570, 7, 77 Liang, G 665, 699, 905 Liang, KP 40 Liang, K 50 Liang, MH 7 Liang, M 50 Liang, P 95 Lianza, AC 87 Liao, J 69 Liao, KP 09, 877, 88 Liao, S 47 Liao, Z 0, 6, 64, 479 Liarski, VM 890 Libanati, C 86 Libanati, C 867 Liberio, B 844 Licht, C 750 Licu, D 59, 55 Lidtke, RH 5, 5, 54 Lie, BA 89 Lie, E 4, 448, 495, 496, 500, 87, 90, 9 Lieberman, L 557, 57 Liebl, A 704 Liebowitz, J 086 Liedholm, R 878 Lien Kveldstad, I 7 Lien Kvelstad, I 88 Liesveld, J 66 Liew, D 87, 8 Lifermann, F 00 Liggitt, D 544 Lightowler, S 5 Lii, J 848 Likhter, M 8 Lilleby, V 676, 677 Lillegraven, S 040 Lim, A 9 Lim, A Lim, E 04 Lim, JH 9 Lim, JE 59 Lim, LSH 7 Lim, MK 66 Lim, MJ 76 Lim, MJ 8 Lim, SS 884, 006, 06, 066, 59, 696 Lim, SY 5 Lima, FR 054, 57, 545 Lima, G 486 Lima, J 597 Lima, M 66 Lima, S 470 Limal, N 744 Limb, C 86 Limburg, PC 78 Lin, A 496 Lin, CP 65 Lin, C 88, 74 Lin, D 75, 869 Lin, D 6, 64 Lin, HY 49 Lin, J 58

417 Lin, J 99 Liu, R 50 López, D 56 Loza, E 47, 90 Lin, LL 5, 850 Liu, S 409, 686 Lopez, H 56 Loza Santamaria, E 448 Lin, L 0 Liu, S 79, 80 Lopez, LR 5 Lozada, CJ 745, 45 Lin, NY 7 Lin, SJ 00, 009 Lin, SK 98 Lin, W 94 Lin, Z 0, 6, 64, 479 Lina, C 499 Linares, L 750, 440, 65 Linares Ferrando, L 0 Linauskas, A 875, 40, 687, 80 Lindblad, S 54 Lindegaard, HM 6, 4, 875, 40, 478, 7, 687, 80 Lindic, J 66 Lindqvist, E 05, 0 Lindqvist, URC 9, 46 Lindroos, E 405, 65, 779 Lindsay, R 4 Lindsley, HB 049 Lineker, SC 986, 96, 9 Ling, E 64 Ling, L 880 Ling, P Link, TM 6, 967 Link, TM 957 Linnik, M 808 Linsenmeyer, KD 6 Lintner, K 86 Linton, D 986, 04 Lioté, F 85, 469 Liphaus, B 9 Lipsky, PE 60 Lipstein, EA Lisignoli, G 54 Lisnevskaia, L 5 Listing, J 77, 806, 56, 55, 798, 80, 45, 466, 88 Litinsky, I 5 Little, CB 49 Little, MA 90 Littlefield, MJ 98 Liu, B 87 Liu, B 88 Liu, C 4 Liu, C 87 Liu, D 7, 75 Liu, F 7, 57, Liu, H 57, 65 Liu, J 5 Liu, J 6, 09, 065, 588, 70 Liu, K 88 Liu, L 50 Liu, M 46 Liu, MF 78 Liu, ML 860 Liu, QR 66 Liu, Q 568 Liu, S Liu, X 770 Liu, Y Liu, Y 44, 0 Liu, YP 50 Liu, Y 65, 78, 90, 864 Liu, Y 889 Liu, Z 50, 7, 645, 7, 77, 94 Liu, Z 76 Ljung, L 804, 805 Lliguicota, M 57, 86 Llobet, J 788 Llobet, JM 44 Llorca, J 8, 8 Llorca, J 975 Llorente, L 598 Llorente-Onaindia, J 46 LLorente-Peters, L 60 Lloret-Linares, C 78 Lltalien, G 0, 04 Lo, GH 4, 4, 9, Lo, KH 874, 768 Lo, Y 97 Lo Gullo, A 666 Lo Schiavo, G 74 Lobo, F 458, 8 Lobosco, S 58, 589 Localio, RA 75 Locci, M 7 Locher, M 9, 5 Locht, H 47 Lockshin, MD 765, 988, 900 Locrelle, H 48, 97 Lodi, A 85 Loell, IM 779, 08 Loeser, RF 67, 757 Loeuille, D 09, 5 Loft, AG 4, 84 Logeart, I 8 Logee, K 4 Lohela Karlsson, M 87 Lohmander, S 99, 64, 670 Lohmeyer, T 99 Lohse, P Lojo, L 469 Lokhnygina, Y 780 Lombardi, A 9 Lombardi Jr, I 099 Londono, J 57 Long, DA 67 Longhurst, H 07 Loo, FA 49 Loo, T 558 Lood, C 0, 659, 576 Looney, RJ 54, 604, 74 López de Figueroa, P 68 Lopez de Padilla, C 057, 07, 08 lopez Mejias, R 8, 8 López-Armada, MJ 94, 87, 846 Lopez-Benitez, J 504 Lopez-Benitez, JM 69 lópez-casla, MT 456 Lopez-Girona, A 4 López-González, T 400 López-Jiménez, EA 550 López-Lasanta, M 48 López-Lasanta, MA 48 López-Longo, FJ 8, 78 Lopez-Olivo, MA 698, 88, 98, 47 Lopez-Pedrera, C Sr., 887 López-Peláez, E 94, 87 López-Solà, M 46 López-Vives, L 40 Lora, M 60 Lorenz, HM 465 Lorenzen, T 84, 056, 44, 478, 7 Loricera, J 788, 687, 750, 975, 0, 65, 6, 64 Lories, RJ 69 Lorleac h, A 750 Lory, S 954 Losina, E 0, 0, 86, 99, 768, 856 Lottenburger, T 40, 687 Lotz, M 68, 7 Lotz, MK 58, 59, 6, 64, 895 Loudig, O 6 Lough, KM 70 Louie, B 876, 88 Louie, JS 58 Louis Plence, P 4 Loupasakis, K 05 Lourdudoss, C 46 Loureiro, J 94, 87, 846 Lourenco, E 885, 66 Lourido, L 56, 64, 876, 878 Louthrenoo, W 566 Louw, I 479 Louzada-Jr, P 6 Love, T 0 Love, TJ 05 Lovell, DJ 69, 70, 7, 7, 76, 790, 79, 69, 79 Lovell, K 848 Low, AS 80 Low, AS 04, 760 Lowe, P 04 Lowe, V 84 Lowin, T 90 Lozano-Morales, R 694 Lu, B, 964, 657 Lu, H 78 Lu, J 0 Lu, L 590 Lu, Q 665, 699, 905 Lu, R 68 Lu, X 59, 065 Lu, Y 54, 45 Lubbeke, A Lubberts, E 7, 6, 656 Luca, N 788 Lucas, M 748, 578 Lucero, E 60 Luchi, M 797 Luciano, N 505, 508, 850, 900, 060 Lucke, M 4 Ludivico, CL 464 Luedtke, CA, Lueking, A 494, 909, 575 Lufkin, J 668 Luft, M 4 Lugli, EB 8, Lugonja, B 57 Lui, LY 95 Luime, JJ 87, 69, 77, 889 Luime, JJ 08, 4, 57 Lukac, J 596 Lukas, C 870, Lukina, G 448, 496, 500 Lumpe, AT 7 Lund, MB 697 Lundberg, IE 405, 65, 777, 779, 884, 98, 056, 077, 08, 648 Lundberg, K 8, 89, 40 Lunt, M 77, 9, 80, 04, 694, 885, 886, 678, 760 Luo, A 454 Luo, B 745 Luo, C, 7, 58 Luo, G 477 Luo, W 57 Luo, Y 046 Luo, Z 794 Luong, P 907 Luqmani, RA 746, 75, 895, 67, 786 Lussier, B 48, 88 Lusson, JR 4 Lustig, S 4 Lutalo, PMK 646 Lutf, A 58 Luthra, HS 8 Lutteri, L 5 Luttringer, O 04, 09 abstract author Index 0 Program Book 45

418 abstract author Index Luu, CT 90 Lux, G 5 Luxembourger, C 808 Ly, KH 86, 00 Lyberg, T 88 Lydon, EJ 509 Lyman, S 7 Lynch, B 58, 588, 59, 59 Lynch, JA 7, 57, Lynch, K 97 Lyons, J 0 Lysengen, J 87, 74 Lyu, R 0 M M Khidre, T 646 Ma, CB 6 Ma, JD 78, 48 Ma, J 865 Ma, Y 568 Maas, F 449, 456 Maas, M 84 Macarrón, P 67 Macaubas, C 88 Macaulay, D 994 Maccheroni, M 5 Macchioni, P 8, 9, 8 MacDonald, AG 776 Macdonald, H 94, 87 MacDonald, PA 78 Macedo, C 4 Macfarlane, G 84 Macfarlane, GJ 776, 848 Macfarlane on behalf of SIRAS and MUSICIAN study investigators, GJ 56 MacGarvie, D 99 Machado, AC 584 Machado, FS 4 Machado, LSG 584 Machado Escobar, M 60 Machida, T 89 Macias, W 4, 796 Macieira, JC 6 Maciejewski, M 8 Maciuca, R 54 Mack, M 48 Mackay, M 604, 884, 59, 74, 765 MacKenzie, CR 967 Mackey, D 47 Mackie, I Mackie, S 66 Mackie, SL 89, 766 MacLaughlin, EJ 5 MacLeod, T 6 MacMullan, PA 959, 470 Macor, P 566 Madar-Balakirsi, N 484 Madar-Balakirski, N 5 Madeo, A 7 Madigan, AM 959, 470, 668 Madsen, OR 84, 5, 46, Maduka, C 4 Maeda, K 465, 76 Maeda, T 94, 77 Maeda, Y 8 Maers, K 765 Maestre, MF 48 Magallares, B 44 Magder, LS 6, 58, 586, 587, 597, 88, 88, 74, 806, 56, 58 Magee, A 85 Maggs, FM 60 Magid, SK 97 Magner, RP 00, 48 Magni-Manzoni, S 6 Magnusson, PK 44 Magnusson Bucher, S 056 Magrey, MN Magro, C 89, 89 Magro, C 709 Mahadevan, U 4 Mahajan, V 784, 0, 04 Maharaj, A 66 Mahé, B 69 Mahendira, D 96 Mahgoub, EY 56 Mahler, E 87 Mahler, M, 8, 9, 0,, 67, 96, 89 Mahmood, Z 95 Mahomed, NN 44 Mahon, C 4 Mahowald, ML 5 Mahr, A 78, 746, 760, 787 Mahtani, KR 67 Maier, R 499 Maier-Moore, JS 50 Maillefert, JF 87 Mailliard, R 70 Mains, T 44 Maíz, O 750, 0, 65 Maiz Alonso, O 08 Majdan, M 844 Majithia, V, 0, 44, 44 Majnemer, A 0 Mak, AC 55 Makaroff, L 54 Maki, H 59 Makino, H 749, 048 Makosso-Kallyth, S 6 Makris, UE 6, 666, 854 Maksimowicz-McKinnon, K 70, 756 Maksymowych, WP 89, 5, 89, 56, 5, 705, 786, 799, 80, 946, 48, 69, 86, 89, 887, 888 Makul, A 559, 56 Malaise, D 5 Malaise, MG 5, 55 Malaise, O 5, 55 Malaisrie, SC 8 Malamet, RL 9, 008 Malattia, C 76, 7 Malaviya, AN 9, 0 Malaviya, AP 46 Malcarne, VL 87, 908, 6 Maldonado, M 476, 49 Maldonado, M 44 Maldonado, MA 6 Maletta, KI 845, 64 Malfait, AM 8, 859 Malhotra, K 47 Maliha, S 0 Malik, F 480 Malik, JM 0 Mallano, T 85 Mallbris, L, 47 Mallen, CD 66, 57 Maller, E 49 Malmström, V 8, 9, 7, 497, 64, 89, 08, 44, 4, 648, 797 Malochet-Guinamand, S 4 Malpeso, J 66 Malspeis, S, 77, 657 Maltret, A 84 Malul, G 64 Mammen, AL 086 Mamoto, K 96, 9, 449, 66 Mamyrova, G 08 Man, A 744 Manabe, I 707 Manara, M 989 Mancini, J 66 Mancuso, C 55 Mandel, DR 794 Mandelbaum, M 5 Mandelboim, M 098 Manders, SHM 49 Mandhadi, R 4 Mandl, LA 980, 506, 768, 97, 5, 8, 0,, 856 Mandl, P 94, 950 Mandl, T 508, 50, 878 Manero, J 750, 65 Manferdini, C 54 Manger, B 405 Manheim, L 778 Mani, P 85 Manichaikul, A 55 Manilo, N 4 Manion, K 564 Mann, HF 480, 950, 957, 5, 947, 084 Mann, R, 7 Mannami, K 9 Manner, PA 80 Mannion, ML 794 Manohar, J 47 Manrique Arija, S 788 Manrique-Arija, S 48 Mantilla, RD 0 Manz, RA 549 Manzi, S 574, 59, 55, 896 Mao, L 5 Mao-Ying, QL 858 Maquet, V 76 Maracle, CX 945 Maradiaga, M 69 Marafon, D 68 Marangoni, RG 57 Marcantonio, G 4 Marcelli, C 469 March, L 87, 4, 47 Marchand Adam, S 60 Marchesoni, A 466, 806 Marchini, M 687 Marcoccia, A 676 Marcora, S 75 Marcorelles, P 50 Marcos, AI 86 Mardekian, J 9 Marder, G 605 Marder, W 4 Mardis, ER 877 Marengo, MF 86 Margaretten, M 75, 607, 774, 665 Margolis, D 0 Margulis, A 50 Marhadour, T 507, 85, 88 Marí-Alfonso, B 89, 89 Maria, NI 6, 656 Mariette, X 80 Mariette, X 495, 5, 88, 96, 4, 469, 488, 88, 69, 770, 77, 877, 880, 90 Marijnissen, RJ 74 Marin, J 60, 60 Marinho, A 00 Marini, F 9 Marini, R 58, 59, 60, 0 Marinov, A 69 Marion, MC 99, 86 Maritati, F 760 Marjanovic, EJ 694 Marks, R 909 Markt, J 8, 78 Markusse, IM 46, 47, 48, 460 Marlow, N 849 Marmorstein, LY Program Book

419 Marmursztejn, J 757 Martínez-López, JA 47, 698, 64 Matsubara, H 448 McBride, A 5, 9 Maron, DD 96 Martinez-Marti, M 45 Matsubara, T 4, 897, 9 McBride, P 07 Marotta, A 5, 89, 786 Marotte, H 60, 69, 469, 48, 97, 97 Marquardt, K 575 Marques, CDL 07 Marquez, A 89 Marra, CA 008 Marras, C 788 Marras, TK 685 Marsal, S 48, 90, 644 Marshak-Rothstein, A 904 Marshall, D 96 Marshall, L 40, 46 Marshall, M 497 Marshall, T 04 Marsili, M 75 Marston, BA 07 Martel-Pelletier, J 48, 5, 8, 88, 45, 669 Martes, MP 08 Martin, A 808 Martin, DA 608, 609 Martin, G 56 Martin, I 40 Martin, J 76, 808, 89, 89, 8, 8, 79 Martin, JE 76, 89, 79 Martin, K 66 Martin, L 95 Martin, M 6 Martin, P 77, 88, 886, 99 Martin, RS 604, 74 Martin, R 9 Martin, S 86, 856 Martin, TM 705 Martin, T 04 Martin Marquez, BT 40 Martin Martinez, M 475 Martín Mola, E 79 Martín Penagos, L 64 Martin-Hervas, C 469 Martin-Marquez, BT 7, 067 Martin-Mola, E 47, 647, 469 Martindale, J 60, Martínez, C 57 Martínez, C 7 Martinez, C Martinez, H 6 Martinez, JM 08 Martinez, MA 777 Martínez, RN 86, 60 Martínez García, E 40 Martínez-Barrio, J 78 Martínez-Becerra, MJ 64 Martínez-Costa, L 750, 65 Martínez-Estupiñán, L 78 Martinez-Galarza, A 00 Martinez-Lavin, M 45 Martinez-Martinez, LA 45 Martinez-Mora, C Martínez-Morillo, M 9 Martínez-Prada, C 67 Martínez-Rodríguez, N 486 Martínez-Sánchez, AH 77 Martínez-Taboada, V 469 Martínez-Taboada, VM 66, 6, 644 Martini, A 69, 70, 7, 7, 76, 80, 89, 96, 79, 7, 69, 68, 98, 75 Martini, C 5 Martini, D 505, 900 Martini, G 7, 605 Martins, G 08 Marty, FM 780 Maruyama, T 45 Marx, R 856 Marzan, KA 66 Marzo-Ortega, H 57, 85, 86 Masalova, V 7 Masetto, A 95 Masferrer, JL 809 Masi, AT 98 Masi, CM 069 Maskell, J 895 Masoller, N 08 Mason, JC 684 Mason, TG II 77 Massardier, C 4 Massarotti, E 476 Massarotti, EM 699, 55 Masseau, A 554, 750, 84 Massó, F 57, 558 Masters, ET, 9, 7 Masui, K 575 Masumoto, J 9 Mat, C 76 Mata, C 64 Mata, C 78 Mata, C 788, 6 Matar, M 67 Mateo, I 47 Mateo, L 9 Mateos, J 4, 56, 64, 849, 876, 878 Mateos-Toledo, H 409 Mathai, SC 579 Mathauda, S 55 Mathew, S 9, 76 Mathian, A 6, 067, 564, 07 Mathiessen, A 79 Mathieu, M 5 Mathieu, S 948 Mathieu, S 4 Mathsson, L 9 Matias, A 55 Matsuda, S 404 Matsui, K 447, 567 Matsui, K 465, 4, 56 Matsui, T 07, 56 Matsui, Y 9, 567 Matsukawa, T 64 Matsuki, Y 5 Matsumoto, A 4, 89 Matsumoto, I 67, 666, 50,, 6 Matsumoto, Y 940, 79, 855,, 6 Matsuno, H 4, 897, 9 Matsuo, K 48 Matsuo, N 50 Matsushita, I 457 Matsushita, M 64 Matsuura, I 885, 66 Matt, B 57 Mattar, M 054 Matteson, EL 60, 64, 67, 68, 69, 868, 66, 66, 669, 67, 674, 675, 678, 998, 999, 5, 70, 85 Mattey, D 874 Matthias, T 547 Mattoo, H 784, 0, 04 Matucci Cerinic, M 69, 9 Matucci-Cerinic, M 989 Matz, H 5 Matzelle, M 65 Matzinger, M 865 Matzkies, F 4 Mauerhan, D 86 Maumus, M 54 Maurer, B 70 Maurer, K 65 Maurer, M 747 Maurier, F 74, 744, 78 Mautalen, C 86 Mavria, G 57 Mavros, P Maw, WW 98, 667 Mawson, P 70 Max, R 0 Maxwell, JL 759 Mayan, MD 69, 849 Mayes, MD 76, 655, 67, 747, 6, 586, 96 Mayes for the US Scleroderma GWAS Group, MD 79 Maynard, JW 9, 9 Mazzaro, C 67 McAdams DeMarco, M 9, 9, 55, 56 McAlear, C 79, 667, 669 McAlindon, TE 4, 4, 56, 9,, 044, 50 McAllister, K 88 McCahan, SM 865 McCann, FE 84 McCann, L 69, 69 McCarthy, C 05 McCarthy, EM 668, 868 McCarthy, GM 959, 470, 664, 668 McCarthy, PM 8 McCarty, K 007 McCauley, D 77 McClemens-McBride, D 70 McClory, D 9 McCloskey, E McClung, MR 867 McClung, M 9 McColl, E 48 McComsey, G 674 McCormick, D 59 McCormick, J 560, 569 McCormick, J 9, 946, 664 McCormick, N 008 McCormick, T 64 McCreesh, K McCune, WJ 605 McCurdy, DK 698 McDaniel, GE 7 McDermott, M 709 McDonald, M 78 McDonald, S 59 McDonald-Blumer, H 96 McDougall, JJ McElroy, H, 7 McElvaney, NG 05 McFadden, M 7 McGeachy, M 485 McGeachy, MJ 4 McGeoch, L 79 McGlasson, R 96, 9 McGonagle, D 65, 8, 586, 604 McGovern, DPB 488 McGowan, D 8, 78 McGowan, J 04 McGuckin, M 695 McGuire, MB 740, 460 McGwin, G Jr. 604 McHaffie, A 95 McHugh, K 7 McHugh, N 5, 57, 67 McHugh, NJ 70, 704, 058, 059, 596 Mcinnes, IB 0,,, 4, 76, 7, 798, 94, 944, 695, 7 McInnes, PIB 947, 9, 4 McIntyre, B 6 McKay, HA 94 McKeever, K 78 McKernan, P 04 abstract author Index 0 Program Book 47

420 abstract author Index McKinnon, J 70 McKinnon-Maksimowicz, K 669 McLain, D 7 McLaughlin, V 579, 584 McLean, J 40 McMahon, MA 604, 885, 77, 66 McManus, R 57 McMenna, M 49 McMurtry, MS 45 McNair, PJ 090 McNamara, C 55 McNett, M, 7 McParland, L 84 McQueen, FM,, 5, 95 McQueenie, R 76 McRae, A 56 McSparron, JI 0, 84 Meadows, A 847 Mease, P 75, 794 Mease, P, 7, 40 Mease, PJ 0,, 7, 8, 6, 8,, 4, 48, 86, 87,, 4, 799, 47, 459, 46 Mebus, C 977 Mebus, CA 44, 48, Mebus, C 6 Mech, C 94, 476, 9 Mechanic, JA Mecoli, C 97 Medema, J 994 Mediero, A 5, 80, 88, 85, 70 Medina, A 86 Medina, G 694 Medina-Chinchon, M 40, 68, 5 Medina-Rodriguez, FG 76 Medsger, TA Jr. 748, 578 Meduri, A 70 Meednu, N 66 Meek, IL 7, 406 Meguro, A 70 Mehbob, A 4 Mehta, A 4 Mehta, A 5 Mehta, B 504 Mehta, J 99 Mehta, NN 0 Mehta, N 968 Mehta, S 568 Meijide-Failde, R 47 Meijs, J 686, 688, 609 Meiners, P 5, 88 Meinke, M 9 Meirelles, ES 470 Meißner, Y 77 Mejia, A 699 Mejia, M 409 Mejia-Otero, C 745 Mekinian, A 686, 09 Melander, O 4 Melchor, S 687 Melhado, TV 6 Melikoglu, M 65 Melikoglu, M 76 Melikoglu, MA 65 Mellemkjær, L 08 Mellins, ED 88, 98 Mello, SBV 57, 545 Melmed, GY 08, 607 Melson, PG 79 Melton, LJ III 0 Meltzer, M 967 Membrez Scalfo, F 8 Menard, H 95 Mendelsohn, AM 9, 0,,, 874, 47, 695, 48, 768 Mendelson, CF 90 Mendelson, E 5 Mendez, B 6 Mendez, L Mendonça, JA 948 Mendoza-Alvarez, S 694 Mendy, D 4 Meneses Villalba, C 08 Mengus, C 50 Menin, R 470 Menon, B 50 Menon, S 444, 445, Menor Almagro, R 60 Menz, HB 899, 90 Merayo-Chalico, J 579 Mercer, LK 04, 760 Mercer, V 67 Mercy, G 85 Meriwether, D 076 Merkel, PA 79, 74, 669, 8, 78 Merkel, PA 747, 756, 76, 667, 05, 786 Merkel of behalf of the Vasculitis Clinical Research Consortium, PA 70 Merkovich, A 54 Merola, JF 74, 699 Meroni, PL 9,, 5, 566, 707, 466 Meroni, PL 8, 0, 89 Merrill, JT 65, 765, 88, 48, 565, 59, 808, 809, 864, 50, 54, 548, 549, 77, 900 Merriman, ME 60, 75 Merriman, TR 60, 75, 87 Merry, SP 66 Mertens, S 94 Merz, EL 87, 6 Mesa, AM 57 Mescam-Mancini, L 07 Mesquida, M 750, 0, 65 Messer, L 808 Messier, SP 757 Messig, M 850 Metes, D 4 Metes, ID 07, 0, 47, 48, 7, 776, 790, 4 Metyas, S 09, 06 Metz, M 747 Metzig, C 70 Meuleners, L 8 Meurling, J 05 Meyer, A 664 Meyer, C 00 Meyer, O 469, 09, 84, 87 Meyer, R 8, 66 Meyer, R 8, 8, 0, 0, 057 Meylan, F 78 Miao, S 79 Miao, Y 7 Miao, Z 79 Miceli, JG 00 Miceli-Richard, C 5, 866, 488, 545, 770, 77 Michaels, A 78 Michaelson, J 54, 56 Michalk, I 9, 64 Michaud, J 59 Michaud, K 47, 78, 09, 047, 055,, 700, 646, 759 Michaud, M 68 Michaux, L 00 Michel, BA 40 Michel, BA 480, 70, 775, 5, 404, 406, 46, 76, 87 Michel, F 4 Micheroli, R 5 Michet, CJ 998, 999 Michishita, K 4, 89 Middleton, JE 9 Midtbø, H 404, 4 Midtvedt, O 690, 697 Miese, DF 954, 955, 956 Miettunen, PM 865 Migita, K 7 Migone, TS 60 Migowa, A 8, 8 Miguel-Perez, M 95 Mihai, C 04 Mikdashi, J 595, 899 Mikecz, K 56, 99, 896, 697, 74 Miki, H 666 Miki, I 0 Miki, K 465, 097, 4, 46 Mikkelsen, CM 7 Mikkelsen, D 84 MIkkelsen, K 4, 7, 88, 405 Mikolaitis, RA 5, 54 Mikuls, TR 47, 486, 809, 8, 09, 08, 78, 44, 7, 87, 968, 6, 406, 659, 660, 877 Mild, M 607, 6 Milic, V 508 Millar, DNL 947 Miller, A 67 Miller, E III 8 Miller, E 9 Miller, FW, 98, 06, 08, 86 Miller, J 454 Miller, J 66 Miller, ML 780 Miller, PD 864 Miller, RE 859 Miller, RJ 859 Millner, J 04 Mills, SD 87, 908 Millson, D 79 Milne, GL 704 Milner, J 894 Milojevic, D 78, 88, 790, 74, 780 Miloslavsky, E 74, 747, 78, 84 Milward, M 57 Mimori, A 7 Mimori, T 465, 588, 89, 4, 9, 0 Mimura, T 45, 880, 80, 477, 570, 8, 99 Min, C 9, 567 Mina, R 90, 96, 675, 79 Minardo, G 7 Minatsuki, S 59 Minden, K 7, 795 Minegishi, K 945, 96, 074 Miner, J 795 Miner, JN 7 Mines, C 5 Minguez, E 750, 65 Mínguez, M 687 Miniaci, A 856 Minisola, G 74 Minisola, G 989 Minkin, SJ 65 Minoda, M 447 Minoia, F 96 Minota, S 74, 65, 477, 60 Minty, G 564 Mintz, S 09 Miossec, P 60 Miossi, R 5 Miotto e Silva, VB 98 Mir, A 856 Miranda, JR 6 Miranda, P 44, 69 Miranda-Carus, ME Program Book

421 Miranda-Filloy, JA 89, 89, 8, 8 Miretti, EM 5 Mirjafari, H 49 Misaki, K 40 Miserocchi, E 707 Misharin, A 56, 70, 744 Misharin, AV 89 Misra, D 4, 65 Misra, R 59, 605, 0, 89 Mistry, A 75 Mitchell, B 984 Mitchell, BD 889 Mitchell, J 7 Mitchell, K 5 Mitchell, L 865 Mitchell, N 767 Mitenko, E 9, 64, 70 Mitmaker, E 6 Mitraud, SAV 98 Mitsugi, N 7 Mitsui, H 58 Mittleman, B 876, 88 Mittoo, S 97 Miura, K 6 Miura, T 4, 897 Miura, Y 94, 77, 76 Miura, Y 7, 98, 57 Miwa, Y 7, 98, 57 Mix, KS 84 Miyake, N 9 Miyamoto, ST 5, 54 Miyamoto, T 97 Miyamoto, T 9 Miyamoto, Y 869 Miyara, M 6, 564 Miyasaka, N 588, 79, 055,,, 769 Miyashita, T 7 Miyazaki, T 9 Miyazaki, Y 648 Miyoshi, F 80, 477, 99 Miyoshi, S 6 Mizui, M 557, 57 Mizuki, N 70, 68 Mizumoto, A 4, 89 Mjaavatten, M 87, 94 Mjaavatten, MD 94 Mjosberg, J 49 Mo, YQ 78, 48 Mobasher, SA 594 Mobley, JA 745 Mochida, Y 7 Mociran, E 48 Moctezuma, JF 69 Moder, KG 8 Modi, S 0 Modorati, G 707 Mogard, EA 05 Mohamed Naim, AN 880 Mohammad, A 787 Mohan, C 68, 58, 894 Mohan, N 8 Mohan, S 65 Mohile, M 578 Moholt, E 9 Moi, JH 45 Moilanen, E 44 Moilanen, T 44 Moir, S 894 Moisio, K 0 Mok, CC 600, 60, 608, 596, 540 Mok, MY 97, 597 Mokuda, S 9 Molano-González, N 0 Molberg, O 676 Molberg, 88, 690, 697, 89 Moldovan, I 60 Molenaar, THE 799 Molina, E 86 Molina, E 76 Molina, T 09 Molina-Aguilar, R 694 Molitor, JA 586 Moll Tuduri, C 788 Moller, I 94, 95 Molloy, D 664 Molloy, ES 664, 668 Molnár, C 59 Molta, CT 006, 585, 587, 740 Moltó, A 57, 59, 55 Momohara, S 74, 86, 6, 40, 44, 459 Momtahen, T 470, 55, 58 Monach, PA 79, 756, 667, 669 Mondot, S 695 Monegal, A 4 Monfort, J 89, 89, 46 Monga, N 064 Moni, M 47 Monnet, E 9 Monnier, G 4 Monrad, SU 909 Monsivais-Urenda, AE 66 Montagna, P 654 Montanelli, G 687 Montañés, F 46 Montastruc, JL 44, 67, 676 Monteagudo, I 78 Montealegre, G 90 Montealegre Sanchez, GA 78 Montecucco, C 576, 700, 989 Montell, E 84 Montell, E 69, 7, 858 Montero, A 40 Montgomery, C 509, 65 Montgomery, CG 88, 489, 565, 770, 77 Montgomery, G 60 Monti, G 67 Monticielo, OA 0, 948, 4 Montiel-Cervantes, L 694 Montiel-Hernandez, JL 40 Montilla, C 750, 440, 65 Montori, VM 758 Montoro Alvarez, M 78 Montoya, H 57 Moon, K 84 Moore, D 990 Moore, K 70 Moore, L 84, 847 Moore, O 678, 59 Moore, TL 96, 97 Moore, TM 79 Moorehead, S 07, Mooren, F 75 Moorthy, LN 69, 504, 86 Moosig, F 760, 786, 89 Moots, R 446 Moots, RJ 79 Mor-Vaknin, N 0 Morado, IC 89, 89 Moraes, JCB 87, 4, 5, 75, 07, 474 Morais, J 84 Morales, K 56 Morales-Nebreda, L 744 Morand, EF 64, 566, 76 Moratz, C 540 Moreau, A 69 Moreau, K 6 Moreau, P 69 Morehouse, C 7 Morehouse, CA 645, 94 Moreira- Navarrete, V 90 Moreira-Navarrete, V 05 Morel, J 447, 458,, 40, 469, 488, 88, 69, 87, 880 Morel, L 548, 567, 75 Morel, N 85, 554, 84 Moreland, LW 40, 79, 876, 47, 790, 87, 890, 88, 406, 4, 646 Morell, A 48 Morelos-Guzmán, M 650 Moreno, M 440 Moreno Martínez, M 0 Moreno Ramos, M 0 Moret, FM 70, 99, 949 Morgacheva, O 974 Morgan, AW 886 Morgan, AW 45, 57, 89, 766 Morgan, C 45 Morgan, GA 8, 77, 087, 089 Morgan, L 0 Morgan, N 0 Morgan, R 85 Morgan, R 6 Morgan DeWitt, E 77,, 789, 79 Morhy, SS 87 Mori, H 56 Mori, S 66 Morimoto, H 8, Morimoto, S 7 Morimura, S 7, 95 Morinobu, A 869, 67 Morio, T 74 Morita, S 465, 4 Morla, RM 440 Morley, T 04 Morlock, R 85, 86 Moroncini, G 705 Morris, D 4 Morris, M 08 Morrison, M 695 Morrison, S 6, 557 Morrone, S 79 Mortensen, SR 7 Morton, R 99, Morytko, M 74 Mosaad, E 646 Mosca, M 505, 559, 850, 56, 607, 6, 677, 900, 5, 55, 68, 60 Moser, KL 77 Moser, K 549 Mosher, DP 96, 9 Mosley-Williams, AD, 58 Mostoller, K 4 Motegi, SI 65 Motomura, H 457 Moulin, DE 8 Moulis, G 44, 67, 68 Moulton, VR 7, 68 Mounts, WM 809 Mountz, JD 7, 9, 7, 745 Mouriño-Rodríguez, C 400 Mourot, L 8 Moussallieh, FM 664 Mouterde, G 870, 96 Mouthon, L 695, 74, 744, 86, 78, 784 Moutsopopoulos, HM 844 Movahedi, M 758 Moverley, AR 84 Mowinckel, P 095 Mozaffarian, N 79, 555, 58, 589, 467 Mpfofu, S 9 Mudivarthy, S 48 Mueller, DL 7 Mueller, R 95, 59 Muhamad, NA 07 Muhammad, A 94 Muhammad, K 95 Mujib, M 504, 749 abstract author Index 0 Program Book 49

422 abstract author Index 40 Mukae, H 069 Mukherjee, A 6 Mukherjee, S 507 Mukhopadhyay, P 705 Mulero, J 440, 475 Mullan, R 484 Mullazehi, M 4 Mulleman, D 807 Muller, S 9, 9 Mulukutla, SR 40 Mumcu, G 69, 60 Mundra, J 87 Muñiz, JR 66 Munneke, M 49 Munoz, LE 8 Muñoz, S 475 Munoz C, DM 57 Muñoz-Fernández, S 908 Muñoz-Valle, JF 546 Munroe, ME 65, 767, 549, 77 Muntner, PM 9, 680 Mura, T 447, 458, 40 Murad, S 07, 96 Murakami, K 80 Murakami, K 465, 89, 4 Muramatsu, T 66 Muraoka, H 59 Muraoka, S 86, 64 Muraro, P 60 Murasawa, A 4 Murata, K 404 Murata, M 6 Murata, N 76 Murata, O Muratore, F 666, 678 Murdoch, L 668 Murphy, CL 95 Murphy, C 664, 668, 779 Murphy, E 95 Murphy, FT 5 Murphy, L 95, 46, 898, 909 Murphy, M 786 Murphy, M 60 Murray, E 44 Murray, M 940 Murray, S 607, 774 Murray-Brown, W 495 Murrell, PGA 947 Murru, V, 7, 55 Murtaza, A 948, 74 Mus, AM 7 Muscal, E 57, 66, 86 Muschter, D 85 Museyko, O 966 Musgrove, H 95 Musial, J 0 MUSICIAN study team, T 848 Musiol, S Program Book Muss, H 09 Musset, L 754 Mustafa, A 569 Mustelin, T Musvasva, E 40 Muth, T 009, 00 Muthana, M 44, 874 Mutlu, G 744 Mutti, A 46 Myasoedova, E 60, 68 Myasoutova, L 5 Myers, L 654 Myerson, GE 85 Myklebust, G 688 Myles, A 89 Myles, JD 4 Müller-Ladner, U 6, 77, 77, 84 Myones, BL 7 Mysiw, WJ 5 Mysiw, WJ 75 Mysler, E 75 Mysler, EF 464 Myslinski, R 96, 06 Månsson, K 90 Möller, B 408 Möller, B 7 Möller, I 79 Möller, S 898 Möricke, R 77 Mörner, A 684 Møller, JM 84 Møller, JM 46, 80 Mørch, UG 805 N Na, YJ 400 Nabozny, G 40 Nacir, B 08 Nackiewicz, D 55 Nada, OH 594 Nadarajah, T 787 Nadkarni, A 44, 458 Nadler, SG 7 Naeem, M 69 Naga, OS 565, 57 Nagahara, H 80 Nagai, K 49 Nagai, K 905 Nagai, R 707 Nagai, T 67, 79, 600, 47, 585 Nagakura, T 7, 75, 08 Nagano, S 05 Nagao, N 76, 90 Nagaoka, S 67, 7 Nagar, S 587 Nagaraja, V 909 Nagaraju, K 779 Nagasawa, H 67 Nagashima, T 65 Nagatani, K 65 Nagelkerke, S 78 Nagpal, K 67 Nagy, G 59 Nah, SS 0, 5 Naides, SJ 90 Naiman, B Nair, A 8, 50, 56 Nair, D 6 Nair, SC 005, 45 Nakabayashi, A 67 Nakabo, S 9 Nakagawa, I 7 Nakahara, H 465, 4, 76 Nakahara, H 6 Nakai, K 67 Nakajima, A 40, 44 Nakajima, R 66 Nakajima, T 49 Nakamura, A 9 Nakamura, H 69, 6, 960, 069 Nakamura, H 96, 9, 449, 66 Nakamura, H 905 Nakamura, H 8 Nakamura, J 65 Nakamura, K 49, 68 Nakamura, M 06 Nakamura, T 4, 897 Nakamura, T 9 Nakamura, Y 6 Nakamura, Y Nakanishi, K 4 Nakanishi, T 76 Nakano, H 49, 905 Nakano, H 447, 567 Nakano, K 87 Nakano, M 785 Nakano, S 5 Nakashima, M 0 Nakashima, R 9, 0 Nakashima, Y 69, 6, 960, 069 Nakayamada, S 468, 9, 774 Nakazawa, T 40 Nakazono, K 4 Nakhleh, A 854 Nakov, R 454 Nalli, C 9 Nam, EJ 58, 69 Nam, JL 766 Namas, R 75 Namas, R 75 Namer, IJ 664 Namour, F 795 Nandakumar, KS 5 Nandiwada, S 67 Nanki, T 66 Nantel, F 9, 45, 47, 48, 490, 46, 550, 50, 5, 5, 85, 87, 7, 84, 458 Napalkov, P 5 Naraghi, A 97 Narayanan, S 54, 45 Narazaki, M 048 Nardo, L 6 Naredo, E 6, 79, 94, 78 Narimatsu, S 4 Narita, I 4, 785 Narita, M 84 Narla, H 049 Narrodi, A 6 Narula, N 896 Narvaez, J 788, 89, 89, 44, 687 Nash, P 44 Nash, P 45, 678, 85 Nashi, EP Nasonov, E 448 Nasonov, E 496, 500, Nasr, A 8,, 70 Nastacio, M 56 Natour, J 98, 4, 89, 8, 099,, 4 Nava, A 546 Navarra, SV 566 Navarro, F 44 Navarro, G 076 Navarro Hernandez, R 40 Navarro Sarabia, F 05 Navarro-Compán, V, 508, 55, 59, 549, 77, 80, 45, 884, 886 Navarro-Coy, N 84 Navarro-Millan, I 6, 50 Navarro-Sarabia, F 48, 90 Navarro-Zarza, JE 960 Navarta, DA 06, 855, 859 Navío-Marco, T 908 Nayak, U 5, 54 Nduaka, CI 9, Neal, M 90 Neary, B 798 Nebesky, JM 77 Nebesky, M 748 Néel, A 69, 750 Negoescu, A 46, 045 Negro, G 89 Neidhart, M 46 Neill, L 66 Nekhai, S 89 Nelissen, R 08 Nelson, AE 49, 6, 67, 900, 76 Nelson, JL 90 Nelson, RE 47 Nelson, S 590 Nelson, SL 844, 675

423 Nemes, D 48 Nieminen, T 779, 0 Noda, S 706, 707 Nyrienda, T 77 Neo, M 64 Neogi, T 4, 65, 85, 07, 8, 9, 67 Neovius, M 996 Neri, D 74 Neri, R 060 Nerome, Y 7, 75 Nerviani, A 4 Nestorowicz, B 6 Netea, MG 94 Neto, CADC 44 Neto, D 495, 90 Neubert, K 7 Neubig, RR 56 Neuen, A 04 Neumaier, W 0 Neumann, E 6, 77, 77, 84 Neumann, T 760 Neuville, S 5, 55 Neuwelt, CM 606, 74 Nevitt, MC 95, 5, 5, 54, 85, 90, 07, 7,,, 8, 9, 67, 75, 754 Nevskaya, T 6 New, A 09 Newman, ED 9, 54 Newmark, R 87 Newsom, D 86 Newsom-Davis, T 65 Newton, R 797 Nezzer, J 047 Ng, AY 47 Ng, B 807 Ng, CK 7 Ng, CT 98 Ng, L 65 Ng, LWK 67 Ng, N 4 Ng, WF 86, 508, 88, 68, 770 Ng, WL 600 Ng ang a, E 8, 8 Nguyen, H 57 Nguyen, S Nguyen, USDT 5, 85, 757 Nguyen, V 64 Ngwiri, T 8, 8 Ní Gabhann, J 868 Nicastro, M 789 Nicholls, SJ 85 Nickerson-Nutter, CL 74 Nickeson, R 08 Nicolás, JM 0 Nicoletti, A 40 Niedermayer, D 950 Niehaus, S 90 Nielsen, CT 60, 659, 576 Nielsen, S 95 Niemann, G 4 Niemela, J 864 Niessen, HW 86, 87 Nieto, JC 78 Nieves, JW 4 Nieves-Plaza, M 97, 0, 48, 60 Niewold, TB 6, 64, 767 Nightingale, AL 57, 67 Nigil Haroon, N 548 Nigon, D, 847 Nigrovic, PA 876, 4, 88, 86 Nihtyanova, SI 674, 745, 588 Niiro, H 5, 94 Nikaï, E 50 Niki, Y 97 Nikiphorou, E 79, 4, 46 Nikishina, I 80 Nikitina, T 89 Nikolaus, S 9 Nikolov, NP 60 Nikotorowicz-Buniak, J 56 Nikpour, M 678, 566, 85 Nilsson, AM 50 Nilsson, J 76, 40, 407, 408, 68 Ninaber, MK 688 Ninomiya, Y Nippe, N 6 Nirmala, NR 69 Nirula, A 8, 87 Nisar, M 4 Nise, L 46 Nishi, E 67 Nishida, J 6, 95 Nishida, K 67 Nishida, N 67 Nishikawa, A 840, 84 Nishimoto, N 465, 4, 67 Nishimoto, T 669 Nishimura, K 67 Nishimura, K 9, 7 Nishino, A 6, 960, 069 Nishino, J 07, 56, 56 Nishio, MJ 686 Nishioka, K 49 Nishioka, Y 9 Nissinen, R 04, 04 Nistala, K 70 Nititham, J 6, 64, 77 Nitsche, A 5 Nitschke, Y 50 Niu, F 857 Niu, J 7, 4, 5, 6, 85, 90, 7, 757, 9 Nived, O 59, 769 Nixon, N 874 Njoya, M 45 Noble, P 5 Nocturne, G 77 Noda, K 5, 94 Noel, D 5, 54 Noel, N 6 Noertersheuser, P 488 Nogi, S 05, 079 Nojima, T 97 Nojima, Y 880 Nolan, A 05, 06 Nolla, JM 44 Nonaka, Y 7, 75, 08 Nondosi, M 844 Noonan, L 768 Noone, D 75, 754 Noordenbos, T 500 Noordenbos, T 49 Noordman, BJ 784 Noort, AR 945 Nordal, E 95, 68 Nordborg, E 66 Nordgren, B 980 Nordin, A 096 Nordin, H 84, 4 Nordmark, G 88, 497, 770, 77 Nordström, D 496, 500 Nordström, DC 448 Noriega, E 40, 68, 5 Norli, ES 87, 095 Norman, GL 9, 0,, 654 Norris, JM 6, 869, 87, 767, 74, 407, 659, 660 Norton, T 699 Notarangelo, LD 95 Notarnicola, A 806 Nott, J 66 Novera, D 67 Nowak, E 508, 50, 880, 88 Nowling, TK 6 Nozaki, Y 465 Nozawa, K 7, 5 Nozawa, T 9, 7 Nugent, K 5 Numano, F 05 Nunes, H 695, 78 Nuñez Atahualpa, A 40 Nuñez Atahualpa, L 40 Núñez-Alvarez, CA 650 Nunziato, CA 96 Nurmohamed, MT 465 Nurmohamed, MT 45 Nurmohamed, MT 46, 455 Nurmohamed, MT 4, 456, 509, 54, 899, 76, 454 Nurmohamed, MT 86, 87, 54 Nurmohamed, MT 57 Nusman, CM 84 Nyberg, F 9, 78, 047, 0, 405, 759 Nye, A 79 Nygaard, H 87, 94 Nyrop, KA 09 Nüßlein, H 465 Nzeusseu Toukap, A 40 Næser, EK 478 Nørregaard, J 84 O O Dell, J 700 O Neill, L 668 O Brien, A O Brien, A 9 O Brien, C 455, 456 O Brien, M 777 O brien, R 948, 74 O Brien, WR 74 O Connell, PG 868, 05 O Dell, AA 57 O Dell, JR 8, 876, 78, 87, 6, 88, 646, 659, 660 O Donnell, JL 98 O Hanlon, T 86 O Kane, SL 6 O Keane, MP 49 O Keefe, A 896 O Keefe, R 70, 9 o Keeffe, A 59 O Leary, DH 76 O Mahony, A 866 O Mahony, M 668 O Malley, C 864 O Meara, C 696 O Neil, KM 78, 790, 780 O Neil, MM 4 O Neill, L 664 O Neill, T 64 O Reilly, J 04 O Rielly, DD 90 O Rourke, C 680, 657, 667, 078 O Rourke, KS 970, 977, 8 O Rourke, MA 779 O Shea, D 484 O Shea, FD O Shea, JJ 78 O Shea, K 40 O Sullivan, M 95 O Sullivan, R 67 O Toole, M 809 Oakley, J 649 Oatis, CA 757, 098 Oberle, EJ 746 Obukhov, Y 89 Obusez, E 658 Ocal, L 680, 45 Ochi, K 86, 6 Ochs, W 64 Ocsko, T 56, 99, 896, 697 Oczakar, L 94 Oda, R 80 abstract author Index 0 Program Book 4

424 abstract author Index Oddis, CV 776, 057, 06, 08 Oddone, EZ 075, 855 Odeh, M 854 Odenbach, J 45 Oemar, B 455 Oen, K 84, 94, 865, 790 Oeser, A 84 Oeser, AM 87 Offord, E 8 Ogale, S 484, 468 Ogando, S 98 Ogasawara, M 5 Ogata, A 40 Ogata, H 840, 84 Ogata, K 00 Ogawa, E 600 Ogawa, F 748 Ogawa, N 477 Ogdie, A 0, 05 Ogino, S 65 Ogishima, H 666 Oglesby, A 070, 740 Ognenovski, VM 909 Oguro, N 7, 98, 57 Oh, A 587 Oh, HJ 67, 95, 07, 44, 4, 476 Oh, J 484, 468 Oh, JM 8 Oh, JH 6 Oh, TH, Oh, U 60 Ohara, R 658, 597 Ohara, RA 774 Ohara, Y 9, 567 Öhman, ML 8 Ohmura, K 465, 89, 4, 707, 9, 0 Ohno, S 70 Ohno, Y 8 Ohrndorf, S 946 Ohshima, S 64 Ohta, A 76, 90 Ohta, H 40, 764 Ohta, K 645 Ohtsuka, K 57 Oikawa, Y Oka, H 06 Oka, S 7 Okada, A 0, 6, 960 Okada, H 80 Okada, J 585 Okada, M 9, 477, 567 Okada, Y 87 Okada, Y 704, 707, 877 Okamoto, A 66 Okamoto, H 60 Okamoto, K 49, 905 Okamoto, M 854 Okamoto, T Okamoto, Y 59, 65, 06, 070, 075 Okamura, K 87 Okamura, Y 75 Okano, T 96, 9, 449, 66 Okano, T 0 Okano, Y 64 Okawa, J 860 Okayama, Y 75 Okazaki, Y 669 Okazawa, T 869 Oktay, V 6 Oku, K 7, 68 Okuda, K 4, 897 Okuno, H 0, 68 Okura, C 87 Okuyama, A 67 Olalekan, S 99, 89, 650 Oldroyd, A 7,, 9, 45 Olech, E 48, 765 Olejarova, M 596, 947 Olesinska, M 844 Olferiev, M 57, 86 Olivé, A 788, 9 Olivé Marqués, A 750, 65 Oliveira, AM 85 Oliveira, HA 4 Oliveira, P 8 Oliveira, S 70, 68 Oliveira, SK 98, 06, 98 Oliveira, W 556 Oliver, MS 789 Oliver-Bell, J 7 Olivieri, I 67 Olmer, M 7 Olschowka, N 5 Olsen, IC 09, 84, 40, 404, 4, 9 Olsen, NJ 569 Olson, JC 845, 64, 79 Olson, L 555, 948, 74 Olsson, P 88 Oma, I 7, 88 Omair, M 97, 96, 599 Ombrello, A 894 Ombrello, AK 60, 0, 78, 7, 7 Ombrello, MJ 70, 879, 98 Omdal, R 88, 770, 77 OMERACT Flare Working Group, 75 Omerovic, E 4 Omma, A 680 Omran, E 646 Onda, A 66 Onel, K 7, 77, 504 Onen, F 5, 544, 48, 465, 47 Ones, T 68 Ong, V 667 Ong, VH 674, 745, 59, 608 Onofrei, AU 9, 0 Onstenk, R 08 Onuoha, S 497 Oo, STH 0 Ooka, S 49, 905 Oozeer, R 74 Opal, S 07 Opava, CH 4, 87, 980 Ophoff, RA 808 Opoka-Winiarska, V 79 Oppe, M 08 Oprenyeszk, F 76 Orbach, A 6 Orbai, AM 59, 4, 80, 84, 867 Orcesi, S 67 Ordi-Ros, J 606 Oreiro-Villar, N 5, 5, 65 Orellana, C 7 Oribe, M 4, 9 Origasa, H, Origuchi, T 69, 6, 960, 069 Orlowsky, EW 858 Ormseth, MJ 87 Ørnbjerg, LM 40 Orquevaux, P 554, 84 Orr, C 05 Orr-Walker, B 74 Orriss, I 7 Orte, J 47 Ortego, N 687, 750, 0, 65 Ortego-Centeno, N 76, 89, 89 Ortiz, AM 47, Ortiz, EC 09 Ortiz, H 46 Ortiz Mayor, SM 60 Ortiz-Sanjuán, F 0, 65, 64 Ortiz-Sanjuan, F 788, 687, 750, 975, 6 Oryoji, D 5, 94 Osako, Y 08 Osborne, RH 84 Oseki, K 486 Oshikawa, H 447 Oshima, H 4 Osorno, H 46 Ospelt, C 5, 404, 406, 850 Ossipova, E 9, 89 Ostanek, L 6 Ostendorf, B 7 Ostendorf, PDB 954, 955, 956 Ostergaard, M 89, 976, 888 Østergaard, M 6, 875, 056, 40, 46, 44, 79, 687, 80, 84 Østergaard, O 60 Østgård, R 96 Österlund, T 980 Ostermeier, E 6 Ostor, AJ 46, 045, 7 Ostrovrsnik, J 65, 66 Ostrower, A 087 Oswald, M 47 Ota, M 570 Ota, SI 5, 94 Ota, T 05 Ota, Y 59, 65, 06, 070, 075 Otabe, K 6, 64 Otawa, SM 9, 45, 47, 48, 490, 46, 550, 554, 49, 50, 5, 5, 85, 87, 7, 84, 458 Otero, M 60 Otsuka, K 7 Ottenbacher, KJ 074 Ottosson, C 779 Ou, J 566 Oude Voshaar, M 6 Outman, RC 4 Ovalles-Bonilla, JG 78 Overend, T 06 Overman, RA 0, 7, 94, 664 Owen, T 66, 890 Ozaki, S 49, 905 Ozaki, Y 465 Ozbayrak, S 0 Ozbek, O 0 Ozbek, S 64 Ozcan, EE 5 Ozdemir, O 096 Ozdogan, H 08, 69 Ozekli Misirlioglu, T 5 Ozen, G 457, 69, 80 Ozen, S 98 Ozgocmen, S 47 Ozisik, L 858 Ozyazgan, Y 70, 66 Ozyilmaz, E 64 Pablos, JL 96, 870 Pabst, H 095 Pachman, LM 8, 77, 08, 087, 089 Pachon, J 54 Packham, J 5, 874 Padbury, H 66 Padeh, S 70 Padeh, S 64 Padley, R 74 Padova, H 484 Padyukov, L 808, 07, 704, 707, 875 Paez, A 57 Paez-Camino, M 60 Paganotti, M 54 Pagel, K 85 P 4 0 Program Book

425 Paget, SA 980, 8 Pagnoux, C 78, 79, 744, 756, 758, 759, 667, 78, 784 Pagovich, OE 556 Pai, SY 95 Pai, V 0 Paik, JJ 699 Paira, S Païta, M 067 Pak, Y 66 Pala, E 5 Pala, O 45 Palagini, L 68 Palanichamy, A 66 Palaniswamy, C 749 Palfreeman, AC 84 Pallot Prades, B 808 Pallot-Prades, B 48 Palmer, RH 40 Palmisani, E 76, 68 Palmisano, A 696 Palominos, PE 948 Paltiel, AD 768 Palumbo, K 80 Palumbo-Zerr, K 8, 8, 85, 690, 704, 708 Pamuk, GE 506 Pamuk, ON 5, 506, 50 Pandya, J 08 Pane, I 4 Panfilov, S 454 Pang, H 9 Pang, H 7 Pang, J 85 Pangan, AL 79, 540, 80, 47, 49, 459 Panopalis, P 8 Panopulos, A 594 Paolazzi, G 8 Pap, T 50, 75, 889, 9,, 78 Papachristos, A 986, 5 Papaioannou, A 8 Papalardo, E Papandrikopoulou, A 86 Papapoulos, S 9 Papassidero, S 5 Papavassilis, C 9 Papo, T 609, 644, 744, 09 Papon, L Papp, K, 4 Papp, M 0 Pappas, DA 9, 6, 70, 9, 78, 040, 047, 0, 45, 885, 69, 44, 759, 87, 877 Pappu, R 740 Paracha, A 47 Paradis, T 809 Paramarta, JE 450 Parameswaran, A 4 Paran, D 8, 5, 098, 484 Pardo, P 74 Parekh, R 75, 754 Parekh, TM 840 Parikh, M 58 Parimi, N 57 Paris, A 08 Parish, MC 80, 407 Parisi, F 70 Park, DJ 0, 5, 6, 5, 577, 54, 547 Park, EJ 7, 006 Park, HJ 5 Park, J 98 Park, JK 07 Park, JS 5 Park, J 46 Park, KS 494, 4, 77 Park, MC 6 Park, PS 9 Park, S 5 Park, SC 7 Park, SH 440, 494, 77 Park, SH 049, 94 Park, SH 4 Park, W 45, 8, 440, 76, 9 Park, YB 69, 787,, 6, 89, 9, 5 Park, YW 5, 6, 5, 577, 54, 547 Park, YE 440 Park, Y 400 Park, YJ 46 Parkes, MJ 694 Parks, CG 059 Parodi, A 654 Parodis, I 797 Parra, ER 84, 90 Parra, JA 975 Parra I, V 57 Parratte, B 4 Parrinello, G 707 Parton, S 4 Parvu, M 48 Pasarikovski, C 576, 577, 6 Pascale, R 850 Paschke, J 946 Pascual, MV 88 Pascual, V 656 Pascual-Ramos, V 6 Pascual-Salcedo, D 8, 456 Pasoto, SG 55 Pasquale, G 906 Pasquali, JL 84 Passalent, LA 99, Passiu, G 66 Passo, MH 6, 79 Pasta, D 909 Pastor-Asurza, CA 40, 68, 5 Patakas, A 7 Patel, AM 47, 790 Patel, DR 75 Patel, J 070, 587 Patel, NJ 64 Patel, R 7, 8 Patelli, M 88 Paternotte, S 866, 7, 57, 59, 50, 55, 545 Paterson, JM 770 Pathan, E 9 Pathmasiri, W 757 Patil, P 98, 07, 667 Patlan, M 57 Pato, E 750, 86, 65 Patrick, JL 850 Patsouras, M 5 Patterson, K 96 Pattloch, D 806 Pattrapornpisut, P 8 Patwardhan, A 86 Pau, E 564 Pauer, L 850 Paul, S 5 Paul, S 60, 69 Paula, L 904 Pauling, JD 70, 704, 596 Paulissen, SMJ 6, 656 Pauwels, E 69 Pavelka, K 446, 465 Pavelka, K 448, 480 Pavelka, K 60, 495, 496, 500, 950, 957, 947, 90 Pavenstädt, H Pavic, M 00 Pavletic, S 60 Pavlides, S 764 Pavlov, P 8 Pavy, S 5 Pawar, R 550, 56 Pawaria, S 765 Pay, S 9, 07 Payne, J 8, 78 Pazzola, G 8 Pearce, A 649 Pearson, D 57 Pease, CT 66 Peat, G 67 Pécourneau, V 48 Pedersen, L 04 Pedersen, R 0, 56, 546, 59, 689 Pedersen, SJ 89, 5, 48, 69, 89, 84, 887, 888 Pedersen, TR 84, 85, 40 Pederzoli, S 76 Pedraza, IF 407 Pedreira, A 08 Pedro, S 055,, 700 Pedroza, C 747 Pedroza, M 567, 57 Peeters, AJ 799, 48 Pego-Reigosa, JM 400 Pegtel, M 884 Pehlivan, O 45 Pehlivan, Y 749 Peikert, T 748 Peiró, ME 687, 64 Peitado-Lopez, D 750, 0, 65 Peiteado, D 469 Peliçari, K 0 Pellegrini, C 0 Pellegrini, V 9 Pellerito, R 806 Pelletier, JP 9, 55, 5, 40, 4, 489, 99 Pelletier, JP 48, 5, 8, 88, 45, 669 Pelletier, JM 9, 55 Pelletier, M 60 Pellett, F 0, 894, 50 Peloso, PM Peltoniemi, S 95 Peña, R 86 Pena Rossi, C 59, 55 Pendl, JD 65 Pendón, G 86 Peng, Q 065 Peng, Y 890 Penmetsa, G 650 Penn, H 59 Pennaforte, JL 554, 84 Pennathur, S 886 Penning-van Beest, FJA 04 Penny, MA 88 Pepe, P 505, 900 Perandini, LA 054, 474, 57, 545 Perandones, CE 5 Perazzio, SF 6, 64 Perdriger, A 469, 488, 880 Pereira, B 4 Pereira, D 86 Pereira, IA 470 Pereira, I 55 Pereira, JX 8 Pereira, PVS 6, 64 Pereira, RM 55 Pereira, RMR 68, 474 Perel, P 66 Perez Alamino, R, 58 perez Aso, M 570 Perez Barrio, S 556 Perez Venegas, JJ 60 Perez Vicente, S 475 Perez-Aso, M 95, 80, 85, 85 Pérez-Baos, S 57, 60 Perez-Barbosa, L 8 Perez-Dorame, R 409 abstract author Index 0 Program Book 4

426 Perez-Ferro, M 64 Pha, M 07 Pitt, V 84 Ponte, C 786 abstract author Index 44 Perez-Ruiz, F 9, 987, 00 Perez-Sanchez, C, 887 Perich-Campos, RA 40, 68, 5 Pericleous, C 8,, 560, 57 Peris, P 4 Perl, A 575, 79, 700 Perlman, HR 56, 70, 5, 744, 8, 89 Pernis, AB 896 Peron, JM 808 Perper, S 555 Perrin, F 69 Perrodeau, E 96, 469 Perron, D 555 Perruccio, AV 44, 66 Perruche, S 5 Perry, B 647 Pers, JO 507, 50, 85, 880, 88 Pers, YM 4, 469, 898 Persselin, JE 984, 996, 997 Pértega-Díaz, S 5, 5 Perugino, C 680 Peruzzi, G 79 Peschken, C 96, 585, 59 Peschken, CA 94 Pesickova, S 596 Peter, HH 465 Peter, WF 08, 09 Petermans, J 89, 48 Peters, C 49 Peters, E 57, 59 Peters, J 684 Peters, MA 46 Petersen, KK 70, 50, 79 Petersen, N 4 Peterson, EJ 07 Peterson, LK 9 Peterson, L Peterson, M 504 Petersson, I 04 Petersson, IF 76,, 789, 68 Petri, M 40 Petri, M 4, 6, 9,, 574, 58, 585, 586, 587, 597, 765, 88, 88, 574, 585, 65, 74, 804, 805, 806, 877, 56, 58, 54, 65 Petri, MA 59, 606, 607, 78, 79 Petri, MA 54 Petronis, A 50 Petsch, C 405 Pettersson, G 670 Pettersson, S 769, 898 Pettit, A 56 Petty, RE 84 Peyrin-Biroulet, L 5 Pfeifer, E 85 Pfister, R 6 0 Program Book Pham, T 88, 69, 87 Phillips, K 909 Philp, K 95 Phipps-Green, A 60, 75 Piacentini, A 54 Pialoux, G 754 Pichardo, DM 905 Pichlmeier, U 54, 55 Pickering, K 04 Piek, E 966 Piemonte, G 69 Pieper, J 8 Piera-Velazquez, S 559, 560, 56 Pierangeli, SS 8,,, 4, 5, 6, 9, 60, 655 Pierce, SB 64 Pierro, L 707 Pietrogrande, M 67 Piette, JC 6, 85, 75, 05, 554, 6, 84 Piette, YP 594 Pignataro, R 96 Pignatti, F 0 Pignone, A 69 Piitulainen, E 50 Pike, VC 79 Pikwer, M 40, 407, 408 Pilari, S 488 Pilataxi, F 50 Pilkington, C 98, 06 Pillai, S 784, 0, 04 Pillinger, MH 86, 79, 95, 986, 8 Pimentel, EAS 07 Pimentel, R 6, 650 Pimienta, O 8, 974 Pimmett, V 888 Pincus, T 88, 049, 4, 94, 47 Pineau, CA, 577, 740, 8, 8, 95 Pineda, C 94 Pineda, L 76 Pinheiro, FAG 4 Pinheiro, GC 6 Pinheiro, MM 6, 470, 486 Pinnell, L 496 Pinney, AJ 657 Pinto, ALS 054, 07, 474 Pinto, MI 486 Pinto, RM 08 Pintus, G 66 Pioltelli, P 67 Pipitone, N 67 Pisetsky, DS 606 Pistorio, A 76, 98, 06, 68 Pitcher, A 640 Pitsillides, A 7 Pitts, L 459 Pitzalis, C 497, 4, 495, 408, 647 Piva, SR 84, 86 Pivot, X 050 Pizzi, LT 856 Pizzino, G 66 Pizzo, AS 05 Pizzorni, C 590, 594, 598 Plans, M 4 Plant, D 45, 886 Plasencia, C 456, 647 Plasencia Rodriguez, C 788 Plass, N 78, 90 Platt, A 878 Platt, A 76 Platt, PN 86 Platt, RW 577, 8, 8 Plenge, RM 704, 707, 885, 877 Plestilova, L 884 Plumas, J 70 Plutzky, J 09 Png, E 78 Poddubnyy, D 56, 55, 798, 49, 45, 49, 88, 84 Poder, A 85 Poelman, C 708 Poelmans, S 87 Poeppel, MD, T 7 Poetzl, J 86 Pohjolainen, T 779, 0 Pohl, C 97 Poil, AR 58 Poiley, J 456 Pol, S 754 Polachek, A 098 Polackek, A 5 Polinski, JM 760 Polito, E 470 Polley, A 865 Pollock, J 08 Pollock, PS 600, 60 Pollock, R 894, 50, 50 Polly, D 6 Polonsky, T 77 Polyak, JL 4, 08, 05 Pomés, I 870 Pomés, J 870 Pomponio, G 705 Ponce de León, A 580 Ponce-Guarneros, JM 407 Poncet, C 465 Poncet, JC 75 Pongratz, G 78 Pons-Estel, B 9, 0, 69 Pons-Estel, B 45 Pons-Estel, GJ 65 Ponsford, MJ 4 Pool, B 860, 75 Poole, JL 90, 09 Popa, C 0, 86, 88 Pope, E 77 Pope, JE 74, 6, 6, 06, 09, 8, 9, 4, 48, 464, 475, 79, 80, 4, 5, 75, 76, 96, 586, 866, 868, 869 Pope, RM 5, 5, 8 Pope, TD 65, 69 Popescu, M 8 Popkova, T 9, 0 Popov, JM 90 Popova, S 8 Pors, D 609 Porter, A 5 Porter, B 50 Porter, D 798, 7 Porter-Brown, B 5 Portugal, L 69 Posadino, AM 66 Posever, J 696 Possemato, N 8, 9 Postal, M 58, 59, 60, 0 Posthumus, MD 808 Postlethwaite, AE 654 Potempa, J 40 Pottier, P 750 Pouchot, J 09 Poulet, B 7 Poulin-Costello, M 464 Poulsen, MK 64 Poulton, C 75 Pouplin, S 59 Pourrat, J 68 Povedo-Gallego, A 57 Powers, J 79 Prado, LL 75 Praestgaard, A 8 Prahalad, S 77, 98, 99, 86 Prajzlerova, K 480, 957 Prakash, N 88 Prakash, P 749 Prakken, BJ 640, 784 Pras, E 64 Prather, K 780 Prati, C 050 Pratt, AG 68 Pratt, AG 70 Precioso, AR 75 Predel, HG 095 Pregnolato, F 8, 9 Prein, C 75 Premaor, MO 4 Prendki, V 09 Prescott, GJ 848 Prestigiacomo, T 5 Preston, D 5

427 Presumey, J 4 Prezant, DJ 05, 06 Price, LL 0, 4, 4, 5, 56, 9, Priest, J 050 Prieto- Candau, C 90 Prieto-Alhambra, D 05 Prieto-Martinez, JM 90 Prince, FHM 09 Principe, JR 5 Prinjha, R 7 Prins, K 4 Prior, D 85 Prior, H 95 Priori, R 79 Prisco, E 74 Pritchard, CH 877, 47 Prlic, H 98 Prodinger, B 979, 50 Proft, F 0 Proglhof, JEP 4 Proietto, J 56 Prokopec, S 557 Propert, KJ 95 Proudman, S 678, 85, 47 Proulx, J 8 Pruijn, GJ 9 Pruthi, R 8 Prøven, A Ptacek, J 876, 88 Pucci, P 5 Puchner, A 6, 99, 0 Puechal, X 74, 744, 488, 750, 78, 784, 880 Pugh, MT 60 Pugnet, G 67, 676 Puig, A 84 Puig, J 5 Puig, L 0,,, 695 Puig-Kröger, A 647 Puissant, B 68 Pujol, J 46 Pulido-Zamudio, TR 558 Pullenayegum, E 7 Punaro, MG 78, 790, 780, 77 Punzi, L 004, 989 Puolakka, K 779, 0 Purcaru, O 6, 50 Purdue, PE 70 Puri, KD 74 Purohit, S 97 Pursche, N 786, 099 Purvis, L 75 Pushparajah, DS 94, 54 Puskas, GJ Puskas, LG 74 Putrik, P 88 Putterman, C 54, 550, 56, 56, 6, 55, 56 Puyraveau, M 5 Pyo, JY 5 Pødenphant, J 6, 875, 40, 687, 80 Q Qayyum, B 06 Qi, Z 06 Quach, C 00 Quach, D 496 Quach, HL 496, 6 Quartier, P 69, 70, 79, 79, 69 Quartuccio, L 004, 67 Queiro, R 440 Quemeneur, T 744, 78 Quentin, J 4 Quesada-Calvo, F 55 Quesada-Masachs, E 48 Quesniaux, V 9 Quinet, R 98 Quinlan, P 97 Quinn, EK 54, 67 Quinn, M 684 Quintero, O 9 Quintin Roue, I 50 Quinzanini, M 55 Quinzanos, I 0, 907 Quirke, AM, 40 Quiroz, C 60, 855 Qureshi, AA 08 Qureshi, F 7 R Ra, C 75 Rabenda, V 89 Rabinovich, A 66 Rabinovich, CE 77 Race, D 87 Rachele, P 508 Rader, T 06 Radfar, L 50, 489, 77 Radjenovic, A 65, 8 Radner, H 950 Radominski, S 76 Radominski, SC 9, 0, 48 Radstake, TRDJ 76, 70, 99, 949, 79 Radstake, TR 45 Radusky, RC 85 Radvanski, DC 990 Radziszewska, A 560 Raffray, L 00 Ragab, GM 67 Raggi, P 84 Raghavan, S 08 Rahal, N 488 Rahbar, M 54, 446, 448, 840 Rahimi, H 8, 8, 978 Rahman, AAP 50 Rahman, A 4, 8,, 6, 66, 640, 59, 5 Rahman, MM 97 Rahman, M 89 Rahman, P 0,,, 45, 50, 550, 554, 695, 705, 90, 50 Rai, S 0,, 04, 66 Rainer, F 465 Rainey, AA 94, 944, 4 Rajan, A Rajan, KB 8 Rajaram, M 68 Rajasekhar, M 50 Rajkumar, SV 868 Rajme-Lopez, S 579, 66 Rakieh, C 6 Ralph, K 40 Ralston, A 9 Raluy, M 99 Ramachandaran, R 9, 6 Ramachandran, V 4, 590 Raman, I 77 Ramanan, AV 57 Ramanathan, A 68 Ramanayake, W 7 Ramanujam, M 40 Ramasamy, P 779 Ramires de Jesus, G 65 Ramirez, J 0, 444, 90, 9, 870 Ramírez-Herráiz, E 48 Ramiro, S 88, 50, 55, 5, 54, 55, 447, 87, 885 Ramkhelawon, B 70 Ramonda, R, 55, 59, 549, 77, 80, 45, 884, 886 Ramoni, V 86 Ramos, E 0, Ramos, MI 8 Ramos, PS 5, 54, 86 Ramos-Casals, M 59, 607, 67 Ramos-Remus, C 57, 884 Rampakakis, E 4, 4, 9, 47, 48, 490, 46, 550, 554, 49, 50, 5, 5, 85, 87, 7, 84, 85 Ramrattan, LA 944 Ramsden-Stein, D 5 Ramsey-Goldman, R 607, 55 Ramsey-Goldman, R 585, 65, 574, 59, 0, 90 Ranade, K 50 Rand-Weaver, J 0 Randazzo, B 695 Ranganath, V 4, 974 Ranganath, VK Ranganna, G 77, 78 Rangaraj, MJ 464 Rangel-Moreno, J 66, 890 Ranger, A 0, 88, 88, 74, 877, 58 Ranieri, E 00 Rannio, T 95 Rannou, F Rantapaa-Dahlqvist, SM 8, 408, 958 Rantapää Dahlqvist, S 97, 9, 769, 7 Rantapää-Dahlqvist, SM 804, 805, 875 Ranz, JV 79 Ranza, R 08, 6 Ranzolin, A 44, 07, 6 Rao, DA 74 Rao, J 8 Rao, M 78 Rao, SA 459, 460, 46 Rao, S 64 Raouf, J 779 Rapp, C 09 Rapsinski, G 895 Rashid, N 857, 007 Rasmussen, A 50, 509, 489 Rasmussen, C 84, 4 Rasmussen, T 94, 859 Rastalsky, N Rastogi, A 9 Rat, AC 5 Rat, AC 04,, 654 Raterman, HG 958, 76 Rathbun, A 044 Rathmann, SS 45, 540, 80, 4, 49 Ratzlaff, C 8, 0,, 4 Rauch, C 465 Rauch, J Rauch, TA 56, 99, 896, 697, 74 Rauen, T 74 Raulf, F 856 Raun, J 875, 40, 478, 687, 80 Rauz, S 57 Ravaud, P 5, 744, 96, 4, 469, 488 Ravelli, A 76, 89, 96, 98, 06 Ravera, F 58 Ravindran, V 59 Ray, DW 64, 758 Ray, L 504 Raya, E 89 Rayahin, JE 0 Raychaudhuri, S 704, 88, 885, 99, 877 Raynauld, JP 5, 40, 4, 489, 064, 45, 99, 669 Raza, K 57, 875 ReACCh Out Investigators, T 790 Rebelatto, M 78 abstract author Index 0 Program Book 45

428 Rech, J 405, 485, 80 Relic, B 5, 55 Richards, A 57 Rivero, M 5 Reckley, KA 77, 8, 0, 4 Rell-Bakalarska, M 976 Richards, HB 50 Riveros-Frutos, A 9 Recknor, C 86 Remáková, M 957 Richards, JS 96, 00 Rivoire, J 6, 967 Recknor, C 7 Remmers, E 894, 70 Richards, J 84 Riyazi, N 47 Recknor, C 8 Remmers, EF 879, 98 Richards, P 08 Rizvi, B 559 Redden, DT 87 Rempell, J 974 Richards, R 06 Roads, E 445 Reddy, A 57, 46 Remy-Moulard, A 946 Richardson, BC 75 Roane, G 464 Reddy, A 574 Ren, B 845 Richardson, R 99 Robert, PY 86 Reddy, PS 809 Ren, P 474 Richbourgh, B 87 Roberts, A 86, Reddy, ST 076 Ren-Fielding, C 58 Richette, P 96 Roberts, D 84 Reddy, V 8 Renaudineau, Y 507, 85, 56 Richey, MC 905, 989, 990 Roberts, MS 06, 07 abstract author Index Redfern, A 49 Redlich, K 6, 99, 0 Redman, R 8, 78 Rednic, S 9 Reed, AM 776, 057, 07, 08 Reed, G 78, 044, 047, 8, 759 Reed, GW 9, 00, 6, 70, 9, 040, 0, 45, 45, 48, 69, 44, 87 Reed, JH 74 Reed, TJ 54 Reedquist, KA 86, 8, 7 Reese, C 647 Reeves, E 49 Reeves, Q 95 Reeves, WH 550, 67, 75 Régent, A 86 Regina, A 69 Reginster, JY 89, 864,, 48, 4, 44 Regnault, A 50 Regnault, V 654 Rego-Pérez, I 5, 5, 65 Rehart, S 6, 77, 77, 84 Rehaume, L 695, 696 Rehman, AA 98 Reich, H 557 Reich, K, 4 Reichmann, W 994 Reid, KF 5 Reiff, A 8, 68, 504, 675 Reijnierse, M 4, 804 Reijnierse, M 0,,,, 55, 59, 549, 77, 78, 80, 4, 45, 46, 884, 886 Reilly, J 9 Reimold, AM 47, 8, 00, 78 Reimundes, C 5 Reina, D 44 Reinhardt, AL 78 Reis, SE 40 Reiss, AB 98 Reiss, W 877 Rejchrt, S 89 Rekvig, OP 60 Relaño-Fernández, S 5, 5, 65 Renbaum, PF 64 Renner, JB 46, 49, 67, 076, 889, 89 Renoux, J 85 Repping-Wuts, H 079 Resche Rigon, M 75 Resche-Rigon, M 760, 6 Research Group, TCS 95 Resende, GG 470 Reshma, V 59 Restrepo, JF 5, 76 Restuccia, G 8 Retamozo, S 67 Reuter, S 547 Reveille, JD 655, 54, 705, 747, 799, 446, 448, 586, 79, 86, 840 Revicki, D 449 Rey Rey, JS 908 Reyna, V 58 Reynisdottir, G 4 Reynolds, JA 64 Reynolds, R 70 Reynolds, RJ 8, 78, 890, 406 Rezaei, H 96, 970 Rezus, E 48 Rharbaoui, F 4 Rhee, H 400 Rhee, RL 7, 8 Rhiannon, JJ 87, 74 Rhodus, NL 489, 770, 77 Ribeiro, ACM 67 Ribeiro, AC 4, 5 Ribeiro, ACM 75, 474 Ribeiro, LHC 89, 099 Ribeiro, SL 470 Ribeiro, TA 4 Ribi, C 784 Ricaurte, M 60 Ricca, LR 88 Ricca, M 605 Ricci, J 88 Riccieri, V 594 Rice, P 55, 65 Rich, S 55 Richard-Miceli, C 877 Richez, C 469 Richter, A 77 Richter, JG 009, 00, 64 Rickenlund, A 980 Rickert, M 6 Rider, LG, 98, 06, 08, 90, 86 Ridgway, W 778 Ridley, A 7, 655 Riebschleger, MP 86 Rieck, M 8 Riega-Torres, JCL 8 Riek, M 448 Riente, L 0 Riese, R 49, 440, 44, 44, 44, 444, 445, 80, 9, 0,, 4 Riese, R 8 Rietschel, C 06, Rigamonti, F 46 Rigante, D 9 Rigby, WFC Rigby, W 877, 95, 767 Rigolet, A 00 Rihl, M 0 Riley, J Rillo, OL, 5, 9 Rillo, OL 9, 0 Rinaldo, C Jr. 70 Rinaudo-Gaujous, M 60, 69 Rincheval, N 870 Ringold, S 77, 78, 790 Rioja, J 48 Ríos, G 97 Ripoll, V 560 Ripoll, VM 4, Rischmueller, M 88, 770 Rispens, T 456, 509, 54 Risselada, A 879 Rist, S 469, 488 Ritchlin, CT 0, 07,,,, 54, 87, 8, 695, 978 Ritter, SY 7 Rivas, AM 5 Rivas, M 0 Riveiro-Naveira, RR 94, 87, 846 Rivera, J 47 Rivera, Y 506 Roberts, N 66 Roberts, N 069 Roberts, T 709 Roberts, VC 65 Robertson, JM 68 Robinson, A 66 Robinson, AB 70, 674 Robinson, DB 586 Robinson, P 705, 498 Robinson, SM 0 Robinson, T 44, 48 Robinson, WH 809, 8, 876, 9, 96, 89, 890, 4, 88, 406, 647, 659 Robles, A 78 Robles-Espinoza, L 694 Roblin, X 69 Robotham, M 57, 86 Robson, J 746, 75, 895, 786 Roccatello, D, 7, 640 Rocha, B 56, 64, 876, 878 Rocha, CM 498 Rocha, FA 470 Rocha Muñoz, AD 407 Rocha Muñoz, DA 40 Rocher, V 4 Rockette, H 98, 06 Roddy, JE 678, 85 Rodiguez-Pintó, I 0 Rodrigues, JJ 08 Rodrigues, JF 9, 47, 85, 7, 458 Rodriguez, ER 670 Rodriguez, E 88 Rodriguez, I Rodriguez, M 75 Rodriguez, R 9 Rodriguez, V 57 Rodriguez Araya, TL 478 Rodriguez de la Serna, A 44 Rodriguez Reyna, T 679 Rodriguez Rodriguez, L 8 Rodriguez Rodriguez, N 74 Rodriguez-Almaraz, E 550 Rodriguez-Ariza, A, 887 Rodriguez-Bellido, Z 40, 68, 5 Rodríguez-Cambrón, AB 67 Rodriguez-Garcia, V 46 0 Program Book

429 Rodriguez-Heredia, JM 47 Ros Vilamajo, I 788 Rovin, BH 590, 884 Russo, P 860 Rodriguez-Hernandez, TM 599 Rosa, J 06, 855, 859 Rowell, L 459, 5 Russo, RAG 979, 79, 98 Rodríguez-Jiménez, M 0 Rosal, M 5 Rowse, AL 745 Ruta, S 06, 855, 859 Rodríguez-López, M 400 Rosales, Z 67, 86 Rowshandel, J 990 Rutgers, A 78, 665 Rodriguez-Muguruza, S 9 Rosário, C Roy, E 504 Ruth, JH 774, 777, 97 Rodríguez-Navedo, Y 60 Rosario, E 06 Roy, R 90 Ruth, NM 57, 6, 69, 780 Rodriguez-Osorio, C 558 Rosas, J 687 Rozema, M 74 Rutkowska-Sak, L 69 Rodriguez-Perez, JM 486 Roschel, H 054, 07, 57, 545 Rúa-Figueroa, 687 Rutten, M 08 Rodriguez-Reyna, T 650 Rose, CD 74, 865 Ruaro, B 58, 590, 598 Rutting, M 697 Rodriguez-Reyna, TS 558 Rodriguez-Rodriguez, L 808, 67, 86 Rodriguez-Saona, L 4 Roebuck-Spencer, T 57 Roeleveld, DM 74 Roemer, F 7, 9, 75, 754 Roger, J 799 Roger, M Rogers, J 0 Rogers, NH 58 Rogers, P 04 Rogier, R 74 Rohde, A 86 Rohekar, S 45 Rohrer, M 77 Rojanasantikul, P 8 Rojas, D 89 Rojas, H 75 Rojas, JE 64 Rojas-Serrano, J 409, 07 Rojas-Villarraga, A 0 Rokutanda, R 9, 567 Rolando, J 98 Roldan, P 97, 978, 87 Roll, P 95 Rollefstad, S 09, 84, 85, 40 Roman Ivorra, JA 908 Romanelli, M 0 Romanowski, W 844 Romanus, C 970 Rombouts, Y 89 Rome, BN 86 Rome, K 090 Romera, E 99 Romero, FI 47, 64 Romero-Barco, CM 48 Romero-Bueno, F 750, 65 Romero-Díaz, J 59, 598, 60, 609 Romero-Sanchez, C 57 Romeu, M 755 Romiti, R 08 Ronday, HK 799, 48 Rooney, M 586 Rooney, T 4 Roorda, LD 45, 89 Roos, AM 576, 577, 6 Roozendaal, C 665 Roque Afonso, AM 808 Roques, CF 09 Rose, JA 905, Rose, S 9 Rose, SR 675 Rosebraugh, M 74 Roselli, E 670 Roselló, R 788 Rosemffet, MG Rosen, A 66, 085, 685 Rosen, LB 844 Rosenbaum, JT 705, 9, 74 Rosenberg, AM 94 Rosenberg, A 4, 798 Rosenberg, IL 4 Rosenblatt, L 56, 8 Rosenblum, GC 98 Rosenfeld, A 4 Rosenwasser, LJ 97, 07 Rosenzwacjg, M 766 Rosenzweig, E 64 Rosenzweig, HL 697, 74 Rosenzweig, S 894 Rosiak-Jedrychowicz, K 79 Rosique-Robles, JD 47 Roskos, L 77, 78, 94 Rosloniec, E 654 Rosner, IA 854 Ross, E 5 Ross, H 94 Rosseisen, L 87, 74 Rossi, A 0 Rossi, D 640 Rossi, E 5 Rotar, 67, 66, 690 Roth, D 585, 60 Roth, J 46, 79, 6, 94, 865, 6, 66, 667, 87 Rother, K 78 Rottinghaus, S 0 Rouanet, S 75 Roubille, C 45, 669 Roudier, MP 80, 98 Roughley, A 58, 589 Rouse, H 678 Rousseau, JC 48, 756 Rout, J 508 Routledge, C 70 Rouvier, P 6 Roux, C 866, 7, 545, 808 Rovensky, J 596 Rovera, G 806 Rovida, F 576 Rubbert-Roth, A 464, 5, 767 Rubin, LA 5 Rubino, M 6 Rubinow, AA 64 Rubio, N 79 Rubio Garrido, J 60 Rubio Romero, E 788 Rucco, M 70 Ruderman, E 460 Rudinskaya, A 609, 74 Rudwaleit, M 5 Rudwaleit, M 57, 50, 56, 55, 55, 799, 45, 49, 88 Rueda, J 975 Rueda de Leon-Aguirre, A 558 Rueda-Gotor, J 8, 8, 6, 64 Ruetsch, C 8 Ruffing, VL Rufibach, K 89, 888 Ruggeri, M 004 Ruhí, R 84 Ruiz, P 565 Ruiz Arruza, I 78 Ruiz Lucea, E 556 Ruiz Moreno, O 750, 65 Ruiz Santacruz, O 9 Ruiz Tudela, MM 60 Ruiz-Esquide, V 0, 444, 9, 870 Ruiz-Irastorza, G 585, 59, 6 Ruiz-Limon, P, 887 Ruiz-Montesinos, D 90 Ruiz-Padilla, AJ 599 Ruiz-Romero, C 56, 64, 876, 878 Rukhkyan, I 854 Rumsey, D 790 Ruperto, N 09 Ruperto, N 69, 70, 7, 7, 76, 80, 8, 89, 79, 7, 69, 68 Ruperto, N 98, 06 Rus, H 64 Rus, V 64 Rusakiewicz, S 77 Rush, S 06, 54 Russell, R 964 Russo, B 906 Russo, LAT 46 Russo, M 668 Ruutu, M 695 Ruyssen-Witrand, A Ruzickova, O 60, 5, 947 Ryan, P 77 Ryan, PC 78 Ryan, S 0 Rybak, L 887 Rybakowska, P 775 Rychak, E 4 Ryffel, B 9, 60 Rygg, M 95 Rynning, SE 405 Rysava, R 596 Ryu, J 45 Rönnblom, L 769, 770, 77 Rönnelid, J 9, 9, 4, 4 Rødevand, E 4 S. Schlesinger, L 68 Sá-Pinto, AL 57, 545 Saad, CGS 4, 5, 75, 07, 474 Saada, S 86 Saadoun, D 0, 78, 75, 754, 766, 00, 07, 6 Saag, KG 6, 05, 78, 95, 4, 9, 40, 45, 680, 76 Saaibi, DL 546 Saas, P 5 Saavedra, MA 960 Sabapathy, A 6 Sabbadini, MG 08, 06 Sabelli, M 06, 60 Saber, R 70, 89 Sabot, E 04 Saccardo, F 67 Sacco, ICN 55 Sackmann, E 4 Sacksen, I 600, 60 Sacre, K 609, 644 Sada, KE 749, 048 Sadanaga, Y 76 Sadeghi, S 9 Saeed, A Saegusa, J 869, 67 Saeki, Y 64 Saevarsdottir, S 4, 7, 80,, 7, 54, 789, 40, 4 S abstract author Index 0 Program Book 47

430 Saferding, V 6, 99, 0 Salt, EG 97, 98 Santacatterina, M 54 Sato, T 9, 7 Sagar, H 75, 85 Salter-Cid, L 85 Santagati, A 0 Sato, T 49 abstract author Index 48 Sagawa, A 4, 897, 9 Sage, JM 65 Saggar, R 574 Saggar, R 574, 579 Sagliker, HS 5 Saha, K 8, 50 Sahakian, L 885, 66 Sahhar, J 678, 85 Sahin, E 99 Sahin, O 9 Sahin, ST 689 Sahl, S 74, 75 Sai, Y 474 Said Nahal, R 477 Said-Nahal, R 489 Saigusa, R 59 Saiki, O 4, 89 Sailler, L 67, 676, 68, 750 Saint Martin, E 9 Saint-cyr, C 865 Saito, E 05, 079 Saito, K 468, 45, 9 Saito, K 85, 6 Saito, M 64, 895 Saito, S 49, 68 Saito, S 75 Saito, T 7 Saitta, A 66 Sajuthi, S 5, 54, 6, 86 Sakai, R 67 Sakai, Y 897, 0 Sakamoto, N 89 Sakatsume, M 785 Saketkoo, LA 0, 04, 580, 589 Sakurai, N 9, 7 Sakurai, T 4, 897 Salaberri, JJ 60 Salaffi, F 989 Salama, A 90 Salazar, G 655, 747, 586 Salazar Paramo, M 407 Salcedo, M 86 Saldanha, M 94, 9 Sale, MM 5, 54 Saleem, N 0 Saleh, ZF 044 Salem, MN 67 Sales-de-Oliveira, D 57, 545 Salifu, M 90 Salli, A 5 Sallum, AM 67 Salmon, J, 808 Salmon, JE 4, 765, 989, 990 Salmon, JH 469 Salom, D 750, 65 Salonen, D 0 Program Book Salvador, G 9 Salvarani, C 8, 9, 696, 660, 66, 66, 666, 8, 67 Salvatierra, G 5 Salvatierra, J 00 Samborski, W 9 Sammaritano, LR 765, 989 Sammon, CJ 67 Sampaio, AL 08 Sampaio-Barros, P 90 sampaio-barros, PD 4, 75, 07, 470 Sampalis, JS 4, 4, 9, 45, 47, 48, 490, 46, 550, 554, 49, 50, 5, 5, 85, 87, 7, 84, 458, 85 Samper-Ternent, R 074 Samson, M 784 Samuels, J 58, 887 Sanchez, A 60 Sanchez, C 8 Sanchez, E 69 Sánchez, L 46 Sanchez, M 75 Sanchez Corona, E 40 Sánchez-Andrade, A 750, 65 Sanchez-Blazquez, M 64 Sánchez-Bursón, J 750, 0, 65 Sanchez-Guerrero, J 486, 59, 598, 60, 605, 609 Sanchez-Lopez, E 85 Sánchez-Martín, J 89 Sanchez-Mosco, D 599, 546 Sanchez-Pernaute, O 64 Sanchez-Ramirez, DC 45 Sandberg, MEC 4 Sandborg, CI 780, 88 Sanders, E 487 Sanders, KM Sanders, M 04, 04 Sandin, C 8 Sandler, D 059 Sandor, K 5 Sandor, V 797 Sandorfi, N 97 Sandoval, E Sandoval-Rios, M 40 Sandoval-Zarate, J 558 Sangani, S 90, 47 Sangle, S 568, 646 Sanin, L 850 Sanint, J 9 Sanjurjo-Rodríguez, C 77 Sanmarti, R 0, 4, 44, 444, 90, 9, 870 Sanna, G, 7, 55 Sano, H 465, 4, 56, 76 Sansonno, D 67 Santana, M 60 Santana-de Anda, K 66 Santaniello, A 687, 706 Santegoets, KC 45 Santiago, M 470 Santiago-Casas, YC 97 Santimaria, R 9 Santoni, A 79 Santora, A 9 Santoriello, D 6 Santos, MCS 5 Santos, M 975 Santos-Gómez, M 0 Sanz, I 0,,, 68, 799 Sanz, I 4, 798 Saracbasi, E 6 Saraiva-Ribeiro, J 7 Sarano, J 86, 594 Saraux, A 507, 508, 50, 85, 870, 96, 0,,, 469, 488, 78, 75, 46, 87, 880, 88 Saravanan, V 4 Sardim, CC 099 Sargeant, I 9 Sari, H 0 Sari, I, 5, 5, 544, 48, 444, 47, 749 Sari, RA 66 Sarkar, S 76 Sarlon, G 66 Sarmiento-Monroy, JC 0 Sarquella-Brugada, G 08 Sartore, A 0 Saruhan-Direskeneli, G 70 Sarzi-Puttini, P, 46, 84, 56, 806 Sasaki, M Sasaki, M 97 Sasaki, N Sasaki, N 05, 079 Sasso, EH 47, 46 Sasso, EH, 45, 788, 789, 68 Satake, M 87 Satchithananda, K 9 Sathi, N 4 Sathoh, T 748 Sato, E 06 Sato, EI 4, 584 Sato, E 44 Sato, H 59 Sato, K 45, 80, 570, 8, 99 Sato, M 85, 6 Sato, S 648, 7, 84, 98, 95, 748, 59, 706, 707 Sato, S 05, 079 Sato, S 558 Sato, T 40 Sato, T 645 Sato, T 49, 905 Sato, Y 9 Satoh, M 7, 67, 67, 96, 067 Satoh, T 6 Satorius, C 70 Sattar, N 49 Saucedo, C 06, 60, 60 Sauer, BC 47, 778 Sauma, MDFLC 470 Sauma, MF 6 Saunders, KC 8, 9, 040, 0 Saura, C 9 Saurigny, D 7, 77, 78 Saurit, V 5 Sauvageau, D 5, 40, 4, 489, 99 Savage, E 59 Saw, YT 0 Sawada, T 56 Sawai, T Sawalha, AH 6, 70, 77 Sawitzke, AD 6, 7, 650 Sawyer, L 8 Saxena, A 74, 75, 80 Saxena, P 757 Saxne, T 76, 4, 684 Sayani, A 064 Sayarlioglu, M 5, 749 Saygin, C 69, 6 Sayles, H 09, 968, 6 Sayre, EC 98, 76, 008, 05, 67, 84, 80, 897 Sblattero, D 497, 566 Scaini, P 67 Scali, JJ 459 Scanzello, CR 8, 50, 56 Scarcia, M 57 Scarpato, S 67 Schabbauer, G 99 Schabert, VF 00 Schachna, L Schachter, C 06 Schaefer, C, 7 Schaeverbeke, T 96, 4 Schafer, P 4, 4, 80 Schainberg, CG 08, 4, 75 Schalkwijk, CG 74 Schall, TJ 79 Schanberg, LE 78, 790, 844, 780, 674 Scharer, C Scharl, M 40 Scharmga, A 97 Schaufelberger, C 976 Schechter, B 008 Schechtman, J 5

431 Scheel-Toellner, D 57 Scheibe, MM 665 Scheiman-Elazary, A 90,, 4 Scheinberg, MA 604, 74 Scheinecker, C 85 Schelbergen, R 46, 79, 77 Schelde, K 94 Schellmann, S 7 Scher, JU 409 Scherbarth, H 69 Scherer, DA 954 Scherer, L Scherle, P 797 Schett, G 0, 7,, 48, 405, 86, 8, 47, 690, 89, 966, 7, 0, 97, 485, 704, 708, 7 Schett, GA 8, 85, 80 Schiappapietra, B 96 Schiavon, F 004, 7 Schicke, B 85 Schieir, O 080 Schiel, A 9 Schiff, M 44, 476, 49 Schiff, MH 6 Schiff, MH 47, 796, 054, Schiffenbauer, A Schillinger, D 758 Schioppo, T 707 Schiopu, E 657, 658, 586 Schirmer, M 66, 66 Schiøttz-Christensen, B 96 Schlatter, E 9 Schleck, C 90, 96, 4 Schleich, DC 955, 956 Schlemmer, A 875, 40, 687, 80 Schlenk, EA 8, 0 Schlesinger, N 95, 990 Schlichting, DE 4, 796 Schmajuk, G 75, 7, 774, 66, 665 Schmalzing, M 78, 95, 97 Schmid, C 50 Schmid, M 8 Schmidt, E 0 Schmidt, J 678 Schmidt, RE 786, 099 Schmidt, WA 6, 85, 66 Schmidt-Lauber, C 9, 904 Schmitt, L 86 Schmitz-Bortz, E 0, 6 Schneck, J 50 Schneeberger, E, 9, 547 Schneeberger, EE 5, 58 Schneeweiss, S 6, 09, 70, 658 Schneider, A 50 Schneider, M 77, 494, 909, 009, 00, 56, 575 Schneider, P 60 Schneider, PDM 954, 955, 956 Schneider, R 69, 77, 750, 69, 86 Schnitzer, TJ Schnure, A 748 Schobers, L 9 Schoenfeld, M 99 Scholey, J 557 Scholman, RC 640 Scholte-Voshaar, M 50 Scholz, J 8 Schons, KRR 0 Schormair, B 64 Schouffoer, AA 688 Schreiber, BE 745, 58, 588, 59 Schreiber, DA 485 Schreiber, E 977 Schroth, R 94 Schröder, J 8 Schuch, F 95 Schuerwegh, AJM 686, 609 Schuetz, C 06 Schulman, E 989 Schulz-Knappe, P 494, 909, 575 Schulze-Koops, H 479, 9 Schulze-Koops, H Schulze-Koops, H 57, 46, 0, 95, 0 Schumacher, HR 00 Schumacher, M 69 Schumacher, R Schur, PH 74, 699 Schwartsmann, G 8 Schwartz, A 74 Schwartz, DM 7 Schwartzman, S 00 Schwartzman-Morris, JS 8 Schwarz, EM, 54, 8, 8, 978 Schwarzkopf, R 99 Schäffler, A 84 Sciascia, S, 7, 55, 640 Scirè, CA 04, 989 Scofield, RH 50, 509, 58, 88, 489, 50, 770, 77, 77 Scofield, RH 9, 64 Scolnik, M 60, 70, 859, 596, 60 Scopelitis, E 98 Scorletti, E 576 Scott, CA 705 Scott, C 979 Scott, J 57 Scott, S 577, 8, 8 Screaton, GR 65 Scrivo, R 79 Scuccimarri, R 865, 8, 8, 790 Seavey, MM 6 Sebastiani, GD 6, 74 Sebastiani, M 09, 67 Sebba, A 5 Seccia, V 759 Secco, A 5 Sederman, R 86 Sedlis, SP 79, 986 Sedova, L 995, 05 Seeman, E 867 Segal, BM 489, 770, 77 Segal, NA 5, 54, 9, 67 Segawa, S 666 Segel, R 64 Segerman, J 79 Segueni, N 9 Segura, S 57 Segurado, O 68 Seguro, L Seguso, M 54 Sehnert, B 7, 0 Sehra, S 7 Seid, M 90 Seidler, D 75 Seisdedos, MR 5 Seitz, L 79 Sejer-Hansen, M 976 Seki, E 457 Seki, M 75 Seki, S 7, 98, 57 Sekigawa, I 7 Sekiguchi, M 465, 4, 56 Sekine, H 89 Sekiyama, J 595 Seldin, MF 877 Sellam, J 469 Sellas-Fernàndez, A 65 Sellas-Fernàndez, A 750 Selman, MHJ 89 Selva O Callaghan, A 777 Selvaag, AM 676, 677 Selvi, E 74 Semanik, PA 5, 778, 077 Semb, AG 84, 85, 40, 86 Semb, AG 09, 404, 4, 88 Semerano, L 9 Semikina, E 64, 70 Semmalidinne, N 00 Sendo, S 869, 67 Sene, D 85, 488, 05, 77 Senécal, JL 064 Senel, S 749 Sengupta, R 57 Seno, T 80 Senolt, L 60, 480, 8, 950, 957, 5, 947, 569, 708 Senturk, T 40 Seo, GH 7 Seo, P 79, 74, 747, 756, 667, 669, 78 Seo, WJ 450, 0, 0, 445 Seo, YH Seo, YI 00 Sepúlveda, J 694 Sepulveda- Delgado, J 7 Sequi, G 605 Serafin, PC 55 Serafini, P 65 Sereika, S 0 Seriolo, B 50 Sernissi, F 505, 850,, 900 Serogodskaia, E 89 Seror, R 5, 74, 488, 880 Serracino Inglott, A 98 Serrano, A 89, 89 Serrano, B 78 Serrano, C 64 Serrano, EV 5, 54 Serrano, R 768 Serratrice, C Sr. 04 Serratrice, J 04 Servettaz, A 04 Sessa, MR 5 Setiadi, AF 07 Seto, Y 40, 44 Setoguchi, K 67 Seton, M 974 Settas, L 477 Sève, P 78 Severino, A 687 Sewerin, DP 954, 955, 956 Seyahi, E 08, 70, 75, 6, 6, 66 Seydaoglu, G 64 Sglunda, O 950 Sha, J 87 Shaban, R 5 Shacham, S 77, 890 Shadakshari, A 575 Shaddick, G 5, 57, 059 Shadick, NA 6, 876, 09, 88, 68, 88 Shadly, SM 685 Shah, A 476, 9 Shah, AA 66, 708 Shah, A 79 Shah, B 79, 986 Shah, K 0, 7,, 48, 85, 86 Shah, M 484, 468 Shah, N 999 Shah, U 54 Shaham, B 09 Shahani, BT 087 Shahbazian, A 076 Shahidul Makki, M 74 Shahrara, S 9, 5 Shahzad, A 559 Shaikh, SA 550, 458 Shakoor, N 5, 5, 54 Shakoory, B 07 Shan, Z 7, 77 0 Program Book 49 abstract author Index

432 abstract author Index 40 Shanahan, EM 0, 090 Shang, L 9 Shang, Q 487 Sharif, R 840 Sharma, L 5, 7, 0, 75 Sharma, M 860 Sharma, S 64 Sharma, TS 9 Shaughnessy, L 4 Shaw, A 795 Shaw, AT 84 Shaw, J 7, 7, 655 Shaw, JW 58, 77 Shaw, O 860 Shaw, Y 06, 07, 4 Shawi, M 9, 45, 47, 48, 490, 46, 550, 554, 49, 50, 5, 5, 85, 87, 7, 84, 458 Sheane, BJ, 64, 58 Sheen, DH 76 Sheen, D 66 Sheffield, A 57 Sheikh, S 66 Shelef, MA 4 Shen, J 76 Shen, N 7, 570, 645, 705, 7, 77 Shen, YK 0,, 4 Shen, Y 848, 8 Shen, Y 94, 06 Shenoi, S 77 Shenouda, N 865 Sheriff, MK 45, 47, 48, 550, 85, 84, 458 Sherina, N 40 Sherman, P 496 Sherrer, YRS, 58 Sherry, DD 75, 780 Shestakova, G 77 Shesternya, P 76 Sheth, H 64 Shewade, A 6, 70, 48, 44, 87 Shewede, A 48 Shi, B 5 Shi, J 869, 90, 88 Shi, K 097, 8, 46 Shi, L 65 Shi, XA 67 Shi, Y 0 Shiau, AL 78 Shibata, A 67 Shiboski, C 55, 56 Shiboski, S 55, 56 Shibuya, A 055 Shibuya, E 68 Shibuya, H 404 Shibuya, K 055 Shichino, Y 84 0 Program Book Shidara, K 44 Shiff, NJ 84 Shih, J 9 Shikano, K 86, 64 Shim, J 5, 80 Shim, SC 66, 440, 6, 76 Shimada, K 7, 56 Shimada, Y 570 Shimamura, Y 00 Shimizu, C 78, 880, 75, 05 Shimizu, H 9, 567 Shimizu, Y 40, 44 Shimmyo, N 465 Shin, DH 9 Shin, KC 00 Shin, K 69 Shindo, E 86, 64 Shinjo, SK 054 Shinmura, Y 66 Shinmyo, N 4 Shinohe, R 85, 6 Shintani, A 87 Shiohira, Y 9 Shiozawa, A 00, 009 Shiozawa, K 6, 0 Shiozawa, S 6, 648, 0 Shipley, JA 70, 704, 596 Shir, Y 8,, 4, 4, 6, 88, 89, 85 Shirai, T 49, 68 Shirai, Y 6, 575 Shiraishi, H 05 Shirota, Y 49, 68 Shiwen, X 667, 56 Shlomchik, M 56 Shmerling, RH 757 Shoemaker, R 59 Shoenfeld, Y, 547, 57, 6, 655, 89 Shohat, M 64 Shojania, K, 76, 67, 84 Shoji, T, Sholter, DE 9, 490, 550, 49, 5, 85, 87, 84, 458 Shono, E 4, 897, 9 Short, EB 849 Shott, S 9, 08, 085, 088, 05 Shourt, C 90 Shoushtari, A 40 Shrestha, A 00 Shu, Q 777 Shu, Y 665, 905 Shuler, CL 8 Shupak, R 986 Shupnik, M 68 Shurmur, R 794 Shuster, D 85 Shyjus, P 59 Si, N 80 Sibilia, J 664, 96, 4, 469, 488, 04, 60, 808, 880 Sibley, C 65 Sibley, M 487 Siddhanti, S 8 Sieber, J 867 Siebuhr, AS 878, 879, 50, 79 Siegel, RM 78, 764, 60, 844 Siemons, L 7 Sieper, J 5 Sieper, J 56, 56, 540, 55, 798, 799, 80, 49, 45, 466, 49, 499, 88 Sierakowska, J 844 Sierakowska, M 844 Sierakowski, S 844 Sierra, RJ 85 Siff, SJ 88, 80 Sifuentes Giraldo, A 788 Sighinolfi, GL 09 Signorovitch, J 77, 7 Sigurgeirsson, B 9 Sikara, M 5 Sikora, KA 55 Silacci, M 9 Sillevis Smitt-Kamminga, N 5 Silva, CA 87, 55, 65, 75, 67, 65, 675 Silva, DR 89 Silva, MB 6 Silva, T 68 Silva-Fernández, L 80 Silveira, I 6 Silveira, LH 57 Silver, RM 647, 586, 907 Silverfield, J 8 Silverman, ED 6, 67, 7, 65, 8 Silverman, GJ 7 Silverman, SL, 9, 7, 8 Simard, JF 060 Simeón, CP 76 Siminovitch, KA 88, 707, 786 Simkin, PA 80, 98 Simms, RW 744, 586, 90 Simon, LS 796 Simonds, MM 865 Simonelli, C 8 Simonini, G 68 Simonsen, O 70, 50, 79 Simpson, K 849 Sims, J 954 Simsek, I 9, 07 Simsek, S 86, 87 Sinclair Roberts, S 40 Sindel, D 40 Sindou, P 86 Singer, LG 98 Singer, NG 64, 780, 504 Singer, O 909 Singh, G Singh, H 975, 976 Singh, JA 70, 5, 86, 00, 90, 96, 984, 985, 988, 994, 996, 997, 005, 6, 9, 6, 4 Singh, N 66 Singh, N 5 Singh, P 799 Singh, S 40 Singh, Y 66, 07 Singhal, AK 794 Sinibaldi, D 77 Sinicato, NA 58, 59, 60, 0 Sinico, RA 760 Siqueira, I 948 Siris, E 8 Sisson, E 8 Sit, M 7 Sivakumar, R 548 Sivils, K 65 Sivils, KL 50, 509, 58, 88, 489, 565, 6, 6, 770, 77, 77 Sjöberg, C 408 Sjöwall, C 769, 54 Skacelova, S 569 Skaggs, B 885, 66 Skapenko, A 57 Skare, TL 470 Skawinski, M 845 Skedgel, C 00, 906 Skeoch, S 94 Skerjanec, A 04 Skillgate, E 40, 4 Skinner, M 95 Skjødt, T 84 Skogh, T 54 Skokos, D 99 Skol, AD 6 Skold, M 4 Sky, K 7 Slan, S 6, 505 Slan, SN 65 Sleeman, MA 77, 78 Sleglova, O 60, 5, 947 Sleptsova, T 9, 64, 70 (SLICC), FTSLICC 65 SLICC, SL 5 SLICC, SLEICC 508 SLICC group, FT 607 (SLICC), SLICC 585, 896 Sliva, MF 65 Sloane, R 8 Slobodin, G 854 Sloetjes, AW 46 Sloman, H 99 Slomian, J 48 Sloots, M 57 Slorach, C 67, 65

433 Sluka, K 7 Slutsky, I 6 Smail, A 750 Small, A 9, 08 Small, BJ 9, 085, 088 Smart, D 5 Smeester, L 89 Smikle, M 9, 60 Smith, CK 6, 886 Smith, E 640 Smith, EA 890, 406 Smith, E 87 Smith, J 50 Smith, MM 49 Smith, M 07 Smith, MD 4 Smith, MW 6 Smith, M 07, Smith, RG 58 Smith, S 868 Smith, S 66 Smith, S 965 Smith, S 49 Smith, V 65, 58, 590, 594, 598 Smith, Z 80 Smithers, N 7 Smoktunowicz, N Smolen, JS 57, 85, 449, 6, 99, 05, 56, 85, 950, 979, 0, 79, 86,, 5, 4 Smrzova, A 05 Snegireva, L 7 Snow, P 74 Snyder, MR 8 Sobanski, V 58, 588, 59, 608 Sobel, ES 67 Sobel-Fox, RM 87, 908 Sode, J 47 Soep, J 80 Sohn, MW 077 Sohn, W 609 Sokka, T 95 Sokol, R 85 Sokolove, J 809, 8, 9, 890, 4, 9, 406, 659 Sokolowska, B 760 Solak, Y 0 Solans, R 74, 89, 89 Solau Gervais, E 87 Solau-Gervais, E 469, 88, 467, 69 Soldal, DM 09, 688 Soldano, S 654 Soler, D 64 Solmaz, D 5,, 5, 5, 544, 48, 444, 465, 47, 749 Solomon, DH 0,, 6, 780, 987, 09, 09, 040, 05, 065, 45, 70, 760, 964, 09, 658, 679, 87, 908 Solomons, N 808 Solorio, D 047 Solow, EB 99, 45 Soltesz, E 670 Solus, JF 84 Solyman, J 09 Soma, K 440, 44, 444, 80, 794 Somaily, M 5, 58 Soman, D 98 Somers, EC 55 Sommerfleck, F 58, 547 Sommerfleck, FA 5 Sommers, T 6, 70, 44, 87 Sommerseth, H Sommet, A 44 Son, CN 6, 80, 80 Son, MB 679 Song, A 07 Song, GG 4, Song, H 590 Song, IH 56, 55, 88 Song, JJ 6, 89, 5 Song, J 5, 778, 077 Song, JS 787, 99,, 995, 00 Song, L 65 Song, M,, 695 Song, P 44 Song, R 464 Song, Y 5 Song, YW 95, 440, 07, 068, 44, 476 Song, YG 6 Song, YW 67, 4 Sonomoto, K 87 Sonsuz, A 75 Sontheimer, C 544 Sood, A 75 Sood, R 894 Soos, G 99, 74 Sopeña, B 89, 89 Sordet, C 664, 04, 808 Sorek, R 56 Sorensen, HT 04 Soriano, E 60 Soriano, ER 06, 60, 855, 859 Sornay-Rendu, E 48, 756 Soto, L 45 Soto-Hermida, A 5, 5, 65 Soubrier, M 96, 4, 469, 4 Souers, A 555 Soussan, M 686 Southwood, TR 9, 678 Souza, AWS 6, 64 Souza, DCC 4 Souza, M 8 Souza, R 6 Spalding, DM 745 Spalding, SJ 78, 85, 790, 780 Sparks, JA, 77, 0, 656 Specks, U 79, 74, 747, 748, 756, 78 Spee, P 805 Spees, C 86 Spencer, CH 86 Spencer, J 646 Sperber, KE 568 Sperotto, F 54, 85 Spevak, L 8 Speyer, I 799 Spiegel, B 08, 607 Spiegelman, A 807 Spieler, W 76, 689 Spiera, RF 709, 74, 74, 747, 896, 66, 566, 78 Spijkervet, F 5 Spina, F 486 Spindler, A 456, 79 Spindler, KP 768, 856 Spinetti, G 66 Spira, A 90 Spits, H 49 Spitz, E 87 Spitz, S 78 Spolidoro, NDO 4 Spoorenberg, A 58, 449, 456 Sportes, C 60 Spring, NH 989, 990 Springer, J 667 Spruill, IJ 5, 54 Spychala, M 765 Squadrito, F 66 Squatrito, D 6 Sree, D 006 Sreih, AG 75, 9 Sridharan, ST 809, 77 Srighanthan, J 548 Srikhum, W 957 Srinivasalu, H 55 Srinivasasainagendra, V 70 Srivastava, P 605 Srivastava, R 0 St Clair, EW 876, 88, 765, 78 St. Clair, EW 74, 747 St. Pierre, Y 585 Stabler, TV 858 Stach, C, 4, 799 Stack, RJ 57 Staelens, F 976 Stagi, S 9 Stagnaro, C, 677, 8, 68, 60 Stamm, TA 979 Stamova, S 64 Stamp, LK 60, 7, 98 Stanford, SM 48 Stangl, H 85 Stanislav, M 76 Starr, M 48, 50, 5, 458 Starz, TW 8 Statnikov, A 887 Staud, R, 7 Stauffer, T 845 Staun, K Stawiarz, L 54 Ste-Marie, PA 8,, 4, 4, 6, 85 Stebbings, S 86 Stebbins, C 88 Steckelings, UM 0 Steel, KJA 88 Steele, A 7 Steen, S 659 Steen, VD 746, 578, 580, 58, 586, 589 Steen Carlsson, K 769 Steen-Louws, C 76, 858 Steengaard-Petersen, K 80 Steenks, M 68 Steere, AC 409 Stefanik, JJ 9 Steffensen, R 6 Stegeman, CA 78 Stehlik, C 5 Stehouwer, CDA 90, 74 Steiman, AJ 584, 57 Stein, CM 87, 84 Steiner, G 586, 85, 979 Steinman, M 7 Steinsson, K 59 Stekhoven, D 7 Stengaard-Pedersen, K 6, 875, 94, 40, 687, 7 Stephanou, A 560, 569 Stephens, J 680 Stephens, W 06 Stephenson, M 96 Sterken, E 0 Stern, K 669 Sterpka, J 556 Sterrett, AG 88 Steultjens, MPM 89 Stevens, K 679 Stevens, RM 0,, 7,, 48, 76, 85, 86 Stevens, W 678, 85, 96 Stevenson, M 59 Stewart, A 75 Stewart, J 80 Stewart, KG 77 Stewart, K 74 Stewart, S 090 Stifano, G 90 Stillman, M 657 abstract author Index 0 Program Book 4

434 Stinson, JN 788 Sturfelt, G 0, 544 Sun, K 778 Szak, S 0 Stinson, W 777 Sturfelt, GK 60, 59 Sun, L 50, 590, 698 Szántó, A 59 Stirling, A 798 Stöhr, T 87 Sun, W 0 Szanto, S 697 Stoch, SA 4 Störk, S 78 Sun, X 77 Szapary, PO 4 Stock, A 54, 56 Su, AI 895 Sun, X 94, 06 Szczeklik, W 760 Stock, JA 79 Su, C 49 Sun, X 70 Szczerba, B 55, 775 Stock, M 7 Su, D 70 Sun, Y 86 Szekanecz, Z 99, 896 Stock, T 6 Su, D 50 Sun, ZC 474 Szentpetery, A 49, 50, 88, 48 Stoffer, M 979 Su, EW 77 Sundararajan, V 78, 04 Szer, IS 790 Stohl, HE 870 Su, L 896 Sundel, RP 790, 05 Szostak, B 7 Stohl, W 545, 7, 60, 870 Su, R 59 Sundman-Engberg, B 976 Szumski, A 40, 46,, 47 Stojan, G 58, 586 Su, W 474 Sundström, B 7 Szücs, G 6 Stokes, L Su, Y 75 Sundström, Y 54 Södergren, A 408 abstract author Index Stolfa, J 995, 05 Stolshek, B 05, 8, 47 Stolt, P 87, 94 Stoltenberg, M 7 Stolwijk, C 50, 55, 54, 447, 48, 87, 885 Stomp, W 804 Stone, D 894, 0 Stone, DU 50, 489, 77 Stone, J 685, 0, 649 Stone, JH 74, 747, 784, 785, 04, 78 Stone, MD 55 Stoop, JN 88 Stopinska-Polaszewska, M 689 Storfa, A 846 Storgard, C 85, 86, 87, 89 Stoykova, B 050 Strand, V 977, 9,, 4 Strand, V 4, 4, 606, 78, 79,, 46, 50, 460, 50 Strandberg-Larsen, M 68 Strangfeld, A 77, 806 Stratton, RJ 56 Straub, RH 78, 90, 8, 86, 9, 4, 85 Strausbauch, MA 67 Strauss, B 56 Street, RL Jr. 57 Strehl, C 97, 98, 7 Streicher, K 50 Striebich, CC 87, 876, 74, 88, 765 Strigini, F 5, 55 Stringer, E 94, 790 Strle, K 409 Strnad, GJ 94 Strober, B, 4 Stropuviene, S 95 Struemper, H 60 Strusberg, I 45 Stuart, JM 654 Stucki, G 86 Studenic, P 950, 86 Study Group (FVSG), FV 784 Suarez, L 594 Suarez-Almazor, ME 4, 698, 88, 80, 98, 47 Suarez-Farinas, M 58, 7 Subedi, A 804 Subramanian, V 57 Suchy, D 995, 05 Suda, A 67, 7 Sudman, M 99 Suematsu, N 49, 905 Suematsu, R 76, 90 Suen, SW 769 Suga, H 7 Sugalski, JM 95, 64 Sugaya, M 7, 95 Sugii, S 7 Sugimoto, N 44 Sugioka, Y 96, 9, 449, 66 Sugiyama, E 97 Sugiyama, K 048 Sugiyama, Y 074 Suh, CH 5, 69, 6, 76, 00 Suh, RD 68 Suh, YS 494, 4, 77 Sulaiman, W 96 Sule, S 749 Sulli, A 654, 58, 590, 598 Sullivan, A 84 Sullivan, B 608, 609, 74 Sullivan, C 484 Sullivan, K 65 Sullivan, KE 76, 860 Sullivan, T 7 Sumer, A 66 Sumida, H 59 Sumida, T 67, 588, 666, 50,, 6 Sumitomo, N 74 Sumner, L 696 Sumner, S 757 Sumova, B 8, 708 Sun, H 85 Sun, H 54 Sun, H 09 Sun, H 997, 0 Sung, IH 90, 80 Sung, M 6 Sung, MS 69 Sung, YK 09, 4, 5, 5, 80, 400 Sunkureddi, P 77 Supp, G 85, 05, 950 Suppiah, R 746, 786 Sur Chowdhury, C 46, 49 Suta, M 48 Sutcliffe, N 495 Suthoff, E 50 Suva, D Suyama, Y 9, 567 Suzuki, A 707, 94 Suzuki, K 840, 84, 40 Suzuki, M 79, 855,, 6 Suzuki, N 905 Suzuki, T 69, 6, 960, 069 Suzuki, T 666 Suzuki, Y 05, 079 Svedbom, A Svegliati, S 705 Svensson, B 60 Svensson, C 5 Svensson, J 056 Svensson, L 670 Svensson, M 90, 76 Svenungsson, E 599, 769, 096, 797, 898 Swaim, B 498 Swearingen, C, 58 Swearingen, CJ 79, 7, 986 Swedler, W 9, 5 Sweiss, NJ 9, 5 Swärdh, E 87 Syed, N 078 Sykes, D 4 Symmons, D 78, 047, 759 Symmons, DP 80, 04, 04, 760 Symmons, DPM 88 Symmons, DP 848 Symons, DM 7, 7 Syngle, A 90 Syrbe, U 499 Söderström, K 805 Søe, NH 805 Sørensen, IJ 84 Sørensen, J 07 Sørensen, VN 478 t Hart, B 8 Taal, E 6, 9 Taams, LS 50 Taberner, C 69 Tacey, M 00, 87, 78, 08, 04, 8 Tachecí, I 89 Tachmazidou, I 98 Tacke, CE 78 Tada, M 96, 9, 449, 66 Tada, Y 76, 90 Taddeo, A 7 Tagami, C 67 Tahara, K 56 Tahara, K 06 Tahir, H 95, 59 Taillefer, RG 679 Tajiri, M 854 Tak, PP 808, 54 Tak, PP 65, 7 Tak, PP 86, 8 Takagi, K 59, 65, 06, 070, 075 Takagi, K 86, 64 Takagishi, K 87 Takahashi, K 6 Takahashi, M 89 Takahashi, N 479, 65, 69, 70 Takahashi, R 6 Takahashi, R 7, 57 Takahashi, T 84, 59, 706, 707 Takahashi, Y 0, 9 Takahashi, Y 7 Takai, N 76 Takakuwa, K 59 Takakuwa, Y 49, 905 Takama, T 4, 89 T 4 0 Program Book

435 Takao, M 6, 95 Tanaka, N 86, 64 Tatu, L 4 Teresa Arango, M 57, 6 Takasaki, Y 67, 7, 5 Tanaka, S 79, 600, 585 Tatum, M 8 Terkeltaub, R 768, 95, 74 Takasugi, K 9 Tanaka, Y 45 Taunton, MJ 85 Terreri, M 69 Takatani, A 6, 069 Takayama, M 66 Takeda, T 0 Takehara, K 748 Takei, H 67 Takei, M 59 Takei, S 7, 75, 45, 08 Takemura, M 85, 6 Takeno, M 945, 96, 074, 68 Takeuchi, M 70 Takeuchi, T 75 Takeuchi, T 588, 6, 669, 940, 84, 45, 7, 840, 84, 066,,, 66, 40, 575, 769, 800 Takeuchi, Y 65 Takezaki, T 7, 75 Takiya, L Takiya, L 444, Takizawa, N 447 Takvorian, SU 74 Talarico, R 559, 850,, 677, 8, 5, 55, 68, 60 Talbert, J 98 Talpin, A 489 Tam, LS 64, 487 Tamai, M 69, 0, 6, 960, 069 Tamaki, M 645 Tambiah, J 4 Tamborenea, N 5 Tamborrini, G 5 Tamhane, A 406 Tamir, I 56 Tammara, B 6 Tamori, A 9 Tamura, Y 6 Tan, AL 65, 586 Tan, C 670 Tan, FK 76 Tan, J 79 Tan, JHT 74 Tan, PK 7 Tan, SL 866 Tan, S 44 Tan, WB 0 Tan, W 77, 00, 857 Tan, Y 699 Tanaka, A 5, 94 Tanaka, A 80 Tanaka, C 6 Tanaka, E 78, 047, 40, 44, 759 Tanaka, E 64 Tanaka, K 855,, 6 Tanaka, L 8 Tanaka, M 840, 84 Tanaka, Y 6 Tanaka, Y 468, 588, 84, 45, 796, 87,,, 66, 9, 769, 774, 800 Tanamas, S 56 Tandon, M 49 Tang, B 654 Tang, CH 49, 058 Tang, H 0 Tang, L 4 Tang, PL 55 Tang, Q 699 Tang, T 585 Tang, X 76, 76 Tang, X 088 Tang, Y 570 Tange, CE 94, 944 Tango, T 66 Tangpricha, V 674 Tani, C 559, 900, 5, 55, 60 Tani, C 677, 68 Taniguchi, A 74, 86, 6, 40, 44, 459 Taniguchi, N 64 Taniguchi, T 84, 706, 707 Taniguchi, Y 00 Tanino, M 05 Tankó, LB Tanner, SB 87 Tanya, M 74 Tao, A 77 Tappuni, A 495 Taraborelli, M 55 Tarantini, G 850 Tarcsa, E 555, 47 Targan, SR 488 Targoff, IN 064 Taroumian, S 00 Tarp, S 499, 65, 69, 7 Tarp, U 448, 496, 500, 44, 7 Tarvin, SE 780 Tas, MN 5 Tas, SW 945 Tascilar, K 69, 66, 6 Tashiro, S 76, 90 Tashjian, RZ 965 Tashkin, D 68 Tasoglu, I 096 Tasoglu, O 096 Tasset, C 8 Tassiulas, I 568 Tatangelo, M 05 Tatebe, N 048 Tateishi, N 055 Tatibouet, S 679, 60, 96 Tatouli, IP 844 Tausche, AK 97 Tausk, FA 07, Tavilla, PP 654 Tavoni, A 505, 060, 67 Taxter, A 76 Tayar, JH 698 Taybulatov, N 9 Taylor, J, 79 Taylor, KE 6, 64, 77 Taylor, P 4 Taylor, PC 9, 644 Taylor, RL 70 Taylor, S Taze, A 60 Tazi, A 78 Tchao, N 74, 747, 78 Tchetverikov, I 57 te Velde, AA 500 Teal, TH 544 Tebo, A 6 Tebo, AE, 4, 67 Tedeschi, SK 5 Tedesco, F 566 Tegla, C 64 Tegzova, D 596, 5 Teichtahl, A 6, 47, 48, 56, 67 Teixeira, R 06 Teixidó, I 08 Tejera, B 9 Tekin, M 64 Tekindal, MA 58 Telaar, A 575 Teleman, A 9, 46 Temel, M 58 Temel, S 468 Temel, T 749 Ten Cate, DF 4 Ten Cate, R 9 ten Klooster, PM 6 Tena, X 9 Tenbrock, K 795 Teng, C 778 Tenner, CT 79 Teodorescu, MC 98 Teodoro, WR 84 Teos, LY 498 Tepper, S 657 ter Horst, S 4 ter Huurne, MC 79 ter Wee, MM 46 Terabe, K 70 Terada, Y 00 Terao, C 89, 707, 9, 0 Terauchi, K 68 Terencio, MC 84 Terreri, MT 98, 486 Terrier, B 74, 757, 67, 78 Terry, K Terry, KK 8 Terslev, L 578, 94, 946 Teruel, M 79 Teruel, R Tesar, V 596 Teshigawara, S 64 Tessier Cloutier, B 585 Tetreault, M 8, 50 Tezcan, ME 60 Thai, A 74, 58 Thakkar, V 678, 85 Thamsborg, G 84 Thanarajasingam, U 8 Thanou, A 809, 548, 549 Thavaneswaran, A, 6, 9, 47, 5, 507, 55, 558, 50, 780, 78 the International Childhood Arthritis Genetics Consortium, OBO 98 Theander, E 9, 46, 508, 50, 88, 77, 878 Theek, C 494, 909, 575 Theis, KA 95, 898 Thenganatt, J 576 Theorell, T 40 Theriault, C 59 Therneau, TM 67, 868, 0 Theulin, A 664 Thévenin, F 0, 46 Thevissen, K 90 Thi Vinh Nguyen, T 06 Thibault, V 754 Thiele, GM 876, 6, 88 Thiele, GM 8, 78 Thiele, K 64 Thiele, RG 07 Thijs, H 06 Thijssen, E 56 Thom, J 4 Thomas, D 7 Thomas, GP 56, 697 Thomas, G 66 Thomas, M 604, 74 Thomas, R 695, 696 Thomas, S 00, 574 Thomas, T, 60, 69, 48, 97 Thompson, AE 6 Thompson, A 585 Thompson, K 00, 59, 906 Thompson, LF 65 Thompson, PR 886, 57 abstract author Index Thompson, SD 88, 88, 98, 99 0 Program Book 4

436 Thomson, W 88, 98, 99 Toloza, S 60, 69 Toyos Saenz de Miera, FJ 05 Tsoukas, A 740 abstract author Index 44 Thornback, A 045 Thorne, JC 74, 48, 6, 06, 09, 8, 9, 4, 464, 475, 74, 770, 4, 50, 5, 5, 5, 75, 76, 85, 87, 9, 96, 7, 84, 866, 868, 869 Thorner, P 75, 754 Thorp, LE 5, 5, 54 Thulasiraman, A 50 Thumboo, J 0 Thunem, C 87, 94 Thurman, J 9 Thurmond, RL Thurston, L 45 Thyberg, I 9 Tian, Q 87 Tierney, C 95 Tilbury, C 08 Tillett, W 5 Tilson, H 748 Tin, D 74, 06, 09, 8, 475, 79, 4, 75, 76, 96, 866, 868, 869 Tincani, A 9, 67, 55 Ting, AE 64 Ting, T 595 Tiniakou, E 556 Tipton, C 4, 798 Tiraboschi, M 06 Tisch, R 57 Titton, DC 6 Titus, N 54 Tive, L 4 Tivon, D 570 Tiwana, R 57 Tiziani, S 85 Tjarnlund, A 884 Tjärnlund, A 056 Tkacz, J 8 To, CH 600, 608 To, S 57 Tobon, G Todoerti, M 806 Toepfer, D 966, 97 Toes, REM 88 Toes, REM 808, 869, 90, 04, 94 Tohma, S 67, 7, 07, 56, 56 Tokuhashi, Y 75 Tokuhisa, T 89 Tokunaga, K 67 Tokunaga, K 447 Tokunaga, T 7, 98 Toledano, D 0 Toledano, E 47 Toledo, RA 6 Toliver, JC 0 0 Program Book Tolusso, B Tomanova-Soltys, I 504 Tomcik, M 957, 690, 569, 704 Tomer, N Tomita, T 47 Tomlinson, GA 05, 45 Tomlinson, S 9 Tommerup, AMM Toms, T 86, 88 Tomsic, M 448, 496, 500, 508, 67, 65, 66, 67, 690 Toncheva, A 9 Toniolo, A 66 Toniolo, M 5 Tonner, C 75, 906, 05, 589, 760, 774, 9 Tonnini, C 705 Tono, T 79 Tonutti, E 55 Tony, HP 77, 46, 97 Tony, HP 78, 95, 6 Too, CL 07, 96 Topazian, M 649 Topless, R 60 Topolewski, K 50 Tordoir, R 08 Tornehave, D 54 Torner, J 85, 07, 7 Tornling, G 405 Toro, C 894 Torok, KS 76, 77 Torp-Pedersen, S 7, 805 Torralba, KD 975, 976, 85 Torralba, KMD 60 Torre, I 750, 65 Torre Salaberri, I 556 Torrealva, H 68 Torrent, A 84 Torres, B 574 Torres-Aguilar, H 655 Tory, HO 05 Tosta, P 884 Toth, E 77 Toth, M 66 Totoritis, MC 49 Touma, Z 6, 55, 807, 54 Toupet, K 54 Tourkina, E 647, 660 Tournadre, A 4 Toussirot, E 8, 4, 5, 44 Towers, H 78 Towns, M 040 Townsend, AF 984, 78 Townsend, MJ 07 Townsend, W 584 Toyama, T 84, 59, 706, 707 Toyama, Y 74, 97 Toyos-Saenz de Miera, J 90 Toz, B 09 Tracy, C 540 Tran, A 79 Tran, MLN 988 Tran, P 859 Tran, TM 59 Tran, T 78, 047, 759 Tran, V 846 Tran-Duy, A 000, 06 Traverse, W 4 Treadwell, EL, 58 Tremoulet, AH 05 Trenkmann, M 775, 76, 87 Treves, R 47 Trigona, W 85 Trigunaite, A 546 Trinder, S 649 Triolo, G 497 Trojanowska, M 84, 706, 707 Trollmo, C 497 Trombini-Souza, F 55 Tronnier, D 66 Tropea, J 00, 8 Trottier, E 464 Troum, O 8, 974 Troum, O 47 Trouvin, AP 8 Trouw, LA 869, 90, 88, 04, 89, 0, 94 Troxel, A 0 Troyanov, Y 064 Truedsson, L 0, 4, 4, 544 Trujillo, X 599, 546 Trupin, L 75, 607, 849, 906, 06, 589, 758, 774, 9, 97, 54, 66 Tryniszewska, B 56, 99, 896, 697 Tsai, W 90 Tsai, WC 546 Tsang, K 7 Tsang-A-Sjoe, MWP 76 Tsao, BP 6, 6, 65, 857, 70, 78 Tsao, H 699, 908 Tse, SML 79 Tse, SM 790 Tseng, CH 68 Tseng, CW 998 Tseng, CE 574 Tseng, HW 56 Tseng, L 78 Tsodikov, A Tsokos, GC 557, 57, 7, 888, 68, 67, 74 Tsolmon, D 96 Tsonaka, R 68 Tsou, PS 657, 658, 777, 97, 56, 597 Tsoukas, M 6 Tsuboi, H 666, 50 Tsuchida, T 4 Tsuchiya, N 67, 7 Tsui, FW 49 Tsui, HW 49 Tsuji, G 869 Tsuji, NM 54 Tsuji, S 64 Tsuji, WH 74 Tsujimoto, M 796 Tsukamoto, H 5, 94 Tsukamoto, H 7, 98 Tsukamoto, M 40 Tsumiyama, K 648 Tsuno, H 56 Tsunoda, S 56 Tsuru, T 4 Tsuruta, D 707 Tsuzaka, K 6, 95 Tsuzuki, H 5, 94 Tu, W 568 Tubach, F 55, 88, 69 Tuber, JS 5 Tucker, LB 84, 94, 57, 87, 790 Tuckwell, K 450 Tugal-tutkun, I 70 Tukel, C 895 Tulanont, D 99 Tunc, R 76, 0 Tunca, M Tuomari, A 068 Tuominen, R 00 Turbelin, C 477 Turesson, C 48 Turesson, C 495, 88, 40, 407, 408, 54, 4, 4, 68, 90 Turgut Ozturk, B 76 Turina, M 59, 886 Turina, MC 49, 549, 80, 45, 450, 884 Turkbey, E Turkiewicz, A 99, 64, 67 Turman, S Turoglu, HT 68 Turpcu, A 484, 468 Tusie-Luna, T 69 Tweardy, DJ 57 Tweddell, S 709 Twerski, S 0 Twilt, M 750, 75, 754, 66 Tydén, H 0, 576 Tyler, W 8 Tyrrell, PN 758, 759 Tzaribachev, C 8 Tzaribachev, N 6, 8 Tzioufas, AG 67

437 Törnqvist, L 9 Ushigusa, T 69, 888 van de Stadt, LA 90, 57 van der Woude, D 94 Törring, O 864 Ushikubo, M 4 van Den Bemt, BJF 7 van der Zee-Neuen, A 88 U Ucar, D 66 Ucar, R 0, 468 Uchida, T 49 Uchii, M 0 Uchimura, S 4 Uchino, K 657, 658 Uchiyama, A 65 Uda, H 4, 89 Udayakumar, PD 67, 674, 675 Uddin, SM 87 Udeh, U 709, 896 Ueda, A 70, 945, 96, 074 Ueda, N 5, 94 Ueda, S 5, 94 Ueda, Y 84 Uehara, A 65 Ueki, N 5, 94 Ueki, Y 0 Uetani, M 6, 960 Uga, H 869 Ugarte-Gil, MF 40, 68, 5 Ugurlu, S 08, 75, 6, 6, 66 Uhlig, T 79, 50 Ulgiati, D 70 Ulmer, C 075 Uludag, M 0 Umeda, N 666 Umekita, K 87 Umemura, M 7, 98 Umesh, N 89 Umlauf, D 78 Underhil, C 800 Unger, B 478 Unizony, S 685 Unk, JA 985 Unnebrink, K 79 Uno, K 85 Unzurrunzaga, A 89, 89 Upcott-Gill, R 5 Upton, R 5 Urata, Y 6 Urban, ML 696 Urbina, EM 6 Ureña, I 48 Uriarte Ecenarro, M 08, 475 Uriarte Isacelaya, E 08 Urowitz, MB 6, 579, 585, 64, 65, 6, 58, 58, 584, 59, 807, 508, 57, 5, 54, 557, 896 Urquhart, A Urraro, T 67 Urruticoechea, A 788 Usategui, A 96 Ustek, D 70 Utset, TO 606, 884, 069 Utz, P 794, 86 Uusküla, A 04 Uyanik, MS 506 Uysal, B 40 Uziel, Y 70 Uzun, CA 6 Uzunaslan, D 69, 6 V Vaamonde-García, C 94, 87, 846 Vad, V 9 Vadillo, C 86 Vaglio, A 5, 696, 760, 789 Vagnani, S 559, 5, 55 Vaillancourt, J 45, 458 Vakil-Gilani, K 57, 46 Valcárcel-Ares, MN 94, 87, 846 Valckenaere, I 469 Valdivielso, P 48 Valente, R 6 Valentin, MA 69 Valentini, G 676, 906 Valenzuela, A 085 Valenzuela Vergara, AM 679 Valeriano-Marcet, J 88 Valero-Esquitino, V 0 Valesini, G 79 Valeyre, D 695 Valiente, GR 68 Valieva, S 9, 64, 70 Valim, V 5, 54, 470 Valino-Seoane, I Valiunas, V 69 Valle-Oñate, R 57 Valleala, H 5 Vallejo, P 550 Vallim, V 6 Valls Pascual, E 750, 65 Valverde-Franco, G 48, 88 van t Klooster, G 478, 8 van Adelsberg, J 470, 55, 58 van Beneden, K 4 van Bodegom-Vos, L 09 van Burgel, ND 809 van Caam, A 56 Van Daele, PL 6, 656 van Dartel, S 079 van de Heijde, D 878 van de Laar, MAFJ 7, 406, 000, 49,, 6, 9 van de Loo, FA 74, 769, 740 van de Loo, FAJ 94, 0, 80 Van de Schoot, M 450 van den Berg, JM 9 van den Berg, R 0,, 55, 59, 549, 77, 78, 80, 4, 45, 46, 884, 886 van den Berg, WB 45 Van den Berg, WB 46, 49, 56, 79, 48, 74, 766, 769, 77, 94, 0, 74, 740, 80 van den Bergh, J 7 Van den Bersselaar, L 94 van Den Bosch, F 85,, 50, 55, 5, 540, 54, 447, 87, 885 van den Bosch, MH 48, 769 van den Broek, M 47, 460 van den Ende, E 87 Van den Eynde, B 67, 7 van den Hombergh, W 70 van den Hoogen, FHJ 48 van den Oever, IAM 86, 87, 4, 54 Van der Aa, A 478, 8 van der Burg, LRA 84 van der Esch, M 45, 89 van der Geest, KSM 58, 645, 665 van der Heijde, D 4, 5, 55, 977, 79, 4, 804 van der Heijde, D, 4, 455, 456, 0,,,, 84, 409, 4, 508, 50, 55, 56, 57, 50, 55, 55, 59, 54, 549, 77, 78, 786, 79, 799, 80, 80,, 6, 406, 4, 45, 46, 447, 459, 800, 86, 87, 884, 885, 886 van der Heijde, DM 6 van der Helm- van Mil, AHM 809 van der Helm-van Mil, AHM 788, 804 van der Helm-van Mil, AHM 68, 808, 94 Van der Horst-Bruinsma, IE 808, 509, 54, 54, 454, 455 van der Kallen, CJH 74 van der Kamp, S 49 van der Kleij, D 456, 509, 54 van Der Kraan, PM 49, 56, 48, 766, 769 van der Leeden, M 45, 89 Van der Linden, A 69 van der Linden, S 90, 74 van der Linden-van der Zwaag, E 08 van der Lubbe, PA 69, 77 van der Maas, A 7 van der Poll, T 748 van der Veer, E 58, 449, 456 van der Ven, M 87 van der Ven, M 4 van der Wees, P 09 van Dieen, J 45 Van Doornum, S 00, 87, 78, 08, 04, 8, 45 van Duivenvoorde, LM 56 van Ede, A 70 van Endert, P 489 van Erp, AE 769 van Gaalen, F, 55, 59, 549, 77, 80, 4, 45, 884, 886 van Greevenbroek, MMJ 74 Van Groenendael, JHLM 799 van Haandel, L 97, 07 van Hagen, M 6, 656 van Hamburg, JP 7, 6, 656 van Helden-Meeuwsen, CG 6, 656 van Herwaarden, N 7 van Hoeven, L 889 van Kuijk, J 079 van Leeuwen, J 7 van Lent, PL 48, 766, 769 van Lent, PLEM 46, 79, 77 van Lieshout, MF 47 van Nies, JAB 804 Van Nieuwenhuijze, AEM 94 van Oosterhout, M 4, 460 van Oosterhout, M, 55, 59, 549, 77, 80, 45, 884, 886 van Riel, P 448, 495, 496, 500 Van Riel, PLC 90 van Riel, PLCM 808, 000, 66, 86, 88 Van Riel, PL 49 van Rijn, RR 84 Van Rompaey, L 478 van Roon, JAG 70, 99, 949, 76, 858, 879 van Rossum, MAJ 84, 9 van Royen-Kerkhof, A 66 van Schaardenburg, D 46, 90, 89, 786, 57 van Schaeybroeck, B 69 van Sijl, AM 86, 87, 54, 899, 57, 76, 455 Van Staa, T 8 van Steenbergen, HW 68 Van Suijlekom-Smit, LWA 84, 9 van Tok, MN 56 van Tubergen, AM 50, 55, 54, 87, 885 Van Tubergen, A 447 van Tuyl, LHD 57 van Vollenhoven, RF 48, 59, 0 van Vollenhoven, RF 448 van Vollenhoven, R 496, 500, 4, 46, 970,, 4 abstract author Index 0 Program Book 45

438 abstract author Index van Vollenhoven, RF, 58, 4, 789 van Vollenhoven, RF 459, 966, 4, 56, 574, 585, 606, 607, 6, 96, 7, 4, 5, 79, 688, 767 van Vugt, R 94 van Wesemael, T 94 van Wijk, F 640 van Zeben, D 87, 69, 77 van Zeben, J 57 van Zoest, KPM 945 Vandal, A 090 Vandam, W 5 Vandeghinste, N 478 Vandenhende, MA 686 Vanderver, A 90 Vanheusden, K 87 Vanhoutte, F 478, 8 Vanhove, B 8 VanLunen, B 4 Vanstone, L 94 VanTongeren, S 40 Varela-Calviño, R 400 Varga, J 57, 586 Vargas, A 45 Vargas, B 90 Vargas Lebrón, C 05 Vargas Ramirez, R 40, 067 Vargas-Alarcon, G 486 Vargas-Lebrón, C 90 Vargas-Ramírez, R 7 Varisco, V, 46, 806 Varley, C 9 Varley, C Vaseer, S 560 Vashisht, P 968 Vassilopoulos, D 67 Vasta, B 70, 596 Vastert, SJ 79, 640, 784 Vastesaeger, N 446, 477, 479, 5, 9 Vaughan, M 845, 846 Vaughn, L 79 Vauthier-Brouzes, D 554 Vayssière, B 478 Vazel, M 469 Vazquez, A 70 Vázquez, J 750, 65 Vazquez Del Mercado, M 407, 40, 599 Vázquez-Del Mercado, M 7, 067 Vazquez-Lamadrid, J 650 Vázquez-Mosquera, ME 5, 5, 65 Vcrc, T 79 Veale, DJ 9, 946, 664, 668, 940, 79, 98 Veel, T 7, 88 Veenhuizen, M 7 Vega Fernandez, P 675 Vega-Fernandez, P 57 Vega-Morales, D 8 Vehe, RK 77 Vehmeijer, S 08 Veissier, C 808 Vejar, M 05 Vela-Anero, A 47 Vela-Ojeda, J 694 Velasco, J 695, 696 Velasco-Sanchez, D 067 Velez, D 684 Velloso Feijoo, ML 788 Velosa, APP 84 Venables, P 8,, 40 Vencovsky, J 454, 884 Vencovsky, J 455, 480, 950, 957, 4, 98, 06, 084, Vendel, N 805 Venkatram, M 85 Venuturupalli, S 58, 884 Vera-Lastra, O 7, 694 Vera-Llonch, M 50 Verazza, S 89 Verbeeck, J 67 Verbruggen, G Verbruggen, N 9 Verbsky, JW 780, 746 Verburg, KM 4 Verdegaal, S 08 Verdet, M 59 Vergés, J 84 Verges, J 69, 7, 6, 858, 46 Vergne-Salle, P 47 Verheugen, E 69 Verhoye, M 69 Verma, I 90 Verma, N 8, 50 Vermaak, E 058, 059 Vermeij, EA 0, 80 Vermeulen, E 08 Vernon, C 46 Veroz Gonzalez, R 478 Verschueren, S 45 Versnel, MA 6, 656 Verstappen, G 88 Verstappen, S 78, 04, 047 Verstappen, SM 04 Verstappen, SMM 759 Verweij, CL 958, 45, 884, 899 Verweij, F 640 Vestergaard, P 056 Vestweber, D Vettori, S 480, 676, 906 Veyssier-Belot, C 00 Viana, R 78 Viana, VST 55 Viatte, S 77, 88 Vicari, A 87, 49 Vida, A 56, 99, 896, 697, 74 Vidakovic, M 009, 00 Vidal, E 86 Viechtbauer, W 90 Vieillard, V 07 Vieira, A 464 Vieira, PL 65 Vieira, SM 556 Vieira, WP 470 Vierboom, MPM 8 Vigano, M 806 Viggiani, R 968 Vigier, S 5 Vignaux, O 757 Vigneau, C 69 Vigone, B 687, 706 Vila, LM 97, 60, 60 Vilá -Rivera, K 60 Vila-Inda, C 598 Vildhøj, S 478 Villa, I 469 Villain, E 84 Villalba, A 647 Villalba, JM 887 Villanueva, FS 40 Villarreal, A 5 Villaseñor-Ovies, P 960 Villaverde, V 47 Villeneuve, E 5, 40, 4, 489, 8, 99, 766 Villeret, B 60 Villiger, PM 7 Vina, ER 069 Vincent, A, Vinet, E, 577, 8, 8, 95 Viñuela-Roldán, J 400 Viola, S 70, 7 Virayavanich, W 957 Virdis, A 559 Virta, LJ 779, 0 Visconti, RP 647, 660 Visman, IM 4 Visovatti, SH 579 Visscher, PM 707 Visser, H 49 Visser, JM 86 Visser, K 75, 868, 869 Vissink, A 5, 88 Vissink, A 508 Vista, EG 77 Viswanathan, H 8 Vital, EM 6 Vitanzo, P Jr. 9 Vitova, J 596 Vittadello, F 54, 85, 605 Vittecoq, O 904 Vittecoq, O 50,,, 469, 488, 59, 8, 87 Vitters, EL 49 Vitton, O 09 Vivar Pomiano, N 89 Vivekanandan-Giri, A 886 Vlachoyiannopoulos, P 5 Vlad, SC 6 Vladimer, G 904 Vlahos, B 80, 56, 546, 59, 689 Vliet Vlieland, T 87 Vliet Vlieland, TPM 09, 609 VlietVlieland, T 08 Voaklander, D 96 Vocelka, M 995, 05 Vockley, J 69 Vodovotz, Y 75 Vogel, U 47 Vogel-Claussen, J 597 Vogels, EWM 500 Vogl, T 46, 79, 667 Vojinovic, J 80 Volin, MV 9, 5 Volk, R 98 Volkmann, E 574 Volkov, A 547 Volkov, S 9, 5 Voll, RE 0 Vollath, S 690 Voloshyna, I 98 von der Bey, U 9, 5 Von Feldt, JM 97, 978, 87 von Kempis, J 95, 59 von Schack, D 809 von Scheven, E 849 Vongpatanasin, W 45 Vonk, MC 686 Vonkeman, HE 7, 406, 49, 6 Vora, H 99 Vora, SS 79 Vordenbäumen, DS 954, 955, 956 Vordenbäumen, S 909, 575 Vorobjov, S 04 Vorup-Jensen, T 96 Vos, T 87 Voskuyl, AE 45, 884, 899 Voskuyl, A 6 Voskuyl, AE 86, 87, 686, 958, 57, 76 Voss, A 64 Voss, J 948, 74 Vosslamber, S 958, 45, 884, 899 Voth, I 64 Voulgarelis, M 67 Vranic, I 464 Vreeswijk, T 809 Vuolteenaho, K Program Book

439 Vyse, TJ 88, 65 Vyse for SLEGEN, TJ 6 Vyskocil, V 46 W Wabnitz, P 5 Wachira, J 8, 8 Wada, J 048 Wada, TT 80, 99 Wada, T 600, 585 Wada, Y 785 Wada, Y Wager, C 88 Waghorn, D 800 Wagman, RB 864, 7 Wagner, A 66 Wagner, C 4 Wagner, ES 986 Wagner, S 46 Wahezi, DM 6 Wahl, D 654 Wahono, S 566 Wahren-Herlenius, M 88, 497, 770, 77 Waimann, CA 86, Wajdula, J 80 Wakabayashi, H 048 Wakabayashi, K 7, 98, 57 Wakefield, D 705 Wakefield, RJ 79, 94 Waldman, M 559 Walgreen, B 766, 94 Walitt, BT, 840, 85 Walke, LM 6 Walker, A 99 Walker, D 0 Walker, J 96 Walker, M 0, 04 Walker, R 5 Walker, S Walker, UA 46, 49, 748 Wallace, CA 78, 790, 780, 675 Wallace, DJ 60 Wallace, DJ 84, 574, 585, 587, 59, 606, 607, 78, 79, 767 Wallace, GL 05 Wallace, G 74 Wallace, ZS 784, 785, 04 Wallenstein, G 9, 4 Wallenstein, G 46 Wallis, D 99, 507,, 480, 488, 777 Walsh, D 79 Walsh, J 7, 799, 778 Walsh, T 64 Walsh, Z Walter, GJ 50 Walter, JE 95 Walters, M 79 Waltman, B 64 Wang, A 867 Wang, A 77 Wang, A 864 Wang, B 78 Wang, B 47 Wang, C 0, 5, 56 Wang, C 608, 609, 74 Wang, CR 78 Wang, D 590 Wang, EC 55 Wang, F 857 Wang, G 59, 065 Wang, H 74 Wang, H 56 Wang, H 86 Wang, H 98 Wang, J 44 Wang, J 0 Wang, J 474 Wang, J 7, 76, 79, 49 Wang, J 70 Wang, JC 568 Wang, L 04, 8 Wang, L 48, 49, 44, 80 Wang, L 7 Wang, LC 555 Wang, L 578, 5, 94 Wang, L 8 Wang, L 568 Wang, M 454 Wang, M 99 Wang, M 79 Wang, N 050 Wang, Q 665, 905 Wang, R 78, 7 Wang, S 6 Wang, S 088 Wang, SX 994 Wang, W 75, 876 Wang, W 94, 97, 004 Wang, W 04, 09 Wang, W 57 Wang, X 799 Wang, X 6 Wang, X 474 Wang, Y 498 Wang, Y 95 Wang, Y 665, 905 Wang, Y 668, 80 Wang, Y 68 Wang, Y 79 Wang, Y 6, 47, 48, 56, 67 Wang, Y 69 Wang, Y, 695 Wang, Y 74 Wang, Z 754 Warabi, E 67 Ward, LM 94, 865, 87 Ward, MM 54, 44, 446, 448, 840 Ward, RJ 9 Wardemann, H 889, 647 Ware, A 96, 79 Warfvinge, G 878 Waring, JF 57 Warmington, K 986 Warner, T 4 Warriner, AH 4 Warrington, KJ 667, 669, 67, 674, 675, 678, 69 Wartenberg-Demand, A 4 Wasfi, Y 4 Washington, AV 60 Wasko, MCM 76, 765 Watanabe, A, Watanabe, H 048 Watanabe, KS 67, 048 Watanabe, M 45 Watanabe, R 49, 68, 0, 68 Watanabe, T 404 Watanabe, T 0, 7 Watanabe Duffy, K 790 Waterton, J 94 Watkins, M 5 Watson, K 04, 760 Watson, KD 80 Watt, J 6 Watts, C 554 Watts, RA 786, 787 Wax, SD 55 Way, EE 74 Weaver, LK 68 Webb, D 9 Webb, K 979 Webb, T 89 Webb-Detiege, TA 98 Webber, MP 05, 06 Webber, S 06 Weber, D 97, 96 Weber, M 97 Weber, U 89, 888 Webster, A 886 Webster, SJ 47 Wechsler, B 75, 00, 554, 6 Wedderburn, LR 98, 99 Wedren, S 4, 80, 40, 4 Weel, AEAM 57, 69, 77, 889 Wei, C 0, 798 Wei, JC 509 Wei, J 57 Wei, K 74 Wei, N 58, 794 Wei, Q 6 Wei, XN 48 Weiden, MD 05 Weigand, S 649 Weiller, PJ 750 Weinberg-Shukron, A 64 Weinblatt, M 454, 75 Weinblatt, ME 476 Weinblatt, M 44 Weinblatt, M 455, 456, 79, 5 Weinblatt, ME 6, 874, 09, 8, 6, 48, 68, 768, 88 Weinhage, T 6 Weinreb, A 984 Weinstein, A 55 Weinstein, SP 470, 55, 58 Weir, W 7 Weisman, MH 6, 58, 59, 60, 505, 54, 69, 705, 767, 407, 446, 448, 488, 659, 660, 840 Weisman, SM 87, 74 Weiss, A 56, 55, 88 Weiss, JE 70, 789, 79 Weiss, KM 98 Weiss, PF 77, 56, 75 Weiss, R 6 Weissbarth-Riedel, E 06 Welcher, A 608, 609, 74 Welihinda, AA Weller, K 747 Wells, AU 68, 745 Wells, C 464, 48 Welsing, PMJ 005, 45 Wen, F 6 Wen, J 54, 56, 56 Wen, L 5, 577 Wendler, J 95, 97 Wendling, D 8, 469, 5, 050, 808, 87 Wener, MH 78, 600, 60 Weng, CT 78 Weng, H 446, 477, 479, 9 Wenglén, C 576 Wenink, MH 45 Wermuth, PJ 560, 564, 565 Werner, J 086 Werner, SG 946 Werth, VP 608, 860, 95, 5 Wesley, A 40, 4 Wessel, A 764 Wesseling, J 75 West, CR 4 West, SG 49 Westby, MD 094 Westedt, M 9 Western, L 744 Westhoff, G 4 Westhovens, R 874, 49, 48, 768 Westman, K 746 Westrich, GH 7 Wetter, D 4 0 Program Book 47 abstract author Index

440 Wevers-de Boer, KVC 799 Williams, K 860 Wolfson, V 854 Wright, E 0 Wevers-de-Boer, K 94 Williams, M 98 Wolk, A 46 Wright, J 86, 768, 7, 856 Weyand, CM 69, 70 Williams, P 79 Wollenhaupt, J 479, 5 Wright, R 856 abstract author Index 48 Wheless, L 505 Whelton, A 78 Whist, JE 88 Whitaker, J 75, 876 White, CJ 79 White, DK 85, 90, 07 White, M 74 White, P 86 White, W 454 White, W 77, 94 Whitehead, G 78 Whitfield, ML 566 Whiting, D 06 Whitley, M 809 Whitlock, M 66 Whitt, IZ Whitworth, A 9, 0 Wiberg, K 8 Wichuk, S 5, 69, 89, 887 Wick, J 96, 96 Wick, JA 049 Wicker, P 440 Wicks, I 00, 78, 04 Wicks, IP 770, 45 Wicks, IP 94 Widdifield, J 770, 5 Wiedeman, A 70, 70 Wiedeman, AE 8, 45 Wierød, A 4 Wigerblad, G 5 Wigler, I 8, 484 Wigley, FM 66, 66, 699, 708, 586 Wijmenga, C 808 Wijnands, JMA 90, 74 Wikerson, E 77 Wiland, P 76, 59 Wilder, T 5, 80, 88 Wildman, HF 709 Wiley, GB 489, 565 Wilhelms, E 58 Wilkerson, ER 0, 485, 776, 4 Wilkins, D 77, 78 Wilkinson, B 48, 977 Wilkinson, B 46 Wilkinson, JM 44 Willemen, H 857, 858 Williams, AS 55 Williams, C 675 Williams, DA 6, Williams, EM 69 Williams, G 57 Williams, H 94 Williams, J 97 Williams, JO 55 0 Program Book Williams, R 79 Williams, RO Williams, S 558 Williams, S 4 Williams, T 59, 689 Williamson, L 5 Willim, M 769, 68 Willis, R 8,, 4, 5, 6, 9, 60 Willner, D 497 Willson, T 47 Willwerth, C 668 Wilson, AG 886 Wilson, AG 45, 44, 874 Wilson, PC 794 Wilson, T 75 Wilton, K 775 Wimalasundera, S 48 Wimmer, MA 5, 5, 54 Winchester, R 5, 88, 884 Winkelmann, J 64 Winkelmayer, WC 780, 679 Winter, J 65 Winter, O 549 Winthrop, KL 486, 05, 9, 45, 58, 680, 76 Wintzell, V Wirth, J 55, 57 Wirth, T 6 Wirth, W 40, 7,, 670, 754 Wise, BL 7, 57, 85 Wishart, N 74 Wislez, M 78 Wisniacki, N 88 Wisniewski, SR 8, 06, 07, 0, 47, 48, 7, 790 Wither, JE 6, 564, 57, 555, 557 Witherington, J 7 witko-sarsat, V 86 Witte, T 786, 88, 89, 099, 770 Wittenborn, E 0 Wittkowski, KM 77 Wittsack, DHJ 954, 956 Witzig, T 649 Wluka, A 6, 47, 48, 56, 67 Woby, S 848 Wofsy, D 884, 59, 55 Wolbink, GJ 808 Wolbink, G 4, 456, 509, 54 Wolf, DC 4 Wolfe, F, 840, 055, 700, 965, 85 Wolff, C 8 Wolff, M 77 Wolff, V 477, 479 Wollenhaupt, J 4 Wollenhaupt, J 0,, 7,, 48, 86, 5, 8 Wollenhaupt-Aguiar, B 44 Wollmer, P 50 Wolman, Y 8, 098 Wolski, K 85 Wolter, R 4 Wolterbeek, R 79 Wolters, P 55 Won, S 4, 5, 80 Won, S 400 Wong, C 540 Wong, CK 64 Wong, D 454 Wong, E 045 Wong, H 98 Wong, J 6, 650 Wong, JB 50 Wong, K 99 Wong, L 74 Wong, M 6 Wong, PCH 487 Wong, R 0 Wong, R 96, 9 Wong, TY 45 Wong-Baeza, I 7, 655 Woo, JMP 698, 65, 69 Woo, P 98 Wood, PR 407 Wood, R 8, 8 Wood, SP 440, Wood, SP 8 Wood, TA 566 Woodhead, F 4 Woodruff, P 59 Woods, D 604 Woods, R 9 Woodworth, D 80 Woodworth, T 974 Woolf, AD 87 Woolf, C 8 Wootton, J 844 Wopereis, H 74 Wordsworth, P 7, 705 Working Party, TT 56 Worthington, J 704, 707, 88, 885, 886, 877 Wortman, J 965 Wouters, C 70, 76 Wouters, H 87 Wray, DW 99 Wray, L 5 Wreath, J 99 Wren, JD 489, 864, 770 Wright, DE 76 Wright, T 9 Wu, CL 78 Wu, CY 78 Wu, C 58 Wu, D 707 Wu, H 40 Wu, H 857, 70 Wu, J 88 Wu, LC 68, 68, 59 Wu, L 4 Wu, M 6 Wu, M 655, 747 Wu, N 99, 999 Wu, P 809 Wu, P 65 Wu, P 56 Wu, Q 5 Wu, Q 7, 9, 7, 745 Wu, Q 94 Wu, R 470, 58 Wu, T 894 Wu, T 568 Wu, W 568 Wu, YL 86 Wu, YL 007 Wu, Z 474 Wu, Z 46, 54 Wuhrer, M 89 Wulffraat, N 69, 7, 69 Wulffraat, NM 79, 640, 784 Wylie, E 80 Wyman, A 4 Wållberg-Jonsson, S 408 Wähämaa, H 89 Xavier, R 79 Xavier, RM 44, 8, 47, 948 Xi, B 5 Xia, X 0 Xia, Y 550, 56 Xiang, Y 88 Xiao, C 570 Xiao, H 405 Xiao, R 665, 905 Xiao, W 0 Xibille-Friedmann, D 40 Xie, F 6, 47, 794, 05, 054, 9, 4, 40, 680, 76 Xie, G 88 Xie, L 0 Xie, L 7 Ximenes, AC 470 Xin, X 0 Xing, J 75 Xing, L 8 X

441 Xiong, H 57 Xiong, J 74, 06, 475, 79, 97, 4, 75, 96, 869 Xiong, Y 09 Xu, B 504 Xu, D 089 Xu, D 94 Xu, H 860 Xu, H 0 Xu, L 00, 857 Xu, M 479 Xu, R 046 Xu, S 4, 45, 44, 800, 5 Xu, W 5 Xu, X 5 Xu, Z 9, 47 Xu, Z 0 Xue, H 4 Y Yılmaz Oner, S 69 Yabe, Y 70 Yacuzzi, MS 86 Yadalam, S 9 Yadav, A 59 Yadav, R 078 Yagci, I 5 Yagensky, A 9 Yagi, N 0 Yagoto, M Yague, J 444 Yagüe, J 78 Yajima, N 7, 98, 57 Yalavarthi, S 54, 66, 4 Yalcinkaya, F 64 Yalcinkaya, Y 45 Yamada, C 05, 079 Yamada, H 40 Yamada, K 65 Yamada, S 40, 764 Yamada, Y 7 Yamada, Y 5 Yamaguchi, A 7 Yamaguchi, KI 9, 567 Yamaguchi, Y 79 Yamakami, L 55, 65 Yamakawa, N 0 Yamamoto, A 465, 80, 4 Yamamoto, K 588, 4,,, 94, 89 Yamamoto, T 86, 64 Yamamoto, Y 85, 6 Yamamura, M 749 Yamamura, Y 048 Yamanaka, H 74, 59, 65, 78, 86, 89, 047, 6, 40, 44, 84, 45, 459, 707, 06, 070, 075,,, 759, 769, 800 Yamane, T 6 Yamano, Y 49 Yamaoka, K 468, 45, 87, 774 Yamasaki, M 4 Yamasaki, S 97, 960 Yamasaki, Y 7, 75 Yamashita, H 7 Yamatou, T 7, 75, 08 Yamauchi, K Yamazaki, K 9, 7 Yan, Q 705 Yanaba, K 648, 98 Yanagida, M 7 Yanagida, T 66 Yanagisawa, M 45 Yanagisawa, M 75 Yanai, R 7, 98, 57 Yancy, WS Jr. 075, 855 Yang, D 894 Yang, E 55, 694 Yang, G 56 Yang, G 76 Yang, G 068 Yang, H 967 Yang, H 065 Yang, H 400 Yang, H 70 Yang, HI 464 Yang, J 7 Yang, M 0 Yang, P 7, 9, 7, 745 Yang, S 486, 866 Yang, T 7 Yang, WH 58 Yang, YC 86 Yang, YW 49, 058 Yang, Y 699 Yang, Y 7 Yang, Y 8 Yang, Z 70 Yano, K 74 Yao, A 59 Yao, HH 75 Yao, J 44 Yao, L 44 Yao, Q 0, 0, Yao, R 446, 477, 479, 5, 9 Yao, Y 50, 7, 645, 7, 77, 94 Yaqub, A 8 Yarwood, A 88, 88, 88, 885 Yasar, S 749 Yasar Bilge, S Yasuda, S 7, 68 Yasuhiro, T 84 Yasumura, J 75, 08 Yasuoka, H 6, 669, 575 Yau, MS 889 Yavasoglu, I 40 Yavuz, S 689 Yazdani, R 946 Yazdany, J 96, 75, 607, 846, 849, 906, 998, 06, 588, 589, 605, 7, 774, 9, 97, 54, 66, 665 Yazici, H 76, 65, 75, 69, 6, 6, 66, 6 Yazici, Y 476 Yazici, Y 9, 4, 76, 65,, 7, 55, 58 Yazisiz, V 749 Yde Dam, M 80 Ye, J 98 Ye, SQ 97 Ye, Y 0 Yeasted, R Yeaw, J 00 Yee, A 89 Yee, A 988 Yeh, JY 0 Yeh, WS 007 Yeleswaram, S 797 Yelin, EH 75, 607, 849, 05, 589, 758, 760, 774, 9, 66, 665, 909 Yellman, B 6 Yemez, S 60 Yen, EY 698 Yeo, KJ 509 Yeo, L 57 Yeremenko, N 500 Yerges-Armstrong, L 889 Yeter, K 09 Yette, GA 70 Yeung, RS 94, 98, 790 Yi, EC 67 Yigit, Z 6 Yildirim, O 0 Yildirim Cetin, G 5, 749 Yildiz, F 749 Yilmaz, H 5 Yilmaz, N 689 Yilmaz, S 9, 07, 749 Yilmaz, S 749 Yilmaz Oner, S 5, 60, 749 Yilmaz-Oner, S 457 Yim, CW 600 Ying, J 590, 76, 675, 79 Ying, KY 600 Yo, N 6 Yoder, L 574 Yokoe, I 59 Yokosawa, M 666 Yokota, A 465, 4 Yokota, K 45, 80, 570, 8, 99 Yokota, M 55 Yokota, S 9, 7, 74 Yokota, T 40 Yokoyama, Y 65 Yoneda, T 84, 800 Yonemoto, Y 87 Yoneyama, K 59 Yonezawa, T 64 Yoo, B 450, 0, 0, 445 Yoo, DH 69, 09, 5, 5, 440, 76, 80, 9, 400, 80 Yoo, HJ 440 Yoo, IS 66 Yoo, JJ 00, 476 Yoo, KH 9 Yoo, SA 46 Yoo, S 578, 5, 94 Yoo, SJ 66 Yoo, WH 69, 8 Yoon, BY 5 Yoon, CH 595 Yoon, G 480 Yoon, MJ 44, 4 Yoshida, H 79, 855,, 6 Yoshida, K 09, 447 Yoshida, K 774 Yoshida, M 9 Yoshida, N 854 Yoshida, N 557 Yoshida, S 74 Yoshida, S 6 Yoshida, T 9 Yoshida, Y 45 Yoshifuji, H 89, 9, 0 Yoshihara, R 6 Yoshii, I 465, 4 Yoshikawa, H 8, 46, 47 Yoshikawa, M 9 Yoshimi, R 945, 96, 074, 68 Yoshimoto, K 940, 840, 84, 40 Yoshimura, M 64 Yoshio, T 65, 59, 60 Yoshioka, T 905 Yoshitomi, H 404 Yoshizawa, T 84 Young, A 79, 4 Young, C 046, 047, 49 Young, K 6 Young, KO 7, 7 Young, KA 767, 659, 660 Young, NA 68, 68, 59 Young, S 875 Youngstein, T 684 Youssef, P 678, 85 Youssef, S 8,, 70 Youssof, E 97 Yow, E 674 Ytterberg, J 89, 4 Ytterberg, SR 79, 756, 667, 669 Yu, A 556 Yu, CY 86 Yu, CM Program Book 49 abstract author Index

442 Yu, F 8, 78 Zavialov, A 894 Zhao, J 70, 78 Zisapel, MZ 484 abstract author Index Yu, F Yu, J 575 Yu, M 0, 04 Yu, N 545 Yu, W 0 Yu, Y 0 Yuan, C 94 Yuan, K 065 Yuce, H 04, 8 Yucel, AE 58 Yucel-Lindberg, T 40 Yudoh, K 49, 645 Yue, B 8 Yukawa, N 9, 0 Yukioka, C 76 Yukioka, K 76 Yukioka, M 097, 46, 76 Yun, H 6, 47, 00, 048, 05, 054, 9, 4, 40, 680, 76 Yun, MJ 07 Yunoue, N 9 Yura, A 64 Yurdakul, S 75, 66 Yurdakul, S 689 Yuzawa, Y 6 Zaal, AI 65, 76 Zacariaz, J 60 Zadeh, A 597 Záhora, R 9, 0 Zajac, AJ 7 Zajic, S 4 Zakaria, R 79 Zakem, JM 98 Zakhem, G 657, 658 Zaki, S 49 Zamani, O 44 Zamanian, S 586 Zámecník, J 084 Zamora, N 86, 5, 58, 547 Zampogna, G 58 Zanchet, D 948 Zanchetta, JR 867 Zandman-Goddard, G 57 Zang, C 80 Zanjani, L 478 Zanola, A 9 Zapalowski, C 864 Zapantis, E 500 Zarco, P 475 Zarnitsky, C 469, 880 Zavada, J 596, 947 Zavaleta Muñíz, SA 407 Zavaleta-Muñiz, SA 546 Zavialov, A 894 Z Zazueta, BM 48 Zazzetti, F, 5, 9 Zbehlik, A 9 Zebaze, RM 867 Zeboulon, N 477 Zeddou, M 55 Zeft, AS 790, 70 Zeggini, E 98 Zeher, M 59 Zeig-Owens, R 05, 06 Zelekis-Cholakis, A 94 Zelko, F 57 Zell, J 846 Zeller, V 807 Zemel, BS 785 Zemel, LS 780 Zeng, X 94 Zeng, X 79, 80 Zerbe, GO 869, 660 Zerbini, C 479 Zerbini, CAF 4 Zerr, P 80, 8, 8, 690, 704, 708 Zevallos-Miranda, F 40, 68, 5 Zha, W 9 Zhang, B 79, 80 Zhang, C 98 Zhang, F 94, 46 Zhang, H 797 Zhang, J 6, 47, 75, 054, 4, 40 Zhang, LH 4 Zhang, M Zhang, M 77, 00, 857 Zhang, M 4, 9 Zhang, P 79 Zhang, S 59 Zhang, W 997, 0, 94 Zhang, W 0 Zhang, W 554 Zhang, W 80, 99 Zhang, W 94 Zhang, X 6, 64 Zhang, X 558 Zhang, X 87 Zhang, X 5 Zhang, Y 0 Zhang, Y 50 Zhang, Y 809 Zhang, Y 88 Zhang, Y 79, 80, 8 Zhang, Y 0 Zhang, Y 7, 4, 54, 57, 85, 90, 744, 757, 66, 67 Zhang, Z 58, 494, 495 Zhao, D 0 Zhao, J 774 Zhao, L 0 Zhao, M 665, 699, 905 Zhao, N Zhao, Q 85 Zhao, S 87 Zhao, W 54, 57 Zhao, X 559 Zhao, Y 94, 0 Zhao, Y 44, 0 Zhao, Y 8 Zhao, Y 646 Zhao, Z 89, 89, 888 Zhenbiao, W 499 Zheng, C 007 Zheng, DH 78, 48 Zheng, Q 70 Zheng, SG 7, 848, 8 Zheng, YY 567, 75 Zhou, B 86 Zhou, H 47 Zhou, JS 7 Zhou, JJ 48 Zhou, L 0 Zhou, M 50 Zhou, Q 894 Zhou, S 570, 7, 77 Zhou, T 809 Zhou, W 49 Zhou, X 778 Zhou, X 76, 655, 747, 79 Zhou, X 76 Zhou, Y 45, 44, 5 Zhou, Y 78 Zhou, Y 8 Zhou, ZY 77 Zhu, B 8, 4 Zhu, J Zhu, LJ 78, 48 Zhu, R 506, 5, 8, 0, Zhu, X 0 Zhuang, Y 46, 54 Zhukov, OS 90 Zickert, A 797 Zidovetski, R 69 Ziegler, JT 69 Zignego, AL 67 Zilberman-Rudenko, J 764 Zilberstein, M 75 Zimmerman, SL 88 Zimmermann, B 77 Zink, A 80 Zink, A 77, 806, 4, 64 Zinke, S 806, 0 Zisman, D 05 Zitvogel, L 77 Ziza, JM 469, 754 Zizic, T 5 Zlateva, G, 7 Zleik, N 998, 999 Zlotnick, S 877 Zlotogorski, A 64 Zlotogorski, Z 78 Zochling, J 678, 85, 04 Zoheir, MN 67 Zohoury, N 8, 0 Zollars, E 58 Zoller, J 849 Zoma, AA 59 Zondlo, S 865 Zong, M 405, 65, 08 Zoog, S 608 Zou, CJ 48 Zou, H 568 Zou, J 78 Zou, L 6 Zuang, H 550 Zuber, Z 79 Zubler, V 89, 888 Zuily, S 654 Zulian, F 54, 7, 85, 605 Zummer, M 48, 9 Zurakowski, D 05 Zusev, M 6 Zwerina, J 760 Zwillich, SH 48, 44, 445, 794, 977, 9, Program Book

443 Ablin, Jacob N., MD Fibromyalgia, Soft Tissue Disorders and Pain: Treatment and Outcome Assessment Disclosure: Pfizer Inc, 8 A Aizer, Juliet, MD, MPH Medical Education Alikhan, Mujahed, MD ARHP Noteworthy Abstracts Alten, Reike, MD Rheumatoid Arthritis - Clinical Aspects VII: Remission, Flare and Outcome Measures in Rheumatoid Arthritis Disclosure: Abbott, BMS, NOVARTIS, PFIZER, UCB, 8; BMS, NOVARTIS, PFIZER, ROCHE, UCB, ; BMS; PFIZER; UCB, Anolik, Jennifer H., MD, PhD 0 Rheumatology Research Foundation Edmond L. Dubois, MD Memorial Lectureship Aranow, Cynthia, MD Systemic Lupus Erythematosus - Clinical Aspects and Treatment: Lupus Nephritis and Genetics Disclosure: Amgen, 5; Bristol-Myers Squibb, 5; Dynavax, ; Eli Lilly and Company, ; Genentech and Biogen IDEC Inc., ; GlaxoSmithKline,, 5; Human Genome Sciences, Inc., ; Pfizer Inc, ; UCB, Asahara, Hiroshi, MD Biology and Pathology of Bone and Joint I: Cartilage Biology and Osteoarthritis Baer, Alan N., MD Sjögren s Syndrome: Clinical Advances B Barnabe, Cheryl, MD, MSc Epidemiology and Health Services Research II: Epidemiology in Systemic Lupus Erythematosus and Rheumatoid Arthritis Baron, Murray, MD Systemic Sclerosis, Fibrosing Syndromes, and Raynaud s - Clinical Aspects and Therapeutics I Bartlett, Susan J., PhD Rehabilitation Sciences Barton, Jennifer, MD Rheumatoid Arthritis - Clinical Aspects VII: Remission, Flare and Outcome Measures in Rheumatoid Arthritis Disclosure: Pfizer, Battistone, Michael J., MD Medical Education Beier, Frank, PhD Biology and Pathology of Bone and Joint I: Cartilage Biology and Osteoarthritis Bingham III, Clifton O., MD Rheumatoid Arthritis - Clinical Aspects I: Treatment Strategies in Rheumatoid Arthritis Disclosure: Abbvie, 5; Amgen, 5; BMS,, 5; Celgene, 5; Genentech/Roche, 5; Janssen Pharmaceutica Product, L.P.,, 5; Novartis Pharmaceutical Corporation, 5; NovoNordisk, 5; UCB,, 5 Blakley, Michael, MD ACR/ARHP Combined Pediatrics Abstract Session Blitz, Jill R., PT, DPT Education/Community Programs Bowman, Simon J., PhD Sjögren s Syndrome: Clinical Advances Disclosure: BSR BSSA, 6; Eli Lilly and Company, 5; GSK, 5; Roche Pharmaceuticals, Boyle, David L., MA Cytokines, Mediators, Cell-cell Adhesion, Cell Trafficking and Angiogenesis I: Identifying Novel Factors that Facilitate Neovascularization and Cell Trafficking Braun, Jürgen, MD Spondylarthropathies and Psoriatic Arthritis: Clinical Aspects and Treatment: Therapeutics and Outcomes in Spondyloarthritis Disclosure: Abbvie (Abbott), Amgen, BMS, Boehringer, Celgene, Celltrion, Chugai, EBEWE Pharma, Janssen, Medac, MSD (Schering- Plough), Mundipharma, Novartis, Pfizer (Wyeth), Roche, Sanofi-Aventis and UCB., 9 Burmester, Gerd R., MD Rheumatoid Arthritis Treatment - Small Molecules, Biologics and Gene Therapy: Novel Treatment Strategies in Rheumatoid Arthritis Disclosure: AbbVie, Essex/Schering-Plough, 5; AbbVie, Essex/Schering-Plough, Novartis, Roche, Wyeth, Bykerk, Vivian P., MD Rheumatoid Arthritis - Clinical Aspects II: Identifying Rheumatoid Arthritis in At-Risk Populations Disclosure: Amgen, 5; BMS, 5; Gennentech, 5; Pfizer Inc, 5; UCB, 5 Caplan, Liron, MD, PhD Epidemiology and Health Services Research III: Healthcare Costs and Mortality in Rheumatic Disease Carmona, Loreto, MD, PhD Rheumatoid Arthritis - Clinical Aspects IV: Comorbidities in Rheumatoid Arthritis Disclosure: Abbvie, ; Merck Sharp Dohme, ; Pfizer Inc, 8; Roche Pharmaceuticals, C Choy, Ernest, MD Rheumatoid Arthritis - Clinical Aspects V: Observational Studies in Rheumatoid Arthritis Disclosure: Abbott Laboratories, 5; Biotest, 5; Boehringer Ingelheim,, 5; Bristol-Myers Squibb, 5; Chugai, 5, 8; Daiichi Pharmaceutical Corporation, 5; Eli Lilly and Company, 5; GSK, 5; MSD, 8; Novartis Pharmaceutical Corporation, ; Novimmune,, 5; Pfizer Inc, 5, 8; Roche Pharmaceuticals,, 8; UCB, Clowse, Megan E. B., MD, MPH Systemic Lupus Erythematosus - Clinical Aspects: Pregnancy Disclosure: UCB, 5 Corr, Marpiat, MD Rheumatoid Arthritis - Pathogenetic Pathways Costedoat-Chalumeau, Nathalie, MD, PhD Miscellaneous Rheumatic and Inflammatory Diseases II: Autoinflammatory Syndromes Cronin, Mary E., MD ACR Plenary Session II: Discovery 0 Cronstein, Bruce N., MD Rheumatoid Arthritis Treatment - Small Molecules, Biologics and Gene Therapy: Safety and Efficacy of Small Molecule Agents Disclosure: Canfite Pharma, ; Merck- SeronoBristol-Myers Squibb, Novartis, CanFite Biopharmaceuticals, Cypress Laboratories, Regeneron (Westat, DSMB), Endocyte, Protalex, Allos, Inc., Savient, Gismo Therapeutics, Antares Pharmaceutical, Medivector, 5; Multiple patents on adenosine receptors and bone metabolism, pharmacology, 9; NIH, Gilead, Takeda, AstraZeneca, ; NYU School of Medicine, Crowson, Cynthia S., MS Epidemiology and Health Services Research I: Comorbidities in Rheumatic Diseases Csuka, Mary Ellen, MD Systemic Sclerosis, Fibrosing Syndromes and Raynaud s-clinical Aspects and Therapeutics III Abstract Moderator disclosure 0 Program Book 44

444 Cush, John J., MD Rheumatoid Arthritis Treatment - Small Molecules, Biologics and Gene Therapy: Safety Issues D D Agostino, Maria-Antonietta, MD, PhD Imaging in Pediatric Arthritis, Spondyloarthritis and Osteoarthritis E Elkon, Keith B., MD 0 Rheumatology Research Foundation Edmond L. Dubois, MD Memorial Lectureship Systemic Lupus Erythematosus - Animal Models Englund, Martin, MD, PhD Osteoarthritis I: Therapeutics in Osteoarthritis Grossman, Jennifer M., MD Systemic Lupus Erythematosus - Clinical Aspects: Non-biologic Disease-modifying Antirheumatic Drugs Disclosure: UCB, Eli Lilly, Medimmune, Pfizer- I am doing lupus clinical trials compounds made by these companies that are in phase or studies. I am an investigator in multicenter trials., Guillevin, Loic P., MD Miscellaneous Rheumatic Diseases Dall Era, Maria, MD Systemic Lupus Erythematosus - Clinical Aspects and Treatment: Lupus Nephritis and Genetics Deane, Kevin D., MD, PhD Rheumatoid Arthritis - Clinical Aspects II: Identifying Rheumatoid Arthritis in At-Risk Populations Dellaripa, Paul F., MD Rheumatoid Arthritis - Clinical Aspects IV: Comorbidities in Rheumatoid Arthritis DeMarco, Paul J., MD Imaging in Pediatric Arthritis, Spondyloarthritis and Osteoarthritis Disclosure: Abbott Immunology Pharmaceuticals, Amgen, Auxilium, 8; Amgen, 8; Auxilium, Denton, Christopher P., PhD Systemic Sclerosis, Fibrosing Syndromes and Raynaud s-pathogenesis, Animal Models and Genetics I: Therapeutic Interventions in Preclinical Animal Models of Sclerodermaoderma Fitzcharles, Mary-Ann, MBChB, MD Fibromyalgia, Soft Tissue Disorders and Pain: Treatment and Outcome Assessment Disclosure: Pfizer Inc, Valeant, Lilly, Purdue, 8 F FitzGerald, Oliver M., MD Spondylarthropathies and Psoriatic Arthritis: Clinical Aspects and Treatment: Therapeutics and Outcomes in Psoriatic Arthritis Disclosure: Abbott, BMS, Pfizer, MSD, ; Abbott, Pfizer, MSD; Janssen and Cellgene, 8; Abbott, UCB, Pfizer, 5 Fox, Robert I., MD, PhD Sjögren s Syndrome: Basic Science Disclosure: UCB, Allergan, Eli Lilly, 5 Foxworth, Judy, PhD, PT Rehabilitation Sciences Frech, Tracy M., MD Systemic Sclerosis, Fibrosing Syndromes and Raynaud s - Clinical Aspects and Therapeutics III Systemic Sclerosis, Fibrosing Syndromes, and Raynaud s - Clinical Aspects and Therapeutics I H Hajj- Ali, Rula, MD Vasculitis II Harley, John B., MD, PhD Genetics and Genomics of Rheumatic Disease I Disclosure: Erba DIagnostice, 7; Erba Diagnostics,, 5; Genentech and Biogen IDEC Inc., 9; Genentech, Inc., 5, 9; Lilly Pharmaceuticals, 5, 9; Regeneron Pharmaceuticals, Inc., 9 Harrington, J. Timothy, MD Health Services Research, Quality Measures and Quality of Care - Rheumatoid Arthritis Disclosure: Corrona, 5; Crescendo Bioscience, 5 Helliwell, Philip S., MA, PhD Spondylarthropathies and Psoriatic Arthritis: Clinical Aspects and Treatment: Therapeutics and Outcomes in Psoriatic Arthritis Disclosure: Abbvie, Celgene, Pfizer, Novartis, Janssen, UCB, BMS, Eli-Lilly, Merck, 5; Pfizer Inc, Abbvie, Hersh, Aimee, MD ACR/ARHP Combined Pediatrics Abstract Session Abstract Moderator disclosure Deodhar, Atul, MD Spondylarthropathies and Psoriatic Arthritis: Clinical Aspects and Treatment: Imaging in Axial Spondylarthropathies: Challenges, Advances Disclosure: Abbott, Pfizer, UCB Pharma, 9; UCB Pharma, Abbott, Amgen, Janssen, Novartis,, 5 Dore, Robin K., MD Osteoporosis and Metabolic Bone Disease: Clinical Aspects and Pathogenesis Disclosure: Amgen, ; Amgen, Eli Lilly, 5; Amgen, Eli Lilly, Novartis, Warner-Chilcott, 8 Dragone, Leonard L., MD, PhD Pediatric Rheumatology - Pathogenesis and Genetics Dufour, Alyssa B., PhD ACR/ARHP Combined Epidemiology Abstract Session G Genovese, Mark C., MD Rheumatoid Arthritis Treatment - Small Molecules, Biologics and Gene Therapy: Efficacy of Approved Biologics I Gladman, Dafna, MD Systemic Lupus Erythematosus - Clinical Aspects and Treatment: Biologic Therapy Disclosure: GSK, 5 Grom, Alexei, MD Pediatric Rheumatology - Pathogenesis and Genetics Disclosure: Novartis Pharmaceutical Corporation, 5 Hetland, Merete, DMSc, MD, PhD Rheumatoid Arthritis - Clinical Aspects I: Treatment Strategies in Rheumatoid Arthritis Disclosure: Pfizer, Roche, Merck Pharmaceuticals, 5 Ho, I-Cheng, MD, PhD T-cell Biology and Targets in Autoimmune Disease Huisinga, Karen, MN, ARNP Clinical Practice/Patient Care Disclosure: Pfizer Inc, 8 Huizinga, Thomas W.J., MD PhD Rheumatoid Arthritis - Autoantibodies and Citrullinated Proteins 44 0 Program Book

445 Hunter, David J., MBBS, PhD Orthopedics, Low Back Pain, Rehabilitation and Mechanisms of Pain in Arthritis Iagnocco, Annamaria, MD Imaging of Rheumatic Diseases: Imaging in Vascular and Extra-articular I Inman, Robert, MD Infection Related Rheumatic Diseases Spondylarthropathies and Psoriatic Arthritis: Clinical Aspects and Treatment: Clinical Features of Spondyloarthritis J Jamal, Shahin, MD, MSc Rheumatoid Arthritis - Clinical Aspects III: Predictors of Disease Course in Rheumatoid Arthritis Disclosure: Abbott Immunology Pharmaceuticals, 5; Amgen, 5; Bristol-Myers Squibb, 5; Janssen Pharmaceutica Product, L.P., 5; Pfizer Inc, 5; Roche Pharmaceuticals, 5; Ucb, 5 Rheumatoid Arthritis - Clinical Aspects VI: Cardiovascular Disease in Rheumatoid Arthritis Disclosure: Abbott Immunology Pharmaceuticals, 5; Amgen, 5; Bristol-Myers Squibb, 5; Janssen Pharmaceutica Product, L.P., 5; Pfizer Inc, 5; Roche Pharmaceuticals, 5; Ucb, 5 Jimenez, Sergio A., MD Systemic Sclerosis, Fibrosing Syndromes and Raynaud s: Pathogenesis, Animal Models, Genetics: Novel Signaling Pathways Mediating Fibrosis Jonsson, Roland, DMD, PhD Sjögren s Syndrome: Basic Science K Kalunian, Kenneth C., MD Systemic Lupus Erythematosus - Clinical Aspects: Non-biologic Disease-modifying Antirheumatic Drugs Disclosure: Ambit, 5; Anthera, 5; Biogen Idec, ; Bristol-Myers Squibb, 5; Eli Lilly and Company, 5; Exagen, 5; Genentech and Biogen IDEC Inc., 5; MedImmune, ; Merck Serono, 5; Questcor, 5; UCB, Kaplan, Mariana J., MD Systemic Lupus Erythematosus - Human Etiology and Pathogenesis I Kavanaugh, Arthur, MD Rheumatoid Arthritis Treatment - Small Molecules, Biologics and Gene Therapy: Novel Treatment Strategies in Rheumatoid Arthritis Disclosure: Amgen abbvie ucb pfizer janssen, Kay, Jonathan, MD Miscellaneous Rheumatic Diseases Disclosure: Abbott Laboratories, ; Amgen Inc., 5; Ardea Biosciences, ; Baxter Healthcare Corporation, 5; Bristol-Myers Squibb Company, 5; Celgene Corp., 5; Eli Lilly and Company, ; Fidia Farmacutici, SpA, ; fourteen Inc., 5; Genentech Inc., 5; Horizon Pharma, Inc., 5; Hospira, Inc., 5; Janssen Biotech, Inc., 5; medac pharma Inc., 5; PanGenetics, B.V., 5; Pfizer Inc, ; Pfizer Inc., 5; Roche Laboratories, ; Roche Laboratories, Inc., 5; sanofi-aventis, ; Savient Pharmaceuticals, Inc., 5; Sun Pharmaceutical Industries Ltd., 5; UCB, Inc., 5 Rheumatoid Arthritis Treatment - Small Molecules, Biologics and Gene Therapy: Efficacy and Safety of Novel Entities Disclosure: Abbott Laboratories, ; Amgen Inc., 5; Ardea Biosciences, ; Baxter Healthcare Corporation, 5; Bristol-Myers Squibb Company, 5; Celgene Corp., 5; Eli Lilly and Company, ; Fidia Farmacutici, SpA, ; fourteen Inc., 5; Genentech Inc., 5; Horizon Pharma, Inc., 5; Hospira, Inc., 5; Janssen Biotech, Inc., 5; medac pharma Inc., 5; PanGenetics, B.V., 5; Pfizer Inc, ; Pfizer Inc., 5; Roche Laboratories, ; Roche Laboratories, Inc., 5; sanofi-aventis, ; Savient Pharmaceuticals, Inc., 5; Sun Pharmaceutical Industries Ltd., 5; UCB, Inc., 5 Kazi, Salahuddin, MD Health Services Research, Quality Measures and Quality of Care - Innovations in Health Care Delivery Khan, Nasim A., MD Epidemiology and Health Services Research II: Epidemiology in Systemic Lupus Erythematosus and Rheumatoid Arthritis Khosroshahi, Arezou, MD Systemic Lupus Erythematosus - Clinical Aspects: Cardiovascular and Other Complications of Lupus Kyburz, Diego, MD Innate Immunity and Rheumatic Disease Kyttaris, Vasileios C., MD Systemic Lupus Erythematosus - Human Etiology and Pathogenesis II L Lacaille, Diane V., MD, MHSc Epidemiology and Health Services Research VI: Risk Factors in Rheumatic Disease Susceptibility Rheumatoid Arthritis - Clinical Aspects III: Predictors of Disease Course in Rheumatoid Arthritis Lafyatis, Robert, MD Systemic Sclerosis, Fibrosing Syndromes and Raynaud s-pathogenesis, Animal Models and Genetics: Pathogenesis of Systemic Sclerosis Disclosure: Actelion Pharmaceuticals US, ; Amira, 5; Biogen Idec,, 5; BMS, 5; Bristol- Myers Squibb, ; Celdara, 5; Celgene, 5; Celltex, 5; Dart Therapeutics, 5; Genentech and Biogen IDEC Inc., ; Human Genome Sciences, Inc., ; Idera, 5; Inception, 5; Intermune, 5; Lycera, 5; Medimmune,, 5; Novartis Pharmaceutical Corporation, 5; Precision Dermatology, 5; PRISM, 5; Promedior, 5; Regeneron,, 5; Roche/ Genentech, 5; Sanofi/Genzyme,, 5; Shire,, 5; Stromedix, ; UCB, ; Zwitter, 5 Lambert, Robert GW, MD Imaging in Rheumatoid Arthritis Landewe, R., MD, PhD Spondylarthropathies and Psoriatic Arthritis: Clinical Aspects and Treatment: Imaging in Axial Spondylarthropathies: Challenges, Advances Disclosure: Pfizer, Janssen, Merck, Abbott, ; Pfizer, Janssen, Merck, Abbott, Amgen, Astra, BMS, Centocor, GSK, UCS, Vertex, 5 Langford, Carol A., MD, MHS Vasculitis III Disclosure: Bristol-Myers Squibb, 9; Genentech and Biogen IDEC Inc., 9 Li, Linda C., PhD, PT Research and Health Services Lightfoot Jr., Robert W., MD ARHP Noteworthy Abstracts Lim, S. Sam, MD, MPH Systemic Lupus Erythematosus - Clinical Aspects: Cardiovascular and Other Complications of Lupus Disclosure: GlaxoSmithKline,, 5; Lilly, 9; MedImmune, 9; Pfizer Inc, 9; UCB, 9 Lindsley, Carol B., MD Muscle Biology, Myositis and Myopathies I: Insights into Mechanisms of the Idiopathic Inflammatory Myopathies Abstract Moderator disclosure 0 Program Book 44

446 Abstract Moderator disclosure 444 Lo, Grace H., MD, MSc Osteoarthritis II: Risk Factors and Natural History of Osteoarthritis Lories, Rik, MD, PhD Spondylarthropathies and Psoriatic Arthritis - Pathogenesis, Etiology Losina, Elena, PhD ACR/ARHP Combined Rehabilitation Abstract Session Disclosure: JBJS, 9 Epidemiology and Health Services Research III: Healthcare Costs and Mortality in Rheumatic Disease Disclosure: JBJS, 9 Louie, James S., MD Infection Related Rheumatic Diseases Disclosure: Amgen, 8; Genentech and Biogen IDEC Inc., 8; Pfizer Inc, 8 M Machado, Pedro, MD Spondylarthropathies and Psoriatic Arthritis: Clinical Aspects and Treatment: Therapeutics and Outcomes in Spondyloarthritis Disclosure: Abbott Laboratories, 5; Merck Pharmaceuticals, 5 Mahr, Alfred, MD, PhD Vasculitis III Makris, Una E., MD Health Services Research, Quality Measures and Quality of Care - Pediatrics, Immunization and Choosing Wisely Maksymowych, Walter P., MD Spondylarthropathies and Psoriatic Arthritis: Clinical Aspects and Treatment: Clinical and Imaging Aspects of Axial Spondyloarthritis Disclosure: Abbvie,, 5; Amgen,, 5; Celgene, 5; Eli Lilly and Company, 5; Janssen Pharmaceutica Product, L.P.,, 5; Pfizer Inc,, 5; UCB, 5 Markenson, Joseph A., MD Rheumatoid Arthritis Treatment - Small Molecules, Biologics and Gene Therapy: Efficacy of Approved Biologics II Disclosure: Abbott Immunology Pharmaceuticals, 8; Amgen, 8; Bristol-Myers Squibb, 8; Janssen Pharmaceutica Product, L.P., 8; Pfizer Inc, 8; TREG, 4; UCB, 8 Matteson, Eric L., MD, MPH ACR Plenary Session II: Discovery 0 Disclosure: Ardea Biosciences, ; Celegene, ; Genentech and Biogen IDEC Inc., ; Hoffmann-La Roche, Inc., ; Janssen Pharmaceutica Product, L.P., ; Mesoblast, ; Novartis Pharmaceutical Corporation, ; Pfizer Inc, ; Rheumatology Research Foundation, ; UCB Pharma, 0 Program Book McInnes, Iain B., PhD Rheumatoid Arthritis Treatment - Small Molecules, Biologics and Gene Therapy: Efficacy and Safety of Novel Entities Disclosure: Astra Zeneca,, 5; BMS, ; Pfizer Inc,, 5; UCB, 5 McLean, Robert R., DSc, MPH Epidemiology and Public Health McMahon, Maureen A., MD Systemic Lupus Erythematosus - Clinical Aspects and Treatment: Biologic Therapy Disclosure: Glaxo Smith Klein, 8; Questcor, 5 Meroni, Pier Luigi, MD Antiphospholipid Syndrome Messier, Stephen P., PhD Osteoarthritis II: Risk Factors and Natural History of Osteoarthritis Miossec, Pierre, MD, PhD Rheumatoid Arthritis - Pathogenetic Pathways Molloy, Eamonn, MD Vasculitis I Morel, Laurence, PhD Systemic Lupus Erythematosus - Animal Models Morgan DeWitt, Esi, MD, MSCE Health Services Research, Quality Measures and Quality of Care - Pediatrics, Immunization and Choosing Wisely Nakamura, Mary C., MD Biology and Pathology of Bone and Joint II: Osteoclast Biology and Arthritis Neogi, Tuhina, MD, PhD Osteoarthritis I: Therapeutics in Osteoarthritis N Newman, Eric D., MD Health Services Research, Quality Measures and Quality of Care-Rheumatoid Arthritis Nigrovic, Peter A., MD Cytokines, Mediators, Cell-cell Adhesion, Cell Trafficking and Angiogenesis II: Mechanisms that contribute to autoimmune inflammation Disclosure: Baxter Healthcare, ; Momenta Pharmaceuticals, 5; Novartis Pharmaceutical Corporation, 5 Nihtyanova, Svetlana I., MBBS Systemic Sclerosis, Fibrosing Syndromes, and Raynaud s - Clinical Aspects and Therapeutics II Disclosure: Roche Pharmaceuticals,, O Oatis, Carol A., PT, PhD Epidemiology and Public Health Oddis, Chester V., MD ACR Plenary Session I: Discovery 0 Oh, Terry H., MD Fibromyalgia, Soft Tissue Disorders and Pain: Diagnosis and Disease Epidemiology Olsen, Nancy J., MD Rheumatoid Arthritis - Autoantibodies and Citrullinated Proteins Ostergaard, Mikkel, DMSc, MD, PhD Imaging in Rheumatoid Arthritis Pap, Thomas, MD Rheumatoid Arthritis - Animal Models I Passo, Murray H., MD Pediatric Rheumatology: Clinical and Therapeutic Disease: Juvenile Idiopathic Arthritis Disclosure: Pfizer Inc, 5 Perez Ruiz, Fernando, MD, PhD Metabolic and Crystal Arthropathies I Disclosure: Astra-Zeneca, 5; Menarini, 5, 8; Metabolex, 5 Metabolic and Crystal Arthropathies II Disclosure: Astra-Zeneca, 5; Menarini, 5, 8; Metabolex, 5 Perlman, Harris R., PhD Rheumatoid Arthritis - Animal Models I Rheumatoid Arthritis - Animal Models II P Pernis, Alessandra B., MD Systemic Lupus Erythematosus - Human Etiology and Pathogenesis II Phillips, Kristine, MD, PhD Rheumatoid Arthritis - Clinical Aspects V: Observational Studies in Rheumatoid Arthritis Pope, Richard M., MD ACR Plenary Session III: Discovery 0

447 Postlethwaite, Arnold E., MD Systemic Sclerosis, Fibrosing Syndromes and Raynaud s-pathogenesis, Animal Models and Genetics: Pathogenesis of Systemic Sclerosis R Rabinovich, C. Egla, MD, MPH Pediatric Rheumatology - Clinical and Therapeutic Aspects II: Autoinflammatory Disease and Systemic Juvenile Idiopathic Arthritis Disclosure: Jannsen; Abbott, UCB, Hoffmann-La Roche Inc., Rauch, Joyce, PhD Antiphospholipid Syndrome Raychaudhuri, Soumya, MD, PhD Genetics and Genomics of Rheumatic Disease II Rigby, William F. C., MD Rheumatoid Arthritis Treatment - Small Molecules, Biologics and Gene Therapy: Efficacy of Approved Biologics II Disclosure: Roche Pharmaceuticals, 5 Russo, Ricardo A. G., MD Pediatric Rheumatology - Clinical and Therapeutic Aspects III: Systemic Lupus Erythematosus and Other Disease Outcomes S Salmon, Jane E., MD Systemic Lupus Erythematosus - Human Etiology and Pathogenesis I Disclosure: Alexion, Regeneron, Movartis, BMS, 5; Alliance for Lupus Research, RRF, Kunkel Society, 6; Biogen Idec, BMS, J and J, Merck, Quest, ; Roche Pharmaceuticals, Salt, Elizabeth G., PhD Education/Community Programs Disclosure: I have a grant with the ACR, ; I review grants for the Pfizer medical education group, 5; Smithkline, Samuels, Jonathan, MD Imaging of Rheumatic Diseases: Imaging in Vascular and Extra-articular Schlesinger, Naomi, MD Metabolic and Crystal Arthropathies I Disclosure: Novartis Pharmaceutical Corporation, ; Novartis Pharmaceutical Corporation:Sobi, 5; Novartis Pharmaceutical Corporation;Sobi, Savient; Takeda, 9; Novartis Pharmaceutical Corporation;Takeda, Savient, 8 Schmajuk, Gabriela, MD, MS Epidemiology and Health Services Research I: Comorbidities in Rheumatic Diseases Schwartzman, Sergio, MD Rheumatoid Arthritis Treatment - Small Molecules, Biologics and Gene Therapy: Safety Issues Disclosure: Abbvie, Pfizer, Janssen, UCB, Genentech, 8; Abbvie, Pfizer, Janssen, UCB, Genentech, Hospira, Crecendo, 5 Schwarz, Edward M., PhD Biology and Pathology of Bone and Joint II: Osteoclast Biology and Arthritis Shahrara, Shiva, PhD Cytokines, Mediators, Cell-cell Adhesion, Cell Trafficking and Angiogenesis I: Identifying Novel Factors that Facilitate Neovascularization and Cell Trafficking Shanmugam, Victoria K., MBBS, MRCP Systemic Lupus Erythematosus - Clinical Aspects: Pregnancy Disclosure: Numerous pharmaceutical companies., 9 Shen, Nan, MD Genetics and Genomics of Rheumatic Disease II Sigal, Leonard H., MD Clinical Practice/Patient Care Silverman, Gregg J., MD B cells in Systemic Lupus Erythematosus Smith, Benjamin J, PA-C ACR/ARHP Combined Rehabilitation Abstract Session Spondylarthropathies and Psoriatic Arthritis - Pathogenesis, Etiology Solomon, Daniel H., MD, MPH Rheumatoid Arthritis Treatment - Small Molecules, Biologics and Gene Therapy: Efficacy of Approved Biologics I Disclosure: Lilly, Amgen, CORRONA, ; Lilly, BMS, Novartis, 9; Lilly, BMS, Novartis, Pfizer, 6 Stamatos, Christine A., DNP, ANP-C Psychology/Social Sciences/Pediatrics Stamp, Lisa K., PhD Metabolic and Crystal Arthropathies II Steen, Virginia D., MD Systemic Sclerosis, Fibrosing Syndromes, and Raynaud s - Clinical Aspects and Therapeutics II Stohl, William, MD, PhD B cells in Systemic Lupus Erythematosus Disclosure: Eli Lilly and Company, 5; GlaxoSmithKline, ; Novartis Pharmaceutical Corporation, 5; Pfizer Inc, ; Xencor, Suter, Lisa, MD Fibromyalgia, Soft Tissue Disorders and Pain: Diagnosis and Disease Epidemiology Disclosure: YNHHSC/CORE, T Tarter, Laura L., MD Epidemiology and Health Services Research VI: Risk Factors in Rheumatic Disease Susceptibility Thomas, Ranjeny, MBBS, MD Innate Immunity and Rheumatic Disease Trojanowska, Maria, PhD Systemic Sclerosis, Fibrosing Syndromes and Raynaud s: Pathogenesis, Animal Models, Genetics: Novel Signaling Pathways Mediating Fibrosis Tsao, Betty P., PhD Genetics and Genomics of Rheumatic Disease I U Uknis, Audrey B., MD ACR Plenary Session I: Discovery 0 Van den Bosch, Filip, MD, PhD Spondylarthropathies and Psoriatic Arthritis: Clinical Aspects and Treatment: Clinical and Imaging Aspects of Axial Spondyloarthritis V van Riel, Piet, MD, PhD Rheumatoid Arthritis - Clinical Aspects VI: Cardiovascular Disease in Rheumatoid Arthritis van Vollenhoven, Ronald F., MD, PhD Rheumatoid Arthritis Treatment - Small Molecules, Biologics and Gene Therapy: Safety and Efficacy of Small Molecule Agents Disclosure: AbbVie, AstraZeneca, Biotest, BMS, GSK, Lilly, Merck, Pfizer, Roche, UCB, Vertex, 5; AbbVie, BMS, GSK, Merck, Pfizer, Roche, UCB, Varga, John, MD ACR Plenary Session III: Discovery 0 Systemic Sclerosis, Fibrosing Syndromes and Raynaud s-pathogenesis, Animal Models and Genetics I: Therapeutic Interventions in Preclinical Animal Models of Sclerodermaoderma Abstract Moderator disclosure 0 Program Book 445

448 Veale, Douglas J., MD Cytokines, Mediators, Cell-cell Adhesion, Cell Trafficking and Angiogenesis II: Mechanisms that contribute to autoimmune inflammation Disclosure: Abbott, Roche, MSD, Pfizer, 5; Pfizer Inc, MSD, Janssen, 8; Pfizer, MSD, Janssen, Roche, 5 Vlad, Steven, MD, PhD Orthopedics, Low Back Pain, Rehabilitation and Mechanisms of Pain in Arthritis von Scheven, Emily, MD Pediatric Rheumatology - Clinical and Therapeutic Aspects III: Systemic Lupus Erythematosus and Other Disease Outcomes Y Yazdany, Jinoos, MD, MPH Health Services Research, Quality Measures and Quality of Care - Innovations in Health Care Delivery Yazici, Yusuf, MD Vasculitis II Disclosure: BMS, Celgene, Genentech, Aie, Pfizer, UC, Medac, 5; Genentech, BMS, Celgene, ; Samumed, Ytterberg, Steven R., MD Muscle Biology, Myositis and Myopathies I: Insights into Mechanisms of the Idiopathic Inflammatory Myopathies Disclosure: Questcor, Inc., 5 W Warrington, Kenneth J., MD Vasculitis I Westby, Marie D., PT, PhD Research and Health Services Zeft, Andrew, MD Pediatric Rheumatology: Clinical and Therapeutic Disease: Juvenile Idiopathic Arthritis Z Woolf, Anthony D., MBBS Osteoporosis and Metabolic Bone Disease: Clinical Aspects and Pathogenesis Abstract Moderator disclosure Program Book

449 Enbrel (etanercept) Brief Summary SEE PACKAGE INSERT FOR FULL PRESCRIBING INFORMATION WARNINGS SERIOUS INFECTIONS AND MALIGNANCIES Patients treated with Enbrel are at increased risk for developing serious infections that may lead to hospitalization or death [see Warnings and Precautions and Adverse Reactions]. Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. Enbrel should be discontinued if a patient develops a serious infection or sepsis. Reported infections include: Active tuberculosis, including reactivation of latent tuberculosis. Patients with tuberculosis have frequently presented with disseminated or extrapulmonary disease. Patients should be tested for latent tuberculosis before Enbrel use and during therapy. Treatment for latent infection should be initiated prior to Enbrel use. Invasive fungal infections, including histoplasmosis, coccidioidomycosis, candidiasis, aspergillosis, blastomycosis, and pneumocystosis. Patients with histoplasmosis or other invasive fungal infections may present with disseminated, rather than localized, disease. Antigen and antibody testing for histoplasmosis may be negative in some patients with active infection. Empiric anti-fungal therapy should be considered in patients at risk for invasive fungal infections who develop severe systemic illness. Bacterial, viral, and other infections due to opportunistic pathogens, including Legionella and Listeria. The risks and benefits of treatment with Enbrel should be carefully considered prior to initiating therapy in patients with chronic or recurrent infection. Patients should be closely monitored for the development of signs and symptoms of infection during and after treatment with Enbrel, including the possible development of tuberculosis in patients who tested negative for latent tuberculosis infection prior to initiating therapy. MALIGNANCIES Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with TNF blockers, including Enbrel. INDICATIONS AND USAGE Rheumatoid Arthritis Enbrel is indicated for reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in patients with moderately to severely active rheumatoid arthritis (RA). Enbrel can be initiated in combination with methotrexate (MTX) or used alone. Polyarticular Juvenile Idiopathic Arthritis Enbrel is indicated for reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis (JIA) in patients ages and older. Psoriatic Arthritis Enbrel is indicated for reducing signs and symptoms, inhibiting the progression of structural damage of active arthritis, and improving physical function in patients with psoriatic arthritis (PsA). Enbrel can be used in combination with methotrexate (MTX) in patients who do not respond adequately to MTX alone. Ankylosing Spondylitis Enbrel is indicated for reducing signs and symptoms in patients with active ankylosing spondylitis (AS). Plaque Psoriasis Enbrel is indicated for the treatment of adult patients (8 years or older) with chronic moderate to severe plaque psoriasis (PsO) who are candidates for systemic therapy or phototherapy. CONTRAINDICATIONS Enbrel should not be administered to patients with sepsis. WARNINGS AND PRECAUTIONS Serious Infections Patients treated with Enbrel are at increased risk for developing serious infections involving various organ systems and sites that may lead to hospitalization or death. Opportunistic infections due to bacterial, mycobacterial, invasive fungal, viral, parasitic, or other opportunistic pathogens including aspergillosis, blastomycosis, candidiasis, coccidioidomycosis, histoplasmosis, legionellosis, listeriosis, pneumocystosis, and tuberculosis have been reported with TNF blockers. Patients have frequently presented with disseminated rather than localized disease. Treatment with Enbrel should not be initiated in patients with an active infection, including clinically important localized infections. Patients greater than 65 years of age, patients with co-morbid conditions, and/or patients taking concomitant immunosuppressants (such as corticosteroids or methotrexate), may be at greater risk of infection. The risks and benefits of treatment should be considered prior to initiating therapy in patients: with chronic or recurrent infection; who have been exposed to tuberculosis; with a history of an opportunistic infection; who have resided or traveled in areas of endemic tuberculosis or endemic mycoses, such as histoplasmosis, coccidioidomycosis, or blastomycosis; or with underlying conditions that may predispose them to infection, such as advanced or poorly controlled diabetes [see Adverse Reactions]. Patients should be closely monitored for the development of signs and symptoms of infection during and after treatment with Enbrel. Enbrel should be discontinued if a patient develops a serious infection or sepsis. A patient who develops a new infection during treatment with Enbrel should be closely monitored, undergo a prompt and complete diagnostic workup appropriate for an immunocompromised patient, and appropriate antimicrobial therapy should be initiated. Tuberculosis Cases of reactivation of tuberculosis or new tuberculosis infections have been observed in patients receiving Enbrel, including patients who have previously received treatment for latent or active tuberculosis. Data from clinical trials and preclinical studies suggest that the risk of reactivation of latent tuberculosis infection is lower with Enbrel than with TNF-blocking monoclonal antibodies. Nonetheless, postmarketing cases of tuberculosis reactivation have been reported for TNF blockers, including Enbrel. Tuberculosis has developed in patients who tested negative for latent tuberculosis prior to initiation of therapy. Patients should be evaluated for tuberculosis risk factors and tested for latent infection prior to initiating Enbrel and periodically during therapy. Tests for latent tuberculosis infection may be falsely negative while on therapy with Enbrel. Treatment of latent tuberculosis infection prior to therapy with TNF-blocking agents has been shown to reduce the risk of tuberculosis reactivation during therapy. Induration of 5 mm or greater with tuberculin skin testing should be considered a positive test result when assessing if treatment for latent tuberculosis is needed prior to initiating Enbrel, even for patients previously vaccinated with Bacille Calmette-Guerin (BCG). Anti-tuberculosis therapy should also be considered prior to initiation of Enbrel in patients with a past history of latent or active tuberculosis in whom an adequate course of treatment cannot be confirmed, and for patients with a negative test for latent tuberculosis but having risk factors for tuberculosis infection. Consultation with a physician with expertise in the treatment of tuberculosis is recommended to aid in the decision whether initiating antituberculosis therapy is appropriate for an individual patient. Tuberculosis should be strongly considered in patients who develop a new infection during Enbrel treatment, especially in patients who have previously or recently traveled to countries with a high prevalence of tuberculosis, or who have had close contact with a person with active tuberculosis. Invasive Fungal Infections Cases of serious and sometimes fatal fungal infections, including histoplasmosis, have been reported with TNF blockers, including Enbrel. For patients who reside or travel in regions where mycoses are endemic, invasive fungal infection should be suspected if they develop a serious systemic illness. Appropriate empiric antifungal therapy should be considered while a diagnostic workup is being performed. Antigen and antibody testing for histoplasmosis may be negative in some patients with active infection. When feasible, the decision to administer empiric antifungal therapy in these patients should be made in consultation with a physician with expertise in the diagnosis and treatment of invasive fungal infections and should take into account both the risk for severe fungal infection and the risks of antifungal therapy. In 8 Enbrel clinical trials and 4 cohort studies in all approved indications representing 7,69 patient-years of exposure (7,696 patients) from the United States and Canada, no histoplasmosis infections were reported among patients treated with Enbrel. Neurologic Events Treatment with TNF-blocking agents, including Enbrel, has been associated with rare (< 0.%) cases of new onset or exacerbation of central nervous system demyelinating disorders, some presenting with mental status changes and some associated with permanent disability. Cases of transverse myelitis, optic neuritis, multiple sclerosis, Guillain-Barré syndromes, other peripheral demyelinating neuropathies, and new onset or exacerbation of seizure disorders have been reported in postmarketing experience with Enbrel therapy. Prescribers should exercise caution in considering the use of Enbrel in patients with preexisting or recent-onset central or peripheral nervous system demyelinating disorders [see Adverse Reactions]. Malignancies Lymphomas In the controlled portions of clinical trials of TNF-blocking agents, more cases of lymphoma have been observed among patients receiving a TNF blocker compared to control patients. During the controlled portions of Enbrel trials in adult patients with RA, AS, and PsA, lymphomas were observed among 06 Enbrel-treated patients versus 0 among 5 control patients (duration of controlled treatment ranged from to 6 months). Among 654 adult rheumatology (RA, PsA, AS) patients treated with Enbrel in controlled and uncontrolled portions of clinical trials, representing approximately,845 patient-years of therapy, the observed rate of lymphoma was 0.0 cases per 00 patient-years. This was -fold higher than the rate of lymphoma expected in the general US population based on the Surveillance, Epidemiology, and End Results (SEER) Database. An increased rate of lymphoma up to several-fold has been reported in the RA patient population, and may be further increased in patients with more severe disease activity. Among 440 adult PsO patients treated with Enbrel in clinical trials up to 6 months, representing approximately 478 patient-years of therapy, the observed rate of lymphoma was 0.05 cases per 00 patient-years, which is comparable to the rate in the general population. No cases were observed in Enbrel- or placebo-treated patients during the controlled portions of these trials. Leukemia Cases of acute and chronic leukemia have been reported in association with postmarketing TNF-blocker use in rheumatoid arthritis and other indications. Even in the absence of TNF-blocker therapy, patients with rheumatoid arthritis may be at higher risk (approximately -fold) than the general population for the development of leukemia. During the controlled portions of Enbrel trials, cases of leukemia were observed among 5445 (0.06 cases per 00 patient-years) Enbrel-treated patients versus 0 among 890 (0%) control patients (duration of controlled treatment ranged from to 48 months). Among 5,40 patients treated with Enbrel in controlled and open portions of clinical trials representing approximately,5 patient-years of therapy, the observed rate of leukemia was 0.0 cases per 00 patient-years. Other Malignancies Information is available from 0,95 adult patients with 7, patient-years and 696 pediatric patients with 8 patient-years of experience across 45 Enbrel clinical studies. For malignancies other than lymphoma and non-melanoma skin cancer, there was no difference in exposure-adjusted rates between the Enbrel and control arms in the controlled portions of clinical studies for all indications. Analysis of the malignancy rate in combined controlled and uncontrolled portions of studies has demonstrated that types and rates are similar to what is expected in the general US population based on the SEER database and suggests no increase in rates over time. Whether treatment with Enbrel might influence the development and course of malignancies in adults is unknown. Melanoma and Non-melanoma skin cancer (NMSC) Melanoma and non-melanoma skin cancer has been reported in patients treated with TNF antagonists including etanercept. Among 5,40 patients treated with Enbrel in controlled and open portions of clinical trials representing approximately,5 patient-years of therapy, the observed rate of melanoma was 0.04 cases per 00 patient-years. Among 06 adult rheumatology (RA, PsA, AS) patients treated with Enbrel in controlled clinical trials representing approximately 669 patient-years of therapy, the observed rate of NMSC was 0.4 cases per 00 patient-years vs 0.7 cases per 00 patient-years among 5 control-treated patients representing 077 patient-years. Among 45 adult psoriasis patients treated with Enbrel in controlled clinical trials, representing approximately 8 patient-years of therapy, the observed rate of NMSC was.54 cases per 00 patient-years vs.8 cases per 00 patient-years among 70 control-treated patients representing 56 patient-years. Postmarketing cases of Merkel cell carcinoma have been reported very infrequently in patients treated with Enbrel. Periodic skin examinations should be considered for all patients at increased risk for skin cancer. Pediatric Patients Malignancies, some fatal, have been reported among children, adolescents, and young adults who received treatment with TNF-blocking agents (initiation of therapy at 8 years of age), including Enbrel. Approximately half the cases were lymphomas, including Hodgkin s and non-hodgkin s lymphoma. The other cases represented a variety of different malignancies and included rare malignancies usually associated with immunosuppression and malignancies that are not usually observed in children and adolescents. The malignancies occurred after a median of 0 months of therapy (range to 84 months). Most of the patients were receiving concomitant immunosuppressants. These cases were reported postmarketing and are derived from a variety of sources, including registries and spontaneous postmarketing reports. In clinical trials of 696 patients representing 8 patient-years of therapy, no malignancies, including lymphoma or NMSC, have been reported. Postmarketing Use In global postmarketing adult and pediatric use, lymphoma and other malignancies have been reported. Patients With Heart Failure Two clinical trials evaluating the use of Enbrel in the treatment of heart failure were terminated early due to lack of efficacy. One of these studies suggested higher mortality in Enbrel-treated patients compared to placebo [see Adverse Reactions]. There have been postmarketing reports of worsening of congestive heart failure (CHF), with and without identifiable precipitating factors, in patients taking Enbrel. There have also been rare (< 0.%) reports of new onset CHF, including CHF in patients without known preexisting cardiovascular disease. Some of these patients have been under 50 years of age. Physicians should exercise caution when using Enbrel in patients who also have heart failure, and monitor patients carefully. Hematologic Events Rare (< 0.%) reports of pancytopenia, including very rare (< 0.0%) reports of aplastic anemia, some with a fatal outcome, have been reported in patients treated with Enbrel. The causal relationship to Enbrel therapy remains unclear. Although no high-risk group has been identified, caution should be exercised in patients being treated with Enbrel who have a previous history of significant hematologic abnormalities. All patients should be advised to seek immediate medical attention if they develop signs and symptoms suggestive of blood dyscrasias or infection (eg, persistent fever, bruising, bleeding, pallor) while on Enbrel. Discontinuation of Enbrel therapy should be considered in patients with confirmed significant hematologic abnormalities. Two percent of patients treated concurrently with Enbrel and anakinra developed neutropenia (ANC < x 0 9 /L). While neutropenic, one patient developed cellulitis that resolved with antibiotic therapy. Hepatitis B Virus Reactivation Use of TNF-blocking agents has been associated with reactivation of hepatitis B virus (HBV), including very rare cases (< 0.0%) with Enbrel, in patients who are chronic carriers of this virus. In some instances, HBV reactivation occurring in conjunction with TNF-blocker therapy has been fatal. The majority of these reports have occurred in patients concomitantly receiving other medications that suppress the immune system, which may also contribute to HBV reactivation. Patients at risk for HBV infection should be evaluated for prior evidence of HBV infection before initiating TNF-blocker therapy. Prescribers should exercise caution in prescribing TNF blockers for patients identified as carriers of HBV. Adequate data are not available on the safety or efficacy of treating patients who are carriers of HBV with anti viral therapy in conjunction with TNF-blocker therapy to prevent HBV reactivation. Patients who are carriers of HBV and require treatment with Enbrel should be closely monitored for clinical and laboratory signs of active HBV infection throughout therapy and for several months following termination of therapy. In patients who develop HBV reactivation, consideration should be given to stopping Enbrel and initiating anti viral therapy with appropriate supportive treatment. The safety of resuming Enbrel therapy after HBV reactivation is controlled is not known. Therefore, prescribers should weigh the risks and benefits when considering resumption of therapy in this situation. Allergic Reactions Allergic reactions associated with administration of Enbrel during clinical trials have been reported in < % of patients. If an anaphylactic reaction or other serious allergic reaction occurs, administration of Enbrel should be discontinued immediately and appropriate therapy initiated. Caution: The following components contain dry natural rubber (a derivative of latex), which may cause allergic reactions in individuals sensitive to latex: the needle cover of the prefilled syringe and the needle cover within the needle cap of the SureClick autoinjector. Immunizations Live vaccines should not be given concurrently with Enbrel. It is recommended that pediatric patients, if possible, be brought up-to-date with all immunizations in agreement with current immunization guidelines prior to initiating Enbrel therapy [see Drug Interactions]. Autoimmunity Treatment with Enbrel may result in the formation of autoantibodies [see Adverse Reactions] and, rarely (< 0.%), in the development of a lupus-like syndrome or autoimmune hepatitis [see Adverse Reactions], which may resolve following withdrawal of Enbrel. If a patient develops symptoms and findings suggestive of a lupus-like syndrome or autoimmune hepatitis following treatment with Enbrel, treatment should be discontinued and the patient should be carefully evaluated. Immunosuppression TNF mediates inflammation and modulates cellular immune responses. TNFblocking agents, including Enbrel, affect host defenses against infections. The effect of TNF inhibition on the development and course of malignancies is not fully understood. In a study of 49 patients with RA treated with Enbrel, there was no evidence of depression of delayed-type hypersensitivity, depression of immunoglobulin levels, or change in enumeration of effector cell populations [see Adverse Reactions]. Use in Wegener s Granulomatosis Patients The use of Enbrel in patients with Wegener s granulomatosis receiving

450 immunosuppressive agents is not recommended. In a study of patients with Wegener s granulomatosis, the addition of Enbrel to standard therapy (including cyclophosphamide) was associated with a higher incidence of non cutaneous solid malignancies and was not associated with improved clinical outcomes when compared with standard therapy alone [see Drug Interactions]. Use with Anakinra or Abatacept Use of Enbrel with anakinra or abatacept is not recommended [s e e Drug Interactions]. Use in Patients with Moderate to Severe Alcoholic Hepatitis In a study of 48 hospitalized patients treated with Enbrel or placebo for moderate to severe alcoholic hepatitis, the mortality rate in patients treated with Enbrel was similar to patients treated with placebo at month but significantly higher after 6 months. Physicians should use caution when using Enbrel in patients with moderate to severe alcoholic hepatitis. ADVERSE REACTIONS Across clinical studies and postmarketing experience, the most serious adverse reactions with Enbrel were infections, neurologic events, CHF, and hematologic events [see Warnings and Precautions]. The most common adverse reactions with Enbrel were infections and injection site reactions. Clinical Studies Experience Adverse Reactions in Adult Patients With Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, or Plaque Psoriasis The data described below reflect exposure to Enbrel in 9 adult patients with RA followed for up to 80 months, in 8 patients with PsA for up to 4 months, in 8 patients with AS for up to 6 months, and in 04 adult patients with PsO for up to 8 months. In controlled trials, the proportion of Enbrel-treated patients who discontinued treatment due to adverse events was approximately 4% in the indications studied. Because clinical trials are conducted under widely varying conditions, adverse reactions rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not predict the rates observed in clinical practice. Infections Infections, including viral, bacterial, and fungal infections, have been observed in adult and pediatric patients. Infections have been noted in all body systems and have been reported in patients receiving Enbrel alone or in combination with other immunosuppressive agents. In controlled portions of trials, the types and severity of infection were similar between Enbrel and the respective control group (placebo or MTX for RA and PsA patients) in RA, PsA, AS and PsO patients. Rates of infections in RA and PsO patients are provided in Table and Table 4, respectively. Infections consisted primarily of upper respiratory tract infection, sinusitis and influenza. In controlled portions of trials in RA, PsA, AS and PsO, the rates of serious infection were similar (0.8% in placebo,.6% in MTX, and.4% in Enbrel/ Enbrel + MTX-treated groups). In clinical trials in rheumatologic indications, serious infections experienced by patients have included, but are not limited to, pneumonia, cellulitis, septic arthritis, bronchitis, gastroenteritis, pyelonephritis, sepsis, abscess and osteomyelitis. In clinical trials in PsO, serious infections experienced by patients have included, but are not limited to, pneumonia, cellulitis, gastroenteritis, abscess and osteomyelitis. The rate of serious infections was not increased in open-label extension trials and was similar to that observed in Enbrel- and placebo-treated patients from controlled trials. In 66 global clinical trials of 7,505 patients (,05 patient-years of therapy), tuberculosis was observed in approximately 0.0% of patients. In 7,696 patients (7,69 patient-years of therapy) from 8 clinical trials and 4 cohort studies in the US and Canada, tuberculosis was observed in approximately 0.006% of patients. These studies include reports of pulmonary and extrapulmonary tuberculosis [see Warnings and Precautions]. Injection Site Reactions In placebo-controlled trials in rheumatologic indications, approximately 7% of patients treated with Enbrel developed injection site reactions. In controlled trials in patients with PsO, 5% of patients treated with Enbrel developed injection site reactions during the first months of treatment. All injection site reactions were described as mild to moderate (erythema, itching, pain, swelling, bleeding, bruising) and generally did not necessitate drug discontinuation. Injection site reactions generally occurred in the first month and subsequently decreased in frequency. The mean duration of injection site reactions was to 5 days. Seven percent of patients experienced redness at a previous injection site when subsequent injections were given. Immunogenicity Patients with RA, PsA, AS or PsO were tested at multiple time points for antibodies to etanercept. Antibodies to the TNF receptor portion or other protein components of the Enbrel drug product were detected at least once in sera of approximately 6% of adult patients with RA, PsA, AS or PsO. These antibodies were all non-neutralizing. Results from JIA patients were similar to those seen in adult RA patients treated with Enbrel. In PsO studies that evaluated the exposure of etanercept for up to 0 weeks, the percentage of patients testing positive at the assessed time points of 4, 48, 7 and 96 weeks ranged from.6% 8.7% and were all non-neutralizing. The percentage of patients testing positive increased with an increase in the duration of study; however, the clinical significance of this finding is unknown. No apparent correlation of antibody development to clinical response or adverse events was observed. The immunogenicity data of Enbrel beyond 0 weeks of exposure are unknown. The data reflect the percentage of patients whose test results were considered positive for antibodies to etanercept in an ELISA assay, and are highly dependent on the sensitivity and specificity of the assay. Additionally, the observed incidence of any antibody positivity in an assay is highly dependent on several factors, including assay sensitivity and specificity, assay methodology, sample handling, timing of sample collection, concomitant medications, and underlying disease. For these reasons, comparison of the incidence of antibodies to etanercept with the incidence of antibodies to other products may be misleading. Autoantibodies Patients with RA had serum samples tested for autoantibodies at multiple time points. In RA Studies I and II, the percentage of patients evaluated for antinuclear antibodies (ANA) who developed new positive ANA (titer :40) was higher in patients treated with Enbrel (%) than in placebo-treated patients (5%). The percentage of patients who developed new positive antidouble-stranded DNA antibodies was also higher by radioimmunoassay (5% of patients treated with Enbrel compared to 4% of placebo-treated patients) and by Crithidia luciliae assay (% of patients treated with Enbrel compared to none of placebo-treated patients). The proportion of patients treated with Enbrel who developed anticardiolipin antibodies was similarly increased compared to placebo-treated patients. In RA Study III, no pattern of increased autoantibody development was seen in Enbrel patients compared to MTX patients [see Warnings and Precautions]. Other Adverse Reactions Table summarizes adverse reactions reported in adult RA patients. The types of adverse reactions seen in patients with PsA or AS were similar to the types of adverse reactions seen in patients with RA. Table. Percent of Adult RA Patients Experiencing Adverse Reactions in Controlled Clinical Trials Placebo Controlled a (Studies I, II, and a Phase Study) Placebo (N = 5) Enbrel c (N = 49) Active Controlled b (Study III) MTX (N = 7) Enbrel c (N = 45) Reaction Percent of Patients Percent of Patients Infection d (total) Upper Respiratory Infections e Non-upper Respiratory Infections Injection Site Reactions Diarrhea Rash Pruritus Pyrexia Urticaria Hypersensitivity a Includes data from the 6-month study in which patients received concurrent MTX therapy in both arms. b Study duration of years. c Any dose. d Includes bacterial, viral, and fungal infections. e Most frequent Upper Respiratory Infections were upper respiratory tract infection, sinusitis, and influenza. In placebo-controlled PsO trials, the percentages of patients reporting adverse reactions in the 50 mg twice a week dose group were similar to those observed in the 5 mg twice a week dose group or placebo group. Table 4 summarizes adverse reactions reported in adult PsO patients from Studies I and II. Table 4. Percent of Adult PsO Patients Experiencing Adverse Reactions in Placebo-Controlled Portions of Clinical Trials (Studies I & II) Placebo (N = 59) Enbrel a (N = 876) Reaction Percent of Patients Infection b (total) Non-upper Respiratory Infections Upper Respiratory Infections c Injection Site Reactions Diarrhea Rash Pruritus Urticaria Hypersensitivity Pyrexia a Includes 5 mg SC QW, 5 mg SC BIW, 50 mg SC QW, and 50 mg SC BIW doses. b Includes bacterial, viral and fungal infections. c Most frequent Upper Respiratory Infections were upper respiratory tract infection, nasopharyngitis and sinusitis. Adverse Reactions in Pediatric Patients In general, the adverse reactions in pediatric patients were similar in frequency and type as those seen in adult patients [see Warnings and Precautions]. The types of infections reported in pediatric patients were generally mild and consistent with those commonly seen in the general pediatric population. Two JIA patients developed varicella infection and signs and symptoms of aseptic meningitis, which resolved without sequelae. In open-label clinical studies of children with JIA, adverse reactions reported in those ages to 4 years were similar to adverse reactions reported in older children. Postmarketing Experience Adverse reactions have been reported during post approval use of Enbrel in adults and pediatric patients. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to Enbrel exposure. Adverse reactions are listed by body system below: Blood and lymphatic system disorders: Cardiac disorders: Gastrointestinal disorders: General disorders: Hepatobiliary disorders: Immune disorders: Musculoskeletal and connective tissue disorders: Neoplasms benign, malignant, and unspecified: Nervous system disorders: Ocular disorders: Respiratory, thoracic and mediastinal disorders: pancytopenia, anemia, leukopenia, neutropenia, thrombocytopenia, lymphadenopathy, aplastic anemia [see Warnings and Precautions] congestive heart failure [see Warnings and Precautions] inflammatory bowel disease (IBD) angioedema, chest pain autoimmune hepatitis, elevated transaminases macrophage activation syndrome, systemic vasculitis lupus-like syndrome melanoma and non-melanoma skin cancers, merkel cell carcinoma [see Warnings and Precautions] convulsions, multiple sclerosis, demyelination, optic neuritis, transverse myelitis, paresthesias [see Warnings and Precautions] uveitis, scleritis interstitial lung disease Skin and subcutaneous tissue disorders: cutaneous lupus erythematous, cutaneous vasculitis (including leukocytoclastic vasculitis), erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis, subcutaneous nodule, new or worsening psoriasis (all sub-types including pustular and palmoplantar) Opportunistic infections, including atypical mycobacterial infection, herpes zoster, aspergillosis and Pneumocystis jiroveci pneumonia, and protozoal infections have also been reported in postmarketing use. DRUG INTERACTIONS Specific drug interaction studies have not been conducted with Enbrel. Vaccines Most PsA patients receiving Enbrel were able to mount effective B-cell immune responses to pneumococcal polysaccharide vaccine, but titers in aggregate were moderately lower and fewer patients had -fold rises in titers compared to patients not receiving Enbrel. The clinical significance of this is unknown. Patients receiving Enbrel may receive concurrent vaccinations, except for live vaccines. No data are available on the secondary transmission of infection by live vaccines in patients receiving Enbrel. Patients with a significant exposure to varicella virus should temporarily discontinue Enbrel therapy and be considered for prophylactic treatment with varicella zoster immune globulin [see Warnings and Precautions]. Immune-Modulating Biologic Products In a study in which patients with active RA were treated for up to 4 weeks with concurrent Enbrel and anakinra therapy, a 7% rate of serious infections was observed, which was higher than that observed with Enbrel alone (0%) [see Warnings and Precautions] and did not result in higher ACR response rates compared to Enbrel alone. The most common infections consisted of bacterial pneumonia (4 cases) and cellulitis (4 cases). One patient with pulmonary fibrosis and pneumonia died due to respiratory failure. Two percent of patients treated concurrently with Enbrel and anakinra developed neutropenia (ANC < x 0 9 /L). In clinical studies, concurrent administration of abatacept and Enbrel resulted in increased incidences of serious adverse events, including infections, and did not demonstrate increased clinical benefit [see Warnings and Precautions]. Cyclophosphamide The use of Enbrel in patients receiving concurrent cyclophosphamide therapy is not recommended [see Warnings and Precautions]. Sulfasalazine Patients in a clinical study who were on established therapy with sulfasalazine, to which Enbrel was added, were noted to develop a mild decrease in mean neutrophil counts in comparison to groups treated with either Enbrel or sulfasalazine alone. The clinical significance of this observation is unknown. USE IN SPECIFIC POPULATIONS Pregnancy Pregnancy Category B. Developmental toxicity studies have been performed in rats and rabbits at doses ranging from 60- to 00-fold higher than the human dose and have revealed no evidence of harm to the fetus due to Enbrel. There are, however, no studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed. Women who become pregnant during Enbrel treatment are encouraged to enroll in Amgen s Pregnancy Surveillance Program. Patients or their physicians should call AMGEN ( ) to enroll. Nursing Mothers It is not known whether Enbrel is excreted in human milk or absorbed systemically after ingestion. Because many drugs and immunoglobulins are excreted in human milk, and because of the potential for serious adverse reactions in nursing infants from Enbrel, a decision should be made whether to discontinue nursing or to discontinue the drug. Women who choose to continue Enbrel treatment while nursing are encouraged to enroll in Amgen s Lactation Surveillance Program. Patients or their physicians should call AMGEN ( ) to enroll. Pediatric Use Enbrel is indicated for treatment of polyarticular JIA in patients ages years and older [see Indications and Usage, Warnings and Precautions, Adverse Reactions]. Enbrel has not been studied in children < years of age with JIA. The safety and efficacy of Enbrel in pediatric patients with PsO have not been studied. Rare (<0.%) cases of IBD have been reported in JIA patients receiving Enbrel, which is not effective for the treatment of IBD [see Adverse Reactions]. Geriatric Use A total of 480 RA patients ages 65 years or older have been studied in clinical trials. In PsO randomized clinical trials, a total of 8 out of 965 subjects treated with Enbrel or placebo were age 65 or older. No overall differences in safety or effectiveness were observed between these patients and younger patients, but the number of geriatric PsO subjects is too small to determine whether they respond differently from younger subjects. Because there is a higher incidence of infections in the elderly population in general, caution should be used in treating the elderly. Use in Diabetics There have been reports of hypoglycemia following initiation of Enbrel therapy in patients receiving medication for diabetes, necessitating a reduction in anti-diabetic medication in some of these patients. Rx Only. This brief summary is based on ENBREL prescribing information v. 5: 06/0 Manufactured by: Immunex Corporation Thousand Oaks, CA US License Number Marketed by Amgen Inc Immunex Corporation. All rights reserved. US Patent Nos. 7,95,5; 5,605,690; Re. 6,755. For more information please call or visit 0 Amgen Inc., Thousand Oaks, CA 90 All rights reserved R-V4

451 IMPORTANT SAFETY INFORMATION SERIOUS INFECTIONS Patients treated with ENBREL (etanercept) are at increased risk for developing serious infections that may lead to hospitalization or death. Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids or were predisposed to infection because of their underlying disease. ENBREL should not be initiated in the presence of sepsis, active infections, or allergy to ENBREL or its components. ENBREL should be discontinued if a patient develops a serious infection or sepsis. Reported infections include: ) Active tuberculosis (TB), including reactivation of latent TB. Patients with TB have frequently presented with disseminated or extrapulmonary disease. Patients should be tested for latent TB before ENBREL use and periodically during therapy. Treatment for latent infection should be initiated prior to ENBREL use, ) Invasive fungal infections, including histoplasmosis, coccidioidomycosis, candidiasis, aspergillosis, blastomycosis, and pneumocystosis. Patients with histoplasmosis or other invasive fungal infections may present with disseminated, rather than localized, disease. Antigen and antibody testing for histoplasmosis may be negative in some patients with active infection. Empiric antifungal therapy should be considered in patients at risk for invasive fungal infections who develop severe systemic illness, and ) Bacterial, viral, and other infections due to opportunistic pathogens, including Legionella and Listeria. The risks and benefits of treatment with ENBREL should be carefully considered prior to initiating therapy in patients ) with chronic or recurrent infection, ) who have been exposed to TB, ) who have resided or traveled in areas of endemic TB or endemic mycoses, or 4) with underlying conditions that may predispose them to infections such as advanced or poorly controlled diabetes. Patients should be closely monitored for the development of signs and symptoms of infection during and after treatment with ENBREL, including the possible development of TB in patients who tested negative for latent TB prior to initiating therapy. MALIGNANCIES Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with tumor necrosis factor (TNF) blockers, including ENBREL. In adult clinical trials of all TNF blockers, more cases of lymphoma were seen compared to control patients. The risk of lymphoma may be up to several-fold higher in RA and psoriasis patients. The role of TNF blocker therapy in the development of malignancies is unknown. Cases of acute and chronic leukemia have been reported in association with postmarketing TNF blocker use in RA and other indications. The risk of leukemia may be higher in patients with RA (approximately -fold) than the general population. Melanoma and non-melanoma skin cancer (NMSC) have been reported in patients treated with TNF blockers, including ENBREL. Periodic skin examinations should be considered for all patients at increased risk for skin cancer. Pediatric Patients In patients who initiated therapy at 8 years of age, approximately half of the reported malignancies were lymphomas (Hodgkin s and non-hodgkin s lymphoma). Other cases included rare malignancies usually associated with immunosuppression and malignancies that are not usually observed in children and adolescents. Most of the patients were receiving concomitant immunosuppressants. NEUROLOGIC EVENTS Treatment with TNF-blocking agents, including ENBREL, has been associated with rare (<0.%) cases of new onset or exacerbation of central nervous system demyelinating disorders, some presenting with mental status changes and some associated with permanent disability, and with peripheral nervous system demyelinating disorders. Cases of transverse myelitis, optic neuritis, multiple sclerosis, Guillain-Barré syndromes, other peripheral demyelinating neuropathies, and new onset or exacerbation of seizure disorders have been reported in postmarketing experience with ENBREL therapy. Prescribers should exercise caution in considering the use of ENBREL in patients with preexisting or recent-onset central or peripheral nervous system demyelinating disorders. CONGESTIVE HEART FAILURE Cases of worsening congestive heart failure (CHF) and, rarely, new-onset cases have been reported in patients taking ENBREL. Caution should be used when using ENBREL in patients with CHF. These patients should be carefully monitored. HEMATOLOGIC EVENTS Rare cases of pancytopenia, including aplastic anemia, some fatal, have been reported. The causal relationship to ENBREL therapy remains unclear. Exercise caution when considering ENBREL in patients who have a previous history of significant hematologic abnormalities. Advise patients to seek immediate medical attention if they develop signs or symptoms of blood dyscrasias or infection. Consider discontinuing ENBREL if significant hematologic abnormalities are confirmed. HEPATITIS B VIRUS REACTIVATION Use of TNF blockers, including ENBREL, has been associated with reactivation of hepatitis B virus (HBV) in chronic carriers of this virus. The majority of these reports occurred in patients on concomitant immunosuppressive agents, which may also contribute to HBV reactivation. Exercise caution when considering ENBREL in patients identified as carriers of HBV. ALLERGIC REACTIONS Allergic reactions associated with administration of ENBREL during clinical trials have been reported in <% of patients. If an anaphylactic reaction or other serious allergic reaction occurs, administration of ENBREL should be discontinued immediately and appropriate therapy initiated. IMMUNIZATIONS Live vaccines should not be administered to patients on ENBREL. JIA patients, if possible, should be brought up to date with all immunizations prior to initiating ENBREL. In patients with exposure to varicella virus, consider temporary discontinuation of ENBREL and prophylactic treatment with Varicella Zoster Immune Globulin. AUTOIMMUNITY Autoantibodies may develop with ENBREL, and rarely lupus-like syndrome or autoimmune hepatitis may occur. These may resolve upon withdrawal of ENBREL. Stop ENBREL if lupus-like syndrome or autoimmune hepatitis develops. WEGENER S GRANULOMATOSIS PATIENTS The use of ENBREL in patients with Wegener s granulomatosis receiving immunosuppressive agents (eg, cyclophosphamide) is not recommended. MODERATE TO SEVERE ALCOHOLIC HEPATITIS Based on a study of patients treated for alcoholic hepatitis, exercise caution when using ENBREL in patients with moderate to severe alcoholic hepatitis. ADVERSE EVENTS The most commonly reported adverse events in RA clinical trials were injection site reaction, infection, and headache. In clinical trials of all other adult indications, adverse events were similar to those reported in RA clinical trials. DRUG INTERACTIONS The use of ENBREL in patients receiving concurrent cyclophosphamide therapy is not recommended. The risk of serious infection may increase with concomitant use of abatacept therapy. Concurrent therapy with ENBREL and anakinra is not recommended. Hypoglycemia has been reported following initiation of ENBREL therapy in patients receiving medication for diabetes, necessitating a reduction in antidiabetic medication in some of these patients. Please see Brief Summary of Prescribing Information on preceding pages. References:. Enbrel (etanercept) Prescribing Information, June 0.. Data on file, Amgen Inc. # Biologic for Rheumatologists, 0.. Data on file, Amgen Inc. TEMPO CSR yr Clinical 06/ R-V

452 In moderately to severely active rheumatoid arthritis (RA) HELP PATIENTS GET BACK TO MANY OF THE ACTIVITIES THEY LOVE ACTIVE MOVEMENT ENABLE EXPLORE SUPPORT ENBREL ENBREL + MTX achieved significant improvements in physical function vs MTX alone as measured by HAQ-DI by Week and out to Year. * Whether your patients are practicing their putt, spending time with family, or walking their dog, ENBREL has been a symbol of change for your patients with moderate to severe RA. Since 998, ENBREL was the first and is still the only approved soluble TNF receptor treatment for appropriate patients. Because of you, ENBREL is the # prescribed biologic by rheumatologists today. ENBREL is indicated for reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in patients with moderately to severely active rheumatoid arthritis. ENBREL can be initiated in combination with methotrexate (MTX) or used alone. Prescription ENBREL is administered by injection. Important Safety Considerations: ENBREL suppresses the immune system and has been associated with serious and sometimes fatal infections, including TB and other opportunistic infections. Other serious and sometimes fatal adverse events including malignancies, neurologic events, hematologic events, congestive heart failure, hepatitis B reactivation, allergic reactions, lupus-like syndrome and autoimmune hepatitis have also been reported. ENBREL is contraindicated in patients with sepsis. Please see Important Safety Information and Brief Summary for additional information. * In the TEMPO study, mean HAQ scores at baseline, week, and year were.7,.5, and. in the MTX arm (n = 8) and.8,., and 0.8 in the ENBREL + MTX arm (n = ), respectively. HAQ-DI = Health Assessment Questionnaire-Disability Index 6-month total of IMS monthly NPA prescription data by rheumatologists. These data include only dispensed total scripts. Visit Booth #00 to see how you can help patients get back to many of the activities they love. Enbrel and the Enbrel logo are registered trademarks of Immunex Corporation.